From 07b96d1e27ea4fb62e846072c295825d683b320b Mon Sep 17 00:00:00 2001
From: James Herr <jherr@flexion.us>
Date: Mon, 16 Dec 2024 16:56:33 -0600
Subject: [PATCH 01/61] WIP Initial setup

---
 .../workflows/golden-staging-test-submit.yml  | 66 +++++++++++++++++++
 .../rse2e/GoldenTest.groovy                   | 24 +++++++
 2 files changed, 90 insertions(+)
 create mode 100644 .github/workflows/golden-staging-test-submit.yml
 create mode 100644 rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenTest.groovy

diff --git a/.github/workflows/golden-staging-test-submit.yml b/.github/workflows/golden-staging-test-submit.yml
new file mode 100644
index 000000000..fb12aa660
--- /dev/null
+++ b/.github/workflows/golden-staging-test-submit.yml
@@ -0,0 +1,66 @@
+name: Automated Staging Test - Submit Messages
+
+on:
+  schedule:
+    - cron: "0 5 * * 2-6"  # Tuesday to Saturday at Midnight EST (5am UTC)
+  workflow_dispatch:
+
+jobs:
+  send_files:
+    runs-on: ubuntu-latest
+
+    steps:
+      - name: Check out the repository
+        uses: actions/checkout@v4
+
+      - name: Install jq
+        run: sudo apt-get install -y jq
+
+      - name: Install jwt-cli
+        run: |
+            curl --silent --location https://github.com/mike-engel/jwt-cli/releases/latest/download/jwt-linux.tar.gz | tar xvz -C /usr/local/bin/
+            sudo chmod +x /usr/local/bin/jwt
+
+      - name: Write private key to file
+        run: |
+          echo "${{ secrets.SIMULATED_SENDER_STAGING_PRIVATE_KEY }}" > /tmp/staging_private_key.pem
+          chmod 600 /tmp/staging_private_key.pem
+
+      - name: Send HL7 sample messages to staging RS
+        run: |
+            host=https://staging.prime.cdc.gov:443
+            client_id=flexion
+            client_sender=simulated-sender
+            jwt=$(jwt encode --exp='+5min' --jti $(uuidgen) --alg RS256 \
+                -k $client_id.$client_sender -i $client_id.$client_sender \
+                -s $client_id.$client_sender -a $host --no-iat -S @/tmp/staging_private_key.pem)
+
+            token=$(curl \
+                    --header "Content-Type: application/x-www-form-urlencoded" \
+                    --data "scope=$client_id.*.report" \
+                    --data "client_assertion=$jwt" \
+                    --data "client_assertion_type=urn:ietf:params:oauth:client-assertion-type:jwt-bearer" \
+                    --data "grant_type=client_credentials" \
+                    --silent \
+                    "$host/api/token" | jq -r ".access_token")
+
+            for file in $(pwd)/examples/Test/Automated/golden*.hl7; do
+                echo "Sending $file"
+                curl \
+                    --header "Content-Type: application/hl7-v2" \
+                    --header "Client: $client_id.$client_sender" \
+                    --header "Authorization: Bearer $token" \
+                    --data-binary "@$file" \
+                    --silent \
+                    "$host/api/waters"
+            done
+
+
+
+
+
+
+      - name: Clean up private key
+        if: always()
+        run: |
+          rm -f /tmp/staging_private_key.pem
diff --git a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenTest.groovy b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenTest.groovy
new file mode 100644
index 000000000..26d61bd39
--- /dev/null
+++ b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenTest.groovy
@@ -0,0 +1,24 @@
+package gov.hhs.cdc.trustedintermediary.rse2e
+
+import spock.lang.Specification
+
+import java.nio.file.Files
+import java.nio.file.Path
+
+class GoldenTest extends Specification {
+
+    def beforeFileJsonFileString = Files.readString(Path.of("../examples/Test/Automated/golden_before.fhir"))
+    def afterFileJsonFileString = Files.readString(Path.of("../examples/Test/Automated/golden_after.fhir"))
+
+    def setup() {
+    }
+    // hola mi amigo fdfdfdji. senor james. el
+    def "Golden Test"() {
+        // notes:
+        // Use workflow to sendoff the file (happens via Github Action)
+
+
+        // compare with known good file
+        // def matchedFiles = fileMatcher.matchFiles(azureFiles, localFiles)
+    }
+}

From 2d14e9a32cf50f534e4c07abb1168feb8bd90e1a Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Mon, 16 Dec 2024 16:29:17 -0700
Subject: [PATCH 02/61] add notes for later and initial setup/cleanup

---
 .../rse2e/GoldenTest.groovy                   | 57 ++++++++++++++++++-
 1 file changed, 56 insertions(+), 1 deletion(-)

diff --git a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenTest.groovy b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenTest.groovy
index 26d61bd39..e50041bb1 100644
--- a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenTest.groovy
+++ b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenTest.groovy
@@ -1,5 +1,14 @@
 package gov.hhs.cdc.trustedintermediary.rse2e
 
+import gov.hhs.cdc.trustedintermediary.context.TestApplicationContext
+import gov.hhs.cdc.trustedintermediary.external.jackson.Jackson
+import gov.hhs.cdc.trustedintermediary.rse2e.external.hapi.HapiHL7ExpressionEvaluator
+import gov.hhs.cdc.trustedintermediary.rse2e.external.hapi.HapiHL7FileMatcher
+import gov.hhs.cdc.trustedintermediary.rse2e.ruleengine.AssertionRuleEngine
+import gov.hhs.cdc.trustedintermediary.ruleengine.RuleLoader
+import gov.hhs.cdc.trustedintermediary.wrappers.HealthDataExpressionEvaluator
+import gov.hhs.cdc.trustedintermediary.wrappers.Logger
+import gov.hhs.cdc.trustedintermediary.wrappers.formatter.Formatter
 import spock.lang.Specification
 
 import java.nio.file.Files
@@ -10,13 +19,59 @@ class GoldenTest extends Specification {
     def beforeFileJsonFileString = Files.readString(Path.of("../examples/Test/Automated/golden_before.fhir"))
     def afterFileJsonFileString = Files.readString(Path.of("../examples/Test/Automated/golden_after.fhir"))
 
+    List<HL7FileStream> azureFiles // output
+    List<HL7FileStream> localFiles // input
+    AssertionRuleEngine engine
+    HapiHL7FileMatcher fileMatcher
+    Logger mockLogger = Mock(Logger)
+    List<String> loggedErrorsAndWarnings = []
+
     def setup() {
+        engine = AssertionRuleEngine.getInstance()
+        fileMatcher =  HapiHL7FileMatcher.getInstance()
+
+        TestApplicationContext.reset()
+        TestApplicationContext.init()
+        TestApplicationContext.register(AssertionRuleEngine, engine)
+        TestApplicationContext.register(RuleLoader, RuleLoader.getInstance())
+        TestApplicationContext.register(Logger, mockLogger)
+        TestApplicationContext.register(Formatter, Jackson.getInstance())
+        TestApplicationContext.register(HapiHL7FileMatcher, fileMatcher)
+        TestApplicationContext.register(HealthDataExpressionEvaluator, HapiHL7ExpressionEvaluator.getInstance())
+        TestApplicationContext.register(LocalFileFetcher, LocalFileFetcher.getInstance())
+        TestApplicationContext.injectRegisteredImplementations()
+
+        mockLogger.logWarning(_ as String, _ as Object) >> { String msg, Object args ->
+            loggedErrorsAndWarnings << msg
+        }
+        mockLogger.logError(_ as String, _ as Exception) >> { String msg, Exception e ->
+            loggedErrorsAndWarnings << msg
+        }
+
+        FileFetcher azureFileFetcher = AzureBlobFileFetcher.getInstance()
+        azureFiles = azureFileFetcher.fetchFiles()
+
+        FileFetcher localFileFetcher = LocalFileFetcher.getInstance()
+        localFiles = localFileFetcher.fetchFiles()
+
+        engine.ensureRulesLoaded() // we don't want this because it uses the hardcoded assertion_definition.json OR we want to modify that method
+    }
+
+    def cleanup() {
+        for (HL7FileStream fileStream : localFiles + azureFiles) {
+            fileStream.inputStream().close()
+        }
     }
-    // hola mi amigo fdfdfdji. senor james. el
+
     def "Golden Test"() {
         // notes:
         // Use workflow to sendoff the file (happens via Github Action)
 
+        // Call the automated-staging-test-submit workflow. Prob use a variable for the path of the folder unless we add to same folder.
+        // Call the automated-staging-test-run workflow. It shouldn't matter if it grabs all Azure files, we can use the MSH-10 to narrow it down like assertion_rules or use something else
+        // Modify the Rules Engine or create a different one
+        // If we do use the rules engine, see if its possible to compare the whole file as a rule rather than individual segments
+        // Update Automated Test README
 
         // compare with known good file
         // def matchedFiles = fileMatcher.matchFiles(azureFiles, localFiles)

From f8afd5469deacefe91cc9ee2968ac416480ed7e4 Mon Sep 17 00:00:00 2001
From: James Herr <jherr@flexion.us>
Date: Tue, 17 Dec 2024 10:42:21 -0600
Subject: [PATCH 03/61] Added basic compare

Co-Authored-By: Sylvie <38440028+somesylvie@users.noreply.github.com>
Co-Authored-By: Samuel Aquino <saquino@flexion.us>
---
 examples/Test/Automated/golden_actual.hl7     |  1 +
 examples/Test/Automated/golden_expected.hl7   |  1 +
 .../rse2e/GoldenTest.groovy                   | 30 ++++++++++++-------
 3 files changed, 22 insertions(+), 10 deletions(-)
 create mode 100644 examples/Test/Automated/golden_actual.hl7
 create mode 100644 examples/Test/Automated/golden_expected.hl7

diff --git a/examples/Test/Automated/golden_actual.hl7 b/examples/Test/Automated/golden_actual.hl7
new file mode 100644
index 000000000..d00491fd7
--- /dev/null
+++ b/examples/Test/Automated/golden_actual.hl7
@@ -0,0 +1 @@
+1
diff --git a/examples/Test/Automated/golden_expected.hl7 b/examples/Test/Automated/golden_expected.hl7
new file mode 100644
index 000000000..d00491fd7
--- /dev/null
+++ b/examples/Test/Automated/golden_expected.hl7
@@ -0,0 +1 @@
+1
diff --git a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenTest.groovy b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenTest.groovy
index e50041bb1..ae711053e 100644
--- a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenTest.groovy
+++ b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenTest.groovy
@@ -16,8 +16,9 @@ import java.nio.file.Path
 
 class GoldenTest extends Specification {
 
-    def beforeFileJsonFileString = Files.readString(Path.of("../examples/Test/Automated/golden_before.fhir"))
-    def afterFileJsonFileString = Files.readString(Path.of("../examples/Test/Automated/golden_after.fhir"))
+    def beforeFileJsonFileString = Files.readString(Path.of("../examples/Test/Automated/golden_actual.hl7"))
+    def afterFileJsonFileString = Files.readString(Path.of("../examples/Test/Automated/golden_expected.hl7"))
+
 
     List<HL7FileStream> azureFiles // output
     List<HL7FileStream> localFiles // input
@@ -48,22 +49,22 @@ class GoldenTest extends Specification {
             loggedErrorsAndWarnings << msg
         }
 
-        FileFetcher azureFileFetcher = AzureBlobFileFetcher.getInstance()
-        azureFiles = azureFileFetcher.fetchFiles()
+        //      FileFetcher azureFileFetcher = AzureBlobFileFetcher.getInstance()
+        //      azureFiles = azureFileFetcher.fetchFiles()
 
-        FileFetcher localFileFetcher = LocalFileFetcher.getInstance()
-        localFiles = localFileFetcher.fetchFiles()
+        //      FileFetcher localFileFetcher = LocalFileFetcher.getInstance()
+        //      localFiles = localFileFetcher.fetchFiles()
 
         engine.ensureRulesLoaded() // we don't want this because it uses the hardcoded assertion_definition.json OR we want to modify that method
     }
 
     def cleanup() {
-        for (HL7FileStream fileStream : localFiles + azureFiles) {
-            fileStream.inputStream().close()
-        }
+        //  for (HL7FileStream fileStream : localFiles + azureFiles) {
+        //     fileStream.inputStream().close()
+        //}
     }
 
-    def "Golden Test"() {
+    def "Compare files"() {
         // notes:
         // Use workflow to sendoff the file (happens via Github Action)
 
@@ -75,5 +76,14 @@ class GoldenTest extends Specification {
 
         // compare with known good file
         // def matchedFiles = fileMatcher.matchFiles(azureFiles, localFiles)
+
+        given:
+
+
+        when:
+        def filesAreIdentical = beforeFileJsonFileString == afterFileJsonFileString
+
+        then:
+        assert filesAreIdentical, "test"
     }
 }

From dad2cd3d8804f8ecf36f7711ef8a75da4ebc9079 Mon Sep 17 00:00:00 2001
From: James Herr <jherr@flexion.us>
Date: Tue, 17 Dec 2024 12:05:32 -0600
Subject: [PATCH 04/61] Testing workflow dispatch

Co-Authored-By: Samuel Aquino <saquino@flexion.us>
Co-Authored-By: Bella L. Quintero <96704946+pluckyswan@users.noreply.github.com>
---
 .../automated-staging-test-submit.yml         |  10 +-
 .../workflows/golden-staging-test-submit.yml  |  66 --------
 ...Indeterminate - SCADD - IBCDD patterns.hl7 | 143 ++++++++++++++++++
 3 files changed, 152 insertions(+), 67 deletions(-)
 delete mode 100644 .github/workflows/golden-staging-test-submit.yml
 create mode 100644 examples/Test/Automated/Acylcarnitine - Indeterminate - SCADD - IBCDD patterns.hl7

diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
index 0733accfa..3ef9b176a 100644
--- a/.github/workflows/automated-staging-test-submit.yml
+++ b/.github/workflows/automated-staging-test-submit.yml
@@ -4,6 +4,13 @@ on:
   schedule:
     - cron: "0 5 * * 2-6"  # Tuesday to Saturday at Midnight EST (5am UTC)
   workflow_dispatch:
+    inputs:
+      name:
+        type: choice
+        description: Type of staging test
+        options:
+          - automated-staging-test
+          - golden-copy-staging-test
 
 jobs:
   send_files:
@@ -44,7 +51,8 @@ jobs:
                     --silent \
                     "$host/api/token" | jq -r ".access_token")
 
-            for file in $(pwd)/examples/Test/Automated/*.hl7; do
+            file_path=Automated/*.hl7
+            for file in $(pwd)/examples/Test/$(file_path); do
                 echo "Sending $file"
                 curl \
                     --header "Content-Type: application/hl7-v2" \
diff --git a/.github/workflows/golden-staging-test-submit.yml b/.github/workflows/golden-staging-test-submit.yml
deleted file mode 100644
index fb12aa660..000000000
--- a/.github/workflows/golden-staging-test-submit.yml
+++ /dev/null
@@ -1,66 +0,0 @@
-name: Automated Staging Test - Submit Messages
-
-on:
-  schedule:
-    - cron: "0 5 * * 2-6"  # Tuesday to Saturday at Midnight EST (5am UTC)
-  workflow_dispatch:
-
-jobs:
-  send_files:
-    runs-on: ubuntu-latest
-
-    steps:
-      - name: Check out the repository
-        uses: actions/checkout@v4
-
-      - name: Install jq
-        run: sudo apt-get install -y jq
-
-      - name: Install jwt-cli
-        run: |
-            curl --silent --location https://github.com/mike-engel/jwt-cli/releases/latest/download/jwt-linux.tar.gz | tar xvz -C /usr/local/bin/
-            sudo chmod +x /usr/local/bin/jwt
-
-      - name: Write private key to file
-        run: |
-          echo "${{ secrets.SIMULATED_SENDER_STAGING_PRIVATE_KEY }}" > /tmp/staging_private_key.pem
-          chmod 600 /tmp/staging_private_key.pem
-
-      - name: Send HL7 sample messages to staging RS
-        run: |
-            host=https://staging.prime.cdc.gov:443
-            client_id=flexion
-            client_sender=simulated-sender
-            jwt=$(jwt encode --exp='+5min' --jti $(uuidgen) --alg RS256 \
-                -k $client_id.$client_sender -i $client_id.$client_sender \
-                -s $client_id.$client_sender -a $host --no-iat -S @/tmp/staging_private_key.pem)
-
-            token=$(curl \
-                    --header "Content-Type: application/x-www-form-urlencoded" \
-                    --data "scope=$client_id.*.report" \
-                    --data "client_assertion=$jwt" \
-                    --data "client_assertion_type=urn:ietf:params:oauth:client-assertion-type:jwt-bearer" \
-                    --data "grant_type=client_credentials" \
-                    --silent \
-                    "$host/api/token" | jq -r ".access_token")
-
-            for file in $(pwd)/examples/Test/Automated/golden*.hl7; do
-                echo "Sending $file"
-                curl \
-                    --header "Content-Type: application/hl7-v2" \
-                    --header "Client: $client_id.$client_sender" \
-                    --header "Authorization: Bearer $token" \
-                    --data-binary "@$file" \
-                    --silent \
-                    "$host/api/waters"
-            done
-
-
-
-
-
-
-      - name: Clean up private key
-        if: always()
-        run: |
-          rm -f /tmp/staging_private_key.pem
diff --git a/examples/Test/Automated/Acylcarnitine - Indeterminate - SCADD - IBCDD patterns.hl7 b/examples/Test/Automated/Acylcarnitine - Indeterminate - SCADD - IBCDD patterns.hl7
new file mode 100644
index 000000000..048d8fe6f
--- /dev/null
+++ b/examples/Test/Automated/Acylcarnitine - Indeterminate - SCADD - IBCDD patterns.hl7	
@@ -0,0 +1,143 @@
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^1477542173^L,M,N|20241015050654||ORU^R01^ORU_R01|244028180|P|2.5.1\r
+PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
+NK1|1|*****PII REMOVED******
+ORC|RE|673678765^FormNumber||M17965^HospOrdNumber||||||||1477542173^BROOKS^STEWART^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804\r
+OBR|1|673678765^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410011420|||||||||||||||20241015050654|||F\r
+OBR|2|673678765^FormNumber||57128-1^Newborn Screening Report summary panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241015050654\r
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241015050654\r
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241015050654\r
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241015050654\r
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241015050654\r
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\R\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241015050654\r
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241015050654\r
+OBR|3|673678765^FormNumber||57717-1^Newborn screen card data panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241015050654\r
+OBX|2|NM|8339-4^Birthweight^LN|1|4020|grams||N|||F|||20241015050654\r
+OBX|3|TM|57715-5^Time of birth^LN|1|1416|||N|||F|||20241015050654\r
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241015050654\r
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241015050654\r
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241015050654\r
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241015050654\r
+OBX|8|CE|67704-7^Feeding types^LN|2|LA16915-3^Lactose formula^LN|||N|||F|||20241015050654\r
+OBX|9|TX|^^^99717-5^Accession Number^L|1|277-86-190/21-2024-32|||N|||F|||20241015050654\r
+OBX|10|TX|62324-9^Post-discharge provider name^LN|1|STEWART BROOKS|||N|||F|||20241015050654\r
+OBX|11|TX|62325-6^Post-discharge provider practice ID^LN|1|1477542173|||N|||F|||20241015050654\r
+OBX|12|TX|62327-2^Post-discharge provider practice address^LN|1|8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA|||N|||F|||20241015050654\r
+OBR|4|673678765^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410011420|||||||||||||||20241015050654|||F\r
+OBR|5|673678765^FormNumber||53261-4^Amino acid newborn screen panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|387|µmol/L||N|||F|||20241015050654\r
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|381|µmol/L|<1000|N|||F|||20241015050654\r
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|92.6|µmol/L||N|||F|||20241015050654\r
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.88595|{Ratio}|<4.3|N|||F|||20241015050654\r
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|86.8|µmol/L|<230|N|||F|||20241015050654\r
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.23|{Ratio}|<1.35|N|||F|||20241015050654\r
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|49.1|µmol/L|<175|N|||F|||20241015050654\r
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.09|{Ratio}|<2.6|N|||F|||20241015050654\r
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|45.1|µmol/L|<680|N|||F|||20241015050654\r
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.24|µmol/L|<6.1|N|||F|||20241015050654\r
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|16.8|µmol/L|6.3-100|N|||F|||20241015050654\r
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|20|µmol/L|5-49|N|||F|||20241015050654\r
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3.22|{Ratio}|<4.8|N|||F|||20241015050654\r
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|74|µmol/L|<800|N|||F|||20241015050654\r
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|3.76|{Ratio}||N|||F|||20241015050654\r
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|6|µmol/L|<63|N|||F|||20241015050654\r
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241015050654\r
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|118|µmol/L|<1500|N|||F|||20241015050654\r
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|6|673678765^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241015050654\r
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with SCADD, IBCDD|||A|||F|||20241015050654\r
+OBR|7|673678765^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|34.3|µmol/L|6.4-125|N|||F|||20241015050654\r
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|5.93|{Ratio}|<70|N|||F|||20241015050654\r
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|33.2|µmol/L|10-80|N|||F|||20241015050654\r
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|1.29565|{Ratio}|<7.6|N|||F|||20241015050654\r
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.136|µmol/L|<0.95|N|||F|||20241015050654\r
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.150|µmol/L|<0.45|N|||F|||20241015050654\r
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.65|{Ratio}||N|||F|||20241015050654\r
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.221|µmol/L|<0.65|N|||F|||20241015050654\r
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.230|µmol/L|<0.65|N|||F|||20241015050654\r
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.088|µmol/L|<0.45|N|||F|||20241015050654\r
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.232|µmol/L|<2|N|||F|||20241015050654\r
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.20|µmol/L||N|||F|||20241015050654\r
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.342|µmol/L|<1.2|N|||F|||20241015050654\r
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.206|µmol/L|<0.9|N|||F|||20241015050654\r
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.02|{Ratio}||N|||F|||20241015050654\r
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241015050654\r
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.029|µmol/L|<0.2|N|||F|||20241015050654\r
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|4.14|µmol/L|<12|N|||F|||20241015050654\r
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.341|µmol/L|<1.4|N|||F|||20241015050654\r
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.049|µmol/L|<0.1|N|||F|||20241015050654\r
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01184|{Ratio}|<0.07|N|||F|||20241015050654\r
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.07|µmol/L|<3.5|N|||F|||20241015050654\r
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.65|µmol/L|<7|N|||F|||20241015050654\r
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.23|µmol/L||N|||F|||20241015050654\r
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.022|µmol/L|<0.1|N|||F|||20241015050654\r
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.053|µmol/L|<0.1|N|||F|||20241015050654\r
+OBR|8|673678765^FormNumber||57085-3^Organic acid newborn screen panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.3|µmol/L|<7.9|N|||F|||20241015050654\r
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.07|{Ratio}|<0.42|N|||F|||20241015050654\r
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.298|µmol/L|<0.48|N|||F|||20241015050654\r
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|1.73|µmol/L|<1.7|H|||F|||20241015050654\r
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.139|µmol/L|<0.95|N|||F|||20241015050654\r
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.06043|{Ratio}|<0.38|N|||F|||20241015050654\r
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.011|µmol/L|<0.5|N|||F|||20241015050654\r
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.306|µmol/L|<1.15|N|||F|||20241015050654\r
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.238|µmol/L|<0.38|N|||F|||20241015050654\r
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.79866|{Ratio}|>0.1|N|||F|||20241015050654\r
+OBR|9|673678765^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|18.10|ng/mL|<69|N|||F|||20241015050654\r
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|10|673678765^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00010.8|nmol/L|<85|N|||F|||20241015050654\r
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|11|673678765^FormNumber||54090-6^Thyroid newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|29575-8^Thyrotropin^LN|1|4.00|mIU/L|<29|N|||F|||20241015050654\r
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|12|673678765^FormNumber||54079-9^Galactosemia newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|267.94|enzyme units|>50|N|||F|||20241015050654\r
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|13|673678765^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241015050654\r
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241015050654\r
+OBR|14|673678765^FormNumber||57087-9^Biotinidase newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|44.16|ERU|>10|N|||F|||20241015050654\r
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|15|673678765^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|84|copies/µL|>18|N|||F|||20241015050654\r
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|16|673678765^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|6.97|µmol/L/h|>=1.51|N|||F|||20241015050654\r
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|17|673678765^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|10.38|µmol/L/h|>=0.77|N|||F|||20241015050654\r
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|18|673678765^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241015050654\r
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241015050654\r
+OBR|19|673678765^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|27.61|µmol/L/h|>=2.75|N|||F|||20241015050654\r
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|20|673678765^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|21|673678765^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.04|µmol/L|<=3|N|||F|||20241015050654\r
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|391.37|µmol/L||N|||F|||20241015050654\r
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.66||<=6|N|||F|||20241015050654\r
+OBR|22|673678765^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241015050654\r
+OBR|23|673678765^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.246|µmol/L|<0.47|N|||F|||20241015050654\r

From 1d8877c1c0b2b68e30c85fd9d39ba28b2d595f5d Mon Sep 17 00:00:00 2001
From: James Herr <jherr@flexion.us>
Date: Tue, 17 Dec 2024 13:03:40 -0600
Subject: [PATCH 05/61] Aded Golden tests to gradle

Co-Authored-By: Samuel Aquino <saquino@flexion.us>
Co-Authored-By: Bella L. Quintero <96704946+pluckyswan@users.noreply.github.com>
---
 rs-e2e/build.gradle | 10 ++++++++++
 1 file changed, 10 insertions(+)

diff --git a/rs-e2e/build.gradle b/rs-e2e/build.gradle
index bff4eafe8..5f45c8e5d 100644
--- a/rs-e2e/build.gradle
+++ b/rs-e2e/build.gradle
@@ -42,3 +42,13 @@ task automatedTest(type: Test) {
         exceptionFormat 'full'
     }
 }
+
+task goldenCopyTest(type: Test) {
+    useJUnitPlatform()
+    include '**/GoldenCopyTest.*'
+
+    testLogging {
+        showStackTraces true
+        exceptionFormat 'full'
+    }
+}

From 9b816880e66094c484771d689ca5a1d6c190a445 Mon Sep 17 00:00:00 2001
From: James Herr <jherr@flexion.us>
Date: Tue, 17 Dec 2024 13:05:08 -0600
Subject: [PATCH 06/61] Adding Golden tests to Workflows

Co-Authored-By: Samuel Aquino <saquino@flexion.us>
Co-Authored-By: Bella L. Quintero <96704946+pluckyswan@users.noreply.github.com>
---
 .../workflows/automated-staging-test-run.yml  | 22 ++++++++-
 .../automated-staging-test-submit.yml         | 11 +++--
 ...Indeterminate - SCADD - IBCDD patterns.hl7 |  0
 ...oldenTest.groovy => GoldenCopyTest.groovy} | 48 ++++++++++++-------
 4 files changed, 58 insertions(+), 23 deletions(-)
 rename examples/Test/Automated/{ => Golden}/Acylcarnitine - Indeterminate - SCADD - IBCDD patterns.hl7 (100%)
 rename rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/{GoldenTest.groovy => GoldenCopyTest.groovy} (66%)

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index ccfafc56e..b54b33f51 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -4,6 +4,14 @@ on:
   schedule:
     - cron: "0 7 * * 2-6"  # Tuesday to Saturday at 2am EST (7am UTC) - two hours after `automated-staging-test-submit` runs
   workflow_dispatch:
+    inputs:
+      name:
+        type: choice
+        description: Type of Staging Test
+        default: Automated Staging Test
+        options:
+          - Automated Staging Test
+          - Golden Copy Staging Test
 
 jobs:
   test_files:
@@ -16,7 +24,17 @@ jobs:
       - name: Run automated tests
         env:
           AZURE_STORAGE_CONNECTION_STRING: ${{ secrets.AUTOMATED_TEST_AZURE_STORAGE_CONNECTION_STRING }}
-        run: ./gradlew rs-e2e:clean rs-e2e:automatedTest
+        run: |
+          if [ ${{ github.event.inputs.name }} = "Automated Staging Test" ]; then
+            test_type=automatedTest
+            title=Automated
+          else
+            test_type=goldenCopyTest
+            title=Golden Copy
+          fi
+          ./gradlew rs-e2e:clean rs-e2e:$(test_type)
+          echo "test_type=$test_type" >> $GITHUB_OUTPUT
+          done
 
       - name: Send slack notification on test failure
         if: failure()
@@ -25,4 +43,4 @@ jobs:
           webhook: ${{ secrets.SLACK_WEBHOOK_URL }}
           webhook-type: incoming-webhook
           payload: |
-            text: "Automated Staging RS Integration Test Failed!: https://github.com/CDCgov/trusted-intermediary/actions/runs/${{ github.run_id }}"
+            text: "${{ steps.getFunctionList.outputs.title }} Staging RS Integration Test Failed!: https://github.com/CDCgov/trusted-intermediary/actions/runs/${{ github.run_id }}"
diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
index 3ef9b176a..3c7411d21 100644
--- a/.github/workflows/automated-staging-test-submit.yml
+++ b/.github/workflows/automated-staging-test-submit.yml
@@ -7,10 +7,11 @@ on:
     inputs:
       name:
         type: choice
-        description: Type of staging test
+        description: Type of Staging Test
+        default: Automated Staging Test
         options:
-          - automated-staging-test
-          - golden-copy-staging-test
+          - Automated Staging Test
+          - Golden Copy Staging Test
 
 jobs:
   send_files:
@@ -52,6 +53,10 @@ jobs:
                     "$host/api/token" | jq -r ".access_token")
 
             file_path=Automated/*.hl7
+            if [ ${{ github.event.inputs.name }} = "Golden Copy Staging Test" ]; then
+               file_path=Automated/Golden/*.hl7
+            fi
+
             for file in $(pwd)/examples/Test/$(file_path); do
                 echo "Sending $file"
                 curl \
diff --git a/examples/Test/Automated/Acylcarnitine - Indeterminate - SCADD - IBCDD patterns.hl7 b/examples/Test/Automated/Golden/Acylcarnitine - Indeterminate - SCADD - IBCDD patterns.hl7
similarity index 100%
rename from examples/Test/Automated/Acylcarnitine - Indeterminate - SCADD - IBCDD patterns.hl7
rename to examples/Test/Automated/Golden/Acylcarnitine - Indeterminate - SCADD - IBCDD patterns.hl7
diff --git a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenTest.groovy b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
similarity index 66%
rename from rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenTest.groovy
rename to rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
index ae711053e..e447adcc1 100644
--- a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenTest.groovy
+++ b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
@@ -14,26 +14,20 @@ import spock.lang.Specification
 import java.nio.file.Files
 import java.nio.file.Path
 
-class GoldenTest extends Specification {
+class GoldenCopyTest extends Specification {
 
-    def beforeFileJsonFileString = Files.readString(Path.of("../examples/Test/Automated/golden_actual.hl7"))
-    def afterFileJsonFileString = Files.readString(Path.of("../examples/Test/Automated/golden_expected.hl7"))
-
-
-    List<HL7FileStream> azureFiles // output
-    List<HL7FileStream> localFiles // input
+    List<HL7FileStream> azureFiles
+    List<HL7FileStream> localFiles
     AssertionRuleEngine engine
     HapiHL7FileMatcher fileMatcher
     Logger mockLogger = Mock(Logger)
     List<String> loggedErrorsAndWarnings = []
 
     def setup() {
-        engine = AssertionRuleEngine.getInstance()
         fileMatcher =  HapiHL7FileMatcher.getInstance()
 
         TestApplicationContext.reset()
         TestApplicationContext.init()
-        TestApplicationContext.register(AssertionRuleEngine, engine)
         TestApplicationContext.register(RuleLoader, RuleLoader.getInstance())
         TestApplicationContext.register(Logger, mockLogger)
         TestApplicationContext.register(Formatter, Jackson.getInstance())
@@ -49,19 +43,17 @@ class GoldenTest extends Specification {
             loggedErrorsAndWarnings << msg
         }
 
-        //      FileFetcher azureFileFetcher = AzureBlobFileFetcher.getInstance()
-        //      azureFiles = azureFileFetcher.fetchFiles()
+        FileFetcher azureFileFetcher = AzureBlobFileFetcher.getInstance()
+        azureFiles = azureFileFetcher.fetchFiles()
 
-        //      FileFetcher localFileFetcher = LocalFileFetcher.getInstance()
-        //      localFiles = localFileFetcher.fetchFiles()
-
-        engine.ensureRulesLoaded() // we don't want this because it uses the hardcoded assertion_definition.json OR we want to modify that method
+        FileFetcher localFileFetcher = LocalFileFetcher.getInstance()
+        localFiles = localFileFetcher.fetchFiles()
     }
 
     def cleanup() {
-        //  for (HL7FileStream fileStream : localFiles + azureFiles) {
-        //     fileStream.inputStream().close()
-        //}
+        for (HL7FileStream fileStream : localFiles + azureFiles) {
+            fileStream.inputStream().close()
+        }
     }
 
     def "Compare files"() {
@@ -78,6 +70,26 @@ class GoldenTest extends Specification {
         // def matchedFiles = fileMatcher.matchFiles(azureFiles, localFiles)
 
         given:
+        def matchedFiles = fileMatcher.matchFiles(azureFiles, localFiles)
+
+        when:
+        for (messagePair in matchedFiles) {
+            def inputMessage = messagePair.getKey()
+            def outputMessage = messagePair.getValue()
+            //            def evaluatedRules = engine.runRules(outputMessage, inputMessage)
+            //            rulesToEvaluate.removeAll(evaluatedRules)
+        }
+
+        then:
+        rulesToEvaluate.collect { it.name }.isEmpty() //Check whether all the rules in the assertions file have been run
+        if (!loggedErrorsAndWarnings.isEmpty()) {
+            throw new AssertionError("Unexpected errors and/or warnings were logged:\n- ${loggedErrorsAndWarnings.join('\n- ')}")
+        }
+
+
+        given:
+        def beforeFileJsonFileString = Files.readString(Path.of("../examples/Test/Automated/golden_actual.hl7"))
+        def afterFileJsonFileString = Files.readString(Path.of("../examples/Test/Automated/golden_expected.hl7"))
 
 
         when:

From d4867f7a2390b769792b25cff27faf3923c24937 Mon Sep 17 00:00:00 2001
From: James Herr <jherr@flexion.us>
Date: Tue, 17 Dec 2024 14:33:19 -0600
Subject: [PATCH 07/61] Added fetch parameter

Co-Authored-By: Samuel Aquino <saquino@flexion.us>
Co-Authored-By: Bella L. Quintero <96704946+pluckyswan@users.noreply.github.com>
---
 .../rse2e/AzureBlobFileFetcher.java           |  2 +-
 .../rse2e/FileFetcher.java                    |  2 +-
 .../rse2e/LocalFileFetcher.java               | 11 ++++--
 .../rse2e/AutomatedTest.groovy                |  4 +-
 .../rse2e/GoldenCopyTest.groovy               | 39 +++++++------------
 5 files changed, 25 insertions(+), 33 deletions(-)

diff --git a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobFileFetcher.java b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobFileFetcher.java
index 4d9a3a478..8d41d35a4 100644
--- a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobFileFetcher.java
+++ b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobFileFetcher.java
@@ -48,7 +48,7 @@ public static FileFetcher getInstance() {
     }
 
     @Override
-    public List<HL7FileStream> fetchFiles() {
+    public List<HL7FileStream> fetchFiles(boolean isAutomated) {
         List<HL7FileStream> relevantFiles = new ArrayList<>();
 
         LocalDate today = LocalDate.now(TIME_ZONE);
diff --git a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/FileFetcher.java b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/FileFetcher.java
index dcd998148..ed4f02943 100644
--- a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/FileFetcher.java
+++ b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/FileFetcher.java
@@ -7,5 +7,5 @@
  * of this interface should provide a way to retrieve a list of HL7FileStream objects.
  */
 public interface FileFetcher {
-    List<HL7FileStream> fetchFiles();
+    List<HL7FileStream> fetchFiles(boolean isAutomatedTest);
 }
diff --git a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/LocalFileFetcher.java b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/LocalFileFetcher.java
index 3172c5e36..0a2232ed0 100644
--- a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/LocalFileFetcher.java
+++ b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/LocalFileFetcher.java
@@ -15,7 +15,7 @@
  */
 public class LocalFileFetcher implements FileFetcher {
 
-    private static final String FILES_PATH = "../examples/Test/Automated/";
+    private static String files_path = "../examples/Test/Automated/";
     private static final String EXTENSION = "hl7";
 
     private static final FileFetcher INSTANCE = new LocalFileFetcher();
@@ -27,8 +27,13 @@ public static FileFetcher getInstance() {
     }
 
     @Override
-    public List<HL7FileStream> fetchFiles() {
-        try (Stream<Path> stream = Files.walk(Paths.get(FILES_PATH))) {
+    public List<HL7FileStream> fetchFiles(boolean isAutomatedTest) {
+        if (!isAutomatedTest) {
+            // there might be problems with this as file_path is static; I'd need to do some more
+            // digging to be sure
+            files_path = "../examples/Test/Automated/Golden/";
+        }
+        try (Stream<Path> stream = Files.walk(Paths.get(files_path))) {
             return stream.filter(Files::isRegularFile)
                     .filter(path -> path.toString().endsWith(EXTENSION))
                     .map(
diff --git a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/AutomatedTest.groovy b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/AutomatedTest.groovy
index c1a4d45ab..c51777da6 100644
--- a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/AutomatedTest.groovy
+++ b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/AutomatedTest.groovy
@@ -43,10 +43,10 @@ class AutomatedTest extends Specification  {
         }
 
         FileFetcher azureFileFetcher = AzureBlobFileFetcher.getInstance()
-        azureFiles = azureFileFetcher.fetchFiles()
+        azureFiles = azureFileFetcher.fetchFiles(true)
 
         FileFetcher localFileFetcher = LocalFileFetcher.getInstance()
-        localFiles = localFileFetcher.fetchFiles()
+        localFiles = localFileFetcher.fetchFiles(true)
 
         engine.ensureRulesLoaded()
     }
diff --git a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
index e447adcc1..e157a4c98 100644
--- a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
+++ b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
@@ -11,17 +11,14 @@ import gov.hhs.cdc.trustedintermediary.wrappers.Logger
 import gov.hhs.cdc.trustedintermediary.wrappers.formatter.Formatter
 import spock.lang.Specification
 
-import java.nio.file.Files
-import java.nio.file.Path
-
 class GoldenCopyTest extends Specification {
 
     List<HL7FileStream> azureFiles
     List<HL7FileStream> localFiles
-    AssertionRuleEngine engine
     HapiHL7FileMatcher fileMatcher
     Logger mockLogger = Mock(Logger)
     List<String> loggedErrorsAndWarnings = []
+    List<HapiHL7Message> failedFiles = []
 
     def setup() {
         fileMatcher =  HapiHL7FileMatcher.getInstance()
@@ -44,10 +41,10 @@ class GoldenCopyTest extends Specification {
         }
 
         FileFetcher azureFileFetcher = AzureBlobFileFetcher.getInstance()
-        azureFiles = azureFileFetcher.fetchFiles()
+        azureFiles = azureFileFetcher.fetchFiles(false)
 
         FileFetcher localFileFetcher = LocalFileFetcher.getInstance()
-        localFiles = localFileFetcher.fetchFiles()
+        localFiles = localFileFetcher.fetchFiles(false)
     }
 
     def cleanup() {
@@ -66,36 +63,26 @@ class GoldenCopyTest extends Specification {
         // If we do use the rules engine, see if its possible to compare the whole file as a rule rather than individual segments
         // Update Automated Test README
 
-        // compare with known good file
-        // def matchedFiles = fileMatcher.matchFiles(azureFiles, localFiles)
+        //         Add a sub folder to /Golden for inputFile - this is so we can get the actual output, we won't use this
+        //        Add a sub folder to /Golden for expectedFileOutput - this is 'hard-coded' and shouldnt change
+        //         make sure to update folder paths in workflow
 
         given:
         def matchedFiles = fileMatcher.matchFiles(azureFiles, localFiles)
 
         when:
-        for (messagePair in matchedFiles) {
-            def inputMessage = messagePair.getKey()
-            def outputMessage = messagePair.getValue()
-            //            def evaluatedRules = engine.runRules(outputMessage, inputMessage)
-            //            rulesToEvaluate.removeAll(evaluatedRules)
+        for (filePair in matchedFiles) {
+            def actualFile = filePair.getKey()
+            def expectedFile = filePair.getValue()
+            if (!actualFile.equals(expectedFile)) {
+                failedFiles.add(expectedFile)
+            }
         }
 
         then:
-        rulesToEvaluate.collect { it.name }.isEmpty() //Check whether all the rules in the assertions file have been run
+        assertTrue(failedFiles.isEmpty())
         if (!loggedErrorsAndWarnings.isEmpty()) {
             throw new AssertionError("Unexpected errors and/or warnings were logged:\n- ${loggedErrorsAndWarnings.join('\n- ')}")
         }
-
-
-        given:
-        def beforeFileJsonFileString = Files.readString(Path.of("../examples/Test/Automated/golden_actual.hl7"))
-        def afterFileJsonFileString = Files.readString(Path.of("../examples/Test/Automated/golden_expected.hl7"))
-
-
-        when:
-        def filesAreIdentical = beforeFileJsonFileString == afterFileJsonFileString
-
-        then:
-        assert filesAreIdentical, "test"
     }
 }

From 87dbc14f34921c3a361b6bf7304b01334b050f23 Mon Sep 17 00:00:00 2001
From: James Herr <jherr@flexion.us>
Date: Tue, 17 Dec 2024 14:39:05 -0600
Subject: [PATCH 08/61] Removed comments

Co-Authored-By: Samuel Aquino <saquino@flexion.us>
Co-Authored-By: Bella L. Quintero <96704946+pluckyswan@users.noreply.github.com>
---
 .../gov/hhs/cdc/trustedintermediary/rse2e/LocalFileFetcher.java | 2 --
 1 file changed, 2 deletions(-)

diff --git a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/LocalFileFetcher.java b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/LocalFileFetcher.java
index 0a2232ed0..d7a3fb8ec 100644
--- a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/LocalFileFetcher.java
+++ b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/LocalFileFetcher.java
@@ -29,8 +29,6 @@ public static FileFetcher getInstance() {
     @Override
     public List<HL7FileStream> fetchFiles(boolean isAutomatedTest) {
         if (!isAutomatedTest) {
-            // there might be problems with this as file_path is static; I'd need to do some more
-            // digging to be sure
             files_path = "../examples/Test/Automated/Golden/";
         }
         try (Stream<Path> stream = Files.walk(Paths.get(files_path))) {

From 5bef9f09b81666eb902ec798ba293995fa289637 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Wed, 18 Dec 2024 15:08:48 -0700
Subject: [PATCH 09/61] add input files and delete unused input files

Co-authored-by: saquino0827 <saquino@flexion.us>
---
 ...001_ORU_R01_golden_copy_input_acylc_1.hl7} |   2 +-
 .../002_ORU_R01_golden_copy_input_acylc_2.hl7 | 142 ++++++++++++++++++
 ...3_ORU_R01_golden_copy_input_aa_unusual.hl7 | 142 ++++++++++++++++++
 ...004_ORU_R01_golden_copy_input_in_range.hl7 | 142 ++++++++++++++++++
 ...ORU_R01_golden_copy_input_out_of_range.hl7 | 142 ++++++++++++++++++
 examples/Test/Automated/golden_actual.hl7     |   1 -
 examples/Test/Automated/golden_expected.hl7   |   1 -
 7 files changed, 569 insertions(+), 3 deletions(-)
 rename examples/Test/Automated/{Golden/Acylcarnitine - Indeterminate - SCADD - IBCDD patterns.hl7 => GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7} (98%)
 create mode 100644 examples/Test/Automated/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
 delete mode 100644 examples/Test/Automated/golden_actual.hl7
 delete mode 100644 examples/Test/Automated/golden_expected.hl7

diff --git a/examples/Test/Automated/Golden/Acylcarnitine - Indeterminate - SCADD - IBCDD patterns.hl7 b/examples/Test/Automated/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
similarity index 98%
rename from examples/Test/Automated/Golden/Acylcarnitine - Indeterminate - SCADD - IBCDD patterns.hl7
rename to examples/Test/Automated/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
index 048d8fe6f..833ef6d16 100644
--- a/examples/Test/Automated/Golden/Acylcarnitine - Indeterminate - SCADD - IBCDD patterns.hl7	
+++ b/examples/Test/Automated/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
@@ -1,4 +1,4 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^1477542173^L,M,N|20241015050654||ORU^R01^ORU_R01|244028180|P|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^1477542173^L,M,N|20241015050654||ORU^R01^ORU_R01|001|P|2.5.1\r
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
 ORC|RE|673678765^FormNumber||M17965^HospOrdNumber||||||||1477542173^BROOKS^STEWART^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804\r
diff --git a/examples/Test/Automated/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7 b/examples/Test/Automated/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
new file mode 100644
index 000000000..2594c49b0
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
@@ -0,0 +1,142 @@
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^1194257170^L,M,N|20241018050234||ORU^R01^ORU_R01|002|P|2.5.1\r
+PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
+NK1|1|*****PII REMOVED******
+ORC|RE|12345667867^FormNumber||S30500^HospOrdNumber||||||||1194257170^MAHMOOD^SARAH^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804\r
+OBR|1|12345667867^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410061300|||||||||||||||20241018050234|||F\r
+OBR|2|12345667867^FormNumber||57128-1^Newborn Screening Report summary panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241018050234\r
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241018050234\r
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241018050234\r
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050234\r
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050234\r
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\R\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241018050234\r
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241018050234\r
+OBR|3|12345667867^FormNumber||57717-1^Newborn screen card data panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241018050234\r
+OBX|2|NM|8339-4^Birthweight^LN|1|3135|grams||N|||F|||20241018050234\r
+OBX|3|TM|57715-5^Time of birth^LN|1|1235|||N|||F|||20241018050234\r
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241018050234\r
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241018050234\r
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241018050234\r
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241018050234\r
+OBX|8|TX|^^^99717-5^Accession Number^L|1|282-18-014/21-2024-32|||N|||F|||20241018050234\r
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|SARAH MAHMOOD|||N|||F|||20241018050234\r
+OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1194257170|||N|||F|||20241018050234\r
+OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA|||N|||F|||20241018050234\r
+OBR|4|12345667867^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410061300|||||||||||||||20241018050234|||F\r
+OBR|5|12345667867^FormNumber||53261-4^Amino acid newborn screen panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|611|µmol/L||N|||F|||20241018050234\r
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|585|µmol/L|<1000|N|||F|||20241018050234\r
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|90.9|µmol/L||N|||F|||20241018050234\r
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.74808|{Ratio}|<4.3|N|||F|||20241018050234\r
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|86.9|µmol/L|<230|N|||F|||20241018050234\r
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.15|{Ratio}|<1.35|N|||F|||20241018050234\r
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|52.0|µmol/L|<175|N|||F|||20241018050234\r
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241018050234\r
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|69.0|µmol/L|<680|N|||F|||20241018050234\r
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.23|µmol/L|<6.1|N|||F|||20241018050234\r
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|22.5|µmol/L|6.3-100|N|||F|||20241018050234\r
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|14|µmol/L|5-49|N|||F|||20241018050234\r
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|2.28|{Ratio}|<4.8|N|||F|||20241018050234\r
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|68|µmol/L|<800|N|||F|||20241018050234\r
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|4.93|{Ratio}||N|||F|||20241018050234\r
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|6|µmol/L|<63|N|||F|||20241018050234\r
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241018050234\r
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|192|µmol/L|<1500|N|||F|||20241018050234\r
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|6|12345667867^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241018050234\r
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with SCADD, IBCDD|||A|||F|||20241018050234\r
+OBR|7|12345667867^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|26.6|µmol/L|6.4-125|N|||F|||20241018050234\r
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|3.27|{Ratio}|<70|N|||F|||20241018050234\r
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|29.2|µmol/L|10-80|N|||F|||20241018050234\r
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.13913|{Ratio}|<7.6|N|||F|||20241018050234\r
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.088|µmol/L|<0.95|N|||F|||20241018050234\r
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.084|µmol/L|<0.45|N|||F|||20241018050234\r
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.73|{Ratio}||N|||F|||20241018050234\r
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.172|µmol/L|<0.65|N|||F|||20241018050234\r
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.115|µmol/L|<0.65|N|||F|||20241018050234\r
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.050|µmol/L|<0.45|N|||F|||20241018050234\r
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.127|µmol/L|<2|N|||F|||20241018050234\r
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.12|µmol/L||N|||F|||20241018050234\r
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.333|µmol/L|<1.2|N|||F|||20241018050234\r
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.132|µmol/L|<0.9|N|||F|||20241018050234\r
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.13|{Ratio}||N|||F|||20241018050234\r
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241018050234\r
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.026|µmol/L|<0.2|N|||F|||20241018050234\r
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|6.19|µmol/L|<12|N|||F|||20241018050234\r
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.445|µmol/L|<1.4|N|||F|||20241018050234\r
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.045|µmol/L|<0.1|N|||F|||20241018050234\r
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00727|{Ratio}|<0.07|N|||F|||20241018050234\r
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.53|µmol/L|<3.5|N|||F|||20241018050234\r
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.96|µmol/L|<7|N|||F|||20241018050234\r
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.21|µmol/L||N|||F|||20241018050234\r
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.017|µmol/L|<0.1|N|||F|||20241018050234\r
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.036|µmol/L|<0.1|N|||F|||20241018050234\r
+OBR|8|12345667867^FormNumber||57085-3^Organic acid newborn screen panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.5|µmol/L|<7.9|N|||F|||20241018050234\r
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.09|{Ratio}|<0.42|N|||F|||20241018050234\r
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.246|µmol/L|<0.48|N|||F|||20241018050234\r
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|1.72|µmol/L|<1.7|H|||F|||20241018050234\r
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.115|µmol/L|<0.95|N|||F|||20241018050234\r
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.04600|{Ratio}|<0.38|N|||F|||20241018050234\r
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.008|µmol/L|<0.5|N|||F|||20241018050234\r
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.232|µmol/L|<1.15|N|||F|||20241018050234\r
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.180|µmol/L|<0.38|N|||F|||20241018050234\r
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.73171|{Ratio}|>0.1|N|||F|||20241018050234\r
+OBR|9|12345667867^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|21.20|ng/mL|<69|N|||F|||20241018050234\r
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|10|12345667867^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00015.6|nmol/L|<85|N|||F|||20241018050234\r
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|11|12345667867^FormNumber||54090-6^Thyroid newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|29575-8^Thyrotropin^LN|1|9.50|mIU/L|<29|N|||F|||20241018050234\r
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|12|12345667867^FormNumber||54079-9^Galactosemia newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|262.95|enzyme units|>50|N|||F|||20241018050234\r
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|13|12345667867^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241018050234\r
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241018050234\r
+OBR|14|12345667867^FormNumber||57087-9^Biotinidase newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|49.77|ERU|>10|N|||F|||20241018050234\r
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|15|12345667867^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|197|copies/µL|>18|N|||F|||20241018050234\r
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|16|12345667867^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.29|µmol/L/h|>=1.47|N|||F|||20241018050234\r
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|17|12345667867^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|13.01|µmol/L/h|>=0.82|N|||F|||20241018050234\r
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|18|12345667867^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241018050234\r
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241018050234\r
+OBR|19|12345667867^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|27.84|µmol/L/h|>=2.79|N|||F|||20241018050234\r
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|20|12345667867^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|21|12345667867^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|0.97|µmol/L|<=3|N|||F|||20241018050234\r
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|496.63|µmol/L||N|||F|||20241018050234\r
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.95||<=6|N|||F|||20241018050234\r
+OBR|22|12345667867^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241018050234\r
+OBR|23|12345667867^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.349|µmol/L|<0.47|N|||F|||20241018050234\r
diff --git a/examples/Test/Automated/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7 b/examples/Test/Automated/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
new file mode 100644
index 000000000..01ec6acd7
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
@@ -0,0 +1,142 @@
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^1043390461^L,M,N|20241023050044||ORU^R01^ORU_R01|003|P|2.5.1\r
+PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
+NK1|1|*****PII REMOVED******
+ORC|RE|45789876^FormNumber||56352742^HospOrdNumber||||||||1043390461^PROFIT^DR JOCHEN^^^^^^^NPI|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601\r
+OBR|1|45789876^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBR|2|45789876^FormNumber||57128-1^Newborn Screening Report summary panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241023050044\r
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241023050044\r
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241023050044\r
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241023050044\r
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241023050044\r
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - ALLIED LABORATORY \\R\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Amino Acid Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241023050044\r
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241023050044\r
+OBR|3|45789876^FormNumber||57717-1^Newborn screen card data panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241023050044\r
+OBX|2|NM|8339-4^Birthweight^LN|1|2230|grams||N|||F|||20241023050044\r
+OBX|3|TM|57715-5^Time of birth^LN|1|1358|||N|||F|||20241023050044\r
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241023050044\r
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|26|hour(s)||N|||F|||20241023050044\r
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241023050044\r
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241023050044\r
+OBX|8|TX|^^^99717-5^Accession Number^L|1|282-38-261/21-2024-12|||N|||F|||20241023050044\r
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DR JOCHEN PROFIT|||N|||F|||20241023050044\r
+OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1043390461|||N|||F|||20241023050044\r
+OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA|||N|||F|||20241023050044\r
+OBR|4|45789876^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBR|5|45789876^FormNumber||53261-4^Amino acid newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|368|µmol/L||N|||F|||20241023050044\r
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|310|µmol/L|<1000|N|||F|||20241023050044\r
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|34.6|µmol/L||N|||F|||20241023050044\r
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.06462|{Ratio}|<4.3|N|||F|||20241023050044\r
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|50.7|µmol/L|<230|N|||F|||20241023050044\r
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.16|{Ratio}|<1.35|N|||F|||20241023050044\r
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|32.5|µmol/L|<175|N|||F|||20241023050044\r
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.13|{Ratio}|<2.6|N|||F|||20241023050044\r
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|28.9|µmol/L|<680|N|||F|||20241023050044\r
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.25|µmol/L|<6.1|N|||F|||20241023050044\r
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|8.6|µmol/L|6.3-100|N|||F|||20241023050044\r
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|5|µmol/L|5-49|N|||F|||20241023050044\r
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.67|{Ratio}|<4.8|N|||F|||20241023050044\r
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|32|µmol/L|<800|N|||F|||20241023050044\r
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|6.41|{Ratio}||N|||F|||20241023050044\r
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|3|µmol/L|<63|N|||F|||20241023050044\r
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241023050044\r
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|55|µmol/L|<1500|N|||F|||20241023050044\r
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|This complex pattern of elevations require further evaluation|||A|||F|||20241023050044\r
+OBR|6|45789876^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|7|45789876^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|34.9|µmol/L|6.4-125|N|||F|||20241023050044\r
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|7.84|{Ratio}|<70|N|||F|||20241023050044\r
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|28.1|µmol/L|10-80|N|||F|||20241023050044\r
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|3.53125|{Ratio}|<7.6|N|||F|||20241023050044\r
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.034|µmol/L|<0.95|N|||F|||20241023050044\r
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.038|µmol/L|<0.45|N|||F|||20241023050044\r
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.19|{Ratio}||N|||F|||20241023050044\r
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.155|µmol/L|<0.65|N|||F|||20241023050044\r
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.032|µmol/L|<0.65|N|||F|||20241023050044\r
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.030|µmol/L|<0.45|N|||F|||20241023050044\r
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.070|µmol/L|<2|N|||F|||20241023050044\r
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.05|µmol/L||N|||F|||20241023050044\r
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.270|µmol/L|<1.2|N|||F|||20241023050044\r
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.084|µmol/L|<0.9|N|||F|||20241023050044\r
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.75|{Ratio}||N|||F|||20241023050044\r
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241023050044\r
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.009|µmol/L|<0.2|N|||F|||20241023050044\r
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|2.87|µmol/L|<12|N|||F|||20241023050044\r
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.236|µmol/L|<1.4|N|||F|||20241023050044\r
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.022|µmol/L|<0.1|N|||F|||20241023050044\r
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00767|{Ratio}|<0.07|N|||F|||20241023050044\r
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|0.987|µmol/L|<3.5|N|||F|||20241023050044\r
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.59|µmol/L|<7|N|||F|||20241023050044\r
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.20|µmol/L||N|||F|||20241023050044\r
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.014|µmol/L|<0.1|N|||F|||20241023050044\r
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.034|µmol/L|<0.1|N|||F|||20241023050044\r
+OBR|8|45789876^FormNumber||57085-3^Organic acid newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|1.9|µmol/L|<7.9|N|||F|||20241023050044\r
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.07|{Ratio}|<0.42|N|||F|||20241023050044\r
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.113|µmol/L|<0.48|N|||F|||20241023050044\r
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.161|µmol/L|<1.7|N|||F|||20241023050044\r
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.111|µmol/L|<0.95|N|||F|||20241023050044\r
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05842|{Ratio}|<0.38|N|||F|||20241023050044\r
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.006|µmol/L|<0.5|N|||F|||20241023050044\r
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.140|µmol/L|<1.15|N|||F|||20241023050044\r
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.091|µmol/L|<0.38|N|||F|||20241023050044\r
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.80531|{Ratio}|>0.1|N|||F|||20241023050044\r
+OBR|9|45789876^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|27.50|ng/mL|<69|N|||F|||20241023050044\r
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|10|45789876^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00029.9|nmol/L|<190|N|||F|||20241023050044\r
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|11|45789876^FormNumber||54090-6^Thyroid newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|29575-8^Thyrotropin^LN|1|6.90|mIU/L|<29|N|||F|||20241023050044\r
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|12|45789876^FormNumber||54079-9^Galactosemia newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|226.51|enzyme units|>50|N|||F|||20241023050044\r
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|13|45789876^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241023050044\r
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241023050044\r
+OBR|14|45789876^FormNumber||57087-9^Biotinidase newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|28.87|ERU|>10|N|||F|||20241023050044\r
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|15|45789876^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|198|copies/µL|>18|N|||F|||20241023050044\r
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|16|45789876^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|7.91|µmol/L/h|>=1.62|N|||F|||20241023050044\r
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|17|45789876^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|7.78|µmol/L/h|>=0.79|N|||F|||20241023050044\r
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|18|45789876^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241023050044\r
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241023050044\r
+OBR|19|45789876^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.94|µmol/L/h|>=2.95|N|||F|||20241023050044\r
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|20|45789876^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|21|45789876^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.00|µmol/L|<=3|N|||F|||20241023050044\r
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|707.37|µmol/L||N|||F|||20241023050044\r
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.41||<=6|N|||F|||20241023050044\r
+OBR|22|45789876^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241023050044\r
+OBR|23|45789876^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.246|µmol/L|<0.47|N|||F|||20241023050044\r
diff --git a/examples/Test/Automated/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7 b/examples/Test/Automated/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
new file mode 100644
index 000000000..47e9e7c81
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
@@ -0,0 +1,142 @@
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^1447323951^L,M,N|20241030050154||ORU^R01^ORU_R01|004|P|2.5.1\r
+PID|1||335441864^^^104638912487&NPI^MR||*****PII REMOVED******
+NK1|1|*****PII REMOVED******
+ORC|RE|356672001^FormNumber||629813494^HospOrdNumber||||||||1093050858^SILVA^RICHARD^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|200 W ARBOR DR^^SAN DIEGO^CA^92103-1911\r
+OBR|1|356672001^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBR|2|356672001^FormNumber||57128-1^Newborn Screening Report summary panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241030050154\r
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241030050154\r
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12428-1^All screening is in range for the conditions tested^LN|||N|||F|||20241030050154\r
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241030050154\r
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241030050154\r
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \\R\\2130 E Illinois Avenue, FRESNO, CA 93701\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (858) 966-8708. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241030050154\r
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241030050154\r
+OBR|3|356672001^FormNumber||57717-1^Newborn screen card data panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241030050154\r
+OBX|2|NM|8339-4^Birthweight^LN|1|3464|grams||N|||F|||20241030050154\r
+OBX|3|TM|57715-5^Time of birth^LN|1|0444|||N|||F|||20241030050154\r
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241030050154\r
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|19|hour(s)||N|||F|||20241030050154\r
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241030050154\r
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241030050154\r
+OBX|8|TX|^^^99717-5^Accession Number^L|1|292-04-123/21-2024-32|||N|||F|||20241030050154\r
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DIANE BEDROSIAN|||N|||F|||20241030050154\r
+OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1447323951|||N|||F|||20241030050154\r
+OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|200 W ARBOR DR SAN DIEGO CA 92103-1911 USA|||N|||F|||20241030050154\r
+OBR|4|356672001^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBR|5|356672001^FormNumber||53261-4^Amino acid newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|536|µmol/L||N|||F|||20241030050154\r
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|559|µmol/L|<1000|N|||F|||20241030050154\r
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|123|µmol/L||N|||F|||20241030050154\r
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|2.14286|{Ratio}|<4.3|N|||F|||20241030050154\r
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|113|µmol/L|<230|N|||F|||20241030050154\r
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.20|{Ratio}|<1.35|N|||F|||20241030050154\r
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|57.4|µmol/L|<175|N|||F|||20241030050154\r
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.05|{Ratio}|<2.6|N|||F|||20241030050154\r
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|54.8|µmol/L|<680|N|||F|||20241030050154\r
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.20|µmol/L|<6.1|N|||F|||20241030050154\r
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|22.8|µmol/L|6.3-100|N|||F|||20241030050154\r
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|10|µmol/L|5-49|N|||F|||20241030050154\r
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.52|{Ratio}|<4.8|N|||F|||20241030050154\r
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|84|µmol/L|<800|N|||F|||20241030050154\r
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|8.40|{Ratio}||N|||F|||20241030050154\r
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|7|µmol/L|<63|N|||F|||20241030050154\r
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241030050154\r
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|154|µmol/L|<1500|N|||F|||20241030050154\r
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|6|356672001^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|7|356672001^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|24.4|µmol/L|6.4-125|N|||F|||20241030050154\r
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|4.32|{Ratio}|<70|N|||F|||20241030050154\r
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|27.3|µmol/L|10-80|N|||F|||20241030050154\r
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.73000|{Ratio}|<7.6|N|||F|||20241030050154\r
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.067|µmol/L|<0.95|N|||F|||20241030050154\r
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.076|µmol/L|<0.45|N|||F|||20241030050154\r
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.76|{Ratio}||N|||F|||20241030050154\r
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.103|µmol/L|<0.65|N|||F|||20241030050154\r
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.100|µmol/L|<0.65|N|||F|||20241030050154\r
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.035|µmol/L|<0.45|N|||F|||20241030050154\r
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.132|µmol/L|<2|N|||F|||20241030050154\r
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.17|µmol/L||N|||F|||20241030050154\r
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.264|µmol/L|<1.2|N|||F|||20241030050154\r
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.189|µmol/L|<0.9|N|||F|||20241030050154\r
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.13|{Ratio}||N|||F|||20241030050154\r
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241030050154\r
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.021|µmol/L|<0.2|N|||F|||20241030050154\r
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|3.88|µmol/L|<12|N|||F|||20241030050154\r
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.371|µmol/L|<1.4|N|||F|||20241030050154\r
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.030|µmol/L|<0.1|N|||F|||20241030050154\r
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00773|{Ratio}|<0.07|N|||F|||20241030050154\r
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.11|µmol/L|<3.5|N|||F|||20241030050154\r
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.76|µmol/L|<7|N|||F|||20241030050154\r
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.15|µmol/L||N|||F|||20241030050154\r
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.015|µmol/L|<0.1|N|||F|||20241030050154\r
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.032|µmol/L|<0.1|N|||F|||20241030050154\r
+OBR|8|356672001^FormNumber||57085-3^Organic acid newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.3|µmol/L|<7.9|N|||F|||20241030050154\r
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.09|{Ratio}|<0.42|N|||F|||20241030050154\r
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.273|µmol/L|<0.48|N|||F|||20241030050154\r
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.315|µmol/L|<1.7|N|||F|||20241030050154\r
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.117|µmol/L|<0.95|N|||F|||20241030050154\r
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05087|{Ratio}|<0.38|N|||F|||20241030050154\r
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.009|µmol/L|<0.5|N|||F|||20241030050154\r
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.217|µmol/L|<1.15|N|||F|||20241030050154\r
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.183|µmol/L|<0.38|N|||F|||20241030050154\r
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.67033|{Ratio}|>0.1|N|||F|||20241030050154\r
+OBR|9|356672001^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|27.20|ng/mL|<69|N|||F|||20241030050154\r
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|10|356672001^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00015.2|nmol/L|<85|N|||F|||20241030050154\r
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|11|356672001^FormNumber||54090-6^Thyroid newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|29575-8^Thyrotropin^LN|1|15.40|mIU/L|<29|N|||F|||20241030050154\r
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|12|356672001^FormNumber||54079-9^Galactosemia newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|273.54|enzyme units|>50|N|||F|||20241030050154\r
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|13|356672001^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241030050154\r
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241030050154\r
+OBR|14|356672001^FormNumber||57087-9^Biotinidase newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|73.00|ERU|>10|N|||F|||20241030050154\r
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|15|356672001^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|120|copies/µL|>18|N|||F|||20241030050154\r
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|16|356672001^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|11.43|µmol/L/h|>=1.54|N|||F|||20241030050154\r
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|17|356672001^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|9.33|µmol/L/h|>=0.86|N|||F|||20241030050154\r
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|18|356672001^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241030050154\r
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241030050154\r
+OBR|19|356672001^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|22.31|µmol/L/h|>=2.84|N|||F|||20241030050154\r
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|20|356672001^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|21|356672001^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.22|µmol/L|<=3|N|||F|||20241030050154\r
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|411.55|µmol/L||N|||F|||20241030050154\r
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.95||<=6|N|||F|||20241030050154\r
+OBR|22|356672001^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241030050154\r
+OBR|23|356672001^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.138|µmol/L|<0.47|N|||F|||20241030050154\r
diff --git a/examples/Test/Automated/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7 b/examples/Test/Automated/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
new file mode 100644
index 000000000..70305c7dc
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
@@ -0,0 +1,142 @@
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^^L,M,N|20241018050017||ORU^R01^ORU_R01|005|P|2.5.1\r
+PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
+NK1|1|*****PII REMOVED******
+ORC|RE|753234567^FormNumber||56155532^HospOrdNumber||||||||^SCALA^MELISSA|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601\r
+OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBR|2|753234567^FormNumber||57128-1^Newborn Screening Report summary panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241018050017\r
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241018050017\r
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241018050017\r
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA16207-5^Hemoglobinopathies^LN|||N|||F|||20241018050017\r
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050017\r
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - ALLIED LABORATORY \\R\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Hb: An immediate referral to a CCS Hematology Center or a pediatric hematologist familiar with alpha thalassemia and Hb H disease is strongly recommended for this infant. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241018050017\r
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241018050017\r
+OBR|3|753234567^FormNumber||57717-1^Newborn screen card data panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241018050017\r
+OBX|2|NM|8339-4^Birthweight^LN|1|2658|grams||N|||F|||20241018050017\r
+OBX|3|TM|57715-5^Time of birth^LN|1|0027|||N|||F|||20241018050017\r
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241018050017\r
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|28|hour(s)||N|||F|||20241018050017\r
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241018050017\r
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241018050017\r
+OBX|8|TX|^^^99717-5^Accession Number^L|1|272-95-009/21-2024-12|||N|||F|||20241018050017\r
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MELISSA SCALA|||N|||F|||20241018050017\r
+OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA|||N|||F|||20241018050017\r
+OBR|4|753234567^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBR|5|753234567^FormNumber||53261-4^Amino acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|926|µmol/L||N|||F|||20241018050017\r
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|588|µmol/L|<1000|N|||F|||20241018050017\r
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|79.4|µmol/L||N|||F|||20241018050017\r
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.29739|{Ratio}|<4.3|N|||F|||20241018050017\r
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|99.2|µmol/L|<230|N|||F|||20241018050017\r
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.17|{Ratio}|<1.35|N|||F|||20241018050017\r
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|61.2|µmol/L|<175|N|||F|||20241018050017\r
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.77|{Ratio}|<2.6|N|||F|||20241018050017\r
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|34.7|µmol/L|<680|N|||F|||20241018050017\r
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.33|µmol/L|<6.1|N|||F|||20241018050017\r
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|20.4|µmol/L|6.3-100|N|||F|||20241018050017\r
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|10|µmol/L|5-49|N|||F|||20241018050017\r
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|2.79|{Ratio}|<4.8|N|||F|||20241018050017\r
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|43|µmol/L|<800|N|||F|||20241018050017\r
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|4.44|{Ratio}||N|||F|||20241018050017\r
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|3|µmol/L|<63|N|||F|||20241018050017\r
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241018050017\r
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|187|µmol/L|<1500|N|||F|||20241018050017\r
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|6|753234567^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|7|753234567^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|39.6|µmol/L|6.4-125|N|||F|||20241018050017\r
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|5.35|{Ratio}|<70|N|||F|||20241018050017\r
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|34.7|µmol/L|10-80|N|||F|||20241018050017\r
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|3.27536|{Ratio}|<7.6|N|||F|||20241018050017\r
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.100|µmol/L|<0.95|N|||F|||20241018050017\r
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.075|µmol/L|<0.45|N|||F|||20241018050017\r
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.09|{Ratio}||N|||F|||20241018050017\r
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.163|µmol/L|<0.65|N|||F|||20241018050017\r
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.069|µmol/L|<0.65|N|||F|||20241018050017\r
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.057|µmol/L|<0.45|N|||F|||20241018050017\r
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.118|µmol/L|<2|N|||F|||20241018050017\r
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.06|µmol/L||N|||F|||20241018050017\r
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.394|µmol/L|<1.2|N|||F|||20241018050017\r
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.130|µmol/L|<0.9|N|||F|||20241018050017\r
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|2.32|{Ratio}||N|||F|||20241018050017\r
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241018050017\r
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.026|µmol/L|<0.2|N|||F|||20241018050017\r
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5.52|µmol/L|<12|N|||F|||20241018050017\r
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.245|µmol/L|<1.4|N|||F|||20241018050017\r
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.042|µmol/L|<0.1|N|||F|||20241018050017\r
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00761|{Ratio}|<0.07|N|||F|||20241018050017\r
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2.13|µmol/L|<3.5|N|||F|||20241018050017\r
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.89|µmol/L|<7|N|||F|||20241018050017\r
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.29|µmol/L||N|||F|||20241018050017\r
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.032|µmol/L|<0.1|N|||F|||20241018050017\r
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.047|µmol/L|<0.1|N|||F|||20241018050017\r
+OBR|8|753234567^FormNumber||57085-3^Organic acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|4.2|µmol/L|<7.9|N|||F|||20241018050017\r
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.12|{Ratio}|<0.42|N|||F|||20241018050017\r
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.226|µmol/L|<0.48|N|||F|||20241018050017\r
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.424|µmol/L|<1.7|N|||F|||20241018050017\r
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.247|µmol/L|<0.95|N|||F|||20241018050017\r
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05881|{Ratio}|<0.38|N|||F|||20241018050017\r
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.008|µmol/L|<0.5|N|||F|||20241018050017\r
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.287|µmol/L|<1.15|N|||F|||20241018050017\r
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.179|µmol/L|<0.38|N|||F|||20241018050017\r
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.79204|{Ratio}|>0.1|N|||F|||20241018050017\r
+OBR|9|753234567^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|18.50|ng/mL|<69|N|||F|||20241018050017\r
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|10|753234567^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00013.8|nmol/L|<85|N|||F|||20241018050017\r
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|11|753234567^FormNumber||54090-6^Thyroid newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|29575-8^Thyrotropin^LN|1|2.40|mIU/L|<29|N|||F|||20241018050017\r
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|12|753234567^FormNumber||54079-9^Galactosemia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|293.00|enzyme units|>50|N|||F|||20241018050017\r
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|13|753234567^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA + Barts||||||F|||20241018050017\r
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|The presence of Hb Barts at a high percentage is consistent with Hb H disease, a clinically significant hemoglobin disorder.||||||F|||20241018050017\r
+OBR|14|753234567^FormNumber||57087-9^Biotinidase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|43.76|ERU|>10|N|||F|||20241018050017\r
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|15|753234567^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|99|copies/µL|>18|N|||F|||20241018050017\r
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|16|753234567^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|7.09|µmol/L/h|>=1.67|N|||F|||20241018050017\r
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|17|753234567^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|8.33|µmol/L/h|>=0.86|N|||F|||20241018050017\r
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|18|753234567^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241018050017\r
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241018050017\r
+OBR|19|753234567^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|15.65|µmol/L/h|>=2.8|N|||F|||20241018050017\r
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|20|753234567^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|21|753234567^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.05|µmol/L|<=3|N|||F|||20241018050017\r
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|616.49|µmol/L||N|||F|||20241018050017\r
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.70||<=6|N|||F|||20241018050017\r
+OBR|22|753234567^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241018050017\r
+OBR|23|753234567^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.260|µmol/L|<0.47|N|||F|||20241018050017\r
diff --git a/examples/Test/Automated/golden_actual.hl7 b/examples/Test/Automated/golden_actual.hl7
deleted file mode 100644
index d00491fd7..000000000
--- a/examples/Test/Automated/golden_actual.hl7
+++ /dev/null
@@ -1 +0,0 @@
-1
diff --git a/examples/Test/Automated/golden_expected.hl7 b/examples/Test/Automated/golden_expected.hl7
deleted file mode 100644
index d00491fd7..000000000
--- a/examples/Test/Automated/golden_expected.hl7
+++ /dev/null
@@ -1 +0,0 @@
-1

From 83edb87a854c88b49115437c7e75aa7f6f6a6867 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Wed, 18 Dec 2024 15:12:18 -0700
Subject: [PATCH 10/61] refactor file fetcher and implementation

Co-authored-by: saquino0827 <saquino@flexion.us>
---
 .../trustedintermediary/rse2e/AzureBlobFileFetcher.java  | 2 +-
 .../hhs/cdc/trustedintermediary/rse2e/FileFetcher.java   | 2 +-
 .../cdc/trustedintermediary/rse2e/LocalFileFetcher.java  | 9 ++++-----
 3 files changed, 6 insertions(+), 7 deletions(-)

diff --git a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobFileFetcher.java b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobFileFetcher.java
index 8d41d35a4..4d9a3a478 100644
--- a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobFileFetcher.java
+++ b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobFileFetcher.java
@@ -48,7 +48,7 @@ public static FileFetcher getInstance() {
     }
 
     @Override
-    public List<HL7FileStream> fetchFiles(boolean isAutomated) {
+    public List<HL7FileStream> fetchFiles() {
         List<HL7FileStream> relevantFiles = new ArrayList<>();
 
         LocalDate today = LocalDate.now(TIME_ZONE);
diff --git a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/FileFetcher.java b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/FileFetcher.java
index ed4f02943..dcd998148 100644
--- a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/FileFetcher.java
+++ b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/FileFetcher.java
@@ -7,5 +7,5 @@
  * of this interface should provide a way to retrieve a list of HL7FileStream objects.
  */
 public interface FileFetcher {
-    List<HL7FileStream> fetchFiles(boolean isAutomatedTest);
+    List<HL7FileStream> fetchFiles();
 }
diff --git a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/LocalFileFetcher.java b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/LocalFileFetcher.java
index d7a3fb8ec..27b0d3f52 100644
--- a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/LocalFileFetcher.java
+++ b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/LocalFileFetcher.java
@@ -14,8 +14,6 @@
  * represents a file fetcher that fetches files from the local file system.
  */
 public class LocalFileFetcher implements FileFetcher {
-
-    private static String files_path = "../examples/Test/Automated/";
     private static final String EXTENSION = "hl7";
 
     private static final FileFetcher INSTANCE = new LocalFileFetcher();
@@ -27,9 +25,10 @@ public static FileFetcher getInstance() {
     }
 
     @Override
-    public List<HL7FileStream> fetchFiles(boolean isAutomatedTest) {
-        if (!isAutomatedTest) {
-            files_path = "../examples/Test/Automated/Golden/";
+    public List<HL7FileStream> fetchFiles() {
+        String files_path = System.getenv("LOCAL_FILE_PATH");
+        if (files_path == null || files_path.isEmpty()) {
+            throw new IllegalArgumentException("Environment variable LOCAL_FILE_PATH is not set");
         }
         try (Stream<Path> stream = Files.walk(Paths.get(files_path))) {
             return stream.filter(Files::isRegularFile)

From 084387db17f46bde0dee2a3776db24d0951d3ca8 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Wed, 18 Dec 2024 15:13:11 -0700
Subject: [PATCH 11/61] refactor file fetcher calls

---
 .../rse2e/AutomatedTest.groovy                |  4 ++--
 .../rse2e/GoldenCopyTest.groovy               | 21 ++++++-------------
 2 files changed, 8 insertions(+), 17 deletions(-)

diff --git a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/AutomatedTest.groovy b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/AutomatedTest.groovy
index c51777da6..c1a4d45ab 100644
--- a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/AutomatedTest.groovy
+++ b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/AutomatedTest.groovy
@@ -43,10 +43,10 @@ class AutomatedTest extends Specification  {
         }
 
         FileFetcher azureFileFetcher = AzureBlobFileFetcher.getInstance()
-        azureFiles = azureFileFetcher.fetchFiles(true)
+        azureFiles = azureFileFetcher.fetchFiles()
 
         FileFetcher localFileFetcher = LocalFileFetcher.getInstance()
-        localFiles = localFileFetcher.fetchFiles(true)
+        localFiles = localFileFetcher.fetchFiles()
 
         engine.ensureRulesLoaded()
     }
diff --git a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
index e157a4c98..9b9b2dea3 100644
--- a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
+++ b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
@@ -4,7 +4,7 @@ import gov.hhs.cdc.trustedintermediary.context.TestApplicationContext
 import gov.hhs.cdc.trustedintermediary.external.jackson.Jackson
 import gov.hhs.cdc.trustedintermediary.rse2e.external.hapi.HapiHL7ExpressionEvaluator
 import gov.hhs.cdc.trustedintermediary.rse2e.external.hapi.HapiHL7FileMatcher
-import gov.hhs.cdc.trustedintermediary.rse2e.ruleengine.AssertionRuleEngine
+import gov.hhs.cdc.trustedintermediary.rse2e.external.hapi.HapiHL7Message
 import gov.hhs.cdc.trustedintermediary.ruleengine.RuleLoader
 import gov.hhs.cdc.trustedintermediary.wrappers.HealthDataExpressionEvaluator
 import gov.hhs.cdc.trustedintermediary.wrappers.Logger
@@ -41,10 +41,10 @@ class GoldenCopyTest extends Specification {
         }
 
         FileFetcher azureFileFetcher = AzureBlobFileFetcher.getInstance()
-        azureFiles = azureFileFetcher.fetchFiles(false)
+        azureFiles = azureFileFetcher.fetchFiles()
 
         FileFetcher localFileFetcher = LocalFileFetcher.getInstance()
-        localFiles = localFileFetcher.fetchFiles(false)
+        localFiles = localFileFetcher.fetchFiles()
     }
 
     def cleanup() {
@@ -54,18 +54,9 @@ class GoldenCopyTest extends Specification {
     }
 
     def "Compare files"() {
-        // notes:
-        // Use workflow to sendoff the file (happens via Github Action)
-
-        // Call the automated-staging-test-submit workflow. Prob use a variable for the path of the folder unless we add to same folder.
-        // Call the automated-staging-test-run workflow. It shouldn't matter if it grabs all Azure files, we can use the MSH-10 to narrow it down like assertion_rules or use something else
-        // Modify the Rules Engine or create a different one
-        // If we do use the rules engine, see if its possible to compare the whole file as a rule rather than individual segments
         // Update Automated Test README
-
-        //         Add a sub folder to /Golden for inputFile - this is so we can get the actual output, we won't use this
-        //        Add a sub folder to /Golden for expectedFileOutput - this is 'hard-coded' and shouldnt change
-        //         make sure to update folder paths in workflow
+        // Currently reusing automated staging test workflows but we might need to pivot for cron schedule
+        // Get golden copy and input
 
         given:
         def matchedFiles = fileMatcher.matchFiles(azureFiles, localFiles)
@@ -80,7 +71,7 @@ class GoldenCopyTest extends Specification {
         }
 
         then:
-        assertTrue(failedFiles.isEmpty())
+        assert failedFiles.isEmpty()
         if (!loggedErrorsAndWarnings.isEmpty()) {
             throw new AssertionError("Unexpected errors and/or warnings were logged:\n- ${loggedErrorsAndWarnings.join('\n- ')}")
         }

From 1e4973171ccefa762751db1bf35ea200704bcdba Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Wed, 18 Dec 2024 15:13:39 -0700
Subject: [PATCH 12/61] add env to workflow and rename file path

Co-authored-by: saquino0827 <saquino@flexion.us>
---
 .../workflows/automated-staging-test-run.yml    | 17 +++++++++++++----
 .../workflows/automated-staging-test-submit.yml |  2 +-
 2 files changed, 14 insertions(+), 5 deletions(-)

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index b54b33f51..78d636679 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -21,19 +21,28 @@ jobs:
       - name: Check out the repository
         uses: actions/checkout@v4
 
-      - name: Run automated tests
-        env:
-          AZURE_STORAGE_CONNECTION_STRING: ${{ secrets.AUTOMATED_TEST_AZURE_STORAGE_CONNECTION_STRING }}
+      - name: Determine variable type
         run: |
           if [ ${{ github.event.inputs.name }} = "Automated Staging Test" ]; then
             test_type=automatedTest
             title=Automated
+            file_path=../examples/Test/Automated/
           else
             test_type=goldenCopyTest
             title=Golden Copy
+            file_path=../examples/Test/Automated/GoldenCopy/Expected/
           fi
+          echo "test_type=test_type" >> $GITHUB_OUTPUT
+          echo "title=$title" >> $GITHUB_OUTPUT
+          echo "file_path=file_path" >> $GITHUB_OUTPUT
+          done
+
+      - name: Run automated tests
+        env:
+          AZURE_STORAGE_CONNECTION_STRING: ${{ secrets.AUTOMATED_TEST_AZURE_STORAGE_CONNECTION_STRING }}
+          LOCAL_FILE_PATH: ${{ steps.getFunctionList.outputs.file_path }}
+        run: |
           ./gradlew rs-e2e:clean rs-e2e:$(test_type)
-          echo "test_type=$test_type" >> $GITHUB_OUTPUT
           done
 
       - name: Send slack notification on test failure
diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
index 3c7411d21..60f2a39cb 100644
--- a/.github/workflows/automated-staging-test-submit.yml
+++ b/.github/workflows/automated-staging-test-submit.yml
@@ -54,7 +54,7 @@ jobs:
 
             file_path=Automated/*.hl7
             if [ ${{ github.event.inputs.name }} = "Golden Copy Staging Test" ]; then
-               file_path=Automated/Golden/*.hl7
+               file_path=Automated/GoldenCopy/Input/*.hl7
             fi
 
             for file in $(pwd)/examples/Test/$(file_path); do

From 3de118726ddb9f21a925c04254a0fbc0713262de Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Wed, 18 Dec 2024 17:04:09 -0700
Subject: [PATCH 13/61] modify example files to be aligned with readme reqs

---
 .../GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7  | 2 +-
 .../GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7  | 2 +-
 .../Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7          | 2 +-
 .../GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7 | 2 +-
 .../Input/005_ORU_R01_golden_copy_input_out_of_range.hl7        | 2 +-
 5 files changed, 5 insertions(+), 5 deletions(-)

diff --git a/examples/Test/Automated/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7 b/examples/Test/Automated/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
index 833ef6d16..f43843e0a 100644
--- a/examples/Test/Automated/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
+++ b/examples/Test/Automated/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
@@ -1,4 +1,4 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^1477542173^L,M,N|20241015050654||ORU^R01^ORU_R01|001|P|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241015050654||ORU^R01^ORU_R01|001|N|2.5.1\r
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
 ORC|RE|673678765^FormNumber||M17965^HospOrdNumber||||||||1477542173^BROOKS^STEWART^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804\r
diff --git a/examples/Test/Automated/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7 b/examples/Test/Automated/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
index 2594c49b0..680a34bad 100644
--- a/examples/Test/Automated/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
+++ b/examples/Test/Automated/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
@@ -1,4 +1,4 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^1194257170^L,M,N|20241018050234||ORU^R01^ORU_R01|002|P|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050234||ORU^R01^ORU_R01|002|N|2.5.1\r
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
 ORC|RE|12345667867^FormNumber||S30500^HospOrdNumber||||||||1194257170^MAHMOOD^SARAH^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804\r
diff --git a/examples/Test/Automated/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7 b/examples/Test/Automated/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
index 01ec6acd7..a1ed92d13 100644
--- a/examples/Test/Automated/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
+++ b/examples/Test/Automated/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
@@ -1,4 +1,4 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^1043390461^L,M,N|20241023050044||ORU^R01^ORU_R01|003|P|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241023050044||ORU^R01^ORU_R01|003|N|2.5.1\r
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
 ORC|RE|45789876^FormNumber||56352742^HospOrdNumber||||||||1043390461^PROFIT^DR JOCHEN^^^^^^^NPI|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601\r
diff --git a/examples/Test/Automated/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7 b/examples/Test/Automated/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
index 47e9e7c81..8e0752090 100644
--- a/examples/Test/Automated/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
+++ b/examples/Test/Automated/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
@@ -1,4 +1,4 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^1447323951^L,M,N|20241030050154||ORU^R01^ORU_R01|004|P|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241030050154||ORU^R01^ORU_R01|004|N|2.5.1\r
 PID|1||335441864^^^104638912487&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
 ORC|RE|356672001^FormNumber||629813494^HospOrdNumber||||||||1093050858^SILVA^RICHARD^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|200 W ARBOR DR^^SAN DIEGO^CA^92103-1911\r
diff --git a/examples/Test/Automated/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7 b/examples/Test/Automated/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
index 70305c7dc..0d67e12e9 100644
--- a/examples/Test/Automated/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
+++ b/examples/Test/Automated/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
@@ -1,4 +1,4 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^^L,M,N|20241018050017||ORU^R01^ORU_R01|005|P|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050017||ORU^R01^ORU_R01|005|N|2.5.1\r
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
 ORC|RE|753234567^FormNumber||56155532^HospOrdNumber||||||||^SCALA^MELISSA|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601\r

From ebe7a4632eaf7a909491b7845868bdb0aa0c972b Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Wed, 18 Dec 2024 17:09:13 -0700
Subject: [PATCH 14/61] move directory up one and fix file paths

---
 .../workflows/automated-staging-test-run.yml   |  2 +-
 .../automated-staging-test-submit.yml          |  2 +-
 .../001_ORU_R01_golden_copy_input_acylc_1.hl7  |  0
 .../002_ORU_R01_golden_copy_input_acylc_2.hl7  |  0
 ...03_ORU_R01_golden_copy_input_aa_unusual.hl7 |  0
 .../004_ORU_R01_golden_copy_input_in_range.hl7 |  0
 ..._ORU_R01_golden_copy_input_out_of_range.hl7 |  0
 examples/Test/GoldenCopy/README.md             | 18 ++++++++++++++++++
 .../rse2e/GoldenCopyTest.groovy                |  1 -
 9 files changed, 20 insertions(+), 3 deletions(-)
 rename examples/Test/{Automated => }/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7 (100%)
 rename examples/Test/{Automated => }/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7 (100%)
 rename examples/Test/{Automated => }/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7 (100%)
 rename examples/Test/{Automated => }/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7 (100%)
 rename examples/Test/{Automated => }/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7 (100%)
 create mode 100644 examples/Test/GoldenCopy/README.md

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index 78d636679..0927d5cc5 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -30,7 +30,7 @@ jobs:
           else
             test_type=goldenCopyTest
             title=Golden Copy
-            file_path=../examples/Test/Automated/GoldenCopy/Expected/
+            file_path=../examples/Test/GoldenCopy/Expected/
           fi
           echo "test_type=test_type" >> $GITHUB_OUTPUT
           echo "title=$title" >> $GITHUB_OUTPUT
diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
index 60f2a39cb..157b3746b 100644
--- a/.github/workflows/automated-staging-test-submit.yml
+++ b/.github/workflows/automated-staging-test-submit.yml
@@ -54,7 +54,7 @@ jobs:
 
             file_path=Automated/*.hl7
             if [ ${{ github.event.inputs.name }} = "Golden Copy Staging Test" ]; then
-               file_path=Automated/GoldenCopy/Input/*.hl7
+               file_path=GoldenCopy/Input/*.hl7
             fi
 
             for file in $(pwd)/examples/Test/$(file_path); do
diff --git a/examples/Test/Automated/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7 b/examples/Test/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
similarity index 100%
rename from examples/Test/Automated/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
rename to examples/Test/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
diff --git a/examples/Test/Automated/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7 b/examples/Test/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
similarity index 100%
rename from examples/Test/Automated/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
rename to examples/Test/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
diff --git a/examples/Test/Automated/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7 b/examples/Test/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
similarity index 100%
rename from examples/Test/Automated/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
rename to examples/Test/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
diff --git a/examples/Test/Automated/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7 b/examples/Test/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
similarity index 100%
rename from examples/Test/Automated/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
rename to examples/Test/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
diff --git a/examples/Test/Automated/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7 b/examples/Test/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
similarity index 100%
rename from examples/Test/Automated/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
rename to examples/Test/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
diff --git a/examples/Test/GoldenCopy/README.md b/examples/Test/GoldenCopy/README.md
new file mode 100644
index 000000000..df9af42a4
--- /dev/null
+++ b/examples/Test/GoldenCopy/README.md
@@ -0,0 +1,18 @@
+This folder contains the HL7 sample files that are used in the Golden Copy ReportStream
+integration tests. The [automated-staging-test-submit.yml](/.github/workflows/automated-staging-test-submit.yml)
+Github workflow that runs daily will grab these files and send them to ReportStream in staging.
+The files are expected to go through the whole flow and to be delivered to an Azure blob
+container that will later be used by the
+[automated-staging-test-run.yml](/.github/workflows/automated-staging-test-run.yml) workflow to run tests on them by comparing the golden copy to the actual output.
+
+## Requirements for the HL7 files
+
+The files are required to:
+
+- Be a valid HL7 file
+- Be a supported HL7 message type: `ORM`, `OML` or `ORU`
+- Have `automated-staging-test-receiver-id` in `MSH-6.2` in order to be routed correctly
+    - If it's a sample file for UCSD, which has transformation that will overwrite `MSH-6.2`, the HL7 is required to have the prefix `AUTOMATEDTEST-` in `MSH-10` as a workaround - there is special routing in ReportStream to handle this
+- Each file must have a unique value in `MSH-10`. We use this value to match the input and output files, so if it's not unique, we won't be able to match the files correctly
+    - We format `MSH-10` based on the file index, like `001` (or `AUTOMATEDTEST-001` for UCSD)
+- `MSH-11` needs to have a value of `N`
diff --git a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
index 9b9b2dea3..86d6b3bc9 100644
--- a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
+++ b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
@@ -54,7 +54,6 @@ class GoldenCopyTest extends Specification {
     }
 
     def "Compare files"() {
-        // Update Automated Test README
         // Currently reusing automated staging test workflows but we might need to pivot for cron schedule
         // Get golden copy and input
 

From 9605cc1b424458da9781fc0bf96248842d6841a7 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Wed, 18 Dec 2024 17:13:15 -0700
Subject: [PATCH 15/61] move golden copy to automated to get files after
 transformed

---
 .../001_ORU_R01_golden_copy_input_acylc_1.hl7 | 143 ++++++++++++++++++
 .../002_ORU_R01_golden_copy_input_acylc_2.hl7 | 142 +++++++++++++++++
 ...3_ORU_R01_golden_copy_input_aa_unusual.hl7 | 142 +++++++++++++++++
 ...004_ORU_R01_golden_copy_input_in_range.hl7 | 142 +++++++++++++++++
 ...ORU_R01_golden_copy_input_out_of_range.hl7 | 142 +++++++++++++++++
 ...taging_ORM_O01_short_linked_to_002_ORU.hl7 |   0
 ...taging_ORU_O01_short_linked_to_001_ORM.hl7 |   0
 .../003_CA_ORU_R01_CDPH_produced.hl7          |   0
 .../004_CA_ORU_R01_leading_zeroes.hl7         |   0
 .../005_CA_ORU_R01_no_leading_zeroes.hl7      |   0
 .../006_CA_ORU_R01_LOINC.hl7                  |   0
 .../007_CA_ORU_R01_PLT.hl7                    |   0
 .../008_ORU_R01_micro_character_encoding.hl7  |   0
 .../009_CA_ORU_R01_remove_99717-5_OBX.hl7     |   0
 ...01_NBS_0_initial_obr_flatten_example_1.hl7 |   0
 15 files changed, 711 insertions(+)
 create mode 100644 examples/Test/Automated/001_ORU_R01_golden_copy_input_acylc_1.hl7
 create mode 100644 examples/Test/Automated/002_ORU_R01_golden_copy_input_acylc_2.hl7
 create mode 100644 examples/Test/Automated/003_ORU_R01_golden_copy_input_aa_unusual.hl7
 create mode 100644 examples/Test/Automated/004_ORU_R01_golden_copy_input_in_range.hl7
 create mode 100644 examples/Test/Automated/005_ORU_R01_golden_copy_input_out_of_range.hl7
 rename examples/Test/{Automated => tempStorage}/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7 (100%)
 rename examples/Test/{Automated => tempStorage}/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7 (100%)
 rename examples/Test/{Automated => tempStorage}/003_CA_ORU_R01_CDPH_produced.hl7 (100%)
 rename examples/Test/{Automated => tempStorage}/004_CA_ORU_R01_leading_zeroes.hl7 (100%)
 rename examples/Test/{Automated => tempStorage}/005_CA_ORU_R01_no_leading_zeroes.hl7 (100%)
 rename examples/Test/{Automated => tempStorage}/006_CA_ORU_R01_LOINC.hl7 (100%)
 rename examples/Test/{Automated => tempStorage}/007_CA_ORU_R01_PLT.hl7 (100%)
 rename examples/Test/{Automated => tempStorage}/008_ORU_R01_micro_character_encoding.hl7 (100%)
 rename examples/Test/{Automated => tempStorage}/009_CA_ORU_R01_remove_99717-5_OBX.hl7 (100%)
 rename examples/Test/{Automated => tempStorage}/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7 (100%)

diff --git a/examples/Test/Automated/001_ORU_R01_golden_copy_input_acylc_1.hl7 b/examples/Test/Automated/001_ORU_R01_golden_copy_input_acylc_1.hl7
new file mode 100644
index 000000000..f43843e0a
--- /dev/null
+++ b/examples/Test/Automated/001_ORU_R01_golden_copy_input_acylc_1.hl7
@@ -0,0 +1,143 @@
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241015050654||ORU^R01^ORU_R01|001|N|2.5.1\r
+PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
+NK1|1|*****PII REMOVED******
+ORC|RE|673678765^FormNumber||M17965^HospOrdNumber||||||||1477542173^BROOKS^STEWART^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804\r
+OBR|1|673678765^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410011420|||||||||||||||20241015050654|||F\r
+OBR|2|673678765^FormNumber||57128-1^Newborn Screening Report summary panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241015050654\r
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241015050654\r
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241015050654\r
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241015050654\r
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241015050654\r
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\R\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241015050654\r
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241015050654\r
+OBR|3|673678765^FormNumber||57717-1^Newborn screen card data panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241015050654\r
+OBX|2|NM|8339-4^Birthweight^LN|1|4020|grams||N|||F|||20241015050654\r
+OBX|3|TM|57715-5^Time of birth^LN|1|1416|||N|||F|||20241015050654\r
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241015050654\r
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241015050654\r
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241015050654\r
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241015050654\r
+OBX|8|CE|67704-7^Feeding types^LN|2|LA16915-3^Lactose formula^LN|||N|||F|||20241015050654\r
+OBX|9|TX|^^^99717-5^Accession Number^L|1|277-86-190/21-2024-32|||N|||F|||20241015050654\r
+OBX|10|TX|62324-9^Post-discharge provider name^LN|1|STEWART BROOKS|||N|||F|||20241015050654\r
+OBX|11|TX|62325-6^Post-discharge provider practice ID^LN|1|1477542173|||N|||F|||20241015050654\r
+OBX|12|TX|62327-2^Post-discharge provider practice address^LN|1|8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA|||N|||F|||20241015050654\r
+OBR|4|673678765^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410011420|||||||||||||||20241015050654|||F\r
+OBR|5|673678765^FormNumber||53261-4^Amino acid newborn screen panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|387|µmol/L||N|||F|||20241015050654\r
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|381|µmol/L|<1000|N|||F|||20241015050654\r
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|92.6|µmol/L||N|||F|||20241015050654\r
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.88595|{Ratio}|<4.3|N|||F|||20241015050654\r
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|86.8|µmol/L|<230|N|||F|||20241015050654\r
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.23|{Ratio}|<1.35|N|||F|||20241015050654\r
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|49.1|µmol/L|<175|N|||F|||20241015050654\r
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.09|{Ratio}|<2.6|N|||F|||20241015050654\r
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|45.1|µmol/L|<680|N|||F|||20241015050654\r
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.24|µmol/L|<6.1|N|||F|||20241015050654\r
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|16.8|µmol/L|6.3-100|N|||F|||20241015050654\r
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|20|µmol/L|5-49|N|||F|||20241015050654\r
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3.22|{Ratio}|<4.8|N|||F|||20241015050654\r
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|74|µmol/L|<800|N|||F|||20241015050654\r
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|3.76|{Ratio}||N|||F|||20241015050654\r
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|6|µmol/L|<63|N|||F|||20241015050654\r
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241015050654\r
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|118|µmol/L|<1500|N|||F|||20241015050654\r
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|6|673678765^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241015050654\r
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with SCADD, IBCDD|||A|||F|||20241015050654\r
+OBR|7|673678765^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|34.3|µmol/L|6.4-125|N|||F|||20241015050654\r
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|5.93|{Ratio}|<70|N|||F|||20241015050654\r
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|33.2|µmol/L|10-80|N|||F|||20241015050654\r
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|1.29565|{Ratio}|<7.6|N|||F|||20241015050654\r
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.136|µmol/L|<0.95|N|||F|||20241015050654\r
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.150|µmol/L|<0.45|N|||F|||20241015050654\r
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.65|{Ratio}||N|||F|||20241015050654\r
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.221|µmol/L|<0.65|N|||F|||20241015050654\r
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.230|µmol/L|<0.65|N|||F|||20241015050654\r
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.088|µmol/L|<0.45|N|||F|||20241015050654\r
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.232|µmol/L|<2|N|||F|||20241015050654\r
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.20|µmol/L||N|||F|||20241015050654\r
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.342|µmol/L|<1.2|N|||F|||20241015050654\r
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.206|µmol/L|<0.9|N|||F|||20241015050654\r
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.02|{Ratio}||N|||F|||20241015050654\r
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241015050654\r
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.029|µmol/L|<0.2|N|||F|||20241015050654\r
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|4.14|µmol/L|<12|N|||F|||20241015050654\r
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.341|µmol/L|<1.4|N|||F|||20241015050654\r
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.049|µmol/L|<0.1|N|||F|||20241015050654\r
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01184|{Ratio}|<0.07|N|||F|||20241015050654\r
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.07|µmol/L|<3.5|N|||F|||20241015050654\r
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.65|µmol/L|<7|N|||F|||20241015050654\r
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.23|µmol/L||N|||F|||20241015050654\r
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.022|µmol/L|<0.1|N|||F|||20241015050654\r
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.053|µmol/L|<0.1|N|||F|||20241015050654\r
+OBR|8|673678765^FormNumber||57085-3^Organic acid newborn screen panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.3|µmol/L|<7.9|N|||F|||20241015050654\r
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.07|{Ratio}|<0.42|N|||F|||20241015050654\r
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.298|µmol/L|<0.48|N|||F|||20241015050654\r
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|1.73|µmol/L|<1.7|H|||F|||20241015050654\r
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.139|µmol/L|<0.95|N|||F|||20241015050654\r
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.06043|{Ratio}|<0.38|N|||F|||20241015050654\r
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.011|µmol/L|<0.5|N|||F|||20241015050654\r
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.306|µmol/L|<1.15|N|||F|||20241015050654\r
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.238|µmol/L|<0.38|N|||F|||20241015050654\r
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.79866|{Ratio}|>0.1|N|||F|||20241015050654\r
+OBR|9|673678765^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|18.10|ng/mL|<69|N|||F|||20241015050654\r
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|10|673678765^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00010.8|nmol/L|<85|N|||F|||20241015050654\r
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|11|673678765^FormNumber||54090-6^Thyroid newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|29575-8^Thyrotropin^LN|1|4.00|mIU/L|<29|N|||F|||20241015050654\r
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|12|673678765^FormNumber||54079-9^Galactosemia newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|267.94|enzyme units|>50|N|||F|||20241015050654\r
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|13|673678765^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241015050654\r
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241015050654\r
+OBR|14|673678765^FormNumber||57087-9^Biotinidase newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|44.16|ERU|>10|N|||F|||20241015050654\r
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|15|673678765^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|84|copies/µL|>18|N|||F|||20241015050654\r
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|16|673678765^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|6.97|µmol/L/h|>=1.51|N|||F|||20241015050654\r
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|17|673678765^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|10.38|µmol/L/h|>=0.77|N|||F|||20241015050654\r
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|18|673678765^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241015050654\r
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241015050654\r
+OBR|19|673678765^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|27.61|µmol/L/h|>=2.75|N|||F|||20241015050654\r
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|20|673678765^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015050654\r
+OBR|21|673678765^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.04|µmol/L|<=3|N|||F|||20241015050654\r
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|391.37|µmol/L||N|||F|||20241015050654\r
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.66||<=6|N|||F|||20241015050654\r
+OBR|22|673678765^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241015050654\r
+OBR|23|673678765^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F\r
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.246|µmol/L|<0.47|N|||F|||20241015050654\r
diff --git a/examples/Test/Automated/002_ORU_R01_golden_copy_input_acylc_2.hl7 b/examples/Test/Automated/002_ORU_R01_golden_copy_input_acylc_2.hl7
new file mode 100644
index 000000000..680a34bad
--- /dev/null
+++ b/examples/Test/Automated/002_ORU_R01_golden_copy_input_acylc_2.hl7
@@ -0,0 +1,142 @@
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050234||ORU^R01^ORU_R01|002|N|2.5.1\r
+PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
+NK1|1|*****PII REMOVED******
+ORC|RE|12345667867^FormNumber||S30500^HospOrdNumber||||||||1194257170^MAHMOOD^SARAH^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804\r
+OBR|1|12345667867^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410061300|||||||||||||||20241018050234|||F\r
+OBR|2|12345667867^FormNumber||57128-1^Newborn Screening Report summary panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241018050234\r
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241018050234\r
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241018050234\r
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050234\r
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050234\r
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\R\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241018050234\r
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241018050234\r
+OBR|3|12345667867^FormNumber||57717-1^Newborn screen card data panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241018050234\r
+OBX|2|NM|8339-4^Birthweight^LN|1|3135|grams||N|||F|||20241018050234\r
+OBX|3|TM|57715-5^Time of birth^LN|1|1235|||N|||F|||20241018050234\r
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241018050234\r
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241018050234\r
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241018050234\r
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241018050234\r
+OBX|8|TX|^^^99717-5^Accession Number^L|1|282-18-014/21-2024-32|||N|||F|||20241018050234\r
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|SARAH MAHMOOD|||N|||F|||20241018050234\r
+OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1194257170|||N|||F|||20241018050234\r
+OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA|||N|||F|||20241018050234\r
+OBR|4|12345667867^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410061300|||||||||||||||20241018050234|||F\r
+OBR|5|12345667867^FormNumber||53261-4^Amino acid newborn screen panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|611|µmol/L||N|||F|||20241018050234\r
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|585|µmol/L|<1000|N|||F|||20241018050234\r
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|90.9|µmol/L||N|||F|||20241018050234\r
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.74808|{Ratio}|<4.3|N|||F|||20241018050234\r
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|86.9|µmol/L|<230|N|||F|||20241018050234\r
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.15|{Ratio}|<1.35|N|||F|||20241018050234\r
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|52.0|µmol/L|<175|N|||F|||20241018050234\r
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241018050234\r
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|69.0|µmol/L|<680|N|||F|||20241018050234\r
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.23|µmol/L|<6.1|N|||F|||20241018050234\r
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|22.5|µmol/L|6.3-100|N|||F|||20241018050234\r
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|14|µmol/L|5-49|N|||F|||20241018050234\r
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|2.28|{Ratio}|<4.8|N|||F|||20241018050234\r
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|68|µmol/L|<800|N|||F|||20241018050234\r
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|4.93|{Ratio}||N|||F|||20241018050234\r
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|6|µmol/L|<63|N|||F|||20241018050234\r
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241018050234\r
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|192|µmol/L|<1500|N|||F|||20241018050234\r
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|6|12345667867^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241018050234\r
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with SCADD, IBCDD|||A|||F|||20241018050234\r
+OBR|7|12345667867^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|26.6|µmol/L|6.4-125|N|||F|||20241018050234\r
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|3.27|{Ratio}|<70|N|||F|||20241018050234\r
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|29.2|µmol/L|10-80|N|||F|||20241018050234\r
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.13913|{Ratio}|<7.6|N|||F|||20241018050234\r
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.088|µmol/L|<0.95|N|||F|||20241018050234\r
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.084|µmol/L|<0.45|N|||F|||20241018050234\r
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.73|{Ratio}||N|||F|||20241018050234\r
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.172|µmol/L|<0.65|N|||F|||20241018050234\r
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.115|µmol/L|<0.65|N|||F|||20241018050234\r
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.050|µmol/L|<0.45|N|||F|||20241018050234\r
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.127|µmol/L|<2|N|||F|||20241018050234\r
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.12|µmol/L||N|||F|||20241018050234\r
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.333|µmol/L|<1.2|N|||F|||20241018050234\r
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.132|µmol/L|<0.9|N|||F|||20241018050234\r
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.13|{Ratio}||N|||F|||20241018050234\r
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241018050234\r
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.026|µmol/L|<0.2|N|||F|||20241018050234\r
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|6.19|µmol/L|<12|N|||F|||20241018050234\r
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.445|µmol/L|<1.4|N|||F|||20241018050234\r
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.045|µmol/L|<0.1|N|||F|||20241018050234\r
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00727|{Ratio}|<0.07|N|||F|||20241018050234\r
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.53|µmol/L|<3.5|N|||F|||20241018050234\r
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.96|µmol/L|<7|N|||F|||20241018050234\r
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.21|µmol/L||N|||F|||20241018050234\r
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.017|µmol/L|<0.1|N|||F|||20241018050234\r
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.036|µmol/L|<0.1|N|||F|||20241018050234\r
+OBR|8|12345667867^FormNumber||57085-3^Organic acid newborn screen panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.5|µmol/L|<7.9|N|||F|||20241018050234\r
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.09|{Ratio}|<0.42|N|||F|||20241018050234\r
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.246|µmol/L|<0.48|N|||F|||20241018050234\r
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|1.72|µmol/L|<1.7|H|||F|||20241018050234\r
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.115|µmol/L|<0.95|N|||F|||20241018050234\r
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.04600|{Ratio}|<0.38|N|||F|||20241018050234\r
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.008|µmol/L|<0.5|N|||F|||20241018050234\r
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.232|µmol/L|<1.15|N|||F|||20241018050234\r
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.180|µmol/L|<0.38|N|||F|||20241018050234\r
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.73171|{Ratio}|>0.1|N|||F|||20241018050234\r
+OBR|9|12345667867^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|21.20|ng/mL|<69|N|||F|||20241018050234\r
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|10|12345667867^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00015.6|nmol/L|<85|N|||F|||20241018050234\r
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|11|12345667867^FormNumber||54090-6^Thyroid newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|29575-8^Thyrotropin^LN|1|9.50|mIU/L|<29|N|||F|||20241018050234\r
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|12|12345667867^FormNumber||54079-9^Galactosemia newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|262.95|enzyme units|>50|N|||F|||20241018050234\r
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|13|12345667867^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241018050234\r
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241018050234\r
+OBR|14|12345667867^FormNumber||57087-9^Biotinidase newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|49.77|ERU|>10|N|||F|||20241018050234\r
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|15|12345667867^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|197|copies/µL|>18|N|||F|||20241018050234\r
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|16|12345667867^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.29|µmol/L/h|>=1.47|N|||F|||20241018050234\r
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|17|12345667867^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|13.01|µmol/L/h|>=0.82|N|||F|||20241018050234\r
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|18|12345667867^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241018050234\r
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241018050234\r
+OBR|19|12345667867^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|27.84|µmol/L/h|>=2.79|N|||F|||20241018050234\r
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|20|12345667867^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050234\r
+OBR|21|12345667867^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|0.97|µmol/L|<=3|N|||F|||20241018050234\r
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|496.63|µmol/L||N|||F|||20241018050234\r
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.95||<=6|N|||F|||20241018050234\r
+OBR|22|12345667867^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241018050234\r
+OBR|23|12345667867^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F\r
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.349|µmol/L|<0.47|N|||F|||20241018050234\r
diff --git a/examples/Test/Automated/003_ORU_R01_golden_copy_input_aa_unusual.hl7 b/examples/Test/Automated/003_ORU_R01_golden_copy_input_aa_unusual.hl7
new file mode 100644
index 000000000..a1ed92d13
--- /dev/null
+++ b/examples/Test/Automated/003_ORU_R01_golden_copy_input_aa_unusual.hl7
@@ -0,0 +1,142 @@
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241023050044||ORU^R01^ORU_R01|003|N|2.5.1\r
+PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
+NK1|1|*****PII REMOVED******
+ORC|RE|45789876^FormNumber||56352742^HospOrdNumber||||||||1043390461^PROFIT^DR JOCHEN^^^^^^^NPI|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601\r
+OBR|1|45789876^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBR|2|45789876^FormNumber||57128-1^Newborn Screening Report summary panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241023050044\r
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241023050044\r
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241023050044\r
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241023050044\r
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241023050044\r
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - ALLIED LABORATORY \\R\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Amino Acid Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241023050044\r
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241023050044\r
+OBR|3|45789876^FormNumber||57717-1^Newborn screen card data panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241023050044\r
+OBX|2|NM|8339-4^Birthweight^LN|1|2230|grams||N|||F|||20241023050044\r
+OBX|3|TM|57715-5^Time of birth^LN|1|1358|||N|||F|||20241023050044\r
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241023050044\r
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|26|hour(s)||N|||F|||20241023050044\r
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241023050044\r
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241023050044\r
+OBX|8|TX|^^^99717-5^Accession Number^L|1|282-38-261/21-2024-12|||N|||F|||20241023050044\r
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DR JOCHEN PROFIT|||N|||F|||20241023050044\r
+OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1043390461|||N|||F|||20241023050044\r
+OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA|||N|||F|||20241023050044\r
+OBR|4|45789876^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBR|5|45789876^FormNumber||53261-4^Amino acid newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|368|µmol/L||N|||F|||20241023050044\r
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|310|µmol/L|<1000|N|||F|||20241023050044\r
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|34.6|µmol/L||N|||F|||20241023050044\r
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.06462|{Ratio}|<4.3|N|||F|||20241023050044\r
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|50.7|µmol/L|<230|N|||F|||20241023050044\r
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.16|{Ratio}|<1.35|N|||F|||20241023050044\r
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|32.5|µmol/L|<175|N|||F|||20241023050044\r
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.13|{Ratio}|<2.6|N|||F|||20241023050044\r
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|28.9|µmol/L|<680|N|||F|||20241023050044\r
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.25|µmol/L|<6.1|N|||F|||20241023050044\r
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|8.6|µmol/L|6.3-100|N|||F|||20241023050044\r
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|5|µmol/L|5-49|N|||F|||20241023050044\r
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.67|{Ratio}|<4.8|N|||F|||20241023050044\r
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|32|µmol/L|<800|N|||F|||20241023050044\r
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|6.41|{Ratio}||N|||F|||20241023050044\r
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|3|µmol/L|<63|N|||F|||20241023050044\r
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241023050044\r
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|55|µmol/L|<1500|N|||F|||20241023050044\r
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|This complex pattern of elevations require further evaluation|||A|||F|||20241023050044\r
+OBR|6|45789876^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|7|45789876^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|34.9|µmol/L|6.4-125|N|||F|||20241023050044\r
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|7.84|{Ratio}|<70|N|||F|||20241023050044\r
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|28.1|µmol/L|10-80|N|||F|||20241023050044\r
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|3.53125|{Ratio}|<7.6|N|||F|||20241023050044\r
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.034|µmol/L|<0.95|N|||F|||20241023050044\r
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.038|µmol/L|<0.45|N|||F|||20241023050044\r
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.19|{Ratio}||N|||F|||20241023050044\r
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.155|µmol/L|<0.65|N|||F|||20241023050044\r
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.032|µmol/L|<0.65|N|||F|||20241023050044\r
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.030|µmol/L|<0.45|N|||F|||20241023050044\r
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.070|µmol/L|<2|N|||F|||20241023050044\r
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.05|µmol/L||N|||F|||20241023050044\r
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.270|µmol/L|<1.2|N|||F|||20241023050044\r
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.084|µmol/L|<0.9|N|||F|||20241023050044\r
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.75|{Ratio}||N|||F|||20241023050044\r
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241023050044\r
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.009|µmol/L|<0.2|N|||F|||20241023050044\r
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|2.87|µmol/L|<12|N|||F|||20241023050044\r
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.236|µmol/L|<1.4|N|||F|||20241023050044\r
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.022|µmol/L|<0.1|N|||F|||20241023050044\r
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00767|{Ratio}|<0.07|N|||F|||20241023050044\r
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|0.987|µmol/L|<3.5|N|||F|||20241023050044\r
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.59|µmol/L|<7|N|||F|||20241023050044\r
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.20|µmol/L||N|||F|||20241023050044\r
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.014|µmol/L|<0.1|N|||F|||20241023050044\r
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.034|µmol/L|<0.1|N|||F|||20241023050044\r
+OBR|8|45789876^FormNumber||57085-3^Organic acid newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|1.9|µmol/L|<7.9|N|||F|||20241023050044\r
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.07|{Ratio}|<0.42|N|||F|||20241023050044\r
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.113|µmol/L|<0.48|N|||F|||20241023050044\r
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.161|µmol/L|<1.7|N|||F|||20241023050044\r
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.111|µmol/L|<0.95|N|||F|||20241023050044\r
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05842|{Ratio}|<0.38|N|||F|||20241023050044\r
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.006|µmol/L|<0.5|N|||F|||20241023050044\r
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.140|µmol/L|<1.15|N|||F|||20241023050044\r
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.091|µmol/L|<0.38|N|||F|||20241023050044\r
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.80531|{Ratio}|>0.1|N|||F|||20241023050044\r
+OBR|9|45789876^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|27.50|ng/mL|<69|N|||F|||20241023050044\r
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|10|45789876^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00029.9|nmol/L|<190|N|||F|||20241023050044\r
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|11|45789876^FormNumber||54090-6^Thyroid newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|29575-8^Thyrotropin^LN|1|6.90|mIU/L|<29|N|||F|||20241023050044\r
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|12|45789876^FormNumber||54079-9^Galactosemia newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|226.51|enzyme units|>50|N|||F|||20241023050044\r
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|13|45789876^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241023050044\r
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241023050044\r
+OBR|14|45789876^FormNumber||57087-9^Biotinidase newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|28.87|ERU|>10|N|||F|||20241023050044\r
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|15|45789876^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|198|copies/µL|>18|N|||F|||20241023050044\r
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|16|45789876^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|7.91|µmol/L/h|>=1.62|N|||F|||20241023050044\r
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|17|45789876^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|7.78|µmol/L/h|>=0.79|N|||F|||20241023050044\r
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|18|45789876^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241023050044\r
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241023050044\r
+OBR|19|45789876^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.94|µmol/L/h|>=2.95|N|||F|||20241023050044\r
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|20|45789876^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241023050044\r
+OBR|21|45789876^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.00|µmol/L|<=3|N|||F|||20241023050044\r
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|707.37|µmol/L||N|||F|||20241023050044\r
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.41||<=6|N|||F|||20241023050044\r
+OBR|22|45789876^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241023050044\r
+OBR|23|45789876^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.246|µmol/L|<0.47|N|||F|||20241023050044\r
diff --git a/examples/Test/Automated/004_ORU_R01_golden_copy_input_in_range.hl7 b/examples/Test/Automated/004_ORU_R01_golden_copy_input_in_range.hl7
new file mode 100644
index 000000000..8e0752090
--- /dev/null
+++ b/examples/Test/Automated/004_ORU_R01_golden_copy_input_in_range.hl7
@@ -0,0 +1,142 @@
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241030050154||ORU^R01^ORU_R01|004|N|2.5.1\r
+PID|1||335441864^^^104638912487&NPI^MR||*****PII REMOVED******
+NK1|1|*****PII REMOVED******
+ORC|RE|356672001^FormNumber||629813494^HospOrdNumber||||||||1093050858^SILVA^RICHARD^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|200 W ARBOR DR^^SAN DIEGO^CA^92103-1911\r
+OBR|1|356672001^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBR|2|356672001^FormNumber||57128-1^Newborn Screening Report summary panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241030050154\r
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241030050154\r
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12428-1^All screening is in range for the conditions tested^LN|||N|||F|||20241030050154\r
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241030050154\r
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241030050154\r
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \\R\\2130 E Illinois Avenue, FRESNO, CA 93701\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (858) 966-8708. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241030050154\r
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241030050154\r
+OBR|3|356672001^FormNumber||57717-1^Newborn screen card data panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241030050154\r
+OBX|2|NM|8339-4^Birthweight^LN|1|3464|grams||N|||F|||20241030050154\r
+OBX|3|TM|57715-5^Time of birth^LN|1|0444|||N|||F|||20241030050154\r
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241030050154\r
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|19|hour(s)||N|||F|||20241030050154\r
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241030050154\r
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241030050154\r
+OBX|8|TX|^^^99717-5^Accession Number^L|1|292-04-123/21-2024-32|||N|||F|||20241030050154\r
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DIANE BEDROSIAN|||N|||F|||20241030050154\r
+OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1447323951|||N|||F|||20241030050154\r
+OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|200 W ARBOR DR SAN DIEGO CA 92103-1911 USA|||N|||F|||20241030050154\r
+OBR|4|356672001^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBR|5|356672001^FormNumber||53261-4^Amino acid newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|536|µmol/L||N|||F|||20241030050154\r
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|559|µmol/L|<1000|N|||F|||20241030050154\r
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|123|µmol/L||N|||F|||20241030050154\r
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|2.14286|{Ratio}|<4.3|N|||F|||20241030050154\r
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|113|µmol/L|<230|N|||F|||20241030050154\r
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.20|{Ratio}|<1.35|N|||F|||20241030050154\r
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|57.4|µmol/L|<175|N|||F|||20241030050154\r
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.05|{Ratio}|<2.6|N|||F|||20241030050154\r
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|54.8|µmol/L|<680|N|||F|||20241030050154\r
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.20|µmol/L|<6.1|N|||F|||20241030050154\r
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|22.8|µmol/L|6.3-100|N|||F|||20241030050154\r
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|10|µmol/L|5-49|N|||F|||20241030050154\r
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.52|{Ratio}|<4.8|N|||F|||20241030050154\r
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|84|µmol/L|<800|N|||F|||20241030050154\r
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|8.40|{Ratio}||N|||F|||20241030050154\r
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|7|µmol/L|<63|N|||F|||20241030050154\r
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241030050154\r
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|154|µmol/L|<1500|N|||F|||20241030050154\r
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|6|356672001^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|7|356672001^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|24.4|µmol/L|6.4-125|N|||F|||20241030050154\r
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|4.32|{Ratio}|<70|N|||F|||20241030050154\r
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|27.3|µmol/L|10-80|N|||F|||20241030050154\r
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.73000|{Ratio}|<7.6|N|||F|||20241030050154\r
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.067|µmol/L|<0.95|N|||F|||20241030050154\r
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.076|µmol/L|<0.45|N|||F|||20241030050154\r
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.76|{Ratio}||N|||F|||20241030050154\r
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.103|µmol/L|<0.65|N|||F|||20241030050154\r
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.100|µmol/L|<0.65|N|||F|||20241030050154\r
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.035|µmol/L|<0.45|N|||F|||20241030050154\r
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.132|µmol/L|<2|N|||F|||20241030050154\r
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.17|µmol/L||N|||F|||20241030050154\r
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.264|µmol/L|<1.2|N|||F|||20241030050154\r
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.189|µmol/L|<0.9|N|||F|||20241030050154\r
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.13|{Ratio}||N|||F|||20241030050154\r
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241030050154\r
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.021|µmol/L|<0.2|N|||F|||20241030050154\r
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|3.88|µmol/L|<12|N|||F|||20241030050154\r
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.371|µmol/L|<1.4|N|||F|||20241030050154\r
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.030|µmol/L|<0.1|N|||F|||20241030050154\r
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00773|{Ratio}|<0.07|N|||F|||20241030050154\r
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.11|µmol/L|<3.5|N|||F|||20241030050154\r
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.76|µmol/L|<7|N|||F|||20241030050154\r
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.15|µmol/L||N|||F|||20241030050154\r
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.015|µmol/L|<0.1|N|||F|||20241030050154\r
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.032|µmol/L|<0.1|N|||F|||20241030050154\r
+OBR|8|356672001^FormNumber||57085-3^Organic acid newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.3|µmol/L|<7.9|N|||F|||20241030050154\r
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.09|{Ratio}|<0.42|N|||F|||20241030050154\r
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.273|µmol/L|<0.48|N|||F|||20241030050154\r
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.315|µmol/L|<1.7|N|||F|||20241030050154\r
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.117|µmol/L|<0.95|N|||F|||20241030050154\r
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05087|{Ratio}|<0.38|N|||F|||20241030050154\r
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.009|µmol/L|<0.5|N|||F|||20241030050154\r
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.217|µmol/L|<1.15|N|||F|||20241030050154\r
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.183|µmol/L|<0.38|N|||F|||20241030050154\r
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.67033|{Ratio}|>0.1|N|||F|||20241030050154\r
+OBR|9|356672001^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|27.20|ng/mL|<69|N|||F|||20241030050154\r
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|10|356672001^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00015.2|nmol/L|<85|N|||F|||20241030050154\r
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|11|356672001^FormNumber||54090-6^Thyroid newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|29575-8^Thyrotropin^LN|1|15.40|mIU/L|<29|N|||F|||20241030050154\r
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|12|356672001^FormNumber||54079-9^Galactosemia newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|273.54|enzyme units|>50|N|||F|||20241030050154\r
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|13|356672001^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241030050154\r
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241030050154\r
+OBR|14|356672001^FormNumber||57087-9^Biotinidase newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|73.00|ERU|>10|N|||F|||20241030050154\r
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|15|356672001^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|120|copies/µL|>18|N|||F|||20241030050154\r
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|16|356672001^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|11.43|µmol/L/h|>=1.54|N|||F|||20241030050154\r
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|17|356672001^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|9.33|µmol/L/h|>=0.86|N|||F|||20241030050154\r
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|18|356672001^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241030050154\r
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241030050154\r
+OBR|19|356672001^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|22.31|µmol/L/h|>=2.84|N|||F|||20241030050154\r
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|20|356672001^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241030050154\r
+OBR|21|356672001^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.22|µmol/L|<=3|N|||F|||20241030050154\r
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|411.55|µmol/L||N|||F|||20241030050154\r
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.95||<=6|N|||F|||20241030050154\r
+OBR|22|356672001^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241030050154\r
+OBR|23|356672001^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.138|µmol/L|<0.47|N|||F|||20241030050154\r
diff --git a/examples/Test/Automated/005_ORU_R01_golden_copy_input_out_of_range.hl7 b/examples/Test/Automated/005_ORU_R01_golden_copy_input_out_of_range.hl7
new file mode 100644
index 000000000..0d67e12e9
--- /dev/null
+++ b/examples/Test/Automated/005_ORU_R01_golden_copy_input_out_of_range.hl7
@@ -0,0 +1,142 @@
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050017||ORU^R01^ORU_R01|005|N|2.5.1\r
+PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
+NK1|1|*****PII REMOVED******
+ORC|RE|753234567^FormNumber||56155532^HospOrdNumber||||||||^SCALA^MELISSA|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601\r
+OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBR|2|753234567^FormNumber||57128-1^Newborn Screening Report summary panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241018050017\r
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241018050017\r
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241018050017\r
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA16207-5^Hemoglobinopathies^LN|||N|||F|||20241018050017\r
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050017\r
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - ALLIED LABORATORY \\R\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Hb: An immediate referral to a CCS Hematology Center or a pediatric hematologist familiar with alpha thalassemia and Hb H disease is strongly recommended for this infant. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241018050017\r
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241018050017\r
+OBR|3|753234567^FormNumber||57717-1^Newborn screen card data panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241018050017\r
+OBX|2|NM|8339-4^Birthweight^LN|1|2658|grams||N|||F|||20241018050017\r
+OBX|3|TM|57715-5^Time of birth^LN|1|0027|||N|||F|||20241018050017\r
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241018050017\r
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|28|hour(s)||N|||F|||20241018050017\r
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241018050017\r
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241018050017\r
+OBX|8|TX|^^^99717-5^Accession Number^L|1|272-95-009/21-2024-12|||N|||F|||20241018050017\r
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MELISSA SCALA|||N|||F|||20241018050017\r
+OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA|||N|||F|||20241018050017\r
+OBR|4|753234567^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBR|5|753234567^FormNumber||53261-4^Amino acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|926|µmol/L||N|||F|||20241018050017\r
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|588|µmol/L|<1000|N|||F|||20241018050017\r
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|79.4|µmol/L||N|||F|||20241018050017\r
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.29739|{Ratio}|<4.3|N|||F|||20241018050017\r
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|99.2|µmol/L|<230|N|||F|||20241018050017\r
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.17|{Ratio}|<1.35|N|||F|||20241018050017\r
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|61.2|µmol/L|<175|N|||F|||20241018050017\r
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.77|{Ratio}|<2.6|N|||F|||20241018050017\r
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|34.7|µmol/L|<680|N|||F|||20241018050017\r
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.33|µmol/L|<6.1|N|||F|||20241018050017\r
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|20.4|µmol/L|6.3-100|N|||F|||20241018050017\r
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|10|µmol/L|5-49|N|||F|||20241018050017\r
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|2.79|{Ratio}|<4.8|N|||F|||20241018050017\r
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|43|µmol/L|<800|N|||F|||20241018050017\r
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|4.44|{Ratio}||N|||F|||20241018050017\r
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|3|µmol/L|<63|N|||F|||20241018050017\r
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241018050017\r
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|187|µmol/L|<1500|N|||F|||20241018050017\r
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|6|753234567^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|7|753234567^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|39.6|µmol/L|6.4-125|N|||F|||20241018050017\r
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|5.35|{Ratio}|<70|N|||F|||20241018050017\r
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|34.7|µmol/L|10-80|N|||F|||20241018050017\r
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|3.27536|{Ratio}|<7.6|N|||F|||20241018050017\r
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.100|µmol/L|<0.95|N|||F|||20241018050017\r
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.075|µmol/L|<0.45|N|||F|||20241018050017\r
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.09|{Ratio}||N|||F|||20241018050017\r
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.163|µmol/L|<0.65|N|||F|||20241018050017\r
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.069|µmol/L|<0.65|N|||F|||20241018050017\r
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.057|µmol/L|<0.45|N|||F|||20241018050017\r
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.118|µmol/L|<2|N|||F|||20241018050017\r
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.06|µmol/L||N|||F|||20241018050017\r
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.394|µmol/L|<1.2|N|||F|||20241018050017\r
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.130|µmol/L|<0.9|N|||F|||20241018050017\r
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|2.32|{Ratio}||N|||F|||20241018050017\r
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241018050017\r
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.026|µmol/L|<0.2|N|||F|||20241018050017\r
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5.52|µmol/L|<12|N|||F|||20241018050017\r
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.245|µmol/L|<1.4|N|||F|||20241018050017\r
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.042|µmol/L|<0.1|N|||F|||20241018050017\r
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00761|{Ratio}|<0.07|N|||F|||20241018050017\r
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2.13|µmol/L|<3.5|N|||F|||20241018050017\r
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.89|µmol/L|<7|N|||F|||20241018050017\r
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.29|µmol/L||N|||F|||20241018050017\r
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.032|µmol/L|<0.1|N|||F|||20241018050017\r
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.047|µmol/L|<0.1|N|||F|||20241018050017\r
+OBR|8|753234567^FormNumber||57085-3^Organic acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|4.2|µmol/L|<7.9|N|||F|||20241018050017\r
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.12|{Ratio}|<0.42|N|||F|||20241018050017\r
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.226|µmol/L|<0.48|N|||F|||20241018050017\r
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.424|µmol/L|<1.7|N|||F|||20241018050017\r
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.247|µmol/L|<0.95|N|||F|||20241018050017\r
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05881|{Ratio}|<0.38|N|||F|||20241018050017\r
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.008|µmol/L|<0.5|N|||F|||20241018050017\r
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.287|µmol/L|<1.15|N|||F|||20241018050017\r
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.179|µmol/L|<0.38|N|||F|||20241018050017\r
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.79204|{Ratio}|>0.1|N|||F|||20241018050017\r
+OBR|9|753234567^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|18.50|ng/mL|<69|N|||F|||20241018050017\r
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|10|753234567^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00013.8|nmol/L|<85|N|||F|||20241018050017\r
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|11|753234567^FormNumber||54090-6^Thyroid newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|29575-8^Thyrotropin^LN|1|2.40|mIU/L|<29|N|||F|||20241018050017\r
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|12|753234567^FormNumber||54079-9^Galactosemia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|293.00|enzyme units|>50|N|||F|||20241018050017\r
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|13|753234567^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA + Barts||||||F|||20241018050017\r
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|The presence of Hb Barts at a high percentage is consistent with Hb H disease, a clinically significant hemoglobin disorder.||||||F|||20241018050017\r
+OBR|14|753234567^FormNumber||57087-9^Biotinidase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|43.76|ERU|>10|N|||F|||20241018050017\r
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|15|753234567^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|99|copies/µL|>18|N|||F|||20241018050017\r
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|16|753234567^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|7.09|µmol/L/h|>=1.67|N|||F|||20241018050017\r
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|17|753234567^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|8.33|µmol/L/h|>=0.86|N|||F|||20241018050017\r
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|18|753234567^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241018050017\r
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241018050017\r
+OBR|19|753234567^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|15.65|µmol/L/h|>=2.8|N|||F|||20241018050017\r
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|20|753234567^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017\r
+OBR|21|753234567^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.05|µmol/L|<=3|N|||F|||20241018050017\r
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|616.49|µmol/L||N|||F|||20241018050017\r
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.70||<=6|N|||F|||20241018050017\r
+OBR|22|753234567^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241018050017\r
+OBR|23|753234567^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.260|µmol/L|<0.47|N|||F|||20241018050017\r
diff --git a/examples/Test/Automated/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7 b/examples/Test/tempStorage/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7
similarity index 100%
rename from examples/Test/Automated/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7
rename to examples/Test/tempStorage/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7
diff --git a/examples/Test/Automated/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7 b/examples/Test/tempStorage/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7
similarity index 100%
rename from examples/Test/Automated/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7
rename to examples/Test/tempStorage/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7
diff --git a/examples/Test/Automated/003_CA_ORU_R01_CDPH_produced.hl7 b/examples/Test/tempStorage/003_CA_ORU_R01_CDPH_produced.hl7
similarity index 100%
rename from examples/Test/Automated/003_CA_ORU_R01_CDPH_produced.hl7
rename to examples/Test/tempStorage/003_CA_ORU_R01_CDPH_produced.hl7
diff --git a/examples/Test/Automated/004_CA_ORU_R01_leading_zeroes.hl7 b/examples/Test/tempStorage/004_CA_ORU_R01_leading_zeroes.hl7
similarity index 100%
rename from examples/Test/Automated/004_CA_ORU_R01_leading_zeroes.hl7
rename to examples/Test/tempStorage/004_CA_ORU_R01_leading_zeroes.hl7
diff --git a/examples/Test/Automated/005_CA_ORU_R01_no_leading_zeroes.hl7 b/examples/Test/tempStorage/005_CA_ORU_R01_no_leading_zeroes.hl7
similarity index 100%
rename from examples/Test/Automated/005_CA_ORU_R01_no_leading_zeroes.hl7
rename to examples/Test/tempStorage/005_CA_ORU_R01_no_leading_zeroes.hl7
diff --git a/examples/Test/Automated/006_CA_ORU_R01_LOINC.hl7 b/examples/Test/tempStorage/006_CA_ORU_R01_LOINC.hl7
similarity index 100%
rename from examples/Test/Automated/006_CA_ORU_R01_LOINC.hl7
rename to examples/Test/tempStorage/006_CA_ORU_R01_LOINC.hl7
diff --git a/examples/Test/Automated/007_CA_ORU_R01_PLT.hl7 b/examples/Test/tempStorage/007_CA_ORU_R01_PLT.hl7
similarity index 100%
rename from examples/Test/Automated/007_CA_ORU_R01_PLT.hl7
rename to examples/Test/tempStorage/007_CA_ORU_R01_PLT.hl7
diff --git a/examples/Test/Automated/008_ORU_R01_micro_character_encoding.hl7 b/examples/Test/tempStorage/008_ORU_R01_micro_character_encoding.hl7
similarity index 100%
rename from examples/Test/Automated/008_ORU_R01_micro_character_encoding.hl7
rename to examples/Test/tempStorage/008_ORU_R01_micro_character_encoding.hl7
diff --git a/examples/Test/Automated/009_CA_ORU_R01_remove_99717-5_OBX.hl7 b/examples/Test/tempStorage/009_CA_ORU_R01_remove_99717-5_OBX.hl7
similarity index 100%
rename from examples/Test/Automated/009_CA_ORU_R01_remove_99717-5_OBX.hl7
rename to examples/Test/tempStorage/009_CA_ORU_R01_remove_99717-5_OBX.hl7
diff --git a/examples/Test/Automated/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7 b/examples/Test/tempStorage/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7
similarity index 100%
rename from examples/Test/Automated/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7
rename to examples/Test/tempStorage/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7

From f63c56c50dc53d041fa4316275d052d30353df87 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 10:33:56 -0700
Subject: [PATCH 16/61] use correct syntax

Co-authored-by: saquino0827 <saquino@flexion.us>
---
 .github/workflows/automated-staging-test-run.yml    | 2 +-
 .github/workflows/automated-staging-test-submit.yml | 2 +-
 2 files changed, 2 insertions(+), 2 deletions(-)

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index 0927d5cc5..962ffe43e 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -42,7 +42,7 @@ jobs:
           AZURE_STORAGE_CONNECTION_STRING: ${{ secrets.AUTOMATED_TEST_AZURE_STORAGE_CONNECTION_STRING }}
           LOCAL_FILE_PATH: ${{ steps.getFunctionList.outputs.file_path }}
         run: |
-          ./gradlew rs-e2e:clean rs-e2e:$(test_type)
+          ./gradlew rs-e2e:clean rs-e2e:${{ test_type }}
           done
 
       - name: Send slack notification on test failure
diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
index 157b3746b..9e1d7542b 100644
--- a/.github/workflows/automated-staging-test-submit.yml
+++ b/.github/workflows/automated-staging-test-submit.yml
@@ -57,7 +57,7 @@ jobs:
                file_path=GoldenCopy/Input/*.hl7
             fi
 
-            for file in $(pwd)/examples/Test/$(file_path); do
+            for file in $(pwd)/examples/Test/${{ file_path }}; do
                 echo "Sending $file"
                 curl \
                     --header "Content-Type: application/hl7-v2" \

From de61fb518681da41b4c2411434c29f1bdc64045d Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 10:41:28 -0700
Subject: [PATCH 17/61] make variables strings

Co-authored-by: saquino0827 <saquino@flexion.us>
---
 .github/workflows/automated-staging-test-run.yml    | 12 ++++++------
 .github/workflows/automated-staging-test-submit.yml |  4 ++--
 2 files changed, 8 insertions(+), 8 deletions(-)

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index 962ffe43e..9e12c06ce 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -24,13 +24,13 @@ jobs:
       - name: Determine variable type
         run: |
           if [ ${{ github.event.inputs.name }} = "Automated Staging Test" ]; then
-            test_type=automatedTest
-            title=Automated
-            file_path=../examples/Test/Automated/
+            test_type="automatedTest"
+            title="Automated"
+            file_path="../examples/Test/Automated/"
           else
-            test_type=goldenCopyTest
-            title=Golden Copy
-            file_path=../examples/Test/GoldenCopy/Expected/
+            test_type="goldenCopyTest"
+            title="Golden Copy"
+            file_path="../examples/Test/GoldenCopy/Expected/"
           fi
           echo "test_type=test_type" >> $GITHUB_OUTPUT
           echo "title=$title" >> $GITHUB_OUTPUT
diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
index 9e1d7542b..0743977db 100644
--- a/.github/workflows/automated-staging-test-submit.yml
+++ b/.github/workflows/automated-staging-test-submit.yml
@@ -52,9 +52,9 @@ jobs:
                     --silent \
                     "$host/api/token" | jq -r ".access_token")
 
-            file_path=Automated/*.hl7
+            file_path="Automated/*.hl7"
             if [ ${{ github.event.inputs.name }} = "Golden Copy Staging Test" ]; then
-               file_path=GoldenCopy/Input/*.hl7
+               file_path="GoldenCopy/Input/*.hl7"
             fi
 
             for file in $(pwd)/examples/Test/${{ file_path }}; do

From 96cae6c41ed012b27e5c0f74b8f7445f091385cd Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 10:44:35 -0700
Subject: [PATCH 18/61] add dollar sign to echo

Co-authored-by: saquino0827 <saquino@flexion.us>
---
 .github/workflows/automated-staging-test-run.yml | 4 ++--
 1 file changed, 2 insertions(+), 2 deletions(-)

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index 9e12c06ce..24cbb4eaa 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -32,9 +32,9 @@ jobs:
             title="Golden Copy"
             file_path="../examples/Test/GoldenCopy/Expected/"
           fi
-          echo "test_type=test_type" >> $GITHUB_OUTPUT
+          echo "test_type=$test_type" >> $GITHUB_OUTPUT
           echo "title=$title" >> $GITHUB_OUTPUT
-          echo "file_path=file_path" >> $GITHUB_OUTPUT
+          echo "file_path=$file_path" >> $GITHUB_OUTPUT
           done
 
       - name: Run automated tests

From e17f1e901b0b5588e2cb00f2c71c3b5ca76e5dfb Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 10:56:02 -0700
Subject: [PATCH 19/61] try fixing format

Co-authored-by: saquino0827 <saquino@flexion.us>
---
 .../automated-staging-test-submit.yml         | 56 +++++++++----------
 1 file changed, 28 insertions(+), 28 deletions(-)

diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
index 0743977db..4c64600b6 100644
--- a/.github/workflows/automated-staging-test-submit.yml
+++ b/.github/workflows/automated-staging-test-submit.yml
@@ -36,37 +36,37 @@ jobs:
 
       - name: Send HL7 sample messages to staging RS
         run: |
-            host=https://staging.prime.cdc.gov:443
-            client_id=flexion
-            client_sender=simulated-sender
-            jwt=$(jwt encode --exp='+5min' --jti $(uuidgen) --alg RS256 \
-                -k $client_id.$client_sender -i $client_id.$client_sender \
-                -s $client_id.$client_sender -a $host --no-iat -S @/tmp/staging_private_key.pem)
+          host=https://staging.prime.cdc.gov:443
+          client_id=flexion
+          client_sender=simulated-sender
+          jwt=$(jwt encode --exp='+5min' --jti $(uuidgen) --alg RS256 \
+              -k $client_id.$client_sender -i $client_id.$client_sender \
+              -s $client_id.$client_sender -a $host --no-iat -S @/tmp/staging_private_key.pem)
 
-            token=$(curl \
-                    --header "Content-Type: application/x-www-form-urlencoded" \
-                    --data "scope=$client_id.*.report" \
-                    --data "client_assertion=$jwt" \
-                    --data "client_assertion_type=urn:ietf:params:oauth:client-assertion-type:jwt-bearer" \
-                    --data "grant_type=client_credentials" \
-                    --silent \
-                    "$host/api/token" | jq -r ".access_token")
+          token=$(curl \
+                  --header "Content-Type: application/x-www-form-urlencoded" \
+                  --data "scope=$client_id.*.report" \
+                  --data "client_assertion=$jwt" \
+                  --data "client_assertion_type=urn:ietf:params:oauth:client-assertion-type:jwt-bearer" \
+                  --data "grant_type=client_credentials" \
+                  --silent \
+                  "$host/api/token" | jq -r ".access_token")
 
-            file_path="Automated/*.hl7"
-            if [ ${{ github.event.inputs.name }} = "Golden Copy Staging Test" ]; then
-               file_path="GoldenCopy/Input/*.hl7"
-            fi
+          file_path="Automated/*.hl7"
+          if [ ${{ github.event.inputs.name }} == "Golden Copy Staging Test" ]; then
+              file_path="GoldenCopy/Input/*.hl7"
+          fi
 
-            for file in $(pwd)/examples/Test/${{ file_path }}; do
-                echo "Sending $file"
-                curl \
-                    --header "Content-Type: application/hl7-v2" \
-                    --header "Client: $client_id.$client_sender" \
-                    --header "Authorization: Bearer $token" \
-                    --data-binary "@$file" \
-                    --silent \
-                    "$host/api/waters"
-            done
+          for file in $(pwd)/examples/Test/${{ file_path }}; do
+              echo "Sending $file"
+              curl \
+                  --header "Content-Type: application/hl7-v2" \
+                  --header "Client: $client_id.$client_sender" \
+                  --header "Authorization: Bearer $token" \
+                  --data-binary "@$file" \
+                  --silent \
+                  "$host/api/waters"
+          done
 
       - name: Clean up private key
         if: always()

From 0747ee83b14ef0bbc04c02ffbd474ae37af269de Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 11:02:25 -0700
Subject: [PATCH 20/61] change syntax

Co-authored-by: saquino0827 <saquino@flexion.us>
---
 .github/workflows/automated-staging-test-run.yml    | 9 ++++-----
 .github/workflows/automated-staging-test-submit.yml | 6 +++---
 2 files changed, 7 insertions(+), 8 deletions(-)

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index 24cbb4eaa..96760ddd9 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -23,11 +23,10 @@ jobs:
 
       - name: Determine variable type
         run: |
-          if [ ${{ github.event.inputs.name }} = "Automated Staging Test" ]; then
-            test_type="automatedTest"
-            title="Automated"
-            file_path="../examples/Test/Automated/"
-          else
+          test_type="automatedTest"
+          title="Automated"
+          file_path="../examples/Test/Automated/"
+          if [ ${{ github.event.inputs.name }} = "Golden Copy Staging Test" ]; then
             test_type="goldenCopyTest"
             title="Golden Copy"
             file_path="../examples/Test/GoldenCopy/Expected/"
diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
index 4c64600b6..ab4b53567 100644
--- a/.github/workflows/automated-staging-test-submit.yml
+++ b/.github/workflows/automated-staging-test-submit.yml
@@ -52,12 +52,12 @@ jobs:
                   --silent \
                   "$host/api/token" | jq -r ".access_token")
 
-          file_path="Automated/*.hl7"
+          file_path=Automated/*.hl7
           if [ ${{ github.event.inputs.name }} == "Golden Copy Staging Test" ]; then
-              file_path="GoldenCopy/Input/*.hl7"
+              file_path=GoldenCopy/Input/*.hl7
           fi
 
-          for file in $(pwd)/examples/Test/${{ file_path }}; do
+          for file in $(pwd)/examples/Test/$file_path; do
               echo "Sending $file"
               curl \
                   --header "Content-Type: application/hl7-v2" \

From bdbed53c599e862a84344aedb116184da1211d28 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 14:02:42 -0700
Subject: [PATCH 21/61] remove line break at end of line in example files

Co-authored-by: saquino0827 <saquino@flexion.us>
Co-authored-by: Sylvie <sschuresko@flexion.us>
Co-authored-by: jcrichlake <145698165+jcrichlake@users.noreply.github.com>
---
 .../001_ORU_R01_golden_copy_input_acylc_1.hl7 | 282 +++++++++---------
 .../002_ORU_R01_golden_copy_input_acylc_2.hl7 | 280 ++++++++---------
 ...3_ORU_R01_golden_copy_input_aa_unusual.hl7 | 280 ++++++++---------
 ...004_ORU_R01_golden_copy_input_in_range.hl7 | 280 ++++++++---------
 ...ORU_R01_golden_copy_input_out_of_range.hl7 | 280 ++++++++---------
 5 files changed, 701 insertions(+), 701 deletions(-)

diff --git a/examples/Test/Automated/001_ORU_R01_golden_copy_input_acylc_1.hl7 b/examples/Test/Automated/001_ORU_R01_golden_copy_input_acylc_1.hl7
index f43843e0a..a93c6ef84 100644
--- a/examples/Test/Automated/001_ORU_R01_golden_copy_input_acylc_1.hl7
+++ b/examples/Test/Automated/001_ORU_R01_golden_copy_input_acylc_1.hl7
@@ -1,143 +1,143 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241015050654||ORU^R01^ORU_R01|001|N|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241015050654||ORU^R01^ORU_R01|001|N|2.5.1
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
-ORC|RE|673678765^FormNumber||M17965^HospOrdNumber||||||||1477542173^BROOKS^STEWART^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804\r
-OBR|1|673678765^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410011420|||||||||||||||20241015050654|||F\r
-OBR|2|673678765^FormNumber||57128-1^Newborn Screening Report summary panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241015050654\r
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241015050654\r
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241015050654\r
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241015050654\r
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241015050654\r
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\R\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241015050654\r
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241015050654\r
-OBR|3|673678765^FormNumber||57717-1^Newborn screen card data panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241015050654\r
-OBX|2|NM|8339-4^Birthweight^LN|1|4020|grams||N|||F|||20241015050654\r
-OBX|3|TM|57715-5^Time of birth^LN|1|1416|||N|||F|||20241015050654\r
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241015050654\r
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241015050654\r
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241015050654\r
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241015050654\r
-OBX|8|CE|67704-7^Feeding types^LN|2|LA16915-3^Lactose formula^LN|||N|||F|||20241015050654\r
-OBX|9|TX|^^^99717-5^Accession Number^L|1|277-86-190/21-2024-32|||N|||F|||20241015050654\r
-OBX|10|TX|62324-9^Post-discharge provider name^LN|1|STEWART BROOKS|||N|||F|||20241015050654\r
-OBX|11|TX|62325-6^Post-discharge provider practice ID^LN|1|1477542173|||N|||F|||20241015050654\r
-OBX|12|TX|62327-2^Post-discharge provider practice address^LN|1|8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA|||N|||F|||20241015050654\r
-OBR|4|673678765^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410011420|||||||||||||||20241015050654|||F\r
-OBR|5|673678765^FormNumber||53261-4^Amino acid newborn screen panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|387|µmol/L||N|||F|||20241015050654\r
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|381|µmol/L|<1000|N|||F|||20241015050654\r
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|92.6|µmol/L||N|||F|||20241015050654\r
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.88595|{Ratio}|<4.3|N|||F|||20241015050654\r
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|86.8|µmol/L|<230|N|||F|||20241015050654\r
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.23|{Ratio}|<1.35|N|||F|||20241015050654\r
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|49.1|µmol/L|<175|N|||F|||20241015050654\r
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.09|{Ratio}|<2.6|N|||F|||20241015050654\r
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|45.1|µmol/L|<680|N|||F|||20241015050654\r
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.24|µmol/L|<6.1|N|||F|||20241015050654\r
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|16.8|µmol/L|6.3-100|N|||F|||20241015050654\r
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|20|µmol/L|5-49|N|||F|||20241015050654\r
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3.22|{Ratio}|<4.8|N|||F|||20241015050654\r
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|74|µmol/L|<800|N|||F|||20241015050654\r
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|3.76|{Ratio}||N|||F|||20241015050654\r
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|6|µmol/L|<63|N|||F|||20241015050654\r
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241015050654\r
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|118|µmol/L|<1500|N|||F|||20241015050654\r
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|6|673678765^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241015050654\r
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with SCADD, IBCDD|||A|||F|||20241015050654\r
-OBR|7|673678765^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|34.3|µmol/L|6.4-125|N|||F|||20241015050654\r
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|5.93|{Ratio}|<70|N|||F|||20241015050654\r
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|33.2|µmol/L|10-80|N|||F|||20241015050654\r
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|1.29565|{Ratio}|<7.6|N|||F|||20241015050654\r
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.136|µmol/L|<0.95|N|||F|||20241015050654\r
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.150|µmol/L|<0.45|N|||F|||20241015050654\r
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.65|{Ratio}||N|||F|||20241015050654\r
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.221|µmol/L|<0.65|N|||F|||20241015050654\r
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.230|µmol/L|<0.65|N|||F|||20241015050654\r
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.088|µmol/L|<0.45|N|||F|||20241015050654\r
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.232|µmol/L|<2|N|||F|||20241015050654\r
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.20|µmol/L||N|||F|||20241015050654\r
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.342|µmol/L|<1.2|N|||F|||20241015050654\r
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.206|µmol/L|<0.9|N|||F|||20241015050654\r
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.02|{Ratio}||N|||F|||20241015050654\r
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241015050654\r
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.029|µmol/L|<0.2|N|||F|||20241015050654\r
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|4.14|µmol/L|<12|N|||F|||20241015050654\r
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.341|µmol/L|<1.4|N|||F|||20241015050654\r
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.049|µmol/L|<0.1|N|||F|||20241015050654\r
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01184|{Ratio}|<0.07|N|||F|||20241015050654\r
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.07|µmol/L|<3.5|N|||F|||20241015050654\r
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.65|µmol/L|<7|N|||F|||20241015050654\r
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.23|µmol/L||N|||F|||20241015050654\r
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.022|µmol/L|<0.1|N|||F|||20241015050654\r
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.053|µmol/L|<0.1|N|||F|||20241015050654\r
-OBR|8|673678765^FormNumber||57085-3^Organic acid newborn screen panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.3|µmol/L|<7.9|N|||F|||20241015050654\r
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.07|{Ratio}|<0.42|N|||F|||20241015050654\r
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.298|µmol/L|<0.48|N|||F|||20241015050654\r
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|1.73|µmol/L|<1.7|H|||F|||20241015050654\r
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.139|µmol/L|<0.95|N|||F|||20241015050654\r
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.06043|{Ratio}|<0.38|N|||F|||20241015050654\r
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.011|µmol/L|<0.5|N|||F|||20241015050654\r
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.306|µmol/L|<1.15|N|||F|||20241015050654\r
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.238|µmol/L|<0.38|N|||F|||20241015050654\r
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.79866|{Ratio}|>0.1|N|||F|||20241015050654\r
-OBR|9|673678765^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|18.10|ng/mL|<69|N|||F|||20241015050654\r
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|10|673678765^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00010.8|nmol/L|<85|N|||F|||20241015050654\r
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|11|673678765^FormNumber||54090-6^Thyroid newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|29575-8^Thyrotropin^LN|1|4.00|mIU/L|<29|N|||F|||20241015050654\r
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|12|673678765^FormNumber||54079-9^Galactosemia newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|267.94|enzyme units|>50|N|||F|||20241015050654\r
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|13|673678765^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241015050654\r
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241015050654\r
-OBR|14|673678765^FormNumber||57087-9^Biotinidase newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|44.16|ERU|>10|N|||F|||20241015050654\r
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|15|673678765^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|84|copies/µL|>18|N|||F|||20241015050654\r
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|16|673678765^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|6.97|µmol/L/h|>=1.51|N|||F|||20241015050654\r
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|17|673678765^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|10.38|µmol/L/h|>=0.77|N|||F|||20241015050654\r
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|18|673678765^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241015050654\r
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241015050654\r
-OBR|19|673678765^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|27.61|µmol/L/h|>=2.75|N|||F|||20241015050654\r
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|20|673678765^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|21|673678765^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.04|µmol/L|<=3|N|||F|||20241015050654\r
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|391.37|µmol/L||N|||F|||20241015050654\r
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.66||<=6|N|||F|||20241015050654\r
-OBR|22|673678765^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241015050654\r
-OBR|23|673678765^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.246|µmol/L|<0.47|N|||F|||20241015050654\r
+ORC|RE|673678765^FormNumber||M17965^HospOrdNumber||||||||1477542173^BROOKS^STEWART^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804
+OBR|1|673678765^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410011420|||||||||||||||20241015050654|||F
+OBR|2|673678765^FormNumber||57128-1^Newborn Screening Report summary panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241015050654
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241015050654
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241015050654
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241015050654
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241015050654
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241015050654
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241015050654
+OBR|3|673678765^FormNumber||57717-1^Newborn screen card data panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241015050654
+OBX|2|NM|8339-4^Birthweight^LN|1|4020|grams||N|||F|||20241015050654
+OBX|3|TM|57715-5^Time of birth^LN|1|1416|||N|||F|||20241015050654
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241015050654
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241015050654
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241015050654
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241015050654
+OBX|8|CE|67704-7^Feeding types^LN|2|LA16915-3^Lactose formula^LN|||N|||F|||20241015050654
+OBX|9|TX|^^^99717-5^Accession Number^L|1|277-86-190/21-2024-32|||N|||F|||20241015050654
+OBX|10|TX|62324-9^Post-discharge provider name^LN|1|STEWART BROOKS|||N|||F|||20241015050654
+OBX|11|TX|62325-6^Post-discharge provider practice ID^LN|1|1477542173|||N|||F|||20241015050654
+OBX|12|TX|62327-2^Post-discharge provider practice address^LN|1|8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA|||N|||F|||20241015050654
+OBR|4|673678765^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410011420|||||||||||||||20241015050654|||F
+OBR|5|673678765^FormNumber||53261-4^Amino acid newborn screen panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|387|µmol/L||N|||F|||20241015050654
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|381|µmol/L|<1000|N|||F|||20241015050654
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|92.6|µmol/L||N|||F|||20241015050654
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.88595|{Ratio}|<4.3|N|||F|||20241015050654
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|86.8|µmol/L|<230|N|||F|||20241015050654
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.23|{Ratio}|<1.35|N|||F|||20241015050654
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|49.1|µmol/L|<175|N|||F|||20241015050654
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.09|{Ratio}|<2.6|N|||F|||20241015050654
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|45.1|µmol/L|<680|N|||F|||20241015050654
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.24|µmol/L|<6.1|N|||F|||20241015050654
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|16.8|µmol/L|6.3-100|N|||F|||20241015050654
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|20|µmol/L|5-49|N|||F|||20241015050654
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3.22|{Ratio}|<4.8|N|||F|||20241015050654
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|74|µmol/L|<800|N|||F|||20241015050654
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|3.76|{Ratio}||N|||F|||20241015050654
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|6|µmol/L|<63|N|||F|||20241015050654
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241015050654
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|118|µmol/L|<1500|N|||F|||20241015050654
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|6|673678765^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241015050654
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with SCADD, IBCDD|||A|||F|||20241015050654
+OBR|7|673678765^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|34.3|µmol/L|6.4-125|N|||F|||20241015050654
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|5.93|{Ratio}|<70|N|||F|||20241015050654
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|33.2|µmol/L|10-80|N|||F|||20241015050654
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|1.29565|{Ratio}|<7.6|N|||F|||20241015050654
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.136|µmol/L|<0.95|N|||F|||20241015050654
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.150|µmol/L|<0.45|N|||F|||20241015050654
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.65|{Ratio}||N|||F|||20241015050654
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.221|µmol/L|<0.65|N|||F|||20241015050654
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.230|µmol/L|<0.65|N|||F|||20241015050654
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.088|µmol/L|<0.45|N|||F|||20241015050654
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.232|µmol/L|<2|N|||F|||20241015050654
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.20|µmol/L||N|||F|||20241015050654
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.342|µmol/L|<1.2|N|||F|||20241015050654
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.206|µmol/L|<0.9|N|||F|||20241015050654
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.02|{Ratio}||N|||F|||20241015050654
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241015050654
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.029|µmol/L|<0.2|N|||F|||20241015050654
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|4.14|µmol/L|<12|N|||F|||20241015050654
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.341|µmol/L|<1.4|N|||F|||20241015050654
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.049|µmol/L|<0.1|N|||F|||20241015050654
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01184|{Ratio}|<0.07|N|||F|||20241015050654
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.07|µmol/L|<3.5|N|||F|||20241015050654
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.65|µmol/L|<7|N|||F|||20241015050654
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.23|µmol/L||N|||F|||20241015050654
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.022|µmol/L|<0.1|N|||F|||20241015050654
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.053|µmol/L|<0.1|N|||F|||20241015050654
+OBR|8|673678765^FormNumber||57085-3^Organic acid newborn screen panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.3|µmol/L|<7.9|N|||F|||20241015050654
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.07|{Ratio}|<0.42|N|||F|||20241015050654
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.298|µmol/L|<0.48|N|||F|||20241015050654
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|1.73|µmol/L|<1.7|H|||F|||20241015050654
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.139|µmol/L|<0.95|N|||F|||20241015050654
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.06043|{Ratio}|<0.38|N|||F|||20241015050654
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.011|µmol/L|<0.5|N|||F|||20241015050654
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.306|µmol/L|<1.15|N|||F|||20241015050654
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.238|µmol/L|<0.38|N|||F|||20241015050654
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.79866|{Ratio}|>0.1|N|||F|||20241015050654
+OBR|9|673678765^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|18.10|ng/mL|<69|N|||F|||20241015050654
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|10|673678765^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00010.8|nmol/L|<85|N|||F|||20241015050654
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|11|673678765^FormNumber||54090-6^Thyroid newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|29575-8^Thyrotropin^LN|1|4.00|mIU/L|<29|N|||F|||20241015050654
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|12|673678765^FormNumber||54079-9^Galactosemia newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|267.94|enzyme units|>50|N|||F|||20241015050654
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|13|673678765^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241015050654
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241015050654
+OBR|14|673678765^FormNumber||57087-9^Biotinidase newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|44.16|ERU|>10|N|||F|||20241015050654
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|15|673678765^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|84|copies/µL|>18|N|||F|||20241015050654
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|16|673678765^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|6.97|µmol/L/h|>=1.51|N|||F|||20241015050654
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|17|673678765^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|10.38|µmol/L/h|>=0.77|N|||F|||20241015050654
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|18|673678765^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241015050654
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241015050654
+OBR|19|673678765^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|27.61|µmol/L/h|>=2.75|N|||F|||20241015050654
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|20|673678765^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|21|673678765^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.04|µmol/L|<=3|N|||F|||20241015050654
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|391.37|µmol/L||N|||F|||20241015050654
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.66||<=6|N|||F|||20241015050654
+OBR|22|673678765^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241015050654
+OBR|23|673678765^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.246|µmol/L|<0.47|N|||F|||20241015050654
diff --git a/examples/Test/Automated/002_ORU_R01_golden_copy_input_acylc_2.hl7 b/examples/Test/Automated/002_ORU_R01_golden_copy_input_acylc_2.hl7
index 680a34bad..eb4377c51 100644
--- a/examples/Test/Automated/002_ORU_R01_golden_copy_input_acylc_2.hl7
+++ b/examples/Test/Automated/002_ORU_R01_golden_copy_input_acylc_2.hl7
@@ -1,142 +1,142 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050234||ORU^R01^ORU_R01|002|N|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050234||ORU^R01^ORU_R01|002|N|2.5.1
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
-ORC|RE|12345667867^FormNumber||S30500^HospOrdNumber||||||||1194257170^MAHMOOD^SARAH^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804\r
-OBR|1|12345667867^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410061300|||||||||||||||20241018050234|||F\r
-OBR|2|12345667867^FormNumber||57128-1^Newborn Screening Report summary panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241018050234\r
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241018050234\r
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241018050234\r
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050234\r
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050234\r
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\R\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241018050234\r
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241018050234\r
-OBR|3|12345667867^FormNumber||57717-1^Newborn screen card data panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241018050234\r
-OBX|2|NM|8339-4^Birthweight^LN|1|3135|grams||N|||F|||20241018050234\r
-OBX|3|TM|57715-5^Time of birth^LN|1|1235|||N|||F|||20241018050234\r
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241018050234\r
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241018050234\r
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241018050234\r
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241018050234\r
-OBX|8|TX|^^^99717-5^Accession Number^L|1|282-18-014/21-2024-32|||N|||F|||20241018050234\r
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|SARAH MAHMOOD|||N|||F|||20241018050234\r
-OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1194257170|||N|||F|||20241018050234\r
-OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA|||N|||F|||20241018050234\r
-OBR|4|12345667867^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410061300|||||||||||||||20241018050234|||F\r
-OBR|5|12345667867^FormNumber||53261-4^Amino acid newborn screen panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|611|µmol/L||N|||F|||20241018050234\r
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|585|µmol/L|<1000|N|||F|||20241018050234\r
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|90.9|µmol/L||N|||F|||20241018050234\r
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.74808|{Ratio}|<4.3|N|||F|||20241018050234\r
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|86.9|µmol/L|<230|N|||F|||20241018050234\r
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.15|{Ratio}|<1.35|N|||F|||20241018050234\r
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|52.0|µmol/L|<175|N|||F|||20241018050234\r
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241018050234\r
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|69.0|µmol/L|<680|N|||F|||20241018050234\r
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.23|µmol/L|<6.1|N|||F|||20241018050234\r
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|22.5|µmol/L|6.3-100|N|||F|||20241018050234\r
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|14|µmol/L|5-49|N|||F|||20241018050234\r
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|2.28|{Ratio}|<4.8|N|||F|||20241018050234\r
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|68|µmol/L|<800|N|||F|||20241018050234\r
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|4.93|{Ratio}||N|||F|||20241018050234\r
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|6|µmol/L|<63|N|||F|||20241018050234\r
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241018050234\r
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|192|µmol/L|<1500|N|||F|||20241018050234\r
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|6|12345667867^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241018050234\r
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with SCADD, IBCDD|||A|||F|||20241018050234\r
-OBR|7|12345667867^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|26.6|µmol/L|6.4-125|N|||F|||20241018050234\r
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|3.27|{Ratio}|<70|N|||F|||20241018050234\r
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|29.2|µmol/L|10-80|N|||F|||20241018050234\r
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.13913|{Ratio}|<7.6|N|||F|||20241018050234\r
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.088|µmol/L|<0.95|N|||F|||20241018050234\r
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.084|µmol/L|<0.45|N|||F|||20241018050234\r
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.73|{Ratio}||N|||F|||20241018050234\r
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.172|µmol/L|<0.65|N|||F|||20241018050234\r
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.115|µmol/L|<0.65|N|||F|||20241018050234\r
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.050|µmol/L|<0.45|N|||F|||20241018050234\r
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.127|µmol/L|<2|N|||F|||20241018050234\r
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.12|µmol/L||N|||F|||20241018050234\r
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.333|µmol/L|<1.2|N|||F|||20241018050234\r
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.132|µmol/L|<0.9|N|||F|||20241018050234\r
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.13|{Ratio}||N|||F|||20241018050234\r
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241018050234\r
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.026|µmol/L|<0.2|N|||F|||20241018050234\r
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|6.19|µmol/L|<12|N|||F|||20241018050234\r
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.445|µmol/L|<1.4|N|||F|||20241018050234\r
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.045|µmol/L|<0.1|N|||F|||20241018050234\r
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00727|{Ratio}|<0.07|N|||F|||20241018050234\r
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.53|µmol/L|<3.5|N|||F|||20241018050234\r
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.96|µmol/L|<7|N|||F|||20241018050234\r
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.21|µmol/L||N|||F|||20241018050234\r
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.017|µmol/L|<0.1|N|||F|||20241018050234\r
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.036|µmol/L|<0.1|N|||F|||20241018050234\r
-OBR|8|12345667867^FormNumber||57085-3^Organic acid newborn screen panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.5|µmol/L|<7.9|N|||F|||20241018050234\r
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.09|{Ratio}|<0.42|N|||F|||20241018050234\r
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.246|µmol/L|<0.48|N|||F|||20241018050234\r
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|1.72|µmol/L|<1.7|H|||F|||20241018050234\r
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.115|µmol/L|<0.95|N|||F|||20241018050234\r
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.04600|{Ratio}|<0.38|N|||F|||20241018050234\r
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.008|µmol/L|<0.5|N|||F|||20241018050234\r
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.232|µmol/L|<1.15|N|||F|||20241018050234\r
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.180|µmol/L|<0.38|N|||F|||20241018050234\r
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.73171|{Ratio}|>0.1|N|||F|||20241018050234\r
-OBR|9|12345667867^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|21.20|ng/mL|<69|N|||F|||20241018050234\r
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|10|12345667867^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00015.6|nmol/L|<85|N|||F|||20241018050234\r
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|11|12345667867^FormNumber||54090-6^Thyroid newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|29575-8^Thyrotropin^LN|1|9.50|mIU/L|<29|N|||F|||20241018050234\r
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|12|12345667867^FormNumber||54079-9^Galactosemia newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|262.95|enzyme units|>50|N|||F|||20241018050234\r
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|13|12345667867^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241018050234\r
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241018050234\r
-OBR|14|12345667867^FormNumber||57087-9^Biotinidase newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|49.77|ERU|>10|N|||F|||20241018050234\r
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|15|12345667867^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|197|copies/µL|>18|N|||F|||20241018050234\r
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|16|12345667867^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.29|µmol/L/h|>=1.47|N|||F|||20241018050234\r
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|17|12345667867^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|13.01|µmol/L/h|>=0.82|N|||F|||20241018050234\r
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|18|12345667867^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241018050234\r
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241018050234\r
-OBR|19|12345667867^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|27.84|µmol/L/h|>=2.79|N|||F|||20241018050234\r
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|20|12345667867^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|21|12345667867^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|0.97|µmol/L|<=3|N|||F|||20241018050234\r
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|496.63|µmol/L||N|||F|||20241018050234\r
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.95||<=6|N|||F|||20241018050234\r
-OBR|22|12345667867^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241018050234\r
-OBR|23|12345667867^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.349|µmol/L|<0.47|N|||F|||20241018050234\r
+ORC|RE|12345667867^FormNumber||S30500^HospOrdNumber||||||||1194257170^MAHMOOD^SARAH^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804
+OBR|1|12345667867^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410061300|||||||||||||||20241018050234|||F
+OBR|2|12345667867^FormNumber||57128-1^Newborn Screening Report summary panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241018050234
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241018050234
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241018050234
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050234
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050234
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241018050234
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241018050234
+OBR|3|12345667867^FormNumber||57717-1^Newborn screen card data panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241018050234
+OBX|2|NM|8339-4^Birthweight^LN|1|3135|grams||N|||F|||20241018050234
+OBX|3|TM|57715-5^Time of birth^LN|1|1235|||N|||F|||20241018050234
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241018050234
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241018050234
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241018050234
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241018050234
+OBX|8|TX|^^^99717-5^Accession Number^L|1|282-18-014/21-2024-32|||N|||F|||20241018050234
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|SARAH MAHMOOD|||N|||F|||20241018050234
+OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1194257170|||N|||F|||20241018050234
+OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA|||N|||F|||20241018050234
+OBR|4|12345667867^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410061300|||||||||||||||20241018050234|||F
+OBR|5|12345667867^FormNumber||53261-4^Amino acid newborn screen panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|611|µmol/L||N|||F|||20241018050234
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|585|µmol/L|<1000|N|||F|||20241018050234
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|90.9|µmol/L||N|||F|||20241018050234
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.74808|{Ratio}|<4.3|N|||F|||20241018050234
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|86.9|µmol/L|<230|N|||F|||20241018050234
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.15|{Ratio}|<1.35|N|||F|||20241018050234
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|52.0|µmol/L|<175|N|||F|||20241018050234
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241018050234
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|69.0|µmol/L|<680|N|||F|||20241018050234
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.23|µmol/L|<6.1|N|||F|||20241018050234
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|22.5|µmol/L|6.3-100|N|||F|||20241018050234
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|14|µmol/L|5-49|N|||F|||20241018050234
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|2.28|{Ratio}|<4.8|N|||F|||20241018050234
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|68|µmol/L|<800|N|||F|||20241018050234
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|4.93|{Ratio}||N|||F|||20241018050234
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|6|µmol/L|<63|N|||F|||20241018050234
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241018050234
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|192|µmol/L|<1500|N|||F|||20241018050234
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|6|12345667867^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241018050234
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with SCADD, IBCDD|||A|||F|||20241018050234
+OBR|7|12345667867^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|26.6|µmol/L|6.4-125|N|||F|||20241018050234
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|3.27|{Ratio}|<70|N|||F|||20241018050234
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|29.2|µmol/L|10-80|N|||F|||20241018050234
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.13913|{Ratio}|<7.6|N|||F|||20241018050234
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.088|µmol/L|<0.95|N|||F|||20241018050234
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.084|µmol/L|<0.45|N|||F|||20241018050234
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.73|{Ratio}||N|||F|||20241018050234
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.172|µmol/L|<0.65|N|||F|||20241018050234
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.115|µmol/L|<0.65|N|||F|||20241018050234
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.050|µmol/L|<0.45|N|||F|||20241018050234
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.127|µmol/L|<2|N|||F|||20241018050234
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.12|µmol/L||N|||F|||20241018050234
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.333|µmol/L|<1.2|N|||F|||20241018050234
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.132|µmol/L|<0.9|N|||F|||20241018050234
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.13|{Ratio}||N|||F|||20241018050234
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241018050234
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.026|µmol/L|<0.2|N|||F|||20241018050234
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|6.19|µmol/L|<12|N|||F|||20241018050234
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.445|µmol/L|<1.4|N|||F|||20241018050234
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.045|µmol/L|<0.1|N|||F|||20241018050234
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00727|{Ratio}|<0.07|N|||F|||20241018050234
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.53|µmol/L|<3.5|N|||F|||20241018050234
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.96|µmol/L|<7|N|||F|||20241018050234
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.21|µmol/L||N|||F|||20241018050234
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.017|µmol/L|<0.1|N|||F|||20241018050234
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.036|µmol/L|<0.1|N|||F|||20241018050234
+OBR|8|12345667867^FormNumber||57085-3^Organic acid newborn screen panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.5|µmol/L|<7.9|N|||F|||20241018050234
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.09|{Ratio}|<0.42|N|||F|||20241018050234
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.246|µmol/L|<0.48|N|||F|||20241018050234
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|1.72|µmol/L|<1.7|H|||F|||20241018050234
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.115|µmol/L|<0.95|N|||F|||20241018050234
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.04600|{Ratio}|<0.38|N|||F|||20241018050234
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.008|µmol/L|<0.5|N|||F|||20241018050234
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.232|µmol/L|<1.15|N|||F|||20241018050234
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.180|µmol/L|<0.38|N|||F|||20241018050234
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.73171|{Ratio}|>0.1|N|||F|||20241018050234
+OBR|9|12345667867^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|21.20|ng/mL|<69|N|||F|||20241018050234
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|10|12345667867^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00015.6|nmol/L|<85|N|||F|||20241018050234
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|11|12345667867^FormNumber||54090-6^Thyroid newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|29575-8^Thyrotropin^LN|1|9.50|mIU/L|<29|N|||F|||20241018050234
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|12|12345667867^FormNumber||54079-9^Galactosemia newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|262.95|enzyme units|>50|N|||F|||20241018050234
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|13|12345667867^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241018050234
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241018050234
+OBR|14|12345667867^FormNumber||57087-9^Biotinidase newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|49.77|ERU|>10|N|||F|||20241018050234
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|15|12345667867^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|197|copies/µL|>18|N|||F|||20241018050234
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|16|12345667867^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.29|µmol/L/h|>=1.47|N|||F|||20241018050234
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|17|12345667867^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|13.01|µmol/L/h|>=0.82|N|||F|||20241018050234
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|18|12345667867^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241018050234
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241018050234
+OBR|19|12345667867^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|27.84|µmol/L/h|>=2.79|N|||F|||20241018050234
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|20|12345667867^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|21|12345667867^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|0.97|µmol/L|<=3|N|||F|||20241018050234
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|496.63|µmol/L||N|||F|||20241018050234
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.95||<=6|N|||F|||20241018050234
+OBR|22|12345667867^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241018050234
+OBR|23|12345667867^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.349|µmol/L|<0.47|N|||F|||20241018050234
diff --git a/examples/Test/Automated/003_ORU_R01_golden_copy_input_aa_unusual.hl7 b/examples/Test/Automated/003_ORU_R01_golden_copy_input_aa_unusual.hl7
index a1ed92d13..d5fb3472e 100644
--- a/examples/Test/Automated/003_ORU_R01_golden_copy_input_aa_unusual.hl7
+++ b/examples/Test/Automated/003_ORU_R01_golden_copy_input_aa_unusual.hl7
@@ -1,142 +1,142 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241023050044||ORU^R01^ORU_R01|003|N|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241023050044||ORU^R01^ORU_R01|003|N|2.5.1
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
-ORC|RE|45789876^FormNumber||56352742^HospOrdNumber||||||||1043390461^PROFIT^DR JOCHEN^^^^^^^NPI|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601\r
-OBR|1|45789876^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBR|2|45789876^FormNumber||57128-1^Newborn Screening Report summary panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241023050044\r
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241023050044\r
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241023050044\r
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241023050044\r
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241023050044\r
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - ALLIED LABORATORY \\R\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Amino Acid Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241023050044\r
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241023050044\r
-OBR|3|45789876^FormNumber||57717-1^Newborn screen card data panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241023050044\r
-OBX|2|NM|8339-4^Birthweight^LN|1|2230|grams||N|||F|||20241023050044\r
-OBX|3|TM|57715-5^Time of birth^LN|1|1358|||N|||F|||20241023050044\r
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241023050044\r
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|26|hour(s)||N|||F|||20241023050044\r
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241023050044\r
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241023050044\r
-OBX|8|TX|^^^99717-5^Accession Number^L|1|282-38-261/21-2024-12|||N|||F|||20241023050044\r
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DR JOCHEN PROFIT|||N|||F|||20241023050044\r
-OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1043390461|||N|||F|||20241023050044\r
-OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA|||N|||F|||20241023050044\r
-OBR|4|45789876^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBR|5|45789876^FormNumber||53261-4^Amino acid newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|368|µmol/L||N|||F|||20241023050044\r
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|310|µmol/L|<1000|N|||F|||20241023050044\r
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|34.6|µmol/L||N|||F|||20241023050044\r
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.06462|{Ratio}|<4.3|N|||F|||20241023050044\r
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|50.7|µmol/L|<230|N|||F|||20241023050044\r
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.16|{Ratio}|<1.35|N|||F|||20241023050044\r
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|32.5|µmol/L|<175|N|||F|||20241023050044\r
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.13|{Ratio}|<2.6|N|||F|||20241023050044\r
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|28.9|µmol/L|<680|N|||F|||20241023050044\r
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.25|µmol/L|<6.1|N|||F|||20241023050044\r
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|8.6|µmol/L|6.3-100|N|||F|||20241023050044\r
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|5|µmol/L|5-49|N|||F|||20241023050044\r
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.67|{Ratio}|<4.8|N|||F|||20241023050044\r
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|32|µmol/L|<800|N|||F|||20241023050044\r
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|6.41|{Ratio}||N|||F|||20241023050044\r
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|3|µmol/L|<63|N|||F|||20241023050044\r
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241023050044\r
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|55|µmol/L|<1500|N|||F|||20241023050044\r
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|This complex pattern of elevations require further evaluation|||A|||F|||20241023050044\r
-OBR|6|45789876^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|7|45789876^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|34.9|µmol/L|6.4-125|N|||F|||20241023050044\r
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|7.84|{Ratio}|<70|N|||F|||20241023050044\r
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|28.1|µmol/L|10-80|N|||F|||20241023050044\r
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|3.53125|{Ratio}|<7.6|N|||F|||20241023050044\r
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.034|µmol/L|<0.95|N|||F|||20241023050044\r
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.038|µmol/L|<0.45|N|||F|||20241023050044\r
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.19|{Ratio}||N|||F|||20241023050044\r
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.155|µmol/L|<0.65|N|||F|||20241023050044\r
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.032|µmol/L|<0.65|N|||F|||20241023050044\r
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.030|µmol/L|<0.45|N|||F|||20241023050044\r
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.070|µmol/L|<2|N|||F|||20241023050044\r
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.05|µmol/L||N|||F|||20241023050044\r
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.270|µmol/L|<1.2|N|||F|||20241023050044\r
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.084|µmol/L|<0.9|N|||F|||20241023050044\r
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.75|{Ratio}||N|||F|||20241023050044\r
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241023050044\r
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.009|µmol/L|<0.2|N|||F|||20241023050044\r
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|2.87|µmol/L|<12|N|||F|||20241023050044\r
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.236|µmol/L|<1.4|N|||F|||20241023050044\r
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.022|µmol/L|<0.1|N|||F|||20241023050044\r
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00767|{Ratio}|<0.07|N|||F|||20241023050044\r
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|0.987|µmol/L|<3.5|N|||F|||20241023050044\r
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.59|µmol/L|<7|N|||F|||20241023050044\r
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.20|µmol/L||N|||F|||20241023050044\r
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.014|µmol/L|<0.1|N|||F|||20241023050044\r
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.034|µmol/L|<0.1|N|||F|||20241023050044\r
-OBR|8|45789876^FormNumber||57085-3^Organic acid newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|1.9|µmol/L|<7.9|N|||F|||20241023050044\r
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.07|{Ratio}|<0.42|N|||F|||20241023050044\r
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.113|µmol/L|<0.48|N|||F|||20241023050044\r
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.161|µmol/L|<1.7|N|||F|||20241023050044\r
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.111|µmol/L|<0.95|N|||F|||20241023050044\r
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05842|{Ratio}|<0.38|N|||F|||20241023050044\r
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.006|µmol/L|<0.5|N|||F|||20241023050044\r
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.140|µmol/L|<1.15|N|||F|||20241023050044\r
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.091|µmol/L|<0.38|N|||F|||20241023050044\r
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.80531|{Ratio}|>0.1|N|||F|||20241023050044\r
-OBR|9|45789876^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|27.50|ng/mL|<69|N|||F|||20241023050044\r
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|10|45789876^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00029.9|nmol/L|<190|N|||F|||20241023050044\r
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|11|45789876^FormNumber||54090-6^Thyroid newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|29575-8^Thyrotropin^LN|1|6.90|mIU/L|<29|N|||F|||20241023050044\r
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|12|45789876^FormNumber||54079-9^Galactosemia newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|226.51|enzyme units|>50|N|||F|||20241023050044\r
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|13|45789876^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241023050044\r
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241023050044\r
-OBR|14|45789876^FormNumber||57087-9^Biotinidase newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|28.87|ERU|>10|N|||F|||20241023050044\r
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|15|45789876^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|198|copies/µL|>18|N|||F|||20241023050044\r
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|16|45789876^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|7.91|µmol/L/h|>=1.62|N|||F|||20241023050044\r
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|17|45789876^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|7.78|µmol/L/h|>=0.79|N|||F|||20241023050044\r
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|18|45789876^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241023050044\r
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241023050044\r
-OBR|19|45789876^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.94|µmol/L/h|>=2.95|N|||F|||20241023050044\r
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|20|45789876^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|21|45789876^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.00|µmol/L|<=3|N|||F|||20241023050044\r
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|707.37|µmol/L||N|||F|||20241023050044\r
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.41||<=6|N|||F|||20241023050044\r
-OBR|22|45789876^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241023050044\r
-OBR|23|45789876^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.246|µmol/L|<0.47|N|||F|||20241023050044\r
+ORC|RE|45789876^FormNumber||56352742^HospOrdNumber||||||||1043390461^PROFIT^DR JOCHEN^^^^^^^NPI|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601
+OBR|1|45789876^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBR|2|45789876^FormNumber||57128-1^Newborn Screening Report summary panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241023050044
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241023050044
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241023050044
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241023050044
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241023050044
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - ALLIED LABORATORY \\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Amino Acid Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241023050044
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241023050044
+OBR|3|45789876^FormNumber||57717-1^Newborn screen card data panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241023050044
+OBX|2|NM|8339-4^Birthweight^LN|1|2230|grams||N|||F|||20241023050044
+OBX|3|TM|57715-5^Time of birth^LN|1|1358|||N|||F|||20241023050044
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241023050044
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|26|hour(s)||N|||F|||20241023050044
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241023050044
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241023050044
+OBX|8|TX|^^^99717-5^Accession Number^L|1|282-38-261/21-2024-12|||N|||F|||20241023050044
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DR JOCHEN PROFIT|||N|||F|||20241023050044
+OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1043390461|||N|||F|||20241023050044
+OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA|||N|||F|||20241023050044
+OBR|4|45789876^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBR|5|45789876^FormNumber||53261-4^Amino acid newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|368|µmol/L||N|||F|||20241023050044
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|310|µmol/L|<1000|N|||F|||20241023050044
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|34.6|µmol/L||N|||F|||20241023050044
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.06462|{Ratio}|<4.3|N|||F|||20241023050044
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|50.7|µmol/L|<230|N|||F|||20241023050044
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.16|{Ratio}|<1.35|N|||F|||20241023050044
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|32.5|µmol/L|<175|N|||F|||20241023050044
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.13|{Ratio}|<2.6|N|||F|||20241023050044
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|28.9|µmol/L|<680|N|||F|||20241023050044
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.25|µmol/L|<6.1|N|||F|||20241023050044
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|8.6|µmol/L|6.3-100|N|||F|||20241023050044
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|5|µmol/L|5-49|N|||F|||20241023050044
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.67|{Ratio}|<4.8|N|||F|||20241023050044
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|32|µmol/L|<800|N|||F|||20241023050044
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|6.41|{Ratio}||N|||F|||20241023050044
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|3|µmol/L|<63|N|||F|||20241023050044
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241023050044
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|55|µmol/L|<1500|N|||F|||20241023050044
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|This complex pattern of elevations require further evaluation|||A|||F|||20241023050044
+OBR|6|45789876^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|7|45789876^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|34.9|µmol/L|6.4-125|N|||F|||20241023050044
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|7.84|{Ratio}|<70|N|||F|||20241023050044
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|28.1|µmol/L|10-80|N|||F|||20241023050044
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|3.53125|{Ratio}|<7.6|N|||F|||20241023050044
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.034|µmol/L|<0.95|N|||F|||20241023050044
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.038|µmol/L|<0.45|N|||F|||20241023050044
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.19|{Ratio}||N|||F|||20241023050044
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.155|µmol/L|<0.65|N|||F|||20241023050044
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.032|µmol/L|<0.65|N|||F|||20241023050044
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.030|µmol/L|<0.45|N|||F|||20241023050044
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.070|µmol/L|<2|N|||F|||20241023050044
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.05|µmol/L||N|||F|||20241023050044
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.270|µmol/L|<1.2|N|||F|||20241023050044
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.084|µmol/L|<0.9|N|||F|||20241023050044
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.75|{Ratio}||N|||F|||20241023050044
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241023050044
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.009|µmol/L|<0.2|N|||F|||20241023050044
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|2.87|µmol/L|<12|N|||F|||20241023050044
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.236|µmol/L|<1.4|N|||F|||20241023050044
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.022|µmol/L|<0.1|N|||F|||20241023050044
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00767|{Ratio}|<0.07|N|||F|||20241023050044
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|0.987|µmol/L|<3.5|N|||F|||20241023050044
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.59|µmol/L|<7|N|||F|||20241023050044
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.20|µmol/L||N|||F|||20241023050044
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.014|µmol/L|<0.1|N|||F|||20241023050044
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.034|µmol/L|<0.1|N|||F|||20241023050044
+OBR|8|45789876^FormNumber||57085-3^Organic acid newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|1.9|µmol/L|<7.9|N|||F|||20241023050044
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.07|{Ratio}|<0.42|N|||F|||20241023050044
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.113|µmol/L|<0.48|N|||F|||20241023050044
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.161|µmol/L|<1.7|N|||F|||20241023050044
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.111|µmol/L|<0.95|N|||F|||20241023050044
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05842|{Ratio}|<0.38|N|||F|||20241023050044
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.006|µmol/L|<0.5|N|||F|||20241023050044
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.140|µmol/L|<1.15|N|||F|||20241023050044
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.091|µmol/L|<0.38|N|||F|||20241023050044
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.80531|{Ratio}|>0.1|N|||F|||20241023050044
+OBR|9|45789876^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|27.50|ng/mL|<69|N|||F|||20241023050044
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|10|45789876^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00029.9|nmol/L|<190|N|||F|||20241023050044
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|11|45789876^FormNumber||54090-6^Thyroid newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|29575-8^Thyrotropin^LN|1|6.90|mIU/L|<29|N|||F|||20241023050044
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|12|45789876^FormNumber||54079-9^Galactosemia newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|226.51|enzyme units|>50|N|||F|||20241023050044
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|13|45789876^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241023050044
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241023050044
+OBR|14|45789876^FormNumber||57087-9^Biotinidase newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|28.87|ERU|>10|N|||F|||20241023050044
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|15|45789876^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|198|copies/µL|>18|N|||F|||20241023050044
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|16|45789876^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|7.91|µmol/L/h|>=1.62|N|||F|||20241023050044
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|17|45789876^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|7.78|µmol/L/h|>=0.79|N|||F|||20241023050044
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|18|45789876^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241023050044
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241023050044
+OBR|19|45789876^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.94|µmol/L/h|>=2.95|N|||F|||20241023050044
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|20|45789876^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|21|45789876^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.00|µmol/L|<=3|N|||F|||20241023050044
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|707.37|µmol/L||N|||F|||20241023050044
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.41||<=6|N|||F|||20241023050044
+OBR|22|45789876^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241023050044
+OBR|23|45789876^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.246|µmol/L|<0.47|N|||F|||20241023050044
diff --git a/examples/Test/Automated/004_ORU_R01_golden_copy_input_in_range.hl7 b/examples/Test/Automated/004_ORU_R01_golden_copy_input_in_range.hl7
index 8e0752090..8b4b6f202 100644
--- a/examples/Test/Automated/004_ORU_R01_golden_copy_input_in_range.hl7
+++ b/examples/Test/Automated/004_ORU_R01_golden_copy_input_in_range.hl7
@@ -1,142 +1,142 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241030050154||ORU^R01^ORU_R01|004|N|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241030050154||ORU^R01^ORU_R01|004|N|2.5.1
 PID|1||335441864^^^104638912487&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
-ORC|RE|356672001^FormNumber||629813494^HospOrdNumber||||||||1093050858^SILVA^RICHARD^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|200 W ARBOR DR^^SAN DIEGO^CA^92103-1911\r
-OBR|1|356672001^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBR|2|356672001^FormNumber||57128-1^Newborn Screening Report summary panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241030050154\r
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241030050154\r
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12428-1^All screening is in range for the conditions tested^LN|||N|||F|||20241030050154\r
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241030050154\r
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241030050154\r
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \\R\\2130 E Illinois Avenue, FRESNO, CA 93701\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (858) 966-8708. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241030050154\r
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241030050154\r
-OBR|3|356672001^FormNumber||57717-1^Newborn screen card data panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241030050154\r
-OBX|2|NM|8339-4^Birthweight^LN|1|3464|grams||N|||F|||20241030050154\r
-OBX|3|TM|57715-5^Time of birth^LN|1|0444|||N|||F|||20241030050154\r
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241030050154\r
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|19|hour(s)||N|||F|||20241030050154\r
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241030050154\r
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241030050154\r
-OBX|8|TX|^^^99717-5^Accession Number^L|1|292-04-123/21-2024-32|||N|||F|||20241030050154\r
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DIANE BEDROSIAN|||N|||F|||20241030050154\r
-OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1447323951|||N|||F|||20241030050154\r
-OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|200 W ARBOR DR SAN DIEGO CA 92103-1911 USA|||N|||F|||20241030050154\r
-OBR|4|356672001^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBR|5|356672001^FormNumber||53261-4^Amino acid newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|536|µmol/L||N|||F|||20241030050154\r
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|559|µmol/L|<1000|N|||F|||20241030050154\r
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|123|µmol/L||N|||F|||20241030050154\r
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|2.14286|{Ratio}|<4.3|N|||F|||20241030050154\r
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|113|µmol/L|<230|N|||F|||20241030050154\r
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.20|{Ratio}|<1.35|N|||F|||20241030050154\r
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|57.4|µmol/L|<175|N|||F|||20241030050154\r
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.05|{Ratio}|<2.6|N|||F|||20241030050154\r
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|54.8|µmol/L|<680|N|||F|||20241030050154\r
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.20|µmol/L|<6.1|N|||F|||20241030050154\r
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|22.8|µmol/L|6.3-100|N|||F|||20241030050154\r
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|10|µmol/L|5-49|N|||F|||20241030050154\r
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.52|{Ratio}|<4.8|N|||F|||20241030050154\r
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|84|µmol/L|<800|N|||F|||20241030050154\r
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|8.40|{Ratio}||N|||F|||20241030050154\r
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|7|µmol/L|<63|N|||F|||20241030050154\r
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241030050154\r
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|154|µmol/L|<1500|N|||F|||20241030050154\r
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|6|356672001^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|7|356672001^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|24.4|µmol/L|6.4-125|N|||F|||20241030050154\r
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|4.32|{Ratio}|<70|N|||F|||20241030050154\r
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|27.3|µmol/L|10-80|N|||F|||20241030050154\r
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.73000|{Ratio}|<7.6|N|||F|||20241030050154\r
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.067|µmol/L|<0.95|N|||F|||20241030050154\r
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.076|µmol/L|<0.45|N|||F|||20241030050154\r
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.76|{Ratio}||N|||F|||20241030050154\r
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.103|µmol/L|<0.65|N|||F|||20241030050154\r
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.100|µmol/L|<0.65|N|||F|||20241030050154\r
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.035|µmol/L|<0.45|N|||F|||20241030050154\r
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.132|µmol/L|<2|N|||F|||20241030050154\r
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.17|µmol/L||N|||F|||20241030050154\r
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.264|µmol/L|<1.2|N|||F|||20241030050154\r
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.189|µmol/L|<0.9|N|||F|||20241030050154\r
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.13|{Ratio}||N|||F|||20241030050154\r
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241030050154\r
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.021|µmol/L|<0.2|N|||F|||20241030050154\r
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|3.88|µmol/L|<12|N|||F|||20241030050154\r
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.371|µmol/L|<1.4|N|||F|||20241030050154\r
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.030|µmol/L|<0.1|N|||F|||20241030050154\r
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00773|{Ratio}|<0.07|N|||F|||20241030050154\r
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.11|µmol/L|<3.5|N|||F|||20241030050154\r
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.76|µmol/L|<7|N|||F|||20241030050154\r
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.15|µmol/L||N|||F|||20241030050154\r
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.015|µmol/L|<0.1|N|||F|||20241030050154\r
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.032|µmol/L|<0.1|N|||F|||20241030050154\r
-OBR|8|356672001^FormNumber||57085-3^Organic acid newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.3|µmol/L|<7.9|N|||F|||20241030050154\r
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.09|{Ratio}|<0.42|N|||F|||20241030050154\r
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.273|µmol/L|<0.48|N|||F|||20241030050154\r
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.315|µmol/L|<1.7|N|||F|||20241030050154\r
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.117|µmol/L|<0.95|N|||F|||20241030050154\r
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05087|{Ratio}|<0.38|N|||F|||20241030050154\r
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.009|µmol/L|<0.5|N|||F|||20241030050154\r
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.217|µmol/L|<1.15|N|||F|||20241030050154\r
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.183|µmol/L|<0.38|N|||F|||20241030050154\r
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.67033|{Ratio}|>0.1|N|||F|||20241030050154\r
-OBR|9|356672001^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|27.20|ng/mL|<69|N|||F|||20241030050154\r
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|10|356672001^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00015.2|nmol/L|<85|N|||F|||20241030050154\r
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|11|356672001^FormNumber||54090-6^Thyroid newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|29575-8^Thyrotropin^LN|1|15.40|mIU/L|<29|N|||F|||20241030050154\r
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|12|356672001^FormNumber||54079-9^Galactosemia newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|273.54|enzyme units|>50|N|||F|||20241030050154\r
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|13|356672001^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241030050154\r
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241030050154\r
-OBR|14|356672001^FormNumber||57087-9^Biotinidase newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|73.00|ERU|>10|N|||F|||20241030050154\r
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|15|356672001^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|120|copies/µL|>18|N|||F|||20241030050154\r
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|16|356672001^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|11.43|µmol/L/h|>=1.54|N|||F|||20241030050154\r
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|17|356672001^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|9.33|µmol/L/h|>=0.86|N|||F|||20241030050154\r
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|18|356672001^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241030050154\r
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241030050154\r
-OBR|19|356672001^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|22.31|µmol/L/h|>=2.84|N|||F|||20241030050154\r
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|20|356672001^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|21|356672001^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.22|µmol/L|<=3|N|||F|||20241030050154\r
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|411.55|µmol/L||N|||F|||20241030050154\r
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.95||<=6|N|||F|||20241030050154\r
-OBR|22|356672001^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241030050154\r
-OBR|23|356672001^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.138|µmol/L|<0.47|N|||F|||20241030050154\r
+ORC|RE|356672001^FormNumber||629813494^HospOrdNumber||||||||1093050858^SILVA^RICHARD^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|200 W ARBOR DR^^SAN DIEGO^CA^92103-1911
+OBR|1|356672001^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBR|2|356672001^FormNumber||57128-1^Newborn Screening Report summary panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241030050154
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241030050154
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12428-1^All screening is in range for the conditions tested^LN|||N|||F|||20241030050154
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241030050154
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241030050154
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \\\2130 E Illinois Avenue, FRESNO, CA 93701\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (858) 966-8708. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241030050154
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241030050154
+OBR|3|356672001^FormNumber||57717-1^Newborn screen card data panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241030050154
+OBX|2|NM|8339-4^Birthweight^LN|1|3464|grams||N|||F|||20241030050154
+OBX|3|TM|57715-5^Time of birth^LN|1|0444|||N|||F|||20241030050154
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241030050154
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|19|hour(s)||N|||F|||20241030050154
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241030050154
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241030050154
+OBX|8|TX|^^^99717-5^Accession Number^L|1|292-04-123/21-2024-32|||N|||F|||20241030050154
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DIANE BEDROSIAN|||N|||F|||20241030050154
+OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1447323951|||N|||F|||20241030050154
+OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|200 W ARBOR DR SAN DIEGO CA 92103-1911 USA|||N|||F|||20241030050154
+OBR|4|356672001^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBR|5|356672001^FormNumber||53261-4^Amino acid newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|536|µmol/L||N|||F|||20241030050154
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|559|µmol/L|<1000|N|||F|||20241030050154
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|123|µmol/L||N|||F|||20241030050154
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|2.14286|{Ratio}|<4.3|N|||F|||20241030050154
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|113|µmol/L|<230|N|||F|||20241030050154
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.20|{Ratio}|<1.35|N|||F|||20241030050154
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|57.4|µmol/L|<175|N|||F|||20241030050154
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.05|{Ratio}|<2.6|N|||F|||20241030050154
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|54.8|µmol/L|<680|N|||F|||20241030050154
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.20|µmol/L|<6.1|N|||F|||20241030050154
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|22.8|µmol/L|6.3-100|N|||F|||20241030050154
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|10|µmol/L|5-49|N|||F|||20241030050154
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.52|{Ratio}|<4.8|N|||F|||20241030050154
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|84|µmol/L|<800|N|||F|||20241030050154
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|8.40|{Ratio}||N|||F|||20241030050154
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|7|µmol/L|<63|N|||F|||20241030050154
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241030050154
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|154|µmol/L|<1500|N|||F|||20241030050154
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|6|356672001^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|7|356672001^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|24.4|µmol/L|6.4-125|N|||F|||20241030050154
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|4.32|{Ratio}|<70|N|||F|||20241030050154
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|27.3|µmol/L|10-80|N|||F|||20241030050154
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.73000|{Ratio}|<7.6|N|||F|||20241030050154
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.067|µmol/L|<0.95|N|||F|||20241030050154
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.076|µmol/L|<0.45|N|||F|||20241030050154
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.76|{Ratio}||N|||F|||20241030050154
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.103|µmol/L|<0.65|N|||F|||20241030050154
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.100|µmol/L|<0.65|N|||F|||20241030050154
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.035|µmol/L|<0.45|N|||F|||20241030050154
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.132|µmol/L|<2|N|||F|||20241030050154
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.17|µmol/L||N|||F|||20241030050154
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.264|µmol/L|<1.2|N|||F|||20241030050154
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.189|µmol/L|<0.9|N|||F|||20241030050154
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.13|{Ratio}||N|||F|||20241030050154
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241030050154
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.021|µmol/L|<0.2|N|||F|||20241030050154
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|3.88|µmol/L|<12|N|||F|||20241030050154
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.371|µmol/L|<1.4|N|||F|||20241030050154
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.030|µmol/L|<0.1|N|||F|||20241030050154
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00773|{Ratio}|<0.07|N|||F|||20241030050154
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.11|µmol/L|<3.5|N|||F|||20241030050154
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.76|µmol/L|<7|N|||F|||20241030050154
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.15|µmol/L||N|||F|||20241030050154
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.015|µmol/L|<0.1|N|||F|||20241030050154
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.032|µmol/L|<0.1|N|||F|||20241030050154
+OBR|8|356672001^FormNumber||57085-3^Organic acid newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.3|µmol/L|<7.9|N|||F|||20241030050154
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.09|{Ratio}|<0.42|N|||F|||20241030050154
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.273|µmol/L|<0.48|N|||F|||20241030050154
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.315|µmol/L|<1.7|N|||F|||20241030050154
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.117|µmol/L|<0.95|N|||F|||20241030050154
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05087|{Ratio}|<0.38|N|||F|||20241030050154
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.009|µmol/L|<0.5|N|||F|||20241030050154
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.217|µmol/L|<1.15|N|||F|||20241030050154
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.183|µmol/L|<0.38|N|||F|||20241030050154
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.67033|{Ratio}|>0.1|N|||F|||20241030050154
+OBR|9|356672001^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|27.20|ng/mL|<69|N|||F|||20241030050154
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|10|356672001^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00015.2|nmol/L|<85|N|||F|||20241030050154
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|11|356672001^FormNumber||54090-6^Thyroid newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|29575-8^Thyrotropin^LN|1|15.40|mIU/L|<29|N|||F|||20241030050154
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|12|356672001^FormNumber||54079-9^Galactosemia newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|273.54|enzyme units|>50|N|||F|||20241030050154
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|13|356672001^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241030050154
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241030050154
+OBR|14|356672001^FormNumber||57087-9^Biotinidase newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|73.00|ERU|>10|N|||F|||20241030050154
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|15|356672001^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|120|copies/µL|>18|N|||F|||20241030050154
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|16|356672001^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|11.43|µmol/L/h|>=1.54|N|||F|||20241030050154
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|17|356672001^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|9.33|µmol/L/h|>=0.86|N|||F|||20241030050154
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|18|356672001^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241030050154
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241030050154
+OBR|19|356672001^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|22.31|µmol/L/h|>=2.84|N|||F|||20241030050154
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|20|356672001^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|21|356672001^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.22|µmol/L|<=3|N|||F|||20241030050154
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|411.55|µmol/L||N|||F|||20241030050154
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.95||<=6|N|||F|||20241030050154
+OBR|22|356672001^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241030050154
+OBR|23|356672001^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.138|µmol/L|<0.47|N|||F|||20241030050154
diff --git a/examples/Test/Automated/005_ORU_R01_golden_copy_input_out_of_range.hl7 b/examples/Test/Automated/005_ORU_R01_golden_copy_input_out_of_range.hl7
index 0d67e12e9..6f949201c 100644
--- a/examples/Test/Automated/005_ORU_R01_golden_copy_input_out_of_range.hl7
+++ b/examples/Test/Automated/005_ORU_R01_golden_copy_input_out_of_range.hl7
@@ -1,142 +1,142 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050017||ORU^R01^ORU_R01|005|N|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050017||ORU^R01^ORU_R01|005|N|2.5.1
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
-ORC|RE|753234567^FormNumber||56155532^HospOrdNumber||||||||^SCALA^MELISSA|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601\r
-OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBR|2|753234567^FormNumber||57128-1^Newborn Screening Report summary panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241018050017\r
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241018050017\r
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241018050017\r
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA16207-5^Hemoglobinopathies^LN|||N|||F|||20241018050017\r
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050017\r
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - ALLIED LABORATORY \\R\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Hb: An immediate referral to a CCS Hematology Center or a pediatric hematologist familiar with alpha thalassemia and Hb H disease is strongly recommended for this infant. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241018050017\r
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241018050017\r
-OBR|3|753234567^FormNumber||57717-1^Newborn screen card data panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241018050017\r
-OBX|2|NM|8339-4^Birthweight^LN|1|2658|grams||N|||F|||20241018050017\r
-OBX|3|TM|57715-5^Time of birth^LN|1|0027|||N|||F|||20241018050017\r
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241018050017\r
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|28|hour(s)||N|||F|||20241018050017\r
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241018050017\r
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241018050017\r
-OBX|8|TX|^^^99717-5^Accession Number^L|1|272-95-009/21-2024-12|||N|||F|||20241018050017\r
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MELISSA SCALA|||N|||F|||20241018050017\r
-OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA|||N|||F|||20241018050017\r
-OBR|4|753234567^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBR|5|753234567^FormNumber||53261-4^Amino acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|926|µmol/L||N|||F|||20241018050017\r
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|588|µmol/L|<1000|N|||F|||20241018050017\r
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|79.4|µmol/L||N|||F|||20241018050017\r
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.29739|{Ratio}|<4.3|N|||F|||20241018050017\r
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|99.2|µmol/L|<230|N|||F|||20241018050017\r
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.17|{Ratio}|<1.35|N|||F|||20241018050017\r
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|61.2|µmol/L|<175|N|||F|||20241018050017\r
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.77|{Ratio}|<2.6|N|||F|||20241018050017\r
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|34.7|µmol/L|<680|N|||F|||20241018050017\r
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.33|µmol/L|<6.1|N|||F|||20241018050017\r
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|20.4|µmol/L|6.3-100|N|||F|||20241018050017\r
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|10|µmol/L|5-49|N|||F|||20241018050017\r
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|2.79|{Ratio}|<4.8|N|||F|||20241018050017\r
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|43|µmol/L|<800|N|||F|||20241018050017\r
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|4.44|{Ratio}||N|||F|||20241018050017\r
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|3|µmol/L|<63|N|||F|||20241018050017\r
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241018050017\r
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|187|µmol/L|<1500|N|||F|||20241018050017\r
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|6|753234567^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|7|753234567^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|39.6|µmol/L|6.4-125|N|||F|||20241018050017\r
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|5.35|{Ratio}|<70|N|||F|||20241018050017\r
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|34.7|µmol/L|10-80|N|||F|||20241018050017\r
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|3.27536|{Ratio}|<7.6|N|||F|||20241018050017\r
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.100|µmol/L|<0.95|N|||F|||20241018050017\r
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.075|µmol/L|<0.45|N|||F|||20241018050017\r
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.09|{Ratio}||N|||F|||20241018050017\r
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.163|µmol/L|<0.65|N|||F|||20241018050017\r
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.069|µmol/L|<0.65|N|||F|||20241018050017\r
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.057|µmol/L|<0.45|N|||F|||20241018050017\r
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.118|µmol/L|<2|N|||F|||20241018050017\r
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.06|µmol/L||N|||F|||20241018050017\r
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.394|µmol/L|<1.2|N|||F|||20241018050017\r
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.130|µmol/L|<0.9|N|||F|||20241018050017\r
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|2.32|{Ratio}||N|||F|||20241018050017\r
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241018050017\r
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.026|µmol/L|<0.2|N|||F|||20241018050017\r
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5.52|µmol/L|<12|N|||F|||20241018050017\r
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.245|µmol/L|<1.4|N|||F|||20241018050017\r
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.042|µmol/L|<0.1|N|||F|||20241018050017\r
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00761|{Ratio}|<0.07|N|||F|||20241018050017\r
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2.13|µmol/L|<3.5|N|||F|||20241018050017\r
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.89|µmol/L|<7|N|||F|||20241018050017\r
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.29|µmol/L||N|||F|||20241018050017\r
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.032|µmol/L|<0.1|N|||F|||20241018050017\r
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.047|µmol/L|<0.1|N|||F|||20241018050017\r
-OBR|8|753234567^FormNumber||57085-3^Organic acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|4.2|µmol/L|<7.9|N|||F|||20241018050017\r
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.12|{Ratio}|<0.42|N|||F|||20241018050017\r
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.226|µmol/L|<0.48|N|||F|||20241018050017\r
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.424|µmol/L|<1.7|N|||F|||20241018050017\r
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.247|µmol/L|<0.95|N|||F|||20241018050017\r
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05881|{Ratio}|<0.38|N|||F|||20241018050017\r
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.008|µmol/L|<0.5|N|||F|||20241018050017\r
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.287|µmol/L|<1.15|N|||F|||20241018050017\r
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.179|µmol/L|<0.38|N|||F|||20241018050017\r
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.79204|{Ratio}|>0.1|N|||F|||20241018050017\r
-OBR|9|753234567^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|18.50|ng/mL|<69|N|||F|||20241018050017\r
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|10|753234567^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00013.8|nmol/L|<85|N|||F|||20241018050017\r
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|11|753234567^FormNumber||54090-6^Thyroid newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|29575-8^Thyrotropin^LN|1|2.40|mIU/L|<29|N|||F|||20241018050017\r
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|12|753234567^FormNumber||54079-9^Galactosemia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|293.00|enzyme units|>50|N|||F|||20241018050017\r
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|13|753234567^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA + Barts||||||F|||20241018050017\r
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|The presence of Hb Barts at a high percentage is consistent with Hb H disease, a clinically significant hemoglobin disorder.||||||F|||20241018050017\r
-OBR|14|753234567^FormNumber||57087-9^Biotinidase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|43.76|ERU|>10|N|||F|||20241018050017\r
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|15|753234567^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|99|copies/µL|>18|N|||F|||20241018050017\r
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|16|753234567^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|7.09|µmol/L/h|>=1.67|N|||F|||20241018050017\r
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|17|753234567^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|8.33|µmol/L/h|>=0.86|N|||F|||20241018050017\r
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|18|753234567^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241018050017\r
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241018050017\r
-OBR|19|753234567^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|15.65|µmol/L/h|>=2.8|N|||F|||20241018050017\r
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|20|753234567^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|21|753234567^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.05|µmol/L|<=3|N|||F|||20241018050017\r
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|616.49|µmol/L||N|||F|||20241018050017\r
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.70||<=6|N|||F|||20241018050017\r
-OBR|22|753234567^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241018050017\r
-OBR|23|753234567^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.260|µmol/L|<0.47|N|||F|||20241018050017\r
+ORC|RE|753234567^FormNumber||56155532^HospOrdNumber||||||||^SCALA^MELISSA|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601
+OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBR|2|753234567^FormNumber||57128-1^Newborn Screening Report summary panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241018050017
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241018050017
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241018050017
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA16207-5^Hemoglobinopathies^LN|||N|||F|||20241018050017
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050017
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - ALLIED LABORATORY \\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Hb: An immediate referral to a CCS Hematology Center or a pediatric hematologist familiar with alpha thalassemia and Hb H disease is strongly recommended for this infant. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241018050017
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241018050017
+OBR|3|753234567^FormNumber||57717-1^Newborn screen card data panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241018050017
+OBX|2|NM|8339-4^Birthweight^LN|1|2658|grams||N|||F|||20241018050017
+OBX|3|TM|57715-5^Time of birth^LN|1|0027|||N|||F|||20241018050017
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241018050017
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|28|hour(s)||N|||F|||20241018050017
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241018050017
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241018050017
+OBX|8|TX|^^^99717-5^Accession Number^L|1|272-95-009/21-2024-12|||N|||F|||20241018050017
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MELISSA SCALA|||N|||F|||20241018050017
+OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA|||N|||F|||20241018050017
+OBR|4|753234567^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBR|5|753234567^FormNumber||53261-4^Amino acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|926|µmol/L||N|||F|||20241018050017
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|588|µmol/L|<1000|N|||F|||20241018050017
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|79.4|µmol/L||N|||F|||20241018050017
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.29739|{Ratio}|<4.3|N|||F|||20241018050017
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|99.2|µmol/L|<230|N|||F|||20241018050017
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.17|{Ratio}|<1.35|N|||F|||20241018050017
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|61.2|µmol/L|<175|N|||F|||20241018050017
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.77|{Ratio}|<2.6|N|||F|||20241018050017
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|34.7|µmol/L|<680|N|||F|||20241018050017
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.33|µmol/L|<6.1|N|||F|||20241018050017
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|20.4|µmol/L|6.3-100|N|||F|||20241018050017
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|10|µmol/L|5-49|N|||F|||20241018050017
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|2.79|{Ratio}|<4.8|N|||F|||20241018050017
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|43|µmol/L|<800|N|||F|||20241018050017
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|4.44|{Ratio}||N|||F|||20241018050017
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|3|µmol/L|<63|N|||F|||20241018050017
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241018050017
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|187|µmol/L|<1500|N|||F|||20241018050017
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|6|753234567^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|7|753234567^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|39.6|µmol/L|6.4-125|N|||F|||20241018050017
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|5.35|{Ratio}|<70|N|||F|||20241018050017
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|34.7|µmol/L|10-80|N|||F|||20241018050017
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|3.27536|{Ratio}|<7.6|N|||F|||20241018050017
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.100|µmol/L|<0.95|N|||F|||20241018050017
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.075|µmol/L|<0.45|N|||F|||20241018050017
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.09|{Ratio}||N|||F|||20241018050017
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.163|µmol/L|<0.65|N|||F|||20241018050017
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.069|µmol/L|<0.65|N|||F|||20241018050017
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.057|µmol/L|<0.45|N|||F|||20241018050017
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.118|µmol/L|<2|N|||F|||20241018050017
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.06|µmol/L||N|||F|||20241018050017
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.394|µmol/L|<1.2|N|||F|||20241018050017
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.130|µmol/L|<0.9|N|||F|||20241018050017
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|2.32|{Ratio}||N|||F|||20241018050017
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241018050017
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.026|µmol/L|<0.2|N|||F|||20241018050017
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5.52|µmol/L|<12|N|||F|||20241018050017
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.245|µmol/L|<1.4|N|||F|||20241018050017
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.042|µmol/L|<0.1|N|||F|||20241018050017
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00761|{Ratio}|<0.07|N|||F|||20241018050017
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2.13|µmol/L|<3.5|N|||F|||20241018050017
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.89|µmol/L|<7|N|||F|||20241018050017
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.29|µmol/L||N|||F|||20241018050017
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.032|µmol/L|<0.1|N|||F|||20241018050017
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.047|µmol/L|<0.1|N|||F|||20241018050017
+OBR|8|753234567^FormNumber||57085-3^Organic acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|4.2|µmol/L|<7.9|N|||F|||20241018050017
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.12|{Ratio}|<0.42|N|||F|||20241018050017
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.226|µmol/L|<0.48|N|||F|||20241018050017
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.424|µmol/L|<1.7|N|||F|||20241018050017
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.247|µmol/L|<0.95|N|||F|||20241018050017
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05881|{Ratio}|<0.38|N|||F|||20241018050017
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.008|µmol/L|<0.5|N|||F|||20241018050017
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.287|µmol/L|<1.15|N|||F|||20241018050017
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.179|µmol/L|<0.38|N|||F|||20241018050017
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.79204|{Ratio}|>0.1|N|||F|||20241018050017
+OBR|9|753234567^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|18.50|ng/mL|<69|N|||F|||20241018050017
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|10|753234567^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00013.8|nmol/L|<85|N|||F|||20241018050017
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|11|753234567^FormNumber||54090-6^Thyroid newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|29575-8^Thyrotropin^LN|1|2.40|mIU/L|<29|N|||F|||20241018050017
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|12|753234567^FormNumber||54079-9^Galactosemia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|293.00|enzyme units|>50|N|||F|||20241018050017
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|13|753234567^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA + Barts||||||F|||20241018050017
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|The presence of Hb Barts at a high percentage is consistent with Hb H disease, a clinically significant hemoglobin disorder.||||||F|||20241018050017
+OBR|14|753234567^FormNumber||57087-9^Biotinidase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|43.76|ERU|>10|N|||F|||20241018050017
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|15|753234567^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|99|copies/µL|>18|N|||F|||20241018050017
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|16|753234567^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|7.09|µmol/L/h|>=1.67|N|||F|||20241018050017
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|17|753234567^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|8.33|µmol/L/h|>=0.86|N|||F|||20241018050017
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|18|753234567^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241018050017
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241018050017
+OBR|19|753234567^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|15.65|µmol/L/h|>=2.8|N|||F|||20241018050017
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|20|753234567^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|21|753234567^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.05|µmol/L|<=3|N|||F|||20241018050017
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|616.49|µmol/L||N|||F|||20241018050017
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.70||<=6|N|||F|||20241018050017
+OBR|22|753234567^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241018050017
+OBR|23|753234567^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.260|µmol/L|<0.47|N|||F|||20241018050017

From 71a243d20f8be0034f3157f6721f895b9b10536b Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 14:13:04 -0700
Subject: [PATCH 22/61] add double quotes to if statement

Co-authored-by: jcrichlake <145698165+jcrichlake@users.noreply.github.com>
---
 .github/workflows/automated-staging-test-submit.yml | 2 +-
 1 file changed, 1 insertion(+), 1 deletion(-)

diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
index ab4b53567..594c5aa28 100644
--- a/.github/workflows/automated-staging-test-submit.yml
+++ b/.github/workflows/automated-staging-test-submit.yml
@@ -53,7 +53,7 @@ jobs:
                   "$host/api/token" | jq -r ".access_token")
 
           file_path=Automated/*.hl7
-          if [ ${{ github.event.inputs.name }} == "Golden Copy Staging Test" ]; then
+          if [ "${{ github.event.inputs.name }}" == "Golden Copy Staging Test" ]; then
               file_path=GoldenCopy/Input/*.hl7
           fi
 

From 24e5ac38651c264ca081350a41e1487b54614a7b Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 14:27:17 -0700
Subject: [PATCH 23/61] add golden copy versions of example files and revert to
 og directory structure

Co-authored-by: jcrichlake <145698165+jcrichlake@users.noreply.github.com>
---
 .../001_ORU_R01_golden_copy_input_acylc_1.hl7 | 143 ---------
 ...taging_ORM_O01_short_linked_to_002_ORU.hl7 |   0
 .../002_ORU_R01_golden_copy_input_acylc_2.hl7 | 142 ---------
 ...taging_ORU_O01_short_linked_to_001_ORM.hl7 |   0
 .../003_CA_ORU_R01_CDPH_produced.hl7          |   0
 ...3_ORU_R01_golden_copy_input_aa_unusual.hl7 | 142 ---------
 .../004_CA_ORU_R01_leading_zeroes.hl7         |   0
 ...004_ORU_R01_golden_copy_input_in_range.hl7 | 142 ---------
 .../005_CA_ORU_R01_no_leading_zeroes.hl7      |   0
 ...ORU_R01_golden_copy_input_out_of_range.hl7 | 142 ---------
 .../006_CA_ORU_R01_LOINC.hl7                  |   0
 .../007_CA_ORU_R01_PLT.hl7                    |   0
 .../008_ORU_R01_micro_character_encoding.hl7  |   0
 .../009_CA_ORU_R01_remove_99717-5_OBX.hl7     |   0
 ...01_NBS_0_initial_obr_flatten_example_1.hl7 |   0
 ..._ORU_R01_golden_copy_expected_acylc_1.fhir |   1 +
 ..._ORU_R01_golden_copy_expected_acylc_2.fhir |   1 +
 ...U_R01_golden_copy_expected_aa_unusual.fhir |   1 +
 ...ORU_R01_golden_copy_expected_in_range.fhir |   1 +
 ...R01_golden_copy_expected_out_of_range.fhir |   1 +
 .../001_ORU_R01_golden_copy_input_acylc_1.hl7 | 282 +++++++++---------
 .../002_ORU_R01_golden_copy_input_acylc_2.hl7 | 280 ++++++++---------
 ...3_ORU_R01_golden_copy_input_aa_unusual.hl7 | 280 ++++++++---------
 ...004_ORU_R01_golden_copy_input_in_range.hl7 | 280 ++++++++---------
 ...ORU_R01_golden_copy_input_out_of_range.hl7 | 280 ++++++++---------
 ...U_R01_golden_copy_input_sma_incomplete.hl7 | 141 +++++++++
 examples/Test/GoldenCopy/README.md            |  11 +
 27 files changed, 858 insertions(+), 1412 deletions(-)
 delete mode 100644 examples/Test/Automated/001_ORU_R01_golden_copy_input_acylc_1.hl7
 rename examples/Test/{tempStorage => Automated}/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7 (100%)
 delete mode 100644 examples/Test/Automated/002_ORU_R01_golden_copy_input_acylc_2.hl7
 rename examples/Test/{tempStorage => Automated}/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7 (100%)
 rename examples/Test/{tempStorage => Automated}/003_CA_ORU_R01_CDPH_produced.hl7 (100%)
 delete mode 100644 examples/Test/Automated/003_ORU_R01_golden_copy_input_aa_unusual.hl7
 rename examples/Test/{tempStorage => Automated}/004_CA_ORU_R01_leading_zeroes.hl7 (100%)
 delete mode 100644 examples/Test/Automated/004_ORU_R01_golden_copy_input_in_range.hl7
 rename examples/Test/{tempStorage => Automated}/005_CA_ORU_R01_no_leading_zeroes.hl7 (100%)
 delete mode 100644 examples/Test/Automated/005_ORU_R01_golden_copy_input_out_of_range.hl7
 rename examples/Test/{tempStorage => Automated}/006_CA_ORU_R01_LOINC.hl7 (100%)
 rename examples/Test/{tempStorage => Automated}/007_CA_ORU_R01_PLT.hl7 (100%)
 rename examples/Test/{tempStorage => Automated}/008_ORU_R01_micro_character_encoding.hl7 (100%)
 rename examples/Test/{tempStorage => Automated}/009_CA_ORU_R01_remove_99717-5_OBX.hl7 (100%)
 rename examples/Test/{tempStorage => Automated}/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7 (100%)
 create mode 100644 examples/Test/GoldenCopy/Expected/001_ORU_R01_golden_copy_expected_acylc_1.fhir
 create mode 100644 examples/Test/GoldenCopy/Expected/002_ORU_R01_golden_copy_expected_acylc_2.fhir
 create mode 100644 examples/Test/GoldenCopy/Expected/003_ORU_R01_golden_copy_expected_aa_unusual.fhir
 create mode 100644 examples/Test/GoldenCopy/Expected/004_ORU_R01_golden_copy_expected_in_range.fhir
 create mode 100644 examples/Test/GoldenCopy/Expected/005_ORU_R01_golden_copy_expected_out_of_range.fhir
 create mode 100644 examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7

diff --git a/examples/Test/Automated/001_ORU_R01_golden_copy_input_acylc_1.hl7 b/examples/Test/Automated/001_ORU_R01_golden_copy_input_acylc_1.hl7
deleted file mode 100644
index a93c6ef84..000000000
--- a/examples/Test/Automated/001_ORU_R01_golden_copy_input_acylc_1.hl7
+++ /dev/null
@@ -1,143 +0,0 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241015050654||ORU^R01^ORU_R01|001|N|2.5.1
-PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
-NK1|1|*****PII REMOVED******
-ORC|RE|673678765^FormNumber||M17965^HospOrdNumber||||||||1477542173^BROOKS^STEWART^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804
-OBR|1|673678765^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410011420|||||||||||||||20241015050654|||F
-OBR|2|673678765^FormNumber||57128-1^Newborn Screening Report summary panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241015050654
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241015050654
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241015050654
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241015050654
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241015050654
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241015050654
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241015050654
-OBR|3|673678765^FormNumber||57717-1^Newborn screen card data panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241015050654
-OBX|2|NM|8339-4^Birthweight^LN|1|4020|grams||N|||F|||20241015050654
-OBX|3|TM|57715-5^Time of birth^LN|1|1416|||N|||F|||20241015050654
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241015050654
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241015050654
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241015050654
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241015050654
-OBX|8|CE|67704-7^Feeding types^LN|2|LA16915-3^Lactose formula^LN|||N|||F|||20241015050654
-OBX|9|TX|^^^99717-5^Accession Number^L|1|277-86-190/21-2024-32|||N|||F|||20241015050654
-OBX|10|TX|62324-9^Post-discharge provider name^LN|1|STEWART BROOKS|||N|||F|||20241015050654
-OBX|11|TX|62325-6^Post-discharge provider practice ID^LN|1|1477542173|||N|||F|||20241015050654
-OBX|12|TX|62327-2^Post-discharge provider practice address^LN|1|8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA|||N|||F|||20241015050654
-OBR|4|673678765^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410011420|||||||||||||||20241015050654|||F
-OBR|5|673678765^FormNumber||53261-4^Amino acid newborn screen panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|387|µmol/L||N|||F|||20241015050654
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|381|µmol/L|<1000|N|||F|||20241015050654
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|92.6|µmol/L||N|||F|||20241015050654
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.88595|{Ratio}|<4.3|N|||F|||20241015050654
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|86.8|µmol/L|<230|N|||F|||20241015050654
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.23|{Ratio}|<1.35|N|||F|||20241015050654
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|49.1|µmol/L|<175|N|||F|||20241015050654
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.09|{Ratio}|<2.6|N|||F|||20241015050654
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|45.1|µmol/L|<680|N|||F|||20241015050654
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.24|µmol/L|<6.1|N|||F|||20241015050654
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|16.8|µmol/L|6.3-100|N|||F|||20241015050654
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|20|µmol/L|5-49|N|||F|||20241015050654
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3.22|{Ratio}|<4.8|N|||F|||20241015050654
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|74|µmol/L|<800|N|||F|||20241015050654
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|3.76|{Ratio}||N|||F|||20241015050654
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|6|µmol/L|<63|N|||F|||20241015050654
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241015050654
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|118|µmol/L|<1500|N|||F|||20241015050654
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|6|673678765^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241015050654
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with SCADD, IBCDD|||A|||F|||20241015050654
-OBR|7|673678765^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|34.3|µmol/L|6.4-125|N|||F|||20241015050654
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|5.93|{Ratio}|<70|N|||F|||20241015050654
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|33.2|µmol/L|10-80|N|||F|||20241015050654
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|1.29565|{Ratio}|<7.6|N|||F|||20241015050654
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.136|µmol/L|<0.95|N|||F|||20241015050654
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.150|µmol/L|<0.45|N|||F|||20241015050654
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.65|{Ratio}||N|||F|||20241015050654
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.221|µmol/L|<0.65|N|||F|||20241015050654
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.230|µmol/L|<0.65|N|||F|||20241015050654
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.088|µmol/L|<0.45|N|||F|||20241015050654
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.232|µmol/L|<2|N|||F|||20241015050654
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.20|µmol/L||N|||F|||20241015050654
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.342|µmol/L|<1.2|N|||F|||20241015050654
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.206|µmol/L|<0.9|N|||F|||20241015050654
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.02|{Ratio}||N|||F|||20241015050654
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241015050654
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.029|µmol/L|<0.2|N|||F|||20241015050654
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|4.14|µmol/L|<12|N|||F|||20241015050654
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.341|µmol/L|<1.4|N|||F|||20241015050654
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.049|µmol/L|<0.1|N|||F|||20241015050654
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01184|{Ratio}|<0.07|N|||F|||20241015050654
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.07|µmol/L|<3.5|N|||F|||20241015050654
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.65|µmol/L|<7|N|||F|||20241015050654
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.23|µmol/L||N|||F|||20241015050654
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.022|µmol/L|<0.1|N|||F|||20241015050654
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.053|µmol/L|<0.1|N|||F|||20241015050654
-OBR|8|673678765^FormNumber||57085-3^Organic acid newborn screen panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.3|µmol/L|<7.9|N|||F|||20241015050654
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.07|{Ratio}|<0.42|N|||F|||20241015050654
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.298|µmol/L|<0.48|N|||F|||20241015050654
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|1.73|µmol/L|<1.7|H|||F|||20241015050654
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.139|µmol/L|<0.95|N|||F|||20241015050654
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.06043|{Ratio}|<0.38|N|||F|||20241015050654
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.011|µmol/L|<0.5|N|||F|||20241015050654
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.306|µmol/L|<1.15|N|||F|||20241015050654
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.238|µmol/L|<0.38|N|||F|||20241015050654
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.79866|{Ratio}|>0.1|N|||F|||20241015050654
-OBR|9|673678765^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|18.10|ng/mL|<69|N|||F|||20241015050654
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|10|673678765^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00010.8|nmol/L|<85|N|||F|||20241015050654
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|11|673678765^FormNumber||54090-6^Thyroid newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|29575-8^Thyrotropin^LN|1|4.00|mIU/L|<29|N|||F|||20241015050654
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|12|673678765^FormNumber||54079-9^Galactosemia newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|267.94|enzyme units|>50|N|||F|||20241015050654
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|13|673678765^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241015050654
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241015050654
-OBR|14|673678765^FormNumber||57087-9^Biotinidase newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|44.16|ERU|>10|N|||F|||20241015050654
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|15|673678765^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|84|copies/µL|>18|N|||F|||20241015050654
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|16|673678765^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|6.97|µmol/L/h|>=1.51|N|||F|||20241015050654
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|17|673678765^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|10.38|µmol/L/h|>=0.77|N|||F|||20241015050654
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|18|673678765^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241015050654
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241015050654
-OBR|19|673678765^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|27.61|µmol/L/h|>=2.75|N|||F|||20241015050654
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|20|673678765^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|21|673678765^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.04|µmol/L|<=3|N|||F|||20241015050654
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|391.37|µmol/L||N|||F|||20241015050654
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.66||<=6|N|||F|||20241015050654
-OBR|22|673678765^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241015050654
-OBR|23|673678765^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.246|µmol/L|<0.47|N|||F|||20241015050654
diff --git a/examples/Test/tempStorage/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7 b/examples/Test/Automated/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7
similarity index 100%
rename from examples/Test/tempStorage/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7
rename to examples/Test/Automated/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7
diff --git a/examples/Test/Automated/002_ORU_R01_golden_copy_input_acylc_2.hl7 b/examples/Test/Automated/002_ORU_R01_golden_copy_input_acylc_2.hl7
deleted file mode 100644
index eb4377c51..000000000
--- a/examples/Test/Automated/002_ORU_R01_golden_copy_input_acylc_2.hl7
+++ /dev/null
@@ -1,142 +0,0 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050234||ORU^R01^ORU_R01|002|N|2.5.1
-PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
-NK1|1|*****PII REMOVED******
-ORC|RE|12345667867^FormNumber||S30500^HospOrdNumber||||||||1194257170^MAHMOOD^SARAH^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804
-OBR|1|12345667867^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410061300|||||||||||||||20241018050234|||F
-OBR|2|12345667867^FormNumber||57128-1^Newborn Screening Report summary panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241018050234
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241018050234
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241018050234
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050234
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050234
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241018050234
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241018050234
-OBR|3|12345667867^FormNumber||57717-1^Newborn screen card data panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241018050234
-OBX|2|NM|8339-4^Birthweight^LN|1|3135|grams||N|||F|||20241018050234
-OBX|3|TM|57715-5^Time of birth^LN|1|1235|||N|||F|||20241018050234
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241018050234
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241018050234
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241018050234
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241018050234
-OBX|8|TX|^^^99717-5^Accession Number^L|1|282-18-014/21-2024-32|||N|||F|||20241018050234
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|SARAH MAHMOOD|||N|||F|||20241018050234
-OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1194257170|||N|||F|||20241018050234
-OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA|||N|||F|||20241018050234
-OBR|4|12345667867^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410061300|||||||||||||||20241018050234|||F
-OBR|5|12345667867^FormNumber||53261-4^Amino acid newborn screen panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|611|µmol/L||N|||F|||20241018050234
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|585|µmol/L|<1000|N|||F|||20241018050234
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|90.9|µmol/L||N|||F|||20241018050234
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.74808|{Ratio}|<4.3|N|||F|||20241018050234
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|86.9|µmol/L|<230|N|||F|||20241018050234
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.15|{Ratio}|<1.35|N|||F|||20241018050234
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|52.0|µmol/L|<175|N|||F|||20241018050234
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241018050234
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|69.0|µmol/L|<680|N|||F|||20241018050234
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.23|µmol/L|<6.1|N|||F|||20241018050234
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|22.5|µmol/L|6.3-100|N|||F|||20241018050234
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|14|µmol/L|5-49|N|||F|||20241018050234
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|2.28|{Ratio}|<4.8|N|||F|||20241018050234
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|68|µmol/L|<800|N|||F|||20241018050234
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|4.93|{Ratio}||N|||F|||20241018050234
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|6|µmol/L|<63|N|||F|||20241018050234
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241018050234
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|192|µmol/L|<1500|N|||F|||20241018050234
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|6|12345667867^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241018050234
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with SCADD, IBCDD|||A|||F|||20241018050234
-OBR|7|12345667867^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|26.6|µmol/L|6.4-125|N|||F|||20241018050234
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|3.27|{Ratio}|<70|N|||F|||20241018050234
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|29.2|µmol/L|10-80|N|||F|||20241018050234
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.13913|{Ratio}|<7.6|N|||F|||20241018050234
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.088|µmol/L|<0.95|N|||F|||20241018050234
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.084|µmol/L|<0.45|N|||F|||20241018050234
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.73|{Ratio}||N|||F|||20241018050234
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.172|µmol/L|<0.65|N|||F|||20241018050234
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.115|µmol/L|<0.65|N|||F|||20241018050234
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.050|µmol/L|<0.45|N|||F|||20241018050234
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.127|µmol/L|<2|N|||F|||20241018050234
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.12|µmol/L||N|||F|||20241018050234
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.333|µmol/L|<1.2|N|||F|||20241018050234
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.132|µmol/L|<0.9|N|||F|||20241018050234
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.13|{Ratio}||N|||F|||20241018050234
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241018050234
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.026|µmol/L|<0.2|N|||F|||20241018050234
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|6.19|µmol/L|<12|N|||F|||20241018050234
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.445|µmol/L|<1.4|N|||F|||20241018050234
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.045|µmol/L|<0.1|N|||F|||20241018050234
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00727|{Ratio}|<0.07|N|||F|||20241018050234
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.53|µmol/L|<3.5|N|||F|||20241018050234
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.96|µmol/L|<7|N|||F|||20241018050234
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.21|µmol/L||N|||F|||20241018050234
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.017|µmol/L|<0.1|N|||F|||20241018050234
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.036|µmol/L|<0.1|N|||F|||20241018050234
-OBR|8|12345667867^FormNumber||57085-3^Organic acid newborn screen panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.5|µmol/L|<7.9|N|||F|||20241018050234
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.09|{Ratio}|<0.42|N|||F|||20241018050234
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.246|µmol/L|<0.48|N|||F|||20241018050234
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|1.72|µmol/L|<1.7|H|||F|||20241018050234
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.115|µmol/L|<0.95|N|||F|||20241018050234
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.04600|{Ratio}|<0.38|N|||F|||20241018050234
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.008|µmol/L|<0.5|N|||F|||20241018050234
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.232|µmol/L|<1.15|N|||F|||20241018050234
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.180|µmol/L|<0.38|N|||F|||20241018050234
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.73171|{Ratio}|>0.1|N|||F|||20241018050234
-OBR|9|12345667867^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|21.20|ng/mL|<69|N|||F|||20241018050234
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|10|12345667867^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00015.6|nmol/L|<85|N|||F|||20241018050234
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|11|12345667867^FormNumber||54090-6^Thyroid newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|29575-8^Thyrotropin^LN|1|9.50|mIU/L|<29|N|||F|||20241018050234
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|12|12345667867^FormNumber||54079-9^Galactosemia newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|262.95|enzyme units|>50|N|||F|||20241018050234
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|13|12345667867^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241018050234
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241018050234
-OBR|14|12345667867^FormNumber||57087-9^Biotinidase newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|49.77|ERU|>10|N|||F|||20241018050234
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|15|12345667867^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|197|copies/µL|>18|N|||F|||20241018050234
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|16|12345667867^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.29|µmol/L/h|>=1.47|N|||F|||20241018050234
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|17|12345667867^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|13.01|µmol/L/h|>=0.82|N|||F|||20241018050234
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|18|12345667867^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241018050234
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241018050234
-OBR|19|12345667867^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|27.84|µmol/L/h|>=2.79|N|||F|||20241018050234
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|20|12345667867^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|21|12345667867^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|0.97|µmol/L|<=3|N|||F|||20241018050234
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|496.63|µmol/L||N|||F|||20241018050234
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.95||<=6|N|||F|||20241018050234
-OBR|22|12345667867^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241018050234
-OBR|23|12345667867^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.349|µmol/L|<0.47|N|||F|||20241018050234
diff --git a/examples/Test/tempStorage/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7 b/examples/Test/Automated/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7
similarity index 100%
rename from examples/Test/tempStorage/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7
rename to examples/Test/Automated/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7
diff --git a/examples/Test/tempStorage/003_CA_ORU_R01_CDPH_produced.hl7 b/examples/Test/Automated/003_CA_ORU_R01_CDPH_produced.hl7
similarity index 100%
rename from examples/Test/tempStorage/003_CA_ORU_R01_CDPH_produced.hl7
rename to examples/Test/Automated/003_CA_ORU_R01_CDPH_produced.hl7
diff --git a/examples/Test/Automated/003_ORU_R01_golden_copy_input_aa_unusual.hl7 b/examples/Test/Automated/003_ORU_R01_golden_copy_input_aa_unusual.hl7
deleted file mode 100644
index d5fb3472e..000000000
--- a/examples/Test/Automated/003_ORU_R01_golden_copy_input_aa_unusual.hl7
+++ /dev/null
@@ -1,142 +0,0 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241023050044||ORU^R01^ORU_R01|003|N|2.5.1
-PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
-NK1|1|*****PII REMOVED******
-ORC|RE|45789876^FormNumber||56352742^HospOrdNumber||||||||1043390461^PROFIT^DR JOCHEN^^^^^^^NPI|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601
-OBR|1|45789876^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBR|2|45789876^FormNumber||57128-1^Newborn Screening Report summary panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241023050044
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241023050044
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241023050044
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241023050044
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241023050044
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - ALLIED LABORATORY \\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Amino Acid Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241023050044
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241023050044
-OBR|3|45789876^FormNumber||57717-1^Newborn screen card data panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241023050044
-OBX|2|NM|8339-4^Birthweight^LN|1|2230|grams||N|||F|||20241023050044
-OBX|3|TM|57715-5^Time of birth^LN|1|1358|||N|||F|||20241023050044
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241023050044
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|26|hour(s)||N|||F|||20241023050044
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241023050044
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241023050044
-OBX|8|TX|^^^99717-5^Accession Number^L|1|282-38-261/21-2024-12|||N|||F|||20241023050044
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DR JOCHEN PROFIT|||N|||F|||20241023050044
-OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1043390461|||N|||F|||20241023050044
-OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA|||N|||F|||20241023050044
-OBR|4|45789876^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBR|5|45789876^FormNumber||53261-4^Amino acid newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|368|µmol/L||N|||F|||20241023050044
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|310|µmol/L|<1000|N|||F|||20241023050044
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|34.6|µmol/L||N|||F|||20241023050044
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.06462|{Ratio}|<4.3|N|||F|||20241023050044
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|50.7|µmol/L|<230|N|||F|||20241023050044
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.16|{Ratio}|<1.35|N|||F|||20241023050044
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|32.5|µmol/L|<175|N|||F|||20241023050044
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.13|{Ratio}|<2.6|N|||F|||20241023050044
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|28.9|µmol/L|<680|N|||F|||20241023050044
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.25|µmol/L|<6.1|N|||F|||20241023050044
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|8.6|µmol/L|6.3-100|N|||F|||20241023050044
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|5|µmol/L|5-49|N|||F|||20241023050044
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.67|{Ratio}|<4.8|N|||F|||20241023050044
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|32|µmol/L|<800|N|||F|||20241023050044
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|6.41|{Ratio}||N|||F|||20241023050044
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|3|µmol/L|<63|N|||F|||20241023050044
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241023050044
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|55|µmol/L|<1500|N|||F|||20241023050044
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|This complex pattern of elevations require further evaluation|||A|||F|||20241023050044
-OBR|6|45789876^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|7|45789876^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|34.9|µmol/L|6.4-125|N|||F|||20241023050044
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|7.84|{Ratio}|<70|N|||F|||20241023050044
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|28.1|µmol/L|10-80|N|||F|||20241023050044
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|3.53125|{Ratio}|<7.6|N|||F|||20241023050044
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.034|µmol/L|<0.95|N|||F|||20241023050044
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.038|µmol/L|<0.45|N|||F|||20241023050044
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.19|{Ratio}||N|||F|||20241023050044
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.155|µmol/L|<0.65|N|||F|||20241023050044
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.032|µmol/L|<0.65|N|||F|||20241023050044
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.030|µmol/L|<0.45|N|||F|||20241023050044
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.070|µmol/L|<2|N|||F|||20241023050044
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.05|µmol/L||N|||F|||20241023050044
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.270|µmol/L|<1.2|N|||F|||20241023050044
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.084|µmol/L|<0.9|N|||F|||20241023050044
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.75|{Ratio}||N|||F|||20241023050044
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241023050044
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.009|µmol/L|<0.2|N|||F|||20241023050044
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|2.87|µmol/L|<12|N|||F|||20241023050044
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.236|µmol/L|<1.4|N|||F|||20241023050044
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.022|µmol/L|<0.1|N|||F|||20241023050044
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00767|{Ratio}|<0.07|N|||F|||20241023050044
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|0.987|µmol/L|<3.5|N|||F|||20241023050044
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.59|µmol/L|<7|N|||F|||20241023050044
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.20|µmol/L||N|||F|||20241023050044
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.014|µmol/L|<0.1|N|||F|||20241023050044
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.034|µmol/L|<0.1|N|||F|||20241023050044
-OBR|8|45789876^FormNumber||57085-3^Organic acid newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|1.9|µmol/L|<7.9|N|||F|||20241023050044
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.07|{Ratio}|<0.42|N|||F|||20241023050044
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.113|µmol/L|<0.48|N|||F|||20241023050044
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.161|µmol/L|<1.7|N|||F|||20241023050044
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.111|µmol/L|<0.95|N|||F|||20241023050044
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05842|{Ratio}|<0.38|N|||F|||20241023050044
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.006|µmol/L|<0.5|N|||F|||20241023050044
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.140|µmol/L|<1.15|N|||F|||20241023050044
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.091|µmol/L|<0.38|N|||F|||20241023050044
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.80531|{Ratio}|>0.1|N|||F|||20241023050044
-OBR|9|45789876^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|27.50|ng/mL|<69|N|||F|||20241023050044
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|10|45789876^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00029.9|nmol/L|<190|N|||F|||20241023050044
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|11|45789876^FormNumber||54090-6^Thyroid newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|29575-8^Thyrotropin^LN|1|6.90|mIU/L|<29|N|||F|||20241023050044
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|12|45789876^FormNumber||54079-9^Galactosemia newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|226.51|enzyme units|>50|N|||F|||20241023050044
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|13|45789876^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241023050044
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241023050044
-OBR|14|45789876^FormNumber||57087-9^Biotinidase newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|28.87|ERU|>10|N|||F|||20241023050044
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|15|45789876^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|198|copies/µL|>18|N|||F|||20241023050044
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|16|45789876^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|7.91|µmol/L/h|>=1.62|N|||F|||20241023050044
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|17|45789876^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|7.78|µmol/L/h|>=0.79|N|||F|||20241023050044
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|18|45789876^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241023050044
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241023050044
-OBR|19|45789876^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.94|µmol/L/h|>=2.95|N|||F|||20241023050044
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|20|45789876^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|21|45789876^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.00|µmol/L|<=3|N|||F|||20241023050044
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|707.37|µmol/L||N|||F|||20241023050044
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.41||<=6|N|||F|||20241023050044
-OBR|22|45789876^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241023050044
-OBR|23|45789876^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.246|µmol/L|<0.47|N|||F|||20241023050044
diff --git a/examples/Test/tempStorage/004_CA_ORU_R01_leading_zeroes.hl7 b/examples/Test/Automated/004_CA_ORU_R01_leading_zeroes.hl7
similarity index 100%
rename from examples/Test/tempStorage/004_CA_ORU_R01_leading_zeroes.hl7
rename to examples/Test/Automated/004_CA_ORU_R01_leading_zeroes.hl7
diff --git a/examples/Test/Automated/004_ORU_R01_golden_copy_input_in_range.hl7 b/examples/Test/Automated/004_ORU_R01_golden_copy_input_in_range.hl7
deleted file mode 100644
index 8b4b6f202..000000000
--- a/examples/Test/Automated/004_ORU_R01_golden_copy_input_in_range.hl7
+++ /dev/null
@@ -1,142 +0,0 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241030050154||ORU^R01^ORU_R01|004|N|2.5.1
-PID|1||335441864^^^104638912487&NPI^MR||*****PII REMOVED******
-NK1|1|*****PII REMOVED******
-ORC|RE|356672001^FormNumber||629813494^HospOrdNumber||||||||1093050858^SILVA^RICHARD^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|200 W ARBOR DR^^SAN DIEGO^CA^92103-1911
-OBR|1|356672001^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBR|2|356672001^FormNumber||57128-1^Newborn Screening Report summary panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241030050154
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241030050154
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12428-1^All screening is in range for the conditions tested^LN|||N|||F|||20241030050154
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241030050154
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241030050154
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \\\2130 E Illinois Avenue, FRESNO, CA 93701\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (858) 966-8708. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241030050154
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241030050154
-OBR|3|356672001^FormNumber||57717-1^Newborn screen card data panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241030050154
-OBX|2|NM|8339-4^Birthweight^LN|1|3464|grams||N|||F|||20241030050154
-OBX|3|TM|57715-5^Time of birth^LN|1|0444|||N|||F|||20241030050154
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241030050154
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|19|hour(s)||N|||F|||20241030050154
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241030050154
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241030050154
-OBX|8|TX|^^^99717-5^Accession Number^L|1|292-04-123/21-2024-32|||N|||F|||20241030050154
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DIANE BEDROSIAN|||N|||F|||20241030050154
-OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1447323951|||N|||F|||20241030050154
-OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|200 W ARBOR DR SAN DIEGO CA 92103-1911 USA|||N|||F|||20241030050154
-OBR|4|356672001^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBR|5|356672001^FormNumber||53261-4^Amino acid newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|536|µmol/L||N|||F|||20241030050154
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|559|µmol/L|<1000|N|||F|||20241030050154
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|123|µmol/L||N|||F|||20241030050154
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|2.14286|{Ratio}|<4.3|N|||F|||20241030050154
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|113|µmol/L|<230|N|||F|||20241030050154
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.20|{Ratio}|<1.35|N|||F|||20241030050154
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|57.4|µmol/L|<175|N|||F|||20241030050154
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.05|{Ratio}|<2.6|N|||F|||20241030050154
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|54.8|µmol/L|<680|N|||F|||20241030050154
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.20|µmol/L|<6.1|N|||F|||20241030050154
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|22.8|µmol/L|6.3-100|N|||F|||20241030050154
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|10|µmol/L|5-49|N|||F|||20241030050154
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.52|{Ratio}|<4.8|N|||F|||20241030050154
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|84|µmol/L|<800|N|||F|||20241030050154
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|8.40|{Ratio}||N|||F|||20241030050154
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|7|µmol/L|<63|N|||F|||20241030050154
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241030050154
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|154|µmol/L|<1500|N|||F|||20241030050154
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|6|356672001^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|7|356672001^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|24.4|µmol/L|6.4-125|N|||F|||20241030050154
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|4.32|{Ratio}|<70|N|||F|||20241030050154
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|27.3|µmol/L|10-80|N|||F|||20241030050154
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.73000|{Ratio}|<7.6|N|||F|||20241030050154
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.067|µmol/L|<0.95|N|||F|||20241030050154
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.076|µmol/L|<0.45|N|||F|||20241030050154
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.76|{Ratio}||N|||F|||20241030050154
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.103|µmol/L|<0.65|N|||F|||20241030050154
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.100|µmol/L|<0.65|N|||F|||20241030050154
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.035|µmol/L|<0.45|N|||F|||20241030050154
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.132|µmol/L|<2|N|||F|||20241030050154
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.17|µmol/L||N|||F|||20241030050154
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.264|µmol/L|<1.2|N|||F|||20241030050154
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.189|µmol/L|<0.9|N|||F|||20241030050154
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.13|{Ratio}||N|||F|||20241030050154
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241030050154
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.021|µmol/L|<0.2|N|||F|||20241030050154
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|3.88|µmol/L|<12|N|||F|||20241030050154
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.371|µmol/L|<1.4|N|||F|||20241030050154
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.030|µmol/L|<0.1|N|||F|||20241030050154
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00773|{Ratio}|<0.07|N|||F|||20241030050154
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.11|µmol/L|<3.5|N|||F|||20241030050154
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.76|µmol/L|<7|N|||F|||20241030050154
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.15|µmol/L||N|||F|||20241030050154
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.015|µmol/L|<0.1|N|||F|||20241030050154
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.032|µmol/L|<0.1|N|||F|||20241030050154
-OBR|8|356672001^FormNumber||57085-3^Organic acid newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.3|µmol/L|<7.9|N|||F|||20241030050154
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.09|{Ratio}|<0.42|N|||F|||20241030050154
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.273|µmol/L|<0.48|N|||F|||20241030050154
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.315|µmol/L|<1.7|N|||F|||20241030050154
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.117|µmol/L|<0.95|N|||F|||20241030050154
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05087|{Ratio}|<0.38|N|||F|||20241030050154
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.009|µmol/L|<0.5|N|||F|||20241030050154
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.217|µmol/L|<1.15|N|||F|||20241030050154
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.183|µmol/L|<0.38|N|||F|||20241030050154
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.67033|{Ratio}|>0.1|N|||F|||20241030050154
-OBR|9|356672001^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|27.20|ng/mL|<69|N|||F|||20241030050154
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|10|356672001^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00015.2|nmol/L|<85|N|||F|||20241030050154
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|11|356672001^FormNumber||54090-6^Thyroid newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|29575-8^Thyrotropin^LN|1|15.40|mIU/L|<29|N|||F|||20241030050154
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|12|356672001^FormNumber||54079-9^Galactosemia newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|273.54|enzyme units|>50|N|||F|||20241030050154
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|13|356672001^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241030050154
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241030050154
-OBR|14|356672001^FormNumber||57087-9^Biotinidase newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|73.00|ERU|>10|N|||F|||20241030050154
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|15|356672001^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|120|copies/µL|>18|N|||F|||20241030050154
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|16|356672001^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|11.43|µmol/L/h|>=1.54|N|||F|||20241030050154
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|17|356672001^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|9.33|µmol/L/h|>=0.86|N|||F|||20241030050154
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|18|356672001^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241030050154
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241030050154
-OBR|19|356672001^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|22.31|µmol/L/h|>=2.84|N|||F|||20241030050154
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|20|356672001^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|21|356672001^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.22|µmol/L|<=3|N|||F|||20241030050154
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|411.55|µmol/L||N|||F|||20241030050154
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.95||<=6|N|||F|||20241030050154
-OBR|22|356672001^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241030050154
-OBR|23|356672001^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.138|µmol/L|<0.47|N|||F|||20241030050154
diff --git a/examples/Test/tempStorage/005_CA_ORU_R01_no_leading_zeroes.hl7 b/examples/Test/Automated/005_CA_ORU_R01_no_leading_zeroes.hl7
similarity index 100%
rename from examples/Test/tempStorage/005_CA_ORU_R01_no_leading_zeroes.hl7
rename to examples/Test/Automated/005_CA_ORU_R01_no_leading_zeroes.hl7
diff --git a/examples/Test/Automated/005_ORU_R01_golden_copy_input_out_of_range.hl7 b/examples/Test/Automated/005_ORU_R01_golden_copy_input_out_of_range.hl7
deleted file mode 100644
index 6f949201c..000000000
--- a/examples/Test/Automated/005_ORU_R01_golden_copy_input_out_of_range.hl7
+++ /dev/null
@@ -1,142 +0,0 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050017||ORU^R01^ORU_R01|005|N|2.5.1
-PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
-NK1|1|*****PII REMOVED******
-ORC|RE|753234567^FormNumber||56155532^HospOrdNumber||||||||^SCALA^MELISSA|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601
-OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBR|2|753234567^FormNumber||57128-1^Newborn Screening Report summary panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241018050017
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241018050017
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241018050017
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA16207-5^Hemoglobinopathies^LN|||N|||F|||20241018050017
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050017
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - ALLIED LABORATORY \\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Hb: An immediate referral to a CCS Hematology Center or a pediatric hematologist familiar with alpha thalassemia and Hb H disease is strongly recommended for this infant. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241018050017
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241018050017
-OBR|3|753234567^FormNumber||57717-1^Newborn screen card data panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241018050017
-OBX|2|NM|8339-4^Birthweight^LN|1|2658|grams||N|||F|||20241018050017
-OBX|3|TM|57715-5^Time of birth^LN|1|0027|||N|||F|||20241018050017
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241018050017
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|28|hour(s)||N|||F|||20241018050017
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241018050017
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241018050017
-OBX|8|TX|^^^99717-5^Accession Number^L|1|272-95-009/21-2024-12|||N|||F|||20241018050017
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MELISSA SCALA|||N|||F|||20241018050017
-OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA|||N|||F|||20241018050017
-OBR|4|753234567^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBR|5|753234567^FormNumber||53261-4^Amino acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|926|µmol/L||N|||F|||20241018050017
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|588|µmol/L|<1000|N|||F|||20241018050017
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|79.4|µmol/L||N|||F|||20241018050017
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.29739|{Ratio}|<4.3|N|||F|||20241018050017
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|99.2|µmol/L|<230|N|||F|||20241018050017
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.17|{Ratio}|<1.35|N|||F|||20241018050017
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|61.2|µmol/L|<175|N|||F|||20241018050017
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.77|{Ratio}|<2.6|N|||F|||20241018050017
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|34.7|µmol/L|<680|N|||F|||20241018050017
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.33|µmol/L|<6.1|N|||F|||20241018050017
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|20.4|µmol/L|6.3-100|N|||F|||20241018050017
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|10|µmol/L|5-49|N|||F|||20241018050017
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|2.79|{Ratio}|<4.8|N|||F|||20241018050017
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|43|µmol/L|<800|N|||F|||20241018050017
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|4.44|{Ratio}||N|||F|||20241018050017
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|3|µmol/L|<63|N|||F|||20241018050017
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241018050017
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|187|µmol/L|<1500|N|||F|||20241018050017
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|6|753234567^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|7|753234567^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|39.6|µmol/L|6.4-125|N|||F|||20241018050017
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|5.35|{Ratio}|<70|N|||F|||20241018050017
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|34.7|µmol/L|10-80|N|||F|||20241018050017
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|3.27536|{Ratio}|<7.6|N|||F|||20241018050017
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.100|µmol/L|<0.95|N|||F|||20241018050017
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.075|µmol/L|<0.45|N|||F|||20241018050017
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.09|{Ratio}||N|||F|||20241018050017
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.163|µmol/L|<0.65|N|||F|||20241018050017
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.069|µmol/L|<0.65|N|||F|||20241018050017
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.057|µmol/L|<0.45|N|||F|||20241018050017
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.118|µmol/L|<2|N|||F|||20241018050017
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.06|µmol/L||N|||F|||20241018050017
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.394|µmol/L|<1.2|N|||F|||20241018050017
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.130|µmol/L|<0.9|N|||F|||20241018050017
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|2.32|{Ratio}||N|||F|||20241018050017
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241018050017
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.026|µmol/L|<0.2|N|||F|||20241018050017
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5.52|µmol/L|<12|N|||F|||20241018050017
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.245|µmol/L|<1.4|N|||F|||20241018050017
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.042|µmol/L|<0.1|N|||F|||20241018050017
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00761|{Ratio}|<0.07|N|||F|||20241018050017
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2.13|µmol/L|<3.5|N|||F|||20241018050017
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.89|µmol/L|<7|N|||F|||20241018050017
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.29|µmol/L||N|||F|||20241018050017
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.032|µmol/L|<0.1|N|||F|||20241018050017
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.047|µmol/L|<0.1|N|||F|||20241018050017
-OBR|8|753234567^FormNumber||57085-3^Organic acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|4.2|µmol/L|<7.9|N|||F|||20241018050017
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.12|{Ratio}|<0.42|N|||F|||20241018050017
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.226|µmol/L|<0.48|N|||F|||20241018050017
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.424|µmol/L|<1.7|N|||F|||20241018050017
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.247|µmol/L|<0.95|N|||F|||20241018050017
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05881|{Ratio}|<0.38|N|||F|||20241018050017
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.008|µmol/L|<0.5|N|||F|||20241018050017
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.287|µmol/L|<1.15|N|||F|||20241018050017
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.179|µmol/L|<0.38|N|||F|||20241018050017
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.79204|{Ratio}|>0.1|N|||F|||20241018050017
-OBR|9|753234567^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|18.50|ng/mL|<69|N|||F|||20241018050017
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|10|753234567^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00013.8|nmol/L|<85|N|||F|||20241018050017
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|11|753234567^FormNumber||54090-6^Thyroid newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|29575-8^Thyrotropin^LN|1|2.40|mIU/L|<29|N|||F|||20241018050017
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|12|753234567^FormNumber||54079-9^Galactosemia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|293.00|enzyme units|>50|N|||F|||20241018050017
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|13|753234567^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA + Barts||||||F|||20241018050017
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|The presence of Hb Barts at a high percentage is consistent with Hb H disease, a clinically significant hemoglobin disorder.||||||F|||20241018050017
-OBR|14|753234567^FormNumber||57087-9^Biotinidase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|43.76|ERU|>10|N|||F|||20241018050017
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|15|753234567^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|99|copies/µL|>18|N|||F|||20241018050017
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|16|753234567^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|7.09|µmol/L/h|>=1.67|N|||F|||20241018050017
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|17|753234567^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|8.33|µmol/L/h|>=0.86|N|||F|||20241018050017
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|18|753234567^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241018050017
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241018050017
-OBR|19|753234567^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|15.65|µmol/L/h|>=2.8|N|||F|||20241018050017
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|20|753234567^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|21|753234567^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.05|µmol/L|<=3|N|||F|||20241018050017
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|616.49|µmol/L||N|||F|||20241018050017
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.70||<=6|N|||F|||20241018050017
-OBR|22|753234567^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241018050017
-OBR|23|753234567^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.260|µmol/L|<0.47|N|||F|||20241018050017
diff --git a/examples/Test/tempStorage/006_CA_ORU_R01_LOINC.hl7 b/examples/Test/Automated/006_CA_ORU_R01_LOINC.hl7
similarity index 100%
rename from examples/Test/tempStorage/006_CA_ORU_R01_LOINC.hl7
rename to examples/Test/Automated/006_CA_ORU_R01_LOINC.hl7
diff --git a/examples/Test/tempStorage/007_CA_ORU_R01_PLT.hl7 b/examples/Test/Automated/007_CA_ORU_R01_PLT.hl7
similarity index 100%
rename from examples/Test/tempStorage/007_CA_ORU_R01_PLT.hl7
rename to examples/Test/Automated/007_CA_ORU_R01_PLT.hl7
diff --git a/examples/Test/tempStorage/008_ORU_R01_micro_character_encoding.hl7 b/examples/Test/Automated/008_ORU_R01_micro_character_encoding.hl7
similarity index 100%
rename from examples/Test/tempStorage/008_ORU_R01_micro_character_encoding.hl7
rename to examples/Test/Automated/008_ORU_R01_micro_character_encoding.hl7
diff --git a/examples/Test/tempStorage/009_CA_ORU_R01_remove_99717-5_OBX.hl7 b/examples/Test/Automated/009_CA_ORU_R01_remove_99717-5_OBX.hl7
similarity index 100%
rename from examples/Test/tempStorage/009_CA_ORU_R01_remove_99717-5_OBX.hl7
rename to examples/Test/Automated/009_CA_ORU_R01_remove_99717-5_OBX.hl7
diff --git a/examples/Test/tempStorage/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7 b/examples/Test/Automated/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7
similarity index 100%
rename from examples/Test/tempStorage/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7
rename to examples/Test/Automated/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7
diff --git a/examples/Test/GoldenCopy/Expected/001_ORU_R01_golden_copy_expected_acylc_1.fhir b/examples/Test/GoldenCopy/Expected/001_ORU_R01_golden_copy_expected_acylc_1.fhir
new file mode 100644
index 000000000..cb65a9201
--- /dev/null
+++ b/examples/Test/GoldenCopy/Expected/001_ORU_R01_golden_copy_expected_acylc_1.fhir
@@ -0,0 +1 @@
+{"resourceType":"Bundle","id":"1734642835067543884.e722b4fd-5373-4857-9ccd-ef0ec825cfcb","meta":{"lastUpdated":"2024-12-19T21:13:55.067+00:00"},"identifier":{"system":"https://reportstream.cdc.gov/prime-router","value":"001"},"type":"message","timestamp":"2024-10-15T05:06:54.000+00:00","entry":[{"fullUrl":"MessageHeader/1734642835068444112.4f9d840b-68c9-40a0-a531-d31dff7b8685","resource":{"resourceType":"MessageHeader","id":"1734642835068444112.4f9d840b-68c9-40a0-a531-d31dff7b8685","meta":{"tag":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0103","code":"N"}]},"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/msh-message-header","extension":[{"url":"MSH.7","valueString":"20241015050654"}]}],"eventCoding":{"system":"http://terminology.hl7.org/CodeSystem/v2-0003","code":"R01","display":"ORU^R01^ORU_R01"},"destination":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id","valueString":"9413816"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id-type","valueString":"L,M,N"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.5"}],"name":"SISHIERECEIVER","receiver":{"reference":"Organization/1734642835068200185.fc1f1b38-709d-409c-91d1-ab0613be9e5c"}}],"sender":{"reference":"Organization/1734642835067731256.9daec844-69a3-4cd5-9129-1cf40049edf4"},"source":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"SISGDSP"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.3"}],"name":"SISGDSP","_endpoint":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}}},{"fullUrl":"Organization/1734642835067731256.9daec844-69a3-4cd5-9129-1cf40049edf4","resource":{"resourceType":"Organization","id":"1734642835067731256.9daec844-69a3-4cd5-9129-1cf40049edf4","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Organization/1734642835068200185.fc1f1b38-709d-409c-91d1-ab0613be9e5c","resource":{"resourceType":"Organization","id":"1734642835068200185.fc1f1b38-709d-409c-91d1-ab0613be9e5c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.6"}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.2,HD.3"}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301","code":"L,M,N"}]},"value":"automated-staging-test-receiver-id"}]}},{"fullUrl":"Provenance/1734642835069690901.9980d2c9-f7f1-424d-8a2a-b06f8122fd4c","resource":{"resourceType":"Provenance","id":"1734642835069690901.9980d2c9-f7f1-424d-8a2a-b06f8122fd4c","target":[{"reference":"MessageHeader/1734642835068444112.4f9d840b-68c9-40a0-a531-d31dff7b8685"},{"reference":"DiagnosticReport/1734642835547275564.00008400-dedd-4c3f-8968-03e87b20168f"},{"reference":"DiagnosticReport/1734642835553041496.905154d3-791c-4e4c-8ca3-4c3696b5c9e5"},{"reference":"DiagnosticReport/1734642835559411751.dbca6ed0-6ffe-4243-8531-f779d28c8c28"},{"reference":"DiagnosticReport/1734642835564422737.2cd120c8-1965-48a9-9f2b-4b44ee7657d9"},{"reference":"DiagnosticReport/1734642835571718859.7bab1bd2-c54b-4be7-bbb3-f538a840b78b"},{"reference":"DiagnosticReport/1734642835576911345.4cea296d-3d84-49d3-b748-8fc14e7ebd0e"},{"reference":"DiagnosticReport/1734642835588311032.5e1f78bb-7715-4fa5-bfd2-90c95c87e070"},{"reference":"DiagnosticReport/1734642835594442249.53dfd7d7-b35b-49f9-9dd4-1a5b215413bd"},{"reference":"DiagnosticReport/1734642835599680210.58ca4c86-9ba4-499d-90ba-e4f5010845db"},{"reference":"DiagnosticReport/1734642835605009383.4f47e62b-55ee-42e4-8b1f-aa4de5dca825"},{"reference":"DiagnosticReport/1734642835610311906.a396e7e0-528b-4007-b2ab-0e3bfc0e71cb"},{"reference":"DiagnosticReport/1734642835615540581.92060203-4181-48bb-ac65-b6f4b2412e1d"},{"reference":"DiagnosticReport/1734642835620764356.aa2f70a5-10a2-4fc5-a91c-a61f4a370dee"},{"reference":"DiagnosticReport/1734642835629477723.a50a508e-79c8-43b9-b740-dc65e70d38b5"},{"reference":"DiagnosticReport/1734642835634765358.f625e7db-f332-4af3-91cd-a982fc5662a3"},{"reference":"DiagnosticReport/1734642835640106874.9696df46-a0d7-4520-907c-de7610ae553a"},{"reference":"DiagnosticReport/1734642835643185858.7d84b3b9-82fa-4665-8995-48496677574d"},{"reference":"DiagnosticReport/1734642835646250675.aaf7e242-0a04-48fc-8fcd-37534054d84c"},{"reference":"DiagnosticReport/1734642835649684624.fd75d2d7-0fe4-4419-bedb-557668b7d57b"},{"reference":"DiagnosticReport/1734642835652690020.0f9c42bb-342e-4304-bcfc-736b4b385ce5"},{"reference":"DiagnosticReport/1734642835655881985.a9bb371f-6f8a-4ef4-a6fd-831000e7a9db"},{"reference":"DiagnosticReport/1734642835658967160.47cc3e88-d62c-4805-8020-c4d50e4dd26f"},{"reference":"DiagnosticReport/1734642835661953110.4e4c493f-1bd7-4664-b919-1d64cda84098"}],"recorded":"2024-10-15T05:06:54Z","activity":{"coding":[{"display":"ORU^R01^ORU_R01"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"author"}]},"who":{"reference":"Organization/1734642835069413500.d3c486c5-6d5c-4d05-9232-7bad25642e1d"}}]}},{"fullUrl":"Organization/1734642835069413500.d3c486c5-6d5c-4d05-9232-7bad25642e1d","resource":{"resourceType":"Organization","id":"1734642835069413500.d3c486c5-6d5c-4d05-9232-7bad25642e1d","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Provenance/1734642835070422943.01e98690-c059-4915-b9ad-09ed58453b64","resource":{"resourceType":"Provenance","id":"1734642835070422943.01e98690-c059-4915-b9ad-09ed58453b64","recorded":"2024-12-19T21:13:55Z","policy":["http://hl7.org/fhir/uv/v2mappings/message-oru-r01-to-bundle"],"activity":{"coding":[{"code":"v2-FHIR transformation"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"assembler"}]},"who":{"reference":"Organization/1734642835070158788.296f2740-5279-4ec2-8b70-9c4fb6a3e7d8"}}]}},{"fullUrl":"Organization/1734642835070158788.296f2740-5279-4ec2-8b70-9c4fb6a3e7d8","resource":{"resourceType":"Organization","id":"1734642835070158788.296f2740-5279-4ec2-8b70-9c4fb6a3e7d8","identifier":[{"value":"CDC PRIME - Atlanta"},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301"}]},"system":"urn:ietf:rfc:3986","value":"2.16.840.1.114222.4.1.237821"}]}},{"fullUrl":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d","resource":{"resourceType":"Patient","id":"1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cx-identifier","extension":[{"url":"CX.5","valueString":"MR"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"PID.3"}],"type":{"coding":[{"code":"MR"}]},"value":"32550867","assigner":{"reference":"Organization/1734642835071351043.e0ccfc27-7def-4ddf-a08b-7579b288853b"}}],"name":[{"family":"*****PII REMOVED******"}],"contact":[{"name":{"family":"*****PII REMOVED******"}}]}},{"fullUrl":"Organization/1734642835071351043.e0ccfc27-7def-4ddf-a08b-7579b288853b","resource":{"resourceType":"Organization","id":"1734642835071351043.e0ccfc27-7def-4ddf-a08b-7579b288853b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"1013163542&NPI"}]}},{"fullUrl":"Provenance/1734642835075013561.7c8d6005-4f66-456f-bce6-935b111d4053","resource":{"resourceType":"Provenance","id":"1734642835075013561.7c8d6005-4f66-456f-bce6-935b111d4053","target":[{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}],"recorded":"2024-12-19T21:13:55Z","activity":{"coding":[{"system":"https://terminology.hl7.org/CodeSystem/v3-DataOperation","code":"UPDATE"}]}}},{"fullUrl":"RelatedPerson/1734642835075868314.21d34048-42a2-4e65-bd8f-be6b9b56abef","resource":{"resourceType":"RelatedPerson","id":"1734642835075868314.21d34048-42a2-4e65-bd8f-be6b9b56abef","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"NK1"}],"patient":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"name":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"NK1.2"}],"family":"*****PII REMOVED******"}]}},{"fullUrl":"Observation/1734642835078369364.c2196b8f-737f-445d-ac4b-45735aeac2e6","resource":{"resourceType":"Observation","id":"1734642835078369364.c2196b8f-737f-445d-ac4b-45735aeac2e6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57721-3","display":"Reason for lab test in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12421-6","display":"Initial screen"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835080495691.7632bb5a-b1c3-4b60-b145-041618ed55c1","resource":{"resourceType":"Observation","id":"1734642835080495691.7632bb5a-b1c3-4b60-b145-041618ed55c1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57718-9","display":"Sample quality of Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12432-3","display":"Acceptable"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835082674046.0a733602-c7ef-4873-94e1-516cb480d33e","resource":{"resourceType":"Observation","id":"1734642835082674046.0a733602-c7ef-4873-94e1-516cb480d33e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57130-7","display":"Newborn screening report - overall interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18944-1","display":"Screen is out of range for at least one condition"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835084793380.e237aaaa-126b-4daa-a608-96962f96de3d","resource":{"resourceType":"Observation","id":"1734642835084793380.e237aaaa-126b-4daa-a608-96962f96de3d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57131-5","display":"Newborn conditions with positive markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835086855126.3ce43713-b917-4307-b320-ce0b2ebf2fe0","resource":{"resourceType":"Observation","id":"1734642835086855126.3ce43713-b917-4307-b320-ce0b2ebf2fe0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57720-5","display":"Newborn conditions with equivocal markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835088717829.68dca08f-1e3a-4579-a954-98257e12481e","resource":{"resourceType":"Observation","id":"1734642835088717829.68dca08f-1e3a-4579-a954-98257e12481e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57724-7","display":"Newborn screening short narrative summary"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"ACTION REQUIRED\\\\.br\\\\\\\\.br\\\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\\\\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\\\.br\\\\\\\\.br\\\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\\\.br\\\\\\\\.br\\\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\\\.br\\\\\\\\.br\\\\Follow-up:\\\\.br\\\\\\\\.br\\\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\\\.br\\\\\\\\.br\\\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\\\.br\\\\\\\\.br\\\\Methods and Limitations:\\\\.br\\\\\\\\.br\\\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\\\.br\\\\Attention Healthcare Provider:\\\\.br\\\\\\\\.br\\\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\\\.br\\\\\\\\.br\\","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835090658378.f9967c85-8bce-483b-8f52-c1f86b5345ab","resource":{"resourceType":"Observation","id":"1734642835090658378.f9967c85-8bce-483b-8f52-c1f86b5345ab","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57129-9","display":"Full newborn screening summary report for display or printing"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835092518015.ecfaa4b9-3cd1-4b28-b03d-d5467ce0256b","resource":{"resourceType":"Observation","id":"1734642835092518015.ecfaa4b9-3cd1-4b28-b03d-d5467ce0256b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"ST"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57716-3","display":"State printed on filter paper card [Identifier] in NBS card"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"CA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835094763425.fbd8468f-31dc-4afc-bd64-011ed531d4f5","resource":{"resourceType":"Observation","id":"1734642835094763425.fbd8468f-31dc-4afc-bd64-011ed531d4f5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"grams"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"8339-4","display":"Birthweight"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":4020,"unit":"grams"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835096753407.335a9405-05bf-4cf8-a784-653c8c7b3f03","resource":{"resourceType":"Observation","id":"1734642835096753407.335a9405-05bf-4cf8-a784-653c8c7b3f03","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57715-5","display":"Time of birth"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueTime":"1416","_valueTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"1416"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835098930860.da2d043f-88c3-4b08-aa9d-8e4b693937b0","resource":{"resourceType":"Observation","id":"1734642835098930860.da2d043f-88c3-4b08-aa9d-8e4b693937b0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57722-1","display":"Birth plurality of Pregnancy"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12411-7","display":"Singleton"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835103742933.94767150-dbad-4916-b838-ccdf292751e8","resource":{"resourceType":"Observation","id":"1734642835103742933.94767150-dbad-4916-b838-ccdf292751e8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"hour(s)"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"73806-2","display":"Newborn age in hours"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":24,"unit":"hour(s)"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835105967955.b8ba9fbf-48cc-497b-9abd-65fc6367fd39","resource":{"resourceType":"Observation","id":"1734642835105967955.b8ba9fbf-48cc-497b-9abd-65fc6367fd39","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57713-0","display":"Infant NICU factors that affect newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835108045581.fd28d933-fe5b-4535-8299-eae01e9f9772","resource":{"resourceType":"Observation","id":"1734642835108045581.fd28d933-fe5b-4535-8299-eae01e9f9772","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67704-7","display":"Feeding types"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA16914-6","display":"Breast milk"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835110135560.5df45eb7-4436-4275-b0f3-a346250ba6a5","resource":{"resourceType":"Observation","id":"1734642835110135560.5df45eb7-4436-4275-b0f3-a346250ba6a5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67704-7","display":"Feeding types"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA16915-3","display":"Lactose formula"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835111937279.a13f52de-fb3e-42c5-b70b-8928b41db139","resource":{"resourceType":"Observation","id":"1734642835111937279.a13f52de-fb3e-42c5-b70b-8928b41db139","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-5","display":"Accession Number"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"277-86-190/21-2024-32","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835113791285.a93e71ad-6e66-4cb1-975c-0b72e1ec82b3","resource":{"resourceType":"Observation","id":"1734642835113791285.a93e71ad-6e66-4cb1-975c-0b72e1ec82b3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62324-9","display":"Post-discharge provider name"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"STEWART BROOKS","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835115568047.503e318a-9232-4da8-9224-3ac70778c436","resource":{"resourceType":"Observation","id":"1734642835115568047.503e318a-9232-4da8-9224-3ac70778c436","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62325-6","display":"Post-discharge provider practice ID"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"1477542173","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835117366028.a90473f2-2703-420c-b243-a76140002965","resource":{"resourceType":"Observation","id":"1734642835117366028.a90473f2-2703-420c-b243-a76140002965","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62327-2","display":"Post-discharge provider practice address"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835119388891.5a6ef168-f3d7-4d65-8702-8ad61c5d91c1","resource":{"resourceType":"Observation","id":"1734642835119388891.5a6ef168-f3d7-4d65-8702-8ad61c5d91c1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47633-3","display":"Glycine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":387,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835121480383.7a5f35b5-fa6e-487e-ab4d-b9e13376e739","resource":{"resourceType":"Observation","id":"1734642835121480383.7a5f35b5-fa6e-487e-ab4d-b9e13376e739","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53150-9","display":"Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":381,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1000"}]}},{"fullUrl":"Observation/1734642835123554132.e09200e9-c15a-4a65-b6b6-e161fdf37208","resource":{"resourceType":"Observation","id":"1734642835123554132.e09200e9-c15a-4a65-b6b6-e161fdf37208","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47799-2","display":"Valine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":92.6,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835125650042.fb0f3ad6-1421-438e-aa27-18b629de869d","resource":{"resourceType":"Observation","id":"1734642835125650042.fb0f3ad6-1421-438e-aa27-18b629de869d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53151-7","display":"Valine/Phenylalanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":1.88595,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.3"}]}},{"fullUrl":"Observation/1734642835127731345.61fe2a05-efe7-465e-bfde-aa231fab366c","resource":{"resourceType":"Observation","id":"1734642835127731345.61fe2a05-efe7-465e-bfde-aa231fab366c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53152-5","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":86.8,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<230"}]}},{"fullUrl":"Observation/1734642835129903108.d4dda740-dd49-43d6-bc9b-25bf1279d5ee","resource":{"resourceType":"Observation","id":"1734642835129903108.d4dda740-dd49-43d6-bc9b-25bf1279d5ee","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53154-1","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.23,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.35"}]}},{"fullUrl":"Observation/1734642835132201607.e6bc54d2-552d-489d-9ae6-62ed2947bbfc","resource":{"resourceType":"Observation","id":"1734642835132201607.e6bc54d2-552d-489d-9ae6-62ed2947bbfc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29573-3","display":"Phenylalanine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":49.1,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<175"}]}},{"fullUrl":"Observation/1734642835134316363.4ed4d624-eb61-48f4-be97-5638df76e5e4","resource":{"resourceType":"Observation","id":"1734642835134316363.4ed4d624-eb61-48f4-be97-5638df76e5e4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35572-7","display":"Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":1.09,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2.6"}]}},{"fullUrl":"Observation/1734642835136414106.c0d7674a-7603-44b7-be2a-69fca6f812be","resource":{"resourceType":"Observation","id":"1734642835136414106.c0d7674a-7603-44b7-be2a-69fca6f812be","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35571-9","display":"Tyrosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":45.1,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<680"}]}},{"fullUrl":"Observation/1734642835138555141.69e9066d-9ec7-4684-856e-6fea5af26e44","resource":{"resourceType":"Observation","id":"1734642835138555141.69e9066d-9ec7-4684-856e-6fea5af26e44","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53231-7","display":"Succinylacetone [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.24,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<6.1"}]}},{"fullUrl":"Observation/1734642835140681458.81b74ae1-30fb-48ee-9715-2cb02de30059","resource":{"resourceType":"Observation","id":"1734642835140681458.81b74ae1-30fb-48ee-9715-2cb02de30059","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47700-0","display":"Methionine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":16.8,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.3-100"}]}},{"fullUrl":"Observation/1734642835142831109.183b9ea7-e9a9-4ae9-8815-e9289498e43e","resource":{"resourceType":"Observation","id":"1734642835142831109.183b9ea7-e9a9-4ae9-8815-e9289498e43e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42892-0","display":"Citrulline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":20,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"5-49"}]}},{"fullUrl":"Observation/1734642835145029071.6d59c882-47f8-468a-9605-b2eac4033062","resource":{"resourceType":"Observation","id":"1734642835145029071.6d59c882-47f8-468a-9605-b2eac4033062","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54092-2","display":"Citrulline/Arginine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":3.22,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.8"}]}},{"fullUrl":"Observation/1734642835147116164.3622f8ea-dadd-4bcb-bdec-4be3ddf0bde7","resource":{"resourceType":"Observation","id":"1734642835147116164.3622f8ea-dadd-4bcb-bdec-4be3ddf0bde7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53155-8","display":"Asparagine+Ornithine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":74,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<800"}]}},{"fullUrl":"Observation/1734642835149213497.5c0bb970-be0d-433d-82c7-bb51bac1b7ee","resource":{"resourceType":"Observation","id":"1734642835149213497.5c0bb970-be0d-433d-82c7-bb51bac1b7ee","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75215-4","display":"Ornithine/Citrulline [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":3.76,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835151303085.143080f8-d26d-4ca3-bd0a-68be0eac89a4","resource":{"resourceType":"Observation","id":"1734642835151303085.143080f8-d26d-4ca3-bd0a-68be0eac89a4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47562-4","display":"Arginine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":6,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<63"}]}},{"fullUrl":"Observation/1734642835153524951.70cca668-8ac5-4daa-ad44-f014db61930b","resource":{"resourceType":"Observation","id":"1734642835153524951.70cca668-8ac5-4daa-ad44-f014db61930b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75214-7","display":"Arginine/Ornithine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.08,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.9"}]}},{"fullUrl":"Observation/1734642835155737450.2fdf26eb-1dad-4753-b21d-07eef73e6e1c","resource":{"resourceType":"Observation","id":"1734642835155737450.2fdf26eb-1dad-4753-b21d-07eef73e6e1c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47732-3","display":"Proline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":118,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1500"}]}},{"fullUrl":"Observation/1734642835157643855.9b2bf0f2-7367-4472-aa24-68cd2e9402e8","resource":{"resourceType":"Observation","id":"1734642835157643855.9b2bf0f2-7367-4472-aa24-68cd2e9402e8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57710-6","display":"Amino acidemias newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835159845143.ec8dc2e0-fac7-423d-82de-df26b1f9fc90","resource":{"resourceType":"Observation","id":"1734642835159845143.ec8dc2e0-fac7-423d-82de-df26b1f9fc90","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58088-6","display":"Acylcarnitine newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA11884-6","display":"Indeterminate"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"A"}]}]}},{"fullUrl":"Observation/1734642835161689441.9fe72387-651d-428a-b97d-3105fa1691f5","resource":{"resourceType":"Observation","id":"1734642835161689441.9fe72387-651d-428a-b97d-3105fa1691f5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58093-6","display":"Acylcarnitine newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"This pattern of elevations is consistent with SCADD, IBCDD","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"A"}]}]}},{"fullUrl":"Observation/1734642835163707606.0e7ac73a-3dd8-4727-82ef-eee6c4d05d14","resource":{"resourceType":"Observation","id":"1734642835163707606.0e7ac73a-3dd8-4727-82ef-eee6c4d05d14","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38481-8","display":"Carnitine.free (C0)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":34.3,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.4-125"}]}},{"fullUrl":"Observation/1734642835165827511.90623ef3-82b0-400c-9455-4378b7797070","resource":{"resourceType":"Observation","id":"1734642835165827511.90623ef3-82b0-400c-9455-4378b7797070","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53235-8","display":"Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":5.93,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<70"}]}},{"fullUrl":"Observation/1734642835167903263.045e84d0-3ee4-4092-8679-e0b8932c27f6","resource":{"resourceType":"Observation","id":"1734642835167903263.045e84d0-3ee4-4092-8679-e0b8932c27f6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50157-7","display":"Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":33.2,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"10-80"}]}},{"fullUrl":"Observation/1734642835170008381.df833064-f458-44c8-aae6-912dad9d9087","resource":{"resourceType":"Observation","id":"1734642835170008381.df833064-f458-44c8-aae6-912dad9d9087","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75212-1","display":"Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":1.29565,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.6"}]}},{"fullUrl":"Observation/1734642835172132283.9f0c7a5d-71ba-47af-9c10-6225b15373f5","resource":{"resourceType":"Observation","id":"1734642835172132283.9f0c7a5d-71ba-47af-9c10-6225b15373f5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45211-0","display":"Hexanoylcarnitine (C6)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.136,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835177087191.d4761a12-0246-469f-8b0a-7739d293f508","resource":{"resourceType":"Observation","id":"1734642835177087191.d4761a12-0246-469f-8b0a-7739d293f508","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53175-6","display":"Octanoylcarnitine (C8)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.150,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835179226894.a1e5f914-f409-483e-8e82-e97c4a9dc4bd","resource":{"resourceType":"Observation","id":"1734642835179226894.a1e5f914-f409-483e-8e82-e97c4a9dc4bd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53177-2","display":"Octanoylcarnitine (C8)/Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.65,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835181327282.deb6ed28-b853-48a8-a693-12199af60ec9","resource":{"resourceType":"Observation","id":"1734642835181327282.deb6ed28-b853-48a8-a693-12199af60ec9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53174-9","display":"Octenoylcarnitine (C8:1)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.221,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835183410599.4769d68b-068a-4463-824b-ca3c936e1b7f","resource":{"resourceType":"Observation","id":"1734642835183410599.4769d68b-068a-4463-824b-ca3c936e1b7f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45197-1","display":"Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.230,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835185557374.a69db609-b0ce-4b99-8746-637931d3a44c","resource":{"resourceType":"Observation","id":"1734642835185557374.a69db609-b0ce-4b99-8746-637931d3a44c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45198-9","display":"Decenoylcarnitine (C10:1)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.088,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835187803676.e0d1ff83-2851-4408-ba12-9c6390114b98","resource":{"resourceType":"Observation","id":"1734642835187803676.e0d1ff83-2851-4408-ba12-9c6390114b98","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45199-7","display":"Dodecanoylcarnitine (C12)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.232,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2"}]}},{"fullUrl":"Observation/1734642835189909665.62d7569d-0a11-4642-bad3-b156e86d58a0","resource":{"resourceType":"Observation","id":"1734642835189909665.62d7569d-0a11-4642-bad3-b156e86d58a0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45200-3","display":"Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.20,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835192058094.bd18c898-1943-47e4-8811-ff5a80ae85a6","resource":{"resourceType":"Observation","id":"1734642835192058094.bd18c898-1943-47e4-8811-ff5a80ae85a6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53192-1","display":"Tetradecanoylcarnitine (C14)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.342,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.2"}]}},{"fullUrl":"Observation/1734642835194313693.22932fcf-61d0-480d-8035-f2a79a45e484","resource":{"resourceType":"Observation","id":"1734642835194313693.22932fcf-61d0-480d-8035-f2a79a45e484","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53191-3","display":"Tetradecenoylcarnitine (C14:1)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.206,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.9"}]}},{"fullUrl":"Observation/1734642835196515723.57267597-c36f-4219-91d0-7c74202d2d52","resource":{"resourceType":"Observation","id":"1734642835196515723.57267597-c36f-4219-91d0-7c74202d2d52","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53194-7","display":"Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":1.02,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835198572800.e5ec271e-b6dd-4e3b-946f-ce198988c137","resource":{"resourceType":"Observation","id":"1734642835198572800.e5ec271e-b6dd-4e3b-946f-ce198988c137","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53190-5","display":"Tetradecadienoylcarnitine (C14:2)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.03,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835200670263.961accbb-4104-4d11-8134-76e59c661438","resource":{"resourceType":"Observation","id":"1734642835200670263.961accbb-4104-4d11-8134-76e59c661438","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50281-5","display":"3-Hydroxytetradecanoylcarnitine (C14-OH)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.029,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.2"}]}},{"fullUrl":"Observation/1734642835202756185.b72b6129-dc37-4fd6-b7f0-5c5bf464d238","resource":{"resourceType":"Observation","id":"1734642835202756185.b72b6129-dc37-4fd6-b7f0-5c5bf464d238","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53199-6","display":"Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":4.14,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<12"}]}},{"fullUrl":"Observation/1734642835204989482.04869e37-ffba-4675-b7ab-3c98773de6a9","resource":{"resourceType":"Observation","id":"1734642835204989482.04869e37-ffba-4675-b7ab-3c98773de6a9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53198-8","display":"Palmitoleylcarnitine (C16:1)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.341,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.4"}]}},{"fullUrl":"Observation/1734642835207217761.ede199f5-0a4b-4351-ad09-4b8881bde701","resource":{"resourceType":"Observation","id":"1734642835207217761.ede199f5-0a4b-4351-ad09-4b8881bde701","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50125-4","display":"3-Hydroxypalmitoylcarnitine (C16-OH)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.049,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835209347895.261b7657-6f9b-432a-8f29-b9874b99b609","resource":{"resourceType":"Observation","id":"1734642835209347895.261b7657-6f9b-432a-8f29-b9874b99b609","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53201-0","display":"3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.01184,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.07"}]}},{"fullUrl":"Observation/1734642835211671422.438e14ff-0281-49e7-b165-a19336723741","resource":{"resourceType":"Observation","id":"1734642835211671422.438e14ff-0281-49e7-b165-a19336723741","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53241-6","display":"Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":1.07,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<3.5"}]}},{"fullUrl":"Observation/1734642835213810493.5b329d38-601f-4845-8033-9be87d25aca5","resource":{"resourceType":"Observation","id":"1734642835213810493.5b329d38-601f-4845-8033-9be87d25aca5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53202-8","display":"Oleoylcarnitine (C18:1)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":1.65,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7"}]}},{"fullUrl":"Observation/1734642835215877980.36b9a8cc-d3df-4d30-a31c-90f2e034379a","resource":{"resourceType":"Observation","id":"1734642835215877980.36b9a8cc-d3df-4d30-a31c-90f2e034379a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45217-7","display":"Linoleoylcarnitine (C18:2)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.23,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835217975733.dc31874a-a4be-4b8a-af75-fd59ad417868","resource":{"resourceType":"Observation","id":"1734642835217975733.dc31874a-a4be-4b8a-af75-fd59ad417868","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50132-0","display":"3-Hydroxystearoylcarnitine (C18-OH)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.022,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835220100768.05a1dc4e-f604-4e77-9ea7-afbf81b8198f","resource":{"resourceType":"Observation","id":"1734642835220100768.05a1dc4e-f604-4e77-9ea7-afbf81b8198f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50113-0","display":"3-Hydroxyoleoylcarnitine (C18:1-OH)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.053,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835222279323.b0f928cc-46cf-4aaa-adff-fe2ce7a5ceef","resource":{"resourceType":"Observation","id":"1734642835222279323.b0f928cc-46cf-4aaa-adff-fe2ce7a5ceef","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53160-8","display":"Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":2.3,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.9"}]}},{"fullUrl":"Observation/1734642835224430367.da780c77-72b4-4336-9039-a31184926686","resource":{"resourceType":"Observation","id":"1734642835224430367.da780c77-72b4-4336-9039-a31184926686","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53163-2","display":"Propionylcarnitine (C3)/Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.07,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.42"}]}},{"fullUrl":"Observation/1734642835226529483.7b86fa71-ee93-43a1-b76d-cd849e73ca00","resource":{"resourceType":"Observation","id":"1734642835226529483.7b86fa71-ee93-43a1-b76d-cd849e73ca00","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67708-8","display":"Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.298,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.48"}]}},{"fullUrl":"Observation/1734642835228718427.086f9d04-6daa-4866-94d7-a65517888d6c","resource":{"resourceType":"Observation","id":"1734642835228718427.086f9d04-6daa-4866-94d7-a65517888d6c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53166-5","display":"Butyrylcarnitine+Isobutyrylcarnitine (C4)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":1.73,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"H"}]}],"referenceRange":[{"text":"<1.7"}]}},{"fullUrl":"Observation/1734642835230835868.279fed09-20e6-49b8-96a2-93eef87155d8","resource":{"resourceType":"Observation","id":"1734642835230835868.279fed09-20e6-49b8-96a2-93eef87155d8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45216-9","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.139,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835233122375.0c6b8d22-57b3-4294-9b1e-c3a0a59070e9","resource":{"resourceType":"Observation","id":"1734642835233122375.0c6b8d22-57b3-4294-9b1e-c3a0a59070e9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53240-8","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.06043,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642835235257058.bdccfc91-c409-4ac8-9243-1ce9a9c8d5e8","resource":{"resourceType":"Observation","id":"1734642835235257058.bdccfc91-c409-4ac8-9243-1ce9a9c8d5e8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53170-7","display":"Tiglylcarnitine (C5:1)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.011,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.5"}]}},{"fullUrl":"Observation/1734642835237360573.bc47837e-0b31-4a8e-b5ed-80ea7f6a5306","resource":{"resourceType":"Observation","id":"1734642835237360573.bc47837e-0b31-4a8e-b5ed-80ea7f6a5306","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50106-4","display":"3-Hydroxyisovalerylcarnitine (C5-OH)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.306,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.15"}]}},{"fullUrl":"Observation/1734642835239462615.dbfb2d97-079e-41cf-a27e-23be7e134d01","resource":{"resourceType":"Observation","id":"1734642835239462615.dbfb2d97-079e-41cf-a27e-23be7e134d01","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67710-4","display":"Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.238,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642835241573904.95e1902d-39bc-4c32-b276-f57426ac9754","resource":{"resourceType":"Observation","id":"1734642835241573904.95e1902d-39bc-4c32-b276-f57426ac9754","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75216-2","display":"Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.79866,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">0.1"}]}},{"fullUrl":"Observation/1734642835243642913.6b373e0e-6c4c-4ba8-bc16-dbeaccbaa242","resource":{"resourceType":"Observation","id":"1734642835243642913.6b373e0e-6c4c-4ba8-bc16-dbeaccbaa242","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ng/mL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"48633-2","display":"Trypsinogen I.free"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":18.10,"unit":"ng/mL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<69"}]}},{"fullUrl":"Observation/1734642835245924111.ba72acbf-fdd2-4ade-a4ea-628501d3932d","resource":{"resourceType":"Observation","id":"1734642835245924111.ba72acbf-fdd2-4ade-a4ea-628501d3932d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46769-6","display":"Cystic fibrosis newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835250748858.075f5f4d-fb95-4b1c-b882-706af112ad10","resource":{"resourceType":"Observation","id":"1734642835250748858.075f5f4d-fb95-4b1c-b882-706af112ad10","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57707-2","display":"Cystic fibrosis newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835252910902.b34746e7-68e4-47e4-8123-c1d143b926c6","resource":{"resourceType":"Observation","id":"1734642835252910902.b34746e7-68e4-47e4-8123-c1d143b926c6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"nmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38473-5","display":"17-Hydroxyprogesterone"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":10.8,"unit":"nmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<85"}]}},{"fullUrl":"Observation/1734642835255176000.1844fffb-f304-497b-8dff-89fb14ade80b","resource":{"resourceType":"Observation","id":"1734642835255176000.1844fffb-f304-497b-8dff-89fb14ade80b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46758-9","display":"Congenital adrenal hyperplasia newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835256981315.d023e3a2-2bae-4586-ade7-0f801c8ecb93","resource":{"resourceType":"Observation","id":"1734642835256981315.d023e3a2-2bae-4586-ade7-0f801c8ecb93","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57706-4","display":"Congenital adrenal hyperplasia newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835258991303.471ccb24-c53b-4247-ae1b-85333058044f","resource":{"resourceType":"Observation","id":"1734642835258991303.471ccb24-c53b-4247-ae1b-85333058044f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"mIU/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29575-8","display":"Thyrotropin"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":4.00,"unit":"mIU/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<29"}]}},{"fullUrl":"Observation/1734642835261094698.216cfc15-4e6b-4054-a562-dc9d010ffdc4","resource":{"resourceType":"Observation","id":"1734642835261094698.216cfc15-4e6b-4054-a562-dc9d010ffdc4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46762-1","display":"Congenital hypothyroidism newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835262847204.678cc366-4570-42a8-9df3-afcdaca9c9ca","resource":{"resourceType":"Observation","id":"1734642835262847204.678cc366-4570-42a8-9df3-afcdaca9c9ca","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57705-6","display":"Congenital hypothyroidism newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835264921283.91ec1af6-893c-4d53-bac5-b0600e963d5f","resource":{"resourceType":"Observation","id":"1734642835264921283.91ec1af6-893c-4d53-bac5-b0600e963d5f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"enzyme units"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42906-8","display":"Galactose 1 phosphate uridyl transferase"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":267.94,"unit":"enzyme units"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">50"}]}},{"fullUrl":"Observation/1734642835267035147.1883610c-4f1d-4119-9f38-02c468008832","resource":{"resourceType":"Observation","id":"1734642835267035147.1883610c-4f1d-4119-9f38-02c468008832","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46737-3","display":"Galactosemias newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835268840823.be073532-267c-4705-bd5d-98f936d8a298","resource":{"resourceType":"Observation","id":"1734642835268840823.be073532-267c-4705-bd5d-98f936d8a298","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57704-9","display":"Galactosemias newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835270610922.3dea9e01-cf45-4440-859b-5f06ec5bcd78","resource":{"resourceType":"Observation","id":"1734642835270610922.3dea9e01-cf45-4440-859b-5f06ec5bcd78","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54104-5","display":"Hemoglobin pattern"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"FA"}},{"fullUrl":"Observation/1734642835272189662.237e8e77-bfda-4b54-8e00-1086f80d5fa5","resource":{"resourceType":"Observation","id":"1734642835272189662.237e8e77-bfda-4b54-8e00-1086f80d5fa5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57703-1","display":"Hemoglobin disorders newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants."}},{"fullUrl":"Observation/1734642835273965232.4d115769-fad3-4470-abfd-0fb327e43527","resource":{"resourceType":"Observation","id":"1734642835273965232.4d115769-fad3-4470-abfd-0fb327e43527","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ERU"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75217-0","display":"Biotinidase [Enzymatic activity/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":44.16,"unit":"ERU"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">10"}]}},{"fullUrl":"Observation/1734642835276087662.698b32ba-eee2-4766-bc7a-d4fa00fa3dd7","resource":{"resourceType":"Observation","id":"1734642835276087662.698b32ba-eee2-4766-bc7a-d4fa00fa3dd7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46761-3","display":"Biotinidase deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835277860797.d3aeb34c-bcb9-4228-8631-558b588db30d","resource":{"resourceType":"Observation","id":"1734642835277860797.d3aeb34c-bcb9-4228-8631-558b588db30d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57699-1","display":"Biotinidase deficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835279841832.a1229730-924c-4549-b477-bf1b2cfd8e13","resource":{"resourceType":"Observation","id":"1734642835279841832.a1229730-924c-4549-b477-bf1b2cfd8e13","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"copies/µL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62320-7","display":"T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":84,"unit":"copies/µL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">18"}]}},{"fullUrl":"Observation/1734642835281978468.f15dce75-3889-43f5-958c-7ed178d61dd9","resource":{"resourceType":"Observation","id":"1734642835281978468.f15dce75-3889-43f5-958c-7ed178d61dd9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62321-5","display":"Severe combined immunodeficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835283734922.786a3096-c83d-41f3-888c-c9f92a602540","resource":{"resourceType":"Observation","id":"1734642835283734922.786a3096-c83d-41f3-888c-c9f92a602540","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62322-3","display":"Severe combined immunodeficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835285827456.e28416c0-d951-49ea-b27f-d348b5138f42","resource":{"resourceType":"Observation","id":"1734642835285827456.e28416c0-d951-49ea-b27f-d348b5138f42","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55827-0","display":"Acid alpha glucosidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":6.97,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=1.51"}]}},{"fullUrl":"Observation/1734642835287968320.ad75f0e5-8ce2-448a-a2a8-7933847307c0","resource":{"resourceType":"Observation","id":"1734642835287968320.ad75f0e5-8ce2-448a-a2a8-7933847307c0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63415-4","display":"Pompe Disease deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835289784355.144718e3-9b36-4dd4-aab8-91378f578a01","resource":{"resourceType":"Observation","id":"1734642835289784355.144718e3-9b36-4dd4-aab8-91378f578a01","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63416-2","display":"Pompe Disease deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835291780468.3717216f-340a-4b57-b6f6-533f29f70555","resource":{"resourceType":"Observation","id":"1734642835291780468.3717216f-340a-4b57-b6f6-533f29f70555","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55909-6","display":"Alpha-L-iduronidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":10.38,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=0.77"}]}},{"fullUrl":"Observation/1734642835293916704.2ae71bb9-0e78-4be4-b12f-2a3e8cf13640","resource":{"resourceType":"Observation","id":"1734642835293916704.2ae71bb9-0e78-4be4-b12f-2a3e8cf13640","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79564-1","display":"Mucopolysaccharidosis type I newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835295825143.3f0cd5e9-e867-40a2-9705-54078fe574fb","resource":{"resourceType":"Observation","id":"1734642835295825143.3f0cd5e9-e867-40a2-9705-54078fe574fb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79565-8","display":"Mucopolysaccharidosis type I newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835298238849.e1f75b37-69a0-4e11-96ba-52cd392bfbb2","resource":{"resourceType":"Observation","id":"1734642835298238849.e1f75b37-69a0-4e11-96ba-52cd392bfbb2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-60","display":"SMN1 Homozygous Deletion Analysis"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Exon 7 Present","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"Exon 7 Present"}]}},{"fullUrl":"Observation/1734642835300320963.6730aa2a-9456-489c-8593-97f2a053ac85","resource":{"resourceType":"Observation","id":"1734642835300320963.6730aa2a-9456-489c-8593-97f2a053ac85","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92004-1","display":"Spinal muscular atrophy newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835302129644.2bd6f20a-35fa-4b4c-a716-59ee8c023bc9","resource":{"resourceType":"Observation","id":"1734642835302129644.2bd6f20a-35fa-4b4c-a716-59ee8c023bc9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92003-3","display":"Spinal muscular atrophy newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"SMA Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835304240262.90534b48-83cc-4456-bee2-4f8adccd3fed","resource":{"resourceType":"Observation","id":"1734642835304240262.90534b48-83cc-4456-bee2-4f8adccd3fed","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79462-8","display":"Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":27.61,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=2.75"}]}},{"fullUrl":"Observation/1734642835306921540.9c7ab076-631e-46de-9f99-4a594333dba0","resource":{"resourceType":"Observation","id":"1734642835306921540.9c7ab076-631e-46de-9f99-4a594333dba0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104189-6","display":"Mucopolysaccharidosis type II newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835308835408.0ef7fd8a-38aa-4a53-8efa-1f4070b8722a","resource":{"resourceType":"Observation","id":"1734642835308835408.0ef7fd8a-38aa-4a53-8efa-1f4070b8722a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104190-4","display":"Mucopolysaccharidosis type II newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835310956776.8e5c8f5d-464e-4d6a-b6ff-aa6317ca2236","resource":{"resourceType":"Observation","id":"1734642835310956776.8e5c8f5d-464e-4d6a-b6ff-aa6317ca2236","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104192-0","display":"Guanidinoacetate methyltransferase deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835312849265.7b1a44be-87f3-4c3e-b8c2-4bb112a00396","resource":{"resourceType":"Observation","id":"1734642835312849265.7b1a44be-87f3-4c3e-b8c2-4bb112a00396","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104193-8","display":"Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835314906112.b7166b68-f03f-4d84-bf2c-0b3b7abe9d18","resource":{"resourceType":"Observation","id":"1734642835314906112.b7166b68-f03f-4d84-bf2c-0b3b7abe9d18","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"93488-5","display":"Guanidinoacetate [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":1.04,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=3"}]}},{"fullUrl":"Observation/1734642835317154138.6f022b94-8600-406a-b8f0-5fc23b87e94f","resource":{"resourceType":"Observation","id":"1734642835317154138.6f022b94-8600-406a-b8f0-5fc23b87e94f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104194-6","display":"Creatine [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":391.37,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835322641287.9e617f2f-7044-4954-ad62-cf9a106d32e7","resource":{"resourceType":"Observation","id":"1734642835322641287.9e617f2f-7044-4954-ad62-cf9a106d32e7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104195-3","display":"GUAC/CRE Ratio [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":2.66},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=6"}]}},{"fullUrl":"Observation/1734642835324840571.1d7a28bf-5661-4d4e-aa75-b787be359580","resource":{"resourceType":"Observation","id":"1734642835324840571.1d7a28bf-5661-4d4e-aa75-b787be359580","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-32","display":"Adrenoleukodystrophy deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835326726838.637b5c0e-2fa3-424f-9919-cc78bd0ac277","resource":{"resourceType":"Observation","id":"1734642835326726838.637b5c0e-2fa3-424f-9919-cc78bd0ac277","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-33","display":"Adrenoleukodystrophy deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835328833769.b1ef8e36-8a86-4ff0-89fb-be9399563adc","resource":{"resourceType":"Observation","id":"1734642835328833769.b1ef8e36-8a86-4ff0-89fb-be9399563adc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79321-6","display":"Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.246,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.47"}]}},{"fullUrl":"Specimen/1734642835339257765.334367ae-6cf8-4c69-bbea-6c69cbe7b03f","resource":{"resourceType":"Specimen","id":"1734642835339257765.334367ae-6cf8-4c69-bbea-6c69cbe7b03f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835340756115.6e87362a-8040-4f57-b680-9d689ccb1713","resource":{"resourceType":"Specimen","id":"1734642835340756115.6e87362a-8040-4f57-b680-9d689ccb1713","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835342128909.4fd4310f-6fb3-47f4-bb83-66ba1586a53c","resource":{"resourceType":"Specimen","id":"1734642835342128909.4fd4310f-6fb3-47f4-bb83-66ba1586a53c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835343507644.b7a33119-8c73-4ac8-ad96-a6ba91294273","resource":{"resourceType":"Specimen","id":"1734642835343507644.b7a33119-8c73-4ac8-ad96-a6ba91294273","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835344937215.6667157e-8de8-47c2-917e-1c05fc4720f3","resource":{"resourceType":"Specimen","id":"1734642835344937215.6667157e-8de8-47c2-917e-1c05fc4720f3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835346298187.44b92531-e550-4f36-bd2f-7cc66563231e","resource":{"resourceType":"Specimen","id":"1734642835346298187.44b92531-e550-4f36-bd2f-7cc66563231e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835347647096.2b33be20-c50f-46cc-82b4-01a32c586924","resource":{"resourceType":"Specimen","id":"1734642835347647096.2b33be20-c50f-46cc-82b4-01a32c586924","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835349049456.62fb98dc-8087-4a66-95d6-f4ed8208a11c","resource":{"resourceType":"Specimen","id":"1734642835349049456.62fb98dc-8087-4a66-95d6-f4ed8208a11c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835350409446.25a13015-e80e-447a-9880-41f54e21c7e7","resource":{"resourceType":"Specimen","id":"1734642835350409446.25a13015-e80e-447a-9880-41f54e21c7e7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835351773143.a2f9e75c-f720-4819-8163-f0869dd878e3","resource":{"resourceType":"Specimen","id":"1734642835351773143.a2f9e75c-f720-4819-8163-f0869dd878e3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835353174381.56974595-1d78-4e47-8689-2c9fa54dd258","resource":{"resourceType":"Specimen","id":"1734642835353174381.56974595-1d78-4e47-8689-2c9fa54dd258","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835354552365.f4274b93-053b-4ea9-8cc0-78f77d14acd8","resource":{"resourceType":"Specimen","id":"1734642835354552365.f4274b93-053b-4ea9-8cc0-78f77d14acd8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835355916653.d20c9e73-898b-40ca-ae6f-d01f3073ecd1","resource":{"resourceType":"Specimen","id":"1734642835355916653.d20c9e73-898b-40ca-ae6f-d01f3073ecd1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835357303103.64850f3f-eae9-466a-9f6e-d8de284c438f","resource":{"resourceType":"Specimen","id":"1734642835357303103.64850f3f-eae9-466a-9f6e-d8de284c438f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835358672621.32ace6ea-8714-4a7c-9dc8-3a8b275f2e11","resource":{"resourceType":"Specimen","id":"1734642835358672621.32ace6ea-8714-4a7c-9dc8-3a8b275f2e11","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835360239980.b2a20ccb-343f-415a-a83f-351513f7aa49","resource":{"resourceType":"Specimen","id":"1734642835360239980.b2a20ccb-343f-415a-a83f-351513f7aa49","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835361666956.cc4f91e2-7a09-452b-8420-a10fd9c80e2b","resource":{"resourceType":"Specimen","id":"1734642835361666956.cc4f91e2-7a09-452b-8420-a10fd9c80e2b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835363030964.3a12ef62-abe5-4a3b-ad91-8b8d05157d1b","resource":{"resourceType":"Specimen","id":"1734642835363030964.3a12ef62-abe5-4a3b-ad91-8b8d05157d1b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835364420439.6a839ff7-18ff-4135-8756-87a3237a1401","resource":{"resourceType":"Specimen","id":"1734642835364420439.6a839ff7-18ff-4135-8756-87a3237a1401","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835365799685.6448fcb2-bb46-4a42-bee7-6b46fc845bff","resource":{"resourceType":"Specimen","id":"1734642835365799685.6448fcb2-bb46-4a42-bee7-6b46fc845bff","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835367153343.0095dbea-0b87-4cbf-8f40-6b1e69d49429","resource":{"resourceType":"Specimen","id":"1734642835367153343.0095dbea-0b87-4cbf-8f40-6b1e69d49429","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835368626987.ce01d466-d2f9-46ed-b51c-a1a843eacc34","resource":{"resourceType":"Specimen","id":"1734642835368626987.ce01d466-d2f9-46ed-b51c-a1a843eacc34","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835370263338.53b0cddb-320b-4d2f-bc6d-0f7ba8191347","resource":{"resourceType":"Specimen","id":"1734642835370263338.53b0cddb-320b-4d2f-bc6d-0f7ba8191347","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"ServiceRequest/1734642835389771409.849e985d-b913-4e36-8996-a26c807d3feb","resource":{"resourceType":"ServiceRequest","id":"1734642835389771409.849e985d-b913-4e36-8996-a26c807d3feb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/business-event","valueCode":"RE"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/orc-common-order","extension":[{"url":"orc-21-ordering-facility-name","valueReference":{"reference":"Organization/1734642835384580134.a52e857e-b1a6-4933-91d3-45b90c6c563b"}},{"url":"orc-22-ordering-facility-address","valueAddress":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"8700 BEVERLY BLVD"}]}]}],"line":["8700 BEVERLY BLVD"],"city":"W HOLLYWOOD","state":"CA","postalCode":"90048-1804"}},{"url":"orc-12-ordering-provider","valueReference":{"reference":"Practitioner/1734642835387126880.1c0115df-b0ab-4194-8b18-e5c9c65c4b49"}}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.2","valueIdentifier":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"value":"673678765"}},{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"M17965"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"M17965"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"requester":{"reference":"PractitionerRole/1734642835376611271.42d862dc-b6bf-423c-838c-3eacb52cdf86"}}},{"fullUrl":"Practitioner/1734642835378152101.971d96a1-05f0-4810-8fc6-99fa1d10dd78","resource":{"resourceType":"Practitioner","id":"1734642835378152101.971d96a1-05f0-4810-8fc6-99fa1d10dd78","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"STEWART"},{"url":"XCN.10","valueString":"NPI"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.12"}],"identifier":[{"value":"1477542173"}],"name":[{"family":"BROOKS","given":["STEWART"]}]}},{"fullUrl":"Organization/1734642835380671425.9dbb655b-63ba-4d49-abe4-55fd0c8c0f60","resource":{"resourceType":"Organization","id":"1734642835380671425.9dbb655b-63ba-4d49-abe4-55fd0c8c0f60","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R150"}]}],"identifier":[{"value":"R150"}],"name":"CEDARS-SINAI MEDICAL CENTER","telecom":[{"_system":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}],"address":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"8700 BEVERLY BLVD"}]}]}],"line":["8700 BEVERLY BLVD"],"city":"W HOLLYWOOD","state":"CA","postalCode":"90048-1804"}]}},{"fullUrl":"PractitionerRole/1734642835376611271.42d862dc-b6bf-423c-838c-3eacb52cdf86","resource":{"resourceType":"PractitionerRole","id":"1734642835376611271.42d862dc-b6bf-423c-838c-3eacb52cdf86","practitioner":{"reference":"Practitioner/1734642835378152101.971d96a1-05f0-4810-8fc6-99fa1d10dd78"},"organization":{"reference":"Organization/1734642835380671425.9dbb655b-63ba-4d49-abe4-55fd0c8c0f60"}}},{"fullUrl":"Organization/1734642835384580134.a52e857e-b1a6-4933-91d3-45b90c6c563b","resource":{"resourceType":"Organization","id":"1734642835384580134.a52e857e-b1a6-4933-91d3-45b90c6c563b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R150"}]}],"identifier":[{"value":"R150"}],"name":"CEDARS-SINAI MEDICAL CENTER"}},{"fullUrl":"Practitioner/1734642835387126880.1c0115df-b0ab-4194-8b18-e5c9c65c4b49","resource":{"resourceType":"Practitioner","id":"1734642835387126880.1c0115df-b0ab-4194-8b18-e5c9c65c4b49","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"STEWART"},{"url":"XCN.10","valueString":"NPI"}]}],"identifier":[{"value":"1477542173"}],"name":[{"family":"BROOKS","given":["STEWART"]}]}},{"fullUrl":"ServiceRequest/1734642835395361722.863d0f9e-84ba-4c05-aacb-84e28edc7fc2","resource":{"resourceType":"ServiceRequest","id":"1734642835395361722.863d0f9e-84ba-4c05-aacb-84e28edc7fc2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835400872986.12375eb1-3d63-42d9-bb51-355690edfe8a","resource":{"resourceType":"ServiceRequest","id":"1734642835400872986.12375eb1-3d63-42d9-bb51-355690edfe8a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835406437470.873d109d-fdaf-48e5-a97b-96dd7508edfd","resource":{"resourceType":"ServiceRequest","id":"1734642835406437470.873d109d-fdaf-48e5-a97b-96dd7508edfd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835411861731.366c9665-9e44-49f7-b141-056ef9afe731","resource":{"resourceType":"ServiceRequest","id":"1734642835411861731.366c9665-9e44-49f7-b141-056ef9afe731","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835417298145.40cb5007-787e-43b6-a70d-f1c828d5bbc6","resource":{"resourceType":"ServiceRequest","id":"1734642835417298145.40cb5007-787e-43b6-a70d-f1c828d5bbc6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835425088233.8d12976a-d164-4d80-97be-1b9f71e738c0","resource":{"resourceType":"ServiceRequest","id":"1734642835425088233.8d12976a-d164-4d80-97be-1b9f71e738c0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835430754809.362999c8-3625-4f94-8e36-4c28d09f45ee","resource":{"resourceType":"ServiceRequest","id":"1734642835430754809.362999c8-3625-4f94-8e36-4c28d09f45ee","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835436203346.9044d092-f867-4b46-92bc-c20a3eb1e97b","resource":{"resourceType":"ServiceRequest","id":"1734642835436203346.9044d092-f867-4b46-92bc-c20a3eb1e97b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835441554780.5d9635c6-82f6-44ed-bd3d-7ac017b33cde","resource":{"resourceType":"ServiceRequest","id":"1734642835441554780.5d9635c6-82f6-44ed-bd3d-7ac017b33cde","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835447147758.fe178ece-2e33-4886-ba8d-e16f02780f58","resource":{"resourceType":"ServiceRequest","id":"1734642835447147758.fe178ece-2e33-4886-ba8d-e16f02780f58","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835452569995.b8c75461-8f83-447c-ace2-0be4fae41c27","resource":{"resourceType":"ServiceRequest","id":"1734642835452569995.b8c75461-8f83-447c-ace2-0be4fae41c27","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835459515248.1198051e-49c0-4499-9cae-4339eb93c3f0","resource":{"resourceType":"ServiceRequest","id":"1734642835459515248.1198051e-49c0-4499-9cae-4339eb93c3f0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835464917559.ae1b81c4-c79b-4158-b91f-cbc60641ca37","resource":{"resourceType":"ServiceRequest","id":"1734642835464917559.ae1b81c4-c79b-4158-b91f-cbc60641ca37","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835477323964.90f61212-4884-4d85-9946-dac6a7b1ac42","resource":{"resourceType":"ServiceRequest","id":"1734642835477323964.90f61212-4884-4d85-9946-dac6a7b1ac42","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835486884512.3211461f-1595-49c4-80a5-ea22dbb62e0f","resource":{"resourceType":"ServiceRequest","id":"1734642835486884512.3211461f-1595-49c4-80a5-ea22dbb62e0f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835496465375.4d30f1d9-c109-4bd6-af73-54881ac39463","resource":{"resourceType":"ServiceRequest","id":"1734642835496465375.4d30f1d9-c109-4bd6-af73-54881ac39463","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835501924522.3cb03c84-dfa0-4538-a60f-fb5e3df03d91","resource":{"resourceType":"ServiceRequest","id":"1734642835501924522.3cb03c84-dfa0-4538-a60f-fb5e3df03d91","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835507251682.d018514e-4372-4a6b-8f53-ea176f4fa8de","resource":{"resourceType":"ServiceRequest","id":"1734642835507251682.d018514e-4372-4a6b-8f53-ea176f4fa8de","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835512588720.2bff229a-7840-4814-a895-a5efe1ec731e","resource":{"resourceType":"ServiceRequest","id":"1734642835512588720.2bff229a-7840-4814-a895-a5efe1ec731e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835517996830.bf220f38-5601-418d-a1e1-b6133e9878bc","resource":{"resourceType":"ServiceRequest","id":"1734642835517996830.bf220f38-5601-418d-a1e1-b6133e9878bc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835527414151.dd23fc0e-b730-4c6e-bd6e-88961e0a02bf","resource":{"resourceType":"ServiceRequest","id":"1734642835527414151.dd23fc0e-b730-4c6e-bd6e-88961e0a02bf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835537115502.7cf8cceb-01d5-42c4-94e1-05190b2b2113","resource":{"resourceType":"ServiceRequest","id":"1734642835537115502.7cf8cceb-01d5-42c4-94e1-05190b2b2113","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"DiagnosticReport/1734642835547275564.00008400-dedd-4c3f-8968-03e87b20168f","resource":{"resourceType":"DiagnosticReport","id":"1734642835547275564.00008400-dedd-4c3f-8968-03e87b20168f","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"M17965"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"M17965"}],"basedOn":[{"reference":"ServiceRequest/1734642835389771409.849e985d-b913-4e36-8996-a26c807d3feb"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835339257765.334367ae-6cf8-4c69-bbea-6c69cbe7b03f"}]}},{"fullUrl":"DiagnosticReport/1734642835553041496.905154d3-791c-4e4c-8ca3-4c3696b5c9e5","resource":{"resourceType":"DiagnosticReport","id":"1734642835553041496.905154d3-791c-4e4c-8ca3-4c3696b5c9e5","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835395361722.863d0f9e-84ba-4c05-aacb-84e28edc7fc2"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835340756115.6e87362a-8040-4f57-b680-9d689ccb1713"}],"result":[{"reference":"Observation/1734642835078369364.c2196b8f-737f-445d-ac4b-45735aeac2e6"},{"reference":"Observation/1734642835080495691.7632bb5a-b1c3-4b60-b145-041618ed55c1"},{"reference":"Observation/1734642835082674046.0a733602-c7ef-4873-94e1-516cb480d33e"},{"reference":"Observation/1734642835084793380.e237aaaa-126b-4daa-a608-96962f96de3d"},{"reference":"Observation/1734642835086855126.3ce43713-b917-4307-b320-ce0b2ebf2fe0"},{"reference":"Observation/1734642835088717829.68dca08f-1e3a-4579-a954-98257e12481e"},{"reference":"Observation/1734642835090658378.f9967c85-8bce-483b-8f52-c1f86b5345ab"}]}},{"fullUrl":"DiagnosticReport/1734642835559411751.dbca6ed0-6ffe-4243-8531-f779d28c8c28","resource":{"resourceType":"DiagnosticReport","id":"1734642835559411751.dbca6ed0-6ffe-4243-8531-f779d28c8c28","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835400872986.12375eb1-3d63-42d9-bb51-355690edfe8a"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835342128909.4fd4310f-6fb3-47f4-bb83-66ba1586a53c"}],"result":[{"reference":"Observation/1734642835092518015.ecfaa4b9-3cd1-4b28-b03d-d5467ce0256b"},{"reference":"Observation/1734642835094763425.fbd8468f-31dc-4afc-bd64-011ed531d4f5"},{"reference":"Observation/1734642835096753407.335a9405-05bf-4cf8-a784-653c8c7b3f03"},{"reference":"Observation/1734642835098930860.da2d043f-88c3-4b08-aa9d-8e4b693937b0"},{"reference":"Observation/1734642835103742933.94767150-dbad-4916-b838-ccdf292751e8"},{"reference":"Observation/1734642835105967955.b8ba9fbf-48cc-497b-9abd-65fc6367fd39"},{"reference":"Observation/1734642835108045581.fd28d933-fe5b-4535-8299-eae01e9f9772"},{"reference":"Observation/1734642835110135560.5df45eb7-4436-4275-b0f3-a346250ba6a5"},{"reference":"Observation/1734642835111937279.a13f52de-fb3e-42c5-b70b-8928b41db139"},{"reference":"Observation/1734642835113791285.a93e71ad-6e66-4cb1-975c-0b72e1ec82b3"},{"reference":"Observation/1734642835115568047.503e318a-9232-4da8-9224-3ac70778c436"},{"reference":"Observation/1734642835117366028.a90473f2-2703-420c-b243-a76140002965"}]}},{"fullUrl":"DiagnosticReport/1734642835564422737.2cd120c8-1965-48a9-9f2b-4b44ee7657d9","resource":{"resourceType":"DiagnosticReport","id":"1734642835564422737.2cd120c8-1965-48a9-9f2b-4b44ee7657d9","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835406437470.873d109d-fdaf-48e5-a97b-96dd7508edfd"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835343507644.b7a33119-8c73-4ac8-ad96-a6ba91294273"}]}},{"fullUrl":"DiagnosticReport/1734642835571718859.7bab1bd2-c54b-4be7-bbb3-f538a840b78b","resource":{"resourceType":"DiagnosticReport","id":"1734642835571718859.7bab1bd2-c54b-4be7-bbb3-f538a840b78b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835411861731.366c9665-9e44-49f7-b141-056ef9afe731"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835344937215.6667157e-8de8-47c2-917e-1c05fc4720f3"}],"result":[{"reference":"Observation/1734642835119388891.5a6ef168-f3d7-4d65-8702-8ad61c5d91c1"},{"reference":"Observation/1734642835121480383.7a5f35b5-fa6e-487e-ab4d-b9e13376e739"},{"reference":"Observation/1734642835123554132.e09200e9-c15a-4a65-b6b6-e161fdf37208"},{"reference":"Observation/1734642835125650042.fb0f3ad6-1421-438e-aa27-18b629de869d"},{"reference":"Observation/1734642835127731345.61fe2a05-efe7-465e-bfde-aa231fab366c"},{"reference":"Observation/1734642835129903108.d4dda740-dd49-43d6-bc9b-25bf1279d5ee"},{"reference":"Observation/1734642835132201607.e6bc54d2-552d-489d-9ae6-62ed2947bbfc"},{"reference":"Observation/1734642835134316363.4ed4d624-eb61-48f4-be97-5638df76e5e4"},{"reference":"Observation/1734642835136414106.c0d7674a-7603-44b7-be2a-69fca6f812be"},{"reference":"Observation/1734642835138555141.69e9066d-9ec7-4684-856e-6fea5af26e44"},{"reference":"Observation/1734642835140681458.81b74ae1-30fb-48ee-9715-2cb02de30059"},{"reference":"Observation/1734642835142831109.183b9ea7-e9a9-4ae9-8815-e9289498e43e"},{"reference":"Observation/1734642835145029071.6d59c882-47f8-468a-9605-b2eac4033062"},{"reference":"Observation/1734642835147116164.3622f8ea-dadd-4bcb-bdec-4be3ddf0bde7"},{"reference":"Observation/1734642835149213497.5c0bb970-be0d-433d-82c7-bb51bac1b7ee"},{"reference":"Observation/1734642835151303085.143080f8-d26d-4ca3-bd0a-68be0eac89a4"},{"reference":"Observation/1734642835153524951.70cca668-8ac5-4daa-ad44-f014db61930b"},{"reference":"Observation/1734642835155737450.2fdf26eb-1dad-4753-b21d-07eef73e6e1c"},{"reference":"Observation/1734642835157643855.9b2bf0f2-7367-4472-aa24-68cd2e9402e8"}]}},{"fullUrl":"DiagnosticReport/1734642835576911345.4cea296d-3d84-49d3-b748-8fc14e7ebd0e","resource":{"resourceType":"DiagnosticReport","id":"1734642835576911345.4cea296d-3d84-49d3-b748-8fc14e7ebd0e","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835417298145.40cb5007-787e-43b6-a70d-f1c828d5bbc6"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835346298187.44b92531-e550-4f36-bd2f-7cc66563231e"}],"result":[{"reference":"Observation/1734642835159845143.ec8dc2e0-fac7-423d-82de-df26b1f9fc90"},{"reference":"Observation/1734642835161689441.9fe72387-651d-428a-b97d-3105fa1691f5"}]}},{"fullUrl":"DiagnosticReport/1734642835588311032.5e1f78bb-7715-4fa5-bfd2-90c95c87e070","resource":{"resourceType":"DiagnosticReport","id":"1734642835588311032.5e1f78bb-7715-4fa5-bfd2-90c95c87e070","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835425088233.8d12976a-d164-4d80-97be-1b9f71e738c0"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835347647096.2b33be20-c50f-46cc-82b4-01a32c586924"}],"result":[{"reference":"Observation/1734642835163707606.0e7ac73a-3dd8-4727-82ef-eee6c4d05d14"},{"reference":"Observation/1734642835165827511.90623ef3-82b0-400c-9455-4378b7797070"},{"reference":"Observation/1734642835167903263.045e84d0-3ee4-4092-8679-e0b8932c27f6"},{"reference":"Observation/1734642835170008381.df833064-f458-44c8-aae6-912dad9d9087"},{"reference":"Observation/1734642835172132283.9f0c7a5d-71ba-47af-9c10-6225b15373f5"},{"reference":"Observation/1734642835177087191.d4761a12-0246-469f-8b0a-7739d293f508"},{"reference":"Observation/1734642835179226894.a1e5f914-f409-483e-8e82-e97c4a9dc4bd"},{"reference":"Observation/1734642835181327282.deb6ed28-b853-48a8-a693-12199af60ec9"},{"reference":"Observation/1734642835183410599.4769d68b-068a-4463-824b-ca3c936e1b7f"},{"reference":"Observation/1734642835185557374.a69db609-b0ce-4b99-8746-637931d3a44c"},{"reference":"Observation/1734642835187803676.e0d1ff83-2851-4408-ba12-9c6390114b98"},{"reference":"Observation/1734642835189909665.62d7569d-0a11-4642-bad3-b156e86d58a0"},{"reference":"Observation/1734642835192058094.bd18c898-1943-47e4-8811-ff5a80ae85a6"},{"reference":"Observation/1734642835194313693.22932fcf-61d0-480d-8035-f2a79a45e484"},{"reference":"Observation/1734642835196515723.57267597-c36f-4219-91d0-7c74202d2d52"},{"reference":"Observation/1734642835198572800.e5ec271e-b6dd-4e3b-946f-ce198988c137"},{"reference":"Observation/1734642835200670263.961accbb-4104-4d11-8134-76e59c661438"},{"reference":"Observation/1734642835202756185.b72b6129-dc37-4fd6-b7f0-5c5bf464d238"},{"reference":"Observation/1734642835204989482.04869e37-ffba-4675-b7ab-3c98773de6a9"},{"reference":"Observation/1734642835207217761.ede199f5-0a4b-4351-ad09-4b8881bde701"},{"reference":"Observation/1734642835209347895.261b7657-6f9b-432a-8f29-b9874b99b609"},{"reference":"Observation/1734642835211671422.438e14ff-0281-49e7-b165-a19336723741"},{"reference":"Observation/1734642835213810493.5b329d38-601f-4845-8033-9be87d25aca5"},{"reference":"Observation/1734642835215877980.36b9a8cc-d3df-4d30-a31c-90f2e034379a"},{"reference":"Observation/1734642835217975733.dc31874a-a4be-4b8a-af75-fd59ad417868"},{"reference":"Observation/1734642835220100768.05a1dc4e-f604-4e77-9ea7-afbf81b8198f"}]}},{"fullUrl":"DiagnosticReport/1734642835594442249.53dfd7d7-b35b-49f9-9dd4-1a5b215413bd","resource":{"resourceType":"DiagnosticReport","id":"1734642835594442249.53dfd7d7-b35b-49f9-9dd4-1a5b215413bd","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835430754809.362999c8-3625-4f94-8e36-4c28d09f45ee"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835349049456.62fb98dc-8087-4a66-95d6-f4ed8208a11c"}],"result":[{"reference":"Observation/1734642835222279323.b0f928cc-46cf-4aaa-adff-fe2ce7a5ceef"},{"reference":"Observation/1734642835224430367.da780c77-72b4-4336-9039-a31184926686"},{"reference":"Observation/1734642835226529483.7b86fa71-ee93-43a1-b76d-cd849e73ca00"},{"reference":"Observation/1734642835228718427.086f9d04-6daa-4866-94d7-a65517888d6c"},{"reference":"Observation/1734642835230835868.279fed09-20e6-49b8-96a2-93eef87155d8"},{"reference":"Observation/1734642835233122375.0c6b8d22-57b3-4294-9b1e-c3a0a59070e9"},{"reference":"Observation/1734642835235257058.bdccfc91-c409-4ac8-9243-1ce9a9c8d5e8"},{"reference":"Observation/1734642835237360573.bc47837e-0b31-4a8e-b5ed-80ea7f6a5306"},{"reference":"Observation/1734642835239462615.dbfb2d97-079e-41cf-a27e-23be7e134d01"},{"reference":"Observation/1734642835241573904.95e1902d-39bc-4c32-b276-f57426ac9754"}]}},{"fullUrl":"DiagnosticReport/1734642835599680210.58ca4c86-9ba4-499d-90ba-e4f5010845db","resource":{"resourceType":"DiagnosticReport","id":"1734642835599680210.58ca4c86-9ba4-499d-90ba-e4f5010845db","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835436203346.9044d092-f867-4b46-92bc-c20a3eb1e97b"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835350409446.25a13015-e80e-447a-9880-41f54e21c7e7"}],"result":[{"reference":"Observation/1734642835243642913.6b373e0e-6c4c-4ba8-bc16-dbeaccbaa242"},{"reference":"Observation/1734642835245924111.ba72acbf-fdd2-4ade-a4ea-628501d3932d"},{"reference":"Observation/1734642835250748858.075f5f4d-fb95-4b1c-b882-706af112ad10"}]}},{"fullUrl":"DiagnosticReport/1734642835605009383.4f47e62b-55ee-42e4-8b1f-aa4de5dca825","resource":{"resourceType":"DiagnosticReport","id":"1734642835605009383.4f47e62b-55ee-42e4-8b1f-aa4de5dca825","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835441554780.5d9635c6-82f6-44ed-bd3d-7ac017b33cde"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835351773143.a2f9e75c-f720-4819-8163-f0869dd878e3"}],"result":[{"reference":"Observation/1734642835252910902.b34746e7-68e4-47e4-8123-c1d143b926c6"},{"reference":"Observation/1734642835255176000.1844fffb-f304-497b-8dff-89fb14ade80b"},{"reference":"Observation/1734642835256981315.d023e3a2-2bae-4586-ade7-0f801c8ecb93"}]}},{"fullUrl":"DiagnosticReport/1734642835610311906.a396e7e0-528b-4007-b2ab-0e3bfc0e71cb","resource":{"resourceType":"DiagnosticReport","id":"1734642835610311906.a396e7e0-528b-4007-b2ab-0e3bfc0e71cb","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835447147758.fe178ece-2e33-4886-ba8d-e16f02780f58"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835353174381.56974595-1d78-4e47-8689-2c9fa54dd258"}],"result":[{"reference":"Observation/1734642835258991303.471ccb24-c53b-4247-ae1b-85333058044f"},{"reference":"Observation/1734642835261094698.216cfc15-4e6b-4054-a562-dc9d010ffdc4"},{"reference":"Observation/1734642835262847204.678cc366-4570-42a8-9df3-afcdaca9c9ca"}]}},{"fullUrl":"DiagnosticReport/1734642835615540581.92060203-4181-48bb-ac65-b6f4b2412e1d","resource":{"resourceType":"DiagnosticReport","id":"1734642835615540581.92060203-4181-48bb-ac65-b6f4b2412e1d","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835452569995.b8c75461-8f83-447c-ace2-0be4fae41c27"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835354552365.f4274b93-053b-4ea9-8cc0-78f77d14acd8"}],"result":[{"reference":"Observation/1734642835264921283.91ec1af6-893c-4d53-bac5-b0600e963d5f"},{"reference":"Observation/1734642835267035147.1883610c-4f1d-4119-9f38-02c468008832"},{"reference":"Observation/1734642835268840823.be073532-267c-4705-bd5d-98f936d8a298"}]}},{"fullUrl":"DiagnosticReport/1734642835620764356.aa2f70a5-10a2-4fc5-a91c-a61f4a370dee","resource":{"resourceType":"DiagnosticReport","id":"1734642835620764356.aa2f70a5-10a2-4fc5-a91c-a61f4a370dee","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835459515248.1198051e-49c0-4499-9cae-4339eb93c3f0"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835355916653.d20c9e73-898b-40ca-ae6f-d01f3073ecd1"}],"result":[{"reference":"Observation/1734642835270610922.3dea9e01-cf45-4440-859b-5f06ec5bcd78"},{"reference":"Observation/1734642835272189662.237e8e77-bfda-4b54-8e00-1086f80d5fa5"}]}},{"fullUrl":"DiagnosticReport/1734642835629477723.a50a508e-79c8-43b9-b740-dc65e70d38b5","resource":{"resourceType":"DiagnosticReport","id":"1734642835629477723.a50a508e-79c8-43b9-b740-dc65e70d38b5","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835464917559.ae1b81c4-c79b-4158-b91f-cbc60641ca37"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835357303103.64850f3f-eae9-466a-9f6e-d8de284c438f"}],"result":[{"reference":"Observation/1734642835273965232.4d115769-fad3-4470-abfd-0fb327e43527"},{"reference":"Observation/1734642835276087662.698b32ba-eee2-4766-bc7a-d4fa00fa3dd7"},{"reference":"Observation/1734642835277860797.d3aeb34c-bcb9-4228-8631-558b588db30d"}]}},{"fullUrl":"DiagnosticReport/1734642835634765358.f625e7db-f332-4af3-91cd-a982fc5662a3","resource":{"resourceType":"DiagnosticReport","id":"1734642835634765358.f625e7db-f332-4af3-91cd-a982fc5662a3","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835477323964.90f61212-4884-4d85-9946-dac6a7b1ac42"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835358672621.32ace6ea-8714-4a7c-9dc8-3a8b275f2e11"}],"result":[{"reference":"Observation/1734642835279841832.a1229730-924c-4549-b477-bf1b2cfd8e13"},{"reference":"Observation/1734642835281978468.f15dce75-3889-43f5-958c-7ed178d61dd9"},{"reference":"Observation/1734642835283734922.786a3096-c83d-41f3-888c-c9f92a602540"}]}},{"fullUrl":"DiagnosticReport/1734642835640106874.9696df46-a0d7-4520-907c-de7610ae553a","resource":{"resourceType":"DiagnosticReport","id":"1734642835640106874.9696df46-a0d7-4520-907c-de7610ae553a","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835486884512.3211461f-1595-49c4-80a5-ea22dbb62e0f"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835360239980.b2a20ccb-343f-415a-a83f-351513f7aa49"}],"result":[{"reference":"Observation/1734642835285827456.e28416c0-d951-49ea-b27f-d348b5138f42"},{"reference":"Observation/1734642835287968320.ad75f0e5-8ce2-448a-a2a8-7933847307c0"},{"reference":"Observation/1734642835289784355.144718e3-9b36-4dd4-aab8-91378f578a01"}]}},{"fullUrl":"DiagnosticReport/1734642835643185858.7d84b3b9-82fa-4665-8995-48496677574d","resource":{"resourceType":"DiagnosticReport","id":"1734642835643185858.7d84b3b9-82fa-4665-8995-48496677574d","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835496465375.4d30f1d9-c109-4bd6-af73-54881ac39463"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835361666956.cc4f91e2-7a09-452b-8420-a10fd9c80e2b"}],"result":[{"reference":"Observation/1734642835291780468.3717216f-340a-4b57-b6f6-533f29f70555"},{"reference":"Observation/1734642835293916704.2ae71bb9-0e78-4be4-b12f-2a3e8cf13640"},{"reference":"Observation/1734642835295825143.3f0cd5e9-e867-40a2-9705-54078fe574fb"}]}},{"fullUrl":"DiagnosticReport/1734642835646250675.aaf7e242-0a04-48fc-8fcd-37534054d84c","resource":{"resourceType":"DiagnosticReport","id":"1734642835646250675.aaf7e242-0a04-48fc-8fcd-37534054d84c","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835501924522.3cb03c84-dfa0-4538-a60f-fb5e3df03d91"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835363030964.3a12ef62-abe5-4a3b-ad91-8b8d05157d1b"}],"result":[{"reference":"Observation/1734642835298238849.e1f75b37-69a0-4e11-96ba-52cd392bfbb2"},{"reference":"Observation/1734642835300320963.6730aa2a-9456-489c-8593-97f2a053ac85"},{"reference":"Observation/1734642835302129644.2bd6f20a-35fa-4b4c-a716-59ee8c023bc9"}]}},{"fullUrl":"DiagnosticReport/1734642835649684624.fd75d2d7-0fe4-4419-bedb-557668b7d57b","resource":{"resourceType":"DiagnosticReport","id":"1734642835649684624.fd75d2d7-0fe4-4419-bedb-557668b7d57b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835507251682.d018514e-4372-4a6b-8f53-ea176f4fa8de"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835364420439.6a839ff7-18ff-4135-8756-87a3237a1401"}],"result":[{"reference":"Observation/1734642835304240262.90534b48-83cc-4456-bee2-4f8adccd3fed"},{"reference":"Observation/1734642835306921540.9c7ab076-631e-46de-9f99-4a594333dba0"},{"reference":"Observation/1734642835308835408.0ef7fd8a-38aa-4a53-8efa-1f4070b8722a"}]}},{"fullUrl":"DiagnosticReport/1734642835652690020.0f9c42bb-342e-4304-bcfc-736b4b385ce5","resource":{"resourceType":"DiagnosticReport","id":"1734642835652690020.0f9c42bb-342e-4304-bcfc-736b4b385ce5","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835512588720.2bff229a-7840-4814-a895-a5efe1ec731e"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835365799685.6448fcb2-bb46-4a42-bee7-6b46fc845bff"}],"result":[{"reference":"Observation/1734642835310956776.8e5c8f5d-464e-4d6a-b6ff-aa6317ca2236"},{"reference":"Observation/1734642835312849265.7b1a44be-87f3-4c3e-b8c2-4bb112a00396"}]}},{"fullUrl":"DiagnosticReport/1734642835655881985.a9bb371f-6f8a-4ef4-a6fd-831000e7a9db","resource":{"resourceType":"DiagnosticReport","id":"1734642835655881985.a9bb371f-6f8a-4ef4-a6fd-831000e7a9db","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835517996830.bf220f38-5601-418d-a1e1-b6133e9878bc"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835367153343.0095dbea-0b87-4cbf-8f40-6b1e69d49429"}],"result":[{"reference":"Observation/1734642835314906112.b7166b68-f03f-4d84-bf2c-0b3b7abe9d18"},{"reference":"Observation/1734642835317154138.6f022b94-8600-406a-b8f0-5fc23b87e94f"},{"reference":"Observation/1734642835322641287.9e617f2f-7044-4954-ad62-cf9a106d32e7"}]}},{"fullUrl":"DiagnosticReport/1734642835658967160.47cc3e88-d62c-4805-8020-c4d50e4dd26f","resource":{"resourceType":"DiagnosticReport","id":"1734642835658967160.47cc3e88-d62c-4805-8020-c4d50e4dd26f","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835527414151.dd23fc0e-b730-4c6e-bd6e-88961e0a02bf"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835368626987.ce01d466-d2f9-46ed-b51c-a1a843eacc34"}],"result":[{"reference":"Observation/1734642835324840571.1d7a28bf-5661-4d4e-aa75-b787be359580"},{"reference":"Observation/1734642835326726838.637b5c0e-2fa3-424f-9919-cc78bd0ac277"}]}},{"fullUrl":"DiagnosticReport/1734642835661953110.4e4c493f-1bd7-4664-b919-1d64cda84098","resource":{"resourceType":"DiagnosticReport","id":"1734642835661953110.4e4c493f-1bd7-4664-b919-1d64cda84098","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835537115502.7cf8cceb-01d5-42c4-94e1-05190b2b2113"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835370263338.53b0cddb-320b-4d2f-bc6d-0f7ba8191347"}],"result":[{"reference":"Observation/1734642835328833769.b1ef8e36-8a86-4ff0-89fb-be9399563adc"}]}}]}
diff --git a/examples/Test/GoldenCopy/Expected/002_ORU_R01_golden_copy_expected_acylc_2.fhir b/examples/Test/GoldenCopy/Expected/002_ORU_R01_golden_copy_expected_acylc_2.fhir
new file mode 100644
index 000000000..a68538524
--- /dev/null
+++ b/examples/Test/GoldenCopy/Expected/002_ORU_R01_golden_copy_expected_acylc_2.fhir
@@ -0,0 +1 @@
+{"resourceType":"Bundle","id":"1734642835060547392.21e6da5c-0381-4a96-b9e8-3fb67dc56990","meta":{"lastUpdated":"2024-12-19T21:13:55.060+00:00"},"identifier":{"system":"https://reportstream.cdc.gov/prime-router","value":"002"},"type":"message","timestamp":"2024-10-18T05:02:34.000+00:00","entry":[{"fullUrl":"MessageHeader/1734642835061657384.add5f635-92d3-4b96-8e57-2effe6679555","resource":{"resourceType":"MessageHeader","id":"1734642835061657384.add5f635-92d3-4b96-8e57-2effe6679555","meta":{"tag":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0103","code":"N"}]},"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/msh-message-header","extension":[{"url":"MSH.7","valueString":"20241018050234"}]}],"eventCoding":{"system":"http://terminology.hl7.org/CodeSystem/v2-0003","code":"R01","display":"ORU^R01^ORU_R01"},"destination":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id","valueString":"9413816"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id-type","valueString":"L,M,N"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.5"}],"name":"SISHIERECEIVER","receiver":{"reference":"Organization/1734642835061400953.3db9afdf-21ec-4970-9e7e-199ee045bc53"}}],"sender":{"reference":"Organization/1734642835060859257.3427f015-5db9-4c6c-9758-cac57157b46d"},"source":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"SISGDSP"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.3"}],"name":"SISGDSP","_endpoint":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}}},{"fullUrl":"Organization/1734642835060859257.3427f015-5db9-4c6c-9758-cac57157b46d","resource":{"resourceType":"Organization","id":"1734642835060859257.3427f015-5db9-4c6c-9758-cac57157b46d","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Organization/1734642835061400953.3db9afdf-21ec-4970-9e7e-199ee045bc53","resource":{"resourceType":"Organization","id":"1734642835061400953.3db9afdf-21ec-4970-9e7e-199ee045bc53","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.6"}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.2,HD.3"}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301","code":"L,M,N"}]},"value":"automated-staging-test-receiver-id"}]}},{"fullUrl":"Provenance/1734642835063129183.098ebe09-12c5-4ad5-a948-d0b906c0855b","resource":{"resourceType":"Provenance","id":"1734642835063129183.098ebe09-12c5-4ad5-a948-d0b906c0855b","target":[{"reference":"MessageHeader/1734642835061657384.add5f635-92d3-4b96-8e57-2effe6679555"},{"reference":"DiagnosticReport/1734642835531809851.7e82b5f0-fa58-4ae3-9ff4-7ef423653005"},{"reference":"DiagnosticReport/1734642835535197914.0b32db56-7860-4c0d-869b-adf9b391aab5"},{"reference":"DiagnosticReport/1734642835538844723.39e47371-22c9-427a-9ec9-36c1e0d304f1"},{"reference":"DiagnosticReport/1734642835541790517.02d1415c-20fe-4c6c-a453-99a6256f1aa3"},{"reference":"DiagnosticReport/1734642835545994009.2ace7868-aa95-484d-b76b-12db078b97f7"},{"reference":"DiagnosticReport/1734642835549572319.e913f1db-3d85-49e2-9d92-abbb0ceca353"},{"reference":"DiagnosticReport/1734642835555248693.f55f879e-9129-4a46-b2cb-b3e8779dc651"},{"reference":"DiagnosticReport/1734642835559283809.7a8b7aca-7378-4e0f-b3b5-e7e311ecdcde"},{"reference":"DiagnosticReport/1734642835562458663.3bdb90b2-527c-4c7e-8542-71484cd7ab99"},{"reference":"DiagnosticReport/1734642835565786613.35dbbd5c-05ba-447e-a90a-b0b8a1d5337c"},{"reference":"DiagnosticReport/1734642835569237875.9ba7d3fc-9967-4075-88be-0335ae188064"},{"reference":"DiagnosticReport/1734642835572429349.a553e636-266f-4c09-b709-d56573b6fe07"},{"reference":"DiagnosticReport/1734642835575571841.d8c12c52-d7ca-43a2-afe8-80132657f9c7"},{"reference":"DiagnosticReport/1734642835581956604.0d9ff39f-34fd-4dd9-a5ac-dc8c2aa43995"},{"reference":"DiagnosticReport/1734642835585075052.1a8ebd8f-0416-4788-b779-b9b111188dd9"},{"reference":"DiagnosticReport/1734642835588257930.2fa53ce1-57c4-4b73-b9fb-5e4be2b9f735"},{"reference":"DiagnosticReport/1734642835591422123.d2f9f942-bfd6-4cbd-8565-822730b7e828"},{"reference":"DiagnosticReport/1734642835594544669.f203eb3d-fb58-425d-aad5-44fe9b3a7bbf"},{"reference":"DiagnosticReport/1734642835597620105.488df753-3823-41cd-84fd-40b72997cffe"},{"reference":"DiagnosticReport/1734642835600653273.375b52d5-1287-4587-af7e-f819678bb126"},{"reference":"DiagnosticReport/1734642835603899090.99cd7384-3aa2-4303-990f-c3d24337cb56"},{"reference":"DiagnosticReport/1734642835607156908.01e08384-7d0d-4a40-a6cd-4b60e2d03248"},{"reference":"DiagnosticReport/1734642835610181350.cbaed3cc-e9a9-43f1-9836-3cd9db54bf2b"}],"recorded":"2024-10-18T05:02:34Z","activity":{"coding":[{"display":"ORU^R01^ORU_R01"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"author"}]},"who":{"reference":"Organization/1734642835062946661.33286771-0420-4f13-a9a1-2f3b72374b4c"}}]}},{"fullUrl":"Organization/1734642835062946661.33286771-0420-4f13-a9a1-2f3b72374b4c","resource":{"resourceType":"Organization","id":"1734642835062946661.33286771-0420-4f13-a9a1-2f3b72374b4c","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Provenance/1734642835063641995.0dd5fd71-aa2e-4c75-9c63-80f6a50d991c","resource":{"resourceType":"Provenance","id":"1734642835063641995.0dd5fd71-aa2e-4c75-9c63-80f6a50d991c","recorded":"2024-12-19T21:13:55Z","policy":["http://hl7.org/fhir/uv/v2mappings/message-oru-r01-to-bundle"],"activity":{"coding":[{"code":"v2-FHIR transformation"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"assembler"}]},"who":{"reference":"Organization/1734642835063497093.435a4916-d2fb-4eb5-9917-f5b7f16e5ef7"}}]}},{"fullUrl":"Organization/1734642835063497093.435a4916-d2fb-4eb5-9917-f5b7f16e5ef7","resource":{"resourceType":"Organization","id":"1734642835063497093.435a4916-d2fb-4eb5-9917-f5b7f16e5ef7","identifier":[{"value":"CDC PRIME - Atlanta"},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301"}]},"system":"urn:ietf:rfc:3986","value":"2.16.840.1.114222.4.1.237821"}]}},{"fullUrl":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68","resource":{"resourceType":"Patient","id":"1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cx-identifier","extension":[{"url":"CX.5","valueString":"MR"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"PID.3"}],"type":{"coding":[{"code":"MR"}]},"value":"32550867","assigner":{"reference":"Organization/1734642835064360673.84470a0b-5ea1-4ff7-962f-eede48e9394d"}}],"name":[{"family":"*****PII REMOVED******"}],"contact":[{"name":{"family":"*****PII REMOVED******"}}]}},{"fullUrl":"Organization/1734642835064360673.84470a0b-5ea1-4ff7-962f-eede48e9394d","resource":{"resourceType":"Organization","id":"1734642835064360673.84470a0b-5ea1-4ff7-962f-eede48e9394d","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"1013163542&NPI"}]}},{"fullUrl":"Provenance/1734642835067918654.a7187d60-ac88-4477-9b29-9e452b9c6f22","resource":{"resourceType":"Provenance","id":"1734642835067918654.a7187d60-ac88-4477-9b29-9e452b9c6f22","target":[{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}],"recorded":"2024-12-19T21:13:55Z","activity":{"coding":[{"system":"https://terminology.hl7.org/CodeSystem/v3-DataOperation","code":"UPDATE"}]}}},{"fullUrl":"RelatedPerson/1734642835068879446.22fcda30-477d-46b1-b0b5-cdb740ecb06b","resource":{"resourceType":"RelatedPerson","id":"1734642835068879446.22fcda30-477d-46b1-b0b5-cdb740ecb06b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"NK1"}],"patient":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"name":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"NK1.2"}],"family":"*****PII REMOVED******"}]}},{"fullUrl":"Observation/1734642835072408964.75266d3b-3e79-44d2-93e7-33464d92421a","resource":{"resourceType":"Observation","id":"1734642835072408964.75266d3b-3e79-44d2-93e7-33464d92421a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57721-3","display":"Reason for lab test in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12421-6","display":"Initial screen"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835074715129.ead6bdf7-05f5-41b4-8301-9fbfd3b816c2","resource":{"resourceType":"Observation","id":"1734642835074715129.ead6bdf7-05f5-41b4-8301-9fbfd3b816c2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57718-9","display":"Sample quality of Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12432-3","display":"Acceptable"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835077037293.45edb036-f68b-40d3-8c09-ea3c6768f49a","resource":{"resourceType":"Observation","id":"1734642835077037293.45edb036-f68b-40d3-8c09-ea3c6768f49a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57130-7","display":"Newborn screening report - overall interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18944-1","display":"Screen is out of range for at least one condition"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835079270551.5131b375-6013-45ab-ab8f-5b72e523ada2","resource":{"resourceType":"Observation","id":"1734642835079270551.5131b375-6013-45ab-ab8f-5b72e523ada2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57131-5","display":"Newborn conditions with positive markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835081533113.ca9632ae-6903-4249-8aa1-80996f4e453c","resource":{"resourceType":"Observation","id":"1734642835081533113.ca9632ae-6903-4249-8aa1-80996f4e453c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57720-5","display":"Newborn conditions with equivocal markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835083506804.de19e7fc-6c52-4be6-bd35-5365359b3060","resource":{"resourceType":"Observation","id":"1734642835083506804.de19e7fc-6c52-4be6-bd35-5365359b3060","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57724-7","display":"Newborn screening short narrative summary"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"ACTION REQUIRED\\\\.br\\\\\\\\.br\\\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\\\\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\\\.br\\\\\\\\.br\\\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\\\.br\\\\\\\\.br\\\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\\\.br\\\\\\\\.br\\\\Follow-up:\\\\.br\\\\\\\\.br\\\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\\\.br\\\\\\\\.br\\\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\\\.br\\\\\\\\.br\\\\Methods and Limitations:\\\\.br\\\\\\\\.br\\\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\\\.br\\\\Attention Healthcare Provider:\\\\.br\\\\\\\\.br\\\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\\\.br\\\\\\\\.br\\","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835085405104.bd0a0117-73b7-476e-b72b-287122ac87a8","resource":{"resourceType":"Observation","id":"1734642835085405104.bd0a0117-73b7-476e-b72b-287122ac87a8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57129-9","display":"Full newborn screening summary report for display or printing"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835087373826.ed98c076-6f17-44ce-81e4-a403326e769f","resource":{"resourceType":"Observation","id":"1734642835087373826.ed98c076-6f17-44ce-81e4-a403326e769f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"ST"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57716-3","display":"State printed on filter paper card [Identifier] in NBS card"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"CA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835089780829.2215db06-44bb-4c59-8466-d9278434cef3","resource":{"resourceType":"Observation","id":"1734642835089780829.2215db06-44bb-4c59-8466-d9278434cef3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"grams"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"8339-4","display":"Birthweight"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":3135,"unit":"grams"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835091972329.7b1c0b54-fc4f-4dd0-a741-e260efc53bc6","resource":{"resourceType":"Observation","id":"1734642835091972329.7b1c0b54-fc4f-4dd0-a741-e260efc53bc6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57715-5","display":"Time of birth"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueTime":"1235","_valueTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"1235"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835094262483.b3cb8767-6c64-472a-a06e-87ecd4f282ef","resource":{"resourceType":"Observation","id":"1734642835094262483.b3cb8767-6c64-472a-a06e-87ecd4f282ef","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57722-1","display":"Birth plurality of Pregnancy"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12411-7","display":"Singleton"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835096506060.48931c5c-b95a-4205-8d31-388a9e378f1d","resource":{"resourceType":"Observation","id":"1734642835096506060.48931c5c-b95a-4205-8d31-388a9e378f1d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"hour(s)"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"73806-2","display":"Newborn age in hours"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":24,"unit":"hour(s)"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835098903976.077e0831-3c99-44cd-beda-c2370b1c502d","resource":{"resourceType":"Observation","id":"1734642835098903976.077e0831-3c99-44cd-beda-c2370b1c502d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57713-0","display":"Infant NICU factors that affect newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835103867243.9ca57891-de1f-40be-acd3-da3de38afe4a","resource":{"resourceType":"Observation","id":"1734642835103867243.9ca57891-de1f-40be-acd3-da3de38afe4a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67704-7","display":"Feeding types"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA16914-6","display":"Breast milk"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835105899995.f5ee9e6d-6a3e-4f82-bfee-a728d4e8a184","resource":{"resourceType":"Observation","id":"1734642835105899995.f5ee9e6d-6a3e-4f82-bfee-a728d4e8a184","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-5","display":"Accession Number"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"282-18-014/21-2024-32","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835107881581.1ebeb1fa-fecb-4de7-b9dc-a149595c0620","resource":{"resourceType":"Observation","id":"1734642835107881581.1ebeb1fa-fecb-4de7-b9dc-a149595c0620","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62324-9","display":"Post-discharge provider name"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"SARAH MAHMOOD","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835109899595.ddc4eb47-c60c-4492-9dad-82bb445a74c0","resource":{"resourceType":"Observation","id":"1734642835109899595.ddc4eb47-c60c-4492-9dad-82bb445a74c0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62325-6","display":"Post-discharge provider practice ID"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"1194257170","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835111786463.26c7efd2-e94c-4ce5-9641-f08f45eedde2","resource":{"resourceType":"Observation","id":"1734642835111786463.26c7efd2-e94c-4ce5-9641-f08f45eedde2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62327-2","display":"Post-discharge provider practice address"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835114032955.393eb749-310a-4618-a511-5cb2afc3e1be","resource":{"resourceType":"Observation","id":"1734642835114032955.393eb749-310a-4618-a511-5cb2afc3e1be","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47633-3","display":"Glycine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":611,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835116331285.57764571-3b71-4975-ab76-caa45272d17d","resource":{"resourceType":"Observation","id":"1734642835116331285.57764571-3b71-4975-ab76-caa45272d17d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53150-9","display":"Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":585,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1000"}]}},{"fullUrl":"Observation/1734642835118618614.42426ad4-7ecb-43fe-bf82-864a08fa2a09","resource":{"resourceType":"Observation","id":"1734642835118618614.42426ad4-7ecb-43fe-bf82-864a08fa2a09","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47799-2","display":"Valine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":90.9,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835120913247.cc61b5bd-2db5-4758-a60b-167569998e49","resource":{"resourceType":"Observation","id":"1734642835120913247.cc61b5bd-2db5-4758-a60b-167569998e49","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53151-7","display":"Valine/Phenylalanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":1.74808,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.3"}]}},{"fullUrl":"Observation/1734642835123269415.c7a6f123-dabd-4ef1-b0f1-b530877298cb","resource":{"resourceType":"Observation","id":"1734642835123269415.c7a6f123-dabd-4ef1-b0f1-b530877298cb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53152-5","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":86.9,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<230"}]}},{"fullUrl":"Observation/1734642835125596349.47098735-1062-4687-b098-d3dab2876010","resource":{"resourceType":"Observation","id":"1734642835125596349.47098735-1062-4687-b098-d3dab2876010","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53154-1","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.15,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.35"}]}},{"fullUrl":"Observation/1734642835127868229.41515f30-507b-47da-92a5-0f50aeda3ec4","resource":{"resourceType":"Observation","id":"1734642835127868229.41515f30-507b-47da-92a5-0f50aeda3ec4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29573-3","display":"Phenylalanine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":52.0,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<175"}]}},{"fullUrl":"Observation/1734642835130189692.2195e0b3-2998-4a0f-9e2b-b94bf4f77834","resource":{"resourceType":"Observation","id":"1734642835130189692.2195e0b3-2998-4a0f-9e2b-b94bf4f77834","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35572-7","display":"Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.75,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2.6"}]}},{"fullUrl":"Observation/1734642835132519691.2c1beca7-95b7-4a5f-b67d-c1a306333238","resource":{"resourceType":"Observation","id":"1734642835132519691.2c1beca7-95b7-4a5f-b67d-c1a306333238","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35571-9","display":"Tyrosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":69.0,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<680"}]}},{"fullUrl":"Observation/1734642835134809435.9e06f783-ffe8-481b-ad80-afa38a0ebd6a","resource":{"resourceType":"Observation","id":"1734642835134809435.9e06f783-ffe8-481b-ad80-afa38a0ebd6a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53231-7","display":"Succinylacetone [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.23,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<6.1"}]}},{"fullUrl":"Observation/1734642835137170923.9947c3f7-90ce-44bd-8b77-bd42ff3749d6","resource":{"resourceType":"Observation","id":"1734642835137170923.9947c3f7-90ce-44bd-8b77-bd42ff3749d6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47700-0","display":"Methionine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":22.5,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.3-100"}]}},{"fullUrl":"Observation/1734642835139466537.91adde4f-a83d-41ed-ac9e-8caf431c4b86","resource":{"resourceType":"Observation","id":"1734642835139466537.91adde4f-a83d-41ed-ac9e-8caf431c4b86","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42892-0","display":"Citrulline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":14,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"5-49"}]}},{"fullUrl":"Observation/1734642835141830360.547825c7-9eba-4167-8cfe-a2465a2f395d","resource":{"resourceType":"Observation","id":"1734642835141830360.547825c7-9eba-4167-8cfe-a2465a2f395d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54092-2","display":"Citrulline/Arginine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":2.28,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.8"}]}},{"fullUrl":"Observation/1734642835144301563.de46881d-1f67-46ff-9858-b6ae89a6b48b","resource":{"resourceType":"Observation","id":"1734642835144301563.de46881d-1f67-46ff-9858-b6ae89a6b48b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53155-8","display":"Asparagine+Ornithine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":68,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<800"}]}},{"fullUrl":"Observation/1734642835146571270.9b822a4e-4daa-43bb-9143-2e71a52a04eb","resource":{"resourceType":"Observation","id":"1734642835146571270.9b822a4e-4daa-43bb-9143-2e71a52a04eb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75215-4","display":"Ornithine/Citrulline [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":4.93,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835148847939.fd51e2fb-5d49-4676-a74e-c342a9d90613","resource":{"resourceType":"Observation","id":"1734642835148847939.fd51e2fb-5d49-4676-a74e-c342a9d90613","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47562-4","display":"Arginine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":6,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<63"}]}},{"fullUrl":"Observation/1734642835151142431.117e42b6-9dc6-4875-94de-1214fde103cf","resource":{"resourceType":"Observation","id":"1734642835151142431.117e42b6-9dc6-4875-94de-1214fde103cf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75214-7","display":"Arginine/Ornithine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.09,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.9"}]}},{"fullUrl":"Observation/1734642835153541720.5989fc4c-89a5-407d-8b3b-e7549c5e89d2","resource":{"resourceType":"Observation","id":"1734642835153541720.5989fc4c-89a5-407d-8b3b-e7549c5e89d2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47732-3","display":"Proline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":192,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1500"}]}},{"fullUrl":"Observation/1734642835155639614.b9014743-7717-4773-b580-45c48b2f201a","resource":{"resourceType":"Observation","id":"1734642835155639614.b9014743-7717-4773-b580-45c48b2f201a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57710-6","display":"Amino acidemias newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835157820193.577aad75-b837-4215-a407-d26006446546","resource":{"resourceType":"Observation","id":"1734642835157820193.577aad75-b837-4215-a407-d26006446546","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58088-6","display":"Acylcarnitine newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA11884-6","display":"Indeterminate"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"A"}]}]}},{"fullUrl":"Observation/1734642835159765200.5b2dae01-a2ce-4f83-9239-8eb5800bcbfb","resource":{"resourceType":"Observation","id":"1734642835159765200.5b2dae01-a2ce-4f83-9239-8eb5800bcbfb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58093-6","display":"Acylcarnitine newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"This pattern of elevations is consistent with SCADD, IBCDD","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"A"}]}]}},{"fullUrl":"Observation/1734642835162045226.9490f56a-187d-4e99-8223-a2e9772b631d","resource":{"resourceType":"Observation","id":"1734642835162045226.9490f56a-187d-4e99-8223-a2e9772b631d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38481-8","display":"Carnitine.free (C0)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":26.6,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.4-125"}]}},{"fullUrl":"Observation/1734642835164354646.81d396e1-073e-4f0e-bfdf-13937d7cd382","resource":{"resourceType":"Observation","id":"1734642835164354646.81d396e1-073e-4f0e-bfdf-13937d7cd382","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53235-8","display":"Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":3.27,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<70"}]}},{"fullUrl":"Observation/1734642835166629993.47eb25f8-6df1-46b3-919c-f7e8913d3cf5","resource":{"resourceType":"Observation","id":"1734642835166629993.47eb25f8-6df1-46b3-919c-f7e8913d3cf5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50157-7","display":"Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":29.2,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"10-80"}]}},{"fullUrl":"Observation/1734642835168943661.97b6d367-d4d7-435a-bd31-b9459e9e18ec","resource":{"resourceType":"Observation","id":"1734642835168943661.97b6d367-d4d7-435a-bd31-b9459e9e18ec","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75212-1","display":"Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":2.13913,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.6"}]}},{"fullUrl":"Observation/1734642835171271146.f04f4637-b85a-43fb-9f72-be114f3e7c91","resource":{"resourceType":"Observation","id":"1734642835171271146.f04f4637-b85a-43fb-9f72-be114f3e7c91","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45211-0","display":"Hexanoylcarnitine (C6)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.088,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835173651229.ec3d9ff9-0f52-4328-9cbb-f31a10f36d37","resource":{"resourceType":"Observation","id":"1734642835173651229.ec3d9ff9-0f52-4328-9cbb-f31a10f36d37","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53175-6","display":"Octanoylcarnitine (C8)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.084,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835178727400.29b6257f-674c-4973-95d6-21b188015189","resource":{"resourceType":"Observation","id":"1734642835178727400.29b6257f-674c-4973-95d6-21b188015189","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53177-2","display":"Octanoylcarnitine (C8)/Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.73,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835180861281.fc593df5-07c9-4233-9cb2-fca44e2c7133","resource":{"resourceType":"Observation","id":"1734642835180861281.fc593df5-07c9-4233-9cb2-fca44e2c7133","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53174-9","display":"Octenoylcarnitine (C8:1)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.172,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835182931393.4305b764-7f39-4ccb-bc9c-5f4bdbb3b7c4","resource":{"resourceType":"Observation","id":"1734642835182931393.4305b764-7f39-4ccb-bc9c-5f4bdbb3b7c4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45197-1","display":"Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.115,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835185116210.5940d493-71de-47be-ac64-c7d47d3debde","resource":{"resourceType":"Observation","id":"1734642835185116210.5940d493-71de-47be-ac64-c7d47d3debde","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45198-9","display":"Decenoylcarnitine (C10:1)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.050,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835187288373.1c64ef7b-e463-43d6-8805-ca936b1c72bf","resource":{"resourceType":"Observation","id":"1734642835187288373.1c64ef7b-e463-43d6-8805-ca936b1c72bf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45199-7","display":"Dodecanoylcarnitine (C12)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.127,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2"}]}},{"fullUrl":"Observation/1734642835189423406.1c9fd186-339a-4e60-9734-28df7b20a7df","resource":{"resourceType":"Observation","id":"1734642835189423406.1c9fd186-339a-4e60-9734-28df7b20a7df","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45200-3","display":"Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.12,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835191534946.0417c3df-4317-463f-9d99-b431e3905b09","resource":{"resourceType":"Observation","id":"1734642835191534946.0417c3df-4317-463f-9d99-b431e3905b09","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53192-1","display":"Tetradecanoylcarnitine (C14)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.333,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.2"}]}},{"fullUrl":"Observation/1734642835193679577.02b69198-ef0d-4b94-9df8-7b27fad40308","resource":{"resourceType":"Observation","id":"1734642835193679577.02b69198-ef0d-4b94-9df8-7b27fad40308","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53191-3","display":"Tetradecenoylcarnitine (C14:1)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.132,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.9"}]}},{"fullUrl":"Observation/1734642835195762763.1a70ae02-e175-49fc-8500-0490ecc22862","resource":{"resourceType":"Observation","id":"1734642835195762763.1a70ae02-e175-49fc-8500-0490ecc22862","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53194-7","display":"Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":1.13,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835197861699.fdc7c7ef-61e7-41b8-9363-279083afadea","resource":{"resourceType":"Observation","id":"1734642835197861699.fdc7c7ef-61e7-41b8-9363-279083afadea","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53190-5","display":"Tetradecadienoylcarnitine (C14:2)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.02,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835199918416.c535e96d-42d2-43da-b498-5a4a63e27221","resource":{"resourceType":"Observation","id":"1734642835199918416.c535e96d-42d2-43da-b498-5a4a63e27221","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50281-5","display":"3-Hydroxytetradecanoylcarnitine (C14-OH)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.026,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.2"}]}},{"fullUrl":"Observation/1734642835202018364.7d47086f-137e-45e4-b97e-529e6410d71c","resource":{"resourceType":"Observation","id":"1734642835202018364.7d47086f-137e-45e4-b97e-529e6410d71c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53199-6","display":"Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":6.19,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<12"}]}},{"fullUrl":"Observation/1734642835204143519.0b293d61-5e06-4ec9-8b16-62b66efaca0a","resource":{"resourceType":"Observation","id":"1734642835204143519.0b293d61-5e06-4ec9-8b16-62b66efaca0a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53198-8","display":"Palmitoleylcarnitine (C16:1)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.445,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.4"}]}},{"fullUrl":"Observation/1734642835206227236.22c3dadc-1b32-4fa8-90f5-e5895e4642dc","resource":{"resourceType":"Observation","id":"1734642835206227236.22c3dadc-1b32-4fa8-90f5-e5895e4642dc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50125-4","display":"3-Hydroxypalmitoylcarnitine (C16-OH)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.045,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835208324649.86b17533-f55e-4b9e-8306-313ca8c8d474","resource":{"resourceType":"Observation","id":"1734642835208324649.86b17533-f55e-4b9e-8306-313ca8c8d474","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53201-0","display":"3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.00727,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.07"}]}},{"fullUrl":"Observation/1734642835210415530.d24aaa22-035b-42ab-a8ad-dd36ee78ea24","resource":{"resourceType":"Observation","id":"1734642835210415530.d24aaa22-035b-42ab-a8ad-dd36ee78ea24","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53241-6","display":"Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":1.53,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<3.5"}]}},{"fullUrl":"Observation/1734642835212653867.d599ae32-6087-4057-ba49-a7f051078cdb","resource":{"resourceType":"Observation","id":"1734642835212653867.d599ae32-6087-4057-ba49-a7f051078cdb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53202-8","display":"Oleoylcarnitine (C18:1)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":1.96,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7"}]}},{"fullUrl":"Observation/1734642835214779794.05d31cbf-102d-45df-b48f-54cc0f715691","resource":{"resourceType":"Observation","id":"1734642835214779794.05d31cbf-102d-45df-b48f-54cc0f715691","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45217-7","display":"Linoleoylcarnitine (C18:2)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.21,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835216894589.19959e3d-cf6d-459e-b0e9-cf9e5400bbf5","resource":{"resourceType":"Observation","id":"1734642835216894589.19959e3d-cf6d-459e-b0e9-cf9e5400bbf5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50132-0","display":"3-Hydroxystearoylcarnitine (C18-OH)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.017,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835218980921.802246ce-c233-406b-8013-2586b6499575","resource":{"resourceType":"Observation","id":"1734642835218980921.802246ce-c233-406b-8013-2586b6499575","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50113-0","display":"3-Hydroxyoleoylcarnitine (C18:1-OH)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.036,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835221107288.81ab8987-7308-4524-ac1a-1429982b0b7e","resource":{"resourceType":"Observation","id":"1734642835221107288.81ab8987-7308-4524-ac1a-1429982b0b7e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53160-8","display":"Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":2.5,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.9"}]}},{"fullUrl":"Observation/1734642835223225480.5a102d3e-c9f8-40a2-9358-651a3c6cd4bf","resource":{"resourceType":"Observation","id":"1734642835223225480.5a102d3e-c9f8-40a2-9358-651a3c6cd4bf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53163-2","display":"Propionylcarnitine (C3)/Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.09,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.42"}]}},{"fullUrl":"Observation/1734642835225460391.367cd09c-a84d-4b74-9012-6208e9cae783","resource":{"resourceType":"Observation","id":"1734642835225460391.367cd09c-a84d-4b74-9012-6208e9cae783","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67708-8","display":"Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.246,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.48"}]}},{"fullUrl":"Observation/1734642835227537436.97f58b93-df12-4ff2-ab2a-cbe874b04d88","resource":{"resourceType":"Observation","id":"1734642835227537436.97f58b93-df12-4ff2-ab2a-cbe874b04d88","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53166-5","display":"Butyrylcarnitine+Isobutyrylcarnitine (C4)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":1.72,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"H"}]}],"referenceRange":[{"text":"<1.7"}]}},{"fullUrl":"Observation/1734642835229643846.878bcfe3-113a-433f-aaa0-bb3269307c1e","resource":{"resourceType":"Observation","id":"1734642835229643846.878bcfe3-113a-433f-aaa0-bb3269307c1e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45216-9","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.115,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835231745977.21c27e63-559a-4ec1-be5b-ad43ab6e0b65","resource":{"resourceType":"Observation","id":"1734642835231745977.21c27e63-559a-4ec1-be5b-ad43ab6e0b65","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53240-8","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.04600,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642835233956282.462ce6c5-4cef-4570-9775-455480579770","resource":{"resourceType":"Observation","id":"1734642835233956282.462ce6c5-4cef-4570-9775-455480579770","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53170-7","display":"Tiglylcarnitine (C5:1)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.008,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.5"}]}},{"fullUrl":"Observation/1734642835236097878.fa6c4155-42c1-4ac4-a809-5e912eb9e191","resource":{"resourceType":"Observation","id":"1734642835236097878.fa6c4155-42c1-4ac4-a809-5e912eb9e191","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50106-4","display":"3-Hydroxyisovalerylcarnitine (C5-OH)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.232,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.15"}]}},{"fullUrl":"Observation/1734642835238198367.c38dc305-07da-435c-a327-d77e95e1348e","resource":{"resourceType":"Observation","id":"1734642835238198367.c38dc305-07da-435c-a327-d77e95e1348e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67710-4","display":"Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.180,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642835240363176.0253a773-b531-4c12-b79f-b45649144356","resource":{"resourceType":"Observation","id":"1734642835240363176.0253a773-b531-4c12-b79f-b45649144356","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75216-2","display":"Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.73171,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">0.1"}]}},{"fullUrl":"Observation/1734642835242457754.6443996c-029e-4fb4-9e7e-b38be0e5271c","resource":{"resourceType":"Observation","id":"1734642835242457754.6443996c-029e-4fb4-9e7e-b38be0e5271c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ng/mL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"48633-2","display":"Trypsinogen I.free"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":21.20,"unit":"ng/mL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<69"}]}},{"fullUrl":"Observation/1734642835244613837.18c12760-d680-4504-a920-22aed27486e6","resource":{"resourceType":"Observation","id":"1734642835244613837.18c12760-d680-4504-a920-22aed27486e6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46769-6","display":"Cystic fibrosis newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835246395758.fd278006-4ca8-4198-9a61-0285d94792d8","resource":{"resourceType":"Observation","id":"1734642835246395758.fd278006-4ca8-4198-9a61-0285d94792d8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57707-2","display":"Cystic fibrosis newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835251390130.1f1ba7f3-55dc-4fd1-8959-cb63ee36fe9b","resource":{"resourceType":"Observation","id":"1734642835251390130.1f1ba7f3-55dc-4fd1-8959-cb63ee36fe9b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"nmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38473-5","display":"17-Hydroxyprogesterone"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":15.6,"unit":"nmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<85"}]}},{"fullUrl":"Observation/1734642835253597740.7a2b5271-eaa4-4ed2-bc88-2bb2ca71b6ea","resource":{"resourceType":"Observation","id":"1734642835253597740.7a2b5271-eaa4-4ed2-bc88-2bb2ca71b6ea","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46758-9","display":"Congenital adrenal hyperplasia newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835255562214.3015bf59-aaee-4495-989e-81a50bf93052","resource":{"resourceType":"Observation","id":"1734642835255562214.3015bf59-aaee-4495-989e-81a50bf93052","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57706-4","display":"Congenital adrenal hyperplasia newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835257602910.abe375b3-0f71-4173-95e9-001a5a884ab7","resource":{"resourceType":"Observation","id":"1734642835257602910.abe375b3-0f71-4173-95e9-001a5a884ab7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"mIU/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29575-8","display":"Thyrotropin"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":9.50,"unit":"mIU/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<29"}]}},{"fullUrl":"Observation/1734642835259698981.43c8b710-7c71-4940-b9d5-25cc3d4e1958","resource":{"resourceType":"Observation","id":"1734642835259698981.43c8b710-7c71-4940-b9d5-25cc3d4e1958","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46762-1","display":"Congenital hypothyroidism newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835261515607.b721c4f8-75bf-4a2c-b5fd-9ff30cbebc4c","resource":{"resourceType":"Observation","id":"1734642835261515607.b721c4f8-75bf-4a2c-b5fd-9ff30cbebc4c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57705-6","display":"Congenital hypothyroidism newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835263526728.6352e178-f7df-4942-b4e5-e369848a3d44","resource":{"resourceType":"Observation","id":"1734642835263526728.6352e178-f7df-4942-b4e5-e369848a3d44","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"enzyme units"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42906-8","display":"Galactose 1 phosphate uridyl transferase"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":262.95,"unit":"enzyme units"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">50"}]}},{"fullUrl":"Observation/1734642835265824537.e04c9caa-53c4-4a27-aac6-9b0ca883fa66","resource":{"resourceType":"Observation","id":"1734642835265824537.e04c9caa-53c4-4a27-aac6-9b0ca883fa66","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46737-3","display":"Galactosemias newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835267640753.9e1c7bf0-8aa2-4291-8928-7d9ad874d770","resource":{"resourceType":"Observation","id":"1734642835267640753.9e1c7bf0-8aa2-4291-8928-7d9ad874d770","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57704-9","display":"Galactosemias newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835269483057.3ed613f4-d1ba-4f9e-94c5-a71a1ded6f45","resource":{"resourceType":"Observation","id":"1734642835269483057.3ed613f4-d1ba-4f9e-94c5-a71a1ded6f45","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54104-5","display":"Hemoglobin pattern"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"FA"}},{"fullUrl":"Observation/1734642835271065745.e760e98a-c57f-4150-a192-9a4815b9e4cc","resource":{"resourceType":"Observation","id":"1734642835271065745.e760e98a-c57f-4150-a192-9a4815b9e4cc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57703-1","display":"Hemoglobin disorders newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants."}},{"fullUrl":"Observation/1734642835272891979.7a36eb88-ef32-49a5-bc5e-7cdf17f63349","resource":{"resourceType":"Observation","id":"1734642835272891979.7a36eb88-ef32-49a5-bc5e-7cdf17f63349","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ERU"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75217-0","display":"Biotinidase [Enzymatic activity/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":49.77,"unit":"ERU"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">10"}]}},{"fullUrl":"Observation/1734642835274997297.6e838878-c98e-44ad-879a-acaa41879d9f","resource":{"resourceType":"Observation","id":"1734642835274997297.6e838878-c98e-44ad-879a-acaa41879d9f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46761-3","display":"Biotinidase deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835276813694.97af3170-7292-4775-ab18-e721d0173e29","resource":{"resourceType":"Observation","id":"1734642835276813694.97af3170-7292-4775-ab18-e721d0173e29","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57699-1","display":"Biotinidase deficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835278833451.2ad1bcd4-0e4b-4eed-8e68-f6f53d9c70dc","resource":{"resourceType":"Observation","id":"1734642835278833451.2ad1bcd4-0e4b-4eed-8e68-f6f53d9c70dc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"copies/µL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62320-7","display":"T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":197,"unit":"copies/µL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">18"}]}},{"fullUrl":"Observation/1734642835280939350.31988676-eaca-4ccf-ae6b-f95724c72091","resource":{"resourceType":"Observation","id":"1734642835280939350.31988676-eaca-4ccf-ae6b-f95724c72091","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62321-5","display":"Severe combined immunodeficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835282741108.a5b64cc6-76f4-47ea-ae94-bb7e8b259ea9","resource":{"resourceType":"Observation","id":"1734642835282741108.a5b64cc6-76f4-47ea-ae94-bb7e8b259ea9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62322-3","display":"Severe combined immunodeficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835284764342.eb4d98d3-2e02-47ac-81e3-f73c2d23cb8b","resource":{"resourceType":"Observation","id":"1734642835284764342.eb4d98d3-2e02-47ac-81e3-f73c2d23cb8b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55827-0","display":"Acid alpha glucosidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":12.29,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=1.47"}]}},{"fullUrl":"Observation/1734642835286864520.58c01a31-8ede-4e3d-a8b6-b7f2a2aaddfd","resource":{"resourceType":"Observation","id":"1734642835286864520.58c01a31-8ede-4e3d-a8b6-b7f2a2aaddfd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63415-4","display":"Pompe Disease deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835288660898.8901b1f0-99f8-4762-9318-77cc13486bfc","resource":{"resourceType":"Observation","id":"1734642835288660898.8901b1f0-99f8-4762-9318-77cc13486bfc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63416-2","display":"Pompe Disease deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835290755476.b2542317-e334-4edf-a07e-2fa17c9679f1","resource":{"resourceType":"Observation","id":"1734642835290755476.b2542317-e334-4edf-a07e-2fa17c9679f1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55909-6","display":"Alpha-L-iduronidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":13.01,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=0.82"}]}},{"fullUrl":"Observation/1734642835292880270.61aaccd6-2df3-4536-b2d4-61eff7ae5eb4","resource":{"resourceType":"Observation","id":"1734642835292880270.61aaccd6-2df3-4536-b2d4-61eff7ae5eb4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79564-1","display":"Mucopolysaccharidosis type I newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835294727053.63b3c494-3f3d-42af-9e1b-6c7b6396b4f8","resource":{"resourceType":"Observation","id":"1734642835294727053.63b3c494-3f3d-42af-9e1b-6c7b6396b4f8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79565-8","display":"Mucopolysaccharidosis type I newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835297387312.feaf65ff-2abb-4738-9b02-c14e949fc66c","resource":{"resourceType":"Observation","id":"1734642835297387312.feaf65ff-2abb-4738-9b02-c14e949fc66c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-60","display":"SMN1 Homozygous Deletion Analysis"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Exon 7 Present","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"Exon 7 Present"}]}},{"fullUrl":"Observation/1734642835300196600.6b956336-be88-4448-8c31-b13512d7a6e8","resource":{"resourceType":"Observation","id":"1734642835300196600.6b956336-be88-4448-8c31-b13512d7a6e8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92004-1","display":"Spinal muscular atrophy newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835302325131.3f9d73bf-5fb0-4b7a-9d19-5c65eca61695","resource":{"resourceType":"Observation","id":"1734642835302325131.3f9d73bf-5fb0-4b7a-9d19-5c65eca61695","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92003-3","display":"Spinal muscular atrophy newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"SMA Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835304478669.58d1fe41-4fe6-439c-ac8c-7ebda34fa2c8","resource":{"resourceType":"Observation","id":"1734642835304478669.58d1fe41-4fe6-439c-ac8c-7ebda34fa2c8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79462-8","display":"Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":27.84,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=2.79"}]}},{"fullUrl":"Observation/1734642835307026637.f53e03f5-3c64-4288-9a28-214161f26772","resource":{"resourceType":"Observation","id":"1734642835307026637.f53e03f5-3c64-4288-9a28-214161f26772","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104189-6","display":"Mucopolysaccharidosis type II newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835308977855.d3c4cd9b-1d7e-4d95-8085-f6edee36ce6a","resource":{"resourceType":"Observation","id":"1734642835308977855.d3c4cd9b-1d7e-4d95-8085-f6edee36ce6a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104190-4","display":"Mucopolysaccharidosis type II newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835311168554.69c8b649-447b-46f2-baae-bab36c3da5a4","resource":{"resourceType":"Observation","id":"1734642835311168554.69c8b649-447b-46f2-baae-bab36c3da5a4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104192-0","display":"Guanidinoacetate methyltransferase deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835313133799.6f0a0b0f-4471-48bd-9ba1-478b444859ce","resource":{"resourceType":"Observation","id":"1734642835313133799.6f0a0b0f-4471-48bd-9ba1-478b444859ce","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104193-8","display":"Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835315205965.5211d2f8-1a92-47e0-a60d-827e1415618d","resource":{"resourceType":"Observation","id":"1734642835315205965.5211d2f8-1a92-47e0-a60d-827e1415618d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"93488-5","display":"Guanidinoacetate [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.97,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=3"}]}},{"fullUrl":"Observation/1734642835317343453.4e89665e-74a5-47f3-99d9-376bcb1180e4","resource":{"resourceType":"Observation","id":"1734642835317343453.4e89665e-74a5-47f3-99d9-376bcb1180e4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104194-6","display":"Creatine [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":496.63,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835323110520.12a4dd67-1010-4b73-8f82-382d41bc1a15","resource":{"resourceType":"Observation","id":"1734642835323110520.12a4dd67-1010-4b73-8f82-382d41bc1a15","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104195-3","display":"GUAC/CRE Ratio [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":1.95},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=6"}]}},{"fullUrl":"Observation/1734642835325439747.8f0de453-fadb-465c-96fa-cc16db1af1ea","resource":{"resourceType":"Observation","id":"1734642835325439747.8f0de453-fadb-465c-96fa-cc16db1af1ea","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-32","display":"Adrenoleukodystrophy deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835327359006.73a0b073-3142-486b-b9a7-9a53237926aa","resource":{"resourceType":"Observation","id":"1734642835327359006.73a0b073-3142-486b-b9a7-9a53237926aa","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-33","display":"Adrenoleukodystrophy deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835329763265.0f40fa13-fedf-496d-9f03-29a65ce7b1bf","resource":{"resourceType":"Observation","id":"1734642835329763265.0f40fa13-fedf-496d-9f03-29a65ce7b1bf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79321-6","display":"Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.349,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.47"}]}},{"fullUrl":"Specimen/1734642835339788223.c729fd06-1344-4383-a056-20482ce8af1b","resource":{"resourceType":"Specimen","id":"1734642835339788223.c729fd06-1344-4383-a056-20482ce8af1b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835341216962.afb81ed4-1938-4d2c-ae58-2c93af81ab8a","resource":{"resourceType":"Specimen","id":"1734642835341216962.afb81ed4-1938-4d2c-ae58-2c93af81ab8a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835342617127.e6180bc9-4138-4189-af57-8aced2fcf501","resource":{"resourceType":"Specimen","id":"1734642835342617127.e6180bc9-4138-4189-af57-8aced2fcf501","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835344217448.792d1d9d-d3a3-46fe-85bc-90f98aa11655","resource":{"resourceType":"Specimen","id":"1734642835344217448.792d1d9d-d3a3-46fe-85bc-90f98aa11655","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835345581636.d23192da-b0a1-4e46-b5cb-4514a5a70a84","resource":{"resourceType":"Specimen","id":"1734642835345581636.d23192da-b0a1-4e46-b5cb-4514a5a70a84","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835346945544.783a59ef-1654-4aae-806a-56d263dd59c3","resource":{"resourceType":"Specimen","id":"1734642835346945544.783a59ef-1654-4aae-806a-56d263dd59c3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835348363853.9e652caf-6856-46c3-b800-dda071ed4ad9","resource":{"resourceType":"Specimen","id":"1734642835348363853.9e652caf-6856-46c3-b800-dda071ed4ad9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835349728452.9cdd7c14-f5a3-46d1-9031-27e8231dd653","resource":{"resourceType":"Specimen","id":"1734642835349728452.9cdd7c14-f5a3-46d1-9031-27e8231dd653","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835351271315.e31cf52e-6cf9-49ac-9a39-8f8d87453d6f","resource":{"resourceType":"Specimen","id":"1734642835351271315.e31cf52e-6cf9-49ac-9a39-8f8d87453d6f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835352696317.c61b9f44-92d0-4e7a-90d7-b46711288b72","resource":{"resourceType":"Specimen","id":"1734642835352696317.c61b9f44-92d0-4e7a-90d7-b46711288b72","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835354045988.5631aacd-2433-42f6-95ce-35b6a9afcf3c","resource":{"resourceType":"Specimen","id":"1734642835354045988.5631aacd-2433-42f6-95ce-35b6a9afcf3c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835355395369.c3f3a14b-e8a0-4520-8cdf-e9174aeabb56","resource":{"resourceType":"Specimen","id":"1734642835355395369.c3f3a14b-e8a0-4520-8cdf-e9174aeabb56","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835356809771.907d3d60-4ee3-4e70-90b8-1c6978b7b6f6","resource":{"resourceType":"Specimen","id":"1734642835356809771.907d3d60-4ee3-4e70-90b8-1c6978b7b6f6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835358162137.9b5c0311-9a41-48bc-8bbd-c74bf03176b9","resource":{"resourceType":"Specimen","id":"1734642835358162137.9b5c0311-9a41-48bc-8bbd-c74bf03176b9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835359622094.6175ae40-ff81-4cf2-be1b-194e3f091225","resource":{"resourceType":"Specimen","id":"1734642835359622094.6175ae40-ff81-4cf2-be1b-194e3f091225","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835361419575.3fe2b96b-3fd7-489a-b6f7-6d62e235b3eb","resource":{"resourceType":"Specimen","id":"1734642835361419575.3fe2b96b-3fd7-489a-b6f7-6d62e235b3eb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835362813018.dc52b61c-7bc3-4025-b223-b1ca2b3c4223","resource":{"resourceType":"Specimen","id":"1734642835362813018.dc52b61c-7bc3-4025-b223-b1ca2b3c4223","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835364224324.f7cb9104-c8d8-44b9-9d2a-61456558dc71","resource":{"resourceType":"Specimen","id":"1734642835364224324.f7cb9104-c8d8-44b9-9d2a-61456558dc71","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835365609582.1af14955-5a50-4899-aba3-59ac8a752604","resource":{"resourceType":"Specimen","id":"1734642835365609582.1af14955-5a50-4899-aba3-59ac8a752604","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835366959533.9c598daa-6478-49d5-bef7-af0f7f2454f6","resource":{"resourceType":"Specimen","id":"1734642835366959533.9c598daa-6478-49d5-bef7-af0f7f2454f6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835368450358.d0a6f2ac-8c36-408a-b974-d9e9ae4faf84","resource":{"resourceType":"Specimen","id":"1734642835368450358.d0a6f2ac-8c36-408a-b974-d9e9ae4faf84","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835370373845.bca755ed-c2eb-43a5-bf93-277c589b9e05","resource":{"resourceType":"Specimen","id":"1734642835370373845.bca755ed-c2eb-43a5-bf93-277c589b9e05","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835375994354.bc12431e-529d-4439-a95c-1a05fc307710","resource":{"resourceType":"Specimen","id":"1734642835375994354.bc12431e-529d-4439-a95c-1a05fc307710","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"ServiceRequest/1734642835391905450.b0809859-bcec-4d5c-99b8-9d428fe31026","resource":{"resourceType":"ServiceRequest","id":"1734642835391905450.b0809859-bcec-4d5c-99b8-9d428fe31026","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/business-event","valueCode":"RE"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/orc-common-order","extension":[{"url":"orc-21-ordering-facility-name","valueReference":{"reference":"Organization/1734642835386599601.719ad5fa-533a-4200-965a-577d7ace98b7"}},{"url":"orc-22-ordering-facility-address","valueAddress":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"8700 BEVERLY BLVD"}]}]}],"line":["8700 BEVERLY BLVD"],"city":"W HOLLYWOOD","state":"CA","postalCode":"90048-1804"}},{"url":"orc-12-ordering-provider","valueReference":{"reference":"Practitioner/1734642835389195518.b545a033-3fb0-44b3-a6ee-683690b4b89c"}}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.2","valueIdentifier":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"value":"12345667867"}},{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"S30500"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"S30500"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"requester":{"reference":"PractitionerRole/1734642835378732910.6d305b23-a512-4553-ad1b-56dfe051ea06"}}},{"fullUrl":"Practitioner/1734642835380322039.b795c0ba-5ede-471c-b1be-980d998c55f6","resource":{"resourceType":"Practitioner","id":"1734642835380322039.b795c0ba-5ede-471c-b1be-980d998c55f6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"SARAH"},{"url":"XCN.10","valueString":"NPI"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.12"}],"identifier":[{"value":"1194257170"}],"name":[{"family":"MAHMOOD","given":["SARAH"]}]}},{"fullUrl":"Organization/1734642835382836003.b835936f-521b-4acf-9cda-47bab6c75eb1","resource":{"resourceType":"Organization","id":"1734642835382836003.b835936f-521b-4acf-9cda-47bab6c75eb1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R150"}]}],"identifier":[{"value":"R150"}],"name":"CEDARS-SINAI MEDICAL CENTER","telecom":[{"_system":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}],"address":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"8700 BEVERLY BLVD"}]}]}],"line":["8700 BEVERLY BLVD"],"city":"W HOLLYWOOD","state":"CA","postalCode":"90048-1804"}]}},{"fullUrl":"PractitionerRole/1734642835378732910.6d305b23-a512-4553-ad1b-56dfe051ea06","resource":{"resourceType":"PractitionerRole","id":"1734642835378732910.6d305b23-a512-4553-ad1b-56dfe051ea06","practitioner":{"reference":"Practitioner/1734642835380322039.b795c0ba-5ede-471c-b1be-980d998c55f6"},"organization":{"reference":"Organization/1734642835382836003.b835936f-521b-4acf-9cda-47bab6c75eb1"}}},{"fullUrl":"Organization/1734642835386599601.719ad5fa-533a-4200-965a-577d7ace98b7","resource":{"resourceType":"Organization","id":"1734642835386599601.719ad5fa-533a-4200-965a-577d7ace98b7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R150"}]}],"identifier":[{"value":"R150"}],"name":"CEDARS-SINAI MEDICAL CENTER"}},{"fullUrl":"Practitioner/1734642835389195518.b545a033-3fb0-44b3-a6ee-683690b4b89c","resource":{"resourceType":"Practitioner","id":"1734642835389195518.b545a033-3fb0-44b3-a6ee-683690b4b89c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"SARAH"},{"url":"XCN.10","valueString":"NPI"}]}],"identifier":[{"value":"1194257170"}],"name":[{"family":"MAHMOOD","given":["SARAH"]}]}},{"fullUrl":"ServiceRequest/1734642835397495653.1fae25a3-5582-4ccd-9c29-4a484b7e1f29","resource":{"resourceType":"ServiceRequest","id":"1734642835397495653.1fae25a3-5582-4ccd-9c29-4a484b7e1f29","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835403253630.e3d62b93-e744-4a08-8c18-438deeeb73d9","resource":{"resourceType":"ServiceRequest","id":"1734642835403253630.e3d62b93-e744-4a08-8c18-438deeeb73d9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835408670517.cf866577-1d94-42fe-a02c-0e470d7f5207","resource":{"resourceType":"ServiceRequest","id":"1734642835408670517.cf866577-1d94-42fe-a02c-0e470d7f5207","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835414449784.f01466ef-240a-4b3a-8bc3-b04e3522f8f9","resource":{"resourceType":"ServiceRequest","id":"1734642835414449784.f01466ef-240a-4b3a-8bc3-b04e3522f8f9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835422219363.7d7b6aff-8cdc-4678-943f-6edacbb208cb","resource":{"resourceType":"ServiceRequest","id":"1734642835422219363.7d7b6aff-8cdc-4678-943f-6edacbb208cb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835427739675.c9301f84-b785-4686-bdc5-3c0cd8844304","resource":{"resourceType":"ServiceRequest","id":"1734642835427739675.c9301f84-b785-4686-bdc5-3c0cd8844304","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835433235370.d0fa1553-b40a-4f2a-b846-641ac78ccc68","resource":{"resourceType":"ServiceRequest","id":"1734642835433235370.d0fa1553-b40a-4f2a-b846-641ac78ccc68","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835438637590.579d5a0a-ec9b-492f-b601-f960c3e733b7","resource":{"resourceType":"ServiceRequest","id":"1734642835438637590.579d5a0a-ec9b-492f-b601-f960c3e733b7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835444149986.a03ffaf6-de04-4b06-a587-3c83426b60d0","resource":{"resourceType":"ServiceRequest","id":"1734642835444149986.a03ffaf6-de04-4b06-a587-3c83426b60d0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835449661802.dba507fd-987a-4e1a-95ec-c136bdaf5a33","resource":{"resourceType":"ServiceRequest","id":"1734642835449661802.dba507fd-987a-4e1a-95ec-c136bdaf5a33","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835455235874.c55b17c3-3661-480c-9a11-65bca1a4648a","resource":{"resourceType":"ServiceRequest","id":"1734642835455235874.c55b17c3-3661-480c-9a11-65bca1a4648a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835462162372.b19482f4-7bc6-443c-bc03-70034042b457","resource":{"resourceType":"ServiceRequest","id":"1734642835462162372.b19482f4-7bc6-443c-bc03-70034042b457","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835470690033.20f1a2d7-5117-4ea6-b18a-97e56a88d8f5","resource":{"resourceType":"ServiceRequest","id":"1734642835470690033.20f1a2d7-5117-4ea6-b18a-97e56a88d8f5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835476595667.93f22471-5b90-416c-a0bc-e17d6861d242","resource":{"resourceType":"ServiceRequest","id":"1734642835476595667.93f22471-5b90-416c-a0bc-e17d6861d242","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835482457398.f9daa409-9a26-42e2-bc43-51c59598c7a0","resource":{"resourceType":"ServiceRequest","id":"1734642835482457398.f9daa409-9a26-42e2-bc43-51c59598c7a0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835488227288.9fd08aed-4676-4606-a346-266b379b6244","resource":{"resourceType":"ServiceRequest","id":"1734642835488227288.9fd08aed-4676-4606-a346-266b379b6244","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835494119016.b7f9bde8-3ab2-43e9-aae8-e7ebab50861f","resource":{"resourceType":"ServiceRequest","id":"1734642835494119016.b7f9bde8-3ab2-43e9-aae8-e7ebab50861f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835500001696.57e5e1e7-56b0-487c-9af2-5fb2e512ac17","resource":{"resourceType":"ServiceRequest","id":"1734642835500001696.57e5e1e7-56b0-487c-9af2-5fb2e512ac17","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835505798657.287287b6-6063-4feb-87e7-656f5f1a0f27","resource":{"resourceType":"ServiceRequest","id":"1734642835505798657.287287b6-6063-4feb-87e7-656f5f1a0f27","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835511627888.82dfd4ea-7a37-405e-9803-60b1ac08a8ff","resource":{"resourceType":"ServiceRequest","id":"1734642835511627888.82dfd4ea-7a37-405e-9803-60b1ac08a8ff","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835517624532.73bd901e-444d-41c7-a6b7-1305f7c86d6c","resource":{"resourceType":"ServiceRequest","id":"1734642835517624532.73bd901e-444d-41c7-a6b7-1305f7c86d6c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835526013302.4b06bda6-3626-42a7-b914-b6288aef3f11","resource":{"resourceType":"ServiceRequest","id":"1734642835526013302.4b06bda6-3626-42a7-b914-b6288aef3f11","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"DiagnosticReport/1734642835531809851.7e82b5f0-fa58-4ae3-9ff4-7ef423653005","resource":{"resourceType":"DiagnosticReport","id":"1734642835531809851.7e82b5f0-fa58-4ae3-9ff4-7ef423653005","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"S30500"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"S30500"}],"basedOn":[{"reference":"ServiceRequest/1734642835391905450.b0809859-bcec-4d5c-99b8-9d428fe31026"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835339788223.c729fd06-1344-4383-a056-20482ce8af1b"}]}},{"fullUrl":"DiagnosticReport/1734642835535197914.0b32db56-7860-4c0d-869b-adf9b391aab5","resource":{"resourceType":"DiagnosticReport","id":"1734642835535197914.0b32db56-7860-4c0d-869b-adf9b391aab5","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835397495653.1fae25a3-5582-4ccd-9c29-4a484b7e1f29"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835341216962.afb81ed4-1938-4d2c-ae58-2c93af81ab8a"}],"result":[{"reference":"Observation/1734642835072408964.75266d3b-3e79-44d2-93e7-33464d92421a"},{"reference":"Observation/1734642835074715129.ead6bdf7-05f5-41b4-8301-9fbfd3b816c2"},{"reference":"Observation/1734642835077037293.45edb036-f68b-40d3-8c09-ea3c6768f49a"},{"reference":"Observation/1734642835079270551.5131b375-6013-45ab-ab8f-5b72e523ada2"},{"reference":"Observation/1734642835081533113.ca9632ae-6903-4249-8aa1-80996f4e453c"},{"reference":"Observation/1734642835083506804.de19e7fc-6c52-4be6-bd35-5365359b3060"},{"reference":"Observation/1734642835085405104.bd0a0117-73b7-476e-b72b-287122ac87a8"}]}},{"fullUrl":"DiagnosticReport/1734642835538844723.39e47371-22c9-427a-9ec9-36c1e0d304f1","resource":{"resourceType":"DiagnosticReport","id":"1734642835538844723.39e47371-22c9-427a-9ec9-36c1e0d304f1","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835403253630.e3d62b93-e744-4a08-8c18-438deeeb73d9"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835342617127.e6180bc9-4138-4189-af57-8aced2fcf501"}],"result":[{"reference":"Observation/1734642835087373826.ed98c076-6f17-44ce-81e4-a403326e769f"},{"reference":"Observation/1734642835089780829.2215db06-44bb-4c59-8466-d9278434cef3"},{"reference":"Observation/1734642835091972329.7b1c0b54-fc4f-4dd0-a741-e260efc53bc6"},{"reference":"Observation/1734642835094262483.b3cb8767-6c64-472a-a06e-87ecd4f282ef"},{"reference":"Observation/1734642835096506060.48931c5c-b95a-4205-8d31-388a9e378f1d"},{"reference":"Observation/1734642835098903976.077e0831-3c99-44cd-beda-c2370b1c502d"},{"reference":"Observation/1734642835103867243.9ca57891-de1f-40be-acd3-da3de38afe4a"},{"reference":"Observation/1734642835105899995.f5ee9e6d-6a3e-4f82-bfee-a728d4e8a184"},{"reference":"Observation/1734642835107881581.1ebeb1fa-fecb-4de7-b9dc-a149595c0620"},{"reference":"Observation/1734642835109899595.ddc4eb47-c60c-4492-9dad-82bb445a74c0"},{"reference":"Observation/1734642835111786463.26c7efd2-e94c-4ce5-9641-f08f45eedde2"}]}},{"fullUrl":"DiagnosticReport/1734642835541790517.02d1415c-20fe-4c6c-a453-99a6256f1aa3","resource":{"resourceType":"DiagnosticReport","id":"1734642835541790517.02d1415c-20fe-4c6c-a453-99a6256f1aa3","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835408670517.cf866577-1d94-42fe-a02c-0e470d7f5207"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835344217448.792d1d9d-d3a3-46fe-85bc-90f98aa11655"}]}},{"fullUrl":"DiagnosticReport/1734642835545994009.2ace7868-aa95-484d-b76b-12db078b97f7","resource":{"resourceType":"DiagnosticReport","id":"1734642835545994009.2ace7868-aa95-484d-b76b-12db078b97f7","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835414449784.f01466ef-240a-4b3a-8bc3-b04e3522f8f9"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835345581636.d23192da-b0a1-4e46-b5cb-4514a5a70a84"}],"result":[{"reference":"Observation/1734642835114032955.393eb749-310a-4618-a511-5cb2afc3e1be"},{"reference":"Observation/1734642835116331285.57764571-3b71-4975-ab76-caa45272d17d"},{"reference":"Observation/1734642835118618614.42426ad4-7ecb-43fe-bf82-864a08fa2a09"},{"reference":"Observation/1734642835120913247.cc61b5bd-2db5-4758-a60b-167569998e49"},{"reference":"Observation/1734642835123269415.c7a6f123-dabd-4ef1-b0f1-b530877298cb"},{"reference":"Observation/1734642835125596349.47098735-1062-4687-b098-d3dab2876010"},{"reference":"Observation/1734642835127868229.41515f30-507b-47da-92a5-0f50aeda3ec4"},{"reference":"Observation/1734642835130189692.2195e0b3-2998-4a0f-9e2b-b94bf4f77834"},{"reference":"Observation/1734642835132519691.2c1beca7-95b7-4a5f-b67d-c1a306333238"},{"reference":"Observation/1734642835134809435.9e06f783-ffe8-481b-ad80-afa38a0ebd6a"},{"reference":"Observation/1734642835137170923.9947c3f7-90ce-44bd-8b77-bd42ff3749d6"},{"reference":"Observation/1734642835139466537.91adde4f-a83d-41ed-ac9e-8caf431c4b86"},{"reference":"Observation/1734642835141830360.547825c7-9eba-4167-8cfe-a2465a2f395d"},{"reference":"Observation/1734642835144301563.de46881d-1f67-46ff-9858-b6ae89a6b48b"},{"reference":"Observation/1734642835146571270.9b822a4e-4daa-43bb-9143-2e71a52a04eb"},{"reference":"Observation/1734642835148847939.fd51e2fb-5d49-4676-a74e-c342a9d90613"},{"reference":"Observation/1734642835151142431.117e42b6-9dc6-4875-94de-1214fde103cf"},{"reference":"Observation/1734642835153541720.5989fc4c-89a5-407d-8b3b-e7549c5e89d2"},{"reference":"Observation/1734642835155639614.b9014743-7717-4773-b580-45c48b2f201a"}]}},{"fullUrl":"DiagnosticReport/1734642835549572319.e913f1db-3d85-49e2-9d92-abbb0ceca353","resource":{"resourceType":"DiagnosticReport","id":"1734642835549572319.e913f1db-3d85-49e2-9d92-abbb0ceca353","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835422219363.7d7b6aff-8cdc-4678-943f-6edacbb208cb"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835346945544.783a59ef-1654-4aae-806a-56d263dd59c3"}],"result":[{"reference":"Observation/1734642835157820193.577aad75-b837-4215-a407-d26006446546"},{"reference":"Observation/1734642835159765200.5b2dae01-a2ce-4f83-9239-8eb5800bcbfb"}]}},{"fullUrl":"DiagnosticReport/1734642835555248693.f55f879e-9129-4a46-b2cb-b3e8779dc651","resource":{"resourceType":"DiagnosticReport","id":"1734642835555248693.f55f879e-9129-4a46-b2cb-b3e8779dc651","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835427739675.c9301f84-b785-4686-bdc5-3c0cd8844304"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835348363853.9e652caf-6856-46c3-b800-dda071ed4ad9"}],"result":[{"reference":"Observation/1734642835162045226.9490f56a-187d-4e99-8223-a2e9772b631d"},{"reference":"Observation/1734642835164354646.81d396e1-073e-4f0e-bfdf-13937d7cd382"},{"reference":"Observation/1734642835166629993.47eb25f8-6df1-46b3-919c-f7e8913d3cf5"},{"reference":"Observation/1734642835168943661.97b6d367-d4d7-435a-bd31-b9459e9e18ec"},{"reference":"Observation/1734642835171271146.f04f4637-b85a-43fb-9f72-be114f3e7c91"},{"reference":"Observation/1734642835173651229.ec3d9ff9-0f52-4328-9cbb-f31a10f36d37"},{"reference":"Observation/1734642835178727400.29b6257f-674c-4973-95d6-21b188015189"},{"reference":"Observation/1734642835180861281.fc593df5-07c9-4233-9cb2-fca44e2c7133"},{"reference":"Observation/1734642835182931393.4305b764-7f39-4ccb-bc9c-5f4bdbb3b7c4"},{"reference":"Observation/1734642835185116210.5940d493-71de-47be-ac64-c7d47d3debde"},{"reference":"Observation/1734642835187288373.1c64ef7b-e463-43d6-8805-ca936b1c72bf"},{"reference":"Observation/1734642835189423406.1c9fd186-339a-4e60-9734-28df7b20a7df"},{"reference":"Observation/1734642835191534946.0417c3df-4317-463f-9d99-b431e3905b09"},{"reference":"Observation/1734642835193679577.02b69198-ef0d-4b94-9df8-7b27fad40308"},{"reference":"Observation/1734642835195762763.1a70ae02-e175-49fc-8500-0490ecc22862"},{"reference":"Observation/1734642835197861699.fdc7c7ef-61e7-41b8-9363-279083afadea"},{"reference":"Observation/1734642835199918416.c535e96d-42d2-43da-b498-5a4a63e27221"},{"reference":"Observation/1734642835202018364.7d47086f-137e-45e4-b97e-529e6410d71c"},{"reference":"Observation/1734642835204143519.0b293d61-5e06-4ec9-8b16-62b66efaca0a"},{"reference":"Observation/1734642835206227236.22c3dadc-1b32-4fa8-90f5-e5895e4642dc"},{"reference":"Observation/1734642835208324649.86b17533-f55e-4b9e-8306-313ca8c8d474"},{"reference":"Observation/1734642835210415530.d24aaa22-035b-42ab-a8ad-dd36ee78ea24"},{"reference":"Observation/1734642835212653867.d599ae32-6087-4057-ba49-a7f051078cdb"},{"reference":"Observation/1734642835214779794.05d31cbf-102d-45df-b48f-54cc0f715691"},{"reference":"Observation/1734642835216894589.19959e3d-cf6d-459e-b0e9-cf9e5400bbf5"},{"reference":"Observation/1734642835218980921.802246ce-c233-406b-8013-2586b6499575"}]}},{"fullUrl":"DiagnosticReport/1734642835559283809.7a8b7aca-7378-4e0f-b3b5-e7e311ecdcde","resource":{"resourceType":"DiagnosticReport","id":"1734642835559283809.7a8b7aca-7378-4e0f-b3b5-e7e311ecdcde","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835433235370.d0fa1553-b40a-4f2a-b846-641ac78ccc68"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835349728452.9cdd7c14-f5a3-46d1-9031-27e8231dd653"}],"result":[{"reference":"Observation/1734642835221107288.81ab8987-7308-4524-ac1a-1429982b0b7e"},{"reference":"Observation/1734642835223225480.5a102d3e-c9f8-40a2-9358-651a3c6cd4bf"},{"reference":"Observation/1734642835225460391.367cd09c-a84d-4b74-9012-6208e9cae783"},{"reference":"Observation/1734642835227537436.97f58b93-df12-4ff2-ab2a-cbe874b04d88"},{"reference":"Observation/1734642835229643846.878bcfe3-113a-433f-aaa0-bb3269307c1e"},{"reference":"Observation/1734642835231745977.21c27e63-559a-4ec1-be5b-ad43ab6e0b65"},{"reference":"Observation/1734642835233956282.462ce6c5-4cef-4570-9775-455480579770"},{"reference":"Observation/1734642835236097878.fa6c4155-42c1-4ac4-a809-5e912eb9e191"},{"reference":"Observation/1734642835238198367.c38dc305-07da-435c-a327-d77e95e1348e"},{"reference":"Observation/1734642835240363176.0253a773-b531-4c12-b79f-b45649144356"}]}},{"fullUrl":"DiagnosticReport/1734642835562458663.3bdb90b2-527c-4c7e-8542-71484cd7ab99","resource":{"resourceType":"DiagnosticReport","id":"1734642835562458663.3bdb90b2-527c-4c7e-8542-71484cd7ab99","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835438637590.579d5a0a-ec9b-492f-b601-f960c3e733b7"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835351271315.e31cf52e-6cf9-49ac-9a39-8f8d87453d6f"}],"result":[{"reference":"Observation/1734642835242457754.6443996c-029e-4fb4-9e7e-b38be0e5271c"},{"reference":"Observation/1734642835244613837.18c12760-d680-4504-a920-22aed27486e6"},{"reference":"Observation/1734642835246395758.fd278006-4ca8-4198-9a61-0285d94792d8"}]}},{"fullUrl":"DiagnosticReport/1734642835565786613.35dbbd5c-05ba-447e-a90a-b0b8a1d5337c","resource":{"resourceType":"DiagnosticReport","id":"1734642835565786613.35dbbd5c-05ba-447e-a90a-b0b8a1d5337c","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835444149986.a03ffaf6-de04-4b06-a587-3c83426b60d0"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835352696317.c61b9f44-92d0-4e7a-90d7-b46711288b72"}],"result":[{"reference":"Observation/1734642835251390130.1f1ba7f3-55dc-4fd1-8959-cb63ee36fe9b"},{"reference":"Observation/1734642835253597740.7a2b5271-eaa4-4ed2-bc88-2bb2ca71b6ea"},{"reference":"Observation/1734642835255562214.3015bf59-aaee-4495-989e-81a50bf93052"}]}},{"fullUrl":"DiagnosticReport/1734642835569237875.9ba7d3fc-9967-4075-88be-0335ae188064","resource":{"resourceType":"DiagnosticReport","id":"1734642835569237875.9ba7d3fc-9967-4075-88be-0335ae188064","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835449661802.dba507fd-987a-4e1a-95ec-c136bdaf5a33"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835354045988.5631aacd-2433-42f6-95ce-35b6a9afcf3c"}],"result":[{"reference":"Observation/1734642835257602910.abe375b3-0f71-4173-95e9-001a5a884ab7"},{"reference":"Observation/1734642835259698981.43c8b710-7c71-4940-b9d5-25cc3d4e1958"},{"reference":"Observation/1734642835261515607.b721c4f8-75bf-4a2c-b5fd-9ff30cbebc4c"}]}},{"fullUrl":"DiagnosticReport/1734642835572429349.a553e636-266f-4c09-b709-d56573b6fe07","resource":{"resourceType":"DiagnosticReport","id":"1734642835572429349.a553e636-266f-4c09-b709-d56573b6fe07","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835455235874.c55b17c3-3661-480c-9a11-65bca1a4648a"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835355395369.c3f3a14b-e8a0-4520-8cdf-e9174aeabb56"}],"result":[{"reference":"Observation/1734642835263526728.6352e178-f7df-4942-b4e5-e369848a3d44"},{"reference":"Observation/1734642835265824537.e04c9caa-53c4-4a27-aac6-9b0ca883fa66"},{"reference":"Observation/1734642835267640753.9e1c7bf0-8aa2-4291-8928-7d9ad874d770"}]}},{"fullUrl":"DiagnosticReport/1734642835575571841.d8c12c52-d7ca-43a2-afe8-80132657f9c7","resource":{"resourceType":"DiagnosticReport","id":"1734642835575571841.d8c12c52-d7ca-43a2-afe8-80132657f9c7","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835462162372.b19482f4-7bc6-443c-bc03-70034042b457"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835356809771.907d3d60-4ee3-4e70-90b8-1c6978b7b6f6"}],"result":[{"reference":"Observation/1734642835269483057.3ed613f4-d1ba-4f9e-94c5-a71a1ded6f45"},{"reference":"Observation/1734642835271065745.e760e98a-c57f-4150-a192-9a4815b9e4cc"}]}},{"fullUrl":"DiagnosticReport/1734642835581956604.0d9ff39f-34fd-4dd9-a5ac-dc8c2aa43995","resource":{"resourceType":"DiagnosticReport","id":"1734642835581956604.0d9ff39f-34fd-4dd9-a5ac-dc8c2aa43995","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835470690033.20f1a2d7-5117-4ea6-b18a-97e56a88d8f5"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835358162137.9b5c0311-9a41-48bc-8bbd-c74bf03176b9"}],"result":[{"reference":"Observation/1734642835272891979.7a36eb88-ef32-49a5-bc5e-7cdf17f63349"},{"reference":"Observation/1734642835274997297.6e838878-c98e-44ad-879a-acaa41879d9f"},{"reference":"Observation/1734642835276813694.97af3170-7292-4775-ab18-e721d0173e29"}]}},{"fullUrl":"DiagnosticReport/1734642835585075052.1a8ebd8f-0416-4788-b779-b9b111188dd9","resource":{"resourceType":"DiagnosticReport","id":"1734642835585075052.1a8ebd8f-0416-4788-b779-b9b111188dd9","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835476595667.93f22471-5b90-416c-a0bc-e17d6861d242"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835359622094.6175ae40-ff81-4cf2-be1b-194e3f091225"}],"result":[{"reference":"Observation/1734642835278833451.2ad1bcd4-0e4b-4eed-8e68-f6f53d9c70dc"},{"reference":"Observation/1734642835280939350.31988676-eaca-4ccf-ae6b-f95724c72091"},{"reference":"Observation/1734642835282741108.a5b64cc6-76f4-47ea-ae94-bb7e8b259ea9"}]}},{"fullUrl":"DiagnosticReport/1734642835588257930.2fa53ce1-57c4-4b73-b9fb-5e4be2b9f735","resource":{"resourceType":"DiagnosticReport","id":"1734642835588257930.2fa53ce1-57c4-4b73-b9fb-5e4be2b9f735","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835482457398.f9daa409-9a26-42e2-bc43-51c59598c7a0"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835361419575.3fe2b96b-3fd7-489a-b6f7-6d62e235b3eb"}],"result":[{"reference":"Observation/1734642835284764342.eb4d98d3-2e02-47ac-81e3-f73c2d23cb8b"},{"reference":"Observation/1734642835286864520.58c01a31-8ede-4e3d-a8b6-b7f2a2aaddfd"},{"reference":"Observation/1734642835288660898.8901b1f0-99f8-4762-9318-77cc13486bfc"}]}},{"fullUrl":"DiagnosticReport/1734642835591422123.d2f9f942-bfd6-4cbd-8565-822730b7e828","resource":{"resourceType":"DiagnosticReport","id":"1734642835591422123.d2f9f942-bfd6-4cbd-8565-822730b7e828","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835488227288.9fd08aed-4676-4606-a346-266b379b6244"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835362813018.dc52b61c-7bc3-4025-b223-b1ca2b3c4223"}],"result":[{"reference":"Observation/1734642835290755476.b2542317-e334-4edf-a07e-2fa17c9679f1"},{"reference":"Observation/1734642835292880270.61aaccd6-2df3-4536-b2d4-61eff7ae5eb4"},{"reference":"Observation/1734642835294727053.63b3c494-3f3d-42af-9e1b-6c7b6396b4f8"}]}},{"fullUrl":"DiagnosticReport/1734642835594544669.f203eb3d-fb58-425d-aad5-44fe9b3a7bbf","resource":{"resourceType":"DiagnosticReport","id":"1734642835594544669.f203eb3d-fb58-425d-aad5-44fe9b3a7bbf","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835494119016.b7f9bde8-3ab2-43e9-aae8-e7ebab50861f"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835364224324.f7cb9104-c8d8-44b9-9d2a-61456558dc71"}],"result":[{"reference":"Observation/1734642835297387312.feaf65ff-2abb-4738-9b02-c14e949fc66c"},{"reference":"Observation/1734642835300196600.6b956336-be88-4448-8c31-b13512d7a6e8"},{"reference":"Observation/1734642835302325131.3f9d73bf-5fb0-4b7a-9d19-5c65eca61695"}]}},{"fullUrl":"DiagnosticReport/1734642835597620105.488df753-3823-41cd-84fd-40b72997cffe","resource":{"resourceType":"DiagnosticReport","id":"1734642835597620105.488df753-3823-41cd-84fd-40b72997cffe","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835500001696.57e5e1e7-56b0-487c-9af2-5fb2e512ac17"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835365609582.1af14955-5a50-4899-aba3-59ac8a752604"}],"result":[{"reference":"Observation/1734642835304478669.58d1fe41-4fe6-439c-ac8c-7ebda34fa2c8"},{"reference":"Observation/1734642835307026637.f53e03f5-3c64-4288-9a28-214161f26772"},{"reference":"Observation/1734642835308977855.d3c4cd9b-1d7e-4d95-8085-f6edee36ce6a"}]}},{"fullUrl":"DiagnosticReport/1734642835600653273.375b52d5-1287-4587-af7e-f819678bb126","resource":{"resourceType":"DiagnosticReport","id":"1734642835600653273.375b52d5-1287-4587-af7e-f819678bb126","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835505798657.287287b6-6063-4feb-87e7-656f5f1a0f27"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835366959533.9c598daa-6478-49d5-bef7-af0f7f2454f6"}],"result":[{"reference":"Observation/1734642835311168554.69c8b649-447b-46f2-baae-bab36c3da5a4"},{"reference":"Observation/1734642835313133799.6f0a0b0f-4471-48bd-9ba1-478b444859ce"}]}},{"fullUrl":"DiagnosticReport/1734642835603899090.99cd7384-3aa2-4303-990f-c3d24337cb56","resource":{"resourceType":"DiagnosticReport","id":"1734642835603899090.99cd7384-3aa2-4303-990f-c3d24337cb56","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835511627888.82dfd4ea-7a37-405e-9803-60b1ac08a8ff"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835368450358.d0a6f2ac-8c36-408a-b974-d9e9ae4faf84"}],"result":[{"reference":"Observation/1734642835315205965.5211d2f8-1a92-47e0-a60d-827e1415618d"},{"reference":"Observation/1734642835317343453.4e89665e-74a5-47f3-99d9-376bcb1180e4"},{"reference":"Observation/1734642835323110520.12a4dd67-1010-4b73-8f82-382d41bc1a15"}]}},{"fullUrl":"DiagnosticReport/1734642835607156908.01e08384-7d0d-4a40-a6cd-4b60e2d03248","resource":{"resourceType":"DiagnosticReport","id":"1734642835607156908.01e08384-7d0d-4a40-a6cd-4b60e2d03248","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835517624532.73bd901e-444d-41c7-a6b7-1305f7c86d6c"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835370373845.bca755ed-c2eb-43a5-bf93-277c589b9e05"}],"result":[{"reference":"Observation/1734642835325439747.8f0de453-fadb-465c-96fa-cc16db1af1ea"},{"reference":"Observation/1734642835327359006.73a0b073-3142-486b-b9a7-9a53237926aa"}]}},{"fullUrl":"DiagnosticReport/1734642835610181350.cbaed3cc-e9a9-43f1-9836-3cd9db54bf2b","resource":{"resourceType":"DiagnosticReport","id":"1734642835610181350.cbaed3cc-e9a9-43f1-9836-3cd9db54bf2b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835526013302.4b06bda6-3626-42a7-b914-b6288aef3f11"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835375994354.bc12431e-529d-4439-a95c-1a05fc307710"}],"result":[{"reference":"Observation/1734642835329763265.0f40fa13-fedf-496d-9f03-29a65ce7b1bf"}]}}]}
diff --git a/examples/Test/GoldenCopy/Expected/003_ORU_R01_golden_copy_expected_aa_unusual.fhir b/examples/Test/GoldenCopy/Expected/003_ORU_R01_golden_copy_expected_aa_unusual.fhir
new file mode 100644
index 000000000..969382e68
--- /dev/null
+++ b/examples/Test/GoldenCopy/Expected/003_ORU_R01_golden_copy_expected_aa_unusual.fhir
@@ -0,0 +1 @@
+{"resourceType":"Bundle","id":"1734642835316676335.97260f02-e474-4674-baae-79cfcbe2f0bc","meta":{"lastUpdated":"2024-12-19T21:13:55.316+00:00"},"identifier":{"system":"https://reportstream.cdc.gov/prime-router","value":"003"},"type":"message","timestamp":"2024-10-23T05:00:44.000+00:00","entry":[{"fullUrl":"MessageHeader/1734642835321323789.e9b795da-63ce-432b-a949-58c5ec4c7909","resource":{"resourceType":"MessageHeader","id":"1734642835321323789.e9b795da-63ce-432b-a949-58c5ec4c7909","meta":{"tag":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0103","code":"N"}]},"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/msh-message-header","extension":[{"url":"MSH.7","valueString":"20241023050044"}]}],"eventCoding":{"system":"http://terminology.hl7.org/CodeSystem/v2-0003","code":"R01","display":"ORU^R01^ORU_R01"},"destination":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id","valueString":"9414049"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id-type","valueString":"L,M,N"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.5"}],"name":"SISHIERECEIVER","receiver":{"reference":"Organization/1734642835317459042.a94abe18-53ef-4bb2-bf5f-bf84f4fb6069"}}],"sender":{"reference":"Organization/1734642835316938787.7c04e091-ec33-47cf-9282-ab875e2769e0"},"source":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"SISGDSP"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.3"}],"name":"SISGDSP","_endpoint":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}}},{"fullUrl":"Organization/1734642835316938787.7c04e091-ec33-47cf-9282-ab875e2769e0","resource":{"resourceType":"Organization","id":"1734642835316938787.7c04e091-ec33-47cf-9282-ab875e2769e0","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Organization/1734642835317459042.a94abe18-53ef-4bb2-bf5f-bf84f4fb6069","resource":{"resourceType":"Organization","id":"1734642835317459042.a94abe18-53ef-4bb2-bf5f-bf84f4fb6069","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.6"}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.2,HD.3"}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301","code":"L,M,N"}]},"value":"automated-staging-test-receiver-id"}]}},{"fullUrl":"Provenance/1734642835322564285.47612a0e-8440-4bf9-9994-8a7026969910","resource":{"resourceType":"Provenance","id":"1734642835322564285.47612a0e-8440-4bf9-9994-8a7026969910","target":[{"reference":"MessageHeader/1734642835321323789.e9b795da-63ce-432b-a949-58c5ec4c7909"},{"reference":"DiagnosticReport/1734642836025400305.ff8ac839-62e2-4ae6-b38b-17f6d262661b"},{"reference":"DiagnosticReport/1734642836029429390.99b9f76a-d712-4a1f-95b8-eaaf390269fb"},{"reference":"DiagnosticReport/1734642836033347527.1423054d-d094-4b59-8fc6-e0e29bce16a4"},{"reference":"DiagnosticReport/1734642836036509076.18aca8a2-26f1-44f3-bc02-74fc6bb9b34f"},{"reference":"DiagnosticReport/1734642836041210852.69c341cb-2144-4f74-b624-c2a7731fa718"},{"reference":"DiagnosticReport/1734642836044537029.4107a300-c273-45d1-b36a-e5144b0c649b"},{"reference":"DiagnosticReport/1734642836049712354.70273afb-c29e-474d-9e06-a1e28f33aee1"},{"reference":"DiagnosticReport/1734642836053923019.128e29de-5e06-4ea9-a20d-420ac9b6c954"},{"reference":"DiagnosticReport/1734642836057537897.2271a1ac-7b0b-4b5a-9134-9d0b11c1aa8e"},{"reference":"DiagnosticReport/1734642836060854116.26790db7-6d6b-4e42-8239-08c7ef372775"},{"reference":"DiagnosticReport/1734642836064630176.92f10d06-cc28-4cb3-9d32-f4aa43dec35b"},{"reference":"DiagnosticReport/1734642836067816571.2149d1a2-417a-4bce-9c2d-a8b96c1a4ce6"},{"reference":"DiagnosticReport/1734642836070885045.9cd3f0af-e328-4e84-bac9-f37614924bad"},{"reference":"DiagnosticReport/1734642836074795647.998e19fd-ef20-48fc-9ffd-dda2719ea5f2"},{"reference":"DiagnosticReport/1734642836079087485.3ab655bd-01db-4c70-9e4b-ce057a3dc21f"},{"reference":"DiagnosticReport/1734642836082360703.e108bbfb-c300-4c64-bcfb-33611923f8d2"},{"reference":"DiagnosticReport/1734642836085564821.5f0e8445-cccc-45a2-9363-029a6c67b1bb"},{"reference":"DiagnosticReport/1734642836089224263.c80abe0a-b8cf-4063-9caf-122710a02b4f"},{"reference":"DiagnosticReport/1734642836092450482.c935b20d-f405-4093-acd7-23d13d02c9d0"},{"reference":"DiagnosticReport/1734642836095781419.9d3f4ff9-f268-408b-a3c9-a9f1563ddd34"},{"reference":"DiagnosticReport/1734642836100016380.06b8079b-3e66-4d76-ba1e-540869bad33a"},{"reference":"DiagnosticReport/1734642836103489783.54433dc4-1532-463c-a3fd-9db074b3439c"},{"reference":"DiagnosticReport/1734642836111794034.e7245026-8c48-44c6-b07c-7d0df43be6d1"}],"recorded":"2024-10-23T05:00:44Z","activity":{"coding":[{"display":"ORU^R01^ORU_R01"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"author"}]},"who":{"reference":"Organization/1734642835322365282.9da1e1a8-2ff8-42dd-ba4c-a140b6fbbe63"}}]}},{"fullUrl":"Organization/1734642835322365282.9da1e1a8-2ff8-42dd-ba4c-a140b6fbbe63","resource":{"resourceType":"Organization","id":"1734642835322365282.9da1e1a8-2ff8-42dd-ba4c-a140b6fbbe63","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Provenance/1734642835323067038.ed16affe-94a8-4572-98a0-496ed35018c2","resource":{"resourceType":"Provenance","id":"1734642835323067038.ed16affe-94a8-4572-98a0-496ed35018c2","recorded":"2024-12-19T21:13:55Z","policy":["http://hl7.org/fhir/uv/v2mappings/message-oru-r01-to-bundle"],"activity":{"coding":[{"code":"v2-FHIR transformation"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"assembler"}]},"who":{"reference":"Organization/1734642835322919191.37fff541-57da-4e65-9a01-feeb24b92a4f"}}]}},{"fullUrl":"Organization/1734642835322919191.37fff541-57da-4e65-9a01-feeb24b92a4f","resource":{"resourceType":"Organization","id":"1734642835322919191.37fff541-57da-4e65-9a01-feeb24b92a4f","identifier":[{"value":"CDC PRIME - Atlanta"},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301"}]},"system":"urn:ietf:rfc:3986","value":"2.16.840.1.114222.4.1.237821"}]}},{"fullUrl":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6","resource":{"resourceType":"Patient","id":"1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cx-identifier","extension":[{"url":"CX.5","valueString":"MR"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"PID.3"}],"type":{"coding":[{"code":"MR"}]},"value":"32550867","assigner":{"reference":"Organization/1734642835323709593.d0e89ced-630a-4420-ac3d-8963187d336f"}}],"name":[{"family":"*****PII REMOVED******"}],"contact":[{"name":{"family":"*****PII REMOVED******"}}]}},{"fullUrl":"Organization/1734642835323709593.d0e89ced-630a-4420-ac3d-8963187d336f","resource":{"resourceType":"Organization","id":"1734642835323709593.d0e89ced-630a-4420-ac3d-8963187d336f","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"1013163542&NPI"}]}},{"fullUrl":"Provenance/1734642835327525228.0339ab4c-4b97-460e-96a0-deb309a41455","resource":{"resourceType":"Provenance","id":"1734642835327525228.0339ab4c-4b97-460e-96a0-deb309a41455","target":[{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"}],"recorded":"2024-12-19T21:13:55Z","activity":{"coding":[{"system":"https://terminology.hl7.org/CodeSystem/v3-DataOperation","code":"UPDATE"}]}}},{"fullUrl":"RelatedPerson/1734642835328476381.06363fc9-8325-4667-bd99-a3b8b5a31bb9","resource":{"resourceType":"RelatedPerson","id":"1734642835328476381.06363fc9-8325-4667-bd99-a3b8b5a31bb9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"NK1"}],"patient":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"name":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"NK1.2"}],"family":"*****PII REMOVED******"}]}},{"fullUrl":"Observation/1734642835331267826.63d36999-ad9d-43cf-9ffa-431a0c8a7bcd","resource":{"resourceType":"Observation","id":"1734642835331267826.63d36999-ad9d-43cf-9ffa-431a0c8a7bcd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57721-3","display":"Reason for lab test in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12421-6","display":"Initial screen"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835333569772.67e5a931-dbac-42f7-a4ca-96331001f5f4","resource":{"resourceType":"Observation","id":"1734642835333569772.67e5a931-dbac-42f7-a4ca-96331001f5f4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57718-9","display":"Sample quality of Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12432-3","display":"Acceptable"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835335722138.55faa56e-a228-4fc8-9165-8fdb9382e0a8","resource":{"resourceType":"Observation","id":"1734642835335722138.55faa56e-a228-4fc8-9165-8fdb9382e0a8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57130-7","display":"Newborn screening report - overall interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18944-1","display":"Screen is out of range for at least one condition"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835337835952.0dad2f6c-eeff-4faf-b63a-a4ba5359a979","resource":{"resourceType":"Observation","id":"1734642835337835952.0dad2f6c-eeff-4faf-b63a-a4ba5359a979","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57131-5","display":"Newborn conditions with positive markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835339907126.8d052379-b998-403b-919e-aa04ce7ae698","resource":{"resourceType":"Observation","id":"1734642835339907126.8d052379-b998-403b-919e-aa04ce7ae698","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57720-5","display":"Newborn conditions with equivocal markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835341768095.0c6fdcb8-2039-49cf-a9fa-6aec62df3cec","resource":{"resourceType":"Observation","id":"1734642835341768095.0c6fdcb8-2039-49cf-a9fa-6aec62df3cec","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57724-7","display":"Newborn screening short narrative summary"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"ACTION REQUIRED\\\\.br\\\\\\\\.br\\\\NBS Testing Lab - ALLIED LABORATORY \\\\\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\\\.br\\\\\\\\.br\\\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\\\.br\\\\\\\\.br\\\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\\\.br\\\\\\\\.br\\\\Follow-up:\\\\.br\\\\\\\\.br\\\\Amino Acid Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\\\.br\\\\\\\\.br\\\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\\\.br\\\\\\\\.br\\\\Methods and Limitations:\\\\.br\\\\\\\\.br\\\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\\\.br\\\\Attention Healthcare Provider:\\\\.br\\\\\\\\.br\\\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\\\.br\\\\\\\\.br\\","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835343782833.af96a85a-767c-43b2-a5a5-04b73664c52f","resource":{"resourceType":"Observation","id":"1734642835343782833.af96a85a-767c-43b2-a5a5-04b73664c52f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57129-9","display":"Full newborn screening summary report for display or printing"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835345802340.93550bd0-515e-43fa-98c0-63214b549372","resource":{"resourceType":"Observation","id":"1734642835345802340.93550bd0-515e-43fa-98c0-63214b549372","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"ST"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57716-3","display":"State printed on filter paper card [Identifier] in NBS card"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"CA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835347854718.6a359b63-1a34-486f-92d9-8b593a70c860","resource":{"resourceType":"Observation","id":"1734642835347854718.6a359b63-1a34-486f-92d9-8b593a70c860","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"grams"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"8339-4","display":"Birthweight"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":2230,"unit":"grams"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835349807480.c7fb14b4-52bc-4f8c-b9da-7d38cd79c9b3","resource":{"resourceType":"Observation","id":"1734642835349807480.c7fb14b4-52bc-4f8c-b9da-7d38cd79c9b3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57715-5","display":"Time of birth"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueTime":"1358","_valueTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"1358"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835352502855.5ff149e3-c3ed-4661-9784-9023409e0447","resource":{"resourceType":"Observation","id":"1734642835352502855.5ff149e3-c3ed-4661-9784-9023409e0447","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57722-1","display":"Birth plurality of Pregnancy"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12412-5","display":"Twins"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835354586642.1df6ef52-e9b7-4e39-b895-fdf2e3437402","resource":{"resourceType":"Observation","id":"1734642835354586642.1df6ef52-e9b7-4e39-b895-fdf2e3437402","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"hour(s)"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"73806-2","display":"Newborn age in hours"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":26,"unit":"hour(s)"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835356828696.da821f16-8972-442a-8568-f322e8e1b276","resource":{"resourceType":"Observation","id":"1734642835356828696.da821f16-8972-442a-8568-f322e8e1b276","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57713-0","display":"Infant NICU factors that affect newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835358990570.b7f0e174-0d5e-4b85-8176-587efa704cd9","resource":{"resourceType":"Observation","id":"1734642835358990570.b7f0e174-0d5e-4b85-8176-587efa704cd9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67704-7","display":"Feeding types"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA16914-6","display":"Breast milk"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835361225290.cc0bd769-7b35-4d29-9b2a-1ed6d1254fc4","resource":{"resourceType":"Observation","id":"1734642835361225290.cc0bd769-7b35-4d29-9b2a-1ed6d1254fc4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-5","display":"Accession Number"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"282-38-261/21-2024-12","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835363248454.779ba7a1-c24e-4a37-abef-4f67466b41dd","resource":{"resourceType":"Observation","id":"1734642835363248454.779ba7a1-c24e-4a37-abef-4f67466b41dd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62324-9","display":"Post-discharge provider name"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"DR JOCHEN PROFIT","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835365113972.4533c579-f036-4a40-9093-a24ab85924c5","resource":{"resourceType":"Observation","id":"1734642835365113972.4533c579-f036-4a40-9093-a24ab85924c5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62325-6","display":"Post-discharge provider practice ID"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"1043390461","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835366924928.1e0adb94-c06a-4c3e-bcb6-ebabf903b26f","resource":{"resourceType":"Observation","id":"1734642835366924928.1e0adb94-c06a-4c3e-bcb6-ebabf903b26f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62327-2","display":"Post-discharge provider practice address"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835369659566.fe38b667-7f7e-4c1e-8612-5c5ff058fc43","resource":{"resourceType":"Observation","id":"1734642835369659566.fe38b667-7f7e-4c1e-8612-5c5ff058fc43","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47633-3","display":"Glycine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":368,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835376452073.9eff88cf-d334-4da6-8a4b-d79cec24a6fa","resource":{"resourceType":"Observation","id":"1734642835376452073.9eff88cf-d334-4da6-8a4b-d79cec24a6fa","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53150-9","display":"Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":310,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1000"}]}},{"fullUrl":"Observation/1734642835378662407.bcab4c6b-5ba4-44e0-bdd5-c937fd3bde84","resource":{"resourceType":"Observation","id":"1734642835378662407.bcab4c6b-5ba4-44e0-bdd5-c937fd3bde84","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47799-2","display":"Valine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":34.6,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835380826375.6b8edc0e-b24d-4395-a601-ea26b581cfa9","resource":{"resourceType":"Observation","id":"1734642835380826375.6b8edc0e-b24d-4395-a601-ea26b581cfa9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53151-7","display":"Valine/Phenylalanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.06462,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.3"}]}},{"fullUrl":"Observation/1734642835382952452.6f507334-0883-4174-ac7a-0ddb0f4df61a","resource":{"resourceType":"Observation","id":"1734642835382952452.6f507334-0883-4174-ac7a-0ddb0f4df61a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53152-5","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":50.7,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<230"}]}},{"fullUrl":"Observation/1734642835385214764.c131d587-e5ac-4f53-94f1-3399562a8db5","resource":{"resourceType":"Observation","id":"1734642835385214764.c131d587-e5ac-4f53-94f1-3399562a8db5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53154-1","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.16,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.35"}]}},{"fullUrl":"Observation/1734642835387460395.cda75646-4eda-4b32-b680-9456e40f562a","resource":{"resourceType":"Observation","id":"1734642835387460395.cda75646-4eda-4b32-b680-9456e40f562a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29573-3","display":"Phenylalanine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":32.5,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<175"}]}},{"fullUrl":"Observation/1734642835389634321.501179b2-c30a-4843-9418-40b2497aad2f","resource":{"resourceType":"Observation","id":"1734642835389634321.501179b2-c30a-4843-9418-40b2497aad2f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35572-7","display":"Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.13,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2.6"}]}},{"fullUrl":"Observation/1734642835391828446.5f433876-3f87-45ec-9b16-1e452a6afe53","resource":{"resourceType":"Observation","id":"1734642835391828446.5f433876-3f87-45ec-9b16-1e452a6afe53","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35571-9","display":"Tyrosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":28.9,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<680"}]}},{"fullUrl":"Observation/1734642835394016309.da7611a9-ab4b-48c4-b7e3-81e3988dc810","resource":{"resourceType":"Observation","id":"1734642835394016309.da7611a9-ab4b-48c4-b7e3-81e3988dc810","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53231-7","display":"Succinylacetone [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.25,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<6.1"}]}},{"fullUrl":"Observation/1734642835396791673.56b08f59-5641-492c-8cb3-9607afdacb01","resource":{"resourceType":"Observation","id":"1734642835396791673.56b08f59-5641-492c-8cb3-9607afdacb01","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47700-0","display":"Methionine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":8.6,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.3-100"}]}},{"fullUrl":"Observation/1734642835399100622.0b4cd402-06ef-4639-be95-30310ae78277","resource":{"resourceType":"Observation","id":"1734642835399100622.0b4cd402-06ef-4639-be95-30310ae78277","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42892-0","display":"Citrulline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":5,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"5-49"}]}},{"fullUrl":"Observation/1734642835401273266.7ec959c0-e661-4977-9ada-564e016aa547","resource":{"resourceType":"Observation","id":"1734642835401273266.7ec959c0-e661-4977-9ada-564e016aa547","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54092-2","display":"Citrulline/Arginine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.67,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.8"}]}},{"fullUrl":"Observation/1734642835403495854.208ba995-f62a-4a32-92ca-6dbd84e7b5bd","resource":{"resourceType":"Observation","id":"1734642835403495854.208ba995-f62a-4a32-92ca-6dbd84e7b5bd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53155-8","display":"Asparagine+Ornithine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":32,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<800"}]}},{"fullUrl":"Observation/1734642835405656826.a6f91d96-0e3a-47ac-8507-ba955e7a55ef","resource":{"resourceType":"Observation","id":"1734642835405656826.a6f91d96-0e3a-47ac-8507-ba955e7a55ef","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75215-4","display":"Ornithine/Citrulline [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":6.41,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835407744861.6c1d97ff-8566-4b14-839f-453d75dd411e","resource":{"resourceType":"Observation","id":"1734642835407744861.6c1d97ff-8566-4b14-839f-453d75dd411e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47562-4","display":"Arginine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":3,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<63"}]}},{"fullUrl":"Observation/1734642835409895063.1deb4048-6a8b-4531-bad0-47b7a192abda","resource":{"resourceType":"Observation","id":"1734642835409895063.1deb4048-6a8b-4531-bad0-47b7a192abda","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75214-7","display":"Arginine/Ornithine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.09,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.9"}]}},{"fullUrl":"Observation/1734642835412122400.c7ff92a9-a371-4bf3-9ca3-8a0e51a7e406","resource":{"resourceType":"Observation","id":"1734642835412122400.c7ff92a9-a371-4bf3-9ca3-8a0e51a7e406","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47732-3","display":"Proline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":55,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1500"}]}},{"fullUrl":"Observation/1734642835414367069.ff02d7b5-fca3-4e42-b46e-e94db9935f98","resource":{"resourceType":"Observation","id":"1734642835414367069.ff02d7b5-fca3-4e42-b46e-e94db9935f98","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57710-6","display":"Amino acidemias newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"This complex pattern of elevations require further evaluation","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"A"}]}]}},{"fullUrl":"Observation/1734642835416488106.e6efc8d9-7149-41bd-b70d-bdd588f1a3dc","resource":{"resourceType":"Observation","id":"1734642835416488106.e6efc8d9-7149-41bd-b70d-bdd588f1a3dc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58088-6","display":"Acylcarnitine newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835418374644.b2a9a7f8-8b31-4790-bbaa-f828b2f86648","resource":{"resourceType":"Observation","id":"1734642835418374644.b2a9a7f8-8b31-4790-bbaa-f828b2f86648","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58093-6","display":"Acylcarnitine newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835422795583.e7b35f09-9dd7-4c76-8415-0d43dc7651dc","resource":{"resourceType":"Observation","id":"1734642835422795583.e7b35f09-9dd7-4c76-8415-0d43dc7651dc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38481-8","display":"Carnitine.free (C0)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":34.9,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.4-125"}]}},{"fullUrl":"Observation/1734642835424973167.286f68ed-7f9b-4388-a6cf-85a5266b7fcb","resource":{"resourceType":"Observation","id":"1734642835424973167.286f68ed-7f9b-4388-a6cf-85a5266b7fcb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53235-8","display":"Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":7.84,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<70"}]}},{"fullUrl":"Observation/1734642835427208008.74ac2dd1-eef7-4003-a69d-8252054806cb","resource":{"resourceType":"Observation","id":"1734642835427208008.74ac2dd1-eef7-4003-a69d-8252054806cb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50157-7","display":"Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":28.1,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"10-80"}]}},{"fullUrl":"Observation/1734642835429434974.1dcdd144-4454-412a-80aa-0e2d822921c4","resource":{"resourceType":"Observation","id":"1734642835429434974.1dcdd144-4454-412a-80aa-0e2d822921c4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75212-1","display":"Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":3.53125,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.6"}]}},{"fullUrl":"Observation/1734642835431520845.08387875-2ad2-4e96-a056-0e34ae30f471","resource":{"resourceType":"Observation","id":"1734642835431520845.08387875-2ad2-4e96-a056-0e34ae30f471","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45211-0","display":"Hexanoylcarnitine (C6)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.034,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835433743443.c53a57f5-0822-45fb-b4a8-f0ccd4a7bc43","resource":{"resourceType":"Observation","id":"1734642835433743443.c53a57f5-0822-45fb-b4a8-f0ccd4a7bc43","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53175-6","display":"Octanoylcarnitine (C8)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.038,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835435894226.465ab60c-9c58-45f3-b8bd-448bda9fafc0","resource":{"resourceType":"Observation","id":"1734642835435894226.465ab60c-9c58-45f3-b8bd-448bda9fafc0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53177-2","display":"Octanoylcarnitine (C8)/Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.19,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835438030121.798cec3a-39a7-4add-b2fd-847a0238d54c","resource":{"resourceType":"Observation","id":"1734642835438030121.798cec3a-39a7-4add-b2fd-847a0238d54c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53174-9","display":"Octenoylcarnitine (C8:1)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.155,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835440167228.f45fe5ba-f30c-49ed-86c3-39fa00ef4e7d","resource":{"resourceType":"Observation","id":"1734642835440167228.f45fe5ba-f30c-49ed-86c3-39fa00ef4e7d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45197-1","display":"Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.032,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835442258119.9003abd4-9d1d-481f-a07b-1e409d499168","resource":{"resourceType":"Observation","id":"1734642835442258119.9003abd4-9d1d-481f-a07b-1e409d499168","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45198-9","display":"Decenoylcarnitine (C10:1)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.030,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835444529488.f90faf32-693d-4e1e-8df9-9e18290745c9","resource":{"resourceType":"Observation","id":"1734642835444529488.f90faf32-693d-4e1e-8df9-9e18290745c9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45199-7","display":"Dodecanoylcarnitine (C12)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.070,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2"}]}},{"fullUrl":"Observation/1734642835446685501.4fa52a50-3582-4d5f-9f50-ae6aca56bdd4","resource":{"resourceType":"Observation","id":"1734642835446685501.4fa52a50-3582-4d5f-9f50-ae6aca56bdd4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45200-3","display":"Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.05,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835448821927.1398ab29-7539-4321-a08a-4dbf80dc6fb0","resource":{"resourceType":"Observation","id":"1734642835448821927.1398ab29-7539-4321-a08a-4dbf80dc6fb0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53192-1","display":"Tetradecanoylcarnitine (C14)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.270,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.2"}]}},{"fullUrl":"Observation/1734642835450906846.7168f890-107b-4837-81db-05146c6b2caf","resource":{"resourceType":"Observation","id":"1734642835450906846.7168f890-107b-4837-81db-05146c6b2caf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53191-3","display":"Tetradecenoylcarnitine (C14:1)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.084,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.9"}]}},{"fullUrl":"Observation/1734642835453132480.cfc11d29-4916-4cdc-bc71-aee747d8575b","resource":{"resourceType":"Observation","id":"1734642835453132480.cfc11d29-4916-4cdc-bc71-aee747d8575b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53194-7","display":"Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.75,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835455753585.0c52c249-a902-49f0-8e21-58ba3bf9a0d6","resource":{"resourceType":"Observation","id":"1734642835455753585.0c52c249-a902-49f0-8e21-58ba3bf9a0d6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53190-5","display":"Tetradecadienoylcarnitine (C14:2)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.02,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835459017886.d4ffc9e5-bfac-41f8-98f0-5d97534dbc20","resource":{"resourceType":"Observation","id":"1734642835459017886.d4ffc9e5-bfac-41f8-98f0-5d97534dbc20","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50281-5","display":"3-Hydroxytetradecanoylcarnitine (C14-OH)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.009,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.2"}]}},{"fullUrl":"Observation/1734642835461170162.a43d16ce-f5f1-4263-b61d-40a0018a85fd","resource":{"resourceType":"Observation","id":"1734642835461170162.a43d16ce-f5f1-4263-b61d-40a0018a85fd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53199-6","display":"Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":2.87,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<12"}]}},{"fullUrl":"Observation/1734642835463250262.fc8c2a06-45f0-4658-a1d3-f8894e36e642","resource":{"resourceType":"Observation","id":"1734642835463250262.fc8c2a06-45f0-4658-a1d3-f8894e36e642","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53198-8","display":"Palmitoleylcarnitine (C16:1)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.236,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.4"}]}},{"fullUrl":"Observation/1734642835465381198.e355d29a-924c-42d3-adf4-d29641f95d65","resource":{"resourceType":"Observation","id":"1734642835465381198.e355d29a-924c-42d3-adf4-d29641f95d65","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50125-4","display":"3-Hydroxypalmitoylcarnitine (C16-OH)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.022,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835470144200.4b1f1f59-8fd5-4f3e-8c17-bfaeba9912cc","resource":{"resourceType":"Observation","id":"1734642835470144200.4b1f1f59-8fd5-4f3e-8c17-bfaeba9912cc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53201-0","display":"3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.00767,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.07"}]}},{"fullUrl":"Observation/1734642835473769838.73b4900a-ada8-4e69-9cc2-d8ad5d147216","resource":{"resourceType":"Observation","id":"1734642835473769838.73b4900a-ada8-4e69-9cc2-d8ad5d147216","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53241-6","display":"Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.987,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<3.5"}]}},{"fullUrl":"Observation/1734642835477324013.976eb27c-3e86-4575-82d2-42090c14cd5e","resource":{"resourceType":"Observation","id":"1734642835477324013.976eb27c-3e86-4575-82d2-42090c14cd5e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53202-8","display":"Oleoylcarnitine (C18:1)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.59,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7"}]}},{"fullUrl":"Observation/1734642835480981371.997509cf-1496-49ce-ae6a-2ab2e210872b","resource":{"resourceType":"Observation","id":"1734642835480981371.997509cf-1496-49ce-ae6a-2ab2e210872b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45217-7","display":"Linoleoylcarnitine (C18:2)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.20,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835484502183.03382ac4-4554-4bd4-a473-b1552aa30d97","resource":{"resourceType":"Observation","id":"1734642835484502183.03382ac4-4554-4bd4-a473-b1552aa30d97","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50132-0","display":"3-Hydroxystearoylcarnitine (C18-OH)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.014,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835488159871.630b3407-29cc-4479-8ca0-6992bbf11d47","resource":{"resourceType":"Observation","id":"1734642835488159871.630b3407-29cc-4479-8ca0-6992bbf11d47","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50113-0","display":"3-Hydroxyoleoylcarnitine (C18:1-OH)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.034,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835491985485.ba51db78-903c-45eb-b9e5-c53ee7b3f2e1","resource":{"resourceType":"Observation","id":"1734642835491985485.ba51db78-903c-45eb-b9e5-c53ee7b3f2e1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53160-8","display":"Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.9,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.9"}]}},{"fullUrl":"Observation/1734642835495570166.99fb27f1-e14d-4142-944b-289d1c3241da","resource":{"resourceType":"Observation","id":"1734642835495570166.99fb27f1-e14d-4142-944b-289d1c3241da","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53163-2","display":"Propionylcarnitine (C3)/Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.07,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.42"}]}},{"fullUrl":"Observation/1734642835498092857.6bb59139-99b0-4b5d-97c8-ffb14263f781","resource":{"resourceType":"Observation","id":"1734642835498092857.6bb59139-99b0-4b5d-97c8-ffb14263f781","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67708-8","display":"Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.113,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.48"}]}},{"fullUrl":"Observation/1734642835500703182.d5ab4f82-7c5b-4c26-bbbc-7dea218979e2","resource":{"resourceType":"Observation","id":"1734642835500703182.d5ab4f82-7c5b-4c26-bbbc-7dea218979e2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53166-5","display":"Butyrylcarnitine+Isobutyrylcarnitine (C4)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.161,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.7"}]}},{"fullUrl":"Observation/1734642835502895012.d0ae8710-cbea-421e-b94a-53d6e14cd248","resource":{"resourceType":"Observation","id":"1734642835502895012.d0ae8710-cbea-421e-b94a-53d6e14cd248","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45216-9","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.111,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835505066664.c4809f26-012b-428d-a228-deb3c1c71f6a","resource":{"resourceType":"Observation","id":"1734642835505066664.c4809f26-012b-428d-a228-deb3c1c71f6a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53240-8","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.05842,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642835507175288.62b29fe7-f047-423f-96b8-613605f1bf43","resource":{"resourceType":"Observation","id":"1734642835507175288.62b29fe7-f047-423f-96b8-613605f1bf43","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53170-7","display":"Tiglylcarnitine (C5:1)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.006,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.5"}]}},{"fullUrl":"Observation/1734642835509285776.6da4db8a-be6a-423f-b00d-e770d332b912","resource":{"resourceType":"Observation","id":"1734642835509285776.6da4db8a-be6a-423f-b00d-e770d332b912","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50106-4","display":"3-Hydroxyisovalerylcarnitine (C5-OH)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.140,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.15"}]}},{"fullUrl":"Observation/1734642835511368501.d417dea6-d6bc-4ccf-89e3-0111ca38a324","resource":{"resourceType":"Observation","id":"1734642835511368501.d417dea6-d6bc-4ccf-89e3-0111ca38a324","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67710-4","display":"Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.091,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642835513513543.70b62c82-fb4b-46aa-bbce-dd43197a4c40","resource":{"resourceType":"Observation","id":"1734642835513513543.70b62c82-fb4b-46aa-bbce-dd43197a4c40","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75216-2","display":"Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.80531,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">0.1"}]}},{"fullUrl":"Observation/1734642835515664627.e7d0dad1-5bbd-46c8-bd9e-6a3c2a0cc749","resource":{"resourceType":"Observation","id":"1734642835515664627.e7d0dad1-5bbd-46c8-bd9e-6a3c2a0cc749","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ng/mL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"48633-2","display":"Trypsinogen I.free"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":27.50,"unit":"ng/mL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<69"}]}},{"fullUrl":"Observation/1734642835517993935.17ec6b98-cacb-4027-820f-4d6998024af3","resource":{"resourceType":"Observation","id":"1734642835517993935.17ec6b98-cacb-4027-820f-4d6998024af3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46769-6","display":"Cystic fibrosis newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835520573001.3c493ebc-ba0f-4b33-aa6b-24b510ca4ff6","resource":{"resourceType":"Observation","id":"1734642835520573001.3c493ebc-ba0f-4b33-aa6b-24b510ca4ff6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57707-2","display":"Cystic fibrosis newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835525904147.1a80681b-c906-4966-937b-e53f0becb2f1","resource":{"resourceType":"Observation","id":"1734642835525904147.1a80681b-c906-4966-937b-e53f0becb2f1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"nmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38473-5","display":"17-Hydroxyprogesterone"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":29.9,"unit":"nmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<190"}]}},{"fullUrl":"Observation/1734642835529512403.bf5ed02a-3c6c-4860-8ca7-7ea37fc1ffeb","resource":{"resourceType":"Observation","id":"1734642835529512403.bf5ed02a-3c6c-4860-8ca7-7ea37fc1ffeb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46758-9","display":"Congenital adrenal hyperplasia newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835532521065.ed84de32-d45a-4b1a-a413-535cb2895ee9","resource":{"resourceType":"Observation","id":"1734642835532521065.ed84de32-d45a-4b1a-a413-535cb2895ee9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57706-4","display":"Congenital adrenal hyperplasia newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835535876457.d760f87e-fc5d-4be1-a52f-66f60a2ae7bd","resource":{"resourceType":"Observation","id":"1734642835535876457.d760f87e-fc5d-4be1-a52f-66f60a2ae7bd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"mIU/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29575-8","display":"Thyrotropin"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":6.90,"unit":"mIU/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<29"}]}},{"fullUrl":"Observation/1734642835539823078.8f08b768-25fc-45d6-aa00-7d0ac78f7680","resource":{"resourceType":"Observation","id":"1734642835539823078.8f08b768-25fc-45d6-aa00-7d0ac78f7680","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46762-1","display":"Congenital hypothyroidism newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835543024561.82b80bcb-0246-4912-8e2d-d887306f7321","resource":{"resourceType":"Observation","id":"1734642835543024561.82b80bcb-0246-4912-8e2d-d887306f7321","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57705-6","display":"Congenital hypothyroidism newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835546355467.83b3714a-1a87-4ac9-8f99-08878e0fd16a","resource":{"resourceType":"Observation","id":"1734642835546355467.83b3714a-1a87-4ac9-8f99-08878e0fd16a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"enzyme units"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42906-8","display":"Galactose 1 phosphate uridyl transferase"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":226.51,"unit":"enzyme units"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">50"}]}},{"fullUrl":"Observation/1734642835549893211.25dd6d46-74e7-4235-ab79-9d8105fa0a00","resource":{"resourceType":"Observation","id":"1734642835549893211.25dd6d46-74e7-4235-ab79-9d8105fa0a00","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46737-3","display":"Galactosemias newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835552869902.ac846058-f0a0-4699-97d2-519dca5cade1","resource":{"resourceType":"Observation","id":"1734642835552869902.ac846058-f0a0-4699-97d2-519dca5cade1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57704-9","display":"Galactosemias newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835555821888.61e203d3-2b7d-430f-bf57-c9f70a3ec4fc","resource":{"resourceType":"Observation","id":"1734642835555821888.61e203d3-2b7d-430f-bf57-c9f70a3ec4fc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54104-5","display":"Hemoglobin pattern"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"FA"}},{"fullUrl":"Observation/1734642835558423075.0fb66141-985a-471c-84ea-0e2507b24dee","resource":{"resourceType":"Observation","id":"1734642835558423075.0fb66141-985a-471c-84ea-0e2507b24dee","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57703-1","display":"Hemoglobin disorders newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants."}},{"fullUrl":"Observation/1734642835561468346.fa1af592-bc70-4f22-a292-dbf8a4ea9fe3","resource":{"resourceType":"Observation","id":"1734642835561468346.fa1af592-bc70-4f22-a292-dbf8a4ea9fe3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ERU"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75217-0","display":"Biotinidase [Enzymatic activity/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":28.87,"unit":"ERU"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">10"}]}},{"fullUrl":"Observation/1734642835564990210.aba2c5e6-f906-465b-9b58-d2a3f6f29dd1","resource":{"resourceType":"Observation","id":"1734642835564990210.aba2c5e6-f906-465b-9b58-d2a3f6f29dd1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46761-3","display":"Biotinidase deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835567985496.fa5f27bf-a0a5-4d52-b4b1-1bf218ce6db4","resource":{"resourceType":"Observation","id":"1734642835567985496.fa5f27bf-a0a5-4d52-b4b1-1bf218ce6db4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57699-1","display":"Biotinidase deficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835571309800.12adfa77-1e2f-48d4-88b8-d20a75429f23","resource":{"resourceType":"Observation","id":"1734642835571309800.12adfa77-1e2f-48d4-88b8-d20a75429f23","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"copies/µL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62320-7","display":"T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":198,"unit":"copies/µL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">18"}]}},{"fullUrl":"Observation/1734642835574850148.21ea8318-4e72-436c-b8fa-e1fd75a19efb","resource":{"resourceType":"Observation","id":"1734642835574850148.21ea8318-4e72-436c-b8fa-e1fd75a19efb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62321-5","display":"Severe combined immunodeficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835581069972.c10bcd96-4829-4e95-a1d9-66376f5d3d45","resource":{"resourceType":"Observation","id":"1734642835581069972.c10bcd96-4829-4e95-a1d9-66376f5d3d45","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62322-3","display":"Severe combined immunodeficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835584576026.aabbb953-5488-4b30-8acc-41bf00db6120","resource":{"resourceType":"Observation","id":"1734642835584576026.aabbb953-5488-4b30-8acc-41bf00db6120","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55827-0","display":"Acid alpha glucosidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":7.91,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=1.62"}]}},{"fullUrl":"Observation/1734642835588092480.08525370-2227-4b69-826d-d9e4032ee0af","resource":{"resourceType":"Observation","id":"1734642835588092480.08525370-2227-4b69-826d-d9e4032ee0af","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63415-4","display":"Pompe Disease deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835591074051.eb0d4858-a135-4a49-9d69-38d256936bb8","resource":{"resourceType":"Observation","id":"1734642835591074051.eb0d4858-a135-4a49-9d69-38d256936bb8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63416-2","display":"Pompe Disease deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835594442237.a15194f2-60a6-4498-b5dc-87aca0c61a66","resource":{"resourceType":"Observation","id":"1734642835594442237.a15194f2-60a6-4498-b5dc-87aca0c61a66","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55909-6","display":"Alpha-L-iduronidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":7.78,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=0.79"}]}},{"fullUrl":"Observation/1734642835597959462.0cdecaae-6f8b-441d-9c80-85c40bef0dae","resource":{"resourceType":"Observation","id":"1734642835597959462.0cdecaae-6f8b-441d-9c80-85c40bef0dae","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79564-1","display":"Mucopolysaccharidosis type I newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835600988341.dc2afa30-6326-48a0-9e3b-28c2aeb08706","resource":{"resourceType":"Observation","id":"1734642835600988341.dc2afa30-6326-48a0-9e3b-28c2aeb08706","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79565-8","display":"Mucopolysaccharidosis type I newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835604036297.40339a51-8dac-4737-809a-539504353d80","resource":{"resourceType":"Observation","id":"1734642835604036297.40339a51-8dac-4737-809a-539504353d80","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-60","display":"SMN1 Homozygous Deletion Analysis"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Exon 7 Present","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"Exon 7 Present"}]}},{"fullUrl":"Observation/1734642835607529266.a4125cf0-de2a-4085-b6de-c410a2215b1f","resource":{"resourceType":"Observation","id":"1734642835607529266.a4125cf0-de2a-4085-b6de-c410a2215b1f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92004-1","display":"Spinal muscular atrophy newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835610542657.f1aef249-54da-4464-97f9-c3fb9ba09a9d","resource":{"resourceType":"Observation","id":"1734642835610542657.f1aef249-54da-4464-97f9-c3fb9ba09a9d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92003-3","display":"Spinal muscular atrophy newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"SMA Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835613935850.7dd54161-8b91-4713-9880-097a8d61b409","resource":{"resourceType":"Observation","id":"1734642835613935850.7dd54161-8b91-4713-9880-097a8d61b409","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79462-8","display":"Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":28.94,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=2.95"}]}},{"fullUrl":"Observation/1734642835617486398.92be0ee0-3ee7-466e-99d6-b61c7e3e5a37","resource":{"resourceType":"Observation","id":"1734642835617486398.92be0ee0-3ee7-466e-99d6-b61c7e3e5a37","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104189-6","display":"Mucopolysaccharidosis type II newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835620525837.cc26ef54-3f3a-47b8-9a7b-047d46f3348b","resource":{"resourceType":"Observation","id":"1734642835620525837.cc26ef54-3f3a-47b8-9a7b-047d46f3348b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104190-4","display":"Mucopolysaccharidosis type II newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835623921985.3e0baca9-bd03-4ed1-8b08-89ba31cab5dd","resource":{"resourceType":"Observation","id":"1734642835623921985.3e0baca9-bd03-4ed1-8b08-89ba31cab5dd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104192-0","display":"Guanidinoacetate methyltransferase deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835630419291.12c4f657-9182-4881-8c31-27b06e3c48c7","resource":{"resourceType":"Observation","id":"1734642835630419291.12c4f657-9182-4881-8c31-27b06e3c48c7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104193-8","display":"Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835633807975.46e97221-a624-4e5e-8859-ff611e85da90","resource":{"resourceType":"Observation","id":"1734642835633807975.46e97221-a624-4e5e-8859-ff611e85da90","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"93488-5","display":"Guanidinoacetate [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.00,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=3"}]}},{"fullUrl":"Observation/1734642835637364704.cfb11c03-e2c7-43f7-8cc9-859c933f8b62","resource":{"resourceType":"Observation","id":"1734642835637364704.cfb11c03-e2c7-43f7-8cc9-859c933f8b62","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104194-6","display":"Creatine [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":707.37,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835649022763.3c31dc08-0d4e-4e81-a1c4-d249999d5869","resource":{"resourceType":"Observation","id":"1734642835649022763.3c31dc08-0d4e-4e81-a1c4-d249999d5869","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104195-3","display":"GUAC/CRE Ratio [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.41},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=6"}]}},{"fullUrl":"Observation/1734642835653194486.57e9dd23-af1b-46e0-99a7-bc5a2461a5e5","resource":{"resourceType":"Observation","id":"1734642835653194486.57e9dd23-af1b-46e0-99a7-bc5a2461a5e5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-32","display":"Adrenoleukodystrophy deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835656742329.2b81d4e2-b30a-4c26-a562-c55c8d886d39","resource":{"resourceType":"Observation","id":"1734642835656742329.2b81d4e2-b30a-4c26-a562-c55c8d886d39","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-33","display":"Adrenoleukodystrophy deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835660757468.12a8eb98-e6e0-4f4d-9bf4-afeeb9525a95","resource":{"resourceType":"Observation","id":"1734642835660757468.12a8eb98-e6e0-4f4d-9bf4-afeeb9525a95","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79321-6","display":"Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.246,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.47"}]}},{"fullUrl":"Specimen/1734642835679809963.f5140095-69f3-4915-8100-62ebb73a9266","resource":{"resourceType":"Specimen","id":"1734642835679809963.f5140095-69f3-4915-8100-62ebb73a9266","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835682132849.c285fe9e-9eef-41c1-b376-4a15512e5477","resource":{"resourceType":"Specimen","id":"1734642835682132849.c285fe9e-9eef-41c1-b376-4a15512e5477","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835683649694.81529006-d9a6-478d-a042-55c556f93b39","resource":{"resourceType":"Specimen","id":"1734642835683649694.81529006-d9a6-478d-a042-55c556f93b39","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835685112005.62776300-71ef-4753-9775-632dbd20fa5a","resource":{"resourceType":"Specimen","id":"1734642835685112005.62776300-71ef-4753-9775-632dbd20fa5a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835687040031.041f7ffc-da54-46c9-8d11-aa5f8de30bb0","resource":{"resourceType":"Specimen","id":"1734642835687040031.041f7ffc-da54-46c9-8d11-aa5f8de30bb0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835689202095.cd50a654-b526-4981-9f5b-699bc6abb850","resource":{"resourceType":"Specimen","id":"1734642835689202095.cd50a654-b526-4981-9f5b-699bc6abb850","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835694345079.5c984bb7-fe34-47af-ba5e-5138ffb45e35","resource":{"resourceType":"Specimen","id":"1734642835694345079.5c984bb7-fe34-47af-ba5e-5138ffb45e35","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835695888844.b9c265b2-7ecc-4fa6-8b6b-fdc320dec738","resource":{"resourceType":"Specimen","id":"1734642835695888844.b9c265b2-7ecc-4fa6-8b6b-fdc320dec738","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835698178878.c6f061fd-6eae-4ca5-8607-5247f471f7ae","resource":{"resourceType":"Specimen","id":"1734642835698178878.c6f061fd-6eae-4ca5-8607-5247f471f7ae","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835700470095.490fe88c-9d7f-48ac-8a2e-de34c0a0122c","resource":{"resourceType":"Specimen","id":"1734642835700470095.490fe88c-9d7f-48ac-8a2e-de34c0a0122c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835702449075.1d1f430f-765e-4097-9fd9-b98c8afe02cb","resource":{"resourceType":"Specimen","id":"1734642835702449075.1d1f430f-765e-4097-9fd9-b98c8afe02cb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835704119568.b958bb18-491b-4ee7-9425-30bd73b53543","resource":{"resourceType":"Specimen","id":"1734642835704119568.b958bb18-491b-4ee7-9425-30bd73b53543","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835705624961.bc2cfb73-382d-4917-a2fb-649f48c96d17","resource":{"resourceType":"Specimen","id":"1734642835705624961.bc2cfb73-382d-4917-a2fb-649f48c96d17","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835707157845.4fe80b95-b4f1-4845-bca1-c066dd61b6d9","resource":{"resourceType":"Specimen","id":"1734642835707157845.4fe80b95-b4f1-4845-bca1-c066dd61b6d9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835708612232.ac4f7578-f103-41a7-b573-007e4db7765b","resource":{"resourceType":"Specimen","id":"1734642835708612232.ac4f7578-f103-41a7-b573-007e4db7765b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835710510722.fc135623-a3f3-43e6-b605-5beba9342283","resource":{"resourceType":"Specimen","id":"1734642835710510722.fc135623-a3f3-43e6-b605-5beba9342283","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835712141821.51833386-6ce0-4b71-b0e4-8d2cf7ee8c86","resource":{"resourceType":"Specimen","id":"1734642835712141821.51833386-6ce0-4b71-b0e4-8d2cf7ee8c86","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835713518763.82aafad2-810d-4c77-a953-975e9b2dfde4","resource":{"resourceType":"Specimen","id":"1734642835713518763.82aafad2-810d-4c77-a953-975e9b2dfde4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835715545523.cab4abb0-08dd-41fc-b108-d8df145f1ba1","resource":{"resourceType":"Specimen","id":"1734642835715545523.cab4abb0-08dd-41fc-b108-d8df145f1ba1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835718057894.457e17fc-100b-49f5-bb92-b4c9acf25c85","resource":{"resourceType":"Specimen","id":"1734642835718057894.457e17fc-100b-49f5-bb92-b4c9acf25c85","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835719713849.d97d4078-fa35-46c5-b71a-983c6c316188","resource":{"resourceType":"Specimen","id":"1734642835719713849.d97d4078-fa35-46c5-b71a-983c6c316188","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835721296777.e0bd5141-acd6-4b4a-ba77-e92176956627","resource":{"resourceType":"Specimen","id":"1734642835721296777.e0bd5141-acd6-4b4a-ba77-e92176956627","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835722645206.a1858c19-14c2-4fef-9cc4-db5e31b7e834","resource":{"resourceType":"Specimen","id":"1734642835722645206.a1858c19-14c2-4fef-9cc4-db5e31b7e834","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"ServiceRequest/1734642835744401522.4ff3345c-4a6d-4397-937b-68ba4e55bd8d","resource":{"resourceType":"ServiceRequest","id":"1734642835744401522.4ff3345c-4a6d-4397-937b-68ba4e55bd8d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/business-event","valueCode":"RE"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/orc-common-order","extension":[{"url":"orc-21-ordering-facility-name","valueReference":{"reference":"Organization/1734642835735798210.495c376f-5387-48ac-91cb-e509faa1e5e6"}},{"url":"orc-22-ordering-facility-address","valueAddress":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"725 WELCH RD, RM  H1524"}]}]}],"line":["725 WELCH RD, RM  H1524"],"city":"PALO ALTO","state":"CA","postalCode":"94304-1601"}},{"url":"orc-12-ordering-provider","valueReference":{"reference":"Practitioner/1734642835739088029.31fe1c60-ff4b-4ee1-a45a-87b46efa190d"}}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.2","valueIdentifier":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"value":"45789876"}},{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835741273888.5c20a08d-a661-46cf-b1f0-ced95f4935eb"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"56352742"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"56352742"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"PractitionerRole/1734642835725673324.d4e3b8dc-f1f7-4a53-965e-f1830dd3b992"}}},{"fullUrl":"Practitioner/1734642835727820210.e30c7146-821c-42b7-8344-c4215695456b","resource":{"resourceType":"Practitioner","id":"1734642835727820210.e30c7146-821c-42b7-8344-c4215695456b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"DR JOCHEN"},{"url":"XCN.10","valueString":"NPI"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.12"}],"identifier":[{"value":"1043390461"}],"name":[{"family":"PROFIT","given":["DR JOCHEN"]}]}},{"fullUrl":"Organization/1734642835731117132.30410059-af3f-4a15-bf64-a3084e81c740","resource":{"resourceType":"Organization","id":"1734642835731117132.30410059-af3f-4a15-bf64-a3084e81c740","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R777"}]}],"identifier":[{"value":"R777"}],"name":"STANFORD/LUCILE PACKARD CHILDREN'S HOSPI","telecom":[{"_system":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}],"address":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"725 WELCH RD, RM  H1524"}]}]}],"line":["725 WELCH RD, RM  H1524"],"city":"PALO ALTO","state":"CA","postalCode":"94304-1601"}]}},{"fullUrl":"PractitionerRole/1734642835725673324.d4e3b8dc-f1f7-4a53-965e-f1830dd3b992","resource":{"resourceType":"PractitionerRole","id":"1734642835725673324.d4e3b8dc-f1f7-4a53-965e-f1830dd3b992","practitioner":{"reference":"Practitioner/1734642835727820210.e30c7146-821c-42b7-8344-c4215695456b"},"organization":{"reference":"Organization/1734642835731117132.30410059-af3f-4a15-bf64-a3084e81c740"}}},{"fullUrl":"Organization/1734642835735798210.495c376f-5387-48ac-91cb-e509faa1e5e6","resource":{"resourceType":"Organization","id":"1734642835735798210.495c376f-5387-48ac-91cb-e509faa1e5e6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R777"}]}],"identifier":[{"value":"R777"}],"name":"STANFORD/LUCILE PACKARD CHILDREN'S HOSPI"}},{"fullUrl":"Practitioner/1734642835739088029.31fe1c60-ff4b-4ee1-a45a-87b46efa190d","resource":{"resourceType":"Practitioner","id":"1734642835739088029.31fe1c60-ff4b-4ee1-a45a-87b46efa190d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"DR JOCHEN"},{"url":"XCN.10","valueString":"NPI"}]}],"identifier":[{"value":"1043390461"}],"name":[{"family":"PROFIT","given":["DR JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835741273888.5c20a08d-a661-46cf-b1f0-ced95f4935eb","resource":{"resourceType":"Practitioner","id":"1734642835741273888.5c20a08d-a661-46cf-b1f0-ced95f4935eb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835758992222.2d75840b-e8b8-43c6-a69b-658b37b1361d","resource":{"resourceType":"ServiceRequest","id":"1734642835758992222.2d75840b-e8b8-43c6-a69b-658b37b1361d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835754613601.d74b2393-0fe6-4f76-af28-52680c8555f5"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835747352195.f55624d9-402a-46a3-ac0b-fca41a709bb4"}}},{"fullUrl":"Practitioner/1734642835747352195.f55624d9-402a-46a3-ac0b-fca41a709bb4","resource":{"resourceType":"Practitioner","id":"1734642835747352195.f55624d9-402a-46a3-ac0b-fca41a709bb4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835754613601.d74b2393-0fe6-4f76-af28-52680c8555f5","resource":{"resourceType":"Practitioner","id":"1734642835754613601.d74b2393-0fe6-4f76-af28-52680c8555f5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835770650794.bfe29259-c5d9-4f16-8ff4-d699d646ee90","resource":{"resourceType":"ServiceRequest","id":"1734642835770650794.bfe29259-c5d9-4f16-8ff4-d699d646ee90","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835768437013.d2705796-f21e-496a-94cf-964ce4224e53"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835762344528.df610ff8-854f-407e-ac0e-acf4592dd9b9"}}},{"fullUrl":"Practitioner/1734642835762344528.df610ff8-854f-407e-ac0e-acf4592dd9b9","resource":{"resourceType":"Practitioner","id":"1734642835762344528.df610ff8-854f-407e-ac0e-acf4592dd9b9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835768437013.d2705796-f21e-496a-94cf-964ce4224e53","resource":{"resourceType":"Practitioner","id":"1734642835768437013.d2705796-f21e-496a-94cf-964ce4224e53","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835780546470.eb10fd70-3fc5-451f-af4a-77763961365b","resource":{"resourceType":"ServiceRequest","id":"1734642835780546470.eb10fd70-3fc5-451f-af4a-77763961365b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835778040631.265277d4-4a77-47f4-aaa7-09ccc56de71e"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835772862321.a6870388-fbbf-4b92-a8be-087d31d4bbc0"}}},{"fullUrl":"Practitioner/1734642835772862321.a6870388-fbbf-4b92-a8be-087d31d4bbc0","resource":{"resourceType":"Practitioner","id":"1734642835772862321.a6870388-fbbf-4b92-a8be-087d31d4bbc0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835778040631.265277d4-4a77-47f4-aaa7-09ccc56de71e","resource":{"resourceType":"Practitioner","id":"1734642835778040631.265277d4-4a77-47f4-aaa7-09ccc56de71e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835791834676.ec7b25fd-682f-4cb7-adbb-ca082237c515","resource":{"resourceType":"ServiceRequest","id":"1734642835791834676.ec7b25fd-682f-4cb7-adbb-ca082237c515","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835788722270.d7651dc5-9325-4cbc-961c-bb909f66d5f6"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835782906885.680b2abc-6eda-4a0a-9f1d-e6bfb42c99f5"}}},{"fullUrl":"Practitioner/1734642835782906885.680b2abc-6eda-4a0a-9f1d-e6bfb42c99f5","resource":{"resourceType":"Practitioner","id":"1734642835782906885.680b2abc-6eda-4a0a-9f1d-e6bfb42c99f5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835788722270.d7651dc5-9325-4cbc-961c-bb909f66d5f6","resource":{"resourceType":"Practitioner","id":"1734642835788722270.d7651dc5-9325-4cbc-961c-bb909f66d5f6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835802084907.25541256-2203-4b6a-8fc2-45c8c95543af","resource":{"resourceType":"ServiceRequest","id":"1734642835802084907.25541256-2203-4b6a-8fc2-45c8c95543af","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835798423151.10bd8f25-7156-4b28-9b8e-0e1bf7084131"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835793778371.0f0a22e9-2747-4376-b565-00db35f8aaa3"}}},{"fullUrl":"Practitioner/1734642835793778371.0f0a22e9-2747-4376-b565-00db35f8aaa3","resource":{"resourceType":"Practitioner","id":"1734642835793778371.0f0a22e9-2747-4376-b565-00db35f8aaa3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835798423151.10bd8f25-7156-4b28-9b8e-0e1bf7084131","resource":{"resourceType":"Practitioner","id":"1734642835798423151.10bd8f25-7156-4b28-9b8e-0e1bf7084131","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835812909625.81dd7562-bd3f-4733-9512-08a1f914da1d","resource":{"resourceType":"ServiceRequest","id":"1734642835812909625.81dd7562-bd3f-4733-9512-08a1f914da1d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835809639373.7eaa67db-5dae-4c96-8291-8cb55ddd7955"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835804285885.e3ea1477-1820-42c4-a3a3-1ca1dc306ea1"}}},{"fullUrl":"Practitioner/1734642835804285885.e3ea1477-1820-42c4-a3a3-1ca1dc306ea1","resource":{"resourceType":"Practitioner","id":"1734642835804285885.e3ea1477-1820-42c4-a3a3-1ca1dc306ea1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835809639373.7eaa67db-5dae-4c96-8291-8cb55ddd7955","resource":{"resourceType":"Practitioner","id":"1734642835809639373.7eaa67db-5dae-4c96-8291-8cb55ddd7955","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835826844004.93e7de95-250e-42ad-962c-5fb6f91a6211","resource":{"resourceType":"ServiceRequest","id":"1734642835826844004.93e7de95-250e-42ad-962c-5fb6f91a6211","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835819933346.5cf240f2-bf06-45d8-b16c-7e3d60e59512"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835814921818.998dd2d9-f1c7-4fdc-b8b0-1051a8d49782"}}},{"fullUrl":"Practitioner/1734642835814921818.998dd2d9-f1c7-4fdc-b8b0-1051a8d49782","resource":{"resourceType":"Practitioner","id":"1734642835814921818.998dd2d9-f1c7-4fdc-b8b0-1051a8d49782","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835819933346.5cf240f2-bf06-45d8-b16c-7e3d60e59512","resource":{"resourceType":"Practitioner","id":"1734642835819933346.5cf240f2-bf06-45d8-b16c-7e3d60e59512","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835841901599.3275048a-bc6c-4092-b850-d38de0ed3651","resource":{"resourceType":"ServiceRequest","id":"1734642835841901599.3275048a-bc6c-4092-b850-d38de0ed3651","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835838140216.bb2141de-76dd-4221-9c4c-acab33d06eea"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835830057961.f7dcb42f-d0ab-4573-9b2e-1b5735b22a39"}}},{"fullUrl":"Practitioner/1734642835830057961.f7dcb42f-d0ab-4573-9b2e-1b5735b22a39","resource":{"resourceType":"Practitioner","id":"1734642835830057961.f7dcb42f-d0ab-4573-9b2e-1b5735b22a39","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835838140216.bb2141de-76dd-4221-9c4c-acab33d06eea","resource":{"resourceType":"Practitioner","id":"1734642835838140216.bb2141de-76dd-4221-9c4c-acab33d06eea","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835856905334.d69097cc-ddb8-4325-81ac-035da095ab9d","resource":{"resourceType":"ServiceRequest","id":"1734642835856905334.d69097cc-ddb8-4325-81ac-035da095ab9d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835853121328.727d467d-c905-4b9c-8b44-1793d96ac519"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835845159438.0eaaaebc-2a26-46d2-a882-514961b42ee8"}}},{"fullUrl":"Practitioner/1734642835845159438.0eaaaebc-2a26-46d2-a882-514961b42ee8","resource":{"resourceType":"Practitioner","id":"1734642835845159438.0eaaaebc-2a26-46d2-a882-514961b42ee8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835853121328.727d467d-c905-4b9c-8b44-1793d96ac519","resource":{"resourceType":"Practitioner","id":"1734642835853121328.727d467d-c905-4b9c-8b44-1793d96ac519","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835871903457.f692a2e9-0b4d-43f0-8261-6bb812d74c1e","resource":{"resourceType":"ServiceRequest","id":"1734642835871903457.f692a2e9-0b4d-43f0-8261-6bb812d74c1e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835868153395.357d31c1-7cad-49ad-9231-25b2176c0546"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835860189612.029a5eec-500a-4552-92dd-7cebdd88fac4"}}},{"fullUrl":"Practitioner/1734642835860189612.029a5eec-500a-4552-92dd-7cebdd88fac4","resource":{"resourceType":"Practitioner","id":"1734642835860189612.029a5eec-500a-4552-92dd-7cebdd88fac4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835868153395.357d31c1-7cad-49ad-9231-25b2176c0546","resource":{"resourceType":"Practitioner","id":"1734642835868153395.357d31c1-7cad-49ad-9231-25b2176c0546","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835886888697.bf61c1b6-56cb-4670-9961-282b6c0f1ebc","resource":{"resourceType":"ServiceRequest","id":"1734642835886888697.bf61c1b6-56cb-4670-9961-282b6c0f1ebc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835883141030.5e511835-9b9c-47ed-94b1-da258656b6f6"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835875151929.97554f88-41fc-48cd-a4e1-01fded4cc6db"}}},{"fullUrl":"Practitioner/1734642835875151929.97554f88-41fc-48cd-a4e1-01fded4cc6db","resource":{"resourceType":"Practitioner","id":"1734642835875151929.97554f88-41fc-48cd-a4e1-01fded4cc6db","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835883141030.5e511835-9b9c-47ed-94b1-da258656b6f6","resource":{"resourceType":"Practitioner","id":"1734642835883141030.5e511835-9b9c-47ed-94b1-da258656b6f6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835902087947.b0625fb0-fc20-4f6c-8cc1-5b44f0187465","resource":{"resourceType":"ServiceRequest","id":"1734642835902087947.b0625fb0-fc20-4f6c-8cc1-5b44f0187465","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835898322577.a6e3a5e0-51e1-44cd-bb54-b4dccad0e3af"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835890164049.14517987-51a5-4b7e-bf77-7e0f5edb53bc"}}},{"fullUrl":"Practitioner/1734642835890164049.14517987-51a5-4b7e-bf77-7e0f5edb53bc","resource":{"resourceType":"Practitioner","id":"1734642835890164049.14517987-51a5-4b7e-bf77-7e0f5edb53bc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835898322577.a6e3a5e0-51e1-44cd-bb54-b4dccad0e3af","resource":{"resourceType":"Practitioner","id":"1734642835898322577.a6e3a5e0-51e1-44cd-bb54-b4dccad0e3af","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835917149069.983f6ce8-159b-45c8-954c-4075b17846af","resource":{"resourceType":"ServiceRequest","id":"1734642835917149069.983f6ce8-159b-45c8-954c-4075b17846af","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835913394629.4475d2a0-1c9c-4795-bf45-41f99db27435"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835905413754.40878ea9-622b-4a63-8e5f-91d421722b4b"}}},{"fullUrl":"Practitioner/1734642835905413754.40878ea9-622b-4a63-8e5f-91d421722b4b","resource":{"resourceType":"Practitioner","id":"1734642835905413754.40878ea9-622b-4a63-8e5f-91d421722b4b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835913394629.4475d2a0-1c9c-4795-bf45-41f99db27435","resource":{"resourceType":"Practitioner","id":"1734642835913394629.4475d2a0-1c9c-4795-bf45-41f99db27435","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835935979239.0e176d4b-30d3-4137-ae0f-9c51656f66c3","resource":{"resourceType":"ServiceRequest","id":"1734642835935979239.0e176d4b-30d3-4137-ae0f-9c51656f66c3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835928339133.024dd940-afd0-41a8-ac6a-8b48e90e7c6d"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835920398884.71f8c3a4-43ee-45cf-9c10-2c35f0e88a5a"}}},{"fullUrl":"Practitioner/1734642835920398884.71f8c3a4-43ee-45cf-9c10-2c35f0e88a5a","resource":{"resourceType":"Practitioner","id":"1734642835920398884.71f8c3a4-43ee-45cf-9c10-2c35f0e88a5a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835928339133.024dd940-afd0-41a8-ac6a-8b48e90e7c6d","resource":{"resourceType":"Practitioner","id":"1734642835928339133.024dd940-afd0-41a8-ac6a-8b48e90e7c6d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835945974251.f0fcd4a8-98bd-4ab4-a492-4645926f24a9","resource":{"resourceType":"ServiceRequest","id":"1734642835945974251.f0fcd4a8-98bd-4ab4-a492-4645926f24a9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835943667846.3e58aab2-4f40-4a4c-b536-53e5c6eb2716"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835938155119.95c97502-5105-497e-ae06-b5801a28627a"}}},{"fullUrl":"Practitioner/1734642835938155119.95c97502-5105-497e-ae06-b5801a28627a","resource":{"resourceType":"Practitioner","id":"1734642835938155119.95c97502-5105-497e-ae06-b5801a28627a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835943667846.3e58aab2-4f40-4a4c-b536-53e5c6eb2716","resource":{"resourceType":"Practitioner","id":"1734642835943667846.3e58aab2-4f40-4a4c-b536-53e5c6eb2716","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835956530516.5b286178-75c7-4255-af1a-49caed4c0082","resource":{"resourceType":"ServiceRequest","id":"1734642835956530516.5b286178-75c7-4255-af1a-49caed4c0082","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835953823169.965e7b1a-871f-451a-a743-8dc7fdf41546"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835948359714.2f445301-5d6c-424c-b2e8-4b273f9dff14"}}},{"fullUrl":"Practitioner/1734642835948359714.2f445301-5d6c-424c-b2e8-4b273f9dff14","resource":{"resourceType":"Practitioner","id":"1734642835948359714.2f445301-5d6c-424c-b2e8-4b273f9dff14","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835953823169.965e7b1a-871f-451a-a743-8dc7fdf41546","resource":{"resourceType":"Practitioner","id":"1734642835953823169.965e7b1a-871f-451a-a743-8dc7fdf41546","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835967140120.6f8af5b3-2a92-469c-adc3-17c5c75716ec","resource":{"resourceType":"ServiceRequest","id":"1734642835967140120.6f8af5b3-2a92-469c-adc3-17c5c75716ec","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835964594817.35a35840-0638-45cb-8ced-73a9792ed258"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835958679495.28aef4a9-84c2-4b3b-94b7-1df1c44749e7"}}},{"fullUrl":"Practitioner/1734642835958679495.28aef4a9-84c2-4b3b-94b7-1df1c44749e7","resource":{"resourceType":"Practitioner","id":"1734642835958679495.28aef4a9-84c2-4b3b-94b7-1df1c44749e7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835964594817.35a35840-0638-45cb-8ced-73a9792ed258","resource":{"resourceType":"Practitioner","id":"1734642835964594817.35a35840-0638-45cb-8ced-73a9792ed258","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835976875515.47645843-2e02-492b-9fa9-10754e5c2eb7","resource":{"resourceType":"ServiceRequest","id":"1734642835976875515.47645843-2e02-492b-9fa9-10754e5c2eb7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835974516742.4222fb2e-821d-4cb1-926f-d8818ff7303d"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835969309959.d700e30e-201a-46b1-a3b0-78ac9fb77dcc"}}},{"fullUrl":"Practitioner/1734642835969309959.d700e30e-201a-46b1-a3b0-78ac9fb77dcc","resource":{"resourceType":"Practitioner","id":"1734642835969309959.d700e30e-201a-46b1-a3b0-78ac9fb77dcc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835974516742.4222fb2e-821d-4cb1-926f-d8818ff7303d","resource":{"resourceType":"Practitioner","id":"1734642835974516742.4222fb2e-821d-4cb1-926f-d8818ff7303d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835986825753.63e23dac-6951-4d16-a6f2-49a37c9a7522","resource":{"resourceType":"ServiceRequest","id":"1734642835986825753.63e23dac-6951-4d16-a6f2-49a37c9a7522","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835984485856.73d96fb8-7c48-4a39-b379-b190f985de60"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835978906253.e9fcd886-885d-4cf2-ba6d-69b36433490c"}}},{"fullUrl":"Practitioner/1734642835978906253.e9fcd886-885d-4cf2-ba6d-69b36433490c","resource":{"resourceType":"Practitioner","id":"1734642835978906253.e9fcd886-885d-4cf2-ba6d-69b36433490c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835984485856.73d96fb8-7c48-4a39-b379-b190f985de60","resource":{"resourceType":"Practitioner","id":"1734642835984485856.73d96fb8-7c48-4a39-b379-b190f985de60","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835996319585.669af306-0630-4ff5-9f86-971447486fa6","resource":{"resourceType":"ServiceRequest","id":"1734642835996319585.669af306-0630-4ff5-9f86-971447486fa6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835993929083.6c57cd61-3f84-4ffe-bd44-8365a5949a9e"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835988842745.3028ecc4-9c8b-4c25-80ff-2014e0eeed42"}}},{"fullUrl":"Practitioner/1734642835988842745.3028ecc4-9c8b-4c25-80ff-2014e0eeed42","resource":{"resourceType":"Practitioner","id":"1734642835988842745.3028ecc4-9c8b-4c25-80ff-2014e0eeed42","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835993929083.6c57cd61-3f84-4ffe-bd44-8365a5949a9e","resource":{"resourceType":"Practitioner","id":"1734642835993929083.6c57cd61-3f84-4ffe-bd44-8365a5949a9e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642836005661413.d54c6c0c-8086-4727-86a2-522b3ef8c450","resource":{"resourceType":"ServiceRequest","id":"1734642836005661413.d54c6c0c-8086-4727-86a2-522b3ef8c450","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836003447832.2320155b-39f7-42a4-81a8-dcab7529592a"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835998320718.83677cf7-aae8-40ed-a246-20477c5263c4"}}},{"fullUrl":"Practitioner/1734642835998320718.83677cf7-aae8-40ed-a246-20477c5263c4","resource":{"resourceType":"Practitioner","id":"1734642835998320718.83677cf7-aae8-40ed-a246-20477c5263c4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642836003447832.2320155b-39f7-42a4-81a8-dcab7529592a","resource":{"resourceType":"Practitioner","id":"1734642836003447832.2320155b-39f7-42a4-81a8-dcab7529592a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642836014302315.5f8956d2-cbdd-41a3-9601-c395d272df5f","resource":{"resourceType":"ServiceRequest","id":"1734642836014302315.5f8956d2-cbdd-41a3-9601-c395d272df5f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836012042027.611dd36e-ef7f-4fa7-a4d1-2b19a392bd38"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642836007489039.74b2ce63-be2e-40a1-8dea-1a0a6dd58476"}}},{"fullUrl":"Practitioner/1734642836007489039.74b2ce63-be2e-40a1-8dea-1a0a6dd58476","resource":{"resourceType":"Practitioner","id":"1734642836007489039.74b2ce63-be2e-40a1-8dea-1a0a6dd58476","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642836012042027.611dd36e-ef7f-4fa7-a4d1-2b19a392bd38","resource":{"resourceType":"Practitioner","id":"1734642836012042027.611dd36e-ef7f-4fa7-a4d1-2b19a392bd38","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"DiagnosticReport/1734642836025400305.ff8ac839-62e2-4ae6-b38b-17f6d262661b","resource":{"resourceType":"DiagnosticReport","id":"1734642836025400305.ff8ac839-62e2-4ae6-b38b-17f6d262661b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"56352742"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"56352742"}],"basedOn":[{"reference":"ServiceRequest/1734642835744401522.4ff3345c-4a6d-4397-937b-68ba4e55bd8d"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835679809963.f5140095-69f3-4915-8100-62ebb73a9266"}]}},{"fullUrl":"DiagnosticReport/1734642836029429390.99b9f76a-d712-4a1f-95b8-eaaf390269fb","resource":{"resourceType":"DiagnosticReport","id":"1734642836029429390.99b9f76a-d712-4a1f-95b8-eaaf390269fb","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835758992222.2d75840b-e8b8-43c6-a69b-658b37b1361d"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835682132849.c285fe9e-9eef-41c1-b376-4a15512e5477"}],"result":[{"reference":"Observation/1734642835331267826.63d36999-ad9d-43cf-9ffa-431a0c8a7bcd"},{"reference":"Observation/1734642835333569772.67e5a931-dbac-42f7-a4ca-96331001f5f4"},{"reference":"Observation/1734642835335722138.55faa56e-a228-4fc8-9165-8fdb9382e0a8"},{"reference":"Observation/1734642835337835952.0dad2f6c-eeff-4faf-b63a-a4ba5359a979"},{"reference":"Observation/1734642835339907126.8d052379-b998-403b-919e-aa04ce7ae698"},{"reference":"Observation/1734642835341768095.0c6fdcb8-2039-49cf-a9fa-6aec62df3cec"},{"reference":"Observation/1734642835343782833.af96a85a-767c-43b2-a5a5-04b73664c52f"}]}},{"fullUrl":"DiagnosticReport/1734642836033347527.1423054d-d094-4b59-8fc6-e0e29bce16a4","resource":{"resourceType":"DiagnosticReport","id":"1734642836033347527.1423054d-d094-4b59-8fc6-e0e29bce16a4","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835770650794.bfe29259-c5d9-4f16-8ff4-d699d646ee90"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835683649694.81529006-d9a6-478d-a042-55c556f93b39"}],"result":[{"reference":"Observation/1734642835345802340.93550bd0-515e-43fa-98c0-63214b549372"},{"reference":"Observation/1734642835347854718.6a359b63-1a34-486f-92d9-8b593a70c860"},{"reference":"Observation/1734642835349807480.c7fb14b4-52bc-4f8c-b9da-7d38cd79c9b3"},{"reference":"Observation/1734642835352502855.5ff149e3-c3ed-4661-9784-9023409e0447"},{"reference":"Observation/1734642835354586642.1df6ef52-e9b7-4e39-b895-fdf2e3437402"},{"reference":"Observation/1734642835356828696.da821f16-8972-442a-8568-f322e8e1b276"},{"reference":"Observation/1734642835358990570.b7f0e174-0d5e-4b85-8176-587efa704cd9"},{"reference":"Observation/1734642835361225290.cc0bd769-7b35-4d29-9b2a-1ed6d1254fc4"},{"reference":"Observation/1734642835363248454.779ba7a1-c24e-4a37-abef-4f67466b41dd"},{"reference":"Observation/1734642835365113972.4533c579-f036-4a40-9093-a24ab85924c5"},{"reference":"Observation/1734642835366924928.1e0adb94-c06a-4c3e-bcb6-ebabf903b26f"}]}},{"fullUrl":"DiagnosticReport/1734642836036509076.18aca8a2-26f1-44f3-bc02-74fc6bb9b34f","resource":{"resourceType":"DiagnosticReport","id":"1734642836036509076.18aca8a2-26f1-44f3-bc02-74fc6bb9b34f","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835780546470.eb10fd70-3fc5-451f-af4a-77763961365b"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835685112005.62776300-71ef-4753-9775-632dbd20fa5a"}]}},{"fullUrl":"DiagnosticReport/1734642836041210852.69c341cb-2144-4f74-b624-c2a7731fa718","resource":{"resourceType":"DiagnosticReport","id":"1734642836041210852.69c341cb-2144-4f74-b624-c2a7731fa718","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835791834676.ec7b25fd-682f-4cb7-adbb-ca082237c515"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835687040031.041f7ffc-da54-46c9-8d11-aa5f8de30bb0"}],"result":[{"reference":"Observation/1734642835369659566.fe38b667-7f7e-4c1e-8612-5c5ff058fc43"},{"reference":"Observation/1734642835376452073.9eff88cf-d334-4da6-8a4b-d79cec24a6fa"},{"reference":"Observation/1734642835378662407.bcab4c6b-5ba4-44e0-bdd5-c937fd3bde84"},{"reference":"Observation/1734642835380826375.6b8edc0e-b24d-4395-a601-ea26b581cfa9"},{"reference":"Observation/1734642835382952452.6f507334-0883-4174-ac7a-0ddb0f4df61a"},{"reference":"Observation/1734642835385214764.c131d587-e5ac-4f53-94f1-3399562a8db5"},{"reference":"Observation/1734642835387460395.cda75646-4eda-4b32-b680-9456e40f562a"},{"reference":"Observation/1734642835389634321.501179b2-c30a-4843-9418-40b2497aad2f"},{"reference":"Observation/1734642835391828446.5f433876-3f87-45ec-9b16-1e452a6afe53"},{"reference":"Observation/1734642835394016309.da7611a9-ab4b-48c4-b7e3-81e3988dc810"},{"reference":"Observation/1734642835396791673.56b08f59-5641-492c-8cb3-9607afdacb01"},{"reference":"Observation/1734642835399100622.0b4cd402-06ef-4639-be95-30310ae78277"},{"reference":"Observation/1734642835401273266.7ec959c0-e661-4977-9ada-564e016aa547"},{"reference":"Observation/1734642835403495854.208ba995-f62a-4a32-92ca-6dbd84e7b5bd"},{"reference":"Observation/1734642835405656826.a6f91d96-0e3a-47ac-8507-ba955e7a55ef"},{"reference":"Observation/1734642835407744861.6c1d97ff-8566-4b14-839f-453d75dd411e"},{"reference":"Observation/1734642835409895063.1deb4048-6a8b-4531-bad0-47b7a192abda"},{"reference":"Observation/1734642835412122400.c7ff92a9-a371-4bf3-9ca3-8a0e51a7e406"},{"reference":"Observation/1734642835414367069.ff02d7b5-fca3-4e42-b46e-e94db9935f98"}]}},{"fullUrl":"DiagnosticReport/1734642836044537029.4107a300-c273-45d1-b36a-e5144b0c649b","resource":{"resourceType":"DiagnosticReport","id":"1734642836044537029.4107a300-c273-45d1-b36a-e5144b0c649b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835802084907.25541256-2203-4b6a-8fc2-45c8c95543af"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835689202095.cd50a654-b526-4981-9f5b-699bc6abb850"}],"result":[{"reference":"Observation/1734642835416488106.e6efc8d9-7149-41bd-b70d-bdd588f1a3dc"},{"reference":"Observation/1734642835418374644.b2a9a7f8-8b31-4790-bbaa-f828b2f86648"}]}},{"fullUrl":"DiagnosticReport/1734642836049712354.70273afb-c29e-474d-9e06-a1e28f33aee1","resource":{"resourceType":"DiagnosticReport","id":"1734642836049712354.70273afb-c29e-474d-9e06-a1e28f33aee1","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835812909625.81dd7562-bd3f-4733-9512-08a1f914da1d"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835694345079.5c984bb7-fe34-47af-ba5e-5138ffb45e35"}],"result":[{"reference":"Observation/1734642835422795583.e7b35f09-9dd7-4c76-8415-0d43dc7651dc"},{"reference":"Observation/1734642835424973167.286f68ed-7f9b-4388-a6cf-85a5266b7fcb"},{"reference":"Observation/1734642835427208008.74ac2dd1-eef7-4003-a69d-8252054806cb"},{"reference":"Observation/1734642835429434974.1dcdd144-4454-412a-80aa-0e2d822921c4"},{"reference":"Observation/1734642835431520845.08387875-2ad2-4e96-a056-0e34ae30f471"},{"reference":"Observation/1734642835433743443.c53a57f5-0822-45fb-b4a8-f0ccd4a7bc43"},{"reference":"Observation/1734642835435894226.465ab60c-9c58-45f3-b8bd-448bda9fafc0"},{"reference":"Observation/1734642835438030121.798cec3a-39a7-4add-b2fd-847a0238d54c"},{"reference":"Observation/1734642835440167228.f45fe5ba-f30c-49ed-86c3-39fa00ef4e7d"},{"reference":"Observation/1734642835442258119.9003abd4-9d1d-481f-a07b-1e409d499168"},{"reference":"Observation/1734642835444529488.f90faf32-693d-4e1e-8df9-9e18290745c9"},{"reference":"Observation/1734642835446685501.4fa52a50-3582-4d5f-9f50-ae6aca56bdd4"},{"reference":"Observation/1734642835448821927.1398ab29-7539-4321-a08a-4dbf80dc6fb0"},{"reference":"Observation/1734642835450906846.7168f890-107b-4837-81db-05146c6b2caf"},{"reference":"Observation/1734642835453132480.cfc11d29-4916-4cdc-bc71-aee747d8575b"},{"reference":"Observation/1734642835455753585.0c52c249-a902-49f0-8e21-58ba3bf9a0d6"},{"reference":"Observation/1734642835459017886.d4ffc9e5-bfac-41f8-98f0-5d97534dbc20"},{"reference":"Observation/1734642835461170162.a43d16ce-f5f1-4263-b61d-40a0018a85fd"},{"reference":"Observation/1734642835463250262.fc8c2a06-45f0-4658-a1d3-f8894e36e642"},{"reference":"Observation/1734642835465381198.e355d29a-924c-42d3-adf4-d29641f95d65"},{"reference":"Observation/1734642835470144200.4b1f1f59-8fd5-4f3e-8c17-bfaeba9912cc"},{"reference":"Observation/1734642835473769838.73b4900a-ada8-4e69-9cc2-d8ad5d147216"},{"reference":"Observation/1734642835477324013.976eb27c-3e86-4575-82d2-42090c14cd5e"},{"reference":"Observation/1734642835480981371.997509cf-1496-49ce-ae6a-2ab2e210872b"},{"reference":"Observation/1734642835484502183.03382ac4-4554-4bd4-a473-b1552aa30d97"},{"reference":"Observation/1734642835488159871.630b3407-29cc-4479-8ca0-6992bbf11d47"}]}},{"fullUrl":"DiagnosticReport/1734642836053923019.128e29de-5e06-4ea9-a20d-420ac9b6c954","resource":{"resourceType":"DiagnosticReport","id":"1734642836053923019.128e29de-5e06-4ea9-a20d-420ac9b6c954","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835826844004.93e7de95-250e-42ad-962c-5fb6f91a6211"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835695888844.b9c265b2-7ecc-4fa6-8b6b-fdc320dec738"}],"result":[{"reference":"Observation/1734642835491985485.ba51db78-903c-45eb-b9e5-c53ee7b3f2e1"},{"reference":"Observation/1734642835495570166.99fb27f1-e14d-4142-944b-289d1c3241da"},{"reference":"Observation/1734642835498092857.6bb59139-99b0-4b5d-97c8-ffb14263f781"},{"reference":"Observation/1734642835500703182.d5ab4f82-7c5b-4c26-bbbc-7dea218979e2"},{"reference":"Observation/1734642835502895012.d0ae8710-cbea-421e-b94a-53d6e14cd248"},{"reference":"Observation/1734642835505066664.c4809f26-012b-428d-a228-deb3c1c71f6a"},{"reference":"Observation/1734642835507175288.62b29fe7-f047-423f-96b8-613605f1bf43"},{"reference":"Observation/1734642835509285776.6da4db8a-be6a-423f-b00d-e770d332b912"},{"reference":"Observation/1734642835511368501.d417dea6-d6bc-4ccf-89e3-0111ca38a324"},{"reference":"Observation/1734642835513513543.70b62c82-fb4b-46aa-bbce-dd43197a4c40"}]}},{"fullUrl":"DiagnosticReport/1734642836057537897.2271a1ac-7b0b-4b5a-9134-9d0b11c1aa8e","resource":{"resourceType":"DiagnosticReport","id":"1734642836057537897.2271a1ac-7b0b-4b5a-9134-9d0b11c1aa8e","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835841901599.3275048a-bc6c-4092-b850-d38de0ed3651"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835698178878.c6f061fd-6eae-4ca5-8607-5247f471f7ae"}],"result":[{"reference":"Observation/1734642835515664627.e7d0dad1-5bbd-46c8-bd9e-6a3c2a0cc749"},{"reference":"Observation/1734642835517993935.17ec6b98-cacb-4027-820f-4d6998024af3"},{"reference":"Observation/1734642835520573001.3c493ebc-ba0f-4b33-aa6b-24b510ca4ff6"}]}},{"fullUrl":"DiagnosticReport/1734642836060854116.26790db7-6d6b-4e42-8239-08c7ef372775","resource":{"resourceType":"DiagnosticReport","id":"1734642836060854116.26790db7-6d6b-4e42-8239-08c7ef372775","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835856905334.d69097cc-ddb8-4325-81ac-035da095ab9d"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835700470095.490fe88c-9d7f-48ac-8a2e-de34c0a0122c"}],"result":[{"reference":"Observation/1734642835525904147.1a80681b-c906-4966-937b-e53f0becb2f1"},{"reference":"Observation/1734642835529512403.bf5ed02a-3c6c-4860-8ca7-7ea37fc1ffeb"},{"reference":"Observation/1734642835532521065.ed84de32-d45a-4b1a-a413-535cb2895ee9"}]}},{"fullUrl":"DiagnosticReport/1734642836064630176.92f10d06-cc28-4cb3-9d32-f4aa43dec35b","resource":{"resourceType":"DiagnosticReport","id":"1734642836064630176.92f10d06-cc28-4cb3-9d32-f4aa43dec35b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835871903457.f692a2e9-0b4d-43f0-8261-6bb812d74c1e"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835702449075.1d1f430f-765e-4097-9fd9-b98c8afe02cb"}],"result":[{"reference":"Observation/1734642835535876457.d760f87e-fc5d-4be1-a52f-66f60a2ae7bd"},{"reference":"Observation/1734642835539823078.8f08b768-25fc-45d6-aa00-7d0ac78f7680"},{"reference":"Observation/1734642835543024561.82b80bcb-0246-4912-8e2d-d887306f7321"}]}},{"fullUrl":"DiagnosticReport/1734642836067816571.2149d1a2-417a-4bce-9c2d-a8b96c1a4ce6","resource":{"resourceType":"DiagnosticReport","id":"1734642836067816571.2149d1a2-417a-4bce-9c2d-a8b96c1a4ce6","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835886888697.bf61c1b6-56cb-4670-9961-282b6c0f1ebc"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835704119568.b958bb18-491b-4ee7-9425-30bd73b53543"}],"result":[{"reference":"Observation/1734642835546355467.83b3714a-1a87-4ac9-8f99-08878e0fd16a"},{"reference":"Observation/1734642835549893211.25dd6d46-74e7-4235-ab79-9d8105fa0a00"},{"reference":"Observation/1734642835552869902.ac846058-f0a0-4699-97d2-519dca5cade1"}]}},{"fullUrl":"DiagnosticReport/1734642836070885045.9cd3f0af-e328-4e84-bac9-f37614924bad","resource":{"resourceType":"DiagnosticReport","id":"1734642836070885045.9cd3f0af-e328-4e84-bac9-f37614924bad","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835902087947.b0625fb0-fc20-4f6c-8cc1-5b44f0187465"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835705624961.bc2cfb73-382d-4917-a2fb-649f48c96d17"}],"result":[{"reference":"Observation/1734642835555821888.61e203d3-2b7d-430f-bf57-c9f70a3ec4fc"},{"reference":"Observation/1734642835558423075.0fb66141-985a-471c-84ea-0e2507b24dee"}]}},{"fullUrl":"DiagnosticReport/1734642836074795647.998e19fd-ef20-48fc-9ffd-dda2719ea5f2","resource":{"resourceType":"DiagnosticReport","id":"1734642836074795647.998e19fd-ef20-48fc-9ffd-dda2719ea5f2","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835917149069.983f6ce8-159b-45c8-954c-4075b17846af"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835707157845.4fe80b95-b4f1-4845-bca1-c066dd61b6d9"}],"result":[{"reference":"Observation/1734642835561468346.fa1af592-bc70-4f22-a292-dbf8a4ea9fe3"},{"reference":"Observation/1734642835564990210.aba2c5e6-f906-465b-9b58-d2a3f6f29dd1"},{"reference":"Observation/1734642835567985496.fa5f27bf-a0a5-4d52-b4b1-1bf218ce6db4"}]}},{"fullUrl":"DiagnosticReport/1734642836079087485.3ab655bd-01db-4c70-9e4b-ce057a3dc21f","resource":{"resourceType":"DiagnosticReport","id":"1734642836079087485.3ab655bd-01db-4c70-9e4b-ce057a3dc21f","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835935979239.0e176d4b-30d3-4137-ae0f-9c51656f66c3"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835708612232.ac4f7578-f103-41a7-b573-007e4db7765b"}],"result":[{"reference":"Observation/1734642835571309800.12adfa77-1e2f-48d4-88b8-d20a75429f23"},{"reference":"Observation/1734642835574850148.21ea8318-4e72-436c-b8fa-e1fd75a19efb"},{"reference":"Observation/1734642835581069972.c10bcd96-4829-4e95-a1d9-66376f5d3d45"}]}},{"fullUrl":"DiagnosticReport/1734642836082360703.e108bbfb-c300-4c64-bcfb-33611923f8d2","resource":{"resourceType":"DiagnosticReport","id":"1734642836082360703.e108bbfb-c300-4c64-bcfb-33611923f8d2","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835945974251.f0fcd4a8-98bd-4ab4-a492-4645926f24a9"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835710510722.fc135623-a3f3-43e6-b605-5beba9342283"}],"result":[{"reference":"Observation/1734642835584576026.aabbb953-5488-4b30-8acc-41bf00db6120"},{"reference":"Observation/1734642835588092480.08525370-2227-4b69-826d-d9e4032ee0af"},{"reference":"Observation/1734642835591074051.eb0d4858-a135-4a49-9d69-38d256936bb8"}]}},{"fullUrl":"DiagnosticReport/1734642836085564821.5f0e8445-cccc-45a2-9363-029a6c67b1bb","resource":{"resourceType":"DiagnosticReport","id":"1734642836085564821.5f0e8445-cccc-45a2-9363-029a6c67b1bb","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835956530516.5b286178-75c7-4255-af1a-49caed4c0082"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835712141821.51833386-6ce0-4b71-b0e4-8d2cf7ee8c86"}],"result":[{"reference":"Observation/1734642835594442237.a15194f2-60a6-4498-b5dc-87aca0c61a66"},{"reference":"Observation/1734642835597959462.0cdecaae-6f8b-441d-9c80-85c40bef0dae"},{"reference":"Observation/1734642835600988341.dc2afa30-6326-48a0-9e3b-28c2aeb08706"}]}},{"fullUrl":"DiagnosticReport/1734642836089224263.c80abe0a-b8cf-4063-9caf-122710a02b4f","resource":{"resourceType":"DiagnosticReport","id":"1734642836089224263.c80abe0a-b8cf-4063-9caf-122710a02b4f","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835967140120.6f8af5b3-2a92-469c-adc3-17c5c75716ec"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835713518763.82aafad2-810d-4c77-a953-975e9b2dfde4"}],"result":[{"reference":"Observation/1734642835604036297.40339a51-8dac-4737-809a-539504353d80"},{"reference":"Observation/1734642835607529266.a4125cf0-de2a-4085-b6de-c410a2215b1f"},{"reference":"Observation/1734642835610542657.f1aef249-54da-4464-97f9-c3fb9ba09a9d"}]}},{"fullUrl":"DiagnosticReport/1734642836092450482.c935b20d-f405-4093-acd7-23d13d02c9d0","resource":{"resourceType":"DiagnosticReport","id":"1734642836092450482.c935b20d-f405-4093-acd7-23d13d02c9d0","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835976875515.47645843-2e02-492b-9fa9-10754e5c2eb7"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835715545523.cab4abb0-08dd-41fc-b108-d8df145f1ba1"}],"result":[{"reference":"Observation/1734642835613935850.7dd54161-8b91-4713-9880-097a8d61b409"},{"reference":"Observation/1734642835617486398.92be0ee0-3ee7-466e-99d6-b61c7e3e5a37"},{"reference":"Observation/1734642835620525837.cc26ef54-3f3a-47b8-9a7b-047d46f3348b"}]}},{"fullUrl":"DiagnosticReport/1734642836095781419.9d3f4ff9-f268-408b-a3c9-a9f1563ddd34","resource":{"resourceType":"DiagnosticReport","id":"1734642836095781419.9d3f4ff9-f268-408b-a3c9-a9f1563ddd34","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835986825753.63e23dac-6951-4d16-a6f2-49a37c9a7522"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835718057894.457e17fc-100b-49f5-bb92-b4c9acf25c85"}],"result":[{"reference":"Observation/1734642835623921985.3e0baca9-bd03-4ed1-8b08-89ba31cab5dd"},{"reference":"Observation/1734642835630419291.12c4f657-9182-4881-8c31-27b06e3c48c7"}]}},{"fullUrl":"DiagnosticReport/1734642836100016380.06b8079b-3e66-4d76-ba1e-540869bad33a","resource":{"resourceType":"DiagnosticReport","id":"1734642836100016380.06b8079b-3e66-4d76-ba1e-540869bad33a","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835996319585.669af306-0630-4ff5-9f86-971447486fa6"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835719713849.d97d4078-fa35-46c5-b71a-983c6c316188"}],"result":[{"reference":"Observation/1734642835633807975.46e97221-a624-4e5e-8859-ff611e85da90"},{"reference":"Observation/1734642835637364704.cfb11c03-e2c7-43f7-8cc9-859c933f8b62"},{"reference":"Observation/1734642835649022763.3c31dc08-0d4e-4e81-a1c4-d249999d5869"}]}},{"fullUrl":"DiagnosticReport/1734642836103489783.54433dc4-1532-463c-a3fd-9db074b3439c","resource":{"resourceType":"DiagnosticReport","id":"1734642836103489783.54433dc4-1532-463c-a3fd-9db074b3439c","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642836005661413.d54c6c0c-8086-4727-86a2-522b3ef8c450"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835721296777.e0bd5141-acd6-4b4a-ba77-e92176956627"}],"result":[{"reference":"Observation/1734642835653194486.57e9dd23-af1b-46e0-99a7-bc5a2461a5e5"},{"reference":"Observation/1734642835656742329.2b81d4e2-b30a-4c26-a562-c55c8d886d39"}]}},{"fullUrl":"DiagnosticReport/1734642836111794034.e7245026-8c48-44c6-b07c-7d0df43be6d1","resource":{"resourceType":"DiagnosticReport","id":"1734642836111794034.e7245026-8c48-44c6-b07c-7d0df43be6d1","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642836014302315.5f8956d2-cbdd-41a3-9601-c395d272df5f"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835722645206.a1858c19-14c2-4fef-9cc4-db5e31b7e834"}],"result":[{"reference":"Observation/1734642835660757468.12a8eb98-e6e0-4f4d-9bf4-afeeb9525a95"}]}}]}
diff --git a/examples/Test/GoldenCopy/Expected/004_ORU_R01_golden_copy_expected_in_range.fhir b/examples/Test/GoldenCopy/Expected/004_ORU_R01_golden_copy_expected_in_range.fhir
new file mode 100644
index 000000000..e548ef905
--- /dev/null
+++ b/examples/Test/GoldenCopy/Expected/004_ORU_R01_golden_copy_expected_in_range.fhir
@@ -0,0 +1 @@
+{"resourceType":"Bundle","id":"1734642835566629290.f0527f75-7aea-4894-97d4-65cf43c71557","meta":{"lastUpdated":"2024-12-19T21:13:55.566+00:00"},"identifier":{"system":"https://reportstream.cdc.gov/prime-router","value":"004"},"type":"message","timestamp":"2024-10-30T05:01:54.000+00:00","entry":[{"fullUrl":"MessageHeader/1734642835567650716.7cd1e404-3141-43cf-a56f-fb6f63cef3a4","resource":{"resourceType":"MessageHeader","id":"1734642835567650716.7cd1e404-3141-43cf-a56f-fb6f63cef3a4","meta":{"tag":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0103","code":"N"}]},"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/msh-message-header","extension":[{"url":"MSH.7","valueString":"20241030050154"}]}],"eventCoding":{"system":"http://terminology.hl7.org/CodeSystem/v2-0003","code":"R01","display":"ORU^R01^ORU_R01"},"destination":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id","valueString":"11903029"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id-type","valueString":"L,M,N"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.5"}],"name":"SISHIERECEIVER","receiver":{"reference":"Organization/1734642835567400025.e6925cd4-97a8-4a1d-a8f8-a71dc567bcdd"}}],"sender":{"reference":"Organization/1734642835566920526.a0211f38-04d7-42df-9a1a-4777110a8bd2"},"source":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"SISGDSP"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.3"}],"name":"SISGDSP","_endpoint":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}}},{"fullUrl":"Organization/1734642835566920526.a0211f38-04d7-42df-9a1a-4777110a8bd2","resource":{"resourceType":"Organization","id":"1734642835566920526.a0211f38-04d7-42df-9a1a-4777110a8bd2","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Organization/1734642835567400025.e6925cd4-97a8-4a1d-a8f8-a71dc567bcdd","resource":{"resourceType":"Organization","id":"1734642835567400025.e6925cd4-97a8-4a1d-a8f8-a71dc567bcdd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.6"}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.2,HD.3"}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301","code":"L,M,N"}]},"value":"automated-staging-test-receiver-id"}]}},{"fullUrl":"Provenance/1734642835568915377.56011851-fd12-4de0-a6bb-57f2199ddb44","resource":{"resourceType":"Provenance","id":"1734642835568915377.56011851-fd12-4de0-a6bb-57f2199ddb44","target":[{"reference":"MessageHeader/1734642835567650716.7cd1e404-3141-43cf-a56f-fb6f63cef3a4"},{"reference":"DiagnosticReport/1734642836152439978.c27b00f3-e85a-4103-a989-e69a6c752aa0"},{"reference":"DiagnosticReport/1734642836155870350.f904bf10-c9bb-461c-a2fb-670399604fd6"},{"reference":"DiagnosticReport/1734642836159725770.57b4f680-c5b0-4705-85dd-f6f743270117"},{"reference":"DiagnosticReport/1734642836163296335.30331610-9333-48d7-aced-405f3bbc49b3"},{"reference":"DiagnosticReport/1734642836170026284.eac8ce49-4557-408b-b25c-603aafd0fbc6"},{"reference":"DiagnosticReport/1734642836174794145.4b4522ad-a76c-40a1-b33f-e956981336b3"},{"reference":"DiagnosticReport/1734642836181665440.cf879ec4-f8ad-4f96-a9af-c27df992d494"},{"reference":"DiagnosticReport/1734642836185431782.2ccfdb9d-6d9f-4b94-b827-a9430b5275bc"},{"reference":"DiagnosticReport/1734642836188456093.6b6e2444-1cb6-4e00-bd3a-aed46f112a17"},{"reference":"DiagnosticReport/1734642836191457080.1b9335a6-456e-4b5a-b8fa-c0246b1b35f5"},{"reference":"DiagnosticReport/1734642836195354398.dfe86879-7556-4767-8397-31a3feac8176"},{"reference":"DiagnosticReport/1734642836198703929.4c2049ad-8f8e-4639-948d-4ca1db4e92e4"},{"reference":"DiagnosticReport/1734642836201721948.3960cf5c-983f-4859-9e35-8c3ac6cd0fe4"},{"reference":"DiagnosticReport/1734642836204801984.350c0e54-ac24-4e7f-838f-71b69a75dd67"},{"reference":"DiagnosticReport/1734642836208398798.60ac234a-0077-45c4-8fa7-838532fcb1a3"},{"reference":"DiagnosticReport/1734642836211461451.b445825b-9bc5-4f0e-8c02-2efec15eea80"},{"reference":"DiagnosticReport/1734642836214831090.ee9eb06b-e557-4f06-a2f9-fa45857f934e"},{"reference":"DiagnosticReport/1734642836222755552.3e6f8397-1b58-4c1a-b40d-beef72dfd7f2"},{"reference":"DiagnosticReport/1734642836226132955.b2820374-c2e0-4889-9afe-bdc2a1dca75b"},{"reference":"DiagnosticReport/1734642836229369304.f3163167-c3a2-4db6-a5d0-b34a381c8f2a"},{"reference":"DiagnosticReport/1734642836232969475.9f766400-c9d9-4ce5-ad62-e68dc8dfcba3"},{"reference":"DiagnosticReport/1734642836236317372.7970abee-6352-427f-ad38-6bd422457de4"},{"reference":"DiagnosticReport/1734642836239591572.8e42c1d3-2acd-4fb2-bd9f-83f12fbcaa69"}],"recorded":"2024-10-30T05:01:54Z","activity":{"coding":[{"display":"ORU^R01^ORU_R01"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"author"}]},"who":{"reference":"Organization/1734642835568737323.d2c8e0a8-aeea-4dd8-ad3a-7d5afffda662"}}]}},{"fullUrl":"Organization/1734642835568737323.d2c8e0a8-aeea-4dd8-ad3a-7d5afffda662","resource":{"resourceType":"Organization","id":"1734642835568737323.d2c8e0a8-aeea-4dd8-ad3a-7d5afffda662","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Provenance/1734642835569413250.85a9e377-4a25-45da-a030-13a4b4353e70","resource":{"resourceType":"Provenance","id":"1734642835569413250.85a9e377-4a25-45da-a030-13a4b4353e70","recorded":"2024-12-19T21:13:55Z","policy":["http://hl7.org/fhir/uv/v2mappings/message-oru-r01-to-bundle"],"activity":{"coding":[{"code":"v2-FHIR transformation"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"assembler"}]},"who":{"reference":"Organization/1734642835569260194.d61dc1b1-2bb3-4dc8-8509-adc3b59c55a0"}}]}},{"fullUrl":"Organization/1734642835569260194.d61dc1b1-2bb3-4dc8-8509-adc3b59c55a0","resource":{"resourceType":"Organization","id":"1734642835569260194.d61dc1b1-2bb3-4dc8-8509-adc3b59c55a0","identifier":[{"value":"CDC PRIME - Atlanta"},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301"}]},"system":"urn:ietf:rfc:3986","value":"2.16.840.1.114222.4.1.237821"}]}},{"fullUrl":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb","resource":{"resourceType":"Patient","id":"1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cx-identifier","extension":[{"url":"CX.5","valueString":"MR"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"PID.3"}],"type":{"coding":[{"code":"MR"}]},"value":"335441864","assigner":{"reference":"Organization/1734642835570049433.f3d530ee-ea42-40d0-bb57-de3dec27eb77"}}],"name":[{"family":"*****PII REMOVED******"}],"contact":[{"name":{"family":"*****PII REMOVED******"}}]}},{"fullUrl":"Organization/1734642835570049433.f3d530ee-ea42-40d0-bb57-de3dec27eb77","resource":{"resourceType":"Organization","id":"1734642835570049433.f3d530ee-ea42-40d0-bb57-de3dec27eb77","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"104638912487&NPI"}]}},{"fullUrl":"Provenance/1734642835573831726.0ce2a9df-32dd-449b-857e-9721f234de84","resource":{"resourceType":"Provenance","id":"1734642835573831726.0ce2a9df-32dd-449b-857e-9721f234de84","target":[{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"}],"recorded":"2024-12-19T21:13:55Z","activity":{"coding":[{"system":"https://terminology.hl7.org/CodeSystem/v3-DataOperation","code":"UPDATE"}]}}},{"fullUrl":"RelatedPerson/1734642835574833975.319061e3-ffe8-4929-affc-8da7b067c9bd","resource":{"resourceType":"RelatedPerson","id":"1734642835574833975.319061e3-ffe8-4929-affc-8da7b067c9bd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"NK1"}],"patient":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"name":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"NK1.2"}],"family":"*****PII REMOVED******"}]}},{"fullUrl":"Observation/1734642835577334424.adac7e49-c88b-4c5c-bda3-24bfaf62119c","resource":{"resourceType":"Observation","id":"1734642835577334424.adac7e49-c88b-4c5c-bda3-24bfaf62119c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57721-3","display":"Reason for lab test in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12421-6","display":"Initial screen"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835582945910.f0c81174-275c-4f6d-9003-10c4c6cee05f","resource":{"resourceType":"Observation","id":"1734642835582945910.f0c81174-275c-4f6d-9003-10c4c6cee05f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57718-9","display":"Sample quality of Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12432-3","display":"Acceptable"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835585626967.e771b53b-9a27-423b-bd97-b0cc10b0fc17","resource":{"resourceType":"Observation","id":"1734642835585626967.e771b53b-9a27-423b-bd97-b0cc10b0fc17","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57130-7","display":"Newborn screening report - overall interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12428-1","display":"All screening is in range for the conditions tested"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835587943501.7508be73-3956-4c30-9fb2-9a420d225bbd","resource":{"resourceType":"Observation","id":"1734642835587943501.7508be73-3956-4c30-9fb2-9a420d225bbd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57131-5","display":"Newborn conditions with positive markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835590874687.0cc4344e-4653-4c68-a6f6-028b9a5cc0a5","resource":{"resourceType":"Observation","id":"1734642835590874687.0cc4344e-4653-4c68-a6f6-028b9a5cc0a5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57720-5","display":"Newborn conditions with equivocal markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835592969425.13fe95c5-d463-4a95-9ae7-acd437529f9a","resource":{"resourceType":"Observation","id":"1734642835592969425.13fe95c5-d463-4a95-9ae7-acd437529f9a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57724-7","display":"Newborn screening short narrative summary"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \\\\\\2130 E Illinois Avenue, FRESNO, CA 93701\\\\.br\\\\\\\\.br\\\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\\\.br\\\\\\\\.br\\\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\\\.br\\\\\\\\.br\\\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (858) 966-8708. \\\\.br\\\\\\\\.br\\\\Methods and Limitations:\\\\.br\\\\\\\\.br\\\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\\\.br\\\\Attention Healthcare Provider:\\\\.br\\\\\\\\.br\\\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\\\.br\\\\\\\\.br\\","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835595033996.cbdcdf22-3e1c-4658-bf95-66d53413f145","resource":{"resourceType":"Observation","id":"1734642835595033996.cbdcdf22-3e1c-4658-bf95-66d53413f145","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57129-9","display":"Full newborn screening summary report for display or printing"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835597001375.991eef6e-98ae-4728-b2a9-eb4dc15ddfe5","resource":{"resourceType":"Observation","id":"1734642835597001375.991eef6e-98ae-4728-b2a9-eb4dc15ddfe5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"ST"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57716-3","display":"State printed on filter paper card [Identifier] in NBS card"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"CA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835599231657.6cd136e8-cdd9-478e-b513-a69682d52dcf","resource":{"resourceType":"Observation","id":"1734642835599231657.6cd136e8-cdd9-478e-b513-a69682d52dcf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"grams"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"8339-4","display":"Birthweight"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":3464,"unit":"grams"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835601376860.20738e16-4487-4275-9d1e-2f1d7899a49b","resource":{"resourceType":"Observation","id":"1734642835601376860.20738e16-4487-4275-9d1e-2f1d7899a49b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57715-5","display":"Time of birth"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueTime":"0444","_valueTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"0444"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835603619726.92836d62-2c43-4fd5-862e-68ccb53f0583","resource":{"resourceType":"Observation","id":"1734642835603619726.92836d62-2c43-4fd5-862e-68ccb53f0583","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57722-1","display":"Birth plurality of Pregnancy"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12411-7","display":"Singleton"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835606051145.294d5bf0-4e62-482d-b456-f5bd54ddf19e","resource":{"resourceType":"Observation","id":"1734642835606051145.294d5bf0-4e62-482d-b456-f5bd54ddf19e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"hour(s)"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"73806-2","display":"Newborn age in hours"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":19,"unit":"hour(s)"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835608401953.3951d7cb-f4c3-43af-a159-eb1c1bf9c2e9","resource":{"resourceType":"Observation","id":"1734642835608401953.3951d7cb-f4c3-43af-a159-eb1c1bf9c2e9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57713-0","display":"Infant NICU factors that affect newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835610633307.d65b7233-9e23-4cbc-9126-9fc566126230","resource":{"resourceType":"Observation","id":"1734642835610633307.d65b7233-9e23-4cbc-9126-9fc566126230","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67704-7","display":"Feeding types"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA16914-6","display":"Breast milk"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835612775124.0d6a0867-1ae6-48c5-a587-cb41a3e52476","resource":{"resourceType":"Observation","id":"1734642835612775124.0d6a0867-1ae6-48c5-a587-cb41a3e52476","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-5","display":"Accession Number"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"292-04-123/21-2024-32","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835615633444.91b240be-e8aa-4061-9564-89f9e6e0d5bb","resource":{"resourceType":"Observation","id":"1734642835615633444.91b240be-e8aa-4061-9564-89f9e6e0d5bb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62324-9","display":"Post-discharge provider name"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"DIANE BEDROSIAN","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835617901266.8e54520a-9875-4c84-b38a-3fbd6709a7a7","resource":{"resourceType":"Observation","id":"1734642835617901266.8e54520a-9875-4c84-b38a-3fbd6709a7a7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62325-6","display":"Post-discharge provider practice ID"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"1447323951","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835619938276.c720e577-5b06-4c8d-8217-8272358029fb","resource":{"resourceType":"Observation","id":"1734642835619938276.c720e577-5b06-4c8d-8217-8272358029fb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62327-2","display":"Post-discharge provider practice address"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"200 W ARBOR DR SAN DIEGO CA 92103-1911 USA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835622290176.0ed5d39e-4af1-41f8-98da-7b956ad1aca9","resource":{"resourceType":"Observation","id":"1734642835622290176.0ed5d39e-4af1-41f8-98da-7b956ad1aca9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47633-3","display":"Glycine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":536,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835624587333.d71f9ce0-54c1-4fb0-9c27-bc6838cc8934","resource":{"resourceType":"Observation","id":"1734642835624587333.d71f9ce0-54c1-4fb0-9c27-bc6838cc8934","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53150-9","display":"Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":559,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1000"}]}},{"fullUrl":"Observation/1734642835630433513.ff02305e-15bd-446f-8015-32a1ccd7995c","resource":{"resourceType":"Observation","id":"1734642835630433513.ff02305e-15bd-446f-8015-32a1ccd7995c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47799-2","display":"Valine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":123,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835632748323.c4c14367-0fae-4255-b87c-e5b6722fce27","resource":{"resourceType":"Observation","id":"1734642835632748323.c4c14367-0fae-4255-b87c-e5b6722fce27","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53151-7","display":"Valine/Phenylalanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":2.14286,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.3"}]}},{"fullUrl":"Observation/1734642835635217113.8be785a8-0375-46eb-94a3-7f2cf7a0dff0","resource":{"resourceType":"Observation","id":"1734642835635217113.8be785a8-0375-46eb-94a3-7f2cf7a0dff0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53152-5","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":113,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<230"}]}},{"fullUrl":"Observation/1734642835637771543.7b620553-e589-49ea-a380-6a8b7474b329","resource":{"resourceType":"Observation","id":"1734642835637771543.7b620553-e589-49ea-a380-6a8b7474b329","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53154-1","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.20,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.35"}]}},{"fullUrl":"Observation/1734642835642122852.6a859c86-d8f1-4d0f-a2d3-b4fdd58a36f4","resource":{"resourceType":"Observation","id":"1734642835642122852.6a859c86-d8f1-4d0f-a2d3-b4fdd58a36f4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29573-3","display":"Phenylalanine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":57.4,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<175"}]}},{"fullUrl":"Observation/1734642835648986983.5fe75d08-ac6d-4ba1-8a89-ac1fa3be0c7c","resource":{"resourceType":"Observation","id":"1734642835648986983.5fe75d08-ac6d-4ba1-8a89-ac1fa3be0c7c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35572-7","display":"Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":1.05,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2.6"}]}},{"fullUrl":"Observation/1734642835651324957.ffdae7fc-33c6-4c8b-b7a6-334986cf820f","resource":{"resourceType":"Observation","id":"1734642835651324957.ffdae7fc-33c6-4c8b-b7a6-334986cf820f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35571-9","display":"Tyrosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":54.8,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<680"}]}},{"fullUrl":"Observation/1734642835653464299.ecdb8485-1be4-4bc7-9921-70ef134ea027","resource":{"resourceType":"Observation","id":"1734642835653464299.ecdb8485-1be4-4bc7-9921-70ef134ea027","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53231-7","display":"Succinylacetone [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.20,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<6.1"}]}},{"fullUrl":"Observation/1734642835655634949.ada7fa6f-d208-4f95-ae2d-c3f94913127e","resource":{"resourceType":"Observation","id":"1734642835655634949.ada7fa6f-d208-4f95-ae2d-c3f94913127e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47700-0","display":"Methionine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":22.8,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.3-100"}]}},{"fullUrl":"Observation/1734642835657787706.19dec618-554e-4232-8b8f-718feb2c0810","resource":{"resourceType":"Observation","id":"1734642835657787706.19dec618-554e-4232-8b8f-718feb2c0810","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42892-0","display":"Citrulline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":10,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"5-49"}]}},{"fullUrl":"Observation/1734642835659892012.7868a556-8258-4cd3-b653-542182d8fcae","resource":{"resourceType":"Observation","id":"1734642835659892012.7868a556-8258-4cd3-b653-542182d8fcae","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54092-2","display":"Citrulline/Arginine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":1.52,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.8"}]}},{"fullUrl":"Observation/1734642835662076538.a387bfe4-b363-4221-89f6-d0f2ea71e213","resource":{"resourceType":"Observation","id":"1734642835662076538.a387bfe4-b363-4221-89f6-d0f2ea71e213","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53155-8","display":"Asparagine+Ornithine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":84,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<800"}]}},{"fullUrl":"Observation/1734642835664344942.f66efdf8-7f8a-4e48-b80b-0e8f843d1a96","resource":{"resourceType":"Observation","id":"1734642835664344942.f66efdf8-7f8a-4e48-b80b-0e8f843d1a96","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75215-4","display":"Ornithine/Citrulline [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":8.40,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835667556273.9a9e4a0b-7125-471c-8001-360221a9cef2","resource":{"resourceType":"Observation","id":"1734642835667556273.9a9e4a0b-7125-471c-8001-360221a9cef2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47562-4","display":"Arginine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":7,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<63"}]}},{"fullUrl":"Observation/1734642835670226080.0806c275-8281-4657-8edd-7f65f0a1d343","resource":{"resourceType":"Observation","id":"1734642835670226080.0806c275-8281-4657-8edd-7f65f0a1d343","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75214-7","display":"Arginine/Ornithine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.08,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.9"}]}},{"fullUrl":"Observation/1734642835672541752.67036c13-e742-4a9e-8a48-18221261335e","resource":{"resourceType":"Observation","id":"1734642835672541752.67036c13-e742-4a9e-8a48-18221261335e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47732-3","display":"Proline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":154,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1500"}]}},{"fullUrl":"Observation/1734642835674459107.60d5c469-6e3b-4dbf-a66d-04ff03f052af","resource":{"resourceType":"Observation","id":"1734642835674459107.60d5c469-6e3b-4dbf-a66d-04ff03f052af","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57710-6","display":"Amino acidemias newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835676555097.d17991b9-f738-4c03-bc2d-eca221d2d49c","resource":{"resourceType":"Observation","id":"1734642835676555097.d17991b9-f738-4c03-bc2d-eca221d2d49c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58088-6","display":"Acylcarnitine newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835678329685.bb4ed8d6-7e4d-4959-972f-a5bc6f2b63d1","resource":{"resourceType":"Observation","id":"1734642835678329685.bb4ed8d6-7e4d-4959-972f-a5bc6f2b63d1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58093-6","display":"Acylcarnitine newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835680351065.d01da517-1280-4a4b-a9fa-42f5aba5354e","resource":{"resourceType":"Observation","id":"1734642835680351065.d01da517-1280-4a4b-a9fa-42f5aba5354e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38481-8","display":"Carnitine.free (C0)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":24.4,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.4-125"}]}},{"fullUrl":"Observation/1734642835683365418.cf9c3b1d-9ef4-4b0e-a8c8-bce7fd481781","resource":{"resourceType":"Observation","id":"1734642835683365418.cf9c3b1d-9ef4-4b0e-a8c8-bce7fd481781","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53235-8","display":"Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":4.32,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<70"}]}},{"fullUrl":"Observation/1734642835686681365.bc96eed3-e560-4185-9b8e-654ec88f2776","resource":{"resourceType":"Observation","id":"1734642835686681365.bc96eed3-e560-4185-9b8e-654ec88f2776","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50157-7","display":"Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":27.3,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"10-80"}]}},{"fullUrl":"Observation/1734642835693717720.57ef4762-7f1a-49c1-afac-2de54e42e258","resource":{"resourceType":"Observation","id":"1734642835693717720.57ef4762-7f1a-49c1-afac-2de54e42e258","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75212-1","display":"Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":2.73000,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.6"}]}},{"fullUrl":"Observation/1734642835696077585.0a2bdff7-f737-4624-8c1b-9cfe764fca68","resource":{"resourceType":"Observation","id":"1734642835696077585.0a2bdff7-f737-4624-8c1b-9cfe764fca68","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45211-0","display":"Hexanoylcarnitine (C6)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.067,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835698315441.7cb7425f-81df-4530-a5c2-76c97210fef3","resource":{"resourceType":"Observation","id":"1734642835698315441.7cb7425f-81df-4530-a5c2-76c97210fef3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53175-6","display":"Octanoylcarnitine (C8)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.076,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835700583725.13e5ba61-8a59-482f-865b-4054fe5a03e1","resource":{"resourceType":"Observation","id":"1734642835700583725.13e5ba61-8a59-482f-865b-4054fe5a03e1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53177-2","display":"Octanoylcarnitine (C8)/Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.76,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835702659758.ecf642b8-29ec-4734-a174-beea3fafc7a9","resource":{"resourceType":"Observation","id":"1734642835702659758.ecf642b8-29ec-4734-a174-beea3fafc7a9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53174-9","display":"Octenoylcarnitine (C8:1)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.103,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835704761468.d497718f-0b69-40cc-9b9f-7dc62c83c950","resource":{"resourceType":"Observation","id":"1734642835704761468.d497718f-0b69-40cc-9b9f-7dc62c83c950","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45197-1","display":"Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.100,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835707309036.fe794609-acd5-4805-9440-2ae4c749af09","resource":{"resourceType":"Observation","id":"1734642835707309036.fe794609-acd5-4805-9440-2ae4c749af09","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45198-9","display":"Decenoylcarnitine (C10:1)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.035,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835709563824.fb6d07a6-0c21-455c-b5c5-6a6d07184265","resource":{"resourceType":"Observation","id":"1734642835709563824.fb6d07a6-0c21-455c-b5c5-6a6d07184265","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45199-7","display":"Dodecanoylcarnitine (C12)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.132,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2"}]}},{"fullUrl":"Observation/1734642835712047531.949c4810-8298-4150-9a2f-60508ec56a7a","resource":{"resourceType":"Observation","id":"1734642835712047531.949c4810-8298-4150-9a2f-60508ec56a7a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45200-3","display":"Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.17,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835714330091.533e0fb7-63d2-4b19-8f6e-837cd278b3e5","resource":{"resourceType":"Observation","id":"1734642835714330091.533e0fb7-63d2-4b19-8f6e-837cd278b3e5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53192-1","display":"Tetradecanoylcarnitine (C14)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.264,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.2"}]}},{"fullUrl":"Observation/1734642835717945851.52ec5e40-d07b-4918-bd1b-7dc4845614dd","resource":{"resourceType":"Observation","id":"1734642835717945851.52ec5e40-d07b-4918-bd1b-7dc4845614dd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53191-3","display":"Tetradecenoylcarnitine (C14:1)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.189,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.9"}]}},{"fullUrl":"Observation/1734642835721515655.e9fdf13b-f915-43b6-b914-c76a2c9170c0","resource":{"resourceType":"Observation","id":"1734642835721515655.e9fdf13b-f915-43b6-b914-c76a2c9170c0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53194-7","display":"Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":1.13,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835724860106.e1972cf2-ded8-44f3-a5dd-3b691a84a20b","resource":{"resourceType":"Observation","id":"1734642835724860106.e1972cf2-ded8-44f3-a5dd-3b691a84a20b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53190-5","display":"Tetradecadienoylcarnitine (C14:2)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.03,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835728591664.6f8f4ce7-ed75-4423-b5d6-f6d826b13667","resource":{"resourceType":"Observation","id":"1734642835728591664.6f8f4ce7-ed75-4423-b5d6-f6d826b13667","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50281-5","display":"3-Hydroxytetradecanoylcarnitine (C14-OH)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.021,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.2"}]}},{"fullUrl":"Observation/1734642835731845756.4261f819-24ea-4e74-b9c6-c0db5c089185","resource":{"resourceType":"Observation","id":"1734642835731845756.4261f819-24ea-4e74-b9c6-c0db5c089185","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53199-6","display":"Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":3.88,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<12"}]}},{"fullUrl":"Observation/1734642835735027652.29fdca8c-a1d4-414a-8878-fa42c159b3b6","resource":{"resourceType":"Observation","id":"1734642835735027652.29fdca8c-a1d4-414a-8878-fa42c159b3b6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53198-8","display":"Palmitoleylcarnitine (C16:1)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.371,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.4"}]}},{"fullUrl":"Observation/1734642835737321944.98a898ef-4d63-406d-bac4-fbd5742651b4","resource":{"resourceType":"Observation","id":"1734642835737321944.98a898ef-4d63-406d-bac4-fbd5742651b4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50125-4","display":"3-Hydroxypalmitoylcarnitine (C16-OH)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.030,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835739581091.e142a554-00dd-421d-b9df-941c59dab7ad","resource":{"resourceType":"Observation","id":"1734642835739581091.e142a554-00dd-421d-b9df-941c59dab7ad","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53201-0","display":"3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.00773,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.07"}]}},{"fullUrl":"Observation/1734642835741723989.c21e4681-4463-4095-97b5-6791c5ae5198","resource":{"resourceType":"Observation","id":"1734642835741723989.c21e4681-4463-4095-97b5-6791c5ae5198","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53241-6","display":"Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":1.11,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<3.5"}]}},{"fullUrl":"Observation/1734642835744517557.8732d578-4481-4f1d-b8c3-2d0bbae471cd","resource":{"resourceType":"Observation","id":"1734642835744517557.8732d578-4481-4f1d-b8c3-2d0bbae471cd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53202-8","display":"Oleoylcarnitine (C18:1)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":1.76,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7"}]}},{"fullUrl":"Observation/1734642835748030945.c1470e5e-264f-4ff2-8fc8-1b9f8af8639e","resource":{"resourceType":"Observation","id":"1734642835748030945.c1470e5e-264f-4ff2-8fc8-1b9f8af8639e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45217-7","display":"Linoleoylcarnitine (C18:2)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.15,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835751159231.2987988f-57e1-4e2b-8ddd-baddd564dab2","resource":{"resourceType":"Observation","id":"1734642835751159231.2987988f-57e1-4e2b-8ddd-baddd564dab2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50132-0","display":"3-Hydroxystearoylcarnitine (C18-OH)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.015,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835754135622.5d7fe074-ad95-4bf9-ad1d-5cbfd0ee5e4a","resource":{"resourceType":"Observation","id":"1734642835754135622.5d7fe074-ad95-4bf9-ad1d-5cbfd0ee5e4a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50113-0","display":"3-Hydroxyoleoylcarnitine (C18:1-OH)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.032,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835757049386.d5e1dc03-14f3-4d09-9e13-40d1b0f3f2ce","resource":{"resourceType":"Observation","id":"1734642835757049386.d5e1dc03-14f3-4d09-9e13-40d1b0f3f2ce","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53160-8","display":"Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":2.3,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.9"}]}},{"fullUrl":"Observation/1734642835761114529.4f646e63-7d80-49fa-87b9-0702fa57873d","resource":{"resourceType":"Observation","id":"1734642835761114529.4f646e63-7d80-49fa-87b9-0702fa57873d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53163-2","display":"Propionylcarnitine (C3)/Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.09,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.42"}]}},{"fullUrl":"Observation/1734642835764257813.60871a6d-a6bc-43fc-9961-fc4c4ef1df91","resource":{"resourceType":"Observation","id":"1734642835764257813.60871a6d-a6bc-43fc-9961-fc4c4ef1df91","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67708-8","display":"Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.273,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.48"}]}},{"fullUrl":"Observation/1734642835767149175.e4116ccc-45b8-45ab-9659-af0eb59ef910","resource":{"resourceType":"Observation","id":"1734642835767149175.e4116ccc-45b8-45ab-9659-af0eb59ef910","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53166-5","display":"Butyrylcarnitine+Isobutyrylcarnitine (C4)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.315,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.7"}]}},{"fullUrl":"Observation/1734642835769714585.15e3f529-9399-466d-9f7b-351063db3081","resource":{"resourceType":"Observation","id":"1734642835769714585.15e3f529-9399-466d-9f7b-351063db3081","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45216-9","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.117,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835771802080.ca112406-b41b-4d50-9b9c-1f76aa6ff9c5","resource":{"resourceType":"Observation","id":"1734642835771802080.ca112406-b41b-4d50-9b9c-1f76aa6ff9c5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53240-8","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.05087,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642835773922456.a87d9766-0905-4819-b5e7-266adca96e79","resource":{"resourceType":"Observation","id":"1734642835773922456.a87d9766-0905-4819-b5e7-266adca96e79","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53170-7","display":"Tiglylcarnitine (C5:1)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.009,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.5"}]}},{"fullUrl":"Observation/1734642835776021562.d1299532-0d18-4892-b398-2ce43afbe648","resource":{"resourceType":"Observation","id":"1734642835776021562.d1299532-0d18-4892-b398-2ce43afbe648","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50106-4","display":"3-Hydroxyisovalerylcarnitine (C5-OH)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.217,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.15"}]}},{"fullUrl":"Observation/1734642835778173517.01535e92-5e00-47e4-ab3d-110a854dad56","resource":{"resourceType":"Observation","id":"1734642835778173517.01535e92-5e00-47e4-ab3d-110a854dad56","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67710-4","display":"Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.183,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642835780284095.308f13e8-a730-46bb-a3b8-ea40778e9d6f","resource":{"resourceType":"Observation","id":"1734642835780284095.308f13e8-a730-46bb-a3b8-ea40778e9d6f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75216-2","display":"Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.67033,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">0.1"}]}},{"fullUrl":"Observation/1734642835782344608.424f6717-4153-4e62-ac87-8042351f8682","resource":{"resourceType":"Observation","id":"1734642835782344608.424f6717-4153-4e62-ac87-8042351f8682","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ng/mL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"48633-2","display":"Trypsinogen I.free"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":27.20,"unit":"ng/mL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<69"}]}},{"fullUrl":"Observation/1734642835784477347.0a8ce02f-9ef6-466a-8d2e-e3302ce84725","resource":{"resourceType":"Observation","id":"1734642835784477347.0a8ce02f-9ef6-466a-8d2e-e3302ce84725","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46769-6","display":"Cystic fibrosis newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835786278986.358222a6-0f06-41da-8340-066d9180f518","resource":{"resourceType":"Observation","id":"1734642835786278986.358222a6-0f06-41da-8340-066d9180f518","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57707-2","display":"Cystic fibrosis newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835788626087.be190f26-4ec7-4ff3-9cbe-2b45da1171c8","resource":{"resourceType":"Observation","id":"1734642835788626087.be190f26-4ec7-4ff3-9cbe-2b45da1171c8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"nmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38473-5","display":"17-Hydroxyprogesterone"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":15.2,"unit":"nmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<85"}]}},{"fullUrl":"Observation/1734642835791198380.12b44a0e-d59a-4599-b787-cf8c952c79d7","resource":{"resourceType":"Observation","id":"1734642835791198380.12b44a0e-d59a-4599-b787-cf8c952c79d7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46758-9","display":"Congenital adrenal hyperplasia newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835793057767.37902251-42da-4eda-9d1f-f8cc30c48bb6","resource":{"resourceType":"Observation","id":"1734642835793057767.37902251-42da-4eda-9d1f-f8cc30c48bb6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57706-4","display":"Congenital adrenal hyperplasia newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835795058388.ef3fb068-7e38-461f-840a-55de5c14e7c9","resource":{"resourceType":"Observation","id":"1734642835795058388.ef3fb068-7e38-461f-840a-55de5c14e7c9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"mIU/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29575-8","display":"Thyrotropin"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":15.40,"unit":"mIU/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<29"}]}},{"fullUrl":"Observation/1734642835797268182.1daf15b4-f748-4976-a0a6-9a517d37c4ab","resource":{"resourceType":"Observation","id":"1734642835797268182.1daf15b4-f748-4976-a0a6-9a517d37c4ab","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46762-1","display":"Congenital hypothyroidism newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835800106975.6f9a33a8-27cb-4c06-ab6f-7bed876d63eb","resource":{"resourceType":"Observation","id":"1734642835800106975.6f9a33a8-27cb-4c06-ab6f-7bed876d63eb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57705-6","display":"Congenital hypothyroidism newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835802627231.8168e21a-25dc-43d9-8188-8943062d61ef","resource":{"resourceType":"Observation","id":"1734642835802627231.8168e21a-25dc-43d9-8188-8943062d61ef","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"enzyme units"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42906-8","display":"Galactose 1 phosphate uridyl transferase"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":273.54,"unit":"enzyme units"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">50"}]}},{"fullUrl":"Observation/1734642835804808662.c39b6f7a-5b9a-49ae-8ffe-d263a848d152","resource":{"resourceType":"Observation","id":"1734642835804808662.c39b6f7a-5b9a-49ae-8ffe-d263a848d152","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46737-3","display":"Galactosemias newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835806808592.2ee61489-aae4-46a6-a99b-4a6235df84ba","resource":{"resourceType":"Observation","id":"1734642835806808592.2ee61489-aae4-46a6-a99b-4a6235df84ba","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57704-9","display":"Galactosemias newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835809150183.7a92d9f1-8ce3-4d31-ac64-0ac7f3a48a37","resource":{"resourceType":"Observation","id":"1734642835809150183.7a92d9f1-8ce3-4d31-ac64-0ac7f3a48a37","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54104-5","display":"Hemoglobin pattern"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"FA"}},{"fullUrl":"Observation/1734642835811093036.f66355a4-96ff-4166-b67f-a902f4ee99f6","resource":{"resourceType":"Observation","id":"1734642835811093036.f66355a4-96ff-4166-b67f-a902f4ee99f6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57703-1","display":"Hemoglobin disorders newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants."}},{"fullUrl":"Observation/1734642835814495506.d6042a6a-0f25-4f28-bc8f-d43f7cc4606d","resource":{"resourceType":"Observation","id":"1734642835814495506.d6042a6a-0f25-4f28-bc8f-d43f7cc4606d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ERU"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75217-0","display":"Biotinidase [Enzymatic activity/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":73.00,"unit":"ERU"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">10"}]}},{"fullUrl":"Observation/1734642835816830655.dd7061fd-a46d-4721-a6b1-f6d34b76fd59","resource":{"resourceType":"Observation","id":"1734642835816830655.dd7061fd-a46d-4721-a6b1-f6d34b76fd59","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46761-3","display":"Biotinidase deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835818678400.3cad2e81-9353-4195-9b85-b4639f2df0a1","resource":{"resourceType":"Observation","id":"1734642835818678400.3cad2e81-9353-4195-9b85-b4639f2df0a1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57699-1","display":"Biotinidase deficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835820822640.78993f3a-2921-4f89-9519-419e2299f964","resource":{"resourceType":"Observation","id":"1734642835820822640.78993f3a-2921-4f89-9519-419e2299f964","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"copies/µL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62320-7","display":"T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":120,"unit":"copies/µL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">18"}]}},{"fullUrl":"Observation/1734642835827458874.9ad19a02-cdf3-486a-b4c8-52715b6f8ff5","resource":{"resourceType":"Observation","id":"1734642835827458874.9ad19a02-cdf3-486a-b4c8-52715b6f8ff5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62321-5","display":"Severe combined immunodeficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835829308613.9a48f9a5-c08e-4bce-83f7-e4baff4085f4","resource":{"resourceType":"Observation","id":"1734642835829308613.9a48f9a5-c08e-4bce-83f7-e4baff4085f4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62322-3","display":"Severe combined immunodeficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835831324272.429f1043-13bd-40b2-83e1-43c39ba641f3","resource":{"resourceType":"Observation","id":"1734642835831324272.429f1043-13bd-40b2-83e1-43c39ba641f3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55827-0","display":"Acid alpha glucosidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":11.43,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=1.54"}]}},{"fullUrl":"Observation/1734642835833543373.3a1f7ad9-e8d2-4ee3-b2c0-f147550c88e1","resource":{"resourceType":"Observation","id":"1734642835833543373.3a1f7ad9-e8d2-4ee3-b2c0-f147550c88e1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63415-4","display":"Pompe Disease deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835835933846.672c48cc-f970-4c68-a58e-783db9cbaf42","resource":{"resourceType":"Observation","id":"1734642835835933846.672c48cc-f970-4c68-a58e-783db9cbaf42","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63416-2","display":"Pompe Disease deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835838105198.47b4cbbc-c75c-42a2-a8b1-af0b49476367","resource":{"resourceType":"Observation","id":"1734642835838105198.47b4cbbc-c75c-42a2-a8b1-af0b49476367","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55909-6","display":"Alpha-L-iduronidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":9.33,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=0.86"}]}},{"fullUrl":"Observation/1734642835840285286.269c7d6b-46ce-44ac-8142-886554ce0e8a","resource":{"resourceType":"Observation","id":"1734642835840285286.269c7d6b-46ce-44ac-8142-886554ce0e8a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79564-1","display":"Mucopolysaccharidosis type I newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835842157116.3f2869cc-9314-4fca-bb36-30d8cf4bac45","resource":{"resourceType":"Observation","id":"1734642835842157116.3f2869cc-9314-4fca-bb36-30d8cf4bac45","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79565-8","display":"Mucopolysaccharidosis type I newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835843922075.7248c8b7-1ca6-4c8d-a7ce-d36eb1313e78","resource":{"resourceType":"Observation","id":"1734642835843922075.7248c8b7-1ca6-4c8d-a7ce-d36eb1313e78","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-60","display":"SMN1 Homozygous Deletion Analysis"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Exon 7 Present","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"Exon 7 Present"}]}},{"fullUrl":"Observation/1734642835845986376.9b3c48f8-00d5-4808-88fb-e863246b8219","resource":{"resourceType":"Observation","id":"1734642835845986376.9b3c48f8-00d5-4808-88fb-e863246b8219","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92004-1","display":"Spinal muscular atrophy newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835847829352.daf1d979-25f0-4626-a59c-d58a1cf752fb","resource":{"resourceType":"Observation","id":"1734642835847829352.daf1d979-25f0-4626-a59c-d58a1cf752fb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92003-3","display":"Spinal muscular atrophy newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"SMA Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835849882262.b094803d-6e75-40ed-afd6-42f5594411fa","resource":{"resourceType":"Observation","id":"1734642835849882262.b094803d-6e75-40ed-afd6-42f5594411fa","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79462-8","display":"Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":22.31,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=2.84"}]}},{"fullUrl":"Observation/1734642835851989233.a88495e1-8d29-4236-bc74-0abc7acc0815","resource":{"resourceType":"Observation","id":"1734642835851989233.a88495e1-8d29-4236-bc74-0abc7acc0815","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104189-6","display":"Mucopolysaccharidosis type II newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835853894515.0b1a6c16-c717-4be4-ba46-443dd67f6f09","resource":{"resourceType":"Observation","id":"1734642835853894515.0b1a6c16-c717-4be4-ba46-443dd67f6f09","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104190-4","display":"Mucopolysaccharidosis type II newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835855901248.604a24fd-9d48-4fe7-bc8d-16c5ddbe126d","resource":{"resourceType":"Observation","id":"1734642835855901248.604a24fd-9d48-4fe7-bc8d-16c5ddbe126d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104192-0","display":"Guanidinoacetate methyltransferase deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835857944600.d19ae395-b211-464f-a382-c075ce46aeaf","resource":{"resourceType":"Observation","id":"1734642835857944600.d19ae395-b211-464f-a382-c075ce46aeaf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104193-8","display":"Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835859986879.bdca2177-dd1f-46e4-ad97-2f668239e329","resource":{"resourceType":"Observation","id":"1734642835859986879.bdca2177-dd1f-46e4-ad97-2f668239e329","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"93488-5","display":"Guanidinoacetate [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":1.22,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=3"}]}},{"fullUrl":"Observation/1734642835862065086.531f3b8f-6253-4dee-9d64-10b73fd08845","resource":{"resourceType":"Observation","id":"1734642835862065086.531f3b8f-6253-4dee-9d64-10b73fd08845","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104194-6","display":"Creatine [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":411.55,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835863895038.33dd14ea-e19d-4ffe-b7b9-e8b63529536d","resource":{"resourceType":"Observation","id":"1734642835863895038.33dd14ea-e19d-4ffe-b7b9-e8b63529536d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104195-3","display":"GUAC/CRE Ratio [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":2.95},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=6"}]}},{"fullUrl":"Observation/1734642835865991418.fd9eb291-6ed5-4586-b773-e47a2259f6da","resource":{"resourceType":"Observation","id":"1734642835865991418.fd9eb291-6ed5-4586-b773-e47a2259f6da","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-32","display":"Adrenoleukodystrophy deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835867833913.65ff906c-ae0d-499b-a553-26c6e03013dd","resource":{"resourceType":"Observation","id":"1734642835867833913.65ff906c-ae0d-499b-a553-26c6e03013dd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-33","display":"Adrenoleukodystrophy deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835869941726.d0b1e57b-e016-4d29-9411-fc0f04444fbe","resource":{"resourceType":"Observation","id":"1734642835869941726.d0b1e57b-e016-4d29-9411-fc0f04444fbe","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79321-6","display":"Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.138,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.47"}]}},{"fullUrl":"Specimen/1734642835879945755.3ee6708d-99bb-4e92-a30f-474a2f12d152","resource":{"resourceType":"Specimen","id":"1734642835879945755.3ee6708d-99bb-4e92-a30f-474a2f12d152","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835881328738.2ece1ee9-b366-462e-8db5-6257c715f607","resource":{"resourceType":"Specimen","id":"1734642835881328738.2ece1ee9-b366-462e-8db5-6257c715f607","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835882661087.e5b0aee2-3f66-4f93-a340-d45570cf5a2a","resource":{"resourceType":"Specimen","id":"1734642835882661087.e5b0aee2-3f66-4f93-a340-d45570cf5a2a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835883994086.44028de6-9879-47ad-be95-b0a7f10d38c2","resource":{"resourceType":"Specimen","id":"1734642835883994086.44028de6-9879-47ad-be95-b0a7f10d38c2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835885323229.ad7c245b-7e02-457a-9ea4-4cf6d2a2e0c2","resource":{"resourceType":"Specimen","id":"1734642835885323229.ad7c245b-7e02-457a-9ea4-4cf6d2a2e0c2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835886677659.bce4faf7-9b2b-4856-93b8-e4e7a6ee1781","resource":{"resourceType":"Specimen","id":"1734642835886677659.bce4faf7-9b2b-4856-93b8-e4e7a6ee1781","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835888069799.b47930f0-3abd-40f8-ad2f-e301dca9511c","resource":{"resourceType":"Specimen","id":"1734642835888069799.b47930f0-3abd-40f8-ad2f-e301dca9511c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835889386628.6c8c4572-8380-4979-8ce1-cf1b8f09f86e","resource":{"resourceType":"Specimen","id":"1734642835889386628.6c8c4572-8380-4979-8ce1-cf1b8f09f86e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835890707054.9d2a93bf-6820-483e-99c2-19c78ad02c24","resource":{"resourceType":"Specimen","id":"1734642835890707054.9d2a93bf-6820-483e-99c2-19c78ad02c24","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835892043500.d4e333c4-01d2-4035-9ee2-aae7fc8ffcb1","resource":{"resourceType":"Specimen","id":"1734642835892043500.d4e333c4-01d2-4035-9ee2-aae7fc8ffcb1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835893446521.c4e97d51-7f4a-4dea-9187-d50689ce9ff8","resource":{"resourceType":"Specimen","id":"1734642835893446521.c4e97d51-7f4a-4dea-9187-d50689ce9ff8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835894846045.9ea6ecb4-bd10-4f14-9cf8-9054fd3deaa3","resource":{"resourceType":"Specimen","id":"1734642835894846045.9ea6ecb4-bd10-4f14-9cf8-9054fd3deaa3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835896278020.66c2f212-d10f-4001-93db-1974b6283e84","resource":{"resourceType":"Specimen","id":"1734642835896278020.66c2f212-d10f-4001-93db-1974b6283e84","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835897674319.bffdfe13-2b1a-4282-97cc-b1fddd091d94","resource":{"resourceType":"Specimen","id":"1734642835897674319.bffdfe13-2b1a-4282-97cc-b1fddd091d94","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835899018790.7c60b51a-4427-41cd-a98c-a5422ae58adc","resource":{"resourceType":"Specimen","id":"1734642835899018790.7c60b51a-4427-41cd-a98c-a5422ae58adc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835900357620.8685ee81-baff-4a99-abe8-cfc067d23e48","resource":{"resourceType":"Specimen","id":"1734642835900357620.8685ee81-baff-4a99-abe8-cfc067d23e48","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835901748849.8e662fe9-7b0e-4d40-a006-6a1805ff10c3","resource":{"resourceType":"Specimen","id":"1734642835901748849.8e662fe9-7b0e-4d40-a006-6a1805ff10c3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835903222171.7a16da03-78a9-45d5-b686-1ff3acf8c25a","resource":{"resourceType":"Specimen","id":"1734642835903222171.7a16da03-78a9-45d5-b686-1ff3acf8c25a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835904754745.9c786fc7-5654-4a1b-99c3-9b4e70acec52","resource":{"resourceType":"Specimen","id":"1734642835904754745.9c786fc7-5654-4a1b-99c3-9b4e70acec52","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835906509786.467fff36-3493-4fef-a417-1e361ed7c9ec","resource":{"resourceType":"Specimen","id":"1734642835906509786.467fff36-3493-4fef-a417-1e361ed7c9ec","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835907887991.1862e56b-e527-479d-bcd5-4e48b66db064","resource":{"resourceType":"Specimen","id":"1734642835907887991.1862e56b-e527-479d-bcd5-4e48b66db064","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835909256276.3006f8e3-c5ec-4176-b52d-5f53f1fa0619","resource":{"resourceType":"Specimen","id":"1734642835909256276.3006f8e3-c5ec-4176-b52d-5f53f1fa0619","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835910566814.cd3d4ef0-25d8-4b61-b944-ab83e982b62e","resource":{"resourceType":"Specimen","id":"1734642835910566814.cd3d4ef0-25d8-4b61-b944-ab83e982b62e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"ServiceRequest/1734642835927550611.15f19c4c-cd05-422d-9a24-75ab8e88a542","resource":{"resourceType":"ServiceRequest","id":"1734642835927550611.15f19c4c-cd05-422d-9a24-75ab8e88a542","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/business-event","valueCode":"RE"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/orc-common-order","extension":[{"url":"orc-21-ordering-facility-name","valueReference":{"reference":"Organization/1734642835921022460.594d5fd9-79ee-4d1b-a5d5-664dd349cb0d"}},{"url":"orc-22-ordering-facility-address","valueAddress":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"200 W ARBOR DR"}]}]}],"line":["200 W ARBOR DR"],"city":"SAN DIEGO","state":"CA","postalCode":"92103-1911"}},{"url":"orc-12-ordering-provider","valueReference":{"reference":"Practitioner/1734642835923547234.6ae72d57-222d-47be-8f61-f54ab4ded604"}}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.2","valueIdentifier":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"value":"356672001"}},{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835925466273.09bffa13-b3ed-4b50-b638-ca641dbca222"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"629813494"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"629813494"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"PractitionerRole/1734642835913129680.bb38c4b3-d1e9-42ea-9200-069b652e3e04"}}},{"fullUrl":"Practitioner/1734642835914722276.b87c6b68-9d2f-4c6d-9af8-9da82b1e96b6","resource":{"resourceType":"Practitioner","id":"1734642835914722276.b87c6b68-9d2f-4c6d-9af8-9da82b1e96b6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"},{"url":"XCN.10","valueString":"NPI"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.12"}],"identifier":[{"value":"1093050858"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Organization/1734642835917283990.25929dec-cfca-4281-a2f6-fe4fa2d7d79d","resource":{"resourceType":"Organization","id":"1734642835917283990.25929dec-cfca-4281-a2f6-fe4fa2d7d79d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R797"}]}],"identifier":[{"value":"R797"}],"name":"UCSD JACOBS MEDICAL CENTER","telecom":[{"_system":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}],"address":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"200 W ARBOR DR"}]}]}],"line":["200 W ARBOR DR"],"city":"SAN DIEGO","state":"CA","postalCode":"92103-1911"}]}},{"fullUrl":"PractitionerRole/1734642835913129680.bb38c4b3-d1e9-42ea-9200-069b652e3e04","resource":{"resourceType":"PractitionerRole","id":"1734642835913129680.bb38c4b3-d1e9-42ea-9200-069b652e3e04","practitioner":{"reference":"Practitioner/1734642835914722276.b87c6b68-9d2f-4c6d-9af8-9da82b1e96b6"},"organization":{"reference":"Organization/1734642835917283990.25929dec-cfca-4281-a2f6-fe4fa2d7d79d"}}},{"fullUrl":"Organization/1734642835921022460.594d5fd9-79ee-4d1b-a5d5-664dd349cb0d","resource":{"resourceType":"Organization","id":"1734642835921022460.594d5fd9-79ee-4d1b-a5d5-664dd349cb0d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R797"}]}],"identifier":[{"value":"R797"}],"name":"UCSD JACOBS MEDICAL CENTER"}},{"fullUrl":"Practitioner/1734642835923547234.6ae72d57-222d-47be-8f61-f54ab4ded604","resource":{"resourceType":"Practitioner","id":"1734642835923547234.6ae72d57-222d-47be-8f61-f54ab4ded604","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"},{"url":"XCN.10","valueString":"NPI"}]}],"identifier":[{"value":"1093050858"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642835925466273.09bffa13-b3ed-4b50-b638-ca641dbca222","resource":{"resourceType":"Practitioner","id":"1734642835925466273.09bffa13-b3ed-4b50-b638-ca641dbca222","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642835941000502.b7fd5885-1310-4bc8-8167-eaa7262486ca","resource":{"resourceType":"ServiceRequest","id":"1734642835941000502.b7fd5885-1310-4bc8-8167-eaa7262486ca","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835938649734.39d0e9fc-0b11-4327-ba0d-7c580998a1ae"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642835929326201.bb03c0ae-dc14-4c06-a3c1-7360c581a2b9"}}},{"fullUrl":"Practitioner/1734642835929326201.bb03c0ae-dc14-4c06-a3c1-7360c581a2b9","resource":{"resourceType":"Practitioner","id":"1734642835929326201.bb03c0ae-dc14-4c06-a3c1-7360c581a2b9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642835938649734.39d0e9fc-0b11-4327-ba0d-7c580998a1ae","resource":{"resourceType":"Practitioner","id":"1734642835938649734.39d0e9fc-0b11-4327-ba0d-7c580998a1ae","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642835949625414.edecca52-c3ce-4d43-8ece-0be736d5ce0a","resource":{"resourceType":"ServiceRequest","id":"1734642835949625414.edecca52-c3ce-4d43-8ece-0be736d5ce0a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835947557437.b6b7b218-af2d-4fb7-8d3d-0f4be4bec06b"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642835942913919.438ef309-5e3a-4b11-81d9-eb9fa15f94f8"}}},{"fullUrl":"Practitioner/1734642835942913919.438ef309-5e3a-4b11-81d9-eb9fa15f94f8","resource":{"resourceType":"Practitioner","id":"1734642835942913919.438ef309-5e3a-4b11-81d9-eb9fa15f94f8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642835947557437.b6b7b218-af2d-4fb7-8d3d-0f4be4bec06b","resource":{"resourceType":"Practitioner","id":"1734642835947557437.b6b7b218-af2d-4fb7-8d3d-0f4be4bec06b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642835958395841.a4adb492-9f43-4800-a3a5-6d63c819c192","resource":{"resourceType":"ServiceRequest","id":"1734642835958395841.a4adb492-9f43-4800-a3a5-6d63c819c192","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835956170268.f506abbd-dac8-4e0d-bef3-8c3a57399461"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642835951492906.490cf49e-e964-487e-a871-551d9a1a1a56"}}},{"fullUrl":"Practitioner/1734642835951492906.490cf49e-e964-487e-a871-551d9a1a1a56","resource":{"resourceType":"Practitioner","id":"1734642835951492906.490cf49e-e964-487e-a871-551d9a1a1a56","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642835956170268.f506abbd-dac8-4e0d-bef3-8c3a57399461","resource":{"resourceType":"Practitioner","id":"1734642835956170268.f506abbd-dac8-4e0d-bef3-8c3a57399461","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642835967830452.6b2c683a-67fb-45af-8256-554caff3c3db","resource":{"resourceType":"ServiceRequest","id":"1734642835967830452.6b2c683a-67fb-45af-8256-554caff3c3db","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835965617783.6072efcd-83c9-47b5-9b1e-85e75d74fab7"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642835960326641.c3484962-98f3-402e-a86a-95c686539980"}}},{"fullUrl":"Practitioner/1734642835960326641.c3484962-98f3-402e-a86a-95c686539980","resource":{"resourceType":"Practitioner","id":"1734642835960326641.c3484962-98f3-402e-a86a-95c686539980","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642835965617783.6072efcd-83c9-47b5-9b1e-85e75d74fab7","resource":{"resourceType":"Practitioner","id":"1734642835965617783.6072efcd-83c9-47b5-9b1e-85e75d74fab7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642835976762751.4671e756-9bc6-47e2-99a9-87cbff04170f","resource":{"resourceType":"ServiceRequest","id":"1734642835976762751.4671e756-9bc6-47e2-99a9-87cbff04170f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835974669356.c25a023d-f810-44a8-94a3-7f917dc51b48"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642835969770830.8b470986-56bb-4d57-807f-3346bce9c056"}}},{"fullUrl":"Practitioner/1734642835969770830.8b470986-56bb-4d57-807f-3346bce9c056","resource":{"resourceType":"Practitioner","id":"1734642835969770830.8b470986-56bb-4d57-807f-3346bce9c056","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642835974669356.c25a023d-f810-44a8-94a3-7f917dc51b48","resource":{"resourceType":"Practitioner","id":"1734642835974669356.c25a023d-f810-44a8-94a3-7f917dc51b48","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642835985781282.f3e1b584-8656-44fa-9cbb-414ec5d518aa","resource":{"resourceType":"ServiceRequest","id":"1734642835985781282.f3e1b584-8656-44fa-9cbb-414ec5d518aa","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835983706351.a96a1f45-25d9-4713-85e1-28b8a8597bdd"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642835978576162.9e42d4ce-9801-4973-9ab5-6d085a7c551e"}}},{"fullUrl":"Practitioner/1734642835978576162.9e42d4ce-9801-4973-9ab5-6d085a7c551e","resource":{"resourceType":"Practitioner","id":"1734642835978576162.9e42d4ce-9801-4973-9ab5-6d085a7c551e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642835983706351.a96a1f45-25d9-4713-85e1-28b8a8597bdd","resource":{"resourceType":"Practitioner","id":"1734642835983706351.a96a1f45-25d9-4713-85e1-28b8a8597bdd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642835994828507.bac52049-d0ec-4b36-9476-265990236057","resource":{"resourceType":"ServiceRequest","id":"1734642835994828507.bac52049-d0ec-4b36-9476-265990236057","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835992787009.10d0ec2d-6cd6-4c65-a79a-b84dd727b5c6"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642835987540992.b337dec4-9563-4909-a246-d59b85ce6337"}}},{"fullUrl":"Practitioner/1734642835987540992.b337dec4-9563-4909-a246-d59b85ce6337","resource":{"resourceType":"Practitioner","id":"1734642835987540992.b337dec4-9563-4909-a246-d59b85ce6337","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642835992787009.10d0ec2d-6cd6-4c65-a79a-b84dd727b5c6","resource":{"resourceType":"Practitioner","id":"1734642835992787009.10d0ec2d-6cd6-4c65-a79a-b84dd727b5c6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836003534371.0bd71a28-7194-446c-87bf-1feb5ed240b9","resource":{"resourceType":"ServiceRequest","id":"1734642836003534371.0bd71a28-7194-446c-87bf-1feb5ed240b9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836001364192.16a5c7ce-9a56-411b-b189-334fd622c4fc"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642835996635956.de24db83-14f5-4249-ba95-a50d5399c6e6"}}},{"fullUrl":"Practitioner/1734642835996635956.de24db83-14f5-4249-ba95-a50d5399c6e6","resource":{"resourceType":"Practitioner","id":"1734642835996635956.de24db83-14f5-4249-ba95-a50d5399c6e6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836001364192.16a5c7ce-9a56-411b-b189-334fd622c4fc","resource":{"resourceType":"Practitioner","id":"1734642836001364192.16a5c7ce-9a56-411b-b189-334fd622c4fc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836012482840.055e9451-e361-44d2-8377-6225bda2e501","resource":{"resourceType":"ServiceRequest","id":"1734642836012482840.055e9451-e361-44d2-8377-6225bda2e501","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836010241127.6701a7d2-1633-468a-ba29-4e07d173349b"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836005560761.b95af861-1c4c-4273-930a-195386da25c8"}}},{"fullUrl":"Practitioner/1734642836005560761.b95af861-1c4c-4273-930a-195386da25c8","resource":{"resourceType":"Practitioner","id":"1734642836005560761.b95af861-1c4c-4273-930a-195386da25c8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836010241127.6701a7d2-1633-468a-ba29-4e07d173349b","resource":{"resourceType":"Practitioner","id":"1734642836010241127.6701a7d2-1633-468a-ba29-4e07d173349b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836025615636.ac170df8-8fbf-43ab-a56f-be6923b5dfe9","resource":{"resourceType":"ServiceRequest","id":"1734642836025615636.ac170df8-8fbf-43ab-a56f-be6923b5dfe9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836023358844.e3dfdefc-6bc0-4b61-a78d-87bf0b8b349c"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836014581185.6ff10732-22df-4b41-a6ba-ba278aea37dd"}}},{"fullUrl":"Practitioner/1734642836014581185.6ff10732-22df-4b41-a6ba-ba278aea37dd","resource":{"resourceType":"Practitioner","id":"1734642836014581185.6ff10732-22df-4b41-a6ba-ba278aea37dd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836023358844.e3dfdefc-6bc0-4b61-a78d-87bf0b8b349c","resource":{"resourceType":"Practitioner","id":"1734642836023358844.e3dfdefc-6bc0-4b61-a78d-87bf0b8b349c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836035456439.3297a780-9e64-4129-9ea6-bd9baff3fff6","resource":{"resourceType":"ServiceRequest","id":"1734642836035456439.3297a780-9e64-4129-9ea6-bd9baff3fff6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836032780201.c8f2dbcb-3483-4678-a390-1c525cba3956"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836028037477.84cad915-cc7b-47f4-bf76-6bf5c8fddf5f"}}},{"fullUrl":"Practitioner/1734642836028037477.84cad915-cc7b-47f4-bf76-6bf5c8fddf5f","resource":{"resourceType":"Practitioner","id":"1734642836028037477.84cad915-cc7b-47f4-bf76-6bf5c8fddf5f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836032780201.c8f2dbcb-3483-4678-a390-1c525cba3956","resource":{"resourceType":"Practitioner","id":"1734642836032780201.c8f2dbcb-3483-4678-a390-1c525cba3956","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836045415173.3608f522-f1dc-443d-8cd4-bce75c901f92","resource":{"resourceType":"ServiceRequest","id":"1734642836045415173.3608f522-f1dc-443d-8cd4-bce75c901f92","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836042759283.95191095-4718-4251-ae12-eaf02f987cab"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836038078205.cb5f53ea-84ef-4d55-a554-7c580c1c52c2"}}},{"fullUrl":"Practitioner/1734642836038078205.cb5f53ea-84ef-4d55-a554-7c580c1c52c2","resource":{"resourceType":"Practitioner","id":"1734642836038078205.cb5f53ea-84ef-4d55-a554-7c580c1c52c2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836042759283.95191095-4718-4251-ae12-eaf02f987cab","resource":{"resourceType":"Practitioner","id":"1734642836042759283.95191095-4718-4251-ae12-eaf02f987cab","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836056452590.3492bfb2-2f73-4054-bb68-2b241edde680","resource":{"resourceType":"ServiceRequest","id":"1734642836056452590.3492bfb2-2f73-4054-bb68-2b241edde680","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836053858816.f13f93ba-683f-4621-9bec-3b6ff32c90f2"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836047488270.ce632d19-87ef-49aa-8d6c-dbc64072435a"}}},{"fullUrl":"Practitioner/1734642836047488270.ce632d19-87ef-49aa-8d6c-dbc64072435a","resource":{"resourceType":"Practitioner","id":"1734642836047488270.ce632d19-87ef-49aa-8d6c-dbc64072435a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836053858816.f13f93ba-683f-4621-9bec-3b6ff32c90f2","resource":{"resourceType":"Practitioner","id":"1734642836053858816.f13f93ba-683f-4621-9bec-3b6ff32c90f2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836065986547.c0024f68-3a31-462d-8c4c-1f8eb40364d2","resource":{"resourceType":"ServiceRequest","id":"1734642836065986547.c0024f68-3a31-462d-8c4c-1f8eb40364d2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836063885066.4fdac6b0-3673-454b-be39-3c47ad99c406"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836058251192.d6154dbf-a713-4851-b5e7-7da65d51328b"}}},{"fullUrl":"Practitioner/1734642836058251192.d6154dbf-a713-4851-b5e7-7da65d51328b","resource":{"resourceType":"Practitioner","id":"1734642836058251192.d6154dbf-a713-4851-b5e7-7da65d51328b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836063885066.4fdac6b0-3673-454b-be39-3c47ad99c406","resource":{"resourceType":"Practitioner","id":"1734642836063885066.4fdac6b0-3673-454b-be39-3c47ad99c406","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836076773403.efc4681d-b823-4b5f-9e64-cfeed8c3674a","resource":{"resourceType":"ServiceRequest","id":"1734642836076773403.efc4681d-b823-4b5f-9e64-cfeed8c3674a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836073556401.f853219e-8dde-4318-a5a9-8ae0289c4b84"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836068261212.ab0b29d1-d48a-4c5e-a083-cc3c3298c40e"}}},{"fullUrl":"Practitioner/1734642836068261212.ab0b29d1-d48a-4c5e-a083-cc3c3298c40e","resource":{"resourceType":"Practitioner","id":"1734642836068261212.ab0b29d1-d48a-4c5e-a083-cc3c3298c40e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836073556401.f853219e-8dde-4318-a5a9-8ae0289c4b84","resource":{"resourceType":"Practitioner","id":"1734642836073556401.f853219e-8dde-4318-a5a9-8ae0289c4b84","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836085204032.3d025d7f-c9f7-44ab-b378-d8e847c9f112","resource":{"resourceType":"ServiceRequest","id":"1734642836085204032.3d025d7f-c9f7-44ab-b378-d8e847c9f112","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836083086551.64e63981-f816-4d43-ab75-ca106ff4a9c0"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836078576043.9fdcc34b-850a-49d1-92d0-4acd76e48db8"}}},{"fullUrl":"Practitioner/1734642836078576043.9fdcc34b-850a-49d1-92d0-4acd76e48db8","resource":{"resourceType":"Practitioner","id":"1734642836078576043.9fdcc34b-850a-49d1-92d0-4acd76e48db8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836083086551.64e63981-f816-4d43-ab75-ca106ff4a9c0","resource":{"resourceType":"Practitioner","id":"1734642836083086551.64e63981-f816-4d43-ab75-ca106ff4a9c0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836093684704.09c2781f-863b-4633-b9d0-254380db9652","resource":{"resourceType":"ServiceRequest","id":"1734642836093684704.09c2781f-863b-4633-b9d0-254380db9652","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836091421470.c57e7997-3156-452d-a1de-fc12947db6c0"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836086977798.3a78e560-72b8-4dc9-9f9c-3c0b7112bde7"}}},{"fullUrl":"Practitioner/1734642836086977798.3a78e560-72b8-4dc9-9f9c-3c0b7112bde7","resource":{"resourceType":"Practitioner","id":"1734642836086977798.3a78e560-72b8-4dc9-9f9c-3c0b7112bde7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836091421470.c57e7997-3156-452d-a1de-fc12947db6c0","resource":{"resourceType":"Practitioner","id":"1734642836091421470.c57e7997-3156-452d-a1de-fc12947db6c0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836104663571.4150e042-8d2d-467e-aecb-0808af0028dc","resource":{"resourceType":"ServiceRequest","id":"1734642836104663571.4150e042-8d2d-467e-aecb-0808af0028dc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836101449394.9e5e17e4-1e5c-48b6-925d-1529a8bffdb8"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836095687129.cb130e9f-e569-4849-9879-883260c1e2d7"}}},{"fullUrl":"Practitioner/1734642836095687129.cb130e9f-e569-4849-9879-883260c1e2d7","resource":{"resourceType":"Practitioner","id":"1734642836095687129.cb130e9f-e569-4849-9879-883260c1e2d7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836101449394.9e5e17e4-1e5c-48b6-925d-1529a8bffdb8","resource":{"resourceType":"Practitioner","id":"1734642836101449394.9e5e17e4-1e5c-48b6-925d-1529a8bffdb8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836118459249.6fd7dcd8-2885-4096-92ca-9fa2d58741ba","resource":{"resourceType":"ServiceRequest","id":"1734642836118459249.6fd7dcd8-2885-4096-92ca-9fa2d58741ba","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836116330468.70813813-8b8f-47f8-b98f-d05c0c139740"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836111219233.c43b56e6-ea7f-4103-876e-b0117b563be5"}}},{"fullUrl":"Practitioner/1734642836111219233.c43b56e6-ea7f-4103-876e-b0117b563be5","resource":{"resourceType":"Practitioner","id":"1734642836111219233.c43b56e6-ea7f-4103-876e-b0117b563be5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836116330468.70813813-8b8f-47f8-b98f-d05c0c139740","resource":{"resourceType":"Practitioner","id":"1734642836116330468.70813813-8b8f-47f8-b98f-d05c0c139740","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836126731581.9639d51d-4694-444e-bfd8-f7db800c297a","resource":{"resourceType":"ServiceRequest","id":"1734642836126731581.9639d51d-4694-444e-bfd8-f7db800c297a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836124660838.c4497539-e198-4195-b0cd-20680c1001cd"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836120364372.101d9f1f-0b20-4019-ba92-a7e21083b3e4"}}},{"fullUrl":"Practitioner/1734642836120364372.101d9f1f-0b20-4019-ba92-a7e21083b3e4","resource":{"resourceType":"Practitioner","id":"1734642836120364372.101d9f1f-0b20-4019-ba92-a7e21083b3e4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836124660838.c4497539-e198-4195-b0cd-20680c1001cd","resource":{"resourceType":"Practitioner","id":"1734642836124660838.c4497539-e198-4195-b0cd-20680c1001cd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836135727690.a5409a06-8973-446d-9c0e-cf6ce30f4415","resource":{"resourceType":"ServiceRequest","id":"1734642836135727690.a5409a06-8973-446d-9c0e-cf6ce30f4415","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836132852599.86fa7dd3-7d9d-46dd-94e2-070441b17583"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836128525094.5478cb97-38bb-473c-b840-7740952ecb80"}}},{"fullUrl":"Practitioner/1734642836128525094.5478cb97-38bb-473c-b840-7740952ecb80","resource":{"resourceType":"Practitioner","id":"1734642836128525094.5478cb97-38bb-473c-b840-7740952ecb80","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836132852599.86fa7dd3-7d9d-46dd-94e2-070441b17583","resource":{"resourceType":"Practitioner","id":"1734642836132852599.86fa7dd3-7d9d-46dd-94e2-070441b17583","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836144984498.b950bb69-4d55-4b65-a036-941ce079722b","resource":{"resourceType":"ServiceRequest","id":"1734642836144984498.b950bb69-4d55-4b65-a036-941ce079722b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836142663055.a1ab8a7b-4324-43bb-b7dd-178be5837024"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836138180169.30d3418b-38b0-4d21-af04-63cee30b882d"}}},{"fullUrl":"Practitioner/1734642836138180169.30d3418b-38b0-4d21-af04-63cee30b882d","resource":{"resourceType":"Practitioner","id":"1734642836138180169.30d3418b-38b0-4d21-af04-63cee30b882d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836142663055.a1ab8a7b-4324-43bb-b7dd-178be5837024","resource":{"resourceType":"Practitioner","id":"1734642836142663055.a1ab8a7b-4324-43bb-b7dd-178be5837024","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"DiagnosticReport/1734642836152439978.c27b00f3-e85a-4103-a989-e69a6c752aa0","resource":{"resourceType":"DiagnosticReport","id":"1734642836152439978.c27b00f3-e85a-4103-a989-e69a6c752aa0","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"629813494"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"629813494"}],"basedOn":[{"reference":"ServiceRequest/1734642835927550611.15f19c4c-cd05-422d-9a24-75ab8e88a542"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835879945755.3ee6708d-99bb-4e92-a30f-474a2f12d152"}]}},{"fullUrl":"DiagnosticReport/1734642836155870350.f904bf10-c9bb-461c-a2fb-670399604fd6","resource":{"resourceType":"DiagnosticReport","id":"1734642836155870350.f904bf10-c9bb-461c-a2fb-670399604fd6","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642835941000502.b7fd5885-1310-4bc8-8167-eaa7262486ca"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835881328738.2ece1ee9-b366-462e-8db5-6257c715f607"}],"result":[{"reference":"Observation/1734642835577334424.adac7e49-c88b-4c5c-bda3-24bfaf62119c"},{"reference":"Observation/1734642835582945910.f0c81174-275c-4f6d-9003-10c4c6cee05f"},{"reference":"Observation/1734642835585626967.e771b53b-9a27-423b-bd97-b0cc10b0fc17"},{"reference":"Observation/1734642835587943501.7508be73-3956-4c30-9fb2-9a420d225bbd"},{"reference":"Observation/1734642835590874687.0cc4344e-4653-4c68-a6f6-028b9a5cc0a5"},{"reference":"Observation/1734642835592969425.13fe95c5-d463-4a95-9ae7-acd437529f9a"},{"reference":"Observation/1734642835595033996.cbdcdf22-3e1c-4658-bf95-66d53413f145"}]}},{"fullUrl":"DiagnosticReport/1734642836159725770.57b4f680-c5b0-4705-85dd-f6f743270117","resource":{"resourceType":"DiagnosticReport","id":"1734642836159725770.57b4f680-c5b0-4705-85dd-f6f743270117","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642835949625414.edecca52-c3ce-4d43-8ece-0be736d5ce0a"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835882661087.e5b0aee2-3f66-4f93-a340-d45570cf5a2a"}],"result":[{"reference":"Observation/1734642835597001375.991eef6e-98ae-4728-b2a9-eb4dc15ddfe5"},{"reference":"Observation/1734642835599231657.6cd136e8-cdd9-478e-b513-a69682d52dcf"},{"reference":"Observation/1734642835601376860.20738e16-4487-4275-9d1e-2f1d7899a49b"},{"reference":"Observation/1734642835603619726.92836d62-2c43-4fd5-862e-68ccb53f0583"},{"reference":"Observation/1734642835606051145.294d5bf0-4e62-482d-b456-f5bd54ddf19e"},{"reference":"Observation/1734642835608401953.3951d7cb-f4c3-43af-a159-eb1c1bf9c2e9"},{"reference":"Observation/1734642835610633307.d65b7233-9e23-4cbc-9126-9fc566126230"},{"reference":"Observation/1734642835612775124.0d6a0867-1ae6-48c5-a587-cb41a3e52476"},{"reference":"Observation/1734642835615633444.91b240be-e8aa-4061-9564-89f9e6e0d5bb"},{"reference":"Observation/1734642835617901266.8e54520a-9875-4c84-b38a-3fbd6709a7a7"},{"reference":"Observation/1734642835619938276.c720e577-5b06-4c8d-8217-8272358029fb"}]}},{"fullUrl":"DiagnosticReport/1734642836163296335.30331610-9333-48d7-aced-405f3bbc49b3","resource":{"resourceType":"DiagnosticReport","id":"1734642836163296335.30331610-9333-48d7-aced-405f3bbc49b3","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642835958395841.a4adb492-9f43-4800-a3a5-6d63c819c192"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835883994086.44028de6-9879-47ad-be95-b0a7f10d38c2"}]}},{"fullUrl":"DiagnosticReport/1734642836170026284.eac8ce49-4557-408b-b25c-603aafd0fbc6","resource":{"resourceType":"DiagnosticReport","id":"1734642836170026284.eac8ce49-4557-408b-b25c-603aafd0fbc6","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642835967830452.6b2c683a-67fb-45af-8256-554caff3c3db"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835885323229.ad7c245b-7e02-457a-9ea4-4cf6d2a2e0c2"}],"result":[{"reference":"Observation/1734642835622290176.0ed5d39e-4af1-41f8-98da-7b956ad1aca9"},{"reference":"Observation/1734642835624587333.d71f9ce0-54c1-4fb0-9c27-bc6838cc8934"},{"reference":"Observation/1734642835630433513.ff02305e-15bd-446f-8015-32a1ccd7995c"},{"reference":"Observation/1734642835632748323.c4c14367-0fae-4255-b87c-e5b6722fce27"},{"reference":"Observation/1734642835635217113.8be785a8-0375-46eb-94a3-7f2cf7a0dff0"},{"reference":"Observation/1734642835637771543.7b620553-e589-49ea-a380-6a8b7474b329"},{"reference":"Observation/1734642835642122852.6a859c86-d8f1-4d0f-a2d3-b4fdd58a36f4"},{"reference":"Observation/1734642835648986983.5fe75d08-ac6d-4ba1-8a89-ac1fa3be0c7c"},{"reference":"Observation/1734642835651324957.ffdae7fc-33c6-4c8b-b7a6-334986cf820f"},{"reference":"Observation/1734642835653464299.ecdb8485-1be4-4bc7-9921-70ef134ea027"},{"reference":"Observation/1734642835655634949.ada7fa6f-d208-4f95-ae2d-c3f94913127e"},{"reference":"Observation/1734642835657787706.19dec618-554e-4232-8b8f-718feb2c0810"},{"reference":"Observation/1734642835659892012.7868a556-8258-4cd3-b653-542182d8fcae"},{"reference":"Observation/1734642835662076538.a387bfe4-b363-4221-89f6-d0f2ea71e213"},{"reference":"Observation/1734642835664344942.f66efdf8-7f8a-4e48-b80b-0e8f843d1a96"},{"reference":"Observation/1734642835667556273.9a9e4a0b-7125-471c-8001-360221a9cef2"},{"reference":"Observation/1734642835670226080.0806c275-8281-4657-8edd-7f65f0a1d343"},{"reference":"Observation/1734642835672541752.67036c13-e742-4a9e-8a48-18221261335e"},{"reference":"Observation/1734642835674459107.60d5c469-6e3b-4dbf-a66d-04ff03f052af"}]}},{"fullUrl":"DiagnosticReport/1734642836174794145.4b4522ad-a76c-40a1-b33f-e956981336b3","resource":{"resourceType":"DiagnosticReport","id":"1734642836174794145.4b4522ad-a76c-40a1-b33f-e956981336b3","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642835976762751.4671e756-9bc6-47e2-99a9-87cbff04170f"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835886677659.bce4faf7-9b2b-4856-93b8-e4e7a6ee1781"}],"result":[{"reference":"Observation/1734642835676555097.d17991b9-f738-4c03-bc2d-eca221d2d49c"},{"reference":"Observation/1734642835678329685.bb4ed8d6-7e4d-4959-972f-a5bc6f2b63d1"}]}},{"fullUrl":"DiagnosticReport/1734642836181665440.cf879ec4-f8ad-4f96-a9af-c27df992d494","resource":{"resourceType":"DiagnosticReport","id":"1734642836181665440.cf879ec4-f8ad-4f96-a9af-c27df992d494","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642835985781282.f3e1b584-8656-44fa-9cbb-414ec5d518aa"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835888069799.b47930f0-3abd-40f8-ad2f-e301dca9511c"}],"result":[{"reference":"Observation/1734642835680351065.d01da517-1280-4a4b-a9fa-42f5aba5354e"},{"reference":"Observation/1734642835683365418.cf9c3b1d-9ef4-4b0e-a8c8-bce7fd481781"},{"reference":"Observation/1734642835686681365.bc96eed3-e560-4185-9b8e-654ec88f2776"},{"reference":"Observation/1734642835693717720.57ef4762-7f1a-49c1-afac-2de54e42e258"},{"reference":"Observation/1734642835696077585.0a2bdff7-f737-4624-8c1b-9cfe764fca68"},{"reference":"Observation/1734642835698315441.7cb7425f-81df-4530-a5c2-76c97210fef3"},{"reference":"Observation/1734642835700583725.13e5ba61-8a59-482f-865b-4054fe5a03e1"},{"reference":"Observation/1734642835702659758.ecf642b8-29ec-4734-a174-beea3fafc7a9"},{"reference":"Observation/1734642835704761468.d497718f-0b69-40cc-9b9f-7dc62c83c950"},{"reference":"Observation/1734642835707309036.fe794609-acd5-4805-9440-2ae4c749af09"},{"reference":"Observation/1734642835709563824.fb6d07a6-0c21-455c-b5c5-6a6d07184265"},{"reference":"Observation/1734642835712047531.949c4810-8298-4150-9a2f-60508ec56a7a"},{"reference":"Observation/1734642835714330091.533e0fb7-63d2-4b19-8f6e-837cd278b3e5"},{"reference":"Observation/1734642835717945851.52ec5e40-d07b-4918-bd1b-7dc4845614dd"},{"reference":"Observation/1734642835721515655.e9fdf13b-f915-43b6-b914-c76a2c9170c0"},{"reference":"Observation/1734642835724860106.e1972cf2-ded8-44f3-a5dd-3b691a84a20b"},{"reference":"Observation/1734642835728591664.6f8f4ce7-ed75-4423-b5d6-f6d826b13667"},{"reference":"Observation/1734642835731845756.4261f819-24ea-4e74-b9c6-c0db5c089185"},{"reference":"Observation/1734642835735027652.29fdca8c-a1d4-414a-8878-fa42c159b3b6"},{"reference":"Observation/1734642835737321944.98a898ef-4d63-406d-bac4-fbd5742651b4"},{"reference":"Observation/1734642835739581091.e142a554-00dd-421d-b9df-941c59dab7ad"},{"reference":"Observation/1734642835741723989.c21e4681-4463-4095-97b5-6791c5ae5198"},{"reference":"Observation/1734642835744517557.8732d578-4481-4f1d-b8c3-2d0bbae471cd"},{"reference":"Observation/1734642835748030945.c1470e5e-264f-4ff2-8fc8-1b9f8af8639e"},{"reference":"Observation/1734642835751159231.2987988f-57e1-4e2b-8ddd-baddd564dab2"},{"reference":"Observation/1734642835754135622.5d7fe074-ad95-4bf9-ad1d-5cbfd0ee5e4a"}]}},{"fullUrl":"DiagnosticReport/1734642836185431782.2ccfdb9d-6d9f-4b94-b827-a9430b5275bc","resource":{"resourceType":"DiagnosticReport","id":"1734642836185431782.2ccfdb9d-6d9f-4b94-b827-a9430b5275bc","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642835994828507.bac52049-d0ec-4b36-9476-265990236057"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835889386628.6c8c4572-8380-4979-8ce1-cf1b8f09f86e"}],"result":[{"reference":"Observation/1734642835757049386.d5e1dc03-14f3-4d09-9e13-40d1b0f3f2ce"},{"reference":"Observation/1734642835761114529.4f646e63-7d80-49fa-87b9-0702fa57873d"},{"reference":"Observation/1734642835764257813.60871a6d-a6bc-43fc-9961-fc4c4ef1df91"},{"reference":"Observation/1734642835767149175.e4116ccc-45b8-45ab-9659-af0eb59ef910"},{"reference":"Observation/1734642835769714585.15e3f529-9399-466d-9f7b-351063db3081"},{"reference":"Observation/1734642835771802080.ca112406-b41b-4d50-9b9c-1f76aa6ff9c5"},{"reference":"Observation/1734642835773922456.a87d9766-0905-4819-b5e7-266adca96e79"},{"reference":"Observation/1734642835776021562.d1299532-0d18-4892-b398-2ce43afbe648"},{"reference":"Observation/1734642835778173517.01535e92-5e00-47e4-ab3d-110a854dad56"},{"reference":"Observation/1734642835780284095.308f13e8-a730-46bb-a3b8-ea40778e9d6f"}]}},{"fullUrl":"DiagnosticReport/1734642836188456093.6b6e2444-1cb6-4e00-bd3a-aed46f112a17","resource":{"resourceType":"DiagnosticReport","id":"1734642836188456093.6b6e2444-1cb6-4e00-bd3a-aed46f112a17","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836003534371.0bd71a28-7194-446c-87bf-1feb5ed240b9"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835890707054.9d2a93bf-6820-483e-99c2-19c78ad02c24"}],"result":[{"reference":"Observation/1734642835782344608.424f6717-4153-4e62-ac87-8042351f8682"},{"reference":"Observation/1734642835784477347.0a8ce02f-9ef6-466a-8d2e-e3302ce84725"},{"reference":"Observation/1734642835786278986.358222a6-0f06-41da-8340-066d9180f518"}]}},{"fullUrl":"DiagnosticReport/1734642836191457080.1b9335a6-456e-4b5a-b8fa-c0246b1b35f5","resource":{"resourceType":"DiagnosticReport","id":"1734642836191457080.1b9335a6-456e-4b5a-b8fa-c0246b1b35f5","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836012482840.055e9451-e361-44d2-8377-6225bda2e501"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835892043500.d4e333c4-01d2-4035-9ee2-aae7fc8ffcb1"}],"result":[{"reference":"Observation/1734642835788626087.be190f26-4ec7-4ff3-9cbe-2b45da1171c8"},{"reference":"Observation/1734642835791198380.12b44a0e-d59a-4599-b787-cf8c952c79d7"},{"reference":"Observation/1734642835793057767.37902251-42da-4eda-9d1f-f8cc30c48bb6"}]}},{"fullUrl":"DiagnosticReport/1734642836195354398.dfe86879-7556-4767-8397-31a3feac8176","resource":{"resourceType":"DiagnosticReport","id":"1734642836195354398.dfe86879-7556-4767-8397-31a3feac8176","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836025615636.ac170df8-8fbf-43ab-a56f-be6923b5dfe9"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835893446521.c4e97d51-7f4a-4dea-9187-d50689ce9ff8"}],"result":[{"reference":"Observation/1734642835795058388.ef3fb068-7e38-461f-840a-55de5c14e7c9"},{"reference":"Observation/1734642835797268182.1daf15b4-f748-4976-a0a6-9a517d37c4ab"},{"reference":"Observation/1734642835800106975.6f9a33a8-27cb-4c06-ab6f-7bed876d63eb"}]}},{"fullUrl":"DiagnosticReport/1734642836198703929.4c2049ad-8f8e-4639-948d-4ca1db4e92e4","resource":{"resourceType":"DiagnosticReport","id":"1734642836198703929.4c2049ad-8f8e-4639-948d-4ca1db4e92e4","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836035456439.3297a780-9e64-4129-9ea6-bd9baff3fff6"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835894846045.9ea6ecb4-bd10-4f14-9cf8-9054fd3deaa3"}],"result":[{"reference":"Observation/1734642835802627231.8168e21a-25dc-43d9-8188-8943062d61ef"},{"reference":"Observation/1734642835804808662.c39b6f7a-5b9a-49ae-8ffe-d263a848d152"},{"reference":"Observation/1734642835806808592.2ee61489-aae4-46a6-a99b-4a6235df84ba"}]}},{"fullUrl":"DiagnosticReport/1734642836201721948.3960cf5c-983f-4859-9e35-8c3ac6cd0fe4","resource":{"resourceType":"DiagnosticReport","id":"1734642836201721948.3960cf5c-983f-4859-9e35-8c3ac6cd0fe4","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836045415173.3608f522-f1dc-443d-8cd4-bce75c901f92"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835896278020.66c2f212-d10f-4001-93db-1974b6283e84"}],"result":[{"reference":"Observation/1734642835809150183.7a92d9f1-8ce3-4d31-ac64-0ac7f3a48a37"},{"reference":"Observation/1734642835811093036.f66355a4-96ff-4166-b67f-a902f4ee99f6"}]}},{"fullUrl":"DiagnosticReport/1734642836204801984.350c0e54-ac24-4e7f-838f-71b69a75dd67","resource":{"resourceType":"DiagnosticReport","id":"1734642836204801984.350c0e54-ac24-4e7f-838f-71b69a75dd67","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836056452590.3492bfb2-2f73-4054-bb68-2b241edde680"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835897674319.bffdfe13-2b1a-4282-97cc-b1fddd091d94"}],"result":[{"reference":"Observation/1734642835814495506.d6042a6a-0f25-4f28-bc8f-d43f7cc4606d"},{"reference":"Observation/1734642835816830655.dd7061fd-a46d-4721-a6b1-f6d34b76fd59"},{"reference":"Observation/1734642835818678400.3cad2e81-9353-4195-9b85-b4639f2df0a1"}]}},{"fullUrl":"DiagnosticReport/1734642836208398798.60ac234a-0077-45c4-8fa7-838532fcb1a3","resource":{"resourceType":"DiagnosticReport","id":"1734642836208398798.60ac234a-0077-45c4-8fa7-838532fcb1a3","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836065986547.c0024f68-3a31-462d-8c4c-1f8eb40364d2"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835899018790.7c60b51a-4427-41cd-a98c-a5422ae58adc"}],"result":[{"reference":"Observation/1734642835820822640.78993f3a-2921-4f89-9519-419e2299f964"},{"reference":"Observation/1734642835827458874.9ad19a02-cdf3-486a-b4c8-52715b6f8ff5"},{"reference":"Observation/1734642835829308613.9a48f9a5-c08e-4bce-83f7-e4baff4085f4"}]}},{"fullUrl":"DiagnosticReport/1734642836211461451.b445825b-9bc5-4f0e-8c02-2efec15eea80","resource":{"resourceType":"DiagnosticReport","id":"1734642836211461451.b445825b-9bc5-4f0e-8c02-2efec15eea80","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836076773403.efc4681d-b823-4b5f-9e64-cfeed8c3674a"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835900357620.8685ee81-baff-4a99-abe8-cfc067d23e48"}],"result":[{"reference":"Observation/1734642835831324272.429f1043-13bd-40b2-83e1-43c39ba641f3"},{"reference":"Observation/1734642835833543373.3a1f7ad9-e8d2-4ee3-b2c0-f147550c88e1"},{"reference":"Observation/1734642835835933846.672c48cc-f970-4c68-a58e-783db9cbaf42"}]}},{"fullUrl":"DiagnosticReport/1734642836214831090.ee9eb06b-e557-4f06-a2f9-fa45857f934e","resource":{"resourceType":"DiagnosticReport","id":"1734642836214831090.ee9eb06b-e557-4f06-a2f9-fa45857f934e","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836085204032.3d025d7f-c9f7-44ab-b378-d8e847c9f112"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835901748849.8e662fe9-7b0e-4d40-a006-6a1805ff10c3"}],"result":[{"reference":"Observation/1734642835838105198.47b4cbbc-c75c-42a2-a8b1-af0b49476367"},{"reference":"Observation/1734642835840285286.269c7d6b-46ce-44ac-8142-886554ce0e8a"},{"reference":"Observation/1734642835842157116.3f2869cc-9314-4fca-bb36-30d8cf4bac45"}]}},{"fullUrl":"DiagnosticReport/1734642836222755552.3e6f8397-1b58-4c1a-b40d-beef72dfd7f2","resource":{"resourceType":"DiagnosticReport","id":"1734642836222755552.3e6f8397-1b58-4c1a-b40d-beef72dfd7f2","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836093684704.09c2781f-863b-4633-b9d0-254380db9652"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835903222171.7a16da03-78a9-45d5-b686-1ff3acf8c25a"}],"result":[{"reference":"Observation/1734642835843922075.7248c8b7-1ca6-4c8d-a7ce-d36eb1313e78"},{"reference":"Observation/1734642835845986376.9b3c48f8-00d5-4808-88fb-e863246b8219"},{"reference":"Observation/1734642835847829352.daf1d979-25f0-4626-a59c-d58a1cf752fb"}]}},{"fullUrl":"DiagnosticReport/1734642836226132955.b2820374-c2e0-4889-9afe-bdc2a1dca75b","resource":{"resourceType":"DiagnosticReport","id":"1734642836226132955.b2820374-c2e0-4889-9afe-bdc2a1dca75b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836104663571.4150e042-8d2d-467e-aecb-0808af0028dc"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835904754745.9c786fc7-5654-4a1b-99c3-9b4e70acec52"}],"result":[{"reference":"Observation/1734642835849882262.b094803d-6e75-40ed-afd6-42f5594411fa"},{"reference":"Observation/1734642835851989233.a88495e1-8d29-4236-bc74-0abc7acc0815"},{"reference":"Observation/1734642835853894515.0b1a6c16-c717-4be4-ba46-443dd67f6f09"}]}},{"fullUrl":"DiagnosticReport/1734642836229369304.f3163167-c3a2-4db6-a5d0-b34a381c8f2a","resource":{"resourceType":"DiagnosticReport","id":"1734642836229369304.f3163167-c3a2-4db6-a5d0-b34a381c8f2a","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836118459249.6fd7dcd8-2885-4096-92ca-9fa2d58741ba"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835906509786.467fff36-3493-4fef-a417-1e361ed7c9ec"}],"result":[{"reference":"Observation/1734642835855901248.604a24fd-9d48-4fe7-bc8d-16c5ddbe126d"},{"reference":"Observation/1734642835857944600.d19ae395-b211-464f-a382-c075ce46aeaf"}]}},{"fullUrl":"DiagnosticReport/1734642836232969475.9f766400-c9d9-4ce5-ad62-e68dc8dfcba3","resource":{"resourceType":"DiagnosticReport","id":"1734642836232969475.9f766400-c9d9-4ce5-ad62-e68dc8dfcba3","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836126731581.9639d51d-4694-444e-bfd8-f7db800c297a"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835907887991.1862e56b-e527-479d-bcd5-4e48b66db064"}],"result":[{"reference":"Observation/1734642835859986879.bdca2177-dd1f-46e4-ad97-2f668239e329"},{"reference":"Observation/1734642835862065086.531f3b8f-6253-4dee-9d64-10b73fd08845"},{"reference":"Observation/1734642835863895038.33dd14ea-e19d-4ffe-b7b9-e8b63529536d"}]}},{"fullUrl":"DiagnosticReport/1734642836236317372.7970abee-6352-427f-ad38-6bd422457de4","resource":{"resourceType":"DiagnosticReport","id":"1734642836236317372.7970abee-6352-427f-ad38-6bd422457de4","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836135727690.a5409a06-8973-446d-9c0e-cf6ce30f4415"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835909256276.3006f8e3-c5ec-4176-b52d-5f53f1fa0619"}],"result":[{"reference":"Observation/1734642835865991418.fd9eb291-6ed5-4586-b773-e47a2259f6da"},{"reference":"Observation/1734642835867833913.65ff906c-ae0d-499b-a553-26c6e03013dd"}]}},{"fullUrl":"DiagnosticReport/1734642836239591572.8e42c1d3-2acd-4fb2-bd9f-83f12fbcaa69","resource":{"resourceType":"DiagnosticReport","id":"1734642836239591572.8e42c1d3-2acd-4fb2-bd9f-83f12fbcaa69","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836144984498.b950bb69-4d55-4b65-a036-941ce079722b"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835910566814.cd3d4ef0-25d8-4b61-b944-ab83e982b62e"}],"result":[{"reference":"Observation/1734642835869941726.d0b1e57b-e016-4d29-9411-fc0f04444fbe"}]}}]}
diff --git a/examples/Test/GoldenCopy/Expected/005_ORU_R01_golden_copy_expected_out_of_range.fhir b/examples/Test/GoldenCopy/Expected/005_ORU_R01_golden_copy_expected_out_of_range.fhir
new file mode 100644
index 000000000..fe3143868
--- /dev/null
+++ b/examples/Test/GoldenCopy/Expected/005_ORU_R01_golden_copy_expected_out_of_range.fhir
@@ -0,0 +1 @@
+{"resourceType":"Bundle","id":"1734642835818825320.534a9032-ba87-4bdb-9a42-fc1d2d43715e","meta":{"lastUpdated":"2024-12-19T21:13:55.818+00:00"},"identifier":{"system":"https://reportstream.cdc.gov/prime-router","value":"005"},"type":"message","timestamp":"2024-10-18T05:00:17.000+00:00","entry":[{"fullUrl":"MessageHeader/1734642835820163649.d346235d-84f1-44c2-8f0d-36f991315f26","resource":{"resourceType":"MessageHeader","id":"1734642835820163649.d346235d-84f1-44c2-8f0d-36f991315f26","meta":{"tag":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0103","code":"N"}]},"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/msh-message-header","extension":[{"url":"MSH.7","valueString":"20241018050017"}]}],"eventCoding":{"system":"http://terminology.hl7.org/CodeSystem/v2-0003","code":"R01","display":"ORU^R01^ORU_R01"},"destination":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id","valueString":"9414049"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id-type","valueString":"L,M,N"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.5"}],"name":"SISHIERECEIVER","receiver":{"reference":"Organization/1734642835819852235.c571e1b3-fe0d-4f46-8857-84a728e6dc99"}}],"sender":{"reference":"Organization/1734642835819067885.7264a948-3f3b-46fc-b834-0a1e75e6c738"},"source":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"SISGDSP"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.3"}],"name":"SISGDSP","_endpoint":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}}},{"fullUrl":"Organization/1734642835819067885.7264a948-3f3b-46fc-b834-0a1e75e6c738","resource":{"resourceType":"Organization","id":"1734642835819067885.7264a948-3f3b-46fc-b834-0a1e75e6c738","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Organization/1734642835819852235.c571e1b3-fe0d-4f46-8857-84a728e6dc99","resource":{"resourceType":"Organization","id":"1734642835819852235.c571e1b3-fe0d-4f46-8857-84a728e6dc99","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.6"}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.2,HD.3"}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301","code":"L,M,N"}]},"value":"automated-staging-test-receiver-id"}]}},{"fullUrl":"Provenance/1734642835821339795.15c2e814-69d8-42c4-9922-e77903ca3ac3","resource":{"resourceType":"Provenance","id":"1734642835821339795.15c2e814-69d8-42c4-9922-e77903ca3ac3","target":[{"reference":"MessageHeader/1734642835820163649.d346235d-84f1-44c2-8f0d-36f991315f26"},{"reference":"DiagnosticReport/1734642836428415372.6590f295-01a4-4daf-8dbe-5bd3622a42e0"},{"reference":"DiagnosticReport/1734642836431845444.b43c3ad3-80b9-4953-8e18-f633dc149e5f"},{"reference":"DiagnosticReport/1734642836435304150.acabebcf-c09a-4a07-831e-36a3a4272bb7"},{"reference":"DiagnosticReport/1734642836438843987.f3795167-105b-4938-addb-6b6b55da9cca"},{"reference":"DiagnosticReport/1734642836441766538.3d5e3d2c-d384-4d90-bae3-c3e267021f88"},{"reference":"DiagnosticReport/1734642836445954190.7119e2b8-859d-4a82-a1d7-cca3136dbecc"},{"reference":"DiagnosticReport/1734642836448954536.99e8049b-82a6-48d5-85c6-590001827d87"},{"reference":"DiagnosticReport/1734642836453527821.28cfe23b-02a1-47c7-829c-e175148e22cf"},{"reference":"DiagnosticReport/1734642836457059804.8101d8e9-73fe-4d92-9ae3-d96d52c24b21"},{"reference":"DiagnosticReport/1734642836460082833.78fc2d69-f794-4288-bfd2-8ae0e241dafa"},{"reference":"DiagnosticReport/1734642836463081496.2b7dca61-1b60-47db-9418-7da5ce8fbf61"},{"reference":"DiagnosticReport/1734642836466120635.370ae00a-25fe-4fa5-a324-f887bbe2a856"},{"reference":"DiagnosticReport/1734642836469187225.77d97fba-4680-41c3-a53d-f3f9fafc8176"},{"reference":"DiagnosticReport/1734642836472186179.2764089d-c788-49cd-a6aa-970788903941"},{"reference":"DiagnosticReport/1734642836475203036.31a490a5-9b63-446e-8f9e-eb2d9fd2721e"},{"reference":"DiagnosticReport/1734642836478257283.e475367b-b110-4a83-971d-f42c9a4a8087"},{"reference":"DiagnosticReport/1734642836481289398.62ce13b4-be11-4411-992a-d77837e17758"},{"reference":"DiagnosticReport/1734642836484595237.313b8922-17ff-47f8-9036-1dd0bb5c0312"},{"reference":"DiagnosticReport/1734642836487660084.7412cbdc-131a-4a55-bc32-826e6c7d55b0"},{"reference":"DiagnosticReport/1734642836490747644.d0b2216d-bb2b-48ee-952f-26eb62e1a6a0"},{"reference":"DiagnosticReport/1734642836493766444.1ef481f0-049d-4035-9636-8ba48034e6e1"},{"reference":"DiagnosticReport/1734642836496970072.faa9ccef-26ff-4273-a633-f56f219b527a"},{"reference":"DiagnosticReport/1734642836500347314.577024eb-c231-462c-821a-e8479ec274fa"},{"reference":"DiagnosticReport/1734642836503350836.519e95d2-5b56-4697-b578-e00abbfe9c74"}],"recorded":"2024-10-18T05:00:17Z","activity":{"coding":[{"display":"ORU^R01^ORU_R01"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"author"}]},"who":{"reference":"Organization/1734642835821162452.537f5845-ade5-4fb1-8a22-84be3254bf1b"}}]}},{"fullUrl":"Organization/1734642835821162452.537f5845-ade5-4fb1-8a22-84be3254bf1b","resource":{"resourceType":"Organization","id":"1734642835821162452.537f5845-ade5-4fb1-8a22-84be3254bf1b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Provenance/1734642835822135557.64f58d82-8e0f-4a41-a9d4-50ea5e8302b5","resource":{"resourceType":"Provenance","id":"1734642835822135557.64f58d82-8e0f-4a41-a9d4-50ea5e8302b5","recorded":"2024-12-19T21:13:55Z","policy":["http://hl7.org/fhir/uv/v2mappings/message-oru-r01-to-bundle"],"activity":{"coding":[{"code":"v2-FHIR transformation"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"assembler"}]},"who":{"reference":"Organization/1734642835821839762.1f61c5d1-11ec-4342-9713-0b5de2240f26"}}]}},{"fullUrl":"Organization/1734642835821839762.1f61c5d1-11ec-4342-9713-0b5de2240f26","resource":{"resourceType":"Organization","id":"1734642835821839762.1f61c5d1-11ec-4342-9713-0b5de2240f26","identifier":[{"value":"CDC PRIME - Atlanta"},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301"}]},"system":"urn:ietf:rfc:3986","value":"2.16.840.1.114222.4.1.237821"}]}},{"fullUrl":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac","resource":{"resourceType":"Patient","id":"1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cx-identifier","extension":[{"url":"CX.5","valueString":"MR"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"PID.3"}],"type":{"coding":[{"code":"MR"}]},"value":"32550867","assigner":{"reference":"Organization/1734642835826932973.ec8b6fe2-94c2-4702-b715-d2c2a4110c5c"}}],"name":[{"family":"*****PII REMOVED******"}],"contact":[{"name":{"family":"*****PII REMOVED******"}}]}},{"fullUrl":"Organization/1734642835826932973.ec8b6fe2-94c2-4702-b715-d2c2a4110c5c","resource":{"resourceType":"Organization","id":"1734642835826932973.ec8b6fe2-94c2-4702-b715-d2c2a4110c5c","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"1013163542&NPI"}]}},{"fullUrl":"Provenance/1734642835832758797.ad87aabb-58b5-4a3d-b373-e749b2e46c31","resource":{"resourceType":"Provenance","id":"1734642835832758797.ad87aabb-58b5-4a3d-b373-e749b2e46c31","target":[{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"}],"recorded":"2024-12-19T21:13:55Z","activity":{"coding":[{"system":"https://terminology.hl7.org/CodeSystem/v3-DataOperation","code":"UPDATE"}]}}},{"fullUrl":"RelatedPerson/1734642835834177778.6a1f1931-0152-46d4-883a-8124f43f0033","resource":{"resourceType":"RelatedPerson","id":"1734642835834177778.6a1f1931-0152-46d4-883a-8124f43f0033","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"NK1"}],"patient":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"name":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"NK1.2"}],"family":"*****PII REMOVED******"}]}},{"fullUrl":"Observation/1734642835838348458.43fb29c2-a1a2-46ee-b73d-60e75cfa96f7","resource":{"resourceType":"Observation","id":"1734642835838348458.43fb29c2-a1a2-46ee-b73d-60e75cfa96f7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57721-3","display":"Reason for lab test in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12421-6","display":"Initial screen"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835841845246.4b04227d-09c0-4420-9c5e-e761434e1f65","resource":{"resourceType":"Observation","id":"1734642835841845246.4b04227d-09c0-4420-9c5e-e761434e1f65","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57718-9","display":"Sample quality of Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12432-3","display":"Acceptable"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835845365186.de231997-4300-4ff5-af9b-cbdd94007344","resource":{"resourceType":"Observation","id":"1734642835845365186.de231997-4300-4ff5-af9b-cbdd94007344","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57130-7","display":"Newborn screening report - overall interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18944-1","display":"Screen is out of range for at least one condition"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835848852014.ee590f13-b4e4-4667-ae32-32dd35b642a9","resource":{"resourceType":"Observation","id":"1734642835848852014.ee590f13-b4e4-4667-ae32-32dd35b642a9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57131-5","display":"Newborn conditions with positive markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA16207-5","display":"Hemoglobinopathies"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835852399236.826318e3-458b-4bcc-a558-a9b733f4aabc","resource":{"resourceType":"Observation","id":"1734642835852399236.826318e3-458b-4bcc-a558-a9b733f4aabc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57720-5","display":"Newborn conditions with equivocal markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835855517012.cdf88ff7-2886-4ac0-93de-0c14600848f9","resource":{"resourceType":"Observation","id":"1734642835855517012.cdf88ff7-2886-4ac0-93de-0c14600848f9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57724-7","display":"Newborn screening short narrative summary"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"ACTION REQUIRED\\\\.br\\\\\\\\.br\\\\NBS Testing Lab - ALLIED LABORATORY \\\\\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\\\.br\\\\\\\\.br\\\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\\\.br\\\\\\\\.br\\\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\\\.br\\\\\\\\.br\\\\Follow-up:\\\\.br\\\\\\\\.br\\\\Hb: An immediate referral to a CCS Hematology Center or a pediatric hematologist familiar with alpha thalassemia and Hb H disease is strongly recommended for this infant. \\\\.br\\\\\\\\.br\\\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\\\.br\\\\\\\\.br\\\\Methods and Limitations:\\\\.br\\\\\\\\.br\\\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\\\.br\\\\Attention Healthcare Provider:\\\\.br\\\\\\\\.br\\\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\\\.br\\\\\\\\.br\\","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835858631442.b3f1cb03-7d61-45d8-9f49-d0d51c019afc","resource":{"resourceType":"Observation","id":"1734642835858631442.b3f1cb03-7d61-45d8-9f49-d0d51c019afc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57129-9","display":"Full newborn screening summary report for display or printing"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835861724723.ddaac99b-c83c-4166-bf66-3abe0caf2011","resource":{"resourceType":"Observation","id":"1734642835861724723.ddaac99b-c83c-4166-bf66-3abe0caf2011","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"ST"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57716-3","display":"State printed on filter paper card [Identifier] in NBS card"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"CA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835865234865.4a0cf0e0-0356-4533-b278-286cffaf37d2","resource":{"resourceType":"Observation","id":"1734642835865234865.4a0cf0e0-0356-4533-b278-286cffaf37d2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"grams"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"8339-4","display":"Birthweight"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":2658,"unit":"grams"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835868488365.95c78f92-bd79-427b-81b2-f58d6b4dec65","resource":{"resourceType":"Observation","id":"1734642835868488365.95c78f92-bd79-427b-81b2-f58d6b4dec65","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57715-5","display":"Time of birth"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueTime":"0027","_valueTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"0027"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835871986425.131c2949-3134-4848-975b-0db4dab5cd69","resource":{"resourceType":"Observation","id":"1734642835871986425.131c2949-3134-4848-975b-0db4dab5cd69","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57722-1","display":"Birth plurality of Pregnancy"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12411-7","display":"Singleton"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835875460509.fe5bc4f0-03dc-4fff-869f-4265efbbcd25","resource":{"resourceType":"Observation","id":"1734642835875460509.fe5bc4f0-03dc-4fff-869f-4265efbbcd25","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"hour(s)"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"73806-2","display":"Newborn age in hours"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":28,"unit":"hour(s)"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835879131162.6fe4e08b-aa38-4172-b2ab-622ad5bea544","resource":{"resourceType":"Observation","id":"1734642835879131162.6fe4e08b-aa38-4172-b2ab-622ad5bea544","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57713-0","display":"Infant NICU factors that affect newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835882630193.254cde97-1b38-4f9b-a44a-ffa9d6f2ddf3","resource":{"resourceType":"Observation","id":"1734642835882630193.254cde97-1b38-4f9b-a44a-ffa9d6f2ddf3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67704-7","display":"Feeding types"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA16914-6","display":"Breast milk"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835885686875.54ed88d3-9a3a-41ac-a26d-999bc55565e8","resource":{"resourceType":"Observation","id":"1734642835885686875.54ed88d3-9a3a-41ac-a26d-999bc55565e8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-5","display":"Accession Number"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"272-95-009/21-2024-12","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835888799281.17429e42-1961-4d38-84fb-df544a3a024b","resource":{"resourceType":"Observation","id":"1734642835888799281.17429e42-1961-4d38-84fb-df544a3a024b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62324-9","display":"Post-discharge provider name"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"MELISSA SCALA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835891927197.09bbcc6f-cb0a-495d-a0fd-3d5a637a6560","resource":{"resourceType":"Observation","id":"1734642835891927197.09bbcc6f-cb0a-495d-a0fd-3d5a637a6560","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62327-2","display":"Post-discharge provider practice address"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835895699811.ac8311f2-11d0-4139-8e75-0d862789fa8e","resource":{"resourceType":"Observation","id":"1734642835895699811.ac8311f2-11d0-4139-8e75-0d862789fa8e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47633-3","display":"Glycine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":926,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835899291305.a684af57-f50d-4b53-8536-877c33b50d96","resource":{"resourceType":"Observation","id":"1734642835899291305.a684af57-f50d-4b53-8536-877c33b50d96","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53150-9","display":"Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":588,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1000"}]}},{"fullUrl":"Observation/1734642835903069350.b34b8876-7d82-4bbd-bc2e-27ed68fb2f0d","resource":{"resourceType":"Observation","id":"1734642835903069350.b34b8876-7d82-4bbd-bc2e-27ed68fb2f0d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47799-2","display":"Valine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":79.4,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835906837265.b0d7f760-36f1-4fc4-be37-ff54bf7d45b2","resource":{"resourceType":"Observation","id":"1734642835906837265.b0d7f760-36f1-4fc4-be37-ff54bf7d45b2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53151-7","display":"Valine/Phenylalanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":1.29739,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.3"}]}},{"fullUrl":"Observation/1734642835910461792.59d3fdd6-b67f-453f-873d-5933012c9c51","resource":{"resourceType":"Observation","id":"1734642835910461792.59d3fdd6-b67f-453f-873d-5933012c9c51","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53152-5","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":99.2,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<230"}]}},{"fullUrl":"Observation/1734642835914078924.b9721f8a-8cca-4307-aaf6-bc33777c448a","resource":{"resourceType":"Observation","id":"1734642835914078924.b9721f8a-8cca-4307-aaf6-bc33777c448a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53154-1","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.17,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.35"}]}},{"fullUrl":"Observation/1734642835917701457.cfcd58d7-2d26-48a1-bb55-b18357110171","resource":{"resourceType":"Observation","id":"1734642835917701457.cfcd58d7-2d26-48a1-bb55-b18357110171","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29573-3","display":"Phenylalanine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":61.2,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<175"}]}},{"fullUrl":"Observation/1734642835921297601.f23ad939-3185-45ba-b799-12cb69a62edb","resource":{"resourceType":"Observation","id":"1734642835921297601.f23ad939-3185-45ba-b799-12cb69a62edb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35572-7","display":"Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":1.77,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2.6"}]}},{"fullUrl":"Observation/1734642835924956562.8a51eada-1b83-4132-aeb9-9e897bcfa7dc","resource":{"resourceType":"Observation","id":"1734642835924956562.8a51eada-1b83-4132-aeb9-9e897bcfa7dc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35571-9","display":"Tyrosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":34.7,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<680"}]}},{"fullUrl":"Observation/1734642835928560610.f11761e5-32ac-4329-8350-d8f336dc2841","resource":{"resourceType":"Observation","id":"1734642835928560610.f11761e5-32ac-4329-8350-d8f336dc2841","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53231-7","display":"Succinylacetone [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.33,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<6.1"}]}},{"fullUrl":"Observation/1734642835936166881.0e234ccb-6d15-49c1-8d85-3e19f162470a","resource":{"resourceType":"Observation","id":"1734642835936166881.0e234ccb-6d15-49c1-8d85-3e19f162470a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47700-0","display":"Methionine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":20.4,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.3-100"}]}},{"fullUrl":"Observation/1734642835938621093.ee5cd03c-4948-4a32-8164-441ef939a2a9","resource":{"resourceType":"Observation","id":"1734642835938621093.ee5cd03c-4948-4a32-8164-441ef939a2a9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42892-0","display":"Citrulline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":10,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"5-49"}]}},{"fullUrl":"Observation/1734642835940962653.12eda31d-70a3-441a-af2a-28141156b3bb","resource":{"resourceType":"Observation","id":"1734642835940962653.12eda31d-70a3-441a-af2a-28141156b3bb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54092-2","display":"Citrulline/Arginine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":2.79,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.8"}]}},{"fullUrl":"Observation/1734642835943140036.2289d344-2124-423a-8324-9e135ed95b3d","resource":{"resourceType":"Observation","id":"1734642835943140036.2289d344-2124-423a-8324-9e135ed95b3d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53155-8","display":"Asparagine+Ornithine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":43,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<800"}]}},{"fullUrl":"Observation/1734642835945246025.c0de0d70-8645-4428-ba13-12b45b8930a3","resource":{"resourceType":"Observation","id":"1734642835945246025.c0de0d70-8645-4428-ba13-12b45b8930a3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75215-4","display":"Ornithine/Citrulline [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":4.44,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835947343138.ae725d80-ad0e-4919-8cb1-d7565941812b","resource":{"resourceType":"Observation","id":"1734642835947343138.ae725d80-ad0e-4919-8cb1-d7565941812b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47562-4","display":"Arginine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":3,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<63"}]}},{"fullUrl":"Observation/1734642835949495904.b12fa676-b353-4141-bdea-ca5aea9ad88b","resource":{"resourceType":"Observation","id":"1734642835949495904.b12fa676-b353-4141-bdea-ca5aea9ad88b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75214-7","display":"Arginine/Ornithine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.08,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.9"}]}},{"fullUrl":"Observation/1734642835951835531.e31d4936-c9dd-4449-961f-91c9451b6a81","resource":{"resourceType":"Observation","id":"1734642835951835531.e31d4936-c9dd-4449-961f-91c9451b6a81","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47732-3","display":"Proline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":187,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1500"}]}},{"fullUrl":"Observation/1734642835953756684.b3b3c9f3-7b72-4744-b798-68ff47d63356","resource":{"resourceType":"Observation","id":"1734642835953756684.b3b3c9f3-7b72-4744-b798-68ff47d63356","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57710-6","display":"Amino acidemias newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835955917426.1cde4345-8899-40b8-8ff8-4e433393dcd8","resource":{"resourceType":"Observation","id":"1734642835955917426.1cde4345-8899-40b8-8ff8-4e433393dcd8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58088-6","display":"Acylcarnitine newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835957880868.bbc96ac7-3744-47f0-808b-09c118350019","resource":{"resourceType":"Observation","id":"1734642835957880868.bbc96ac7-3744-47f0-808b-09c118350019","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58093-6","display":"Acylcarnitine newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835959899623.1ece5b91-20e1-4c7f-a96a-6365931b5a9c","resource":{"resourceType":"Observation","id":"1734642835959899623.1ece5b91-20e1-4c7f-a96a-6365931b5a9c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38481-8","display":"Carnitine.free (C0)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":39.6,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.4-125"}]}},{"fullUrl":"Observation/1734642835962463120.73f4c091-a419-4206-9afc-a32499ccbbe2","resource":{"resourceType":"Observation","id":"1734642835962463120.73f4c091-a419-4206-9afc-a32499ccbbe2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53235-8","display":"Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":5.35,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<70"}]}},{"fullUrl":"Observation/1734642835964812345.8d6a15f2-71d7-4ed4-afc6-da14e26b77aa","resource":{"resourceType":"Observation","id":"1734642835964812345.8d6a15f2-71d7-4ed4-afc6-da14e26b77aa","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50157-7","display":"Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":34.7,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"10-80"}]}},{"fullUrl":"Observation/1734642835966984488.bd58a5fd-e687-4bf3-b0fd-b3e31acfcf99","resource":{"resourceType":"Observation","id":"1734642835966984488.bd58a5fd-e687-4bf3-b0fd-b3e31acfcf99","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75212-1","display":"Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":3.27536,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.6"}]}},{"fullUrl":"Observation/1734642835969111537.1eea330d-e9e8-4c4a-a9b2-1f1541a5ad8f","resource":{"resourceType":"Observation","id":"1734642835969111537.1eea330d-e9e8-4c4a-a9b2-1f1541a5ad8f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45211-0","display":"Hexanoylcarnitine (C6)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.100,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835971804997.244ed723-05f6-4536-8789-637c500de1a7","resource":{"resourceType":"Observation","id":"1734642835971804997.244ed723-05f6-4536-8789-637c500de1a7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53175-6","display":"Octanoylcarnitine (C8)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.075,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835974458253.c66715d8-79f1-4446-be41-939ceb8f8b97","resource":{"resourceType":"Observation","id":"1734642835974458253.c66715d8-79f1-4446-be41-939ceb8f8b97","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53177-2","display":"Octanoylcarnitine (C8)/Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":1.09,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835976904089.fb7f61f4-2721-4abc-9c7b-26a7cbc10af8","resource":{"resourceType":"Observation","id":"1734642835976904089.fb7f61f4-2721-4abc-9c7b-26a7cbc10af8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53174-9","display":"Octenoylcarnitine (C8:1)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.163,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835979548217.e7fe453b-12a1-44f4-a3b8-b37095ef4ae3","resource":{"resourceType":"Observation","id":"1734642835979548217.e7fe453b-12a1-44f4-a3b8-b37095ef4ae3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45197-1","display":"Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.069,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835982249112.ad92ca2f-cfb4-40ab-b7ce-b944af3e8cde","resource":{"resourceType":"Observation","id":"1734642835982249112.ad92ca2f-cfb4-40ab-b7ce-b944af3e8cde","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45198-9","display":"Decenoylcarnitine (C10:1)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.057,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835984907707.60807b7e-f053-4dc3-837f-09887470d85c","resource":{"resourceType":"Observation","id":"1734642835984907707.60807b7e-f053-4dc3-837f-09887470d85c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45199-7","display":"Dodecanoylcarnitine (C12)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.118,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2"}]}},{"fullUrl":"Observation/1734642835987496421.d5cd8995-f998-42cb-a3ca-ce0a1166a6fc","resource":{"resourceType":"Observation","id":"1734642835987496421.d5cd8995-f998-42cb-a3ca-ce0a1166a6fc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45200-3","display":"Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.06,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835989963036.a7394af9-094b-4902-a20a-0fe9201175da","resource":{"resourceType":"Observation","id":"1734642835989963036.a7394af9-094b-4902-a20a-0fe9201175da","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53192-1","display":"Tetradecanoylcarnitine (C14)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.394,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.2"}]}},{"fullUrl":"Observation/1734642835992538956.3f21d58a-11a9-43cc-a553-2935221156d3","resource":{"resourceType":"Observation","id":"1734642835992538956.3f21d58a-11a9-43cc-a553-2935221156d3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53191-3","display":"Tetradecenoylcarnitine (C14:1)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.130,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.9"}]}},{"fullUrl":"Observation/1734642835994923608.548f1b1b-6afc-463a-9c33-e9ce81ad97fc","resource":{"resourceType":"Observation","id":"1734642835994923608.548f1b1b-6afc-463a-9c33-e9ce81ad97fc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53194-7","display":"Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":2.32,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835997573677.80a6dfc6-fa09-4358-815a-dfe757959f09","resource":{"resourceType":"Observation","id":"1734642835997573677.80a6dfc6-fa09-4358-815a-dfe757959f09","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53190-5","display":"Tetradecadienoylcarnitine (C14:2)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.03,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835999720703.41a6d967-ca64-4620-8712-30ab2f044fdd","resource":{"resourceType":"Observation","id":"1734642835999720703.41a6d967-ca64-4620-8712-30ab2f044fdd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50281-5","display":"3-Hydroxytetradecanoylcarnitine (C14-OH)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.026,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.2"}]}},{"fullUrl":"Observation/1734642836002687025.4f2f8fcb-9a4a-4f1f-a8c0-15de90b82d98","resource":{"resourceType":"Observation","id":"1734642836002687025.4f2f8fcb-9a4a-4f1f-a8c0-15de90b82d98","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53199-6","display":"Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":5.52,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<12"}]}},{"fullUrl":"Observation/1734642836004850091.e50d0cb3-2299-41e8-bfb2-7d3cd8c9061f","resource":{"resourceType":"Observation","id":"1734642836004850091.e50d0cb3-2299-41e8-bfb2-7d3cd8c9061f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53198-8","display":"Palmitoleylcarnitine (C16:1)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.245,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.4"}]}},{"fullUrl":"Observation/1734642836006922607.f157c594-316e-4ad2-a17d-6c8d4f744f41","resource":{"resourceType":"Observation","id":"1734642836006922607.f157c594-316e-4ad2-a17d-6c8d4f744f41","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50125-4","display":"3-Hydroxypalmitoylcarnitine (C16-OH)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.042,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642836009344819.27f90a06-82ed-4274-add4-afe438e2671a","resource":{"resourceType":"Observation","id":"1734642836009344819.27f90a06-82ed-4274-add4-afe438e2671a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53201-0","display":"3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.00761,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.07"}]}},{"fullUrl":"Observation/1734642836011736344.7bb83079-f18b-4ab0-a7f7-36af690cf1d9","resource":{"resourceType":"Observation","id":"1734642836011736344.7bb83079-f18b-4ab0-a7f7-36af690cf1d9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53241-6","display":"Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":2.13,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<3.5"}]}},{"fullUrl":"Observation/1734642836014288509.034f071a-2364-49c7-9e4f-c2b9e6b15e69","resource":{"resourceType":"Observation","id":"1734642836014288509.034f071a-2364-49c7-9e4f-c2b9e6b15e69","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53202-8","display":"Oleoylcarnitine (C18:1)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":1.89,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7"}]}},{"fullUrl":"Observation/1734642836020924763.4b54fab8-026d-4850-a9a8-6f43840e571d","resource":{"resourceType":"Observation","id":"1734642836020924763.4b54fab8-026d-4850-a9a8-6f43840e571d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45217-7","display":"Linoleoylcarnitine (C18:2)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.29,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836023364107.7bd159a4-9cba-43ea-8dc1-2b75b155250c","resource":{"resourceType":"Observation","id":"1734642836023364107.7bd159a4-9cba-43ea-8dc1-2b75b155250c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50132-0","display":"3-Hydroxystearoylcarnitine (C18-OH)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.032,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642836026388919.f459fd2a-e75c-46d2-a0f1-acce29409873","resource":{"resourceType":"Observation","id":"1734642836026388919.f459fd2a-e75c-46d2-a0f1-acce29409873","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50113-0","display":"3-Hydroxyoleoylcarnitine (C18:1-OH)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.047,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642836029102116.af3487b7-83d4-417b-afbc-23b988c99cb7","resource":{"resourceType":"Observation","id":"1734642836029102116.af3487b7-83d4-417b-afbc-23b988c99cb7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53160-8","display":"Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":4.2,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.9"}]}},{"fullUrl":"Observation/1734642836031499131.0ef60ce2-0887-4e14-87e6-70602f11724c","resource":{"resourceType":"Observation","id":"1734642836031499131.0ef60ce2-0887-4e14-87e6-70602f11724c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53163-2","display":"Propionylcarnitine (C3)/Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.12,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.42"}]}},{"fullUrl":"Observation/1734642836034335821.b39a86ae-626b-4de3-baf9-7c4b3bdb918f","resource":{"resourceType":"Observation","id":"1734642836034335821.b39a86ae-626b-4de3-baf9-7c4b3bdb918f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67708-8","display":"Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.226,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.48"}]}},{"fullUrl":"Observation/1734642836037044299.5e380009-0025-4a93-8a79-9157e9ee5091","resource":{"resourceType":"Observation","id":"1734642836037044299.5e380009-0025-4a93-8a79-9157e9ee5091","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53166-5","display":"Butyrylcarnitine+Isobutyrylcarnitine (C4)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.424,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.7"}]}},{"fullUrl":"Observation/1734642836039552863.a1775955-14a6-4d3d-9d00-1d1576b13957","resource":{"resourceType":"Observation","id":"1734642836039552863.a1775955-14a6-4d3d-9d00-1d1576b13957","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45216-9","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.247,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642836042252094.e4c7436e-2453-4d6f-bf3f-154218717c33","resource":{"resourceType":"Observation","id":"1734642836042252094.e4c7436e-2453-4d6f-bf3f-154218717c33","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53240-8","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.05881,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642836045172871.81c16756-2212-4514-b387-82ba937fae20","resource":{"resourceType":"Observation","id":"1734642836045172871.81c16756-2212-4514-b387-82ba937fae20","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53170-7","display":"Tiglylcarnitine (C5:1)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.008,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.5"}]}},{"fullUrl":"Observation/1734642836047619739.dfa41c8d-ee19-47ba-9771-62f7680ee29e","resource":{"resourceType":"Observation","id":"1734642836047619739.dfa41c8d-ee19-47ba-9771-62f7680ee29e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50106-4","display":"3-Hydroxyisovalerylcarnitine (C5-OH)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.287,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.15"}]}},{"fullUrl":"Observation/1734642836050378483.896e302c-e7e0-462e-ac40-e786d95bed3a","resource":{"resourceType":"Observation","id":"1734642836050378483.896e302c-e7e0-462e-ac40-e786d95bed3a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67710-4","display":"Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.179,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642836052717969.aa4e6425-a295-4d7c-82a0-f966e6899c2b","resource":{"resourceType":"Observation","id":"1734642836052717969.aa4e6425-a295-4d7c-82a0-f966e6899c2b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75216-2","display":"Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.79204,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">0.1"}]}},{"fullUrl":"Observation/1734642836056150155.3c7a51ac-07b3-47e3-a124-9c8b9e3a3b83","resource":{"resourceType":"Observation","id":"1734642836056150155.3c7a51ac-07b3-47e3-a124-9c8b9e3a3b83","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ng/mL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"48633-2","display":"Trypsinogen I.free"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":18.50,"unit":"ng/mL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<69"}]}},{"fullUrl":"Observation/1734642836059098674.3ddbdc33-426e-4b74-b71a-759e225539e4","resource":{"resourceType":"Observation","id":"1734642836059098674.3ddbdc33-426e-4b74-b71a-759e225539e4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46769-6","display":"Cystic fibrosis newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836061148087.724aa224-ce9b-48ba-9cd3-7f046341d894","resource":{"resourceType":"Observation","id":"1734642836061148087.724aa224-ce9b-48ba-9cd3-7f046341d894","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57707-2","display":"Cystic fibrosis newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836064192896.545f0cb5-2bb4-4ce7-8d40-188c2094ae6b","resource":{"resourceType":"Observation","id":"1734642836064192896.545f0cb5-2bb4-4ce7-8d40-188c2094ae6b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"nmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38473-5","display":"17-Hydroxyprogesterone"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":13.8,"unit":"nmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<85"}]}},{"fullUrl":"Observation/1734642836066734031.752fc16a-f2b9-4fc6-9f0f-5fc9afdefbb2","resource":{"resourceType":"Observation","id":"1734642836066734031.752fc16a-f2b9-4fc6-9f0f-5fc9afdefbb2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46758-9","display":"Congenital adrenal hyperplasia newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836068882770.6b6e0b85-241b-47b3-b747-37a61fa1d240","resource":{"resourceType":"Observation","id":"1734642836068882770.6b6e0b85-241b-47b3-b747-37a61fa1d240","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57706-4","display":"Congenital adrenal hyperplasia newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836071577363.c6d07390-087c-4753-a459-ed7fcd308e48","resource":{"resourceType":"Observation","id":"1734642836071577363.c6d07390-087c-4753-a459-ed7fcd308e48","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"mIU/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29575-8","display":"Thyrotropin"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":2.40,"unit":"mIU/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<29"}]}},{"fullUrl":"Observation/1734642836075082024.1c1fcb05-42db-464b-8ada-6df001524653","resource":{"resourceType":"Observation","id":"1734642836075082024.1c1fcb05-42db-464b-8ada-6df001524653","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46762-1","display":"Congenital hypothyroidism newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836078093261.63f313f4-c070-492f-afbd-a33b562df097","resource":{"resourceType":"Observation","id":"1734642836078093261.63f313f4-c070-492f-afbd-a33b562df097","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57705-6","display":"Congenital hypothyroidism newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836080350664.f0388aa8-665c-4f91-8fd5-9c301df81913","resource":{"resourceType":"Observation","id":"1734642836080350664.f0388aa8-665c-4f91-8fd5-9c301df81913","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"enzyme units"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42906-8","display":"Galactose 1 phosphate uridyl transferase"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":293.00,"unit":"enzyme units"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">50"}]}},{"fullUrl":"Observation/1734642836082734985.98cc37d6-f03e-4f09-8a30-dc91c3cb4a44","resource":{"resourceType":"Observation","id":"1734642836082734985.98cc37d6-f03e-4f09-8a30-dc91c3cb4a44","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46737-3","display":"Galactosemias newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836084978451.e5032aa6-893e-432b-bf94-24bbafd2f6ec","resource":{"resourceType":"Observation","id":"1734642836084978451.e5032aa6-893e-432b-bf94-24bbafd2f6ec","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57704-9","display":"Galactosemias newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836086819173.3e285432-ee21-489e-a223-fc5c7689b06d","resource":{"resourceType":"Observation","id":"1734642836086819173.3e285432-ee21-489e-a223-fc5c7689b06d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54104-5","display":"Hemoglobin pattern"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"FA + Barts"}},{"fullUrl":"Observation/1734642836088611323.1bde1240-4adb-4827-b673-5427483e3dea","resource":{"resourceType":"Observation","id":"1734642836088611323.1bde1240-4adb-4827-b673-5427483e3dea","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57703-1","display":"Hemoglobin disorders newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"The presence of Hb Barts at a high percentage is consistent with Hb H disease, a clinically significant hemoglobin disorder."}},{"fullUrl":"Observation/1734642836090904183.4b2226ec-6c0b-4031-909f-235e2f04976c","resource":{"resourceType":"Observation","id":"1734642836090904183.4b2226ec-6c0b-4031-909f-235e2f04976c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ERU"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75217-0","display":"Biotinidase [Enzymatic activity/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":43.76,"unit":"ERU"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">10"}]}},{"fullUrl":"Observation/1734642836093566986.b14e7d8d-5b96-4964-8572-da5fb4327281","resource":{"resourceType":"Observation","id":"1734642836093566986.b14e7d8d-5b96-4964-8572-da5fb4327281","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46761-3","display":"Biotinidase deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836095654951.3db665e3-0f5c-48e7-a07b-72fcbc002aa0","resource":{"resourceType":"Observation","id":"1734642836095654951.3db665e3-0f5c-48e7-a07b-72fcbc002aa0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57699-1","display":"Biotinidase deficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836099363255.b57829c9-31a7-4f2b-923c-7177397914e0","resource":{"resourceType":"Observation","id":"1734642836099363255.b57829c9-31a7-4f2b-923c-7177397914e0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"copies/µL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62320-7","display":"T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":99,"unit":"copies/µL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">18"}]}},{"fullUrl":"Observation/1734642836101959590.ae5c736c-5301-4b7a-9aa6-6e4398046e5b","resource":{"resourceType":"Observation","id":"1734642836101959590.ae5c736c-5301-4b7a-9aa6-6e4398046e5b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62321-5","display":"Severe combined immunodeficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836104365842.7148179d-564a-4df9-bd22-c230f7dcb93e","resource":{"resourceType":"Observation","id":"1734642836104365842.7148179d-564a-4df9-bd22-c230f7dcb93e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62322-3","display":"Severe combined immunodeficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836111297162.b3873451-14ee-44c4-97d5-9bb41c989626","resource":{"resourceType":"Observation","id":"1734642836111297162.b3873451-14ee-44c4-97d5-9bb41c989626","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55827-0","display":"Acid alpha glucosidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":7.09,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=1.67"}]}},{"fullUrl":"Observation/1734642836113467783.741e468e-7fc0-4423-ac97-ee219ed19842","resource":{"resourceType":"Observation","id":"1734642836113467783.741e468e-7fc0-4423-ac97-ee219ed19842","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63415-4","display":"Pompe Disease deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836115303725.d20a44c7-6828-4a2f-a4a7-14339af82c03","resource":{"resourceType":"Observation","id":"1734642836115303725.d20a44c7-6828-4a2f-a4a7-14339af82c03","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63416-2","display":"Pompe Disease deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836117814203.b4e4cf66-b844-451b-9c87-24832b6fe6ad","resource":{"resourceType":"Observation","id":"1734642836117814203.b4e4cf66-b844-451b-9c87-24832b6fe6ad","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55909-6","display":"Alpha-L-iduronidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":8.33,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=0.86"}]}},{"fullUrl":"Observation/1734642836119999360.04908077-17c5-4224-80f7-49d2066cbedb","resource":{"resourceType":"Observation","id":"1734642836119999360.04908077-17c5-4224-80f7-49d2066cbedb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79564-1","display":"Mucopolysaccharidosis type I newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836121872623.119d758a-9078-4420-aacb-94a01f1eb724","resource":{"resourceType":"Observation","id":"1734642836121872623.119d758a-9078-4420-aacb-94a01f1eb724","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79565-8","display":"Mucopolysaccharidosis type I newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836123642191.b1b92497-7ecb-42f0-9a46-d8106853e8fe","resource":{"resourceType":"Observation","id":"1734642836123642191.b1b92497-7ecb-42f0-9a46-d8106853e8fe","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-60","display":"SMN1 Homozygous Deletion Analysis"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Exon 7 Present","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"Exon 7 Present"}]}},{"fullUrl":"Observation/1734642836125756856.c973f1c9-f4fe-4e66-8f37-7172ebe581d6","resource":{"resourceType":"Observation","id":"1734642836125756856.c973f1c9-f4fe-4e66-8f37-7172ebe581d6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92004-1","display":"Spinal muscular atrophy newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836127597888.34e36b07-2b51-4642-ae9d-0a8c918d2778","resource":{"resourceType":"Observation","id":"1734642836127597888.34e36b07-2b51-4642-ae9d-0a8c918d2778","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92003-3","display":"Spinal muscular atrophy newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"SMA Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836129662139.3d5d2c39-e93f-4dfd-886e-6af0424b7a9e","resource":{"resourceType":"Observation","id":"1734642836129662139.3d5d2c39-e93f-4dfd-886e-6af0424b7a9e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79462-8","display":"Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":15.65,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=2.8"}]}},{"fullUrl":"Observation/1734642836131734335.0443a079-34d1-4cf9-9176-8515df7cba8a","resource":{"resourceType":"Observation","id":"1734642836131734335.0443a079-34d1-4cf9-9176-8515df7cba8a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104189-6","display":"Mucopolysaccharidosis type II newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836133599152.b964ea85-cf95-49f2-b92f-62328d3ea799","resource":{"resourceType":"Observation","id":"1734642836133599152.b964ea85-cf95-49f2-b92f-62328d3ea799","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104190-4","display":"Mucopolysaccharidosis type II newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836136544444.76dec855-2215-4747-b563-5edf391e7414","resource":{"resourceType":"Observation","id":"1734642836136544444.76dec855-2215-4747-b563-5edf391e7414","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104192-0","display":"Guanidinoacetate methyltransferase deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836138511032.bbdd868a-ccbc-4dc8-afb3-ab91b493db75","resource":{"resourceType":"Observation","id":"1734642836138511032.bbdd868a-ccbc-4dc8-afb3-ab91b493db75","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104193-8","display":"Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836140773031.ca60eb5f-4792-4f47-9cda-4f2336385def","resource":{"resourceType":"Observation","id":"1734642836140773031.ca60eb5f-4792-4f47-9cda-4f2336385def","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"93488-5","display":"Guanidinoacetate [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":1.05,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=3"}]}},{"fullUrl":"Observation/1734642836142897444.274531bb-aba7-40ac-a4c6-b6777fa2656c","resource":{"resourceType":"Observation","id":"1734642836142897444.274531bb-aba7-40ac-a4c6-b6777fa2656c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104194-6","display":"Creatine [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":616.49,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836144844706.bf279162-4e5f-474c-bf4f-c7405b754eed","resource":{"resourceType":"Observation","id":"1734642836144844706.bf279162-4e5f-474c-bf4f-c7405b754eed","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104195-3","display":"GUAC/CRE Ratio [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":1.70},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=6"}]}},{"fullUrl":"Observation/1734642836146921300.a099f493-8f4b-406d-80e2-9937c06c29af","resource":{"resourceType":"Observation","id":"1734642836146921300.a099f493-8f4b-406d-80e2-9937c06c29af","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-32","display":"Adrenoleukodystrophy deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836148732836.1f0c3ba7-cca4-4716-8e12-bd556367776e","resource":{"resourceType":"Observation","id":"1734642836148732836.1f0c3ba7-cca4-4716-8e12-bd556367776e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-33","display":"Adrenoleukodystrophy deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836150737746.37519cf1-4f37-441a-b91c-2effb9f3579f","resource":{"resourceType":"Observation","id":"1734642836150737746.37519cf1-4f37-441a-b91c-2effb9f3579f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79321-6","display":"Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.260,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.47"}]}},{"fullUrl":"Specimen/1734642836161032270.46570000-7b65-48ff-a4ee-7c6884e3bc40","resource":{"resourceType":"Specimen","id":"1734642836161032270.46570000-7b65-48ff-a4ee-7c6884e3bc40","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836162665332.ff5b8563-8157-4e83-83b7-56c7b7498c70","resource":{"resourceType":"Specimen","id":"1734642836162665332.ff5b8563-8157-4e83-83b7-56c7b7498c70","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836164126261.eda6980d-7ef7-406f-81de-aa435e2a5c4e","resource":{"resourceType":"Specimen","id":"1734642836164126261.eda6980d-7ef7-406f-81de-aa435e2a5c4e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836165479489.dd1334bf-e8a9-416b-9122-2cd311dc2d5c","resource":{"resourceType":"Specimen","id":"1734642836165479489.dd1334bf-e8a9-416b-9122-2cd311dc2d5c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836166821946.c1ea71c7-fb40-4cd0-80fb-0a4f134f9425","resource":{"resourceType":"Specimen","id":"1734642836166821946.c1ea71c7-fb40-4cd0-80fb-0a4f134f9425","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836168190152.6fe40301-21fe-4402-b76d-c685c08a42e0","resource":{"resourceType":"Specimen","id":"1734642836168190152.6fe40301-21fe-4402-b76d-c685c08a42e0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836169622397.6e71209d-2b34-4b42-8090-f7d67db1f966","resource":{"resourceType":"Specimen","id":"1734642836169622397.6e71209d-2b34-4b42-8090-f7d67db1f966","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836171065203.9d232828-25d2-4c83-a58e-1c74cadfd08f","resource":{"resourceType":"Specimen","id":"1734642836171065203.9d232828-25d2-4c83-a58e-1c74cadfd08f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836172450811.05f794fb-ae21-4cc3-ab91-44959988c1c4","resource":{"resourceType":"Specimen","id":"1734642836172450811.05f794fb-ae21-4cc3-ab91-44959988c1c4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836173953849.216555b6-7718-4724-a40b-446a1535ac35","resource":{"resourceType":"Specimen","id":"1734642836173953849.216555b6-7718-4724-a40b-446a1535ac35","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836175318167.1f1e6b32-2c14-44a7-9f7e-a1b9239f31ab","resource":{"resourceType":"Specimen","id":"1734642836175318167.1f1e6b32-2c14-44a7-9f7e-a1b9239f31ab","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836176692945.c095756a-2f25-4c51-bdb1-6f412c956bae","resource":{"resourceType":"Specimen","id":"1734642836176692945.c095756a-2f25-4c51-bdb1-6f412c956bae","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836178034140.e3cbe5e4-708b-4e4e-8d3d-bd83a6713778","resource":{"resourceType":"Specimen","id":"1734642836178034140.e3cbe5e4-708b-4e4e-8d3d-bd83a6713778","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836179371708.16d8ceab-0511-4309-9db9-fd4c8429c595","resource":{"resourceType":"Specimen","id":"1734642836179371708.16d8ceab-0511-4309-9db9-fd4c8429c595","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836180747027.6df950ea-03a3-435b-912f-8261319782b4","resource":{"resourceType":"Specimen","id":"1734642836180747027.6df950ea-03a3-435b-912f-8261319782b4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836182114562.8cc3bdf7-2378-4050-8915-2fba8d0cb66c","resource":{"resourceType":"Specimen","id":"1734642836182114562.8cc3bdf7-2378-4050-8915-2fba8d0cb66c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836183461107.69dcb642-2f99-4373-9e1b-e826e9ebcc68","resource":{"resourceType":"Specimen","id":"1734642836183461107.69dcb642-2f99-4373-9e1b-e826e9ebcc68","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836184837918.8979b6cf-1ab8-4204-9afc-82152ecd657c","resource":{"resourceType":"Specimen","id":"1734642836184837918.8979b6cf-1ab8-4204-9afc-82152ecd657c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836186184714.3c7264fe-459a-4e2e-a9c4-010092f02c47","resource":{"resourceType":"Specimen","id":"1734642836186184714.3c7264fe-459a-4e2e-a9c4-010092f02c47","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836187533964.1477cdc6-64f4-4fdb-9280-bf1f389fb11b","resource":{"resourceType":"Specimen","id":"1734642836187533964.1477cdc6-64f4-4fdb-9280-bf1f389fb11b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836188904223.d33485a5-6a3c-471a-8ea6-261635fcadb2","resource":{"resourceType":"Specimen","id":"1734642836188904223.d33485a5-6a3c-471a-8ea6-261635fcadb2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836190292366.cb0738a0-5e1a-4416-94e0-b7a606b153d0","resource":{"resourceType":"Specimen","id":"1734642836190292366.cb0738a0-5e1a-4416-94e0-b7a606b153d0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836191672224.0ba34d35-8ff2-417a-b212-c582abb903c6","resource":{"resourceType":"Specimen","id":"1734642836191672224.0ba34d35-8ff2-417a-b212-c582abb903c6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836193133473.9d77732e-0d8d-46d2-a589-d1f41fa01f86","resource":{"resourceType":"Specimen","id":"1734642836193133473.9d77732e-0d8d-46d2-a589-d1f41fa01f86","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"ServiceRequest/1734642836211469125.e6e076d4-8334-47db-9cc0-1c4fe300de8d","resource":{"resourceType":"ServiceRequest","id":"1734642836211469125.e6e076d4-8334-47db-9cc0-1c4fe300de8d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/business-event","valueCode":"RE"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/orc-common-order","extension":[{"url":"orc-21-ordering-facility-name","valueReference":{"reference":"Organization/1734642836204360035.7352be17-3267-4fbf-a835-334c12d284a9"}},{"url":"orc-22-ordering-facility-address","valueAddress":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"725 WELCH RD, RM  H1524"}]}]}],"line":["725 WELCH RD, RM  H1524"],"city":"PALO ALTO","state":"CA","postalCode":"94304-1601"}},{"url":"orc-12-ordering-provider","valueReference":{"reference":"Practitioner/1734642836206890770.48cba7af-963b-4ab1-842e-4d877f2a68a4"}}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.2","valueIdentifier":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"value":"753234567"}},{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836209338771.77e8acfd-a6f3-4102-af99-b6fe3776767a"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"56155532"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"56155532"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"PractitionerRole/1734642836196504374.553e1722-a2c1-40a4-9e89-b8035989adfa"}}},{"fullUrl":"Practitioner/1734642836198040786.bbb4bb12-266d-4544-874b-b42e8f11c834","resource":{"resourceType":"Practitioner","id":"1734642836198040786.bbb4bb12-266d-4544-874b-b42e8f11c834","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.12"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Organization/1734642836200585447.a82635d1-0b3b-493c-bab5-dae183caf306","resource":{"resourceType":"Organization","id":"1734642836200585447.a82635d1-0b3b-493c-bab5-dae183caf306","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R777"}]}],"identifier":[{"value":"R777"}],"name":"STANFORD/LUCILE PACKARD CHILDREN'S HOSPI","telecom":[{"_system":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}],"address":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"725 WELCH RD, RM  H1524"}]}]}],"line":["725 WELCH RD, RM  H1524"],"city":"PALO ALTO","state":"CA","postalCode":"94304-1601"}]}},{"fullUrl":"PractitionerRole/1734642836196504374.553e1722-a2c1-40a4-9e89-b8035989adfa","resource":{"resourceType":"PractitionerRole","id":"1734642836196504374.553e1722-a2c1-40a4-9e89-b8035989adfa","practitioner":{"reference":"Practitioner/1734642836198040786.bbb4bb12-266d-4544-874b-b42e8f11c834"},"organization":{"reference":"Organization/1734642836200585447.a82635d1-0b3b-493c-bab5-dae183caf306"}}},{"fullUrl":"Organization/1734642836204360035.7352be17-3267-4fbf-a835-334c12d284a9","resource":{"resourceType":"Organization","id":"1734642836204360035.7352be17-3267-4fbf-a835-334c12d284a9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R777"}]}],"identifier":[{"value":"R777"}],"name":"STANFORD/LUCILE PACKARD CHILDREN'S HOSPI"}},{"fullUrl":"Practitioner/1734642836206890770.48cba7af-963b-4ab1-842e-4d877f2a68a4","resource":{"resourceType":"Practitioner","id":"1734642836206890770.48cba7af-963b-4ab1-842e-4d877f2a68a4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836209338771.77e8acfd-a6f3-4102-af99-b6fe3776767a","resource":{"resourceType":"Practitioner","id":"1734642836209338771.77e8acfd-a6f3-4102-af99-b6fe3776767a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836224689866.d50d5411-c894-4903-a74d-23409a7158a7","resource":{"resourceType":"ServiceRequest","id":"1734642836224689866.d50d5411-c894-4903-a74d-23409a7158a7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836222544273.34e245a2-ac0d-4c11-87a5-7aa5ad39e3e6"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836213559265.f5c0e90d-f0dc-45c6-b92e-fab08e92ff26"}}},{"fullUrl":"Practitioner/1734642836213559265.f5c0e90d-f0dc-45c6-b92e-fab08e92ff26","resource":{"resourceType":"Practitioner","id":"1734642836213559265.f5c0e90d-f0dc-45c6-b92e-fab08e92ff26","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836222544273.34e245a2-ac0d-4c11-87a5-7aa5ad39e3e6","resource":{"resourceType":"Practitioner","id":"1734642836222544273.34e245a2-ac0d-4c11-87a5-7aa5ad39e3e6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836233361116.ae32ec13-3bd0-450c-a8b0-e2db6dfa8a58","resource":{"resourceType":"ServiceRequest","id":"1734642836233361116.ae32ec13-3bd0-450c-a8b0-e2db6dfa8a58","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836230877078.f074c9d5-d6e9-4119-b497-46dbcb2cbae5"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836226494590.299f670c-e03a-4f30-8544-a497182fe3eb"}}},{"fullUrl":"Practitioner/1734642836226494590.299f670c-e03a-4f30-8544-a497182fe3eb","resource":{"resourceType":"Practitioner","id":"1734642836226494590.299f670c-e03a-4f30-8544-a497182fe3eb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836230877078.f074c9d5-d6e9-4119-b497-46dbcb2cbae5","resource":{"resourceType":"Practitioner","id":"1734642836230877078.f074c9d5-d6e9-4119-b497-46dbcb2cbae5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836241950442.fa7ec720-835f-40fe-9d85-64302547c7da","resource":{"resourceType":"ServiceRequest","id":"1734642836241950442.fa7ec720-835f-40fe-9d85-64302547c7da","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836239697527.c561c605-6b06-4e19-b75b-c1da643e125c"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836235261519.2472cb4b-dbcf-4b3b-8a07-75d1cf8255dd"}}},{"fullUrl":"Practitioner/1734642836235261519.2472cb4b-dbcf-4b3b-8a07-75d1cf8255dd","resource":{"resourceType":"Practitioner","id":"1734642836235261519.2472cb4b-dbcf-4b3b-8a07-75d1cf8255dd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836239697527.c561c605-6b06-4e19-b75b-c1da643e125c","resource":{"resourceType":"Practitioner","id":"1734642836239697527.c561c605-6b06-4e19-b75b-c1da643e125c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836250765712.59a67878-8cad-4343-8fd8-7922dad33cd9","resource":{"resourceType":"ServiceRequest","id":"1734642836250765712.59a67878-8cad-4343-8fd8-7922dad33cd9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836248679349.01b87c3f-b73e-49ed-8cb6-07ad7076c452"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836244172929.7e5d76cb-a94b-4373-a0ab-c54e7555f294"}}},{"fullUrl":"Practitioner/1734642836244172929.7e5d76cb-a94b-4373-a0ab-c54e7555f294","resource":{"resourceType":"Practitioner","id":"1734642836244172929.7e5d76cb-a94b-4373-a0ab-c54e7555f294","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836248679349.01b87c3f-b73e-49ed-8cb6-07ad7076c452","resource":{"resourceType":"Practitioner","id":"1734642836248679349.01b87c3f-b73e-49ed-8cb6-07ad7076c452","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836259325462.67b6c411-50a0-4d81-be09-068910902638","resource":{"resourceType":"ServiceRequest","id":"1734642836259325462.67b6c411-50a0-4d81-be09-068910902638","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836257242887.da0683b6-63bf-4e56-b90c-aae51cbeaaa7"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836252618376.c495ca8c-c05a-4efb-809e-af5407f36162"}}},{"fullUrl":"Practitioner/1734642836252618376.c495ca8c-c05a-4efb-809e-af5407f36162","resource":{"resourceType":"Practitioner","id":"1734642836252618376.c495ca8c-c05a-4efb-809e-af5407f36162","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836257242887.da0683b6-63bf-4e56-b90c-aae51cbeaaa7","resource":{"resourceType":"Practitioner","id":"1734642836257242887.da0683b6-63bf-4e56-b90c-aae51cbeaaa7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836268500066.fa067df2-9282-4977-8b95-7911c976c2ed","resource":{"resourceType":"ServiceRequest","id":"1734642836268500066.fa067df2-9282-4977-8b95-7911c976c2ed","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836266384549.7057c900-1832-439a-8694-389fc0bb14ad"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836261156576.32b1c0c7-95ec-4f54-92ed-d3d18d03b98e"}}},{"fullUrl":"Practitioner/1734642836261156576.32b1c0c7-95ec-4f54-92ed-d3d18d03b98e","resource":{"resourceType":"Practitioner","id":"1734642836261156576.32b1c0c7-95ec-4f54-92ed-d3d18d03b98e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836266384549.7057c900-1832-439a-8694-389fc0bb14ad","resource":{"resourceType":"Practitioner","id":"1734642836266384549.7057c900-1832-439a-8694-389fc0bb14ad","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836276842830.0d9448c9-73c6-4837-b7bb-a4c879444fbc","resource":{"resourceType":"ServiceRequest","id":"1734642836276842830.0d9448c9-73c6-4837-b7bb-a4c879444fbc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836274734246.f4075098-601e-4aa3-9427-8dcacda90f76"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836270293839.119538e7-6c0a-4bc5-844f-ef460b78fb94"}}},{"fullUrl":"Practitioner/1734642836270293839.119538e7-6c0a-4bc5-844f-ef460b78fb94","resource":{"resourceType":"Practitioner","id":"1734642836270293839.119538e7-6c0a-4bc5-844f-ef460b78fb94","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836274734246.f4075098-601e-4aa3-9427-8dcacda90f76","resource":{"resourceType":"Practitioner","id":"1734642836274734246.f4075098-601e-4aa3-9427-8dcacda90f76","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836285130680.8f6eaf5b-40c9-4189-8aca-08101b2bcdf3","resource":{"resourceType":"ServiceRequest","id":"1734642836285130680.8f6eaf5b-40c9-4189-8aca-08101b2bcdf3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836283027487.358f15cf-cf7c-4d13-9624-c1e5a46b30be"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836278642815.bccf7510-f6e6-41cb-ba97-c1662024145d"}}},{"fullUrl":"Practitioner/1734642836278642815.bccf7510-f6e6-41cb-ba97-c1662024145d","resource":{"resourceType":"Practitioner","id":"1734642836278642815.bccf7510-f6e6-41cb-ba97-c1662024145d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836283027487.358f15cf-cf7c-4d13-9624-c1e5a46b30be","resource":{"resourceType":"Practitioner","id":"1734642836283027487.358f15cf-cf7c-4d13-9624-c1e5a46b30be","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836294761079.da990083-15d9-410c-b401-f51a41982afb","resource":{"resourceType":"ServiceRequest","id":"1734642836294761079.da990083-15d9-410c-b401-f51a41982afb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836291946982.83a8c3e9-73fa-4d89-8030-222dbb5d01e9"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836286914856.e4fd3a16-5d21-4427-8484-61c424625fc0"}}},{"fullUrl":"Practitioner/1734642836286914856.e4fd3a16-5d21-4427-8484-61c424625fc0","resource":{"resourceType":"Practitioner","id":"1734642836286914856.e4fd3a16-5d21-4427-8484-61c424625fc0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836291946982.83a8c3e9-73fa-4d89-8030-222dbb5d01e9","resource":{"resourceType":"Practitioner","id":"1734642836291946982.83a8c3e9-73fa-4d89-8030-222dbb5d01e9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836303617155.292bdcf8-998f-49b4-b53d-75cada578a97","resource":{"resourceType":"ServiceRequest","id":"1734642836303617155.292bdcf8-998f-49b4-b53d-75cada578a97","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836301308646.62572931-9042-4b83-821f-3f3cb5a413ef"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836296737034.74c1a466-5a08-440b-a537-0780f70e2845"}}},{"fullUrl":"Practitioner/1734642836296737034.74c1a466-5a08-440b-a537-0780f70e2845","resource":{"resourceType":"Practitioner","id":"1734642836296737034.74c1a466-5a08-440b-a537-0780f70e2845","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836301308646.62572931-9042-4b83-821f-3f3cb5a413ef","resource":{"resourceType":"Practitioner","id":"1734642836301308646.62572931-9042-4b83-821f-3f3cb5a413ef","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836312111042.04bf133a-a60f-4d5a-b1db-b3bb78f3bb7b","resource":{"resourceType":"ServiceRequest","id":"1734642836312111042.04bf133a-a60f-4d5a-b1db-b3bb78f3bb7b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836310046480.9199b5f8-e066-43ec-9b9d-a963aa525c23"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836305570097.c9cdb421-6dca-426c-a37f-5e214fadd913"}}},{"fullUrl":"Practitioner/1734642836305570097.c9cdb421-6dca-426c-a37f-5e214fadd913","resource":{"resourceType":"Practitioner","id":"1734642836305570097.c9cdb421-6dca-426c-a37f-5e214fadd913","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836310046480.9199b5f8-e066-43ec-9b9d-a963aa525c23","resource":{"resourceType":"Practitioner","id":"1734642836310046480.9199b5f8-e066-43ec-9b9d-a963aa525c23","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836321191278.496e5d2d-aaa9-4f32-bf5f-25e44b00c369","resource":{"resourceType":"ServiceRequest","id":"1734642836321191278.496e5d2d-aaa9-4f32-bf5f-25e44b00c369","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836318900012.0e06a628-c8e9-4b44-8449-1bc60964460c"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836313920395.a78587ce-9a8a-4fc6-bb67-5f8ba6c72889"}}},{"fullUrl":"Practitioner/1734642836313920395.a78587ce-9a8a-4fc6-bb67-5f8ba6c72889","resource":{"resourceType":"Practitioner","id":"1734642836313920395.a78587ce-9a8a-4fc6-bb67-5f8ba6c72889","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836318900012.0e06a628-c8e9-4b44-8449-1bc60964460c","resource":{"resourceType":"Practitioner","id":"1734642836318900012.0e06a628-c8e9-4b44-8449-1bc60964460c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836331263295.6c66392a-d008-4df9-a51c-7c8a63466ed6","resource":{"resourceType":"ServiceRequest","id":"1734642836331263295.6c66392a-d008-4df9-a51c-7c8a63466ed6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836328872472.04481bf4-ed20-4c54-a1e0-4a74e6099d38"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836323077295.0dbe568e-3726-49d7-9642-8d4ee820c3cc"}}},{"fullUrl":"Practitioner/1734642836323077295.0dbe568e-3726-49d7-9642-8d4ee820c3cc","resource":{"resourceType":"Practitioner","id":"1734642836323077295.0dbe568e-3726-49d7-9642-8d4ee820c3cc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836328872472.04481bf4-ed20-4c54-a1e0-4a74e6099d38","resource":{"resourceType":"Practitioner","id":"1734642836328872472.04481bf4-ed20-4c54-a1e0-4a74e6099d38","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836339797758.e4e9a447-a036-4f1f-b48b-4e8ced41f368","resource":{"resourceType":"ServiceRequest","id":"1734642836339797758.e4e9a447-a036-4f1f-b48b-4e8ced41f368","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836337532681.9e62e6db-dffd-40d5-a33c-8155e32f56ff"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836333096472.c5394f35-158f-46e6-aa45-9be08f9170c0"}}},{"fullUrl":"Practitioner/1734642836333096472.c5394f35-158f-46e6-aa45-9be08f9170c0","resource":{"resourceType":"Practitioner","id":"1734642836333096472.c5394f35-158f-46e6-aa45-9be08f9170c0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836337532681.9e62e6db-dffd-40d5-a33c-8155e32f56ff","resource":{"resourceType":"Practitioner","id":"1734642836337532681.9e62e6db-dffd-40d5-a33c-8155e32f56ff","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836348221083.f121f33c-f711-40d6-be41-9d517d9b6c1e","resource":{"resourceType":"ServiceRequest","id":"1734642836348221083.f121f33c-f711-40d6-be41-9d517d9b6c1e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836346097591.dc186fd6-f7e4-4768-a653-0dd3d6f3988c"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836341666442.06f20797-ab8c-45c2-aa96-c7af5d416ac0"}}},{"fullUrl":"Practitioner/1734642836341666442.06f20797-ab8c-45c2-aa96-c7af5d416ac0","resource":{"resourceType":"Practitioner","id":"1734642836341666442.06f20797-ab8c-45c2-aa96-c7af5d416ac0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836346097591.dc186fd6-f7e4-4768-a653-0dd3d6f3988c","resource":{"resourceType":"Practitioner","id":"1734642836346097591.dc186fd6-f7e4-4768-a653-0dd3d6f3988c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836356921477.f8969abf-1d45-4fdb-82ca-12ec23f1a198","resource":{"resourceType":"ServiceRequest","id":"1734642836356921477.f8969abf-1d45-4fdb-82ca-12ec23f1a198","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836354586799.cf893361-f02a-4132-b59b-1d6ce994e353"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836350085819.efcf8b61-a602-4339-a2ef-8a2f47623d8b"}}},{"fullUrl":"Practitioner/1734642836350085819.efcf8b61-a602-4339-a2ef-8a2f47623d8b","resource":{"resourceType":"Practitioner","id":"1734642836350085819.efcf8b61-a602-4339-a2ef-8a2f47623d8b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836354586799.cf893361-f02a-4132-b59b-1d6ce994e353","resource":{"resourceType":"Practitioner","id":"1734642836354586799.cf893361-f02a-4132-b59b-1d6ce994e353","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836365734843.823e99b0-bf45-433b-9dda-0fb8e7ec362c","resource":{"resourceType":"ServiceRequest","id":"1734642836365734843.823e99b0-bf45-433b-9dda-0fb8e7ec362c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836363507717.ec23000e-bcbd-42d4-9efb-4521b705545c"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836358741089.b2e0b632-f079-4da7-b957-730116772c53"}}},{"fullUrl":"Practitioner/1734642836358741089.b2e0b632-f079-4da7-b957-730116772c53","resource":{"resourceType":"Practitioner","id":"1734642836358741089.b2e0b632-f079-4da7-b957-730116772c53","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836363507717.ec23000e-bcbd-42d4-9efb-4521b705545c","resource":{"resourceType":"Practitioner","id":"1734642836363507717.ec23000e-bcbd-42d4-9efb-4521b705545c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836374544853.68f48201-4b0d-4906-ab6e-3ae7f8a93837","resource":{"resourceType":"ServiceRequest","id":"1734642836374544853.68f48201-4b0d-4906-ab6e-3ae7f8a93837","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836372240793.51304049-c464-4bf3-9cb7-eb97b8c9f843"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836367538425.34f98b24-38de-40fd-a4f0-2acc388ffe17"}}},{"fullUrl":"Practitioner/1734642836367538425.34f98b24-38de-40fd-a4f0-2acc388ffe17","resource":{"resourceType":"Practitioner","id":"1734642836367538425.34f98b24-38de-40fd-a4f0-2acc388ffe17","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836372240793.51304049-c464-4bf3-9cb7-eb97b8c9f843","resource":{"resourceType":"Practitioner","id":"1734642836372240793.51304049-c464-4bf3-9cb7-eb97b8c9f843","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836383016629.001af554-7412-4c8d-9f84-b09b1cee4b11","resource":{"resourceType":"ServiceRequest","id":"1734642836383016629.001af554-7412-4c8d-9f84-b09b1cee4b11","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836380857551.2b2e3398-ae31-4005-b2d3-1bec0244ca36"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836376429818.3e9c03cf-6044-44b6-8efd-e736e9ba9f9f"}}},{"fullUrl":"Practitioner/1734642836376429818.3e9c03cf-6044-44b6-8efd-e736e9ba9f9f","resource":{"resourceType":"Practitioner","id":"1734642836376429818.3e9c03cf-6044-44b6-8efd-e736e9ba9f9f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836380857551.2b2e3398-ae31-4005-b2d3-1bec0244ca36","resource":{"resourceType":"Practitioner","id":"1734642836380857551.2b2e3398-ae31-4005-b2d3-1bec0244ca36","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836394811491.34277100-a636-4818-bb0f-d52e9da86550","resource":{"resourceType":"ServiceRequest","id":"1734642836394811491.34277100-a636-4818-bb0f-d52e9da86550","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836392676668.5ff1633e-088a-4ab1-b25d-50517197f09a"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836384947380.3aa1c366-1db4-4515-bab6-b7264ea8e928"}}},{"fullUrl":"Practitioner/1734642836384947380.3aa1c366-1db4-4515-bab6-b7264ea8e928","resource":{"resourceType":"Practitioner","id":"1734642836384947380.3aa1c366-1db4-4515-bab6-b7264ea8e928","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836392676668.5ff1633e-088a-4ab1-b25d-50517197f09a","resource":{"resourceType":"Practitioner","id":"1734642836392676668.5ff1633e-088a-4ab1-b25d-50517197f09a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836403274640.ed48ac0b-8672-428d-8673-915efc13d3f1","resource":{"resourceType":"ServiceRequest","id":"1734642836403274640.ed48ac0b-8672-428d-8673-915efc13d3f1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836401129848.a41e731d-a4d4-46cc-a526-a8af0ddf53ba"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836396693860.9719d599-2d11-4168-a11b-b73b6992d2ae"}}},{"fullUrl":"Practitioner/1734642836396693860.9719d599-2d11-4168-a11b-b73b6992d2ae","resource":{"resourceType":"Practitioner","id":"1734642836396693860.9719d599-2d11-4168-a11b-b73b6992d2ae","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836401129848.a41e731d-a4d4-46cc-a526-a8af0ddf53ba","resource":{"resourceType":"Practitioner","id":"1734642836401129848.a41e731d-a4d4-46cc-a526-a8af0ddf53ba","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836411995102.fe0cfdee-2504-4550-87e1-7cb602a894ee","resource":{"resourceType":"ServiceRequest","id":"1734642836411995102.fe0cfdee-2504-4550-87e1-7cb602a894ee","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836409693667.9db820b2-e5cd-48b1-a3af-396425df5a6e"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836405248201.ae913fb5-8576-4b72-97ef-ca860c67a532"}}},{"fullUrl":"Practitioner/1734642836405248201.ae913fb5-8576-4b72-97ef-ca860c67a532","resource":{"resourceType":"Practitioner","id":"1734642836405248201.ae913fb5-8576-4b72-97ef-ca860c67a532","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836409693667.9db820b2-e5cd-48b1-a3af-396425df5a6e","resource":{"resourceType":"Practitioner","id":"1734642836409693667.9db820b2-e5cd-48b1-a3af-396425df5a6e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836420484381.73a022e0-4c1a-432c-8026-e6a1182ae0c6","resource":{"resourceType":"ServiceRequest","id":"1734642836420484381.73a022e0-4c1a-432c-8026-e6a1182ae0c6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836418139674.64c5f60a-10ea-4036-97dd-6cddf7734479"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836413774870.782031bf-bbfc-4f1f-9f65-b219858ebcc1"}}},{"fullUrl":"Practitioner/1734642836413774870.782031bf-bbfc-4f1f-9f65-b219858ebcc1","resource":{"resourceType":"Practitioner","id":"1734642836413774870.782031bf-bbfc-4f1f-9f65-b219858ebcc1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836418139674.64c5f60a-10ea-4036-97dd-6cddf7734479","resource":{"resourceType":"Practitioner","id":"1734642836418139674.64c5f60a-10ea-4036-97dd-6cddf7734479","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"DiagnosticReport/1734642836428415372.6590f295-01a4-4daf-8dbe-5bd3622a42e0","resource":{"resourceType":"DiagnosticReport","id":"1734642836428415372.6590f295-01a4-4daf-8dbe-5bd3622a42e0","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"56155532"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"56155532"}],"basedOn":[{"reference":"ServiceRequest/1734642836211469125.e6e076d4-8334-47db-9cc0-1c4fe300de8d"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836161032270.46570000-7b65-48ff-a4ee-7c6884e3bc40"}]}},{"fullUrl":"DiagnosticReport/1734642836431845444.b43c3ad3-80b9-4953-8e18-f633dc149e5f","resource":{"resourceType":"DiagnosticReport","id":"1734642836431845444.b43c3ad3-80b9-4953-8e18-f633dc149e5f","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836224689866.d50d5411-c894-4903-a74d-23409a7158a7"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836162665332.ff5b8563-8157-4e83-83b7-56c7b7498c70"}]}},{"fullUrl":"DiagnosticReport/1734642836435304150.acabebcf-c09a-4a07-831e-36a3a4272bb7","resource":{"resourceType":"DiagnosticReport","id":"1734642836435304150.acabebcf-c09a-4a07-831e-36a3a4272bb7","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836233361116.ae32ec13-3bd0-450c-a8b0-e2db6dfa8a58"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836164126261.eda6980d-7ef7-406f-81de-aa435e2a5c4e"}],"result":[{"reference":"Observation/1734642835838348458.43fb29c2-a1a2-46ee-b73d-60e75cfa96f7"},{"reference":"Observation/1734642835841845246.4b04227d-09c0-4420-9c5e-e761434e1f65"},{"reference":"Observation/1734642835845365186.de231997-4300-4ff5-af9b-cbdd94007344"},{"reference":"Observation/1734642835848852014.ee590f13-b4e4-4667-ae32-32dd35b642a9"},{"reference":"Observation/1734642835852399236.826318e3-458b-4bcc-a558-a9b733f4aabc"},{"reference":"Observation/1734642835855517012.cdf88ff7-2886-4ac0-93de-0c14600848f9"},{"reference":"Observation/1734642835858631442.b3f1cb03-7d61-45d8-9f49-d0d51c019afc"}]}},{"fullUrl":"DiagnosticReport/1734642836438843987.f3795167-105b-4938-addb-6b6b55da9cca","resource":{"resourceType":"DiagnosticReport","id":"1734642836438843987.f3795167-105b-4938-addb-6b6b55da9cca","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836241950442.fa7ec720-835f-40fe-9d85-64302547c7da"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836165479489.dd1334bf-e8a9-416b-9122-2cd311dc2d5c"}],"result":[{"reference":"Observation/1734642835861724723.ddaac99b-c83c-4166-bf66-3abe0caf2011"},{"reference":"Observation/1734642835865234865.4a0cf0e0-0356-4533-b278-286cffaf37d2"},{"reference":"Observation/1734642835868488365.95c78f92-bd79-427b-81b2-f58d6b4dec65"},{"reference":"Observation/1734642835871986425.131c2949-3134-4848-975b-0db4dab5cd69"},{"reference":"Observation/1734642835875460509.fe5bc4f0-03dc-4fff-869f-4265efbbcd25"},{"reference":"Observation/1734642835879131162.6fe4e08b-aa38-4172-b2ab-622ad5bea544"},{"reference":"Observation/1734642835882630193.254cde97-1b38-4f9b-a44a-ffa9d6f2ddf3"},{"reference":"Observation/1734642835885686875.54ed88d3-9a3a-41ac-a26d-999bc55565e8"},{"reference":"Observation/1734642835888799281.17429e42-1961-4d38-84fb-df544a3a024b"},{"reference":"Observation/1734642835891927197.09bbcc6f-cb0a-495d-a0fd-3d5a637a6560"}]}},{"fullUrl":"DiagnosticReport/1734642836441766538.3d5e3d2c-d384-4d90-bae3-c3e267021f88","resource":{"resourceType":"DiagnosticReport","id":"1734642836441766538.3d5e3d2c-d384-4d90-bae3-c3e267021f88","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836250765712.59a67878-8cad-4343-8fd8-7922dad33cd9"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836166821946.c1ea71c7-fb40-4cd0-80fb-0a4f134f9425"}]}},{"fullUrl":"DiagnosticReport/1734642836445954190.7119e2b8-859d-4a82-a1d7-cca3136dbecc","resource":{"resourceType":"DiagnosticReport","id":"1734642836445954190.7119e2b8-859d-4a82-a1d7-cca3136dbecc","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836259325462.67b6c411-50a0-4d81-be09-068910902638"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836168190152.6fe40301-21fe-4402-b76d-c685c08a42e0"}],"result":[{"reference":"Observation/1734642835895699811.ac8311f2-11d0-4139-8e75-0d862789fa8e"},{"reference":"Observation/1734642835899291305.a684af57-f50d-4b53-8536-877c33b50d96"},{"reference":"Observation/1734642835903069350.b34b8876-7d82-4bbd-bc2e-27ed68fb2f0d"},{"reference":"Observation/1734642835906837265.b0d7f760-36f1-4fc4-be37-ff54bf7d45b2"},{"reference":"Observation/1734642835910461792.59d3fdd6-b67f-453f-873d-5933012c9c51"},{"reference":"Observation/1734642835914078924.b9721f8a-8cca-4307-aaf6-bc33777c448a"},{"reference":"Observation/1734642835917701457.cfcd58d7-2d26-48a1-bb55-b18357110171"},{"reference":"Observation/1734642835921297601.f23ad939-3185-45ba-b799-12cb69a62edb"},{"reference":"Observation/1734642835924956562.8a51eada-1b83-4132-aeb9-9e897bcfa7dc"},{"reference":"Observation/1734642835928560610.f11761e5-32ac-4329-8350-d8f336dc2841"},{"reference":"Observation/1734642835936166881.0e234ccb-6d15-49c1-8d85-3e19f162470a"},{"reference":"Observation/1734642835938621093.ee5cd03c-4948-4a32-8164-441ef939a2a9"},{"reference":"Observation/1734642835940962653.12eda31d-70a3-441a-af2a-28141156b3bb"},{"reference":"Observation/1734642835943140036.2289d344-2124-423a-8324-9e135ed95b3d"},{"reference":"Observation/1734642835945246025.c0de0d70-8645-4428-ba13-12b45b8930a3"},{"reference":"Observation/1734642835947343138.ae725d80-ad0e-4919-8cb1-d7565941812b"},{"reference":"Observation/1734642835949495904.b12fa676-b353-4141-bdea-ca5aea9ad88b"},{"reference":"Observation/1734642835951835531.e31d4936-c9dd-4449-961f-91c9451b6a81"},{"reference":"Observation/1734642835953756684.b3b3c9f3-7b72-4744-b798-68ff47d63356"}]}},{"fullUrl":"DiagnosticReport/1734642836448954536.99e8049b-82a6-48d5-85c6-590001827d87","resource":{"resourceType":"DiagnosticReport","id":"1734642836448954536.99e8049b-82a6-48d5-85c6-590001827d87","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836268500066.fa067df2-9282-4977-8b95-7911c976c2ed"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836169622397.6e71209d-2b34-4b42-8090-f7d67db1f966"}],"result":[{"reference":"Observation/1734642835955917426.1cde4345-8899-40b8-8ff8-4e433393dcd8"},{"reference":"Observation/1734642835957880868.bbc96ac7-3744-47f0-808b-09c118350019"}]}},{"fullUrl":"DiagnosticReport/1734642836453527821.28cfe23b-02a1-47c7-829c-e175148e22cf","resource":{"resourceType":"DiagnosticReport","id":"1734642836453527821.28cfe23b-02a1-47c7-829c-e175148e22cf","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836276842830.0d9448c9-73c6-4837-b7bb-a4c879444fbc"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836171065203.9d232828-25d2-4c83-a58e-1c74cadfd08f"}],"result":[{"reference":"Observation/1734642835959899623.1ece5b91-20e1-4c7f-a96a-6365931b5a9c"},{"reference":"Observation/1734642835962463120.73f4c091-a419-4206-9afc-a32499ccbbe2"},{"reference":"Observation/1734642835964812345.8d6a15f2-71d7-4ed4-afc6-da14e26b77aa"},{"reference":"Observation/1734642835966984488.bd58a5fd-e687-4bf3-b0fd-b3e31acfcf99"},{"reference":"Observation/1734642835969111537.1eea330d-e9e8-4c4a-a9b2-1f1541a5ad8f"},{"reference":"Observation/1734642835971804997.244ed723-05f6-4536-8789-637c500de1a7"},{"reference":"Observation/1734642835974458253.c66715d8-79f1-4446-be41-939ceb8f8b97"},{"reference":"Observation/1734642835976904089.fb7f61f4-2721-4abc-9c7b-26a7cbc10af8"},{"reference":"Observation/1734642835979548217.e7fe453b-12a1-44f4-a3b8-b37095ef4ae3"},{"reference":"Observation/1734642835982249112.ad92ca2f-cfb4-40ab-b7ce-b944af3e8cde"},{"reference":"Observation/1734642835984907707.60807b7e-f053-4dc3-837f-09887470d85c"},{"reference":"Observation/1734642835987496421.d5cd8995-f998-42cb-a3ca-ce0a1166a6fc"},{"reference":"Observation/1734642835989963036.a7394af9-094b-4902-a20a-0fe9201175da"},{"reference":"Observation/1734642835992538956.3f21d58a-11a9-43cc-a553-2935221156d3"},{"reference":"Observation/1734642835994923608.548f1b1b-6afc-463a-9c33-e9ce81ad97fc"},{"reference":"Observation/1734642835997573677.80a6dfc6-fa09-4358-815a-dfe757959f09"},{"reference":"Observation/1734642835999720703.41a6d967-ca64-4620-8712-30ab2f044fdd"},{"reference":"Observation/1734642836002687025.4f2f8fcb-9a4a-4f1f-a8c0-15de90b82d98"},{"reference":"Observation/1734642836004850091.e50d0cb3-2299-41e8-bfb2-7d3cd8c9061f"},{"reference":"Observation/1734642836006922607.f157c594-316e-4ad2-a17d-6c8d4f744f41"},{"reference":"Observation/1734642836009344819.27f90a06-82ed-4274-add4-afe438e2671a"},{"reference":"Observation/1734642836011736344.7bb83079-f18b-4ab0-a7f7-36af690cf1d9"},{"reference":"Observation/1734642836014288509.034f071a-2364-49c7-9e4f-c2b9e6b15e69"},{"reference":"Observation/1734642836020924763.4b54fab8-026d-4850-a9a8-6f43840e571d"},{"reference":"Observation/1734642836023364107.7bd159a4-9cba-43ea-8dc1-2b75b155250c"},{"reference":"Observation/1734642836026388919.f459fd2a-e75c-46d2-a0f1-acce29409873"}]}},{"fullUrl":"DiagnosticReport/1734642836457059804.8101d8e9-73fe-4d92-9ae3-d96d52c24b21","resource":{"resourceType":"DiagnosticReport","id":"1734642836457059804.8101d8e9-73fe-4d92-9ae3-d96d52c24b21","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836285130680.8f6eaf5b-40c9-4189-8aca-08101b2bcdf3"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836172450811.05f794fb-ae21-4cc3-ab91-44959988c1c4"}],"result":[{"reference":"Observation/1734642836029102116.af3487b7-83d4-417b-afbc-23b988c99cb7"},{"reference":"Observation/1734642836031499131.0ef60ce2-0887-4e14-87e6-70602f11724c"},{"reference":"Observation/1734642836034335821.b39a86ae-626b-4de3-baf9-7c4b3bdb918f"},{"reference":"Observation/1734642836037044299.5e380009-0025-4a93-8a79-9157e9ee5091"},{"reference":"Observation/1734642836039552863.a1775955-14a6-4d3d-9d00-1d1576b13957"},{"reference":"Observation/1734642836042252094.e4c7436e-2453-4d6f-bf3f-154218717c33"},{"reference":"Observation/1734642836045172871.81c16756-2212-4514-b387-82ba937fae20"},{"reference":"Observation/1734642836047619739.dfa41c8d-ee19-47ba-9771-62f7680ee29e"},{"reference":"Observation/1734642836050378483.896e302c-e7e0-462e-ac40-e786d95bed3a"},{"reference":"Observation/1734642836052717969.aa4e6425-a295-4d7c-82a0-f966e6899c2b"}]}},{"fullUrl":"DiagnosticReport/1734642836460082833.78fc2d69-f794-4288-bfd2-8ae0e241dafa","resource":{"resourceType":"DiagnosticReport","id":"1734642836460082833.78fc2d69-f794-4288-bfd2-8ae0e241dafa","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836294761079.da990083-15d9-410c-b401-f51a41982afb"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836173953849.216555b6-7718-4724-a40b-446a1535ac35"}],"result":[{"reference":"Observation/1734642836056150155.3c7a51ac-07b3-47e3-a124-9c8b9e3a3b83"},{"reference":"Observation/1734642836059098674.3ddbdc33-426e-4b74-b71a-759e225539e4"},{"reference":"Observation/1734642836061148087.724aa224-ce9b-48ba-9cd3-7f046341d894"}]}},{"fullUrl":"DiagnosticReport/1734642836463081496.2b7dca61-1b60-47db-9418-7da5ce8fbf61","resource":{"resourceType":"DiagnosticReport","id":"1734642836463081496.2b7dca61-1b60-47db-9418-7da5ce8fbf61","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836303617155.292bdcf8-998f-49b4-b53d-75cada578a97"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836175318167.1f1e6b32-2c14-44a7-9f7e-a1b9239f31ab"}],"result":[{"reference":"Observation/1734642836064192896.545f0cb5-2bb4-4ce7-8d40-188c2094ae6b"},{"reference":"Observation/1734642836066734031.752fc16a-f2b9-4fc6-9f0f-5fc9afdefbb2"},{"reference":"Observation/1734642836068882770.6b6e0b85-241b-47b3-b747-37a61fa1d240"}]}},{"fullUrl":"DiagnosticReport/1734642836466120635.370ae00a-25fe-4fa5-a324-f887bbe2a856","resource":{"resourceType":"DiagnosticReport","id":"1734642836466120635.370ae00a-25fe-4fa5-a324-f887bbe2a856","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836312111042.04bf133a-a60f-4d5a-b1db-b3bb78f3bb7b"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836176692945.c095756a-2f25-4c51-bdb1-6f412c956bae"}],"result":[{"reference":"Observation/1734642836071577363.c6d07390-087c-4753-a459-ed7fcd308e48"},{"reference":"Observation/1734642836075082024.1c1fcb05-42db-464b-8ada-6df001524653"},{"reference":"Observation/1734642836078093261.63f313f4-c070-492f-afbd-a33b562df097"}]}},{"fullUrl":"DiagnosticReport/1734642836469187225.77d97fba-4680-41c3-a53d-f3f9fafc8176","resource":{"resourceType":"DiagnosticReport","id":"1734642836469187225.77d97fba-4680-41c3-a53d-f3f9fafc8176","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836321191278.496e5d2d-aaa9-4f32-bf5f-25e44b00c369"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836178034140.e3cbe5e4-708b-4e4e-8d3d-bd83a6713778"}],"result":[{"reference":"Observation/1734642836080350664.f0388aa8-665c-4f91-8fd5-9c301df81913"},{"reference":"Observation/1734642836082734985.98cc37d6-f03e-4f09-8a30-dc91c3cb4a44"},{"reference":"Observation/1734642836084978451.e5032aa6-893e-432b-bf94-24bbafd2f6ec"}]}},{"fullUrl":"DiagnosticReport/1734642836472186179.2764089d-c788-49cd-a6aa-970788903941","resource":{"resourceType":"DiagnosticReport","id":"1734642836472186179.2764089d-c788-49cd-a6aa-970788903941","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836331263295.6c66392a-d008-4df9-a51c-7c8a63466ed6"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836179371708.16d8ceab-0511-4309-9db9-fd4c8429c595"}],"result":[{"reference":"Observation/1734642836086819173.3e285432-ee21-489e-a223-fc5c7689b06d"},{"reference":"Observation/1734642836088611323.1bde1240-4adb-4827-b673-5427483e3dea"}]}},{"fullUrl":"DiagnosticReport/1734642836475203036.31a490a5-9b63-446e-8f9e-eb2d9fd2721e","resource":{"resourceType":"DiagnosticReport","id":"1734642836475203036.31a490a5-9b63-446e-8f9e-eb2d9fd2721e","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836339797758.e4e9a447-a036-4f1f-b48b-4e8ced41f368"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836180747027.6df950ea-03a3-435b-912f-8261319782b4"}],"result":[{"reference":"Observation/1734642836090904183.4b2226ec-6c0b-4031-909f-235e2f04976c"},{"reference":"Observation/1734642836093566986.b14e7d8d-5b96-4964-8572-da5fb4327281"},{"reference":"Observation/1734642836095654951.3db665e3-0f5c-48e7-a07b-72fcbc002aa0"}]}},{"fullUrl":"DiagnosticReport/1734642836478257283.e475367b-b110-4a83-971d-f42c9a4a8087","resource":{"resourceType":"DiagnosticReport","id":"1734642836478257283.e475367b-b110-4a83-971d-f42c9a4a8087","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836348221083.f121f33c-f711-40d6-be41-9d517d9b6c1e"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836182114562.8cc3bdf7-2378-4050-8915-2fba8d0cb66c"}],"result":[{"reference":"Observation/1734642836099363255.b57829c9-31a7-4f2b-923c-7177397914e0"},{"reference":"Observation/1734642836101959590.ae5c736c-5301-4b7a-9aa6-6e4398046e5b"},{"reference":"Observation/1734642836104365842.7148179d-564a-4df9-bd22-c230f7dcb93e"}]}},{"fullUrl":"DiagnosticReport/1734642836481289398.62ce13b4-be11-4411-992a-d77837e17758","resource":{"resourceType":"DiagnosticReport","id":"1734642836481289398.62ce13b4-be11-4411-992a-d77837e17758","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836356921477.f8969abf-1d45-4fdb-82ca-12ec23f1a198"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836183461107.69dcb642-2f99-4373-9e1b-e826e9ebcc68"}],"result":[{"reference":"Observation/1734642836111297162.b3873451-14ee-44c4-97d5-9bb41c989626"},{"reference":"Observation/1734642836113467783.741e468e-7fc0-4423-ac97-ee219ed19842"},{"reference":"Observation/1734642836115303725.d20a44c7-6828-4a2f-a4a7-14339af82c03"}]}},{"fullUrl":"DiagnosticReport/1734642836484595237.313b8922-17ff-47f8-9036-1dd0bb5c0312","resource":{"resourceType":"DiagnosticReport","id":"1734642836484595237.313b8922-17ff-47f8-9036-1dd0bb5c0312","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836365734843.823e99b0-bf45-433b-9dda-0fb8e7ec362c"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836184837918.8979b6cf-1ab8-4204-9afc-82152ecd657c"}],"result":[{"reference":"Observation/1734642836117814203.b4e4cf66-b844-451b-9c87-24832b6fe6ad"},{"reference":"Observation/1734642836119999360.04908077-17c5-4224-80f7-49d2066cbedb"},{"reference":"Observation/1734642836121872623.119d758a-9078-4420-aacb-94a01f1eb724"}]}},{"fullUrl":"DiagnosticReport/1734642836487660084.7412cbdc-131a-4a55-bc32-826e6c7d55b0","resource":{"resourceType":"DiagnosticReport","id":"1734642836487660084.7412cbdc-131a-4a55-bc32-826e6c7d55b0","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836374544853.68f48201-4b0d-4906-ab6e-3ae7f8a93837"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836186184714.3c7264fe-459a-4e2e-a9c4-010092f02c47"}],"result":[{"reference":"Observation/1734642836123642191.b1b92497-7ecb-42f0-9a46-d8106853e8fe"},{"reference":"Observation/1734642836125756856.c973f1c9-f4fe-4e66-8f37-7172ebe581d6"},{"reference":"Observation/1734642836127597888.34e36b07-2b51-4642-ae9d-0a8c918d2778"}]}},{"fullUrl":"DiagnosticReport/1734642836490747644.d0b2216d-bb2b-48ee-952f-26eb62e1a6a0","resource":{"resourceType":"DiagnosticReport","id":"1734642836490747644.d0b2216d-bb2b-48ee-952f-26eb62e1a6a0","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836383016629.001af554-7412-4c8d-9f84-b09b1cee4b11"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836187533964.1477cdc6-64f4-4fdb-9280-bf1f389fb11b"}],"result":[{"reference":"Observation/1734642836129662139.3d5d2c39-e93f-4dfd-886e-6af0424b7a9e"},{"reference":"Observation/1734642836131734335.0443a079-34d1-4cf9-9176-8515df7cba8a"},{"reference":"Observation/1734642836133599152.b964ea85-cf95-49f2-b92f-62328d3ea799"}]}},{"fullUrl":"DiagnosticReport/1734642836493766444.1ef481f0-049d-4035-9636-8ba48034e6e1","resource":{"resourceType":"DiagnosticReport","id":"1734642836493766444.1ef481f0-049d-4035-9636-8ba48034e6e1","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836394811491.34277100-a636-4818-bb0f-d52e9da86550"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836188904223.d33485a5-6a3c-471a-8ea6-261635fcadb2"}],"result":[{"reference":"Observation/1734642836136544444.76dec855-2215-4747-b563-5edf391e7414"},{"reference":"Observation/1734642836138511032.bbdd868a-ccbc-4dc8-afb3-ab91b493db75"}]}},{"fullUrl":"DiagnosticReport/1734642836496970072.faa9ccef-26ff-4273-a633-f56f219b527a","resource":{"resourceType":"DiagnosticReport","id":"1734642836496970072.faa9ccef-26ff-4273-a633-f56f219b527a","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836403274640.ed48ac0b-8672-428d-8673-915efc13d3f1"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836190292366.cb0738a0-5e1a-4416-94e0-b7a606b153d0"}],"result":[{"reference":"Observation/1734642836140773031.ca60eb5f-4792-4f47-9cda-4f2336385def"},{"reference":"Observation/1734642836142897444.274531bb-aba7-40ac-a4c6-b6777fa2656c"},{"reference":"Observation/1734642836144844706.bf279162-4e5f-474c-bf4f-c7405b754eed"}]}},{"fullUrl":"DiagnosticReport/1734642836500347314.577024eb-c231-462c-821a-e8479ec274fa","resource":{"resourceType":"DiagnosticReport","id":"1734642836500347314.577024eb-c231-462c-821a-e8479ec274fa","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836411995102.fe0cfdee-2504-4550-87e1-7cb602a894ee"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836191672224.0ba34d35-8ff2-417a-b212-c582abb903c6"}],"result":[{"reference":"Observation/1734642836146921300.a099f493-8f4b-406d-80e2-9937c06c29af"},{"reference":"Observation/1734642836148732836.1f0c3ba7-cca4-4716-8e12-bd556367776e"}]}},{"fullUrl":"DiagnosticReport/1734642836503350836.519e95d2-5b56-4697-b578-e00abbfe9c74","resource":{"resourceType":"DiagnosticReport","id":"1734642836503350836.519e95d2-5b56-4697-b578-e00abbfe9c74","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836420484381.73a022e0-4c1a-432c-8026-e6a1182ae0c6"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836193133473.9d77732e-0d8d-46d2-a589-d1f41fa01f86"}],"result":[{"reference":"Observation/1734642836150737746.37519cf1-4f37-441a-b91c-2effb9f3579f"}]}}]}
diff --git a/examples/Test/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7 b/examples/Test/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
index f43843e0a..a93c6ef84 100644
--- a/examples/Test/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
+++ b/examples/Test/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
@@ -1,143 +1,143 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241015050654||ORU^R01^ORU_R01|001|N|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241015050654||ORU^R01^ORU_R01|001|N|2.5.1
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
-ORC|RE|673678765^FormNumber||M17965^HospOrdNumber||||||||1477542173^BROOKS^STEWART^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804\r
-OBR|1|673678765^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410011420|||||||||||||||20241015050654|||F\r
-OBR|2|673678765^FormNumber||57128-1^Newborn Screening Report summary panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241015050654\r
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241015050654\r
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241015050654\r
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241015050654\r
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241015050654\r
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\R\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241015050654\r
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241015050654\r
-OBR|3|673678765^FormNumber||57717-1^Newborn screen card data panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241015050654\r
-OBX|2|NM|8339-4^Birthweight^LN|1|4020|grams||N|||F|||20241015050654\r
-OBX|3|TM|57715-5^Time of birth^LN|1|1416|||N|||F|||20241015050654\r
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241015050654\r
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241015050654\r
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241015050654\r
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241015050654\r
-OBX|8|CE|67704-7^Feeding types^LN|2|LA16915-3^Lactose formula^LN|||N|||F|||20241015050654\r
-OBX|9|TX|^^^99717-5^Accession Number^L|1|277-86-190/21-2024-32|||N|||F|||20241015050654\r
-OBX|10|TX|62324-9^Post-discharge provider name^LN|1|STEWART BROOKS|||N|||F|||20241015050654\r
-OBX|11|TX|62325-6^Post-discharge provider practice ID^LN|1|1477542173|||N|||F|||20241015050654\r
-OBX|12|TX|62327-2^Post-discharge provider practice address^LN|1|8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA|||N|||F|||20241015050654\r
-OBR|4|673678765^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410011420|||||||||||||||20241015050654|||F\r
-OBR|5|673678765^FormNumber||53261-4^Amino acid newborn screen panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|387|µmol/L||N|||F|||20241015050654\r
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|381|µmol/L|<1000|N|||F|||20241015050654\r
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|92.6|µmol/L||N|||F|||20241015050654\r
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.88595|{Ratio}|<4.3|N|||F|||20241015050654\r
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|86.8|µmol/L|<230|N|||F|||20241015050654\r
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.23|{Ratio}|<1.35|N|||F|||20241015050654\r
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|49.1|µmol/L|<175|N|||F|||20241015050654\r
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.09|{Ratio}|<2.6|N|||F|||20241015050654\r
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|45.1|µmol/L|<680|N|||F|||20241015050654\r
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.24|µmol/L|<6.1|N|||F|||20241015050654\r
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|16.8|µmol/L|6.3-100|N|||F|||20241015050654\r
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|20|µmol/L|5-49|N|||F|||20241015050654\r
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3.22|{Ratio}|<4.8|N|||F|||20241015050654\r
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|74|µmol/L|<800|N|||F|||20241015050654\r
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|3.76|{Ratio}||N|||F|||20241015050654\r
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|6|µmol/L|<63|N|||F|||20241015050654\r
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241015050654\r
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|118|µmol/L|<1500|N|||F|||20241015050654\r
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|6|673678765^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241015050654\r
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with SCADD, IBCDD|||A|||F|||20241015050654\r
-OBR|7|673678765^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|34.3|µmol/L|6.4-125|N|||F|||20241015050654\r
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|5.93|{Ratio}|<70|N|||F|||20241015050654\r
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|33.2|µmol/L|10-80|N|||F|||20241015050654\r
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|1.29565|{Ratio}|<7.6|N|||F|||20241015050654\r
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.136|µmol/L|<0.95|N|||F|||20241015050654\r
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.150|µmol/L|<0.45|N|||F|||20241015050654\r
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.65|{Ratio}||N|||F|||20241015050654\r
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.221|µmol/L|<0.65|N|||F|||20241015050654\r
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.230|µmol/L|<0.65|N|||F|||20241015050654\r
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.088|µmol/L|<0.45|N|||F|||20241015050654\r
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.232|µmol/L|<2|N|||F|||20241015050654\r
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.20|µmol/L||N|||F|||20241015050654\r
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.342|µmol/L|<1.2|N|||F|||20241015050654\r
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.206|µmol/L|<0.9|N|||F|||20241015050654\r
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.02|{Ratio}||N|||F|||20241015050654\r
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241015050654\r
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.029|µmol/L|<0.2|N|||F|||20241015050654\r
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|4.14|µmol/L|<12|N|||F|||20241015050654\r
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.341|µmol/L|<1.4|N|||F|||20241015050654\r
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.049|µmol/L|<0.1|N|||F|||20241015050654\r
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01184|{Ratio}|<0.07|N|||F|||20241015050654\r
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.07|µmol/L|<3.5|N|||F|||20241015050654\r
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.65|µmol/L|<7|N|||F|||20241015050654\r
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.23|µmol/L||N|||F|||20241015050654\r
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.022|µmol/L|<0.1|N|||F|||20241015050654\r
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.053|µmol/L|<0.1|N|||F|||20241015050654\r
-OBR|8|673678765^FormNumber||57085-3^Organic acid newborn screen panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.3|µmol/L|<7.9|N|||F|||20241015050654\r
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.07|{Ratio}|<0.42|N|||F|||20241015050654\r
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.298|µmol/L|<0.48|N|||F|||20241015050654\r
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|1.73|µmol/L|<1.7|H|||F|||20241015050654\r
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.139|µmol/L|<0.95|N|||F|||20241015050654\r
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.06043|{Ratio}|<0.38|N|||F|||20241015050654\r
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.011|µmol/L|<0.5|N|||F|||20241015050654\r
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.306|µmol/L|<1.15|N|||F|||20241015050654\r
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.238|µmol/L|<0.38|N|||F|||20241015050654\r
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.79866|{Ratio}|>0.1|N|||F|||20241015050654\r
-OBR|9|673678765^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|18.10|ng/mL|<69|N|||F|||20241015050654\r
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|10|673678765^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00010.8|nmol/L|<85|N|||F|||20241015050654\r
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|11|673678765^FormNumber||54090-6^Thyroid newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|29575-8^Thyrotropin^LN|1|4.00|mIU/L|<29|N|||F|||20241015050654\r
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|12|673678765^FormNumber||54079-9^Galactosemia newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|267.94|enzyme units|>50|N|||F|||20241015050654\r
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|13|673678765^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241015050654\r
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241015050654\r
-OBR|14|673678765^FormNumber||57087-9^Biotinidase newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|44.16|ERU|>10|N|||F|||20241015050654\r
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|15|673678765^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|84|copies/µL|>18|N|||F|||20241015050654\r
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|16|673678765^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|6.97|µmol/L/h|>=1.51|N|||F|||20241015050654\r
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|17|673678765^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|10.38|µmol/L/h|>=0.77|N|||F|||20241015050654\r
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|18|673678765^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241015050654\r
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241015050654\r
-OBR|19|673678765^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|27.61|µmol/L/h|>=2.75|N|||F|||20241015050654\r
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|20|673678765^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015050654\r
-OBR|21|673678765^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.04|µmol/L|<=3|N|||F|||20241015050654\r
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|391.37|µmol/L||N|||F|||20241015050654\r
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.66||<=6|N|||F|||20241015050654\r
-OBR|22|673678765^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241015050654\r
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241015050654\r
-OBR|23|673678765^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F\r
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.246|µmol/L|<0.47|N|||F|||20241015050654\r
+ORC|RE|673678765^FormNumber||M17965^HospOrdNumber||||||||1477542173^BROOKS^STEWART^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804
+OBR|1|673678765^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410011420|||||||||||||||20241015050654|||F
+OBR|2|673678765^FormNumber||57128-1^Newborn Screening Report summary panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241015050654
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241015050654
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241015050654
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241015050654
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241015050654
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241015050654
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241015050654
+OBR|3|673678765^FormNumber||57717-1^Newborn screen card data panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241015050654
+OBX|2|NM|8339-4^Birthweight^LN|1|4020|grams||N|||F|||20241015050654
+OBX|3|TM|57715-5^Time of birth^LN|1|1416|||N|||F|||20241015050654
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241015050654
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241015050654
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241015050654
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241015050654
+OBX|8|CE|67704-7^Feeding types^LN|2|LA16915-3^Lactose formula^LN|||N|||F|||20241015050654
+OBX|9|TX|^^^99717-5^Accession Number^L|1|277-86-190/21-2024-32|||N|||F|||20241015050654
+OBX|10|TX|62324-9^Post-discharge provider name^LN|1|STEWART BROOKS|||N|||F|||20241015050654
+OBX|11|TX|62325-6^Post-discharge provider practice ID^LN|1|1477542173|||N|||F|||20241015050654
+OBX|12|TX|62327-2^Post-discharge provider practice address^LN|1|8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA|||N|||F|||20241015050654
+OBR|4|673678765^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410011420|||||||||||||||20241015050654|||F
+OBR|5|673678765^FormNumber||53261-4^Amino acid newborn screen panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|387|µmol/L||N|||F|||20241015050654
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|381|µmol/L|<1000|N|||F|||20241015050654
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|92.6|µmol/L||N|||F|||20241015050654
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.88595|{Ratio}|<4.3|N|||F|||20241015050654
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|86.8|µmol/L|<230|N|||F|||20241015050654
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.23|{Ratio}|<1.35|N|||F|||20241015050654
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|49.1|µmol/L|<175|N|||F|||20241015050654
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.09|{Ratio}|<2.6|N|||F|||20241015050654
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|45.1|µmol/L|<680|N|||F|||20241015050654
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.24|µmol/L|<6.1|N|||F|||20241015050654
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|16.8|µmol/L|6.3-100|N|||F|||20241015050654
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|20|µmol/L|5-49|N|||F|||20241015050654
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3.22|{Ratio}|<4.8|N|||F|||20241015050654
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|74|µmol/L|<800|N|||F|||20241015050654
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|3.76|{Ratio}||N|||F|||20241015050654
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|6|µmol/L|<63|N|||F|||20241015050654
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241015050654
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|118|µmol/L|<1500|N|||F|||20241015050654
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|6|673678765^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241015050654
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with SCADD, IBCDD|||A|||F|||20241015050654
+OBR|7|673678765^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|34.3|µmol/L|6.4-125|N|||F|||20241015050654
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|5.93|{Ratio}|<70|N|||F|||20241015050654
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|33.2|µmol/L|10-80|N|||F|||20241015050654
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|1.29565|{Ratio}|<7.6|N|||F|||20241015050654
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.136|µmol/L|<0.95|N|||F|||20241015050654
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.150|µmol/L|<0.45|N|||F|||20241015050654
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.65|{Ratio}||N|||F|||20241015050654
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.221|µmol/L|<0.65|N|||F|||20241015050654
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.230|µmol/L|<0.65|N|||F|||20241015050654
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.088|µmol/L|<0.45|N|||F|||20241015050654
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.232|µmol/L|<2|N|||F|||20241015050654
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.20|µmol/L||N|||F|||20241015050654
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.342|µmol/L|<1.2|N|||F|||20241015050654
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.206|µmol/L|<0.9|N|||F|||20241015050654
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.02|{Ratio}||N|||F|||20241015050654
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241015050654
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.029|µmol/L|<0.2|N|||F|||20241015050654
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|4.14|µmol/L|<12|N|||F|||20241015050654
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.341|µmol/L|<1.4|N|||F|||20241015050654
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.049|µmol/L|<0.1|N|||F|||20241015050654
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01184|{Ratio}|<0.07|N|||F|||20241015050654
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.07|µmol/L|<3.5|N|||F|||20241015050654
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.65|µmol/L|<7|N|||F|||20241015050654
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.23|µmol/L||N|||F|||20241015050654
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.022|µmol/L|<0.1|N|||F|||20241015050654
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.053|µmol/L|<0.1|N|||F|||20241015050654
+OBR|8|673678765^FormNumber||57085-3^Organic acid newborn screen panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.3|µmol/L|<7.9|N|||F|||20241015050654
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.07|{Ratio}|<0.42|N|||F|||20241015050654
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.298|µmol/L|<0.48|N|||F|||20241015050654
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|1.73|µmol/L|<1.7|H|||F|||20241015050654
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.139|µmol/L|<0.95|N|||F|||20241015050654
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.06043|{Ratio}|<0.38|N|||F|||20241015050654
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.011|µmol/L|<0.5|N|||F|||20241015050654
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.306|µmol/L|<1.15|N|||F|||20241015050654
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.238|µmol/L|<0.38|N|||F|||20241015050654
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.79866|{Ratio}|>0.1|N|||F|||20241015050654
+OBR|9|673678765^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|18.10|ng/mL|<69|N|||F|||20241015050654
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|10|673678765^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00010.8|nmol/L|<85|N|||F|||20241015050654
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|11|673678765^FormNumber||54090-6^Thyroid newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|29575-8^Thyrotropin^LN|1|4.00|mIU/L|<29|N|||F|||20241015050654
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|12|673678765^FormNumber||54079-9^Galactosemia newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|267.94|enzyme units|>50|N|||F|||20241015050654
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|13|673678765^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241015050654
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241015050654
+OBR|14|673678765^FormNumber||57087-9^Biotinidase newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|44.16|ERU|>10|N|||F|||20241015050654
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|15|673678765^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|84|copies/µL|>18|N|||F|||20241015050654
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|16|673678765^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|6.97|µmol/L/h|>=1.51|N|||F|||20241015050654
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|17|673678765^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|10.38|µmol/L/h|>=0.77|N|||F|||20241015050654
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|18|673678765^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241015050654
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241015050654
+OBR|19|673678765^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|27.61|µmol/L/h|>=2.75|N|||F|||20241015050654
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|20|673678765^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015050654
+OBR|21|673678765^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.04|µmol/L|<=3|N|||F|||20241015050654
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|391.37|µmol/L||N|||F|||20241015050654
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.66||<=6|N|||F|||20241015050654
+OBR|22|673678765^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241015050654
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241015050654
+OBR|23|673678765^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.246|µmol/L|<0.47|N|||F|||20241015050654
diff --git a/examples/Test/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7 b/examples/Test/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
index 680a34bad..eb4377c51 100644
--- a/examples/Test/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
+++ b/examples/Test/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
@@ -1,142 +1,142 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050234||ORU^R01^ORU_R01|002|N|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050234||ORU^R01^ORU_R01|002|N|2.5.1
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
-ORC|RE|12345667867^FormNumber||S30500^HospOrdNumber||||||||1194257170^MAHMOOD^SARAH^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804\r
-OBR|1|12345667867^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410061300|||||||||||||||20241018050234|||F\r
-OBR|2|12345667867^FormNumber||57128-1^Newborn Screening Report summary panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241018050234\r
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241018050234\r
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241018050234\r
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050234\r
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050234\r
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\R\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241018050234\r
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241018050234\r
-OBR|3|12345667867^FormNumber||57717-1^Newborn screen card data panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241018050234\r
-OBX|2|NM|8339-4^Birthweight^LN|1|3135|grams||N|||F|||20241018050234\r
-OBX|3|TM|57715-5^Time of birth^LN|1|1235|||N|||F|||20241018050234\r
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241018050234\r
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241018050234\r
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241018050234\r
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241018050234\r
-OBX|8|TX|^^^99717-5^Accession Number^L|1|282-18-014/21-2024-32|||N|||F|||20241018050234\r
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|SARAH MAHMOOD|||N|||F|||20241018050234\r
-OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1194257170|||N|||F|||20241018050234\r
-OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA|||N|||F|||20241018050234\r
-OBR|4|12345667867^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410061300|||||||||||||||20241018050234|||F\r
-OBR|5|12345667867^FormNumber||53261-4^Amino acid newborn screen panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|611|µmol/L||N|||F|||20241018050234\r
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|585|µmol/L|<1000|N|||F|||20241018050234\r
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|90.9|µmol/L||N|||F|||20241018050234\r
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.74808|{Ratio}|<4.3|N|||F|||20241018050234\r
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|86.9|µmol/L|<230|N|||F|||20241018050234\r
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.15|{Ratio}|<1.35|N|||F|||20241018050234\r
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|52.0|µmol/L|<175|N|||F|||20241018050234\r
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241018050234\r
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|69.0|µmol/L|<680|N|||F|||20241018050234\r
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.23|µmol/L|<6.1|N|||F|||20241018050234\r
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|22.5|µmol/L|6.3-100|N|||F|||20241018050234\r
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|14|µmol/L|5-49|N|||F|||20241018050234\r
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|2.28|{Ratio}|<4.8|N|||F|||20241018050234\r
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|68|µmol/L|<800|N|||F|||20241018050234\r
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|4.93|{Ratio}||N|||F|||20241018050234\r
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|6|µmol/L|<63|N|||F|||20241018050234\r
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241018050234\r
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|192|µmol/L|<1500|N|||F|||20241018050234\r
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|6|12345667867^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241018050234\r
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with SCADD, IBCDD|||A|||F|||20241018050234\r
-OBR|7|12345667867^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|26.6|µmol/L|6.4-125|N|||F|||20241018050234\r
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|3.27|{Ratio}|<70|N|||F|||20241018050234\r
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|29.2|µmol/L|10-80|N|||F|||20241018050234\r
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.13913|{Ratio}|<7.6|N|||F|||20241018050234\r
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.088|µmol/L|<0.95|N|||F|||20241018050234\r
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.084|µmol/L|<0.45|N|||F|||20241018050234\r
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.73|{Ratio}||N|||F|||20241018050234\r
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.172|µmol/L|<0.65|N|||F|||20241018050234\r
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.115|µmol/L|<0.65|N|||F|||20241018050234\r
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.050|µmol/L|<0.45|N|||F|||20241018050234\r
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.127|µmol/L|<2|N|||F|||20241018050234\r
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.12|µmol/L||N|||F|||20241018050234\r
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.333|µmol/L|<1.2|N|||F|||20241018050234\r
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.132|µmol/L|<0.9|N|||F|||20241018050234\r
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.13|{Ratio}||N|||F|||20241018050234\r
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241018050234\r
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.026|µmol/L|<0.2|N|||F|||20241018050234\r
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|6.19|µmol/L|<12|N|||F|||20241018050234\r
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.445|µmol/L|<1.4|N|||F|||20241018050234\r
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.045|µmol/L|<0.1|N|||F|||20241018050234\r
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00727|{Ratio}|<0.07|N|||F|||20241018050234\r
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.53|µmol/L|<3.5|N|||F|||20241018050234\r
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.96|µmol/L|<7|N|||F|||20241018050234\r
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.21|µmol/L||N|||F|||20241018050234\r
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.017|µmol/L|<0.1|N|||F|||20241018050234\r
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.036|µmol/L|<0.1|N|||F|||20241018050234\r
-OBR|8|12345667867^FormNumber||57085-3^Organic acid newborn screen panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.5|µmol/L|<7.9|N|||F|||20241018050234\r
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.09|{Ratio}|<0.42|N|||F|||20241018050234\r
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.246|µmol/L|<0.48|N|||F|||20241018050234\r
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|1.72|µmol/L|<1.7|H|||F|||20241018050234\r
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.115|µmol/L|<0.95|N|||F|||20241018050234\r
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.04600|{Ratio}|<0.38|N|||F|||20241018050234\r
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.008|µmol/L|<0.5|N|||F|||20241018050234\r
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.232|µmol/L|<1.15|N|||F|||20241018050234\r
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.180|µmol/L|<0.38|N|||F|||20241018050234\r
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.73171|{Ratio}|>0.1|N|||F|||20241018050234\r
-OBR|9|12345667867^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|21.20|ng/mL|<69|N|||F|||20241018050234\r
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|10|12345667867^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00015.6|nmol/L|<85|N|||F|||20241018050234\r
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|11|12345667867^FormNumber||54090-6^Thyroid newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|29575-8^Thyrotropin^LN|1|9.50|mIU/L|<29|N|||F|||20241018050234\r
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|12|12345667867^FormNumber||54079-9^Galactosemia newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|262.95|enzyme units|>50|N|||F|||20241018050234\r
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|13|12345667867^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241018050234\r
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241018050234\r
-OBR|14|12345667867^FormNumber||57087-9^Biotinidase newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|49.77|ERU|>10|N|||F|||20241018050234\r
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|15|12345667867^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|197|copies/µL|>18|N|||F|||20241018050234\r
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|16|12345667867^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.29|µmol/L/h|>=1.47|N|||F|||20241018050234\r
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|17|12345667867^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|13.01|µmol/L/h|>=0.82|N|||F|||20241018050234\r
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|18|12345667867^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241018050234\r
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241018050234\r
-OBR|19|12345667867^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|27.84|µmol/L/h|>=2.79|N|||F|||20241018050234\r
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|20|12345667867^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050234\r
-OBR|21|12345667867^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|0.97|µmol/L|<=3|N|||F|||20241018050234\r
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|496.63|µmol/L||N|||F|||20241018050234\r
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.95||<=6|N|||F|||20241018050234\r
-OBR|22|12345667867^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241018050234\r
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241018050234\r
-OBR|23|12345667867^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F\r
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.349|µmol/L|<0.47|N|||F|||20241018050234\r
+ORC|RE|12345667867^FormNumber||S30500^HospOrdNumber||||||||1194257170^MAHMOOD^SARAH^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804
+OBR|1|12345667867^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410061300|||||||||||||||20241018050234|||F
+OBR|2|12345667867^FormNumber||57128-1^Newborn Screening Report summary panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241018050234
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241018050234
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241018050234
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050234
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050234
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241018050234
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241018050234
+OBR|3|12345667867^FormNumber||57717-1^Newborn screen card data panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241018050234
+OBX|2|NM|8339-4^Birthweight^LN|1|3135|grams||N|||F|||20241018050234
+OBX|3|TM|57715-5^Time of birth^LN|1|1235|||N|||F|||20241018050234
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241018050234
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241018050234
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241018050234
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241018050234
+OBX|8|TX|^^^99717-5^Accession Number^L|1|282-18-014/21-2024-32|||N|||F|||20241018050234
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|SARAH MAHMOOD|||N|||F|||20241018050234
+OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1194257170|||N|||F|||20241018050234
+OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA|||N|||F|||20241018050234
+OBR|4|12345667867^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410061300|||||||||||||||20241018050234|||F
+OBR|5|12345667867^FormNumber||53261-4^Amino acid newborn screen panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|611|µmol/L||N|||F|||20241018050234
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|585|µmol/L|<1000|N|||F|||20241018050234
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|90.9|µmol/L||N|||F|||20241018050234
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.74808|{Ratio}|<4.3|N|||F|||20241018050234
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|86.9|µmol/L|<230|N|||F|||20241018050234
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.15|{Ratio}|<1.35|N|||F|||20241018050234
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|52.0|µmol/L|<175|N|||F|||20241018050234
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241018050234
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|69.0|µmol/L|<680|N|||F|||20241018050234
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.23|µmol/L|<6.1|N|||F|||20241018050234
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|22.5|µmol/L|6.3-100|N|||F|||20241018050234
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|14|µmol/L|5-49|N|||F|||20241018050234
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|2.28|{Ratio}|<4.8|N|||F|||20241018050234
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|68|µmol/L|<800|N|||F|||20241018050234
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|4.93|{Ratio}||N|||F|||20241018050234
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|6|µmol/L|<63|N|||F|||20241018050234
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241018050234
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|192|µmol/L|<1500|N|||F|||20241018050234
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|6|12345667867^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241018050234
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with SCADD, IBCDD|||A|||F|||20241018050234
+OBR|7|12345667867^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|26.6|µmol/L|6.4-125|N|||F|||20241018050234
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|3.27|{Ratio}|<70|N|||F|||20241018050234
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|29.2|µmol/L|10-80|N|||F|||20241018050234
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.13913|{Ratio}|<7.6|N|||F|||20241018050234
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.088|µmol/L|<0.95|N|||F|||20241018050234
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.084|µmol/L|<0.45|N|||F|||20241018050234
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.73|{Ratio}||N|||F|||20241018050234
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.172|µmol/L|<0.65|N|||F|||20241018050234
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.115|µmol/L|<0.65|N|||F|||20241018050234
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.050|µmol/L|<0.45|N|||F|||20241018050234
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.127|µmol/L|<2|N|||F|||20241018050234
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.12|µmol/L||N|||F|||20241018050234
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.333|µmol/L|<1.2|N|||F|||20241018050234
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.132|µmol/L|<0.9|N|||F|||20241018050234
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.13|{Ratio}||N|||F|||20241018050234
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241018050234
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.026|µmol/L|<0.2|N|||F|||20241018050234
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|6.19|µmol/L|<12|N|||F|||20241018050234
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.445|µmol/L|<1.4|N|||F|||20241018050234
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.045|µmol/L|<0.1|N|||F|||20241018050234
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00727|{Ratio}|<0.07|N|||F|||20241018050234
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.53|µmol/L|<3.5|N|||F|||20241018050234
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.96|µmol/L|<7|N|||F|||20241018050234
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.21|µmol/L||N|||F|||20241018050234
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.017|µmol/L|<0.1|N|||F|||20241018050234
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.036|µmol/L|<0.1|N|||F|||20241018050234
+OBR|8|12345667867^FormNumber||57085-3^Organic acid newborn screen panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.5|µmol/L|<7.9|N|||F|||20241018050234
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.09|{Ratio}|<0.42|N|||F|||20241018050234
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.246|µmol/L|<0.48|N|||F|||20241018050234
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|1.72|µmol/L|<1.7|H|||F|||20241018050234
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.115|µmol/L|<0.95|N|||F|||20241018050234
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.04600|{Ratio}|<0.38|N|||F|||20241018050234
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.008|µmol/L|<0.5|N|||F|||20241018050234
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.232|µmol/L|<1.15|N|||F|||20241018050234
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.180|µmol/L|<0.38|N|||F|||20241018050234
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.73171|{Ratio}|>0.1|N|||F|||20241018050234
+OBR|9|12345667867^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|21.20|ng/mL|<69|N|||F|||20241018050234
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|10|12345667867^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00015.6|nmol/L|<85|N|||F|||20241018050234
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|11|12345667867^FormNumber||54090-6^Thyroid newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|29575-8^Thyrotropin^LN|1|9.50|mIU/L|<29|N|||F|||20241018050234
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|12|12345667867^FormNumber||54079-9^Galactosemia newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|262.95|enzyme units|>50|N|||F|||20241018050234
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|13|12345667867^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241018050234
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241018050234
+OBR|14|12345667867^FormNumber||57087-9^Biotinidase newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|49.77|ERU|>10|N|||F|||20241018050234
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|15|12345667867^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|197|copies/µL|>18|N|||F|||20241018050234
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|16|12345667867^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.29|µmol/L/h|>=1.47|N|||F|||20241018050234
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|17|12345667867^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|13.01|µmol/L/h|>=0.82|N|||F|||20241018050234
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|18|12345667867^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241018050234
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241018050234
+OBR|19|12345667867^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|27.84|µmol/L/h|>=2.79|N|||F|||20241018050234
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|20|12345667867^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050234
+OBR|21|12345667867^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|0.97|µmol/L|<=3|N|||F|||20241018050234
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|496.63|µmol/L||N|||F|||20241018050234
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.95||<=6|N|||F|||20241018050234
+OBR|22|12345667867^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241018050234
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241018050234
+OBR|23|12345667867^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.349|µmol/L|<0.47|N|||F|||20241018050234
diff --git a/examples/Test/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7 b/examples/Test/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
index a1ed92d13..d5fb3472e 100644
--- a/examples/Test/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
+++ b/examples/Test/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
@@ -1,142 +1,142 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241023050044||ORU^R01^ORU_R01|003|N|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241023050044||ORU^R01^ORU_R01|003|N|2.5.1
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
-ORC|RE|45789876^FormNumber||56352742^HospOrdNumber||||||||1043390461^PROFIT^DR JOCHEN^^^^^^^NPI|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601\r
-OBR|1|45789876^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBR|2|45789876^FormNumber||57128-1^Newborn Screening Report summary panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241023050044\r
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241023050044\r
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241023050044\r
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241023050044\r
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241023050044\r
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - ALLIED LABORATORY \\R\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Amino Acid Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241023050044\r
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241023050044\r
-OBR|3|45789876^FormNumber||57717-1^Newborn screen card data panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241023050044\r
-OBX|2|NM|8339-4^Birthweight^LN|1|2230|grams||N|||F|||20241023050044\r
-OBX|3|TM|57715-5^Time of birth^LN|1|1358|||N|||F|||20241023050044\r
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241023050044\r
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|26|hour(s)||N|||F|||20241023050044\r
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241023050044\r
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241023050044\r
-OBX|8|TX|^^^99717-5^Accession Number^L|1|282-38-261/21-2024-12|||N|||F|||20241023050044\r
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DR JOCHEN PROFIT|||N|||F|||20241023050044\r
-OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1043390461|||N|||F|||20241023050044\r
-OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA|||N|||F|||20241023050044\r
-OBR|4|45789876^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBR|5|45789876^FormNumber||53261-4^Amino acid newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|368|µmol/L||N|||F|||20241023050044\r
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|310|µmol/L|<1000|N|||F|||20241023050044\r
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|34.6|µmol/L||N|||F|||20241023050044\r
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.06462|{Ratio}|<4.3|N|||F|||20241023050044\r
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|50.7|µmol/L|<230|N|||F|||20241023050044\r
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.16|{Ratio}|<1.35|N|||F|||20241023050044\r
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|32.5|µmol/L|<175|N|||F|||20241023050044\r
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.13|{Ratio}|<2.6|N|||F|||20241023050044\r
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|28.9|µmol/L|<680|N|||F|||20241023050044\r
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.25|µmol/L|<6.1|N|||F|||20241023050044\r
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|8.6|µmol/L|6.3-100|N|||F|||20241023050044\r
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|5|µmol/L|5-49|N|||F|||20241023050044\r
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.67|{Ratio}|<4.8|N|||F|||20241023050044\r
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|32|µmol/L|<800|N|||F|||20241023050044\r
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|6.41|{Ratio}||N|||F|||20241023050044\r
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|3|µmol/L|<63|N|||F|||20241023050044\r
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241023050044\r
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|55|µmol/L|<1500|N|||F|||20241023050044\r
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|This complex pattern of elevations require further evaluation|||A|||F|||20241023050044\r
-OBR|6|45789876^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|7|45789876^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|34.9|µmol/L|6.4-125|N|||F|||20241023050044\r
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|7.84|{Ratio}|<70|N|||F|||20241023050044\r
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|28.1|µmol/L|10-80|N|||F|||20241023050044\r
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|3.53125|{Ratio}|<7.6|N|||F|||20241023050044\r
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.034|µmol/L|<0.95|N|||F|||20241023050044\r
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.038|µmol/L|<0.45|N|||F|||20241023050044\r
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.19|{Ratio}||N|||F|||20241023050044\r
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.155|µmol/L|<0.65|N|||F|||20241023050044\r
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.032|µmol/L|<0.65|N|||F|||20241023050044\r
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.030|µmol/L|<0.45|N|||F|||20241023050044\r
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.070|µmol/L|<2|N|||F|||20241023050044\r
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.05|µmol/L||N|||F|||20241023050044\r
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.270|µmol/L|<1.2|N|||F|||20241023050044\r
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.084|µmol/L|<0.9|N|||F|||20241023050044\r
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.75|{Ratio}||N|||F|||20241023050044\r
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241023050044\r
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.009|µmol/L|<0.2|N|||F|||20241023050044\r
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|2.87|µmol/L|<12|N|||F|||20241023050044\r
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.236|µmol/L|<1.4|N|||F|||20241023050044\r
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.022|µmol/L|<0.1|N|||F|||20241023050044\r
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00767|{Ratio}|<0.07|N|||F|||20241023050044\r
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|0.987|µmol/L|<3.5|N|||F|||20241023050044\r
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.59|µmol/L|<7|N|||F|||20241023050044\r
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.20|µmol/L||N|||F|||20241023050044\r
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.014|µmol/L|<0.1|N|||F|||20241023050044\r
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.034|µmol/L|<0.1|N|||F|||20241023050044\r
-OBR|8|45789876^FormNumber||57085-3^Organic acid newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|1.9|µmol/L|<7.9|N|||F|||20241023050044\r
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.07|{Ratio}|<0.42|N|||F|||20241023050044\r
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.113|µmol/L|<0.48|N|||F|||20241023050044\r
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.161|µmol/L|<1.7|N|||F|||20241023050044\r
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.111|µmol/L|<0.95|N|||F|||20241023050044\r
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05842|{Ratio}|<0.38|N|||F|||20241023050044\r
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.006|µmol/L|<0.5|N|||F|||20241023050044\r
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.140|µmol/L|<1.15|N|||F|||20241023050044\r
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.091|µmol/L|<0.38|N|||F|||20241023050044\r
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.80531|{Ratio}|>0.1|N|||F|||20241023050044\r
-OBR|9|45789876^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|27.50|ng/mL|<69|N|||F|||20241023050044\r
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|10|45789876^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00029.9|nmol/L|<190|N|||F|||20241023050044\r
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|11|45789876^FormNumber||54090-6^Thyroid newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|29575-8^Thyrotropin^LN|1|6.90|mIU/L|<29|N|||F|||20241023050044\r
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|12|45789876^FormNumber||54079-9^Galactosemia newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|226.51|enzyme units|>50|N|||F|||20241023050044\r
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|13|45789876^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241023050044\r
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241023050044\r
-OBR|14|45789876^FormNumber||57087-9^Biotinidase newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|28.87|ERU|>10|N|||F|||20241023050044\r
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|15|45789876^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|198|copies/µL|>18|N|||F|||20241023050044\r
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|16|45789876^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|7.91|µmol/L/h|>=1.62|N|||F|||20241023050044\r
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|17|45789876^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|7.78|µmol/L/h|>=0.79|N|||F|||20241023050044\r
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|18|45789876^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241023050044\r
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241023050044\r
-OBR|19|45789876^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.94|µmol/L/h|>=2.95|N|||F|||20241023050044\r
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|20|45789876^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241023050044\r
-OBR|21|45789876^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.00|µmol/L|<=3|N|||F|||20241023050044\r
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|707.37|µmol/L||N|||F|||20241023050044\r
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.41||<=6|N|||F|||20241023050044\r
-OBR|22|45789876^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241023050044\r
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241023050044\r
-OBR|23|45789876^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F\r
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.246|µmol/L|<0.47|N|||F|||20241023050044\r
+ORC|RE|45789876^FormNumber||56352742^HospOrdNumber||||||||1043390461^PROFIT^DR JOCHEN^^^^^^^NPI|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601
+OBR|1|45789876^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBR|2|45789876^FormNumber||57128-1^Newborn Screening Report summary panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241023050044
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241023050044
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241023050044
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241023050044
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241023050044
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - ALLIED LABORATORY \\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Amino Acid Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241023050044
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241023050044
+OBR|3|45789876^FormNumber||57717-1^Newborn screen card data panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241023050044
+OBX|2|NM|8339-4^Birthweight^LN|1|2230|grams||N|||F|||20241023050044
+OBX|3|TM|57715-5^Time of birth^LN|1|1358|||N|||F|||20241023050044
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241023050044
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|26|hour(s)||N|||F|||20241023050044
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241023050044
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241023050044
+OBX|8|TX|^^^99717-5^Accession Number^L|1|282-38-261/21-2024-12|||N|||F|||20241023050044
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DR JOCHEN PROFIT|||N|||F|||20241023050044
+OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1043390461|||N|||F|||20241023050044
+OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA|||N|||F|||20241023050044
+OBR|4|45789876^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBR|5|45789876^FormNumber||53261-4^Amino acid newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|368|µmol/L||N|||F|||20241023050044
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|310|µmol/L|<1000|N|||F|||20241023050044
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|34.6|µmol/L||N|||F|||20241023050044
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.06462|{Ratio}|<4.3|N|||F|||20241023050044
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|50.7|µmol/L|<230|N|||F|||20241023050044
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.16|{Ratio}|<1.35|N|||F|||20241023050044
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|32.5|µmol/L|<175|N|||F|||20241023050044
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.13|{Ratio}|<2.6|N|||F|||20241023050044
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|28.9|µmol/L|<680|N|||F|||20241023050044
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.25|µmol/L|<6.1|N|||F|||20241023050044
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|8.6|µmol/L|6.3-100|N|||F|||20241023050044
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|5|µmol/L|5-49|N|||F|||20241023050044
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.67|{Ratio}|<4.8|N|||F|||20241023050044
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|32|µmol/L|<800|N|||F|||20241023050044
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|6.41|{Ratio}||N|||F|||20241023050044
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|3|µmol/L|<63|N|||F|||20241023050044
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241023050044
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|55|µmol/L|<1500|N|||F|||20241023050044
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|This complex pattern of elevations require further evaluation|||A|||F|||20241023050044
+OBR|6|45789876^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|7|45789876^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|34.9|µmol/L|6.4-125|N|||F|||20241023050044
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|7.84|{Ratio}|<70|N|||F|||20241023050044
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|28.1|µmol/L|10-80|N|||F|||20241023050044
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|3.53125|{Ratio}|<7.6|N|||F|||20241023050044
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.034|µmol/L|<0.95|N|||F|||20241023050044
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.038|µmol/L|<0.45|N|||F|||20241023050044
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.19|{Ratio}||N|||F|||20241023050044
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.155|µmol/L|<0.65|N|||F|||20241023050044
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.032|µmol/L|<0.65|N|||F|||20241023050044
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.030|µmol/L|<0.45|N|||F|||20241023050044
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.070|µmol/L|<2|N|||F|||20241023050044
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.05|µmol/L||N|||F|||20241023050044
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.270|µmol/L|<1.2|N|||F|||20241023050044
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.084|µmol/L|<0.9|N|||F|||20241023050044
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.75|{Ratio}||N|||F|||20241023050044
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241023050044
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.009|µmol/L|<0.2|N|||F|||20241023050044
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|2.87|µmol/L|<12|N|||F|||20241023050044
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.236|µmol/L|<1.4|N|||F|||20241023050044
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.022|µmol/L|<0.1|N|||F|||20241023050044
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00767|{Ratio}|<0.07|N|||F|||20241023050044
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|0.987|µmol/L|<3.5|N|||F|||20241023050044
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.59|µmol/L|<7|N|||F|||20241023050044
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.20|µmol/L||N|||F|||20241023050044
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.014|µmol/L|<0.1|N|||F|||20241023050044
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.034|µmol/L|<0.1|N|||F|||20241023050044
+OBR|8|45789876^FormNumber||57085-3^Organic acid newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|1.9|µmol/L|<7.9|N|||F|||20241023050044
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.07|{Ratio}|<0.42|N|||F|||20241023050044
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.113|µmol/L|<0.48|N|||F|||20241023050044
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.161|µmol/L|<1.7|N|||F|||20241023050044
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.111|µmol/L|<0.95|N|||F|||20241023050044
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05842|{Ratio}|<0.38|N|||F|||20241023050044
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.006|µmol/L|<0.5|N|||F|||20241023050044
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.140|µmol/L|<1.15|N|||F|||20241023050044
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.091|µmol/L|<0.38|N|||F|||20241023050044
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.80531|{Ratio}|>0.1|N|||F|||20241023050044
+OBR|9|45789876^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|27.50|ng/mL|<69|N|||F|||20241023050044
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|10|45789876^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00029.9|nmol/L|<190|N|||F|||20241023050044
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|11|45789876^FormNumber||54090-6^Thyroid newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|29575-8^Thyrotropin^LN|1|6.90|mIU/L|<29|N|||F|||20241023050044
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|12|45789876^FormNumber||54079-9^Galactosemia newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|226.51|enzyme units|>50|N|||F|||20241023050044
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|13|45789876^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241023050044
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241023050044
+OBR|14|45789876^FormNumber||57087-9^Biotinidase newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|28.87|ERU|>10|N|||F|||20241023050044
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|15|45789876^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|198|copies/µL|>18|N|||F|||20241023050044
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|16|45789876^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|7.91|µmol/L/h|>=1.62|N|||F|||20241023050044
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|17|45789876^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|7.78|µmol/L/h|>=0.79|N|||F|||20241023050044
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|18|45789876^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241023050044
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241023050044
+OBR|19|45789876^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.94|µmol/L/h|>=2.95|N|||F|||20241023050044
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|20|45789876^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241023050044
+OBR|21|45789876^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.00|µmol/L|<=3|N|||F|||20241023050044
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|707.37|µmol/L||N|||F|||20241023050044
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.41||<=6|N|||F|||20241023050044
+OBR|22|45789876^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241023050044
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241023050044
+OBR|23|45789876^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.246|µmol/L|<0.47|N|||F|||20241023050044
diff --git a/examples/Test/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7 b/examples/Test/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
index 8e0752090..8b4b6f202 100644
--- a/examples/Test/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
+++ b/examples/Test/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
@@ -1,142 +1,142 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241030050154||ORU^R01^ORU_R01|004|N|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241030050154||ORU^R01^ORU_R01|004|N|2.5.1
 PID|1||335441864^^^104638912487&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
-ORC|RE|356672001^FormNumber||629813494^HospOrdNumber||||||||1093050858^SILVA^RICHARD^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|200 W ARBOR DR^^SAN DIEGO^CA^92103-1911\r
-OBR|1|356672001^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBR|2|356672001^FormNumber||57128-1^Newborn Screening Report summary panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241030050154\r
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241030050154\r
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12428-1^All screening is in range for the conditions tested^LN|||N|||F|||20241030050154\r
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241030050154\r
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241030050154\r
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \\R\\2130 E Illinois Avenue, FRESNO, CA 93701\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (858) 966-8708. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241030050154\r
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241030050154\r
-OBR|3|356672001^FormNumber||57717-1^Newborn screen card data panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241030050154\r
-OBX|2|NM|8339-4^Birthweight^LN|1|3464|grams||N|||F|||20241030050154\r
-OBX|3|TM|57715-5^Time of birth^LN|1|0444|||N|||F|||20241030050154\r
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241030050154\r
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|19|hour(s)||N|||F|||20241030050154\r
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241030050154\r
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241030050154\r
-OBX|8|TX|^^^99717-5^Accession Number^L|1|292-04-123/21-2024-32|||N|||F|||20241030050154\r
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DIANE BEDROSIAN|||N|||F|||20241030050154\r
-OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1447323951|||N|||F|||20241030050154\r
-OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|200 W ARBOR DR SAN DIEGO CA 92103-1911 USA|||N|||F|||20241030050154\r
-OBR|4|356672001^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBR|5|356672001^FormNumber||53261-4^Amino acid newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|536|µmol/L||N|||F|||20241030050154\r
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|559|µmol/L|<1000|N|||F|||20241030050154\r
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|123|µmol/L||N|||F|||20241030050154\r
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|2.14286|{Ratio}|<4.3|N|||F|||20241030050154\r
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|113|µmol/L|<230|N|||F|||20241030050154\r
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.20|{Ratio}|<1.35|N|||F|||20241030050154\r
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|57.4|µmol/L|<175|N|||F|||20241030050154\r
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.05|{Ratio}|<2.6|N|||F|||20241030050154\r
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|54.8|µmol/L|<680|N|||F|||20241030050154\r
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.20|µmol/L|<6.1|N|||F|||20241030050154\r
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|22.8|µmol/L|6.3-100|N|||F|||20241030050154\r
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|10|µmol/L|5-49|N|||F|||20241030050154\r
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.52|{Ratio}|<4.8|N|||F|||20241030050154\r
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|84|µmol/L|<800|N|||F|||20241030050154\r
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|8.40|{Ratio}||N|||F|||20241030050154\r
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|7|µmol/L|<63|N|||F|||20241030050154\r
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241030050154\r
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|154|µmol/L|<1500|N|||F|||20241030050154\r
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|6|356672001^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|7|356672001^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|24.4|µmol/L|6.4-125|N|||F|||20241030050154\r
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|4.32|{Ratio}|<70|N|||F|||20241030050154\r
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|27.3|µmol/L|10-80|N|||F|||20241030050154\r
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.73000|{Ratio}|<7.6|N|||F|||20241030050154\r
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.067|µmol/L|<0.95|N|||F|||20241030050154\r
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.076|µmol/L|<0.45|N|||F|||20241030050154\r
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.76|{Ratio}||N|||F|||20241030050154\r
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.103|µmol/L|<0.65|N|||F|||20241030050154\r
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.100|µmol/L|<0.65|N|||F|||20241030050154\r
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.035|µmol/L|<0.45|N|||F|||20241030050154\r
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.132|µmol/L|<2|N|||F|||20241030050154\r
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.17|µmol/L||N|||F|||20241030050154\r
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.264|µmol/L|<1.2|N|||F|||20241030050154\r
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.189|µmol/L|<0.9|N|||F|||20241030050154\r
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.13|{Ratio}||N|||F|||20241030050154\r
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241030050154\r
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.021|µmol/L|<0.2|N|||F|||20241030050154\r
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|3.88|µmol/L|<12|N|||F|||20241030050154\r
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.371|µmol/L|<1.4|N|||F|||20241030050154\r
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.030|µmol/L|<0.1|N|||F|||20241030050154\r
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00773|{Ratio}|<0.07|N|||F|||20241030050154\r
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.11|µmol/L|<3.5|N|||F|||20241030050154\r
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.76|µmol/L|<7|N|||F|||20241030050154\r
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.15|µmol/L||N|||F|||20241030050154\r
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.015|µmol/L|<0.1|N|||F|||20241030050154\r
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.032|µmol/L|<0.1|N|||F|||20241030050154\r
-OBR|8|356672001^FormNumber||57085-3^Organic acid newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.3|µmol/L|<7.9|N|||F|||20241030050154\r
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.09|{Ratio}|<0.42|N|||F|||20241030050154\r
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.273|µmol/L|<0.48|N|||F|||20241030050154\r
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.315|µmol/L|<1.7|N|||F|||20241030050154\r
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.117|µmol/L|<0.95|N|||F|||20241030050154\r
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05087|{Ratio}|<0.38|N|||F|||20241030050154\r
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.009|µmol/L|<0.5|N|||F|||20241030050154\r
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.217|µmol/L|<1.15|N|||F|||20241030050154\r
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.183|µmol/L|<0.38|N|||F|||20241030050154\r
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.67033|{Ratio}|>0.1|N|||F|||20241030050154\r
-OBR|9|356672001^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|27.20|ng/mL|<69|N|||F|||20241030050154\r
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|10|356672001^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00015.2|nmol/L|<85|N|||F|||20241030050154\r
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|11|356672001^FormNumber||54090-6^Thyroid newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|29575-8^Thyrotropin^LN|1|15.40|mIU/L|<29|N|||F|||20241030050154\r
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|12|356672001^FormNumber||54079-9^Galactosemia newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|273.54|enzyme units|>50|N|||F|||20241030050154\r
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|13|356672001^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241030050154\r
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241030050154\r
-OBR|14|356672001^FormNumber||57087-9^Biotinidase newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|73.00|ERU|>10|N|||F|||20241030050154\r
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|15|356672001^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|120|copies/µL|>18|N|||F|||20241030050154\r
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|16|356672001^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|11.43|µmol/L/h|>=1.54|N|||F|||20241030050154\r
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|17|356672001^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|9.33|µmol/L/h|>=0.86|N|||F|||20241030050154\r
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|18|356672001^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241030050154\r
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241030050154\r
-OBR|19|356672001^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|22.31|µmol/L/h|>=2.84|N|||F|||20241030050154\r
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|20|356672001^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241030050154\r
-OBR|21|356672001^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.22|µmol/L|<=3|N|||F|||20241030050154\r
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|411.55|µmol/L||N|||F|||20241030050154\r
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.95||<=6|N|||F|||20241030050154\r
-OBR|22|356672001^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241030050154\r
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241030050154\r
-OBR|23|356672001^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F\r
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.138|µmol/L|<0.47|N|||F|||20241030050154\r
+ORC|RE|356672001^FormNumber||629813494^HospOrdNumber||||||||1093050858^SILVA^RICHARD^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|200 W ARBOR DR^^SAN DIEGO^CA^92103-1911
+OBR|1|356672001^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBR|2|356672001^FormNumber||57128-1^Newborn Screening Report summary panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241030050154
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241030050154
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12428-1^All screening is in range for the conditions tested^LN|||N|||F|||20241030050154
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241030050154
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241030050154
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \\\2130 E Illinois Avenue, FRESNO, CA 93701\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (858) 966-8708. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241030050154
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241030050154
+OBR|3|356672001^FormNumber||57717-1^Newborn screen card data panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241030050154
+OBX|2|NM|8339-4^Birthweight^LN|1|3464|grams||N|||F|||20241030050154
+OBX|3|TM|57715-5^Time of birth^LN|1|0444|||N|||F|||20241030050154
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241030050154
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|19|hour(s)||N|||F|||20241030050154
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241030050154
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241030050154
+OBX|8|TX|^^^99717-5^Accession Number^L|1|292-04-123/21-2024-32|||N|||F|||20241030050154
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DIANE BEDROSIAN|||N|||F|||20241030050154
+OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1447323951|||N|||F|||20241030050154
+OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|200 W ARBOR DR SAN DIEGO CA 92103-1911 USA|||N|||F|||20241030050154
+OBR|4|356672001^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBR|5|356672001^FormNumber||53261-4^Amino acid newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|536|µmol/L||N|||F|||20241030050154
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|559|µmol/L|<1000|N|||F|||20241030050154
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|123|µmol/L||N|||F|||20241030050154
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|2.14286|{Ratio}|<4.3|N|||F|||20241030050154
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|113|µmol/L|<230|N|||F|||20241030050154
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.20|{Ratio}|<1.35|N|||F|||20241030050154
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|57.4|µmol/L|<175|N|||F|||20241030050154
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.05|{Ratio}|<2.6|N|||F|||20241030050154
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|54.8|µmol/L|<680|N|||F|||20241030050154
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.20|µmol/L|<6.1|N|||F|||20241030050154
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|22.8|µmol/L|6.3-100|N|||F|||20241030050154
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|10|µmol/L|5-49|N|||F|||20241030050154
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.52|{Ratio}|<4.8|N|||F|||20241030050154
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|84|µmol/L|<800|N|||F|||20241030050154
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|8.40|{Ratio}||N|||F|||20241030050154
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|7|µmol/L|<63|N|||F|||20241030050154
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241030050154
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|154|µmol/L|<1500|N|||F|||20241030050154
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|6|356672001^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|7|356672001^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|24.4|µmol/L|6.4-125|N|||F|||20241030050154
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|4.32|{Ratio}|<70|N|||F|||20241030050154
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|27.3|µmol/L|10-80|N|||F|||20241030050154
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.73000|{Ratio}|<7.6|N|||F|||20241030050154
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.067|µmol/L|<0.95|N|||F|||20241030050154
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.076|µmol/L|<0.45|N|||F|||20241030050154
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.76|{Ratio}||N|||F|||20241030050154
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.103|µmol/L|<0.65|N|||F|||20241030050154
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.100|µmol/L|<0.65|N|||F|||20241030050154
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.035|µmol/L|<0.45|N|||F|||20241030050154
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.132|µmol/L|<2|N|||F|||20241030050154
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.17|µmol/L||N|||F|||20241030050154
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.264|µmol/L|<1.2|N|||F|||20241030050154
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.189|µmol/L|<0.9|N|||F|||20241030050154
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.13|{Ratio}||N|||F|||20241030050154
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241030050154
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.021|µmol/L|<0.2|N|||F|||20241030050154
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|3.88|µmol/L|<12|N|||F|||20241030050154
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.371|µmol/L|<1.4|N|||F|||20241030050154
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.030|µmol/L|<0.1|N|||F|||20241030050154
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00773|{Ratio}|<0.07|N|||F|||20241030050154
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.11|µmol/L|<3.5|N|||F|||20241030050154
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.76|µmol/L|<7|N|||F|||20241030050154
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.15|µmol/L||N|||F|||20241030050154
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.015|µmol/L|<0.1|N|||F|||20241030050154
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.032|µmol/L|<0.1|N|||F|||20241030050154
+OBR|8|356672001^FormNumber||57085-3^Organic acid newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.3|µmol/L|<7.9|N|||F|||20241030050154
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.09|{Ratio}|<0.42|N|||F|||20241030050154
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.273|µmol/L|<0.48|N|||F|||20241030050154
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.315|µmol/L|<1.7|N|||F|||20241030050154
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.117|µmol/L|<0.95|N|||F|||20241030050154
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05087|{Ratio}|<0.38|N|||F|||20241030050154
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.009|µmol/L|<0.5|N|||F|||20241030050154
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.217|µmol/L|<1.15|N|||F|||20241030050154
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.183|µmol/L|<0.38|N|||F|||20241030050154
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.67033|{Ratio}|>0.1|N|||F|||20241030050154
+OBR|9|356672001^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|27.20|ng/mL|<69|N|||F|||20241030050154
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|10|356672001^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00015.2|nmol/L|<85|N|||F|||20241030050154
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|11|356672001^FormNumber||54090-6^Thyroid newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|29575-8^Thyrotropin^LN|1|15.40|mIU/L|<29|N|||F|||20241030050154
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|12|356672001^FormNumber||54079-9^Galactosemia newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|273.54|enzyme units|>50|N|||F|||20241030050154
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|13|356672001^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241030050154
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241030050154
+OBR|14|356672001^FormNumber||57087-9^Biotinidase newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|73.00|ERU|>10|N|||F|||20241030050154
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|15|356672001^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|120|copies/µL|>18|N|||F|||20241030050154
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|16|356672001^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|11.43|µmol/L/h|>=1.54|N|||F|||20241030050154
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|17|356672001^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|9.33|µmol/L/h|>=0.86|N|||F|||20241030050154
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|18|356672001^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241030050154
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241030050154
+OBR|19|356672001^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|22.31|µmol/L/h|>=2.84|N|||F|||20241030050154
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|20|356672001^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241030050154
+OBR|21|356672001^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.22|µmol/L|<=3|N|||F|||20241030050154
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|411.55|µmol/L||N|||F|||20241030050154
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.95||<=6|N|||F|||20241030050154
+OBR|22|356672001^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241030050154
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241030050154
+OBR|23|356672001^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.138|µmol/L|<0.47|N|||F|||20241030050154
diff --git a/examples/Test/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7 b/examples/Test/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
index 0d67e12e9..6f949201c 100644
--- a/examples/Test/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
+++ b/examples/Test/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
@@ -1,142 +1,142 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050017||ORU^R01^ORU_R01|005|N|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050017||ORU^R01^ORU_R01|005|N|2.5.1
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
-ORC|RE|753234567^FormNumber||56155532^HospOrdNumber||||||||^SCALA^MELISSA|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601\r
-OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBR|2|753234567^FormNumber||57128-1^Newborn Screening Report summary panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241018050017\r
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241018050017\r
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241018050017\r
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA16207-5^Hemoglobinopathies^LN|||N|||F|||20241018050017\r
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050017\r
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - ALLIED LABORATORY \\R\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Hb: An immediate referral to a CCS Hematology Center or a pediatric hematologist familiar with alpha thalassemia and Hb H disease is strongly recommended for this infant. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241018050017\r
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241018050017\r
-OBR|3|753234567^FormNumber||57717-1^Newborn screen card data panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241018050017\r
-OBX|2|NM|8339-4^Birthweight^LN|1|2658|grams||N|||F|||20241018050017\r
-OBX|3|TM|57715-5^Time of birth^LN|1|0027|||N|||F|||20241018050017\r
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241018050017\r
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|28|hour(s)||N|||F|||20241018050017\r
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241018050017\r
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241018050017\r
-OBX|8|TX|^^^99717-5^Accession Number^L|1|272-95-009/21-2024-12|||N|||F|||20241018050017\r
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MELISSA SCALA|||N|||F|||20241018050017\r
-OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA|||N|||F|||20241018050017\r
-OBR|4|753234567^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBR|5|753234567^FormNumber||53261-4^Amino acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|926|µmol/L||N|||F|||20241018050017\r
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|588|µmol/L|<1000|N|||F|||20241018050017\r
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|79.4|µmol/L||N|||F|||20241018050017\r
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.29739|{Ratio}|<4.3|N|||F|||20241018050017\r
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|99.2|µmol/L|<230|N|||F|||20241018050017\r
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.17|{Ratio}|<1.35|N|||F|||20241018050017\r
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|61.2|µmol/L|<175|N|||F|||20241018050017\r
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.77|{Ratio}|<2.6|N|||F|||20241018050017\r
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|34.7|µmol/L|<680|N|||F|||20241018050017\r
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.33|µmol/L|<6.1|N|||F|||20241018050017\r
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|20.4|µmol/L|6.3-100|N|||F|||20241018050017\r
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|10|µmol/L|5-49|N|||F|||20241018050017\r
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|2.79|{Ratio}|<4.8|N|||F|||20241018050017\r
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|43|µmol/L|<800|N|||F|||20241018050017\r
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|4.44|{Ratio}||N|||F|||20241018050017\r
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|3|µmol/L|<63|N|||F|||20241018050017\r
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241018050017\r
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|187|µmol/L|<1500|N|||F|||20241018050017\r
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|6|753234567^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|7|753234567^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|39.6|µmol/L|6.4-125|N|||F|||20241018050017\r
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|5.35|{Ratio}|<70|N|||F|||20241018050017\r
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|34.7|µmol/L|10-80|N|||F|||20241018050017\r
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|3.27536|{Ratio}|<7.6|N|||F|||20241018050017\r
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.100|µmol/L|<0.95|N|||F|||20241018050017\r
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.075|µmol/L|<0.45|N|||F|||20241018050017\r
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.09|{Ratio}||N|||F|||20241018050017\r
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.163|µmol/L|<0.65|N|||F|||20241018050017\r
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.069|µmol/L|<0.65|N|||F|||20241018050017\r
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.057|µmol/L|<0.45|N|||F|||20241018050017\r
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.118|µmol/L|<2|N|||F|||20241018050017\r
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.06|µmol/L||N|||F|||20241018050017\r
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.394|µmol/L|<1.2|N|||F|||20241018050017\r
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.130|µmol/L|<0.9|N|||F|||20241018050017\r
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|2.32|{Ratio}||N|||F|||20241018050017\r
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241018050017\r
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.026|µmol/L|<0.2|N|||F|||20241018050017\r
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5.52|µmol/L|<12|N|||F|||20241018050017\r
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.245|µmol/L|<1.4|N|||F|||20241018050017\r
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.042|µmol/L|<0.1|N|||F|||20241018050017\r
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00761|{Ratio}|<0.07|N|||F|||20241018050017\r
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2.13|µmol/L|<3.5|N|||F|||20241018050017\r
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.89|µmol/L|<7|N|||F|||20241018050017\r
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.29|µmol/L||N|||F|||20241018050017\r
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.032|µmol/L|<0.1|N|||F|||20241018050017\r
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.047|µmol/L|<0.1|N|||F|||20241018050017\r
-OBR|8|753234567^FormNumber||57085-3^Organic acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|4.2|µmol/L|<7.9|N|||F|||20241018050017\r
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.12|{Ratio}|<0.42|N|||F|||20241018050017\r
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.226|µmol/L|<0.48|N|||F|||20241018050017\r
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.424|µmol/L|<1.7|N|||F|||20241018050017\r
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.247|µmol/L|<0.95|N|||F|||20241018050017\r
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05881|{Ratio}|<0.38|N|||F|||20241018050017\r
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.008|µmol/L|<0.5|N|||F|||20241018050017\r
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.287|µmol/L|<1.15|N|||F|||20241018050017\r
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.179|µmol/L|<0.38|N|||F|||20241018050017\r
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.79204|{Ratio}|>0.1|N|||F|||20241018050017\r
-OBR|9|753234567^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|18.50|ng/mL|<69|N|||F|||20241018050017\r
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|10|753234567^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00013.8|nmol/L|<85|N|||F|||20241018050017\r
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|11|753234567^FormNumber||54090-6^Thyroid newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|29575-8^Thyrotropin^LN|1|2.40|mIU/L|<29|N|||F|||20241018050017\r
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|12|753234567^FormNumber||54079-9^Galactosemia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|293.00|enzyme units|>50|N|||F|||20241018050017\r
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|13|753234567^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA + Barts||||||F|||20241018050017\r
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|The presence of Hb Barts at a high percentage is consistent with Hb H disease, a clinically significant hemoglobin disorder.||||||F|||20241018050017\r
-OBR|14|753234567^FormNumber||57087-9^Biotinidase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|43.76|ERU|>10|N|||F|||20241018050017\r
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|15|753234567^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|99|copies/µL|>18|N|||F|||20241018050017\r
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|16|753234567^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|7.09|µmol/L/h|>=1.67|N|||F|||20241018050017\r
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|17|753234567^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|8.33|µmol/L/h|>=0.86|N|||F|||20241018050017\r
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|18|753234567^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241018050017\r
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241018050017\r
-OBR|19|753234567^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|15.65|µmol/L/h|>=2.8|N|||F|||20241018050017\r
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|20|753234567^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017\r
-OBR|21|753234567^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.05|µmol/L|<=3|N|||F|||20241018050017\r
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|616.49|µmol/L||N|||F|||20241018050017\r
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.70||<=6|N|||F|||20241018050017\r
-OBR|22|753234567^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241018050017\r
-OBR|23|753234567^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.260|µmol/L|<0.47|N|||F|||20241018050017\r
+ORC|RE|753234567^FormNumber||56155532^HospOrdNumber||||||||^SCALA^MELISSA|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601
+OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBR|2|753234567^FormNumber||57128-1^Newborn Screening Report summary panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241018050017
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241018050017
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241018050017
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA16207-5^Hemoglobinopathies^LN|||N|||F|||20241018050017
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050017
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - ALLIED LABORATORY \\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Hb: An immediate referral to a CCS Hematology Center or a pediatric hematologist familiar with alpha thalassemia and Hb H disease is strongly recommended for this infant. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241018050017
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241018050017
+OBR|3|753234567^FormNumber||57717-1^Newborn screen card data panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241018050017
+OBX|2|NM|8339-4^Birthweight^LN|1|2658|grams||N|||F|||20241018050017
+OBX|3|TM|57715-5^Time of birth^LN|1|0027|||N|||F|||20241018050017
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241018050017
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|28|hour(s)||N|||F|||20241018050017
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241018050017
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241018050017
+OBX|8|TX|^^^99717-5^Accession Number^L|1|272-95-009/21-2024-12|||N|||F|||20241018050017
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MELISSA SCALA|||N|||F|||20241018050017
+OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA|||N|||F|||20241018050017
+OBR|4|753234567^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBR|5|753234567^FormNumber||53261-4^Amino acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|926|µmol/L||N|||F|||20241018050017
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|588|µmol/L|<1000|N|||F|||20241018050017
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|79.4|µmol/L||N|||F|||20241018050017
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.29739|{Ratio}|<4.3|N|||F|||20241018050017
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|99.2|µmol/L|<230|N|||F|||20241018050017
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.17|{Ratio}|<1.35|N|||F|||20241018050017
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|61.2|µmol/L|<175|N|||F|||20241018050017
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.77|{Ratio}|<2.6|N|||F|||20241018050017
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|34.7|µmol/L|<680|N|||F|||20241018050017
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.33|µmol/L|<6.1|N|||F|||20241018050017
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|20.4|µmol/L|6.3-100|N|||F|||20241018050017
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|10|µmol/L|5-49|N|||F|||20241018050017
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|2.79|{Ratio}|<4.8|N|||F|||20241018050017
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|43|µmol/L|<800|N|||F|||20241018050017
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|4.44|{Ratio}||N|||F|||20241018050017
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|3|µmol/L|<63|N|||F|||20241018050017
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241018050017
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|187|µmol/L|<1500|N|||F|||20241018050017
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|6|753234567^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|7|753234567^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|39.6|µmol/L|6.4-125|N|||F|||20241018050017
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|5.35|{Ratio}|<70|N|||F|||20241018050017
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|34.7|µmol/L|10-80|N|||F|||20241018050017
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|3.27536|{Ratio}|<7.6|N|||F|||20241018050017
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.100|µmol/L|<0.95|N|||F|||20241018050017
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.075|µmol/L|<0.45|N|||F|||20241018050017
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.09|{Ratio}||N|||F|||20241018050017
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.163|µmol/L|<0.65|N|||F|||20241018050017
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.069|µmol/L|<0.65|N|||F|||20241018050017
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.057|µmol/L|<0.45|N|||F|||20241018050017
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.118|µmol/L|<2|N|||F|||20241018050017
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.06|µmol/L||N|||F|||20241018050017
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.394|µmol/L|<1.2|N|||F|||20241018050017
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.130|µmol/L|<0.9|N|||F|||20241018050017
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|2.32|{Ratio}||N|||F|||20241018050017
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241018050017
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.026|µmol/L|<0.2|N|||F|||20241018050017
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5.52|µmol/L|<12|N|||F|||20241018050017
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.245|µmol/L|<1.4|N|||F|||20241018050017
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.042|µmol/L|<0.1|N|||F|||20241018050017
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00761|{Ratio}|<0.07|N|||F|||20241018050017
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2.13|µmol/L|<3.5|N|||F|||20241018050017
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.89|µmol/L|<7|N|||F|||20241018050017
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.29|µmol/L||N|||F|||20241018050017
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.032|µmol/L|<0.1|N|||F|||20241018050017
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.047|µmol/L|<0.1|N|||F|||20241018050017
+OBR|8|753234567^FormNumber||57085-3^Organic acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|4.2|µmol/L|<7.9|N|||F|||20241018050017
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.12|{Ratio}|<0.42|N|||F|||20241018050017
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.226|µmol/L|<0.48|N|||F|||20241018050017
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.424|µmol/L|<1.7|N|||F|||20241018050017
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.247|µmol/L|<0.95|N|||F|||20241018050017
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05881|{Ratio}|<0.38|N|||F|||20241018050017
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.008|µmol/L|<0.5|N|||F|||20241018050017
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.287|µmol/L|<1.15|N|||F|||20241018050017
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.179|µmol/L|<0.38|N|||F|||20241018050017
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.79204|{Ratio}|>0.1|N|||F|||20241018050017
+OBR|9|753234567^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|18.50|ng/mL|<69|N|||F|||20241018050017
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|10|753234567^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00013.8|nmol/L|<85|N|||F|||20241018050017
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|11|753234567^FormNumber||54090-6^Thyroid newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|29575-8^Thyrotropin^LN|1|2.40|mIU/L|<29|N|||F|||20241018050017
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|12|753234567^FormNumber||54079-9^Galactosemia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|293.00|enzyme units|>50|N|||F|||20241018050017
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|13|753234567^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA + Barts||||||F|||20241018050017
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|The presence of Hb Barts at a high percentage is consistent with Hb H disease, a clinically significant hemoglobin disorder.||||||F|||20241018050017
+OBR|14|753234567^FormNumber||57087-9^Biotinidase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|43.76|ERU|>10|N|||F|||20241018050017
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|15|753234567^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|99|copies/µL|>18|N|||F|||20241018050017
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|16|753234567^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|7.09|µmol/L/h|>=1.67|N|||F|||20241018050017
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|17|753234567^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|8.33|µmol/L/h|>=0.86|N|||F|||20241018050017
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|18|753234567^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241018050017
+OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241018050017
+OBR|19|753234567^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|15.65|µmol/L/h|>=2.8|N|||F|||20241018050017
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|20|753234567^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017
+OBR|21|753234567^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.05|µmol/L|<=3|N|||F|||20241018050017
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|616.49|µmol/L||N|||F|||20241018050017
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.70||<=6|N|||F|||20241018050017
+OBR|22|753234567^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241018050017
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241018050017
+OBR|23|753234567^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.260|µmol/L|<0.47|N|||F|||20241018050017
diff --git a/examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7 b/examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7
new file mode 100644
index 000000000..b59a7680c
--- /dev/null
+++ b/examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7
@@ -0,0 +1,141 @@
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413799^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241017050025||ORU^R01^ORU_R01|244014485|N|2.5.1\r
+PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
+NK1|1|*****PII REMOVED******
+ORC|RE|789876543^FormNumber||||||||||1164928032^MURUGESAN^CHEZHIYAN^^^^^^^NPI|||||||||KERN MEDICAL CENTER^^^^^^^^^R092|1700 MOUNT VERNON AVE^^BAKERSFIELD^CA^93306-4018\r
+OBR|1|789876543^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBR|2|789876543^FormNumber||57128-1^Newborn Screening Report summary panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241017050025\r
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241017050025\r
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12430-7^Out of range requiring further dried blood spot testing for at least one condition^LN|||N|||F|||20241017050025\r
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241017050025\r
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA22279-6^SMA^LN|||N|||F|||20241017050025\r
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \\R\\2130 E Illinois Avenue, FRESNO, CA 93701\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Spinal Muscular Atrophy (SMA): The sample was not adequate to complete testing for SMA. A repeat NBS specimen MUST be collected. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Valley Children's Hospital at (559) 353-6416. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241017050025\r
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241017050025\r
+OBR|3|789876543^FormNumber||57717-1^Newborn screen card data panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241017050025\r
+OBX|2|NM|8339-4^Birthweight^LN|1|2875|grams||N|||F|||20241017050025\r
+OBX|3|TM|57715-5^Time of birth^LN|1|0202|||N|||F|||20241017050025\r
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241017050025\r
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|27|hour(s)||N|||F|||20241017050025\r
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241017050025\r
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241017050025\r
+OBX|8|TX|^^^99717-5^Accession Number^L|1|269-80-133/21-2024-21|||N|||F|||20241017050025\r
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|CHEZHIYAN MURUGESAN|||N|||F|||20241017050025\r
+OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1164928032|||N|||F|||20241017050025\r
+OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|1700 MOUNT VERNON AVE BAKERSFIELD CA 93306-4018 USA|||N|||F|||20241017050025\r
+OBR|4|789876543^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBR|5|789876543^FormNumber||53261-4^Amino acid newborn screen panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|357|µmol/L||N|||F|||20241017050025\r
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|398|µmol/L|<1000|N|||F|||20241017050025\r
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|92.2|µmol/L||N|||F|||20241017050025\r
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|2.05804|{Ratio}|<4.3|N|||F|||20241017050025\r
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|84.2|µmol/L|<230|N|||F|||20241017050025\r
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.21|{Ratio}|<1.35|N|||F|||20241017050025\r
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|44.8|µmol/L|<175|N|||F|||20241017050025\r
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.55|{Ratio}|<2.6|N|||F|||20241017050025\r
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|81.7|µmol/L|<680|N|||F|||20241017050025\r
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.20|µmol/L|<6.1|N|||F|||20241017050025\r
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|11.1|µmol/L|6.3-100|N|||F|||20241017050025\r
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|12|µmol/L|5-49|N|||F|||20241017050025\r
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.72|{Ratio}|<4.8|N|||F|||20241017050025\r
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|77|µmol/L|<800|N|||F|||20241017050025\r
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|6.36|{Ratio}||N|||F|||20241017050025\r
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|7|µmol/L|<63|N|||F|||20241017050025\r
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241017050025\r
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|136|µmol/L|<1500|N|||F|||20241017050025\r
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241017050025\r
+OBR|6|789876543^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241017050025\r
+OBR|7|789876543^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|16.4|µmol/L|6.4-125|N|||F|||20241017050025\r
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|3.65|{Ratio}|<70|N|||F|||20241017050025\r
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|16.1|µmol/L|10-80|N|||F|||20241017050025\r
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.06977|{Ratio}|<7.6|N|||F|||20241017050025\r
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.075|µmol/L|<0.95|N|||F|||20241017050025\r
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.049|µmol/L|<0.45|N|||F|||20241017050025\r
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.14|{Ratio}||N|||F|||20241017050025\r
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.042|µmol/L|<0.65|N|||F|||20241017050025\r
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.043|µmol/L|<0.65|N|||F|||20241017050025\r
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.026|µmol/L|<0.45|N|||F|||20241017050025\r
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.071|µmol/L|<2|N|||F|||20241017050025\r
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.05|µmol/L||N|||F|||20241017050025\r
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.169|µmol/L|<1.2|N|||F|||20241017050025\r
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.099|µmol/L|<0.9|N|||F|||20241017050025\r
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.98|{Ratio}||N|||F|||20241017050025\r
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241017050025\r
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.015|µmol/L|<0.2|N|||F|||20241017050025\r
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|2.91|µmol/L|<12|N|||F|||20241017050025\r
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.221|µmol/L|<1.4|N|||F|||20241017050025\r
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.021|µmol/L|<0.1|N|||F|||20241017050025\r
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00722|{Ratio}|<0.07|N|||F|||20241017050025\r
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|0.827|µmol/L|<3.5|N|||F|||20241017050025\r
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.58|µmol/L|<7|N|||F|||20241017050025\r
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.14|µmol/L||N|||F|||20241017050025\r
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.013|µmol/L|<0.1|N|||F|||20241017050025\r
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.028|µmol/L|<0.1|N|||F|||20241017050025\r
+OBR|8|789876543^FormNumber||57085-3^Organic acid newborn screen panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|1.7|µmol/L|<7.9|N|||F|||20241017050025\r
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.10|{Ratio}|<0.42|N|||F|||20241017050025\r
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.089|µmol/L|<0.48|N|||F|||20241017050025\r
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.229|µmol/L|<1.7|N|||F|||20241017050025\r
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.081|µmol/L|<0.95|N|||F|||20241017050025\r
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.04765|{Ratio}|<0.38|N|||F|||20241017050025\r
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.005|µmol/L|<0.5|N|||F|||20241017050025\r
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.216|µmol/L|<1.15|N|||F|||20241017050025\r
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.080|µmol/L|<0.38|N|||F|||20241017050025\r
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.89888|{Ratio}|>0.1|N|||F|||20241017050025\r
+OBR|9|789876543^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|20.90|ng/mL|<69|N|||F|||20241017050025\r
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241017050025\r
+OBR|10|789876543^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00007.6|nmol/L|<85|N|||F|||20241017050025\r
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025\r
+OBR|11|789876543^FormNumber||54090-6^Thyroid newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|NM|29575-8^Thyrotropin^LN|1|6.10|mIU/L|<29|N|||F|||20241017050025\r
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025\r
+OBR|12|789876543^FormNumber||54079-9^Galactosemia newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|173.29|enzyme units|>50|N|||F|||20241017050025\r
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025\r
+OBR|13|789876543^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241017050025\r
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241017050025\r
+OBR|14|789876543^FormNumber||57087-9^Biotinidase newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|45.57|ERU|>10|N|||F|||20241017050025\r
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025\r
+OBR|15|789876543^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|215|copies/µL|>18|N|||F|||20241017050025\r
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025\r
+OBR|16|789876543^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|6.94|µmol/L/h|>=1.54|N|||F|||20241017050025\r
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241017050025\r
+OBR|17|789876543^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|6.11|µmol/L/h|>=0.79|N|||F|||20241017050025\r
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025\r
+OBR|18|789876543^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA12430-7^Out of range requiring further dried blood spot testing for at least one condition^LN|||A|||F|||20241017050025\r
+OBX|2|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Incomplete|||A|||F|||20241017050025\r
+OBR|19|789876543^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|25.27|µmol/L/h|>=2.91|N|||F|||20241017050025\r
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025\r
+OBR|20|789876543^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241017050025\r
+OBR|21|789876543^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.10|µmol/L|<=3|N|||F|||20241017050025\r
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|431.20|µmol/L||N|||F|||20241017050025\r
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.56||<=6|N|||F|||20241017050025\r
+OBR|22|789876543^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241017050025\r
+OBR|23|789876543^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.242|µmol/L|<0.47|N|||F|||20241017050025\r
diff --git a/examples/Test/GoldenCopy/README.md b/examples/Test/GoldenCopy/README.md
index df9af42a4..169f15e99 100644
--- a/examples/Test/GoldenCopy/README.md
+++ b/examples/Test/GoldenCopy/README.md
@@ -16,3 +16,14 @@ The files are required to:
 - Each file must have a unique value in `MSH-10`. We use this value to match the input and output files, so if it's not unique, we won't be able to match the files correctly
     - We format `MSH-10` based on the file index, like `001` (or `AUTOMATEDTEST-001` for UCSD)
 - `MSH-11` needs to have a value of `N`
+
+## Corresponding File Names
+
+The files map to each test scenario with the following naming:
+
+- 001_ORU_R01_golden_copy_input_acylc_1.hl7 -> Acylcarnitine - Indeterminate - SCADD - IBCDD patterns.hl7
+- 002_ORU_R01_golden_copy_input_acylc_2.hl7 -> Acylcarnitine - Indeterminate_2nd_example.hl7
+- 003_ORU_R01_golden_copy_input_aa_unusual.hl7 -> Amino Acid - Unusual Pattern.hl7.hl7
+- 004_ORU_R01_golden_copy_input_in_range.hl7 -> Out of Range - Hemoglobinopathies - Positive Marker.hl7
+- 005_ORU_R01_golden_copy_input_out_of_range.hl7 -> In range example.hl7
+- 006_ORU_R01_golden_copy_input_sma_incomplete.hl7 -> SMA Incomplete - Equivocal - Inadequate Specimen for SMA.hl7

From 401c50f253540bc6cbc61327a2c6ee75ebf0f4bb Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 14:28:10 -0700
Subject: [PATCH 24/61] modify msh-10 header in example file

Co-authored-by: jcrichlake <145698165+jcrichlake@users.noreply.github.com>
---
 .../Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7      | 2 +-
 1 file changed, 1 insertion(+), 1 deletion(-)

diff --git a/examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7 b/examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7
index b59a7680c..15913a9b9 100644
--- a/examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7
+++ b/examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7
@@ -1,4 +1,4 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413799^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241017050025||ORU^R01^ORU_R01|244014485|N|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413799^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241017050025||ORU^R01^ORU_R01|006|N|2.5.1\r
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
 ORC|RE|789876543^FormNumber||||||||||1164928032^MURUGESAN^CHEZHIYAN^^^^^^^NPI|||||||||KERN MEDICAL CENTER^^^^^^^^^R092|1700 MOUNT VERNON AVE^^BAKERSFIELD^CA^93306-4018\r

From 229af631194a945722cb833b0702321839323f3f Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 14:33:06 -0700
Subject: [PATCH 25/61] fix syntax

Co-authored-by: jcrichlake <145698165+jcrichlake@users.noreply.github.com>
---
 .github/workflows/automated-staging-test-run.yml | 16 ++++++++--------
 .../rse2e/GoldenCopyTest.groovy                  |  2 +-
 2 files changed, 9 insertions(+), 9 deletions(-)

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index 96760ddd9..f28a27d79 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -23,13 +23,13 @@ jobs:
 
       - name: Determine variable type
         run: |
-          test_type="automatedTest"
-          title="Automated"
-          file_path="../examples/Test/Automated/"
-          if [ ${{ github.event.inputs.name }} = "Golden Copy Staging Test" ]; then
-            test_type="goldenCopyTest"
-            title="Golden Copy"
-            file_path="../examples/Test/GoldenCopy/Expected/"
+          test_type=automatedTest
+          title=Automated
+          file_path=../examples/Test/Automated/
+          if [ "${{ github.event.inputs.name }}" == "Golden Copy Staging Test" ]; then
+            test_type=goldenCopyTest
+            title=Golden Copy
+            file_path=../examples/Test/GoldenCopy/Expected/
           fi
           echo "test_type=$test_type" >> $GITHUB_OUTPUT
           echo "title=$title" >> $GITHUB_OUTPUT
@@ -41,7 +41,7 @@ jobs:
           AZURE_STORAGE_CONNECTION_STRING: ${{ secrets.AUTOMATED_TEST_AZURE_STORAGE_CONNECTION_STRING }}
           LOCAL_FILE_PATH: ${{ steps.getFunctionList.outputs.file_path }}
         run: |
-          ./gradlew rs-e2e:clean rs-e2e:${{ test_type }}
+          ./gradlew rs-e2e:clean rs-e2e:${{ steps.getFunctionList.outputs.test_type }}
           done
 
       - name: Send slack notification on test failure
diff --git a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
index 86d6b3bc9..678379ec4 100644
--- a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
+++ b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
@@ -55,7 +55,7 @@ class GoldenCopyTest extends Specification {
 
     def "Compare files"() {
         // Currently reusing automated staging test workflows but we might need to pivot for cron schedule
-        // Get golden copy and input
+        // Get golden copy for 006
 
         given:
         def matchedFiles = fileMatcher.matchFiles(azureFiles, localFiles)

From 9485cdacd38ae52e7ffcf680d7fcfa28e2024038 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 14:39:25 -0700
Subject: [PATCH 26/61] remove breaks from example file

Co-authored-by: jcrichlake <145698165+jcrichlake@users.noreply.github.com>
Co-authored-by: James Herr <jherr@flexion.us>
---
 ...U_R01_golden_copy_input_sma_incomplete.hl7 | 278 +++++++++---------
 1 file changed, 139 insertions(+), 139 deletions(-)

diff --git a/examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7 b/examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7
index 15913a9b9..41e56f5e9 100644
--- a/examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7
+++ b/examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7
@@ -1,141 +1,141 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413799^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241017050025||ORU^R01^ORU_R01|006|N|2.5.1\r
+MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413799^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241017050025||ORU^R01^ORU_R01|006|N|2.5.1
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
-ORC|RE|789876543^FormNumber||||||||||1164928032^MURUGESAN^CHEZHIYAN^^^^^^^NPI|||||||||KERN MEDICAL CENTER^^^^^^^^^R092|1700 MOUNT VERNON AVE^^BAKERSFIELD^CA^93306-4018\r
-OBR|1|789876543^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBR|2|789876543^FormNumber||57128-1^Newborn Screening Report summary panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241017050025\r
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241017050025\r
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12430-7^Out of range requiring further dried blood spot testing for at least one condition^LN|||N|||F|||20241017050025\r
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241017050025\r
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA22279-6^SMA^LN|||N|||F|||20241017050025\r
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \\R\\2130 E Illinois Avenue, FRESNO, CA 93701\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Spinal Muscular Atrophy (SMA): The sample was not adequate to complete testing for SMA. A repeat NBS specimen MUST be collected. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Valley Children's Hospital at (559) 353-6416. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241017050025\r
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241017050025\r
-OBR|3|789876543^FormNumber||57717-1^Newborn screen card data panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241017050025\r
-OBX|2|NM|8339-4^Birthweight^LN|1|2875|grams||N|||F|||20241017050025\r
-OBX|3|TM|57715-5^Time of birth^LN|1|0202|||N|||F|||20241017050025\r
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241017050025\r
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|27|hour(s)||N|||F|||20241017050025\r
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241017050025\r
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241017050025\r
-OBX|8|TX|^^^99717-5^Accession Number^L|1|269-80-133/21-2024-21|||N|||F|||20241017050025\r
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|CHEZHIYAN MURUGESAN|||N|||F|||20241017050025\r
-OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1164928032|||N|||F|||20241017050025\r
-OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|1700 MOUNT VERNON AVE BAKERSFIELD CA 93306-4018 USA|||N|||F|||20241017050025\r
-OBR|4|789876543^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBR|5|789876543^FormNumber||53261-4^Amino acid newborn screen panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|357|µmol/L||N|||F|||20241017050025\r
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|398|µmol/L|<1000|N|||F|||20241017050025\r
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|92.2|µmol/L||N|||F|||20241017050025\r
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|2.05804|{Ratio}|<4.3|N|||F|||20241017050025\r
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|84.2|µmol/L|<230|N|||F|||20241017050025\r
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.21|{Ratio}|<1.35|N|||F|||20241017050025\r
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|44.8|µmol/L|<175|N|||F|||20241017050025\r
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.55|{Ratio}|<2.6|N|||F|||20241017050025\r
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|81.7|µmol/L|<680|N|||F|||20241017050025\r
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.20|µmol/L|<6.1|N|||F|||20241017050025\r
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|11.1|µmol/L|6.3-100|N|||F|||20241017050025\r
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|12|µmol/L|5-49|N|||F|||20241017050025\r
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.72|{Ratio}|<4.8|N|||F|||20241017050025\r
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|77|µmol/L|<800|N|||F|||20241017050025\r
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|6.36|{Ratio}||N|||F|||20241017050025\r
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|7|µmol/L|<63|N|||F|||20241017050025\r
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241017050025\r
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|136|µmol/L|<1500|N|||F|||20241017050025\r
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241017050025\r
-OBR|6|789876543^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241017050025\r
-OBR|7|789876543^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|16.4|µmol/L|6.4-125|N|||F|||20241017050025\r
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|3.65|{Ratio}|<70|N|||F|||20241017050025\r
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|16.1|µmol/L|10-80|N|||F|||20241017050025\r
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.06977|{Ratio}|<7.6|N|||F|||20241017050025\r
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.075|µmol/L|<0.95|N|||F|||20241017050025\r
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.049|µmol/L|<0.45|N|||F|||20241017050025\r
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.14|{Ratio}||N|||F|||20241017050025\r
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.042|µmol/L|<0.65|N|||F|||20241017050025\r
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.043|µmol/L|<0.65|N|||F|||20241017050025\r
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.026|µmol/L|<0.45|N|||F|||20241017050025\r
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.071|µmol/L|<2|N|||F|||20241017050025\r
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.05|µmol/L||N|||F|||20241017050025\r
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.169|µmol/L|<1.2|N|||F|||20241017050025\r
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.099|µmol/L|<0.9|N|||F|||20241017050025\r
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.98|{Ratio}||N|||F|||20241017050025\r
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241017050025\r
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.015|µmol/L|<0.2|N|||F|||20241017050025\r
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|2.91|µmol/L|<12|N|||F|||20241017050025\r
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.221|µmol/L|<1.4|N|||F|||20241017050025\r
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.021|µmol/L|<0.1|N|||F|||20241017050025\r
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00722|{Ratio}|<0.07|N|||F|||20241017050025\r
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|0.827|µmol/L|<3.5|N|||F|||20241017050025\r
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.58|µmol/L|<7|N|||F|||20241017050025\r
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.14|µmol/L||N|||F|||20241017050025\r
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.013|µmol/L|<0.1|N|||F|||20241017050025\r
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.028|µmol/L|<0.1|N|||F|||20241017050025\r
-OBR|8|789876543^FormNumber||57085-3^Organic acid newborn screen panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|1.7|µmol/L|<7.9|N|||F|||20241017050025\r
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.10|{Ratio}|<0.42|N|||F|||20241017050025\r
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.089|µmol/L|<0.48|N|||F|||20241017050025\r
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.229|µmol/L|<1.7|N|||F|||20241017050025\r
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.081|µmol/L|<0.95|N|||F|||20241017050025\r
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.04765|{Ratio}|<0.38|N|||F|||20241017050025\r
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.005|µmol/L|<0.5|N|||F|||20241017050025\r
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.216|µmol/L|<1.15|N|||F|||20241017050025\r
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.080|µmol/L|<0.38|N|||F|||20241017050025\r
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.89888|{Ratio}|>0.1|N|||F|||20241017050025\r
-OBR|9|789876543^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|20.90|ng/mL|<69|N|||F|||20241017050025\r
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241017050025\r
-OBR|10|789876543^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00007.6|nmol/L|<85|N|||F|||20241017050025\r
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025\r
-OBR|11|789876543^FormNumber||54090-6^Thyroid newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|NM|29575-8^Thyrotropin^LN|1|6.10|mIU/L|<29|N|||F|||20241017050025\r
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025\r
-OBR|12|789876543^FormNumber||54079-9^Galactosemia newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|173.29|enzyme units|>50|N|||F|||20241017050025\r
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025\r
-OBR|13|789876543^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241017050025\r
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241017050025\r
-OBR|14|789876543^FormNumber||57087-9^Biotinidase newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|45.57|ERU|>10|N|||F|||20241017050025\r
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025\r
-OBR|15|789876543^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|215|copies/µL|>18|N|||F|||20241017050025\r
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025\r
-OBR|16|789876543^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|6.94|µmol/L/h|>=1.54|N|||F|||20241017050025\r
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241017050025\r
-OBR|17|789876543^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|6.11|µmol/L/h|>=0.79|N|||F|||20241017050025\r
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025\r
-OBR|18|789876543^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA12430-7^Out of range requiring further dried blood spot testing for at least one condition^LN|||A|||F|||20241017050025\r
-OBX|2|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Incomplete|||A|||F|||20241017050025\r
-OBR|19|789876543^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|25.27|µmol/L/h|>=2.91|N|||F|||20241017050025\r
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025\r
-OBR|20|789876543^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241017050025\r
-OBR|21|789876543^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.10|µmol/L|<=3|N|||F|||20241017050025\r
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|431.20|µmol/L||N|||F|||20241017050025\r
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.56||<=6|N|||F|||20241017050025\r
-OBR|22|789876543^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241017050025\r
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241017050025\r
-OBR|23|789876543^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F\r
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.242|µmol/L|<0.47|N|||F|||20241017050025\r
+ORC|RE|789876543^FormNumber||||||||||1164928032^MURUGESAN^CHEZHIYAN^^^^^^^NPI|||||||||KERN MEDICAL CENTER^^^^^^^^^R092|1700 MOUNT VERNON AVE^^BAKERSFIELD^CA^93306-4018
+OBR|1|789876543^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBR|2|789876543^FormNumber||57128-1^Newborn Screening Report summary panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241017050025
+OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241017050025
+OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12430-7^Out of range requiring further dried blood spot testing for at least one condition^LN|||N|||F|||20241017050025
+OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241017050025
+OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA22279-6^SMA^LN|||N|||F|||20241017050025
+OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \\\2130 E Illinois Avenue, FRESNO, CA 93701\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Spinal Muscular Atrophy (SMA): The sample was not adequate to complete testing for SMA. A repeat NBS specimen MUST be collected. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Valley Children's Hospital at (559) 353-6416. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241017050025
+OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241017050025
+OBR|3|789876543^FormNumber||57717-1^Newborn screen card data panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241017050025
+OBX|2|NM|8339-4^Birthweight^LN|1|2875|grams||N|||F|||20241017050025
+OBX|3|TM|57715-5^Time of birth^LN|1|0202|||N|||F|||20241017050025
+OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241017050025
+OBX|5|NM|73806-2^Newborn age in hours^LN|1|27|hour(s)||N|||F|||20241017050025
+OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241017050025
+OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241017050025
+OBX|8|TX|^^^99717-5^Accession Number^L|1|269-80-133/21-2024-21|||N|||F|||20241017050025
+OBX|9|TX|62324-9^Post-discharge provider name^LN|1|CHEZHIYAN MURUGESAN|||N|||F|||20241017050025
+OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1164928032|||N|||F|||20241017050025
+OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|1700 MOUNT VERNON AVE BAKERSFIELD CA 93306-4018 USA|||N|||F|||20241017050025
+OBR|4|789876543^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBR|5|789876543^FormNumber||53261-4^Amino acid newborn screen panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|357|µmol/L||N|||F|||20241017050025
+OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|398|µmol/L|<1000|N|||F|||20241017050025
+OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|92.2|µmol/L||N|||F|||20241017050025
+OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|2.05804|{Ratio}|<4.3|N|||F|||20241017050025
+OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|84.2|µmol/L|<230|N|||F|||20241017050025
+OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.21|{Ratio}|<1.35|N|||F|||20241017050025
+OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|44.8|µmol/L|<175|N|||F|||20241017050025
+OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.55|{Ratio}|<2.6|N|||F|||20241017050025
+OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|81.7|µmol/L|<680|N|||F|||20241017050025
+OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.20|µmol/L|<6.1|N|||F|||20241017050025
+OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|11.1|µmol/L|6.3-100|N|||F|||20241017050025
+OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|12|µmol/L|5-49|N|||F|||20241017050025
+OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.72|{Ratio}|<4.8|N|||F|||20241017050025
+OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|77|µmol/L|<800|N|||F|||20241017050025
+OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|6.36|{Ratio}||N|||F|||20241017050025
+OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|7|µmol/L|<63|N|||F|||20241017050025
+OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241017050025
+OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|136|µmol/L|<1500|N|||F|||20241017050025
+OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241017050025
+OBR|6|789876543^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
+OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241017050025
+OBR|7|789876543^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|16.4|µmol/L|6.4-125|N|||F|||20241017050025
+OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|3.65|{Ratio}|<70|N|||F|||20241017050025
+OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|16.1|µmol/L|10-80|N|||F|||20241017050025
+OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.06977|{Ratio}|<7.6|N|||F|||20241017050025
+OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.075|µmol/L|<0.95|N|||F|||20241017050025
+OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.049|µmol/L|<0.45|N|||F|||20241017050025
+OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.14|{Ratio}||N|||F|||20241017050025
+OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.042|µmol/L|<0.65|N|||F|||20241017050025
+OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.043|µmol/L|<0.65|N|||F|||20241017050025
+OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.026|µmol/L|<0.45|N|||F|||20241017050025
+OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.071|µmol/L|<2|N|||F|||20241017050025
+OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.05|µmol/L||N|||F|||20241017050025
+OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.169|µmol/L|<1.2|N|||F|||20241017050025
+OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.099|µmol/L|<0.9|N|||F|||20241017050025
+OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.98|{Ratio}||N|||F|||20241017050025
+OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241017050025
+OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.015|µmol/L|<0.2|N|||F|||20241017050025
+OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|2.91|µmol/L|<12|N|||F|||20241017050025
+OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.221|µmol/L|<1.4|N|||F|||20241017050025
+OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.021|µmol/L|<0.1|N|||F|||20241017050025
+OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00722|{Ratio}|<0.07|N|||F|||20241017050025
+OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|0.827|µmol/L|<3.5|N|||F|||20241017050025
+OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.58|µmol/L|<7|N|||F|||20241017050025
+OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.14|µmol/L||N|||F|||20241017050025
+OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.013|µmol/L|<0.1|N|||F|||20241017050025
+OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.028|µmol/L|<0.1|N|||F|||20241017050025
+OBR|8|789876543^FormNumber||57085-3^Organic acid newborn screen panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|1.7|µmol/L|<7.9|N|||F|||20241017050025
+OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.10|{Ratio}|<0.42|N|||F|||20241017050025
+OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.089|µmol/L|<0.48|N|||F|||20241017050025
+OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.229|µmol/L|<1.7|N|||F|||20241017050025
+OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.081|µmol/L|<0.95|N|||F|||20241017050025
+OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.04765|{Ratio}|<0.38|N|||F|||20241017050025
+OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.005|µmol/L|<0.5|N|||F|||20241017050025
+OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.216|µmol/L|<1.15|N|||F|||20241017050025
+OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.080|µmol/L|<0.38|N|||F|||20241017050025
+OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.89888|{Ratio}|>0.1|N|||F|||20241017050025
+OBR|9|789876543^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|20.90|ng/mL|<69|N|||F|||20241017050025
+OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
+OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241017050025
+OBR|10|789876543^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00007.6|nmol/L|<85|N|||F|||20241017050025
+OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
+OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025
+OBR|11|789876543^FormNumber||54090-6^Thyroid newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|NM|29575-8^Thyrotropin^LN|1|6.10|mIU/L|<29|N|||F|||20241017050025
+OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
+OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025
+OBR|12|789876543^FormNumber||54079-9^Galactosemia newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|173.29|enzyme units|>50|N|||F|||20241017050025
+OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
+OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025
+OBR|13|789876543^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241017050025
+OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241017050025
+OBR|14|789876543^FormNumber||57087-9^Biotinidase newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|45.57|ERU|>10|N|||F|||20241017050025
+OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
+OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025
+OBR|15|789876543^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|215|copies/µL|>18|N|||F|||20241017050025
+OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
+OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025
+OBR|16|789876543^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|6.94|µmol/L/h|>=1.54|N|||F|||20241017050025
+OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
+OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241017050025
+OBR|17|789876543^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|6.11|µmol/L/h|>=0.79|N|||F|||20241017050025
+OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
+OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025
+OBR|18|789876543^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA12430-7^Out of range requiring further dried blood spot testing for at least one condition^LN|||A|||F|||20241017050025
+OBX|2|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Incomplete|||A|||F|||20241017050025
+OBR|19|789876543^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|25.27|µmol/L/h|>=2.91|N|||F|||20241017050025
+OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
+OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025
+OBR|20|789876543^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
+OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241017050025
+OBR|21|789876543^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.10|µmol/L|<=3|N|||F|||20241017050025
+OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|431.20|µmol/L||N|||F|||20241017050025
+OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.56||<=6|N|||F|||20241017050025
+OBR|22|789876543^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241017050025
+OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241017050025
+OBR|23|789876543^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
+OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.242|µmol/L|<0.47|N|||F|||20241017050025

From 3c850de67739e8ed7cffc4b1d3a416b40ceb6578 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 14:45:13 -0700
Subject: [PATCH 27/61] add example file

Co-authored-by: James Herr <jherr@flexion.us>
Co-authored-by: jcrichlake <145698165+jcrichlake@users.noreply.github.com>
---
 .../006_ORU_R01_golden_copy_expected_sma_incomplete.fhir         | 1 +
 1 file changed, 1 insertion(+)
 create mode 100644 examples/Test/GoldenCopy/Expected/006_ORU_R01_golden_copy_expected_sma_incomplete.fhir

diff --git a/examples/Test/GoldenCopy/Expected/006_ORU_R01_golden_copy_expected_sma_incomplete.fhir b/examples/Test/GoldenCopy/Expected/006_ORU_R01_golden_copy_expected_sma_incomplete.fhir
new file mode 100644
index 000000000..e5e8127a6
--- /dev/null
+++ b/examples/Test/GoldenCopy/Expected/006_ORU_R01_golden_copy_expected_sma_incomplete.fhir
@@ -0,0 +1 @@
+{"resourceType":"Bundle","id":"1734644417712989374.cc55157b-dcbe-4370-b6c6-4a3ea3771c14","meta":{"lastUpdated":"2024-12-19T21:40:17.713+00:00"},"identifier":{"system":"https://reportstream.cdc.gov/prime-router","value":"006"},"type":"message","timestamp":"2024-10-17T05:00:25.000+00:00","entry":[{"fullUrl":"MessageHeader/1734644417721058658.7a886438-6b05-4bb2-8fe1-0f0c6a6d4766","resource":{"resourceType":"MessageHeader","id":"1734644417721058658.7a886438-6b05-4bb2-8fe1-0f0c6a6d4766","meta":{"tag":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0103","code":"N"}]},"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/msh-message-header","extension":[{"url":"MSH.7","valueString":"20241017050025"}]}],"eventCoding":{"system":"http://terminology.hl7.org/CodeSystem/v2-0003","code":"R01","display":"ORU^R01^ORU_R01"},"destination":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id","valueString":"9413799"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id-type","valueString":"L,M,N"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.5"}],"name":"SISHIERECEIVER","receiver":{"reference":"Organization/1734644417720024427.da55d14f-568a-4b6f-8c93-bdcbf3cf27ab"}}],"sender":{"reference":"Organization/1734644417715230486.eba98586-c642-451e-9d42-69355ad93fec"},"source":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"SISGDSP"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.3"}],"name":"SISGDSP","_endpoint":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}}},{"fullUrl":"Organization/1734644417715230486.eba98586-c642-451e-9d42-69355ad93fec","resource":{"resourceType":"Organization","id":"1734644417715230486.eba98586-c642-451e-9d42-69355ad93fec","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Organization/1734644417720024427.da55d14f-568a-4b6f-8c93-bdcbf3cf27ab","resource":{"resourceType":"Organization","id":"1734644417720024427.da55d14f-568a-4b6f-8c93-bdcbf3cf27ab","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.6"}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.2,HD.3"}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301","code":"L,M,N"}]},"value":"automated-staging-test-receiver-id"}]}},{"fullUrl":"Provenance/1734644417725209468.99f9e6df-7eea-4f6c-8141-01bd0dc0635c","resource":{"resourceType":"Provenance","id":"1734644417725209468.99f9e6df-7eea-4f6c-8141-01bd0dc0635c","target":[{"reference":"MessageHeader/1734644417721058658.7a886438-6b05-4bb2-8fe1-0f0c6a6d4766"},{"reference":"DiagnosticReport/1734644419692201133.2ad02aef-7ed6-4bc3-adce-9e824308af53"},{"reference":"DiagnosticReport/1734644419699746133.2856d179-89ab-489a-b2c5-8a833fde050b"},{"reference":"DiagnosticReport/1734644419708101541.7f3385cd-e700-42c9-bf9f-f64c95825783"},{"reference":"DiagnosticReport/1734644419713813197.ad7780f2-1e1a-400e-93d9-99840b8473f7"},{"reference":"DiagnosticReport/1734644419724024842.1bdb9bcf-c477-47e5-9e0f-be76109a5cd8"},{"reference":"DiagnosticReport/1734644419729907926.637687d5-f285-4d85-8250-cdb314373590"},{"reference":"DiagnosticReport/1734644419743254406.7d857b02-136c-4d65-9fbc-3e6e6e2fa2ba"},{"reference":"DiagnosticReport/1734644419753320971.b9e3b94b-0e80-437c-94b5-a77d995ce0d2"},{"reference":"DiagnosticReport/1734644419795641896.8702cee9-f54e-498e-a150-2f00ad76356c"},{"reference":"DiagnosticReport/1734644419801980108.5b9208e0-8d9c-45c8-bd50-885179dadb43"},{"reference":"DiagnosticReport/1734644419808292983.dff75e1f-d5d1-47f5-bd35-5bd07b7f84af"},{"reference":"DiagnosticReport/1734644419815428530.5f90805a-95cf-46d6-b09c-621a5a04ea2d"},{"reference":"DiagnosticReport/1734644419824626319.2533508b-b790-45d2-ac8d-300eb7132397"},{"reference":"DiagnosticReport/1734644419834916739.fc89b70e-a2b9-4e36-b5d6-8e2a97559cbb"},{"reference":"DiagnosticReport/1734644419844156113.7e989ddd-0edc-4a05-8396-c9fdb47c50fa"},{"reference":"DiagnosticReport/1734644419853217247.ff790c55-8249-4b13-a6bd-9759c12d684e"},{"reference":"DiagnosticReport/1734644419891605519.7daa771e-1756-4760-9382-68cd500982d7"},{"reference":"DiagnosticReport/1734644419895767159.f14226b8-44f4-40bf-a324-7a7a8016dee0"},{"reference":"DiagnosticReport/1734644419902517717.17c0b4a4-255c-43f9-be8f-703d9070208b"},{"reference":"DiagnosticReport/1734644419909213707.7cfdaa0f-a324-4518-ab6f-5c948abbdc9e"},{"reference":"DiagnosticReport/1734644419915028414.66b10e65-9fb1-4019-a18d-72882f136896"},{"reference":"DiagnosticReport/1734644419920406329.ce421d8f-a0f0-4635-b581-927247c9fe9f"},{"reference":"DiagnosticReport/1734644419925358861.4ed59a37-bfc4-4deb-8e1e-feb8b7980f00"}],"recorded":"2024-10-17T05:00:25Z","activity":{"coding":[{"display":"ORU^R01^ORU_R01"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"author"}]},"who":{"reference":"Organization/1734644417724501145.59bad71a-1348-471f-bdcb-cc8f9e31fd5b"}}]}},{"fullUrl":"Organization/1734644417724501145.59bad71a-1348-471f-bdcb-cc8f9e31fd5b","resource":{"resourceType":"Organization","id":"1734644417724501145.59bad71a-1348-471f-bdcb-cc8f9e31fd5b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Provenance/1734644417726648504.bf799ce1-2efd-4cf7-8f95-a31f4366a757","resource":{"resourceType":"Provenance","id":"1734644417726648504.bf799ce1-2efd-4cf7-8f95-a31f4366a757","recorded":"2024-12-19T21:40:17Z","policy":["http://hl7.org/fhir/uv/v2mappings/message-oru-r01-to-bundle"],"activity":{"coding":[{"code":"v2-FHIR transformation"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"assembler"}]},"who":{"reference":"Organization/1734644417726072719.1c99714e-4ce2-4647-b374-24e3fc74e1b2"}}]}},{"fullUrl":"Organization/1734644417726072719.1c99714e-4ce2-4647-b374-24e3fc74e1b2","resource":{"resourceType":"Organization","id":"1734644417726072719.1c99714e-4ce2-4647-b374-24e3fc74e1b2","identifier":[{"value":"CDC PRIME - Atlanta"},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301"}]},"system":"urn:ietf:rfc:3986","value":"2.16.840.1.114222.4.1.237821"}]}},{"fullUrl":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e","resource":{"resourceType":"Patient","id":"1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cx-identifier","extension":[{"url":"CX.5","valueString":"MR"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"PID.3"}],"type":{"coding":[{"code":"MR"}]},"value":"32550867","assigner":{"reference":"Organization/1734644417728574610.d6426e71-7ff7-4b1b-a59e-978745b32a9b"}}],"name":[{"family":"*****PII REMOVED******"}],"contact":[{"name":{"family":"*****PII REMOVED******"}}]}},{"fullUrl":"Organization/1734644417728574610.d6426e71-7ff7-4b1b-a59e-978745b32a9b","resource":{"resourceType":"Organization","id":"1734644417728574610.d6426e71-7ff7-4b1b-a59e-978745b32a9b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"1013163542&NPI"}]}},{"fullUrl":"Provenance/1734644417745743684.5c76bf7e-820b-4601-8c16-73dfb7e196c6","resource":{"resourceType":"Provenance","id":"1734644417745743684.5c76bf7e-820b-4601-8c16-73dfb7e196c6","target":[{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"}],"recorded":"2024-12-19T21:40:17Z","activity":{"coding":[{"system":"https://terminology.hl7.org/CodeSystem/v3-DataOperation","code":"UPDATE"}]}}},{"fullUrl":"RelatedPerson/1734644417748512892.3fc55e81-98c8-46e3-b07f-afd26c0e93ba","resource":{"resourceType":"RelatedPerson","id":"1734644417748512892.3fc55e81-98c8-46e3-b07f-afd26c0e93ba","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"NK1"}],"patient":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"name":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"NK1.2"}],"family":"*****PII REMOVED******"}]}},{"fullUrl":"Observation/1734644417796265313.e1027f5b-062f-4104-a7de-a437ae0c3842","resource":{"resourceType":"Observation","id":"1734644417796265313.e1027f5b-062f-4104-a7de-a437ae0c3842","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57721-3","display":"Reason for lab test in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12421-6","display":"Initial screen"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417801791651.d1966e09-74fb-4baa-b4b0-40544e8c0c1d","resource":{"resourceType":"Observation","id":"1734644417801791651.d1966e09-74fb-4baa-b4b0-40544e8c0c1d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57718-9","display":"Sample quality of Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12432-3","display":"Acceptable"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417817280488.4709f99d-783d-45b7-9ff6-01b35715b870","resource":{"resourceType":"Observation","id":"1734644417817280488.4709f99d-783d-45b7-9ff6-01b35715b870","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57130-7","display":"Newborn screening report - overall interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12430-7","display":"Out of range requiring further dried blood spot testing for at least one condition"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417822834817.bcb381eb-be32-44ea-ae5a-d53d349a2a8e","resource":{"resourceType":"Observation","id":"1734644417822834817.bcb381eb-be32-44ea-ae5a-d53d349a2a8e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57131-5","display":"Newborn conditions with positive markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417828340736.feb0b0a3-20f9-4dc8-ace3-1b1e85f11a91","resource":{"resourceType":"Observation","id":"1734644417828340736.feb0b0a3-20f9-4dc8-ace3-1b1e85f11a91","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57720-5","display":"Newborn conditions with equivocal markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA22279-6","display":"SMA"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417832150308.c320d4f8-9a39-4f05-9836-039b965e24ff","resource":{"resourceType":"Observation","id":"1734644417832150308.c320d4f8-9a39-4f05-9836-039b965e24ff","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57724-7","display":"Newborn screening short narrative summary"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"ACTION REQUIRED\\\\.br\\\\\\\\.br\\\\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \\\\\\2130 E Illinois Avenue, FRESNO, CA 93701\\\\.br\\\\\\\\.br\\\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\\\.br\\\\\\\\.br\\\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\\\.br\\\\\\\\.br\\\\Follow-up:\\\\.br\\\\\\\\.br\\\\Spinal Muscular Atrophy (SMA): The sample was not adequate to complete testing for SMA. A repeat NBS specimen MUST be collected. \\\\.br\\\\\\\\.br\\\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Valley Children's Hospital at (559) 353-6416. \\\\.br\\\\\\\\.br\\\\Methods and Limitations:\\\\.br\\\\\\\\.br\\\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\\\.br\\\\Attention Healthcare Provider:\\\\.br\\\\\\\\.br\\\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\\\.br\\\\\\\\.br\\","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417835810822.88a720fe-d538-48d6-9794-0a3ed0ead41e","resource":{"resourceType":"Observation","id":"1734644417835810822.88a720fe-d538-48d6-9794-0a3ed0ead41e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57129-9","display":"Full newborn screening summary report for display or printing"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417839535536.85f9af6b-5ef2-4530-9974-6e21db509d5a","resource":{"resourceType":"Observation","id":"1734644417839535536.85f9af6b-5ef2-4530-9974-6e21db509d5a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"ST"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57716-3","display":"State printed on filter paper card [Identifier] in NBS card"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"CA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417843879005.412d9eb1-44e0-4b56-982b-0f2bad4203da","resource":{"resourceType":"Observation","id":"1734644417843879005.412d9eb1-44e0-4b56-982b-0f2bad4203da","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"grams"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"8339-4","display":"Birthweight"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":2875,"unit":"grams"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417847226896.1e8f8200-472d-409b-8f41-04c8ec4a81ef","resource":{"resourceType":"Observation","id":"1734644417847226896.1e8f8200-472d-409b-8f41-04c8ec4a81ef","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57715-5","display":"Time of birth"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueTime":"0202","_valueTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"0202"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417849620675.2859d891-5519-4f09-a6e2-20fa5cd90db1","resource":{"resourceType":"Observation","id":"1734644417849620675.2859d891-5519-4f09-a6e2-20fa5cd90db1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57722-1","display":"Birth plurality of Pregnancy"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12411-7","display":"Singleton"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417901619353.594eb9e5-afae-4e85-922f-198372d6c515","resource":{"resourceType":"Observation","id":"1734644417901619353.594eb9e5-afae-4e85-922f-198372d6c515","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"hour(s)"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"73806-2","display":"Newborn age in hours"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":27,"unit":"hour(s)"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417905836296.262e3b31-827d-44c8-8c59-b7529737b23d","resource":{"resourceType":"Observation","id":"1734644417905836296.262e3b31-827d-44c8-8c59-b7529737b23d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57713-0","display":"Infant NICU factors that affect newborn screening interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417910044573.c13ffa5d-6957-44eb-b015-f1201536e849","resource":{"resourceType":"Observation","id":"1734644417910044573.c13ffa5d-6957-44eb-b015-f1201536e849","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67704-7","display":"Feeding types"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA16914-6","display":"Breast milk"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417913731055.ab8ae7df-d58e-4414-a546-e6c9fd583447","resource":{"resourceType":"Observation","id":"1734644417913731055.ab8ae7df-d58e-4414-a546-e6c9fd583447","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-5","display":"Accession Number"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"269-80-133/21-2024-21","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417917768954.50056553-e6ef-4dc4-b44e-3eb5654785ed","resource":{"resourceType":"Observation","id":"1734644417917768954.50056553-e6ef-4dc4-b44e-3eb5654785ed","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62324-9","display":"Post-discharge provider name"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"CHEZHIYAN MURUGESAN","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417921408098.bea1529d-7f6b-4881-82e8-cfc11f86fcb9","resource":{"resourceType":"Observation","id":"1734644417921408098.bea1529d-7f6b-4881-82e8-cfc11f86fcb9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62325-6","display":"Post-discharge provider practice ID"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"1164928032","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417926192001.558052e7-a20f-4082-b482-d15cc78f36db","resource":{"resourceType":"Observation","id":"1734644417926192001.558052e7-a20f-4082-b482-d15cc78f36db","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62327-2","display":"Post-discharge provider practice address"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"1700 MOUNT VERNON AVE BAKERSFIELD CA 93306-4018 USA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417934188839.9e003f64-2cd4-4ce8-b35d-c19ef12574a0","resource":{"resourceType":"Observation","id":"1734644417934188839.9e003f64-2cd4-4ce8-b35d-c19ef12574a0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47633-3","display":"Glycine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":357,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417940929624.cb81d9fd-a16b-4379-8940-516118aa6777","resource":{"resourceType":"Observation","id":"1734644417940929624.cb81d9fd-a16b-4379-8940-516118aa6777","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53150-9","display":"Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":398,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1000"}]}},{"fullUrl":"Observation/1734644417945053774.0b37fbbe-851f-4b8d-ad0e-fa11edf1a52a","resource":{"resourceType":"Observation","id":"1734644417945053774.0b37fbbe-851f-4b8d-ad0e-fa11edf1a52a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47799-2","display":"Valine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":92.2,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417948680715.cbea7c69-142e-4373-b0b1-90df672e6862","resource":{"resourceType":"Observation","id":"1734644417948680715.cbea7c69-142e-4373-b0b1-90df672e6862","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53151-7","display":"Valine/Phenylalanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":2.05804,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.3"}]}},{"fullUrl":"Observation/1734644417995017914.8ab59c9f-02bf-48a8-bf3c-d8ea7ec96914","resource":{"resourceType":"Observation","id":"1734644417995017914.8ab59c9f-02bf-48a8-bf3c-d8ea7ec96914","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53152-5","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":84.2,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<230"}]}},{"fullUrl":"Observation/1734644417999433067.13ba34a2-018a-4a84-8fe9-9e7ace7bcc87","resource":{"resourceType":"Observation","id":"1734644417999433067.13ba34a2-018a-4a84-8fe9-9e7ace7bcc87","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53154-1","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.21,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.35"}]}},{"fullUrl":"Observation/1734644418003515930.4796ac80-baa6-49b8-9771-3a7469ee2bb2","resource":{"resourceType":"Observation","id":"1734644418003515930.4796ac80-baa6-49b8-9771-3a7469ee2bb2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29573-3","display":"Phenylalanine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":44.8,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<175"}]}},{"fullUrl":"Observation/1734644418008267091.02fa4769-70d2-4054-bc36-4f90b3120c6d","resource":{"resourceType":"Observation","id":"1734644418008267091.02fa4769-70d2-4054-bc36-4f90b3120c6d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35572-7","display":"Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.55,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2.6"}]}},{"fullUrl":"Observation/1734644418012713502.2f78fefe-c6c8-4c8b-acc7-c1df8afeb156","resource":{"resourceType":"Observation","id":"1734644418012713502.2f78fefe-c6c8-4c8b-acc7-c1df8afeb156","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35571-9","display":"Tyrosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":81.7,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<680"}]}},{"fullUrl":"Observation/1734644418021388799.e22403f3-7063-4e1f-af4d-50186683a151","resource":{"resourceType":"Observation","id":"1734644418021388799.e22403f3-7063-4e1f-af4d-50186683a151","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53231-7","display":"Succinylacetone [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.20,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<6.1"}]}},{"fullUrl":"Observation/1734644418026031315.75cd7314-4f23-4832-8d01-abf7aef0274d","resource":{"resourceType":"Observation","id":"1734644418026031315.75cd7314-4f23-4832-8d01-abf7aef0274d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47700-0","display":"Methionine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":11.1,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.3-100"}]}},{"fullUrl":"Observation/1734644418029829796.368ea25e-8c14-4c22-bbc7-3588ae105bbf","resource":{"resourceType":"Observation","id":"1734644418029829796.368ea25e-8c14-4c22-bbc7-3588ae105bbf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42892-0","display":"Citrulline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":12,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"5-49"}]}},{"fullUrl":"Observation/1734644418033695132.917f591d-3498-4d01-80e7-873f7ffd7f95","resource":{"resourceType":"Observation","id":"1734644418033695132.917f591d-3498-4d01-80e7-873f7ffd7f95","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54092-2","display":"Citrulline/Arginine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":1.72,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.8"}]}},{"fullUrl":"Observation/1734644418040086104.5505ce91-e769-41c0-873c-ef885b42d953","resource":{"resourceType":"Observation","id":"1734644418040086104.5505ce91-e769-41c0-873c-ef885b42d953","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53155-8","display":"Asparagine+Ornithine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":77,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<800"}]}},{"fullUrl":"Observation/1734644418044605051.f55b07d2-8020-4fbb-b2be-1b46e9a79c9d","resource":{"resourceType":"Observation","id":"1734644418044605051.f55b07d2-8020-4fbb-b2be-1b46e9a79c9d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75215-4","display":"Ornithine/Citrulline [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":6.36,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418093990132.cc313c65-e85f-42a1-88ee-9814ad9e94ea","resource":{"resourceType":"Observation","id":"1734644418093990132.cc313c65-e85f-42a1-88ee-9814ad9e94ea","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47562-4","display":"Arginine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":7,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<63"}]}},{"fullUrl":"Observation/1734644418098585802.cf01bcc2-5850-43e2-8eb9-a86c44a39080","resource":{"resourceType":"Observation","id":"1734644418098585802.cf01bcc2-5850-43e2-8eb9-a86c44a39080","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75214-7","display":"Arginine/Ornithine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.09,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.9"}]}},{"fullUrl":"Observation/1734644418102931204.e5eda334-8162-4db0-9190-24d0fe3c672b","resource":{"resourceType":"Observation","id":"1734644418102931204.e5eda334-8162-4db0-9190-24d0fe3c672b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47732-3","display":"Proline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":136,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1500"}]}},{"fullUrl":"Observation/1734644418107103955.74d90a40-ba93-4a8d-a75c-7b9c59ccf5f4","resource":{"resourceType":"Observation","id":"1734644418107103955.74d90a40-ba93-4a8d-a75c-7b9c59ccf5f4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57710-6","display":"Amino acidemias newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418111524768.93fe9a7e-4aa3-4caa-9089-55680c2d733a","resource":{"resourceType":"Observation","id":"1734644418111524768.93fe9a7e-4aa3-4caa-9089-55680c2d733a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58088-6","display":"Acylcarnitine newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418115768261.bee34a03-fcca-4734-9362-e100f2d283d3","resource":{"resourceType":"Observation","id":"1734644418115768261.bee34a03-fcca-4734-9362-e100f2d283d3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58093-6","display":"Acylcarnitine newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418119703177.721be05d-2352-4e12-b098-5abf93c94476","resource":{"resourceType":"Observation","id":"1734644418119703177.721be05d-2352-4e12-b098-5abf93c94476","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38481-8","display":"Carnitine.free (C0)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":16.4,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.4-125"}]}},{"fullUrl":"Observation/1734644418123703845.f6f91fa7-f88a-4b8c-a2f5-3393be2541fb","resource":{"resourceType":"Observation","id":"1734644418123703845.f6f91fa7-f88a-4b8c-a2f5-3393be2541fb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53235-8","display":"Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":3.65,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<70"}]}},{"fullUrl":"Observation/1734644418127929775.83fdc8dd-09f2-48d2-a3c6-d3ed0b9d2e8a","resource":{"resourceType":"Observation","id":"1734644418127929775.83fdc8dd-09f2-48d2-a3c6-d3ed0b9d2e8a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50157-7","display":"Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":16.1,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"10-80"}]}},{"fullUrl":"Observation/1734644418132508163.f290c980-f194-41af-b4cf-96dbe04d1922","resource":{"resourceType":"Observation","id":"1734644418132508163.f290c980-f194-41af-b4cf-96dbe04d1922","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75212-1","display":"Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":2.06977,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.6"}]}},{"fullUrl":"Observation/1734644418136460852.49698eb0-f1bb-49da-a2c9-15aa906f5ab7","resource":{"resourceType":"Observation","id":"1734644418136460852.49698eb0-f1bb-49da-a2c9-15aa906f5ab7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45211-0","display":"Hexanoylcarnitine (C6)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.075,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734644418140546971.d1ec4a52-6d49-4afa-b000-46992ea08cca","resource":{"resourceType":"Observation","id":"1734644418140546971.d1ec4a52-6d49-4afa-b000-46992ea08cca","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53175-6","display":"Octanoylcarnitine (C8)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.049,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734644418144386619.7e5499dd-ad54-4277-81e4-e0d87915ed35","resource":{"resourceType":"Observation","id":"1734644418144386619.7e5499dd-ad54-4277-81e4-e0d87915ed35","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53177-2","display":"Octanoylcarnitine (C8)/Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":1.14,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418148488928.7ba1d26d-aebe-4485-bceb-6b2d8e2dd188","resource":{"resourceType":"Observation","id":"1734644418148488928.7ba1d26d-aebe-4485-bceb-6b2d8e2dd188","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53174-9","display":"Octenoylcarnitine (C8:1)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.042,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734644418191368502.288fd0c2-03af-4187-85b8-ab768fa53a09","resource":{"resourceType":"Observation","id":"1734644418191368502.288fd0c2-03af-4187-85b8-ab768fa53a09","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45197-1","display":"Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.043,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734644418196156441.744c7d3a-5d71-4e9a-81c3-c8dc52d50f4d","resource":{"resourceType":"Observation","id":"1734644418196156441.744c7d3a-5d71-4e9a-81c3-c8dc52d50f4d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45198-9","display":"Decenoylcarnitine (C10:1)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.026,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734644418199881245.c30f9674-dc49-4092-a2e8-91af248d5f7a","resource":{"resourceType":"Observation","id":"1734644418199881245.c30f9674-dc49-4092-a2e8-91af248d5f7a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45199-7","display":"Dodecanoylcarnitine (C12)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.071,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2"}]}},{"fullUrl":"Observation/1734644418203506753.3bab0f68-99a9-49bf-bfb1-aeb3c9c77ec7","resource":{"resourceType":"Observation","id":"1734644418203506753.3bab0f68-99a9-49bf-bfb1-aeb3c9c77ec7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45200-3","display":"Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.05,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418207148533.cfc80263-3390-43a3-871a-d1a2ae645258","resource":{"resourceType":"Observation","id":"1734644418207148533.cfc80263-3390-43a3-871a-d1a2ae645258","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53192-1","display":"Tetradecanoylcarnitine (C14)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.169,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.2"}]}},{"fullUrl":"Observation/1734644418210779091.028a38d8-7995-4c1d-9b88-eaaa5ba7c96e","resource":{"resourceType":"Observation","id":"1734644418210779091.028a38d8-7995-4c1d-9b88-eaaa5ba7c96e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53191-3","display":"Tetradecenoylcarnitine (C14:1)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.099,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.9"}]}},{"fullUrl":"Observation/1734644418213596932.7f4c433c-ee26-44a9-8455-2769977faf77","resource":{"resourceType":"Observation","id":"1734644418213596932.7f4c433c-ee26-44a9-8455-2769977faf77","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53194-7","display":"Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":1.98,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418216350292.40cd4740-470e-4f15-8981-2329f67c1c94","resource":{"resourceType":"Observation","id":"1734644418216350292.40cd4740-470e-4f15-8981-2329f67c1c94","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53190-5","display":"Tetradecadienoylcarnitine (C14:2)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.02,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418218653241.149832b5-0f86-47ed-bb76-05ce5ca9aab0","resource":{"resourceType":"Observation","id":"1734644418218653241.149832b5-0f86-47ed-bb76-05ce5ca9aab0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50281-5","display":"3-Hydroxytetradecanoylcarnitine (C14-OH)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.015,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.2"}]}},{"fullUrl":"Observation/1734644418221583851.593fe756-7b65-4bbd-92db-582d5e5afbc2","resource":{"resourceType":"Observation","id":"1734644418221583851.593fe756-7b65-4bbd-92db-582d5e5afbc2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53199-6","display":"Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":2.91,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<12"}]}},{"fullUrl":"Observation/1734644418225384797.3e7f8946-d817-4a06-9a98-7b737600509e","resource":{"resourceType":"Observation","id":"1734644418225384797.3e7f8946-d817-4a06-9a98-7b737600509e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53198-8","display":"Palmitoleylcarnitine (C16:1)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.221,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.4"}]}},{"fullUrl":"Observation/1734644418229985066.d45b748c-ce86-4727-b2b4-f129aa596d8e","resource":{"resourceType":"Observation","id":"1734644418229985066.d45b748c-ce86-4727-b2b4-f129aa596d8e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50125-4","display":"3-Hydroxypalmitoylcarnitine (C16-OH)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.021,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734644418234159048.af1803d4-bf00-473c-83f5-615b44d3edce","resource":{"resourceType":"Observation","id":"1734644418234159048.af1803d4-bf00-473c-83f5-615b44d3edce","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53201-0","display":"3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.00722,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.07"}]}},{"fullUrl":"Observation/1734644418238266898.2ce39b9d-24ba-4d82-bb08-dadf2f95d23e","resource":{"resourceType":"Observation","id":"1734644418238266898.2ce39b9d-24ba-4d82-bb08-dadf2f95d23e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53241-6","display":"Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.827,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<3.5"}]}},{"fullUrl":"Observation/1734644418242142654.4f2ffedd-052e-4a97-a19a-54dae982f8f2","resource":{"resourceType":"Observation","id":"1734644418242142654.4f2ffedd-052e-4a97-a19a-54dae982f8f2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53202-8","display":"Oleoylcarnitine (C18:1)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":1.58,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7"}]}},{"fullUrl":"Observation/1734644418245893376.05943385-5946-4586-8cf0-1d7d13a692da","resource":{"resourceType":"Observation","id":"1734644418245893376.05943385-5946-4586-8cf0-1d7d13a692da","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45217-7","display":"Linoleoylcarnitine (C18:2)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.14,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418249640091.14f79a31-0c80-46ef-89f5-40709968d8d2","resource":{"resourceType":"Observation","id":"1734644418249640091.14f79a31-0c80-46ef-89f5-40709968d8d2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50132-0","display":"3-Hydroxystearoylcarnitine (C18-OH)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.013,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734644418253450154.8d0b683a-d872-4129-bfb6-c321e28bfa6c","resource":{"resourceType":"Observation","id":"1734644418253450154.8d0b683a-d872-4129-bfb6-c321e28bfa6c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50113-0","display":"3-Hydroxyoleoylcarnitine (C18:1-OH)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.028,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734644418293578752.14a30ea3-9496-4275-9041-0d4f226b3e10","resource":{"resourceType":"Observation","id":"1734644418293578752.14a30ea3-9496-4275-9041-0d4f226b3e10","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53160-8","display":"Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":1.7,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.9"}]}},{"fullUrl":"Observation/1734644418297352457.ca225056-4647-42f7-9d82-8666c248bfd3","resource":{"resourceType":"Observation","id":"1734644418297352457.ca225056-4647-42f7-9d82-8666c248bfd3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53163-2","display":"Propionylcarnitine (C3)/Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.10,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.42"}]}},{"fullUrl":"Observation/1734644418301167169.dc0d0885-fbbe-42a9-8f4f-c4039fd42832","resource":{"resourceType":"Observation","id":"1734644418301167169.dc0d0885-fbbe-42a9-8f4f-c4039fd42832","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67708-8","display":"Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.089,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.48"}]}},{"fullUrl":"Observation/1734644418304937408.28c2882f-3e75-415d-aad7-a1ee08e419f3","resource":{"resourceType":"Observation","id":"1734644418304937408.28c2882f-3e75-415d-aad7-a1ee08e419f3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53166-5","display":"Butyrylcarnitine+Isobutyrylcarnitine (C4)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.229,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.7"}]}},{"fullUrl":"Observation/1734644418308939570.1de34fdf-fdd0-4874-be02-304d3373d9ff","resource":{"resourceType":"Observation","id":"1734644418308939570.1de34fdf-fdd0-4874-be02-304d3373d9ff","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45216-9","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.081,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734644418312767997.dfb7ee39-8914-431d-afc1-00f585bb57fd","resource":{"resourceType":"Observation","id":"1734644418312767997.dfb7ee39-8914-431d-afc1-00f585bb57fd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53240-8","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.04765,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734644418316602957.c6889d3f-c145-45ea-8205-8649bff1e55c","resource":{"resourceType":"Observation","id":"1734644418316602957.c6889d3f-c145-45ea-8205-8649bff1e55c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53170-7","display":"Tiglylcarnitine (C5:1)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.005,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.5"}]}},{"fullUrl":"Observation/1734644418320444569.2adf1156-3d36-431c-bc8b-28338e20e858","resource":{"resourceType":"Observation","id":"1734644418320444569.2adf1156-3d36-431c-bc8b-28338e20e858","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50106-4","display":"3-Hydroxyisovalerylcarnitine (C5-OH)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.216,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.15"}]}},{"fullUrl":"Observation/1734644418326047982.ba4822cb-d64b-4acf-958e-6b9c8db6d3d4","resource":{"resourceType":"Observation","id":"1734644418326047982.ba4822cb-d64b-4acf-958e-6b9c8db6d3d4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67710-4","display":"Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.080,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734644418330183463.5d0101f7-90b2-4eee-9a2e-47386c89b7a0","resource":{"resourceType":"Observation","id":"1734644418330183463.5d0101f7-90b2-4eee-9a2e-47386c89b7a0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75216-2","display":"Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.89888,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">0.1"}]}},{"fullUrl":"Observation/1734644418333982285.fcc21c8a-6157-427e-b6f8-62fefe57d81a","resource":{"resourceType":"Observation","id":"1734644418333982285.fcc21c8a-6157-427e-b6f8-62fefe57d81a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ng/mL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"48633-2","display":"Trypsinogen I.free"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":20.90,"unit":"ng/mL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<69"}]}},{"fullUrl":"Observation/1734644418337729531.0f74bef2-2ae5-4599-b4ba-6a4adc56d5ff","resource":{"resourceType":"Observation","id":"1734644418337729531.0f74bef2-2ae5-4599-b4ba-6a4adc56d5ff","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46769-6","display":"Cystic fibrosis newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418340904849.5e94cf89-bdd1-467d-a1c6-82f3582339b8","resource":{"resourceType":"Observation","id":"1734644418340904849.5e94cf89-bdd1-467d-a1c6-82f3582339b8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57707-2","display":"Cystic fibrosis newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418344428438.9c359bf0-d4f2-4239-b942-6f4cd91861bb","resource":{"resourceType":"Observation","id":"1734644418344428438.9c359bf0-d4f2-4239-b942-6f4cd91861bb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"nmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38473-5","display":"17-Hydroxyprogesterone"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":7.6,"unit":"nmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<85"}]}},{"fullUrl":"Observation/1734644418348157459.988552ff-1822-44f3-86a8-dc7e3e817126","resource":{"resourceType":"Observation","id":"1734644418348157459.988552ff-1822-44f3-86a8-dc7e3e817126","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46758-9","display":"Congenital adrenal hyperplasia newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418351257387.1c0d6804-ff3d-4450-857f-e4fc186532ac","resource":{"resourceType":"Observation","id":"1734644418351257387.1c0d6804-ff3d-4450-857f-e4fc186532ac","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57706-4","display":"Congenital adrenal hyperplasia newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418354740069.f2d1242a-d7ef-4e64-969f-8bd8197ad869","resource":{"resourceType":"Observation","id":"1734644418354740069.f2d1242a-d7ef-4e64-969f-8bd8197ad869","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"mIU/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29575-8","display":"Thyrotropin"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":6.10,"unit":"mIU/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<29"}]}},{"fullUrl":"Observation/1734644418358362071.2488ad7b-566c-4537-9135-55507da8d836","resource":{"resourceType":"Observation","id":"1734644418358362071.2488ad7b-566c-4537-9135-55507da8d836","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46762-1","display":"Congenital hypothyroidism newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418361380556.25749106-cfb2-4331-9185-dfd0950ef84f","resource":{"resourceType":"Observation","id":"1734644418361380556.25749106-cfb2-4331-9185-dfd0950ef84f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57705-6","display":"Congenital hypothyroidism newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418393365701.2a730407-04f1-4256-b77c-eb0b3f0a998e","resource":{"resourceType":"Observation","id":"1734644418393365701.2a730407-04f1-4256-b77c-eb0b3f0a998e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"enzyme units"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42906-8","display":"Galactose 1 phosphate uridyl transferase"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":173.29,"unit":"enzyme units"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">50"}]}},{"fullUrl":"Observation/1734644418397214977.1ce1b2dd-c08c-4ec5-80e2-e8a755828a4d","resource":{"resourceType":"Observation","id":"1734644418397214977.1ce1b2dd-c08c-4ec5-80e2-e8a755828a4d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46737-3","display":"Galactosemias newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418400448865.1b9837e7-ea8a-4660-a819-d7676389342f","resource":{"resourceType":"Observation","id":"1734644418400448865.1b9837e7-ea8a-4660-a819-d7676389342f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57704-9","display":"Galactosemias newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418404113797.7610a136-ea9b-4e83-adc2-f7ff013917f0","resource":{"resourceType":"Observation","id":"1734644418404113797.7610a136-ea9b-4e83-adc2-f7ff013917f0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54104-5","display":"Hemoglobin pattern"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"FA"}},{"fullUrl":"Observation/1734644418407114199.402af6e9-5586-4d2a-a454-631b42f198aa","resource":{"resourceType":"Observation","id":"1734644418407114199.402af6e9-5586-4d2a-a454-631b42f198aa","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57703-1","display":"Hemoglobin disorders newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants."}},{"fullUrl":"Observation/1734644418410319112.d5601183-0925-4034-8c0c-9093786f4eaf","resource":{"resourceType":"Observation","id":"1734644418410319112.d5601183-0925-4034-8c0c-9093786f4eaf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ERU"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75217-0","display":"Biotinidase [Enzymatic activity/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":45.57,"unit":"ERU"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">10"}]}},{"fullUrl":"Observation/1734644418414140146.2afa3160-ba41-4195-bbfc-3a52ed753110","resource":{"resourceType":"Observation","id":"1734644418414140146.2afa3160-ba41-4195-bbfc-3a52ed753110","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46761-3","display":"Biotinidase deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418417337565.c54cbd66-59e0-42ab-b1cf-9951adef0da2","resource":{"resourceType":"Observation","id":"1734644418417337565.c54cbd66-59e0-42ab-b1cf-9951adef0da2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57699-1","display":"Biotinidase deficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418421163518.e6b7164c-753b-47dc-a9fa-5f4f42d2e3b4","resource":{"resourceType":"Observation","id":"1734644418421163518.e6b7164c-753b-47dc-a9fa-5f4f42d2e3b4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"copies/µL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62320-7","display":"T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":215,"unit":"copies/µL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">18"}]}},{"fullUrl":"Observation/1734644418424925822.56a4ebf0-c340-44d8-b9c2-9f6c84adfc83","resource":{"resourceType":"Observation","id":"1734644418424925822.56a4ebf0-c340-44d8-b9c2-9f6c84adfc83","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62321-5","display":"Severe combined immunodeficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418428008677.d1c355fd-aa64-4f6f-83ed-facf1540b17f","resource":{"resourceType":"Observation","id":"1734644418428008677.d1c355fd-aa64-4f6f-83ed-facf1540b17f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62322-3","display":"Severe combined immunodeficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418431524932.c31b6c3b-c057-4ce7-b829-ebfc3b80d4d2","resource":{"resourceType":"Observation","id":"1734644418431524932.c31b6c3b-c057-4ce7-b829-ebfc3b80d4d2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55827-0","display":"Acid alpha glucosidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":6.94,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=1.54"}]}},{"fullUrl":"Observation/1734644418435131746.67b40486-a401-4f82-8575-dd4b8c30a0f0","resource":{"resourceType":"Observation","id":"1734644418435131746.67b40486-a401-4f82-8575-dd4b8c30a0f0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63415-4","display":"Pompe Disease deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418438178153.78db2e15-e743-43b1-80bb-db636e6de3c5","resource":{"resourceType":"Observation","id":"1734644418438178153.78db2e15-e743-43b1-80bb-db636e6de3c5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63416-2","display":"Pompe Disease deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418441661076.c9805208-4a21-4978-9655-a19ad765ec84","resource":{"resourceType":"Observation","id":"1734644418441661076.c9805208-4a21-4978-9655-a19ad765ec84","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55909-6","display":"Alpha-L-iduronidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":6.11,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=0.79"}]}},{"fullUrl":"Observation/1734644418448447536.bee743ae-abb4-4b2e-b85d-2570afb8be3f","resource":{"resourceType":"Observation","id":"1734644418448447536.bee743ae-abb4-4b2e-b85d-2570afb8be3f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79564-1","display":"Mucopolysaccharidosis type I newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418493996336.22471e9e-7dfc-469f-bcea-a38b92726aa9","resource":{"resourceType":"Observation","id":"1734644418493996336.22471e9e-7dfc-469f-bcea-a38b92726aa9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79565-8","display":"Mucopolysaccharidosis type I newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418498838813.52242f5f-fbf3-4a2a-b760-989a9c456d6e","resource":{"resourceType":"Observation","id":"1734644418498838813.52242f5f-fbf3-4a2a-b760-989a9c456d6e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92004-1","display":"Spinal muscular atrophy newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12430-7","display":"Out of range requiring further dried blood spot testing for at least one condition"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"A"}]}]}},{"fullUrl":"Observation/1734644418502456380.093781b0-cfed-4ae7-a908-4f436a995c79","resource":{"resourceType":"Observation","id":"1734644418502456380.093781b0-cfed-4ae7-a908-4f436a995c79","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92003-3","display":"Spinal muscular atrophy newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"SMA Incomplete","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"A"}]}]}},{"fullUrl":"Observation/1734644418506522742.50a3e79d-3451-4210-8959-d95579c2a5f9","resource":{"resourceType":"Observation","id":"1734644418506522742.50a3e79d-3451-4210-8959-d95579c2a5f9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79462-8","display":"Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":25.27,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=2.91"}]}},{"fullUrl":"Observation/1734644418510765923.b268b63d-6738-4acc-a52c-1f93cc540c6d","resource":{"resourceType":"Observation","id":"1734644418510765923.b268b63d-6738-4acc-a52c-1f93cc540c6d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104189-6","display":"Mucopolysaccharidosis type II newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418514265800.fb13696e-d60b-4387-ab7d-5e390c6785f8","resource":{"resourceType":"Observation","id":"1734644418514265800.fb13696e-d60b-4387-ab7d-5e390c6785f8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104190-4","display":"Mucopolysaccharidosis type II newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418523112493.124c6ef4-414a-4c05-ac23-ce4a55fa0d36","resource":{"resourceType":"Observation","id":"1734644418523112493.124c6ef4-414a-4c05-ac23-ce4a55fa0d36","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104192-0","display":"Guanidinoacetate methyltransferase deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418526909052.d1f48023-23d5-4ba4-aa24-8cbc40397c14","resource":{"resourceType":"Observation","id":"1734644418526909052.d1f48023-23d5-4ba4-aa24-8cbc40397c14","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104193-8","display":"Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418530955497.84aa3c0e-67f7-4b13-b789-ab6f0feafdb6","resource":{"resourceType":"Observation","id":"1734644418530955497.84aa3c0e-67f7-4b13-b789-ab6f0feafdb6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"93488-5","display":"Guanidinoacetate [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":1.10,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=3"}]}},{"fullUrl":"Observation/1734644418534982045.9a9f7f72-97b4-4c19-872f-20f2394874e0","resource":{"resourceType":"Observation","id":"1734644418534982045.9a9f7f72-97b4-4c19-872f-20f2394874e0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104194-6","display":"Creatine [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":431.20,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418538478716.748366b9-a826-4acf-a52d-d851375becbc","resource":{"resourceType":"Observation","id":"1734644418538478716.748366b9-a826-4acf-a52d-d851375becbc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104195-3","display":"GUAC/CRE Ratio [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":2.56},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=6"}]}},{"fullUrl":"Observation/1734644418542644844.703dd0ec-0ac3-4d6a-8b48-a876529184f2","resource":{"resourceType":"Observation","id":"1734644418542644844.703dd0ec-0ac3-4d6a-8b48-a876529184f2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-32","display":"Adrenoleukodystrophy deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418546025989.a78bf05f-9bbd-4182-a893-c88b2a757930","resource":{"resourceType":"Observation","id":"1734644418546025989.a78bf05f-9bbd-4182-a893-c88b2a757930","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-33","display":"Adrenoleukodystrophy deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418594486407.d26e1831-e4a9-4eed-a2e3-9e160856d54c","resource":{"resourceType":"Observation","id":"1734644418594486407.d26e1831-e4a9-4eed-a2e3-9e160856d54c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79321-6","display":"Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.242,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.47"}]}},{"fullUrl":"Specimen/1734644418620013889.578eeedf-2fac-4a73-b8e8-e2f399dd8080","resource":{"resourceType":"Specimen","id":"1734644418620013889.578eeedf-2fac-4a73-b8e8-e2f399dd8080","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418623086931.a10f8b61-0456-42ac-93fb-71963e42e3af","resource":{"resourceType":"Specimen","id":"1734644418623086931.a10f8b61-0456-42ac-93fb-71963e42e3af","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418625861998.068c0946-33c1-4698-b262-4e7424380350","resource":{"resourceType":"Specimen","id":"1734644418625861998.068c0946-33c1-4698-b262-4e7424380350","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418628855693.4abd5487-e297-4db8-a03e-ad70e82ea7e0","resource":{"resourceType":"Specimen","id":"1734644418628855693.4abd5487-e297-4db8-a03e-ad70e82ea7e0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418631682897.6a14062a-0df8-478b-80f6-a2818b88b0b2","resource":{"resourceType":"Specimen","id":"1734644418631682897.6a14062a-0df8-478b-80f6-a2818b88b0b2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418634469316.8d4cdaf4-1d61-48a9-8208-ab69319553bf","resource":{"resourceType":"Specimen","id":"1734644418634469316.8d4cdaf4-1d61-48a9-8208-ab69319553bf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418637227352.d3880a49-7276-46f6-b4a6-c2275c7e258a","resource":{"resourceType":"Specimen","id":"1734644418637227352.d3880a49-7276-46f6-b4a6-c2275c7e258a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418640004242.4c4fbcdf-9bb7-42c3-a7fd-b23a6bf81c6d","resource":{"resourceType":"Specimen","id":"1734644418640004242.4c4fbcdf-9bb7-42c3-a7fd-b23a6bf81c6d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418642858898.e93b7cc7-d555-4fdb-ad7c-60fd187217ab","resource":{"resourceType":"Specimen","id":"1734644418642858898.e93b7cc7-d555-4fdb-ad7c-60fd187217ab","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418645609720.a2aeb8f8-c2d0-4c45-8524-369c698ab7e9","resource":{"resourceType":"Specimen","id":"1734644418645609720.a2aeb8f8-c2d0-4c45-8524-369c698ab7e9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418692924444.2362eec6-8892-4e80-b9a5-92159ca55d7a","resource":{"resourceType":"Specimen","id":"1734644418692924444.2362eec6-8892-4e80-b9a5-92159ca55d7a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418697846760.72e82496-50e8-48d9-ab40-7aad8ef84ebc","resource":{"resourceType":"Specimen","id":"1734644418697846760.72e82496-50e8-48d9-ab40-7aad8ef84ebc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418700728436.ebc0946d-66c6-4188-a3fb-3c81fb392782","resource":{"resourceType":"Specimen","id":"1734644418700728436.ebc0946d-66c6-4188-a3fb-3c81fb392782","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418703664102.7fc22a83-8356-4ab2-9428-7e35ea9e9d86","resource":{"resourceType":"Specimen","id":"1734644418703664102.7fc22a83-8356-4ab2-9428-7e35ea9e9d86","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418706669478.8228a2e2-0c7e-498c-a308-7a3f71673738","resource":{"resourceType":"Specimen","id":"1734644418706669478.8228a2e2-0c7e-498c-a308-7a3f71673738","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418709452811.2b287078-a334-49ad-b97f-3acecf74cf69","resource":{"resourceType":"Specimen","id":"1734644418709452811.2b287078-a334-49ad-b97f-3acecf74cf69","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418713689710.c3c889e5-e87f-4c32-bf89-1cd1441c6b1e","resource":{"resourceType":"Specimen","id":"1734644418713689710.c3c889e5-e87f-4c32-bf89-1cd1441c6b1e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418716488452.b532b0c6-066b-4835-a0cb-73fa3d91c5a3","resource":{"resourceType":"Specimen","id":"1734644418716488452.b532b0c6-066b-4835-a0cb-73fa3d91c5a3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418720058990.326688c9-38c2-47c9-b11b-f09becbe0353","resource":{"resourceType":"Specimen","id":"1734644418720058990.326688c9-38c2-47c9-b11b-f09becbe0353","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418722906983.caa6ec68-8fe7-4db7-a48a-fe3ae2803810","resource":{"resourceType":"Specimen","id":"1734644418722906983.caa6ec68-8fe7-4db7-a48a-fe3ae2803810","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418725664248.3b13f6ec-0467-45ef-a3b9-224ea8059b9a","resource":{"resourceType":"Specimen","id":"1734644418725664248.3b13f6ec-0467-45ef-a3b9-224ea8059b9a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418728439666.e23f8e93-1f86-42b3-956d-952e01b4d8a8","resource":{"resourceType":"Specimen","id":"1734644418728439666.e23f8e93-1f86-42b3-956d-952e01b4d8a8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418731522697.fcb6d558-720e-4d6f-9a85-25ea41a92f68","resource":{"resourceType":"Specimen","id":"1734644418731522697.fcb6d558-720e-4d6f-9a85-25ea41a92f68","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"ServiceRequest/1734644418806932054.3ea607c6-5dbb-4897-9078-d6595b5abb1c","resource":{"resourceType":"ServiceRequest","id":"1734644418806932054.3ea607c6-5dbb-4897-9078-d6595b5abb1c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/business-event","valueCode":"RE"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/orc-common-order","extension":[{"url":"orc-21-ordering-facility-name","valueReference":{"reference":"Organization/1734644418793486307.9ac2044f-5f92-4f10-8dc4-194eb41d27c3"}},{"url":"orc-22-ordering-facility-address","valueAddress":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"1700 MOUNT VERNON AVE"}]}]}],"line":["1700 MOUNT VERNON AVE"],"city":"BAKERSFIELD","state":"CA","postalCode":"93306-4018"}},{"url":"orc-12-ordering-provider","valueReference":{"reference":"Practitioner/1734644418798757553.b363d07f-34dd-4bd5-8f90-c78d2c0aa7f3"}}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.2","valueIdentifier":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"value":"789876543"}},{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644418802666952.3e10c967-c5ef-4bfb-a3ec-8e4692398f37"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"PractitionerRole/1734644418736978436.993f62a0-6365-45c2-83dd-3faa19bd5b9e"}}},{"fullUrl":"Practitioner/1734644418740136656.66835f6f-a425-4c14-82c5-93e6f75f3286","resource":{"resourceType":"Practitioner","id":"1734644418740136656.66835f6f-a425-4c14-82c5-93e6f75f3286","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"},{"url":"XCN.10","valueString":"NPI"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.12"}],"identifier":[{"value":"1164928032"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Organization/1734644418744448816.a0f710bf-02ad-4497-98ac-ec5fd7321503","resource":{"resourceType":"Organization","id":"1734644418744448816.a0f710bf-02ad-4497-98ac-ec5fd7321503","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R092"}]}],"identifier":[{"value":"R092"}],"name":"KERN MEDICAL CENTER","telecom":[{"_system":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}],"address":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"1700 MOUNT VERNON AVE"}]}]}],"line":["1700 MOUNT VERNON AVE"],"city":"BAKERSFIELD","state":"CA","postalCode":"93306-4018"}]}},{"fullUrl":"PractitionerRole/1734644418736978436.993f62a0-6365-45c2-83dd-3faa19bd5b9e","resource":{"resourceType":"PractitionerRole","id":"1734644418736978436.993f62a0-6365-45c2-83dd-3faa19bd5b9e","practitioner":{"reference":"Practitioner/1734644418740136656.66835f6f-a425-4c14-82c5-93e6f75f3286"},"organization":{"reference":"Organization/1734644418744448816.a0f710bf-02ad-4497-98ac-ec5fd7321503"}}},{"fullUrl":"Organization/1734644418793486307.9ac2044f-5f92-4f10-8dc4-194eb41d27c3","resource":{"resourceType":"Organization","id":"1734644418793486307.9ac2044f-5f92-4f10-8dc4-194eb41d27c3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R092"}]}],"identifier":[{"value":"R092"}],"name":"KERN MEDICAL CENTER"}},{"fullUrl":"Practitioner/1734644418798757553.b363d07f-34dd-4bd5-8f90-c78d2c0aa7f3","resource":{"resourceType":"Practitioner","id":"1734644418798757553.b363d07f-34dd-4bd5-8f90-c78d2c0aa7f3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"},{"url":"XCN.10","valueString":"NPI"}]}],"identifier":[{"value":"1164928032"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644418802666952.3e10c967-c5ef-4bfb-a3ec-8e4692398f37","resource":{"resourceType":"Practitioner","id":"1734644418802666952.3e10c967-c5ef-4bfb-a3ec-8e4692398f37","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644418826177151.9467ba59-d656-4e97-b205-9216579c51da","resource":{"resourceType":"ServiceRequest","id":"1734644418826177151.9467ba59-d656-4e97-b205-9216579c51da","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644418822074572.2e2677b8-f738-4d2a-a25e-718e3fa66958"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644418813567431.eb4478c0-4152-4791-9aee-fef8268f068e"}}},{"fullUrl":"Practitioner/1734644418813567431.eb4478c0-4152-4791-9aee-fef8268f068e","resource":{"resourceType":"Practitioner","id":"1734644418813567431.eb4478c0-4152-4791-9aee-fef8268f068e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644418822074572.2e2677b8-f738-4d2a-a25e-718e3fa66958","resource":{"resourceType":"Practitioner","id":"1734644418822074572.2e2677b8-f738-4d2a-a25e-718e3fa66958","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644418890800645.caa36224-9fba-4460-8812-f58e39a6ca08","resource":{"resourceType":"ServiceRequest","id":"1734644418890800645.caa36224-9fba-4460-8812-f58e39a6ca08","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644418838391566.230bde36-dad9-483b-b2fe-c9bfb1239df9"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644418829744474.8679ed02-5629-4eb1-a8bc-75876825c60b"}}},{"fullUrl":"Practitioner/1734644418829744474.8679ed02-5629-4eb1-a8bc-75876825c60b","resource":{"resourceType":"Practitioner","id":"1734644418829744474.8679ed02-5629-4eb1-a8bc-75876825c60b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644418838391566.230bde36-dad9-483b-b2fe-c9bfb1239df9","resource":{"resourceType":"Practitioner","id":"1734644418838391566.230bde36-dad9-483b-b2fe-c9bfb1239df9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644418918999562.efa015f9-2c73-449e-94b2-2d947e48c94a","resource":{"resourceType":"ServiceRequest","id":"1734644418918999562.efa015f9-2c73-449e-94b2-2d947e48c94a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644418903976600.d7df21ab-e118-45aa-ad5f-8251d698e9d5"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644418894679007.2caa4fc8-f7f3-4716-9029-c0ed17469a78"}}},{"fullUrl":"Practitioner/1734644418894679007.2caa4fc8-f7f3-4716-9029-c0ed17469a78","resource":{"resourceType":"Practitioner","id":"1734644418894679007.2caa4fc8-f7f3-4716-9029-c0ed17469a78","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644418903976600.d7df21ab-e118-45aa-ad5f-8251d698e9d5","resource":{"resourceType":"Practitioner","id":"1734644418903976600.d7df21ab-e118-45aa-ad5f-8251d698e9d5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644418936540454.e958080b-66d3-4128-8f49-77ebdf43e321","resource":{"resourceType":"ServiceRequest","id":"1734644418936540454.e958080b-66d3-4128-8f49-77ebdf43e321","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644418932422877.e028d956-3aa0-45d5-8bb2-a286d63232ea"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644418923279702.c0659eca-dff1-456b-83e3-e4c583c0b6e8"}}},{"fullUrl":"Practitioner/1734644418923279702.c0659eca-dff1-456b-83e3-e4c583c0b6e8","resource":{"resourceType":"Practitioner","id":"1734644418923279702.c0659eca-dff1-456b-83e3-e4c583c0b6e8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644418932422877.e028d956-3aa0-45d5-8bb2-a286d63232ea","resource":{"resourceType":"Practitioner","id":"1734644418932422877.e028d956-3aa0-45d5-8bb2-a286d63232ea","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644418997080895.b86d66d5-a480-4ddb-a6cd-5a2926d5df16","resource":{"resourceType":"ServiceRequest","id":"1734644418997080895.b86d66d5-a480-4ddb-a6cd-5a2926d5df16","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644418993004073.6e5b162c-d89d-4f61-ad66-de5302afb476"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644418940074505.490cb9e3-dc29-4c66-9c76-d256ba7837ee"}}},{"fullUrl":"Practitioner/1734644418940074505.490cb9e3-dc29-4c66-9c76-d256ba7837ee","resource":{"resourceType":"Practitioner","id":"1734644418940074505.490cb9e3-dc29-4c66-9c76-d256ba7837ee","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644418993004073.6e5b162c-d89d-4f61-ad66-de5302afb476","resource":{"resourceType":"Practitioner","id":"1734644418993004073.6e5b162c-d89d-4f61-ad66-de5302afb476","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419013462108.def28f11-ee1e-40ad-97f4-d4b12ce71c7b","resource":{"resourceType":"ServiceRequest","id":"1734644419013462108.def28f11-ee1e-40ad-97f4-d4b12ce71c7b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419008878223.6495ca34-2c21-4624-8de2-1e4c31eb4cd6"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419000542120.558b842e-c22a-4e0d-81be-4861dd7681f2"}}},{"fullUrl":"Practitioner/1734644419000542120.558b842e-c22a-4e0d-81be-4861dd7681f2","resource":{"resourceType":"Practitioner","id":"1734644419000542120.558b842e-c22a-4e0d-81be-4861dd7681f2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419008878223.6495ca34-2c21-4624-8de2-1e4c31eb4cd6","resource":{"resourceType":"Practitioner","id":"1734644419008878223.6495ca34-2c21-4624-8de2-1e4c31eb4cd6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419029952304.7fe5e75c-e5bb-41eb-8e81-f82605fbac0c","resource":{"resourceType":"ServiceRequest","id":"1734644419029952304.7fe5e75c-e5bb-41eb-8e81-f82605fbac0c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419025895590.c3513930-d250-4d97-b75a-5c149eed2394"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419017528911.db7a59fa-7921-4963-8f63-6a667781c888"}}},{"fullUrl":"Practitioner/1734644419017528911.db7a59fa-7921-4963-8f63-6a667781c888","resource":{"resourceType":"Practitioner","id":"1734644419017528911.db7a59fa-7921-4963-8f63-6a667781c888","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419025895590.c3513930-d250-4d97-b75a-5c149eed2394","resource":{"resourceType":"Practitioner","id":"1734644419025895590.c3513930-d250-4d97-b75a-5c149eed2394","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419045997111.32514986-73aa-40b5-8546-d18abe8434bf","resource":{"resourceType":"ServiceRequest","id":"1734644419045997111.32514986-73aa-40b5-8546-d18abe8434bf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419041926742.32a79bfe-9fdb-4e1c-8258-3964025cdf3c"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419033469724.252c6f91-9cc6-4a59-8931-c8964e19101f"}}},{"fullUrl":"Practitioner/1734644419033469724.252c6f91-9cc6-4a59-8931-c8964e19101f","resource":{"resourceType":"Practitioner","id":"1734644419033469724.252c6f91-9cc6-4a59-8931-c8964e19101f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419041926742.32a79bfe-9fdb-4e1c-8258-3964025cdf3c","resource":{"resourceType":"Practitioner","id":"1734644419041926742.32a79bfe-9fdb-4e1c-8258-3964025cdf3c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419106349552.888dd644-2c77-43d1-bf1f-9c4f3f7e4e5e","resource":{"resourceType":"ServiceRequest","id":"1734644419106349552.888dd644-2c77-43d1-bf1f-9c4f3f7e4e5e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419102259226.b4694d5f-64be-4180-bd5f-40ccc5a76ad4"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419093782111.e23eb990-690d-441d-8338-c13fead1fd26"}}},{"fullUrl":"Practitioner/1734644419093782111.e23eb990-690d-441d-8338-c13fead1fd26","resource":{"resourceType":"Practitioner","id":"1734644419093782111.e23eb990-690d-441d-8338-c13fead1fd26","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419102259226.b4694d5f-64be-4180-bd5f-40ccc5a76ad4","resource":{"resourceType":"Practitioner","id":"1734644419102259226.b4694d5f-64be-4180-bd5f-40ccc5a76ad4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419137536515.cc0e7644-2a4c-40af-9d57-d3e537d728e3","resource":{"resourceType":"ServiceRequest","id":"1734644419137536515.cc0e7644-2a4c-40af-9d57-d3e537d728e3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419118572562.4c81a773-e14b-4349-9c0e-e5f27d6f61b5"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419109923798.3102f1fc-d92d-4ccf-8d44-db09e22ed3a9"}}},{"fullUrl":"Practitioner/1734644419109923798.3102f1fc-d92d-4ccf-8d44-db09e22ed3a9","resource":{"resourceType":"Practitioner","id":"1734644419109923798.3102f1fc-d92d-4ccf-8d44-db09e22ed3a9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419118572562.4c81a773-e14b-4349-9c0e-e5f27d6f61b5","resource":{"resourceType":"Practitioner","id":"1734644419118572562.4c81a773-e14b-4349-9c0e-e5f27d6f61b5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419197079535.cfe1ac19-cb37-4ecf-9fbd-d53dbdddc459","resource":{"resourceType":"ServiceRequest","id":"1734644419197079535.cfe1ac19-cb37-4ecf-9fbd-d53dbdddc459","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419192248682.57f463e2-787c-4fa4-b28f-7dd182664303"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419141935386.97fd5e80-4be3-4778-b8bb-5e3f398175eb"}}},{"fullUrl":"Practitioner/1734644419141935386.97fd5e80-4be3-4778-b8bb-5e3f398175eb","resource":{"resourceType":"Practitioner","id":"1734644419141935386.97fd5e80-4be3-4778-b8bb-5e3f398175eb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419192248682.57f463e2-787c-4fa4-b28f-7dd182664303","resource":{"resourceType":"Practitioner","id":"1734644419192248682.57f463e2-787c-4fa4-b28f-7dd182664303","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419214307275.eba61dcd-4650-4da8-9575-320d898d30b1","resource":{"resourceType":"ServiceRequest","id":"1734644419214307275.eba61dcd-4650-4da8-9575-320d898d30b1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419209993763.17933554-8345-441e-9403-7a916a4caadf"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419200863030.2a170f5e-04be-42fe-a1ab-ab07d4d45141"}}},{"fullUrl":"Practitioner/1734644419200863030.2a170f5e-04be-42fe-a1ab-ab07d4d45141","resource":{"resourceType":"Practitioner","id":"1734644419200863030.2a170f5e-04be-42fe-a1ab-ab07d4d45141","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419209993763.17933554-8345-441e-9403-7a916a4caadf","resource":{"resourceType":"Practitioner","id":"1734644419209993763.17933554-8345-441e-9403-7a916a4caadf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419236010077.dcc879a6-c3bd-47d8-9277-50480021008a","resource":{"resourceType":"ServiceRequest","id":"1734644419236010077.dcc879a6-c3bd-47d8-9277-50480021008a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419232454907.27fc46cc-3b88-407e-bf66-661f07c65159"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419218072035.08fc9857-3110-4bae-a178-cff23aa4fa90"}}},{"fullUrl":"Practitioner/1734644419218072035.08fc9857-3110-4bae-a178-cff23aa4fa90","resource":{"resourceType":"Practitioner","id":"1734644419218072035.08fc9857-3110-4bae-a178-cff23aa4fa90","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419232454907.27fc46cc-3b88-407e-bf66-661f07c65159","resource":{"resourceType":"Practitioner","id":"1734644419232454907.27fc46cc-3b88-407e-bf66-661f07c65159","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419297425938.516e8411-9afc-4d82-baaa-cf4a2cf1f3e2","resource":{"resourceType":"ServiceRequest","id":"1734644419297425938.516e8411-9afc-4d82-baaa-cf4a2cf1f3e2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419293971265.6da609c6-c0a2-43f3-a716-24930d6c3032"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419239847553.40dd9e82-ca37-4eb6-9e76-aaeeeaf8f0ff"}}},{"fullUrl":"Practitioner/1734644419239847553.40dd9e82-ca37-4eb6-9e76-aaeeeaf8f0ff","resource":{"resourceType":"Practitioner","id":"1734644419239847553.40dd9e82-ca37-4eb6-9e76-aaeeeaf8f0ff","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419293971265.6da609c6-c0a2-43f3-a716-24930d6c3032","resource":{"resourceType":"Practitioner","id":"1734644419293971265.6da609c6-c0a2-43f3-a716-24930d6c3032","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419319444040.d2c90ef7-c39c-48df-a8da-5b20d47b2445","resource":{"resourceType":"ServiceRequest","id":"1734644419319444040.d2c90ef7-c39c-48df-a8da-5b20d47b2445","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419315137431.1c92b584-2007-4c30-b64d-29031112320c"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419300377554.6c6e9567-a437-4d8c-b933-6f1b492bc06c"}}},{"fullUrl":"Practitioner/1734644419300377554.6c6e9567-a437-4d8c-b933-6f1b492bc06c","resource":{"resourceType":"Practitioner","id":"1734644419300377554.6c6e9567-a437-4d8c-b933-6f1b492bc06c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419315137431.1c92b584-2007-4c30-b64d-29031112320c","resource":{"resourceType":"Practitioner","id":"1734644419315137431.1c92b584-2007-4c30-b64d-29031112320c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419397002211.7e391b3d-2aae-43d7-a194-b266d685c60d","resource":{"resourceType":"ServiceRequest","id":"1734644419397002211.7e391b3d-2aae-43d7-a194-b266d685c60d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419348815855.7a90971b-c4ce-4c6f-bbf5-df4bf1f27525"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419328854934.9a213bb4-2513-453f-84c5-56afaf2768db"}}},{"fullUrl":"Practitioner/1734644419328854934.9a213bb4-2513-453f-84c5-56afaf2768db","resource":{"resourceType":"Practitioner","id":"1734644419328854934.9a213bb4-2513-453f-84c5-56afaf2768db","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419348815855.7a90971b-c4ce-4c6f-bbf5-df4bf1f27525","resource":{"resourceType":"Practitioner","id":"1734644419348815855.7a90971b-c4ce-4c6f-bbf5-df4bf1f27525","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419428311530.830368f7-34ea-4a81-b244-8805301a8a24","resource":{"resourceType":"ServiceRequest","id":"1734644419428311530.830368f7-34ea-4a81-b244-8805301a8a24","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419419838329.eae91935-f10e-484c-acd3-a089a69847d2"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419404624524.be9930ba-d39b-4613-90ff-194c5a290444"}}},{"fullUrl":"Practitioner/1734644419404624524.be9930ba-d39b-4613-90ff-194c5a290444","resource":{"resourceType":"Practitioner","id":"1734644419404624524.be9930ba-d39b-4613-90ff-194c5a290444","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419419838329.eae91935-f10e-484c-acd3-a089a69847d2","resource":{"resourceType":"Practitioner","id":"1734644419419838329.eae91935-f10e-484c-acd3-a089a69847d2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419494699971.08d0d462-11e0-49e5-97db-bbf2f5eb9c77","resource":{"resourceType":"ServiceRequest","id":"1734644419494699971.08d0d462-11e0-49e5-97db-bbf2f5eb9c77","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419445886778.7a9b7231-688a-481f-81dd-af5e79193517"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419436121623.47ec8f29-acce-4bb6-a0fe-71d82296824e"}}},{"fullUrl":"Practitioner/1734644419436121623.47ec8f29-acce-4bb6-a0fe-71d82296824e","resource":{"resourceType":"Practitioner","id":"1734644419436121623.47ec8f29-acce-4bb6-a0fe-71d82296824e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419445886778.7a9b7231-688a-481f-81dd-af5e79193517","resource":{"resourceType":"Practitioner","id":"1734644419445886778.7a9b7231-688a-481f-81dd-af5e79193517","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419513149876.afd8e753-85d3-45f9-b513-be9a4884a9be","resource":{"resourceType":"ServiceRequest","id":"1734644419513149876.afd8e753-85d3-45f9-b513-be9a4884a9be","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419508608159.038de597-15b4-4785-8fc7-b310667fb884"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419498723113.588c969b-ec78-43fd-b794-8254b42a71b8"}}},{"fullUrl":"Practitioner/1734644419498723113.588c969b-ec78-43fd-b794-8254b42a71b8","resource":{"resourceType":"Practitioner","id":"1734644419498723113.588c969b-ec78-43fd-b794-8254b42a71b8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419508608159.038de597-15b4-4785-8fc7-b310667fb884","resource":{"resourceType":"Practitioner","id":"1734644419508608159.038de597-15b4-4785-8fc7-b310667fb884","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419535684737.834874ab-cb9d-461d-b6de-328154f3118d","resource":{"resourceType":"ServiceRequest","id":"1734644419535684737.834874ab-cb9d-461d-b6de-328154f3118d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419530139611.99f42ed3-e56d-4921-b847-9294ae1ce561"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419517125549.5a3e9f90-1995-42c0-bf9d-adfe50038397"}}},{"fullUrl":"Practitioner/1734644419517125549.5a3e9f90-1995-42c0-bf9d-adfe50038397","resource":{"resourceType":"Practitioner","id":"1734644419517125549.5a3e9f90-1995-42c0-bf9d-adfe50038397","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419530139611.99f42ed3-e56d-4921-b847-9294ae1ce561","resource":{"resourceType":"Practitioner","id":"1734644419530139611.99f42ed3-e56d-4921-b847-9294ae1ce561","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419600074256.d444d4a3-32d1-4567-9fcf-129cd26ac8ca","resource":{"resourceType":"ServiceRequest","id":"1734644419600074256.d444d4a3-32d1-4567-9fcf-129cd26ac8ca","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419560134414.3613b790-a3f7-48c0-ab5a-004a610b0587"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419542250352.3585e872-35c8-406b-8cb5-fd98299025c5"}}},{"fullUrl":"Practitioner/1734644419542250352.3585e872-35c8-406b-8cb5-fd98299025c5","resource":{"resourceType":"Practitioner","id":"1734644419542250352.3585e872-35c8-406b-8cb5-fd98299025c5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419560134414.3613b790-a3f7-48c0-ab5a-004a610b0587","resource":{"resourceType":"Practitioner","id":"1734644419560134414.3613b790-a3f7-48c0-ab5a-004a610b0587","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419638173568.57950b0c-8947-45ed-9d91-7d6c3fdb77ae","resource":{"resourceType":"ServiceRequest","id":"1734644419638173568.57950b0c-8947-45ed-9d91-7d6c3fdb77ae","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419631635975.d99bdb85-bb53-44ca-a267-7bfaff706f18"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419605493227.a0205aa2-0dbb-4d01-b730-fc5af202ffff"}}},{"fullUrl":"Practitioner/1734644419605493227.a0205aa2-0dbb-4d01-b730-fc5af202ffff","resource":{"resourceType":"Practitioner","id":"1734644419605493227.a0205aa2-0dbb-4d01-b730-fc5af202ffff","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419631635975.d99bdb85-bb53-44ca-a267-7bfaff706f18","resource":{"resourceType":"Practitioner","id":"1734644419631635975.d99bdb85-bb53-44ca-a267-7bfaff706f18","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"DiagnosticReport/1734644419692201133.2ad02aef-7ed6-4bc3-adce-9e824308af53","resource":{"resourceType":"DiagnosticReport","id":"1734644419692201133.2ad02aef-7ed6-4bc3-adce-9e824308af53","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644418806932054.3ea607c6-5dbb-4897-9078-d6595b5abb1c"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418620013889.578eeedf-2fac-4a73-b8e8-e2f399dd8080"}]}},{"fullUrl":"DiagnosticReport/1734644419699746133.2856d179-89ab-489a-b2c5-8a833fde050b","resource":{"resourceType":"DiagnosticReport","id":"1734644419699746133.2856d179-89ab-489a-b2c5-8a833fde050b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644418826177151.9467ba59-d656-4e97-b205-9216579c51da"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418623086931.a10f8b61-0456-42ac-93fb-71963e42e3af"}],"result":[{"reference":"Observation/1734644417796265313.e1027f5b-062f-4104-a7de-a437ae0c3842"},{"reference":"Observation/1734644417801791651.d1966e09-74fb-4baa-b4b0-40544e8c0c1d"},{"reference":"Observation/1734644417817280488.4709f99d-783d-45b7-9ff6-01b35715b870"},{"reference":"Observation/1734644417822834817.bcb381eb-be32-44ea-ae5a-d53d349a2a8e"},{"reference":"Observation/1734644417828340736.feb0b0a3-20f9-4dc8-ace3-1b1e85f11a91"},{"reference":"Observation/1734644417832150308.c320d4f8-9a39-4f05-9836-039b965e24ff"},{"reference":"Observation/1734644417835810822.88a720fe-d538-48d6-9794-0a3ed0ead41e"}]}},{"fullUrl":"DiagnosticReport/1734644419708101541.7f3385cd-e700-42c9-bf9f-f64c95825783","resource":{"resourceType":"DiagnosticReport","id":"1734644419708101541.7f3385cd-e700-42c9-bf9f-f64c95825783","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644418890800645.caa36224-9fba-4460-8812-f58e39a6ca08"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418625861998.068c0946-33c1-4698-b262-4e7424380350"}],"result":[{"reference":"Observation/1734644417839535536.85f9af6b-5ef2-4530-9974-6e21db509d5a"},{"reference":"Observation/1734644417843879005.412d9eb1-44e0-4b56-982b-0f2bad4203da"},{"reference":"Observation/1734644417847226896.1e8f8200-472d-409b-8f41-04c8ec4a81ef"},{"reference":"Observation/1734644417849620675.2859d891-5519-4f09-a6e2-20fa5cd90db1"},{"reference":"Observation/1734644417901619353.594eb9e5-afae-4e85-922f-198372d6c515"},{"reference":"Observation/1734644417905836296.262e3b31-827d-44c8-8c59-b7529737b23d"},{"reference":"Observation/1734644417910044573.c13ffa5d-6957-44eb-b015-f1201536e849"},{"reference":"Observation/1734644417913731055.ab8ae7df-d58e-4414-a546-e6c9fd583447"},{"reference":"Observation/1734644417917768954.50056553-e6ef-4dc4-b44e-3eb5654785ed"},{"reference":"Observation/1734644417921408098.bea1529d-7f6b-4881-82e8-cfc11f86fcb9"},{"reference":"Observation/1734644417926192001.558052e7-a20f-4082-b482-d15cc78f36db"}]}},{"fullUrl":"DiagnosticReport/1734644419713813197.ad7780f2-1e1a-400e-93d9-99840b8473f7","resource":{"resourceType":"DiagnosticReport","id":"1734644419713813197.ad7780f2-1e1a-400e-93d9-99840b8473f7","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644418918999562.efa015f9-2c73-449e-94b2-2d947e48c94a"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418628855693.4abd5487-e297-4db8-a03e-ad70e82ea7e0"}]}},{"fullUrl":"DiagnosticReport/1734644419724024842.1bdb9bcf-c477-47e5-9e0f-be76109a5cd8","resource":{"resourceType":"DiagnosticReport","id":"1734644419724024842.1bdb9bcf-c477-47e5-9e0f-be76109a5cd8","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644418936540454.e958080b-66d3-4128-8f49-77ebdf43e321"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418631682897.6a14062a-0df8-478b-80f6-a2818b88b0b2"}],"result":[{"reference":"Observation/1734644417934188839.9e003f64-2cd4-4ce8-b35d-c19ef12574a0"},{"reference":"Observation/1734644417940929624.cb81d9fd-a16b-4379-8940-516118aa6777"},{"reference":"Observation/1734644417945053774.0b37fbbe-851f-4b8d-ad0e-fa11edf1a52a"},{"reference":"Observation/1734644417948680715.cbea7c69-142e-4373-b0b1-90df672e6862"},{"reference":"Observation/1734644417995017914.8ab59c9f-02bf-48a8-bf3c-d8ea7ec96914"},{"reference":"Observation/1734644417999433067.13ba34a2-018a-4a84-8fe9-9e7ace7bcc87"},{"reference":"Observation/1734644418003515930.4796ac80-baa6-49b8-9771-3a7469ee2bb2"},{"reference":"Observation/1734644418008267091.02fa4769-70d2-4054-bc36-4f90b3120c6d"},{"reference":"Observation/1734644418012713502.2f78fefe-c6c8-4c8b-acc7-c1df8afeb156"},{"reference":"Observation/1734644418021388799.e22403f3-7063-4e1f-af4d-50186683a151"},{"reference":"Observation/1734644418026031315.75cd7314-4f23-4832-8d01-abf7aef0274d"},{"reference":"Observation/1734644418029829796.368ea25e-8c14-4c22-bbc7-3588ae105bbf"},{"reference":"Observation/1734644418033695132.917f591d-3498-4d01-80e7-873f7ffd7f95"},{"reference":"Observation/1734644418040086104.5505ce91-e769-41c0-873c-ef885b42d953"},{"reference":"Observation/1734644418044605051.f55b07d2-8020-4fbb-b2be-1b46e9a79c9d"},{"reference":"Observation/1734644418093990132.cc313c65-e85f-42a1-88ee-9814ad9e94ea"},{"reference":"Observation/1734644418098585802.cf01bcc2-5850-43e2-8eb9-a86c44a39080"},{"reference":"Observation/1734644418102931204.e5eda334-8162-4db0-9190-24d0fe3c672b"},{"reference":"Observation/1734644418107103955.74d90a40-ba93-4a8d-a75c-7b9c59ccf5f4"}]}},{"fullUrl":"DiagnosticReport/1734644419729907926.637687d5-f285-4d85-8250-cdb314373590","resource":{"resourceType":"DiagnosticReport","id":"1734644419729907926.637687d5-f285-4d85-8250-cdb314373590","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644418997080895.b86d66d5-a480-4ddb-a6cd-5a2926d5df16"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418634469316.8d4cdaf4-1d61-48a9-8208-ab69319553bf"}],"result":[{"reference":"Observation/1734644418111524768.93fe9a7e-4aa3-4caa-9089-55680c2d733a"},{"reference":"Observation/1734644418115768261.bee34a03-fcca-4734-9362-e100f2d283d3"}]}},{"fullUrl":"DiagnosticReport/1734644419743254406.7d857b02-136c-4d65-9fbc-3e6e6e2fa2ba","resource":{"resourceType":"DiagnosticReport","id":"1734644419743254406.7d857b02-136c-4d65-9fbc-3e6e6e2fa2ba","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419013462108.def28f11-ee1e-40ad-97f4-d4b12ce71c7b"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418637227352.d3880a49-7276-46f6-b4a6-c2275c7e258a"}],"result":[{"reference":"Observation/1734644418119703177.721be05d-2352-4e12-b098-5abf93c94476"},{"reference":"Observation/1734644418123703845.f6f91fa7-f88a-4b8c-a2f5-3393be2541fb"},{"reference":"Observation/1734644418127929775.83fdc8dd-09f2-48d2-a3c6-d3ed0b9d2e8a"},{"reference":"Observation/1734644418132508163.f290c980-f194-41af-b4cf-96dbe04d1922"},{"reference":"Observation/1734644418136460852.49698eb0-f1bb-49da-a2c9-15aa906f5ab7"},{"reference":"Observation/1734644418140546971.d1ec4a52-6d49-4afa-b000-46992ea08cca"},{"reference":"Observation/1734644418144386619.7e5499dd-ad54-4277-81e4-e0d87915ed35"},{"reference":"Observation/1734644418148488928.7ba1d26d-aebe-4485-bceb-6b2d8e2dd188"},{"reference":"Observation/1734644418191368502.288fd0c2-03af-4187-85b8-ab768fa53a09"},{"reference":"Observation/1734644418196156441.744c7d3a-5d71-4e9a-81c3-c8dc52d50f4d"},{"reference":"Observation/1734644418199881245.c30f9674-dc49-4092-a2e8-91af248d5f7a"},{"reference":"Observation/1734644418203506753.3bab0f68-99a9-49bf-bfb1-aeb3c9c77ec7"},{"reference":"Observation/1734644418207148533.cfc80263-3390-43a3-871a-d1a2ae645258"},{"reference":"Observation/1734644418210779091.028a38d8-7995-4c1d-9b88-eaaa5ba7c96e"},{"reference":"Observation/1734644418213596932.7f4c433c-ee26-44a9-8455-2769977faf77"},{"reference":"Observation/1734644418216350292.40cd4740-470e-4f15-8981-2329f67c1c94"},{"reference":"Observation/1734644418218653241.149832b5-0f86-47ed-bb76-05ce5ca9aab0"},{"reference":"Observation/1734644418221583851.593fe756-7b65-4bbd-92db-582d5e5afbc2"},{"reference":"Observation/1734644418225384797.3e7f8946-d817-4a06-9a98-7b737600509e"},{"reference":"Observation/1734644418229985066.d45b748c-ce86-4727-b2b4-f129aa596d8e"},{"reference":"Observation/1734644418234159048.af1803d4-bf00-473c-83f5-615b44d3edce"},{"reference":"Observation/1734644418238266898.2ce39b9d-24ba-4d82-bb08-dadf2f95d23e"},{"reference":"Observation/1734644418242142654.4f2ffedd-052e-4a97-a19a-54dae982f8f2"},{"reference":"Observation/1734644418245893376.05943385-5946-4586-8cf0-1d7d13a692da"},{"reference":"Observation/1734644418249640091.14f79a31-0c80-46ef-89f5-40709968d8d2"},{"reference":"Observation/1734644418253450154.8d0b683a-d872-4129-bfb6-c321e28bfa6c"}]}},{"fullUrl":"DiagnosticReport/1734644419753320971.b9e3b94b-0e80-437c-94b5-a77d995ce0d2","resource":{"resourceType":"DiagnosticReport","id":"1734644419753320971.b9e3b94b-0e80-437c-94b5-a77d995ce0d2","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419029952304.7fe5e75c-e5bb-41eb-8e81-f82605fbac0c"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418640004242.4c4fbcdf-9bb7-42c3-a7fd-b23a6bf81c6d"}],"result":[{"reference":"Observation/1734644418293578752.14a30ea3-9496-4275-9041-0d4f226b3e10"},{"reference":"Observation/1734644418297352457.ca225056-4647-42f7-9d82-8666c248bfd3"},{"reference":"Observation/1734644418301167169.dc0d0885-fbbe-42a9-8f4f-c4039fd42832"},{"reference":"Observation/1734644418304937408.28c2882f-3e75-415d-aad7-a1ee08e419f3"},{"reference":"Observation/1734644418308939570.1de34fdf-fdd0-4874-be02-304d3373d9ff"},{"reference":"Observation/1734644418312767997.dfb7ee39-8914-431d-afc1-00f585bb57fd"},{"reference":"Observation/1734644418316602957.c6889d3f-c145-45ea-8205-8649bff1e55c"},{"reference":"Observation/1734644418320444569.2adf1156-3d36-431c-bc8b-28338e20e858"},{"reference":"Observation/1734644418326047982.ba4822cb-d64b-4acf-958e-6b9c8db6d3d4"},{"reference":"Observation/1734644418330183463.5d0101f7-90b2-4eee-9a2e-47386c89b7a0"}]}},{"fullUrl":"DiagnosticReport/1734644419795641896.8702cee9-f54e-498e-a150-2f00ad76356c","resource":{"resourceType":"DiagnosticReport","id":"1734644419795641896.8702cee9-f54e-498e-a150-2f00ad76356c","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419045997111.32514986-73aa-40b5-8546-d18abe8434bf"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418642858898.e93b7cc7-d555-4fdb-ad7c-60fd187217ab"}],"result":[{"reference":"Observation/1734644418333982285.fcc21c8a-6157-427e-b6f8-62fefe57d81a"},{"reference":"Observation/1734644418337729531.0f74bef2-2ae5-4599-b4ba-6a4adc56d5ff"},{"reference":"Observation/1734644418340904849.5e94cf89-bdd1-467d-a1c6-82f3582339b8"}]}},{"fullUrl":"DiagnosticReport/1734644419801980108.5b9208e0-8d9c-45c8-bd50-885179dadb43","resource":{"resourceType":"DiagnosticReport","id":"1734644419801980108.5b9208e0-8d9c-45c8-bd50-885179dadb43","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419106349552.888dd644-2c77-43d1-bf1f-9c4f3f7e4e5e"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418645609720.a2aeb8f8-c2d0-4c45-8524-369c698ab7e9"}],"result":[{"reference":"Observation/1734644418344428438.9c359bf0-d4f2-4239-b942-6f4cd91861bb"},{"reference":"Observation/1734644418348157459.988552ff-1822-44f3-86a8-dc7e3e817126"},{"reference":"Observation/1734644418351257387.1c0d6804-ff3d-4450-857f-e4fc186532ac"}]}},{"fullUrl":"DiagnosticReport/1734644419808292983.dff75e1f-d5d1-47f5-bd35-5bd07b7f84af","resource":{"resourceType":"DiagnosticReport","id":"1734644419808292983.dff75e1f-d5d1-47f5-bd35-5bd07b7f84af","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419137536515.cc0e7644-2a4c-40af-9d57-d3e537d728e3"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418692924444.2362eec6-8892-4e80-b9a5-92159ca55d7a"}],"result":[{"reference":"Observation/1734644418354740069.f2d1242a-d7ef-4e64-969f-8bd8197ad869"},{"reference":"Observation/1734644418358362071.2488ad7b-566c-4537-9135-55507da8d836"},{"reference":"Observation/1734644418361380556.25749106-cfb2-4331-9185-dfd0950ef84f"}]}},{"fullUrl":"DiagnosticReport/1734644419815428530.5f90805a-95cf-46d6-b09c-621a5a04ea2d","resource":{"resourceType":"DiagnosticReport","id":"1734644419815428530.5f90805a-95cf-46d6-b09c-621a5a04ea2d","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419197079535.cfe1ac19-cb37-4ecf-9fbd-d53dbdddc459"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418697846760.72e82496-50e8-48d9-ab40-7aad8ef84ebc"}],"result":[{"reference":"Observation/1734644418393365701.2a730407-04f1-4256-b77c-eb0b3f0a998e"},{"reference":"Observation/1734644418397214977.1ce1b2dd-c08c-4ec5-80e2-e8a755828a4d"},{"reference":"Observation/1734644418400448865.1b9837e7-ea8a-4660-a819-d7676389342f"}]}},{"fullUrl":"DiagnosticReport/1734644419824626319.2533508b-b790-45d2-ac8d-300eb7132397","resource":{"resourceType":"DiagnosticReport","id":"1734644419824626319.2533508b-b790-45d2-ac8d-300eb7132397","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419214307275.eba61dcd-4650-4da8-9575-320d898d30b1"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418700728436.ebc0946d-66c6-4188-a3fb-3c81fb392782"}],"result":[{"reference":"Observation/1734644418404113797.7610a136-ea9b-4e83-adc2-f7ff013917f0"},{"reference":"Observation/1734644418407114199.402af6e9-5586-4d2a-a454-631b42f198aa"}]}},{"fullUrl":"DiagnosticReport/1734644419834916739.fc89b70e-a2b9-4e36-b5d6-8e2a97559cbb","resource":{"resourceType":"DiagnosticReport","id":"1734644419834916739.fc89b70e-a2b9-4e36-b5d6-8e2a97559cbb","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419236010077.dcc879a6-c3bd-47d8-9277-50480021008a"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418703664102.7fc22a83-8356-4ab2-9428-7e35ea9e9d86"}],"result":[{"reference":"Observation/1734644418410319112.d5601183-0925-4034-8c0c-9093786f4eaf"},{"reference":"Observation/1734644418414140146.2afa3160-ba41-4195-bbfc-3a52ed753110"},{"reference":"Observation/1734644418417337565.c54cbd66-59e0-42ab-b1cf-9951adef0da2"}]}},{"fullUrl":"DiagnosticReport/1734644419844156113.7e989ddd-0edc-4a05-8396-c9fdb47c50fa","resource":{"resourceType":"DiagnosticReport","id":"1734644419844156113.7e989ddd-0edc-4a05-8396-c9fdb47c50fa","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419297425938.516e8411-9afc-4d82-baaa-cf4a2cf1f3e2"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418706669478.8228a2e2-0c7e-498c-a308-7a3f71673738"}],"result":[{"reference":"Observation/1734644418421163518.e6b7164c-753b-47dc-a9fa-5f4f42d2e3b4"},{"reference":"Observation/1734644418424925822.56a4ebf0-c340-44d8-b9c2-9f6c84adfc83"},{"reference":"Observation/1734644418428008677.d1c355fd-aa64-4f6f-83ed-facf1540b17f"}]}},{"fullUrl":"DiagnosticReport/1734644419853217247.ff790c55-8249-4b13-a6bd-9759c12d684e","resource":{"resourceType":"DiagnosticReport","id":"1734644419853217247.ff790c55-8249-4b13-a6bd-9759c12d684e","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419319444040.d2c90ef7-c39c-48df-a8da-5b20d47b2445"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418709452811.2b287078-a334-49ad-b97f-3acecf74cf69"}],"result":[{"reference":"Observation/1734644418431524932.c31b6c3b-c057-4ce7-b829-ebfc3b80d4d2"},{"reference":"Observation/1734644418435131746.67b40486-a401-4f82-8575-dd4b8c30a0f0"},{"reference":"Observation/1734644418438178153.78db2e15-e743-43b1-80bb-db636e6de3c5"}]}},{"fullUrl":"DiagnosticReport/1734644419891605519.7daa771e-1756-4760-9382-68cd500982d7","resource":{"resourceType":"DiagnosticReport","id":"1734644419891605519.7daa771e-1756-4760-9382-68cd500982d7","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419397002211.7e391b3d-2aae-43d7-a194-b266d685c60d"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418713689710.c3c889e5-e87f-4c32-bf89-1cd1441c6b1e"}],"result":[{"reference":"Observation/1734644418441661076.c9805208-4a21-4978-9655-a19ad765ec84"},{"reference":"Observation/1734644418448447536.bee743ae-abb4-4b2e-b85d-2570afb8be3f"},{"reference":"Observation/1734644418493996336.22471e9e-7dfc-469f-bcea-a38b92726aa9"}]}},{"fullUrl":"DiagnosticReport/1734644419895767159.f14226b8-44f4-40bf-a324-7a7a8016dee0","resource":{"resourceType":"DiagnosticReport","id":"1734644419895767159.f14226b8-44f4-40bf-a324-7a7a8016dee0","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419428311530.830368f7-34ea-4a81-b244-8805301a8a24"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418716488452.b532b0c6-066b-4835-a0cb-73fa3d91c5a3"}],"result":[{"reference":"Observation/1734644418498838813.52242f5f-fbf3-4a2a-b760-989a9c456d6e"},{"reference":"Observation/1734644418502456380.093781b0-cfed-4ae7-a908-4f436a995c79"}]}},{"fullUrl":"DiagnosticReport/1734644419902517717.17c0b4a4-255c-43f9-be8f-703d9070208b","resource":{"resourceType":"DiagnosticReport","id":"1734644419902517717.17c0b4a4-255c-43f9-be8f-703d9070208b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419494699971.08d0d462-11e0-49e5-97db-bbf2f5eb9c77"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418720058990.326688c9-38c2-47c9-b11b-f09becbe0353"}],"result":[{"reference":"Observation/1734644418506522742.50a3e79d-3451-4210-8959-d95579c2a5f9"},{"reference":"Observation/1734644418510765923.b268b63d-6738-4acc-a52c-1f93cc540c6d"},{"reference":"Observation/1734644418514265800.fb13696e-d60b-4387-ab7d-5e390c6785f8"}]}},{"fullUrl":"DiagnosticReport/1734644419909213707.7cfdaa0f-a324-4518-ab6f-5c948abbdc9e","resource":{"resourceType":"DiagnosticReport","id":"1734644419909213707.7cfdaa0f-a324-4518-ab6f-5c948abbdc9e","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419513149876.afd8e753-85d3-45f9-b513-be9a4884a9be"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418722906983.caa6ec68-8fe7-4db7-a48a-fe3ae2803810"}],"result":[{"reference":"Observation/1734644418523112493.124c6ef4-414a-4c05-ac23-ce4a55fa0d36"},{"reference":"Observation/1734644418526909052.d1f48023-23d5-4ba4-aa24-8cbc40397c14"}]}},{"fullUrl":"DiagnosticReport/1734644419915028414.66b10e65-9fb1-4019-a18d-72882f136896","resource":{"resourceType":"DiagnosticReport","id":"1734644419915028414.66b10e65-9fb1-4019-a18d-72882f136896","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419535684737.834874ab-cb9d-461d-b6de-328154f3118d"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418725664248.3b13f6ec-0467-45ef-a3b9-224ea8059b9a"}],"result":[{"reference":"Observation/1734644418530955497.84aa3c0e-67f7-4b13-b789-ab6f0feafdb6"},{"reference":"Observation/1734644418534982045.9a9f7f72-97b4-4c19-872f-20f2394874e0"},{"reference":"Observation/1734644418538478716.748366b9-a826-4acf-a52d-d851375becbc"}]}},{"fullUrl":"DiagnosticReport/1734644419920406329.ce421d8f-a0f0-4635-b581-927247c9fe9f","resource":{"resourceType":"DiagnosticReport","id":"1734644419920406329.ce421d8f-a0f0-4635-b581-927247c9fe9f","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419600074256.d444d4a3-32d1-4567-9fcf-129cd26ac8ca"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418728439666.e23f8e93-1f86-42b3-956d-952e01b4d8a8"}],"result":[{"reference":"Observation/1734644418542644844.703dd0ec-0ac3-4d6a-8b48-a876529184f2"},{"reference":"Observation/1734644418546025989.a78bf05f-9bbd-4182-a893-c88b2a757930"}]}},{"fullUrl":"DiagnosticReport/1734644419925358861.4ed59a37-bfc4-4deb-8e1e-feb8b7980f00","resource":{"resourceType":"DiagnosticReport","id":"1734644419925358861.4ed59a37-bfc4-4deb-8e1e-feb8b7980f00","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419638173568.57950b0c-8947-45ed-9d91-7d6c3fdb77ae"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418731522697.fcb6d558-720e-4d6f-9a85-25ea41a92f68"}],"result":[{"reference":"Observation/1734644418594486407.d26e1831-e4a9-4eed-a2e3-9e160856d54c"}]}}]}

From 1f0dde268d1590276489a9f8033ea68b7051937c Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 15:01:00 -0700
Subject: [PATCH 28/61] remove comment, add quotes to variable, and create
 workflow file

Co-authored-by: James Herr <jherr@flexion.us>
---
 .github/workflows/automated-staging-test-run.yml                | 2 +-
 .github/workflows/golden-copy-staging-test-submit.yml           | 0
 .../gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy | 1 -
 3 files changed, 1 insertion(+), 2 deletions(-)
 create mode 100644 .github/workflows/golden-copy-staging-test-submit.yml

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index f28a27d79..6b52e5300 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -28,7 +28,7 @@ jobs:
           file_path=../examples/Test/Automated/
           if [ "${{ github.event.inputs.name }}" == "Golden Copy Staging Test" ]; then
             test_type=goldenCopyTest
-            title=Golden Copy
+            title="Golden Copy"
             file_path=../examples/Test/GoldenCopy/Expected/
           fi
           echo "test_type=$test_type" >> $GITHUB_OUTPUT
diff --git a/.github/workflows/golden-copy-staging-test-submit.yml b/.github/workflows/golden-copy-staging-test-submit.yml
new file mode 100644
index 000000000..e69de29bb
diff --git a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
index 678379ec4..f54c664c0 100644
--- a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
+++ b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/GoldenCopyTest.groovy
@@ -55,7 +55,6 @@ class GoldenCopyTest extends Specification {
 
     def "Compare files"() {
         // Currently reusing automated staging test workflows but we might need to pivot for cron schedule
-        // Get golden copy for 006
 
         given:
         def matchedFiles = fileMatcher.matchFiles(azureFiles, localFiles)

From d7623aeac3954594c0a74e8ff7d76063912ddf0d Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 15:04:12 -0700
Subject: [PATCH 29/61] remove done

Co-authored-by: James Herr <jherr@flexion.us>
---
 .github/workflows/automated-staging-test-run.yml | 1 -
 1 file changed, 1 deletion(-)

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index 6b52e5300..0555b6ec0 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -34,7 +34,6 @@ jobs:
           echo "test_type=$test_type" >> $GITHUB_OUTPUT
           echo "title=$title" >> $GITHUB_OUTPUT
           echo "file_path=$file_path" >> $GITHUB_OUTPUT
-          done
 
       - name: Run automated tests
         env:

From 92c039c5fa4cf9bcb2b33fc05c885d74cc7900ed Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 15:05:15 -0700
Subject: [PATCH 30/61] remove unused workflow

Co-authored-by: James Herr <jherr@flexion.us>
---
 .github/workflows/golden-copy-staging-test-submit.yml | 0
 1 file changed, 0 insertions(+), 0 deletions(-)
 delete mode 100644 .github/workflows/golden-copy-staging-test-submit.yml

diff --git a/.github/workflows/golden-copy-staging-test-submit.yml b/.github/workflows/golden-copy-staging-test-submit.yml
deleted file mode 100644
index e69de29bb..000000000

From f29edc1e9f2748ac52702d829cf7966a88a9c8a0 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 15:12:40 -0700
Subject: [PATCH 31/61] add id to workflow step

Co-authored-by: James Herr <jherr@flexion.us>
---
 .github/workflows/automated-staging-test-run.yml | 7 ++++---
 1 file changed, 4 insertions(+), 3 deletions(-)

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index 0555b6ec0..e75ecf99e 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -34,13 +34,14 @@ jobs:
           echo "test_type=$test_type" >> $GITHUB_OUTPUT
           echo "title=$title" >> $GITHUB_OUTPUT
           echo "file_path=$file_path" >> $GITHUB_OUTPUT
+        id: getVariableType
 
       - name: Run automated tests
         env:
           AZURE_STORAGE_CONNECTION_STRING: ${{ secrets.AUTOMATED_TEST_AZURE_STORAGE_CONNECTION_STRING }}
-          LOCAL_FILE_PATH: ${{ steps.getFunctionList.outputs.file_path }}
+          LOCAL_FILE_PATH: ${{ steps.getVariableType.outputs.file_path }}
         run: |
-          ./gradlew rs-e2e:clean rs-e2e:${{ steps.getFunctionList.outputs.test_type }}
+          ./gradlew rs-e2e:clean rs-e2e:${{ steps.getVariableType.outputs.test_type }}
           done
 
       - name: Send slack notification on test failure
@@ -50,4 +51,4 @@ jobs:
           webhook: ${{ secrets.SLACK_WEBHOOK_URL }}
           webhook-type: incoming-webhook
           payload: |
-            text: "${{ steps.getFunctionList.outputs.title }} Staging RS Integration Test Failed!: https://github.com/CDCgov/trusted-intermediary/actions/runs/${{ github.run_id }}"
+            text: "${{ steps.getVariableType.outputs.title }} Staging RS Integration Test Failed!: https://github.com/CDCgov/trusted-intermediary/actions/runs/${{ github.run_id }}"

From 5b648b77b5da9f2ee270a8611cf6a6b8ce37b1ee Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 16:14:30 -0700
Subject: [PATCH 32/61] separate workflows and update readme

---
 .../workflows/automated-staging-test-run.yml  | 49 ++------------
 .../automated-staging-test-submit.yml         | 67 ++-----------------
 .../golden-copy-staging-test-run.yml          | 17 +++++
 .../golden-copy-staging-test-submit.yml       | 16 +++++
 .../workflows/staging-test-run-reusable.yml   | 42 ++++++++++++
 .../staging-test-submit-reusable.yml          | 64 ++++++++++++++++++
 examples/Test/GoldenCopy/README.md            |  4 +-
 7 files changed, 151 insertions(+), 108 deletions(-)
 create mode 100644 .github/workflows/golden-copy-staging-test-run.yml
 create mode 100644 .github/workflows/golden-copy-staging-test-submit.yml
 create mode 100644 .github/workflows/staging-test-run-reusable.yml
 create mode 100644 .github/workflows/staging-test-submit-reusable.yml

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index e75ecf99e..3cef43b98 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -3,52 +3,15 @@ name: Automated Staging Test - Run integration tests
 on:
   schedule:
     - cron: "0 7 * * 2-6"  # Tuesday to Saturday at 2am EST (7am UTC) - two hours after `automated-staging-test-submit` runs
-  workflow_dispatch:
-    inputs:
-      name:
-        type: choice
-        description: Type of Staging Test
-        default: Automated Staging Test
-        options:
-          - Automated Staging Test
-          - Golden Copy Staging Test
 
 jobs:
-  test_files:
+  send_files:
     runs-on: ubuntu-latest
 
     steps:
-      - name: Check out the repository
-        uses: actions/checkout@v4
-
-      - name: Determine variable type
-        run: |
-          test_type=automatedTest
-          title=Automated
-          file_path=../examples/Test/Automated/
-          if [ "${{ github.event.inputs.name }}" == "Golden Copy Staging Test" ]; then
-            test_type=goldenCopyTest
-            title="Golden Copy"
-            file_path=../examples/Test/GoldenCopy/Expected/
-          fi
-          echo "test_type=$test_type" >> $GITHUB_OUTPUT
-          echo "title=$title" >> $GITHUB_OUTPUT
-          echo "file_path=$file_path" >> $GITHUB_OUTPUT
-        id: getVariableType
-
-      - name: Run automated tests
-        env:
-          AZURE_STORAGE_CONNECTION_STRING: ${{ secrets.AUTOMATED_TEST_AZURE_STORAGE_CONNECTION_STRING }}
-          LOCAL_FILE_PATH: ${{ steps.getVariableType.outputs.file_path }}
-        run: |
-          ./gradlew rs-e2e:clean rs-e2e:${{ steps.getVariableType.outputs.test_type }}
-          done
-
-      - name: Send slack notification on test failure
-        if: failure()
-        uses: slackapi/slack-github-action@v2.0.0
+      - name: Call staging-test-run.yml
+        uses: .github/workflows/staging-test-run-reusable.yml
         with:
-          webhook: ${{ secrets.SLACK_WEBHOOK_URL }}
-          webhook-type: incoming-webhook
-          payload: |
-            text: "${{ steps.getVariableType.outputs.title }} Staging RS Integration Test Failed!: https://github.com/CDCgov/trusted-intermediary/actions/runs/${{ github.run_id }}"
+          FILE_PATH: '../examples/Test/Automated/'
+          NAME: 'Automated'
+          TEST_TYPE: 'automatedTest'
diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
index 594c5aa28..278d01807 100644
--- a/.github/workflows/automated-staging-test-submit.yml
+++ b/.github/workflows/automated-staging-test-submit.yml
@@ -3,72 +3,13 @@ name: Automated Staging Test - Submit Messages
 on:
   schedule:
     - cron: "0 5 * * 2-6"  # Tuesday to Saturday at Midnight EST (5am UTC)
-  workflow_dispatch:
-    inputs:
-      name:
-        type: choice
-        description: Type of Staging Test
-        default: Automated Staging Test
-        options:
-          - Automated Staging Test
-          - Golden Copy Staging Test
 
 jobs:
   send_files:
     runs-on: ubuntu-latest
 
     steps:
-      - name: Check out the repository
-        uses: actions/checkout@v4
-
-      - name: Install jq
-        run: sudo apt-get install -y jq
-
-      - name: Install jwt-cli
-        run: |
-            curl --silent --location https://github.com/mike-engel/jwt-cli/releases/latest/download/jwt-linux.tar.gz | tar xvz -C /usr/local/bin/
-            sudo chmod +x /usr/local/bin/jwt
-
-      - name: Write private key to file
-        run: |
-          echo "${{ secrets.SIMULATED_SENDER_STAGING_PRIVATE_KEY }}" > /tmp/staging_private_key.pem
-          chmod 600 /tmp/staging_private_key.pem
-
-      - name: Send HL7 sample messages to staging RS
-        run: |
-          host=https://staging.prime.cdc.gov:443
-          client_id=flexion
-          client_sender=simulated-sender
-          jwt=$(jwt encode --exp='+5min' --jti $(uuidgen) --alg RS256 \
-              -k $client_id.$client_sender -i $client_id.$client_sender \
-              -s $client_id.$client_sender -a $host --no-iat -S @/tmp/staging_private_key.pem)
-
-          token=$(curl \
-                  --header "Content-Type: application/x-www-form-urlencoded" \
-                  --data "scope=$client_id.*.report" \
-                  --data "client_assertion=$jwt" \
-                  --data "client_assertion_type=urn:ietf:params:oauth:client-assertion-type:jwt-bearer" \
-                  --data "grant_type=client_credentials" \
-                  --silent \
-                  "$host/api/token" | jq -r ".access_token")
-
-          file_path=Automated/*.hl7
-          if [ "${{ github.event.inputs.name }}" == "Golden Copy Staging Test" ]; then
-              file_path=GoldenCopy/Input/*.hl7
-          fi
-
-          for file in $(pwd)/examples/Test/$file_path; do
-              echo "Sending $file"
-              curl \
-                  --header "Content-Type: application/hl7-v2" \
-                  --header "Client: $client_id.$client_sender" \
-                  --header "Authorization: Bearer $token" \
-                  --data-binary "@$file" \
-                  --silent \
-                  "$host/api/waters"
-          done
-
-      - name: Clean up private key
-        if: always()
-        run: |
-          rm -f /tmp/staging_private_key.pem
+      - name: Call staging-test-submit.yml
+        uses: .github/workflows/staging-test-submit-reusable.yml
+        with:
+          FILE_PATH: 'Automated/*.hl7'
diff --git a/.github/workflows/golden-copy-staging-test-run.yml b/.github/workflows/golden-copy-staging-test-run.yml
new file mode 100644
index 000000000..14ff1dae6
--- /dev/null
+++ b/.github/workflows/golden-copy-staging-test-run.yml
@@ -0,0 +1,17 @@
+name: Golden Copy Staging Test - Run integration tests
+
+on:
+  schedule:
+    - cron: "0 7 * * 2-6"  # Tuesday to Saturday at 2am EST (7am UTC) - two hours after `automated-staging-test-submit` runs
+
+jobs:
+  send_files:
+    runs-on: ubuntu-latest
+
+    steps:
+      - name: Call staging-test-run.yml
+        uses: .github/workflows/staging-test-run-reusable.yml
+        with:
+          FILE_PATH: '../examples/Test/GoldenCopy/Expected/'
+          NAME: 'Golden Copy'
+          TEST_TYPE: 'goldenCopyTest'
diff --git a/.github/workflows/golden-copy-staging-test-submit.yml b/.github/workflows/golden-copy-staging-test-submit.yml
new file mode 100644
index 000000000..fddc8e11f
--- /dev/null
+++ b/.github/workflows/golden-copy-staging-test-submit.yml
@@ -0,0 +1,16 @@
+name: Golden Copy Staging Test - Submit Messages
+
+on:
+  schedule:
+    - cron: "0 5 * * 2-6"
+  workflow_dispatch:
+
+jobs:
+  send_files:
+    runs-on: ubuntu-latest
+
+    steps:
+      - name: Call staging-test-submit.yml
+        uses: .github/workflows/staging-test-submit-reusable.yml
+        with:
+          FILE_PATH: 'GoldenCopy/Input/*.hl7'
diff --git a/.github/workflows/staging-test-run-reusable.yml b/.github/workflows/staging-test-run-reusable.yml
new file mode 100644
index 000000000..e12a31404
--- /dev/null
+++ b/.github/workflows/staging-test-run-reusable.yml
@@ -0,0 +1,42 @@
+name: Staging Test - Run integration tests
+
+on:
+  workflow_call:
+    inputs:
+      TEST_TYPE:
+        type: string
+        description: The e2e test to run
+        required: true
+      NAME:
+        type: string
+        description: The name of test
+        required: true
+      FILE_PATH:
+        type: string
+        description: The path to local files
+        required: true
+
+jobs:
+  test_files:
+    runs-on: ubuntu-latest
+
+    steps:
+      - name: Check out the repository
+        uses: actions/checkout@v4
+
+      - name: Run automated tests
+        env:
+          AZURE_STORAGE_CONNECTION_STRING: ${{ secrets.AUTOMATED_TEST_AZURE_STORAGE_CONNECTION_STRING }}
+          LOCAL_FILE_PATH: ${{ github.event.inputs.FILE_PATH }}
+        run: |
+          ./gradlew rs-e2e:clean rs-e2e:${{ github.event.inputs.TEST_TYPE }}
+          done
+
+      - name: Send slack notification on test failure
+        if: failure()
+        uses: slackapi/slack-github-action@v2.0.0
+        with:
+          webhook: ${{ secrets.SLACK_WEBHOOK_URL }}
+          webhook-type: incoming-webhook
+          payload: |
+            text: "${{ github.event.inputs.NAME }} Staging RS Integration Test Failed!: https://github.com/CDCgov/trusted-intermediary/actions/runs/${{ github.run_id }}"
diff --git a/.github/workflows/staging-test-submit-reusable.yml b/.github/workflows/staging-test-submit-reusable.yml
new file mode 100644
index 000000000..6d1736743
--- /dev/null
+++ b/.github/workflows/staging-test-submit-reusable.yml
@@ -0,0 +1,64 @@
+name: Staging Test - Submit Messages
+
+on:
+  workflow_call:
+    inputs:
+      FILE_PATH:
+        required: true
+        type: string
+        description: File path location to submit
+
+jobs:
+  send_files:
+    runs-on: ubuntu-latest
+
+    steps:
+      - name: Check out the repository
+        uses: actions/checkout@v4
+
+      - name: Install jq
+        run: sudo apt-get install -y jq
+
+      - name: Install jwt-cli
+        run: |
+            curl --silent --location https://github.com/mike-engel/jwt-cli/releases/latest/download/jwt-linux.tar.gz | tar xvz -C /usr/local/bin/
+            sudo chmod +x /usr/local/bin/jwt
+
+      - name: Write private key to file
+        run: |
+          echo "${{ secrets.SIMULATED_SENDER_STAGING_PRIVATE_KEY }}" > /tmp/staging_private_key.pem
+          chmod 600 /tmp/staging_private_key.pem
+
+      - name: Send HL7 sample messages to staging RS
+        run: |
+          host=https://staging.prime.cdc.gov:443
+          client_id=flexion
+          client_sender=simulated-sender
+          jwt=$(jwt encode --exp='+5min' --jti $(uuidgen) --alg RS256 \
+              -k $client_id.$client_sender -i $client_id.$client_sender \
+              -s $client_id.$client_sender -a $host --no-iat -S @/tmp/staging_private_key.pem)
+
+          token=$(curl \
+                  --header "Content-Type: application/x-www-form-urlencoded" \
+                  --data "scope=$client_id.*.report" \
+                  --data "client_assertion=$jwt" \
+                  --data "client_assertion_type=urn:ietf:params:oauth:client-assertion-type:jwt-bearer" \
+                  --data "grant_type=client_credentials" \
+                  --silent \
+                  "$host/api/token" | jq -r ".access_token")
+
+          for file in $(pwd)/examples/Test/${{ github.event.inputs.FILE_PATH }}; do
+              echo "Sending $file"
+              curl \
+                  --header "Content-Type: application/hl7-v2" \
+                  --header "Client: $client_id.$client_sender" \
+                  --header "Authorization: Bearer $token" \
+                  --data-binary "@$file" \
+                  --silent \
+                  "$host/api/waters"
+          done
+
+      - name: Clean up private key
+        if: always()
+        run: |
+          rm -f /tmp/staging_private_key.pem
diff --git a/examples/Test/GoldenCopy/README.md b/examples/Test/GoldenCopy/README.md
index 169f15e99..fa012933e 100644
--- a/examples/Test/GoldenCopy/README.md
+++ b/examples/Test/GoldenCopy/README.md
@@ -1,9 +1,9 @@
 This folder contains the HL7 sample files that are used in the Golden Copy ReportStream
-integration tests. The [automated-staging-test-submit.yml](/.github/workflows/automated-staging-test-submit.yml)
+integration tests. The [golden-copy-staging-test-submit.yml](/.github/workflows/golden-copy-staging-test-submit.yml)
 Github workflow that runs daily will grab these files and send them to ReportStream in staging.
 The files are expected to go through the whole flow and to be delivered to an Azure blob
 container that will later be used by the
-[automated-staging-test-run.yml](/.github/workflows/automated-staging-test-run.yml) workflow to run tests on them by comparing the golden copy to the actual output.
+[golden-copy-staging-test-run.yml](/.github/workflows/golden-copy-staging-test-run.yml) workflow to run tests on them by comparing the golden copy to the actual output.
 
 ## Requirements for the HL7 files
 

From 7b545da348462f059576ae663e812d73115dd874 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Thu, 19 Dec 2024 17:34:11 -0700
Subject: [PATCH 33/61] add notes on next steps

---
 .../trustedintermediary/rse2e/AzureBlobOrganizer.java    | 9 ++++++++-
 1 file changed, 8 insertions(+), 1 deletion(-)

diff --git a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobOrganizer.java b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobOrganizer.java
index 4f61997e0..3a7345216 100644
--- a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobOrganizer.java
+++ b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobOrganizer.java
@@ -46,13 +46,20 @@ public void organizeAndCleanupBlobsByDate(int retentionDays, ZoneId timeZone) {
                     continue;
                 }
 
+                // TODO - separate the content by golden or automated so it can be distinguished
+                // when its pulled down
+                //  modify destinationName to be test folder specific
+                //  possibly read blob and modify parseAndMapMessageByControlId or use its parts to
+                // get a different MSH header like getIdentifier
+                // possibly use a different receiver and filter on that
+
                 String destinationName =
                         AzureBlobHelper.createDateBasedPath(sourceCreationDate, sourceName);
+
                 BlobClient destinationBlob = blobContainerClient.getBlobClient(destinationName);
                 destinationBlob
                         .beginCopy(sourceBlob.getBlobUrl(), null)
                         .waitForCompletion(Duration.ofSeconds(30));
-
                 CopyStatusType copyStatus = destinationBlob.getProperties().getCopyStatus();
                 if (copyStatus == CopyStatusType.SUCCESS) {
                     sourceBlob.delete();

From ccca6ab5d24c1c303bcd320350e3e5f35fd68476 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Fri, 20 Dec 2024 10:32:21 -0700
Subject: [PATCH 34/61] stub out filter for organizing and fetching azure files

Co-authored-by: James Herr <jherr@flexion.us>
Co-authored-by: Sylvie <sschuresko@flexion.us>
---
 .../rse2e/AzureBlobFileFetcher.java               | 15 ++++++++++++++-
 .../rse2e/AzureBlobOrganizer.java                 | 13 ++++++++-----
 2 files changed, 22 insertions(+), 6 deletions(-)

diff --git a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobFileFetcher.java b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobFileFetcher.java
index 4d9a3a478..d6d950916 100644
--- a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobFileFetcher.java
+++ b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobFileFetcher.java
@@ -47,12 +47,25 @@ public static FileFetcher getInstance() {
         return INSTANCE;
     }
 
+    //  TODO - we need to modify the guts to only grab the golden or automated path
     @Override
     public List<HL7FileStream> fetchFiles() {
+        String files_path = System.getenv("LOCAL_FILE_PATH");
+        if (files_path == null || files_path.isEmpty()) {
+            throw new IllegalArgumentException("Environment variable LOCAL_FILE_PATH is not set");
+        }
+
         List<HL7FileStream> relevantFiles = new ArrayList<>();
 
         LocalDate today = LocalDate.now(TIME_ZONE);
-        String pathPrefix = AzureBlobHelper.buildDatePathPrefix(today);
+        String datePrefix = AzureBlobHelper.buildDatePathPrefix(today);
+
+        // TODO - update base on AzureBlobOrganizer
+        String pathPrefix = datePrefix + "Automated/";
+        if (files_path.contains("GoldenCopy")) {
+            pathPrefix += datePrefix + "GoldenCopy/";
+        }
+
         ListBlobsOptions options = new ListBlobsOptions().setPrefix(pathPrefix);
         for (BlobItem blobItem : blobContainerClient.listBlobs(options, null)) {
             BlobClient blobClient = blobContainerClient.getBlobClient(blobItem.getName());
diff --git a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobOrganizer.java b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobOrganizer.java
index 3a7345216..11a0be79e 100644
--- a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobOrganizer.java
+++ b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobOrganizer.java
@@ -47,14 +47,17 @@ public void organizeAndCleanupBlobsByDate(int retentionDays, ZoneId timeZone) {
                 }
 
                 // TODO - separate the content by golden or automated so it can be distinguished
-                // when its pulled down
-                //  modify destinationName to be test folder specific
-                //  possibly read blob and modify parseAndMapMessageByControlId or use its parts to
-                // get a different MSH header like getIdentifier
+                // when its pulled down and modify destinationName to be test folder specific
                 // possibly use a different receiver and filter on that
 
+                String testTypeAndSourceName = "Automated/" + sourceName;
+                if (sourceBlob.getBlobName().contains("golden")) {
+                    testTypeAndSourceName = "GoldenCopy/" + sourceName;
+                }
+
                 String destinationName =
-                        AzureBlobHelper.createDateBasedPath(sourceCreationDate, sourceName);
+                        AzureBlobHelper.createDateBasedPath(
+                                sourceCreationDate, testTypeAndSourceName);
 
                 BlobClient destinationBlob = blobContainerClient.getBlobClient(destinationName);
                 destinationBlob

From 6873446efe0e5926e400ee964be7919e00466c20 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Mon, 23 Dec 2024 11:08:34 -0700
Subject: [PATCH 35/61] modify filter for file paths

Co-authored-by: James Herr <jherr@flexion.us>
---
 .../hhs/cdc/trustedintermediary/rse2e/AzureBlobOrganizer.java   | 2 +-
 1 file changed, 1 insertion(+), 1 deletion(-)

diff --git a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobOrganizer.java b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobOrganizer.java
index 11a0be79e..094b0c739 100644
--- a/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobOrganizer.java
+++ b/rs-e2e/src/main/java/gov/hhs/cdc/trustedintermediary/rse2e/AzureBlobOrganizer.java
@@ -51,7 +51,7 @@ public void organizeAndCleanupBlobsByDate(int retentionDays, ZoneId timeZone) {
                 // possibly use a different receiver and filter on that
 
                 String testTypeAndSourceName = "Automated/" + sourceName;
-                if (sourceBlob.getBlobName().contains("golden")) {
+                if (sourceBlob.getBlobName().contains("GOLDEN-COPY")) {
                     testTypeAndSourceName = "GoldenCopy/" + sourceName;
                 }
 

From 9fbe6fa0533773c879ebd12591ea783e7c67ae59 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Mon, 23 Dec 2024 11:09:31 -0700
Subject: [PATCH 36/61] update readme and file examples base on filter for new
 receiver

Co-authored-by: James Herr <jherr@flexion.us>
---
 .../GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7  | 2 +-
 .../GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7  | 2 +-
 .../Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7          | 2 +-
 .../GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7 | 2 +-
 .../Input/005_ORU_R01_golden_copy_input_out_of_range.hl7        | 2 +-
 .../Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7      | 2 +-
 examples/Test/GoldenCopy/README.md                              | 1 +
 7 files changed, 7 insertions(+), 6 deletions(-)

diff --git a/examples/Test/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7 b/examples/Test/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
index a93c6ef84..1a235664a 100644
--- a/examples/Test/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
+++ b/examples/Test/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
@@ -1,4 +1,4 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241015050654||ORU^R01^ORU_R01|001|N|2.5.1
+MSH|^~\\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241015050654||ORU^R01^ORU_R01|001|N|2.5.1
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
 ORC|RE|673678765^FormNumber||M17965^HospOrdNumber||||||||1477542173^BROOKS^STEWART^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804
diff --git a/examples/Test/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7 b/examples/Test/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
index eb4377c51..971a44185 100644
--- a/examples/Test/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
+++ b/examples/Test/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
@@ -1,4 +1,4 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050234||ORU^R01^ORU_R01|002|N|2.5.1
+MSH|^~\\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050234||ORU^R01^ORU_R01|002|N|2.5.1
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
 ORC|RE|12345667867^FormNumber||S30500^HospOrdNumber||||||||1194257170^MAHMOOD^SARAH^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804
diff --git a/examples/Test/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7 b/examples/Test/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
index d5fb3472e..7f48ad1ff 100644
--- a/examples/Test/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
+++ b/examples/Test/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
@@ -1,4 +1,4 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241023050044||ORU^R01^ORU_R01|003|N|2.5.1
+MSH|^~\\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241023050044||ORU^R01^ORU_R01|003|N|2.5.1
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
 ORC|RE|45789876^FormNumber||56352742^HospOrdNumber||||||||1043390461^PROFIT^DR JOCHEN^^^^^^^NPI|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601
diff --git a/examples/Test/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7 b/examples/Test/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
index 8b4b6f202..fac1f1dc2 100644
--- a/examples/Test/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
+++ b/examples/Test/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
@@ -1,4 +1,4 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241030050154||ORU^R01^ORU_R01|004|N|2.5.1
+MSH|^~\\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241030050154||ORU^R01^ORU_R01|004|N|2.5.1
 PID|1||335441864^^^104638912487&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
 ORC|RE|356672001^FormNumber||629813494^HospOrdNumber||||||||1093050858^SILVA^RICHARD^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|200 W ARBOR DR^^SAN DIEGO^CA^92103-1911
diff --git a/examples/Test/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7 b/examples/Test/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
index 6f949201c..f4f0b0172 100644
--- a/examples/Test/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
+++ b/examples/Test/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
@@ -1,4 +1,4 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050017||ORU^R01^ORU_R01|005|N|2.5.1
+MSH|^~\\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050017||ORU^R01^ORU_R01|005|N|2.5.1
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
 ORC|RE|753234567^FormNumber||56155532^HospOrdNumber||||||||^SCALA^MELISSA|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601
diff --git a/examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7 b/examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7
index 41e56f5e9..0c4469d8c 100644
--- a/examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7
+++ b/examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7
@@ -1,4 +1,4 @@
-MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9413799^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241017050025||ORU^R01^ORU_R01|006|N|2.5.1
+MSH|^~\\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^9413799^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241017050025||ORU^R01^ORU_R01|006|N|2.5.1
 PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
 NK1|1|*****PII REMOVED******
 ORC|RE|789876543^FormNumber||||||||||1164928032^MURUGESAN^CHEZHIYAN^^^^^^^NPI|||||||||KERN MEDICAL CENTER^^^^^^^^^R092|1700 MOUNT VERNON AVE^^BAKERSFIELD^CA^93306-4018
diff --git a/examples/Test/GoldenCopy/README.md b/examples/Test/GoldenCopy/README.md
index fa012933e..8ca036481 100644
--- a/examples/Test/GoldenCopy/README.md
+++ b/examples/Test/GoldenCopy/README.md
@@ -16,6 +16,7 @@ The files are required to:
 - Each file must have a unique value in `MSH-10`. We use this value to match the input and output files, so if it's not unique, we won't be able to match the files correctly
     - We format `MSH-10` based on the file index, like `001` (or `AUTOMATEDTEST-001` for UCSD)
 - `MSH-11` needs to have a value of `N`
+- `MSH-3` needs to be `GOLDEN-COPY`
 
 ## Corresponding File Names
 

From 885cd21f0c6255fc6c79cfd6a3cff157fcf7f7a7 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Mon, 23 Dec 2024 11:14:55 -0700
Subject: [PATCH 37/61] fix uses pathing

Co-authored-by: James Herr <jherr@flexion.us>
---
 .github/workflows/automated-staging-test-run.yml    | 2 +-
 .github/workflows/automated-staging-test-submit.yml | 2 +-
 2 files changed, 2 insertions(+), 2 deletions(-)

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index 3cef43b98..b5e0bb8c1 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -10,7 +10,7 @@ jobs:
 
     steps:
       - name: Call staging-test-run.yml
-        uses: .github/workflows/staging-test-run-reusable.yml
+        uses: ./.github/workflows/staging-test-run-reusable.yml
         with:
           FILE_PATH: '../examples/Test/Automated/'
           NAME: 'Automated'
diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
index 278d01807..7e11f648c 100644
--- a/.github/workflows/automated-staging-test-submit.yml
+++ b/.github/workflows/automated-staging-test-submit.yml
@@ -10,6 +10,6 @@ jobs:
 
     steps:
       - name: Call staging-test-submit.yml
-        uses: .github/workflows/staging-test-submit-reusable.yml
+        uses: ./.github/workflows/staging-test-submit-reusable.yml
         with:
           FILE_PATH: 'Automated/*.hl7'

From bc8382096040ab14564f308c4ecfebd8626c9c9c Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Mon, 23 Dec 2024 11:16:43 -0700
Subject: [PATCH 38/61] fix uses pathing

Co-authored-by: James Herr <jherr@flexion.us>
---
 .github/workflows/golden-copy-staging-test-run.yml    | 2 +-
 .github/workflows/golden-copy-staging-test-submit.yml | 2 +-
 2 files changed, 2 insertions(+), 2 deletions(-)

diff --git a/.github/workflows/golden-copy-staging-test-run.yml b/.github/workflows/golden-copy-staging-test-run.yml
index 14ff1dae6..39a8e38a3 100644
--- a/.github/workflows/golden-copy-staging-test-run.yml
+++ b/.github/workflows/golden-copy-staging-test-run.yml
@@ -10,7 +10,7 @@ jobs:
 
     steps:
       - name: Call staging-test-run.yml
-        uses: .github/workflows/staging-test-run-reusable.yml
+        uses: ./.github/workflows/staging-test-run-reusable.yml
         with:
           FILE_PATH: '../examples/Test/GoldenCopy/Expected/'
           NAME: 'Golden Copy'
diff --git a/.github/workflows/golden-copy-staging-test-submit.yml b/.github/workflows/golden-copy-staging-test-submit.yml
index fddc8e11f..2ce5e49fc 100644
--- a/.github/workflows/golden-copy-staging-test-submit.yml
+++ b/.github/workflows/golden-copy-staging-test-submit.yml
@@ -11,6 +11,6 @@ jobs:
 
     steps:
       - name: Call staging-test-submit.yml
-        uses: .github/workflows/staging-test-submit-reusable.yml
+        uses: ./.github/workflows/staging-test-submit-reusable.yml
         with:
           FILE_PATH: 'GoldenCopy/Input/*.hl7'

From cf0489f3c8f178ef5eeb1833d6f8a232954ebc84 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Mon, 23 Dec 2024 11:23:36 -0700
Subject: [PATCH 39/61] add workflow dispatch

Co-authored-by: James Herr <jherr@flexion.us>
---
 .github/workflows/automated-staging-test-run.yml    | 1 +
 .github/workflows/automated-staging-test-submit.yml | 1 +
 .github/workflows/golden-copy-staging-test-run.yml  | 1 +
 3 files changed, 3 insertions(+)

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index b5e0bb8c1..c0d4e8b3e 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -3,6 +3,7 @@ name: Automated Staging Test - Run integration tests
 on:
   schedule:
     - cron: "0 7 * * 2-6"  # Tuesday to Saturday at 2am EST (7am UTC) - two hours after `automated-staging-test-submit` runs
+  workflow_dispatch:
 
 jobs:
   send_files:
diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
index 7e11f648c..56cc4fab4 100644
--- a/.github/workflows/automated-staging-test-submit.yml
+++ b/.github/workflows/automated-staging-test-submit.yml
@@ -3,6 +3,7 @@ name: Automated Staging Test - Submit Messages
 on:
   schedule:
     - cron: "0 5 * * 2-6"  # Tuesday to Saturday at Midnight EST (5am UTC)
+  workflow_dispatch:
 
 jobs:
   send_files:
diff --git a/.github/workflows/golden-copy-staging-test-run.yml b/.github/workflows/golden-copy-staging-test-run.yml
index 39a8e38a3..e10d8cf2e 100644
--- a/.github/workflows/golden-copy-staging-test-run.yml
+++ b/.github/workflows/golden-copy-staging-test-run.yml
@@ -3,6 +3,7 @@ name: Golden Copy Staging Test - Run integration tests
 on:
   schedule:
     - cron: "0 7 * * 2-6"  # Tuesday to Saturday at 2am EST (7am UTC) - two hours after `automated-staging-test-submit` runs
+  workflow_dispatch:
 
 jobs:
   send_files:

From 91371ae2f5adf7e8ebf5a1c191ec6c32502ed758 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Mon, 23 Dec 2024 14:11:01 -0700
Subject: [PATCH 40/61] combine submit workflows into one and update readmes

Co-authored-by: James Herr <jherr@flexion.us>
---
 .../automated-staging-test-submit.yml         | 16 -----
 .../golden-copy-staging-test-submit.yml       | 16 -----
 .../staging-test-submit-reusable.yml          |  8 +--
 .github/workflows/staging-test-submit.yml     | 66 +++++++++++++++++++
 examples/Test/Automated/README.md             |  2 +-
 examples/Test/GoldenCopy/README.md            |  2 +-
 6 files changed, 72 insertions(+), 38 deletions(-)
 delete mode 100644 .github/workflows/automated-staging-test-submit.yml
 delete mode 100644 .github/workflows/golden-copy-staging-test-submit.yml
 create mode 100644 .github/workflows/staging-test-submit.yml

diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
deleted file mode 100644
index 56cc4fab4..000000000
--- a/.github/workflows/automated-staging-test-submit.yml
+++ /dev/null
@@ -1,16 +0,0 @@
-name: Automated Staging Test - Submit Messages
-
-on:
-  schedule:
-    - cron: "0 5 * * 2-6"  # Tuesday to Saturday at Midnight EST (5am UTC)
-  workflow_dispatch:
-
-jobs:
-  send_files:
-    runs-on: ubuntu-latest
-
-    steps:
-      - name: Call staging-test-submit.yml
-        uses: ./.github/workflows/staging-test-submit-reusable.yml
-        with:
-          FILE_PATH: 'Automated/*.hl7'
diff --git a/.github/workflows/golden-copy-staging-test-submit.yml b/.github/workflows/golden-copy-staging-test-submit.yml
deleted file mode 100644
index 2ce5e49fc..000000000
--- a/.github/workflows/golden-copy-staging-test-submit.yml
+++ /dev/null
@@ -1,16 +0,0 @@
-name: Golden Copy Staging Test - Submit Messages
-
-on:
-  schedule:
-    - cron: "0 5 * * 2-6"
-  workflow_dispatch:
-
-jobs:
-  send_files:
-    runs-on: ubuntu-latest
-
-    steps:
-      - name: Call staging-test-submit.yml
-        uses: ./.github/workflows/staging-test-submit-reusable.yml
-        with:
-          FILE_PATH: 'GoldenCopy/Input/*.hl7'
diff --git a/.github/workflows/staging-test-submit-reusable.yml b/.github/workflows/staging-test-submit-reusable.yml
index 6d1736743..a8b0c449e 100644
--- a/.github/workflows/staging-test-submit-reusable.yml
+++ b/.github/workflows/staging-test-submit-reusable.yml
@@ -10,8 +10,6 @@ on:
 
 jobs:
   send_files:
-    runs-on: ubuntu-latest
-
     steps:
       - name: Check out the repository
         uses: actions/checkout@v4
@@ -21,8 +19,8 @@ jobs:
 
       - name: Install jwt-cli
         run: |
-            curl --silent --location https://github.com/mike-engel/jwt-cli/releases/latest/download/jwt-linux.tar.gz | tar xvz -C /usr/local/bin/
-            sudo chmod +x /usr/local/bin/jwt
+          curl --silent --location https://github.com/mike-engel/jwt-cli/releases/latest/download/jwt-linux.tar.gz | tar xvz -C /usr/local/bin/
+          sudo chmod +x /usr/local/bin/jwt
 
       - name: Write private key to file
         run: |
@@ -62,3 +60,5 @@ jobs:
         if: always()
         run: |
           rm -f /tmp/staging_private_key.pem
+
+    runs-on:
diff --git a/.github/workflows/staging-test-submit.yml b/.github/workflows/staging-test-submit.yml
new file mode 100644
index 000000000..8fe4a9898
--- /dev/null
+++ b/.github/workflows/staging-test-submit.yml
@@ -0,0 +1,66 @@
+name: Staging Test - Submit Messages
+
+on:
+  schedule:
+    - cron: "0 5 * * 2-6"  # Tuesday to Saturday at Midnight EST (5am UTC)
+  workflow_dispatch:
+
+jobs:
+  send_files:
+    runs-on: ubuntu-latest
+
+    steps:
+      - name: Check out the repository
+        uses: actions/checkout@v4
+
+      - name: Install jq
+        run: sudo apt-get install -y jq
+
+      - name: Install jwt-cli
+        run: |
+          curl --silent --location https://github.com/mike-engel/jwt-cli/releases/latest/download/jwt-linux.tar.gz | tar xvz -C /usr/local/bin/
+          sudo chmod +x /usr/local/bin/jwt
+
+      - name: Write private key to file
+        run: |
+          echo "${{ secrets.SIMULATED_SENDER_STAGING_PRIVATE_KEY }}" > /tmp/staging_private_key.pem
+          chmod 600 /tmp/staging_private_key.pem
+
+      - name: Send HL7 sample messages to staging RS
+        run: |
+          host=https://staging.prime.cdc.gov:443
+          client_id=flexion
+          client_sender=simulated-sender
+          jwt=$(jwt encode --exp='+5min' --jti $(uuidgen) --alg RS256 \
+              -k $client_id.$client_sender -i $client_id.$client_sender \
+              -s $client_id.$client_sender -a $host --no-iat -S @/tmp/staging_private_key.pem)
+
+          token=$(curl \
+                  --header "Content-Type: application/x-www-form-urlencoded" \
+                  --data "scope=$client_id.*.report" \
+                  --data "client_assertion=$jwt" \
+                  --data "client_assertion_type=urn:ietf:params:oauth:client-assertion-type:jwt-bearer" \
+                  --data "grant_type=client_credentials" \
+                  --silent \
+                  "$host/api/token" | jq -r ".access_token")
+
+          sendFiles () {
+            folder_path=$1
+            for file in "$(pwd)/examples/Test/$folder_path"; do
+              echo "Sending $file"
+              curl \
+                  --header "Content-Type: application/hl7-v2" \
+                  --header "Client: $client_id.$client_sender" \
+                  --header "Authorization: Bearer $token" \
+                  --data-binary "@$file" \
+                  --silent \
+                  "$host/api/waters"
+            done
+          }
+          sendFiles "'Automated/*.hl7'"
+          sendFiles "'GoldenCopy/Input/*.hl7'"
+
+      - name: Clean up private key
+        if: always()
+        run: |
+          rm -f /tmp/staging_private_key.pem
diff --git a/examples/Test/Automated/README.md b/examples/Test/Automated/README.md
index c7a01e231..122330276 100644
--- a/examples/Test/Automated/README.md
+++ b/examples/Test/Automated/README.md
@@ -1,5 +1,5 @@
 This folder contains the HL7 sample files that are used in the automated ReportStream
-integration tests. The [automated-staging-test-submit.yml](/.github/workflows/automated-staging-test-submit.yml)
+integration tests. The [automated-staging-test-submit.yml](/.github/workflows/staging-test-submit.yml)
 Github workflow that runs daily will grab these files and send them to ReportStream in staging.
 The files are expected to go through the whole flow and to be delivered to an Azure blob
 container that will later be used by the
diff --git a/examples/Test/GoldenCopy/README.md b/examples/Test/GoldenCopy/README.md
index 8ca036481..bf104ae6b 100644
--- a/examples/Test/GoldenCopy/README.md
+++ b/examples/Test/GoldenCopy/README.md
@@ -1,5 +1,5 @@
 This folder contains the HL7 sample files that are used in the Golden Copy ReportStream
-integration tests. The [golden-copy-staging-test-submit.yml](/.github/workflows/golden-copy-staging-test-submit.yml)
+integration tests. The [golden-copy-staging-test-submit.yml](/.github/workflows/staging-test-submit.yml)
 Github workflow that runs daily will grab these files and send them to ReportStream in staging.
 The files are expected to go through the whole flow and to be delivered to an Azure blob
 container that will later be used by the

From 000d590157f1f040228568949adfea5e66e52047 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Mon, 23 Dec 2024 14:11:48 -0700
Subject: [PATCH 41/61] delete unused workflow

Co-authored-by: James Herr <jherr@flexion.us>
---
 .../staging-test-submit-reusable.yml          | 64 -------------------
 1 file changed, 64 deletions(-)
 delete mode 100644 .github/workflows/staging-test-submit-reusable.yml

diff --git a/.github/workflows/staging-test-submit-reusable.yml b/.github/workflows/staging-test-submit-reusable.yml
deleted file mode 100644
index a8b0c449e..000000000
--- a/.github/workflows/staging-test-submit-reusable.yml
+++ /dev/null
@@ -1,64 +0,0 @@
-name: Staging Test - Submit Messages
-
-on:
-  workflow_call:
-    inputs:
-      FILE_PATH:
-        required: true
-        type: string
-        description: File path location to submit
-
-jobs:
-  send_files:
-    steps:
-      - name: Check out the repository
-        uses: actions/checkout@v4
-
-      - name: Install jq
-        run: sudo apt-get install -y jq
-
-      - name: Install jwt-cli
-        run: |
-          curl --silent --location https://github.com/mike-engel/jwt-cli/releases/latest/download/jwt-linux.tar.gz | tar xvz -C /usr/local/bin/
-          sudo chmod +x /usr/local/bin/jwt
-
-      - name: Write private key to file
-        run: |
-          echo "${{ secrets.SIMULATED_SENDER_STAGING_PRIVATE_KEY }}" > /tmp/staging_private_key.pem
-          chmod 600 /tmp/staging_private_key.pem
-
-      - name: Send HL7 sample messages to staging RS
-        run: |
-          host=https://staging.prime.cdc.gov:443
-          client_id=flexion
-          client_sender=simulated-sender
-          jwt=$(jwt encode --exp='+5min' --jti $(uuidgen) --alg RS256 \
-              -k $client_id.$client_sender -i $client_id.$client_sender \
-              -s $client_id.$client_sender -a $host --no-iat -S @/tmp/staging_private_key.pem)
-
-          token=$(curl \
-                  --header "Content-Type: application/x-www-form-urlencoded" \
-                  --data "scope=$client_id.*.report" \
-                  --data "client_assertion=$jwt" \
-                  --data "client_assertion_type=urn:ietf:params:oauth:client-assertion-type:jwt-bearer" \
-                  --data "grant_type=client_credentials" \
-                  --silent \
-                  "$host/api/token" | jq -r ".access_token")
-
-          for file in $(pwd)/examples/Test/${{ github.event.inputs.FILE_PATH }}; do
-              echo "Sending $file"
-              curl \
-                  --header "Content-Type: application/hl7-v2" \
-                  --header "Client: $client_id.$client_sender" \
-                  --header "Authorization: Bearer $token" \
-                  --data-binary "@$file" \
-                  --silent \
-                  "$host/api/waters"
-          done
-
-      - name: Clean up private key
-        if: always()
-        run: |
-          rm -f /tmp/staging_private_key.pem
-
-    runs-on:

From 06558f7cccc2f9cf8438334a1852624a0f1b971f Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Mon, 23 Dec 2024 14:16:51 -0700
Subject: [PATCH 42/61] rename reusable workflow

Co-authored-by: James Herr <jherr@flexion.us>
---
 .github/workflows/automated-staging-test-run.yml              | 2 +-
 .github/workflows/golden-copy-staging-test-run.yml            | 4 ++--
 ...ng-test-run-reusable.yml => staging-test-run_reusable.yml} | 0
 3 files changed, 3 insertions(+), 3 deletions(-)
 rename .github/workflows/{staging-test-run-reusable.yml => staging-test-run_reusable.yml} (100%)

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index c0d4e8b3e..493e9b24c 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -11,7 +11,7 @@ jobs:
 
     steps:
       - name: Call staging-test-run.yml
-        uses: ./.github/workflows/staging-test-run-reusable.yml
+        uses: ./.github/workflows/staging-test-run_reusable.yml
         with:
           FILE_PATH: '../examples/Test/Automated/'
           NAME: 'Automated'
diff --git a/.github/workflows/golden-copy-staging-test-run.yml b/.github/workflows/golden-copy-staging-test-run.yml
index e10d8cf2e..af5ef38a6 100644
--- a/.github/workflows/golden-copy-staging-test-run.yml
+++ b/.github/workflows/golden-copy-staging-test-run.yml
@@ -2,7 +2,7 @@ name: Golden Copy Staging Test - Run integration tests
 
 on:
   schedule:
-    - cron: "0 7 * * 2-6"  # Tuesday to Saturday at 2am EST (7am UTC) - two hours after `automated-staging-test-submit` runs
+    - cron: "10 7 * * 2-6"  # Tuesday to Saturday at 2am EST (7:10am UTC) - two hours after `automated-staging-test-submit` runs
   workflow_dispatch:
 
 jobs:
@@ -11,7 +11,7 @@ jobs:
 
     steps:
       - name: Call staging-test-run.yml
-        uses: ./.github/workflows/staging-test-run-reusable.yml
+        uses: ./.github/workflows/staging-test-run_reusable.yml
         with:
           FILE_PATH: '../examples/Test/GoldenCopy/Expected/'
           NAME: 'Golden Copy'
diff --git a/.github/workflows/staging-test-run-reusable.yml b/.github/workflows/staging-test-run_reusable.yml
similarity index 100%
rename from .github/workflows/staging-test-run-reusable.yml
rename to .github/workflows/staging-test-run_reusable.yml

From 0fba3fb5098b042a0faad338b859ebc302234a69 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Mon, 23 Dec 2024 14:30:43 -0700
Subject: [PATCH 43/61] readd the og workflow and delete new one

Co-authored-by: James Herr <jherr@flexion.us>
Co-authored-by: basiliskus <541149+basiliskus@users.noreply.github.com>
---
 ...{staging-test-submit.yml => automated-staging-test-submit.yml} | 0
 1 file changed, 0 insertions(+), 0 deletions(-)
 rename .github/workflows/{staging-test-submit.yml => automated-staging-test-submit.yml} (100%)

diff --git a/.github/workflows/staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
similarity index 100%
rename from .github/workflows/staging-test-submit.yml
rename to .github/workflows/automated-staging-test-submit.yml

From a9cf564832dd9fbd75d42ad157c83ae8a4425fc4 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Mon, 23 Dec 2024 14:37:44 -0700
Subject: [PATCH 44/61] move folders around

Co-authored-by: James Herr <jherr@flexion.us>
Co-authored-by: basiliskus <541149+basiliskus@users.noreply.github.com>
---
 .../automated-staging-test-submit.yml         | 25 ++++++++-----------
 ...taging_ORM_O01_short_linked_to_002_ORU.hl7 |  0
 ...taging_ORU_O01_short_linked_to_001_ORM.hl7 |  0
 .../003_CA_ORU_R01_CDPH_produced.hl7          |  0
 .../004_CA_ORU_R01_leading_zeroes.hl7         |  0
 .../005_CA_ORU_R01_no_leading_zeroes.hl7      |  0
 .../{ => Assertion}/006_CA_ORU_R01_LOINC.hl7  |  0
 .../{ => Assertion}/007_CA_ORU_R01_PLT.hl7    |  0
 .../008_ORU_R01_micro_character_encoding.hl7  |  0
 .../009_CA_ORU_R01_remove_99717-5_OBX.hl7     |  0
 ...01_NBS_0_initial_obr_flatten_example_1.hl7 |  0
 .../Test/Automated/{ => Assertion}/README.md  |  2 +-
 ..._ORU_R01_golden_copy_expected_acylc_1.fhir |  0
 ..._ORU_R01_golden_copy_expected_acylc_2.fhir |  0
 ...U_R01_golden_copy_expected_aa_unusual.fhir |  0
 ...ORU_R01_golden_copy_expected_in_range.fhir |  0
 ...R01_golden_copy_expected_out_of_range.fhir |  0
 ...1_golden_copy_expected_sma_incomplete.fhir |  0
 .../001_ORU_R01_golden_copy_input_acylc_1.hl7 |  0
 .../002_ORU_R01_golden_copy_input_acylc_2.hl7 |  0
 ...3_ORU_R01_golden_copy_input_aa_unusual.hl7 |  0
 ...004_ORU_R01_golden_copy_input_in_range.hl7 |  0
 ...ORU_R01_golden_copy_input_out_of_range.hl7 |  0
 ...U_R01_golden_copy_input_sma_incomplete.hl7 |  0
 .../Test/{ => Automated}/GoldenCopy/README.md |  2 +-
 25 files changed, 12 insertions(+), 17 deletions(-)
 rename examples/Test/Automated/{ => Assertion}/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7 (100%)
 rename examples/Test/Automated/{ => Assertion}/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7 (100%)
 rename examples/Test/Automated/{ => Assertion}/003_CA_ORU_R01_CDPH_produced.hl7 (100%)
 rename examples/Test/Automated/{ => Assertion}/004_CA_ORU_R01_leading_zeroes.hl7 (100%)
 rename examples/Test/Automated/{ => Assertion}/005_CA_ORU_R01_no_leading_zeroes.hl7 (100%)
 rename examples/Test/Automated/{ => Assertion}/006_CA_ORU_R01_LOINC.hl7 (100%)
 rename examples/Test/Automated/{ => Assertion}/007_CA_ORU_R01_PLT.hl7 (100%)
 rename examples/Test/Automated/{ => Assertion}/008_ORU_R01_micro_character_encoding.hl7 (100%)
 rename examples/Test/Automated/{ => Assertion}/009_CA_ORU_R01_remove_99717-5_OBX.hl7 (100%)
 rename examples/Test/Automated/{ => Assertion}/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7 (100%)
 rename examples/Test/Automated/{ => Assertion}/README.md (96%)
 rename examples/Test/{ => Automated}/GoldenCopy/Expected/001_ORU_R01_golden_copy_expected_acylc_1.fhir (100%)
 rename examples/Test/{ => Automated}/GoldenCopy/Expected/002_ORU_R01_golden_copy_expected_acylc_2.fhir (100%)
 rename examples/Test/{ => Automated}/GoldenCopy/Expected/003_ORU_R01_golden_copy_expected_aa_unusual.fhir (100%)
 rename examples/Test/{ => Automated}/GoldenCopy/Expected/004_ORU_R01_golden_copy_expected_in_range.fhir (100%)
 rename examples/Test/{ => Automated}/GoldenCopy/Expected/005_ORU_R01_golden_copy_expected_out_of_range.fhir (100%)
 rename examples/Test/{ => Automated}/GoldenCopy/Expected/006_ORU_R01_golden_copy_expected_sma_incomplete.fhir (100%)
 rename examples/Test/{ => Automated}/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7 (100%)
 rename examples/Test/{ => Automated}/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7 (100%)
 rename examples/Test/{ => Automated}/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7 (100%)
 rename examples/Test/{ => Automated}/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7 (100%)
 rename examples/Test/{ => Automated}/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7 (100%)
 rename examples/Test/{ => Automated}/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7 (100%)
 rename examples/Test/{ => Automated}/GoldenCopy/README.md (97%)

diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
index 8fe4a9898..51c6527a4 100644
--- a/.github/workflows/automated-staging-test-submit.yml
+++ b/.github/workflows/automated-staging-test-submit.yml
@@ -44,21 +44,16 @@ jobs:
                   --silent \
                   "$host/api/token" | jq -r ".access_token")
 
-          sendFiles () {
-            folder_path=$1
-            for file in "$(pwd)/examples/Test/$folder_path"; do
-              echo "Sending $file"
-              curl \
-                  --header "Content-Type: application/hl7-v2" \
-                  --header "Client: $client_id.$client_sender" \
-                  --header "Authorization: Bearer $token" \
-                  --data-binary "@$file" \
-                  --silent \
-                  "$host/api/waters"
-            done
-          }
-          sendFiles "'Automated/*.hl7'"
-          sendFiles "'GoldenCopy/Input/*.hl7'"
+          for file in $(pwd)/examples/Test/Automated/**/*.hl7; do
+            echo "Sending $file"
+            curl \
+                --header "Content-Type: application/hl7-v2" \
+                --header "Client: $client_id.$client_sender" \
+                --header "Authorization: Bearer $token" \
+                --data-binary "@$file" \
+                --silent \
+                "$host/api/waters"
+          done
 
       - name: Clean up private key
         if: always()
diff --git a/examples/Test/Automated/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7 b/examples/Test/Automated/Assertion/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7
similarity index 100%
rename from examples/Test/Automated/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7
rename to examples/Test/Automated/Assertion/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7
diff --git a/examples/Test/Automated/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7 b/examples/Test/Automated/Assertion/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7
similarity index 100%
rename from examples/Test/Automated/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7
rename to examples/Test/Automated/Assertion/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7
diff --git a/examples/Test/Automated/003_CA_ORU_R01_CDPH_produced.hl7 b/examples/Test/Automated/Assertion/003_CA_ORU_R01_CDPH_produced.hl7
similarity index 100%
rename from examples/Test/Automated/003_CA_ORU_R01_CDPH_produced.hl7
rename to examples/Test/Automated/Assertion/003_CA_ORU_R01_CDPH_produced.hl7
diff --git a/examples/Test/Automated/004_CA_ORU_R01_leading_zeroes.hl7 b/examples/Test/Automated/Assertion/004_CA_ORU_R01_leading_zeroes.hl7
similarity index 100%
rename from examples/Test/Automated/004_CA_ORU_R01_leading_zeroes.hl7
rename to examples/Test/Automated/Assertion/004_CA_ORU_R01_leading_zeroes.hl7
diff --git a/examples/Test/Automated/005_CA_ORU_R01_no_leading_zeroes.hl7 b/examples/Test/Automated/Assertion/005_CA_ORU_R01_no_leading_zeroes.hl7
similarity index 100%
rename from examples/Test/Automated/005_CA_ORU_R01_no_leading_zeroes.hl7
rename to examples/Test/Automated/Assertion/005_CA_ORU_R01_no_leading_zeroes.hl7
diff --git a/examples/Test/Automated/006_CA_ORU_R01_LOINC.hl7 b/examples/Test/Automated/Assertion/006_CA_ORU_R01_LOINC.hl7
similarity index 100%
rename from examples/Test/Automated/006_CA_ORU_R01_LOINC.hl7
rename to examples/Test/Automated/Assertion/006_CA_ORU_R01_LOINC.hl7
diff --git a/examples/Test/Automated/007_CA_ORU_R01_PLT.hl7 b/examples/Test/Automated/Assertion/007_CA_ORU_R01_PLT.hl7
similarity index 100%
rename from examples/Test/Automated/007_CA_ORU_R01_PLT.hl7
rename to examples/Test/Automated/Assertion/007_CA_ORU_R01_PLT.hl7
diff --git a/examples/Test/Automated/008_ORU_R01_micro_character_encoding.hl7 b/examples/Test/Automated/Assertion/008_ORU_R01_micro_character_encoding.hl7
similarity index 100%
rename from examples/Test/Automated/008_ORU_R01_micro_character_encoding.hl7
rename to examples/Test/Automated/Assertion/008_ORU_R01_micro_character_encoding.hl7
diff --git a/examples/Test/Automated/009_CA_ORU_R01_remove_99717-5_OBX.hl7 b/examples/Test/Automated/Assertion/009_CA_ORU_R01_remove_99717-5_OBX.hl7
similarity index 100%
rename from examples/Test/Automated/009_CA_ORU_R01_remove_99717-5_OBX.hl7
rename to examples/Test/Automated/Assertion/009_CA_ORU_R01_remove_99717-5_OBX.hl7
diff --git a/examples/Test/Automated/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7 b/examples/Test/Automated/Assertion/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7
similarity index 100%
rename from examples/Test/Automated/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7
rename to examples/Test/Automated/Assertion/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7
diff --git a/examples/Test/Automated/README.md b/examples/Test/Automated/Assertion/README.md
similarity index 96%
rename from examples/Test/Automated/README.md
rename to examples/Test/Automated/Assertion/README.md
index 122330276..c7a01e231 100644
--- a/examples/Test/Automated/README.md
+++ b/examples/Test/Automated/Assertion/README.md
@@ -1,5 +1,5 @@
 This folder contains the HL7 sample files that are used in the automated ReportStream
-integration tests. The [automated-staging-test-submit.yml](/.github/workflows/staging-test-submit.yml)
+integration tests. The [automated-staging-test-submit.yml](/.github/workflows/automated-staging-test-submit.yml)
 Github workflow that runs daily will grab these files and send them to ReportStream in staging.
 The files are expected to go through the whole flow and to be delivered to an Azure blob
 container that will later be used by the
diff --git a/examples/Test/GoldenCopy/Expected/001_ORU_R01_golden_copy_expected_acylc_1.fhir b/examples/Test/Automated/GoldenCopy/Expected/001_ORU_R01_golden_copy_expected_acylc_1.fhir
similarity index 100%
rename from examples/Test/GoldenCopy/Expected/001_ORU_R01_golden_copy_expected_acylc_1.fhir
rename to examples/Test/Automated/GoldenCopy/Expected/001_ORU_R01_golden_copy_expected_acylc_1.fhir
diff --git a/examples/Test/GoldenCopy/Expected/002_ORU_R01_golden_copy_expected_acylc_2.fhir b/examples/Test/Automated/GoldenCopy/Expected/002_ORU_R01_golden_copy_expected_acylc_2.fhir
similarity index 100%
rename from examples/Test/GoldenCopy/Expected/002_ORU_R01_golden_copy_expected_acylc_2.fhir
rename to examples/Test/Automated/GoldenCopy/Expected/002_ORU_R01_golden_copy_expected_acylc_2.fhir
diff --git a/examples/Test/GoldenCopy/Expected/003_ORU_R01_golden_copy_expected_aa_unusual.fhir b/examples/Test/Automated/GoldenCopy/Expected/003_ORU_R01_golden_copy_expected_aa_unusual.fhir
similarity index 100%
rename from examples/Test/GoldenCopy/Expected/003_ORU_R01_golden_copy_expected_aa_unusual.fhir
rename to examples/Test/Automated/GoldenCopy/Expected/003_ORU_R01_golden_copy_expected_aa_unusual.fhir
diff --git a/examples/Test/GoldenCopy/Expected/004_ORU_R01_golden_copy_expected_in_range.fhir b/examples/Test/Automated/GoldenCopy/Expected/004_ORU_R01_golden_copy_expected_in_range.fhir
similarity index 100%
rename from examples/Test/GoldenCopy/Expected/004_ORU_R01_golden_copy_expected_in_range.fhir
rename to examples/Test/Automated/GoldenCopy/Expected/004_ORU_R01_golden_copy_expected_in_range.fhir
diff --git a/examples/Test/GoldenCopy/Expected/005_ORU_R01_golden_copy_expected_out_of_range.fhir b/examples/Test/Automated/GoldenCopy/Expected/005_ORU_R01_golden_copy_expected_out_of_range.fhir
similarity index 100%
rename from examples/Test/GoldenCopy/Expected/005_ORU_R01_golden_copy_expected_out_of_range.fhir
rename to examples/Test/Automated/GoldenCopy/Expected/005_ORU_R01_golden_copy_expected_out_of_range.fhir
diff --git a/examples/Test/GoldenCopy/Expected/006_ORU_R01_golden_copy_expected_sma_incomplete.fhir b/examples/Test/Automated/GoldenCopy/Expected/006_ORU_R01_golden_copy_expected_sma_incomplete.fhir
similarity index 100%
rename from examples/Test/GoldenCopy/Expected/006_ORU_R01_golden_copy_expected_sma_incomplete.fhir
rename to examples/Test/Automated/GoldenCopy/Expected/006_ORU_R01_golden_copy_expected_sma_incomplete.fhir
diff --git a/examples/Test/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7 b/examples/Test/Automated/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
similarity index 100%
rename from examples/Test/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
rename to examples/Test/Automated/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
diff --git a/examples/Test/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7 b/examples/Test/Automated/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
similarity index 100%
rename from examples/Test/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
rename to examples/Test/Automated/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
diff --git a/examples/Test/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7 b/examples/Test/Automated/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
similarity index 100%
rename from examples/Test/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
rename to examples/Test/Automated/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
diff --git a/examples/Test/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7 b/examples/Test/Automated/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
similarity index 100%
rename from examples/Test/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
rename to examples/Test/Automated/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
diff --git a/examples/Test/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7 b/examples/Test/Automated/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
similarity index 100%
rename from examples/Test/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
rename to examples/Test/Automated/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
diff --git a/examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7 b/examples/Test/Automated/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7
similarity index 100%
rename from examples/Test/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7
rename to examples/Test/Automated/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7
diff --git a/examples/Test/GoldenCopy/README.md b/examples/Test/Automated/GoldenCopy/README.md
similarity index 97%
rename from examples/Test/GoldenCopy/README.md
rename to examples/Test/Automated/GoldenCopy/README.md
index bf104ae6b..74cee7714 100644
--- a/examples/Test/GoldenCopy/README.md
+++ b/examples/Test/Automated/GoldenCopy/README.md
@@ -1,5 +1,5 @@
 This folder contains the HL7 sample files that are used in the Golden Copy ReportStream
-integration tests. The [golden-copy-staging-test-submit.yml](/.github/workflows/staging-test-submit.yml)
+integration tests. The [golden-copy-staging-test-submit.yml](/.github/workflows/automated-staging-test-submit.yml)
 Github workflow that runs daily will grab these files and send them to ReportStream in staging.
 The files are expected to go through the whole flow and to be delivered to an Azure blob
 container that will later be used by the

From 7a13855d735787e15cc6e38718684628974399b2 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Mon, 23 Dec 2024 14:40:26 -0700
Subject: [PATCH 45/61] fix file changes

Co-authored-by: James Herr <jherr@flexion.us>
Co-authored-by: basiliskus <541149+basiliskus@users.noreply.github.com>
---
 .../automated-staging-test-submit.yml          | 18 +++++++++---------
 1 file changed, 9 insertions(+), 9 deletions(-)

diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
index 51c6527a4..095db5807 100644
--- a/.github/workflows/automated-staging-test-submit.yml
+++ b/.github/workflows/automated-staging-test-submit.yml
@@ -1,4 +1,4 @@
-name: Staging Test - Submit Messages
+name: Automated Staging Test - Submit Messages
 
 on:
   schedule:
@@ -45,14 +45,14 @@ jobs:
                   "$host/api/token" | jq -r ".access_token")
 
           for file in $(pwd)/examples/Test/Automated/**/*.hl7; do
-            echo "Sending $file"
-            curl \
-                --header "Content-Type: application/hl7-v2" \
-                --header "Client: $client_id.$client_sender" \
-                --header "Authorization: Bearer $token" \
-                --data-binary "@$file" \
-                --silent \
-                "$host/api/waters"
+              echo "Sending $file"
+              curl \
+                  --header "Content-Type: application/hl7-v2" \
+                  --header "Client: $client_id.$client_sender" \
+                  --header "Authorization: Bearer $token" \
+                  --data-binary "@$file" \
+                  --silent \
+                  "$host/api/waters"
           done
 
       - name: Clean up private key

From 8ca33372c88e49e74f9b1cb8a8bb4b94f07cdb3a Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Mon, 23 Dec 2024 14:51:55 -0700
Subject: [PATCH 46/61] change file path

Co-authored-by: James Herr <jherr@flexion.us>
Co-authored-by: basiliskus <541149+basiliskus@users.noreply.github.com>
---
 .github/workflows/automated-staging-test-submit.yml | 2 +-
 1 file changed, 1 insertion(+), 1 deletion(-)

diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
index 095db5807..17e3008fb 100644
--- a/.github/workflows/automated-staging-test-submit.yml
+++ b/.github/workflows/automated-staging-test-submit.yml
@@ -44,7 +44,7 @@ jobs:
                   --silent \
                   "$host/api/token" | jq -r ".access_token")
 
-          for file in $(pwd)/examples/Test/Automated/**/*.hl7; do
+          for file in $(pwd)/examples/Test/Automated/**/*/*.hl7;; do
               echo "Sending $file"
               curl \
                   --header "Content-Type: application/hl7-v2" \

From 5086197eee92ac96476ea489e17a18131ad4626a Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Mon, 23 Dec 2024 14:53:05 -0700
Subject: [PATCH 47/61] remove semi colon

Co-authored-by: basiliskus <541149+basiliskus@users.noreply.github.com>
---
 .github/workflows/automated-staging-test-submit.yml | 2 +-
 1 file changed, 1 insertion(+), 1 deletion(-)

diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
index 17e3008fb..3e3350c4f 100644
--- a/.github/workflows/automated-staging-test-submit.yml
+++ b/.github/workflows/automated-staging-test-submit.yml
@@ -44,7 +44,7 @@ jobs:
                   --silent \
                   "$host/api/token" | jq -r ".access_token")
 
-          for file in $(pwd)/examples/Test/Automated/**/*/*.hl7;; do
+          for file in $(pwd)/examples/Test/Automated/**/*/*.hl7; do
               echo "Sending $file"
               curl \
                   --header "Content-Type: application/hl7-v2" \

From 85b11b620a3009dcc507606e9743068d35dad3a0 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Mon, 23 Dec 2024 14:57:18 -0700
Subject: [PATCH 48/61] mess with pathing regex

Co-authored-by: basiliskus <541149+basiliskus@users.noreply.github.com>
---
 .github/workflows/automated-staging-test-submit.yml | 3 ++-
 1 file changed, 2 insertions(+), 1 deletion(-)

diff --git a/.github/workflows/automated-staging-test-submit.yml b/.github/workflows/automated-staging-test-submit.yml
index 3e3350c4f..77461cf33 100644
--- a/.github/workflows/automated-staging-test-submit.yml
+++ b/.github/workflows/automated-staging-test-submit.yml
@@ -28,6 +28,7 @@ jobs:
 
       - name: Send HL7 sample messages to staging RS
         run: |
+          shopt -s globstar
           host=https://staging.prime.cdc.gov:443
           client_id=flexion
           client_sender=simulated-sender
@@ -44,7 +45,7 @@ jobs:
                   --silent \
                   "$host/api/token" | jq -r ".access_token")
 
-          for file in $(pwd)/examples/Test/Automated/**/*/*.hl7; do
+          for file in $(pwd)/examples/Test/Automated/**/*.hl7; do
               echo "Sending $file"
               curl \
                   --header "Content-Type: application/hl7-v2" \

From 17a5382923fd672b57a42ec69187128f5a406a49 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Tue, 24 Dec 2024 09:51:33 -0700
Subject: [PATCH 49/61] correct naming in workflow

---
 .github/workflows/automated-staging-test-run.yml   | 2 +-
 .github/workflows/golden-copy-staging-test-run.yml | 4 ++--
 2 files changed, 3 insertions(+), 3 deletions(-)

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index 493e9b24c..58b7b6118 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -6,7 +6,7 @@ on:
   workflow_dispatch:
 
 jobs:
-  send_files:
+  test_files:
     runs-on: ubuntu-latest
 
     steps:
diff --git a/.github/workflows/golden-copy-staging-test-run.yml b/.github/workflows/golden-copy-staging-test-run.yml
index af5ef38a6..4c3cfb509 100644
--- a/.github/workflows/golden-copy-staging-test-run.yml
+++ b/.github/workflows/golden-copy-staging-test-run.yml
@@ -6,13 +6,13 @@ on:
   workflow_dispatch:
 
 jobs:
-  send_files:
+  test_files:
     runs-on: ubuntu-latest
 
     steps:
       - name: Call staging-test-run.yml
         uses: ./.github/workflows/staging-test-run_reusable.yml
         with:
-          FILE_PATH: '../examples/Test/GoldenCopy/Expected/'
+          FILE_PATH: '../examples/Test/Automated/GoldenCopy/Expected/'
           NAME: 'Golden Copy'
           TEST_TYPE: 'goldenCopyTest'

From 77d9c71cd821e83a60f3a982c76deefcbcc7959c Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Tue, 24 Dec 2024 10:08:02 -0700
Subject: [PATCH 50/61] use correct inputs syntax

---
 .github/workflows/staging-test-run_reusable.yml | 7 +++----
 1 file changed, 3 insertions(+), 4 deletions(-)

diff --git a/.github/workflows/staging-test-run_reusable.yml b/.github/workflows/staging-test-run_reusable.yml
index e12a31404..f1987f35e 100644
--- a/.github/workflows/staging-test-run_reusable.yml
+++ b/.github/workflows/staging-test-run_reusable.yml
@@ -27,10 +27,9 @@ jobs:
       - name: Run automated tests
         env:
           AZURE_STORAGE_CONNECTION_STRING: ${{ secrets.AUTOMATED_TEST_AZURE_STORAGE_CONNECTION_STRING }}
-          LOCAL_FILE_PATH: ${{ github.event.inputs.FILE_PATH }}
+          LOCAL_FILE_PATH: ${{ inputs.FILE_PATH }}
         run: |
-          ./gradlew rs-e2e:clean rs-e2e:${{ github.event.inputs.TEST_TYPE }}
-          done
+          ./gradlew rs-e2e:clean rs-e2e:${{ inputs.TEST_TYPE }}
 
       - name: Send slack notification on test failure
         if: failure()
@@ -39,4 +38,4 @@ jobs:
           webhook: ${{ secrets.SLACK_WEBHOOK_URL }}
           webhook-type: incoming-webhook
           payload: |
-            text: "${{ github.event.inputs.NAME }} Staging RS Integration Test Failed!: https://github.com/CDCgov/trusted-intermediary/actions/runs/${{ github.run_id }}"
+            text: "${{ inputs.NAME }} Staging RS Integration Test Failed!: https://github.com/CDCgov/trusted-intermediary/actions/runs/${{ github.run_id }}"

From b67cd88bf957fd73cfd9edea9e3eebe4269700ec Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Tue, 24 Dec 2024 10:19:22 -0700
Subject: [PATCH 51/61] workflow fixes

---
 .github/workflows/automated-staging-test-run.yml | 16 ++++++----------
 .../workflows/golden-copy-staging-test-run.yml   | 16 ++++++----------
 .github/workflows/staging-test-run_reusable.yml  |  3 +++
 3 files changed, 15 insertions(+), 20 deletions(-)

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index 58b7b6118..5a0f2c27d 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -6,13 +6,9 @@ on:
   workflow_dispatch:
 
 jobs:
-  test_files:
-    runs-on: ubuntu-latest
-
-    steps:
-      - name: Call staging-test-run.yml
-        uses: ./.github/workflows/staging-test-run_reusable.yml
-        with:
-          FILE_PATH: '../examples/Test/Automated/'
-          NAME: 'Automated'
-          TEST_TYPE: 'automatedTest'
+  call-staging-test-run:
+    uses: ./.github/workflows/staging-test-run_reusable.yml
+    with:
+      FILE_PATH: '../examples/Test/Automated/'
+      NAME: 'Automated'
+      TEST_TYPE: 'automatedTest'
diff --git a/.github/workflows/golden-copy-staging-test-run.yml b/.github/workflows/golden-copy-staging-test-run.yml
index 4c3cfb509..eb27dfa4f 100644
--- a/.github/workflows/golden-copy-staging-test-run.yml
+++ b/.github/workflows/golden-copy-staging-test-run.yml
@@ -6,13 +6,9 @@ on:
   workflow_dispatch:
 
 jobs:
-  test_files:
-    runs-on: ubuntu-latest
-
-    steps:
-      - name: Call staging-test-run.yml
-        uses: ./.github/workflows/staging-test-run_reusable.yml
-        with:
-          FILE_PATH: '../examples/Test/Automated/GoldenCopy/Expected/'
-          NAME: 'Golden Copy'
-          TEST_TYPE: 'goldenCopyTest'
+  call-staging-test-run:
+    uses: ./.github/workflows/staging-test-run_reusable.yml
+    with:
+      FILE_PATH: '../examples/Test/Automated/GoldenCopy/Expected/'
+      NAME: 'Golden Copy'
+      TEST_TYPE: 'goldenCopyTest'
diff --git a/.github/workflows/staging-test-run_reusable.yml b/.github/workflows/staging-test-run_reusable.yml
index f1987f35e..b7f4c2181 100644
--- a/.github/workflows/staging-test-run_reusable.yml
+++ b/.github/workflows/staging-test-run_reusable.yml
@@ -7,14 +7,17 @@ on:
         type: string
         description: The e2e test to run
         required: true
+        default: 'automatedTest'
       NAME:
         type: string
         description: The name of test
         required: true
+        default: 'Automated'
       FILE_PATH:
         type: string
         description: The path to local files
         required: true
+        default: '../examples/Test/Automated/'
 
 jobs:
   test_files:

From 714356296cdeb573108230b97344a2e4220b1f9e Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Tue, 24 Dec 2024 10:35:54 -0700
Subject: [PATCH 52/61] pass secrets to workflow

---
 .github/workflows/automated-staging-test-run.yml   | 1 +
 .github/workflows/golden-copy-staging-test-run.yml | 1 +
 .github/workflows/staging-test-run_reusable.yml    | 5 +++++
 3 files changed, 7 insertions(+)

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index 5a0f2c27d..222061f42 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -12,3 +12,4 @@ jobs:
       FILE_PATH: '../examples/Test/Automated/'
       NAME: 'Automated'
       TEST_TYPE: 'automatedTest'
+    secrets: inherit # pragma: allowlist secret
diff --git a/.github/workflows/golden-copy-staging-test-run.yml b/.github/workflows/golden-copy-staging-test-run.yml
index eb27dfa4f..c1f079196 100644
--- a/.github/workflows/golden-copy-staging-test-run.yml
+++ b/.github/workflows/golden-copy-staging-test-run.yml
@@ -12,3 +12,4 @@ jobs:
       FILE_PATH: '../examples/Test/Automated/GoldenCopy/Expected/'
       NAME: 'Golden Copy'
       TEST_TYPE: 'goldenCopyTest'
+    secrets: inherit # pragma: allowlist secret
diff --git a/.github/workflows/staging-test-run_reusable.yml b/.github/workflows/staging-test-run_reusable.yml
index b7f4c2181..bfbbbdb11 100644
--- a/.github/workflows/staging-test-run_reusable.yml
+++ b/.github/workflows/staging-test-run_reusable.yml
@@ -18,6 +18,11 @@ on:
         description: The path to local files
         required: true
         default: '../examples/Test/Automated/'
+    secrets:
+        AUTOMATED_TEST_AZURE_STORAGE_CONNECTION_STRING:
+          required: true
+        SLACK_WEBHOOK_URL:
+          required: true
 
 jobs:
   test_files:

From c87d402bd20fb45463fabdd8d37fa58bf9bd4763 Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Tue, 24 Dec 2024 10:41:52 -0700
Subject: [PATCH 53/61] fix file path and exclude from test

---
 .github/workflows/automated-staging-test-run.yml | 2 +-
 .github/workflows/staging-test-run_reusable.yml  | 2 +-
 rs-e2e/build.gradle                              | 1 +
 3 files changed, 3 insertions(+), 2 deletions(-)

diff --git a/.github/workflows/automated-staging-test-run.yml b/.github/workflows/automated-staging-test-run.yml
index 222061f42..2027aa78f 100644
--- a/.github/workflows/automated-staging-test-run.yml
+++ b/.github/workflows/automated-staging-test-run.yml
@@ -9,7 +9,7 @@ jobs:
   call-staging-test-run:
     uses: ./.github/workflows/staging-test-run_reusable.yml
     with:
-      FILE_PATH: '../examples/Test/Automated/'
+      FILE_PATH: '../examples/Test/Automated/Assertion/'
       NAME: 'Automated'
       TEST_TYPE: 'automatedTest'
     secrets: inherit # pragma: allowlist secret
diff --git a/.github/workflows/staging-test-run_reusable.yml b/.github/workflows/staging-test-run_reusable.yml
index bfbbbdb11..18b847ea8 100644
--- a/.github/workflows/staging-test-run_reusable.yml
+++ b/.github/workflows/staging-test-run_reusable.yml
@@ -17,7 +17,7 @@ on:
         type: string
         description: The path to local files
         required: true
-        default: '../examples/Test/Automated/'
+        default: '../examples/Test/Automated/Assertion/'
     secrets:
         AUTOMATED_TEST_AZURE_STORAGE_CONNECTION_STRING:
           required: true
diff --git a/rs-e2e/build.gradle b/rs-e2e/build.gradle
index 5f45c8e5d..c0bd1166d 100644
--- a/rs-e2e/build.gradle
+++ b/rs-e2e/build.gradle
@@ -31,6 +31,7 @@ dependencies {
 tasks.named('test') {
     useJUnitPlatform()
     exclude '**/AutomatedTest.*'
+    exclude '**/GoldenCopyTest.*'
 }
 
 task automatedTest(type: Test) {

From e6e7fbd4aec1f038b7f66faf2f279b875180e9de Mon Sep 17 00:00:00 2001
From: Bella Luz Quintero <bquintero@flexion.us>
Date: Tue, 24 Dec 2024 15:09:30 -0700
Subject: [PATCH 54/61] remove incorrect expected files and replace input files

---
 ..._ORU_R01_golden_copy_expected_acylc_1.fhir |   1 -
 ..._ORU_R01_golden_copy_expected_acylc_2.fhir |   1 -
 ...U_R01_golden_copy_expected_aa_unusual.fhir |   1 -
 ...ORU_R01_golden_copy_expected_in_range.fhir |   1 -
 ...R01_golden_copy_expected_out_of_range.fhir |   1 -
 ...1_golden_copy_expected_sma_incomplete.fhir |   1 -
 ..._R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7 |   1 +
 .../001_ORU_R01_golden_copy_input_acylc_1.hl7 | 143 ------------------
 ..._R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7 |   1 +
 .../002_ORU_R01_golden_copy_input_acylc_2.hl7 | 142 -----------------
 ...U_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7 |   1 +
 ...3_ORU_R01_golden_copy_input_aa_unusual.hl7 | 142 -----------------
 ...U_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7 |   1 +
 ...004_ORU_R01_golden_copy_input_in_range.hl7 | 142 -----------------
 ..._R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7 |   1 +
 ...ORU_R01_golden_copy_input_out_of_range.hl7 | 142 -----------------
 ..._R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7 |   1 +
 ...U_R01_golden_copy_input_sma_incomplete.hl7 | 141 -----------------
 ..._UCSD_189717091_80015955_pre_TI_TC007A.hl7 |   1 +
 ...1_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7 |   1 +
 ...SD_MRN_80009320_pre_TI_TC001_Corrected.hl7 |   1 +
 ...01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7 |   1 +
 ...01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7 |   1 +
 examples/Test/Automated/GoldenCopy/README.md  |  11 --
 24 files changed, 11 insertions(+), 869 deletions(-)
 delete mode 100644 examples/Test/Automated/GoldenCopy/Expected/001_ORU_R01_golden_copy_expected_acylc_1.fhir
 delete mode 100644 examples/Test/Automated/GoldenCopy/Expected/002_ORU_R01_golden_copy_expected_acylc_2.fhir
 delete mode 100644 examples/Test/Automated/GoldenCopy/Expected/003_ORU_R01_golden_copy_expected_aa_unusual.fhir
 delete mode 100644 examples/Test/Automated/GoldenCopy/Expected/004_ORU_R01_golden_copy_expected_in_range.fhir
 delete mode 100644 examples/Test/Automated/GoldenCopy/Expected/005_ORU_R01_golden_copy_expected_out_of_range.fhir
 delete mode 100644 examples/Test/Automated/GoldenCopy/Expected/006_ORU_R01_golden_copy_expected_sma_incomplete.fhir
 create mode 100644 examples/Test/Automated/GoldenCopy/Input/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
 delete mode 100644 examples/Test/Automated/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Input/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7
 delete mode 100644 examples/Test/Automated/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Input/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7
 delete mode 100644 examples/Test/Automated/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Input/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7
 delete mode 100644 examples/Test/Automated/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Input/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7
 delete mode 100644 examples/Test/Automated/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Input/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7
 delete mode 100644 examples/Test/Automated/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Input/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Input/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Input/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Input/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Input/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7

diff --git a/examples/Test/Automated/GoldenCopy/Expected/001_ORU_R01_golden_copy_expected_acylc_1.fhir b/examples/Test/Automated/GoldenCopy/Expected/001_ORU_R01_golden_copy_expected_acylc_1.fhir
deleted file mode 100644
index cb65a9201..000000000
--- a/examples/Test/Automated/GoldenCopy/Expected/001_ORU_R01_golden_copy_expected_acylc_1.fhir
+++ /dev/null
@@ -1 +0,0 @@
-{"resourceType":"Bundle","id":"1734642835067543884.e722b4fd-5373-4857-9ccd-ef0ec825cfcb","meta":{"lastUpdated":"2024-12-19T21:13:55.067+00:00"},"identifier":{"system":"https://reportstream.cdc.gov/prime-router","value":"001"},"type":"message","timestamp":"2024-10-15T05:06:54.000+00:00","entry":[{"fullUrl":"MessageHeader/1734642835068444112.4f9d840b-68c9-40a0-a531-d31dff7b8685","resource":{"resourceType":"MessageHeader","id":"1734642835068444112.4f9d840b-68c9-40a0-a531-d31dff7b8685","meta":{"tag":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0103","code":"N"}]},"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/msh-message-header","extension":[{"url":"MSH.7","valueString":"20241015050654"}]}],"eventCoding":{"system":"http://terminology.hl7.org/CodeSystem/v2-0003","code":"R01","display":"ORU^R01^ORU_R01"},"destination":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id","valueString":"9413816"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id-type","valueString":"L,M,N"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.5"}],"name":"SISHIERECEIVER","receiver":{"reference":"Organization/1734642835068200185.fc1f1b38-709d-409c-91d1-ab0613be9e5c"}}],"sender":{"reference":"Organization/1734642835067731256.9daec844-69a3-4cd5-9129-1cf40049edf4"},"source":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"SISGDSP"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.3"}],"name":"SISGDSP","_endpoint":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}}},{"fullUrl":"Organization/1734642835067731256.9daec844-69a3-4cd5-9129-1cf40049edf4","resource":{"resourceType":"Organization","id":"1734642835067731256.9daec844-69a3-4cd5-9129-1cf40049edf4","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Organization/1734642835068200185.fc1f1b38-709d-409c-91d1-ab0613be9e5c","resource":{"resourceType":"Organization","id":"1734642835068200185.fc1f1b38-709d-409c-91d1-ab0613be9e5c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.6"}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.2,HD.3"}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301","code":"L,M,N"}]},"value":"automated-staging-test-receiver-id"}]}},{"fullUrl":"Provenance/1734642835069690901.9980d2c9-f7f1-424d-8a2a-b06f8122fd4c","resource":{"resourceType":"Provenance","id":"1734642835069690901.9980d2c9-f7f1-424d-8a2a-b06f8122fd4c","target":[{"reference":"MessageHeader/1734642835068444112.4f9d840b-68c9-40a0-a531-d31dff7b8685"},{"reference":"DiagnosticReport/1734642835547275564.00008400-dedd-4c3f-8968-03e87b20168f"},{"reference":"DiagnosticReport/1734642835553041496.905154d3-791c-4e4c-8ca3-4c3696b5c9e5"},{"reference":"DiagnosticReport/1734642835559411751.dbca6ed0-6ffe-4243-8531-f779d28c8c28"},{"reference":"DiagnosticReport/1734642835564422737.2cd120c8-1965-48a9-9f2b-4b44ee7657d9"},{"reference":"DiagnosticReport/1734642835571718859.7bab1bd2-c54b-4be7-bbb3-f538a840b78b"},{"reference":"DiagnosticReport/1734642835576911345.4cea296d-3d84-49d3-b748-8fc14e7ebd0e"},{"reference":"DiagnosticReport/1734642835588311032.5e1f78bb-7715-4fa5-bfd2-90c95c87e070"},{"reference":"DiagnosticReport/1734642835594442249.53dfd7d7-b35b-49f9-9dd4-1a5b215413bd"},{"reference":"DiagnosticReport/1734642835599680210.58ca4c86-9ba4-499d-90ba-e4f5010845db"},{"reference":"DiagnosticReport/1734642835605009383.4f47e62b-55ee-42e4-8b1f-aa4de5dca825"},{"reference":"DiagnosticReport/1734642835610311906.a396e7e0-528b-4007-b2ab-0e3bfc0e71cb"},{"reference":"DiagnosticReport/1734642835615540581.92060203-4181-48bb-ac65-b6f4b2412e1d"},{"reference":"DiagnosticReport/1734642835620764356.aa2f70a5-10a2-4fc5-a91c-a61f4a370dee"},{"reference":"DiagnosticReport/1734642835629477723.a50a508e-79c8-43b9-b740-dc65e70d38b5"},{"reference":"DiagnosticReport/1734642835634765358.f625e7db-f332-4af3-91cd-a982fc5662a3"},{"reference":"DiagnosticReport/1734642835640106874.9696df46-a0d7-4520-907c-de7610ae553a"},{"reference":"DiagnosticReport/1734642835643185858.7d84b3b9-82fa-4665-8995-48496677574d"},{"reference":"DiagnosticReport/1734642835646250675.aaf7e242-0a04-48fc-8fcd-37534054d84c"},{"reference":"DiagnosticReport/1734642835649684624.fd75d2d7-0fe4-4419-bedb-557668b7d57b"},{"reference":"DiagnosticReport/1734642835652690020.0f9c42bb-342e-4304-bcfc-736b4b385ce5"},{"reference":"DiagnosticReport/1734642835655881985.a9bb371f-6f8a-4ef4-a6fd-831000e7a9db"},{"reference":"DiagnosticReport/1734642835658967160.47cc3e88-d62c-4805-8020-c4d50e4dd26f"},{"reference":"DiagnosticReport/1734642835661953110.4e4c493f-1bd7-4664-b919-1d64cda84098"}],"recorded":"2024-10-15T05:06:54Z","activity":{"coding":[{"display":"ORU^R01^ORU_R01"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"author"}]},"who":{"reference":"Organization/1734642835069413500.d3c486c5-6d5c-4d05-9232-7bad25642e1d"}}]}},{"fullUrl":"Organization/1734642835069413500.d3c486c5-6d5c-4d05-9232-7bad25642e1d","resource":{"resourceType":"Organization","id":"1734642835069413500.d3c486c5-6d5c-4d05-9232-7bad25642e1d","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Provenance/1734642835070422943.01e98690-c059-4915-b9ad-09ed58453b64","resource":{"resourceType":"Provenance","id":"1734642835070422943.01e98690-c059-4915-b9ad-09ed58453b64","recorded":"2024-12-19T21:13:55Z","policy":["http://hl7.org/fhir/uv/v2mappings/message-oru-r01-to-bundle"],"activity":{"coding":[{"code":"v2-FHIR transformation"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"assembler"}]},"who":{"reference":"Organization/1734642835070158788.296f2740-5279-4ec2-8b70-9c4fb6a3e7d8"}}]}},{"fullUrl":"Organization/1734642835070158788.296f2740-5279-4ec2-8b70-9c4fb6a3e7d8","resource":{"resourceType":"Organization","id":"1734642835070158788.296f2740-5279-4ec2-8b70-9c4fb6a3e7d8","identifier":[{"value":"CDC PRIME - Atlanta"},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301"}]},"system":"urn:ietf:rfc:3986","value":"2.16.840.1.114222.4.1.237821"}]}},{"fullUrl":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d","resource":{"resourceType":"Patient","id":"1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cx-identifier","extension":[{"url":"CX.5","valueString":"MR"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"PID.3"}],"type":{"coding":[{"code":"MR"}]},"value":"32550867","assigner":{"reference":"Organization/1734642835071351043.e0ccfc27-7def-4ddf-a08b-7579b288853b"}}],"name":[{"family":"*****PII REMOVED******"}],"contact":[{"name":{"family":"*****PII REMOVED******"}}]}},{"fullUrl":"Organization/1734642835071351043.e0ccfc27-7def-4ddf-a08b-7579b288853b","resource":{"resourceType":"Organization","id":"1734642835071351043.e0ccfc27-7def-4ddf-a08b-7579b288853b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"1013163542&NPI"}]}},{"fullUrl":"Provenance/1734642835075013561.7c8d6005-4f66-456f-bce6-935b111d4053","resource":{"resourceType":"Provenance","id":"1734642835075013561.7c8d6005-4f66-456f-bce6-935b111d4053","target":[{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}],"recorded":"2024-12-19T21:13:55Z","activity":{"coding":[{"system":"https://terminology.hl7.org/CodeSystem/v3-DataOperation","code":"UPDATE"}]}}},{"fullUrl":"RelatedPerson/1734642835075868314.21d34048-42a2-4e65-bd8f-be6b9b56abef","resource":{"resourceType":"RelatedPerson","id":"1734642835075868314.21d34048-42a2-4e65-bd8f-be6b9b56abef","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"NK1"}],"patient":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"name":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"NK1.2"}],"family":"*****PII REMOVED******"}]}},{"fullUrl":"Observation/1734642835078369364.c2196b8f-737f-445d-ac4b-45735aeac2e6","resource":{"resourceType":"Observation","id":"1734642835078369364.c2196b8f-737f-445d-ac4b-45735aeac2e6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57721-3","display":"Reason for lab test in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12421-6","display":"Initial screen"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835080495691.7632bb5a-b1c3-4b60-b145-041618ed55c1","resource":{"resourceType":"Observation","id":"1734642835080495691.7632bb5a-b1c3-4b60-b145-041618ed55c1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57718-9","display":"Sample quality of Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12432-3","display":"Acceptable"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835082674046.0a733602-c7ef-4873-94e1-516cb480d33e","resource":{"resourceType":"Observation","id":"1734642835082674046.0a733602-c7ef-4873-94e1-516cb480d33e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57130-7","display":"Newborn screening report - overall interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18944-1","display":"Screen is out of range for at least one condition"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835084793380.e237aaaa-126b-4daa-a608-96962f96de3d","resource":{"resourceType":"Observation","id":"1734642835084793380.e237aaaa-126b-4daa-a608-96962f96de3d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57131-5","display":"Newborn conditions with positive markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835086855126.3ce43713-b917-4307-b320-ce0b2ebf2fe0","resource":{"resourceType":"Observation","id":"1734642835086855126.3ce43713-b917-4307-b320-ce0b2ebf2fe0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57720-5","display":"Newborn conditions with equivocal markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835088717829.68dca08f-1e3a-4579-a954-98257e12481e","resource":{"resourceType":"Observation","id":"1734642835088717829.68dca08f-1e3a-4579-a954-98257e12481e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57724-7","display":"Newborn screening short narrative summary"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"ACTION REQUIRED\\\\.br\\\\\\\\.br\\\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\\\\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\\\.br\\\\\\\\.br\\\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\\\.br\\\\\\\\.br\\\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\\\.br\\\\\\\\.br\\\\Follow-up:\\\\.br\\\\\\\\.br\\\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\\\.br\\\\\\\\.br\\\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\\\.br\\\\\\\\.br\\\\Methods and Limitations:\\\\.br\\\\\\\\.br\\\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\\\.br\\\\Attention Healthcare Provider:\\\\.br\\\\\\\\.br\\\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\\\.br\\\\\\\\.br\\","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835090658378.f9967c85-8bce-483b-8f52-c1f86b5345ab","resource":{"resourceType":"Observation","id":"1734642835090658378.f9967c85-8bce-483b-8f52-c1f86b5345ab","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57129-9","display":"Full newborn screening summary report for display or printing"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835092518015.ecfaa4b9-3cd1-4b28-b03d-d5467ce0256b","resource":{"resourceType":"Observation","id":"1734642835092518015.ecfaa4b9-3cd1-4b28-b03d-d5467ce0256b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"ST"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57716-3","display":"State printed on filter paper card [Identifier] in NBS card"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"CA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835094763425.fbd8468f-31dc-4afc-bd64-011ed531d4f5","resource":{"resourceType":"Observation","id":"1734642835094763425.fbd8468f-31dc-4afc-bd64-011ed531d4f5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"grams"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"8339-4","display":"Birthweight"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":4020,"unit":"grams"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835096753407.335a9405-05bf-4cf8-a784-653c8c7b3f03","resource":{"resourceType":"Observation","id":"1734642835096753407.335a9405-05bf-4cf8-a784-653c8c7b3f03","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57715-5","display":"Time of birth"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueTime":"1416","_valueTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"1416"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835098930860.da2d043f-88c3-4b08-aa9d-8e4b693937b0","resource":{"resourceType":"Observation","id":"1734642835098930860.da2d043f-88c3-4b08-aa9d-8e4b693937b0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57722-1","display":"Birth plurality of Pregnancy"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12411-7","display":"Singleton"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835103742933.94767150-dbad-4916-b838-ccdf292751e8","resource":{"resourceType":"Observation","id":"1734642835103742933.94767150-dbad-4916-b838-ccdf292751e8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"hour(s)"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"73806-2","display":"Newborn age in hours"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":24,"unit":"hour(s)"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835105967955.b8ba9fbf-48cc-497b-9abd-65fc6367fd39","resource":{"resourceType":"Observation","id":"1734642835105967955.b8ba9fbf-48cc-497b-9abd-65fc6367fd39","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57713-0","display":"Infant NICU factors that affect newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835108045581.fd28d933-fe5b-4535-8299-eae01e9f9772","resource":{"resourceType":"Observation","id":"1734642835108045581.fd28d933-fe5b-4535-8299-eae01e9f9772","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67704-7","display":"Feeding types"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA16914-6","display":"Breast milk"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835110135560.5df45eb7-4436-4275-b0f3-a346250ba6a5","resource":{"resourceType":"Observation","id":"1734642835110135560.5df45eb7-4436-4275-b0f3-a346250ba6a5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67704-7","display":"Feeding types"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA16915-3","display":"Lactose formula"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835111937279.a13f52de-fb3e-42c5-b70b-8928b41db139","resource":{"resourceType":"Observation","id":"1734642835111937279.a13f52de-fb3e-42c5-b70b-8928b41db139","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-5","display":"Accession Number"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"277-86-190/21-2024-32","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835113791285.a93e71ad-6e66-4cb1-975c-0b72e1ec82b3","resource":{"resourceType":"Observation","id":"1734642835113791285.a93e71ad-6e66-4cb1-975c-0b72e1ec82b3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62324-9","display":"Post-discharge provider name"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"STEWART BROOKS","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835115568047.503e318a-9232-4da8-9224-3ac70778c436","resource":{"resourceType":"Observation","id":"1734642835115568047.503e318a-9232-4da8-9224-3ac70778c436","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62325-6","display":"Post-discharge provider practice ID"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"1477542173","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835117366028.a90473f2-2703-420c-b243-a76140002965","resource":{"resourceType":"Observation","id":"1734642835117366028.a90473f2-2703-420c-b243-a76140002965","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62327-2","display":"Post-discharge provider practice address"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835119388891.5a6ef168-f3d7-4d65-8702-8ad61c5d91c1","resource":{"resourceType":"Observation","id":"1734642835119388891.5a6ef168-f3d7-4d65-8702-8ad61c5d91c1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47633-3","display":"Glycine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":387,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835121480383.7a5f35b5-fa6e-487e-ab4d-b9e13376e739","resource":{"resourceType":"Observation","id":"1734642835121480383.7a5f35b5-fa6e-487e-ab4d-b9e13376e739","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53150-9","display":"Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":381,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1000"}]}},{"fullUrl":"Observation/1734642835123554132.e09200e9-c15a-4a65-b6b6-e161fdf37208","resource":{"resourceType":"Observation","id":"1734642835123554132.e09200e9-c15a-4a65-b6b6-e161fdf37208","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47799-2","display":"Valine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":92.6,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835125650042.fb0f3ad6-1421-438e-aa27-18b629de869d","resource":{"resourceType":"Observation","id":"1734642835125650042.fb0f3ad6-1421-438e-aa27-18b629de869d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53151-7","display":"Valine/Phenylalanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":1.88595,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.3"}]}},{"fullUrl":"Observation/1734642835127731345.61fe2a05-efe7-465e-bfde-aa231fab366c","resource":{"resourceType":"Observation","id":"1734642835127731345.61fe2a05-efe7-465e-bfde-aa231fab366c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53152-5","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":86.8,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<230"}]}},{"fullUrl":"Observation/1734642835129903108.d4dda740-dd49-43d6-bc9b-25bf1279d5ee","resource":{"resourceType":"Observation","id":"1734642835129903108.d4dda740-dd49-43d6-bc9b-25bf1279d5ee","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53154-1","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.23,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.35"}]}},{"fullUrl":"Observation/1734642835132201607.e6bc54d2-552d-489d-9ae6-62ed2947bbfc","resource":{"resourceType":"Observation","id":"1734642835132201607.e6bc54d2-552d-489d-9ae6-62ed2947bbfc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29573-3","display":"Phenylalanine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":49.1,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<175"}]}},{"fullUrl":"Observation/1734642835134316363.4ed4d624-eb61-48f4-be97-5638df76e5e4","resource":{"resourceType":"Observation","id":"1734642835134316363.4ed4d624-eb61-48f4-be97-5638df76e5e4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35572-7","display":"Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":1.09,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2.6"}]}},{"fullUrl":"Observation/1734642835136414106.c0d7674a-7603-44b7-be2a-69fca6f812be","resource":{"resourceType":"Observation","id":"1734642835136414106.c0d7674a-7603-44b7-be2a-69fca6f812be","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35571-9","display":"Tyrosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":45.1,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<680"}]}},{"fullUrl":"Observation/1734642835138555141.69e9066d-9ec7-4684-856e-6fea5af26e44","resource":{"resourceType":"Observation","id":"1734642835138555141.69e9066d-9ec7-4684-856e-6fea5af26e44","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53231-7","display":"Succinylacetone [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.24,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<6.1"}]}},{"fullUrl":"Observation/1734642835140681458.81b74ae1-30fb-48ee-9715-2cb02de30059","resource":{"resourceType":"Observation","id":"1734642835140681458.81b74ae1-30fb-48ee-9715-2cb02de30059","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47700-0","display":"Methionine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":16.8,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.3-100"}]}},{"fullUrl":"Observation/1734642835142831109.183b9ea7-e9a9-4ae9-8815-e9289498e43e","resource":{"resourceType":"Observation","id":"1734642835142831109.183b9ea7-e9a9-4ae9-8815-e9289498e43e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42892-0","display":"Citrulline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":20,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"5-49"}]}},{"fullUrl":"Observation/1734642835145029071.6d59c882-47f8-468a-9605-b2eac4033062","resource":{"resourceType":"Observation","id":"1734642835145029071.6d59c882-47f8-468a-9605-b2eac4033062","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54092-2","display":"Citrulline/Arginine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":3.22,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.8"}]}},{"fullUrl":"Observation/1734642835147116164.3622f8ea-dadd-4bcb-bdec-4be3ddf0bde7","resource":{"resourceType":"Observation","id":"1734642835147116164.3622f8ea-dadd-4bcb-bdec-4be3ddf0bde7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53155-8","display":"Asparagine+Ornithine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":74,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<800"}]}},{"fullUrl":"Observation/1734642835149213497.5c0bb970-be0d-433d-82c7-bb51bac1b7ee","resource":{"resourceType":"Observation","id":"1734642835149213497.5c0bb970-be0d-433d-82c7-bb51bac1b7ee","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75215-4","display":"Ornithine/Citrulline [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":3.76,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835151303085.143080f8-d26d-4ca3-bd0a-68be0eac89a4","resource":{"resourceType":"Observation","id":"1734642835151303085.143080f8-d26d-4ca3-bd0a-68be0eac89a4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47562-4","display":"Arginine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":6,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<63"}]}},{"fullUrl":"Observation/1734642835153524951.70cca668-8ac5-4daa-ad44-f014db61930b","resource":{"resourceType":"Observation","id":"1734642835153524951.70cca668-8ac5-4daa-ad44-f014db61930b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75214-7","display":"Arginine/Ornithine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.08,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.9"}]}},{"fullUrl":"Observation/1734642835155737450.2fdf26eb-1dad-4753-b21d-07eef73e6e1c","resource":{"resourceType":"Observation","id":"1734642835155737450.2fdf26eb-1dad-4753-b21d-07eef73e6e1c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47732-3","display":"Proline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":118,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1500"}]}},{"fullUrl":"Observation/1734642835157643855.9b2bf0f2-7367-4472-aa24-68cd2e9402e8","resource":{"resourceType":"Observation","id":"1734642835157643855.9b2bf0f2-7367-4472-aa24-68cd2e9402e8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57710-6","display":"Amino acidemias newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835159845143.ec8dc2e0-fac7-423d-82de-df26b1f9fc90","resource":{"resourceType":"Observation","id":"1734642835159845143.ec8dc2e0-fac7-423d-82de-df26b1f9fc90","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58088-6","display":"Acylcarnitine newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA11884-6","display":"Indeterminate"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"A"}]}]}},{"fullUrl":"Observation/1734642835161689441.9fe72387-651d-428a-b97d-3105fa1691f5","resource":{"resourceType":"Observation","id":"1734642835161689441.9fe72387-651d-428a-b97d-3105fa1691f5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58093-6","display":"Acylcarnitine newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"This pattern of elevations is consistent with SCADD, IBCDD","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"A"}]}]}},{"fullUrl":"Observation/1734642835163707606.0e7ac73a-3dd8-4727-82ef-eee6c4d05d14","resource":{"resourceType":"Observation","id":"1734642835163707606.0e7ac73a-3dd8-4727-82ef-eee6c4d05d14","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38481-8","display":"Carnitine.free (C0)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":34.3,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.4-125"}]}},{"fullUrl":"Observation/1734642835165827511.90623ef3-82b0-400c-9455-4378b7797070","resource":{"resourceType":"Observation","id":"1734642835165827511.90623ef3-82b0-400c-9455-4378b7797070","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53235-8","display":"Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":5.93,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<70"}]}},{"fullUrl":"Observation/1734642835167903263.045e84d0-3ee4-4092-8679-e0b8932c27f6","resource":{"resourceType":"Observation","id":"1734642835167903263.045e84d0-3ee4-4092-8679-e0b8932c27f6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50157-7","display":"Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":33.2,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"10-80"}]}},{"fullUrl":"Observation/1734642835170008381.df833064-f458-44c8-aae6-912dad9d9087","resource":{"resourceType":"Observation","id":"1734642835170008381.df833064-f458-44c8-aae6-912dad9d9087","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75212-1","display":"Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":1.29565,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.6"}]}},{"fullUrl":"Observation/1734642835172132283.9f0c7a5d-71ba-47af-9c10-6225b15373f5","resource":{"resourceType":"Observation","id":"1734642835172132283.9f0c7a5d-71ba-47af-9c10-6225b15373f5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45211-0","display":"Hexanoylcarnitine (C6)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.136,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835177087191.d4761a12-0246-469f-8b0a-7739d293f508","resource":{"resourceType":"Observation","id":"1734642835177087191.d4761a12-0246-469f-8b0a-7739d293f508","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53175-6","display":"Octanoylcarnitine (C8)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.150,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835179226894.a1e5f914-f409-483e-8e82-e97c4a9dc4bd","resource":{"resourceType":"Observation","id":"1734642835179226894.a1e5f914-f409-483e-8e82-e97c4a9dc4bd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53177-2","display":"Octanoylcarnitine (C8)/Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.65,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835181327282.deb6ed28-b853-48a8-a693-12199af60ec9","resource":{"resourceType":"Observation","id":"1734642835181327282.deb6ed28-b853-48a8-a693-12199af60ec9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53174-9","display":"Octenoylcarnitine (C8:1)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.221,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835183410599.4769d68b-068a-4463-824b-ca3c936e1b7f","resource":{"resourceType":"Observation","id":"1734642835183410599.4769d68b-068a-4463-824b-ca3c936e1b7f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45197-1","display":"Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.230,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835185557374.a69db609-b0ce-4b99-8746-637931d3a44c","resource":{"resourceType":"Observation","id":"1734642835185557374.a69db609-b0ce-4b99-8746-637931d3a44c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45198-9","display":"Decenoylcarnitine (C10:1)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.088,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835187803676.e0d1ff83-2851-4408-ba12-9c6390114b98","resource":{"resourceType":"Observation","id":"1734642835187803676.e0d1ff83-2851-4408-ba12-9c6390114b98","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45199-7","display":"Dodecanoylcarnitine (C12)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.232,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2"}]}},{"fullUrl":"Observation/1734642835189909665.62d7569d-0a11-4642-bad3-b156e86d58a0","resource":{"resourceType":"Observation","id":"1734642835189909665.62d7569d-0a11-4642-bad3-b156e86d58a0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45200-3","display":"Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.20,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835192058094.bd18c898-1943-47e4-8811-ff5a80ae85a6","resource":{"resourceType":"Observation","id":"1734642835192058094.bd18c898-1943-47e4-8811-ff5a80ae85a6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53192-1","display":"Tetradecanoylcarnitine (C14)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.342,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.2"}]}},{"fullUrl":"Observation/1734642835194313693.22932fcf-61d0-480d-8035-f2a79a45e484","resource":{"resourceType":"Observation","id":"1734642835194313693.22932fcf-61d0-480d-8035-f2a79a45e484","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53191-3","display":"Tetradecenoylcarnitine (C14:1)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.206,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.9"}]}},{"fullUrl":"Observation/1734642835196515723.57267597-c36f-4219-91d0-7c74202d2d52","resource":{"resourceType":"Observation","id":"1734642835196515723.57267597-c36f-4219-91d0-7c74202d2d52","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53194-7","display":"Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":1.02,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835198572800.e5ec271e-b6dd-4e3b-946f-ce198988c137","resource":{"resourceType":"Observation","id":"1734642835198572800.e5ec271e-b6dd-4e3b-946f-ce198988c137","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53190-5","display":"Tetradecadienoylcarnitine (C14:2)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.03,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835200670263.961accbb-4104-4d11-8134-76e59c661438","resource":{"resourceType":"Observation","id":"1734642835200670263.961accbb-4104-4d11-8134-76e59c661438","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50281-5","display":"3-Hydroxytetradecanoylcarnitine (C14-OH)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.029,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.2"}]}},{"fullUrl":"Observation/1734642835202756185.b72b6129-dc37-4fd6-b7f0-5c5bf464d238","resource":{"resourceType":"Observation","id":"1734642835202756185.b72b6129-dc37-4fd6-b7f0-5c5bf464d238","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53199-6","display":"Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":4.14,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<12"}]}},{"fullUrl":"Observation/1734642835204989482.04869e37-ffba-4675-b7ab-3c98773de6a9","resource":{"resourceType":"Observation","id":"1734642835204989482.04869e37-ffba-4675-b7ab-3c98773de6a9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53198-8","display":"Palmitoleylcarnitine (C16:1)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.341,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.4"}]}},{"fullUrl":"Observation/1734642835207217761.ede199f5-0a4b-4351-ad09-4b8881bde701","resource":{"resourceType":"Observation","id":"1734642835207217761.ede199f5-0a4b-4351-ad09-4b8881bde701","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50125-4","display":"3-Hydroxypalmitoylcarnitine (C16-OH)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.049,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835209347895.261b7657-6f9b-432a-8f29-b9874b99b609","resource":{"resourceType":"Observation","id":"1734642835209347895.261b7657-6f9b-432a-8f29-b9874b99b609","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53201-0","display":"3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.01184,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.07"}]}},{"fullUrl":"Observation/1734642835211671422.438e14ff-0281-49e7-b165-a19336723741","resource":{"resourceType":"Observation","id":"1734642835211671422.438e14ff-0281-49e7-b165-a19336723741","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53241-6","display":"Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":1.07,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<3.5"}]}},{"fullUrl":"Observation/1734642835213810493.5b329d38-601f-4845-8033-9be87d25aca5","resource":{"resourceType":"Observation","id":"1734642835213810493.5b329d38-601f-4845-8033-9be87d25aca5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53202-8","display":"Oleoylcarnitine (C18:1)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":1.65,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7"}]}},{"fullUrl":"Observation/1734642835215877980.36b9a8cc-d3df-4d30-a31c-90f2e034379a","resource":{"resourceType":"Observation","id":"1734642835215877980.36b9a8cc-d3df-4d30-a31c-90f2e034379a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45217-7","display":"Linoleoylcarnitine (C18:2)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.23,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835217975733.dc31874a-a4be-4b8a-af75-fd59ad417868","resource":{"resourceType":"Observation","id":"1734642835217975733.dc31874a-a4be-4b8a-af75-fd59ad417868","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50132-0","display":"3-Hydroxystearoylcarnitine (C18-OH)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.022,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835220100768.05a1dc4e-f604-4e77-9ea7-afbf81b8198f","resource":{"resourceType":"Observation","id":"1734642835220100768.05a1dc4e-f604-4e77-9ea7-afbf81b8198f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50113-0","display":"3-Hydroxyoleoylcarnitine (C18:1-OH)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.053,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835222279323.b0f928cc-46cf-4aaa-adff-fe2ce7a5ceef","resource":{"resourceType":"Observation","id":"1734642835222279323.b0f928cc-46cf-4aaa-adff-fe2ce7a5ceef","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53160-8","display":"Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":2.3,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.9"}]}},{"fullUrl":"Observation/1734642835224430367.da780c77-72b4-4336-9039-a31184926686","resource":{"resourceType":"Observation","id":"1734642835224430367.da780c77-72b4-4336-9039-a31184926686","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53163-2","display":"Propionylcarnitine (C3)/Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.07,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.42"}]}},{"fullUrl":"Observation/1734642835226529483.7b86fa71-ee93-43a1-b76d-cd849e73ca00","resource":{"resourceType":"Observation","id":"1734642835226529483.7b86fa71-ee93-43a1-b76d-cd849e73ca00","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67708-8","display":"Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.298,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.48"}]}},{"fullUrl":"Observation/1734642835228718427.086f9d04-6daa-4866-94d7-a65517888d6c","resource":{"resourceType":"Observation","id":"1734642835228718427.086f9d04-6daa-4866-94d7-a65517888d6c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53166-5","display":"Butyrylcarnitine+Isobutyrylcarnitine (C4)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":1.73,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"H"}]}],"referenceRange":[{"text":"<1.7"}]}},{"fullUrl":"Observation/1734642835230835868.279fed09-20e6-49b8-96a2-93eef87155d8","resource":{"resourceType":"Observation","id":"1734642835230835868.279fed09-20e6-49b8-96a2-93eef87155d8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45216-9","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.139,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835233122375.0c6b8d22-57b3-4294-9b1e-c3a0a59070e9","resource":{"resourceType":"Observation","id":"1734642835233122375.0c6b8d22-57b3-4294-9b1e-c3a0a59070e9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53240-8","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.06043,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642835235257058.bdccfc91-c409-4ac8-9243-1ce9a9c8d5e8","resource":{"resourceType":"Observation","id":"1734642835235257058.bdccfc91-c409-4ac8-9243-1ce9a9c8d5e8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53170-7","display":"Tiglylcarnitine (C5:1)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.011,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.5"}]}},{"fullUrl":"Observation/1734642835237360573.bc47837e-0b31-4a8e-b5ed-80ea7f6a5306","resource":{"resourceType":"Observation","id":"1734642835237360573.bc47837e-0b31-4a8e-b5ed-80ea7f6a5306","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50106-4","display":"3-Hydroxyisovalerylcarnitine (C5-OH)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.306,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.15"}]}},{"fullUrl":"Observation/1734642835239462615.dbfb2d97-079e-41cf-a27e-23be7e134d01","resource":{"resourceType":"Observation","id":"1734642835239462615.dbfb2d97-079e-41cf-a27e-23be7e134d01","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67710-4","display":"Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.238,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642835241573904.95e1902d-39bc-4c32-b276-f57426ac9754","resource":{"resourceType":"Observation","id":"1734642835241573904.95e1902d-39bc-4c32-b276-f57426ac9754","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75216-2","display":"Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.79866,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">0.1"}]}},{"fullUrl":"Observation/1734642835243642913.6b373e0e-6c4c-4ba8-bc16-dbeaccbaa242","resource":{"resourceType":"Observation","id":"1734642835243642913.6b373e0e-6c4c-4ba8-bc16-dbeaccbaa242","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ng/mL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"48633-2","display":"Trypsinogen I.free"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":18.10,"unit":"ng/mL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<69"}]}},{"fullUrl":"Observation/1734642835245924111.ba72acbf-fdd2-4ade-a4ea-628501d3932d","resource":{"resourceType":"Observation","id":"1734642835245924111.ba72acbf-fdd2-4ade-a4ea-628501d3932d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46769-6","display":"Cystic fibrosis newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835250748858.075f5f4d-fb95-4b1c-b882-706af112ad10","resource":{"resourceType":"Observation","id":"1734642835250748858.075f5f4d-fb95-4b1c-b882-706af112ad10","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57707-2","display":"Cystic fibrosis newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835252910902.b34746e7-68e4-47e4-8123-c1d143b926c6","resource":{"resourceType":"Observation","id":"1734642835252910902.b34746e7-68e4-47e4-8123-c1d143b926c6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"nmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38473-5","display":"17-Hydroxyprogesterone"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":10.8,"unit":"nmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<85"}]}},{"fullUrl":"Observation/1734642835255176000.1844fffb-f304-497b-8dff-89fb14ade80b","resource":{"resourceType":"Observation","id":"1734642835255176000.1844fffb-f304-497b-8dff-89fb14ade80b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46758-9","display":"Congenital adrenal hyperplasia newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835256981315.d023e3a2-2bae-4586-ade7-0f801c8ecb93","resource":{"resourceType":"Observation","id":"1734642835256981315.d023e3a2-2bae-4586-ade7-0f801c8ecb93","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57706-4","display":"Congenital adrenal hyperplasia newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835258991303.471ccb24-c53b-4247-ae1b-85333058044f","resource":{"resourceType":"Observation","id":"1734642835258991303.471ccb24-c53b-4247-ae1b-85333058044f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"mIU/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29575-8","display":"Thyrotropin"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":4.00,"unit":"mIU/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<29"}]}},{"fullUrl":"Observation/1734642835261094698.216cfc15-4e6b-4054-a562-dc9d010ffdc4","resource":{"resourceType":"Observation","id":"1734642835261094698.216cfc15-4e6b-4054-a562-dc9d010ffdc4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46762-1","display":"Congenital hypothyroidism newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835262847204.678cc366-4570-42a8-9df3-afcdaca9c9ca","resource":{"resourceType":"Observation","id":"1734642835262847204.678cc366-4570-42a8-9df3-afcdaca9c9ca","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57705-6","display":"Congenital hypothyroidism newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835264921283.91ec1af6-893c-4d53-bac5-b0600e963d5f","resource":{"resourceType":"Observation","id":"1734642835264921283.91ec1af6-893c-4d53-bac5-b0600e963d5f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"enzyme units"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42906-8","display":"Galactose 1 phosphate uridyl transferase"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":267.94,"unit":"enzyme units"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">50"}]}},{"fullUrl":"Observation/1734642835267035147.1883610c-4f1d-4119-9f38-02c468008832","resource":{"resourceType":"Observation","id":"1734642835267035147.1883610c-4f1d-4119-9f38-02c468008832","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46737-3","display":"Galactosemias newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835268840823.be073532-267c-4705-bd5d-98f936d8a298","resource":{"resourceType":"Observation","id":"1734642835268840823.be073532-267c-4705-bd5d-98f936d8a298","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57704-9","display":"Galactosemias newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835270610922.3dea9e01-cf45-4440-859b-5f06ec5bcd78","resource":{"resourceType":"Observation","id":"1734642835270610922.3dea9e01-cf45-4440-859b-5f06ec5bcd78","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54104-5","display":"Hemoglobin pattern"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"FA"}},{"fullUrl":"Observation/1734642835272189662.237e8e77-bfda-4b54-8e00-1086f80d5fa5","resource":{"resourceType":"Observation","id":"1734642835272189662.237e8e77-bfda-4b54-8e00-1086f80d5fa5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57703-1","display":"Hemoglobin disorders newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants."}},{"fullUrl":"Observation/1734642835273965232.4d115769-fad3-4470-abfd-0fb327e43527","resource":{"resourceType":"Observation","id":"1734642835273965232.4d115769-fad3-4470-abfd-0fb327e43527","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ERU"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75217-0","display":"Biotinidase [Enzymatic activity/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":44.16,"unit":"ERU"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">10"}]}},{"fullUrl":"Observation/1734642835276087662.698b32ba-eee2-4766-bc7a-d4fa00fa3dd7","resource":{"resourceType":"Observation","id":"1734642835276087662.698b32ba-eee2-4766-bc7a-d4fa00fa3dd7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46761-3","display":"Biotinidase deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835277860797.d3aeb34c-bcb9-4228-8631-558b588db30d","resource":{"resourceType":"Observation","id":"1734642835277860797.d3aeb34c-bcb9-4228-8631-558b588db30d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57699-1","display":"Biotinidase deficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835279841832.a1229730-924c-4549-b477-bf1b2cfd8e13","resource":{"resourceType":"Observation","id":"1734642835279841832.a1229730-924c-4549-b477-bf1b2cfd8e13","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"copies/µL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62320-7","display":"T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":84,"unit":"copies/µL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">18"}]}},{"fullUrl":"Observation/1734642835281978468.f15dce75-3889-43f5-958c-7ed178d61dd9","resource":{"resourceType":"Observation","id":"1734642835281978468.f15dce75-3889-43f5-958c-7ed178d61dd9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62321-5","display":"Severe combined immunodeficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835283734922.786a3096-c83d-41f3-888c-c9f92a602540","resource":{"resourceType":"Observation","id":"1734642835283734922.786a3096-c83d-41f3-888c-c9f92a602540","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62322-3","display":"Severe combined immunodeficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835285827456.e28416c0-d951-49ea-b27f-d348b5138f42","resource":{"resourceType":"Observation","id":"1734642835285827456.e28416c0-d951-49ea-b27f-d348b5138f42","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55827-0","display":"Acid alpha glucosidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":6.97,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=1.51"}]}},{"fullUrl":"Observation/1734642835287968320.ad75f0e5-8ce2-448a-a2a8-7933847307c0","resource":{"resourceType":"Observation","id":"1734642835287968320.ad75f0e5-8ce2-448a-a2a8-7933847307c0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63415-4","display":"Pompe Disease deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835289784355.144718e3-9b36-4dd4-aab8-91378f578a01","resource":{"resourceType":"Observation","id":"1734642835289784355.144718e3-9b36-4dd4-aab8-91378f578a01","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63416-2","display":"Pompe Disease deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835291780468.3717216f-340a-4b57-b6f6-533f29f70555","resource":{"resourceType":"Observation","id":"1734642835291780468.3717216f-340a-4b57-b6f6-533f29f70555","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55909-6","display":"Alpha-L-iduronidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":10.38,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=0.77"}]}},{"fullUrl":"Observation/1734642835293916704.2ae71bb9-0e78-4be4-b12f-2a3e8cf13640","resource":{"resourceType":"Observation","id":"1734642835293916704.2ae71bb9-0e78-4be4-b12f-2a3e8cf13640","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79564-1","display":"Mucopolysaccharidosis type I newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835295825143.3f0cd5e9-e867-40a2-9705-54078fe574fb","resource":{"resourceType":"Observation","id":"1734642835295825143.3f0cd5e9-e867-40a2-9705-54078fe574fb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79565-8","display":"Mucopolysaccharidosis type I newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835298238849.e1f75b37-69a0-4e11-96ba-52cd392bfbb2","resource":{"resourceType":"Observation","id":"1734642835298238849.e1f75b37-69a0-4e11-96ba-52cd392bfbb2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-60","display":"SMN1 Homozygous Deletion Analysis"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Exon 7 Present","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"Exon 7 Present"}]}},{"fullUrl":"Observation/1734642835300320963.6730aa2a-9456-489c-8593-97f2a053ac85","resource":{"resourceType":"Observation","id":"1734642835300320963.6730aa2a-9456-489c-8593-97f2a053ac85","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92004-1","display":"Spinal muscular atrophy newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835302129644.2bd6f20a-35fa-4b4c-a716-59ee8c023bc9","resource":{"resourceType":"Observation","id":"1734642835302129644.2bd6f20a-35fa-4b4c-a716-59ee8c023bc9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92003-3","display":"Spinal muscular atrophy newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"SMA Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835304240262.90534b48-83cc-4456-bee2-4f8adccd3fed","resource":{"resourceType":"Observation","id":"1734642835304240262.90534b48-83cc-4456-bee2-4f8adccd3fed","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79462-8","display":"Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":27.61,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=2.75"}]}},{"fullUrl":"Observation/1734642835306921540.9c7ab076-631e-46de-9f99-4a594333dba0","resource":{"resourceType":"Observation","id":"1734642835306921540.9c7ab076-631e-46de-9f99-4a594333dba0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104189-6","display":"Mucopolysaccharidosis type II newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835308835408.0ef7fd8a-38aa-4a53-8efa-1f4070b8722a","resource":{"resourceType":"Observation","id":"1734642835308835408.0ef7fd8a-38aa-4a53-8efa-1f4070b8722a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104190-4","display":"Mucopolysaccharidosis type II newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835310956776.8e5c8f5d-464e-4d6a-b6ff-aa6317ca2236","resource":{"resourceType":"Observation","id":"1734642835310956776.8e5c8f5d-464e-4d6a-b6ff-aa6317ca2236","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104192-0","display":"Guanidinoacetate methyltransferase deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835312849265.7b1a44be-87f3-4c3e-b8c2-4bb112a00396","resource":{"resourceType":"Observation","id":"1734642835312849265.7b1a44be-87f3-4c3e-b8c2-4bb112a00396","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104193-8","display":"Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835314906112.b7166b68-f03f-4d84-bf2c-0b3b7abe9d18","resource":{"resourceType":"Observation","id":"1734642835314906112.b7166b68-f03f-4d84-bf2c-0b3b7abe9d18","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"93488-5","display":"Guanidinoacetate [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":1.04,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=3"}]}},{"fullUrl":"Observation/1734642835317154138.6f022b94-8600-406a-b8f0-5fc23b87e94f","resource":{"resourceType":"Observation","id":"1734642835317154138.6f022b94-8600-406a-b8f0-5fc23b87e94f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104194-6","display":"Creatine [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":391.37,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835322641287.9e617f2f-7044-4954-ad62-cf9a106d32e7","resource":{"resourceType":"Observation","id":"1734642835322641287.9e617f2f-7044-4954-ad62-cf9a106d32e7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104195-3","display":"GUAC/CRE Ratio [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":2.66},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=6"}]}},{"fullUrl":"Observation/1734642835324840571.1d7a28bf-5661-4d4e-aa75-b787be359580","resource":{"resourceType":"Observation","id":"1734642835324840571.1d7a28bf-5661-4d4e-aa75-b787be359580","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-32","display":"Adrenoleukodystrophy deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835326726838.637b5c0e-2fa3-424f-9919-cc78bd0ac277","resource":{"resourceType":"Observation","id":"1734642835326726838.637b5c0e-2fa3-424f-9919-cc78bd0ac277","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-33","display":"Adrenoleukodystrophy deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835328833769.b1ef8e36-8a86-4ff0-89fb-be9399563adc","resource":{"resourceType":"Observation","id":"1734642835328833769.b1ef8e36-8a86-4ff0-89fb-be9399563adc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79321-6","display":"Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-15T05:06:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"valueQuantity":{"value":0.246,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.47"}]}},{"fullUrl":"Specimen/1734642835339257765.334367ae-6cf8-4c69-bbea-6c69cbe7b03f","resource":{"resourceType":"Specimen","id":"1734642835339257765.334367ae-6cf8-4c69-bbea-6c69cbe7b03f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835340756115.6e87362a-8040-4f57-b680-9d689ccb1713","resource":{"resourceType":"Specimen","id":"1734642835340756115.6e87362a-8040-4f57-b680-9d689ccb1713","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835342128909.4fd4310f-6fb3-47f4-bb83-66ba1586a53c","resource":{"resourceType":"Specimen","id":"1734642835342128909.4fd4310f-6fb3-47f4-bb83-66ba1586a53c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835343507644.b7a33119-8c73-4ac8-ad96-a6ba91294273","resource":{"resourceType":"Specimen","id":"1734642835343507644.b7a33119-8c73-4ac8-ad96-a6ba91294273","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835344937215.6667157e-8de8-47c2-917e-1c05fc4720f3","resource":{"resourceType":"Specimen","id":"1734642835344937215.6667157e-8de8-47c2-917e-1c05fc4720f3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835346298187.44b92531-e550-4f36-bd2f-7cc66563231e","resource":{"resourceType":"Specimen","id":"1734642835346298187.44b92531-e550-4f36-bd2f-7cc66563231e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835347647096.2b33be20-c50f-46cc-82b4-01a32c586924","resource":{"resourceType":"Specimen","id":"1734642835347647096.2b33be20-c50f-46cc-82b4-01a32c586924","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835349049456.62fb98dc-8087-4a66-95d6-f4ed8208a11c","resource":{"resourceType":"Specimen","id":"1734642835349049456.62fb98dc-8087-4a66-95d6-f4ed8208a11c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835350409446.25a13015-e80e-447a-9880-41f54e21c7e7","resource":{"resourceType":"Specimen","id":"1734642835350409446.25a13015-e80e-447a-9880-41f54e21c7e7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835351773143.a2f9e75c-f720-4819-8163-f0869dd878e3","resource":{"resourceType":"Specimen","id":"1734642835351773143.a2f9e75c-f720-4819-8163-f0869dd878e3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835353174381.56974595-1d78-4e47-8689-2c9fa54dd258","resource":{"resourceType":"Specimen","id":"1734642835353174381.56974595-1d78-4e47-8689-2c9fa54dd258","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835354552365.f4274b93-053b-4ea9-8cc0-78f77d14acd8","resource":{"resourceType":"Specimen","id":"1734642835354552365.f4274b93-053b-4ea9-8cc0-78f77d14acd8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835355916653.d20c9e73-898b-40ca-ae6f-d01f3073ecd1","resource":{"resourceType":"Specimen","id":"1734642835355916653.d20c9e73-898b-40ca-ae6f-d01f3073ecd1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835357303103.64850f3f-eae9-466a-9f6e-d8de284c438f","resource":{"resourceType":"Specimen","id":"1734642835357303103.64850f3f-eae9-466a-9f6e-d8de284c438f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835358672621.32ace6ea-8714-4a7c-9dc8-3a8b275f2e11","resource":{"resourceType":"Specimen","id":"1734642835358672621.32ace6ea-8714-4a7c-9dc8-3a8b275f2e11","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835360239980.b2a20ccb-343f-415a-a83f-351513f7aa49","resource":{"resourceType":"Specimen","id":"1734642835360239980.b2a20ccb-343f-415a-a83f-351513f7aa49","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835361666956.cc4f91e2-7a09-452b-8420-a10fd9c80e2b","resource":{"resourceType":"Specimen","id":"1734642835361666956.cc4f91e2-7a09-452b-8420-a10fd9c80e2b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835363030964.3a12ef62-abe5-4a3b-ad91-8b8d05157d1b","resource":{"resourceType":"Specimen","id":"1734642835363030964.3a12ef62-abe5-4a3b-ad91-8b8d05157d1b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835364420439.6a839ff7-18ff-4135-8756-87a3237a1401","resource":{"resourceType":"Specimen","id":"1734642835364420439.6a839ff7-18ff-4135-8756-87a3237a1401","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835365799685.6448fcb2-bb46-4a42-bee7-6b46fc845bff","resource":{"resourceType":"Specimen","id":"1734642835365799685.6448fcb2-bb46-4a42-bee7-6b46fc845bff","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835367153343.0095dbea-0b87-4cbf-8f40-6b1e69d49429","resource":{"resourceType":"Specimen","id":"1734642835367153343.0095dbea-0b87-4cbf-8f40-6b1e69d49429","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835368626987.ce01d466-d2f9-46ed-b51c-a1a843eacc34","resource":{"resourceType":"Specimen","id":"1734642835368626987.ce01d466-d2f9-46ed-b51c-a1a843eacc34","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"Specimen/1734642835370263338.53b0cddb-320b-4d2f-bc6d-0f7ba8191347","resource":{"resourceType":"Specimen","id":"1734642835370263338.53b0cddb-320b-4d2f-bc6d-0f7ba8191347","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-01T14:20:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}}}},{"fullUrl":"ServiceRequest/1734642835389771409.849e985d-b913-4e36-8996-a26c807d3feb","resource":{"resourceType":"ServiceRequest","id":"1734642835389771409.849e985d-b913-4e36-8996-a26c807d3feb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/business-event","valueCode":"RE"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/orc-common-order","extension":[{"url":"orc-21-ordering-facility-name","valueReference":{"reference":"Organization/1734642835384580134.a52e857e-b1a6-4933-91d3-45b90c6c563b"}},{"url":"orc-22-ordering-facility-address","valueAddress":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"8700 BEVERLY BLVD"}]}]}],"line":["8700 BEVERLY BLVD"],"city":"W HOLLYWOOD","state":"CA","postalCode":"90048-1804"}},{"url":"orc-12-ordering-provider","valueReference":{"reference":"Practitioner/1734642835387126880.1c0115df-b0ab-4194-8b18-e5c9c65c4b49"}}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.2","valueIdentifier":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"value":"673678765"}},{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"M17965"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"M17965"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"requester":{"reference":"PractitionerRole/1734642835376611271.42d862dc-b6bf-423c-838c-3eacb52cdf86"}}},{"fullUrl":"Practitioner/1734642835378152101.971d96a1-05f0-4810-8fc6-99fa1d10dd78","resource":{"resourceType":"Practitioner","id":"1734642835378152101.971d96a1-05f0-4810-8fc6-99fa1d10dd78","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"STEWART"},{"url":"XCN.10","valueString":"NPI"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.12"}],"identifier":[{"value":"1477542173"}],"name":[{"family":"BROOKS","given":["STEWART"]}]}},{"fullUrl":"Organization/1734642835380671425.9dbb655b-63ba-4d49-abe4-55fd0c8c0f60","resource":{"resourceType":"Organization","id":"1734642835380671425.9dbb655b-63ba-4d49-abe4-55fd0c8c0f60","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R150"}]}],"identifier":[{"value":"R150"}],"name":"CEDARS-SINAI MEDICAL CENTER","telecom":[{"_system":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}],"address":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"8700 BEVERLY BLVD"}]}]}],"line":["8700 BEVERLY BLVD"],"city":"W HOLLYWOOD","state":"CA","postalCode":"90048-1804"}]}},{"fullUrl":"PractitionerRole/1734642835376611271.42d862dc-b6bf-423c-838c-3eacb52cdf86","resource":{"resourceType":"PractitionerRole","id":"1734642835376611271.42d862dc-b6bf-423c-838c-3eacb52cdf86","practitioner":{"reference":"Practitioner/1734642835378152101.971d96a1-05f0-4810-8fc6-99fa1d10dd78"},"organization":{"reference":"Organization/1734642835380671425.9dbb655b-63ba-4d49-abe4-55fd0c8c0f60"}}},{"fullUrl":"Organization/1734642835384580134.a52e857e-b1a6-4933-91d3-45b90c6c563b","resource":{"resourceType":"Organization","id":"1734642835384580134.a52e857e-b1a6-4933-91d3-45b90c6c563b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R150"}]}],"identifier":[{"value":"R150"}],"name":"CEDARS-SINAI MEDICAL CENTER"}},{"fullUrl":"Practitioner/1734642835387126880.1c0115df-b0ab-4194-8b18-e5c9c65c4b49","resource":{"resourceType":"Practitioner","id":"1734642835387126880.1c0115df-b0ab-4194-8b18-e5c9c65c4b49","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"STEWART"},{"url":"XCN.10","valueString":"NPI"}]}],"identifier":[{"value":"1477542173"}],"name":[{"family":"BROOKS","given":["STEWART"]}]}},{"fullUrl":"ServiceRequest/1734642835395361722.863d0f9e-84ba-4c05-aacb-84e28edc7fc2","resource":{"resourceType":"ServiceRequest","id":"1734642835395361722.863d0f9e-84ba-4c05-aacb-84e28edc7fc2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835400872986.12375eb1-3d63-42d9-bb51-355690edfe8a","resource":{"resourceType":"ServiceRequest","id":"1734642835400872986.12375eb1-3d63-42d9-bb51-355690edfe8a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835406437470.873d109d-fdaf-48e5-a97b-96dd7508edfd","resource":{"resourceType":"ServiceRequest","id":"1734642835406437470.873d109d-fdaf-48e5-a97b-96dd7508edfd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835411861731.366c9665-9e44-49f7-b141-056ef9afe731","resource":{"resourceType":"ServiceRequest","id":"1734642835411861731.366c9665-9e44-49f7-b141-056ef9afe731","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835417298145.40cb5007-787e-43b6-a70d-f1c828d5bbc6","resource":{"resourceType":"ServiceRequest","id":"1734642835417298145.40cb5007-787e-43b6-a70d-f1c828d5bbc6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835425088233.8d12976a-d164-4d80-97be-1b9f71e738c0","resource":{"resourceType":"ServiceRequest","id":"1734642835425088233.8d12976a-d164-4d80-97be-1b9f71e738c0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835430754809.362999c8-3625-4f94-8e36-4c28d09f45ee","resource":{"resourceType":"ServiceRequest","id":"1734642835430754809.362999c8-3625-4f94-8e36-4c28d09f45ee","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835436203346.9044d092-f867-4b46-92bc-c20a3eb1e97b","resource":{"resourceType":"ServiceRequest","id":"1734642835436203346.9044d092-f867-4b46-92bc-c20a3eb1e97b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835441554780.5d9635c6-82f6-44ed-bd3d-7ac017b33cde","resource":{"resourceType":"ServiceRequest","id":"1734642835441554780.5d9635c6-82f6-44ed-bd3d-7ac017b33cde","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835447147758.fe178ece-2e33-4886-ba8d-e16f02780f58","resource":{"resourceType":"ServiceRequest","id":"1734642835447147758.fe178ece-2e33-4886-ba8d-e16f02780f58","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835452569995.b8c75461-8f83-447c-ace2-0be4fae41c27","resource":{"resourceType":"ServiceRequest","id":"1734642835452569995.b8c75461-8f83-447c-ace2-0be4fae41c27","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835459515248.1198051e-49c0-4499-9cae-4339eb93c3f0","resource":{"resourceType":"ServiceRequest","id":"1734642835459515248.1198051e-49c0-4499-9cae-4339eb93c3f0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835464917559.ae1b81c4-c79b-4158-b91f-cbc60641ca37","resource":{"resourceType":"ServiceRequest","id":"1734642835464917559.ae1b81c4-c79b-4158-b91f-cbc60641ca37","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835477323964.90f61212-4884-4d85-9946-dac6a7b1ac42","resource":{"resourceType":"ServiceRequest","id":"1734642835477323964.90f61212-4884-4d85-9946-dac6a7b1ac42","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835486884512.3211461f-1595-49c4-80a5-ea22dbb62e0f","resource":{"resourceType":"ServiceRequest","id":"1734642835486884512.3211461f-1595-49c4-80a5-ea22dbb62e0f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835496465375.4d30f1d9-c109-4bd6-af73-54881ac39463","resource":{"resourceType":"ServiceRequest","id":"1734642835496465375.4d30f1d9-c109-4bd6-af73-54881ac39463","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835501924522.3cb03c84-dfa0-4538-a60f-fb5e3df03d91","resource":{"resourceType":"ServiceRequest","id":"1734642835501924522.3cb03c84-dfa0-4538-a60f-fb5e3df03d91","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835507251682.d018514e-4372-4a6b-8f53-ea176f4fa8de","resource":{"resourceType":"ServiceRequest","id":"1734642835507251682.d018514e-4372-4a6b-8f53-ea176f4fa8de","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835512588720.2bff229a-7840-4814-a895-a5efe1ec731e","resource":{"resourceType":"ServiceRequest","id":"1734642835512588720.2bff229a-7840-4814-a895-a5efe1ec731e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835517996830.bf220f38-5601-418d-a1e1-b6133e9878bc","resource":{"resourceType":"ServiceRequest","id":"1734642835517996830.bf220f38-5601-418d-a1e1-b6133e9878bc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835527414151.dd23fc0e-b730-4c6e-bd6e-88961e0a02bf","resource":{"resourceType":"ServiceRequest","id":"1734642835527414151.dd23fc0e-b730-4c6e-bd6e-88961e0a02bf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"ServiceRequest/1734642835537115502.7cf8cceb-01d5-42c4-94e1-05190b2b2113","resource":{"resourceType":"ServiceRequest","id":"1734642835537115502.7cf8cceb-01d5-42c4-94e1-05190b2b2113","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-01T14:20:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]}},{"url":"OBR.22","valueString":"20241015050654"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"}}},{"fullUrl":"DiagnosticReport/1734642835547275564.00008400-dedd-4c3f-8968-03e87b20168f","resource":{"resourceType":"DiagnosticReport","id":"1734642835547275564.00008400-dedd-4c3f-8968-03e87b20168f","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"M17965"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"M17965"}],"basedOn":[{"reference":"ServiceRequest/1734642835389771409.849e985d-b913-4e36-8996-a26c807d3feb"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835339257765.334367ae-6cf8-4c69-bbea-6c69cbe7b03f"}]}},{"fullUrl":"DiagnosticReport/1734642835553041496.905154d3-791c-4e4c-8ca3-4c3696b5c9e5","resource":{"resourceType":"DiagnosticReport","id":"1734642835553041496.905154d3-791c-4e4c-8ca3-4c3696b5c9e5","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835395361722.863d0f9e-84ba-4c05-aacb-84e28edc7fc2"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835340756115.6e87362a-8040-4f57-b680-9d689ccb1713"}],"result":[{"reference":"Observation/1734642835078369364.c2196b8f-737f-445d-ac4b-45735aeac2e6"},{"reference":"Observation/1734642835080495691.7632bb5a-b1c3-4b60-b145-041618ed55c1"},{"reference":"Observation/1734642835082674046.0a733602-c7ef-4873-94e1-516cb480d33e"},{"reference":"Observation/1734642835084793380.e237aaaa-126b-4daa-a608-96962f96de3d"},{"reference":"Observation/1734642835086855126.3ce43713-b917-4307-b320-ce0b2ebf2fe0"},{"reference":"Observation/1734642835088717829.68dca08f-1e3a-4579-a954-98257e12481e"},{"reference":"Observation/1734642835090658378.f9967c85-8bce-483b-8f52-c1f86b5345ab"}]}},{"fullUrl":"DiagnosticReport/1734642835559411751.dbca6ed0-6ffe-4243-8531-f779d28c8c28","resource":{"resourceType":"DiagnosticReport","id":"1734642835559411751.dbca6ed0-6ffe-4243-8531-f779d28c8c28","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835400872986.12375eb1-3d63-42d9-bb51-355690edfe8a"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835342128909.4fd4310f-6fb3-47f4-bb83-66ba1586a53c"}],"result":[{"reference":"Observation/1734642835092518015.ecfaa4b9-3cd1-4b28-b03d-d5467ce0256b"},{"reference":"Observation/1734642835094763425.fbd8468f-31dc-4afc-bd64-011ed531d4f5"},{"reference":"Observation/1734642835096753407.335a9405-05bf-4cf8-a784-653c8c7b3f03"},{"reference":"Observation/1734642835098930860.da2d043f-88c3-4b08-aa9d-8e4b693937b0"},{"reference":"Observation/1734642835103742933.94767150-dbad-4916-b838-ccdf292751e8"},{"reference":"Observation/1734642835105967955.b8ba9fbf-48cc-497b-9abd-65fc6367fd39"},{"reference":"Observation/1734642835108045581.fd28d933-fe5b-4535-8299-eae01e9f9772"},{"reference":"Observation/1734642835110135560.5df45eb7-4436-4275-b0f3-a346250ba6a5"},{"reference":"Observation/1734642835111937279.a13f52de-fb3e-42c5-b70b-8928b41db139"},{"reference":"Observation/1734642835113791285.a93e71ad-6e66-4cb1-975c-0b72e1ec82b3"},{"reference":"Observation/1734642835115568047.503e318a-9232-4da8-9224-3ac70778c436"},{"reference":"Observation/1734642835117366028.a90473f2-2703-420c-b243-a76140002965"}]}},{"fullUrl":"DiagnosticReport/1734642835564422737.2cd120c8-1965-48a9-9f2b-4b44ee7657d9","resource":{"resourceType":"DiagnosticReport","id":"1734642835564422737.2cd120c8-1965-48a9-9f2b-4b44ee7657d9","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835406437470.873d109d-fdaf-48e5-a97b-96dd7508edfd"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835343507644.b7a33119-8c73-4ac8-ad96-a6ba91294273"}]}},{"fullUrl":"DiagnosticReport/1734642835571718859.7bab1bd2-c54b-4be7-bbb3-f538a840b78b","resource":{"resourceType":"DiagnosticReport","id":"1734642835571718859.7bab1bd2-c54b-4be7-bbb3-f538a840b78b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835411861731.366c9665-9e44-49f7-b141-056ef9afe731"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835344937215.6667157e-8de8-47c2-917e-1c05fc4720f3"}],"result":[{"reference":"Observation/1734642835119388891.5a6ef168-f3d7-4d65-8702-8ad61c5d91c1"},{"reference":"Observation/1734642835121480383.7a5f35b5-fa6e-487e-ab4d-b9e13376e739"},{"reference":"Observation/1734642835123554132.e09200e9-c15a-4a65-b6b6-e161fdf37208"},{"reference":"Observation/1734642835125650042.fb0f3ad6-1421-438e-aa27-18b629de869d"},{"reference":"Observation/1734642835127731345.61fe2a05-efe7-465e-bfde-aa231fab366c"},{"reference":"Observation/1734642835129903108.d4dda740-dd49-43d6-bc9b-25bf1279d5ee"},{"reference":"Observation/1734642835132201607.e6bc54d2-552d-489d-9ae6-62ed2947bbfc"},{"reference":"Observation/1734642835134316363.4ed4d624-eb61-48f4-be97-5638df76e5e4"},{"reference":"Observation/1734642835136414106.c0d7674a-7603-44b7-be2a-69fca6f812be"},{"reference":"Observation/1734642835138555141.69e9066d-9ec7-4684-856e-6fea5af26e44"},{"reference":"Observation/1734642835140681458.81b74ae1-30fb-48ee-9715-2cb02de30059"},{"reference":"Observation/1734642835142831109.183b9ea7-e9a9-4ae9-8815-e9289498e43e"},{"reference":"Observation/1734642835145029071.6d59c882-47f8-468a-9605-b2eac4033062"},{"reference":"Observation/1734642835147116164.3622f8ea-dadd-4bcb-bdec-4be3ddf0bde7"},{"reference":"Observation/1734642835149213497.5c0bb970-be0d-433d-82c7-bb51bac1b7ee"},{"reference":"Observation/1734642835151303085.143080f8-d26d-4ca3-bd0a-68be0eac89a4"},{"reference":"Observation/1734642835153524951.70cca668-8ac5-4daa-ad44-f014db61930b"},{"reference":"Observation/1734642835155737450.2fdf26eb-1dad-4753-b21d-07eef73e6e1c"},{"reference":"Observation/1734642835157643855.9b2bf0f2-7367-4472-aa24-68cd2e9402e8"}]}},{"fullUrl":"DiagnosticReport/1734642835576911345.4cea296d-3d84-49d3-b748-8fc14e7ebd0e","resource":{"resourceType":"DiagnosticReport","id":"1734642835576911345.4cea296d-3d84-49d3-b748-8fc14e7ebd0e","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835417298145.40cb5007-787e-43b6-a70d-f1c828d5bbc6"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835346298187.44b92531-e550-4f36-bd2f-7cc66563231e"}],"result":[{"reference":"Observation/1734642835159845143.ec8dc2e0-fac7-423d-82de-df26b1f9fc90"},{"reference":"Observation/1734642835161689441.9fe72387-651d-428a-b97d-3105fa1691f5"}]}},{"fullUrl":"DiagnosticReport/1734642835588311032.5e1f78bb-7715-4fa5-bfd2-90c95c87e070","resource":{"resourceType":"DiagnosticReport","id":"1734642835588311032.5e1f78bb-7715-4fa5-bfd2-90c95c87e070","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835425088233.8d12976a-d164-4d80-97be-1b9f71e738c0"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835347647096.2b33be20-c50f-46cc-82b4-01a32c586924"}],"result":[{"reference":"Observation/1734642835163707606.0e7ac73a-3dd8-4727-82ef-eee6c4d05d14"},{"reference":"Observation/1734642835165827511.90623ef3-82b0-400c-9455-4378b7797070"},{"reference":"Observation/1734642835167903263.045e84d0-3ee4-4092-8679-e0b8932c27f6"},{"reference":"Observation/1734642835170008381.df833064-f458-44c8-aae6-912dad9d9087"},{"reference":"Observation/1734642835172132283.9f0c7a5d-71ba-47af-9c10-6225b15373f5"},{"reference":"Observation/1734642835177087191.d4761a12-0246-469f-8b0a-7739d293f508"},{"reference":"Observation/1734642835179226894.a1e5f914-f409-483e-8e82-e97c4a9dc4bd"},{"reference":"Observation/1734642835181327282.deb6ed28-b853-48a8-a693-12199af60ec9"},{"reference":"Observation/1734642835183410599.4769d68b-068a-4463-824b-ca3c936e1b7f"},{"reference":"Observation/1734642835185557374.a69db609-b0ce-4b99-8746-637931d3a44c"},{"reference":"Observation/1734642835187803676.e0d1ff83-2851-4408-ba12-9c6390114b98"},{"reference":"Observation/1734642835189909665.62d7569d-0a11-4642-bad3-b156e86d58a0"},{"reference":"Observation/1734642835192058094.bd18c898-1943-47e4-8811-ff5a80ae85a6"},{"reference":"Observation/1734642835194313693.22932fcf-61d0-480d-8035-f2a79a45e484"},{"reference":"Observation/1734642835196515723.57267597-c36f-4219-91d0-7c74202d2d52"},{"reference":"Observation/1734642835198572800.e5ec271e-b6dd-4e3b-946f-ce198988c137"},{"reference":"Observation/1734642835200670263.961accbb-4104-4d11-8134-76e59c661438"},{"reference":"Observation/1734642835202756185.b72b6129-dc37-4fd6-b7f0-5c5bf464d238"},{"reference":"Observation/1734642835204989482.04869e37-ffba-4675-b7ab-3c98773de6a9"},{"reference":"Observation/1734642835207217761.ede199f5-0a4b-4351-ad09-4b8881bde701"},{"reference":"Observation/1734642835209347895.261b7657-6f9b-432a-8f29-b9874b99b609"},{"reference":"Observation/1734642835211671422.438e14ff-0281-49e7-b165-a19336723741"},{"reference":"Observation/1734642835213810493.5b329d38-601f-4845-8033-9be87d25aca5"},{"reference":"Observation/1734642835215877980.36b9a8cc-d3df-4d30-a31c-90f2e034379a"},{"reference":"Observation/1734642835217975733.dc31874a-a4be-4b8a-af75-fd59ad417868"},{"reference":"Observation/1734642835220100768.05a1dc4e-f604-4e77-9ea7-afbf81b8198f"}]}},{"fullUrl":"DiagnosticReport/1734642835594442249.53dfd7d7-b35b-49f9-9dd4-1a5b215413bd","resource":{"resourceType":"DiagnosticReport","id":"1734642835594442249.53dfd7d7-b35b-49f9-9dd4-1a5b215413bd","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835430754809.362999c8-3625-4f94-8e36-4c28d09f45ee"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835349049456.62fb98dc-8087-4a66-95d6-f4ed8208a11c"}],"result":[{"reference":"Observation/1734642835222279323.b0f928cc-46cf-4aaa-adff-fe2ce7a5ceef"},{"reference":"Observation/1734642835224430367.da780c77-72b4-4336-9039-a31184926686"},{"reference":"Observation/1734642835226529483.7b86fa71-ee93-43a1-b76d-cd849e73ca00"},{"reference":"Observation/1734642835228718427.086f9d04-6daa-4866-94d7-a65517888d6c"},{"reference":"Observation/1734642835230835868.279fed09-20e6-49b8-96a2-93eef87155d8"},{"reference":"Observation/1734642835233122375.0c6b8d22-57b3-4294-9b1e-c3a0a59070e9"},{"reference":"Observation/1734642835235257058.bdccfc91-c409-4ac8-9243-1ce9a9c8d5e8"},{"reference":"Observation/1734642835237360573.bc47837e-0b31-4a8e-b5ed-80ea7f6a5306"},{"reference":"Observation/1734642835239462615.dbfb2d97-079e-41cf-a27e-23be7e134d01"},{"reference":"Observation/1734642835241573904.95e1902d-39bc-4c32-b276-f57426ac9754"}]}},{"fullUrl":"DiagnosticReport/1734642835599680210.58ca4c86-9ba4-499d-90ba-e4f5010845db","resource":{"resourceType":"DiagnosticReport","id":"1734642835599680210.58ca4c86-9ba4-499d-90ba-e4f5010845db","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835436203346.9044d092-f867-4b46-92bc-c20a3eb1e97b"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835350409446.25a13015-e80e-447a-9880-41f54e21c7e7"}],"result":[{"reference":"Observation/1734642835243642913.6b373e0e-6c4c-4ba8-bc16-dbeaccbaa242"},{"reference":"Observation/1734642835245924111.ba72acbf-fdd2-4ade-a4ea-628501d3932d"},{"reference":"Observation/1734642835250748858.075f5f4d-fb95-4b1c-b882-706af112ad10"}]}},{"fullUrl":"DiagnosticReport/1734642835605009383.4f47e62b-55ee-42e4-8b1f-aa4de5dca825","resource":{"resourceType":"DiagnosticReport","id":"1734642835605009383.4f47e62b-55ee-42e4-8b1f-aa4de5dca825","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835441554780.5d9635c6-82f6-44ed-bd3d-7ac017b33cde"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835351773143.a2f9e75c-f720-4819-8163-f0869dd878e3"}],"result":[{"reference":"Observation/1734642835252910902.b34746e7-68e4-47e4-8123-c1d143b926c6"},{"reference":"Observation/1734642835255176000.1844fffb-f304-497b-8dff-89fb14ade80b"},{"reference":"Observation/1734642835256981315.d023e3a2-2bae-4586-ade7-0f801c8ecb93"}]}},{"fullUrl":"DiagnosticReport/1734642835610311906.a396e7e0-528b-4007-b2ab-0e3bfc0e71cb","resource":{"resourceType":"DiagnosticReport","id":"1734642835610311906.a396e7e0-528b-4007-b2ab-0e3bfc0e71cb","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835447147758.fe178ece-2e33-4886-ba8d-e16f02780f58"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835353174381.56974595-1d78-4e47-8689-2c9fa54dd258"}],"result":[{"reference":"Observation/1734642835258991303.471ccb24-c53b-4247-ae1b-85333058044f"},{"reference":"Observation/1734642835261094698.216cfc15-4e6b-4054-a562-dc9d010ffdc4"},{"reference":"Observation/1734642835262847204.678cc366-4570-42a8-9df3-afcdaca9c9ca"}]}},{"fullUrl":"DiagnosticReport/1734642835615540581.92060203-4181-48bb-ac65-b6f4b2412e1d","resource":{"resourceType":"DiagnosticReport","id":"1734642835615540581.92060203-4181-48bb-ac65-b6f4b2412e1d","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835452569995.b8c75461-8f83-447c-ace2-0be4fae41c27"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835354552365.f4274b93-053b-4ea9-8cc0-78f77d14acd8"}],"result":[{"reference":"Observation/1734642835264921283.91ec1af6-893c-4d53-bac5-b0600e963d5f"},{"reference":"Observation/1734642835267035147.1883610c-4f1d-4119-9f38-02c468008832"},{"reference":"Observation/1734642835268840823.be073532-267c-4705-bd5d-98f936d8a298"}]}},{"fullUrl":"DiagnosticReport/1734642835620764356.aa2f70a5-10a2-4fc5-a91c-a61f4a370dee","resource":{"resourceType":"DiagnosticReport","id":"1734642835620764356.aa2f70a5-10a2-4fc5-a91c-a61f4a370dee","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835459515248.1198051e-49c0-4499-9cae-4339eb93c3f0"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835355916653.d20c9e73-898b-40ca-ae6f-d01f3073ecd1"}],"result":[{"reference":"Observation/1734642835270610922.3dea9e01-cf45-4440-859b-5f06ec5bcd78"},{"reference":"Observation/1734642835272189662.237e8e77-bfda-4b54-8e00-1086f80d5fa5"}]}},{"fullUrl":"DiagnosticReport/1734642835629477723.a50a508e-79c8-43b9-b740-dc65e70d38b5","resource":{"resourceType":"DiagnosticReport","id":"1734642835629477723.a50a508e-79c8-43b9-b740-dc65e70d38b5","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835464917559.ae1b81c4-c79b-4158-b91f-cbc60641ca37"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835357303103.64850f3f-eae9-466a-9f6e-d8de284c438f"}],"result":[{"reference":"Observation/1734642835273965232.4d115769-fad3-4470-abfd-0fb327e43527"},{"reference":"Observation/1734642835276087662.698b32ba-eee2-4766-bc7a-d4fa00fa3dd7"},{"reference":"Observation/1734642835277860797.d3aeb34c-bcb9-4228-8631-558b588db30d"}]}},{"fullUrl":"DiagnosticReport/1734642835634765358.f625e7db-f332-4af3-91cd-a982fc5662a3","resource":{"resourceType":"DiagnosticReport","id":"1734642835634765358.f625e7db-f332-4af3-91cd-a982fc5662a3","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835477323964.90f61212-4884-4d85-9946-dac6a7b1ac42"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835358672621.32ace6ea-8714-4a7c-9dc8-3a8b275f2e11"}],"result":[{"reference":"Observation/1734642835279841832.a1229730-924c-4549-b477-bf1b2cfd8e13"},{"reference":"Observation/1734642835281978468.f15dce75-3889-43f5-958c-7ed178d61dd9"},{"reference":"Observation/1734642835283734922.786a3096-c83d-41f3-888c-c9f92a602540"}]}},{"fullUrl":"DiagnosticReport/1734642835640106874.9696df46-a0d7-4520-907c-de7610ae553a","resource":{"resourceType":"DiagnosticReport","id":"1734642835640106874.9696df46-a0d7-4520-907c-de7610ae553a","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835486884512.3211461f-1595-49c4-80a5-ea22dbb62e0f"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835360239980.b2a20ccb-343f-415a-a83f-351513f7aa49"}],"result":[{"reference":"Observation/1734642835285827456.e28416c0-d951-49ea-b27f-d348b5138f42"},{"reference":"Observation/1734642835287968320.ad75f0e5-8ce2-448a-a2a8-7933847307c0"},{"reference":"Observation/1734642835289784355.144718e3-9b36-4dd4-aab8-91378f578a01"}]}},{"fullUrl":"DiagnosticReport/1734642835643185858.7d84b3b9-82fa-4665-8995-48496677574d","resource":{"resourceType":"DiagnosticReport","id":"1734642835643185858.7d84b3b9-82fa-4665-8995-48496677574d","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835496465375.4d30f1d9-c109-4bd6-af73-54881ac39463"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835361666956.cc4f91e2-7a09-452b-8420-a10fd9c80e2b"}],"result":[{"reference":"Observation/1734642835291780468.3717216f-340a-4b57-b6f6-533f29f70555"},{"reference":"Observation/1734642835293916704.2ae71bb9-0e78-4be4-b12f-2a3e8cf13640"},{"reference":"Observation/1734642835295825143.3f0cd5e9-e867-40a2-9705-54078fe574fb"}]}},{"fullUrl":"DiagnosticReport/1734642835646250675.aaf7e242-0a04-48fc-8fcd-37534054d84c","resource":{"resourceType":"DiagnosticReport","id":"1734642835646250675.aaf7e242-0a04-48fc-8fcd-37534054d84c","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835501924522.3cb03c84-dfa0-4538-a60f-fb5e3df03d91"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835363030964.3a12ef62-abe5-4a3b-ad91-8b8d05157d1b"}],"result":[{"reference":"Observation/1734642835298238849.e1f75b37-69a0-4e11-96ba-52cd392bfbb2"},{"reference":"Observation/1734642835300320963.6730aa2a-9456-489c-8593-97f2a053ac85"},{"reference":"Observation/1734642835302129644.2bd6f20a-35fa-4b4c-a716-59ee8c023bc9"}]}},{"fullUrl":"DiagnosticReport/1734642835649684624.fd75d2d7-0fe4-4419-bedb-557668b7d57b","resource":{"resourceType":"DiagnosticReport","id":"1734642835649684624.fd75d2d7-0fe4-4419-bedb-557668b7d57b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835507251682.d018514e-4372-4a6b-8f53-ea176f4fa8de"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835364420439.6a839ff7-18ff-4135-8756-87a3237a1401"}],"result":[{"reference":"Observation/1734642835304240262.90534b48-83cc-4456-bee2-4f8adccd3fed"},{"reference":"Observation/1734642835306921540.9c7ab076-631e-46de-9f99-4a594333dba0"},{"reference":"Observation/1734642835308835408.0ef7fd8a-38aa-4a53-8efa-1f4070b8722a"}]}},{"fullUrl":"DiagnosticReport/1734642835652690020.0f9c42bb-342e-4304-bcfc-736b4b385ce5","resource":{"resourceType":"DiagnosticReport","id":"1734642835652690020.0f9c42bb-342e-4304-bcfc-736b4b385ce5","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835512588720.2bff229a-7840-4814-a895-a5efe1ec731e"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835365799685.6448fcb2-bb46-4a42-bee7-6b46fc845bff"}],"result":[{"reference":"Observation/1734642835310956776.8e5c8f5d-464e-4d6a-b6ff-aa6317ca2236"},{"reference":"Observation/1734642835312849265.7b1a44be-87f3-4c3e-b8c2-4bb112a00396"}]}},{"fullUrl":"DiagnosticReport/1734642835655881985.a9bb371f-6f8a-4ef4-a6fd-831000e7a9db","resource":{"resourceType":"DiagnosticReport","id":"1734642835655881985.a9bb371f-6f8a-4ef4-a6fd-831000e7a9db","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835517996830.bf220f38-5601-418d-a1e1-b6133e9878bc"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835367153343.0095dbea-0b87-4cbf-8f40-6b1e69d49429"}],"result":[{"reference":"Observation/1734642835314906112.b7166b68-f03f-4d84-bf2c-0b3b7abe9d18"},{"reference":"Observation/1734642835317154138.6f022b94-8600-406a-b8f0-5fc23b87e94f"},{"reference":"Observation/1734642835322641287.9e617f2f-7044-4954-ad62-cf9a106d32e7"}]}},{"fullUrl":"DiagnosticReport/1734642835658967160.47cc3e88-d62c-4805-8020-c4d50e4dd26f","resource":{"resourceType":"DiagnosticReport","id":"1734642835658967160.47cc3e88-d62c-4805-8020-c4d50e4dd26f","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835527414151.dd23fc0e-b730-4c6e-bd6e-88961e0a02bf"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835368626987.ce01d466-d2f9-46ed-b51c-a1a843eacc34"}],"result":[{"reference":"Observation/1734642835324840571.1d7a28bf-5661-4d4e-aa75-b787be359580"},{"reference":"Observation/1734642835326726838.637b5c0e-2fa3-424f-9919-cc78bd0ac277"}]}},{"fullUrl":"DiagnosticReport/1734642835661953110.4e4c493f-1bd7-4664-b919-1d64cda84098","resource":{"resourceType":"DiagnosticReport","id":"1734642835661953110.4e4c493f-1bd7-4664-b919-1d64cda84098","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"673678765"}],"basedOn":[{"reference":"ServiceRequest/1734642835537115502.7cf8cceb-01d5-42c4-94e1-05190b2b2113"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835074698551.5475cf26-2b01-44e1-b4c2-99a3410c634d"},"effectiveDateTime":"2024-10-01T14:20:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410011420"}]},"issued":"2024-10-15T05:06:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241015050654"}]},"specimen":[{"reference":"Specimen/1734642835370263338.53b0cddb-320b-4d2f-bc6d-0f7ba8191347"}],"result":[{"reference":"Observation/1734642835328833769.b1ef8e36-8a86-4ff0-89fb-be9399563adc"}]}}]}
diff --git a/examples/Test/Automated/GoldenCopy/Expected/002_ORU_R01_golden_copy_expected_acylc_2.fhir b/examples/Test/Automated/GoldenCopy/Expected/002_ORU_R01_golden_copy_expected_acylc_2.fhir
deleted file mode 100644
index a68538524..000000000
--- a/examples/Test/Automated/GoldenCopy/Expected/002_ORU_R01_golden_copy_expected_acylc_2.fhir
+++ /dev/null
@@ -1 +0,0 @@
-{"resourceType":"Bundle","id":"1734642835060547392.21e6da5c-0381-4a96-b9e8-3fb67dc56990","meta":{"lastUpdated":"2024-12-19T21:13:55.060+00:00"},"identifier":{"system":"https://reportstream.cdc.gov/prime-router","value":"002"},"type":"message","timestamp":"2024-10-18T05:02:34.000+00:00","entry":[{"fullUrl":"MessageHeader/1734642835061657384.add5f635-92d3-4b96-8e57-2effe6679555","resource":{"resourceType":"MessageHeader","id":"1734642835061657384.add5f635-92d3-4b96-8e57-2effe6679555","meta":{"tag":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0103","code":"N"}]},"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/msh-message-header","extension":[{"url":"MSH.7","valueString":"20241018050234"}]}],"eventCoding":{"system":"http://terminology.hl7.org/CodeSystem/v2-0003","code":"R01","display":"ORU^R01^ORU_R01"},"destination":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id","valueString":"9413816"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id-type","valueString":"L,M,N"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.5"}],"name":"SISHIERECEIVER","receiver":{"reference":"Organization/1734642835061400953.3db9afdf-21ec-4970-9e7e-199ee045bc53"}}],"sender":{"reference":"Organization/1734642835060859257.3427f015-5db9-4c6c-9758-cac57157b46d"},"source":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"SISGDSP"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.3"}],"name":"SISGDSP","_endpoint":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}}},{"fullUrl":"Organization/1734642835060859257.3427f015-5db9-4c6c-9758-cac57157b46d","resource":{"resourceType":"Organization","id":"1734642835060859257.3427f015-5db9-4c6c-9758-cac57157b46d","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Organization/1734642835061400953.3db9afdf-21ec-4970-9e7e-199ee045bc53","resource":{"resourceType":"Organization","id":"1734642835061400953.3db9afdf-21ec-4970-9e7e-199ee045bc53","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.6"}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.2,HD.3"}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301","code":"L,M,N"}]},"value":"automated-staging-test-receiver-id"}]}},{"fullUrl":"Provenance/1734642835063129183.098ebe09-12c5-4ad5-a948-d0b906c0855b","resource":{"resourceType":"Provenance","id":"1734642835063129183.098ebe09-12c5-4ad5-a948-d0b906c0855b","target":[{"reference":"MessageHeader/1734642835061657384.add5f635-92d3-4b96-8e57-2effe6679555"},{"reference":"DiagnosticReport/1734642835531809851.7e82b5f0-fa58-4ae3-9ff4-7ef423653005"},{"reference":"DiagnosticReport/1734642835535197914.0b32db56-7860-4c0d-869b-adf9b391aab5"},{"reference":"DiagnosticReport/1734642835538844723.39e47371-22c9-427a-9ec9-36c1e0d304f1"},{"reference":"DiagnosticReport/1734642835541790517.02d1415c-20fe-4c6c-a453-99a6256f1aa3"},{"reference":"DiagnosticReport/1734642835545994009.2ace7868-aa95-484d-b76b-12db078b97f7"},{"reference":"DiagnosticReport/1734642835549572319.e913f1db-3d85-49e2-9d92-abbb0ceca353"},{"reference":"DiagnosticReport/1734642835555248693.f55f879e-9129-4a46-b2cb-b3e8779dc651"},{"reference":"DiagnosticReport/1734642835559283809.7a8b7aca-7378-4e0f-b3b5-e7e311ecdcde"},{"reference":"DiagnosticReport/1734642835562458663.3bdb90b2-527c-4c7e-8542-71484cd7ab99"},{"reference":"DiagnosticReport/1734642835565786613.35dbbd5c-05ba-447e-a90a-b0b8a1d5337c"},{"reference":"DiagnosticReport/1734642835569237875.9ba7d3fc-9967-4075-88be-0335ae188064"},{"reference":"DiagnosticReport/1734642835572429349.a553e636-266f-4c09-b709-d56573b6fe07"},{"reference":"DiagnosticReport/1734642835575571841.d8c12c52-d7ca-43a2-afe8-80132657f9c7"},{"reference":"DiagnosticReport/1734642835581956604.0d9ff39f-34fd-4dd9-a5ac-dc8c2aa43995"},{"reference":"DiagnosticReport/1734642835585075052.1a8ebd8f-0416-4788-b779-b9b111188dd9"},{"reference":"DiagnosticReport/1734642835588257930.2fa53ce1-57c4-4b73-b9fb-5e4be2b9f735"},{"reference":"DiagnosticReport/1734642835591422123.d2f9f942-bfd6-4cbd-8565-822730b7e828"},{"reference":"DiagnosticReport/1734642835594544669.f203eb3d-fb58-425d-aad5-44fe9b3a7bbf"},{"reference":"DiagnosticReport/1734642835597620105.488df753-3823-41cd-84fd-40b72997cffe"},{"reference":"DiagnosticReport/1734642835600653273.375b52d5-1287-4587-af7e-f819678bb126"},{"reference":"DiagnosticReport/1734642835603899090.99cd7384-3aa2-4303-990f-c3d24337cb56"},{"reference":"DiagnosticReport/1734642835607156908.01e08384-7d0d-4a40-a6cd-4b60e2d03248"},{"reference":"DiagnosticReport/1734642835610181350.cbaed3cc-e9a9-43f1-9836-3cd9db54bf2b"}],"recorded":"2024-10-18T05:02:34Z","activity":{"coding":[{"display":"ORU^R01^ORU_R01"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"author"}]},"who":{"reference":"Organization/1734642835062946661.33286771-0420-4f13-a9a1-2f3b72374b4c"}}]}},{"fullUrl":"Organization/1734642835062946661.33286771-0420-4f13-a9a1-2f3b72374b4c","resource":{"resourceType":"Organization","id":"1734642835062946661.33286771-0420-4f13-a9a1-2f3b72374b4c","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Provenance/1734642835063641995.0dd5fd71-aa2e-4c75-9c63-80f6a50d991c","resource":{"resourceType":"Provenance","id":"1734642835063641995.0dd5fd71-aa2e-4c75-9c63-80f6a50d991c","recorded":"2024-12-19T21:13:55Z","policy":["http://hl7.org/fhir/uv/v2mappings/message-oru-r01-to-bundle"],"activity":{"coding":[{"code":"v2-FHIR transformation"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"assembler"}]},"who":{"reference":"Organization/1734642835063497093.435a4916-d2fb-4eb5-9917-f5b7f16e5ef7"}}]}},{"fullUrl":"Organization/1734642835063497093.435a4916-d2fb-4eb5-9917-f5b7f16e5ef7","resource":{"resourceType":"Organization","id":"1734642835063497093.435a4916-d2fb-4eb5-9917-f5b7f16e5ef7","identifier":[{"value":"CDC PRIME - Atlanta"},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301"}]},"system":"urn:ietf:rfc:3986","value":"2.16.840.1.114222.4.1.237821"}]}},{"fullUrl":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68","resource":{"resourceType":"Patient","id":"1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cx-identifier","extension":[{"url":"CX.5","valueString":"MR"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"PID.3"}],"type":{"coding":[{"code":"MR"}]},"value":"32550867","assigner":{"reference":"Organization/1734642835064360673.84470a0b-5ea1-4ff7-962f-eede48e9394d"}}],"name":[{"family":"*****PII REMOVED******"}],"contact":[{"name":{"family":"*****PII REMOVED******"}}]}},{"fullUrl":"Organization/1734642835064360673.84470a0b-5ea1-4ff7-962f-eede48e9394d","resource":{"resourceType":"Organization","id":"1734642835064360673.84470a0b-5ea1-4ff7-962f-eede48e9394d","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"1013163542&NPI"}]}},{"fullUrl":"Provenance/1734642835067918654.a7187d60-ac88-4477-9b29-9e452b9c6f22","resource":{"resourceType":"Provenance","id":"1734642835067918654.a7187d60-ac88-4477-9b29-9e452b9c6f22","target":[{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}],"recorded":"2024-12-19T21:13:55Z","activity":{"coding":[{"system":"https://terminology.hl7.org/CodeSystem/v3-DataOperation","code":"UPDATE"}]}}},{"fullUrl":"RelatedPerson/1734642835068879446.22fcda30-477d-46b1-b0b5-cdb740ecb06b","resource":{"resourceType":"RelatedPerson","id":"1734642835068879446.22fcda30-477d-46b1-b0b5-cdb740ecb06b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"NK1"}],"patient":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"name":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"NK1.2"}],"family":"*****PII REMOVED******"}]}},{"fullUrl":"Observation/1734642835072408964.75266d3b-3e79-44d2-93e7-33464d92421a","resource":{"resourceType":"Observation","id":"1734642835072408964.75266d3b-3e79-44d2-93e7-33464d92421a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57721-3","display":"Reason for lab test in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12421-6","display":"Initial screen"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835074715129.ead6bdf7-05f5-41b4-8301-9fbfd3b816c2","resource":{"resourceType":"Observation","id":"1734642835074715129.ead6bdf7-05f5-41b4-8301-9fbfd3b816c2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57718-9","display":"Sample quality of Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12432-3","display":"Acceptable"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835077037293.45edb036-f68b-40d3-8c09-ea3c6768f49a","resource":{"resourceType":"Observation","id":"1734642835077037293.45edb036-f68b-40d3-8c09-ea3c6768f49a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57130-7","display":"Newborn screening report - overall interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18944-1","display":"Screen is out of range for at least one condition"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835079270551.5131b375-6013-45ab-ab8f-5b72e523ada2","resource":{"resourceType":"Observation","id":"1734642835079270551.5131b375-6013-45ab-ab8f-5b72e523ada2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57131-5","display":"Newborn conditions with positive markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835081533113.ca9632ae-6903-4249-8aa1-80996f4e453c","resource":{"resourceType":"Observation","id":"1734642835081533113.ca9632ae-6903-4249-8aa1-80996f4e453c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57720-5","display":"Newborn conditions with equivocal markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835083506804.de19e7fc-6c52-4be6-bd35-5365359b3060","resource":{"resourceType":"Observation","id":"1734642835083506804.de19e7fc-6c52-4be6-bd35-5365359b3060","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57724-7","display":"Newborn screening short narrative summary"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"ACTION REQUIRED\\\\.br\\\\\\\\.br\\\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\\\\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\\\.br\\\\\\\\.br\\\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\\\.br\\\\\\\\.br\\\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\\\.br\\\\\\\\.br\\\\Follow-up:\\\\.br\\\\\\\\.br\\\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\\\.br\\\\\\\\.br\\\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\\\.br\\\\\\\\.br\\\\Methods and Limitations:\\\\.br\\\\\\\\.br\\\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\\\.br\\\\Attention Healthcare Provider:\\\\.br\\\\\\\\.br\\\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\\\.br\\\\\\\\.br\\","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835085405104.bd0a0117-73b7-476e-b72b-287122ac87a8","resource":{"resourceType":"Observation","id":"1734642835085405104.bd0a0117-73b7-476e-b72b-287122ac87a8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57129-9","display":"Full newborn screening summary report for display or printing"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835087373826.ed98c076-6f17-44ce-81e4-a403326e769f","resource":{"resourceType":"Observation","id":"1734642835087373826.ed98c076-6f17-44ce-81e4-a403326e769f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"ST"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57716-3","display":"State printed on filter paper card [Identifier] in NBS card"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"CA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835089780829.2215db06-44bb-4c59-8466-d9278434cef3","resource":{"resourceType":"Observation","id":"1734642835089780829.2215db06-44bb-4c59-8466-d9278434cef3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"grams"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"8339-4","display":"Birthweight"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":3135,"unit":"grams"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835091972329.7b1c0b54-fc4f-4dd0-a741-e260efc53bc6","resource":{"resourceType":"Observation","id":"1734642835091972329.7b1c0b54-fc4f-4dd0-a741-e260efc53bc6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57715-5","display":"Time of birth"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueTime":"1235","_valueTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"1235"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835094262483.b3cb8767-6c64-472a-a06e-87ecd4f282ef","resource":{"resourceType":"Observation","id":"1734642835094262483.b3cb8767-6c64-472a-a06e-87ecd4f282ef","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57722-1","display":"Birth plurality of Pregnancy"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12411-7","display":"Singleton"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835096506060.48931c5c-b95a-4205-8d31-388a9e378f1d","resource":{"resourceType":"Observation","id":"1734642835096506060.48931c5c-b95a-4205-8d31-388a9e378f1d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"hour(s)"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"73806-2","display":"Newborn age in hours"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":24,"unit":"hour(s)"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835098903976.077e0831-3c99-44cd-beda-c2370b1c502d","resource":{"resourceType":"Observation","id":"1734642835098903976.077e0831-3c99-44cd-beda-c2370b1c502d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57713-0","display":"Infant NICU factors that affect newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835103867243.9ca57891-de1f-40be-acd3-da3de38afe4a","resource":{"resourceType":"Observation","id":"1734642835103867243.9ca57891-de1f-40be-acd3-da3de38afe4a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67704-7","display":"Feeding types"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA16914-6","display":"Breast milk"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835105899995.f5ee9e6d-6a3e-4f82-bfee-a728d4e8a184","resource":{"resourceType":"Observation","id":"1734642835105899995.f5ee9e6d-6a3e-4f82-bfee-a728d4e8a184","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-5","display":"Accession Number"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"282-18-014/21-2024-32","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835107881581.1ebeb1fa-fecb-4de7-b9dc-a149595c0620","resource":{"resourceType":"Observation","id":"1734642835107881581.1ebeb1fa-fecb-4de7-b9dc-a149595c0620","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62324-9","display":"Post-discharge provider name"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"SARAH MAHMOOD","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835109899595.ddc4eb47-c60c-4492-9dad-82bb445a74c0","resource":{"resourceType":"Observation","id":"1734642835109899595.ddc4eb47-c60c-4492-9dad-82bb445a74c0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62325-6","display":"Post-discharge provider practice ID"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"1194257170","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835111786463.26c7efd2-e94c-4ce5-9641-f08f45eedde2","resource":{"resourceType":"Observation","id":"1734642835111786463.26c7efd2-e94c-4ce5-9641-f08f45eedde2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62327-2","display":"Post-discharge provider practice address"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835114032955.393eb749-310a-4618-a511-5cb2afc3e1be","resource":{"resourceType":"Observation","id":"1734642835114032955.393eb749-310a-4618-a511-5cb2afc3e1be","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47633-3","display":"Glycine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":611,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835116331285.57764571-3b71-4975-ab76-caa45272d17d","resource":{"resourceType":"Observation","id":"1734642835116331285.57764571-3b71-4975-ab76-caa45272d17d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53150-9","display":"Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":585,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1000"}]}},{"fullUrl":"Observation/1734642835118618614.42426ad4-7ecb-43fe-bf82-864a08fa2a09","resource":{"resourceType":"Observation","id":"1734642835118618614.42426ad4-7ecb-43fe-bf82-864a08fa2a09","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47799-2","display":"Valine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":90.9,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835120913247.cc61b5bd-2db5-4758-a60b-167569998e49","resource":{"resourceType":"Observation","id":"1734642835120913247.cc61b5bd-2db5-4758-a60b-167569998e49","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53151-7","display":"Valine/Phenylalanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":1.74808,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.3"}]}},{"fullUrl":"Observation/1734642835123269415.c7a6f123-dabd-4ef1-b0f1-b530877298cb","resource":{"resourceType":"Observation","id":"1734642835123269415.c7a6f123-dabd-4ef1-b0f1-b530877298cb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53152-5","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":86.9,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<230"}]}},{"fullUrl":"Observation/1734642835125596349.47098735-1062-4687-b098-d3dab2876010","resource":{"resourceType":"Observation","id":"1734642835125596349.47098735-1062-4687-b098-d3dab2876010","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53154-1","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.15,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.35"}]}},{"fullUrl":"Observation/1734642835127868229.41515f30-507b-47da-92a5-0f50aeda3ec4","resource":{"resourceType":"Observation","id":"1734642835127868229.41515f30-507b-47da-92a5-0f50aeda3ec4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29573-3","display":"Phenylalanine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":52.0,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<175"}]}},{"fullUrl":"Observation/1734642835130189692.2195e0b3-2998-4a0f-9e2b-b94bf4f77834","resource":{"resourceType":"Observation","id":"1734642835130189692.2195e0b3-2998-4a0f-9e2b-b94bf4f77834","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35572-7","display":"Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.75,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2.6"}]}},{"fullUrl":"Observation/1734642835132519691.2c1beca7-95b7-4a5f-b67d-c1a306333238","resource":{"resourceType":"Observation","id":"1734642835132519691.2c1beca7-95b7-4a5f-b67d-c1a306333238","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35571-9","display":"Tyrosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":69.0,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<680"}]}},{"fullUrl":"Observation/1734642835134809435.9e06f783-ffe8-481b-ad80-afa38a0ebd6a","resource":{"resourceType":"Observation","id":"1734642835134809435.9e06f783-ffe8-481b-ad80-afa38a0ebd6a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53231-7","display":"Succinylacetone [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.23,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<6.1"}]}},{"fullUrl":"Observation/1734642835137170923.9947c3f7-90ce-44bd-8b77-bd42ff3749d6","resource":{"resourceType":"Observation","id":"1734642835137170923.9947c3f7-90ce-44bd-8b77-bd42ff3749d6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47700-0","display":"Methionine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":22.5,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.3-100"}]}},{"fullUrl":"Observation/1734642835139466537.91adde4f-a83d-41ed-ac9e-8caf431c4b86","resource":{"resourceType":"Observation","id":"1734642835139466537.91adde4f-a83d-41ed-ac9e-8caf431c4b86","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42892-0","display":"Citrulline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":14,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"5-49"}]}},{"fullUrl":"Observation/1734642835141830360.547825c7-9eba-4167-8cfe-a2465a2f395d","resource":{"resourceType":"Observation","id":"1734642835141830360.547825c7-9eba-4167-8cfe-a2465a2f395d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54092-2","display":"Citrulline/Arginine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":2.28,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.8"}]}},{"fullUrl":"Observation/1734642835144301563.de46881d-1f67-46ff-9858-b6ae89a6b48b","resource":{"resourceType":"Observation","id":"1734642835144301563.de46881d-1f67-46ff-9858-b6ae89a6b48b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53155-8","display":"Asparagine+Ornithine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":68,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<800"}]}},{"fullUrl":"Observation/1734642835146571270.9b822a4e-4daa-43bb-9143-2e71a52a04eb","resource":{"resourceType":"Observation","id":"1734642835146571270.9b822a4e-4daa-43bb-9143-2e71a52a04eb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75215-4","display":"Ornithine/Citrulline [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":4.93,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835148847939.fd51e2fb-5d49-4676-a74e-c342a9d90613","resource":{"resourceType":"Observation","id":"1734642835148847939.fd51e2fb-5d49-4676-a74e-c342a9d90613","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47562-4","display":"Arginine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":6,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<63"}]}},{"fullUrl":"Observation/1734642835151142431.117e42b6-9dc6-4875-94de-1214fde103cf","resource":{"resourceType":"Observation","id":"1734642835151142431.117e42b6-9dc6-4875-94de-1214fde103cf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75214-7","display":"Arginine/Ornithine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.09,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.9"}]}},{"fullUrl":"Observation/1734642835153541720.5989fc4c-89a5-407d-8b3b-e7549c5e89d2","resource":{"resourceType":"Observation","id":"1734642835153541720.5989fc4c-89a5-407d-8b3b-e7549c5e89d2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47732-3","display":"Proline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":192,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1500"}]}},{"fullUrl":"Observation/1734642835155639614.b9014743-7717-4773-b580-45c48b2f201a","resource":{"resourceType":"Observation","id":"1734642835155639614.b9014743-7717-4773-b580-45c48b2f201a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57710-6","display":"Amino acidemias newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835157820193.577aad75-b837-4215-a407-d26006446546","resource":{"resourceType":"Observation","id":"1734642835157820193.577aad75-b837-4215-a407-d26006446546","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58088-6","display":"Acylcarnitine newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA11884-6","display":"Indeterminate"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"A"}]}]}},{"fullUrl":"Observation/1734642835159765200.5b2dae01-a2ce-4f83-9239-8eb5800bcbfb","resource":{"resourceType":"Observation","id":"1734642835159765200.5b2dae01-a2ce-4f83-9239-8eb5800bcbfb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58093-6","display":"Acylcarnitine newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"This pattern of elevations is consistent with SCADD, IBCDD","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"A"}]}]}},{"fullUrl":"Observation/1734642835162045226.9490f56a-187d-4e99-8223-a2e9772b631d","resource":{"resourceType":"Observation","id":"1734642835162045226.9490f56a-187d-4e99-8223-a2e9772b631d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38481-8","display":"Carnitine.free (C0)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":26.6,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.4-125"}]}},{"fullUrl":"Observation/1734642835164354646.81d396e1-073e-4f0e-bfdf-13937d7cd382","resource":{"resourceType":"Observation","id":"1734642835164354646.81d396e1-073e-4f0e-bfdf-13937d7cd382","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53235-8","display":"Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":3.27,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<70"}]}},{"fullUrl":"Observation/1734642835166629993.47eb25f8-6df1-46b3-919c-f7e8913d3cf5","resource":{"resourceType":"Observation","id":"1734642835166629993.47eb25f8-6df1-46b3-919c-f7e8913d3cf5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50157-7","display":"Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":29.2,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"10-80"}]}},{"fullUrl":"Observation/1734642835168943661.97b6d367-d4d7-435a-bd31-b9459e9e18ec","resource":{"resourceType":"Observation","id":"1734642835168943661.97b6d367-d4d7-435a-bd31-b9459e9e18ec","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75212-1","display":"Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":2.13913,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.6"}]}},{"fullUrl":"Observation/1734642835171271146.f04f4637-b85a-43fb-9f72-be114f3e7c91","resource":{"resourceType":"Observation","id":"1734642835171271146.f04f4637-b85a-43fb-9f72-be114f3e7c91","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45211-0","display":"Hexanoylcarnitine (C6)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.088,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835173651229.ec3d9ff9-0f52-4328-9cbb-f31a10f36d37","resource":{"resourceType":"Observation","id":"1734642835173651229.ec3d9ff9-0f52-4328-9cbb-f31a10f36d37","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53175-6","display":"Octanoylcarnitine (C8)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.084,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835178727400.29b6257f-674c-4973-95d6-21b188015189","resource":{"resourceType":"Observation","id":"1734642835178727400.29b6257f-674c-4973-95d6-21b188015189","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53177-2","display":"Octanoylcarnitine (C8)/Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.73,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835180861281.fc593df5-07c9-4233-9cb2-fca44e2c7133","resource":{"resourceType":"Observation","id":"1734642835180861281.fc593df5-07c9-4233-9cb2-fca44e2c7133","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53174-9","display":"Octenoylcarnitine (C8:1)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.172,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835182931393.4305b764-7f39-4ccb-bc9c-5f4bdbb3b7c4","resource":{"resourceType":"Observation","id":"1734642835182931393.4305b764-7f39-4ccb-bc9c-5f4bdbb3b7c4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45197-1","display":"Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.115,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835185116210.5940d493-71de-47be-ac64-c7d47d3debde","resource":{"resourceType":"Observation","id":"1734642835185116210.5940d493-71de-47be-ac64-c7d47d3debde","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45198-9","display":"Decenoylcarnitine (C10:1)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.050,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835187288373.1c64ef7b-e463-43d6-8805-ca936b1c72bf","resource":{"resourceType":"Observation","id":"1734642835187288373.1c64ef7b-e463-43d6-8805-ca936b1c72bf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45199-7","display":"Dodecanoylcarnitine (C12)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.127,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2"}]}},{"fullUrl":"Observation/1734642835189423406.1c9fd186-339a-4e60-9734-28df7b20a7df","resource":{"resourceType":"Observation","id":"1734642835189423406.1c9fd186-339a-4e60-9734-28df7b20a7df","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45200-3","display":"Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.12,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835191534946.0417c3df-4317-463f-9d99-b431e3905b09","resource":{"resourceType":"Observation","id":"1734642835191534946.0417c3df-4317-463f-9d99-b431e3905b09","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53192-1","display":"Tetradecanoylcarnitine (C14)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.333,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.2"}]}},{"fullUrl":"Observation/1734642835193679577.02b69198-ef0d-4b94-9df8-7b27fad40308","resource":{"resourceType":"Observation","id":"1734642835193679577.02b69198-ef0d-4b94-9df8-7b27fad40308","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53191-3","display":"Tetradecenoylcarnitine (C14:1)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.132,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.9"}]}},{"fullUrl":"Observation/1734642835195762763.1a70ae02-e175-49fc-8500-0490ecc22862","resource":{"resourceType":"Observation","id":"1734642835195762763.1a70ae02-e175-49fc-8500-0490ecc22862","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53194-7","display":"Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":1.13,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835197861699.fdc7c7ef-61e7-41b8-9363-279083afadea","resource":{"resourceType":"Observation","id":"1734642835197861699.fdc7c7ef-61e7-41b8-9363-279083afadea","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53190-5","display":"Tetradecadienoylcarnitine (C14:2)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.02,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835199918416.c535e96d-42d2-43da-b498-5a4a63e27221","resource":{"resourceType":"Observation","id":"1734642835199918416.c535e96d-42d2-43da-b498-5a4a63e27221","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50281-5","display":"3-Hydroxytetradecanoylcarnitine (C14-OH)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.026,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.2"}]}},{"fullUrl":"Observation/1734642835202018364.7d47086f-137e-45e4-b97e-529e6410d71c","resource":{"resourceType":"Observation","id":"1734642835202018364.7d47086f-137e-45e4-b97e-529e6410d71c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53199-6","display":"Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":6.19,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<12"}]}},{"fullUrl":"Observation/1734642835204143519.0b293d61-5e06-4ec9-8b16-62b66efaca0a","resource":{"resourceType":"Observation","id":"1734642835204143519.0b293d61-5e06-4ec9-8b16-62b66efaca0a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53198-8","display":"Palmitoleylcarnitine (C16:1)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.445,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.4"}]}},{"fullUrl":"Observation/1734642835206227236.22c3dadc-1b32-4fa8-90f5-e5895e4642dc","resource":{"resourceType":"Observation","id":"1734642835206227236.22c3dadc-1b32-4fa8-90f5-e5895e4642dc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50125-4","display":"3-Hydroxypalmitoylcarnitine (C16-OH)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.045,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835208324649.86b17533-f55e-4b9e-8306-313ca8c8d474","resource":{"resourceType":"Observation","id":"1734642835208324649.86b17533-f55e-4b9e-8306-313ca8c8d474","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53201-0","display":"3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.00727,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.07"}]}},{"fullUrl":"Observation/1734642835210415530.d24aaa22-035b-42ab-a8ad-dd36ee78ea24","resource":{"resourceType":"Observation","id":"1734642835210415530.d24aaa22-035b-42ab-a8ad-dd36ee78ea24","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53241-6","display":"Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":1.53,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<3.5"}]}},{"fullUrl":"Observation/1734642835212653867.d599ae32-6087-4057-ba49-a7f051078cdb","resource":{"resourceType":"Observation","id":"1734642835212653867.d599ae32-6087-4057-ba49-a7f051078cdb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53202-8","display":"Oleoylcarnitine (C18:1)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":1.96,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7"}]}},{"fullUrl":"Observation/1734642835214779794.05d31cbf-102d-45df-b48f-54cc0f715691","resource":{"resourceType":"Observation","id":"1734642835214779794.05d31cbf-102d-45df-b48f-54cc0f715691","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45217-7","display":"Linoleoylcarnitine (C18:2)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.21,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835216894589.19959e3d-cf6d-459e-b0e9-cf9e5400bbf5","resource":{"resourceType":"Observation","id":"1734642835216894589.19959e3d-cf6d-459e-b0e9-cf9e5400bbf5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50132-0","display":"3-Hydroxystearoylcarnitine (C18-OH)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.017,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835218980921.802246ce-c233-406b-8013-2586b6499575","resource":{"resourceType":"Observation","id":"1734642835218980921.802246ce-c233-406b-8013-2586b6499575","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50113-0","display":"3-Hydroxyoleoylcarnitine (C18:1-OH)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.036,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835221107288.81ab8987-7308-4524-ac1a-1429982b0b7e","resource":{"resourceType":"Observation","id":"1734642835221107288.81ab8987-7308-4524-ac1a-1429982b0b7e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53160-8","display":"Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":2.5,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.9"}]}},{"fullUrl":"Observation/1734642835223225480.5a102d3e-c9f8-40a2-9358-651a3c6cd4bf","resource":{"resourceType":"Observation","id":"1734642835223225480.5a102d3e-c9f8-40a2-9358-651a3c6cd4bf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53163-2","display":"Propionylcarnitine (C3)/Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.09,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.42"}]}},{"fullUrl":"Observation/1734642835225460391.367cd09c-a84d-4b74-9012-6208e9cae783","resource":{"resourceType":"Observation","id":"1734642835225460391.367cd09c-a84d-4b74-9012-6208e9cae783","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67708-8","display":"Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.246,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.48"}]}},{"fullUrl":"Observation/1734642835227537436.97f58b93-df12-4ff2-ab2a-cbe874b04d88","resource":{"resourceType":"Observation","id":"1734642835227537436.97f58b93-df12-4ff2-ab2a-cbe874b04d88","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53166-5","display":"Butyrylcarnitine+Isobutyrylcarnitine (C4)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":1.72,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"H"}]}],"referenceRange":[{"text":"<1.7"}]}},{"fullUrl":"Observation/1734642835229643846.878bcfe3-113a-433f-aaa0-bb3269307c1e","resource":{"resourceType":"Observation","id":"1734642835229643846.878bcfe3-113a-433f-aaa0-bb3269307c1e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45216-9","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.115,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835231745977.21c27e63-559a-4ec1-be5b-ad43ab6e0b65","resource":{"resourceType":"Observation","id":"1734642835231745977.21c27e63-559a-4ec1-be5b-ad43ab6e0b65","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53240-8","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.04600,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642835233956282.462ce6c5-4cef-4570-9775-455480579770","resource":{"resourceType":"Observation","id":"1734642835233956282.462ce6c5-4cef-4570-9775-455480579770","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53170-7","display":"Tiglylcarnitine (C5:1)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.008,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.5"}]}},{"fullUrl":"Observation/1734642835236097878.fa6c4155-42c1-4ac4-a809-5e912eb9e191","resource":{"resourceType":"Observation","id":"1734642835236097878.fa6c4155-42c1-4ac4-a809-5e912eb9e191","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50106-4","display":"3-Hydroxyisovalerylcarnitine (C5-OH)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.232,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.15"}]}},{"fullUrl":"Observation/1734642835238198367.c38dc305-07da-435c-a327-d77e95e1348e","resource":{"resourceType":"Observation","id":"1734642835238198367.c38dc305-07da-435c-a327-d77e95e1348e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67710-4","display":"Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.180,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642835240363176.0253a773-b531-4c12-b79f-b45649144356","resource":{"resourceType":"Observation","id":"1734642835240363176.0253a773-b531-4c12-b79f-b45649144356","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75216-2","display":"Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.73171,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">0.1"}]}},{"fullUrl":"Observation/1734642835242457754.6443996c-029e-4fb4-9e7e-b38be0e5271c","resource":{"resourceType":"Observation","id":"1734642835242457754.6443996c-029e-4fb4-9e7e-b38be0e5271c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ng/mL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"48633-2","display":"Trypsinogen I.free"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":21.20,"unit":"ng/mL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<69"}]}},{"fullUrl":"Observation/1734642835244613837.18c12760-d680-4504-a920-22aed27486e6","resource":{"resourceType":"Observation","id":"1734642835244613837.18c12760-d680-4504-a920-22aed27486e6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46769-6","display":"Cystic fibrosis newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835246395758.fd278006-4ca8-4198-9a61-0285d94792d8","resource":{"resourceType":"Observation","id":"1734642835246395758.fd278006-4ca8-4198-9a61-0285d94792d8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57707-2","display":"Cystic fibrosis newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835251390130.1f1ba7f3-55dc-4fd1-8959-cb63ee36fe9b","resource":{"resourceType":"Observation","id":"1734642835251390130.1f1ba7f3-55dc-4fd1-8959-cb63ee36fe9b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"nmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38473-5","display":"17-Hydroxyprogesterone"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":15.6,"unit":"nmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<85"}]}},{"fullUrl":"Observation/1734642835253597740.7a2b5271-eaa4-4ed2-bc88-2bb2ca71b6ea","resource":{"resourceType":"Observation","id":"1734642835253597740.7a2b5271-eaa4-4ed2-bc88-2bb2ca71b6ea","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46758-9","display":"Congenital adrenal hyperplasia newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835255562214.3015bf59-aaee-4495-989e-81a50bf93052","resource":{"resourceType":"Observation","id":"1734642835255562214.3015bf59-aaee-4495-989e-81a50bf93052","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57706-4","display":"Congenital adrenal hyperplasia newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835257602910.abe375b3-0f71-4173-95e9-001a5a884ab7","resource":{"resourceType":"Observation","id":"1734642835257602910.abe375b3-0f71-4173-95e9-001a5a884ab7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"mIU/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29575-8","display":"Thyrotropin"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":9.50,"unit":"mIU/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<29"}]}},{"fullUrl":"Observation/1734642835259698981.43c8b710-7c71-4940-b9d5-25cc3d4e1958","resource":{"resourceType":"Observation","id":"1734642835259698981.43c8b710-7c71-4940-b9d5-25cc3d4e1958","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46762-1","display":"Congenital hypothyroidism newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835261515607.b721c4f8-75bf-4a2c-b5fd-9ff30cbebc4c","resource":{"resourceType":"Observation","id":"1734642835261515607.b721c4f8-75bf-4a2c-b5fd-9ff30cbebc4c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57705-6","display":"Congenital hypothyroidism newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835263526728.6352e178-f7df-4942-b4e5-e369848a3d44","resource":{"resourceType":"Observation","id":"1734642835263526728.6352e178-f7df-4942-b4e5-e369848a3d44","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"enzyme units"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42906-8","display":"Galactose 1 phosphate uridyl transferase"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":262.95,"unit":"enzyme units"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">50"}]}},{"fullUrl":"Observation/1734642835265824537.e04c9caa-53c4-4a27-aac6-9b0ca883fa66","resource":{"resourceType":"Observation","id":"1734642835265824537.e04c9caa-53c4-4a27-aac6-9b0ca883fa66","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46737-3","display":"Galactosemias newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835267640753.9e1c7bf0-8aa2-4291-8928-7d9ad874d770","resource":{"resourceType":"Observation","id":"1734642835267640753.9e1c7bf0-8aa2-4291-8928-7d9ad874d770","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57704-9","display":"Galactosemias newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835269483057.3ed613f4-d1ba-4f9e-94c5-a71a1ded6f45","resource":{"resourceType":"Observation","id":"1734642835269483057.3ed613f4-d1ba-4f9e-94c5-a71a1ded6f45","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54104-5","display":"Hemoglobin pattern"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"FA"}},{"fullUrl":"Observation/1734642835271065745.e760e98a-c57f-4150-a192-9a4815b9e4cc","resource":{"resourceType":"Observation","id":"1734642835271065745.e760e98a-c57f-4150-a192-9a4815b9e4cc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57703-1","display":"Hemoglobin disorders newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants."}},{"fullUrl":"Observation/1734642835272891979.7a36eb88-ef32-49a5-bc5e-7cdf17f63349","resource":{"resourceType":"Observation","id":"1734642835272891979.7a36eb88-ef32-49a5-bc5e-7cdf17f63349","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ERU"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75217-0","display":"Biotinidase [Enzymatic activity/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":49.77,"unit":"ERU"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">10"}]}},{"fullUrl":"Observation/1734642835274997297.6e838878-c98e-44ad-879a-acaa41879d9f","resource":{"resourceType":"Observation","id":"1734642835274997297.6e838878-c98e-44ad-879a-acaa41879d9f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46761-3","display":"Biotinidase deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835276813694.97af3170-7292-4775-ab18-e721d0173e29","resource":{"resourceType":"Observation","id":"1734642835276813694.97af3170-7292-4775-ab18-e721d0173e29","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57699-1","display":"Biotinidase deficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835278833451.2ad1bcd4-0e4b-4eed-8e68-f6f53d9c70dc","resource":{"resourceType":"Observation","id":"1734642835278833451.2ad1bcd4-0e4b-4eed-8e68-f6f53d9c70dc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"copies/µL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62320-7","display":"T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":197,"unit":"copies/µL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">18"}]}},{"fullUrl":"Observation/1734642835280939350.31988676-eaca-4ccf-ae6b-f95724c72091","resource":{"resourceType":"Observation","id":"1734642835280939350.31988676-eaca-4ccf-ae6b-f95724c72091","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62321-5","display":"Severe combined immunodeficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835282741108.a5b64cc6-76f4-47ea-ae94-bb7e8b259ea9","resource":{"resourceType":"Observation","id":"1734642835282741108.a5b64cc6-76f4-47ea-ae94-bb7e8b259ea9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62322-3","display":"Severe combined immunodeficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835284764342.eb4d98d3-2e02-47ac-81e3-f73c2d23cb8b","resource":{"resourceType":"Observation","id":"1734642835284764342.eb4d98d3-2e02-47ac-81e3-f73c2d23cb8b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55827-0","display":"Acid alpha glucosidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":12.29,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=1.47"}]}},{"fullUrl":"Observation/1734642835286864520.58c01a31-8ede-4e3d-a8b6-b7f2a2aaddfd","resource":{"resourceType":"Observation","id":"1734642835286864520.58c01a31-8ede-4e3d-a8b6-b7f2a2aaddfd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63415-4","display":"Pompe Disease deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835288660898.8901b1f0-99f8-4762-9318-77cc13486bfc","resource":{"resourceType":"Observation","id":"1734642835288660898.8901b1f0-99f8-4762-9318-77cc13486bfc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63416-2","display":"Pompe Disease deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835290755476.b2542317-e334-4edf-a07e-2fa17c9679f1","resource":{"resourceType":"Observation","id":"1734642835290755476.b2542317-e334-4edf-a07e-2fa17c9679f1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55909-6","display":"Alpha-L-iduronidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":13.01,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=0.82"}]}},{"fullUrl":"Observation/1734642835292880270.61aaccd6-2df3-4536-b2d4-61eff7ae5eb4","resource":{"resourceType":"Observation","id":"1734642835292880270.61aaccd6-2df3-4536-b2d4-61eff7ae5eb4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79564-1","display":"Mucopolysaccharidosis type I newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835294727053.63b3c494-3f3d-42af-9e1b-6c7b6396b4f8","resource":{"resourceType":"Observation","id":"1734642835294727053.63b3c494-3f3d-42af-9e1b-6c7b6396b4f8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79565-8","display":"Mucopolysaccharidosis type I newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835297387312.feaf65ff-2abb-4738-9b02-c14e949fc66c","resource":{"resourceType":"Observation","id":"1734642835297387312.feaf65ff-2abb-4738-9b02-c14e949fc66c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-60","display":"SMN1 Homozygous Deletion Analysis"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Exon 7 Present","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"Exon 7 Present"}]}},{"fullUrl":"Observation/1734642835300196600.6b956336-be88-4448-8c31-b13512d7a6e8","resource":{"resourceType":"Observation","id":"1734642835300196600.6b956336-be88-4448-8c31-b13512d7a6e8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92004-1","display":"Spinal muscular atrophy newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835302325131.3f9d73bf-5fb0-4b7a-9d19-5c65eca61695","resource":{"resourceType":"Observation","id":"1734642835302325131.3f9d73bf-5fb0-4b7a-9d19-5c65eca61695","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92003-3","display":"Spinal muscular atrophy newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"SMA Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835304478669.58d1fe41-4fe6-439c-ac8c-7ebda34fa2c8","resource":{"resourceType":"Observation","id":"1734642835304478669.58d1fe41-4fe6-439c-ac8c-7ebda34fa2c8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79462-8","display":"Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":27.84,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=2.79"}]}},{"fullUrl":"Observation/1734642835307026637.f53e03f5-3c64-4288-9a28-214161f26772","resource":{"resourceType":"Observation","id":"1734642835307026637.f53e03f5-3c64-4288-9a28-214161f26772","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104189-6","display":"Mucopolysaccharidosis type II newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835308977855.d3c4cd9b-1d7e-4d95-8085-f6edee36ce6a","resource":{"resourceType":"Observation","id":"1734642835308977855.d3c4cd9b-1d7e-4d95-8085-f6edee36ce6a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104190-4","display":"Mucopolysaccharidosis type II newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835311168554.69c8b649-447b-46f2-baae-bab36c3da5a4","resource":{"resourceType":"Observation","id":"1734642835311168554.69c8b649-447b-46f2-baae-bab36c3da5a4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104192-0","display":"Guanidinoacetate methyltransferase deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835313133799.6f0a0b0f-4471-48bd-9ba1-478b444859ce","resource":{"resourceType":"Observation","id":"1734642835313133799.6f0a0b0f-4471-48bd-9ba1-478b444859ce","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104193-8","display":"Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835315205965.5211d2f8-1a92-47e0-a60d-827e1415618d","resource":{"resourceType":"Observation","id":"1734642835315205965.5211d2f8-1a92-47e0-a60d-827e1415618d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"93488-5","display":"Guanidinoacetate [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.97,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=3"}]}},{"fullUrl":"Observation/1734642835317343453.4e89665e-74a5-47f3-99d9-376bcb1180e4","resource":{"resourceType":"Observation","id":"1734642835317343453.4e89665e-74a5-47f3-99d9-376bcb1180e4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104194-6","display":"Creatine [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":496.63,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835323110520.12a4dd67-1010-4b73-8f82-382d41bc1a15","resource":{"resourceType":"Observation","id":"1734642835323110520.12a4dd67-1010-4b73-8f82-382d41bc1a15","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104195-3","display":"GUAC/CRE Ratio [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":1.95},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=6"}]}},{"fullUrl":"Observation/1734642835325439747.8f0de453-fadb-465c-96fa-cc16db1af1ea","resource":{"resourceType":"Observation","id":"1734642835325439747.8f0de453-fadb-465c-96fa-cc16db1af1ea","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-32","display":"Adrenoleukodystrophy deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835327359006.73a0b073-3142-486b-b9a7-9a53237926aa","resource":{"resourceType":"Observation","id":"1734642835327359006.73a0b073-3142-486b-b9a7-9a53237926aa","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-33","display":"Adrenoleukodystrophy deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835329763265.0f40fa13-fedf-496d-9f03-29a65ce7b1bf","resource":{"resourceType":"Observation","id":"1734642835329763265.0f40fa13-fedf-496d-9f03-29a65ce7b1bf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79321-6","display":"Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-18T05:02:34Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"valueQuantity":{"value":0.349,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.47"}]}},{"fullUrl":"Specimen/1734642835339788223.c729fd06-1344-4383-a056-20482ce8af1b","resource":{"resourceType":"Specimen","id":"1734642835339788223.c729fd06-1344-4383-a056-20482ce8af1b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835341216962.afb81ed4-1938-4d2c-ae58-2c93af81ab8a","resource":{"resourceType":"Specimen","id":"1734642835341216962.afb81ed4-1938-4d2c-ae58-2c93af81ab8a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835342617127.e6180bc9-4138-4189-af57-8aced2fcf501","resource":{"resourceType":"Specimen","id":"1734642835342617127.e6180bc9-4138-4189-af57-8aced2fcf501","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835344217448.792d1d9d-d3a3-46fe-85bc-90f98aa11655","resource":{"resourceType":"Specimen","id":"1734642835344217448.792d1d9d-d3a3-46fe-85bc-90f98aa11655","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835345581636.d23192da-b0a1-4e46-b5cb-4514a5a70a84","resource":{"resourceType":"Specimen","id":"1734642835345581636.d23192da-b0a1-4e46-b5cb-4514a5a70a84","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835346945544.783a59ef-1654-4aae-806a-56d263dd59c3","resource":{"resourceType":"Specimen","id":"1734642835346945544.783a59ef-1654-4aae-806a-56d263dd59c3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835348363853.9e652caf-6856-46c3-b800-dda071ed4ad9","resource":{"resourceType":"Specimen","id":"1734642835348363853.9e652caf-6856-46c3-b800-dda071ed4ad9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835349728452.9cdd7c14-f5a3-46d1-9031-27e8231dd653","resource":{"resourceType":"Specimen","id":"1734642835349728452.9cdd7c14-f5a3-46d1-9031-27e8231dd653","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835351271315.e31cf52e-6cf9-49ac-9a39-8f8d87453d6f","resource":{"resourceType":"Specimen","id":"1734642835351271315.e31cf52e-6cf9-49ac-9a39-8f8d87453d6f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835352696317.c61b9f44-92d0-4e7a-90d7-b46711288b72","resource":{"resourceType":"Specimen","id":"1734642835352696317.c61b9f44-92d0-4e7a-90d7-b46711288b72","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835354045988.5631aacd-2433-42f6-95ce-35b6a9afcf3c","resource":{"resourceType":"Specimen","id":"1734642835354045988.5631aacd-2433-42f6-95ce-35b6a9afcf3c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835355395369.c3f3a14b-e8a0-4520-8cdf-e9174aeabb56","resource":{"resourceType":"Specimen","id":"1734642835355395369.c3f3a14b-e8a0-4520-8cdf-e9174aeabb56","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835356809771.907d3d60-4ee3-4e70-90b8-1c6978b7b6f6","resource":{"resourceType":"Specimen","id":"1734642835356809771.907d3d60-4ee3-4e70-90b8-1c6978b7b6f6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835358162137.9b5c0311-9a41-48bc-8bbd-c74bf03176b9","resource":{"resourceType":"Specimen","id":"1734642835358162137.9b5c0311-9a41-48bc-8bbd-c74bf03176b9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835359622094.6175ae40-ff81-4cf2-be1b-194e3f091225","resource":{"resourceType":"Specimen","id":"1734642835359622094.6175ae40-ff81-4cf2-be1b-194e3f091225","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835361419575.3fe2b96b-3fd7-489a-b6f7-6d62e235b3eb","resource":{"resourceType":"Specimen","id":"1734642835361419575.3fe2b96b-3fd7-489a-b6f7-6d62e235b3eb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835362813018.dc52b61c-7bc3-4025-b223-b1ca2b3c4223","resource":{"resourceType":"Specimen","id":"1734642835362813018.dc52b61c-7bc3-4025-b223-b1ca2b3c4223","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835364224324.f7cb9104-c8d8-44b9-9d2a-61456558dc71","resource":{"resourceType":"Specimen","id":"1734642835364224324.f7cb9104-c8d8-44b9-9d2a-61456558dc71","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835365609582.1af14955-5a50-4899-aba3-59ac8a752604","resource":{"resourceType":"Specimen","id":"1734642835365609582.1af14955-5a50-4899-aba3-59ac8a752604","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835366959533.9c598daa-6478-49d5-bef7-af0f7f2454f6","resource":{"resourceType":"Specimen","id":"1734642835366959533.9c598daa-6478-49d5-bef7-af0f7f2454f6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835368450358.d0a6f2ac-8c36-408a-b974-d9e9ae4faf84","resource":{"resourceType":"Specimen","id":"1734642835368450358.d0a6f2ac-8c36-408a-b974-d9e9ae4faf84","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835370373845.bca755ed-c2eb-43a5-bf93-277c589b9e05","resource":{"resourceType":"Specimen","id":"1734642835370373845.bca755ed-c2eb-43a5-bf93-277c589b9e05","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"Specimen/1734642835375994354.bc12431e-529d-4439-a95c-1a05fc307710","resource":{"resourceType":"Specimen","id":"1734642835375994354.bc12431e-529d-4439-a95c-1a05fc307710","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-06T13:00:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}}}},{"fullUrl":"ServiceRequest/1734642835391905450.b0809859-bcec-4d5c-99b8-9d428fe31026","resource":{"resourceType":"ServiceRequest","id":"1734642835391905450.b0809859-bcec-4d5c-99b8-9d428fe31026","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/business-event","valueCode":"RE"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/orc-common-order","extension":[{"url":"orc-21-ordering-facility-name","valueReference":{"reference":"Organization/1734642835386599601.719ad5fa-533a-4200-965a-577d7ace98b7"}},{"url":"orc-22-ordering-facility-address","valueAddress":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"8700 BEVERLY BLVD"}]}]}],"line":["8700 BEVERLY BLVD"],"city":"W HOLLYWOOD","state":"CA","postalCode":"90048-1804"}},{"url":"orc-12-ordering-provider","valueReference":{"reference":"Practitioner/1734642835389195518.b545a033-3fb0-44b3-a6ee-683690b4b89c"}}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.2","valueIdentifier":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"value":"12345667867"}},{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"S30500"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"S30500"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"requester":{"reference":"PractitionerRole/1734642835378732910.6d305b23-a512-4553-ad1b-56dfe051ea06"}}},{"fullUrl":"Practitioner/1734642835380322039.b795c0ba-5ede-471c-b1be-980d998c55f6","resource":{"resourceType":"Practitioner","id":"1734642835380322039.b795c0ba-5ede-471c-b1be-980d998c55f6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"SARAH"},{"url":"XCN.10","valueString":"NPI"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.12"}],"identifier":[{"value":"1194257170"}],"name":[{"family":"MAHMOOD","given":["SARAH"]}]}},{"fullUrl":"Organization/1734642835382836003.b835936f-521b-4acf-9cda-47bab6c75eb1","resource":{"resourceType":"Organization","id":"1734642835382836003.b835936f-521b-4acf-9cda-47bab6c75eb1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R150"}]}],"identifier":[{"value":"R150"}],"name":"CEDARS-SINAI MEDICAL CENTER","telecom":[{"_system":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}],"address":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"8700 BEVERLY BLVD"}]}]}],"line":["8700 BEVERLY BLVD"],"city":"W HOLLYWOOD","state":"CA","postalCode":"90048-1804"}]}},{"fullUrl":"PractitionerRole/1734642835378732910.6d305b23-a512-4553-ad1b-56dfe051ea06","resource":{"resourceType":"PractitionerRole","id":"1734642835378732910.6d305b23-a512-4553-ad1b-56dfe051ea06","practitioner":{"reference":"Practitioner/1734642835380322039.b795c0ba-5ede-471c-b1be-980d998c55f6"},"organization":{"reference":"Organization/1734642835382836003.b835936f-521b-4acf-9cda-47bab6c75eb1"}}},{"fullUrl":"Organization/1734642835386599601.719ad5fa-533a-4200-965a-577d7ace98b7","resource":{"resourceType":"Organization","id":"1734642835386599601.719ad5fa-533a-4200-965a-577d7ace98b7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R150"}]}],"identifier":[{"value":"R150"}],"name":"CEDARS-SINAI MEDICAL CENTER"}},{"fullUrl":"Practitioner/1734642835389195518.b545a033-3fb0-44b3-a6ee-683690b4b89c","resource":{"resourceType":"Practitioner","id":"1734642835389195518.b545a033-3fb0-44b3-a6ee-683690b4b89c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"SARAH"},{"url":"XCN.10","valueString":"NPI"}]}],"identifier":[{"value":"1194257170"}],"name":[{"family":"MAHMOOD","given":["SARAH"]}]}},{"fullUrl":"ServiceRequest/1734642835397495653.1fae25a3-5582-4ccd-9c29-4a484b7e1f29","resource":{"resourceType":"ServiceRequest","id":"1734642835397495653.1fae25a3-5582-4ccd-9c29-4a484b7e1f29","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835403253630.e3d62b93-e744-4a08-8c18-438deeeb73d9","resource":{"resourceType":"ServiceRequest","id":"1734642835403253630.e3d62b93-e744-4a08-8c18-438deeeb73d9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835408670517.cf866577-1d94-42fe-a02c-0e470d7f5207","resource":{"resourceType":"ServiceRequest","id":"1734642835408670517.cf866577-1d94-42fe-a02c-0e470d7f5207","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835414449784.f01466ef-240a-4b3a-8bc3-b04e3522f8f9","resource":{"resourceType":"ServiceRequest","id":"1734642835414449784.f01466ef-240a-4b3a-8bc3-b04e3522f8f9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835422219363.7d7b6aff-8cdc-4678-943f-6edacbb208cb","resource":{"resourceType":"ServiceRequest","id":"1734642835422219363.7d7b6aff-8cdc-4678-943f-6edacbb208cb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835427739675.c9301f84-b785-4686-bdc5-3c0cd8844304","resource":{"resourceType":"ServiceRequest","id":"1734642835427739675.c9301f84-b785-4686-bdc5-3c0cd8844304","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835433235370.d0fa1553-b40a-4f2a-b846-641ac78ccc68","resource":{"resourceType":"ServiceRequest","id":"1734642835433235370.d0fa1553-b40a-4f2a-b846-641ac78ccc68","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835438637590.579d5a0a-ec9b-492f-b601-f960c3e733b7","resource":{"resourceType":"ServiceRequest","id":"1734642835438637590.579d5a0a-ec9b-492f-b601-f960c3e733b7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835444149986.a03ffaf6-de04-4b06-a587-3c83426b60d0","resource":{"resourceType":"ServiceRequest","id":"1734642835444149986.a03ffaf6-de04-4b06-a587-3c83426b60d0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835449661802.dba507fd-987a-4e1a-95ec-c136bdaf5a33","resource":{"resourceType":"ServiceRequest","id":"1734642835449661802.dba507fd-987a-4e1a-95ec-c136bdaf5a33","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835455235874.c55b17c3-3661-480c-9a11-65bca1a4648a","resource":{"resourceType":"ServiceRequest","id":"1734642835455235874.c55b17c3-3661-480c-9a11-65bca1a4648a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835462162372.b19482f4-7bc6-443c-bc03-70034042b457","resource":{"resourceType":"ServiceRequest","id":"1734642835462162372.b19482f4-7bc6-443c-bc03-70034042b457","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835470690033.20f1a2d7-5117-4ea6-b18a-97e56a88d8f5","resource":{"resourceType":"ServiceRequest","id":"1734642835470690033.20f1a2d7-5117-4ea6-b18a-97e56a88d8f5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835476595667.93f22471-5b90-416c-a0bc-e17d6861d242","resource":{"resourceType":"ServiceRequest","id":"1734642835476595667.93f22471-5b90-416c-a0bc-e17d6861d242","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835482457398.f9daa409-9a26-42e2-bc43-51c59598c7a0","resource":{"resourceType":"ServiceRequest","id":"1734642835482457398.f9daa409-9a26-42e2-bc43-51c59598c7a0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835488227288.9fd08aed-4676-4606-a346-266b379b6244","resource":{"resourceType":"ServiceRequest","id":"1734642835488227288.9fd08aed-4676-4606-a346-266b379b6244","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835494119016.b7f9bde8-3ab2-43e9-aae8-e7ebab50861f","resource":{"resourceType":"ServiceRequest","id":"1734642835494119016.b7f9bde8-3ab2-43e9-aae8-e7ebab50861f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835500001696.57e5e1e7-56b0-487c-9af2-5fb2e512ac17","resource":{"resourceType":"ServiceRequest","id":"1734642835500001696.57e5e1e7-56b0-487c-9af2-5fb2e512ac17","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835505798657.287287b6-6063-4feb-87e7-656f5f1a0f27","resource":{"resourceType":"ServiceRequest","id":"1734642835505798657.287287b6-6063-4feb-87e7-656f5f1a0f27","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835511627888.82dfd4ea-7a37-405e-9803-60b1ac08a8ff","resource":{"resourceType":"ServiceRequest","id":"1734642835511627888.82dfd4ea-7a37-405e-9803-60b1ac08a8ff","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835517624532.73bd901e-444d-41c7-a6b7-1305f7c86d6c","resource":{"resourceType":"ServiceRequest","id":"1734642835517624532.73bd901e-444d-41c7-a6b7-1305f7c86d6c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"ServiceRequest/1734642835526013302.4b06bda6-3626-42a7-b914-b6288aef3f11","resource":{"resourceType":"ServiceRequest","id":"1734642835526013302.4b06bda6-3626-42a7-b914-b6288aef3f11","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.7","valueDateTime":"2024-10-06T13:00:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]}},{"url":"OBR.22","valueString":"20241018050234"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"}}},{"fullUrl":"DiagnosticReport/1734642835531809851.7e82b5f0-fa58-4ae3-9ff4-7ef423653005","resource":{"resourceType":"DiagnosticReport","id":"1734642835531809851.7e82b5f0-fa58-4ae3-9ff4-7ef423653005","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"S30500"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"S30500"}],"basedOn":[{"reference":"ServiceRequest/1734642835391905450.b0809859-bcec-4d5c-99b8-9d428fe31026"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835339788223.c729fd06-1344-4383-a056-20482ce8af1b"}]}},{"fullUrl":"DiagnosticReport/1734642835535197914.0b32db56-7860-4c0d-869b-adf9b391aab5","resource":{"resourceType":"DiagnosticReport","id":"1734642835535197914.0b32db56-7860-4c0d-869b-adf9b391aab5","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835397495653.1fae25a3-5582-4ccd-9c29-4a484b7e1f29"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835341216962.afb81ed4-1938-4d2c-ae58-2c93af81ab8a"}],"result":[{"reference":"Observation/1734642835072408964.75266d3b-3e79-44d2-93e7-33464d92421a"},{"reference":"Observation/1734642835074715129.ead6bdf7-05f5-41b4-8301-9fbfd3b816c2"},{"reference":"Observation/1734642835077037293.45edb036-f68b-40d3-8c09-ea3c6768f49a"},{"reference":"Observation/1734642835079270551.5131b375-6013-45ab-ab8f-5b72e523ada2"},{"reference":"Observation/1734642835081533113.ca9632ae-6903-4249-8aa1-80996f4e453c"},{"reference":"Observation/1734642835083506804.de19e7fc-6c52-4be6-bd35-5365359b3060"},{"reference":"Observation/1734642835085405104.bd0a0117-73b7-476e-b72b-287122ac87a8"}]}},{"fullUrl":"DiagnosticReport/1734642835538844723.39e47371-22c9-427a-9ec9-36c1e0d304f1","resource":{"resourceType":"DiagnosticReport","id":"1734642835538844723.39e47371-22c9-427a-9ec9-36c1e0d304f1","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835403253630.e3d62b93-e744-4a08-8c18-438deeeb73d9"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835342617127.e6180bc9-4138-4189-af57-8aced2fcf501"}],"result":[{"reference":"Observation/1734642835087373826.ed98c076-6f17-44ce-81e4-a403326e769f"},{"reference":"Observation/1734642835089780829.2215db06-44bb-4c59-8466-d9278434cef3"},{"reference":"Observation/1734642835091972329.7b1c0b54-fc4f-4dd0-a741-e260efc53bc6"},{"reference":"Observation/1734642835094262483.b3cb8767-6c64-472a-a06e-87ecd4f282ef"},{"reference":"Observation/1734642835096506060.48931c5c-b95a-4205-8d31-388a9e378f1d"},{"reference":"Observation/1734642835098903976.077e0831-3c99-44cd-beda-c2370b1c502d"},{"reference":"Observation/1734642835103867243.9ca57891-de1f-40be-acd3-da3de38afe4a"},{"reference":"Observation/1734642835105899995.f5ee9e6d-6a3e-4f82-bfee-a728d4e8a184"},{"reference":"Observation/1734642835107881581.1ebeb1fa-fecb-4de7-b9dc-a149595c0620"},{"reference":"Observation/1734642835109899595.ddc4eb47-c60c-4492-9dad-82bb445a74c0"},{"reference":"Observation/1734642835111786463.26c7efd2-e94c-4ce5-9641-f08f45eedde2"}]}},{"fullUrl":"DiagnosticReport/1734642835541790517.02d1415c-20fe-4c6c-a453-99a6256f1aa3","resource":{"resourceType":"DiagnosticReport","id":"1734642835541790517.02d1415c-20fe-4c6c-a453-99a6256f1aa3","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835408670517.cf866577-1d94-42fe-a02c-0e470d7f5207"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835344217448.792d1d9d-d3a3-46fe-85bc-90f98aa11655"}]}},{"fullUrl":"DiagnosticReport/1734642835545994009.2ace7868-aa95-484d-b76b-12db078b97f7","resource":{"resourceType":"DiagnosticReport","id":"1734642835545994009.2ace7868-aa95-484d-b76b-12db078b97f7","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835414449784.f01466ef-240a-4b3a-8bc3-b04e3522f8f9"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835345581636.d23192da-b0a1-4e46-b5cb-4514a5a70a84"}],"result":[{"reference":"Observation/1734642835114032955.393eb749-310a-4618-a511-5cb2afc3e1be"},{"reference":"Observation/1734642835116331285.57764571-3b71-4975-ab76-caa45272d17d"},{"reference":"Observation/1734642835118618614.42426ad4-7ecb-43fe-bf82-864a08fa2a09"},{"reference":"Observation/1734642835120913247.cc61b5bd-2db5-4758-a60b-167569998e49"},{"reference":"Observation/1734642835123269415.c7a6f123-dabd-4ef1-b0f1-b530877298cb"},{"reference":"Observation/1734642835125596349.47098735-1062-4687-b098-d3dab2876010"},{"reference":"Observation/1734642835127868229.41515f30-507b-47da-92a5-0f50aeda3ec4"},{"reference":"Observation/1734642835130189692.2195e0b3-2998-4a0f-9e2b-b94bf4f77834"},{"reference":"Observation/1734642835132519691.2c1beca7-95b7-4a5f-b67d-c1a306333238"},{"reference":"Observation/1734642835134809435.9e06f783-ffe8-481b-ad80-afa38a0ebd6a"},{"reference":"Observation/1734642835137170923.9947c3f7-90ce-44bd-8b77-bd42ff3749d6"},{"reference":"Observation/1734642835139466537.91adde4f-a83d-41ed-ac9e-8caf431c4b86"},{"reference":"Observation/1734642835141830360.547825c7-9eba-4167-8cfe-a2465a2f395d"},{"reference":"Observation/1734642835144301563.de46881d-1f67-46ff-9858-b6ae89a6b48b"},{"reference":"Observation/1734642835146571270.9b822a4e-4daa-43bb-9143-2e71a52a04eb"},{"reference":"Observation/1734642835148847939.fd51e2fb-5d49-4676-a74e-c342a9d90613"},{"reference":"Observation/1734642835151142431.117e42b6-9dc6-4875-94de-1214fde103cf"},{"reference":"Observation/1734642835153541720.5989fc4c-89a5-407d-8b3b-e7549c5e89d2"},{"reference":"Observation/1734642835155639614.b9014743-7717-4773-b580-45c48b2f201a"}]}},{"fullUrl":"DiagnosticReport/1734642835549572319.e913f1db-3d85-49e2-9d92-abbb0ceca353","resource":{"resourceType":"DiagnosticReport","id":"1734642835549572319.e913f1db-3d85-49e2-9d92-abbb0ceca353","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835422219363.7d7b6aff-8cdc-4678-943f-6edacbb208cb"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835346945544.783a59ef-1654-4aae-806a-56d263dd59c3"}],"result":[{"reference":"Observation/1734642835157820193.577aad75-b837-4215-a407-d26006446546"},{"reference":"Observation/1734642835159765200.5b2dae01-a2ce-4f83-9239-8eb5800bcbfb"}]}},{"fullUrl":"DiagnosticReport/1734642835555248693.f55f879e-9129-4a46-b2cb-b3e8779dc651","resource":{"resourceType":"DiagnosticReport","id":"1734642835555248693.f55f879e-9129-4a46-b2cb-b3e8779dc651","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835427739675.c9301f84-b785-4686-bdc5-3c0cd8844304"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835348363853.9e652caf-6856-46c3-b800-dda071ed4ad9"}],"result":[{"reference":"Observation/1734642835162045226.9490f56a-187d-4e99-8223-a2e9772b631d"},{"reference":"Observation/1734642835164354646.81d396e1-073e-4f0e-bfdf-13937d7cd382"},{"reference":"Observation/1734642835166629993.47eb25f8-6df1-46b3-919c-f7e8913d3cf5"},{"reference":"Observation/1734642835168943661.97b6d367-d4d7-435a-bd31-b9459e9e18ec"},{"reference":"Observation/1734642835171271146.f04f4637-b85a-43fb-9f72-be114f3e7c91"},{"reference":"Observation/1734642835173651229.ec3d9ff9-0f52-4328-9cbb-f31a10f36d37"},{"reference":"Observation/1734642835178727400.29b6257f-674c-4973-95d6-21b188015189"},{"reference":"Observation/1734642835180861281.fc593df5-07c9-4233-9cb2-fca44e2c7133"},{"reference":"Observation/1734642835182931393.4305b764-7f39-4ccb-bc9c-5f4bdbb3b7c4"},{"reference":"Observation/1734642835185116210.5940d493-71de-47be-ac64-c7d47d3debde"},{"reference":"Observation/1734642835187288373.1c64ef7b-e463-43d6-8805-ca936b1c72bf"},{"reference":"Observation/1734642835189423406.1c9fd186-339a-4e60-9734-28df7b20a7df"},{"reference":"Observation/1734642835191534946.0417c3df-4317-463f-9d99-b431e3905b09"},{"reference":"Observation/1734642835193679577.02b69198-ef0d-4b94-9df8-7b27fad40308"},{"reference":"Observation/1734642835195762763.1a70ae02-e175-49fc-8500-0490ecc22862"},{"reference":"Observation/1734642835197861699.fdc7c7ef-61e7-41b8-9363-279083afadea"},{"reference":"Observation/1734642835199918416.c535e96d-42d2-43da-b498-5a4a63e27221"},{"reference":"Observation/1734642835202018364.7d47086f-137e-45e4-b97e-529e6410d71c"},{"reference":"Observation/1734642835204143519.0b293d61-5e06-4ec9-8b16-62b66efaca0a"},{"reference":"Observation/1734642835206227236.22c3dadc-1b32-4fa8-90f5-e5895e4642dc"},{"reference":"Observation/1734642835208324649.86b17533-f55e-4b9e-8306-313ca8c8d474"},{"reference":"Observation/1734642835210415530.d24aaa22-035b-42ab-a8ad-dd36ee78ea24"},{"reference":"Observation/1734642835212653867.d599ae32-6087-4057-ba49-a7f051078cdb"},{"reference":"Observation/1734642835214779794.05d31cbf-102d-45df-b48f-54cc0f715691"},{"reference":"Observation/1734642835216894589.19959e3d-cf6d-459e-b0e9-cf9e5400bbf5"},{"reference":"Observation/1734642835218980921.802246ce-c233-406b-8013-2586b6499575"}]}},{"fullUrl":"DiagnosticReport/1734642835559283809.7a8b7aca-7378-4e0f-b3b5-e7e311ecdcde","resource":{"resourceType":"DiagnosticReport","id":"1734642835559283809.7a8b7aca-7378-4e0f-b3b5-e7e311ecdcde","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835433235370.d0fa1553-b40a-4f2a-b846-641ac78ccc68"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835349728452.9cdd7c14-f5a3-46d1-9031-27e8231dd653"}],"result":[{"reference":"Observation/1734642835221107288.81ab8987-7308-4524-ac1a-1429982b0b7e"},{"reference":"Observation/1734642835223225480.5a102d3e-c9f8-40a2-9358-651a3c6cd4bf"},{"reference":"Observation/1734642835225460391.367cd09c-a84d-4b74-9012-6208e9cae783"},{"reference":"Observation/1734642835227537436.97f58b93-df12-4ff2-ab2a-cbe874b04d88"},{"reference":"Observation/1734642835229643846.878bcfe3-113a-433f-aaa0-bb3269307c1e"},{"reference":"Observation/1734642835231745977.21c27e63-559a-4ec1-be5b-ad43ab6e0b65"},{"reference":"Observation/1734642835233956282.462ce6c5-4cef-4570-9775-455480579770"},{"reference":"Observation/1734642835236097878.fa6c4155-42c1-4ac4-a809-5e912eb9e191"},{"reference":"Observation/1734642835238198367.c38dc305-07da-435c-a327-d77e95e1348e"},{"reference":"Observation/1734642835240363176.0253a773-b531-4c12-b79f-b45649144356"}]}},{"fullUrl":"DiagnosticReport/1734642835562458663.3bdb90b2-527c-4c7e-8542-71484cd7ab99","resource":{"resourceType":"DiagnosticReport","id":"1734642835562458663.3bdb90b2-527c-4c7e-8542-71484cd7ab99","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835438637590.579d5a0a-ec9b-492f-b601-f960c3e733b7"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835351271315.e31cf52e-6cf9-49ac-9a39-8f8d87453d6f"}],"result":[{"reference":"Observation/1734642835242457754.6443996c-029e-4fb4-9e7e-b38be0e5271c"},{"reference":"Observation/1734642835244613837.18c12760-d680-4504-a920-22aed27486e6"},{"reference":"Observation/1734642835246395758.fd278006-4ca8-4198-9a61-0285d94792d8"}]}},{"fullUrl":"DiagnosticReport/1734642835565786613.35dbbd5c-05ba-447e-a90a-b0b8a1d5337c","resource":{"resourceType":"DiagnosticReport","id":"1734642835565786613.35dbbd5c-05ba-447e-a90a-b0b8a1d5337c","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835444149986.a03ffaf6-de04-4b06-a587-3c83426b60d0"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835352696317.c61b9f44-92d0-4e7a-90d7-b46711288b72"}],"result":[{"reference":"Observation/1734642835251390130.1f1ba7f3-55dc-4fd1-8959-cb63ee36fe9b"},{"reference":"Observation/1734642835253597740.7a2b5271-eaa4-4ed2-bc88-2bb2ca71b6ea"},{"reference":"Observation/1734642835255562214.3015bf59-aaee-4495-989e-81a50bf93052"}]}},{"fullUrl":"DiagnosticReport/1734642835569237875.9ba7d3fc-9967-4075-88be-0335ae188064","resource":{"resourceType":"DiagnosticReport","id":"1734642835569237875.9ba7d3fc-9967-4075-88be-0335ae188064","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835449661802.dba507fd-987a-4e1a-95ec-c136bdaf5a33"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835354045988.5631aacd-2433-42f6-95ce-35b6a9afcf3c"}],"result":[{"reference":"Observation/1734642835257602910.abe375b3-0f71-4173-95e9-001a5a884ab7"},{"reference":"Observation/1734642835259698981.43c8b710-7c71-4940-b9d5-25cc3d4e1958"},{"reference":"Observation/1734642835261515607.b721c4f8-75bf-4a2c-b5fd-9ff30cbebc4c"}]}},{"fullUrl":"DiagnosticReport/1734642835572429349.a553e636-266f-4c09-b709-d56573b6fe07","resource":{"resourceType":"DiagnosticReport","id":"1734642835572429349.a553e636-266f-4c09-b709-d56573b6fe07","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835455235874.c55b17c3-3661-480c-9a11-65bca1a4648a"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835355395369.c3f3a14b-e8a0-4520-8cdf-e9174aeabb56"}],"result":[{"reference":"Observation/1734642835263526728.6352e178-f7df-4942-b4e5-e369848a3d44"},{"reference":"Observation/1734642835265824537.e04c9caa-53c4-4a27-aac6-9b0ca883fa66"},{"reference":"Observation/1734642835267640753.9e1c7bf0-8aa2-4291-8928-7d9ad874d770"}]}},{"fullUrl":"DiagnosticReport/1734642835575571841.d8c12c52-d7ca-43a2-afe8-80132657f9c7","resource":{"resourceType":"DiagnosticReport","id":"1734642835575571841.d8c12c52-d7ca-43a2-afe8-80132657f9c7","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835462162372.b19482f4-7bc6-443c-bc03-70034042b457"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835356809771.907d3d60-4ee3-4e70-90b8-1c6978b7b6f6"}],"result":[{"reference":"Observation/1734642835269483057.3ed613f4-d1ba-4f9e-94c5-a71a1ded6f45"},{"reference":"Observation/1734642835271065745.e760e98a-c57f-4150-a192-9a4815b9e4cc"}]}},{"fullUrl":"DiagnosticReport/1734642835581956604.0d9ff39f-34fd-4dd9-a5ac-dc8c2aa43995","resource":{"resourceType":"DiagnosticReport","id":"1734642835581956604.0d9ff39f-34fd-4dd9-a5ac-dc8c2aa43995","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835470690033.20f1a2d7-5117-4ea6-b18a-97e56a88d8f5"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835358162137.9b5c0311-9a41-48bc-8bbd-c74bf03176b9"}],"result":[{"reference":"Observation/1734642835272891979.7a36eb88-ef32-49a5-bc5e-7cdf17f63349"},{"reference":"Observation/1734642835274997297.6e838878-c98e-44ad-879a-acaa41879d9f"},{"reference":"Observation/1734642835276813694.97af3170-7292-4775-ab18-e721d0173e29"}]}},{"fullUrl":"DiagnosticReport/1734642835585075052.1a8ebd8f-0416-4788-b779-b9b111188dd9","resource":{"resourceType":"DiagnosticReport","id":"1734642835585075052.1a8ebd8f-0416-4788-b779-b9b111188dd9","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835476595667.93f22471-5b90-416c-a0bc-e17d6861d242"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835359622094.6175ae40-ff81-4cf2-be1b-194e3f091225"}],"result":[{"reference":"Observation/1734642835278833451.2ad1bcd4-0e4b-4eed-8e68-f6f53d9c70dc"},{"reference":"Observation/1734642835280939350.31988676-eaca-4ccf-ae6b-f95724c72091"},{"reference":"Observation/1734642835282741108.a5b64cc6-76f4-47ea-ae94-bb7e8b259ea9"}]}},{"fullUrl":"DiagnosticReport/1734642835588257930.2fa53ce1-57c4-4b73-b9fb-5e4be2b9f735","resource":{"resourceType":"DiagnosticReport","id":"1734642835588257930.2fa53ce1-57c4-4b73-b9fb-5e4be2b9f735","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835482457398.f9daa409-9a26-42e2-bc43-51c59598c7a0"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835361419575.3fe2b96b-3fd7-489a-b6f7-6d62e235b3eb"}],"result":[{"reference":"Observation/1734642835284764342.eb4d98d3-2e02-47ac-81e3-f73c2d23cb8b"},{"reference":"Observation/1734642835286864520.58c01a31-8ede-4e3d-a8b6-b7f2a2aaddfd"},{"reference":"Observation/1734642835288660898.8901b1f0-99f8-4762-9318-77cc13486bfc"}]}},{"fullUrl":"DiagnosticReport/1734642835591422123.d2f9f942-bfd6-4cbd-8565-822730b7e828","resource":{"resourceType":"DiagnosticReport","id":"1734642835591422123.d2f9f942-bfd6-4cbd-8565-822730b7e828","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835488227288.9fd08aed-4676-4606-a346-266b379b6244"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835362813018.dc52b61c-7bc3-4025-b223-b1ca2b3c4223"}],"result":[{"reference":"Observation/1734642835290755476.b2542317-e334-4edf-a07e-2fa17c9679f1"},{"reference":"Observation/1734642835292880270.61aaccd6-2df3-4536-b2d4-61eff7ae5eb4"},{"reference":"Observation/1734642835294727053.63b3c494-3f3d-42af-9e1b-6c7b6396b4f8"}]}},{"fullUrl":"DiagnosticReport/1734642835594544669.f203eb3d-fb58-425d-aad5-44fe9b3a7bbf","resource":{"resourceType":"DiagnosticReport","id":"1734642835594544669.f203eb3d-fb58-425d-aad5-44fe9b3a7bbf","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835494119016.b7f9bde8-3ab2-43e9-aae8-e7ebab50861f"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835364224324.f7cb9104-c8d8-44b9-9d2a-61456558dc71"}],"result":[{"reference":"Observation/1734642835297387312.feaf65ff-2abb-4738-9b02-c14e949fc66c"},{"reference":"Observation/1734642835300196600.6b956336-be88-4448-8c31-b13512d7a6e8"},{"reference":"Observation/1734642835302325131.3f9d73bf-5fb0-4b7a-9d19-5c65eca61695"}]}},{"fullUrl":"DiagnosticReport/1734642835597620105.488df753-3823-41cd-84fd-40b72997cffe","resource":{"resourceType":"DiagnosticReport","id":"1734642835597620105.488df753-3823-41cd-84fd-40b72997cffe","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835500001696.57e5e1e7-56b0-487c-9af2-5fb2e512ac17"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835365609582.1af14955-5a50-4899-aba3-59ac8a752604"}],"result":[{"reference":"Observation/1734642835304478669.58d1fe41-4fe6-439c-ac8c-7ebda34fa2c8"},{"reference":"Observation/1734642835307026637.f53e03f5-3c64-4288-9a28-214161f26772"},{"reference":"Observation/1734642835308977855.d3c4cd9b-1d7e-4d95-8085-f6edee36ce6a"}]}},{"fullUrl":"DiagnosticReport/1734642835600653273.375b52d5-1287-4587-af7e-f819678bb126","resource":{"resourceType":"DiagnosticReport","id":"1734642835600653273.375b52d5-1287-4587-af7e-f819678bb126","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835505798657.287287b6-6063-4feb-87e7-656f5f1a0f27"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835366959533.9c598daa-6478-49d5-bef7-af0f7f2454f6"}],"result":[{"reference":"Observation/1734642835311168554.69c8b649-447b-46f2-baae-bab36c3da5a4"},{"reference":"Observation/1734642835313133799.6f0a0b0f-4471-48bd-9ba1-478b444859ce"}]}},{"fullUrl":"DiagnosticReport/1734642835603899090.99cd7384-3aa2-4303-990f-c3d24337cb56","resource":{"resourceType":"DiagnosticReport","id":"1734642835603899090.99cd7384-3aa2-4303-990f-c3d24337cb56","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835511627888.82dfd4ea-7a37-405e-9803-60b1ac08a8ff"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835368450358.d0a6f2ac-8c36-408a-b974-d9e9ae4faf84"}],"result":[{"reference":"Observation/1734642835315205965.5211d2f8-1a92-47e0-a60d-827e1415618d"},{"reference":"Observation/1734642835317343453.4e89665e-74a5-47f3-99d9-376bcb1180e4"},{"reference":"Observation/1734642835323110520.12a4dd67-1010-4b73-8f82-382d41bc1a15"}]}},{"fullUrl":"DiagnosticReport/1734642835607156908.01e08384-7d0d-4a40-a6cd-4b60e2d03248","resource":{"resourceType":"DiagnosticReport","id":"1734642835607156908.01e08384-7d0d-4a40-a6cd-4b60e2d03248","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835517624532.73bd901e-444d-41c7-a6b7-1305f7c86d6c"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835370373845.bca755ed-c2eb-43a5-bf93-277c589b9e05"}],"result":[{"reference":"Observation/1734642835325439747.8f0de453-fadb-465c-96fa-cc16db1af1ea"},{"reference":"Observation/1734642835327359006.73a0b073-3142-486b-b9a7-9a53237926aa"}]}},{"fullUrl":"DiagnosticReport/1734642835610181350.cbaed3cc-e9a9-43f1-9836-3cd9db54bf2b","resource":{"resourceType":"DiagnosticReport","id":"1734642835610181350.cbaed3cc-e9a9-43f1-9836-3cd9db54bf2b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"12345667867"}],"basedOn":[{"reference":"ServiceRequest/1734642835526013302.4b06bda6-3626-42a7-b914-b6288aef3f11"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835067633019.9ef8ed93-85aa-453b-82a2-130309f8af68"},"effectiveDateTime":"2024-10-06T13:00:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410061300"}]},"issued":"2024-10-18T05:02:34Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050234"}]},"specimen":[{"reference":"Specimen/1734642835375994354.bc12431e-529d-4439-a95c-1a05fc307710"}],"result":[{"reference":"Observation/1734642835329763265.0f40fa13-fedf-496d-9f03-29a65ce7b1bf"}]}}]}
diff --git a/examples/Test/Automated/GoldenCopy/Expected/003_ORU_R01_golden_copy_expected_aa_unusual.fhir b/examples/Test/Automated/GoldenCopy/Expected/003_ORU_R01_golden_copy_expected_aa_unusual.fhir
deleted file mode 100644
index 969382e68..000000000
--- a/examples/Test/Automated/GoldenCopy/Expected/003_ORU_R01_golden_copy_expected_aa_unusual.fhir
+++ /dev/null
@@ -1 +0,0 @@
-{"resourceType":"Bundle","id":"1734642835316676335.97260f02-e474-4674-baae-79cfcbe2f0bc","meta":{"lastUpdated":"2024-12-19T21:13:55.316+00:00"},"identifier":{"system":"https://reportstream.cdc.gov/prime-router","value":"003"},"type":"message","timestamp":"2024-10-23T05:00:44.000+00:00","entry":[{"fullUrl":"MessageHeader/1734642835321323789.e9b795da-63ce-432b-a949-58c5ec4c7909","resource":{"resourceType":"MessageHeader","id":"1734642835321323789.e9b795da-63ce-432b-a949-58c5ec4c7909","meta":{"tag":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0103","code":"N"}]},"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/msh-message-header","extension":[{"url":"MSH.7","valueString":"20241023050044"}]}],"eventCoding":{"system":"http://terminology.hl7.org/CodeSystem/v2-0003","code":"R01","display":"ORU^R01^ORU_R01"},"destination":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id","valueString":"9414049"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id-type","valueString":"L,M,N"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.5"}],"name":"SISHIERECEIVER","receiver":{"reference":"Organization/1734642835317459042.a94abe18-53ef-4bb2-bf5f-bf84f4fb6069"}}],"sender":{"reference":"Organization/1734642835316938787.7c04e091-ec33-47cf-9282-ab875e2769e0"},"source":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"SISGDSP"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.3"}],"name":"SISGDSP","_endpoint":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}}},{"fullUrl":"Organization/1734642835316938787.7c04e091-ec33-47cf-9282-ab875e2769e0","resource":{"resourceType":"Organization","id":"1734642835316938787.7c04e091-ec33-47cf-9282-ab875e2769e0","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Organization/1734642835317459042.a94abe18-53ef-4bb2-bf5f-bf84f4fb6069","resource":{"resourceType":"Organization","id":"1734642835317459042.a94abe18-53ef-4bb2-bf5f-bf84f4fb6069","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.6"}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.2,HD.3"}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301","code":"L,M,N"}]},"value":"automated-staging-test-receiver-id"}]}},{"fullUrl":"Provenance/1734642835322564285.47612a0e-8440-4bf9-9994-8a7026969910","resource":{"resourceType":"Provenance","id":"1734642835322564285.47612a0e-8440-4bf9-9994-8a7026969910","target":[{"reference":"MessageHeader/1734642835321323789.e9b795da-63ce-432b-a949-58c5ec4c7909"},{"reference":"DiagnosticReport/1734642836025400305.ff8ac839-62e2-4ae6-b38b-17f6d262661b"},{"reference":"DiagnosticReport/1734642836029429390.99b9f76a-d712-4a1f-95b8-eaaf390269fb"},{"reference":"DiagnosticReport/1734642836033347527.1423054d-d094-4b59-8fc6-e0e29bce16a4"},{"reference":"DiagnosticReport/1734642836036509076.18aca8a2-26f1-44f3-bc02-74fc6bb9b34f"},{"reference":"DiagnosticReport/1734642836041210852.69c341cb-2144-4f74-b624-c2a7731fa718"},{"reference":"DiagnosticReport/1734642836044537029.4107a300-c273-45d1-b36a-e5144b0c649b"},{"reference":"DiagnosticReport/1734642836049712354.70273afb-c29e-474d-9e06-a1e28f33aee1"},{"reference":"DiagnosticReport/1734642836053923019.128e29de-5e06-4ea9-a20d-420ac9b6c954"},{"reference":"DiagnosticReport/1734642836057537897.2271a1ac-7b0b-4b5a-9134-9d0b11c1aa8e"},{"reference":"DiagnosticReport/1734642836060854116.26790db7-6d6b-4e42-8239-08c7ef372775"},{"reference":"DiagnosticReport/1734642836064630176.92f10d06-cc28-4cb3-9d32-f4aa43dec35b"},{"reference":"DiagnosticReport/1734642836067816571.2149d1a2-417a-4bce-9c2d-a8b96c1a4ce6"},{"reference":"DiagnosticReport/1734642836070885045.9cd3f0af-e328-4e84-bac9-f37614924bad"},{"reference":"DiagnosticReport/1734642836074795647.998e19fd-ef20-48fc-9ffd-dda2719ea5f2"},{"reference":"DiagnosticReport/1734642836079087485.3ab655bd-01db-4c70-9e4b-ce057a3dc21f"},{"reference":"DiagnosticReport/1734642836082360703.e108bbfb-c300-4c64-bcfb-33611923f8d2"},{"reference":"DiagnosticReport/1734642836085564821.5f0e8445-cccc-45a2-9363-029a6c67b1bb"},{"reference":"DiagnosticReport/1734642836089224263.c80abe0a-b8cf-4063-9caf-122710a02b4f"},{"reference":"DiagnosticReport/1734642836092450482.c935b20d-f405-4093-acd7-23d13d02c9d0"},{"reference":"DiagnosticReport/1734642836095781419.9d3f4ff9-f268-408b-a3c9-a9f1563ddd34"},{"reference":"DiagnosticReport/1734642836100016380.06b8079b-3e66-4d76-ba1e-540869bad33a"},{"reference":"DiagnosticReport/1734642836103489783.54433dc4-1532-463c-a3fd-9db074b3439c"},{"reference":"DiagnosticReport/1734642836111794034.e7245026-8c48-44c6-b07c-7d0df43be6d1"}],"recorded":"2024-10-23T05:00:44Z","activity":{"coding":[{"display":"ORU^R01^ORU_R01"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"author"}]},"who":{"reference":"Organization/1734642835322365282.9da1e1a8-2ff8-42dd-ba4c-a140b6fbbe63"}}]}},{"fullUrl":"Organization/1734642835322365282.9da1e1a8-2ff8-42dd-ba4c-a140b6fbbe63","resource":{"resourceType":"Organization","id":"1734642835322365282.9da1e1a8-2ff8-42dd-ba4c-a140b6fbbe63","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Provenance/1734642835323067038.ed16affe-94a8-4572-98a0-496ed35018c2","resource":{"resourceType":"Provenance","id":"1734642835323067038.ed16affe-94a8-4572-98a0-496ed35018c2","recorded":"2024-12-19T21:13:55Z","policy":["http://hl7.org/fhir/uv/v2mappings/message-oru-r01-to-bundle"],"activity":{"coding":[{"code":"v2-FHIR transformation"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"assembler"}]},"who":{"reference":"Organization/1734642835322919191.37fff541-57da-4e65-9a01-feeb24b92a4f"}}]}},{"fullUrl":"Organization/1734642835322919191.37fff541-57da-4e65-9a01-feeb24b92a4f","resource":{"resourceType":"Organization","id":"1734642835322919191.37fff541-57da-4e65-9a01-feeb24b92a4f","identifier":[{"value":"CDC PRIME - Atlanta"},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301"}]},"system":"urn:ietf:rfc:3986","value":"2.16.840.1.114222.4.1.237821"}]}},{"fullUrl":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6","resource":{"resourceType":"Patient","id":"1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cx-identifier","extension":[{"url":"CX.5","valueString":"MR"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"PID.3"}],"type":{"coding":[{"code":"MR"}]},"value":"32550867","assigner":{"reference":"Organization/1734642835323709593.d0e89ced-630a-4420-ac3d-8963187d336f"}}],"name":[{"family":"*****PII REMOVED******"}],"contact":[{"name":{"family":"*****PII REMOVED******"}}]}},{"fullUrl":"Organization/1734642835323709593.d0e89ced-630a-4420-ac3d-8963187d336f","resource":{"resourceType":"Organization","id":"1734642835323709593.d0e89ced-630a-4420-ac3d-8963187d336f","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"1013163542&NPI"}]}},{"fullUrl":"Provenance/1734642835327525228.0339ab4c-4b97-460e-96a0-deb309a41455","resource":{"resourceType":"Provenance","id":"1734642835327525228.0339ab4c-4b97-460e-96a0-deb309a41455","target":[{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"}],"recorded":"2024-12-19T21:13:55Z","activity":{"coding":[{"system":"https://terminology.hl7.org/CodeSystem/v3-DataOperation","code":"UPDATE"}]}}},{"fullUrl":"RelatedPerson/1734642835328476381.06363fc9-8325-4667-bd99-a3b8b5a31bb9","resource":{"resourceType":"RelatedPerson","id":"1734642835328476381.06363fc9-8325-4667-bd99-a3b8b5a31bb9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"NK1"}],"patient":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"name":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"NK1.2"}],"family":"*****PII REMOVED******"}]}},{"fullUrl":"Observation/1734642835331267826.63d36999-ad9d-43cf-9ffa-431a0c8a7bcd","resource":{"resourceType":"Observation","id":"1734642835331267826.63d36999-ad9d-43cf-9ffa-431a0c8a7bcd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57721-3","display":"Reason for lab test in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12421-6","display":"Initial screen"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835333569772.67e5a931-dbac-42f7-a4ca-96331001f5f4","resource":{"resourceType":"Observation","id":"1734642835333569772.67e5a931-dbac-42f7-a4ca-96331001f5f4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57718-9","display":"Sample quality of Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12432-3","display":"Acceptable"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835335722138.55faa56e-a228-4fc8-9165-8fdb9382e0a8","resource":{"resourceType":"Observation","id":"1734642835335722138.55faa56e-a228-4fc8-9165-8fdb9382e0a8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57130-7","display":"Newborn screening report - overall interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18944-1","display":"Screen is out of range for at least one condition"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835337835952.0dad2f6c-eeff-4faf-b63a-a4ba5359a979","resource":{"resourceType":"Observation","id":"1734642835337835952.0dad2f6c-eeff-4faf-b63a-a4ba5359a979","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57131-5","display":"Newborn conditions with positive markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835339907126.8d052379-b998-403b-919e-aa04ce7ae698","resource":{"resourceType":"Observation","id":"1734642835339907126.8d052379-b998-403b-919e-aa04ce7ae698","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57720-5","display":"Newborn conditions with equivocal markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835341768095.0c6fdcb8-2039-49cf-a9fa-6aec62df3cec","resource":{"resourceType":"Observation","id":"1734642835341768095.0c6fdcb8-2039-49cf-a9fa-6aec62df3cec","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57724-7","display":"Newborn screening short narrative summary"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"ACTION REQUIRED\\\\.br\\\\\\\\.br\\\\NBS Testing Lab - ALLIED LABORATORY \\\\\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\\\.br\\\\\\\\.br\\\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\\\.br\\\\\\\\.br\\\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\\\.br\\\\\\\\.br\\\\Follow-up:\\\\.br\\\\\\\\.br\\\\Amino Acid Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\\\.br\\\\\\\\.br\\\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\\\.br\\\\\\\\.br\\\\Methods and Limitations:\\\\.br\\\\\\\\.br\\\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\\\.br\\\\Attention Healthcare Provider:\\\\.br\\\\\\\\.br\\\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\\\.br\\\\\\\\.br\\","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835343782833.af96a85a-767c-43b2-a5a5-04b73664c52f","resource":{"resourceType":"Observation","id":"1734642835343782833.af96a85a-767c-43b2-a5a5-04b73664c52f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57129-9","display":"Full newborn screening summary report for display or printing"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835345802340.93550bd0-515e-43fa-98c0-63214b549372","resource":{"resourceType":"Observation","id":"1734642835345802340.93550bd0-515e-43fa-98c0-63214b549372","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"ST"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57716-3","display":"State printed on filter paper card [Identifier] in NBS card"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"CA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835347854718.6a359b63-1a34-486f-92d9-8b593a70c860","resource":{"resourceType":"Observation","id":"1734642835347854718.6a359b63-1a34-486f-92d9-8b593a70c860","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"grams"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"8339-4","display":"Birthweight"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":2230,"unit":"grams"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835349807480.c7fb14b4-52bc-4f8c-b9da-7d38cd79c9b3","resource":{"resourceType":"Observation","id":"1734642835349807480.c7fb14b4-52bc-4f8c-b9da-7d38cd79c9b3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57715-5","display":"Time of birth"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueTime":"1358","_valueTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"1358"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835352502855.5ff149e3-c3ed-4661-9784-9023409e0447","resource":{"resourceType":"Observation","id":"1734642835352502855.5ff149e3-c3ed-4661-9784-9023409e0447","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57722-1","display":"Birth plurality of Pregnancy"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12412-5","display":"Twins"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835354586642.1df6ef52-e9b7-4e39-b895-fdf2e3437402","resource":{"resourceType":"Observation","id":"1734642835354586642.1df6ef52-e9b7-4e39-b895-fdf2e3437402","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"hour(s)"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"73806-2","display":"Newborn age in hours"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":26,"unit":"hour(s)"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835356828696.da821f16-8972-442a-8568-f322e8e1b276","resource":{"resourceType":"Observation","id":"1734642835356828696.da821f16-8972-442a-8568-f322e8e1b276","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57713-0","display":"Infant NICU factors that affect newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835358990570.b7f0e174-0d5e-4b85-8176-587efa704cd9","resource":{"resourceType":"Observation","id":"1734642835358990570.b7f0e174-0d5e-4b85-8176-587efa704cd9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67704-7","display":"Feeding types"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA16914-6","display":"Breast milk"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835361225290.cc0bd769-7b35-4d29-9b2a-1ed6d1254fc4","resource":{"resourceType":"Observation","id":"1734642835361225290.cc0bd769-7b35-4d29-9b2a-1ed6d1254fc4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-5","display":"Accession Number"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"282-38-261/21-2024-12","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835363248454.779ba7a1-c24e-4a37-abef-4f67466b41dd","resource":{"resourceType":"Observation","id":"1734642835363248454.779ba7a1-c24e-4a37-abef-4f67466b41dd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62324-9","display":"Post-discharge provider name"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"DR JOCHEN PROFIT","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835365113972.4533c579-f036-4a40-9093-a24ab85924c5","resource":{"resourceType":"Observation","id":"1734642835365113972.4533c579-f036-4a40-9093-a24ab85924c5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62325-6","display":"Post-discharge provider practice ID"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"1043390461","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835366924928.1e0adb94-c06a-4c3e-bcb6-ebabf903b26f","resource":{"resourceType":"Observation","id":"1734642835366924928.1e0adb94-c06a-4c3e-bcb6-ebabf903b26f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62327-2","display":"Post-discharge provider practice address"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835369659566.fe38b667-7f7e-4c1e-8612-5c5ff058fc43","resource":{"resourceType":"Observation","id":"1734642835369659566.fe38b667-7f7e-4c1e-8612-5c5ff058fc43","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47633-3","display":"Glycine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":368,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835376452073.9eff88cf-d334-4da6-8a4b-d79cec24a6fa","resource":{"resourceType":"Observation","id":"1734642835376452073.9eff88cf-d334-4da6-8a4b-d79cec24a6fa","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53150-9","display":"Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":310,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1000"}]}},{"fullUrl":"Observation/1734642835378662407.bcab4c6b-5ba4-44e0-bdd5-c937fd3bde84","resource":{"resourceType":"Observation","id":"1734642835378662407.bcab4c6b-5ba4-44e0-bdd5-c937fd3bde84","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47799-2","display":"Valine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":34.6,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835380826375.6b8edc0e-b24d-4395-a601-ea26b581cfa9","resource":{"resourceType":"Observation","id":"1734642835380826375.6b8edc0e-b24d-4395-a601-ea26b581cfa9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53151-7","display":"Valine/Phenylalanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.06462,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.3"}]}},{"fullUrl":"Observation/1734642835382952452.6f507334-0883-4174-ac7a-0ddb0f4df61a","resource":{"resourceType":"Observation","id":"1734642835382952452.6f507334-0883-4174-ac7a-0ddb0f4df61a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53152-5","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":50.7,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<230"}]}},{"fullUrl":"Observation/1734642835385214764.c131d587-e5ac-4f53-94f1-3399562a8db5","resource":{"resourceType":"Observation","id":"1734642835385214764.c131d587-e5ac-4f53-94f1-3399562a8db5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53154-1","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.16,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.35"}]}},{"fullUrl":"Observation/1734642835387460395.cda75646-4eda-4b32-b680-9456e40f562a","resource":{"resourceType":"Observation","id":"1734642835387460395.cda75646-4eda-4b32-b680-9456e40f562a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29573-3","display":"Phenylalanine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":32.5,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<175"}]}},{"fullUrl":"Observation/1734642835389634321.501179b2-c30a-4843-9418-40b2497aad2f","resource":{"resourceType":"Observation","id":"1734642835389634321.501179b2-c30a-4843-9418-40b2497aad2f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35572-7","display":"Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.13,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2.6"}]}},{"fullUrl":"Observation/1734642835391828446.5f433876-3f87-45ec-9b16-1e452a6afe53","resource":{"resourceType":"Observation","id":"1734642835391828446.5f433876-3f87-45ec-9b16-1e452a6afe53","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35571-9","display":"Tyrosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":28.9,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<680"}]}},{"fullUrl":"Observation/1734642835394016309.da7611a9-ab4b-48c4-b7e3-81e3988dc810","resource":{"resourceType":"Observation","id":"1734642835394016309.da7611a9-ab4b-48c4-b7e3-81e3988dc810","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53231-7","display":"Succinylacetone [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.25,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<6.1"}]}},{"fullUrl":"Observation/1734642835396791673.56b08f59-5641-492c-8cb3-9607afdacb01","resource":{"resourceType":"Observation","id":"1734642835396791673.56b08f59-5641-492c-8cb3-9607afdacb01","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47700-0","display":"Methionine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":8.6,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.3-100"}]}},{"fullUrl":"Observation/1734642835399100622.0b4cd402-06ef-4639-be95-30310ae78277","resource":{"resourceType":"Observation","id":"1734642835399100622.0b4cd402-06ef-4639-be95-30310ae78277","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42892-0","display":"Citrulline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":5,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"5-49"}]}},{"fullUrl":"Observation/1734642835401273266.7ec959c0-e661-4977-9ada-564e016aa547","resource":{"resourceType":"Observation","id":"1734642835401273266.7ec959c0-e661-4977-9ada-564e016aa547","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54092-2","display":"Citrulline/Arginine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.67,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.8"}]}},{"fullUrl":"Observation/1734642835403495854.208ba995-f62a-4a32-92ca-6dbd84e7b5bd","resource":{"resourceType":"Observation","id":"1734642835403495854.208ba995-f62a-4a32-92ca-6dbd84e7b5bd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53155-8","display":"Asparagine+Ornithine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":32,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<800"}]}},{"fullUrl":"Observation/1734642835405656826.a6f91d96-0e3a-47ac-8507-ba955e7a55ef","resource":{"resourceType":"Observation","id":"1734642835405656826.a6f91d96-0e3a-47ac-8507-ba955e7a55ef","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75215-4","display":"Ornithine/Citrulline [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":6.41,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835407744861.6c1d97ff-8566-4b14-839f-453d75dd411e","resource":{"resourceType":"Observation","id":"1734642835407744861.6c1d97ff-8566-4b14-839f-453d75dd411e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47562-4","display":"Arginine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":3,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<63"}]}},{"fullUrl":"Observation/1734642835409895063.1deb4048-6a8b-4531-bad0-47b7a192abda","resource":{"resourceType":"Observation","id":"1734642835409895063.1deb4048-6a8b-4531-bad0-47b7a192abda","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75214-7","display":"Arginine/Ornithine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.09,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.9"}]}},{"fullUrl":"Observation/1734642835412122400.c7ff92a9-a371-4bf3-9ca3-8a0e51a7e406","resource":{"resourceType":"Observation","id":"1734642835412122400.c7ff92a9-a371-4bf3-9ca3-8a0e51a7e406","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47732-3","display":"Proline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":55,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1500"}]}},{"fullUrl":"Observation/1734642835414367069.ff02d7b5-fca3-4e42-b46e-e94db9935f98","resource":{"resourceType":"Observation","id":"1734642835414367069.ff02d7b5-fca3-4e42-b46e-e94db9935f98","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57710-6","display":"Amino acidemias newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"This complex pattern of elevations require further evaluation","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"A"}]}]}},{"fullUrl":"Observation/1734642835416488106.e6efc8d9-7149-41bd-b70d-bdd588f1a3dc","resource":{"resourceType":"Observation","id":"1734642835416488106.e6efc8d9-7149-41bd-b70d-bdd588f1a3dc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58088-6","display":"Acylcarnitine newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835418374644.b2a9a7f8-8b31-4790-bbaa-f828b2f86648","resource":{"resourceType":"Observation","id":"1734642835418374644.b2a9a7f8-8b31-4790-bbaa-f828b2f86648","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58093-6","display":"Acylcarnitine newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835422795583.e7b35f09-9dd7-4c76-8415-0d43dc7651dc","resource":{"resourceType":"Observation","id":"1734642835422795583.e7b35f09-9dd7-4c76-8415-0d43dc7651dc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38481-8","display":"Carnitine.free (C0)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":34.9,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.4-125"}]}},{"fullUrl":"Observation/1734642835424973167.286f68ed-7f9b-4388-a6cf-85a5266b7fcb","resource":{"resourceType":"Observation","id":"1734642835424973167.286f68ed-7f9b-4388-a6cf-85a5266b7fcb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53235-8","display":"Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":7.84,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<70"}]}},{"fullUrl":"Observation/1734642835427208008.74ac2dd1-eef7-4003-a69d-8252054806cb","resource":{"resourceType":"Observation","id":"1734642835427208008.74ac2dd1-eef7-4003-a69d-8252054806cb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50157-7","display":"Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":28.1,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"10-80"}]}},{"fullUrl":"Observation/1734642835429434974.1dcdd144-4454-412a-80aa-0e2d822921c4","resource":{"resourceType":"Observation","id":"1734642835429434974.1dcdd144-4454-412a-80aa-0e2d822921c4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75212-1","display":"Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":3.53125,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.6"}]}},{"fullUrl":"Observation/1734642835431520845.08387875-2ad2-4e96-a056-0e34ae30f471","resource":{"resourceType":"Observation","id":"1734642835431520845.08387875-2ad2-4e96-a056-0e34ae30f471","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45211-0","display":"Hexanoylcarnitine (C6)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.034,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835433743443.c53a57f5-0822-45fb-b4a8-f0ccd4a7bc43","resource":{"resourceType":"Observation","id":"1734642835433743443.c53a57f5-0822-45fb-b4a8-f0ccd4a7bc43","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53175-6","display":"Octanoylcarnitine (C8)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.038,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835435894226.465ab60c-9c58-45f3-b8bd-448bda9fafc0","resource":{"resourceType":"Observation","id":"1734642835435894226.465ab60c-9c58-45f3-b8bd-448bda9fafc0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53177-2","display":"Octanoylcarnitine (C8)/Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.19,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835438030121.798cec3a-39a7-4add-b2fd-847a0238d54c","resource":{"resourceType":"Observation","id":"1734642835438030121.798cec3a-39a7-4add-b2fd-847a0238d54c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53174-9","display":"Octenoylcarnitine (C8:1)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.155,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835440167228.f45fe5ba-f30c-49ed-86c3-39fa00ef4e7d","resource":{"resourceType":"Observation","id":"1734642835440167228.f45fe5ba-f30c-49ed-86c3-39fa00ef4e7d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45197-1","display":"Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.032,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835442258119.9003abd4-9d1d-481f-a07b-1e409d499168","resource":{"resourceType":"Observation","id":"1734642835442258119.9003abd4-9d1d-481f-a07b-1e409d499168","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45198-9","display":"Decenoylcarnitine (C10:1)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.030,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835444529488.f90faf32-693d-4e1e-8df9-9e18290745c9","resource":{"resourceType":"Observation","id":"1734642835444529488.f90faf32-693d-4e1e-8df9-9e18290745c9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45199-7","display":"Dodecanoylcarnitine (C12)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.070,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2"}]}},{"fullUrl":"Observation/1734642835446685501.4fa52a50-3582-4d5f-9f50-ae6aca56bdd4","resource":{"resourceType":"Observation","id":"1734642835446685501.4fa52a50-3582-4d5f-9f50-ae6aca56bdd4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45200-3","display":"Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.05,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835448821927.1398ab29-7539-4321-a08a-4dbf80dc6fb0","resource":{"resourceType":"Observation","id":"1734642835448821927.1398ab29-7539-4321-a08a-4dbf80dc6fb0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53192-1","display":"Tetradecanoylcarnitine (C14)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.270,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.2"}]}},{"fullUrl":"Observation/1734642835450906846.7168f890-107b-4837-81db-05146c6b2caf","resource":{"resourceType":"Observation","id":"1734642835450906846.7168f890-107b-4837-81db-05146c6b2caf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53191-3","display":"Tetradecenoylcarnitine (C14:1)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.084,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.9"}]}},{"fullUrl":"Observation/1734642835453132480.cfc11d29-4916-4cdc-bc71-aee747d8575b","resource":{"resourceType":"Observation","id":"1734642835453132480.cfc11d29-4916-4cdc-bc71-aee747d8575b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53194-7","display":"Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.75,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835455753585.0c52c249-a902-49f0-8e21-58ba3bf9a0d6","resource":{"resourceType":"Observation","id":"1734642835455753585.0c52c249-a902-49f0-8e21-58ba3bf9a0d6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53190-5","display":"Tetradecadienoylcarnitine (C14:2)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.02,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835459017886.d4ffc9e5-bfac-41f8-98f0-5d97534dbc20","resource":{"resourceType":"Observation","id":"1734642835459017886.d4ffc9e5-bfac-41f8-98f0-5d97534dbc20","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50281-5","display":"3-Hydroxytetradecanoylcarnitine (C14-OH)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.009,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.2"}]}},{"fullUrl":"Observation/1734642835461170162.a43d16ce-f5f1-4263-b61d-40a0018a85fd","resource":{"resourceType":"Observation","id":"1734642835461170162.a43d16ce-f5f1-4263-b61d-40a0018a85fd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53199-6","display":"Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":2.87,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<12"}]}},{"fullUrl":"Observation/1734642835463250262.fc8c2a06-45f0-4658-a1d3-f8894e36e642","resource":{"resourceType":"Observation","id":"1734642835463250262.fc8c2a06-45f0-4658-a1d3-f8894e36e642","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53198-8","display":"Palmitoleylcarnitine (C16:1)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.236,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.4"}]}},{"fullUrl":"Observation/1734642835465381198.e355d29a-924c-42d3-adf4-d29641f95d65","resource":{"resourceType":"Observation","id":"1734642835465381198.e355d29a-924c-42d3-adf4-d29641f95d65","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50125-4","display":"3-Hydroxypalmitoylcarnitine (C16-OH)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.022,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835470144200.4b1f1f59-8fd5-4f3e-8c17-bfaeba9912cc","resource":{"resourceType":"Observation","id":"1734642835470144200.4b1f1f59-8fd5-4f3e-8c17-bfaeba9912cc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53201-0","display":"3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.00767,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.07"}]}},{"fullUrl":"Observation/1734642835473769838.73b4900a-ada8-4e69-9cc2-d8ad5d147216","resource":{"resourceType":"Observation","id":"1734642835473769838.73b4900a-ada8-4e69-9cc2-d8ad5d147216","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53241-6","display":"Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.987,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<3.5"}]}},{"fullUrl":"Observation/1734642835477324013.976eb27c-3e86-4575-82d2-42090c14cd5e","resource":{"resourceType":"Observation","id":"1734642835477324013.976eb27c-3e86-4575-82d2-42090c14cd5e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53202-8","display":"Oleoylcarnitine (C18:1)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.59,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7"}]}},{"fullUrl":"Observation/1734642835480981371.997509cf-1496-49ce-ae6a-2ab2e210872b","resource":{"resourceType":"Observation","id":"1734642835480981371.997509cf-1496-49ce-ae6a-2ab2e210872b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45217-7","display":"Linoleoylcarnitine (C18:2)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.20,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835484502183.03382ac4-4554-4bd4-a473-b1552aa30d97","resource":{"resourceType":"Observation","id":"1734642835484502183.03382ac4-4554-4bd4-a473-b1552aa30d97","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50132-0","display":"3-Hydroxystearoylcarnitine (C18-OH)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.014,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835488159871.630b3407-29cc-4479-8ca0-6992bbf11d47","resource":{"resourceType":"Observation","id":"1734642835488159871.630b3407-29cc-4479-8ca0-6992bbf11d47","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50113-0","display":"3-Hydroxyoleoylcarnitine (C18:1-OH)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.034,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835491985485.ba51db78-903c-45eb-b9e5-c53ee7b3f2e1","resource":{"resourceType":"Observation","id":"1734642835491985485.ba51db78-903c-45eb-b9e5-c53ee7b3f2e1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53160-8","display":"Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.9,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.9"}]}},{"fullUrl":"Observation/1734642835495570166.99fb27f1-e14d-4142-944b-289d1c3241da","resource":{"resourceType":"Observation","id":"1734642835495570166.99fb27f1-e14d-4142-944b-289d1c3241da","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53163-2","display":"Propionylcarnitine (C3)/Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.07,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.42"}]}},{"fullUrl":"Observation/1734642835498092857.6bb59139-99b0-4b5d-97c8-ffb14263f781","resource":{"resourceType":"Observation","id":"1734642835498092857.6bb59139-99b0-4b5d-97c8-ffb14263f781","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67708-8","display":"Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.113,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.48"}]}},{"fullUrl":"Observation/1734642835500703182.d5ab4f82-7c5b-4c26-bbbc-7dea218979e2","resource":{"resourceType":"Observation","id":"1734642835500703182.d5ab4f82-7c5b-4c26-bbbc-7dea218979e2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53166-5","display":"Butyrylcarnitine+Isobutyrylcarnitine (C4)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.161,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.7"}]}},{"fullUrl":"Observation/1734642835502895012.d0ae8710-cbea-421e-b94a-53d6e14cd248","resource":{"resourceType":"Observation","id":"1734642835502895012.d0ae8710-cbea-421e-b94a-53d6e14cd248","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45216-9","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.111,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835505066664.c4809f26-012b-428d-a228-deb3c1c71f6a","resource":{"resourceType":"Observation","id":"1734642835505066664.c4809f26-012b-428d-a228-deb3c1c71f6a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53240-8","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.05842,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642835507175288.62b29fe7-f047-423f-96b8-613605f1bf43","resource":{"resourceType":"Observation","id":"1734642835507175288.62b29fe7-f047-423f-96b8-613605f1bf43","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53170-7","display":"Tiglylcarnitine (C5:1)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.006,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.5"}]}},{"fullUrl":"Observation/1734642835509285776.6da4db8a-be6a-423f-b00d-e770d332b912","resource":{"resourceType":"Observation","id":"1734642835509285776.6da4db8a-be6a-423f-b00d-e770d332b912","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50106-4","display":"3-Hydroxyisovalerylcarnitine (C5-OH)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.140,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.15"}]}},{"fullUrl":"Observation/1734642835511368501.d417dea6-d6bc-4ccf-89e3-0111ca38a324","resource":{"resourceType":"Observation","id":"1734642835511368501.d417dea6-d6bc-4ccf-89e3-0111ca38a324","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67710-4","display":"Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.091,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642835513513543.70b62c82-fb4b-46aa-bbce-dd43197a4c40","resource":{"resourceType":"Observation","id":"1734642835513513543.70b62c82-fb4b-46aa-bbce-dd43197a4c40","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75216-2","display":"Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.80531,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">0.1"}]}},{"fullUrl":"Observation/1734642835515664627.e7d0dad1-5bbd-46c8-bd9e-6a3c2a0cc749","resource":{"resourceType":"Observation","id":"1734642835515664627.e7d0dad1-5bbd-46c8-bd9e-6a3c2a0cc749","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ng/mL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"48633-2","display":"Trypsinogen I.free"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":27.50,"unit":"ng/mL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<69"}]}},{"fullUrl":"Observation/1734642835517993935.17ec6b98-cacb-4027-820f-4d6998024af3","resource":{"resourceType":"Observation","id":"1734642835517993935.17ec6b98-cacb-4027-820f-4d6998024af3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46769-6","display":"Cystic fibrosis newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835520573001.3c493ebc-ba0f-4b33-aa6b-24b510ca4ff6","resource":{"resourceType":"Observation","id":"1734642835520573001.3c493ebc-ba0f-4b33-aa6b-24b510ca4ff6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57707-2","display":"Cystic fibrosis newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835525904147.1a80681b-c906-4966-937b-e53f0becb2f1","resource":{"resourceType":"Observation","id":"1734642835525904147.1a80681b-c906-4966-937b-e53f0becb2f1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"nmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38473-5","display":"17-Hydroxyprogesterone"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":29.9,"unit":"nmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<190"}]}},{"fullUrl":"Observation/1734642835529512403.bf5ed02a-3c6c-4860-8ca7-7ea37fc1ffeb","resource":{"resourceType":"Observation","id":"1734642835529512403.bf5ed02a-3c6c-4860-8ca7-7ea37fc1ffeb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46758-9","display":"Congenital adrenal hyperplasia newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835532521065.ed84de32-d45a-4b1a-a413-535cb2895ee9","resource":{"resourceType":"Observation","id":"1734642835532521065.ed84de32-d45a-4b1a-a413-535cb2895ee9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57706-4","display":"Congenital adrenal hyperplasia newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835535876457.d760f87e-fc5d-4be1-a52f-66f60a2ae7bd","resource":{"resourceType":"Observation","id":"1734642835535876457.d760f87e-fc5d-4be1-a52f-66f60a2ae7bd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"mIU/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29575-8","display":"Thyrotropin"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":6.90,"unit":"mIU/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<29"}]}},{"fullUrl":"Observation/1734642835539823078.8f08b768-25fc-45d6-aa00-7d0ac78f7680","resource":{"resourceType":"Observation","id":"1734642835539823078.8f08b768-25fc-45d6-aa00-7d0ac78f7680","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46762-1","display":"Congenital hypothyroidism newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835543024561.82b80bcb-0246-4912-8e2d-d887306f7321","resource":{"resourceType":"Observation","id":"1734642835543024561.82b80bcb-0246-4912-8e2d-d887306f7321","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57705-6","display":"Congenital hypothyroidism newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835546355467.83b3714a-1a87-4ac9-8f99-08878e0fd16a","resource":{"resourceType":"Observation","id":"1734642835546355467.83b3714a-1a87-4ac9-8f99-08878e0fd16a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"enzyme units"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42906-8","display":"Galactose 1 phosphate uridyl transferase"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":226.51,"unit":"enzyme units"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">50"}]}},{"fullUrl":"Observation/1734642835549893211.25dd6d46-74e7-4235-ab79-9d8105fa0a00","resource":{"resourceType":"Observation","id":"1734642835549893211.25dd6d46-74e7-4235-ab79-9d8105fa0a00","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46737-3","display":"Galactosemias newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835552869902.ac846058-f0a0-4699-97d2-519dca5cade1","resource":{"resourceType":"Observation","id":"1734642835552869902.ac846058-f0a0-4699-97d2-519dca5cade1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57704-9","display":"Galactosemias newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835555821888.61e203d3-2b7d-430f-bf57-c9f70a3ec4fc","resource":{"resourceType":"Observation","id":"1734642835555821888.61e203d3-2b7d-430f-bf57-c9f70a3ec4fc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54104-5","display":"Hemoglobin pattern"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"FA"}},{"fullUrl":"Observation/1734642835558423075.0fb66141-985a-471c-84ea-0e2507b24dee","resource":{"resourceType":"Observation","id":"1734642835558423075.0fb66141-985a-471c-84ea-0e2507b24dee","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57703-1","display":"Hemoglobin disorders newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants."}},{"fullUrl":"Observation/1734642835561468346.fa1af592-bc70-4f22-a292-dbf8a4ea9fe3","resource":{"resourceType":"Observation","id":"1734642835561468346.fa1af592-bc70-4f22-a292-dbf8a4ea9fe3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ERU"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75217-0","display":"Biotinidase [Enzymatic activity/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":28.87,"unit":"ERU"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">10"}]}},{"fullUrl":"Observation/1734642835564990210.aba2c5e6-f906-465b-9b58-d2a3f6f29dd1","resource":{"resourceType":"Observation","id":"1734642835564990210.aba2c5e6-f906-465b-9b58-d2a3f6f29dd1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46761-3","display":"Biotinidase deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835567985496.fa5f27bf-a0a5-4d52-b4b1-1bf218ce6db4","resource":{"resourceType":"Observation","id":"1734642835567985496.fa5f27bf-a0a5-4d52-b4b1-1bf218ce6db4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57699-1","display":"Biotinidase deficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835571309800.12adfa77-1e2f-48d4-88b8-d20a75429f23","resource":{"resourceType":"Observation","id":"1734642835571309800.12adfa77-1e2f-48d4-88b8-d20a75429f23","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"copies/µL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62320-7","display":"T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":198,"unit":"copies/µL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">18"}]}},{"fullUrl":"Observation/1734642835574850148.21ea8318-4e72-436c-b8fa-e1fd75a19efb","resource":{"resourceType":"Observation","id":"1734642835574850148.21ea8318-4e72-436c-b8fa-e1fd75a19efb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62321-5","display":"Severe combined immunodeficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835581069972.c10bcd96-4829-4e95-a1d9-66376f5d3d45","resource":{"resourceType":"Observation","id":"1734642835581069972.c10bcd96-4829-4e95-a1d9-66376f5d3d45","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62322-3","display":"Severe combined immunodeficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835584576026.aabbb953-5488-4b30-8acc-41bf00db6120","resource":{"resourceType":"Observation","id":"1734642835584576026.aabbb953-5488-4b30-8acc-41bf00db6120","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55827-0","display":"Acid alpha glucosidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":7.91,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=1.62"}]}},{"fullUrl":"Observation/1734642835588092480.08525370-2227-4b69-826d-d9e4032ee0af","resource":{"resourceType":"Observation","id":"1734642835588092480.08525370-2227-4b69-826d-d9e4032ee0af","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63415-4","display":"Pompe Disease deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835591074051.eb0d4858-a135-4a49-9d69-38d256936bb8","resource":{"resourceType":"Observation","id":"1734642835591074051.eb0d4858-a135-4a49-9d69-38d256936bb8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63416-2","display":"Pompe Disease deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835594442237.a15194f2-60a6-4498-b5dc-87aca0c61a66","resource":{"resourceType":"Observation","id":"1734642835594442237.a15194f2-60a6-4498-b5dc-87aca0c61a66","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55909-6","display":"Alpha-L-iduronidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":7.78,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=0.79"}]}},{"fullUrl":"Observation/1734642835597959462.0cdecaae-6f8b-441d-9c80-85c40bef0dae","resource":{"resourceType":"Observation","id":"1734642835597959462.0cdecaae-6f8b-441d-9c80-85c40bef0dae","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79564-1","display":"Mucopolysaccharidosis type I newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835600988341.dc2afa30-6326-48a0-9e3b-28c2aeb08706","resource":{"resourceType":"Observation","id":"1734642835600988341.dc2afa30-6326-48a0-9e3b-28c2aeb08706","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79565-8","display":"Mucopolysaccharidosis type I newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835604036297.40339a51-8dac-4737-809a-539504353d80","resource":{"resourceType":"Observation","id":"1734642835604036297.40339a51-8dac-4737-809a-539504353d80","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-60","display":"SMN1 Homozygous Deletion Analysis"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Exon 7 Present","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"Exon 7 Present"}]}},{"fullUrl":"Observation/1734642835607529266.a4125cf0-de2a-4085-b6de-c410a2215b1f","resource":{"resourceType":"Observation","id":"1734642835607529266.a4125cf0-de2a-4085-b6de-c410a2215b1f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92004-1","display":"Spinal muscular atrophy newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835610542657.f1aef249-54da-4464-97f9-c3fb9ba09a9d","resource":{"resourceType":"Observation","id":"1734642835610542657.f1aef249-54da-4464-97f9-c3fb9ba09a9d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92003-3","display":"Spinal muscular atrophy newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"SMA Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835613935850.7dd54161-8b91-4713-9880-097a8d61b409","resource":{"resourceType":"Observation","id":"1734642835613935850.7dd54161-8b91-4713-9880-097a8d61b409","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79462-8","display":"Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":28.94,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=2.95"}]}},{"fullUrl":"Observation/1734642835617486398.92be0ee0-3ee7-466e-99d6-b61c7e3e5a37","resource":{"resourceType":"Observation","id":"1734642835617486398.92be0ee0-3ee7-466e-99d6-b61c7e3e5a37","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104189-6","display":"Mucopolysaccharidosis type II newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835620525837.cc26ef54-3f3a-47b8-9a7b-047d46f3348b","resource":{"resourceType":"Observation","id":"1734642835620525837.cc26ef54-3f3a-47b8-9a7b-047d46f3348b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104190-4","display":"Mucopolysaccharidosis type II newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835623921985.3e0baca9-bd03-4ed1-8b08-89ba31cab5dd","resource":{"resourceType":"Observation","id":"1734642835623921985.3e0baca9-bd03-4ed1-8b08-89ba31cab5dd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104192-0","display":"Guanidinoacetate methyltransferase deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835630419291.12c4f657-9182-4881-8c31-27b06e3c48c7","resource":{"resourceType":"Observation","id":"1734642835630419291.12c4f657-9182-4881-8c31-27b06e3c48c7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104193-8","display":"Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835633807975.46e97221-a624-4e5e-8859-ff611e85da90","resource":{"resourceType":"Observation","id":"1734642835633807975.46e97221-a624-4e5e-8859-ff611e85da90","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"93488-5","display":"Guanidinoacetate [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.00,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=3"}]}},{"fullUrl":"Observation/1734642835637364704.cfb11c03-e2c7-43f7-8cc9-859c933f8b62","resource":{"resourceType":"Observation","id":"1734642835637364704.cfb11c03-e2c7-43f7-8cc9-859c933f8b62","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104194-6","display":"Creatine [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":707.37,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835649022763.3c31dc08-0d4e-4e81-a1c4-d249999d5869","resource":{"resourceType":"Observation","id":"1734642835649022763.3c31dc08-0d4e-4e81-a1c4-d249999d5869","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104195-3","display":"GUAC/CRE Ratio [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":1.41},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=6"}]}},{"fullUrl":"Observation/1734642835653194486.57e9dd23-af1b-46e0-99a7-bc5a2461a5e5","resource":{"resourceType":"Observation","id":"1734642835653194486.57e9dd23-af1b-46e0-99a7-bc5a2461a5e5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-32","display":"Adrenoleukodystrophy deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835656742329.2b81d4e2-b30a-4c26-a562-c55c8d886d39","resource":{"resourceType":"Observation","id":"1734642835656742329.2b81d4e2-b30a-4c26-a562-c55c8d886d39","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-33","display":"Adrenoleukodystrophy deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835660757468.12a8eb98-e6e0-4f4d-9bf4-afeeb9525a95","resource":{"resourceType":"Observation","id":"1734642835660757468.12a8eb98-e6e0-4f4d-9bf4-afeeb9525a95","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79321-6","display":"Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-23T05:00:44Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"valueQuantity":{"value":0.246,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.47"}]}},{"fullUrl":"Specimen/1734642835679809963.f5140095-69f3-4915-8100-62ebb73a9266","resource":{"resourceType":"Specimen","id":"1734642835679809963.f5140095-69f3-4915-8100-62ebb73a9266","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835682132849.c285fe9e-9eef-41c1-b376-4a15512e5477","resource":{"resourceType":"Specimen","id":"1734642835682132849.c285fe9e-9eef-41c1-b376-4a15512e5477","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835683649694.81529006-d9a6-478d-a042-55c556f93b39","resource":{"resourceType":"Specimen","id":"1734642835683649694.81529006-d9a6-478d-a042-55c556f93b39","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835685112005.62776300-71ef-4753-9775-632dbd20fa5a","resource":{"resourceType":"Specimen","id":"1734642835685112005.62776300-71ef-4753-9775-632dbd20fa5a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835687040031.041f7ffc-da54-46c9-8d11-aa5f8de30bb0","resource":{"resourceType":"Specimen","id":"1734642835687040031.041f7ffc-da54-46c9-8d11-aa5f8de30bb0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835689202095.cd50a654-b526-4981-9f5b-699bc6abb850","resource":{"resourceType":"Specimen","id":"1734642835689202095.cd50a654-b526-4981-9f5b-699bc6abb850","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835694345079.5c984bb7-fe34-47af-ba5e-5138ffb45e35","resource":{"resourceType":"Specimen","id":"1734642835694345079.5c984bb7-fe34-47af-ba5e-5138ffb45e35","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835695888844.b9c265b2-7ecc-4fa6-8b6b-fdc320dec738","resource":{"resourceType":"Specimen","id":"1734642835695888844.b9c265b2-7ecc-4fa6-8b6b-fdc320dec738","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835698178878.c6f061fd-6eae-4ca5-8607-5247f471f7ae","resource":{"resourceType":"Specimen","id":"1734642835698178878.c6f061fd-6eae-4ca5-8607-5247f471f7ae","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835700470095.490fe88c-9d7f-48ac-8a2e-de34c0a0122c","resource":{"resourceType":"Specimen","id":"1734642835700470095.490fe88c-9d7f-48ac-8a2e-de34c0a0122c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835702449075.1d1f430f-765e-4097-9fd9-b98c8afe02cb","resource":{"resourceType":"Specimen","id":"1734642835702449075.1d1f430f-765e-4097-9fd9-b98c8afe02cb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835704119568.b958bb18-491b-4ee7-9425-30bd73b53543","resource":{"resourceType":"Specimen","id":"1734642835704119568.b958bb18-491b-4ee7-9425-30bd73b53543","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835705624961.bc2cfb73-382d-4917-a2fb-649f48c96d17","resource":{"resourceType":"Specimen","id":"1734642835705624961.bc2cfb73-382d-4917-a2fb-649f48c96d17","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835707157845.4fe80b95-b4f1-4845-bca1-c066dd61b6d9","resource":{"resourceType":"Specimen","id":"1734642835707157845.4fe80b95-b4f1-4845-bca1-c066dd61b6d9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835708612232.ac4f7578-f103-41a7-b573-007e4db7765b","resource":{"resourceType":"Specimen","id":"1734642835708612232.ac4f7578-f103-41a7-b573-007e4db7765b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835710510722.fc135623-a3f3-43e6-b605-5beba9342283","resource":{"resourceType":"Specimen","id":"1734642835710510722.fc135623-a3f3-43e6-b605-5beba9342283","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835712141821.51833386-6ce0-4b71-b0e4-8d2cf7ee8c86","resource":{"resourceType":"Specimen","id":"1734642835712141821.51833386-6ce0-4b71-b0e4-8d2cf7ee8c86","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835713518763.82aafad2-810d-4c77-a953-975e9b2dfde4","resource":{"resourceType":"Specimen","id":"1734642835713518763.82aafad2-810d-4c77-a953-975e9b2dfde4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835715545523.cab4abb0-08dd-41fc-b108-d8df145f1ba1","resource":{"resourceType":"Specimen","id":"1734642835715545523.cab4abb0-08dd-41fc-b108-d8df145f1ba1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835718057894.457e17fc-100b-49f5-bb92-b4c9acf25c85","resource":{"resourceType":"Specimen","id":"1734642835718057894.457e17fc-100b-49f5-bb92-b4c9acf25c85","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835719713849.d97d4078-fa35-46c5-b71a-983c6c316188","resource":{"resourceType":"Specimen","id":"1734642835719713849.d97d4078-fa35-46c5-b71a-983c6c316188","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835721296777.e0bd5141-acd6-4b4a-ba77-e92176956627","resource":{"resourceType":"Specimen","id":"1734642835721296777.e0bd5141-acd6-4b4a-ba77-e92176956627","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"Specimen/1734642835722645206.a1858c19-14c2-4fef-9cc4-db5e31b7e834","resource":{"resourceType":"Specimen","id":"1734642835722645206.a1858c19-14c2-4fef-9cc4-db5e31b7e834","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-03T16:03:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}}}},{"fullUrl":"ServiceRequest/1734642835744401522.4ff3345c-4a6d-4397-937b-68ba4e55bd8d","resource":{"resourceType":"ServiceRequest","id":"1734642835744401522.4ff3345c-4a6d-4397-937b-68ba4e55bd8d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/business-event","valueCode":"RE"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/orc-common-order","extension":[{"url":"orc-21-ordering-facility-name","valueReference":{"reference":"Organization/1734642835735798210.495c376f-5387-48ac-91cb-e509faa1e5e6"}},{"url":"orc-22-ordering-facility-address","valueAddress":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"725 WELCH RD, RM  H1524"}]}]}],"line":["725 WELCH RD, RM  H1524"],"city":"PALO ALTO","state":"CA","postalCode":"94304-1601"}},{"url":"orc-12-ordering-provider","valueReference":{"reference":"Practitioner/1734642835739088029.31fe1c60-ff4b-4ee1-a45a-87b46efa190d"}}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.2","valueIdentifier":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"value":"45789876"}},{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835741273888.5c20a08d-a661-46cf-b1f0-ced95f4935eb"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"56352742"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"56352742"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"PractitionerRole/1734642835725673324.d4e3b8dc-f1f7-4a53-965e-f1830dd3b992"}}},{"fullUrl":"Practitioner/1734642835727820210.e30c7146-821c-42b7-8344-c4215695456b","resource":{"resourceType":"Practitioner","id":"1734642835727820210.e30c7146-821c-42b7-8344-c4215695456b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"DR JOCHEN"},{"url":"XCN.10","valueString":"NPI"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.12"}],"identifier":[{"value":"1043390461"}],"name":[{"family":"PROFIT","given":["DR JOCHEN"]}]}},{"fullUrl":"Organization/1734642835731117132.30410059-af3f-4a15-bf64-a3084e81c740","resource":{"resourceType":"Organization","id":"1734642835731117132.30410059-af3f-4a15-bf64-a3084e81c740","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R777"}]}],"identifier":[{"value":"R777"}],"name":"STANFORD/LUCILE PACKARD CHILDREN'S HOSPI","telecom":[{"_system":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}],"address":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"725 WELCH RD, RM  H1524"}]}]}],"line":["725 WELCH RD, RM  H1524"],"city":"PALO ALTO","state":"CA","postalCode":"94304-1601"}]}},{"fullUrl":"PractitionerRole/1734642835725673324.d4e3b8dc-f1f7-4a53-965e-f1830dd3b992","resource":{"resourceType":"PractitionerRole","id":"1734642835725673324.d4e3b8dc-f1f7-4a53-965e-f1830dd3b992","practitioner":{"reference":"Practitioner/1734642835727820210.e30c7146-821c-42b7-8344-c4215695456b"},"organization":{"reference":"Organization/1734642835731117132.30410059-af3f-4a15-bf64-a3084e81c740"}}},{"fullUrl":"Organization/1734642835735798210.495c376f-5387-48ac-91cb-e509faa1e5e6","resource":{"resourceType":"Organization","id":"1734642835735798210.495c376f-5387-48ac-91cb-e509faa1e5e6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R777"}]}],"identifier":[{"value":"R777"}],"name":"STANFORD/LUCILE PACKARD CHILDREN'S HOSPI"}},{"fullUrl":"Practitioner/1734642835739088029.31fe1c60-ff4b-4ee1-a45a-87b46efa190d","resource":{"resourceType":"Practitioner","id":"1734642835739088029.31fe1c60-ff4b-4ee1-a45a-87b46efa190d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"DR JOCHEN"},{"url":"XCN.10","valueString":"NPI"}]}],"identifier":[{"value":"1043390461"}],"name":[{"family":"PROFIT","given":["DR JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835741273888.5c20a08d-a661-46cf-b1f0-ced95f4935eb","resource":{"resourceType":"Practitioner","id":"1734642835741273888.5c20a08d-a661-46cf-b1f0-ced95f4935eb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835758992222.2d75840b-e8b8-43c6-a69b-658b37b1361d","resource":{"resourceType":"ServiceRequest","id":"1734642835758992222.2d75840b-e8b8-43c6-a69b-658b37b1361d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835754613601.d74b2393-0fe6-4f76-af28-52680c8555f5"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835747352195.f55624d9-402a-46a3-ac0b-fca41a709bb4"}}},{"fullUrl":"Practitioner/1734642835747352195.f55624d9-402a-46a3-ac0b-fca41a709bb4","resource":{"resourceType":"Practitioner","id":"1734642835747352195.f55624d9-402a-46a3-ac0b-fca41a709bb4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835754613601.d74b2393-0fe6-4f76-af28-52680c8555f5","resource":{"resourceType":"Practitioner","id":"1734642835754613601.d74b2393-0fe6-4f76-af28-52680c8555f5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835770650794.bfe29259-c5d9-4f16-8ff4-d699d646ee90","resource":{"resourceType":"ServiceRequest","id":"1734642835770650794.bfe29259-c5d9-4f16-8ff4-d699d646ee90","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835768437013.d2705796-f21e-496a-94cf-964ce4224e53"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835762344528.df610ff8-854f-407e-ac0e-acf4592dd9b9"}}},{"fullUrl":"Practitioner/1734642835762344528.df610ff8-854f-407e-ac0e-acf4592dd9b9","resource":{"resourceType":"Practitioner","id":"1734642835762344528.df610ff8-854f-407e-ac0e-acf4592dd9b9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835768437013.d2705796-f21e-496a-94cf-964ce4224e53","resource":{"resourceType":"Practitioner","id":"1734642835768437013.d2705796-f21e-496a-94cf-964ce4224e53","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835780546470.eb10fd70-3fc5-451f-af4a-77763961365b","resource":{"resourceType":"ServiceRequest","id":"1734642835780546470.eb10fd70-3fc5-451f-af4a-77763961365b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835778040631.265277d4-4a77-47f4-aaa7-09ccc56de71e"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835772862321.a6870388-fbbf-4b92-a8be-087d31d4bbc0"}}},{"fullUrl":"Practitioner/1734642835772862321.a6870388-fbbf-4b92-a8be-087d31d4bbc0","resource":{"resourceType":"Practitioner","id":"1734642835772862321.a6870388-fbbf-4b92-a8be-087d31d4bbc0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835778040631.265277d4-4a77-47f4-aaa7-09ccc56de71e","resource":{"resourceType":"Practitioner","id":"1734642835778040631.265277d4-4a77-47f4-aaa7-09ccc56de71e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835791834676.ec7b25fd-682f-4cb7-adbb-ca082237c515","resource":{"resourceType":"ServiceRequest","id":"1734642835791834676.ec7b25fd-682f-4cb7-adbb-ca082237c515","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835788722270.d7651dc5-9325-4cbc-961c-bb909f66d5f6"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835782906885.680b2abc-6eda-4a0a-9f1d-e6bfb42c99f5"}}},{"fullUrl":"Practitioner/1734642835782906885.680b2abc-6eda-4a0a-9f1d-e6bfb42c99f5","resource":{"resourceType":"Practitioner","id":"1734642835782906885.680b2abc-6eda-4a0a-9f1d-e6bfb42c99f5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835788722270.d7651dc5-9325-4cbc-961c-bb909f66d5f6","resource":{"resourceType":"Practitioner","id":"1734642835788722270.d7651dc5-9325-4cbc-961c-bb909f66d5f6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835802084907.25541256-2203-4b6a-8fc2-45c8c95543af","resource":{"resourceType":"ServiceRequest","id":"1734642835802084907.25541256-2203-4b6a-8fc2-45c8c95543af","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835798423151.10bd8f25-7156-4b28-9b8e-0e1bf7084131"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835793778371.0f0a22e9-2747-4376-b565-00db35f8aaa3"}}},{"fullUrl":"Practitioner/1734642835793778371.0f0a22e9-2747-4376-b565-00db35f8aaa3","resource":{"resourceType":"Practitioner","id":"1734642835793778371.0f0a22e9-2747-4376-b565-00db35f8aaa3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835798423151.10bd8f25-7156-4b28-9b8e-0e1bf7084131","resource":{"resourceType":"Practitioner","id":"1734642835798423151.10bd8f25-7156-4b28-9b8e-0e1bf7084131","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835812909625.81dd7562-bd3f-4733-9512-08a1f914da1d","resource":{"resourceType":"ServiceRequest","id":"1734642835812909625.81dd7562-bd3f-4733-9512-08a1f914da1d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835809639373.7eaa67db-5dae-4c96-8291-8cb55ddd7955"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835804285885.e3ea1477-1820-42c4-a3a3-1ca1dc306ea1"}}},{"fullUrl":"Practitioner/1734642835804285885.e3ea1477-1820-42c4-a3a3-1ca1dc306ea1","resource":{"resourceType":"Practitioner","id":"1734642835804285885.e3ea1477-1820-42c4-a3a3-1ca1dc306ea1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835809639373.7eaa67db-5dae-4c96-8291-8cb55ddd7955","resource":{"resourceType":"Practitioner","id":"1734642835809639373.7eaa67db-5dae-4c96-8291-8cb55ddd7955","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835826844004.93e7de95-250e-42ad-962c-5fb6f91a6211","resource":{"resourceType":"ServiceRequest","id":"1734642835826844004.93e7de95-250e-42ad-962c-5fb6f91a6211","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835819933346.5cf240f2-bf06-45d8-b16c-7e3d60e59512"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835814921818.998dd2d9-f1c7-4fdc-b8b0-1051a8d49782"}}},{"fullUrl":"Practitioner/1734642835814921818.998dd2d9-f1c7-4fdc-b8b0-1051a8d49782","resource":{"resourceType":"Practitioner","id":"1734642835814921818.998dd2d9-f1c7-4fdc-b8b0-1051a8d49782","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835819933346.5cf240f2-bf06-45d8-b16c-7e3d60e59512","resource":{"resourceType":"Practitioner","id":"1734642835819933346.5cf240f2-bf06-45d8-b16c-7e3d60e59512","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835841901599.3275048a-bc6c-4092-b850-d38de0ed3651","resource":{"resourceType":"ServiceRequest","id":"1734642835841901599.3275048a-bc6c-4092-b850-d38de0ed3651","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835838140216.bb2141de-76dd-4221-9c4c-acab33d06eea"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835830057961.f7dcb42f-d0ab-4573-9b2e-1b5735b22a39"}}},{"fullUrl":"Practitioner/1734642835830057961.f7dcb42f-d0ab-4573-9b2e-1b5735b22a39","resource":{"resourceType":"Practitioner","id":"1734642835830057961.f7dcb42f-d0ab-4573-9b2e-1b5735b22a39","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835838140216.bb2141de-76dd-4221-9c4c-acab33d06eea","resource":{"resourceType":"Practitioner","id":"1734642835838140216.bb2141de-76dd-4221-9c4c-acab33d06eea","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835856905334.d69097cc-ddb8-4325-81ac-035da095ab9d","resource":{"resourceType":"ServiceRequest","id":"1734642835856905334.d69097cc-ddb8-4325-81ac-035da095ab9d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835853121328.727d467d-c905-4b9c-8b44-1793d96ac519"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835845159438.0eaaaebc-2a26-46d2-a882-514961b42ee8"}}},{"fullUrl":"Practitioner/1734642835845159438.0eaaaebc-2a26-46d2-a882-514961b42ee8","resource":{"resourceType":"Practitioner","id":"1734642835845159438.0eaaaebc-2a26-46d2-a882-514961b42ee8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835853121328.727d467d-c905-4b9c-8b44-1793d96ac519","resource":{"resourceType":"Practitioner","id":"1734642835853121328.727d467d-c905-4b9c-8b44-1793d96ac519","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835871903457.f692a2e9-0b4d-43f0-8261-6bb812d74c1e","resource":{"resourceType":"ServiceRequest","id":"1734642835871903457.f692a2e9-0b4d-43f0-8261-6bb812d74c1e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835868153395.357d31c1-7cad-49ad-9231-25b2176c0546"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835860189612.029a5eec-500a-4552-92dd-7cebdd88fac4"}}},{"fullUrl":"Practitioner/1734642835860189612.029a5eec-500a-4552-92dd-7cebdd88fac4","resource":{"resourceType":"Practitioner","id":"1734642835860189612.029a5eec-500a-4552-92dd-7cebdd88fac4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835868153395.357d31c1-7cad-49ad-9231-25b2176c0546","resource":{"resourceType":"Practitioner","id":"1734642835868153395.357d31c1-7cad-49ad-9231-25b2176c0546","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835886888697.bf61c1b6-56cb-4670-9961-282b6c0f1ebc","resource":{"resourceType":"ServiceRequest","id":"1734642835886888697.bf61c1b6-56cb-4670-9961-282b6c0f1ebc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835883141030.5e511835-9b9c-47ed-94b1-da258656b6f6"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835875151929.97554f88-41fc-48cd-a4e1-01fded4cc6db"}}},{"fullUrl":"Practitioner/1734642835875151929.97554f88-41fc-48cd-a4e1-01fded4cc6db","resource":{"resourceType":"Practitioner","id":"1734642835875151929.97554f88-41fc-48cd-a4e1-01fded4cc6db","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835883141030.5e511835-9b9c-47ed-94b1-da258656b6f6","resource":{"resourceType":"Practitioner","id":"1734642835883141030.5e511835-9b9c-47ed-94b1-da258656b6f6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835902087947.b0625fb0-fc20-4f6c-8cc1-5b44f0187465","resource":{"resourceType":"ServiceRequest","id":"1734642835902087947.b0625fb0-fc20-4f6c-8cc1-5b44f0187465","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835898322577.a6e3a5e0-51e1-44cd-bb54-b4dccad0e3af"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835890164049.14517987-51a5-4b7e-bf77-7e0f5edb53bc"}}},{"fullUrl":"Practitioner/1734642835890164049.14517987-51a5-4b7e-bf77-7e0f5edb53bc","resource":{"resourceType":"Practitioner","id":"1734642835890164049.14517987-51a5-4b7e-bf77-7e0f5edb53bc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835898322577.a6e3a5e0-51e1-44cd-bb54-b4dccad0e3af","resource":{"resourceType":"Practitioner","id":"1734642835898322577.a6e3a5e0-51e1-44cd-bb54-b4dccad0e3af","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835917149069.983f6ce8-159b-45c8-954c-4075b17846af","resource":{"resourceType":"ServiceRequest","id":"1734642835917149069.983f6ce8-159b-45c8-954c-4075b17846af","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835913394629.4475d2a0-1c9c-4795-bf45-41f99db27435"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835905413754.40878ea9-622b-4a63-8e5f-91d421722b4b"}}},{"fullUrl":"Practitioner/1734642835905413754.40878ea9-622b-4a63-8e5f-91d421722b4b","resource":{"resourceType":"Practitioner","id":"1734642835905413754.40878ea9-622b-4a63-8e5f-91d421722b4b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835913394629.4475d2a0-1c9c-4795-bf45-41f99db27435","resource":{"resourceType":"Practitioner","id":"1734642835913394629.4475d2a0-1c9c-4795-bf45-41f99db27435","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835935979239.0e176d4b-30d3-4137-ae0f-9c51656f66c3","resource":{"resourceType":"ServiceRequest","id":"1734642835935979239.0e176d4b-30d3-4137-ae0f-9c51656f66c3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835928339133.024dd940-afd0-41a8-ac6a-8b48e90e7c6d"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835920398884.71f8c3a4-43ee-45cf-9c10-2c35f0e88a5a"}}},{"fullUrl":"Practitioner/1734642835920398884.71f8c3a4-43ee-45cf-9c10-2c35f0e88a5a","resource":{"resourceType":"Practitioner","id":"1734642835920398884.71f8c3a4-43ee-45cf-9c10-2c35f0e88a5a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835928339133.024dd940-afd0-41a8-ac6a-8b48e90e7c6d","resource":{"resourceType":"Practitioner","id":"1734642835928339133.024dd940-afd0-41a8-ac6a-8b48e90e7c6d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835945974251.f0fcd4a8-98bd-4ab4-a492-4645926f24a9","resource":{"resourceType":"ServiceRequest","id":"1734642835945974251.f0fcd4a8-98bd-4ab4-a492-4645926f24a9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835943667846.3e58aab2-4f40-4a4c-b536-53e5c6eb2716"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835938155119.95c97502-5105-497e-ae06-b5801a28627a"}}},{"fullUrl":"Practitioner/1734642835938155119.95c97502-5105-497e-ae06-b5801a28627a","resource":{"resourceType":"Practitioner","id":"1734642835938155119.95c97502-5105-497e-ae06-b5801a28627a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835943667846.3e58aab2-4f40-4a4c-b536-53e5c6eb2716","resource":{"resourceType":"Practitioner","id":"1734642835943667846.3e58aab2-4f40-4a4c-b536-53e5c6eb2716","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835956530516.5b286178-75c7-4255-af1a-49caed4c0082","resource":{"resourceType":"ServiceRequest","id":"1734642835956530516.5b286178-75c7-4255-af1a-49caed4c0082","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835953823169.965e7b1a-871f-451a-a743-8dc7fdf41546"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835948359714.2f445301-5d6c-424c-b2e8-4b273f9dff14"}}},{"fullUrl":"Practitioner/1734642835948359714.2f445301-5d6c-424c-b2e8-4b273f9dff14","resource":{"resourceType":"Practitioner","id":"1734642835948359714.2f445301-5d6c-424c-b2e8-4b273f9dff14","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835953823169.965e7b1a-871f-451a-a743-8dc7fdf41546","resource":{"resourceType":"Practitioner","id":"1734642835953823169.965e7b1a-871f-451a-a743-8dc7fdf41546","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835967140120.6f8af5b3-2a92-469c-adc3-17c5c75716ec","resource":{"resourceType":"ServiceRequest","id":"1734642835967140120.6f8af5b3-2a92-469c-adc3-17c5c75716ec","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835964594817.35a35840-0638-45cb-8ced-73a9792ed258"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835958679495.28aef4a9-84c2-4b3b-94b7-1df1c44749e7"}}},{"fullUrl":"Practitioner/1734642835958679495.28aef4a9-84c2-4b3b-94b7-1df1c44749e7","resource":{"resourceType":"Practitioner","id":"1734642835958679495.28aef4a9-84c2-4b3b-94b7-1df1c44749e7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835964594817.35a35840-0638-45cb-8ced-73a9792ed258","resource":{"resourceType":"Practitioner","id":"1734642835964594817.35a35840-0638-45cb-8ced-73a9792ed258","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835976875515.47645843-2e02-492b-9fa9-10754e5c2eb7","resource":{"resourceType":"ServiceRequest","id":"1734642835976875515.47645843-2e02-492b-9fa9-10754e5c2eb7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835974516742.4222fb2e-821d-4cb1-926f-d8818ff7303d"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835969309959.d700e30e-201a-46b1-a3b0-78ac9fb77dcc"}}},{"fullUrl":"Practitioner/1734642835969309959.d700e30e-201a-46b1-a3b0-78ac9fb77dcc","resource":{"resourceType":"Practitioner","id":"1734642835969309959.d700e30e-201a-46b1-a3b0-78ac9fb77dcc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835974516742.4222fb2e-821d-4cb1-926f-d8818ff7303d","resource":{"resourceType":"Practitioner","id":"1734642835974516742.4222fb2e-821d-4cb1-926f-d8818ff7303d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835986825753.63e23dac-6951-4d16-a6f2-49a37c9a7522","resource":{"resourceType":"ServiceRequest","id":"1734642835986825753.63e23dac-6951-4d16-a6f2-49a37c9a7522","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835984485856.73d96fb8-7c48-4a39-b379-b190f985de60"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835978906253.e9fcd886-885d-4cf2-ba6d-69b36433490c"}}},{"fullUrl":"Practitioner/1734642835978906253.e9fcd886-885d-4cf2-ba6d-69b36433490c","resource":{"resourceType":"Practitioner","id":"1734642835978906253.e9fcd886-885d-4cf2-ba6d-69b36433490c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835984485856.73d96fb8-7c48-4a39-b379-b190f985de60","resource":{"resourceType":"Practitioner","id":"1734642835984485856.73d96fb8-7c48-4a39-b379-b190f985de60","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642835996319585.669af306-0630-4ff5-9f86-971447486fa6","resource":{"resourceType":"ServiceRequest","id":"1734642835996319585.669af306-0630-4ff5-9f86-971447486fa6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835993929083.6c57cd61-3f84-4ffe-bd44-8365a5949a9e"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835988842745.3028ecc4-9c8b-4c25-80ff-2014e0eeed42"}}},{"fullUrl":"Practitioner/1734642835988842745.3028ecc4-9c8b-4c25-80ff-2014e0eeed42","resource":{"resourceType":"Practitioner","id":"1734642835988842745.3028ecc4-9c8b-4c25-80ff-2014e0eeed42","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642835993929083.6c57cd61-3f84-4ffe-bd44-8365a5949a9e","resource":{"resourceType":"Practitioner","id":"1734642835993929083.6c57cd61-3f84-4ffe-bd44-8365a5949a9e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642836005661413.d54c6c0c-8086-4727-86a2-522b3ef8c450","resource":{"resourceType":"ServiceRequest","id":"1734642836005661413.d54c6c0c-8086-4727-86a2-522b3ef8c450","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836003447832.2320155b-39f7-42a4-81a8-dcab7529592a"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642835998320718.83677cf7-aae8-40ed-a246-20477c5263c4"}}},{"fullUrl":"Practitioner/1734642835998320718.83677cf7-aae8-40ed-a246-20477c5263c4","resource":{"resourceType":"Practitioner","id":"1734642835998320718.83677cf7-aae8-40ed-a246-20477c5263c4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642836003447832.2320155b-39f7-42a4-81a8-dcab7529592a","resource":{"resourceType":"Practitioner","id":"1734642836003447832.2320155b-39f7-42a4-81a8-dcab7529592a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"ServiceRequest/1734642836014302315.5f8956d2-cbdd-41a3-9601-c395d272df5f","resource":{"resourceType":"ServiceRequest","id":"1734642836014302315.5f8956d2-cbdd-41a3-9601-c395d272df5f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836012042027.611dd36e-ef7f-4fa7-a4d1-2b19a392bd38"}},{"url":"OBR.7","valueDateTime":"2024-10-03T16:03:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]}},{"url":"OBR.22","valueString":"20241023050044"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"requester":{"reference":"Practitioner/1734642836007489039.74b2ce63-be2e-40a1-8dea-1a0a6dd58476"}}},{"fullUrl":"Practitioner/1734642836007489039.74b2ce63-be2e-40a1-8dea-1a0a6dd58476","resource":{"resourceType":"Practitioner","id":"1734642836007489039.74b2ce63-be2e-40a1-8dea-1a0a6dd58476","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"Practitioner/1734642836012042027.611dd36e-ef7f-4fa7-a4d1-2b19a392bd38","resource":{"resourceType":"Practitioner","id":"1734642836012042027.611dd36e-ef7f-4fa7-a4d1-2b19a392bd38","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"JOCHEN"}]}],"name":[{"family":"PROFIT","given":["JOCHEN"]}]}},{"fullUrl":"DiagnosticReport/1734642836025400305.ff8ac839-62e2-4ae6-b38b-17f6d262661b","resource":{"resourceType":"DiagnosticReport","id":"1734642836025400305.ff8ac839-62e2-4ae6-b38b-17f6d262661b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"56352742"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"56352742"}],"basedOn":[{"reference":"ServiceRequest/1734642835744401522.4ff3345c-4a6d-4397-937b-68ba4e55bd8d"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835679809963.f5140095-69f3-4915-8100-62ebb73a9266"}]}},{"fullUrl":"DiagnosticReport/1734642836029429390.99b9f76a-d712-4a1f-95b8-eaaf390269fb","resource":{"resourceType":"DiagnosticReport","id":"1734642836029429390.99b9f76a-d712-4a1f-95b8-eaaf390269fb","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835758992222.2d75840b-e8b8-43c6-a69b-658b37b1361d"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835682132849.c285fe9e-9eef-41c1-b376-4a15512e5477"}],"result":[{"reference":"Observation/1734642835331267826.63d36999-ad9d-43cf-9ffa-431a0c8a7bcd"},{"reference":"Observation/1734642835333569772.67e5a931-dbac-42f7-a4ca-96331001f5f4"},{"reference":"Observation/1734642835335722138.55faa56e-a228-4fc8-9165-8fdb9382e0a8"},{"reference":"Observation/1734642835337835952.0dad2f6c-eeff-4faf-b63a-a4ba5359a979"},{"reference":"Observation/1734642835339907126.8d052379-b998-403b-919e-aa04ce7ae698"},{"reference":"Observation/1734642835341768095.0c6fdcb8-2039-49cf-a9fa-6aec62df3cec"},{"reference":"Observation/1734642835343782833.af96a85a-767c-43b2-a5a5-04b73664c52f"}]}},{"fullUrl":"DiagnosticReport/1734642836033347527.1423054d-d094-4b59-8fc6-e0e29bce16a4","resource":{"resourceType":"DiagnosticReport","id":"1734642836033347527.1423054d-d094-4b59-8fc6-e0e29bce16a4","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835770650794.bfe29259-c5d9-4f16-8ff4-d699d646ee90"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835683649694.81529006-d9a6-478d-a042-55c556f93b39"}],"result":[{"reference":"Observation/1734642835345802340.93550bd0-515e-43fa-98c0-63214b549372"},{"reference":"Observation/1734642835347854718.6a359b63-1a34-486f-92d9-8b593a70c860"},{"reference":"Observation/1734642835349807480.c7fb14b4-52bc-4f8c-b9da-7d38cd79c9b3"},{"reference":"Observation/1734642835352502855.5ff149e3-c3ed-4661-9784-9023409e0447"},{"reference":"Observation/1734642835354586642.1df6ef52-e9b7-4e39-b895-fdf2e3437402"},{"reference":"Observation/1734642835356828696.da821f16-8972-442a-8568-f322e8e1b276"},{"reference":"Observation/1734642835358990570.b7f0e174-0d5e-4b85-8176-587efa704cd9"},{"reference":"Observation/1734642835361225290.cc0bd769-7b35-4d29-9b2a-1ed6d1254fc4"},{"reference":"Observation/1734642835363248454.779ba7a1-c24e-4a37-abef-4f67466b41dd"},{"reference":"Observation/1734642835365113972.4533c579-f036-4a40-9093-a24ab85924c5"},{"reference":"Observation/1734642835366924928.1e0adb94-c06a-4c3e-bcb6-ebabf903b26f"}]}},{"fullUrl":"DiagnosticReport/1734642836036509076.18aca8a2-26f1-44f3-bc02-74fc6bb9b34f","resource":{"resourceType":"DiagnosticReport","id":"1734642836036509076.18aca8a2-26f1-44f3-bc02-74fc6bb9b34f","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835780546470.eb10fd70-3fc5-451f-af4a-77763961365b"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835685112005.62776300-71ef-4753-9775-632dbd20fa5a"}]}},{"fullUrl":"DiagnosticReport/1734642836041210852.69c341cb-2144-4f74-b624-c2a7731fa718","resource":{"resourceType":"DiagnosticReport","id":"1734642836041210852.69c341cb-2144-4f74-b624-c2a7731fa718","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835791834676.ec7b25fd-682f-4cb7-adbb-ca082237c515"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835687040031.041f7ffc-da54-46c9-8d11-aa5f8de30bb0"}],"result":[{"reference":"Observation/1734642835369659566.fe38b667-7f7e-4c1e-8612-5c5ff058fc43"},{"reference":"Observation/1734642835376452073.9eff88cf-d334-4da6-8a4b-d79cec24a6fa"},{"reference":"Observation/1734642835378662407.bcab4c6b-5ba4-44e0-bdd5-c937fd3bde84"},{"reference":"Observation/1734642835380826375.6b8edc0e-b24d-4395-a601-ea26b581cfa9"},{"reference":"Observation/1734642835382952452.6f507334-0883-4174-ac7a-0ddb0f4df61a"},{"reference":"Observation/1734642835385214764.c131d587-e5ac-4f53-94f1-3399562a8db5"},{"reference":"Observation/1734642835387460395.cda75646-4eda-4b32-b680-9456e40f562a"},{"reference":"Observation/1734642835389634321.501179b2-c30a-4843-9418-40b2497aad2f"},{"reference":"Observation/1734642835391828446.5f433876-3f87-45ec-9b16-1e452a6afe53"},{"reference":"Observation/1734642835394016309.da7611a9-ab4b-48c4-b7e3-81e3988dc810"},{"reference":"Observation/1734642835396791673.56b08f59-5641-492c-8cb3-9607afdacb01"},{"reference":"Observation/1734642835399100622.0b4cd402-06ef-4639-be95-30310ae78277"},{"reference":"Observation/1734642835401273266.7ec959c0-e661-4977-9ada-564e016aa547"},{"reference":"Observation/1734642835403495854.208ba995-f62a-4a32-92ca-6dbd84e7b5bd"},{"reference":"Observation/1734642835405656826.a6f91d96-0e3a-47ac-8507-ba955e7a55ef"},{"reference":"Observation/1734642835407744861.6c1d97ff-8566-4b14-839f-453d75dd411e"},{"reference":"Observation/1734642835409895063.1deb4048-6a8b-4531-bad0-47b7a192abda"},{"reference":"Observation/1734642835412122400.c7ff92a9-a371-4bf3-9ca3-8a0e51a7e406"},{"reference":"Observation/1734642835414367069.ff02d7b5-fca3-4e42-b46e-e94db9935f98"}]}},{"fullUrl":"DiagnosticReport/1734642836044537029.4107a300-c273-45d1-b36a-e5144b0c649b","resource":{"resourceType":"DiagnosticReport","id":"1734642836044537029.4107a300-c273-45d1-b36a-e5144b0c649b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835802084907.25541256-2203-4b6a-8fc2-45c8c95543af"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835689202095.cd50a654-b526-4981-9f5b-699bc6abb850"}],"result":[{"reference":"Observation/1734642835416488106.e6efc8d9-7149-41bd-b70d-bdd588f1a3dc"},{"reference":"Observation/1734642835418374644.b2a9a7f8-8b31-4790-bbaa-f828b2f86648"}]}},{"fullUrl":"DiagnosticReport/1734642836049712354.70273afb-c29e-474d-9e06-a1e28f33aee1","resource":{"resourceType":"DiagnosticReport","id":"1734642836049712354.70273afb-c29e-474d-9e06-a1e28f33aee1","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835812909625.81dd7562-bd3f-4733-9512-08a1f914da1d"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835694345079.5c984bb7-fe34-47af-ba5e-5138ffb45e35"}],"result":[{"reference":"Observation/1734642835422795583.e7b35f09-9dd7-4c76-8415-0d43dc7651dc"},{"reference":"Observation/1734642835424973167.286f68ed-7f9b-4388-a6cf-85a5266b7fcb"},{"reference":"Observation/1734642835427208008.74ac2dd1-eef7-4003-a69d-8252054806cb"},{"reference":"Observation/1734642835429434974.1dcdd144-4454-412a-80aa-0e2d822921c4"},{"reference":"Observation/1734642835431520845.08387875-2ad2-4e96-a056-0e34ae30f471"},{"reference":"Observation/1734642835433743443.c53a57f5-0822-45fb-b4a8-f0ccd4a7bc43"},{"reference":"Observation/1734642835435894226.465ab60c-9c58-45f3-b8bd-448bda9fafc0"},{"reference":"Observation/1734642835438030121.798cec3a-39a7-4add-b2fd-847a0238d54c"},{"reference":"Observation/1734642835440167228.f45fe5ba-f30c-49ed-86c3-39fa00ef4e7d"},{"reference":"Observation/1734642835442258119.9003abd4-9d1d-481f-a07b-1e409d499168"},{"reference":"Observation/1734642835444529488.f90faf32-693d-4e1e-8df9-9e18290745c9"},{"reference":"Observation/1734642835446685501.4fa52a50-3582-4d5f-9f50-ae6aca56bdd4"},{"reference":"Observation/1734642835448821927.1398ab29-7539-4321-a08a-4dbf80dc6fb0"},{"reference":"Observation/1734642835450906846.7168f890-107b-4837-81db-05146c6b2caf"},{"reference":"Observation/1734642835453132480.cfc11d29-4916-4cdc-bc71-aee747d8575b"},{"reference":"Observation/1734642835455753585.0c52c249-a902-49f0-8e21-58ba3bf9a0d6"},{"reference":"Observation/1734642835459017886.d4ffc9e5-bfac-41f8-98f0-5d97534dbc20"},{"reference":"Observation/1734642835461170162.a43d16ce-f5f1-4263-b61d-40a0018a85fd"},{"reference":"Observation/1734642835463250262.fc8c2a06-45f0-4658-a1d3-f8894e36e642"},{"reference":"Observation/1734642835465381198.e355d29a-924c-42d3-adf4-d29641f95d65"},{"reference":"Observation/1734642835470144200.4b1f1f59-8fd5-4f3e-8c17-bfaeba9912cc"},{"reference":"Observation/1734642835473769838.73b4900a-ada8-4e69-9cc2-d8ad5d147216"},{"reference":"Observation/1734642835477324013.976eb27c-3e86-4575-82d2-42090c14cd5e"},{"reference":"Observation/1734642835480981371.997509cf-1496-49ce-ae6a-2ab2e210872b"},{"reference":"Observation/1734642835484502183.03382ac4-4554-4bd4-a473-b1552aa30d97"},{"reference":"Observation/1734642835488159871.630b3407-29cc-4479-8ca0-6992bbf11d47"}]}},{"fullUrl":"DiagnosticReport/1734642836053923019.128e29de-5e06-4ea9-a20d-420ac9b6c954","resource":{"resourceType":"DiagnosticReport","id":"1734642836053923019.128e29de-5e06-4ea9-a20d-420ac9b6c954","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835826844004.93e7de95-250e-42ad-962c-5fb6f91a6211"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835695888844.b9c265b2-7ecc-4fa6-8b6b-fdc320dec738"}],"result":[{"reference":"Observation/1734642835491985485.ba51db78-903c-45eb-b9e5-c53ee7b3f2e1"},{"reference":"Observation/1734642835495570166.99fb27f1-e14d-4142-944b-289d1c3241da"},{"reference":"Observation/1734642835498092857.6bb59139-99b0-4b5d-97c8-ffb14263f781"},{"reference":"Observation/1734642835500703182.d5ab4f82-7c5b-4c26-bbbc-7dea218979e2"},{"reference":"Observation/1734642835502895012.d0ae8710-cbea-421e-b94a-53d6e14cd248"},{"reference":"Observation/1734642835505066664.c4809f26-012b-428d-a228-deb3c1c71f6a"},{"reference":"Observation/1734642835507175288.62b29fe7-f047-423f-96b8-613605f1bf43"},{"reference":"Observation/1734642835509285776.6da4db8a-be6a-423f-b00d-e770d332b912"},{"reference":"Observation/1734642835511368501.d417dea6-d6bc-4ccf-89e3-0111ca38a324"},{"reference":"Observation/1734642835513513543.70b62c82-fb4b-46aa-bbce-dd43197a4c40"}]}},{"fullUrl":"DiagnosticReport/1734642836057537897.2271a1ac-7b0b-4b5a-9134-9d0b11c1aa8e","resource":{"resourceType":"DiagnosticReport","id":"1734642836057537897.2271a1ac-7b0b-4b5a-9134-9d0b11c1aa8e","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835841901599.3275048a-bc6c-4092-b850-d38de0ed3651"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835698178878.c6f061fd-6eae-4ca5-8607-5247f471f7ae"}],"result":[{"reference":"Observation/1734642835515664627.e7d0dad1-5bbd-46c8-bd9e-6a3c2a0cc749"},{"reference":"Observation/1734642835517993935.17ec6b98-cacb-4027-820f-4d6998024af3"},{"reference":"Observation/1734642835520573001.3c493ebc-ba0f-4b33-aa6b-24b510ca4ff6"}]}},{"fullUrl":"DiagnosticReport/1734642836060854116.26790db7-6d6b-4e42-8239-08c7ef372775","resource":{"resourceType":"DiagnosticReport","id":"1734642836060854116.26790db7-6d6b-4e42-8239-08c7ef372775","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835856905334.d69097cc-ddb8-4325-81ac-035da095ab9d"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835700470095.490fe88c-9d7f-48ac-8a2e-de34c0a0122c"}],"result":[{"reference":"Observation/1734642835525904147.1a80681b-c906-4966-937b-e53f0becb2f1"},{"reference":"Observation/1734642835529512403.bf5ed02a-3c6c-4860-8ca7-7ea37fc1ffeb"},{"reference":"Observation/1734642835532521065.ed84de32-d45a-4b1a-a413-535cb2895ee9"}]}},{"fullUrl":"DiagnosticReport/1734642836064630176.92f10d06-cc28-4cb3-9d32-f4aa43dec35b","resource":{"resourceType":"DiagnosticReport","id":"1734642836064630176.92f10d06-cc28-4cb3-9d32-f4aa43dec35b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835871903457.f692a2e9-0b4d-43f0-8261-6bb812d74c1e"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835702449075.1d1f430f-765e-4097-9fd9-b98c8afe02cb"}],"result":[{"reference":"Observation/1734642835535876457.d760f87e-fc5d-4be1-a52f-66f60a2ae7bd"},{"reference":"Observation/1734642835539823078.8f08b768-25fc-45d6-aa00-7d0ac78f7680"},{"reference":"Observation/1734642835543024561.82b80bcb-0246-4912-8e2d-d887306f7321"}]}},{"fullUrl":"DiagnosticReport/1734642836067816571.2149d1a2-417a-4bce-9c2d-a8b96c1a4ce6","resource":{"resourceType":"DiagnosticReport","id":"1734642836067816571.2149d1a2-417a-4bce-9c2d-a8b96c1a4ce6","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835886888697.bf61c1b6-56cb-4670-9961-282b6c0f1ebc"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835704119568.b958bb18-491b-4ee7-9425-30bd73b53543"}],"result":[{"reference":"Observation/1734642835546355467.83b3714a-1a87-4ac9-8f99-08878e0fd16a"},{"reference":"Observation/1734642835549893211.25dd6d46-74e7-4235-ab79-9d8105fa0a00"},{"reference":"Observation/1734642835552869902.ac846058-f0a0-4699-97d2-519dca5cade1"}]}},{"fullUrl":"DiagnosticReport/1734642836070885045.9cd3f0af-e328-4e84-bac9-f37614924bad","resource":{"resourceType":"DiagnosticReport","id":"1734642836070885045.9cd3f0af-e328-4e84-bac9-f37614924bad","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835902087947.b0625fb0-fc20-4f6c-8cc1-5b44f0187465"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835705624961.bc2cfb73-382d-4917-a2fb-649f48c96d17"}],"result":[{"reference":"Observation/1734642835555821888.61e203d3-2b7d-430f-bf57-c9f70a3ec4fc"},{"reference":"Observation/1734642835558423075.0fb66141-985a-471c-84ea-0e2507b24dee"}]}},{"fullUrl":"DiagnosticReport/1734642836074795647.998e19fd-ef20-48fc-9ffd-dda2719ea5f2","resource":{"resourceType":"DiagnosticReport","id":"1734642836074795647.998e19fd-ef20-48fc-9ffd-dda2719ea5f2","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835917149069.983f6ce8-159b-45c8-954c-4075b17846af"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835707157845.4fe80b95-b4f1-4845-bca1-c066dd61b6d9"}],"result":[{"reference":"Observation/1734642835561468346.fa1af592-bc70-4f22-a292-dbf8a4ea9fe3"},{"reference":"Observation/1734642835564990210.aba2c5e6-f906-465b-9b58-d2a3f6f29dd1"},{"reference":"Observation/1734642835567985496.fa5f27bf-a0a5-4d52-b4b1-1bf218ce6db4"}]}},{"fullUrl":"DiagnosticReport/1734642836079087485.3ab655bd-01db-4c70-9e4b-ce057a3dc21f","resource":{"resourceType":"DiagnosticReport","id":"1734642836079087485.3ab655bd-01db-4c70-9e4b-ce057a3dc21f","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835935979239.0e176d4b-30d3-4137-ae0f-9c51656f66c3"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835708612232.ac4f7578-f103-41a7-b573-007e4db7765b"}],"result":[{"reference":"Observation/1734642835571309800.12adfa77-1e2f-48d4-88b8-d20a75429f23"},{"reference":"Observation/1734642835574850148.21ea8318-4e72-436c-b8fa-e1fd75a19efb"},{"reference":"Observation/1734642835581069972.c10bcd96-4829-4e95-a1d9-66376f5d3d45"}]}},{"fullUrl":"DiagnosticReport/1734642836082360703.e108bbfb-c300-4c64-bcfb-33611923f8d2","resource":{"resourceType":"DiagnosticReport","id":"1734642836082360703.e108bbfb-c300-4c64-bcfb-33611923f8d2","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835945974251.f0fcd4a8-98bd-4ab4-a492-4645926f24a9"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835710510722.fc135623-a3f3-43e6-b605-5beba9342283"}],"result":[{"reference":"Observation/1734642835584576026.aabbb953-5488-4b30-8acc-41bf00db6120"},{"reference":"Observation/1734642835588092480.08525370-2227-4b69-826d-d9e4032ee0af"},{"reference":"Observation/1734642835591074051.eb0d4858-a135-4a49-9d69-38d256936bb8"}]}},{"fullUrl":"DiagnosticReport/1734642836085564821.5f0e8445-cccc-45a2-9363-029a6c67b1bb","resource":{"resourceType":"DiagnosticReport","id":"1734642836085564821.5f0e8445-cccc-45a2-9363-029a6c67b1bb","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835956530516.5b286178-75c7-4255-af1a-49caed4c0082"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835712141821.51833386-6ce0-4b71-b0e4-8d2cf7ee8c86"}],"result":[{"reference":"Observation/1734642835594442237.a15194f2-60a6-4498-b5dc-87aca0c61a66"},{"reference":"Observation/1734642835597959462.0cdecaae-6f8b-441d-9c80-85c40bef0dae"},{"reference":"Observation/1734642835600988341.dc2afa30-6326-48a0-9e3b-28c2aeb08706"}]}},{"fullUrl":"DiagnosticReport/1734642836089224263.c80abe0a-b8cf-4063-9caf-122710a02b4f","resource":{"resourceType":"DiagnosticReport","id":"1734642836089224263.c80abe0a-b8cf-4063-9caf-122710a02b4f","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835967140120.6f8af5b3-2a92-469c-adc3-17c5c75716ec"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835713518763.82aafad2-810d-4c77-a953-975e9b2dfde4"}],"result":[{"reference":"Observation/1734642835604036297.40339a51-8dac-4737-809a-539504353d80"},{"reference":"Observation/1734642835607529266.a4125cf0-de2a-4085-b6de-c410a2215b1f"},{"reference":"Observation/1734642835610542657.f1aef249-54da-4464-97f9-c3fb9ba09a9d"}]}},{"fullUrl":"DiagnosticReport/1734642836092450482.c935b20d-f405-4093-acd7-23d13d02c9d0","resource":{"resourceType":"DiagnosticReport","id":"1734642836092450482.c935b20d-f405-4093-acd7-23d13d02c9d0","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835976875515.47645843-2e02-492b-9fa9-10754e5c2eb7"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835715545523.cab4abb0-08dd-41fc-b108-d8df145f1ba1"}],"result":[{"reference":"Observation/1734642835613935850.7dd54161-8b91-4713-9880-097a8d61b409"},{"reference":"Observation/1734642835617486398.92be0ee0-3ee7-466e-99d6-b61c7e3e5a37"},{"reference":"Observation/1734642835620525837.cc26ef54-3f3a-47b8-9a7b-047d46f3348b"}]}},{"fullUrl":"DiagnosticReport/1734642836095781419.9d3f4ff9-f268-408b-a3c9-a9f1563ddd34","resource":{"resourceType":"DiagnosticReport","id":"1734642836095781419.9d3f4ff9-f268-408b-a3c9-a9f1563ddd34","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835986825753.63e23dac-6951-4d16-a6f2-49a37c9a7522"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835718057894.457e17fc-100b-49f5-bb92-b4c9acf25c85"}],"result":[{"reference":"Observation/1734642835623921985.3e0baca9-bd03-4ed1-8b08-89ba31cab5dd"},{"reference":"Observation/1734642835630419291.12c4f657-9182-4881-8c31-27b06e3c48c7"}]}},{"fullUrl":"DiagnosticReport/1734642836100016380.06b8079b-3e66-4d76-ba1e-540869bad33a","resource":{"resourceType":"DiagnosticReport","id":"1734642836100016380.06b8079b-3e66-4d76-ba1e-540869bad33a","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642835996319585.669af306-0630-4ff5-9f86-971447486fa6"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835719713849.d97d4078-fa35-46c5-b71a-983c6c316188"}],"result":[{"reference":"Observation/1734642835633807975.46e97221-a624-4e5e-8859-ff611e85da90"},{"reference":"Observation/1734642835637364704.cfb11c03-e2c7-43f7-8cc9-859c933f8b62"},{"reference":"Observation/1734642835649022763.3c31dc08-0d4e-4e81-a1c4-d249999d5869"}]}},{"fullUrl":"DiagnosticReport/1734642836103489783.54433dc4-1532-463c-a3fd-9db074b3439c","resource":{"resourceType":"DiagnosticReport","id":"1734642836103489783.54433dc4-1532-463c-a3fd-9db074b3439c","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642836005661413.d54c6c0c-8086-4727-86a2-522b3ef8c450"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835721296777.e0bd5141-acd6-4b4a-ba77-e92176956627"}],"result":[{"reference":"Observation/1734642835653194486.57e9dd23-af1b-46e0-99a7-bc5a2461a5e5"},{"reference":"Observation/1734642835656742329.2b81d4e2-b30a-4c26-a562-c55c8d886d39"}]}},{"fullUrl":"DiagnosticReport/1734642836111794034.e7245026-8c48-44c6-b07c-7d0df43be6d1","resource":{"resourceType":"DiagnosticReport","id":"1734642836111794034.e7245026-8c48-44c6-b07c-7d0df43be6d1","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"45789876"}],"basedOn":[{"reference":"ServiceRequest/1734642836014302315.5f8956d2-cbdd-41a3-9601-c395d272df5f"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835327111853.3ac66319-23de-47b0-8df7-4751eac29fe6"},"effectiveDateTime":"2024-10-03T16:03:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410031603"}]},"issued":"2024-10-23T05:00:44Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241023050044"}]},"specimen":[{"reference":"Specimen/1734642835722645206.a1858c19-14c2-4fef-9cc4-db5e31b7e834"}],"result":[{"reference":"Observation/1734642835660757468.12a8eb98-e6e0-4f4d-9bf4-afeeb9525a95"}]}}]}
diff --git a/examples/Test/Automated/GoldenCopy/Expected/004_ORU_R01_golden_copy_expected_in_range.fhir b/examples/Test/Automated/GoldenCopy/Expected/004_ORU_R01_golden_copy_expected_in_range.fhir
deleted file mode 100644
index e548ef905..000000000
--- a/examples/Test/Automated/GoldenCopy/Expected/004_ORU_R01_golden_copy_expected_in_range.fhir
+++ /dev/null
@@ -1 +0,0 @@
-{"resourceType":"Bundle","id":"1734642835566629290.f0527f75-7aea-4894-97d4-65cf43c71557","meta":{"lastUpdated":"2024-12-19T21:13:55.566+00:00"},"identifier":{"system":"https://reportstream.cdc.gov/prime-router","value":"004"},"type":"message","timestamp":"2024-10-30T05:01:54.000+00:00","entry":[{"fullUrl":"MessageHeader/1734642835567650716.7cd1e404-3141-43cf-a56f-fb6f63cef3a4","resource":{"resourceType":"MessageHeader","id":"1734642835567650716.7cd1e404-3141-43cf-a56f-fb6f63cef3a4","meta":{"tag":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0103","code":"N"}]},"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/msh-message-header","extension":[{"url":"MSH.7","valueString":"20241030050154"}]}],"eventCoding":{"system":"http://terminology.hl7.org/CodeSystem/v2-0003","code":"R01","display":"ORU^R01^ORU_R01"},"destination":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id","valueString":"11903029"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id-type","valueString":"L,M,N"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.5"}],"name":"SISHIERECEIVER","receiver":{"reference":"Organization/1734642835567400025.e6925cd4-97a8-4a1d-a8f8-a71dc567bcdd"}}],"sender":{"reference":"Organization/1734642835566920526.a0211f38-04d7-42df-9a1a-4777110a8bd2"},"source":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"SISGDSP"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.3"}],"name":"SISGDSP","_endpoint":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}}},{"fullUrl":"Organization/1734642835566920526.a0211f38-04d7-42df-9a1a-4777110a8bd2","resource":{"resourceType":"Organization","id":"1734642835566920526.a0211f38-04d7-42df-9a1a-4777110a8bd2","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Organization/1734642835567400025.e6925cd4-97a8-4a1d-a8f8-a71dc567bcdd","resource":{"resourceType":"Organization","id":"1734642835567400025.e6925cd4-97a8-4a1d-a8f8-a71dc567bcdd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.6"}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.2,HD.3"}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301","code":"L,M,N"}]},"value":"automated-staging-test-receiver-id"}]}},{"fullUrl":"Provenance/1734642835568915377.56011851-fd12-4de0-a6bb-57f2199ddb44","resource":{"resourceType":"Provenance","id":"1734642835568915377.56011851-fd12-4de0-a6bb-57f2199ddb44","target":[{"reference":"MessageHeader/1734642835567650716.7cd1e404-3141-43cf-a56f-fb6f63cef3a4"},{"reference":"DiagnosticReport/1734642836152439978.c27b00f3-e85a-4103-a989-e69a6c752aa0"},{"reference":"DiagnosticReport/1734642836155870350.f904bf10-c9bb-461c-a2fb-670399604fd6"},{"reference":"DiagnosticReport/1734642836159725770.57b4f680-c5b0-4705-85dd-f6f743270117"},{"reference":"DiagnosticReport/1734642836163296335.30331610-9333-48d7-aced-405f3bbc49b3"},{"reference":"DiagnosticReport/1734642836170026284.eac8ce49-4557-408b-b25c-603aafd0fbc6"},{"reference":"DiagnosticReport/1734642836174794145.4b4522ad-a76c-40a1-b33f-e956981336b3"},{"reference":"DiagnosticReport/1734642836181665440.cf879ec4-f8ad-4f96-a9af-c27df992d494"},{"reference":"DiagnosticReport/1734642836185431782.2ccfdb9d-6d9f-4b94-b827-a9430b5275bc"},{"reference":"DiagnosticReport/1734642836188456093.6b6e2444-1cb6-4e00-bd3a-aed46f112a17"},{"reference":"DiagnosticReport/1734642836191457080.1b9335a6-456e-4b5a-b8fa-c0246b1b35f5"},{"reference":"DiagnosticReport/1734642836195354398.dfe86879-7556-4767-8397-31a3feac8176"},{"reference":"DiagnosticReport/1734642836198703929.4c2049ad-8f8e-4639-948d-4ca1db4e92e4"},{"reference":"DiagnosticReport/1734642836201721948.3960cf5c-983f-4859-9e35-8c3ac6cd0fe4"},{"reference":"DiagnosticReport/1734642836204801984.350c0e54-ac24-4e7f-838f-71b69a75dd67"},{"reference":"DiagnosticReport/1734642836208398798.60ac234a-0077-45c4-8fa7-838532fcb1a3"},{"reference":"DiagnosticReport/1734642836211461451.b445825b-9bc5-4f0e-8c02-2efec15eea80"},{"reference":"DiagnosticReport/1734642836214831090.ee9eb06b-e557-4f06-a2f9-fa45857f934e"},{"reference":"DiagnosticReport/1734642836222755552.3e6f8397-1b58-4c1a-b40d-beef72dfd7f2"},{"reference":"DiagnosticReport/1734642836226132955.b2820374-c2e0-4889-9afe-bdc2a1dca75b"},{"reference":"DiagnosticReport/1734642836229369304.f3163167-c3a2-4db6-a5d0-b34a381c8f2a"},{"reference":"DiagnosticReport/1734642836232969475.9f766400-c9d9-4ce5-ad62-e68dc8dfcba3"},{"reference":"DiagnosticReport/1734642836236317372.7970abee-6352-427f-ad38-6bd422457de4"},{"reference":"DiagnosticReport/1734642836239591572.8e42c1d3-2acd-4fb2-bd9f-83f12fbcaa69"}],"recorded":"2024-10-30T05:01:54Z","activity":{"coding":[{"display":"ORU^R01^ORU_R01"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"author"}]},"who":{"reference":"Organization/1734642835568737323.d2c8e0a8-aeea-4dd8-ad3a-7d5afffda662"}}]}},{"fullUrl":"Organization/1734642835568737323.d2c8e0a8-aeea-4dd8-ad3a-7d5afffda662","resource":{"resourceType":"Organization","id":"1734642835568737323.d2c8e0a8-aeea-4dd8-ad3a-7d5afffda662","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Provenance/1734642835569413250.85a9e377-4a25-45da-a030-13a4b4353e70","resource":{"resourceType":"Provenance","id":"1734642835569413250.85a9e377-4a25-45da-a030-13a4b4353e70","recorded":"2024-12-19T21:13:55Z","policy":["http://hl7.org/fhir/uv/v2mappings/message-oru-r01-to-bundle"],"activity":{"coding":[{"code":"v2-FHIR transformation"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"assembler"}]},"who":{"reference":"Organization/1734642835569260194.d61dc1b1-2bb3-4dc8-8509-adc3b59c55a0"}}]}},{"fullUrl":"Organization/1734642835569260194.d61dc1b1-2bb3-4dc8-8509-adc3b59c55a0","resource":{"resourceType":"Organization","id":"1734642835569260194.d61dc1b1-2bb3-4dc8-8509-adc3b59c55a0","identifier":[{"value":"CDC PRIME - Atlanta"},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301"}]},"system":"urn:ietf:rfc:3986","value":"2.16.840.1.114222.4.1.237821"}]}},{"fullUrl":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb","resource":{"resourceType":"Patient","id":"1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cx-identifier","extension":[{"url":"CX.5","valueString":"MR"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"PID.3"}],"type":{"coding":[{"code":"MR"}]},"value":"335441864","assigner":{"reference":"Organization/1734642835570049433.f3d530ee-ea42-40d0-bb57-de3dec27eb77"}}],"name":[{"family":"*****PII REMOVED******"}],"contact":[{"name":{"family":"*****PII REMOVED******"}}]}},{"fullUrl":"Organization/1734642835570049433.f3d530ee-ea42-40d0-bb57-de3dec27eb77","resource":{"resourceType":"Organization","id":"1734642835570049433.f3d530ee-ea42-40d0-bb57-de3dec27eb77","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"104638912487&NPI"}]}},{"fullUrl":"Provenance/1734642835573831726.0ce2a9df-32dd-449b-857e-9721f234de84","resource":{"resourceType":"Provenance","id":"1734642835573831726.0ce2a9df-32dd-449b-857e-9721f234de84","target":[{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"}],"recorded":"2024-12-19T21:13:55Z","activity":{"coding":[{"system":"https://terminology.hl7.org/CodeSystem/v3-DataOperation","code":"UPDATE"}]}}},{"fullUrl":"RelatedPerson/1734642835574833975.319061e3-ffe8-4929-affc-8da7b067c9bd","resource":{"resourceType":"RelatedPerson","id":"1734642835574833975.319061e3-ffe8-4929-affc-8da7b067c9bd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"NK1"}],"patient":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"name":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"NK1.2"}],"family":"*****PII REMOVED******"}]}},{"fullUrl":"Observation/1734642835577334424.adac7e49-c88b-4c5c-bda3-24bfaf62119c","resource":{"resourceType":"Observation","id":"1734642835577334424.adac7e49-c88b-4c5c-bda3-24bfaf62119c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57721-3","display":"Reason for lab test in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12421-6","display":"Initial screen"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835582945910.f0c81174-275c-4f6d-9003-10c4c6cee05f","resource":{"resourceType":"Observation","id":"1734642835582945910.f0c81174-275c-4f6d-9003-10c4c6cee05f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57718-9","display":"Sample quality of Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12432-3","display":"Acceptable"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835585626967.e771b53b-9a27-423b-bd97-b0cc10b0fc17","resource":{"resourceType":"Observation","id":"1734642835585626967.e771b53b-9a27-423b-bd97-b0cc10b0fc17","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57130-7","display":"Newborn screening report - overall interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12428-1","display":"All screening is in range for the conditions tested"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835587943501.7508be73-3956-4c30-9fb2-9a420d225bbd","resource":{"resourceType":"Observation","id":"1734642835587943501.7508be73-3956-4c30-9fb2-9a420d225bbd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57131-5","display":"Newborn conditions with positive markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835590874687.0cc4344e-4653-4c68-a6f6-028b9a5cc0a5","resource":{"resourceType":"Observation","id":"1734642835590874687.0cc4344e-4653-4c68-a6f6-028b9a5cc0a5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57720-5","display":"Newborn conditions with equivocal markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835592969425.13fe95c5-d463-4a95-9ae7-acd437529f9a","resource":{"resourceType":"Observation","id":"1734642835592969425.13fe95c5-d463-4a95-9ae7-acd437529f9a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57724-7","display":"Newborn screening short narrative summary"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \\\\\\2130 E Illinois Avenue, FRESNO, CA 93701\\\\.br\\\\\\\\.br\\\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\\\.br\\\\\\\\.br\\\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\\\.br\\\\\\\\.br\\\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (858) 966-8708. \\\\.br\\\\\\\\.br\\\\Methods and Limitations:\\\\.br\\\\\\\\.br\\\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\\\.br\\\\Attention Healthcare Provider:\\\\.br\\\\\\\\.br\\\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\\\.br\\\\\\\\.br\\","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835595033996.cbdcdf22-3e1c-4658-bf95-66d53413f145","resource":{"resourceType":"Observation","id":"1734642835595033996.cbdcdf22-3e1c-4658-bf95-66d53413f145","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57129-9","display":"Full newborn screening summary report for display or printing"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835597001375.991eef6e-98ae-4728-b2a9-eb4dc15ddfe5","resource":{"resourceType":"Observation","id":"1734642835597001375.991eef6e-98ae-4728-b2a9-eb4dc15ddfe5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"ST"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57716-3","display":"State printed on filter paper card [Identifier] in NBS card"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"CA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835599231657.6cd136e8-cdd9-478e-b513-a69682d52dcf","resource":{"resourceType":"Observation","id":"1734642835599231657.6cd136e8-cdd9-478e-b513-a69682d52dcf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"grams"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"8339-4","display":"Birthweight"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":3464,"unit":"grams"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835601376860.20738e16-4487-4275-9d1e-2f1d7899a49b","resource":{"resourceType":"Observation","id":"1734642835601376860.20738e16-4487-4275-9d1e-2f1d7899a49b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57715-5","display":"Time of birth"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueTime":"0444","_valueTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"0444"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835603619726.92836d62-2c43-4fd5-862e-68ccb53f0583","resource":{"resourceType":"Observation","id":"1734642835603619726.92836d62-2c43-4fd5-862e-68ccb53f0583","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57722-1","display":"Birth plurality of Pregnancy"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12411-7","display":"Singleton"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835606051145.294d5bf0-4e62-482d-b456-f5bd54ddf19e","resource":{"resourceType":"Observation","id":"1734642835606051145.294d5bf0-4e62-482d-b456-f5bd54ddf19e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"hour(s)"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"73806-2","display":"Newborn age in hours"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":19,"unit":"hour(s)"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835608401953.3951d7cb-f4c3-43af-a159-eb1c1bf9c2e9","resource":{"resourceType":"Observation","id":"1734642835608401953.3951d7cb-f4c3-43af-a159-eb1c1bf9c2e9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57713-0","display":"Infant NICU factors that affect newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835610633307.d65b7233-9e23-4cbc-9126-9fc566126230","resource":{"resourceType":"Observation","id":"1734642835610633307.d65b7233-9e23-4cbc-9126-9fc566126230","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67704-7","display":"Feeding types"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA16914-6","display":"Breast milk"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835612775124.0d6a0867-1ae6-48c5-a587-cb41a3e52476","resource":{"resourceType":"Observation","id":"1734642835612775124.0d6a0867-1ae6-48c5-a587-cb41a3e52476","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-5","display":"Accession Number"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"292-04-123/21-2024-32","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835615633444.91b240be-e8aa-4061-9564-89f9e6e0d5bb","resource":{"resourceType":"Observation","id":"1734642835615633444.91b240be-e8aa-4061-9564-89f9e6e0d5bb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62324-9","display":"Post-discharge provider name"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"DIANE BEDROSIAN","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835617901266.8e54520a-9875-4c84-b38a-3fbd6709a7a7","resource":{"resourceType":"Observation","id":"1734642835617901266.8e54520a-9875-4c84-b38a-3fbd6709a7a7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62325-6","display":"Post-discharge provider practice ID"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"1447323951","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835619938276.c720e577-5b06-4c8d-8217-8272358029fb","resource":{"resourceType":"Observation","id":"1734642835619938276.c720e577-5b06-4c8d-8217-8272358029fb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62327-2","display":"Post-discharge provider practice address"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"200 W ARBOR DR SAN DIEGO CA 92103-1911 USA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835622290176.0ed5d39e-4af1-41f8-98da-7b956ad1aca9","resource":{"resourceType":"Observation","id":"1734642835622290176.0ed5d39e-4af1-41f8-98da-7b956ad1aca9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47633-3","display":"Glycine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":536,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835624587333.d71f9ce0-54c1-4fb0-9c27-bc6838cc8934","resource":{"resourceType":"Observation","id":"1734642835624587333.d71f9ce0-54c1-4fb0-9c27-bc6838cc8934","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53150-9","display":"Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":559,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1000"}]}},{"fullUrl":"Observation/1734642835630433513.ff02305e-15bd-446f-8015-32a1ccd7995c","resource":{"resourceType":"Observation","id":"1734642835630433513.ff02305e-15bd-446f-8015-32a1ccd7995c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47799-2","display":"Valine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":123,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835632748323.c4c14367-0fae-4255-b87c-e5b6722fce27","resource":{"resourceType":"Observation","id":"1734642835632748323.c4c14367-0fae-4255-b87c-e5b6722fce27","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53151-7","display":"Valine/Phenylalanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":2.14286,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.3"}]}},{"fullUrl":"Observation/1734642835635217113.8be785a8-0375-46eb-94a3-7f2cf7a0dff0","resource":{"resourceType":"Observation","id":"1734642835635217113.8be785a8-0375-46eb-94a3-7f2cf7a0dff0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53152-5","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":113,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<230"}]}},{"fullUrl":"Observation/1734642835637771543.7b620553-e589-49ea-a380-6a8b7474b329","resource":{"resourceType":"Observation","id":"1734642835637771543.7b620553-e589-49ea-a380-6a8b7474b329","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53154-1","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.20,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.35"}]}},{"fullUrl":"Observation/1734642835642122852.6a859c86-d8f1-4d0f-a2d3-b4fdd58a36f4","resource":{"resourceType":"Observation","id":"1734642835642122852.6a859c86-d8f1-4d0f-a2d3-b4fdd58a36f4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29573-3","display":"Phenylalanine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":57.4,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<175"}]}},{"fullUrl":"Observation/1734642835648986983.5fe75d08-ac6d-4ba1-8a89-ac1fa3be0c7c","resource":{"resourceType":"Observation","id":"1734642835648986983.5fe75d08-ac6d-4ba1-8a89-ac1fa3be0c7c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35572-7","display":"Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":1.05,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2.6"}]}},{"fullUrl":"Observation/1734642835651324957.ffdae7fc-33c6-4c8b-b7a6-334986cf820f","resource":{"resourceType":"Observation","id":"1734642835651324957.ffdae7fc-33c6-4c8b-b7a6-334986cf820f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35571-9","display":"Tyrosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":54.8,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<680"}]}},{"fullUrl":"Observation/1734642835653464299.ecdb8485-1be4-4bc7-9921-70ef134ea027","resource":{"resourceType":"Observation","id":"1734642835653464299.ecdb8485-1be4-4bc7-9921-70ef134ea027","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53231-7","display":"Succinylacetone [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.20,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<6.1"}]}},{"fullUrl":"Observation/1734642835655634949.ada7fa6f-d208-4f95-ae2d-c3f94913127e","resource":{"resourceType":"Observation","id":"1734642835655634949.ada7fa6f-d208-4f95-ae2d-c3f94913127e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47700-0","display":"Methionine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":22.8,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.3-100"}]}},{"fullUrl":"Observation/1734642835657787706.19dec618-554e-4232-8b8f-718feb2c0810","resource":{"resourceType":"Observation","id":"1734642835657787706.19dec618-554e-4232-8b8f-718feb2c0810","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42892-0","display":"Citrulline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":10,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"5-49"}]}},{"fullUrl":"Observation/1734642835659892012.7868a556-8258-4cd3-b653-542182d8fcae","resource":{"resourceType":"Observation","id":"1734642835659892012.7868a556-8258-4cd3-b653-542182d8fcae","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54092-2","display":"Citrulline/Arginine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":1.52,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.8"}]}},{"fullUrl":"Observation/1734642835662076538.a387bfe4-b363-4221-89f6-d0f2ea71e213","resource":{"resourceType":"Observation","id":"1734642835662076538.a387bfe4-b363-4221-89f6-d0f2ea71e213","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53155-8","display":"Asparagine+Ornithine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":84,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<800"}]}},{"fullUrl":"Observation/1734642835664344942.f66efdf8-7f8a-4e48-b80b-0e8f843d1a96","resource":{"resourceType":"Observation","id":"1734642835664344942.f66efdf8-7f8a-4e48-b80b-0e8f843d1a96","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75215-4","display":"Ornithine/Citrulline [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":8.40,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835667556273.9a9e4a0b-7125-471c-8001-360221a9cef2","resource":{"resourceType":"Observation","id":"1734642835667556273.9a9e4a0b-7125-471c-8001-360221a9cef2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47562-4","display":"Arginine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":7,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<63"}]}},{"fullUrl":"Observation/1734642835670226080.0806c275-8281-4657-8edd-7f65f0a1d343","resource":{"resourceType":"Observation","id":"1734642835670226080.0806c275-8281-4657-8edd-7f65f0a1d343","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75214-7","display":"Arginine/Ornithine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.08,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.9"}]}},{"fullUrl":"Observation/1734642835672541752.67036c13-e742-4a9e-8a48-18221261335e","resource":{"resourceType":"Observation","id":"1734642835672541752.67036c13-e742-4a9e-8a48-18221261335e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47732-3","display":"Proline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":154,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1500"}]}},{"fullUrl":"Observation/1734642835674459107.60d5c469-6e3b-4dbf-a66d-04ff03f052af","resource":{"resourceType":"Observation","id":"1734642835674459107.60d5c469-6e3b-4dbf-a66d-04ff03f052af","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57710-6","display":"Amino acidemias newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835676555097.d17991b9-f738-4c03-bc2d-eca221d2d49c","resource":{"resourceType":"Observation","id":"1734642835676555097.d17991b9-f738-4c03-bc2d-eca221d2d49c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58088-6","display":"Acylcarnitine newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835678329685.bb4ed8d6-7e4d-4959-972f-a5bc6f2b63d1","resource":{"resourceType":"Observation","id":"1734642835678329685.bb4ed8d6-7e4d-4959-972f-a5bc6f2b63d1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58093-6","display":"Acylcarnitine newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835680351065.d01da517-1280-4a4b-a9fa-42f5aba5354e","resource":{"resourceType":"Observation","id":"1734642835680351065.d01da517-1280-4a4b-a9fa-42f5aba5354e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38481-8","display":"Carnitine.free (C0)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":24.4,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.4-125"}]}},{"fullUrl":"Observation/1734642835683365418.cf9c3b1d-9ef4-4b0e-a8c8-bce7fd481781","resource":{"resourceType":"Observation","id":"1734642835683365418.cf9c3b1d-9ef4-4b0e-a8c8-bce7fd481781","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53235-8","display":"Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":4.32,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<70"}]}},{"fullUrl":"Observation/1734642835686681365.bc96eed3-e560-4185-9b8e-654ec88f2776","resource":{"resourceType":"Observation","id":"1734642835686681365.bc96eed3-e560-4185-9b8e-654ec88f2776","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50157-7","display":"Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":27.3,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"10-80"}]}},{"fullUrl":"Observation/1734642835693717720.57ef4762-7f1a-49c1-afac-2de54e42e258","resource":{"resourceType":"Observation","id":"1734642835693717720.57ef4762-7f1a-49c1-afac-2de54e42e258","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75212-1","display":"Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":2.73000,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.6"}]}},{"fullUrl":"Observation/1734642835696077585.0a2bdff7-f737-4624-8c1b-9cfe764fca68","resource":{"resourceType":"Observation","id":"1734642835696077585.0a2bdff7-f737-4624-8c1b-9cfe764fca68","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45211-0","display":"Hexanoylcarnitine (C6)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.067,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835698315441.7cb7425f-81df-4530-a5c2-76c97210fef3","resource":{"resourceType":"Observation","id":"1734642835698315441.7cb7425f-81df-4530-a5c2-76c97210fef3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53175-6","display":"Octanoylcarnitine (C8)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.076,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835700583725.13e5ba61-8a59-482f-865b-4054fe5a03e1","resource":{"resourceType":"Observation","id":"1734642835700583725.13e5ba61-8a59-482f-865b-4054fe5a03e1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53177-2","display":"Octanoylcarnitine (C8)/Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.76,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835702659758.ecf642b8-29ec-4734-a174-beea3fafc7a9","resource":{"resourceType":"Observation","id":"1734642835702659758.ecf642b8-29ec-4734-a174-beea3fafc7a9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53174-9","display":"Octenoylcarnitine (C8:1)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.103,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835704761468.d497718f-0b69-40cc-9b9f-7dc62c83c950","resource":{"resourceType":"Observation","id":"1734642835704761468.d497718f-0b69-40cc-9b9f-7dc62c83c950","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45197-1","display":"Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.100,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835707309036.fe794609-acd5-4805-9440-2ae4c749af09","resource":{"resourceType":"Observation","id":"1734642835707309036.fe794609-acd5-4805-9440-2ae4c749af09","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45198-9","display":"Decenoylcarnitine (C10:1)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.035,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835709563824.fb6d07a6-0c21-455c-b5c5-6a6d07184265","resource":{"resourceType":"Observation","id":"1734642835709563824.fb6d07a6-0c21-455c-b5c5-6a6d07184265","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45199-7","display":"Dodecanoylcarnitine (C12)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.132,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2"}]}},{"fullUrl":"Observation/1734642835712047531.949c4810-8298-4150-9a2f-60508ec56a7a","resource":{"resourceType":"Observation","id":"1734642835712047531.949c4810-8298-4150-9a2f-60508ec56a7a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45200-3","display":"Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.17,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835714330091.533e0fb7-63d2-4b19-8f6e-837cd278b3e5","resource":{"resourceType":"Observation","id":"1734642835714330091.533e0fb7-63d2-4b19-8f6e-837cd278b3e5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53192-1","display":"Tetradecanoylcarnitine (C14)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.264,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.2"}]}},{"fullUrl":"Observation/1734642835717945851.52ec5e40-d07b-4918-bd1b-7dc4845614dd","resource":{"resourceType":"Observation","id":"1734642835717945851.52ec5e40-d07b-4918-bd1b-7dc4845614dd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53191-3","display":"Tetradecenoylcarnitine (C14:1)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.189,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.9"}]}},{"fullUrl":"Observation/1734642835721515655.e9fdf13b-f915-43b6-b914-c76a2c9170c0","resource":{"resourceType":"Observation","id":"1734642835721515655.e9fdf13b-f915-43b6-b914-c76a2c9170c0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53194-7","display":"Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":1.13,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835724860106.e1972cf2-ded8-44f3-a5dd-3b691a84a20b","resource":{"resourceType":"Observation","id":"1734642835724860106.e1972cf2-ded8-44f3-a5dd-3b691a84a20b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53190-5","display":"Tetradecadienoylcarnitine (C14:2)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.03,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835728591664.6f8f4ce7-ed75-4423-b5d6-f6d826b13667","resource":{"resourceType":"Observation","id":"1734642835728591664.6f8f4ce7-ed75-4423-b5d6-f6d826b13667","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50281-5","display":"3-Hydroxytetradecanoylcarnitine (C14-OH)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.021,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.2"}]}},{"fullUrl":"Observation/1734642835731845756.4261f819-24ea-4e74-b9c6-c0db5c089185","resource":{"resourceType":"Observation","id":"1734642835731845756.4261f819-24ea-4e74-b9c6-c0db5c089185","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53199-6","display":"Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":3.88,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<12"}]}},{"fullUrl":"Observation/1734642835735027652.29fdca8c-a1d4-414a-8878-fa42c159b3b6","resource":{"resourceType":"Observation","id":"1734642835735027652.29fdca8c-a1d4-414a-8878-fa42c159b3b6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53198-8","display":"Palmitoleylcarnitine (C16:1)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.371,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.4"}]}},{"fullUrl":"Observation/1734642835737321944.98a898ef-4d63-406d-bac4-fbd5742651b4","resource":{"resourceType":"Observation","id":"1734642835737321944.98a898ef-4d63-406d-bac4-fbd5742651b4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50125-4","display":"3-Hydroxypalmitoylcarnitine (C16-OH)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.030,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835739581091.e142a554-00dd-421d-b9df-941c59dab7ad","resource":{"resourceType":"Observation","id":"1734642835739581091.e142a554-00dd-421d-b9df-941c59dab7ad","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53201-0","display":"3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.00773,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.07"}]}},{"fullUrl":"Observation/1734642835741723989.c21e4681-4463-4095-97b5-6791c5ae5198","resource":{"resourceType":"Observation","id":"1734642835741723989.c21e4681-4463-4095-97b5-6791c5ae5198","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53241-6","display":"Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":1.11,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<3.5"}]}},{"fullUrl":"Observation/1734642835744517557.8732d578-4481-4f1d-b8c3-2d0bbae471cd","resource":{"resourceType":"Observation","id":"1734642835744517557.8732d578-4481-4f1d-b8c3-2d0bbae471cd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53202-8","display":"Oleoylcarnitine (C18:1)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":1.76,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7"}]}},{"fullUrl":"Observation/1734642835748030945.c1470e5e-264f-4ff2-8fc8-1b9f8af8639e","resource":{"resourceType":"Observation","id":"1734642835748030945.c1470e5e-264f-4ff2-8fc8-1b9f8af8639e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45217-7","display":"Linoleoylcarnitine (C18:2)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.15,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835751159231.2987988f-57e1-4e2b-8ddd-baddd564dab2","resource":{"resourceType":"Observation","id":"1734642835751159231.2987988f-57e1-4e2b-8ddd-baddd564dab2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50132-0","display":"3-Hydroxystearoylcarnitine (C18-OH)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.015,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835754135622.5d7fe074-ad95-4bf9-ad1d-5cbfd0ee5e4a","resource":{"resourceType":"Observation","id":"1734642835754135622.5d7fe074-ad95-4bf9-ad1d-5cbfd0ee5e4a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50113-0","display":"3-Hydroxyoleoylcarnitine (C18:1-OH)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.032,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642835757049386.d5e1dc03-14f3-4d09-9e13-40d1b0f3f2ce","resource":{"resourceType":"Observation","id":"1734642835757049386.d5e1dc03-14f3-4d09-9e13-40d1b0f3f2ce","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53160-8","display":"Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":2.3,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.9"}]}},{"fullUrl":"Observation/1734642835761114529.4f646e63-7d80-49fa-87b9-0702fa57873d","resource":{"resourceType":"Observation","id":"1734642835761114529.4f646e63-7d80-49fa-87b9-0702fa57873d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53163-2","display":"Propionylcarnitine (C3)/Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.09,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.42"}]}},{"fullUrl":"Observation/1734642835764257813.60871a6d-a6bc-43fc-9961-fc4c4ef1df91","resource":{"resourceType":"Observation","id":"1734642835764257813.60871a6d-a6bc-43fc-9961-fc4c4ef1df91","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67708-8","display":"Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.273,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.48"}]}},{"fullUrl":"Observation/1734642835767149175.e4116ccc-45b8-45ab-9659-af0eb59ef910","resource":{"resourceType":"Observation","id":"1734642835767149175.e4116ccc-45b8-45ab-9659-af0eb59ef910","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53166-5","display":"Butyrylcarnitine+Isobutyrylcarnitine (C4)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.315,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.7"}]}},{"fullUrl":"Observation/1734642835769714585.15e3f529-9399-466d-9f7b-351063db3081","resource":{"resourceType":"Observation","id":"1734642835769714585.15e3f529-9399-466d-9f7b-351063db3081","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45216-9","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.117,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835771802080.ca112406-b41b-4d50-9b9c-1f76aa6ff9c5","resource":{"resourceType":"Observation","id":"1734642835771802080.ca112406-b41b-4d50-9b9c-1f76aa6ff9c5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53240-8","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.05087,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642835773922456.a87d9766-0905-4819-b5e7-266adca96e79","resource":{"resourceType":"Observation","id":"1734642835773922456.a87d9766-0905-4819-b5e7-266adca96e79","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53170-7","display":"Tiglylcarnitine (C5:1)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.009,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.5"}]}},{"fullUrl":"Observation/1734642835776021562.d1299532-0d18-4892-b398-2ce43afbe648","resource":{"resourceType":"Observation","id":"1734642835776021562.d1299532-0d18-4892-b398-2ce43afbe648","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50106-4","display":"3-Hydroxyisovalerylcarnitine (C5-OH)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.217,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.15"}]}},{"fullUrl":"Observation/1734642835778173517.01535e92-5e00-47e4-ab3d-110a854dad56","resource":{"resourceType":"Observation","id":"1734642835778173517.01535e92-5e00-47e4-ab3d-110a854dad56","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67710-4","display":"Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.183,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642835780284095.308f13e8-a730-46bb-a3b8-ea40778e9d6f","resource":{"resourceType":"Observation","id":"1734642835780284095.308f13e8-a730-46bb-a3b8-ea40778e9d6f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75216-2","display":"Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.67033,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">0.1"}]}},{"fullUrl":"Observation/1734642835782344608.424f6717-4153-4e62-ac87-8042351f8682","resource":{"resourceType":"Observation","id":"1734642835782344608.424f6717-4153-4e62-ac87-8042351f8682","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ng/mL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"48633-2","display":"Trypsinogen I.free"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":27.20,"unit":"ng/mL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<69"}]}},{"fullUrl":"Observation/1734642835784477347.0a8ce02f-9ef6-466a-8d2e-e3302ce84725","resource":{"resourceType":"Observation","id":"1734642835784477347.0a8ce02f-9ef6-466a-8d2e-e3302ce84725","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46769-6","display":"Cystic fibrosis newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835786278986.358222a6-0f06-41da-8340-066d9180f518","resource":{"resourceType":"Observation","id":"1734642835786278986.358222a6-0f06-41da-8340-066d9180f518","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57707-2","display":"Cystic fibrosis newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835788626087.be190f26-4ec7-4ff3-9cbe-2b45da1171c8","resource":{"resourceType":"Observation","id":"1734642835788626087.be190f26-4ec7-4ff3-9cbe-2b45da1171c8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"nmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38473-5","display":"17-Hydroxyprogesterone"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":15.2,"unit":"nmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<85"}]}},{"fullUrl":"Observation/1734642835791198380.12b44a0e-d59a-4599-b787-cf8c952c79d7","resource":{"resourceType":"Observation","id":"1734642835791198380.12b44a0e-d59a-4599-b787-cf8c952c79d7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46758-9","display":"Congenital adrenal hyperplasia newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835793057767.37902251-42da-4eda-9d1f-f8cc30c48bb6","resource":{"resourceType":"Observation","id":"1734642835793057767.37902251-42da-4eda-9d1f-f8cc30c48bb6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57706-4","display":"Congenital adrenal hyperplasia newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835795058388.ef3fb068-7e38-461f-840a-55de5c14e7c9","resource":{"resourceType":"Observation","id":"1734642835795058388.ef3fb068-7e38-461f-840a-55de5c14e7c9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"mIU/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29575-8","display":"Thyrotropin"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":15.40,"unit":"mIU/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<29"}]}},{"fullUrl":"Observation/1734642835797268182.1daf15b4-f748-4976-a0a6-9a517d37c4ab","resource":{"resourceType":"Observation","id":"1734642835797268182.1daf15b4-f748-4976-a0a6-9a517d37c4ab","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46762-1","display":"Congenital hypothyroidism newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835800106975.6f9a33a8-27cb-4c06-ab6f-7bed876d63eb","resource":{"resourceType":"Observation","id":"1734642835800106975.6f9a33a8-27cb-4c06-ab6f-7bed876d63eb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57705-6","display":"Congenital hypothyroidism newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835802627231.8168e21a-25dc-43d9-8188-8943062d61ef","resource":{"resourceType":"Observation","id":"1734642835802627231.8168e21a-25dc-43d9-8188-8943062d61ef","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"enzyme units"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42906-8","display":"Galactose 1 phosphate uridyl transferase"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":273.54,"unit":"enzyme units"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">50"}]}},{"fullUrl":"Observation/1734642835804808662.c39b6f7a-5b9a-49ae-8ffe-d263a848d152","resource":{"resourceType":"Observation","id":"1734642835804808662.c39b6f7a-5b9a-49ae-8ffe-d263a848d152","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46737-3","display":"Galactosemias newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835806808592.2ee61489-aae4-46a6-a99b-4a6235df84ba","resource":{"resourceType":"Observation","id":"1734642835806808592.2ee61489-aae4-46a6-a99b-4a6235df84ba","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57704-9","display":"Galactosemias newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835809150183.7a92d9f1-8ce3-4d31-ac64-0ac7f3a48a37","resource":{"resourceType":"Observation","id":"1734642835809150183.7a92d9f1-8ce3-4d31-ac64-0ac7f3a48a37","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54104-5","display":"Hemoglobin pattern"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"FA"}},{"fullUrl":"Observation/1734642835811093036.f66355a4-96ff-4166-b67f-a902f4ee99f6","resource":{"resourceType":"Observation","id":"1734642835811093036.f66355a4-96ff-4166-b67f-a902f4ee99f6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57703-1","display":"Hemoglobin disorders newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants."}},{"fullUrl":"Observation/1734642835814495506.d6042a6a-0f25-4f28-bc8f-d43f7cc4606d","resource":{"resourceType":"Observation","id":"1734642835814495506.d6042a6a-0f25-4f28-bc8f-d43f7cc4606d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ERU"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75217-0","display":"Biotinidase [Enzymatic activity/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":73.00,"unit":"ERU"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">10"}]}},{"fullUrl":"Observation/1734642835816830655.dd7061fd-a46d-4721-a6b1-f6d34b76fd59","resource":{"resourceType":"Observation","id":"1734642835816830655.dd7061fd-a46d-4721-a6b1-f6d34b76fd59","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46761-3","display":"Biotinidase deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835818678400.3cad2e81-9353-4195-9b85-b4639f2df0a1","resource":{"resourceType":"Observation","id":"1734642835818678400.3cad2e81-9353-4195-9b85-b4639f2df0a1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57699-1","display":"Biotinidase deficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835820822640.78993f3a-2921-4f89-9519-419e2299f964","resource":{"resourceType":"Observation","id":"1734642835820822640.78993f3a-2921-4f89-9519-419e2299f964","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"copies/µL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62320-7","display":"T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":120,"unit":"copies/µL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">18"}]}},{"fullUrl":"Observation/1734642835827458874.9ad19a02-cdf3-486a-b4c8-52715b6f8ff5","resource":{"resourceType":"Observation","id":"1734642835827458874.9ad19a02-cdf3-486a-b4c8-52715b6f8ff5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62321-5","display":"Severe combined immunodeficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835829308613.9a48f9a5-c08e-4bce-83f7-e4baff4085f4","resource":{"resourceType":"Observation","id":"1734642835829308613.9a48f9a5-c08e-4bce-83f7-e4baff4085f4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62322-3","display":"Severe combined immunodeficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835831324272.429f1043-13bd-40b2-83e1-43c39ba641f3","resource":{"resourceType":"Observation","id":"1734642835831324272.429f1043-13bd-40b2-83e1-43c39ba641f3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55827-0","display":"Acid alpha glucosidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":11.43,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=1.54"}]}},{"fullUrl":"Observation/1734642835833543373.3a1f7ad9-e8d2-4ee3-b2c0-f147550c88e1","resource":{"resourceType":"Observation","id":"1734642835833543373.3a1f7ad9-e8d2-4ee3-b2c0-f147550c88e1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63415-4","display":"Pompe Disease deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835835933846.672c48cc-f970-4c68-a58e-783db9cbaf42","resource":{"resourceType":"Observation","id":"1734642835835933846.672c48cc-f970-4c68-a58e-783db9cbaf42","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63416-2","display":"Pompe Disease deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835838105198.47b4cbbc-c75c-42a2-a8b1-af0b49476367","resource":{"resourceType":"Observation","id":"1734642835838105198.47b4cbbc-c75c-42a2-a8b1-af0b49476367","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55909-6","display":"Alpha-L-iduronidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":9.33,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=0.86"}]}},{"fullUrl":"Observation/1734642835840285286.269c7d6b-46ce-44ac-8142-886554ce0e8a","resource":{"resourceType":"Observation","id":"1734642835840285286.269c7d6b-46ce-44ac-8142-886554ce0e8a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79564-1","display":"Mucopolysaccharidosis type I newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835842157116.3f2869cc-9314-4fca-bb36-30d8cf4bac45","resource":{"resourceType":"Observation","id":"1734642835842157116.3f2869cc-9314-4fca-bb36-30d8cf4bac45","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79565-8","display":"Mucopolysaccharidosis type I newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835843922075.7248c8b7-1ca6-4c8d-a7ce-d36eb1313e78","resource":{"resourceType":"Observation","id":"1734642835843922075.7248c8b7-1ca6-4c8d-a7ce-d36eb1313e78","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-60","display":"SMN1 Homozygous Deletion Analysis"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Exon 7 Present","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"Exon 7 Present"}]}},{"fullUrl":"Observation/1734642835845986376.9b3c48f8-00d5-4808-88fb-e863246b8219","resource":{"resourceType":"Observation","id":"1734642835845986376.9b3c48f8-00d5-4808-88fb-e863246b8219","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92004-1","display":"Spinal muscular atrophy newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835847829352.daf1d979-25f0-4626-a59c-d58a1cf752fb","resource":{"resourceType":"Observation","id":"1734642835847829352.daf1d979-25f0-4626-a59c-d58a1cf752fb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92003-3","display":"Spinal muscular atrophy newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"SMA Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835849882262.b094803d-6e75-40ed-afd6-42f5594411fa","resource":{"resourceType":"Observation","id":"1734642835849882262.b094803d-6e75-40ed-afd6-42f5594411fa","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79462-8","display":"Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":22.31,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=2.84"}]}},{"fullUrl":"Observation/1734642835851989233.a88495e1-8d29-4236-bc74-0abc7acc0815","resource":{"resourceType":"Observation","id":"1734642835851989233.a88495e1-8d29-4236-bc74-0abc7acc0815","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104189-6","display":"Mucopolysaccharidosis type II newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835853894515.0b1a6c16-c717-4be4-ba46-443dd67f6f09","resource":{"resourceType":"Observation","id":"1734642835853894515.0b1a6c16-c717-4be4-ba46-443dd67f6f09","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104190-4","display":"Mucopolysaccharidosis type II newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835855901248.604a24fd-9d48-4fe7-bc8d-16c5ddbe126d","resource":{"resourceType":"Observation","id":"1734642835855901248.604a24fd-9d48-4fe7-bc8d-16c5ddbe126d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104192-0","display":"Guanidinoacetate methyltransferase deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835857944600.d19ae395-b211-464f-a382-c075ce46aeaf","resource":{"resourceType":"Observation","id":"1734642835857944600.d19ae395-b211-464f-a382-c075ce46aeaf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104193-8","display":"Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835859986879.bdca2177-dd1f-46e4-ad97-2f668239e329","resource":{"resourceType":"Observation","id":"1734642835859986879.bdca2177-dd1f-46e4-ad97-2f668239e329","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"93488-5","display":"Guanidinoacetate [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":1.22,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=3"}]}},{"fullUrl":"Observation/1734642835862065086.531f3b8f-6253-4dee-9d64-10b73fd08845","resource":{"resourceType":"Observation","id":"1734642835862065086.531f3b8f-6253-4dee-9d64-10b73fd08845","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104194-6","display":"Creatine [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":411.55,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835863895038.33dd14ea-e19d-4ffe-b7b9-e8b63529536d","resource":{"resourceType":"Observation","id":"1734642835863895038.33dd14ea-e19d-4ffe-b7b9-e8b63529536d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104195-3","display":"GUAC/CRE Ratio [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":2.95},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=6"}]}},{"fullUrl":"Observation/1734642835865991418.fd9eb291-6ed5-4586-b773-e47a2259f6da","resource":{"resourceType":"Observation","id":"1734642835865991418.fd9eb291-6ed5-4586-b773-e47a2259f6da","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-32","display":"Adrenoleukodystrophy deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835867833913.65ff906c-ae0d-499b-a553-26c6e03013dd","resource":{"resourceType":"Observation","id":"1734642835867833913.65ff906c-ae0d-499b-a553-26c6e03013dd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-33","display":"Adrenoleukodystrophy deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835869941726.d0b1e57b-e016-4d29-9411-fc0f04444fbe","resource":{"resourceType":"Observation","id":"1734642835869941726.d0b1e57b-e016-4d29-9411-fc0f04444fbe","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79321-6","display":"Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-30T05:01:54Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"valueQuantity":{"value":0.138,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.47"}]}},{"fullUrl":"Specimen/1734642835879945755.3ee6708d-99bb-4e92-a30f-474a2f12d152","resource":{"resourceType":"Specimen","id":"1734642835879945755.3ee6708d-99bb-4e92-a30f-474a2f12d152","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835881328738.2ece1ee9-b366-462e-8db5-6257c715f607","resource":{"resourceType":"Specimen","id":"1734642835881328738.2ece1ee9-b366-462e-8db5-6257c715f607","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835882661087.e5b0aee2-3f66-4f93-a340-d45570cf5a2a","resource":{"resourceType":"Specimen","id":"1734642835882661087.e5b0aee2-3f66-4f93-a340-d45570cf5a2a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835883994086.44028de6-9879-47ad-be95-b0a7f10d38c2","resource":{"resourceType":"Specimen","id":"1734642835883994086.44028de6-9879-47ad-be95-b0a7f10d38c2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835885323229.ad7c245b-7e02-457a-9ea4-4cf6d2a2e0c2","resource":{"resourceType":"Specimen","id":"1734642835885323229.ad7c245b-7e02-457a-9ea4-4cf6d2a2e0c2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835886677659.bce4faf7-9b2b-4856-93b8-e4e7a6ee1781","resource":{"resourceType":"Specimen","id":"1734642835886677659.bce4faf7-9b2b-4856-93b8-e4e7a6ee1781","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835888069799.b47930f0-3abd-40f8-ad2f-e301dca9511c","resource":{"resourceType":"Specimen","id":"1734642835888069799.b47930f0-3abd-40f8-ad2f-e301dca9511c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835889386628.6c8c4572-8380-4979-8ce1-cf1b8f09f86e","resource":{"resourceType":"Specimen","id":"1734642835889386628.6c8c4572-8380-4979-8ce1-cf1b8f09f86e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835890707054.9d2a93bf-6820-483e-99c2-19c78ad02c24","resource":{"resourceType":"Specimen","id":"1734642835890707054.9d2a93bf-6820-483e-99c2-19c78ad02c24","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835892043500.d4e333c4-01d2-4035-9ee2-aae7fc8ffcb1","resource":{"resourceType":"Specimen","id":"1734642835892043500.d4e333c4-01d2-4035-9ee2-aae7fc8ffcb1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835893446521.c4e97d51-7f4a-4dea-9187-d50689ce9ff8","resource":{"resourceType":"Specimen","id":"1734642835893446521.c4e97d51-7f4a-4dea-9187-d50689ce9ff8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835894846045.9ea6ecb4-bd10-4f14-9cf8-9054fd3deaa3","resource":{"resourceType":"Specimen","id":"1734642835894846045.9ea6ecb4-bd10-4f14-9cf8-9054fd3deaa3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835896278020.66c2f212-d10f-4001-93db-1974b6283e84","resource":{"resourceType":"Specimen","id":"1734642835896278020.66c2f212-d10f-4001-93db-1974b6283e84","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835897674319.bffdfe13-2b1a-4282-97cc-b1fddd091d94","resource":{"resourceType":"Specimen","id":"1734642835897674319.bffdfe13-2b1a-4282-97cc-b1fddd091d94","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835899018790.7c60b51a-4427-41cd-a98c-a5422ae58adc","resource":{"resourceType":"Specimen","id":"1734642835899018790.7c60b51a-4427-41cd-a98c-a5422ae58adc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835900357620.8685ee81-baff-4a99-abe8-cfc067d23e48","resource":{"resourceType":"Specimen","id":"1734642835900357620.8685ee81-baff-4a99-abe8-cfc067d23e48","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835901748849.8e662fe9-7b0e-4d40-a006-6a1805ff10c3","resource":{"resourceType":"Specimen","id":"1734642835901748849.8e662fe9-7b0e-4d40-a006-6a1805ff10c3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835903222171.7a16da03-78a9-45d5-b686-1ff3acf8c25a","resource":{"resourceType":"Specimen","id":"1734642835903222171.7a16da03-78a9-45d5-b686-1ff3acf8c25a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835904754745.9c786fc7-5654-4a1b-99c3-9b4e70acec52","resource":{"resourceType":"Specimen","id":"1734642835904754745.9c786fc7-5654-4a1b-99c3-9b4e70acec52","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835906509786.467fff36-3493-4fef-a417-1e361ed7c9ec","resource":{"resourceType":"Specimen","id":"1734642835906509786.467fff36-3493-4fef-a417-1e361ed7c9ec","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835907887991.1862e56b-e527-479d-bcd5-4e48b66db064","resource":{"resourceType":"Specimen","id":"1734642835907887991.1862e56b-e527-479d-bcd5-4e48b66db064","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835909256276.3006f8e3-c5ec-4176-b52d-5f53f1fa0619","resource":{"resourceType":"Specimen","id":"1734642835909256276.3006f8e3-c5ec-4176-b52d-5f53f1fa0619","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"Specimen/1734642835910566814.cd3d4ef0-25d8-4b61-b944-ab83e982b62e","resource":{"resourceType":"Specimen","id":"1734642835910566814.cd3d4ef0-25d8-4b61-b944-ab83e982b62e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-10-18T23:35:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}}}},{"fullUrl":"ServiceRequest/1734642835927550611.15f19c4c-cd05-422d-9a24-75ab8e88a542","resource":{"resourceType":"ServiceRequest","id":"1734642835927550611.15f19c4c-cd05-422d-9a24-75ab8e88a542","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/business-event","valueCode":"RE"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/orc-common-order","extension":[{"url":"orc-21-ordering-facility-name","valueReference":{"reference":"Organization/1734642835921022460.594d5fd9-79ee-4d1b-a5d5-664dd349cb0d"}},{"url":"orc-22-ordering-facility-address","valueAddress":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"200 W ARBOR DR"}]}]}],"line":["200 W ARBOR DR"],"city":"SAN DIEGO","state":"CA","postalCode":"92103-1911"}},{"url":"orc-12-ordering-provider","valueReference":{"reference":"Practitioner/1734642835923547234.6ae72d57-222d-47be-8f61-f54ab4ded604"}}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.2","valueIdentifier":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"value":"356672001"}},{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835925466273.09bffa13-b3ed-4b50-b638-ca641dbca222"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"629813494"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"629813494"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"PractitionerRole/1734642835913129680.bb38c4b3-d1e9-42ea-9200-069b652e3e04"}}},{"fullUrl":"Practitioner/1734642835914722276.b87c6b68-9d2f-4c6d-9af8-9da82b1e96b6","resource":{"resourceType":"Practitioner","id":"1734642835914722276.b87c6b68-9d2f-4c6d-9af8-9da82b1e96b6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"},{"url":"XCN.10","valueString":"NPI"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.12"}],"identifier":[{"value":"1093050858"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Organization/1734642835917283990.25929dec-cfca-4281-a2f6-fe4fa2d7d79d","resource":{"resourceType":"Organization","id":"1734642835917283990.25929dec-cfca-4281-a2f6-fe4fa2d7d79d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R797"}]}],"identifier":[{"value":"R797"}],"name":"UCSD JACOBS MEDICAL CENTER","telecom":[{"_system":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}],"address":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"200 W ARBOR DR"}]}]}],"line":["200 W ARBOR DR"],"city":"SAN DIEGO","state":"CA","postalCode":"92103-1911"}]}},{"fullUrl":"PractitionerRole/1734642835913129680.bb38c4b3-d1e9-42ea-9200-069b652e3e04","resource":{"resourceType":"PractitionerRole","id":"1734642835913129680.bb38c4b3-d1e9-42ea-9200-069b652e3e04","practitioner":{"reference":"Practitioner/1734642835914722276.b87c6b68-9d2f-4c6d-9af8-9da82b1e96b6"},"organization":{"reference":"Organization/1734642835917283990.25929dec-cfca-4281-a2f6-fe4fa2d7d79d"}}},{"fullUrl":"Organization/1734642835921022460.594d5fd9-79ee-4d1b-a5d5-664dd349cb0d","resource":{"resourceType":"Organization","id":"1734642835921022460.594d5fd9-79ee-4d1b-a5d5-664dd349cb0d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R797"}]}],"identifier":[{"value":"R797"}],"name":"UCSD JACOBS MEDICAL CENTER"}},{"fullUrl":"Practitioner/1734642835923547234.6ae72d57-222d-47be-8f61-f54ab4ded604","resource":{"resourceType":"Practitioner","id":"1734642835923547234.6ae72d57-222d-47be-8f61-f54ab4ded604","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"},{"url":"XCN.10","valueString":"NPI"}]}],"identifier":[{"value":"1093050858"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642835925466273.09bffa13-b3ed-4b50-b638-ca641dbca222","resource":{"resourceType":"Practitioner","id":"1734642835925466273.09bffa13-b3ed-4b50-b638-ca641dbca222","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642835941000502.b7fd5885-1310-4bc8-8167-eaa7262486ca","resource":{"resourceType":"ServiceRequest","id":"1734642835941000502.b7fd5885-1310-4bc8-8167-eaa7262486ca","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835938649734.39d0e9fc-0b11-4327-ba0d-7c580998a1ae"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642835929326201.bb03c0ae-dc14-4c06-a3c1-7360c581a2b9"}}},{"fullUrl":"Practitioner/1734642835929326201.bb03c0ae-dc14-4c06-a3c1-7360c581a2b9","resource":{"resourceType":"Practitioner","id":"1734642835929326201.bb03c0ae-dc14-4c06-a3c1-7360c581a2b9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642835938649734.39d0e9fc-0b11-4327-ba0d-7c580998a1ae","resource":{"resourceType":"Practitioner","id":"1734642835938649734.39d0e9fc-0b11-4327-ba0d-7c580998a1ae","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642835949625414.edecca52-c3ce-4d43-8ece-0be736d5ce0a","resource":{"resourceType":"ServiceRequest","id":"1734642835949625414.edecca52-c3ce-4d43-8ece-0be736d5ce0a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835947557437.b6b7b218-af2d-4fb7-8d3d-0f4be4bec06b"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642835942913919.438ef309-5e3a-4b11-81d9-eb9fa15f94f8"}}},{"fullUrl":"Practitioner/1734642835942913919.438ef309-5e3a-4b11-81d9-eb9fa15f94f8","resource":{"resourceType":"Practitioner","id":"1734642835942913919.438ef309-5e3a-4b11-81d9-eb9fa15f94f8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642835947557437.b6b7b218-af2d-4fb7-8d3d-0f4be4bec06b","resource":{"resourceType":"Practitioner","id":"1734642835947557437.b6b7b218-af2d-4fb7-8d3d-0f4be4bec06b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642835958395841.a4adb492-9f43-4800-a3a5-6d63c819c192","resource":{"resourceType":"ServiceRequest","id":"1734642835958395841.a4adb492-9f43-4800-a3a5-6d63c819c192","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835956170268.f506abbd-dac8-4e0d-bef3-8c3a57399461"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642835951492906.490cf49e-e964-487e-a871-551d9a1a1a56"}}},{"fullUrl":"Practitioner/1734642835951492906.490cf49e-e964-487e-a871-551d9a1a1a56","resource":{"resourceType":"Practitioner","id":"1734642835951492906.490cf49e-e964-487e-a871-551d9a1a1a56","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642835956170268.f506abbd-dac8-4e0d-bef3-8c3a57399461","resource":{"resourceType":"Practitioner","id":"1734642835956170268.f506abbd-dac8-4e0d-bef3-8c3a57399461","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642835967830452.6b2c683a-67fb-45af-8256-554caff3c3db","resource":{"resourceType":"ServiceRequest","id":"1734642835967830452.6b2c683a-67fb-45af-8256-554caff3c3db","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835965617783.6072efcd-83c9-47b5-9b1e-85e75d74fab7"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642835960326641.c3484962-98f3-402e-a86a-95c686539980"}}},{"fullUrl":"Practitioner/1734642835960326641.c3484962-98f3-402e-a86a-95c686539980","resource":{"resourceType":"Practitioner","id":"1734642835960326641.c3484962-98f3-402e-a86a-95c686539980","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642835965617783.6072efcd-83c9-47b5-9b1e-85e75d74fab7","resource":{"resourceType":"Practitioner","id":"1734642835965617783.6072efcd-83c9-47b5-9b1e-85e75d74fab7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642835976762751.4671e756-9bc6-47e2-99a9-87cbff04170f","resource":{"resourceType":"ServiceRequest","id":"1734642835976762751.4671e756-9bc6-47e2-99a9-87cbff04170f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835974669356.c25a023d-f810-44a8-94a3-7f917dc51b48"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642835969770830.8b470986-56bb-4d57-807f-3346bce9c056"}}},{"fullUrl":"Practitioner/1734642835969770830.8b470986-56bb-4d57-807f-3346bce9c056","resource":{"resourceType":"Practitioner","id":"1734642835969770830.8b470986-56bb-4d57-807f-3346bce9c056","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642835974669356.c25a023d-f810-44a8-94a3-7f917dc51b48","resource":{"resourceType":"Practitioner","id":"1734642835974669356.c25a023d-f810-44a8-94a3-7f917dc51b48","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642835985781282.f3e1b584-8656-44fa-9cbb-414ec5d518aa","resource":{"resourceType":"ServiceRequest","id":"1734642835985781282.f3e1b584-8656-44fa-9cbb-414ec5d518aa","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835983706351.a96a1f45-25d9-4713-85e1-28b8a8597bdd"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642835978576162.9e42d4ce-9801-4973-9ab5-6d085a7c551e"}}},{"fullUrl":"Practitioner/1734642835978576162.9e42d4ce-9801-4973-9ab5-6d085a7c551e","resource":{"resourceType":"Practitioner","id":"1734642835978576162.9e42d4ce-9801-4973-9ab5-6d085a7c551e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642835983706351.a96a1f45-25d9-4713-85e1-28b8a8597bdd","resource":{"resourceType":"Practitioner","id":"1734642835983706351.a96a1f45-25d9-4713-85e1-28b8a8597bdd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642835994828507.bac52049-d0ec-4b36-9476-265990236057","resource":{"resourceType":"ServiceRequest","id":"1734642835994828507.bac52049-d0ec-4b36-9476-265990236057","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642835992787009.10d0ec2d-6cd6-4c65-a79a-b84dd727b5c6"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642835987540992.b337dec4-9563-4909-a246-d59b85ce6337"}}},{"fullUrl":"Practitioner/1734642835987540992.b337dec4-9563-4909-a246-d59b85ce6337","resource":{"resourceType":"Practitioner","id":"1734642835987540992.b337dec4-9563-4909-a246-d59b85ce6337","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642835992787009.10d0ec2d-6cd6-4c65-a79a-b84dd727b5c6","resource":{"resourceType":"Practitioner","id":"1734642835992787009.10d0ec2d-6cd6-4c65-a79a-b84dd727b5c6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836003534371.0bd71a28-7194-446c-87bf-1feb5ed240b9","resource":{"resourceType":"ServiceRequest","id":"1734642836003534371.0bd71a28-7194-446c-87bf-1feb5ed240b9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836001364192.16a5c7ce-9a56-411b-b189-334fd622c4fc"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642835996635956.de24db83-14f5-4249-ba95-a50d5399c6e6"}}},{"fullUrl":"Practitioner/1734642835996635956.de24db83-14f5-4249-ba95-a50d5399c6e6","resource":{"resourceType":"Practitioner","id":"1734642835996635956.de24db83-14f5-4249-ba95-a50d5399c6e6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836001364192.16a5c7ce-9a56-411b-b189-334fd622c4fc","resource":{"resourceType":"Practitioner","id":"1734642836001364192.16a5c7ce-9a56-411b-b189-334fd622c4fc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836012482840.055e9451-e361-44d2-8377-6225bda2e501","resource":{"resourceType":"ServiceRequest","id":"1734642836012482840.055e9451-e361-44d2-8377-6225bda2e501","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836010241127.6701a7d2-1633-468a-ba29-4e07d173349b"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836005560761.b95af861-1c4c-4273-930a-195386da25c8"}}},{"fullUrl":"Practitioner/1734642836005560761.b95af861-1c4c-4273-930a-195386da25c8","resource":{"resourceType":"Practitioner","id":"1734642836005560761.b95af861-1c4c-4273-930a-195386da25c8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836010241127.6701a7d2-1633-468a-ba29-4e07d173349b","resource":{"resourceType":"Practitioner","id":"1734642836010241127.6701a7d2-1633-468a-ba29-4e07d173349b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836025615636.ac170df8-8fbf-43ab-a56f-be6923b5dfe9","resource":{"resourceType":"ServiceRequest","id":"1734642836025615636.ac170df8-8fbf-43ab-a56f-be6923b5dfe9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836023358844.e3dfdefc-6bc0-4b61-a78d-87bf0b8b349c"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836014581185.6ff10732-22df-4b41-a6ba-ba278aea37dd"}}},{"fullUrl":"Practitioner/1734642836014581185.6ff10732-22df-4b41-a6ba-ba278aea37dd","resource":{"resourceType":"Practitioner","id":"1734642836014581185.6ff10732-22df-4b41-a6ba-ba278aea37dd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836023358844.e3dfdefc-6bc0-4b61-a78d-87bf0b8b349c","resource":{"resourceType":"Practitioner","id":"1734642836023358844.e3dfdefc-6bc0-4b61-a78d-87bf0b8b349c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836035456439.3297a780-9e64-4129-9ea6-bd9baff3fff6","resource":{"resourceType":"ServiceRequest","id":"1734642836035456439.3297a780-9e64-4129-9ea6-bd9baff3fff6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836032780201.c8f2dbcb-3483-4678-a390-1c525cba3956"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836028037477.84cad915-cc7b-47f4-bf76-6bf5c8fddf5f"}}},{"fullUrl":"Practitioner/1734642836028037477.84cad915-cc7b-47f4-bf76-6bf5c8fddf5f","resource":{"resourceType":"Practitioner","id":"1734642836028037477.84cad915-cc7b-47f4-bf76-6bf5c8fddf5f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836032780201.c8f2dbcb-3483-4678-a390-1c525cba3956","resource":{"resourceType":"Practitioner","id":"1734642836032780201.c8f2dbcb-3483-4678-a390-1c525cba3956","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836045415173.3608f522-f1dc-443d-8cd4-bce75c901f92","resource":{"resourceType":"ServiceRequest","id":"1734642836045415173.3608f522-f1dc-443d-8cd4-bce75c901f92","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836042759283.95191095-4718-4251-ae12-eaf02f987cab"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836038078205.cb5f53ea-84ef-4d55-a554-7c580c1c52c2"}}},{"fullUrl":"Practitioner/1734642836038078205.cb5f53ea-84ef-4d55-a554-7c580c1c52c2","resource":{"resourceType":"Practitioner","id":"1734642836038078205.cb5f53ea-84ef-4d55-a554-7c580c1c52c2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836042759283.95191095-4718-4251-ae12-eaf02f987cab","resource":{"resourceType":"Practitioner","id":"1734642836042759283.95191095-4718-4251-ae12-eaf02f987cab","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836056452590.3492bfb2-2f73-4054-bb68-2b241edde680","resource":{"resourceType":"ServiceRequest","id":"1734642836056452590.3492bfb2-2f73-4054-bb68-2b241edde680","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836053858816.f13f93ba-683f-4621-9bec-3b6ff32c90f2"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836047488270.ce632d19-87ef-49aa-8d6c-dbc64072435a"}}},{"fullUrl":"Practitioner/1734642836047488270.ce632d19-87ef-49aa-8d6c-dbc64072435a","resource":{"resourceType":"Practitioner","id":"1734642836047488270.ce632d19-87ef-49aa-8d6c-dbc64072435a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836053858816.f13f93ba-683f-4621-9bec-3b6ff32c90f2","resource":{"resourceType":"Practitioner","id":"1734642836053858816.f13f93ba-683f-4621-9bec-3b6ff32c90f2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836065986547.c0024f68-3a31-462d-8c4c-1f8eb40364d2","resource":{"resourceType":"ServiceRequest","id":"1734642836065986547.c0024f68-3a31-462d-8c4c-1f8eb40364d2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836063885066.4fdac6b0-3673-454b-be39-3c47ad99c406"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836058251192.d6154dbf-a713-4851-b5e7-7da65d51328b"}}},{"fullUrl":"Practitioner/1734642836058251192.d6154dbf-a713-4851-b5e7-7da65d51328b","resource":{"resourceType":"Practitioner","id":"1734642836058251192.d6154dbf-a713-4851-b5e7-7da65d51328b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836063885066.4fdac6b0-3673-454b-be39-3c47ad99c406","resource":{"resourceType":"Practitioner","id":"1734642836063885066.4fdac6b0-3673-454b-be39-3c47ad99c406","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836076773403.efc4681d-b823-4b5f-9e64-cfeed8c3674a","resource":{"resourceType":"ServiceRequest","id":"1734642836076773403.efc4681d-b823-4b5f-9e64-cfeed8c3674a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836073556401.f853219e-8dde-4318-a5a9-8ae0289c4b84"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836068261212.ab0b29d1-d48a-4c5e-a083-cc3c3298c40e"}}},{"fullUrl":"Practitioner/1734642836068261212.ab0b29d1-d48a-4c5e-a083-cc3c3298c40e","resource":{"resourceType":"Practitioner","id":"1734642836068261212.ab0b29d1-d48a-4c5e-a083-cc3c3298c40e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836073556401.f853219e-8dde-4318-a5a9-8ae0289c4b84","resource":{"resourceType":"Practitioner","id":"1734642836073556401.f853219e-8dde-4318-a5a9-8ae0289c4b84","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836085204032.3d025d7f-c9f7-44ab-b378-d8e847c9f112","resource":{"resourceType":"ServiceRequest","id":"1734642836085204032.3d025d7f-c9f7-44ab-b378-d8e847c9f112","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836083086551.64e63981-f816-4d43-ab75-ca106ff4a9c0"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836078576043.9fdcc34b-850a-49d1-92d0-4acd76e48db8"}}},{"fullUrl":"Practitioner/1734642836078576043.9fdcc34b-850a-49d1-92d0-4acd76e48db8","resource":{"resourceType":"Practitioner","id":"1734642836078576043.9fdcc34b-850a-49d1-92d0-4acd76e48db8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836083086551.64e63981-f816-4d43-ab75-ca106ff4a9c0","resource":{"resourceType":"Practitioner","id":"1734642836083086551.64e63981-f816-4d43-ab75-ca106ff4a9c0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836093684704.09c2781f-863b-4633-b9d0-254380db9652","resource":{"resourceType":"ServiceRequest","id":"1734642836093684704.09c2781f-863b-4633-b9d0-254380db9652","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836091421470.c57e7997-3156-452d-a1de-fc12947db6c0"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836086977798.3a78e560-72b8-4dc9-9f9c-3c0b7112bde7"}}},{"fullUrl":"Practitioner/1734642836086977798.3a78e560-72b8-4dc9-9f9c-3c0b7112bde7","resource":{"resourceType":"Practitioner","id":"1734642836086977798.3a78e560-72b8-4dc9-9f9c-3c0b7112bde7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836091421470.c57e7997-3156-452d-a1de-fc12947db6c0","resource":{"resourceType":"Practitioner","id":"1734642836091421470.c57e7997-3156-452d-a1de-fc12947db6c0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836104663571.4150e042-8d2d-467e-aecb-0808af0028dc","resource":{"resourceType":"ServiceRequest","id":"1734642836104663571.4150e042-8d2d-467e-aecb-0808af0028dc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836101449394.9e5e17e4-1e5c-48b6-925d-1529a8bffdb8"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836095687129.cb130e9f-e569-4849-9879-883260c1e2d7"}}},{"fullUrl":"Practitioner/1734642836095687129.cb130e9f-e569-4849-9879-883260c1e2d7","resource":{"resourceType":"Practitioner","id":"1734642836095687129.cb130e9f-e569-4849-9879-883260c1e2d7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836101449394.9e5e17e4-1e5c-48b6-925d-1529a8bffdb8","resource":{"resourceType":"Practitioner","id":"1734642836101449394.9e5e17e4-1e5c-48b6-925d-1529a8bffdb8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836118459249.6fd7dcd8-2885-4096-92ca-9fa2d58741ba","resource":{"resourceType":"ServiceRequest","id":"1734642836118459249.6fd7dcd8-2885-4096-92ca-9fa2d58741ba","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836116330468.70813813-8b8f-47f8-b98f-d05c0c139740"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836111219233.c43b56e6-ea7f-4103-876e-b0117b563be5"}}},{"fullUrl":"Practitioner/1734642836111219233.c43b56e6-ea7f-4103-876e-b0117b563be5","resource":{"resourceType":"Practitioner","id":"1734642836111219233.c43b56e6-ea7f-4103-876e-b0117b563be5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836116330468.70813813-8b8f-47f8-b98f-d05c0c139740","resource":{"resourceType":"Practitioner","id":"1734642836116330468.70813813-8b8f-47f8-b98f-d05c0c139740","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836126731581.9639d51d-4694-444e-bfd8-f7db800c297a","resource":{"resourceType":"ServiceRequest","id":"1734642836126731581.9639d51d-4694-444e-bfd8-f7db800c297a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836124660838.c4497539-e198-4195-b0cd-20680c1001cd"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836120364372.101d9f1f-0b20-4019-ba92-a7e21083b3e4"}}},{"fullUrl":"Practitioner/1734642836120364372.101d9f1f-0b20-4019-ba92-a7e21083b3e4","resource":{"resourceType":"Practitioner","id":"1734642836120364372.101d9f1f-0b20-4019-ba92-a7e21083b3e4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836124660838.c4497539-e198-4195-b0cd-20680c1001cd","resource":{"resourceType":"Practitioner","id":"1734642836124660838.c4497539-e198-4195-b0cd-20680c1001cd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836135727690.a5409a06-8973-446d-9c0e-cf6ce30f4415","resource":{"resourceType":"ServiceRequest","id":"1734642836135727690.a5409a06-8973-446d-9c0e-cf6ce30f4415","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836132852599.86fa7dd3-7d9d-46dd-94e2-070441b17583"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836128525094.5478cb97-38bb-473c-b840-7740952ecb80"}}},{"fullUrl":"Practitioner/1734642836128525094.5478cb97-38bb-473c-b840-7740952ecb80","resource":{"resourceType":"Practitioner","id":"1734642836128525094.5478cb97-38bb-473c-b840-7740952ecb80","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836132852599.86fa7dd3-7d9d-46dd-94e2-070441b17583","resource":{"resourceType":"Practitioner","id":"1734642836132852599.86fa7dd3-7d9d-46dd-94e2-070441b17583","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"ServiceRequest/1734642836144984498.b950bb69-4d55-4b65-a036-941ce079722b","resource":{"resourceType":"ServiceRequest","id":"1734642836144984498.b950bb69-4d55-4b65-a036-941ce079722b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836142663055.a1ab8a7b-4324-43bb-b7dd-178be5837024"}},{"url":"OBR.7","valueDateTime":"2024-10-18T23:35:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]}},{"url":"OBR.22","valueString":"20241030050154"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"requester":{"reference":"Practitioner/1734642836138180169.30d3418b-38b0-4d21-af04-63cee30b882d"}}},{"fullUrl":"Practitioner/1734642836138180169.30d3418b-38b0-4d21-af04-63cee30b882d","resource":{"resourceType":"Practitioner","id":"1734642836138180169.30d3418b-38b0-4d21-af04-63cee30b882d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"Practitioner/1734642836142663055.a1ab8a7b-4324-43bb-b7dd-178be5837024","resource":{"resourceType":"Practitioner","id":"1734642836142663055.a1ab8a7b-4324-43bb-b7dd-178be5837024","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"RICHARD"}]}],"name":[{"family":"SILVA","given":["RICHARD"]}]}},{"fullUrl":"DiagnosticReport/1734642836152439978.c27b00f3-e85a-4103-a989-e69a6c752aa0","resource":{"resourceType":"DiagnosticReport","id":"1734642836152439978.c27b00f3-e85a-4103-a989-e69a6c752aa0","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"629813494"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"629813494"}],"basedOn":[{"reference":"ServiceRequest/1734642835927550611.15f19c4c-cd05-422d-9a24-75ab8e88a542"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835879945755.3ee6708d-99bb-4e92-a30f-474a2f12d152"}]}},{"fullUrl":"DiagnosticReport/1734642836155870350.f904bf10-c9bb-461c-a2fb-670399604fd6","resource":{"resourceType":"DiagnosticReport","id":"1734642836155870350.f904bf10-c9bb-461c-a2fb-670399604fd6","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642835941000502.b7fd5885-1310-4bc8-8167-eaa7262486ca"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835881328738.2ece1ee9-b366-462e-8db5-6257c715f607"}],"result":[{"reference":"Observation/1734642835577334424.adac7e49-c88b-4c5c-bda3-24bfaf62119c"},{"reference":"Observation/1734642835582945910.f0c81174-275c-4f6d-9003-10c4c6cee05f"},{"reference":"Observation/1734642835585626967.e771b53b-9a27-423b-bd97-b0cc10b0fc17"},{"reference":"Observation/1734642835587943501.7508be73-3956-4c30-9fb2-9a420d225bbd"},{"reference":"Observation/1734642835590874687.0cc4344e-4653-4c68-a6f6-028b9a5cc0a5"},{"reference":"Observation/1734642835592969425.13fe95c5-d463-4a95-9ae7-acd437529f9a"},{"reference":"Observation/1734642835595033996.cbdcdf22-3e1c-4658-bf95-66d53413f145"}]}},{"fullUrl":"DiagnosticReport/1734642836159725770.57b4f680-c5b0-4705-85dd-f6f743270117","resource":{"resourceType":"DiagnosticReport","id":"1734642836159725770.57b4f680-c5b0-4705-85dd-f6f743270117","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642835949625414.edecca52-c3ce-4d43-8ece-0be736d5ce0a"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835882661087.e5b0aee2-3f66-4f93-a340-d45570cf5a2a"}],"result":[{"reference":"Observation/1734642835597001375.991eef6e-98ae-4728-b2a9-eb4dc15ddfe5"},{"reference":"Observation/1734642835599231657.6cd136e8-cdd9-478e-b513-a69682d52dcf"},{"reference":"Observation/1734642835601376860.20738e16-4487-4275-9d1e-2f1d7899a49b"},{"reference":"Observation/1734642835603619726.92836d62-2c43-4fd5-862e-68ccb53f0583"},{"reference":"Observation/1734642835606051145.294d5bf0-4e62-482d-b456-f5bd54ddf19e"},{"reference":"Observation/1734642835608401953.3951d7cb-f4c3-43af-a159-eb1c1bf9c2e9"},{"reference":"Observation/1734642835610633307.d65b7233-9e23-4cbc-9126-9fc566126230"},{"reference":"Observation/1734642835612775124.0d6a0867-1ae6-48c5-a587-cb41a3e52476"},{"reference":"Observation/1734642835615633444.91b240be-e8aa-4061-9564-89f9e6e0d5bb"},{"reference":"Observation/1734642835617901266.8e54520a-9875-4c84-b38a-3fbd6709a7a7"},{"reference":"Observation/1734642835619938276.c720e577-5b06-4c8d-8217-8272358029fb"}]}},{"fullUrl":"DiagnosticReport/1734642836163296335.30331610-9333-48d7-aced-405f3bbc49b3","resource":{"resourceType":"DiagnosticReport","id":"1734642836163296335.30331610-9333-48d7-aced-405f3bbc49b3","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642835958395841.a4adb492-9f43-4800-a3a5-6d63c819c192"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835883994086.44028de6-9879-47ad-be95-b0a7f10d38c2"}]}},{"fullUrl":"DiagnosticReport/1734642836170026284.eac8ce49-4557-408b-b25c-603aafd0fbc6","resource":{"resourceType":"DiagnosticReport","id":"1734642836170026284.eac8ce49-4557-408b-b25c-603aafd0fbc6","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642835967830452.6b2c683a-67fb-45af-8256-554caff3c3db"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835885323229.ad7c245b-7e02-457a-9ea4-4cf6d2a2e0c2"}],"result":[{"reference":"Observation/1734642835622290176.0ed5d39e-4af1-41f8-98da-7b956ad1aca9"},{"reference":"Observation/1734642835624587333.d71f9ce0-54c1-4fb0-9c27-bc6838cc8934"},{"reference":"Observation/1734642835630433513.ff02305e-15bd-446f-8015-32a1ccd7995c"},{"reference":"Observation/1734642835632748323.c4c14367-0fae-4255-b87c-e5b6722fce27"},{"reference":"Observation/1734642835635217113.8be785a8-0375-46eb-94a3-7f2cf7a0dff0"},{"reference":"Observation/1734642835637771543.7b620553-e589-49ea-a380-6a8b7474b329"},{"reference":"Observation/1734642835642122852.6a859c86-d8f1-4d0f-a2d3-b4fdd58a36f4"},{"reference":"Observation/1734642835648986983.5fe75d08-ac6d-4ba1-8a89-ac1fa3be0c7c"},{"reference":"Observation/1734642835651324957.ffdae7fc-33c6-4c8b-b7a6-334986cf820f"},{"reference":"Observation/1734642835653464299.ecdb8485-1be4-4bc7-9921-70ef134ea027"},{"reference":"Observation/1734642835655634949.ada7fa6f-d208-4f95-ae2d-c3f94913127e"},{"reference":"Observation/1734642835657787706.19dec618-554e-4232-8b8f-718feb2c0810"},{"reference":"Observation/1734642835659892012.7868a556-8258-4cd3-b653-542182d8fcae"},{"reference":"Observation/1734642835662076538.a387bfe4-b363-4221-89f6-d0f2ea71e213"},{"reference":"Observation/1734642835664344942.f66efdf8-7f8a-4e48-b80b-0e8f843d1a96"},{"reference":"Observation/1734642835667556273.9a9e4a0b-7125-471c-8001-360221a9cef2"},{"reference":"Observation/1734642835670226080.0806c275-8281-4657-8edd-7f65f0a1d343"},{"reference":"Observation/1734642835672541752.67036c13-e742-4a9e-8a48-18221261335e"},{"reference":"Observation/1734642835674459107.60d5c469-6e3b-4dbf-a66d-04ff03f052af"}]}},{"fullUrl":"DiagnosticReport/1734642836174794145.4b4522ad-a76c-40a1-b33f-e956981336b3","resource":{"resourceType":"DiagnosticReport","id":"1734642836174794145.4b4522ad-a76c-40a1-b33f-e956981336b3","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642835976762751.4671e756-9bc6-47e2-99a9-87cbff04170f"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835886677659.bce4faf7-9b2b-4856-93b8-e4e7a6ee1781"}],"result":[{"reference":"Observation/1734642835676555097.d17991b9-f738-4c03-bc2d-eca221d2d49c"},{"reference":"Observation/1734642835678329685.bb4ed8d6-7e4d-4959-972f-a5bc6f2b63d1"}]}},{"fullUrl":"DiagnosticReport/1734642836181665440.cf879ec4-f8ad-4f96-a9af-c27df992d494","resource":{"resourceType":"DiagnosticReport","id":"1734642836181665440.cf879ec4-f8ad-4f96-a9af-c27df992d494","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642835985781282.f3e1b584-8656-44fa-9cbb-414ec5d518aa"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835888069799.b47930f0-3abd-40f8-ad2f-e301dca9511c"}],"result":[{"reference":"Observation/1734642835680351065.d01da517-1280-4a4b-a9fa-42f5aba5354e"},{"reference":"Observation/1734642835683365418.cf9c3b1d-9ef4-4b0e-a8c8-bce7fd481781"},{"reference":"Observation/1734642835686681365.bc96eed3-e560-4185-9b8e-654ec88f2776"},{"reference":"Observation/1734642835693717720.57ef4762-7f1a-49c1-afac-2de54e42e258"},{"reference":"Observation/1734642835696077585.0a2bdff7-f737-4624-8c1b-9cfe764fca68"},{"reference":"Observation/1734642835698315441.7cb7425f-81df-4530-a5c2-76c97210fef3"},{"reference":"Observation/1734642835700583725.13e5ba61-8a59-482f-865b-4054fe5a03e1"},{"reference":"Observation/1734642835702659758.ecf642b8-29ec-4734-a174-beea3fafc7a9"},{"reference":"Observation/1734642835704761468.d497718f-0b69-40cc-9b9f-7dc62c83c950"},{"reference":"Observation/1734642835707309036.fe794609-acd5-4805-9440-2ae4c749af09"},{"reference":"Observation/1734642835709563824.fb6d07a6-0c21-455c-b5c5-6a6d07184265"},{"reference":"Observation/1734642835712047531.949c4810-8298-4150-9a2f-60508ec56a7a"},{"reference":"Observation/1734642835714330091.533e0fb7-63d2-4b19-8f6e-837cd278b3e5"},{"reference":"Observation/1734642835717945851.52ec5e40-d07b-4918-bd1b-7dc4845614dd"},{"reference":"Observation/1734642835721515655.e9fdf13b-f915-43b6-b914-c76a2c9170c0"},{"reference":"Observation/1734642835724860106.e1972cf2-ded8-44f3-a5dd-3b691a84a20b"},{"reference":"Observation/1734642835728591664.6f8f4ce7-ed75-4423-b5d6-f6d826b13667"},{"reference":"Observation/1734642835731845756.4261f819-24ea-4e74-b9c6-c0db5c089185"},{"reference":"Observation/1734642835735027652.29fdca8c-a1d4-414a-8878-fa42c159b3b6"},{"reference":"Observation/1734642835737321944.98a898ef-4d63-406d-bac4-fbd5742651b4"},{"reference":"Observation/1734642835739581091.e142a554-00dd-421d-b9df-941c59dab7ad"},{"reference":"Observation/1734642835741723989.c21e4681-4463-4095-97b5-6791c5ae5198"},{"reference":"Observation/1734642835744517557.8732d578-4481-4f1d-b8c3-2d0bbae471cd"},{"reference":"Observation/1734642835748030945.c1470e5e-264f-4ff2-8fc8-1b9f8af8639e"},{"reference":"Observation/1734642835751159231.2987988f-57e1-4e2b-8ddd-baddd564dab2"},{"reference":"Observation/1734642835754135622.5d7fe074-ad95-4bf9-ad1d-5cbfd0ee5e4a"}]}},{"fullUrl":"DiagnosticReport/1734642836185431782.2ccfdb9d-6d9f-4b94-b827-a9430b5275bc","resource":{"resourceType":"DiagnosticReport","id":"1734642836185431782.2ccfdb9d-6d9f-4b94-b827-a9430b5275bc","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642835994828507.bac52049-d0ec-4b36-9476-265990236057"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835889386628.6c8c4572-8380-4979-8ce1-cf1b8f09f86e"}],"result":[{"reference":"Observation/1734642835757049386.d5e1dc03-14f3-4d09-9e13-40d1b0f3f2ce"},{"reference":"Observation/1734642835761114529.4f646e63-7d80-49fa-87b9-0702fa57873d"},{"reference":"Observation/1734642835764257813.60871a6d-a6bc-43fc-9961-fc4c4ef1df91"},{"reference":"Observation/1734642835767149175.e4116ccc-45b8-45ab-9659-af0eb59ef910"},{"reference":"Observation/1734642835769714585.15e3f529-9399-466d-9f7b-351063db3081"},{"reference":"Observation/1734642835771802080.ca112406-b41b-4d50-9b9c-1f76aa6ff9c5"},{"reference":"Observation/1734642835773922456.a87d9766-0905-4819-b5e7-266adca96e79"},{"reference":"Observation/1734642835776021562.d1299532-0d18-4892-b398-2ce43afbe648"},{"reference":"Observation/1734642835778173517.01535e92-5e00-47e4-ab3d-110a854dad56"},{"reference":"Observation/1734642835780284095.308f13e8-a730-46bb-a3b8-ea40778e9d6f"}]}},{"fullUrl":"DiagnosticReport/1734642836188456093.6b6e2444-1cb6-4e00-bd3a-aed46f112a17","resource":{"resourceType":"DiagnosticReport","id":"1734642836188456093.6b6e2444-1cb6-4e00-bd3a-aed46f112a17","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836003534371.0bd71a28-7194-446c-87bf-1feb5ed240b9"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835890707054.9d2a93bf-6820-483e-99c2-19c78ad02c24"}],"result":[{"reference":"Observation/1734642835782344608.424f6717-4153-4e62-ac87-8042351f8682"},{"reference":"Observation/1734642835784477347.0a8ce02f-9ef6-466a-8d2e-e3302ce84725"},{"reference":"Observation/1734642835786278986.358222a6-0f06-41da-8340-066d9180f518"}]}},{"fullUrl":"DiagnosticReport/1734642836191457080.1b9335a6-456e-4b5a-b8fa-c0246b1b35f5","resource":{"resourceType":"DiagnosticReport","id":"1734642836191457080.1b9335a6-456e-4b5a-b8fa-c0246b1b35f5","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836012482840.055e9451-e361-44d2-8377-6225bda2e501"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835892043500.d4e333c4-01d2-4035-9ee2-aae7fc8ffcb1"}],"result":[{"reference":"Observation/1734642835788626087.be190f26-4ec7-4ff3-9cbe-2b45da1171c8"},{"reference":"Observation/1734642835791198380.12b44a0e-d59a-4599-b787-cf8c952c79d7"},{"reference":"Observation/1734642835793057767.37902251-42da-4eda-9d1f-f8cc30c48bb6"}]}},{"fullUrl":"DiagnosticReport/1734642836195354398.dfe86879-7556-4767-8397-31a3feac8176","resource":{"resourceType":"DiagnosticReport","id":"1734642836195354398.dfe86879-7556-4767-8397-31a3feac8176","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836025615636.ac170df8-8fbf-43ab-a56f-be6923b5dfe9"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835893446521.c4e97d51-7f4a-4dea-9187-d50689ce9ff8"}],"result":[{"reference":"Observation/1734642835795058388.ef3fb068-7e38-461f-840a-55de5c14e7c9"},{"reference":"Observation/1734642835797268182.1daf15b4-f748-4976-a0a6-9a517d37c4ab"},{"reference":"Observation/1734642835800106975.6f9a33a8-27cb-4c06-ab6f-7bed876d63eb"}]}},{"fullUrl":"DiagnosticReport/1734642836198703929.4c2049ad-8f8e-4639-948d-4ca1db4e92e4","resource":{"resourceType":"DiagnosticReport","id":"1734642836198703929.4c2049ad-8f8e-4639-948d-4ca1db4e92e4","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836035456439.3297a780-9e64-4129-9ea6-bd9baff3fff6"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835894846045.9ea6ecb4-bd10-4f14-9cf8-9054fd3deaa3"}],"result":[{"reference":"Observation/1734642835802627231.8168e21a-25dc-43d9-8188-8943062d61ef"},{"reference":"Observation/1734642835804808662.c39b6f7a-5b9a-49ae-8ffe-d263a848d152"},{"reference":"Observation/1734642835806808592.2ee61489-aae4-46a6-a99b-4a6235df84ba"}]}},{"fullUrl":"DiagnosticReport/1734642836201721948.3960cf5c-983f-4859-9e35-8c3ac6cd0fe4","resource":{"resourceType":"DiagnosticReport","id":"1734642836201721948.3960cf5c-983f-4859-9e35-8c3ac6cd0fe4","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836045415173.3608f522-f1dc-443d-8cd4-bce75c901f92"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835896278020.66c2f212-d10f-4001-93db-1974b6283e84"}],"result":[{"reference":"Observation/1734642835809150183.7a92d9f1-8ce3-4d31-ac64-0ac7f3a48a37"},{"reference":"Observation/1734642835811093036.f66355a4-96ff-4166-b67f-a902f4ee99f6"}]}},{"fullUrl":"DiagnosticReport/1734642836204801984.350c0e54-ac24-4e7f-838f-71b69a75dd67","resource":{"resourceType":"DiagnosticReport","id":"1734642836204801984.350c0e54-ac24-4e7f-838f-71b69a75dd67","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836056452590.3492bfb2-2f73-4054-bb68-2b241edde680"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835897674319.bffdfe13-2b1a-4282-97cc-b1fddd091d94"}],"result":[{"reference":"Observation/1734642835814495506.d6042a6a-0f25-4f28-bc8f-d43f7cc4606d"},{"reference":"Observation/1734642835816830655.dd7061fd-a46d-4721-a6b1-f6d34b76fd59"},{"reference":"Observation/1734642835818678400.3cad2e81-9353-4195-9b85-b4639f2df0a1"}]}},{"fullUrl":"DiagnosticReport/1734642836208398798.60ac234a-0077-45c4-8fa7-838532fcb1a3","resource":{"resourceType":"DiagnosticReport","id":"1734642836208398798.60ac234a-0077-45c4-8fa7-838532fcb1a3","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836065986547.c0024f68-3a31-462d-8c4c-1f8eb40364d2"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835899018790.7c60b51a-4427-41cd-a98c-a5422ae58adc"}],"result":[{"reference":"Observation/1734642835820822640.78993f3a-2921-4f89-9519-419e2299f964"},{"reference":"Observation/1734642835827458874.9ad19a02-cdf3-486a-b4c8-52715b6f8ff5"},{"reference":"Observation/1734642835829308613.9a48f9a5-c08e-4bce-83f7-e4baff4085f4"}]}},{"fullUrl":"DiagnosticReport/1734642836211461451.b445825b-9bc5-4f0e-8c02-2efec15eea80","resource":{"resourceType":"DiagnosticReport","id":"1734642836211461451.b445825b-9bc5-4f0e-8c02-2efec15eea80","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836076773403.efc4681d-b823-4b5f-9e64-cfeed8c3674a"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835900357620.8685ee81-baff-4a99-abe8-cfc067d23e48"}],"result":[{"reference":"Observation/1734642835831324272.429f1043-13bd-40b2-83e1-43c39ba641f3"},{"reference":"Observation/1734642835833543373.3a1f7ad9-e8d2-4ee3-b2c0-f147550c88e1"},{"reference":"Observation/1734642835835933846.672c48cc-f970-4c68-a58e-783db9cbaf42"}]}},{"fullUrl":"DiagnosticReport/1734642836214831090.ee9eb06b-e557-4f06-a2f9-fa45857f934e","resource":{"resourceType":"DiagnosticReport","id":"1734642836214831090.ee9eb06b-e557-4f06-a2f9-fa45857f934e","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836085204032.3d025d7f-c9f7-44ab-b378-d8e847c9f112"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835901748849.8e662fe9-7b0e-4d40-a006-6a1805ff10c3"}],"result":[{"reference":"Observation/1734642835838105198.47b4cbbc-c75c-42a2-a8b1-af0b49476367"},{"reference":"Observation/1734642835840285286.269c7d6b-46ce-44ac-8142-886554ce0e8a"},{"reference":"Observation/1734642835842157116.3f2869cc-9314-4fca-bb36-30d8cf4bac45"}]}},{"fullUrl":"DiagnosticReport/1734642836222755552.3e6f8397-1b58-4c1a-b40d-beef72dfd7f2","resource":{"resourceType":"DiagnosticReport","id":"1734642836222755552.3e6f8397-1b58-4c1a-b40d-beef72dfd7f2","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836093684704.09c2781f-863b-4633-b9d0-254380db9652"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835903222171.7a16da03-78a9-45d5-b686-1ff3acf8c25a"}],"result":[{"reference":"Observation/1734642835843922075.7248c8b7-1ca6-4c8d-a7ce-d36eb1313e78"},{"reference":"Observation/1734642835845986376.9b3c48f8-00d5-4808-88fb-e863246b8219"},{"reference":"Observation/1734642835847829352.daf1d979-25f0-4626-a59c-d58a1cf752fb"}]}},{"fullUrl":"DiagnosticReport/1734642836226132955.b2820374-c2e0-4889-9afe-bdc2a1dca75b","resource":{"resourceType":"DiagnosticReport","id":"1734642836226132955.b2820374-c2e0-4889-9afe-bdc2a1dca75b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836104663571.4150e042-8d2d-467e-aecb-0808af0028dc"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835904754745.9c786fc7-5654-4a1b-99c3-9b4e70acec52"}],"result":[{"reference":"Observation/1734642835849882262.b094803d-6e75-40ed-afd6-42f5594411fa"},{"reference":"Observation/1734642835851989233.a88495e1-8d29-4236-bc74-0abc7acc0815"},{"reference":"Observation/1734642835853894515.0b1a6c16-c717-4be4-ba46-443dd67f6f09"}]}},{"fullUrl":"DiagnosticReport/1734642836229369304.f3163167-c3a2-4db6-a5d0-b34a381c8f2a","resource":{"resourceType":"DiagnosticReport","id":"1734642836229369304.f3163167-c3a2-4db6-a5d0-b34a381c8f2a","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836118459249.6fd7dcd8-2885-4096-92ca-9fa2d58741ba"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835906509786.467fff36-3493-4fef-a417-1e361ed7c9ec"}],"result":[{"reference":"Observation/1734642835855901248.604a24fd-9d48-4fe7-bc8d-16c5ddbe126d"},{"reference":"Observation/1734642835857944600.d19ae395-b211-464f-a382-c075ce46aeaf"}]}},{"fullUrl":"DiagnosticReport/1734642836232969475.9f766400-c9d9-4ce5-ad62-e68dc8dfcba3","resource":{"resourceType":"DiagnosticReport","id":"1734642836232969475.9f766400-c9d9-4ce5-ad62-e68dc8dfcba3","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836126731581.9639d51d-4694-444e-bfd8-f7db800c297a"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835907887991.1862e56b-e527-479d-bcd5-4e48b66db064"}],"result":[{"reference":"Observation/1734642835859986879.bdca2177-dd1f-46e4-ad97-2f668239e329"},{"reference":"Observation/1734642835862065086.531f3b8f-6253-4dee-9d64-10b73fd08845"},{"reference":"Observation/1734642835863895038.33dd14ea-e19d-4ffe-b7b9-e8b63529536d"}]}},{"fullUrl":"DiagnosticReport/1734642836236317372.7970abee-6352-427f-ad38-6bd422457de4","resource":{"resourceType":"DiagnosticReport","id":"1734642836236317372.7970abee-6352-427f-ad38-6bd422457de4","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836135727690.a5409a06-8973-446d-9c0e-cf6ce30f4415"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835909256276.3006f8e3-c5ec-4176-b52d-5f53f1fa0619"}],"result":[{"reference":"Observation/1734642835865991418.fd9eb291-6ed5-4586-b773-e47a2259f6da"},{"reference":"Observation/1734642835867833913.65ff906c-ae0d-499b-a553-26c6e03013dd"}]}},{"fullUrl":"DiagnosticReport/1734642836239591572.8e42c1d3-2acd-4fb2-bd9f-83f12fbcaa69","resource":{"resourceType":"DiagnosticReport","id":"1734642836239591572.8e42c1d3-2acd-4fb2-bd9f-83f12fbcaa69","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"356672001"}],"basedOn":[{"reference":"ServiceRequest/1734642836144984498.b950bb69-4d55-4b65-a036-941ce079722b"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835573447595.42413a9f-547e-450a-a566-80548335f1bb"},"effectiveDateTime":"2024-10-18T23:35:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202410182335"}]},"issued":"2024-10-30T05:01:54Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241030050154"}]},"specimen":[{"reference":"Specimen/1734642835910566814.cd3d4ef0-25d8-4b61-b944-ab83e982b62e"}],"result":[{"reference":"Observation/1734642835869941726.d0b1e57b-e016-4d29-9411-fc0f04444fbe"}]}}]}
diff --git a/examples/Test/Automated/GoldenCopy/Expected/005_ORU_R01_golden_copy_expected_out_of_range.fhir b/examples/Test/Automated/GoldenCopy/Expected/005_ORU_R01_golden_copy_expected_out_of_range.fhir
deleted file mode 100644
index fe3143868..000000000
--- a/examples/Test/Automated/GoldenCopy/Expected/005_ORU_R01_golden_copy_expected_out_of_range.fhir
+++ /dev/null
@@ -1 +0,0 @@
-{"resourceType":"Bundle","id":"1734642835818825320.534a9032-ba87-4bdb-9a42-fc1d2d43715e","meta":{"lastUpdated":"2024-12-19T21:13:55.818+00:00"},"identifier":{"system":"https://reportstream.cdc.gov/prime-router","value":"005"},"type":"message","timestamp":"2024-10-18T05:00:17.000+00:00","entry":[{"fullUrl":"MessageHeader/1734642835820163649.d346235d-84f1-44c2-8f0d-36f991315f26","resource":{"resourceType":"MessageHeader","id":"1734642835820163649.d346235d-84f1-44c2-8f0d-36f991315f26","meta":{"tag":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0103","code":"N"}]},"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/msh-message-header","extension":[{"url":"MSH.7","valueString":"20241018050017"}]}],"eventCoding":{"system":"http://terminology.hl7.org/CodeSystem/v2-0003","code":"R01","display":"ORU^R01^ORU_R01"},"destination":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id","valueString":"9414049"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id-type","valueString":"L,M,N"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.5"}],"name":"SISHIERECEIVER","receiver":{"reference":"Organization/1734642835819852235.c571e1b3-fe0d-4f46-8857-84a728e6dc99"}}],"sender":{"reference":"Organization/1734642835819067885.7264a948-3f3b-46fc-b834-0a1e75e6c738"},"source":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"SISGDSP"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.3"}],"name":"SISGDSP","_endpoint":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}}},{"fullUrl":"Organization/1734642835819067885.7264a948-3f3b-46fc-b834-0a1e75e6c738","resource":{"resourceType":"Organization","id":"1734642835819067885.7264a948-3f3b-46fc-b834-0a1e75e6c738","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Organization/1734642835819852235.c571e1b3-fe0d-4f46-8857-84a728e6dc99","resource":{"resourceType":"Organization","id":"1734642835819852235.c571e1b3-fe0d-4f46-8857-84a728e6dc99","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.6"}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.2,HD.3"}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301","code":"L,M,N"}]},"value":"automated-staging-test-receiver-id"}]}},{"fullUrl":"Provenance/1734642835821339795.15c2e814-69d8-42c4-9922-e77903ca3ac3","resource":{"resourceType":"Provenance","id":"1734642835821339795.15c2e814-69d8-42c4-9922-e77903ca3ac3","target":[{"reference":"MessageHeader/1734642835820163649.d346235d-84f1-44c2-8f0d-36f991315f26"},{"reference":"DiagnosticReport/1734642836428415372.6590f295-01a4-4daf-8dbe-5bd3622a42e0"},{"reference":"DiagnosticReport/1734642836431845444.b43c3ad3-80b9-4953-8e18-f633dc149e5f"},{"reference":"DiagnosticReport/1734642836435304150.acabebcf-c09a-4a07-831e-36a3a4272bb7"},{"reference":"DiagnosticReport/1734642836438843987.f3795167-105b-4938-addb-6b6b55da9cca"},{"reference":"DiagnosticReport/1734642836441766538.3d5e3d2c-d384-4d90-bae3-c3e267021f88"},{"reference":"DiagnosticReport/1734642836445954190.7119e2b8-859d-4a82-a1d7-cca3136dbecc"},{"reference":"DiagnosticReport/1734642836448954536.99e8049b-82a6-48d5-85c6-590001827d87"},{"reference":"DiagnosticReport/1734642836453527821.28cfe23b-02a1-47c7-829c-e175148e22cf"},{"reference":"DiagnosticReport/1734642836457059804.8101d8e9-73fe-4d92-9ae3-d96d52c24b21"},{"reference":"DiagnosticReport/1734642836460082833.78fc2d69-f794-4288-bfd2-8ae0e241dafa"},{"reference":"DiagnosticReport/1734642836463081496.2b7dca61-1b60-47db-9418-7da5ce8fbf61"},{"reference":"DiagnosticReport/1734642836466120635.370ae00a-25fe-4fa5-a324-f887bbe2a856"},{"reference":"DiagnosticReport/1734642836469187225.77d97fba-4680-41c3-a53d-f3f9fafc8176"},{"reference":"DiagnosticReport/1734642836472186179.2764089d-c788-49cd-a6aa-970788903941"},{"reference":"DiagnosticReport/1734642836475203036.31a490a5-9b63-446e-8f9e-eb2d9fd2721e"},{"reference":"DiagnosticReport/1734642836478257283.e475367b-b110-4a83-971d-f42c9a4a8087"},{"reference":"DiagnosticReport/1734642836481289398.62ce13b4-be11-4411-992a-d77837e17758"},{"reference":"DiagnosticReport/1734642836484595237.313b8922-17ff-47f8-9036-1dd0bb5c0312"},{"reference":"DiagnosticReport/1734642836487660084.7412cbdc-131a-4a55-bc32-826e6c7d55b0"},{"reference":"DiagnosticReport/1734642836490747644.d0b2216d-bb2b-48ee-952f-26eb62e1a6a0"},{"reference":"DiagnosticReport/1734642836493766444.1ef481f0-049d-4035-9636-8ba48034e6e1"},{"reference":"DiagnosticReport/1734642836496970072.faa9ccef-26ff-4273-a633-f56f219b527a"},{"reference":"DiagnosticReport/1734642836500347314.577024eb-c231-462c-821a-e8479ec274fa"},{"reference":"DiagnosticReport/1734642836503350836.519e95d2-5b56-4697-b578-e00abbfe9c74"}],"recorded":"2024-10-18T05:00:17Z","activity":{"coding":[{"display":"ORU^R01^ORU_R01"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"author"}]},"who":{"reference":"Organization/1734642835821162452.537f5845-ade5-4fb1-8a22-84be3254bf1b"}}]}},{"fullUrl":"Organization/1734642835821162452.537f5845-ade5-4fb1-8a22-84be3254bf1b","resource":{"resourceType":"Organization","id":"1734642835821162452.537f5845-ade5-4fb1-8a22-84be3254bf1b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Provenance/1734642835822135557.64f58d82-8e0f-4a41-a9d4-50ea5e8302b5","resource":{"resourceType":"Provenance","id":"1734642835822135557.64f58d82-8e0f-4a41-a9d4-50ea5e8302b5","recorded":"2024-12-19T21:13:55Z","policy":["http://hl7.org/fhir/uv/v2mappings/message-oru-r01-to-bundle"],"activity":{"coding":[{"code":"v2-FHIR transformation"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"assembler"}]},"who":{"reference":"Organization/1734642835821839762.1f61c5d1-11ec-4342-9713-0b5de2240f26"}}]}},{"fullUrl":"Organization/1734642835821839762.1f61c5d1-11ec-4342-9713-0b5de2240f26","resource":{"resourceType":"Organization","id":"1734642835821839762.1f61c5d1-11ec-4342-9713-0b5de2240f26","identifier":[{"value":"CDC PRIME - Atlanta"},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301"}]},"system":"urn:ietf:rfc:3986","value":"2.16.840.1.114222.4.1.237821"}]}},{"fullUrl":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac","resource":{"resourceType":"Patient","id":"1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cx-identifier","extension":[{"url":"CX.5","valueString":"MR"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"PID.3"}],"type":{"coding":[{"code":"MR"}]},"value":"32550867","assigner":{"reference":"Organization/1734642835826932973.ec8b6fe2-94c2-4702-b715-d2c2a4110c5c"}}],"name":[{"family":"*****PII REMOVED******"}],"contact":[{"name":{"family":"*****PII REMOVED******"}}]}},{"fullUrl":"Organization/1734642835826932973.ec8b6fe2-94c2-4702-b715-d2c2a4110c5c","resource":{"resourceType":"Organization","id":"1734642835826932973.ec8b6fe2-94c2-4702-b715-d2c2a4110c5c","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"1013163542&NPI"}]}},{"fullUrl":"Provenance/1734642835832758797.ad87aabb-58b5-4a3d-b373-e749b2e46c31","resource":{"resourceType":"Provenance","id":"1734642835832758797.ad87aabb-58b5-4a3d-b373-e749b2e46c31","target":[{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"}],"recorded":"2024-12-19T21:13:55Z","activity":{"coding":[{"system":"https://terminology.hl7.org/CodeSystem/v3-DataOperation","code":"UPDATE"}]}}},{"fullUrl":"RelatedPerson/1734642835834177778.6a1f1931-0152-46d4-883a-8124f43f0033","resource":{"resourceType":"RelatedPerson","id":"1734642835834177778.6a1f1931-0152-46d4-883a-8124f43f0033","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"NK1"}],"patient":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"name":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"NK1.2"}],"family":"*****PII REMOVED******"}]}},{"fullUrl":"Observation/1734642835838348458.43fb29c2-a1a2-46ee-b73d-60e75cfa96f7","resource":{"resourceType":"Observation","id":"1734642835838348458.43fb29c2-a1a2-46ee-b73d-60e75cfa96f7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57721-3","display":"Reason for lab test in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12421-6","display":"Initial screen"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835841845246.4b04227d-09c0-4420-9c5e-e761434e1f65","resource":{"resourceType":"Observation","id":"1734642835841845246.4b04227d-09c0-4420-9c5e-e761434e1f65","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57718-9","display":"Sample quality of Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12432-3","display":"Acceptable"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835845365186.de231997-4300-4ff5-af9b-cbdd94007344","resource":{"resourceType":"Observation","id":"1734642835845365186.de231997-4300-4ff5-af9b-cbdd94007344","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57130-7","display":"Newborn screening report - overall interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18944-1","display":"Screen is out of range for at least one condition"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835848852014.ee590f13-b4e4-4667-ae32-32dd35b642a9","resource":{"resourceType":"Observation","id":"1734642835848852014.ee590f13-b4e4-4667-ae32-32dd35b642a9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57131-5","display":"Newborn conditions with positive markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA16207-5","display":"Hemoglobinopathies"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835852399236.826318e3-458b-4bcc-a558-a9b733f4aabc","resource":{"resourceType":"Observation","id":"1734642835852399236.826318e3-458b-4bcc-a558-a9b733f4aabc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57720-5","display":"Newborn conditions with equivocal markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835855517012.cdf88ff7-2886-4ac0-93de-0c14600848f9","resource":{"resourceType":"Observation","id":"1734642835855517012.cdf88ff7-2886-4ac0-93de-0c14600848f9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57724-7","display":"Newborn screening short narrative summary"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"ACTION REQUIRED\\\\.br\\\\\\\\.br\\\\NBS Testing Lab - ALLIED LABORATORY \\\\\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\\\.br\\\\\\\\.br\\\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\\\.br\\\\\\\\.br\\\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\\\.br\\\\\\\\.br\\\\Follow-up:\\\\.br\\\\\\\\.br\\\\Hb: An immediate referral to a CCS Hematology Center or a pediatric hematologist familiar with alpha thalassemia and Hb H disease is strongly recommended for this infant. \\\\.br\\\\\\\\.br\\\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\\\.br\\\\\\\\.br\\\\Methods and Limitations:\\\\.br\\\\\\\\.br\\\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\\\.br\\\\Attention Healthcare Provider:\\\\.br\\\\\\\\.br\\\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\\\.br\\\\\\\\.br\\","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835858631442.b3f1cb03-7d61-45d8-9f49-d0d51c019afc","resource":{"resourceType":"Observation","id":"1734642835858631442.b3f1cb03-7d61-45d8-9f49-d0d51c019afc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57129-9","display":"Full newborn screening summary report for display or printing"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835861724723.ddaac99b-c83c-4166-bf66-3abe0caf2011","resource":{"resourceType":"Observation","id":"1734642835861724723.ddaac99b-c83c-4166-bf66-3abe0caf2011","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"ST"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57716-3","display":"State printed on filter paper card [Identifier] in NBS card"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"CA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835865234865.4a0cf0e0-0356-4533-b278-286cffaf37d2","resource":{"resourceType":"Observation","id":"1734642835865234865.4a0cf0e0-0356-4533-b278-286cffaf37d2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"grams"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"8339-4","display":"Birthweight"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":2658,"unit":"grams"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835868488365.95c78f92-bd79-427b-81b2-f58d6b4dec65","resource":{"resourceType":"Observation","id":"1734642835868488365.95c78f92-bd79-427b-81b2-f58d6b4dec65","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57715-5","display":"Time of birth"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueTime":"0027","_valueTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"0027"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835871986425.131c2949-3134-4848-975b-0db4dab5cd69","resource":{"resourceType":"Observation","id":"1734642835871986425.131c2949-3134-4848-975b-0db4dab5cd69","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57722-1","display":"Birth plurality of Pregnancy"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12411-7","display":"Singleton"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835875460509.fe5bc4f0-03dc-4fff-869f-4265efbbcd25","resource":{"resourceType":"Observation","id":"1734642835875460509.fe5bc4f0-03dc-4fff-869f-4265efbbcd25","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"hour(s)"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"73806-2","display":"Newborn age in hours"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":28,"unit":"hour(s)"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835879131162.6fe4e08b-aa38-4172-b2ab-622ad5bea544","resource":{"resourceType":"Observation","id":"1734642835879131162.6fe4e08b-aa38-4172-b2ab-622ad5bea544","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57713-0","display":"Infant NICU factors that affect newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835882630193.254cde97-1b38-4f9b-a44a-ffa9d6f2ddf3","resource":{"resourceType":"Observation","id":"1734642835882630193.254cde97-1b38-4f9b-a44a-ffa9d6f2ddf3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67704-7","display":"Feeding types"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA16914-6","display":"Breast milk"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835885686875.54ed88d3-9a3a-41ac-a26d-999bc55565e8","resource":{"resourceType":"Observation","id":"1734642835885686875.54ed88d3-9a3a-41ac-a26d-999bc55565e8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-5","display":"Accession Number"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"272-95-009/21-2024-12","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835888799281.17429e42-1961-4d38-84fb-df544a3a024b","resource":{"resourceType":"Observation","id":"1734642835888799281.17429e42-1961-4d38-84fb-df544a3a024b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62324-9","display":"Post-discharge provider name"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"MELISSA SCALA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835891927197.09bbcc6f-cb0a-495d-a0fd-3d5a637a6560","resource":{"resourceType":"Observation","id":"1734642835891927197.09bbcc6f-cb0a-495d-a0fd-3d5a637a6560","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62327-2","display":"Post-discharge provider practice address"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835895699811.ac8311f2-11d0-4139-8e75-0d862789fa8e","resource":{"resourceType":"Observation","id":"1734642835895699811.ac8311f2-11d0-4139-8e75-0d862789fa8e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47633-3","display":"Glycine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":926,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835899291305.a684af57-f50d-4b53-8536-877c33b50d96","resource":{"resourceType":"Observation","id":"1734642835899291305.a684af57-f50d-4b53-8536-877c33b50d96","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53150-9","display":"Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":588,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1000"}]}},{"fullUrl":"Observation/1734642835903069350.b34b8876-7d82-4bbd-bc2e-27ed68fb2f0d","resource":{"resourceType":"Observation","id":"1734642835903069350.b34b8876-7d82-4bbd-bc2e-27ed68fb2f0d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47799-2","display":"Valine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":79.4,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835906837265.b0d7f760-36f1-4fc4-be37-ff54bf7d45b2","resource":{"resourceType":"Observation","id":"1734642835906837265.b0d7f760-36f1-4fc4-be37-ff54bf7d45b2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53151-7","display":"Valine/Phenylalanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":1.29739,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.3"}]}},{"fullUrl":"Observation/1734642835910461792.59d3fdd6-b67f-453f-873d-5933012c9c51","resource":{"resourceType":"Observation","id":"1734642835910461792.59d3fdd6-b67f-453f-873d-5933012c9c51","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53152-5","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":99.2,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<230"}]}},{"fullUrl":"Observation/1734642835914078924.b9721f8a-8cca-4307-aaf6-bc33777c448a","resource":{"resourceType":"Observation","id":"1734642835914078924.b9721f8a-8cca-4307-aaf6-bc33777c448a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53154-1","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.17,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.35"}]}},{"fullUrl":"Observation/1734642835917701457.cfcd58d7-2d26-48a1-bb55-b18357110171","resource":{"resourceType":"Observation","id":"1734642835917701457.cfcd58d7-2d26-48a1-bb55-b18357110171","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29573-3","display":"Phenylalanine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":61.2,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<175"}]}},{"fullUrl":"Observation/1734642835921297601.f23ad939-3185-45ba-b799-12cb69a62edb","resource":{"resourceType":"Observation","id":"1734642835921297601.f23ad939-3185-45ba-b799-12cb69a62edb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35572-7","display":"Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":1.77,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2.6"}]}},{"fullUrl":"Observation/1734642835924956562.8a51eada-1b83-4132-aeb9-9e897bcfa7dc","resource":{"resourceType":"Observation","id":"1734642835924956562.8a51eada-1b83-4132-aeb9-9e897bcfa7dc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35571-9","display":"Tyrosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":34.7,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<680"}]}},{"fullUrl":"Observation/1734642835928560610.f11761e5-32ac-4329-8350-d8f336dc2841","resource":{"resourceType":"Observation","id":"1734642835928560610.f11761e5-32ac-4329-8350-d8f336dc2841","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53231-7","display":"Succinylacetone [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.33,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<6.1"}]}},{"fullUrl":"Observation/1734642835936166881.0e234ccb-6d15-49c1-8d85-3e19f162470a","resource":{"resourceType":"Observation","id":"1734642835936166881.0e234ccb-6d15-49c1-8d85-3e19f162470a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47700-0","display":"Methionine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":20.4,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.3-100"}]}},{"fullUrl":"Observation/1734642835938621093.ee5cd03c-4948-4a32-8164-441ef939a2a9","resource":{"resourceType":"Observation","id":"1734642835938621093.ee5cd03c-4948-4a32-8164-441ef939a2a9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42892-0","display":"Citrulline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":10,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"5-49"}]}},{"fullUrl":"Observation/1734642835940962653.12eda31d-70a3-441a-af2a-28141156b3bb","resource":{"resourceType":"Observation","id":"1734642835940962653.12eda31d-70a3-441a-af2a-28141156b3bb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54092-2","display":"Citrulline/Arginine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":2.79,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.8"}]}},{"fullUrl":"Observation/1734642835943140036.2289d344-2124-423a-8324-9e135ed95b3d","resource":{"resourceType":"Observation","id":"1734642835943140036.2289d344-2124-423a-8324-9e135ed95b3d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53155-8","display":"Asparagine+Ornithine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":43,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<800"}]}},{"fullUrl":"Observation/1734642835945246025.c0de0d70-8645-4428-ba13-12b45b8930a3","resource":{"resourceType":"Observation","id":"1734642835945246025.c0de0d70-8645-4428-ba13-12b45b8930a3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75215-4","display":"Ornithine/Citrulline [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":4.44,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835947343138.ae725d80-ad0e-4919-8cb1-d7565941812b","resource":{"resourceType":"Observation","id":"1734642835947343138.ae725d80-ad0e-4919-8cb1-d7565941812b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47562-4","display":"Arginine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":3,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<63"}]}},{"fullUrl":"Observation/1734642835949495904.b12fa676-b353-4141-bdea-ca5aea9ad88b","resource":{"resourceType":"Observation","id":"1734642835949495904.b12fa676-b353-4141-bdea-ca5aea9ad88b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75214-7","display":"Arginine/Ornithine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.08,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.9"}]}},{"fullUrl":"Observation/1734642835951835531.e31d4936-c9dd-4449-961f-91c9451b6a81","resource":{"resourceType":"Observation","id":"1734642835951835531.e31d4936-c9dd-4449-961f-91c9451b6a81","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47732-3","display":"Proline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":187,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1500"}]}},{"fullUrl":"Observation/1734642835953756684.b3b3c9f3-7b72-4744-b798-68ff47d63356","resource":{"resourceType":"Observation","id":"1734642835953756684.b3b3c9f3-7b72-4744-b798-68ff47d63356","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57710-6","display":"Amino acidemias newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835955917426.1cde4345-8899-40b8-8ff8-4e433393dcd8","resource":{"resourceType":"Observation","id":"1734642835955917426.1cde4345-8899-40b8-8ff8-4e433393dcd8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58088-6","display":"Acylcarnitine newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835957880868.bbc96ac7-3744-47f0-808b-09c118350019","resource":{"resourceType":"Observation","id":"1734642835957880868.bbc96ac7-3744-47f0-808b-09c118350019","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58093-6","display":"Acylcarnitine newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835959899623.1ece5b91-20e1-4c7f-a96a-6365931b5a9c","resource":{"resourceType":"Observation","id":"1734642835959899623.1ece5b91-20e1-4c7f-a96a-6365931b5a9c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38481-8","display":"Carnitine.free (C0)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":39.6,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.4-125"}]}},{"fullUrl":"Observation/1734642835962463120.73f4c091-a419-4206-9afc-a32499ccbbe2","resource":{"resourceType":"Observation","id":"1734642835962463120.73f4c091-a419-4206-9afc-a32499ccbbe2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53235-8","display":"Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":5.35,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<70"}]}},{"fullUrl":"Observation/1734642835964812345.8d6a15f2-71d7-4ed4-afc6-da14e26b77aa","resource":{"resourceType":"Observation","id":"1734642835964812345.8d6a15f2-71d7-4ed4-afc6-da14e26b77aa","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50157-7","display":"Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":34.7,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"10-80"}]}},{"fullUrl":"Observation/1734642835966984488.bd58a5fd-e687-4bf3-b0fd-b3e31acfcf99","resource":{"resourceType":"Observation","id":"1734642835966984488.bd58a5fd-e687-4bf3-b0fd-b3e31acfcf99","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75212-1","display":"Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":3.27536,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.6"}]}},{"fullUrl":"Observation/1734642835969111537.1eea330d-e9e8-4c4a-a9b2-1f1541a5ad8f","resource":{"resourceType":"Observation","id":"1734642835969111537.1eea330d-e9e8-4c4a-a9b2-1f1541a5ad8f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45211-0","display":"Hexanoylcarnitine (C6)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.100,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642835971804997.244ed723-05f6-4536-8789-637c500de1a7","resource":{"resourceType":"Observation","id":"1734642835971804997.244ed723-05f6-4536-8789-637c500de1a7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53175-6","display":"Octanoylcarnitine (C8)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.075,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835974458253.c66715d8-79f1-4446-be41-939ceb8f8b97","resource":{"resourceType":"Observation","id":"1734642835974458253.c66715d8-79f1-4446-be41-939ceb8f8b97","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53177-2","display":"Octanoylcarnitine (C8)/Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":1.09,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835976904089.fb7f61f4-2721-4abc-9c7b-26a7cbc10af8","resource":{"resourceType":"Observation","id":"1734642835976904089.fb7f61f4-2721-4abc-9c7b-26a7cbc10af8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53174-9","display":"Octenoylcarnitine (C8:1)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.163,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835979548217.e7fe453b-12a1-44f4-a3b8-b37095ef4ae3","resource":{"resourceType":"Observation","id":"1734642835979548217.e7fe453b-12a1-44f4-a3b8-b37095ef4ae3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45197-1","display":"Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.069,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734642835982249112.ad92ca2f-cfb4-40ab-b7ce-b944af3e8cde","resource":{"resourceType":"Observation","id":"1734642835982249112.ad92ca2f-cfb4-40ab-b7ce-b944af3e8cde","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45198-9","display":"Decenoylcarnitine (C10:1)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.057,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734642835984907707.60807b7e-f053-4dc3-837f-09887470d85c","resource":{"resourceType":"Observation","id":"1734642835984907707.60807b7e-f053-4dc3-837f-09887470d85c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45199-7","display":"Dodecanoylcarnitine (C12)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.118,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2"}]}},{"fullUrl":"Observation/1734642835987496421.d5cd8995-f998-42cb-a3ca-ce0a1166a6fc","resource":{"resourceType":"Observation","id":"1734642835987496421.d5cd8995-f998-42cb-a3ca-ce0a1166a6fc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45200-3","display":"Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.06,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835989963036.a7394af9-094b-4902-a20a-0fe9201175da","resource":{"resourceType":"Observation","id":"1734642835989963036.a7394af9-094b-4902-a20a-0fe9201175da","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53192-1","display":"Tetradecanoylcarnitine (C14)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.394,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.2"}]}},{"fullUrl":"Observation/1734642835992538956.3f21d58a-11a9-43cc-a553-2935221156d3","resource":{"resourceType":"Observation","id":"1734642835992538956.3f21d58a-11a9-43cc-a553-2935221156d3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53191-3","display":"Tetradecenoylcarnitine (C14:1)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.130,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.9"}]}},{"fullUrl":"Observation/1734642835994923608.548f1b1b-6afc-463a-9c33-e9ce81ad97fc","resource":{"resourceType":"Observation","id":"1734642835994923608.548f1b1b-6afc-463a-9c33-e9ce81ad97fc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53194-7","display":"Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":2.32,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835997573677.80a6dfc6-fa09-4358-815a-dfe757959f09","resource":{"resourceType":"Observation","id":"1734642835997573677.80a6dfc6-fa09-4358-815a-dfe757959f09","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53190-5","display":"Tetradecadienoylcarnitine (C14:2)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.03,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642835999720703.41a6d967-ca64-4620-8712-30ab2f044fdd","resource":{"resourceType":"Observation","id":"1734642835999720703.41a6d967-ca64-4620-8712-30ab2f044fdd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50281-5","display":"3-Hydroxytetradecanoylcarnitine (C14-OH)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.026,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.2"}]}},{"fullUrl":"Observation/1734642836002687025.4f2f8fcb-9a4a-4f1f-a8c0-15de90b82d98","resource":{"resourceType":"Observation","id":"1734642836002687025.4f2f8fcb-9a4a-4f1f-a8c0-15de90b82d98","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53199-6","display":"Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":5.52,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<12"}]}},{"fullUrl":"Observation/1734642836004850091.e50d0cb3-2299-41e8-bfb2-7d3cd8c9061f","resource":{"resourceType":"Observation","id":"1734642836004850091.e50d0cb3-2299-41e8-bfb2-7d3cd8c9061f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53198-8","display":"Palmitoleylcarnitine (C16:1)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.245,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.4"}]}},{"fullUrl":"Observation/1734642836006922607.f157c594-316e-4ad2-a17d-6c8d4f744f41","resource":{"resourceType":"Observation","id":"1734642836006922607.f157c594-316e-4ad2-a17d-6c8d4f744f41","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50125-4","display":"3-Hydroxypalmitoylcarnitine (C16-OH)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.042,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642836009344819.27f90a06-82ed-4274-add4-afe438e2671a","resource":{"resourceType":"Observation","id":"1734642836009344819.27f90a06-82ed-4274-add4-afe438e2671a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53201-0","display":"3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.00761,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.07"}]}},{"fullUrl":"Observation/1734642836011736344.7bb83079-f18b-4ab0-a7f7-36af690cf1d9","resource":{"resourceType":"Observation","id":"1734642836011736344.7bb83079-f18b-4ab0-a7f7-36af690cf1d9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53241-6","display":"Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":2.13,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<3.5"}]}},{"fullUrl":"Observation/1734642836014288509.034f071a-2364-49c7-9e4f-c2b9e6b15e69","resource":{"resourceType":"Observation","id":"1734642836014288509.034f071a-2364-49c7-9e4f-c2b9e6b15e69","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53202-8","display":"Oleoylcarnitine (C18:1)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":1.89,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7"}]}},{"fullUrl":"Observation/1734642836020924763.4b54fab8-026d-4850-a9a8-6f43840e571d","resource":{"resourceType":"Observation","id":"1734642836020924763.4b54fab8-026d-4850-a9a8-6f43840e571d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45217-7","display":"Linoleoylcarnitine (C18:2)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.29,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836023364107.7bd159a4-9cba-43ea-8dc1-2b75b155250c","resource":{"resourceType":"Observation","id":"1734642836023364107.7bd159a4-9cba-43ea-8dc1-2b75b155250c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50132-0","display":"3-Hydroxystearoylcarnitine (C18-OH)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.032,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642836026388919.f459fd2a-e75c-46d2-a0f1-acce29409873","resource":{"resourceType":"Observation","id":"1734642836026388919.f459fd2a-e75c-46d2-a0f1-acce29409873","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50113-0","display":"3-Hydroxyoleoylcarnitine (C18:1-OH)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.047,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734642836029102116.af3487b7-83d4-417b-afbc-23b988c99cb7","resource":{"resourceType":"Observation","id":"1734642836029102116.af3487b7-83d4-417b-afbc-23b988c99cb7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53160-8","display":"Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":4.2,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.9"}]}},{"fullUrl":"Observation/1734642836031499131.0ef60ce2-0887-4e14-87e6-70602f11724c","resource":{"resourceType":"Observation","id":"1734642836031499131.0ef60ce2-0887-4e14-87e6-70602f11724c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53163-2","display":"Propionylcarnitine (C3)/Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.12,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.42"}]}},{"fullUrl":"Observation/1734642836034335821.b39a86ae-626b-4de3-baf9-7c4b3bdb918f","resource":{"resourceType":"Observation","id":"1734642836034335821.b39a86ae-626b-4de3-baf9-7c4b3bdb918f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67708-8","display":"Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.226,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.48"}]}},{"fullUrl":"Observation/1734642836037044299.5e380009-0025-4a93-8a79-9157e9ee5091","resource":{"resourceType":"Observation","id":"1734642836037044299.5e380009-0025-4a93-8a79-9157e9ee5091","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53166-5","display":"Butyrylcarnitine+Isobutyrylcarnitine (C4)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.424,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.7"}]}},{"fullUrl":"Observation/1734642836039552863.a1775955-14a6-4d3d-9d00-1d1576b13957","resource":{"resourceType":"Observation","id":"1734642836039552863.a1775955-14a6-4d3d-9d00-1d1576b13957","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45216-9","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.247,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734642836042252094.e4c7436e-2453-4d6f-bf3f-154218717c33","resource":{"resourceType":"Observation","id":"1734642836042252094.e4c7436e-2453-4d6f-bf3f-154218717c33","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53240-8","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.05881,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642836045172871.81c16756-2212-4514-b387-82ba937fae20","resource":{"resourceType":"Observation","id":"1734642836045172871.81c16756-2212-4514-b387-82ba937fae20","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53170-7","display":"Tiglylcarnitine (C5:1)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.008,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.5"}]}},{"fullUrl":"Observation/1734642836047619739.dfa41c8d-ee19-47ba-9771-62f7680ee29e","resource":{"resourceType":"Observation","id":"1734642836047619739.dfa41c8d-ee19-47ba-9771-62f7680ee29e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50106-4","display":"3-Hydroxyisovalerylcarnitine (C5-OH)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.287,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.15"}]}},{"fullUrl":"Observation/1734642836050378483.896e302c-e7e0-462e-ac40-e786d95bed3a","resource":{"resourceType":"Observation","id":"1734642836050378483.896e302c-e7e0-462e-ac40-e786d95bed3a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67710-4","display":"Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.179,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734642836052717969.aa4e6425-a295-4d7c-82a0-f966e6899c2b","resource":{"resourceType":"Observation","id":"1734642836052717969.aa4e6425-a295-4d7c-82a0-f966e6899c2b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75216-2","display":"Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.79204,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">0.1"}]}},{"fullUrl":"Observation/1734642836056150155.3c7a51ac-07b3-47e3-a124-9c8b9e3a3b83","resource":{"resourceType":"Observation","id":"1734642836056150155.3c7a51ac-07b3-47e3-a124-9c8b9e3a3b83","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ng/mL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"48633-2","display":"Trypsinogen I.free"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":18.50,"unit":"ng/mL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<69"}]}},{"fullUrl":"Observation/1734642836059098674.3ddbdc33-426e-4b74-b71a-759e225539e4","resource":{"resourceType":"Observation","id":"1734642836059098674.3ddbdc33-426e-4b74-b71a-759e225539e4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46769-6","display":"Cystic fibrosis newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836061148087.724aa224-ce9b-48ba-9cd3-7f046341d894","resource":{"resourceType":"Observation","id":"1734642836061148087.724aa224-ce9b-48ba-9cd3-7f046341d894","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57707-2","display":"Cystic fibrosis newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836064192896.545f0cb5-2bb4-4ce7-8d40-188c2094ae6b","resource":{"resourceType":"Observation","id":"1734642836064192896.545f0cb5-2bb4-4ce7-8d40-188c2094ae6b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"nmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38473-5","display":"17-Hydroxyprogesterone"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":13.8,"unit":"nmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<85"}]}},{"fullUrl":"Observation/1734642836066734031.752fc16a-f2b9-4fc6-9f0f-5fc9afdefbb2","resource":{"resourceType":"Observation","id":"1734642836066734031.752fc16a-f2b9-4fc6-9f0f-5fc9afdefbb2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46758-9","display":"Congenital adrenal hyperplasia newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836068882770.6b6e0b85-241b-47b3-b747-37a61fa1d240","resource":{"resourceType":"Observation","id":"1734642836068882770.6b6e0b85-241b-47b3-b747-37a61fa1d240","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57706-4","display":"Congenital adrenal hyperplasia newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836071577363.c6d07390-087c-4753-a459-ed7fcd308e48","resource":{"resourceType":"Observation","id":"1734642836071577363.c6d07390-087c-4753-a459-ed7fcd308e48","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"mIU/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29575-8","display":"Thyrotropin"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":2.40,"unit":"mIU/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<29"}]}},{"fullUrl":"Observation/1734642836075082024.1c1fcb05-42db-464b-8ada-6df001524653","resource":{"resourceType":"Observation","id":"1734642836075082024.1c1fcb05-42db-464b-8ada-6df001524653","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46762-1","display":"Congenital hypothyroidism newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836078093261.63f313f4-c070-492f-afbd-a33b562df097","resource":{"resourceType":"Observation","id":"1734642836078093261.63f313f4-c070-492f-afbd-a33b562df097","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57705-6","display":"Congenital hypothyroidism newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836080350664.f0388aa8-665c-4f91-8fd5-9c301df81913","resource":{"resourceType":"Observation","id":"1734642836080350664.f0388aa8-665c-4f91-8fd5-9c301df81913","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"enzyme units"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42906-8","display":"Galactose 1 phosphate uridyl transferase"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":293.00,"unit":"enzyme units"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">50"}]}},{"fullUrl":"Observation/1734642836082734985.98cc37d6-f03e-4f09-8a30-dc91c3cb4a44","resource":{"resourceType":"Observation","id":"1734642836082734985.98cc37d6-f03e-4f09-8a30-dc91c3cb4a44","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46737-3","display":"Galactosemias newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836084978451.e5032aa6-893e-432b-bf94-24bbafd2f6ec","resource":{"resourceType":"Observation","id":"1734642836084978451.e5032aa6-893e-432b-bf94-24bbafd2f6ec","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57704-9","display":"Galactosemias newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836086819173.3e285432-ee21-489e-a223-fc5c7689b06d","resource":{"resourceType":"Observation","id":"1734642836086819173.3e285432-ee21-489e-a223-fc5c7689b06d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54104-5","display":"Hemoglobin pattern"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"FA + Barts"}},{"fullUrl":"Observation/1734642836088611323.1bde1240-4adb-4827-b673-5427483e3dea","resource":{"resourceType":"Observation","id":"1734642836088611323.1bde1240-4adb-4827-b673-5427483e3dea","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57703-1","display":"Hemoglobin disorders newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"The presence of Hb Barts at a high percentage is consistent with Hb H disease, a clinically significant hemoglobin disorder."}},{"fullUrl":"Observation/1734642836090904183.4b2226ec-6c0b-4031-909f-235e2f04976c","resource":{"resourceType":"Observation","id":"1734642836090904183.4b2226ec-6c0b-4031-909f-235e2f04976c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ERU"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75217-0","display":"Biotinidase [Enzymatic activity/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":43.76,"unit":"ERU"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">10"}]}},{"fullUrl":"Observation/1734642836093566986.b14e7d8d-5b96-4964-8572-da5fb4327281","resource":{"resourceType":"Observation","id":"1734642836093566986.b14e7d8d-5b96-4964-8572-da5fb4327281","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46761-3","display":"Biotinidase deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836095654951.3db665e3-0f5c-48e7-a07b-72fcbc002aa0","resource":{"resourceType":"Observation","id":"1734642836095654951.3db665e3-0f5c-48e7-a07b-72fcbc002aa0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57699-1","display":"Biotinidase deficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836099363255.b57829c9-31a7-4f2b-923c-7177397914e0","resource":{"resourceType":"Observation","id":"1734642836099363255.b57829c9-31a7-4f2b-923c-7177397914e0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"copies/µL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62320-7","display":"T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":99,"unit":"copies/µL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">18"}]}},{"fullUrl":"Observation/1734642836101959590.ae5c736c-5301-4b7a-9aa6-6e4398046e5b","resource":{"resourceType":"Observation","id":"1734642836101959590.ae5c736c-5301-4b7a-9aa6-6e4398046e5b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62321-5","display":"Severe combined immunodeficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836104365842.7148179d-564a-4df9-bd22-c230f7dcb93e","resource":{"resourceType":"Observation","id":"1734642836104365842.7148179d-564a-4df9-bd22-c230f7dcb93e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62322-3","display":"Severe combined immunodeficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836111297162.b3873451-14ee-44c4-97d5-9bb41c989626","resource":{"resourceType":"Observation","id":"1734642836111297162.b3873451-14ee-44c4-97d5-9bb41c989626","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55827-0","display":"Acid alpha glucosidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":7.09,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=1.67"}]}},{"fullUrl":"Observation/1734642836113467783.741e468e-7fc0-4423-ac97-ee219ed19842","resource":{"resourceType":"Observation","id":"1734642836113467783.741e468e-7fc0-4423-ac97-ee219ed19842","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63415-4","display":"Pompe Disease deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836115303725.d20a44c7-6828-4a2f-a4a7-14339af82c03","resource":{"resourceType":"Observation","id":"1734642836115303725.d20a44c7-6828-4a2f-a4a7-14339af82c03","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63416-2","display":"Pompe Disease deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836117814203.b4e4cf66-b844-451b-9c87-24832b6fe6ad","resource":{"resourceType":"Observation","id":"1734642836117814203.b4e4cf66-b844-451b-9c87-24832b6fe6ad","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55909-6","display":"Alpha-L-iduronidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":8.33,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=0.86"}]}},{"fullUrl":"Observation/1734642836119999360.04908077-17c5-4224-80f7-49d2066cbedb","resource":{"resourceType":"Observation","id":"1734642836119999360.04908077-17c5-4224-80f7-49d2066cbedb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79564-1","display":"Mucopolysaccharidosis type I newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836121872623.119d758a-9078-4420-aacb-94a01f1eb724","resource":{"resourceType":"Observation","id":"1734642836121872623.119d758a-9078-4420-aacb-94a01f1eb724","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79565-8","display":"Mucopolysaccharidosis type I newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836123642191.b1b92497-7ecb-42f0-9a46-d8106853e8fe","resource":{"resourceType":"Observation","id":"1734642836123642191.b1b92497-7ecb-42f0-9a46-d8106853e8fe","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-60","display":"SMN1 Homozygous Deletion Analysis"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Exon 7 Present","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"Exon 7 Present"}]}},{"fullUrl":"Observation/1734642836125756856.c973f1c9-f4fe-4e66-8f37-7172ebe581d6","resource":{"resourceType":"Observation","id":"1734642836125756856.c973f1c9-f4fe-4e66-8f37-7172ebe581d6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92004-1","display":"Spinal muscular atrophy newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836127597888.34e36b07-2b51-4642-ae9d-0a8c918d2778","resource":{"resourceType":"Observation","id":"1734642836127597888.34e36b07-2b51-4642-ae9d-0a8c918d2778","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92003-3","display":"Spinal muscular atrophy newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"SMA Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836129662139.3d5d2c39-e93f-4dfd-886e-6af0424b7a9e","resource":{"resourceType":"Observation","id":"1734642836129662139.3d5d2c39-e93f-4dfd-886e-6af0424b7a9e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79462-8","display":"Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":15.65,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=2.8"}]}},{"fullUrl":"Observation/1734642836131734335.0443a079-34d1-4cf9-9176-8515df7cba8a","resource":{"resourceType":"Observation","id":"1734642836131734335.0443a079-34d1-4cf9-9176-8515df7cba8a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104189-6","display":"Mucopolysaccharidosis type II newborn screen interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836133599152.b964ea85-cf95-49f2-b92f-62328d3ea799","resource":{"resourceType":"Observation","id":"1734642836133599152.b964ea85-cf95-49f2-b92f-62328d3ea799","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104190-4","display":"Mucopolysaccharidosis type II newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836136544444.76dec855-2215-4747-b563-5edf391e7414","resource":{"resourceType":"Observation","id":"1734642836136544444.76dec855-2215-4747-b563-5edf391e7414","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104192-0","display":"Guanidinoacetate methyltransferase deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836138511032.bbdd868a-ccbc-4dc8-afb3-ab91b493db75","resource":{"resourceType":"Observation","id":"1734642836138511032.bbdd868a-ccbc-4dc8-afb3-ab91b493db75","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104193-8","display":"Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836140773031.ca60eb5f-4792-4f47-9cda-4f2336385def","resource":{"resourceType":"Observation","id":"1734642836140773031.ca60eb5f-4792-4f47-9cda-4f2336385def","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"93488-5","display":"Guanidinoacetate [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":1.05,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=3"}]}},{"fullUrl":"Observation/1734642836142897444.274531bb-aba7-40ac-a4c6-b6777fa2656c","resource":{"resourceType":"Observation","id":"1734642836142897444.274531bb-aba7-40ac-a4c6-b6777fa2656c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104194-6","display":"Creatine [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":616.49,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836144844706.bf279162-4e5f-474c-bf4f-c7405b754eed","resource":{"resourceType":"Observation","id":"1734642836144844706.bf279162-4e5f-474c-bf4f-c7405b754eed","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104195-3","display":"GUAC/CRE Ratio [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":1.70},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=6"}]}},{"fullUrl":"Observation/1734642836146921300.a099f493-8f4b-406d-80e2-9937c06c29af","resource":{"resourceType":"Observation","id":"1734642836146921300.a099f493-8f4b-406d-80e2-9937c06c29af","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-32","display":"Adrenoleukodystrophy deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836148732836.1f0c3ba7-cca4-4716-8e12-bd556367776e","resource":{"resourceType":"Observation","id":"1734642836148732836.1f0c3ba7-cca4-4716-8e12-bd556367776e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-33","display":"Adrenoleukodystrophy deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734642836150737746.37519cf1-4f37-441a-b91c-2effb9f3579f","resource":{"resourceType":"Observation","id":"1734642836150737746.37519cf1-4f37-441a-b91c-2effb9f3579f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79321-6","display":"Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-10-18T05:00:17Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"valueQuantity":{"value":0.260,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.47"}]}},{"fullUrl":"Specimen/1734642836161032270.46570000-7b65-48ff-a4ee-7c6884e3bc40","resource":{"resourceType":"Specimen","id":"1734642836161032270.46570000-7b65-48ff-a4ee-7c6884e3bc40","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836162665332.ff5b8563-8157-4e83-83b7-56c7b7498c70","resource":{"resourceType":"Specimen","id":"1734642836162665332.ff5b8563-8157-4e83-83b7-56c7b7498c70","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836164126261.eda6980d-7ef7-406f-81de-aa435e2a5c4e","resource":{"resourceType":"Specimen","id":"1734642836164126261.eda6980d-7ef7-406f-81de-aa435e2a5c4e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836165479489.dd1334bf-e8a9-416b-9122-2cd311dc2d5c","resource":{"resourceType":"Specimen","id":"1734642836165479489.dd1334bf-e8a9-416b-9122-2cd311dc2d5c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836166821946.c1ea71c7-fb40-4cd0-80fb-0a4f134f9425","resource":{"resourceType":"Specimen","id":"1734642836166821946.c1ea71c7-fb40-4cd0-80fb-0a4f134f9425","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836168190152.6fe40301-21fe-4402-b76d-c685c08a42e0","resource":{"resourceType":"Specimen","id":"1734642836168190152.6fe40301-21fe-4402-b76d-c685c08a42e0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836169622397.6e71209d-2b34-4b42-8090-f7d67db1f966","resource":{"resourceType":"Specimen","id":"1734642836169622397.6e71209d-2b34-4b42-8090-f7d67db1f966","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836171065203.9d232828-25d2-4c83-a58e-1c74cadfd08f","resource":{"resourceType":"Specimen","id":"1734642836171065203.9d232828-25d2-4c83-a58e-1c74cadfd08f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836172450811.05f794fb-ae21-4cc3-ab91-44959988c1c4","resource":{"resourceType":"Specimen","id":"1734642836172450811.05f794fb-ae21-4cc3-ab91-44959988c1c4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836173953849.216555b6-7718-4724-a40b-446a1535ac35","resource":{"resourceType":"Specimen","id":"1734642836173953849.216555b6-7718-4724-a40b-446a1535ac35","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836175318167.1f1e6b32-2c14-44a7-9f7e-a1b9239f31ab","resource":{"resourceType":"Specimen","id":"1734642836175318167.1f1e6b32-2c14-44a7-9f7e-a1b9239f31ab","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836176692945.c095756a-2f25-4c51-bdb1-6f412c956bae","resource":{"resourceType":"Specimen","id":"1734642836176692945.c095756a-2f25-4c51-bdb1-6f412c956bae","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836178034140.e3cbe5e4-708b-4e4e-8d3d-bd83a6713778","resource":{"resourceType":"Specimen","id":"1734642836178034140.e3cbe5e4-708b-4e4e-8d3d-bd83a6713778","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836179371708.16d8ceab-0511-4309-9db9-fd4c8429c595","resource":{"resourceType":"Specimen","id":"1734642836179371708.16d8ceab-0511-4309-9db9-fd4c8429c595","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836180747027.6df950ea-03a3-435b-912f-8261319782b4","resource":{"resourceType":"Specimen","id":"1734642836180747027.6df950ea-03a3-435b-912f-8261319782b4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836182114562.8cc3bdf7-2378-4050-8915-2fba8d0cb66c","resource":{"resourceType":"Specimen","id":"1734642836182114562.8cc3bdf7-2378-4050-8915-2fba8d0cb66c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836183461107.69dcb642-2f99-4373-9e1b-e826e9ebcc68","resource":{"resourceType":"Specimen","id":"1734642836183461107.69dcb642-2f99-4373-9e1b-e826e9ebcc68","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836184837918.8979b6cf-1ab8-4204-9afc-82152ecd657c","resource":{"resourceType":"Specimen","id":"1734642836184837918.8979b6cf-1ab8-4204-9afc-82152ecd657c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836186184714.3c7264fe-459a-4e2e-a9c4-010092f02c47","resource":{"resourceType":"Specimen","id":"1734642836186184714.3c7264fe-459a-4e2e-a9c4-010092f02c47","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836187533964.1477cdc6-64f4-4fdb-9280-bf1f389fb11b","resource":{"resourceType":"Specimen","id":"1734642836187533964.1477cdc6-64f4-4fdb-9280-bf1f389fb11b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836188904223.d33485a5-6a3c-471a-8ea6-261635fcadb2","resource":{"resourceType":"Specimen","id":"1734642836188904223.d33485a5-6a3c-471a-8ea6-261635fcadb2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836190292366.cb0738a0-5e1a-4416-94e0-b7a606b153d0","resource":{"resourceType":"Specimen","id":"1734642836190292366.cb0738a0-5e1a-4416-94e0-b7a606b153d0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836191672224.0ba34d35-8ff2-417a-b212-c582abb903c6","resource":{"resourceType":"Specimen","id":"1734642836191672224.0ba34d35-8ff2-417a-b212-c582abb903c6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"Specimen/1734642836193133473.9d77732e-0d8d-46d2-a589-d1f41fa01f86","resource":{"resourceType":"Specimen","id":"1734642836193133473.9d77732e-0d8d-46d2-a589-d1f41fa01f86","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-26T05:12:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}}}},{"fullUrl":"ServiceRequest/1734642836211469125.e6e076d4-8334-47db-9cc0-1c4fe300de8d","resource":{"resourceType":"ServiceRequest","id":"1734642836211469125.e6e076d4-8334-47db-9cc0-1c4fe300de8d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/business-event","valueCode":"RE"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/orc-common-order","extension":[{"url":"orc-21-ordering-facility-name","valueReference":{"reference":"Organization/1734642836204360035.7352be17-3267-4fbf-a835-334c12d284a9"}},{"url":"orc-22-ordering-facility-address","valueAddress":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"725 WELCH RD, RM  H1524"}]}]}],"line":["725 WELCH RD, RM  H1524"],"city":"PALO ALTO","state":"CA","postalCode":"94304-1601"}},{"url":"orc-12-ordering-provider","valueReference":{"reference":"Practitioner/1734642836206890770.48cba7af-963b-4ab1-842e-4d877f2a68a4"}}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.2","valueIdentifier":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"value":"753234567"}},{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836209338771.77e8acfd-a6f3-4102-af99-b6fe3776767a"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"56155532"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.4"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"56155532"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"PractitionerRole/1734642836196504374.553e1722-a2c1-40a4-9e89-b8035989adfa"}}},{"fullUrl":"Practitioner/1734642836198040786.bbb4bb12-266d-4544-874b-b42e8f11c834","resource":{"resourceType":"Practitioner","id":"1734642836198040786.bbb4bb12-266d-4544-874b-b42e8f11c834","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.12"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Organization/1734642836200585447.a82635d1-0b3b-493c-bab5-dae183caf306","resource":{"resourceType":"Organization","id":"1734642836200585447.a82635d1-0b3b-493c-bab5-dae183caf306","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R777"}]}],"identifier":[{"value":"R777"}],"name":"STANFORD/LUCILE PACKARD CHILDREN'S HOSPI","telecom":[{"_system":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}],"address":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"725 WELCH RD, RM  H1524"}]}]}],"line":["725 WELCH RD, RM  H1524"],"city":"PALO ALTO","state":"CA","postalCode":"94304-1601"}]}},{"fullUrl":"PractitionerRole/1734642836196504374.553e1722-a2c1-40a4-9e89-b8035989adfa","resource":{"resourceType":"PractitionerRole","id":"1734642836196504374.553e1722-a2c1-40a4-9e89-b8035989adfa","practitioner":{"reference":"Practitioner/1734642836198040786.bbb4bb12-266d-4544-874b-b42e8f11c834"},"organization":{"reference":"Organization/1734642836200585447.a82635d1-0b3b-493c-bab5-dae183caf306"}}},{"fullUrl":"Organization/1734642836204360035.7352be17-3267-4fbf-a835-334c12d284a9","resource":{"resourceType":"Organization","id":"1734642836204360035.7352be17-3267-4fbf-a835-334c12d284a9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R777"}]}],"identifier":[{"value":"R777"}],"name":"STANFORD/LUCILE PACKARD CHILDREN'S HOSPI"}},{"fullUrl":"Practitioner/1734642836206890770.48cba7af-963b-4ab1-842e-4d877f2a68a4","resource":{"resourceType":"Practitioner","id":"1734642836206890770.48cba7af-963b-4ab1-842e-4d877f2a68a4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836209338771.77e8acfd-a6f3-4102-af99-b6fe3776767a","resource":{"resourceType":"Practitioner","id":"1734642836209338771.77e8acfd-a6f3-4102-af99-b6fe3776767a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836224689866.d50d5411-c894-4903-a74d-23409a7158a7","resource":{"resourceType":"ServiceRequest","id":"1734642836224689866.d50d5411-c894-4903-a74d-23409a7158a7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836222544273.34e245a2-ac0d-4c11-87a5-7aa5ad39e3e6"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836213559265.f5c0e90d-f0dc-45c6-b92e-fab08e92ff26"}}},{"fullUrl":"Practitioner/1734642836213559265.f5c0e90d-f0dc-45c6-b92e-fab08e92ff26","resource":{"resourceType":"Practitioner","id":"1734642836213559265.f5c0e90d-f0dc-45c6-b92e-fab08e92ff26","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836222544273.34e245a2-ac0d-4c11-87a5-7aa5ad39e3e6","resource":{"resourceType":"Practitioner","id":"1734642836222544273.34e245a2-ac0d-4c11-87a5-7aa5ad39e3e6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836233361116.ae32ec13-3bd0-450c-a8b0-e2db6dfa8a58","resource":{"resourceType":"ServiceRequest","id":"1734642836233361116.ae32ec13-3bd0-450c-a8b0-e2db6dfa8a58","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836230877078.f074c9d5-d6e9-4119-b497-46dbcb2cbae5"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836226494590.299f670c-e03a-4f30-8544-a497182fe3eb"}}},{"fullUrl":"Practitioner/1734642836226494590.299f670c-e03a-4f30-8544-a497182fe3eb","resource":{"resourceType":"Practitioner","id":"1734642836226494590.299f670c-e03a-4f30-8544-a497182fe3eb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836230877078.f074c9d5-d6e9-4119-b497-46dbcb2cbae5","resource":{"resourceType":"Practitioner","id":"1734642836230877078.f074c9d5-d6e9-4119-b497-46dbcb2cbae5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836241950442.fa7ec720-835f-40fe-9d85-64302547c7da","resource":{"resourceType":"ServiceRequest","id":"1734642836241950442.fa7ec720-835f-40fe-9d85-64302547c7da","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836239697527.c561c605-6b06-4e19-b75b-c1da643e125c"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836235261519.2472cb4b-dbcf-4b3b-8a07-75d1cf8255dd"}}},{"fullUrl":"Practitioner/1734642836235261519.2472cb4b-dbcf-4b3b-8a07-75d1cf8255dd","resource":{"resourceType":"Practitioner","id":"1734642836235261519.2472cb4b-dbcf-4b3b-8a07-75d1cf8255dd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836239697527.c561c605-6b06-4e19-b75b-c1da643e125c","resource":{"resourceType":"Practitioner","id":"1734642836239697527.c561c605-6b06-4e19-b75b-c1da643e125c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836250765712.59a67878-8cad-4343-8fd8-7922dad33cd9","resource":{"resourceType":"ServiceRequest","id":"1734642836250765712.59a67878-8cad-4343-8fd8-7922dad33cd9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836248679349.01b87c3f-b73e-49ed-8cb6-07ad7076c452"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836244172929.7e5d76cb-a94b-4373-a0ab-c54e7555f294"}}},{"fullUrl":"Practitioner/1734642836244172929.7e5d76cb-a94b-4373-a0ab-c54e7555f294","resource":{"resourceType":"Practitioner","id":"1734642836244172929.7e5d76cb-a94b-4373-a0ab-c54e7555f294","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836248679349.01b87c3f-b73e-49ed-8cb6-07ad7076c452","resource":{"resourceType":"Practitioner","id":"1734642836248679349.01b87c3f-b73e-49ed-8cb6-07ad7076c452","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836259325462.67b6c411-50a0-4d81-be09-068910902638","resource":{"resourceType":"ServiceRequest","id":"1734642836259325462.67b6c411-50a0-4d81-be09-068910902638","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836257242887.da0683b6-63bf-4e56-b90c-aae51cbeaaa7"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836252618376.c495ca8c-c05a-4efb-809e-af5407f36162"}}},{"fullUrl":"Practitioner/1734642836252618376.c495ca8c-c05a-4efb-809e-af5407f36162","resource":{"resourceType":"Practitioner","id":"1734642836252618376.c495ca8c-c05a-4efb-809e-af5407f36162","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836257242887.da0683b6-63bf-4e56-b90c-aae51cbeaaa7","resource":{"resourceType":"Practitioner","id":"1734642836257242887.da0683b6-63bf-4e56-b90c-aae51cbeaaa7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836268500066.fa067df2-9282-4977-8b95-7911c976c2ed","resource":{"resourceType":"ServiceRequest","id":"1734642836268500066.fa067df2-9282-4977-8b95-7911c976c2ed","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836266384549.7057c900-1832-439a-8694-389fc0bb14ad"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836261156576.32b1c0c7-95ec-4f54-92ed-d3d18d03b98e"}}},{"fullUrl":"Practitioner/1734642836261156576.32b1c0c7-95ec-4f54-92ed-d3d18d03b98e","resource":{"resourceType":"Practitioner","id":"1734642836261156576.32b1c0c7-95ec-4f54-92ed-d3d18d03b98e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836266384549.7057c900-1832-439a-8694-389fc0bb14ad","resource":{"resourceType":"Practitioner","id":"1734642836266384549.7057c900-1832-439a-8694-389fc0bb14ad","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836276842830.0d9448c9-73c6-4837-b7bb-a4c879444fbc","resource":{"resourceType":"ServiceRequest","id":"1734642836276842830.0d9448c9-73c6-4837-b7bb-a4c879444fbc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836274734246.f4075098-601e-4aa3-9427-8dcacda90f76"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836270293839.119538e7-6c0a-4bc5-844f-ef460b78fb94"}}},{"fullUrl":"Practitioner/1734642836270293839.119538e7-6c0a-4bc5-844f-ef460b78fb94","resource":{"resourceType":"Practitioner","id":"1734642836270293839.119538e7-6c0a-4bc5-844f-ef460b78fb94","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836274734246.f4075098-601e-4aa3-9427-8dcacda90f76","resource":{"resourceType":"Practitioner","id":"1734642836274734246.f4075098-601e-4aa3-9427-8dcacda90f76","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836285130680.8f6eaf5b-40c9-4189-8aca-08101b2bcdf3","resource":{"resourceType":"ServiceRequest","id":"1734642836285130680.8f6eaf5b-40c9-4189-8aca-08101b2bcdf3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836283027487.358f15cf-cf7c-4d13-9624-c1e5a46b30be"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836278642815.bccf7510-f6e6-41cb-ba97-c1662024145d"}}},{"fullUrl":"Practitioner/1734642836278642815.bccf7510-f6e6-41cb-ba97-c1662024145d","resource":{"resourceType":"Practitioner","id":"1734642836278642815.bccf7510-f6e6-41cb-ba97-c1662024145d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836283027487.358f15cf-cf7c-4d13-9624-c1e5a46b30be","resource":{"resourceType":"Practitioner","id":"1734642836283027487.358f15cf-cf7c-4d13-9624-c1e5a46b30be","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836294761079.da990083-15d9-410c-b401-f51a41982afb","resource":{"resourceType":"ServiceRequest","id":"1734642836294761079.da990083-15d9-410c-b401-f51a41982afb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836291946982.83a8c3e9-73fa-4d89-8030-222dbb5d01e9"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836286914856.e4fd3a16-5d21-4427-8484-61c424625fc0"}}},{"fullUrl":"Practitioner/1734642836286914856.e4fd3a16-5d21-4427-8484-61c424625fc0","resource":{"resourceType":"Practitioner","id":"1734642836286914856.e4fd3a16-5d21-4427-8484-61c424625fc0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836291946982.83a8c3e9-73fa-4d89-8030-222dbb5d01e9","resource":{"resourceType":"Practitioner","id":"1734642836291946982.83a8c3e9-73fa-4d89-8030-222dbb5d01e9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836303617155.292bdcf8-998f-49b4-b53d-75cada578a97","resource":{"resourceType":"ServiceRequest","id":"1734642836303617155.292bdcf8-998f-49b4-b53d-75cada578a97","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836301308646.62572931-9042-4b83-821f-3f3cb5a413ef"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836296737034.74c1a466-5a08-440b-a537-0780f70e2845"}}},{"fullUrl":"Practitioner/1734642836296737034.74c1a466-5a08-440b-a537-0780f70e2845","resource":{"resourceType":"Practitioner","id":"1734642836296737034.74c1a466-5a08-440b-a537-0780f70e2845","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836301308646.62572931-9042-4b83-821f-3f3cb5a413ef","resource":{"resourceType":"Practitioner","id":"1734642836301308646.62572931-9042-4b83-821f-3f3cb5a413ef","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836312111042.04bf133a-a60f-4d5a-b1db-b3bb78f3bb7b","resource":{"resourceType":"ServiceRequest","id":"1734642836312111042.04bf133a-a60f-4d5a-b1db-b3bb78f3bb7b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836310046480.9199b5f8-e066-43ec-9b9d-a963aa525c23"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836305570097.c9cdb421-6dca-426c-a37f-5e214fadd913"}}},{"fullUrl":"Practitioner/1734642836305570097.c9cdb421-6dca-426c-a37f-5e214fadd913","resource":{"resourceType":"Practitioner","id":"1734642836305570097.c9cdb421-6dca-426c-a37f-5e214fadd913","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836310046480.9199b5f8-e066-43ec-9b9d-a963aa525c23","resource":{"resourceType":"Practitioner","id":"1734642836310046480.9199b5f8-e066-43ec-9b9d-a963aa525c23","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836321191278.496e5d2d-aaa9-4f32-bf5f-25e44b00c369","resource":{"resourceType":"ServiceRequest","id":"1734642836321191278.496e5d2d-aaa9-4f32-bf5f-25e44b00c369","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836318900012.0e06a628-c8e9-4b44-8449-1bc60964460c"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836313920395.a78587ce-9a8a-4fc6-bb67-5f8ba6c72889"}}},{"fullUrl":"Practitioner/1734642836313920395.a78587ce-9a8a-4fc6-bb67-5f8ba6c72889","resource":{"resourceType":"Practitioner","id":"1734642836313920395.a78587ce-9a8a-4fc6-bb67-5f8ba6c72889","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836318900012.0e06a628-c8e9-4b44-8449-1bc60964460c","resource":{"resourceType":"Practitioner","id":"1734642836318900012.0e06a628-c8e9-4b44-8449-1bc60964460c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836331263295.6c66392a-d008-4df9-a51c-7c8a63466ed6","resource":{"resourceType":"ServiceRequest","id":"1734642836331263295.6c66392a-d008-4df9-a51c-7c8a63466ed6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836328872472.04481bf4-ed20-4c54-a1e0-4a74e6099d38"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836323077295.0dbe568e-3726-49d7-9642-8d4ee820c3cc"}}},{"fullUrl":"Practitioner/1734642836323077295.0dbe568e-3726-49d7-9642-8d4ee820c3cc","resource":{"resourceType":"Practitioner","id":"1734642836323077295.0dbe568e-3726-49d7-9642-8d4ee820c3cc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836328872472.04481bf4-ed20-4c54-a1e0-4a74e6099d38","resource":{"resourceType":"Practitioner","id":"1734642836328872472.04481bf4-ed20-4c54-a1e0-4a74e6099d38","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836339797758.e4e9a447-a036-4f1f-b48b-4e8ced41f368","resource":{"resourceType":"ServiceRequest","id":"1734642836339797758.e4e9a447-a036-4f1f-b48b-4e8ced41f368","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836337532681.9e62e6db-dffd-40d5-a33c-8155e32f56ff"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836333096472.c5394f35-158f-46e6-aa45-9be08f9170c0"}}},{"fullUrl":"Practitioner/1734642836333096472.c5394f35-158f-46e6-aa45-9be08f9170c0","resource":{"resourceType":"Practitioner","id":"1734642836333096472.c5394f35-158f-46e6-aa45-9be08f9170c0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836337532681.9e62e6db-dffd-40d5-a33c-8155e32f56ff","resource":{"resourceType":"Practitioner","id":"1734642836337532681.9e62e6db-dffd-40d5-a33c-8155e32f56ff","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836348221083.f121f33c-f711-40d6-be41-9d517d9b6c1e","resource":{"resourceType":"ServiceRequest","id":"1734642836348221083.f121f33c-f711-40d6-be41-9d517d9b6c1e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836346097591.dc186fd6-f7e4-4768-a653-0dd3d6f3988c"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836341666442.06f20797-ab8c-45c2-aa96-c7af5d416ac0"}}},{"fullUrl":"Practitioner/1734642836341666442.06f20797-ab8c-45c2-aa96-c7af5d416ac0","resource":{"resourceType":"Practitioner","id":"1734642836341666442.06f20797-ab8c-45c2-aa96-c7af5d416ac0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836346097591.dc186fd6-f7e4-4768-a653-0dd3d6f3988c","resource":{"resourceType":"Practitioner","id":"1734642836346097591.dc186fd6-f7e4-4768-a653-0dd3d6f3988c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836356921477.f8969abf-1d45-4fdb-82ca-12ec23f1a198","resource":{"resourceType":"ServiceRequest","id":"1734642836356921477.f8969abf-1d45-4fdb-82ca-12ec23f1a198","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836354586799.cf893361-f02a-4132-b59b-1d6ce994e353"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836350085819.efcf8b61-a602-4339-a2ef-8a2f47623d8b"}}},{"fullUrl":"Practitioner/1734642836350085819.efcf8b61-a602-4339-a2ef-8a2f47623d8b","resource":{"resourceType":"Practitioner","id":"1734642836350085819.efcf8b61-a602-4339-a2ef-8a2f47623d8b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836354586799.cf893361-f02a-4132-b59b-1d6ce994e353","resource":{"resourceType":"Practitioner","id":"1734642836354586799.cf893361-f02a-4132-b59b-1d6ce994e353","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836365734843.823e99b0-bf45-433b-9dda-0fb8e7ec362c","resource":{"resourceType":"ServiceRequest","id":"1734642836365734843.823e99b0-bf45-433b-9dda-0fb8e7ec362c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836363507717.ec23000e-bcbd-42d4-9efb-4521b705545c"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836358741089.b2e0b632-f079-4da7-b957-730116772c53"}}},{"fullUrl":"Practitioner/1734642836358741089.b2e0b632-f079-4da7-b957-730116772c53","resource":{"resourceType":"Practitioner","id":"1734642836358741089.b2e0b632-f079-4da7-b957-730116772c53","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836363507717.ec23000e-bcbd-42d4-9efb-4521b705545c","resource":{"resourceType":"Practitioner","id":"1734642836363507717.ec23000e-bcbd-42d4-9efb-4521b705545c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836374544853.68f48201-4b0d-4906-ab6e-3ae7f8a93837","resource":{"resourceType":"ServiceRequest","id":"1734642836374544853.68f48201-4b0d-4906-ab6e-3ae7f8a93837","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836372240793.51304049-c464-4bf3-9cb7-eb97b8c9f843"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836367538425.34f98b24-38de-40fd-a4f0-2acc388ffe17"}}},{"fullUrl":"Practitioner/1734642836367538425.34f98b24-38de-40fd-a4f0-2acc388ffe17","resource":{"resourceType":"Practitioner","id":"1734642836367538425.34f98b24-38de-40fd-a4f0-2acc388ffe17","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836372240793.51304049-c464-4bf3-9cb7-eb97b8c9f843","resource":{"resourceType":"Practitioner","id":"1734642836372240793.51304049-c464-4bf3-9cb7-eb97b8c9f843","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836383016629.001af554-7412-4c8d-9f84-b09b1cee4b11","resource":{"resourceType":"ServiceRequest","id":"1734642836383016629.001af554-7412-4c8d-9f84-b09b1cee4b11","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836380857551.2b2e3398-ae31-4005-b2d3-1bec0244ca36"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836376429818.3e9c03cf-6044-44b6-8efd-e736e9ba9f9f"}}},{"fullUrl":"Practitioner/1734642836376429818.3e9c03cf-6044-44b6-8efd-e736e9ba9f9f","resource":{"resourceType":"Practitioner","id":"1734642836376429818.3e9c03cf-6044-44b6-8efd-e736e9ba9f9f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836380857551.2b2e3398-ae31-4005-b2d3-1bec0244ca36","resource":{"resourceType":"Practitioner","id":"1734642836380857551.2b2e3398-ae31-4005-b2d3-1bec0244ca36","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836394811491.34277100-a636-4818-bb0f-d52e9da86550","resource":{"resourceType":"ServiceRequest","id":"1734642836394811491.34277100-a636-4818-bb0f-d52e9da86550","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836392676668.5ff1633e-088a-4ab1-b25d-50517197f09a"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836384947380.3aa1c366-1db4-4515-bab6-b7264ea8e928"}}},{"fullUrl":"Practitioner/1734642836384947380.3aa1c366-1db4-4515-bab6-b7264ea8e928","resource":{"resourceType":"Practitioner","id":"1734642836384947380.3aa1c366-1db4-4515-bab6-b7264ea8e928","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836392676668.5ff1633e-088a-4ab1-b25d-50517197f09a","resource":{"resourceType":"Practitioner","id":"1734642836392676668.5ff1633e-088a-4ab1-b25d-50517197f09a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836403274640.ed48ac0b-8672-428d-8673-915efc13d3f1","resource":{"resourceType":"ServiceRequest","id":"1734642836403274640.ed48ac0b-8672-428d-8673-915efc13d3f1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836401129848.a41e731d-a4d4-46cc-a526-a8af0ddf53ba"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836396693860.9719d599-2d11-4168-a11b-b73b6992d2ae"}}},{"fullUrl":"Practitioner/1734642836396693860.9719d599-2d11-4168-a11b-b73b6992d2ae","resource":{"resourceType":"Practitioner","id":"1734642836396693860.9719d599-2d11-4168-a11b-b73b6992d2ae","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836401129848.a41e731d-a4d4-46cc-a526-a8af0ddf53ba","resource":{"resourceType":"Practitioner","id":"1734642836401129848.a41e731d-a4d4-46cc-a526-a8af0ddf53ba","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836411995102.fe0cfdee-2504-4550-87e1-7cb602a894ee","resource":{"resourceType":"ServiceRequest","id":"1734642836411995102.fe0cfdee-2504-4550-87e1-7cb602a894ee","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836409693667.9db820b2-e5cd-48b1-a3af-396425df5a6e"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836405248201.ae913fb5-8576-4b72-97ef-ca860c67a532"}}},{"fullUrl":"Practitioner/1734642836405248201.ae913fb5-8576-4b72-97ef-ca860c67a532","resource":{"resourceType":"Practitioner","id":"1734642836405248201.ae913fb5-8576-4b72-97ef-ca860c67a532","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836409693667.9db820b2-e5cd-48b1-a3af-396425df5a6e","resource":{"resourceType":"Practitioner","id":"1734642836409693667.9db820b2-e5cd-48b1-a3af-396425df5a6e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"ServiceRequest/1734642836420484381.73a022e0-4c1a-432c-8026-e6a1182ae0c6","resource":{"resourceType":"ServiceRequest","id":"1734642836420484381.73a022e0-4c1a-432c-8026-e6a1182ae0c6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734642836418139674.64c5f60a-10ea-4036-97dd-6cddf7734479"}},{"url":"OBR.7","valueDateTime":"2024-09-26T05:12:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]}},{"url":"OBR.22","valueString":"20241018050017"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"requester":{"reference":"Practitioner/1734642836413774870.782031bf-bbfc-4f1f-9f65-b219858ebcc1"}}},{"fullUrl":"Practitioner/1734642836413774870.782031bf-bbfc-4f1f-9f65-b219858ebcc1","resource":{"resourceType":"Practitioner","id":"1734642836413774870.782031bf-bbfc-4f1f-9f65-b219858ebcc1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"Practitioner/1734642836418139674.64c5f60a-10ea-4036-97dd-6cddf7734479","resource":{"resourceType":"Practitioner","id":"1734642836418139674.64c5f60a-10ea-4036-97dd-6cddf7734479","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"MELISSA"}]}],"name":[{"family":"SCALA","given":["MELISSA"]}]}},{"fullUrl":"DiagnosticReport/1734642836428415372.6590f295-01a4-4daf-8dbe-5bd3622a42e0","resource":{"resourceType":"DiagnosticReport","id":"1734642836428415372.6590f295-01a4-4daf-8dbe-5bd3622a42e0","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PGN"}]},"value":"56155532"},{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"HospOrdNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"FGN"}]},"value":"56155532"}],"basedOn":[{"reference":"ServiceRequest/1734642836211469125.e6e076d4-8334-47db-9cc0-1c4fe300de8d"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836161032270.46570000-7b65-48ff-a4ee-7c6884e3bc40"}]}},{"fullUrl":"DiagnosticReport/1734642836431845444.b43c3ad3-80b9-4953-8e18-f633dc149e5f","resource":{"resourceType":"DiagnosticReport","id":"1734642836431845444.b43c3ad3-80b9-4953-8e18-f633dc149e5f","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836224689866.d50d5411-c894-4903-a74d-23409a7158a7"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836162665332.ff5b8563-8157-4e83-83b7-56c7b7498c70"}]}},{"fullUrl":"DiagnosticReport/1734642836435304150.acabebcf-c09a-4a07-831e-36a3a4272bb7","resource":{"resourceType":"DiagnosticReport","id":"1734642836435304150.acabebcf-c09a-4a07-831e-36a3a4272bb7","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836233361116.ae32ec13-3bd0-450c-a8b0-e2db6dfa8a58"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836164126261.eda6980d-7ef7-406f-81de-aa435e2a5c4e"}],"result":[{"reference":"Observation/1734642835838348458.43fb29c2-a1a2-46ee-b73d-60e75cfa96f7"},{"reference":"Observation/1734642835841845246.4b04227d-09c0-4420-9c5e-e761434e1f65"},{"reference":"Observation/1734642835845365186.de231997-4300-4ff5-af9b-cbdd94007344"},{"reference":"Observation/1734642835848852014.ee590f13-b4e4-4667-ae32-32dd35b642a9"},{"reference":"Observation/1734642835852399236.826318e3-458b-4bcc-a558-a9b733f4aabc"},{"reference":"Observation/1734642835855517012.cdf88ff7-2886-4ac0-93de-0c14600848f9"},{"reference":"Observation/1734642835858631442.b3f1cb03-7d61-45d8-9f49-d0d51c019afc"}]}},{"fullUrl":"DiagnosticReport/1734642836438843987.f3795167-105b-4938-addb-6b6b55da9cca","resource":{"resourceType":"DiagnosticReport","id":"1734642836438843987.f3795167-105b-4938-addb-6b6b55da9cca","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836241950442.fa7ec720-835f-40fe-9d85-64302547c7da"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836165479489.dd1334bf-e8a9-416b-9122-2cd311dc2d5c"}],"result":[{"reference":"Observation/1734642835861724723.ddaac99b-c83c-4166-bf66-3abe0caf2011"},{"reference":"Observation/1734642835865234865.4a0cf0e0-0356-4533-b278-286cffaf37d2"},{"reference":"Observation/1734642835868488365.95c78f92-bd79-427b-81b2-f58d6b4dec65"},{"reference":"Observation/1734642835871986425.131c2949-3134-4848-975b-0db4dab5cd69"},{"reference":"Observation/1734642835875460509.fe5bc4f0-03dc-4fff-869f-4265efbbcd25"},{"reference":"Observation/1734642835879131162.6fe4e08b-aa38-4172-b2ab-622ad5bea544"},{"reference":"Observation/1734642835882630193.254cde97-1b38-4f9b-a44a-ffa9d6f2ddf3"},{"reference":"Observation/1734642835885686875.54ed88d3-9a3a-41ac-a26d-999bc55565e8"},{"reference":"Observation/1734642835888799281.17429e42-1961-4d38-84fb-df544a3a024b"},{"reference":"Observation/1734642835891927197.09bbcc6f-cb0a-495d-a0fd-3d5a637a6560"}]}},{"fullUrl":"DiagnosticReport/1734642836441766538.3d5e3d2c-d384-4d90-bae3-c3e267021f88","resource":{"resourceType":"DiagnosticReport","id":"1734642836441766538.3d5e3d2c-d384-4d90-bae3-c3e267021f88","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836250765712.59a67878-8cad-4343-8fd8-7922dad33cd9"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836166821946.c1ea71c7-fb40-4cd0-80fb-0a4f134f9425"}]}},{"fullUrl":"DiagnosticReport/1734642836445954190.7119e2b8-859d-4a82-a1d7-cca3136dbecc","resource":{"resourceType":"DiagnosticReport","id":"1734642836445954190.7119e2b8-859d-4a82-a1d7-cca3136dbecc","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836259325462.67b6c411-50a0-4d81-be09-068910902638"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836168190152.6fe40301-21fe-4402-b76d-c685c08a42e0"}],"result":[{"reference":"Observation/1734642835895699811.ac8311f2-11d0-4139-8e75-0d862789fa8e"},{"reference":"Observation/1734642835899291305.a684af57-f50d-4b53-8536-877c33b50d96"},{"reference":"Observation/1734642835903069350.b34b8876-7d82-4bbd-bc2e-27ed68fb2f0d"},{"reference":"Observation/1734642835906837265.b0d7f760-36f1-4fc4-be37-ff54bf7d45b2"},{"reference":"Observation/1734642835910461792.59d3fdd6-b67f-453f-873d-5933012c9c51"},{"reference":"Observation/1734642835914078924.b9721f8a-8cca-4307-aaf6-bc33777c448a"},{"reference":"Observation/1734642835917701457.cfcd58d7-2d26-48a1-bb55-b18357110171"},{"reference":"Observation/1734642835921297601.f23ad939-3185-45ba-b799-12cb69a62edb"},{"reference":"Observation/1734642835924956562.8a51eada-1b83-4132-aeb9-9e897bcfa7dc"},{"reference":"Observation/1734642835928560610.f11761e5-32ac-4329-8350-d8f336dc2841"},{"reference":"Observation/1734642835936166881.0e234ccb-6d15-49c1-8d85-3e19f162470a"},{"reference":"Observation/1734642835938621093.ee5cd03c-4948-4a32-8164-441ef939a2a9"},{"reference":"Observation/1734642835940962653.12eda31d-70a3-441a-af2a-28141156b3bb"},{"reference":"Observation/1734642835943140036.2289d344-2124-423a-8324-9e135ed95b3d"},{"reference":"Observation/1734642835945246025.c0de0d70-8645-4428-ba13-12b45b8930a3"},{"reference":"Observation/1734642835947343138.ae725d80-ad0e-4919-8cb1-d7565941812b"},{"reference":"Observation/1734642835949495904.b12fa676-b353-4141-bdea-ca5aea9ad88b"},{"reference":"Observation/1734642835951835531.e31d4936-c9dd-4449-961f-91c9451b6a81"},{"reference":"Observation/1734642835953756684.b3b3c9f3-7b72-4744-b798-68ff47d63356"}]}},{"fullUrl":"DiagnosticReport/1734642836448954536.99e8049b-82a6-48d5-85c6-590001827d87","resource":{"resourceType":"DiagnosticReport","id":"1734642836448954536.99e8049b-82a6-48d5-85c6-590001827d87","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836268500066.fa067df2-9282-4977-8b95-7911c976c2ed"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836169622397.6e71209d-2b34-4b42-8090-f7d67db1f966"}],"result":[{"reference":"Observation/1734642835955917426.1cde4345-8899-40b8-8ff8-4e433393dcd8"},{"reference":"Observation/1734642835957880868.bbc96ac7-3744-47f0-808b-09c118350019"}]}},{"fullUrl":"DiagnosticReport/1734642836453527821.28cfe23b-02a1-47c7-829c-e175148e22cf","resource":{"resourceType":"DiagnosticReport","id":"1734642836453527821.28cfe23b-02a1-47c7-829c-e175148e22cf","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836276842830.0d9448c9-73c6-4837-b7bb-a4c879444fbc"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836171065203.9d232828-25d2-4c83-a58e-1c74cadfd08f"}],"result":[{"reference":"Observation/1734642835959899623.1ece5b91-20e1-4c7f-a96a-6365931b5a9c"},{"reference":"Observation/1734642835962463120.73f4c091-a419-4206-9afc-a32499ccbbe2"},{"reference":"Observation/1734642835964812345.8d6a15f2-71d7-4ed4-afc6-da14e26b77aa"},{"reference":"Observation/1734642835966984488.bd58a5fd-e687-4bf3-b0fd-b3e31acfcf99"},{"reference":"Observation/1734642835969111537.1eea330d-e9e8-4c4a-a9b2-1f1541a5ad8f"},{"reference":"Observation/1734642835971804997.244ed723-05f6-4536-8789-637c500de1a7"},{"reference":"Observation/1734642835974458253.c66715d8-79f1-4446-be41-939ceb8f8b97"},{"reference":"Observation/1734642835976904089.fb7f61f4-2721-4abc-9c7b-26a7cbc10af8"},{"reference":"Observation/1734642835979548217.e7fe453b-12a1-44f4-a3b8-b37095ef4ae3"},{"reference":"Observation/1734642835982249112.ad92ca2f-cfb4-40ab-b7ce-b944af3e8cde"},{"reference":"Observation/1734642835984907707.60807b7e-f053-4dc3-837f-09887470d85c"},{"reference":"Observation/1734642835987496421.d5cd8995-f998-42cb-a3ca-ce0a1166a6fc"},{"reference":"Observation/1734642835989963036.a7394af9-094b-4902-a20a-0fe9201175da"},{"reference":"Observation/1734642835992538956.3f21d58a-11a9-43cc-a553-2935221156d3"},{"reference":"Observation/1734642835994923608.548f1b1b-6afc-463a-9c33-e9ce81ad97fc"},{"reference":"Observation/1734642835997573677.80a6dfc6-fa09-4358-815a-dfe757959f09"},{"reference":"Observation/1734642835999720703.41a6d967-ca64-4620-8712-30ab2f044fdd"},{"reference":"Observation/1734642836002687025.4f2f8fcb-9a4a-4f1f-a8c0-15de90b82d98"},{"reference":"Observation/1734642836004850091.e50d0cb3-2299-41e8-bfb2-7d3cd8c9061f"},{"reference":"Observation/1734642836006922607.f157c594-316e-4ad2-a17d-6c8d4f744f41"},{"reference":"Observation/1734642836009344819.27f90a06-82ed-4274-add4-afe438e2671a"},{"reference":"Observation/1734642836011736344.7bb83079-f18b-4ab0-a7f7-36af690cf1d9"},{"reference":"Observation/1734642836014288509.034f071a-2364-49c7-9e4f-c2b9e6b15e69"},{"reference":"Observation/1734642836020924763.4b54fab8-026d-4850-a9a8-6f43840e571d"},{"reference":"Observation/1734642836023364107.7bd159a4-9cba-43ea-8dc1-2b75b155250c"},{"reference":"Observation/1734642836026388919.f459fd2a-e75c-46d2-a0f1-acce29409873"}]}},{"fullUrl":"DiagnosticReport/1734642836457059804.8101d8e9-73fe-4d92-9ae3-d96d52c24b21","resource":{"resourceType":"DiagnosticReport","id":"1734642836457059804.8101d8e9-73fe-4d92-9ae3-d96d52c24b21","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836285130680.8f6eaf5b-40c9-4189-8aca-08101b2bcdf3"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836172450811.05f794fb-ae21-4cc3-ab91-44959988c1c4"}],"result":[{"reference":"Observation/1734642836029102116.af3487b7-83d4-417b-afbc-23b988c99cb7"},{"reference":"Observation/1734642836031499131.0ef60ce2-0887-4e14-87e6-70602f11724c"},{"reference":"Observation/1734642836034335821.b39a86ae-626b-4de3-baf9-7c4b3bdb918f"},{"reference":"Observation/1734642836037044299.5e380009-0025-4a93-8a79-9157e9ee5091"},{"reference":"Observation/1734642836039552863.a1775955-14a6-4d3d-9d00-1d1576b13957"},{"reference":"Observation/1734642836042252094.e4c7436e-2453-4d6f-bf3f-154218717c33"},{"reference":"Observation/1734642836045172871.81c16756-2212-4514-b387-82ba937fae20"},{"reference":"Observation/1734642836047619739.dfa41c8d-ee19-47ba-9771-62f7680ee29e"},{"reference":"Observation/1734642836050378483.896e302c-e7e0-462e-ac40-e786d95bed3a"},{"reference":"Observation/1734642836052717969.aa4e6425-a295-4d7c-82a0-f966e6899c2b"}]}},{"fullUrl":"DiagnosticReport/1734642836460082833.78fc2d69-f794-4288-bfd2-8ae0e241dafa","resource":{"resourceType":"DiagnosticReport","id":"1734642836460082833.78fc2d69-f794-4288-bfd2-8ae0e241dafa","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836294761079.da990083-15d9-410c-b401-f51a41982afb"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836173953849.216555b6-7718-4724-a40b-446a1535ac35"}],"result":[{"reference":"Observation/1734642836056150155.3c7a51ac-07b3-47e3-a124-9c8b9e3a3b83"},{"reference":"Observation/1734642836059098674.3ddbdc33-426e-4b74-b71a-759e225539e4"},{"reference":"Observation/1734642836061148087.724aa224-ce9b-48ba-9cd3-7f046341d894"}]}},{"fullUrl":"DiagnosticReport/1734642836463081496.2b7dca61-1b60-47db-9418-7da5ce8fbf61","resource":{"resourceType":"DiagnosticReport","id":"1734642836463081496.2b7dca61-1b60-47db-9418-7da5ce8fbf61","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836303617155.292bdcf8-998f-49b4-b53d-75cada578a97"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836175318167.1f1e6b32-2c14-44a7-9f7e-a1b9239f31ab"}],"result":[{"reference":"Observation/1734642836064192896.545f0cb5-2bb4-4ce7-8d40-188c2094ae6b"},{"reference":"Observation/1734642836066734031.752fc16a-f2b9-4fc6-9f0f-5fc9afdefbb2"},{"reference":"Observation/1734642836068882770.6b6e0b85-241b-47b3-b747-37a61fa1d240"}]}},{"fullUrl":"DiagnosticReport/1734642836466120635.370ae00a-25fe-4fa5-a324-f887bbe2a856","resource":{"resourceType":"DiagnosticReport","id":"1734642836466120635.370ae00a-25fe-4fa5-a324-f887bbe2a856","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836312111042.04bf133a-a60f-4d5a-b1db-b3bb78f3bb7b"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836176692945.c095756a-2f25-4c51-bdb1-6f412c956bae"}],"result":[{"reference":"Observation/1734642836071577363.c6d07390-087c-4753-a459-ed7fcd308e48"},{"reference":"Observation/1734642836075082024.1c1fcb05-42db-464b-8ada-6df001524653"},{"reference":"Observation/1734642836078093261.63f313f4-c070-492f-afbd-a33b562df097"}]}},{"fullUrl":"DiagnosticReport/1734642836469187225.77d97fba-4680-41c3-a53d-f3f9fafc8176","resource":{"resourceType":"DiagnosticReport","id":"1734642836469187225.77d97fba-4680-41c3-a53d-f3f9fafc8176","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836321191278.496e5d2d-aaa9-4f32-bf5f-25e44b00c369"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836178034140.e3cbe5e4-708b-4e4e-8d3d-bd83a6713778"}],"result":[{"reference":"Observation/1734642836080350664.f0388aa8-665c-4f91-8fd5-9c301df81913"},{"reference":"Observation/1734642836082734985.98cc37d6-f03e-4f09-8a30-dc91c3cb4a44"},{"reference":"Observation/1734642836084978451.e5032aa6-893e-432b-bf94-24bbafd2f6ec"}]}},{"fullUrl":"DiagnosticReport/1734642836472186179.2764089d-c788-49cd-a6aa-970788903941","resource":{"resourceType":"DiagnosticReport","id":"1734642836472186179.2764089d-c788-49cd-a6aa-970788903941","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836331263295.6c66392a-d008-4df9-a51c-7c8a63466ed6"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836179371708.16d8ceab-0511-4309-9db9-fd4c8429c595"}],"result":[{"reference":"Observation/1734642836086819173.3e285432-ee21-489e-a223-fc5c7689b06d"},{"reference":"Observation/1734642836088611323.1bde1240-4adb-4827-b673-5427483e3dea"}]}},{"fullUrl":"DiagnosticReport/1734642836475203036.31a490a5-9b63-446e-8f9e-eb2d9fd2721e","resource":{"resourceType":"DiagnosticReport","id":"1734642836475203036.31a490a5-9b63-446e-8f9e-eb2d9fd2721e","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836339797758.e4e9a447-a036-4f1f-b48b-4e8ced41f368"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836180747027.6df950ea-03a3-435b-912f-8261319782b4"}],"result":[{"reference":"Observation/1734642836090904183.4b2226ec-6c0b-4031-909f-235e2f04976c"},{"reference":"Observation/1734642836093566986.b14e7d8d-5b96-4964-8572-da5fb4327281"},{"reference":"Observation/1734642836095654951.3db665e3-0f5c-48e7-a07b-72fcbc002aa0"}]}},{"fullUrl":"DiagnosticReport/1734642836478257283.e475367b-b110-4a83-971d-f42c9a4a8087","resource":{"resourceType":"DiagnosticReport","id":"1734642836478257283.e475367b-b110-4a83-971d-f42c9a4a8087","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836348221083.f121f33c-f711-40d6-be41-9d517d9b6c1e"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836182114562.8cc3bdf7-2378-4050-8915-2fba8d0cb66c"}],"result":[{"reference":"Observation/1734642836099363255.b57829c9-31a7-4f2b-923c-7177397914e0"},{"reference":"Observation/1734642836101959590.ae5c736c-5301-4b7a-9aa6-6e4398046e5b"},{"reference":"Observation/1734642836104365842.7148179d-564a-4df9-bd22-c230f7dcb93e"}]}},{"fullUrl":"DiagnosticReport/1734642836481289398.62ce13b4-be11-4411-992a-d77837e17758","resource":{"resourceType":"DiagnosticReport","id":"1734642836481289398.62ce13b4-be11-4411-992a-d77837e17758","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836356921477.f8969abf-1d45-4fdb-82ca-12ec23f1a198"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836183461107.69dcb642-2f99-4373-9e1b-e826e9ebcc68"}],"result":[{"reference":"Observation/1734642836111297162.b3873451-14ee-44c4-97d5-9bb41c989626"},{"reference":"Observation/1734642836113467783.741e468e-7fc0-4423-ac97-ee219ed19842"},{"reference":"Observation/1734642836115303725.d20a44c7-6828-4a2f-a4a7-14339af82c03"}]}},{"fullUrl":"DiagnosticReport/1734642836484595237.313b8922-17ff-47f8-9036-1dd0bb5c0312","resource":{"resourceType":"DiagnosticReport","id":"1734642836484595237.313b8922-17ff-47f8-9036-1dd0bb5c0312","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836365734843.823e99b0-bf45-433b-9dda-0fb8e7ec362c"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836184837918.8979b6cf-1ab8-4204-9afc-82152ecd657c"}],"result":[{"reference":"Observation/1734642836117814203.b4e4cf66-b844-451b-9c87-24832b6fe6ad"},{"reference":"Observation/1734642836119999360.04908077-17c5-4224-80f7-49d2066cbedb"},{"reference":"Observation/1734642836121872623.119d758a-9078-4420-aacb-94a01f1eb724"}]}},{"fullUrl":"DiagnosticReport/1734642836487660084.7412cbdc-131a-4a55-bc32-826e6c7d55b0","resource":{"resourceType":"DiagnosticReport","id":"1734642836487660084.7412cbdc-131a-4a55-bc32-826e6c7d55b0","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836374544853.68f48201-4b0d-4906-ab6e-3ae7f8a93837"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836186184714.3c7264fe-459a-4e2e-a9c4-010092f02c47"}],"result":[{"reference":"Observation/1734642836123642191.b1b92497-7ecb-42f0-9a46-d8106853e8fe"},{"reference":"Observation/1734642836125756856.c973f1c9-f4fe-4e66-8f37-7172ebe581d6"},{"reference":"Observation/1734642836127597888.34e36b07-2b51-4642-ae9d-0a8c918d2778"}]}},{"fullUrl":"DiagnosticReport/1734642836490747644.d0b2216d-bb2b-48ee-952f-26eb62e1a6a0","resource":{"resourceType":"DiagnosticReport","id":"1734642836490747644.d0b2216d-bb2b-48ee-952f-26eb62e1a6a0","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836383016629.001af554-7412-4c8d-9f84-b09b1cee4b11"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836187533964.1477cdc6-64f4-4fdb-9280-bf1f389fb11b"}],"result":[{"reference":"Observation/1734642836129662139.3d5d2c39-e93f-4dfd-886e-6af0424b7a9e"},{"reference":"Observation/1734642836131734335.0443a079-34d1-4cf9-9176-8515df7cba8a"},{"reference":"Observation/1734642836133599152.b964ea85-cf95-49f2-b92f-62328d3ea799"}]}},{"fullUrl":"DiagnosticReport/1734642836493766444.1ef481f0-049d-4035-9636-8ba48034e6e1","resource":{"resourceType":"DiagnosticReport","id":"1734642836493766444.1ef481f0-049d-4035-9636-8ba48034e6e1","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836394811491.34277100-a636-4818-bb0f-d52e9da86550"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836188904223.d33485a5-6a3c-471a-8ea6-261635fcadb2"}],"result":[{"reference":"Observation/1734642836136544444.76dec855-2215-4747-b563-5edf391e7414"},{"reference":"Observation/1734642836138511032.bbdd868a-ccbc-4dc8-afb3-ab91b493db75"}]}},{"fullUrl":"DiagnosticReport/1734642836496970072.faa9ccef-26ff-4273-a633-f56f219b527a","resource":{"resourceType":"DiagnosticReport","id":"1734642836496970072.faa9ccef-26ff-4273-a633-f56f219b527a","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836403274640.ed48ac0b-8672-428d-8673-915efc13d3f1"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836190292366.cb0738a0-5e1a-4416-94e0-b7a606b153d0"}],"result":[{"reference":"Observation/1734642836140773031.ca60eb5f-4792-4f47-9cda-4f2336385def"},{"reference":"Observation/1734642836142897444.274531bb-aba7-40ac-a4c6-b6777fa2656c"},{"reference":"Observation/1734642836144844706.bf279162-4e5f-474c-bf4f-c7405b754eed"}]}},{"fullUrl":"DiagnosticReport/1734642836500347314.577024eb-c231-462c-821a-e8479ec274fa","resource":{"resourceType":"DiagnosticReport","id":"1734642836500347314.577024eb-c231-462c-821a-e8479ec274fa","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836411995102.fe0cfdee-2504-4550-87e1-7cb602a894ee"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836191672224.0ba34d35-8ff2-417a-b212-c582abb903c6"}],"result":[{"reference":"Observation/1734642836146921300.a099f493-8f4b-406d-80e2-9937c06c29af"},{"reference":"Observation/1734642836148732836.1f0c3ba7-cca4-4716-8e12-bd556367776e"}]}},{"fullUrl":"DiagnosticReport/1734642836503350836.519e95d2-5b56-4697-b578-e00abbfe9c74","resource":{"resourceType":"DiagnosticReport","id":"1734642836503350836.519e95d2-5b56-4697-b578-e00abbfe9c74","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"753234567"}],"basedOn":[{"reference":"ServiceRequest/1734642836420484381.73a022e0-4c1a-432c-8026-e6a1182ae0c6"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734642835832318231.c7ecf760-3de3-458b-9fdf-111dd58e48ac"},"effectiveDateTime":"2024-09-26T05:12:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409260512"}]},"issued":"2024-10-18T05:00:17Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241018050017"}]},"specimen":[{"reference":"Specimen/1734642836193133473.9d77732e-0d8d-46d2-a589-d1f41fa01f86"}],"result":[{"reference":"Observation/1734642836150737746.37519cf1-4f37-441a-b91c-2effb9f3579f"}]}}]}
diff --git a/examples/Test/Automated/GoldenCopy/Expected/006_ORU_R01_golden_copy_expected_sma_incomplete.fhir b/examples/Test/Automated/GoldenCopy/Expected/006_ORU_R01_golden_copy_expected_sma_incomplete.fhir
deleted file mode 100644
index e5e8127a6..000000000
--- a/examples/Test/Automated/GoldenCopy/Expected/006_ORU_R01_golden_copy_expected_sma_incomplete.fhir
+++ /dev/null
@@ -1 +0,0 @@
-{"resourceType":"Bundle","id":"1734644417712989374.cc55157b-dcbe-4370-b6c6-4a3ea3771c14","meta":{"lastUpdated":"2024-12-19T21:40:17.713+00:00"},"identifier":{"system":"https://reportstream.cdc.gov/prime-router","value":"006"},"type":"message","timestamp":"2024-10-17T05:00:25.000+00:00","entry":[{"fullUrl":"MessageHeader/1734644417721058658.7a886438-6b05-4bb2-8fe1-0f0c6a6d4766","resource":{"resourceType":"MessageHeader","id":"1734644417721058658.7a886438-6b05-4bb2-8fe1-0f0c6a6d4766","meta":{"tag":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0103","code":"N"}]},"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/msh-message-header","extension":[{"url":"MSH.7","valueString":"20241017050025"}]}],"eventCoding":{"system":"http://terminology.hl7.org/CodeSystem/v2-0003","code":"R01","display":"ORU^R01^ORU_R01"},"destination":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id","valueString":"9413799"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/universal-id-type","valueString":"L,M,N"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.5"}],"name":"SISHIERECEIVER","receiver":{"reference":"Organization/1734644417720024427.da55d14f-568a-4b6f-8c93-bdcbf3cf27ab"}}],"sender":{"reference":"Organization/1734644417715230486.eba98586-c642-451e-9d42-69355ad93fec"},"source":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"SISGDSP"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.3"}],"name":"SISGDSP","_endpoint":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}}},{"fullUrl":"Organization/1734644417715230486.eba98586-c642-451e-9d42-69355ad93fec","resource":{"resourceType":"Organization","id":"1734644417715230486.eba98586-c642-451e-9d42-69355ad93fec","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Organization/1734644417720024427.da55d14f-568a-4b6f-8c93-bdcbf3cf27ab","resource":{"resourceType":"Organization","id":"1734644417720024427.da55d14f-568a-4b6f-8c93-bdcbf3cf27ab","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"MSH.6"}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.2,HD.3"}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301","code":"L,M,N"}]},"value":"automated-staging-test-receiver-id"}]}},{"fullUrl":"Provenance/1734644417725209468.99f9e6df-7eea-4f6c-8141-01bd0dc0635c","resource":{"resourceType":"Provenance","id":"1734644417725209468.99f9e6df-7eea-4f6c-8141-01bd0dc0635c","target":[{"reference":"MessageHeader/1734644417721058658.7a886438-6b05-4bb2-8fe1-0f0c6a6d4766"},{"reference":"DiagnosticReport/1734644419692201133.2ad02aef-7ed6-4bc3-adce-9e824308af53"},{"reference":"DiagnosticReport/1734644419699746133.2856d179-89ab-489a-b2c5-8a833fde050b"},{"reference":"DiagnosticReport/1734644419708101541.7f3385cd-e700-42c9-bf9f-f64c95825783"},{"reference":"DiagnosticReport/1734644419713813197.ad7780f2-1e1a-400e-93d9-99840b8473f7"},{"reference":"DiagnosticReport/1734644419724024842.1bdb9bcf-c477-47e5-9e0f-be76109a5cd8"},{"reference":"DiagnosticReport/1734644419729907926.637687d5-f285-4d85-8250-cdb314373590"},{"reference":"DiagnosticReport/1734644419743254406.7d857b02-136c-4d65-9fbc-3e6e6e2fa2ba"},{"reference":"DiagnosticReport/1734644419753320971.b9e3b94b-0e80-437c-94b5-a77d995ce0d2"},{"reference":"DiagnosticReport/1734644419795641896.8702cee9-f54e-498e-a150-2f00ad76356c"},{"reference":"DiagnosticReport/1734644419801980108.5b9208e0-8d9c-45c8-bd50-885179dadb43"},{"reference":"DiagnosticReport/1734644419808292983.dff75e1f-d5d1-47f5-bd35-5bd07b7f84af"},{"reference":"DiagnosticReport/1734644419815428530.5f90805a-95cf-46d6-b09c-621a5a04ea2d"},{"reference":"DiagnosticReport/1734644419824626319.2533508b-b790-45d2-ac8d-300eb7132397"},{"reference":"DiagnosticReport/1734644419834916739.fc89b70e-a2b9-4e36-b5d6-8e2a97559cbb"},{"reference":"DiagnosticReport/1734644419844156113.7e989ddd-0edc-4a05-8396-c9fdb47c50fa"},{"reference":"DiagnosticReport/1734644419853217247.ff790c55-8249-4b13-a6bd-9759c12d684e"},{"reference":"DiagnosticReport/1734644419891605519.7daa771e-1756-4760-9382-68cd500982d7"},{"reference":"DiagnosticReport/1734644419895767159.f14226b8-44f4-40bf-a324-7a7a8016dee0"},{"reference":"DiagnosticReport/1734644419902517717.17c0b4a4-255c-43f9-be8f-703d9070208b"},{"reference":"DiagnosticReport/1734644419909213707.7cfdaa0f-a324-4518-ab6f-5c948abbdc9e"},{"reference":"DiagnosticReport/1734644419915028414.66b10e65-9fb1-4019-a18d-72882f136896"},{"reference":"DiagnosticReport/1734644419920406329.ce421d8f-a0f0-4635-b581-927247c9fe9f"},{"reference":"DiagnosticReport/1734644419925358861.4ed59a37-bfc4-4deb-8e1e-feb8b7980f00"}],"recorded":"2024-10-17T05:00:25Z","activity":{"coding":[{"display":"ORU^R01^ORU_R01"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"author"}]},"who":{"reference":"Organization/1734644417724501145.59bad71a-1348-471f-bdcb-cc8f9e31fd5b"}}]}},{"fullUrl":"Organization/1734644417724501145.59bad71a-1348-471f-bdcb-cc8f9e31fd5b","resource":{"resourceType":"Organization","id":"1734644417724501145.59bad71a-1348-471f-bdcb-cc8f9e31fd5b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"SISGDSP"}]}},{"fullUrl":"Provenance/1734644417726648504.bf799ce1-2efd-4cf7-8f95-a31f4366a757","resource":{"resourceType":"Provenance","id":"1734644417726648504.bf799ce1-2efd-4cf7-8f95-a31f4366a757","recorded":"2024-12-19T21:40:17Z","policy":["http://hl7.org/fhir/uv/v2mappings/message-oru-r01-to-bundle"],"activity":{"coding":[{"code":"v2-FHIR transformation"}]},"agent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/provenance-participant-type","code":"assembler"}]},"who":{"reference":"Organization/1734644417726072719.1c99714e-4ce2-4647-b374-24e3fc74e1b2"}}]}},{"fullUrl":"Organization/1734644417726072719.1c99714e-4ce2-4647-b374-24e3fc74e1b2","resource":{"resourceType":"Organization","id":"1734644417726072719.1c99714e-4ce2-4647-b374-24e3fc74e1b2","identifier":[{"value":"CDC PRIME - Atlanta"},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0301"}]},"system":"urn:ietf:rfc:3986","value":"2.16.840.1.114222.4.1.237821"}]}},{"fullUrl":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e","resource":{"resourceType":"Patient","id":"1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cx-identifier","extension":[{"url":"CX.5","valueString":"MR"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"PID.3"}],"type":{"coding":[{"code":"MR"}]},"value":"32550867","assigner":{"reference":"Organization/1734644417728574610.d6426e71-7ff7-4b1b-a59e-978745b32a9b"}}],"name":[{"family":"*****PII REMOVED******"}],"contact":[{"name":{"family":"*****PII REMOVED******"}}]}},{"fullUrl":"Organization/1734644417728574610.d6426e71-7ff7-4b1b-a59e-978745b32a9b","resource":{"resourceType":"Organization","id":"1734644417728574610.d6426e71-7ff7-4b1b-a59e-978745b32a9b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"HD.1"}],"value":"1013163542&NPI"}]}},{"fullUrl":"Provenance/1734644417745743684.5c76bf7e-820b-4601-8c16-73dfb7e196c6","resource":{"resourceType":"Provenance","id":"1734644417745743684.5c76bf7e-820b-4601-8c16-73dfb7e196c6","target":[{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"}],"recorded":"2024-12-19T21:40:17Z","activity":{"coding":[{"system":"https://terminology.hl7.org/CodeSystem/v3-DataOperation","code":"UPDATE"}]}}},{"fullUrl":"RelatedPerson/1734644417748512892.3fc55e81-98c8-46e3-b07f-afd26c0e93ba","resource":{"resourceType":"RelatedPerson","id":"1734644417748512892.3fc55e81-98c8-46e3-b07f-afd26c0e93ba","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"NK1"}],"patient":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"name":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"NK1.2"}],"family":"*****PII REMOVED******"}]}},{"fullUrl":"Observation/1734644417796265313.e1027f5b-062f-4104-a7de-a437ae0c3842","resource":{"resourceType":"Observation","id":"1734644417796265313.e1027f5b-062f-4104-a7de-a437ae0c3842","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57721-3","display":"Reason for lab test in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12421-6","display":"Initial screen"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417801791651.d1966e09-74fb-4baa-b4b0-40544e8c0c1d","resource":{"resourceType":"Observation","id":"1734644417801791651.d1966e09-74fb-4baa-b4b0-40544e8c0c1d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57718-9","display":"Sample quality of Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12432-3","display":"Acceptable"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417817280488.4709f99d-783d-45b7-9ff6-01b35715b870","resource":{"resourceType":"Observation","id":"1734644417817280488.4709f99d-783d-45b7-9ff6-01b35715b870","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57130-7","display":"Newborn screening report - overall interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12430-7","display":"Out of range requiring further dried blood spot testing for at least one condition"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417822834817.bcb381eb-be32-44ea-ae5a-d53d349a2a8e","resource":{"resourceType":"Observation","id":"1734644417822834817.bcb381eb-be32-44ea-ae5a-d53d349a2a8e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57131-5","display":"Newborn conditions with positive markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417828340736.feb0b0a3-20f9-4dc8-ace3-1b1e85f11a91","resource":{"resourceType":"Observation","id":"1734644417828340736.feb0b0a3-20f9-4dc8-ace3-1b1e85f11a91","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57720-5","display":"Newborn conditions with equivocal markers [Identifier] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA22279-6","display":"SMA"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417832150308.c320d4f8-9a39-4f05-9836-039b965e24ff","resource":{"resourceType":"Observation","id":"1734644417832150308.c320d4f8-9a39-4f05-9836-039b965e24ff","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57724-7","display":"Newborn screening short narrative summary"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"ACTION REQUIRED\\\\.br\\\\\\\\.br\\\\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \\\\\\2130 E Illinois Avenue, FRESNO, CA 93701\\\\.br\\\\\\\\.br\\\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\\\.br\\\\\\\\.br\\\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\\\.br\\\\\\\\.br\\\\Follow-up:\\\\.br\\\\\\\\.br\\\\Spinal Muscular Atrophy (SMA): The sample was not adequate to complete testing for SMA. A repeat NBS specimen MUST be collected. \\\\.br\\\\\\\\.br\\\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Valley Children's Hospital at (559) 353-6416. \\\\.br\\\\\\\\.br\\\\Methods and Limitations:\\\\.br\\\\\\\\.br\\\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\\\.br\\\\Attention Healthcare Provider:\\\\.br\\\\\\\\.br\\\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\\\.br\\\\\\\\.br\\","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417835810822.88a720fe-d538-48d6-9794-0a3ed0ead41e","resource":{"resourceType":"Observation","id":"1734644417835810822.88a720fe-d538-48d6-9794-0a3ed0ead41e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57129-9","display":"Full newborn screening summary report for display or printing"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417839535536.85f9af6b-5ef2-4530-9974-6e21db509d5a","resource":{"resourceType":"Observation","id":"1734644417839535536.85f9af6b-5ef2-4530-9974-6e21db509d5a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"ST"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57716-3","display":"State printed on filter paper card [Identifier] in NBS card"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"CA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417843879005.412d9eb1-44e0-4b56-982b-0f2bad4203da","resource":{"resourceType":"Observation","id":"1734644417843879005.412d9eb1-44e0-4b56-982b-0f2bad4203da","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"grams"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"8339-4","display":"Birthweight"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":2875,"unit":"grams"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417847226896.1e8f8200-472d-409b-8f41-04c8ec4a81ef","resource":{"resourceType":"Observation","id":"1734644417847226896.1e8f8200-472d-409b-8f41-04c8ec4a81ef","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57715-5","display":"Time of birth"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueTime":"0202","_valueTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"0202"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417849620675.2859d891-5519-4f09-a6e2-20fa5cd90db1","resource":{"resourceType":"Observation","id":"1734644417849620675.2859d891-5519-4f09-a6e2-20fa5cd90db1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57722-1","display":"Birth plurality of Pregnancy"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12411-7","display":"Singleton"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417901619353.594eb9e5-afae-4e85-922f-198372d6c515","resource":{"resourceType":"Observation","id":"1734644417901619353.594eb9e5-afae-4e85-922f-198372d6c515","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"hour(s)"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"73806-2","display":"Newborn age in hours"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":27,"unit":"hour(s)"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417905836296.262e3b31-827d-44c8-8c59-b7529737b23d","resource":{"resourceType":"Observation","id":"1734644417905836296.262e3b31-827d-44c8-8c59-b7529737b23d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57713-0","display":"Infant NICU factors that affect newborn screening interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA137-2","display":"None"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417910044573.c13ffa5d-6957-44eb-b015-f1201536e849","resource":{"resourceType":"Observation","id":"1734644417910044573.c13ffa5d-6957-44eb-b015-f1201536e849","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67704-7","display":"Feeding types"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA16914-6","display":"Breast milk"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417913731055.ab8ae7df-d58e-4414-a546-e6c9fd583447","resource":{"resourceType":"Observation","id":"1734644417913731055.ab8ae7df-d58e-4414-a546-e6c9fd583447","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-5","display":"Accession Number"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"269-80-133/21-2024-21","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417917768954.50056553-e6ef-4dc4-b44e-3eb5654785ed","resource":{"resourceType":"Observation","id":"1734644417917768954.50056553-e6ef-4dc4-b44e-3eb5654785ed","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62324-9","display":"Post-discharge provider name"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"CHEZHIYAN MURUGESAN","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417921408098.bea1529d-7f6b-4881-82e8-cfc11f86fcb9","resource":{"resourceType":"Observation","id":"1734644417921408098.bea1529d-7f6b-4881-82e8-cfc11f86fcb9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62325-6","display":"Post-discharge provider practice ID"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"1164928032","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417926192001.558052e7-a20f-4082-b482-d15cc78f36db","resource":{"resourceType":"Observation","id":"1734644417926192001.558052e7-a20f-4082-b482-d15cc78f36db","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62327-2","display":"Post-discharge provider practice address"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"1700 MOUNT VERNON AVE BAKERSFIELD CA 93306-4018 USA","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417934188839.9e003f64-2cd4-4ce8-b35d-c19ef12574a0","resource":{"resourceType":"Observation","id":"1734644417934188839.9e003f64-2cd4-4ce8-b35d-c19ef12574a0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47633-3","display":"Glycine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":357,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417940929624.cb81d9fd-a16b-4379-8940-516118aa6777","resource":{"resourceType":"Observation","id":"1734644417940929624.cb81d9fd-a16b-4379-8940-516118aa6777","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53150-9","display":"Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":398,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1000"}]}},{"fullUrl":"Observation/1734644417945053774.0b37fbbe-851f-4b8d-ad0e-fa11edf1a52a","resource":{"resourceType":"Observation","id":"1734644417945053774.0b37fbbe-851f-4b8d-ad0e-fa11edf1a52a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47799-2","display":"Valine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":92.2,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644417948680715.cbea7c69-142e-4373-b0b1-90df672e6862","resource":{"resourceType":"Observation","id":"1734644417948680715.cbea7c69-142e-4373-b0b1-90df672e6862","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53151-7","display":"Valine/Phenylalanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":2.05804,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.3"}]}},{"fullUrl":"Observation/1734644417995017914.8ab59c9f-02bf-48a8-bf3c-d8ea7ec96914","resource":{"resourceType":"Observation","id":"1734644417995017914.8ab59c9f-02bf-48a8-bf3c-d8ea7ec96914","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53152-5","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":84.2,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<230"}]}},{"fullUrl":"Observation/1734644417999433067.13ba34a2-018a-4a84-8fe9-9e7ace7bcc87","resource":{"resourceType":"Observation","id":"1734644417999433067.13ba34a2-018a-4a84-8fe9-9e7ace7bcc87","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53154-1","display":"Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.21,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.35"}]}},{"fullUrl":"Observation/1734644418003515930.4796ac80-baa6-49b8-9771-3a7469ee2bb2","resource":{"resourceType":"Observation","id":"1734644418003515930.4796ac80-baa6-49b8-9771-3a7469ee2bb2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29573-3","display":"Phenylalanine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":44.8,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<175"}]}},{"fullUrl":"Observation/1734644418008267091.02fa4769-70d2-4054-bc36-4f90b3120c6d","resource":{"resourceType":"Observation","id":"1734644418008267091.02fa4769-70d2-4054-bc36-4f90b3120c6d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35572-7","display":"Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.55,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2.6"}]}},{"fullUrl":"Observation/1734644418012713502.2f78fefe-c6c8-4c8b-acc7-c1df8afeb156","resource":{"resourceType":"Observation","id":"1734644418012713502.2f78fefe-c6c8-4c8b-acc7-c1df8afeb156","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"35571-9","display":"Tyrosine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":81.7,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<680"}]}},{"fullUrl":"Observation/1734644418021388799.e22403f3-7063-4e1f-af4d-50186683a151","resource":{"resourceType":"Observation","id":"1734644418021388799.e22403f3-7063-4e1f-af4d-50186683a151","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53231-7","display":"Succinylacetone [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.20,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<6.1"}]}},{"fullUrl":"Observation/1734644418026031315.75cd7314-4f23-4832-8d01-abf7aef0274d","resource":{"resourceType":"Observation","id":"1734644418026031315.75cd7314-4f23-4832-8d01-abf7aef0274d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47700-0","display":"Methionine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":11.1,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.3-100"}]}},{"fullUrl":"Observation/1734644418029829796.368ea25e-8c14-4c22-bbc7-3588ae105bbf","resource":{"resourceType":"Observation","id":"1734644418029829796.368ea25e-8c14-4c22-bbc7-3588ae105bbf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42892-0","display":"Citrulline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":12,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"5-49"}]}},{"fullUrl":"Observation/1734644418033695132.917f591d-3498-4d01-80e7-873f7ffd7f95","resource":{"resourceType":"Observation","id":"1734644418033695132.917f591d-3498-4d01-80e7-873f7ffd7f95","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54092-2","display":"Citrulline/Arginine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":1.72,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<4.8"}]}},{"fullUrl":"Observation/1734644418040086104.5505ce91-e769-41c0-873c-ef885b42d953","resource":{"resourceType":"Observation","id":"1734644418040086104.5505ce91-e769-41c0-873c-ef885b42d953","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53155-8","display":"Asparagine+Ornithine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":77,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<800"}]}},{"fullUrl":"Observation/1734644418044605051.f55b07d2-8020-4fbb-b2be-1b46e9a79c9d","resource":{"resourceType":"Observation","id":"1734644418044605051.f55b07d2-8020-4fbb-b2be-1b46e9a79c9d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75215-4","display":"Ornithine/Citrulline [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":6.36,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418093990132.cc313c65-e85f-42a1-88ee-9814ad9e94ea","resource":{"resourceType":"Observation","id":"1734644418093990132.cc313c65-e85f-42a1-88ee-9814ad9e94ea","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47562-4","display":"Arginine [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":7,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<63"}]}},{"fullUrl":"Observation/1734644418098585802.cf01bcc2-5850-43e2-8eb9-a86c44a39080","resource":{"resourceType":"Observation","id":"1734644418098585802.cf01bcc2-5850-43e2-8eb9-a86c44a39080","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75214-7","display":"Arginine/Ornithine [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.09,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.9"}]}},{"fullUrl":"Observation/1734644418102931204.e5eda334-8162-4db0-9190-24d0fe3c672b","resource":{"resourceType":"Observation","id":"1734644418102931204.e5eda334-8162-4db0-9190-24d0fe3c672b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"47732-3","display":"Proline [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":136,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1500"}]}},{"fullUrl":"Observation/1734644418107103955.74d90a40-ba93-4a8d-a75c-7b9c59ccf5f4","resource":{"resourceType":"Observation","id":"1734644418107103955.74d90a40-ba93-4a8d-a75c-7b9c59ccf5f4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57710-6","display":"Amino acidemias newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418111524768.93fe9a7e-4aa3-4caa-9089-55680c2d733a","resource":{"resourceType":"Observation","id":"1734644418111524768.93fe9a7e-4aa3-4caa-9089-55680c2d733a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58088-6","display":"Acylcarnitine newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418115768261.bee34a03-fcca-4734-9362-e100f2d283d3","resource":{"resourceType":"Observation","id":"1734644418115768261.bee34a03-fcca-4734-9362-e100f2d283d3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"58093-6","display":"Acylcarnitine newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418119703177.721be05d-2352-4e12-b098-5abf93c94476","resource":{"resourceType":"Observation","id":"1734644418119703177.721be05d-2352-4e12-b098-5abf93c94476","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38481-8","display":"Carnitine.free (C0)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":16.4,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"6.4-125"}]}},{"fullUrl":"Observation/1734644418123703845.f6f91fa7-f88a-4b8c-a2f5-3393be2541fb","resource":{"resourceType":"Observation","id":"1734644418123703845.f6f91fa7-f88a-4b8c-a2f5-3393be2541fb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53235-8","display":"Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":3.65,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<70"}]}},{"fullUrl":"Observation/1734644418127929775.83fdc8dd-09f2-48d2-a3c6-d3ed0b9d2e8a","resource":{"resourceType":"Observation","id":"1734644418127929775.83fdc8dd-09f2-48d2-a3c6-d3ed0b9d2e8a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50157-7","display":"Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":16.1,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"10-80"}]}},{"fullUrl":"Observation/1734644418132508163.f290c980-f194-41af-b4cf-96dbe04d1922","resource":{"resourceType":"Observation","id":"1734644418132508163.f290c980-f194-41af-b4cf-96dbe04d1922","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75212-1","display":"Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":2.06977,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.6"}]}},{"fullUrl":"Observation/1734644418136460852.49698eb0-f1bb-49da-a2c9-15aa906f5ab7","resource":{"resourceType":"Observation","id":"1734644418136460852.49698eb0-f1bb-49da-a2c9-15aa906f5ab7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45211-0","display":"Hexanoylcarnitine (C6)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.075,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734644418140546971.d1ec4a52-6d49-4afa-b000-46992ea08cca","resource":{"resourceType":"Observation","id":"1734644418140546971.d1ec4a52-6d49-4afa-b000-46992ea08cca","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53175-6","display":"Octanoylcarnitine (C8)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.049,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734644418144386619.7e5499dd-ad54-4277-81e4-e0d87915ed35","resource":{"resourceType":"Observation","id":"1734644418144386619.7e5499dd-ad54-4277-81e4-e0d87915ed35","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53177-2","display":"Octanoylcarnitine (C8)/Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":1.14,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418148488928.7ba1d26d-aebe-4485-bceb-6b2d8e2dd188","resource":{"resourceType":"Observation","id":"1734644418148488928.7ba1d26d-aebe-4485-bceb-6b2d8e2dd188","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53174-9","display":"Octenoylcarnitine (C8:1)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.042,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734644418191368502.288fd0c2-03af-4187-85b8-ab768fa53a09","resource":{"resourceType":"Observation","id":"1734644418191368502.288fd0c2-03af-4187-85b8-ab768fa53a09","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45197-1","display":"Decanoylcarnitine (C10)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.043,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.65"}]}},{"fullUrl":"Observation/1734644418196156441.744c7d3a-5d71-4e9a-81c3-c8dc52d50f4d","resource":{"resourceType":"Observation","id":"1734644418196156441.744c7d3a-5d71-4e9a-81c3-c8dc52d50f4d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45198-9","display":"Decenoylcarnitine (C10:1)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.026,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.45"}]}},{"fullUrl":"Observation/1734644418199881245.c30f9674-dc49-4092-a2e8-91af248d5f7a","resource":{"resourceType":"Observation","id":"1734644418199881245.c30f9674-dc49-4092-a2e8-91af248d5f7a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45199-7","display":"Dodecanoylcarnitine (C12)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.071,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<2"}]}},{"fullUrl":"Observation/1734644418203506753.3bab0f68-99a9-49bf-bfb1-aeb3c9c77ec7","resource":{"resourceType":"Observation","id":"1734644418203506753.3bab0f68-99a9-49bf-bfb1-aeb3c9c77ec7","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45200-3","display":"Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.05,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418207148533.cfc80263-3390-43a3-871a-d1a2ae645258","resource":{"resourceType":"Observation","id":"1734644418207148533.cfc80263-3390-43a3-871a-d1a2ae645258","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53192-1","display":"Tetradecanoylcarnitine (C14)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.169,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.2"}]}},{"fullUrl":"Observation/1734644418210779091.028a38d8-7995-4c1d-9b88-eaaa5ba7c96e","resource":{"resourceType":"Observation","id":"1734644418210779091.028a38d8-7995-4c1d-9b88-eaaa5ba7c96e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53191-3","display":"Tetradecenoylcarnitine (C14:1)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.099,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.9"}]}},{"fullUrl":"Observation/1734644418213596932.7f4c433c-ee26-44a9-8455-2769977faf77","resource":{"resourceType":"Observation","id":"1734644418213596932.7f4c433c-ee26-44a9-8455-2769977faf77","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53194-7","display":"Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":1.98,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418216350292.40cd4740-470e-4f15-8981-2329f67c1c94","resource":{"resourceType":"Observation","id":"1734644418216350292.40cd4740-470e-4f15-8981-2329f67c1c94","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53190-5","display":"Tetradecadienoylcarnitine (C14:2)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.02,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418218653241.149832b5-0f86-47ed-bb76-05ce5ca9aab0","resource":{"resourceType":"Observation","id":"1734644418218653241.149832b5-0f86-47ed-bb76-05ce5ca9aab0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50281-5","display":"3-Hydroxytetradecanoylcarnitine (C14-OH)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.015,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.2"}]}},{"fullUrl":"Observation/1734644418221583851.593fe756-7b65-4bbd-92db-582d5e5afbc2","resource":{"resourceType":"Observation","id":"1734644418221583851.593fe756-7b65-4bbd-92db-582d5e5afbc2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53199-6","display":"Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":2.91,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<12"}]}},{"fullUrl":"Observation/1734644418225384797.3e7f8946-d817-4a06-9a98-7b737600509e","resource":{"resourceType":"Observation","id":"1734644418225384797.3e7f8946-d817-4a06-9a98-7b737600509e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53198-8","display":"Palmitoleylcarnitine (C16:1)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.221,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.4"}]}},{"fullUrl":"Observation/1734644418229985066.d45b748c-ce86-4727-b2b4-f129aa596d8e","resource":{"resourceType":"Observation","id":"1734644418229985066.d45b748c-ce86-4727-b2b4-f129aa596d8e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50125-4","display":"3-Hydroxypalmitoylcarnitine (C16-OH)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.021,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734644418234159048.af1803d4-bf00-473c-83f5-615b44d3edce","resource":{"resourceType":"Observation","id":"1734644418234159048.af1803d4-bf00-473c-83f5-615b44d3edce","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53201-0","display":"3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.00722,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.07"}]}},{"fullUrl":"Observation/1734644418238266898.2ce39b9d-24ba-4d82-bb08-dadf2f95d23e","resource":{"resourceType":"Observation","id":"1734644418238266898.2ce39b9d-24ba-4d82-bb08-dadf2f95d23e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53241-6","display":"Stearoylcarnitine (C18)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.827,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<3.5"}]}},{"fullUrl":"Observation/1734644418242142654.4f2ffedd-052e-4a97-a19a-54dae982f8f2","resource":{"resourceType":"Observation","id":"1734644418242142654.4f2ffedd-052e-4a97-a19a-54dae982f8f2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53202-8","display":"Oleoylcarnitine (C18:1)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":1.58,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7"}]}},{"fullUrl":"Observation/1734644418245893376.05943385-5946-4586-8cf0-1d7d13a692da","resource":{"resourceType":"Observation","id":"1734644418245893376.05943385-5946-4586-8cf0-1d7d13a692da","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45217-7","display":"Linoleoylcarnitine (C18:2)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.14,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418249640091.14f79a31-0c80-46ef-89f5-40709968d8d2","resource":{"resourceType":"Observation","id":"1734644418249640091.14f79a31-0c80-46ef-89f5-40709968d8d2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50132-0","display":"3-Hydroxystearoylcarnitine (C18-OH)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.013,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734644418253450154.8d0b683a-d872-4129-bfb6-c321e28bfa6c","resource":{"resourceType":"Observation","id":"1734644418253450154.8d0b683a-d872-4129-bfb6-c321e28bfa6c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50113-0","display":"3-Hydroxyoleoylcarnitine (C18:1-OH)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.028,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.1"}]}},{"fullUrl":"Observation/1734644418293578752.14a30ea3-9496-4275-9041-0d4f226b3e10","resource":{"resourceType":"Observation","id":"1734644418293578752.14a30ea3-9496-4275-9041-0d4f226b3e10","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53160-8","display":"Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":1.7,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<7.9"}]}},{"fullUrl":"Observation/1734644418297352457.ca225056-4647-42f7-9d82-8666c248bfd3","resource":{"resourceType":"Observation","id":"1734644418297352457.ca225056-4647-42f7-9d82-8666c248bfd3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53163-2","display":"Propionylcarnitine (C3)/Acetylcarnitine (C2)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.10,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.42"}]}},{"fullUrl":"Observation/1734644418301167169.dc0d0885-fbbe-42a9-8f4f-c4039fd42832","resource":{"resourceType":"Observation","id":"1734644418301167169.dc0d0885-fbbe-42a9-8f4f-c4039fd42832","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67708-8","display":"Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.089,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.48"}]}},{"fullUrl":"Observation/1734644418304937408.28c2882f-3e75-415d-aad7-a1ee08e419f3","resource":{"resourceType":"Observation","id":"1734644418304937408.28c2882f-3e75-415d-aad7-a1ee08e419f3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53166-5","display":"Butyrylcarnitine+Isobutyrylcarnitine (C4)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.229,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.7"}]}},{"fullUrl":"Observation/1734644418308939570.1de34fdf-fdd0-4874-be02-304d3373d9ff","resource":{"resourceType":"Observation","id":"1734644418308939570.1de34fdf-fdd0-4874-be02-304d3373d9ff","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"45216-9","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.081,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.95"}]}},{"fullUrl":"Observation/1734644418312767997.dfb7ee39-8914-431d-afc1-00f585bb57fd","resource":{"resourceType":"Observation","id":"1734644418312767997.dfb7ee39-8914-431d-afc1-00f585bb57fd","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53240-8","display":"Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.04765,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734644418316602957.c6889d3f-c145-45ea-8205-8649bff1e55c","resource":{"resourceType":"Observation","id":"1734644418316602957.c6889d3f-c145-45ea-8205-8649bff1e55c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"53170-7","display":"Tiglylcarnitine (C5:1)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.005,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.5"}]}},{"fullUrl":"Observation/1734644418320444569.2adf1156-3d36-431c-bc8b-28338e20e858","resource":{"resourceType":"Observation","id":"1734644418320444569.2adf1156-3d36-431c-bc8b-28338e20e858","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"50106-4","display":"3-Hydroxyisovalerylcarnitine (C5-OH)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.216,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<1.15"}]}},{"fullUrl":"Observation/1734644418326047982.ba4822cb-d64b-4acf-958e-6b9c8db6d3d4","resource":{"resourceType":"Observation","id":"1734644418326047982.ba4822cb-d64b-4acf-958e-6b9c8db6d3d4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"67710-4","display":"Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.080,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.38"}]}},{"fullUrl":"Observation/1734644418330183463.5d0101f7-90b2-4eee-9a2e-47386c89b7a0","resource":{"resourceType":"Observation","id":"1734644418330183463.5d0101f7-90b2-4eee-9a2e-47386c89b7a0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"{Ratio}"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75216-2","display":"Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.89888,"unit":"{Ratio}"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">0.1"}]}},{"fullUrl":"Observation/1734644418333982285.fcc21c8a-6157-427e-b6f8-62fefe57d81a","resource":{"resourceType":"Observation","id":"1734644418333982285.fcc21c8a-6157-427e-b6f8-62fefe57d81a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ng/mL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"48633-2","display":"Trypsinogen I.free"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":20.90,"unit":"ng/mL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<69"}]}},{"fullUrl":"Observation/1734644418337729531.0f74bef2-2ae5-4599-b4ba-6a4adc56d5ff","resource":{"resourceType":"Observation","id":"1734644418337729531.0f74bef2-2ae5-4599-b4ba-6a4adc56d5ff","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46769-6","display":"Cystic fibrosis newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418340904849.5e94cf89-bdd1-467d-a1c6-82f3582339b8","resource":{"resourceType":"Observation","id":"1734644418340904849.5e94cf89-bdd1-467d-a1c6-82f3582339b8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57707-2","display":"Cystic fibrosis newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418344428438.9c359bf0-d4f2-4239-b942-6f4cd91861bb","resource":{"resourceType":"Observation","id":"1734644418344428438.9c359bf0-d4f2-4239-b942-6f4cd91861bb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"nmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"38473-5","display":"17-Hydroxyprogesterone"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":7.6,"unit":"nmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<85"}]}},{"fullUrl":"Observation/1734644418348157459.988552ff-1822-44f3-86a8-dc7e3e817126","resource":{"resourceType":"Observation","id":"1734644418348157459.988552ff-1822-44f3-86a8-dc7e3e817126","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46758-9","display":"Congenital adrenal hyperplasia newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418351257387.1c0d6804-ff3d-4450-857f-e4fc186532ac","resource":{"resourceType":"Observation","id":"1734644418351257387.1c0d6804-ff3d-4450-857f-e4fc186532ac","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57706-4","display":"Congenital adrenal hyperplasia newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418354740069.f2d1242a-d7ef-4e64-969f-8bd8197ad869","resource":{"resourceType":"Observation","id":"1734644418354740069.f2d1242a-d7ef-4e64-969f-8bd8197ad869","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"mIU/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"29575-8","display":"Thyrotropin"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":6.10,"unit":"mIU/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<29"}]}},{"fullUrl":"Observation/1734644418358362071.2488ad7b-566c-4537-9135-55507da8d836","resource":{"resourceType":"Observation","id":"1734644418358362071.2488ad7b-566c-4537-9135-55507da8d836","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46762-1","display":"Congenital hypothyroidism newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418361380556.25749106-cfb2-4331-9185-dfd0950ef84f","resource":{"resourceType":"Observation","id":"1734644418361380556.25749106-cfb2-4331-9185-dfd0950ef84f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57705-6","display":"Congenital hypothyroidism newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418393365701.2a730407-04f1-4256-b77c-eb0b3f0a998e","resource":{"resourceType":"Observation","id":"1734644418393365701.2a730407-04f1-4256-b77c-eb0b3f0a998e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"enzyme units"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"42906-8","display":"Galactose 1 phosphate uridyl transferase"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":173.29,"unit":"enzyme units"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">50"}]}},{"fullUrl":"Observation/1734644418397214977.1ce1b2dd-c08c-4ec5-80e2-e8a755828a4d","resource":{"resourceType":"Observation","id":"1734644418397214977.1ce1b2dd-c08c-4ec5-80e2-e8a755828a4d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46737-3","display":"Galactosemias newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418400448865.1b9837e7-ea8a-4660-a819-d7676389342f","resource":{"resourceType":"Observation","id":"1734644418400448865.1b9837e7-ea8a-4660-a819-d7676389342f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57704-9","display":"Galactosemias newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418404113797.7610a136-ea9b-4e83-adc2-f7ff013917f0","resource":{"resourceType":"Observation","id":"1734644418404113797.7610a136-ea9b-4e83-adc2-f7ff013917f0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"54104-5","display":"Hemoglobin pattern"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"FA"}},{"fullUrl":"Observation/1734644418407114199.402af6e9-5586-4d2a-a454-631b42f198aa","resource":{"resourceType":"Observation","id":"1734644418407114199.402af6e9-5586-4d2a-a454-631b42f198aa","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57703-1","display":"Hemoglobin disorders newborn screening comment/discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants."}},{"fullUrl":"Observation/1734644418410319112.d5601183-0925-4034-8c0c-9093786f4eaf","resource":{"resourceType":"Observation","id":"1734644418410319112.d5601183-0925-4034-8c0c-9093786f4eaf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"ERU"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"75217-0","display":"Biotinidase [Enzymatic activity/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":45.57,"unit":"ERU"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">10"}]}},{"fullUrl":"Observation/1734644418414140146.2afa3160-ba41-4195-bbfc-3a52ed753110","resource":{"resourceType":"Observation","id":"1734644418414140146.2afa3160-ba41-4195-bbfc-3a52ed753110","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"46761-3","display":"Biotinidase deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418417337565.c54cbd66-59e0-42ab-b1cf-9951adef0da2","resource":{"resourceType":"Observation","id":"1734644418417337565.c54cbd66-59e0-42ab-b1cf-9951adef0da2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"57699-1","display":"Biotinidase deficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418421163518.e6b7164c-753b-47dc-a9fa-5f4f42d2e3b4","resource":{"resourceType":"Observation","id":"1734644418421163518.e6b7164c-753b-47dc-a9fa-5f4f42d2e3b4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"copies/µL"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62320-7","display":"T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":215,"unit":"copies/µL"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">18"}]}},{"fullUrl":"Observation/1734644418424925822.56a4ebf0-c340-44d8-b9c2-9f6c84adfc83","resource":{"resourceType":"Observation","id":"1734644418424925822.56a4ebf0-c340-44d8-b9c2-9f6c84adfc83","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62321-5","display":"Severe combined immunodeficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418428008677.d1c355fd-aa64-4f6f-83ed-facf1540b17f","resource":{"resourceType":"Observation","id":"1734644418428008677.d1c355fd-aa64-4f6f-83ed-facf1540b17f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"62322-3","display":"Severe combined immunodeficiency newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418431524932.c31b6c3b-c057-4ce7-b829-ebfc3b80d4d2","resource":{"resourceType":"Observation","id":"1734644418431524932.c31b6c3b-c057-4ce7-b829-ebfc3b80d4d2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55827-0","display":"Acid alpha glucosidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":6.94,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=1.54"}]}},{"fullUrl":"Observation/1734644418435131746.67b40486-a401-4f82-8575-dd4b8c30a0f0","resource":{"resourceType":"Observation","id":"1734644418435131746.67b40486-a401-4f82-8575-dd4b8c30a0f0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63415-4","display":"Pompe Disease deficiency newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418438178153.78db2e15-e743-43b1-80bb-db636e6de3c5","resource":{"resourceType":"Observation","id":"1734644418438178153.78db2e15-e743-43b1-80bb-db636e6de3c5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"63416-2","display":"Pompe Disease deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418441661076.c9805208-4a21-4978-9655-a19ad765ec84","resource":{"resourceType":"Observation","id":"1734644418441661076.c9805208-4a21-4978-9655-a19ad765ec84","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"55909-6","display":"Alpha-L-iduronidase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":6.11,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=0.79"}]}},{"fullUrl":"Observation/1734644418448447536.bee743ae-abb4-4b2e-b85d-2570afb8be3f","resource":{"resourceType":"Observation","id":"1734644418448447536.bee743ae-abb4-4b2e-b85d-2570afb8be3f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79564-1","display":"Mucopolysaccharidosis type I newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418493996336.22471e9e-7dfc-469f-bcea-a38b92726aa9","resource":{"resourceType":"Observation","id":"1734644418493996336.22471e9e-7dfc-469f-bcea-a38b92726aa9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79565-8","display":"Mucopolysaccharidosis type I newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418498838813.52242f5f-fbf3-4a2a-b760-989a9c456d6e","resource":{"resourceType":"Observation","id":"1734644418498838813.52242f5f-fbf3-4a2a-b760-989a9c456d6e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92004-1","display":"Spinal muscular atrophy newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA12430-7","display":"Out of range requiring further dried blood spot testing for at least one condition"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"A"}]}]}},{"fullUrl":"Observation/1734644418502456380.093781b0-cfed-4ae7-a908-4f436a995c79","resource":{"resourceType":"Observation","id":"1734644418502456380.093781b0-cfed-4ae7-a908-4f436a995c79","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"92003-3","display":"Spinal muscular atrophy newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"SMA Incomplete","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"A"}]}]}},{"fullUrl":"Observation/1734644418506522742.50a3e79d-3451-4210-8959-d95579c2a5f9","resource":{"resourceType":"Observation","id":"1734644418506522742.50a3e79d-3451-4210-8959-d95579c2a5f9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L/h"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79462-8","display":"Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":25.27,"unit":"µmol/L/h"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":">=2.91"}]}},{"fullUrl":"Observation/1734644418510765923.b268b63d-6738-4acc-a52c-1f93cc540c6d","resource":{"resourceType":"Observation","id":"1734644418510765923.b268b63d-6738-4acc-a52c-1f93cc540c6d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104189-6","display":"Mucopolysaccharidosis type II newborn screen interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418514265800.fb13696e-d60b-4387-ab7d-5e390c6785f8","resource":{"resourceType":"Observation","id":"1734644418514265800.fb13696e-d60b-4387-ab7d-5e390c6785f8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104190-4","display":"Mucopolysaccharidosis type II newborn screening comment-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418523112493.124c6ef4-414a-4c05-ac23-ce4a55fa0d36","resource":{"resourceType":"Observation","id":"1734644418523112493.124c6ef4-414a-4c05-ac23-ce4a55fa0d36","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104192-0","display":"Guanidinoacetate methyltransferase deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418526909052.d1f48023-23d5-4ba4-aa24-8cbc40397c14","resource":{"resourceType":"Observation","id":"1734644418526909052.d1f48023-23d5-4ba4-aa24-8cbc40397c14","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104193-8","display":"Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418530955497.84aa3c0e-67f7-4b13-b789-ab6f0feafdb6","resource":{"resourceType":"Observation","id":"1734644418530955497.84aa3c0e-67f7-4b13-b789-ab6f0feafdb6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"93488-5","display":"Guanidinoacetate [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":1.10,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=3"}]}},{"fullUrl":"Observation/1734644418534982045.9a9f7f72-97b4-4c19-872f-20f2394874e0","resource":{"resourceType":"Observation","id":"1734644418534982045.9a9f7f72-97b4-4c19-872f-20f2394874e0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104194-6","display":"Creatine [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":431.20,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418538478716.748366b9-a826-4acf-a52d-d851375becbc","resource":{"resourceType":"Observation","id":"1734644418538478716.748366b9-a826-4acf-a52d-d851375becbc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"104195-3","display":"GUAC/CRE Ratio [moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":2.56},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<=6"}]}},{"fullUrl":"Observation/1734644418542644844.703dd0ec-0ac3-4d6a-8b48-a876529184f2","resource":{"resourceType":"Observation","id":"1734644418542644844.703dd0ec-0ac3-4d6a-8b48-a876529184f2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"CE"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-32","display":"Adrenoleukodystrophy deficiency newborn screening interpretation"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"LA18592-8","display":"In range"}]},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418546025989.a78bf05f-9bbd-4182-a893-c88b2a757930","resource":{"resourceType":"Observation","id":"1734644418546025989.a78bf05f-9bbd-4182-a893-c88b2a757930","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"TX"},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-33","display":"Adrenoleukodystrophy deficiency newborn screening comments-discussion"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueString":"Negative","interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}]}},{"fullUrl":"Observation/1734644418594486407.d26e1831-e4a9-4eed-a2e3-9e160856d54c","resource":{"resourceType":"Observation","id":"1734644418594486407.d26e1831-e4a9-4eed-a2e3-9e160856d54c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sub-id","valueString":"1"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obx-observation","extension":[{"url":"OBX.2","valueId":"NM"},{"url":"OBX.6","valueCodeableConcept":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"µmol/L"}]}},{"url":"OBX.11","valueString":"F"}]}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"LN"}],"system":"http://loinc.org","code":"79321-6","display":"Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-10-17T05:00:25Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"valueQuantity":{"value":0.242,"unit":"µmol/L"},"interpretation":[{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"N"}]}],"referenceRange":[{"text":"<0.47"}]}},{"fullUrl":"Specimen/1734644418620013889.578eeedf-2fac-4a73-b8e8-e2f399dd8080","resource":{"resourceType":"Specimen","id":"1734644418620013889.578eeedf-2fac-4a73-b8e8-e2f399dd8080","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418623086931.a10f8b61-0456-42ac-93fb-71963e42e3af","resource":{"resourceType":"Specimen","id":"1734644418623086931.a10f8b61-0456-42ac-93fb-71963e42e3af","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418625861998.068c0946-33c1-4698-b262-4e7424380350","resource":{"resourceType":"Specimen","id":"1734644418625861998.068c0946-33c1-4698-b262-4e7424380350","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418628855693.4abd5487-e297-4db8-a03e-ad70e82ea7e0","resource":{"resourceType":"Specimen","id":"1734644418628855693.4abd5487-e297-4db8-a03e-ad70e82ea7e0","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418631682897.6a14062a-0df8-478b-80f6-a2818b88b0b2","resource":{"resourceType":"Specimen","id":"1734644418631682897.6a14062a-0df8-478b-80f6-a2818b88b0b2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418634469316.8d4cdaf4-1d61-48a9-8208-ab69319553bf","resource":{"resourceType":"Specimen","id":"1734644418634469316.8d4cdaf4-1d61-48a9-8208-ab69319553bf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418637227352.d3880a49-7276-46f6-b4a6-c2275c7e258a","resource":{"resourceType":"Specimen","id":"1734644418637227352.d3880a49-7276-46f6-b4a6-c2275c7e258a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418640004242.4c4fbcdf-9bb7-42c3-a7fd-b23a6bf81c6d","resource":{"resourceType":"Specimen","id":"1734644418640004242.4c4fbcdf-9bb7-42c3-a7fd-b23a6bf81c6d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418642858898.e93b7cc7-d555-4fdb-ad7c-60fd187217ab","resource":{"resourceType":"Specimen","id":"1734644418642858898.e93b7cc7-d555-4fdb-ad7c-60fd187217ab","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418645609720.a2aeb8f8-c2d0-4c45-8524-369c698ab7e9","resource":{"resourceType":"Specimen","id":"1734644418645609720.a2aeb8f8-c2d0-4c45-8524-369c698ab7e9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418692924444.2362eec6-8892-4e80-b9a5-92159ca55d7a","resource":{"resourceType":"Specimen","id":"1734644418692924444.2362eec6-8892-4e80-b9a5-92159ca55d7a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418697846760.72e82496-50e8-48d9-ab40-7aad8ef84ebc","resource":{"resourceType":"Specimen","id":"1734644418697846760.72e82496-50e8-48d9-ab40-7aad8ef84ebc","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418700728436.ebc0946d-66c6-4188-a3fb-3c81fb392782","resource":{"resourceType":"Specimen","id":"1734644418700728436.ebc0946d-66c6-4188-a3fb-3c81fb392782","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418703664102.7fc22a83-8356-4ab2-9428-7e35ea9e9d86","resource":{"resourceType":"Specimen","id":"1734644418703664102.7fc22a83-8356-4ab2-9428-7e35ea9e9d86","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418706669478.8228a2e2-0c7e-498c-a308-7a3f71673738","resource":{"resourceType":"Specimen","id":"1734644418706669478.8228a2e2-0c7e-498c-a308-7a3f71673738","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418709452811.2b287078-a334-49ad-b97f-3acecf74cf69","resource":{"resourceType":"Specimen","id":"1734644418709452811.2b287078-a334-49ad-b97f-3acecf74cf69","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418713689710.c3c889e5-e87f-4c32-bf89-1cd1441c6b1e","resource":{"resourceType":"Specimen","id":"1734644418713689710.c3c889e5-e87f-4c32-bf89-1cd1441c6b1e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418716488452.b532b0c6-066b-4835-a0cb-73fa3d91c5a3","resource":{"resourceType":"Specimen","id":"1734644418716488452.b532b0c6-066b-4835-a0cb-73fa3d91c5a3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418720058990.326688c9-38c2-47c9-b11b-f09becbe0353","resource":{"resourceType":"Specimen","id":"1734644418720058990.326688c9-38c2-47c9-b11b-f09becbe0353","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418722906983.caa6ec68-8fe7-4db7-a48a-fe3ae2803810","resource":{"resourceType":"Specimen","id":"1734644418722906983.caa6ec68-8fe7-4db7-a48a-fe3ae2803810","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418725664248.3b13f6ec-0467-45ef-a3b9-224ea8059b9a","resource":{"resourceType":"Specimen","id":"1734644418725664248.3b13f6ec-0467-45ef-a3b9-224ea8059b9a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418728439666.e23f8e93-1f86-42b3-956d-952e01b4d8a8","resource":{"resourceType":"Specimen","id":"1734644418728439666.e23f8e93-1f86-42b3-956d-952e01b4d8a8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"Specimen/1734644418731522697.fcb6d558-720e-4d6f-9a85-25ea41a92f68","resource":{"resourceType":"Specimen","id":"1734644418731522697.fcb6d558-720e-4d6f-9a85-25ea41a92f68","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Segment","valueString":"OBR"}],"collection":{"collectedDateTime":"2024-09-24T05:45:00Z","_collectedDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}}}},{"fullUrl":"ServiceRequest/1734644418806932054.3ea607c6-5dbb-4897-9078-d6595b5abb1c","resource":{"resourceType":"ServiceRequest","id":"1734644418806932054.3ea607c6-5dbb-4897-9078-d6595b5abb1c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/business-event","valueCode":"RE"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/orc-common-order","extension":[{"url":"orc-21-ordering-facility-name","valueReference":{"reference":"Organization/1734644418793486307.9ac2044f-5f92-4f10-8dc4-194eb41d27c3"}},{"url":"orc-22-ordering-facility-address","valueAddress":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"1700 MOUNT VERNON AVE"}]}]}],"line":["1700 MOUNT VERNON AVE"],"city":"BAKERSFIELD","state":"CA","postalCode":"93306-4018"}},{"url":"orc-12-ordering-provider","valueReference":{"reference":"Practitioner/1734644418798757553.b363d07f-34dd-4bd5-8f90-c78d2c0aa7f3"}}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.2","valueIdentifier":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"value":"789876543"}},{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644418802666952.3e10c967-c5ef-4bfb-a3ec-8e4692398f37"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"PractitionerRole/1734644418736978436.993f62a0-6365-45c2-83dd-3faa19bd5b9e"}}},{"fullUrl":"Practitioner/1734644418740136656.66835f6f-a425-4c14-82c5-93e6f75f3286","resource":{"resourceType":"Practitioner","id":"1734644418740136656.66835f6f-a425-4c14-82c5-93e6f75f3286","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"},{"url":"XCN.10","valueString":"NPI"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.12"}],"identifier":[{"value":"1164928032"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Organization/1734644418744448816.a0f710bf-02ad-4497-98ac-ec5fd7321503","resource":{"resourceType":"Organization","id":"1734644418744448816.a0f710bf-02ad-4497-98ac-ec5fd7321503","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R092"}]}],"identifier":[{"value":"R092"}],"name":"KERN MEDICAL CENTER","telecom":[{"_system":{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/data-absent-reason","valueCode":"unknown"}]}}],"address":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xad-address","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/sad-address-line","extension":[{"url":"SAD.1","valueString":"1700 MOUNT VERNON AVE"}]}]}],"line":["1700 MOUNT VERNON AVE"],"city":"BAKERSFIELD","state":"CA","postalCode":"93306-4018"}]}},{"fullUrl":"PractitionerRole/1734644418736978436.993f62a0-6365-45c2-83dd-3faa19bd5b9e","resource":{"resourceType":"PractitionerRole","id":"1734644418736978436.993f62a0-6365-45c2-83dd-3faa19bd5b9e","practitioner":{"reference":"Practitioner/1734644418740136656.66835f6f-a425-4c14-82c5-93e6f75f3286"},"organization":{"reference":"Organization/1734644418744448816.a0f710bf-02ad-4497-98ac-ec5fd7321503"}}},{"fullUrl":"Organization/1734644418793486307.9ac2044f-5f92-4f10-8dc4-194eb41d27c3","resource":{"resourceType":"Organization","id":"1734644418793486307.9ac2044f-5f92-4f10-8dc4-194eb41d27c3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xon-organization","extension":[{"url":"XON.10","valueString":"R092"}]}],"identifier":[{"value":"R092"}],"name":"KERN MEDICAL CENTER"}},{"fullUrl":"Practitioner/1734644418798757553.b363d07f-34dd-4bd5-8f90-c78d2c0aa7f3","resource":{"resourceType":"Practitioner","id":"1734644418798757553.b363d07f-34dd-4bd5-8f90-c78d2c0aa7f3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"},{"url":"XCN.10","valueString":"NPI"}]}],"identifier":[{"value":"1164928032"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644418802666952.3e10c967-c5ef-4bfb-a3ec-8e4692398f37","resource":{"resourceType":"Practitioner","id":"1734644418802666952.3e10c967-c5ef-4bfb-a3ec-8e4692398f37","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644418826177151.9467ba59-d656-4e97-b205-9216579c51da","resource":{"resourceType":"ServiceRequest","id":"1734644418826177151.9467ba59-d656-4e97-b205-9216579c51da","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644418822074572.2e2677b8-f738-4d2a-a25e-718e3fa66958"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644418813567431.eb4478c0-4152-4791-9aee-fef8268f068e"}}},{"fullUrl":"Practitioner/1734644418813567431.eb4478c0-4152-4791-9aee-fef8268f068e","resource":{"resourceType":"Practitioner","id":"1734644418813567431.eb4478c0-4152-4791-9aee-fef8268f068e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644418822074572.2e2677b8-f738-4d2a-a25e-718e3fa66958","resource":{"resourceType":"Practitioner","id":"1734644418822074572.2e2677b8-f738-4d2a-a25e-718e3fa66958","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644418890800645.caa36224-9fba-4460-8812-f58e39a6ca08","resource":{"resourceType":"ServiceRequest","id":"1734644418890800645.caa36224-9fba-4460-8812-f58e39a6ca08","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644418838391566.230bde36-dad9-483b-b2fe-c9bfb1239df9"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644418829744474.8679ed02-5629-4eb1-a8bc-75876825c60b"}}},{"fullUrl":"Practitioner/1734644418829744474.8679ed02-5629-4eb1-a8bc-75876825c60b","resource":{"resourceType":"Practitioner","id":"1734644418829744474.8679ed02-5629-4eb1-a8bc-75876825c60b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644418838391566.230bde36-dad9-483b-b2fe-c9bfb1239df9","resource":{"resourceType":"Practitioner","id":"1734644418838391566.230bde36-dad9-483b-b2fe-c9bfb1239df9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644418918999562.efa015f9-2c73-449e-94b2-2d947e48c94a","resource":{"resourceType":"ServiceRequest","id":"1734644418918999562.efa015f9-2c73-449e-94b2-2d947e48c94a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644418903976600.d7df21ab-e118-45aa-ad5f-8251d698e9d5"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644418894679007.2caa4fc8-f7f3-4716-9029-c0ed17469a78"}}},{"fullUrl":"Practitioner/1734644418894679007.2caa4fc8-f7f3-4716-9029-c0ed17469a78","resource":{"resourceType":"Practitioner","id":"1734644418894679007.2caa4fc8-f7f3-4716-9029-c0ed17469a78","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644418903976600.d7df21ab-e118-45aa-ad5f-8251d698e9d5","resource":{"resourceType":"Practitioner","id":"1734644418903976600.d7df21ab-e118-45aa-ad5f-8251d698e9d5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644418936540454.e958080b-66d3-4128-8f49-77ebdf43e321","resource":{"resourceType":"ServiceRequest","id":"1734644418936540454.e958080b-66d3-4128-8f49-77ebdf43e321","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644418932422877.e028d956-3aa0-45d5-8bb2-a286d63232ea"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644418923279702.c0659eca-dff1-456b-83e3-e4c583c0b6e8"}}},{"fullUrl":"Practitioner/1734644418923279702.c0659eca-dff1-456b-83e3-e4c583c0b6e8","resource":{"resourceType":"Practitioner","id":"1734644418923279702.c0659eca-dff1-456b-83e3-e4c583c0b6e8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644418932422877.e028d956-3aa0-45d5-8bb2-a286d63232ea","resource":{"resourceType":"Practitioner","id":"1734644418932422877.e028d956-3aa0-45d5-8bb2-a286d63232ea","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644418997080895.b86d66d5-a480-4ddb-a6cd-5a2926d5df16","resource":{"resourceType":"ServiceRequest","id":"1734644418997080895.b86d66d5-a480-4ddb-a6cd-5a2926d5df16","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644418993004073.6e5b162c-d89d-4f61-ad66-de5302afb476"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644418940074505.490cb9e3-dc29-4c66-9c76-d256ba7837ee"}}},{"fullUrl":"Practitioner/1734644418940074505.490cb9e3-dc29-4c66-9c76-d256ba7837ee","resource":{"resourceType":"Practitioner","id":"1734644418940074505.490cb9e3-dc29-4c66-9c76-d256ba7837ee","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644418993004073.6e5b162c-d89d-4f61-ad66-de5302afb476","resource":{"resourceType":"Practitioner","id":"1734644418993004073.6e5b162c-d89d-4f61-ad66-de5302afb476","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419013462108.def28f11-ee1e-40ad-97f4-d4b12ce71c7b","resource":{"resourceType":"ServiceRequest","id":"1734644419013462108.def28f11-ee1e-40ad-97f4-d4b12ce71c7b","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419008878223.6495ca34-2c21-4624-8de2-1e4c31eb4cd6"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419000542120.558b842e-c22a-4e0d-81be-4861dd7681f2"}}},{"fullUrl":"Practitioner/1734644419000542120.558b842e-c22a-4e0d-81be-4861dd7681f2","resource":{"resourceType":"Practitioner","id":"1734644419000542120.558b842e-c22a-4e0d-81be-4861dd7681f2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419008878223.6495ca34-2c21-4624-8de2-1e4c31eb4cd6","resource":{"resourceType":"Practitioner","id":"1734644419008878223.6495ca34-2c21-4624-8de2-1e4c31eb4cd6","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419029952304.7fe5e75c-e5bb-41eb-8e81-f82605fbac0c","resource":{"resourceType":"ServiceRequest","id":"1734644419029952304.7fe5e75c-e5bb-41eb-8e81-f82605fbac0c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419025895590.c3513930-d250-4d97-b75a-5c149eed2394"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419017528911.db7a59fa-7921-4963-8f63-6a667781c888"}}},{"fullUrl":"Practitioner/1734644419017528911.db7a59fa-7921-4963-8f63-6a667781c888","resource":{"resourceType":"Practitioner","id":"1734644419017528911.db7a59fa-7921-4963-8f63-6a667781c888","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419025895590.c3513930-d250-4d97-b75a-5c149eed2394","resource":{"resourceType":"Practitioner","id":"1734644419025895590.c3513930-d250-4d97-b75a-5c149eed2394","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419045997111.32514986-73aa-40b5-8546-d18abe8434bf","resource":{"resourceType":"ServiceRequest","id":"1734644419045997111.32514986-73aa-40b5-8546-d18abe8434bf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419041926742.32a79bfe-9fdb-4e1c-8258-3964025cdf3c"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419033469724.252c6f91-9cc6-4a59-8931-c8964e19101f"}}},{"fullUrl":"Practitioner/1734644419033469724.252c6f91-9cc6-4a59-8931-c8964e19101f","resource":{"resourceType":"Practitioner","id":"1734644419033469724.252c6f91-9cc6-4a59-8931-c8964e19101f","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419041926742.32a79bfe-9fdb-4e1c-8258-3964025cdf3c","resource":{"resourceType":"Practitioner","id":"1734644419041926742.32a79bfe-9fdb-4e1c-8258-3964025cdf3c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419106349552.888dd644-2c77-43d1-bf1f-9c4f3f7e4e5e","resource":{"resourceType":"ServiceRequest","id":"1734644419106349552.888dd644-2c77-43d1-bf1f-9c4f3f7e4e5e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419102259226.b4694d5f-64be-4180-bd5f-40ccc5a76ad4"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419093782111.e23eb990-690d-441d-8338-c13fead1fd26"}}},{"fullUrl":"Practitioner/1734644419093782111.e23eb990-690d-441d-8338-c13fead1fd26","resource":{"resourceType":"Practitioner","id":"1734644419093782111.e23eb990-690d-441d-8338-c13fead1fd26","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419102259226.b4694d5f-64be-4180-bd5f-40ccc5a76ad4","resource":{"resourceType":"Practitioner","id":"1734644419102259226.b4694d5f-64be-4180-bd5f-40ccc5a76ad4","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419137536515.cc0e7644-2a4c-40af-9d57-d3e537d728e3","resource":{"resourceType":"ServiceRequest","id":"1734644419137536515.cc0e7644-2a4c-40af-9d57-d3e537d728e3","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419118572562.4c81a773-e14b-4349-9c0e-e5f27d6f61b5"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419109923798.3102f1fc-d92d-4ccf-8d44-db09e22ed3a9"}}},{"fullUrl":"Practitioner/1734644419109923798.3102f1fc-d92d-4ccf-8d44-db09e22ed3a9","resource":{"resourceType":"Practitioner","id":"1734644419109923798.3102f1fc-d92d-4ccf-8d44-db09e22ed3a9","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419118572562.4c81a773-e14b-4349-9c0e-e5f27d6f61b5","resource":{"resourceType":"Practitioner","id":"1734644419118572562.4c81a773-e14b-4349-9c0e-e5f27d6f61b5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419197079535.cfe1ac19-cb37-4ecf-9fbd-d53dbdddc459","resource":{"resourceType":"ServiceRequest","id":"1734644419197079535.cfe1ac19-cb37-4ecf-9fbd-d53dbdddc459","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419192248682.57f463e2-787c-4fa4-b28f-7dd182664303"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419141935386.97fd5e80-4be3-4778-b8bb-5e3f398175eb"}}},{"fullUrl":"Practitioner/1734644419141935386.97fd5e80-4be3-4778-b8bb-5e3f398175eb","resource":{"resourceType":"Practitioner","id":"1734644419141935386.97fd5e80-4be3-4778-b8bb-5e3f398175eb","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419192248682.57f463e2-787c-4fa4-b28f-7dd182664303","resource":{"resourceType":"Practitioner","id":"1734644419192248682.57f463e2-787c-4fa4-b28f-7dd182664303","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419214307275.eba61dcd-4650-4da8-9575-320d898d30b1","resource":{"resourceType":"ServiceRequest","id":"1734644419214307275.eba61dcd-4650-4da8-9575-320d898d30b1","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419209993763.17933554-8345-441e-9403-7a916a4caadf"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419200863030.2a170f5e-04be-42fe-a1ab-ab07d4d45141"}}},{"fullUrl":"Practitioner/1734644419200863030.2a170f5e-04be-42fe-a1ab-ab07d4d45141","resource":{"resourceType":"Practitioner","id":"1734644419200863030.2a170f5e-04be-42fe-a1ab-ab07d4d45141","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419209993763.17933554-8345-441e-9403-7a916a4caadf","resource":{"resourceType":"Practitioner","id":"1734644419209993763.17933554-8345-441e-9403-7a916a4caadf","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419236010077.dcc879a6-c3bd-47d8-9277-50480021008a","resource":{"resourceType":"ServiceRequest","id":"1734644419236010077.dcc879a6-c3bd-47d8-9277-50480021008a","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419232454907.27fc46cc-3b88-407e-bf66-661f07c65159"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419218072035.08fc9857-3110-4bae-a178-cff23aa4fa90"}}},{"fullUrl":"Practitioner/1734644419218072035.08fc9857-3110-4bae-a178-cff23aa4fa90","resource":{"resourceType":"Practitioner","id":"1734644419218072035.08fc9857-3110-4bae-a178-cff23aa4fa90","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419232454907.27fc46cc-3b88-407e-bf66-661f07c65159","resource":{"resourceType":"Practitioner","id":"1734644419232454907.27fc46cc-3b88-407e-bf66-661f07c65159","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419297425938.516e8411-9afc-4d82-baaa-cf4a2cf1f3e2","resource":{"resourceType":"ServiceRequest","id":"1734644419297425938.516e8411-9afc-4d82-baaa-cf4a2cf1f3e2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419293971265.6da609c6-c0a2-43f3-a716-24930d6c3032"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419239847553.40dd9e82-ca37-4eb6-9e76-aaeeeaf8f0ff"}}},{"fullUrl":"Practitioner/1734644419239847553.40dd9e82-ca37-4eb6-9e76-aaeeeaf8f0ff","resource":{"resourceType":"Practitioner","id":"1734644419239847553.40dd9e82-ca37-4eb6-9e76-aaeeeaf8f0ff","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419293971265.6da609c6-c0a2-43f3-a716-24930d6c3032","resource":{"resourceType":"Practitioner","id":"1734644419293971265.6da609c6-c0a2-43f3-a716-24930d6c3032","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419319444040.d2c90ef7-c39c-48df-a8da-5b20d47b2445","resource":{"resourceType":"ServiceRequest","id":"1734644419319444040.d2c90ef7-c39c-48df-a8da-5b20d47b2445","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419315137431.1c92b584-2007-4c30-b64d-29031112320c"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419300377554.6c6e9567-a437-4d8c-b933-6f1b492bc06c"}}},{"fullUrl":"Practitioner/1734644419300377554.6c6e9567-a437-4d8c-b933-6f1b492bc06c","resource":{"resourceType":"Practitioner","id":"1734644419300377554.6c6e9567-a437-4d8c-b933-6f1b492bc06c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419315137431.1c92b584-2007-4c30-b64d-29031112320c","resource":{"resourceType":"Practitioner","id":"1734644419315137431.1c92b584-2007-4c30-b64d-29031112320c","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419397002211.7e391b3d-2aae-43d7-a194-b266d685c60d","resource":{"resourceType":"ServiceRequest","id":"1734644419397002211.7e391b3d-2aae-43d7-a194-b266d685c60d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419348815855.7a90971b-c4ce-4c6f-bbf5-df4bf1f27525"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419328854934.9a213bb4-2513-453f-84c5-56afaf2768db"}}},{"fullUrl":"Practitioner/1734644419328854934.9a213bb4-2513-453f-84c5-56afaf2768db","resource":{"resourceType":"Practitioner","id":"1734644419328854934.9a213bb4-2513-453f-84c5-56afaf2768db","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419348815855.7a90971b-c4ce-4c6f-bbf5-df4bf1f27525","resource":{"resourceType":"Practitioner","id":"1734644419348815855.7a90971b-c4ce-4c6f-bbf5-df4bf1f27525","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419428311530.830368f7-34ea-4a81-b244-8805301a8a24","resource":{"resourceType":"ServiceRequest","id":"1734644419428311530.830368f7-34ea-4a81-b244-8805301a8a24","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419419838329.eae91935-f10e-484c-acd3-a089a69847d2"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419404624524.be9930ba-d39b-4613-90ff-194c5a290444"}}},{"fullUrl":"Practitioner/1734644419404624524.be9930ba-d39b-4613-90ff-194c5a290444","resource":{"resourceType":"Practitioner","id":"1734644419404624524.be9930ba-d39b-4613-90ff-194c5a290444","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419419838329.eae91935-f10e-484c-acd3-a089a69847d2","resource":{"resourceType":"Practitioner","id":"1734644419419838329.eae91935-f10e-484c-acd3-a089a69847d2","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419494699971.08d0d462-11e0-49e5-97db-bbf2f5eb9c77","resource":{"resourceType":"ServiceRequest","id":"1734644419494699971.08d0d462-11e0-49e5-97db-bbf2f5eb9c77","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419445886778.7a9b7231-688a-481f-81dd-af5e79193517"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419436121623.47ec8f29-acce-4bb6-a0fe-71d82296824e"}}},{"fullUrl":"Practitioner/1734644419436121623.47ec8f29-acce-4bb6-a0fe-71d82296824e","resource":{"resourceType":"Practitioner","id":"1734644419436121623.47ec8f29-acce-4bb6-a0fe-71d82296824e","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419445886778.7a9b7231-688a-481f-81dd-af5e79193517","resource":{"resourceType":"Practitioner","id":"1734644419445886778.7a9b7231-688a-481f-81dd-af5e79193517","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419513149876.afd8e753-85d3-45f9-b513-be9a4884a9be","resource":{"resourceType":"ServiceRequest","id":"1734644419513149876.afd8e753-85d3-45f9-b513-be9a4884a9be","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419508608159.038de597-15b4-4785-8fc7-b310667fb884"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419498723113.588c969b-ec78-43fd-b794-8254b42a71b8"}}},{"fullUrl":"Practitioner/1734644419498723113.588c969b-ec78-43fd-b794-8254b42a71b8","resource":{"resourceType":"Practitioner","id":"1734644419498723113.588c969b-ec78-43fd-b794-8254b42a71b8","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419508608159.038de597-15b4-4785-8fc7-b310667fb884","resource":{"resourceType":"Practitioner","id":"1734644419508608159.038de597-15b4-4785-8fc7-b310667fb884","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419535684737.834874ab-cb9d-461d-b6de-328154f3118d","resource":{"resourceType":"ServiceRequest","id":"1734644419535684737.834874ab-cb9d-461d-b6de-328154f3118d","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419530139611.99f42ed3-e56d-4921-b847-9294ae1ce561"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419517125549.5a3e9f90-1995-42c0-bf9d-adfe50038397"}}},{"fullUrl":"Practitioner/1734644419517125549.5a3e9f90-1995-42c0-bf9d-adfe50038397","resource":{"resourceType":"Practitioner","id":"1734644419517125549.5a3e9f90-1995-42c0-bf9d-adfe50038397","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419530139611.99f42ed3-e56d-4921-b847-9294ae1ce561","resource":{"resourceType":"Practitioner","id":"1734644419530139611.99f42ed3-e56d-4921-b847-9294ae1ce561","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419600074256.d444d4a3-32d1-4567-9fcf-129cd26ac8ca","resource":{"resourceType":"ServiceRequest","id":"1734644419600074256.d444d4a3-32d1-4567-9fcf-129cd26ac8ca","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419560134414.3613b790-a3f7-48c0-ab5a-004a610b0587"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419542250352.3585e872-35c8-406b-8cb5-fd98299025c5"}}},{"fullUrl":"Practitioner/1734644419542250352.3585e872-35c8-406b-8cb5-fd98299025c5","resource":{"resourceType":"Practitioner","id":"1734644419542250352.3585e872-35c8-406b-8cb5-fd98299025c5","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419560134414.3613b790-a3f7-48c0-ab5a-004a610b0587","resource":{"resourceType":"Practitioner","id":"1734644419560134414.3613b790-a3f7-48c0-ab5a-004a610b0587","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"ServiceRequest/1734644419638173568.57950b0c-8947-45ed-9d91-7d6c3fdb77ae","resource":{"resourceType":"ServiceRequest","id":"1734644419638173568.57950b0c-8947-45ed-9d91-7d6c3fdb77ae","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/obr-observation-request","extension":[{"url":"OBR.16","valueReference":{"reference":"Practitioner/1734644419631635975.d99bdb85-bb53-44ca-a267-7bfaff706f18"}},{"url":"OBR.7","valueDateTime":"2024-09-24T05:45:00Z","_valueDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]}},{"url":"OBR.22","valueString":"20241017050025"},{"url":"OBR.25","valueId":"F"}]}],"identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"status":"unknown","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"requester":{"reference":"Practitioner/1734644419605493227.a0205aa2-0dbb-4d01-b730-fc5af202ffff"}}},{"fullUrl":"Practitioner/1734644419605493227.a0205aa2-0dbb-4d01-b730-fc5af202ffff","resource":{"resourceType":"Practitioner","id":"1734644419605493227.a0205aa2-0dbb-4d01-b730-fc5af202ffff","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.16"}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"Practitioner/1734644419631635975.d99bdb85-bb53-44ca-a267-7bfaff706f18","resource":{"resourceType":"Practitioner","id":"1734644419631635975.d99bdb85-bb53-44ca-a267-7bfaff706f18","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/xcn-practitioner","extension":[{"url":"XCN.3","valueString":"CHEZHIYAN"}]}],"name":[{"family":"MURUGESAN","given":["CHEZHIYAN"]}]}},{"fullUrl":"DiagnosticReport/1734644419692201133.2ad02aef-7ed6-4bc3-adce-9e824308af53","resource":{"resourceType":"DiagnosticReport","id":"1734644419692201133.2ad02aef-7ed6-4bc3-adce-9e824308af53","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"ORC.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644418806932054.3ea607c6-5dbb-4897-9078-d6595b5abb1c"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54089-8","display":"NB Screen Panel Patient AHIC"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418620013889.578eeedf-2fac-4a73-b8e8-e2f399dd8080"}]}},{"fullUrl":"DiagnosticReport/1734644419699746133.2856d179-89ab-489a-b2c5-8a833fde050b","resource":{"resourceType":"DiagnosticReport","id":"1734644419699746133.2856d179-89ab-489a-b2c5-8a833fde050b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644418826177151.9467ba59-d656-4e97-b205-9216579c51da"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57128-1","display":"Newborn Screening Report summary panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418623086931.a10f8b61-0456-42ac-93fb-71963e42e3af"}],"result":[{"reference":"Observation/1734644417796265313.e1027f5b-062f-4104-a7de-a437ae0c3842"},{"reference":"Observation/1734644417801791651.d1966e09-74fb-4baa-b4b0-40544e8c0c1d"},{"reference":"Observation/1734644417817280488.4709f99d-783d-45b7-9ff6-01b35715b870"},{"reference":"Observation/1734644417822834817.bcb381eb-be32-44ea-ae5a-d53d349a2a8e"},{"reference":"Observation/1734644417828340736.feb0b0a3-20f9-4dc8-ace3-1b1e85f11a91"},{"reference":"Observation/1734644417832150308.c320d4f8-9a39-4f05-9836-039b965e24ff"},{"reference":"Observation/1734644417835810822.88a720fe-d538-48d6-9794-0a3ed0ead41e"}]}},{"fullUrl":"DiagnosticReport/1734644419708101541.7f3385cd-e700-42c9-bf9f-f64c95825783","resource":{"resourceType":"DiagnosticReport","id":"1734644419708101541.7f3385cd-e700-42c9-bf9f-f64c95825783","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644418890800645.caa36224-9fba-4460-8812-f58e39a6ca08"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57717-1","display":"Newborn screen card data panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418625861998.068c0946-33c1-4698-b262-4e7424380350"}],"result":[{"reference":"Observation/1734644417839535536.85f9af6b-5ef2-4530-9974-6e21db509d5a"},{"reference":"Observation/1734644417843879005.412d9eb1-44e0-4b56-982b-0f2bad4203da"},{"reference":"Observation/1734644417847226896.1e8f8200-472d-409b-8f41-04c8ec4a81ef"},{"reference":"Observation/1734644417849620675.2859d891-5519-4f09-a6e2-20fa5cd90db1"},{"reference":"Observation/1734644417901619353.594eb9e5-afae-4e85-922f-198372d6c515"},{"reference":"Observation/1734644417905836296.262e3b31-827d-44c8-8c59-b7529737b23d"},{"reference":"Observation/1734644417910044573.c13ffa5d-6957-44eb-b015-f1201536e849"},{"reference":"Observation/1734644417913731055.ab8ae7df-d58e-4414-a546-e6c9fd583447"},{"reference":"Observation/1734644417917768954.50056553-e6ef-4dc4-b44e-3eb5654785ed"},{"reference":"Observation/1734644417921408098.bea1529d-7f6b-4881-82e8-cfc11f86fcb9"},{"reference":"Observation/1734644417926192001.558052e7-a20f-4082-b482-d15cc78f36db"}]}},{"fullUrl":"DiagnosticReport/1734644419713813197.ad7780f2-1e1a-400e-93d9-99840b8473f7","resource":{"resourceType":"DiagnosticReport","id":"1734644419713813197.ad7780f2-1e1a-400e-93d9-99840b8473f7","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644418918999562.efa015f9-2c73-449e-94b2-2d947e48c94a"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57794-0","display":"Newborn screening test results panel in Dried blood spot"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418628855693.4abd5487-e297-4db8-a03e-ad70e82ea7e0"}]}},{"fullUrl":"DiagnosticReport/1734644419724024842.1bdb9bcf-c477-47e5-9e0f-be76109a5cd8","resource":{"resourceType":"DiagnosticReport","id":"1734644419724024842.1bdb9bcf-c477-47e5-9e0f-be76109a5cd8","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644418936540454.e958080b-66d3-4128-8f49-77ebdf43e321"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"53261-4","display":"Amino acid newborn screen panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418631682897.6a14062a-0df8-478b-80f6-a2818b88b0b2"}],"result":[{"reference":"Observation/1734644417934188839.9e003f64-2cd4-4ce8-b35d-c19ef12574a0"},{"reference":"Observation/1734644417940929624.cb81d9fd-a16b-4379-8940-516118aa6777"},{"reference":"Observation/1734644417945053774.0b37fbbe-851f-4b8d-ad0e-fa11edf1a52a"},{"reference":"Observation/1734644417948680715.cbea7c69-142e-4373-b0b1-90df672e6862"},{"reference":"Observation/1734644417995017914.8ab59c9f-02bf-48a8-bf3c-d8ea7ec96914"},{"reference":"Observation/1734644417999433067.13ba34a2-018a-4a84-8fe9-9e7ace7bcc87"},{"reference":"Observation/1734644418003515930.4796ac80-baa6-49b8-9771-3a7469ee2bb2"},{"reference":"Observation/1734644418008267091.02fa4769-70d2-4054-bc36-4f90b3120c6d"},{"reference":"Observation/1734644418012713502.2f78fefe-c6c8-4c8b-acc7-c1df8afeb156"},{"reference":"Observation/1734644418021388799.e22403f3-7063-4e1f-af4d-50186683a151"},{"reference":"Observation/1734644418026031315.75cd7314-4f23-4832-8d01-abf7aef0274d"},{"reference":"Observation/1734644418029829796.368ea25e-8c14-4c22-bbc7-3588ae105bbf"},{"reference":"Observation/1734644418033695132.917f591d-3498-4d01-80e7-873f7ffd7f95"},{"reference":"Observation/1734644418040086104.5505ce91-e769-41c0-873c-ef885b42d953"},{"reference":"Observation/1734644418044605051.f55b07d2-8020-4fbb-b2be-1b46e9a79c9d"},{"reference":"Observation/1734644418093990132.cc313c65-e85f-42a1-88ee-9814ad9e94ea"},{"reference":"Observation/1734644418098585802.cf01bcc2-5850-43e2-8eb9-a86c44a39080"},{"reference":"Observation/1734644418102931204.e5eda334-8162-4db0-9190-24d0fe3c672b"},{"reference":"Observation/1734644418107103955.74d90a40-ba93-4a8d-a75c-7b9c59ccf5f4"}]}},{"fullUrl":"DiagnosticReport/1734644419729907926.637687d5-f285-4d85-8250-cdb314373590","resource":{"resourceType":"DiagnosticReport","id":"1734644419729907926.637687d5-f285-4d85-8250-cdb314373590","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644418997080895.b86d66d5-a480-4ddb-a6cd-5a2926d5df16"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"58092-8","display":"Acylcarnitine newborn screen panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418634469316.8d4cdaf4-1d61-48a9-8208-ab69319553bf"}],"result":[{"reference":"Observation/1734644418111524768.93fe9a7e-4aa3-4caa-9089-55680c2d733a"},{"reference":"Observation/1734644418115768261.bee34a03-fcca-4734-9362-e100f2d283d3"}]}},{"fullUrl":"DiagnosticReport/1734644419743254406.7d857b02-136c-4d65-9fbc-3e6e6e2fa2ba","resource":{"resourceType":"DiagnosticReport","id":"1734644419743254406.7d857b02-136c-4d65-9fbc-3e6e6e2fa2ba","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419013462108.def28f11-ee1e-40ad-97f4-d4b12ce71c7b"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57084-6","display":"Fatty acid oxidation newborn screen panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418637227352.d3880a49-7276-46f6-b4a6-c2275c7e258a"}],"result":[{"reference":"Observation/1734644418119703177.721be05d-2352-4e12-b098-5abf93c94476"},{"reference":"Observation/1734644418123703845.f6f91fa7-f88a-4b8c-a2f5-3393be2541fb"},{"reference":"Observation/1734644418127929775.83fdc8dd-09f2-48d2-a3c6-d3ed0b9d2e8a"},{"reference":"Observation/1734644418132508163.f290c980-f194-41af-b4cf-96dbe04d1922"},{"reference":"Observation/1734644418136460852.49698eb0-f1bb-49da-a2c9-15aa906f5ab7"},{"reference":"Observation/1734644418140546971.d1ec4a52-6d49-4afa-b000-46992ea08cca"},{"reference":"Observation/1734644418144386619.7e5499dd-ad54-4277-81e4-e0d87915ed35"},{"reference":"Observation/1734644418148488928.7ba1d26d-aebe-4485-bceb-6b2d8e2dd188"},{"reference":"Observation/1734644418191368502.288fd0c2-03af-4187-85b8-ab768fa53a09"},{"reference":"Observation/1734644418196156441.744c7d3a-5d71-4e9a-81c3-c8dc52d50f4d"},{"reference":"Observation/1734644418199881245.c30f9674-dc49-4092-a2e8-91af248d5f7a"},{"reference":"Observation/1734644418203506753.3bab0f68-99a9-49bf-bfb1-aeb3c9c77ec7"},{"reference":"Observation/1734644418207148533.cfc80263-3390-43a3-871a-d1a2ae645258"},{"reference":"Observation/1734644418210779091.028a38d8-7995-4c1d-9b88-eaaa5ba7c96e"},{"reference":"Observation/1734644418213596932.7f4c433c-ee26-44a9-8455-2769977faf77"},{"reference":"Observation/1734644418216350292.40cd4740-470e-4f15-8981-2329f67c1c94"},{"reference":"Observation/1734644418218653241.149832b5-0f86-47ed-bb76-05ce5ca9aab0"},{"reference":"Observation/1734644418221583851.593fe756-7b65-4bbd-92db-582d5e5afbc2"},{"reference":"Observation/1734644418225384797.3e7f8946-d817-4a06-9a98-7b737600509e"},{"reference":"Observation/1734644418229985066.d45b748c-ce86-4727-b2b4-f129aa596d8e"},{"reference":"Observation/1734644418234159048.af1803d4-bf00-473c-83f5-615b44d3edce"},{"reference":"Observation/1734644418238266898.2ce39b9d-24ba-4d82-bb08-dadf2f95d23e"},{"reference":"Observation/1734644418242142654.4f2ffedd-052e-4a97-a19a-54dae982f8f2"},{"reference":"Observation/1734644418245893376.05943385-5946-4586-8cf0-1d7d13a692da"},{"reference":"Observation/1734644418249640091.14f79a31-0c80-46ef-89f5-40709968d8d2"},{"reference":"Observation/1734644418253450154.8d0b683a-d872-4129-bfb6-c321e28bfa6c"}]}},{"fullUrl":"DiagnosticReport/1734644419753320971.b9e3b94b-0e80-437c-94b5-a77d995ce0d2","resource":{"resourceType":"DiagnosticReport","id":"1734644419753320971.b9e3b94b-0e80-437c-94b5-a77d995ce0d2","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419029952304.7fe5e75c-e5bb-41eb-8e81-f82605fbac0c"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57085-3","display":"Organic acid newborn screen panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418640004242.4c4fbcdf-9bb7-42c3-a7fd-b23a6bf81c6d"}],"result":[{"reference":"Observation/1734644418293578752.14a30ea3-9496-4275-9041-0d4f226b3e10"},{"reference":"Observation/1734644418297352457.ca225056-4647-42f7-9d82-8666c248bfd3"},{"reference":"Observation/1734644418301167169.dc0d0885-fbbe-42a9-8f4f-c4039fd42832"},{"reference":"Observation/1734644418304937408.28c2882f-3e75-415d-aad7-a1ee08e419f3"},{"reference":"Observation/1734644418308939570.1de34fdf-fdd0-4874-be02-304d3373d9ff"},{"reference":"Observation/1734644418312767997.dfb7ee39-8914-431d-afc1-00f585bb57fd"},{"reference":"Observation/1734644418316602957.c6889d3f-c145-45ea-8205-8649bff1e55c"},{"reference":"Observation/1734644418320444569.2adf1156-3d36-431c-bc8b-28338e20e858"},{"reference":"Observation/1734644418326047982.ba4822cb-d64b-4acf-958e-6b9c8db6d3d4"},{"reference":"Observation/1734644418330183463.5d0101f7-90b2-4eee-9a2e-47386c89b7a0"}]}},{"fullUrl":"DiagnosticReport/1734644419795641896.8702cee9-f54e-498e-a150-2f00ad76356c","resource":{"resourceType":"DiagnosticReport","id":"1734644419795641896.8702cee9-f54e-498e-a150-2f00ad76356c","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419045997111.32514986-73aa-40b5-8546-d18abe8434bf"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54078-1","display":"Cystic fibrosis newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418642858898.e93b7cc7-d555-4fdb-ad7c-60fd187217ab"}],"result":[{"reference":"Observation/1734644418333982285.fcc21c8a-6157-427e-b6f8-62fefe57d81a"},{"reference":"Observation/1734644418337729531.0f74bef2-2ae5-4599-b4ba-6a4adc56d5ff"},{"reference":"Observation/1734644418340904849.5e94cf89-bdd1-467d-a1c6-82f3582339b8"}]}},{"fullUrl":"DiagnosticReport/1734644419801980108.5b9208e0-8d9c-45c8-bd50-885179dadb43","resource":{"resourceType":"DiagnosticReport","id":"1734644419801980108.5b9208e0-8d9c-45c8-bd50-885179dadb43","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419106349552.888dd644-2c77-43d1-bf1f-9c4f3f7e4e5e"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57086-1","display":"Congenital adrenal hyperplasia newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418645609720.a2aeb8f8-c2d0-4c45-8524-369c698ab7e9"}],"result":[{"reference":"Observation/1734644418344428438.9c359bf0-d4f2-4239-b942-6f4cd91861bb"},{"reference":"Observation/1734644418348157459.988552ff-1822-44f3-86a8-dc7e3e817126"},{"reference":"Observation/1734644418351257387.1c0d6804-ff3d-4450-857f-e4fc186532ac"}]}},{"fullUrl":"DiagnosticReport/1734644419808292983.dff75e1f-d5d1-47f5-bd35-5bd07b7f84af","resource":{"resourceType":"DiagnosticReport","id":"1734644419808292983.dff75e1f-d5d1-47f5-bd35-5bd07b7f84af","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419137536515.cc0e7644-2a4c-40af-9d57-d3e537d728e3"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54090-6","display":"Thyroid newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418692924444.2362eec6-8892-4e80-b9a5-92159ca55d7a"}],"result":[{"reference":"Observation/1734644418354740069.f2d1242a-d7ef-4e64-969f-8bd8197ad869"},{"reference":"Observation/1734644418358362071.2488ad7b-566c-4537-9135-55507da8d836"},{"reference":"Observation/1734644418361380556.25749106-cfb2-4331-9185-dfd0950ef84f"}]}},{"fullUrl":"DiagnosticReport/1734644419815428530.5f90805a-95cf-46d6-b09c-621a5a04ea2d","resource":{"resourceType":"DiagnosticReport","id":"1734644419815428530.5f90805a-95cf-46d6-b09c-621a5a04ea2d","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419197079535.cfe1ac19-cb37-4ecf-9fbd-d53dbdddc459"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54079-9","display":"Galactosemia newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418697846760.72e82496-50e8-48d9-ab40-7aad8ef84ebc"}],"result":[{"reference":"Observation/1734644418393365701.2a730407-04f1-4256-b77c-eb0b3f0a998e"},{"reference":"Observation/1734644418397214977.1ce1b2dd-c08c-4ec5-80e2-e8a755828a4d"},{"reference":"Observation/1734644418400448865.1b9837e7-ea8a-4660-a819-d7676389342f"}]}},{"fullUrl":"DiagnosticReport/1734644419824626319.2533508b-b790-45d2-ac8d-300eb7132397","resource":{"resourceType":"DiagnosticReport","id":"1734644419824626319.2533508b-b790-45d2-ac8d-300eb7132397","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419214307275.eba61dcd-4650-4da8-9575-320d898d30b1"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"54081-5","display":"Hemoglobinopathies newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418700728436.ebc0946d-66c6-4188-a3fb-3c81fb392782"}],"result":[{"reference":"Observation/1734644418404113797.7610a136-ea9b-4e83-adc2-f7ff013917f0"},{"reference":"Observation/1734644418407114199.402af6e9-5586-4d2a-a454-631b42f198aa"}]}},{"fullUrl":"DiagnosticReport/1734644419834916739.fc89b70e-a2b9-4e36-b5d6-8e2a97559cbb","resource":{"resourceType":"DiagnosticReport","id":"1734644419834916739.fc89b70e-a2b9-4e36-b5d6-8e2a97559cbb","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419236010077.dcc879a6-c3bd-47d8-9277-50480021008a"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"57087-9","display":"Biotinidase newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418703664102.7fc22a83-8356-4ab2-9428-7e35ea9e9d86"}],"result":[{"reference":"Observation/1734644418410319112.d5601183-0925-4034-8c0c-9093786f4eaf"},{"reference":"Observation/1734644418414140146.2afa3160-ba41-4195-bbfc-3a52ed753110"},{"reference":"Observation/1734644418417337565.c54cbd66-59e0-42ab-b1cf-9951adef0da2"}]}},{"fullUrl":"DiagnosticReport/1734644419844156113.7e989ddd-0edc-4a05-8396-c9fdb47c50fa","resource":{"resourceType":"DiagnosticReport","id":"1734644419844156113.7e989ddd-0edc-4a05-8396-c9fdb47c50fa","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419297425938.516e8411-9afc-4d82-baaa-cf4a2cf1f3e2"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"62333-0","display":"Severe combined immunodeficiency (SCID) newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418706669478.8228a2e2-0c7e-498c-a308-7a3f71673738"}],"result":[{"reference":"Observation/1734644418421163518.e6b7164c-753b-47dc-a9fa-5f4f42d2e3b4"},{"reference":"Observation/1734644418424925822.56a4ebf0-c340-44d8-b9c2-9f6c84adfc83"},{"reference":"Observation/1734644418428008677.d1c355fd-aa64-4f6f-83ed-facf1540b17f"}]}},{"fullUrl":"DiagnosticReport/1734644419853217247.ff790c55-8249-4b13-a6bd-9759c12d684e","resource":{"resourceType":"DiagnosticReport","id":"1734644419853217247.ff790c55-8249-4b13-a6bd-9759c12d684e","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419319444040.d2c90ef7-c39c-48df-a8da-5b20d47b2445"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"63414-7","display":"Pompe Disease newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418709452811.2b287078-a334-49ad-b97f-3acecf74cf69"}],"result":[{"reference":"Observation/1734644418431524932.c31b6c3b-c057-4ce7-b829-ebfc3b80d4d2"},{"reference":"Observation/1734644418435131746.67b40486-a401-4f82-8575-dd4b8c30a0f0"},{"reference":"Observation/1734644418438178153.78db2e15-e743-43b1-80bb-db636e6de3c5"}]}},{"fullUrl":"DiagnosticReport/1734644419891605519.7daa771e-1756-4760-9382-68cd500982d7","resource":{"resourceType":"DiagnosticReport","id":"1734644419891605519.7daa771e-1756-4760-9382-68cd500982d7","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419397002211.7e391b3d-2aae-43d7-a194-b266d685c60d"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"79563-3","display":"Mucopolysaccharidosis type I newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418713689710.c3c889e5-e87f-4c32-bf89-1cd1441c6b1e"}],"result":[{"reference":"Observation/1734644418441661076.c9805208-4a21-4978-9655-a19ad765ec84"},{"reference":"Observation/1734644418448447536.bee743ae-abb4-4b2e-b85d-2570afb8be3f"},{"reference":"Observation/1734644418493996336.22471e9e-7dfc-469f-bcea-a38b92726aa9"}]}},{"fullUrl":"DiagnosticReport/1734644419895767159.f14226b8-44f4-40bf-a324-7a7a8016dee0","resource":{"resourceType":"DiagnosticReport","id":"1734644419895767159.f14226b8-44f4-40bf-a324-7a7a8016dee0","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419428311530.830368f7-34ea-4a81-b244-8805301a8a24"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"92005-8","display":"Spinal muscular atrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418716488452.b532b0c6-066b-4835-a0cb-73fa3d91c5a3"}],"result":[{"reference":"Observation/1734644418498838813.52242f5f-fbf3-4a2a-b760-989a9c456d6e"},{"reference":"Observation/1734644418502456380.093781b0-cfed-4ae7-a908-4f436a995c79"}]}},{"fullUrl":"DiagnosticReport/1734644419902517717.17c0b4a4-255c-43f9-be8f-703d9070208b","resource":{"resourceType":"DiagnosticReport","id":"1734644419902517717.17c0b4a4-255c-43f9-be8f-703d9070208b","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419494699971.08d0d462-11e0-49e5-97db-bbf2f5eb9c77"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104188-8","display":"Mucopolysaccharidosis type II newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418720058990.326688c9-38c2-47c9-b11b-f09becbe0353"}],"result":[{"reference":"Observation/1734644418506522742.50a3e79d-3451-4210-8959-d95579c2a5f9"},{"reference":"Observation/1734644418510765923.b268b63d-6738-4acc-a52c-1f93cc540c6d"},{"reference":"Observation/1734644418514265800.fb13696e-d60b-4387-ab7d-5e390c6785f8"}]}},{"fullUrl":"DiagnosticReport/1734644419909213707.7cfdaa0f-a324-4518-ab6f-5c948abbdc9e","resource":{"resourceType":"DiagnosticReport","id":"1734644419909213707.7cfdaa0f-a324-4518-ab6f-5c948abbdc9e","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419513149876.afd8e753-85d3-45f9-b513-be9a4884a9be"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"coding"}],"code":"104191-2","display":"Guanidinoacetate methyltransferase newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418722906983.caa6ec68-8fe7-4db7-a48a-fe3ae2803810"}],"result":[{"reference":"Observation/1734644418523112493.124c6ef4-414a-4c05-ac23-ce4a55fa0d36"},{"reference":"Observation/1734644418526909052.d1f48023-23d5-4ba4-aa24-8cbc40397c14"}]}},{"fullUrl":"DiagnosticReport/1734644419915028414.66b10e65-9fb1-4019-a18d-72882f136896","resource":{"resourceType":"DiagnosticReport","id":"1734644419915028414.66b10e65-9fb1-4019-a18d-72882f136896","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419535684737.834874ab-cb9d-461d-b6de-328154f3118d"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-52","display":"Guanidinoacetate methyltransferase Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418725664248.3b13f6ec-0467-45ef-a3b9-224ea8059b9a"}],"result":[{"reference":"Observation/1734644418530955497.84aa3c0e-67f7-4b13-b789-ab6f0feafdb6"},{"reference":"Observation/1734644418534982045.9a9f7f72-97b4-4c19-872f-20f2394874e0"},{"reference":"Observation/1734644418538478716.748366b9-a826-4acf-a52d-d851375becbc"}]}},{"fullUrl":"DiagnosticReport/1734644419920406329.ce421d8f-a0f0-4635-b581-927247c9fe9f","resource":{"resourceType":"DiagnosticReport","id":"1734644419920406329.ce421d8f-a0f0-4635-b581-927247c9fe9f","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419600074256.d444d4a3-32d1-4567-9fcf-129cd26ac8ca"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-28","display":"Adrenoleukodystrophy newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418728439666.e23f8e93-1f86-42b3-956d-952e01b4d8a8"}],"result":[{"reference":"Observation/1734644418542644844.703dd0ec-0ac3-4d6a-8b48-a876529184f2"},{"reference":"Observation/1734644418546025989.a78bf05f-9bbd-4182-a893-c88b2a757930"}]}},{"fullUrl":"DiagnosticReport/1734644419925358861.4ed59a37-bfc4-4deb-8e1e-feb8b7980f00","resource":{"resourceType":"DiagnosticReport","id":"1734644419925358861.4ed59a37-bfc4-4deb-8e1e-feb8b7980f00","identifier":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2Field","valueString":"OBR.2"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/assigning-authority","extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/namespace-id","valueString":"FormNumber"}]}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/v2-0203","code":"PLAC"}]},"value":"789876543"}],"basedOn":[{"reference":"ServiceRequest/1734644419638173568.57950b0c-8947-45ed-9d91-7d6c3fdb77ae"}],"status":"final","code":{"coding":[{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding","valueString":"alt-coding"},{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/cwe-coding-system","valueString":"L"}],"system":"https://terminology.hl7.org/CodeSystem-v2-0396.html#v2-0396-99zzzorL","code":"99717-29","display":"Adrenoleukodystrophy Tier-1 newborn screening panel"}]},"subject":{"reference":"Patient/1734644417743785538.10c2aad2-5f4a-43c3-a39a-f4a9d881366e"},"effectiveDateTime":"2024-09-24T05:45:00Z","_effectiveDateTime":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"202409240545"}]},"issued":"2024-10-17T05:00:25Z","_issued":{"extension":[{"url":"https://reportstream.cdc.gov/fhir/StructureDefinition/hl7v2-date-time","valueString":"20241017050025"}]},"specimen":[{"reference":"Specimen/1734644418731522697.fcb6d558-720e-4d6f-9a85-25ea41a92f68"}],"result":[{"reference":"Observation/1734644418594486407.d26e1831-e4a9-4eed-a2e3-9e160856d54c"}]}}]}
diff --git a/examples/Test/Automated/GoldenCopy/Input/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7 b/examples/Test/Automated/GoldenCopy/Input/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
new file mode 100644
index 000000000..b47644b66
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Input/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241015054631||ORU^R01^ORU_R01|001|N|2.5.1
PID|1||80015867^^^&NPI^MR||CDPHTWO^GIRL  MOMTWO^^^^^B||202410071025|F||2076-8^Native Hawaiian or Other Pacific Islander||||||||||||2186-5^Not Hispanic or Latino||N|1
NK1|1|CDPHTWO^MOMTWO|MTH^Mother|2 SECOND ST^^SAN DIEGO^CA^92121^USA||||||||||||20000202
ORC|RE|7371237714^FormNumber||189688314^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7371237714^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBR|2|7371237714^FormNumber||57128-1^Newborn Screening Report summary panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12427-3^Subsequent screen - for clarification of initial results (not by law or protocol)^LN|||N|||F|||20241015054631
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241015054631
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241015054631
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12543-7^GALT^LN|||N|||F|||20241015054631
OBX|5|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|2|LA12533-8^CAH^LN|||N|||F|||20241015054631
OBX|6|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA12566-8^SCID^LN|||N|||F|||20241015054631
OBX|7|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|2|LA14037-8^GAA^LN|||N|||F|||20241015054631
OBX|8|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\CAH: An immediate referral to a CCS endocrine center or pediatric endocrinologist, for evaluation and additional testing, is strongly recommended. \.br\\.br\Pompe: Another dried blood specimen MUST be collected for this child. Call your Newborn Screening Coordinator for assistance. \.br\\.br\SCID: Another dried blood specimen MUST be collected for this child. Call your Newborn Screening Coordinator for assistance. \.br\\.br\Galactosemia: Additional testing is required to rule out disorder.�Call your Newborn Screening Coordinator for assistance. \.br\\.br\ATTENTION: THIS CHILD HAS TESTED POSITIVE FOR MORE THAN ONE TEST. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241015054631
OBX|9|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241015054631
OBR|3|7371237714^FormNumber||57717-1^Newborn screen card data panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241015054631
OBX|2|NM|8339-4^Birthweight^LN|1|3175|grams||N|||F|||20241015054631
OBX|3|TM|57715-5^Time of birth^LN|1|1025|||N|||F|||20241015054631
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241015054631
OBX|5|NM|73806-2^Newborn age in hours^LN|1|25|hour(s)||N|||F|||20241015054631
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241015054631
OBX|7|CE|67704-7^Feeding types^LN|1|LA4489-6^Unknown^LN|||N|||F|||20241015054631
OBX|8|TX|^^^99717-5^Accession Number^L|1|282-49-252/21-2024-21|||N|||F|||20241015054631
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DENISE COYLE|||N|||F|||20241015054631
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241015054631
OBR|4|7371237714^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBR|5|7371237714^FormNumber||53261-4^Amino acid newborn screen panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241015054631
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20241015054631
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241015054631
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241015054631
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20241015054631
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241015054631
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20241015054631
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241015054631
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20241015054631
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20241015054631
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20241015054631
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|�mol/L|5-49|N|||F|||20241015054631
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241015054631
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20241015054631
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20241015054631
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241015054631
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20241015054631
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|6|7371237714^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|7|7371237714^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20241015054631
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241015054631
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20241015054631
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241015054631
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20241015054631
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20241015054631
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20241015054631
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20241015054631
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20241015054631
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20241015054631
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20241015054631
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20241015054631
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20241015054631
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20241015054631
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20241015054631
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20241015054631
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20241015054631
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241015054631
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241015054631
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20241015054631
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20241015054631
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20241015054631
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241015054631
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241015054631
OBR|8|7371237714^FormNumber||57085-3^Organic acid newborn screen panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20241015054631
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241015054631
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20241015054631
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20241015054631
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20241015054631
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241015054631
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20241015054631
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20241015054631
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20241015054631
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241015054631
OBR|9|7371237714^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241015054631
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|10|7371237714^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|305|nmol/L|<85|H|||F|||20241015054631
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241015054631
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241015054631
OBR|11|7371237714^FormNumber||54090-6^Thyroid newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241015054631
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|12|7371237714^FormNumber||54079-9^Galactosemia newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|48.00|enzyme units|>50|L|||F|||20241015054631
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241015054631
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241015054631
OBR|13|7371237714^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241015054631
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.�These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241015054631
OBR|14|7371237714^FormNumber||57087-9^Biotinidase newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241015054631
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|15|7371237714^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|2|copies/�L|>18|L|||F|||20241015054631
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241015054631
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Incomplete|||A|||F|||20241015054631
OBR|16|7371237714^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA16205-9^Specimen unsatisfactory for at least one condition^LN|||A|||F|||20241015054631
OBX|2|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Incomplete|||A|||F|||20241015054631
OBR|17|7371237714^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20241015054631
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|18|7371237714^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241015054631
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241015054631
OBR|19|7371237714^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20241015054631
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|20|7371237714^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|21|7371237714^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|�mol/L|<=3|N|||F|||20241015054631
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|�mol/L||N|||F|||20241015054631
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241015054631
OBR|22|7371237714^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241015054631
OBR|23|7371237714^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20241015054631
diff --git a/examples/Test/Automated/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7 b/examples/Test/Automated/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
deleted file mode 100644
index 1a235664a..000000000
--- a/examples/Test/Automated/GoldenCopy/Input/001_ORU_R01_golden_copy_input_acylc_1.hl7
+++ /dev/null
@@ -1,143 +0,0 @@
-MSH|^~\\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241015050654||ORU^R01^ORU_R01|001|N|2.5.1
-PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
-NK1|1|*****PII REMOVED******
-ORC|RE|673678765^FormNumber||M17965^HospOrdNumber||||||||1477542173^BROOKS^STEWART^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804
-OBR|1|673678765^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410011420|||||||||||||||20241015050654|||F
-OBR|2|673678765^FormNumber||57128-1^Newborn Screening Report summary panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241015050654
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241015050654
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241015050654
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241015050654
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241015050654
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241015050654
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241015050654
-OBR|3|673678765^FormNumber||57717-1^Newborn screen card data panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241015050654
-OBX|2|NM|8339-4^Birthweight^LN|1|4020|grams||N|||F|||20241015050654
-OBX|3|TM|57715-5^Time of birth^LN|1|1416|||N|||F|||20241015050654
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241015050654
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241015050654
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241015050654
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241015050654
-OBX|8|CE|67704-7^Feeding types^LN|2|LA16915-3^Lactose formula^LN|||N|||F|||20241015050654
-OBX|9|TX|^^^99717-5^Accession Number^L|1|277-86-190/21-2024-32|||N|||F|||20241015050654
-OBX|10|TX|62324-9^Post-discharge provider name^LN|1|STEWART BROOKS|||N|||F|||20241015050654
-OBX|11|TX|62325-6^Post-discharge provider practice ID^LN|1|1477542173|||N|||F|||20241015050654
-OBX|12|TX|62327-2^Post-discharge provider practice address^LN|1|8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA|||N|||F|||20241015050654
-OBR|4|673678765^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410011420|||||||||||||||20241015050654|||F
-OBR|5|673678765^FormNumber||53261-4^Amino acid newborn screen panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|387|µmol/L||N|||F|||20241015050654
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|381|µmol/L|<1000|N|||F|||20241015050654
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|92.6|µmol/L||N|||F|||20241015050654
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.88595|{Ratio}|<4.3|N|||F|||20241015050654
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|86.8|µmol/L|<230|N|||F|||20241015050654
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.23|{Ratio}|<1.35|N|||F|||20241015050654
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|49.1|µmol/L|<175|N|||F|||20241015050654
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.09|{Ratio}|<2.6|N|||F|||20241015050654
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|45.1|µmol/L|<680|N|||F|||20241015050654
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.24|µmol/L|<6.1|N|||F|||20241015050654
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|16.8|µmol/L|6.3-100|N|||F|||20241015050654
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|20|µmol/L|5-49|N|||F|||20241015050654
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3.22|{Ratio}|<4.8|N|||F|||20241015050654
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|74|µmol/L|<800|N|||F|||20241015050654
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|3.76|{Ratio}||N|||F|||20241015050654
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|6|µmol/L|<63|N|||F|||20241015050654
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241015050654
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|118|µmol/L|<1500|N|||F|||20241015050654
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|6|673678765^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241015050654
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with SCADD, IBCDD|||A|||F|||20241015050654
-OBR|7|673678765^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|34.3|µmol/L|6.4-125|N|||F|||20241015050654
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|5.93|{Ratio}|<70|N|||F|||20241015050654
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|33.2|µmol/L|10-80|N|||F|||20241015050654
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|1.29565|{Ratio}|<7.6|N|||F|||20241015050654
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.136|µmol/L|<0.95|N|||F|||20241015050654
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.150|µmol/L|<0.45|N|||F|||20241015050654
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.65|{Ratio}||N|||F|||20241015050654
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.221|µmol/L|<0.65|N|||F|||20241015050654
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.230|µmol/L|<0.65|N|||F|||20241015050654
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.088|µmol/L|<0.45|N|||F|||20241015050654
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.232|µmol/L|<2|N|||F|||20241015050654
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.20|µmol/L||N|||F|||20241015050654
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.342|µmol/L|<1.2|N|||F|||20241015050654
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.206|µmol/L|<0.9|N|||F|||20241015050654
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.02|{Ratio}||N|||F|||20241015050654
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241015050654
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.029|µmol/L|<0.2|N|||F|||20241015050654
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|4.14|µmol/L|<12|N|||F|||20241015050654
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.341|µmol/L|<1.4|N|||F|||20241015050654
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.049|µmol/L|<0.1|N|||F|||20241015050654
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01184|{Ratio}|<0.07|N|||F|||20241015050654
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.07|µmol/L|<3.5|N|||F|||20241015050654
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.65|µmol/L|<7|N|||F|||20241015050654
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.23|µmol/L||N|||F|||20241015050654
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.022|µmol/L|<0.1|N|||F|||20241015050654
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.053|µmol/L|<0.1|N|||F|||20241015050654
-OBR|8|673678765^FormNumber||57085-3^Organic acid newborn screen panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.3|µmol/L|<7.9|N|||F|||20241015050654
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.07|{Ratio}|<0.42|N|||F|||20241015050654
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.298|µmol/L|<0.48|N|||F|||20241015050654
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|1.73|µmol/L|<1.7|H|||F|||20241015050654
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.139|µmol/L|<0.95|N|||F|||20241015050654
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.06043|{Ratio}|<0.38|N|||F|||20241015050654
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.011|µmol/L|<0.5|N|||F|||20241015050654
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.306|µmol/L|<1.15|N|||F|||20241015050654
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.238|µmol/L|<0.38|N|||F|||20241015050654
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.79866|{Ratio}|>0.1|N|||F|||20241015050654
-OBR|9|673678765^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|18.10|ng/mL|<69|N|||F|||20241015050654
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|10|673678765^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00010.8|nmol/L|<85|N|||F|||20241015050654
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|11|673678765^FormNumber||54090-6^Thyroid newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|29575-8^Thyrotropin^LN|1|4.00|mIU/L|<29|N|||F|||20241015050654
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|12|673678765^FormNumber||54079-9^Galactosemia newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|267.94|enzyme units|>50|N|||F|||20241015050654
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|13|673678765^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241015050654
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241015050654
-OBR|14|673678765^FormNumber||57087-9^Biotinidase newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|44.16|ERU|>10|N|||F|||20241015050654
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|15|673678765^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|84|copies/µL|>18|N|||F|||20241015050654
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|16|673678765^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|6.97|µmol/L/h|>=1.51|N|||F|||20241015050654
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|17|673678765^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|10.38|µmol/L/h|>=0.77|N|||F|||20241015050654
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|18|673678765^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241015050654
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241015050654
-OBR|19|673678765^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|27.61|µmol/L/h|>=2.75|N|||F|||20241015050654
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|20|673678765^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015050654
-OBR|21|673678765^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.04|µmol/L|<=3|N|||F|||20241015050654
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|391.37|µmol/L||N|||F|||20241015050654
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.66||<=6|N|||F|||20241015050654
-OBR|22|673678765^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241015050654
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241015050654
-OBR|23|673678765^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410011420|||||||||||||||20241015050654|||F
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.246|µmol/L|<0.47|N|||F|||20241015050654
diff --git a/examples/Test/Automated/GoldenCopy/Input/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7 b/examples/Test/Automated/GoldenCopy/Input/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7
new file mode 100644
index 000000000..09e8c2ce4
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Input/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241022024155||ORU^R01^ORU_R01|002|N|2.5.1
PID|1||80015887^^^&NPI^MR||CDPHTHREE^BOY B MOMTHREE^^^^^B|||M||2131-1^Other Race||||||||||||UNK^Unknown||Y|2
NK1|1|CDPHTHREE^MOMTHREE|MTH^Mother|3 3RD ST^^SAN DIEGO^CA^92126^USA|^^^^^858^2490007|||||||||||20031007
ORC|RE|7381238055^FormNumber||189693889^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7381238055^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBR|2|7381238055^FormNumber||57128-1^Newborn Screening Report summary panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241022024155
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241022024155
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241022024155
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA16207-5^Hemoglobinopathies^LN|||N|||F|||20241022024155
OBX|5|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|2|LA12537-9^CF^LN|||N|||F|||20241022024155
OBX|6|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241022024155
OBX|7|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Amino Acid Panel: There was insufficient data to determine whether or not this newborn was at least 12 hours old when this specimen was collected. Testing of amino acids at less than 12 hours of age is not reliable for detecting certain metabolic disorder. \.br\\.br\Hb: An immediate referral to a CCS Sickle Cell Disease/Hemoglobinopathies Center is strongly recommended. \.br\\.br\Cystic Fibrosis (CF): An immediate referral to a CCS approved Cystic Fibrosis Center for evaluation and additional testing is strongly recommended. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Screen for CF based on IRT and the California CFTR DNA mutation panel which consists of the following mutations: 1078delT, 1288insTA, 1677delTA, 1717-1G>A, 1812-1G>A, 1898+1G>A, 1898+5G>T, 2055del9>A, 2105-2117del13insAGAAA, 2143delT, 2183AA>G, 2184delA, 2307insA, 2789+5G>A, 2869insG, 3120+1G>A, 3120G>A, 3199del6, 3272-26A>G, 3659delC, 3791delC, 3849+10kbC>T, 3876delA, 3905insT, 394delTT, 405+3A>C, 406-1G>A, 444delA, 621+1G>T, 663delT, 711+1G>T, 935delA, A455E, A559T, CFTRdel2,3(21kb), delF311, delF508, delI507, E60X, G178R, G330X, G542X, G551D, G85E, H199Y, K710X, L206W, M1101K, N1303K, P205S, Q493X, Q890X, Q98R, R1066C, R1158X, R1162X, R117C, R334W, R347H, R347P, R352Q, R553X, R560T, R75X, S1196X, S1255X, S492F, S549N, S549R(T>G), V520F, W1089X, W1204X(3743G>A), W1204X(3744G>A), W1282X, Y1092X(C>A), Y1092X(C>G), Y122X. California CFTR Mutation Panel was run at Stanford Health Care, Molecular Pathology Laboratory, 3375 Hillview Avenue, Palo Alto, CA 94304. Directors: James Zehnder, MD; Christian Kunder, MD, PhD; Carlos J. Suarez, MD; (650) 723-6574. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241022024155
OBX|8|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241022024155
OBR|3|7381238055^FormNumber||57717-1^Newborn screen card data panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241022024155
OBX|2|NM|8339-4^Birthweight^LN|1|2948|grams||N|||F|||20241022024155
OBX|3|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241022024155
OBX|4|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241022024155
OBX|5|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241022024155
OBX|6|TX|^^^99717-5^Accession Number^L|1|282-12-459/21-2024-21|||N|||F|||20241022024155
OBX|7|TX|62324-9^Post-discharge provider name^LN|1|MICHELLE LEFF|||N|||F|||20241022024155
OBX|8|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241022024155
OBR|4|7381238055^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBR|5|7381238055^FormNumber||53261-4^Amino acid newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241022024155
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20241022024155
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241022024155
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241022024155
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20241022024155
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241022024155
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20241022024155
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241022024155
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20241022024155
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20241022024155
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20241022024155
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|�mol/L|5-49|N|||F|||20241022024155
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241022024155
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20241022024155
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241022024155
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20241022024155
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241022024155
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20241022024155
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Collected Early. No Interpretation.|||A|||F|||20241022024155
OBR|6|7381238055^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|7|7381238055^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20241022024155
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241022024155
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20241022024155
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241022024155
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20241022024155
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20241022024155
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241022024155
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20241022024155
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20241022024155
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20241022024155
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20241022024155
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20241022024155
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20241022024155
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20241022024155
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241022024155
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20241022024155
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20241022024155
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20241022024155
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20241022024155
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241022024155
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241022024155
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20241022024155
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20241022024155
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20241022024155
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241022024155
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241022024155
OBR|8|7381238055^FormNumber||57085-3^Organic acid newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20241022024155
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241022024155
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20241022024155
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20241022024155
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20241022024155
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241022024155
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20241022024155
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20241022024155
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20241022024155
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241022024155
OBR|9|7381238055^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|72.00|ng/mL|<69|H|||F|||20241022024155
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241022024155
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Consistent with Cystic Fibrosis (delF508 and delI507 mutations)|||A|||F|||20241022024155
OBR|10|7381238055^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241022024155
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|11|7381238055^FormNumber||54090-6^Thyroid newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241022024155
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|12|7381238055^FormNumber||54079-9^Galactosemia newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241022024155
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|13|7381238055^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|F||||||F|||20241022024155
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Consistent with Beta thalassemia major (Cooley's anemia).||||||F|||20241022024155
OBR|14|7381238055^FormNumber||57087-9^Biotinidase newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241022024155
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|15|7381238055^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/�L|>18|N|||F|||20241022024155
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|16|7381238055^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|�mol/L/h|>=18.2|N|||F|||20241022024155
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|17|7381238055^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20241022024155
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|18|7381238055^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241022024155
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241022024155
OBR|19|7381238055^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20241022024155
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|20|7381238055^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|21|7381238055^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|�mol/L|<=3|N|||F|||20241022024155
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|�mol/L||N|||F|||20241022024155
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241022024155
OBR|22|7381238055^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241022024155
OBR|23|7381238055^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20241022024155
diff --git a/examples/Test/Automated/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7 b/examples/Test/Automated/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
deleted file mode 100644
index 971a44185..000000000
--- a/examples/Test/Automated/GoldenCopy/Input/002_ORU_R01_golden_copy_input_acylc_2.hl7
+++ /dev/null
@@ -1,142 +0,0 @@
-MSH|^~\\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^9413816^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050234||ORU^R01^ORU_R01|002|N|2.5.1
-PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
-NK1|1|*****PII REMOVED******
-ORC|RE|12345667867^FormNumber||S30500^HospOrdNumber||||||||1194257170^MAHMOOD^SARAH^^^^^^^NPI|||||||||CEDARS-SINAI MEDICAL CENTER^^^^^^^^^R150|8700 BEVERLY BLVD^^W HOLLYWOOD^CA^90048-1804
-OBR|1|12345667867^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410061300|||||||||||||||20241018050234|||F
-OBR|2|12345667867^FormNumber||57128-1^Newborn Screening Report summary panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241018050234
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241018050234
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241018050234
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050234
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050234
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - LONG BEACH MEMORIAL MEDICAL CENTER \\\3747 LONG BEACH BLVD, LONG BEACH, CA 90807-3309\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Acyl Carnitine Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at UCLA Medical Center at (310) 826-4458. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241018050234
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241018050234
-OBR|3|12345667867^FormNumber||57717-1^Newborn screen card data panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241018050234
-OBX|2|NM|8339-4^Birthweight^LN|1|3135|grams||N|||F|||20241018050234
-OBX|3|TM|57715-5^Time of birth^LN|1|1235|||N|||F|||20241018050234
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241018050234
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241018050234
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241018050234
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241018050234
-OBX|8|TX|^^^99717-5^Accession Number^L|1|282-18-014/21-2024-32|||N|||F|||20241018050234
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|SARAH MAHMOOD|||N|||F|||20241018050234
-OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1194257170|||N|||F|||20241018050234
-OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|8700 BEVERLY BLVD W HOLLYWOOD CA 90048-1804 USA|||N|||F|||20241018050234
-OBR|4|12345667867^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410061300|||||||||||||||20241018050234|||F
-OBR|5|12345667867^FormNumber||53261-4^Amino acid newborn screen panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|611|µmol/L||N|||F|||20241018050234
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|585|µmol/L|<1000|N|||F|||20241018050234
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|90.9|µmol/L||N|||F|||20241018050234
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.74808|{Ratio}|<4.3|N|||F|||20241018050234
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|86.9|µmol/L|<230|N|||F|||20241018050234
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.15|{Ratio}|<1.35|N|||F|||20241018050234
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|52.0|µmol/L|<175|N|||F|||20241018050234
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241018050234
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|69.0|µmol/L|<680|N|||F|||20241018050234
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.23|µmol/L|<6.1|N|||F|||20241018050234
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|22.5|µmol/L|6.3-100|N|||F|||20241018050234
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|14|µmol/L|5-49|N|||F|||20241018050234
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|2.28|{Ratio}|<4.8|N|||F|||20241018050234
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|68|µmol/L|<800|N|||F|||20241018050234
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|4.93|{Ratio}||N|||F|||20241018050234
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|6|µmol/L|<63|N|||F|||20241018050234
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241018050234
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|192|µmol/L|<1500|N|||F|||20241018050234
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|6|12345667867^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241018050234
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with SCADD, IBCDD|||A|||F|||20241018050234
-OBR|7|12345667867^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|26.6|µmol/L|6.4-125|N|||F|||20241018050234
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|3.27|{Ratio}|<70|N|||F|||20241018050234
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|29.2|µmol/L|10-80|N|||F|||20241018050234
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.13913|{Ratio}|<7.6|N|||F|||20241018050234
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.088|µmol/L|<0.95|N|||F|||20241018050234
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.084|µmol/L|<0.45|N|||F|||20241018050234
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.73|{Ratio}||N|||F|||20241018050234
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.172|µmol/L|<0.65|N|||F|||20241018050234
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.115|µmol/L|<0.65|N|||F|||20241018050234
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.050|µmol/L|<0.45|N|||F|||20241018050234
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.127|µmol/L|<2|N|||F|||20241018050234
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.12|µmol/L||N|||F|||20241018050234
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.333|µmol/L|<1.2|N|||F|||20241018050234
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.132|µmol/L|<0.9|N|||F|||20241018050234
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.13|{Ratio}||N|||F|||20241018050234
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241018050234
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.026|µmol/L|<0.2|N|||F|||20241018050234
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|6.19|µmol/L|<12|N|||F|||20241018050234
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.445|µmol/L|<1.4|N|||F|||20241018050234
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.045|µmol/L|<0.1|N|||F|||20241018050234
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00727|{Ratio}|<0.07|N|||F|||20241018050234
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.53|µmol/L|<3.5|N|||F|||20241018050234
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.96|µmol/L|<7|N|||F|||20241018050234
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.21|µmol/L||N|||F|||20241018050234
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.017|µmol/L|<0.1|N|||F|||20241018050234
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.036|µmol/L|<0.1|N|||F|||20241018050234
-OBR|8|12345667867^FormNumber||57085-3^Organic acid newborn screen panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.5|µmol/L|<7.9|N|||F|||20241018050234
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.09|{Ratio}|<0.42|N|||F|||20241018050234
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.246|µmol/L|<0.48|N|||F|||20241018050234
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|1.72|µmol/L|<1.7|H|||F|||20241018050234
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.115|µmol/L|<0.95|N|||F|||20241018050234
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.04600|{Ratio}|<0.38|N|||F|||20241018050234
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.008|µmol/L|<0.5|N|||F|||20241018050234
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.232|µmol/L|<1.15|N|||F|||20241018050234
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.180|µmol/L|<0.38|N|||F|||20241018050234
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.73171|{Ratio}|>0.1|N|||F|||20241018050234
-OBR|9|12345667867^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|21.20|ng/mL|<69|N|||F|||20241018050234
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|10|12345667867^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00015.6|nmol/L|<85|N|||F|||20241018050234
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|11|12345667867^FormNumber||54090-6^Thyroid newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|29575-8^Thyrotropin^LN|1|9.50|mIU/L|<29|N|||F|||20241018050234
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|12|12345667867^FormNumber||54079-9^Galactosemia newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|262.95|enzyme units|>50|N|||F|||20241018050234
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|13|12345667867^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241018050234
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241018050234
-OBR|14|12345667867^FormNumber||57087-9^Biotinidase newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|49.77|ERU|>10|N|||F|||20241018050234
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|15|12345667867^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|197|copies/µL|>18|N|||F|||20241018050234
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|16|12345667867^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.29|µmol/L/h|>=1.47|N|||F|||20241018050234
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|17|12345667867^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|13.01|µmol/L/h|>=0.82|N|||F|||20241018050234
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|18|12345667867^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241018050234
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241018050234
-OBR|19|12345667867^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|27.84|µmol/L/h|>=2.79|N|||F|||20241018050234
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|20|12345667867^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050234
-OBR|21|12345667867^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|0.97|µmol/L|<=3|N|||F|||20241018050234
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|496.63|µmol/L||N|||F|||20241018050234
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.95||<=6|N|||F|||20241018050234
-OBR|22|12345667867^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241018050234
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241018050234
-OBR|23|12345667867^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410061300|||||||||||||||20241018050234|||F
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.349|µmol/L|<0.47|N|||F|||20241018050234
diff --git a/examples/Test/Automated/GoldenCopy/Input/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7 b/examples/Test/Automated/GoldenCopy/Input/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7
new file mode 100644
index 000000000..fcff71fd7
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Input/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20240930011140||ORU^R01^ORU_R01|003|N|2.5.1
PID|1||80009320^^^&NPI^MR||NEWBORNSCREEN^BOY  RED^^^^^B||202408150826|M||1002-5^American Indian or Alaska Native||||||||||||2186-5^Not Hispanic or Latino||N|1
NK1|1|NEWBORNSCREEN^RED|MTH^Mother|9560 TOWNE CENTRE DR^^SAN DIEGO^CA^92121-1972^USA|^^^^^619^1234567|||||||||||19850426
ORC|RE|7341237093^FormNumber||189671588^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7341237093^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBR|2|7341237093^FormNumber||57128-1^Newborn Screening Report summary panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20240930011140
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20240930011140
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12428-1^All screening is in range for the conditions tested^LN|||N|||F|||20240930011140
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20240930011140
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20240930011140
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Acyl Carnitine Panel: Reference Ranges for acylcarnitines are based on specimens collected on newborns who are less than 10 days old. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20240930011140
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20240930011140
OBR|3|7341237093^FormNumber||57717-1^Newborn screen card data panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20240930011140
OBX|2|NM|8339-4^Birthweight^LN|1|3084|grams||N|||F|||20240930011140
OBX|3|TM|57715-5^Time of birth^LN|1|0826|||N|||F|||20240930011140
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20240930011140
OBX|5|NM|73806-2^Newborn age in hours^LN|1|46|day(s)||N|||F|||20240930011140
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20240930011140
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20240930011140
OBX|8|TX|^^^99717-5^Accession Number^L|1|271-39-356/21-2024-21|||N|||F|||20240930011140
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MARVIN ZAGULI|||N|||F|||20240930011140
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20240930011140
OBR|4|7341237093^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBR|5|7341237093^FormNumber||53261-4^Amino acid newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20240930011140
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20240930011140
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20240930011140
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20240930011140
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20240930011140
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20240930011140
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20240930011140
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20240930011140
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20240930011140
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20240930011140
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20240930011140
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|�mol/L|5-49|N|||F|||20240930011140
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20240930011140
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20240930011140
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20240930011140
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20240930011140
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20240930011140
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20240930011140
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|6|7341237093^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|7|7341237093^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20240930011140
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20240930011140
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20240930011140
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20240930011140
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20240930011140
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20240930011140
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20240930011140
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20240930011140
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20240930011140
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20240930011140
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20240930011140
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20240930011140
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20240930011140
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20240930011140
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20240930011140
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20240930011140
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20240930011140
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20240930011140
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20240930011140
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20240930011140
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20240930011140
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20240930011140
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20240930011140
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20240930011140
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20240930011140
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20240930011140
OBR|8|7341237093^FormNumber||57085-3^Organic acid newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20240930011140
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20240930011140
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20240930011140
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20240930011140
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20240930011140
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20240930011140
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20240930011140
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20240930011140
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20240930011140
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20240930011140
OBR|9|7341237093^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20240930011140
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|10|7341237093^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20240930011140
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|11|7341237093^FormNumber||54090-6^Thyroid newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20240930011140
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|12|7341237093^FormNumber||54079-9^Galactosemia newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20240930011140
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|13|7341237093^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20240930011140
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.�These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20240930011140
OBR|14|7341237093^FormNumber||57087-9^Biotinidase newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20240930011140
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|15|7341237093^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/�L|>18|N|||F|||20240930011140
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|16|7341237093^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|�mol/L/h|>=18.2|N|||F|||20240930011140
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|17|7341237093^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20240930011140
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|18|7341237093^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20240930011140
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20240930011140
OBR|19|7341237093^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20240930011140
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|20|7341237093^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|21|7341237093^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|�mol/L|<=3|N|||F|||20240930011140
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|�mol/L||N|||F|||20240930011140
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20240930011140
OBR|22|7341237093^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20240930011140
OBR|23|7341237093^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20240930011140
diff --git a/examples/Test/Automated/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7 b/examples/Test/Automated/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
deleted file mode 100644
index 7f48ad1ff..000000000
--- a/examples/Test/Automated/GoldenCopy/Input/003_ORU_R01_golden_copy_input_aa_unusual.hl7
+++ /dev/null
@@ -1,142 +0,0 @@
-MSH|^~\\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241023050044||ORU^R01^ORU_R01|003|N|2.5.1
-PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
-NK1|1|*****PII REMOVED******
-ORC|RE|45789876^FormNumber||56352742^HospOrdNumber||||||||1043390461^PROFIT^DR JOCHEN^^^^^^^NPI|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601
-OBR|1|45789876^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBR|2|45789876^FormNumber||57128-1^Newborn Screening Report summary panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241023050044
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241023050044
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241023050044
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241023050044
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241023050044
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - ALLIED LABORATORY \\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Amino Acid Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241023050044
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241023050044
-OBR|3|45789876^FormNumber||57717-1^Newborn screen card data panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241023050044
-OBX|2|NM|8339-4^Birthweight^LN|1|2230|grams||N|||F|||20241023050044
-OBX|3|TM|57715-5^Time of birth^LN|1|1358|||N|||F|||20241023050044
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241023050044
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|26|hour(s)||N|||F|||20241023050044
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241023050044
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241023050044
-OBX|8|TX|^^^99717-5^Accession Number^L|1|282-38-261/21-2024-12|||N|||F|||20241023050044
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DR JOCHEN PROFIT|||N|||F|||20241023050044
-OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1043390461|||N|||F|||20241023050044
-OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA|||N|||F|||20241023050044
-OBR|4|45789876^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBR|5|45789876^FormNumber||53261-4^Amino acid newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|368|µmol/L||N|||F|||20241023050044
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|310|µmol/L|<1000|N|||F|||20241023050044
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|34.6|µmol/L||N|||F|||20241023050044
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.06462|{Ratio}|<4.3|N|||F|||20241023050044
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|50.7|µmol/L|<230|N|||F|||20241023050044
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.16|{Ratio}|<1.35|N|||F|||20241023050044
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|32.5|µmol/L|<175|N|||F|||20241023050044
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.13|{Ratio}|<2.6|N|||F|||20241023050044
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|28.9|µmol/L|<680|N|||F|||20241023050044
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.25|µmol/L|<6.1|N|||F|||20241023050044
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|8.6|µmol/L|6.3-100|N|||F|||20241023050044
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|5|µmol/L|5-49|N|||F|||20241023050044
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.67|{Ratio}|<4.8|N|||F|||20241023050044
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|32|µmol/L|<800|N|||F|||20241023050044
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|6.41|{Ratio}||N|||F|||20241023050044
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|3|µmol/L|<63|N|||F|||20241023050044
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241023050044
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|55|µmol/L|<1500|N|||F|||20241023050044
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|This complex pattern of elevations require further evaluation|||A|||F|||20241023050044
-OBR|6|45789876^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|7|45789876^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|34.9|µmol/L|6.4-125|N|||F|||20241023050044
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|7.84|{Ratio}|<70|N|||F|||20241023050044
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|28.1|µmol/L|10-80|N|||F|||20241023050044
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|3.53125|{Ratio}|<7.6|N|||F|||20241023050044
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.034|µmol/L|<0.95|N|||F|||20241023050044
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.038|µmol/L|<0.45|N|||F|||20241023050044
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.19|{Ratio}||N|||F|||20241023050044
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.155|µmol/L|<0.65|N|||F|||20241023050044
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.032|µmol/L|<0.65|N|||F|||20241023050044
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.030|µmol/L|<0.45|N|||F|||20241023050044
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.070|µmol/L|<2|N|||F|||20241023050044
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.05|µmol/L||N|||F|||20241023050044
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.270|µmol/L|<1.2|N|||F|||20241023050044
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.084|µmol/L|<0.9|N|||F|||20241023050044
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.75|{Ratio}||N|||F|||20241023050044
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241023050044
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.009|µmol/L|<0.2|N|||F|||20241023050044
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|2.87|µmol/L|<12|N|||F|||20241023050044
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.236|µmol/L|<1.4|N|||F|||20241023050044
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.022|µmol/L|<0.1|N|||F|||20241023050044
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00767|{Ratio}|<0.07|N|||F|||20241023050044
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|0.987|µmol/L|<3.5|N|||F|||20241023050044
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.59|µmol/L|<7|N|||F|||20241023050044
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.20|µmol/L||N|||F|||20241023050044
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.014|µmol/L|<0.1|N|||F|||20241023050044
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.034|µmol/L|<0.1|N|||F|||20241023050044
-OBR|8|45789876^FormNumber||57085-3^Organic acid newborn screen panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|1.9|µmol/L|<7.9|N|||F|||20241023050044
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.07|{Ratio}|<0.42|N|||F|||20241023050044
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.113|µmol/L|<0.48|N|||F|||20241023050044
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.161|µmol/L|<1.7|N|||F|||20241023050044
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.111|µmol/L|<0.95|N|||F|||20241023050044
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05842|{Ratio}|<0.38|N|||F|||20241023050044
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.006|µmol/L|<0.5|N|||F|||20241023050044
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.140|µmol/L|<1.15|N|||F|||20241023050044
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.091|µmol/L|<0.38|N|||F|||20241023050044
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.80531|{Ratio}|>0.1|N|||F|||20241023050044
-OBR|9|45789876^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|27.50|ng/mL|<69|N|||F|||20241023050044
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|10|45789876^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00029.9|nmol/L|<190|N|||F|||20241023050044
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|11|45789876^FormNumber||54090-6^Thyroid newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|29575-8^Thyrotropin^LN|1|6.90|mIU/L|<29|N|||F|||20241023050044
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|12|45789876^FormNumber||54079-9^Galactosemia newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|226.51|enzyme units|>50|N|||F|||20241023050044
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|13|45789876^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241023050044
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241023050044
-OBR|14|45789876^FormNumber||57087-9^Biotinidase newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|28.87|ERU|>10|N|||F|||20241023050044
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|15|45789876^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|198|copies/µL|>18|N|||F|||20241023050044
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|16|45789876^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|7.91|µmol/L/h|>=1.62|N|||F|||20241023050044
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|17|45789876^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|7.78|µmol/L/h|>=0.79|N|||F|||20241023050044
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|18|45789876^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241023050044
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241023050044
-OBR|19|45789876^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.94|µmol/L/h|>=2.95|N|||F|||20241023050044
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|20|45789876^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241023050044
-OBR|21|45789876^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.00|µmol/L|<=3|N|||F|||20241023050044
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|707.37|µmol/L||N|||F|||20241023050044
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.41||<=6|N|||F|||20241023050044
-OBR|22|45789876^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241023050044
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241023050044
-OBR|23|45789876^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410031603|||||||||^PROFIT^JOCHEN||||||20241023050044|||F
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.246|µmol/L|<0.47|N|||F|||20241023050044
diff --git a/examples/Test/Automated/GoldenCopy/Input/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7 b/examples/Test/Automated/GoldenCopy/Input/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7
new file mode 100644
index 000000000..2826e7995
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Input/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241118050532||ORU^R01^ORU_R01|004|N|2.5.1
PID|1||80015913^^^&NPI^MR||CDPHRESULT^GIRL C MARY^^^^^B||202410241550|F||2076-8^Native Hawaiian or Other Pacific Islander||||||||||||2186-5^Not Hispanic or Latino||Y|3
NK1|1|CDPHRESULT^MARY|MTH^Mother|123 ST^^SAN DIEGO^CA^92123^USA|^^^^^858^2490014|||||||||||19981024
ORC|RE|7312693833^FormNumber||189700664^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7312693833^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBR|2|7312693833^FormNumber||57128-1^Newborn Screening Report summary panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241118050532
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241118050532
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12428-1^All screening is in range for the conditions tested^LN|||N|||F|||20241118050532
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241118050532
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241118050532
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241118050532
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241118050532
OBR|3|7312693833^FormNumber||57717-1^Newborn screen card data panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241118050532
OBX|2|NM|8339-4^Birthweight^LN|1|2722|grams||N|||F|||20241118050532
OBX|3|TM|57715-5^Time of birth^LN|1|1550|||N|||F|||20241118050532
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12413-3^Triplets^LN|||N|||F|||20241118050532
OBX|5|NM|73806-2^Newborn age in hours^LN|1|23|hour(s)||N|||F|||20241118050532
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241118050532
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241118050532
OBX|8|TX|^^^99717-5^Accession Number^L|1|306-98-178/21-2024-21|||N|||F|||20241118050532
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MARVIN ZAGULI|||N|||F|||20241118050532
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241118050532
OBR|4|7312693833^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBR|5|7312693833^FormNumber||53261-4^Amino acid newborn screen panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241118050532
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20241118050532
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241118050532
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241118050532
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20241118050532
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241118050532
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20241118050532
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241118050532
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20241118050532
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20241118050532
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20241118050532
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|�mol/L|5-49|N|||F|||20241118050532
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241118050532
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20241118050532
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241118050532
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20241118050532
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241118050532
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20241118050532
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|6|7312693833^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|7|7312693833^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20241118050532
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241118050532
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20241118050532
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241118050532
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20241118050532
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20241118050532
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241118050532
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20241118050532
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20241118050532
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20241118050532
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20241118050532
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20241118050532
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20241118050532
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20241118050532
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241118050532
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20241118050532
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20241118050532
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20241118050532
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20241118050532
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241118050532
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241118050532
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20241118050532
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20241118050532
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20241118050532
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241118050532
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241118050532
OBR|8|7312693833^FormNumber||57085-3^Organic acid newborn screen panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20241118050532
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241118050532
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20241118050532
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20241118050532
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20241118050532
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241118050532
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20241118050532
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20241118050532
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20241118050532
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241118050532
OBR|9|7312693833^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241118050532
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|10|7312693833^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241118050532
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|11|7312693833^FormNumber||54090-6^Thyroid newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241118050532
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|12|7312693833^FormNumber||54079-9^Galactosemia newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241118050532
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|13|7312693833^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241118050532
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.�These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241118050532
OBR|14|7312693833^FormNumber||57087-9^Biotinidase newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241118050532
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|15|7312693833^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/�L|>18|N|||F|||20241118050532
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|16|7312693833^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|�mol/L/h|>=18.2|N|||F|||20241118050532
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|17|7312693833^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20241118050532
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|18|7312693833^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241118050532
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241118050532
OBR|19|7312693833^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20241118050532
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|20|7312693833^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|21|7312693833^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|�mol/L|<=3|N|||F|||20241118050532
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|�mol/L||N|||F|||20241118050532
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.93||<=10|N|||F|||20241118050532
OBR|22|7312693833^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241118050532
OBR|23|7312693833^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20241118050532
diff --git a/examples/Test/Automated/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7 b/examples/Test/Automated/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
deleted file mode 100644
index fac1f1dc2..000000000
--- a/examples/Test/Automated/GoldenCopy/Input/004_ORU_R01_golden_copy_input_in_range.hl7
+++ /dev/null
@@ -1,142 +0,0 @@
-MSH|^~\\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241030050154||ORU^R01^ORU_R01|004|N|2.5.1
-PID|1||335441864^^^104638912487&NPI^MR||*****PII REMOVED******
-NK1|1|*****PII REMOVED******
-ORC|RE|356672001^FormNumber||629813494^HospOrdNumber||||||||1093050858^SILVA^RICHARD^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|200 W ARBOR DR^^SAN DIEGO^CA^92103-1911
-OBR|1|356672001^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBR|2|356672001^FormNumber||57128-1^Newborn Screening Report summary panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241030050154
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241030050154
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12428-1^All screening is in range for the conditions tested^LN|||N|||F|||20241030050154
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241030050154
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241030050154
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \\\2130 E Illinois Avenue, FRESNO, CA 93701\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (858) 966-8708. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241030050154
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241030050154
-OBR|3|356672001^FormNumber||57717-1^Newborn screen card data panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241030050154
-OBX|2|NM|8339-4^Birthweight^LN|1|3464|grams||N|||F|||20241030050154
-OBX|3|TM|57715-5^Time of birth^LN|1|0444|||N|||F|||20241030050154
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241030050154
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|19|hour(s)||N|||F|||20241030050154
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241030050154
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241030050154
-OBX|8|TX|^^^99717-5^Accession Number^L|1|292-04-123/21-2024-32|||N|||F|||20241030050154
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DIANE BEDROSIAN|||N|||F|||20241030050154
-OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1447323951|||N|||F|||20241030050154
-OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|200 W ARBOR DR SAN DIEGO CA 92103-1911 USA|||N|||F|||20241030050154
-OBR|4|356672001^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBR|5|356672001^FormNumber||53261-4^Amino acid newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|536|µmol/L||N|||F|||20241030050154
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|559|µmol/L|<1000|N|||F|||20241030050154
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|123|µmol/L||N|||F|||20241030050154
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|2.14286|{Ratio}|<4.3|N|||F|||20241030050154
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|113|µmol/L|<230|N|||F|||20241030050154
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.20|{Ratio}|<1.35|N|||F|||20241030050154
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|57.4|µmol/L|<175|N|||F|||20241030050154
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.05|{Ratio}|<2.6|N|||F|||20241030050154
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|54.8|µmol/L|<680|N|||F|||20241030050154
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.20|µmol/L|<6.1|N|||F|||20241030050154
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|22.8|µmol/L|6.3-100|N|||F|||20241030050154
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|10|µmol/L|5-49|N|||F|||20241030050154
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.52|{Ratio}|<4.8|N|||F|||20241030050154
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|84|µmol/L|<800|N|||F|||20241030050154
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|8.40|{Ratio}||N|||F|||20241030050154
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|7|µmol/L|<63|N|||F|||20241030050154
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241030050154
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|154|µmol/L|<1500|N|||F|||20241030050154
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|6|356672001^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|7|356672001^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|24.4|µmol/L|6.4-125|N|||F|||20241030050154
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|4.32|{Ratio}|<70|N|||F|||20241030050154
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|27.3|µmol/L|10-80|N|||F|||20241030050154
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.73000|{Ratio}|<7.6|N|||F|||20241030050154
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.067|µmol/L|<0.95|N|||F|||20241030050154
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.076|µmol/L|<0.45|N|||F|||20241030050154
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.76|{Ratio}||N|||F|||20241030050154
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.103|µmol/L|<0.65|N|||F|||20241030050154
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.100|µmol/L|<0.65|N|||F|||20241030050154
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.035|µmol/L|<0.45|N|||F|||20241030050154
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.132|µmol/L|<2|N|||F|||20241030050154
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.17|µmol/L||N|||F|||20241030050154
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.264|µmol/L|<1.2|N|||F|||20241030050154
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.189|µmol/L|<0.9|N|||F|||20241030050154
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.13|{Ratio}||N|||F|||20241030050154
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241030050154
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.021|µmol/L|<0.2|N|||F|||20241030050154
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|3.88|µmol/L|<12|N|||F|||20241030050154
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.371|µmol/L|<1.4|N|||F|||20241030050154
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.030|µmol/L|<0.1|N|||F|||20241030050154
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00773|{Ratio}|<0.07|N|||F|||20241030050154
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|1.11|µmol/L|<3.5|N|||F|||20241030050154
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.76|µmol/L|<7|N|||F|||20241030050154
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.15|µmol/L||N|||F|||20241030050154
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.015|µmol/L|<0.1|N|||F|||20241030050154
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.032|µmol/L|<0.1|N|||F|||20241030050154
-OBR|8|356672001^FormNumber||57085-3^Organic acid newborn screen panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|2.3|µmol/L|<7.9|N|||F|||20241030050154
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.09|{Ratio}|<0.42|N|||F|||20241030050154
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.273|µmol/L|<0.48|N|||F|||20241030050154
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.315|µmol/L|<1.7|N|||F|||20241030050154
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.117|µmol/L|<0.95|N|||F|||20241030050154
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05087|{Ratio}|<0.38|N|||F|||20241030050154
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.009|µmol/L|<0.5|N|||F|||20241030050154
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.217|µmol/L|<1.15|N|||F|||20241030050154
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.183|µmol/L|<0.38|N|||F|||20241030050154
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.67033|{Ratio}|>0.1|N|||F|||20241030050154
-OBR|9|356672001^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|27.20|ng/mL|<69|N|||F|||20241030050154
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|10|356672001^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00015.2|nmol/L|<85|N|||F|||20241030050154
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|11|356672001^FormNumber||54090-6^Thyroid newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|29575-8^Thyrotropin^LN|1|15.40|mIU/L|<29|N|||F|||20241030050154
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|12|356672001^FormNumber||54079-9^Galactosemia newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|273.54|enzyme units|>50|N|||F|||20241030050154
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|13|356672001^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241030050154
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241030050154
-OBR|14|356672001^FormNumber||57087-9^Biotinidase newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|73.00|ERU|>10|N|||F|||20241030050154
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|15|356672001^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|120|copies/µL|>18|N|||F|||20241030050154
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|16|356672001^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|11.43|µmol/L/h|>=1.54|N|||F|||20241030050154
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|17|356672001^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|9.33|µmol/L/h|>=0.86|N|||F|||20241030050154
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|18|356672001^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241030050154
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241030050154
-OBR|19|356672001^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|22.31|µmol/L/h|>=2.84|N|||F|||20241030050154
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|20|356672001^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241030050154
-OBR|21|356672001^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.22|µmol/L|<=3|N|||F|||20241030050154
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|411.55|µmol/L||N|||F|||20241030050154
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.95||<=6|N|||F|||20241030050154
-OBR|22|356672001^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241030050154
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241030050154
-OBR|23|356672001^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410182335|||||||||^SILVA^RICHARD||||||20241030050154|||F
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.138|µmol/L|<0.47|N|||F|||20241030050154
diff --git a/examples/Test/Automated/GoldenCopy/Input/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7 b/examples/Test/Automated/GoldenCopy/Input/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7
new file mode 100644
index 000000000..e61dbf1a6
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Input/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241118030201||ORU^R01^ORU_R01|005|N|2.5.1
PID|1||80015887^^^&NPI^MR||CDPHTHREE^BOY B MOMTHREE^^^^^B||202410161318|M||2131-1^Other Race||||||||||||UNK^Unknown||Y|2
NK1|1|CDPHTHREE^MOMTHREE|MTH^Mother|3 3RD ST^^SAN DIEGO^CA^92126^USA|^^^^^858^2490007|||||||||||20031007
ORC|RE|7381238055^FormNumber||189693889^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7381238055^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBR|2|7381238055^FormNumber||57128-1^Newborn Screening Report summary panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241118030201
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241118030201
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241118030201
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241118030201
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241118030201
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Amino Acid Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241118030201
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241118030201
OBR|3|7381238055^FormNumber||57717-1^Newborn screen card data panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241118030201
OBX|2|NM|8339-4^Birthweight^LN|1|2948|grams||N|||F|||20241118030201
OBX|3|TM|57715-5^Time of birth^LN|1|1318|||N|||F|||20241118030201
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241118030201
OBX|5|NM|73806-2^Newborn age in hours^LN|1|3|hour(s)||N|||F|||20241118030201
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241118030201
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241118030201
OBX|8|TX|^^^99717-5^Accession Number^L|1|290-84-459/21-2024-21|||N|||F|||20241118030201
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MICHELLE LEFF|||N|||F|||20241118030201
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241118030201
OBR|4|7381238055^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBR|5|7381238055^FormNumber||53261-4^Amino acid newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241118030201
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20241118030201
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241118030201
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241118030201
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20241118030201
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241118030201
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20241118030201
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241118030201
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20241118030201
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20241118030201
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20241118030201
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|275|�mol/L|5-49|H|||F|||20241118030201
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|11|{Ratio}|<4.8|H|||F|||20241118030201
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20241118030201
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241118030201
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20241118030201
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241118030201
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20241118030201
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with Citrullinemia (I/II), ASAL Deficiency|||A|||F|||20241118030201
OBR|6|7381238055^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|7|7381238055^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20241118030201
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241118030201
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20241118030201
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241118030201
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20241118030201
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20241118030201
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241118030201
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20241118030201
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20241118030201
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20241118030201
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20241118030201
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20241118030201
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20241118030201
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20241118030201
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241118030201
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20241118030201
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20241118030201
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20241118030201
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20241118030201
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241118030201
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241118030201
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20241118030201
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20241118030201
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20241118030201
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241118030201
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241118030201
OBR|8|7381238055^FormNumber||57085-3^Organic acid newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20241118030201
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241118030201
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20241118030201
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20241118030201
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20241118030201
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241118030201
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20241118030201
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20241118030201
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20241118030201
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241118030201
OBR|9|7381238055^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241118030201
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|10|7381238055^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241118030201
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|11|7381238055^FormNumber||54090-6^Thyroid newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241118030201
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|12|7381238055^FormNumber||54079-9^Galactosemia newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241118030201
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|13|7381238055^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241118030201
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.�These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241118030201
OBR|14|7381238055^FormNumber||57087-9^Biotinidase newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241118030201
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|15|7381238055^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/�L|>18|N|||F|||20241118030201
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|16|7381238055^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|�mol/L/h|>=18.2|N|||F|||20241118030201
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|17|7381238055^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20241118030201
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|18|7381238055^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241118030201
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241118030201
OBR|19|7381238055^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20241118030201
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|20|7381238055^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|21|7381238055^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|�mol/L|<=3|N|||F|||20241118030201
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|�mol/L||N|||F|||20241118030201
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241118030201
OBR|22|7381238055^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241118030201
OBR|23|7381238055^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20241118030201
diff --git a/examples/Test/Automated/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7 b/examples/Test/Automated/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
deleted file mode 100644
index f4f0b0172..000000000
--- a/examples/Test/Automated/GoldenCopy/Input/005_ORU_R01_golden_copy_input_out_of_range.hl7
+++ /dev/null
@@ -1,142 +0,0 @@
-MSH|^~\\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241018050017||ORU^R01^ORU_R01|005|N|2.5.1
-PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
-NK1|1|*****PII REMOVED******
-ORC|RE|753234567^FormNumber||56155532^HospOrdNumber||||||||^SCALA^MELISSA|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601
-OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBR|2|753234567^FormNumber||57128-1^Newborn Screening Report summary panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241018050017
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241018050017
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241018050017
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA16207-5^Hemoglobinopathies^LN|||N|||F|||20241018050017
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050017
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - ALLIED LABORATORY \\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Hb: An immediate referral to a CCS Hematology Center or a pediatric hematologist familiar with alpha thalassemia and Hb H disease is strongly recommended for this infant. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241018050017
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241018050017
-OBR|3|753234567^FormNumber||57717-1^Newborn screen card data panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241018050017
-OBX|2|NM|8339-4^Birthweight^LN|1|2658|grams||N|||F|||20241018050017
-OBX|3|TM|57715-5^Time of birth^LN|1|0027|||N|||F|||20241018050017
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241018050017
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|28|hour(s)||N|||F|||20241018050017
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241018050017
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241018050017
-OBX|8|TX|^^^99717-5^Accession Number^L|1|272-95-009/21-2024-12|||N|||F|||20241018050017
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MELISSA SCALA|||N|||F|||20241018050017
-OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA|||N|||F|||20241018050017
-OBR|4|753234567^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBR|5|753234567^FormNumber||53261-4^Amino acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|926|µmol/L||N|||F|||20241018050017
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|588|µmol/L|<1000|N|||F|||20241018050017
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|79.4|µmol/L||N|||F|||20241018050017
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.29739|{Ratio}|<4.3|N|||F|||20241018050017
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|99.2|µmol/L|<230|N|||F|||20241018050017
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.17|{Ratio}|<1.35|N|||F|||20241018050017
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|61.2|µmol/L|<175|N|||F|||20241018050017
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.77|{Ratio}|<2.6|N|||F|||20241018050017
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|34.7|µmol/L|<680|N|||F|||20241018050017
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.33|µmol/L|<6.1|N|||F|||20241018050017
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|20.4|µmol/L|6.3-100|N|||F|||20241018050017
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|10|µmol/L|5-49|N|||F|||20241018050017
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|2.79|{Ratio}|<4.8|N|||F|||20241018050017
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|43|µmol/L|<800|N|||F|||20241018050017
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|4.44|{Ratio}||N|||F|||20241018050017
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|3|µmol/L|<63|N|||F|||20241018050017
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241018050017
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|187|µmol/L|<1500|N|||F|||20241018050017
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|6|753234567^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|7|753234567^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|39.6|µmol/L|6.4-125|N|||F|||20241018050017
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|5.35|{Ratio}|<70|N|||F|||20241018050017
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|34.7|µmol/L|10-80|N|||F|||20241018050017
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|3.27536|{Ratio}|<7.6|N|||F|||20241018050017
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.100|µmol/L|<0.95|N|||F|||20241018050017
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.075|µmol/L|<0.45|N|||F|||20241018050017
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.09|{Ratio}||N|||F|||20241018050017
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.163|µmol/L|<0.65|N|||F|||20241018050017
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.069|µmol/L|<0.65|N|||F|||20241018050017
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.057|µmol/L|<0.45|N|||F|||20241018050017
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.118|µmol/L|<2|N|||F|||20241018050017
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.06|µmol/L||N|||F|||20241018050017
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.394|µmol/L|<1.2|N|||F|||20241018050017
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.130|µmol/L|<0.9|N|||F|||20241018050017
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|2.32|{Ratio}||N|||F|||20241018050017
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241018050017
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.026|µmol/L|<0.2|N|||F|||20241018050017
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5.52|µmol/L|<12|N|||F|||20241018050017
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.245|µmol/L|<1.4|N|||F|||20241018050017
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.042|µmol/L|<0.1|N|||F|||20241018050017
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00761|{Ratio}|<0.07|N|||F|||20241018050017
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2.13|µmol/L|<3.5|N|||F|||20241018050017
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.89|µmol/L|<7|N|||F|||20241018050017
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.29|µmol/L||N|||F|||20241018050017
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.032|µmol/L|<0.1|N|||F|||20241018050017
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.047|µmol/L|<0.1|N|||F|||20241018050017
-OBR|8|753234567^FormNumber||57085-3^Organic acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|4.2|µmol/L|<7.9|N|||F|||20241018050017
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.12|{Ratio}|<0.42|N|||F|||20241018050017
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.226|µmol/L|<0.48|N|||F|||20241018050017
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.424|µmol/L|<1.7|N|||F|||20241018050017
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.247|µmol/L|<0.95|N|||F|||20241018050017
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05881|{Ratio}|<0.38|N|||F|||20241018050017
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.008|µmol/L|<0.5|N|||F|||20241018050017
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.287|µmol/L|<1.15|N|||F|||20241018050017
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.179|µmol/L|<0.38|N|||F|||20241018050017
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.79204|{Ratio}|>0.1|N|||F|||20241018050017
-OBR|9|753234567^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|18.50|ng/mL|<69|N|||F|||20241018050017
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|10|753234567^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00013.8|nmol/L|<85|N|||F|||20241018050017
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|11|753234567^FormNumber||54090-6^Thyroid newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|29575-8^Thyrotropin^LN|1|2.40|mIU/L|<29|N|||F|||20241018050017
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|12|753234567^FormNumber||54079-9^Galactosemia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|293.00|enzyme units|>50|N|||F|||20241018050017
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|13|753234567^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA + Barts||||||F|||20241018050017
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|The presence of Hb Barts at a high percentage is consistent with Hb H disease, a clinically significant hemoglobin disorder.||||||F|||20241018050017
-OBR|14|753234567^FormNumber||57087-9^Biotinidase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|43.76|ERU|>10|N|||F|||20241018050017
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|15|753234567^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|99|copies/µL|>18|N|||F|||20241018050017
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|16|753234567^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|7.09|µmol/L/h|>=1.67|N|||F|||20241018050017
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|17|753234567^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|8.33|µmol/L/h|>=0.86|N|||F|||20241018050017
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|18|753234567^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241018050017
-OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241018050017
-OBR|19|753234567^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|15.65|µmol/L/h|>=2.8|N|||F|||20241018050017
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|20|753234567^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017
-OBR|21|753234567^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.05|µmol/L|<=3|N|||F|||20241018050017
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|616.49|µmol/L||N|||F|||20241018050017
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.70||<=6|N|||F|||20241018050017
-OBR|22|753234567^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241018050017
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241018050017
-OBR|23|753234567^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.260|µmol/L|<0.47|N|||F|||20241018050017
diff --git a/examples/Test/Automated/GoldenCopy/Input/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7 b/examples/Test/Automated/GoldenCopy/Input/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7
new file mode 100644
index 000000000..7ba118a0f
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Input/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241203094445||ORU^R01^ORU_R01|006|N|2.5.1
PID|1||80015959^^^&NPI^MR||INTERFACE^GIRL B CDPHTWO^^^^^B||20241118084900|F||2028-9^Asian||||||||||||2186-5^Not Hispanic or Latino||Y|2
NK1|1|INTERFACE^CDPHTWO|MTH^Mother|9877 7TH ST^^SAN DIEGO^CA^92126^USA|^^^^^619^4704213|||||||||||19961118
ORC|RE|7872697780^FormNumber||189716938^HospOrdNumber||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7872697780^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBR|2|7872697780^FormNumber||57128-1^Newborn Screening Report summary panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241203094445
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241203094445
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241203094445
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|99717-3^Hypothyroidism^L|||N|||F|||20241203094445
OBX|5|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|2|LA12543-7^GALT^LN|||N|||F|||20241203094445
OBX|6|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|3|LA22279-6^SMA^LN|||N|||F|||20241203094445
OBX|7|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|4|LA30113-7^GAMT^LN|||N|||F|||20241203094445
OBX|8|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|5|LA12532-0^BIO^LN|||N|||F|||20241203094445
OBX|9|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241203094445
OBX|10|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Biotinidase Deficiency: This screen for Biotinidase Deficiency was positive. Another specimen MUST be collected on this infant. \.br\\.br\Guanidinoacetate Methyltransferase (GAMT): An immediate referral to a CCS-approved Metabolic Center for evaluation and additional testing is strongly recommended. \.br\\.br\Spinal Muscular Atrophy (SMA): An immediate referral to a CCS-approved Neuromuscular Center for evaluation and additional testing is strongly recommended due an apparent SMN1 exon 7 homozygous deletion. \.br\\.br\Galactosemia: Additional testing is required to rule out disorder.�Call your Newborn Screening Coordinator for assistance. \.br\\.br\Primary Congenital Hypothyroidism: Additional testing in consultation with a CCS-approved Endocrine Center or Pediatric Endocrinologist is strongly recommended.�Call your Newborn Screening Coordinator for assistance. \.br\\.br\ATTENTION: THIS CHILD HAS TESTED POSITIVE FOR MORE THAN ONE TEST. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241203094445
OBX|11|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241203094445
OBR|3|7872697780^FormNumber||57717-1^Newborn screen card data panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241203094445
OBX|2|NM|8339-4^Birthweight^LN|1|2495|grams||N|||F|||20241203094445
OBX|3|TM|57715-5^Time of birth^LN|1|8490|||N|||F|||20241203094445
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241203094445
OBX|5|NM|73806-2^Newborn age in hours^LN|1|82|hour(s)||N|||F|||20241203094445
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241203094445
OBX|7|CE|67704-7^Feeding types^LN|1|LA16915-3^Lactose formula^LN|||N|||F|||20241203094445
OBX|8|TX|^^^99717-5^Accession Number^L|1|326-64-675/21-2024-21|||N|||F|||20241203094445
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MICHELLE LEFF|||N|||F|||20241203094445
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241203094445
OBR|4|7872697780^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBR|5|7872697780^FormNumber||53261-4^Amino acid newborn screen panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241203094445
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20241203094445
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241203094445
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241203094445
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20241203094445
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241203094445
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20241203094445
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241203094445
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20241203094445
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20241203094445
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20241203094445
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|�mol/L|5-49|N|||F|||20241203094445
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241203094445
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20241203094445
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241203094445
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20241203094445
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241203094445
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20241203094445
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|6|7872697780^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|7|7872697780^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20241203094445
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241203094445
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20241203094445
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241203094445
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20241203094445
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20241203094445
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241203094445
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20241203094445
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20241203094445
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20241203094445
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20241203094445
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20241203094445
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20241203094445
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20241203094445
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241203094445
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20241203094445
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20241203094445
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20241203094445
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20241203094445
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241203094445
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241203094445
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20241203094445
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20241203094445
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20241203094445
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241203094445
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241203094445
OBR|8|7872697780^FormNumber||57085-3^Organic acid newborn screen panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20241203094445
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241203094445
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20241203094445
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20241203094445
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20241203094445
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241203094445
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20241203094445
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20241203094445
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20241203094445
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241203094445
OBR|9|7872697780^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241203094445
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|10|7872697780^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<190|N|||F|||20241203094445
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|11|7872697780^FormNumber||54090-6^Thyroid newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|34.00|mIU/L|<29|H|||F|||20241203094445
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241203094445
OBR|12|7872697780^FormNumber||54079-9^Galactosemia newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|48.00|enzyme units|>50|L|||F|||20241203094445
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241203094445
OBR|13|7872697780^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241203094445
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.�These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241203094445
OBR|14|7872697780^FormNumber||57087-9^Biotinidase newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|8.00|ERU|>10|L|||F|||20241203094445
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241203094445
OBR|15|7872697780^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/�L|>18|N|||F|||20241203094445
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|16|7872697780^FormNumber||63414-7^Pompe Disease newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|�mol/L/h|>=18.2|N|||F|||20241203094445
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|17|7872697780^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20241203094445
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|18|7872697780^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Absent||Exon 7 Present|A|||F|||20241203094445
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Positive|||A|||F|||20241203094445
OBR|19|7872697780^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20241203094445
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|20|7872697780^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Positive|||A|||F|||20241203094445
OBR|21|7872697780^FormNumber||^^^99717-57^Guanidinoacetate methyltransferase Tier-2 newborn screening panel^L|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|5.25|�mol/L/h|<=5|H|||F|||20241203094445
OBR|22|7872697780^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241203094445
OBR|23|7872697780^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20241203094445
diff --git a/examples/Test/Automated/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7 b/examples/Test/Automated/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7
deleted file mode 100644
index 0c4469d8c..000000000
--- a/examples/Test/Automated/GoldenCopy/Input/006_ORU_R01_golden_copy_input_sma_incomplete.hl7
+++ /dev/null
@@ -1,141 +0,0 @@
-MSH|^~\\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^9413799^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241017050025||ORU^R01^ORU_R01|006|N|2.5.1
-PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
-NK1|1|*****PII REMOVED******
-ORC|RE|789876543^FormNumber||||||||||1164928032^MURUGESAN^CHEZHIYAN^^^^^^^NPI|||||||||KERN MEDICAL CENTER^^^^^^^^^R092|1700 MOUNT VERNON AVE^^BAKERSFIELD^CA^93306-4018
-OBR|1|789876543^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBR|2|789876543^FormNumber||57128-1^Newborn Screening Report summary panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241017050025
-OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241017050025
-OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12430-7^Out of range requiring further dried blood spot testing for at least one condition^LN|||N|||F|||20241017050025
-OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241017050025
-OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA22279-6^SMA^LN|||N|||F|||20241017050025
-OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \\\2130 E Illinois Avenue, FRESNO, CA 93701\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Spinal Muscular Atrophy (SMA): The sample was not adequate to complete testing for SMA. A repeat NBS specimen MUST be collected. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Valley Children's Hospital at (559) 353-6416. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241017050025
-OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241017050025
-OBR|3|789876543^FormNumber||57717-1^Newborn screen card data panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241017050025
-OBX|2|NM|8339-4^Birthweight^LN|1|2875|grams||N|||F|||20241017050025
-OBX|3|TM|57715-5^Time of birth^LN|1|0202|||N|||F|||20241017050025
-OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241017050025
-OBX|5|NM|73806-2^Newborn age in hours^LN|1|27|hour(s)||N|||F|||20241017050025
-OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241017050025
-OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241017050025
-OBX|8|TX|^^^99717-5^Accession Number^L|1|269-80-133/21-2024-21|||N|||F|||20241017050025
-OBX|9|TX|62324-9^Post-discharge provider name^LN|1|CHEZHIYAN MURUGESAN|||N|||F|||20241017050025
-OBX|10|TX|62325-6^Post-discharge provider practice ID^LN|1|1164928032|||N|||F|||20241017050025
-OBX|11|TX|62327-2^Post-discharge provider practice address^LN|1|1700 MOUNT VERNON AVE BAKERSFIELD CA 93306-4018 USA|||N|||F|||20241017050025
-OBR|4|789876543^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBR|5|789876543^FormNumber||53261-4^Amino acid newborn screen panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|357|µmol/L||N|||F|||20241017050025
-OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|398|µmol/L|<1000|N|||F|||20241017050025
-OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|92.2|µmol/L||N|||F|||20241017050025
-OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|2.05804|{Ratio}|<4.3|N|||F|||20241017050025
-OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|84.2|µmol/L|<230|N|||F|||20241017050025
-OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.21|{Ratio}|<1.35|N|||F|||20241017050025
-OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|44.8|µmol/L|<175|N|||F|||20241017050025
-OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.55|{Ratio}|<2.6|N|||F|||20241017050025
-OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|81.7|µmol/L|<680|N|||F|||20241017050025
-OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.20|µmol/L|<6.1|N|||F|||20241017050025
-OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|11.1|µmol/L|6.3-100|N|||F|||20241017050025
-OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|12|µmol/L|5-49|N|||F|||20241017050025
-OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|1.72|{Ratio}|<4.8|N|||F|||20241017050025
-OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|77|µmol/L|<800|N|||F|||20241017050025
-OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|6.36|{Ratio}||N|||F|||20241017050025
-OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|7|µmol/L|<63|N|||F|||20241017050025
-OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.09|{Ratio}|<1.9|N|||F|||20241017050025
-OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|136|µmol/L|<1500|N|||F|||20241017050025
-OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241017050025
-OBR|6|789876543^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
-OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241017050025
-OBR|7|789876543^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|16.4|µmol/L|6.4-125|N|||F|||20241017050025
-OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|3.65|{Ratio}|<70|N|||F|||20241017050025
-OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|16.1|µmol/L|10-80|N|||F|||20241017050025
-OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|2.06977|{Ratio}|<7.6|N|||F|||20241017050025
-OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.075|µmol/L|<0.95|N|||F|||20241017050025
-OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.049|µmol/L|<0.45|N|||F|||20241017050025
-OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.14|{Ratio}||N|||F|||20241017050025
-OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.042|µmol/L|<0.65|N|||F|||20241017050025
-OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.043|µmol/L|<0.65|N|||F|||20241017050025
-OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.026|µmol/L|<0.45|N|||F|||20241017050025
-OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.071|µmol/L|<2|N|||F|||20241017050025
-OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.05|µmol/L||N|||F|||20241017050025
-OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.169|µmol/L|<1.2|N|||F|||20241017050025
-OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.099|µmol/L|<0.9|N|||F|||20241017050025
-OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|1.98|{Ratio}||N|||F|||20241017050025
-OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.02|µmol/L||N|||F|||20241017050025
-OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.015|µmol/L|<0.2|N|||F|||20241017050025
-OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|2.91|µmol/L|<12|N|||F|||20241017050025
-OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.221|µmol/L|<1.4|N|||F|||20241017050025
-OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.021|µmol/L|<0.1|N|||F|||20241017050025
-OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00722|{Ratio}|<0.07|N|||F|||20241017050025
-OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|0.827|µmol/L|<3.5|N|||F|||20241017050025
-OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.58|µmol/L|<7|N|||F|||20241017050025
-OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.14|µmol/L||N|||F|||20241017050025
-OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.013|µmol/L|<0.1|N|||F|||20241017050025
-OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.028|µmol/L|<0.1|N|||F|||20241017050025
-OBR|8|789876543^FormNumber||57085-3^Organic acid newborn screen panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|1.7|µmol/L|<7.9|N|||F|||20241017050025
-OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.10|{Ratio}|<0.42|N|||F|||20241017050025
-OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.089|µmol/L|<0.48|N|||F|||20241017050025
-OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.229|µmol/L|<1.7|N|||F|||20241017050025
-OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.081|µmol/L|<0.95|N|||F|||20241017050025
-OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.04765|{Ratio}|<0.38|N|||F|||20241017050025
-OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.005|µmol/L|<0.5|N|||F|||20241017050025
-OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.216|µmol/L|<1.15|N|||F|||20241017050025
-OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.080|µmol/L|<0.38|N|||F|||20241017050025
-OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.89888|{Ratio}|>0.1|N|||F|||20241017050025
-OBR|9|789876543^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|20.90|ng/mL|<69|N|||F|||20241017050025
-OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
-OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241017050025
-OBR|10|789876543^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00007.6|nmol/L|<85|N|||F|||20241017050025
-OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
-OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025
-OBR|11|789876543^FormNumber||54090-6^Thyroid newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|NM|29575-8^Thyrotropin^LN|1|6.10|mIU/L|<29|N|||F|||20241017050025
-OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
-OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025
-OBR|12|789876543^FormNumber||54079-9^Galactosemia newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|173.29|enzyme units|>50|N|||F|||20241017050025
-OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
-OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025
-OBR|13|789876543^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241017050025
-OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern. These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241017050025
-OBR|14|789876543^FormNumber||57087-9^Biotinidase newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|45.57|ERU|>10|N|||F|||20241017050025
-OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
-OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025
-OBR|15|789876543^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|215|copies/µL|>18|N|||F|||20241017050025
-OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
-OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025
-OBR|16|789876543^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|6.94|µmol/L/h|>=1.54|N|||F|||20241017050025
-OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
-OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241017050025
-OBR|17|789876543^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|6.11|µmol/L/h|>=0.79|N|||F|||20241017050025
-OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
-OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025
-OBR|18|789876543^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA12430-7^Out of range requiring further dried blood spot testing for at least one condition^LN|||A|||F|||20241017050025
-OBX|2|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Incomplete|||A|||F|||20241017050025
-OBR|19|789876543^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|25.27|µmol/L/h|>=2.91|N|||F|||20241017050025
-OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
-OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241017050025
-OBR|20|789876543^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241017050025
-OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241017050025
-OBR|21|789876543^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.10|µmol/L|<=3|N|||F|||20241017050025
-OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|431.20|µmol/L||N|||F|||20241017050025
-OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.56||<=6|N|||F|||20241017050025
-OBR|22|789876543^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241017050025
-OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241017050025
-OBR|23|789876543^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409240545|||||||||^MURUGESAN^CHEZHIYAN||||||20241017050025|||F
-OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.242|µmol/L|<0.47|N|||F|||20241017050025
diff --git a/examples/Test/Automated/GoldenCopy/Input/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7 b/examples/Test/Automated/GoldenCopy/Input/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7
new file mode 100644
index 000000000..1c6a29d54
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Input/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241206093739||ORU^R01^ORU_R01|007|N|2.5.1
PID|1||80015955^^^&NPI^MR||INTERFACE^BOY A CDPHONE^^^^^B||202411180830|M||2028-9^Asian||||||||||||2186-5^Not Hispanic or Latino||Y|1
NK1|1|INTERFACE^CDPHONE|MTH^Mother|456 ST^^SAN DIEGO^CA^92123^USA|^^^^^858^2490016|||||||||||19921118
ORC|RE|7902698491^FormNumber||189717091^HospOrdNumber||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7902698491^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBR|2|7902698491^FormNumber||57128-1^Newborn Screening Report summary panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241206093739
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241206093739
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241206093739
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12566-8^SCID^LN|||N|||F|||20241206093739
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241206093739
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\SCID: A liquid blood specimen for CBC differential and flow cytometry at Quest Diagnostics is required to rule out or confirm SCID or a related immune disorder. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241206093739
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241206093739
OBR|3|7902698491^FormNumber||57717-1^Newborn screen card data panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241206093739
OBX|2|NM|8339-4^Birthweight^LN|1|2722|grams||N|||F|||20241206093739
OBX|3|TM|57715-5^Time of birth^LN|1|0830|||N|||F|||20241206093739
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241206093739
OBX|5|NM|73806-2^Newborn age in hours^LN|1|73|hour(s)||N|||F|||20241206093739
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241206093739
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241206093739
OBX|8|TX|^^^99717-5^Accession Number^L|1|326-65-211/21-2024-21|||N|||F|||20241206093739
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|KRISHELLE MARC-AURELE|||N|||F|||20241206093739
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241206093739
OBR|4|7902698491^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBR|5|7902698491^FormNumber||53261-4^Amino acid newborn screen panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241206093739
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20241206093739
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241206093739
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241206093739
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20241206093739
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241206093739
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20241206093739
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241206093739
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20241206093739
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20241206093739
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20241206093739
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|�mol/L|5-49|N|||F|||20241206093739
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241206093739
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20241206093739
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241206093739
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20241206093739
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241206093739
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20241206093739
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|6|7902698491^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|7|7902698491^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20241206093739
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241206093739
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20241206093739
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241206093739
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20241206093739
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20241206093739
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241206093739
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20241206093739
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20241206093739
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20241206093739
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20241206093739
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20241206093739
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20241206093739
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20241206093739
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241206093739
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20241206093739
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20241206093739
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20241206093739
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20241206093739
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241206093739
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241206093739
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20241206093739
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20241206093739
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20241206093739
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241206093739
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241206093739
OBR|8|7902698491^FormNumber||57085-3^Organic acid newborn screen panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20241206093739
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241206093739
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20241206093739
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20241206093739
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20241206093739
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241206093739
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20241206093739
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20241206093739
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20241206093739
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241206093739
OBR|9|7902698491^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241206093739
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|10|7902698491^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241206093739
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|11|7902698491^FormNumber||54090-6^Thyroid newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241206093739
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|12|7902698491^FormNumber||54079-9^Galactosemia newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241206093739
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|13|7902698491^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241206093739
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.�These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241206093739
OBR|14|7902698491^FormNumber||57087-9^Biotinidase newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241206093739
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|15|7902698491^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|2|copies/�L|>18|L|||F|||20241206093739
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241206093739
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241206093739
OBR|16|7902698491^FormNumber||63414-7^Pompe Disease newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|�mol/L/h|>=18.2|N|||F|||20241206093739
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|17|7902698491^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20241206093739
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|18|7902698491^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241206093739
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241206093739
OBR|19|7902698491^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20241206093739
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|20|7902698491^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|21|7902698491^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|�mol/L|<=3|N|||F|||20241206093739
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|�mol/L||N|||F|||20241206093739
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241206093739
OBR|22|7902698491^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241206093739
OBR|23|7902698491^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20241206093739
diff --git a/examples/Test/Automated/GoldenCopy/Input/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7 b/examples/Test/Automated/GoldenCopy/Input/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7
new file mode 100644
index 000000000..119d43a67
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Input/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241206093739||ORU^R01^ORU_R01|008|N|2.5.1
PID|1||80015955^^^&NPI^MR||INTERFACE^BOY A CDPHONE^^^^^B||202411180830|M||2131-1^Other Race||||||||||||UNK^Unknown||Y|1
NK1|1|INTERFACE^CDPHONE|MTH^Mother|456 ST^^SAN DIEGO^CA^92123^USA|^^^^^858^2490016|||||||||||19921118
ORC|RE|7902698491^FormNumber||^HospOrdNumber||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI|||||||||^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7902698491^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202411021023|||||||202411031023||||||||20241206093739|||F
OBR|2|7902698491^FormNumber||57128-1^Newborn Screening Report summary panel|||202411021023|||||||202411031023||||||||20241206093739|||F
OBX|1|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\Testing Lab - Quest \R\ S W 0094DVLB TESNU, SAN JUAN CAPISTRANO, CA 99999-9999\.br\\.br\Lab Director - Daisydoublek Toulousep, MD,PhD, Quest, (491)154-5445\.br\\.br\SCID Reviewer - Meadowsaffronpa Maxrm\.br\\.br\Lab Remarks: CD3/CD8/CD45RO, Percent:This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. \.br\\.br\Follow-up:\.br\\.br\Clinical Reviewer Comments: Testing\.br\\.br\Follow-up Recommendation: Refer to CCS-approved Immunology Center\.br\\.br\Disclaimer:\.br\\.br\This test was developed and its performance characteristics have been determined by Quest Diagnostics Nichols Institute, San Juan Capistrano. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test. \.br\\.br\|||N|||F|||20241206093739
OBR|3|7902698491^FormNumber||57717-1^Newborn screen card data panel|||202411021023|||||||202411031023||||||||20241206093739|||F
OBX|1|TM|57715-5^Time of birth^LN|1|0830|||N|||F|||20241206093739
OBX|2|NM|73806-2^Newborn age in hours^LN|1|73|hour(s)||N|||F|||20241206093739
OBX|3|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241206093739
OBR|4|7902698491^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202411021023|||||||202411031023||||||||20241206093739|||F
OBR|5|7902698491^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202411021023|||||||202411031023||||||||20241206093739|||F
OBX|1|NM|6690-2^Leukocytes [#/volume] in Blood by Automated count^LN|1|45.1|Thousand/uL|9.0-30.0|H|||F|||20241206093739
OBX|2|NM|789-8^Erythrocytes [#/volume] in Blood by Automated count^LN|1|4.25|Million/uL|3.90-5.90||||F|||20241206093739
OBX|3|NM|718-7^Hemoglobin [Mass/volume] in Blood^LN|1|18.1|g/dL|13.4-19.9||||F|||20241206093739
OBX|4|NM|4544-3^Hematocrit [Volume Fraction] of Blood by Automated count^LN|1|50.1|%|42.0-65.0||||F|||20241206093739
OBX|5|NM|787-2^Erythrocyte mean corpuscular volume [Entitic volume] by Automated count^LN|1|100.0|fL|88.0-123.0||||F|||20241206093739
OBX|6|NM|785-6^Erythrocyte mean corpuscular hemoglobin [Entitic mass] by Automated count^LN|1|35.1|pg|31.0-37.0||||F|||20241206093739
OBX|7|NM|786-4^Erythrocyte mean corpuscular hemoglobin concentration [Mass/volume] by Automated count^LN|1|30.2|g/dL|28.0-36.0||||F|||20241206093739
OBX|8|NM|777-3^Platelets [#/volume] in Blood by Automated count^LN|1|200|Thousand/uL|150-450||||F|||20241206093739
OBX|9|NM|776-5^Platelet mean volume [Entitic volume] in Blood by Rees-Ecker^LN|1|11.1|fL|7.5-12.5||||F|||20241206093739
OBX|10|NM|788-0^Erythrocyte distribution width [Ratio] by Automated count^LN|1|14.1|%|13.0-18.0||||F|||20241206093739
OBX|11|NM|751-8^Neutrophils [#/volume] in Blood by Automated count^LN|1|7000|cells/uL|5000-21000||||F|||20241206093739
OBX|12|NM|26507-4^Neutrophils.band form [#/volume] in Blood^LN^29153|1|3000|cells/uL|1500-4200||||F|||20241206093739
OBX|13|NM|30433-7^Metamyelocytes [#/volume] in Blood^LN^29154|1|1|cells/uL|0|H|||F|||20241206093739
OBX|14|NM|30446-9^Myelocytes [#/volume] in Blood^LN^29162|1|0|cells/uL|0||||F|||20241206093739
OBX|15|NM|26523-1^Promyelocytes [#/volume] in Blood^LN^29163|1|0|cells/uL|0||||F|||20241206093739
OBX|16|NM|731-0^Lymphocytes [#/volume] in Blood by Automated count^LN^29164|1|6000|cells/uL|2000-11500||||F|||20241206093739
OBX|17|NM|742-7^Monocytes [#/volume] in Blood by Automated count^LN^29165|1|1200|cells/uL|300-2400||||F|||20241206093739
OBX|18|NM|711-2^Eosinophils [#/volume] in Blood by Automated count^LN^29166|1|600|cells/uL|15-800||||F|||20241206093739
OBX|19|NM|704-7^Basophils [#/volume] in Blood by Automated count^LN^29167|1|200|cells/uL|0-300||||F|||20241206093739
OBX|20|NM|30376-8^Blasts [#/volume] in Blood^LN^29168|1|0|cells/uL|0||||F|||20241206093739
OBX|21|NM|30392-5^Nucleated erythrocytes [#/volume] in Blood^LN^29169|1|300|cells/uL|0-5000||||F|||20241206093739
OBX|22|NM|770-8^Neutrophils/100 leukocytes in Blood by Automated count^LN^29170|1|20|%|||||F|||20241206093739
OBX|23|NM|26508-2^Neutrophils.band form/100 leukocytes in Blood^LN^29171|1|2|%|||||F|||20241206093739
OBX|24|NM|28541-1^Metamyelocytes/100 leukocytes in Blood^LN^29172|1|1|%|||||F|||20241206093739
OBX|25|NM|26498-6^Myelocytes/100 leukocytes in Blood^LN^29173|1|1|%|||||F|||20241206093739
OBX|26|NM|26524-9^Promyelocytes/100 leukocytes in Blood^LN^29174|1|1|%|||||F|||20241206093739
OBX|27|NM|736-9^Lymphocytes/100 leukocytes in Blood by Automated count^LN^29175|1|1|%|||||F|||20241206093739
OBX|28|NM|13046-8^Lymphocytes Variant/100 leukocytes in Blood^LN^29176|1|1|%|0-10||||F|||20241206093739
OBX|29|NM|5905-5^Monocytes/100 leukocytes in Blood by Automated count^LN^29177|1|1|%|||||F|||20241206093739
OBX|30|NM|713-8^Eosinophils/100 leukocytes in Blood by Automated count^LN^29178|1|1|%|||||F|||20241206093739
OBX|31|NM|706-2^Basophils/100 leukocytes in Blood by Automated count^LN^29179|1|1|%|||||F|||20241206093739
OBX|32|NM|26446-5^Blasts/100 leukocytes in Blood^LN^29180|1|1|%|||||F|||20241206093739
OBX|33|NM|19048-8^Nucleated erythrocytes/100 leukocytes [Ratio] in Blood^LN^29181|1|1|/100 WBC|0|H|||F|||20241206093739
OBX|34|NM|8122-4^CD3 cells [#/volume] in Blood^LN^86007711^CD3+ T-Cells, Absolute^L|1|3000|cells/uL|2500-5500||||F|||20241206093739
OBX|35|NM|8124-0^CD3 cells/100 cells in Blood^LN^86007712^CD3+ T-Cells, Percent^L|1|60|% of Lymphs|53-84||||F|||20241206093739
OBX|36|NM|24467-3^CD3+CD4+ (T4 helper) cells [#/volume] in Blood^LN^86007713^CD3+/CD4+ T-Helper, Abs^L|1|2000|cells/uL|1600-4000||||F|||20241206093739
OBX|37|NM|8123-2^CD3+CD4+ (T4 helper) cells/100 cells in Blood^LN^86007714^CD3+/CD4+ T-Helper,Percent^L|1|40|% of Lymphs|35-64||||F|||20241206093739
OBX|38|NM|14135-8^CD3+CD8+ (T8 suppressor cells) cells [#/volume] in Blood^LN^86007715^CD3+/CD8+ T-Cytotoxic, Abs^L|1|1000|cells/uL|560-1700||||F|||20241206093739
OBX|39|NM|8101-8^CD3+CD8+ (T8 suppressor cells) cells/100 cells in Blood^LN^86007716^CD3+/CD8+T-Cytotox,Percent^L|1|15|% of Lymphs|12-28||||F|||20241206093739
OBX|40|NM|8116-6^CD19 cells [#/volume] in Blood^LN^86007717^CD19+ B-cells, Absolute^L|1|500|cells/uL|300-2000||||F|||20241206093739
OBX|41|NM|8117-4^CD19 cells/100 cells in Blood^LN^86007718^CD19+ B-cells, Percent^L|1|10|% of Lymphs|6-32||||F|||20241206093739
OBX|42|NM|9728-7^CD16C+CD56+ cells [#/volume] in Blood^LN^86007719^CD16/CD56 NK-cells, Abs^L|1|200|cells/uL|170-1100||||F|||20241206093739
OBX|43|NM|8112-5^CD16+CD56+ cells/100 cells in Blood^LN^86007720^CD16/CD56 NK-cells,Percent^L|1|9|% of Lymphs|4-18||||F|||20241206093739
OBX|44|NM|26759-1^CD4+CD45RA+cells [#/volume] in Blood^LN^86007721^CD3/CD4/CD45RA, Absolute^L|1|1500|cells/uL|1200-3700||||F|||20241206093739
OBX|45|NM|13336-3^CD4+CD45RA+cells/100 cells in Blood^LN^^CD3/CD4/CD45RA, Percent^L|1|8|% CD4|||||F|||20241206093739
OBX|46|NM|82743-6^CD8+CD45RA+ Cells # Bld^LN^86007723^CD3/CD8/CD45RA, Absolute^L|1|600|cells/uL|450-1500||||F|||20241206093739
OBX|47|NM|82744-4^CD8+CD45RA+ Cells/100 CD8 NFr Bld^LN^86007724^CD3/CD8/CD45RA, Percent^L|1|10|% CD8|||||F|||20241206093739
OBX|48|NM|85792-0^CD3+CD4+CD45RO+ # Bld^LN^86007725^CD3/CD4/CD45RO, Absolute^L|1|500|cells/uL|60-900||||F|||20241206093739
OBX|49|NM|85791-2^CD3+CD4+CD45RO+/100 CD3 NFr Bld^LN^86007726^CD3/CD4/CD45RO, Percent^L|1|5|% CD4|2-22||||F|||20241206093739
OBX|50|NM|85790-4^CD3+CD8+CD45RO+ # Bld^LN^86007727^CD3/CD8/CD45RO, Absolute^L|1|50|cells/uL|30-330||||F|||20241206093739
OBX|51|NM|85789-6^CD3+CD8+CD45RO+/100 CD3 NFr Bld^LN^86007728^CD3/CD8/CD45RO, Percent^L|1|2|% CD8|1-9||||F|||20241206093739
OBX|52|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241206093739
OBX|53|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Refer to CCS-approved Immunology Center|||A|||F|||20241206093739
diff --git a/examples/Test/Automated/GoldenCopy/Input/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7 b/examples/Test/Automated/GoldenCopy/Input/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7
new file mode 100644
index 000000000..a16c55aa1
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Input/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241211115659||ORU^R01^ORU_R01|009|N|2.5.1
PID|1||80009320^^^&NPI^MR||NEWBORNSCREEN^BOY  RED^^^^^B||202408150826|M||1002-5^American Indian or Alaska Native||||||||||||2186-5^Not Hispanic or Latino||N|1
NK1|1|NEWBORNSCREEN^RED|MTH^Mother|9560 TOWNE CENTRE DR^^SAN DIEGO^CA^92121-1972^USA|^^^^^619^1234567|||||||||||19850426
ORC|RE|7341237093^FormNumber||189671588^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7341237093^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBR|2|7341237093^FormNumber||57128-1^Newborn Screening Report summary panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241211115659
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241211115659
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241211115659
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12543-7^GALT^LN|||N|||F|||20241211115659
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241211115659
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Acyl Carnitine Panel: Reference Ranges for acylcarnitines are based on specimens collected on newborns who are less than 10 days old. \.br\\.br\Galactosemia: Additional testing is required to rule out disorder.�Call your Newborn Screening Coordinator for assistance. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241211115659
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241211115659
OBR|3|7341237093^FormNumber||57717-1^Newborn screen card data panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241211115659
OBX|2|NM|8339-4^Birthweight^LN|1|3084|grams||N|||F|||20241211115659
OBX|3|TM|57715-5^Time of birth^LN|1|0826|||N|||F|||20241211115659
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241211115659
OBX|5|NM|73806-2^Newborn age in hours^LN|1|46|day(s)||N|||F|||20241211115659
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241211115659
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241211115659
OBX|8|TX|^^^99717-5^Accession Number^L|1|275-71-453/21-2024-21|||N|||F|||20241211115659
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MARVIN ZAGULI|||N|||F|||20241211115659
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241211115659
OBR|4|7341237093^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBR|5|7341237093^FormNumber||53261-4^Amino acid newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241211115659
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20241211115659
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241211115659
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241211115659
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20241211115659
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241211115659
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20241211115659
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241211115659
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20241211115659
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20241211115659
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20241211115659
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|�mol/L|5-49|N|||F|||20241211115659
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241211115659
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20241211115659
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241211115659
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20241211115659
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241211115659
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20241211115659
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|6|7341237093^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|7|7341237093^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20241211115659
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241211115659
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20241211115659
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241211115659
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20241211115659
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20241211115659
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241211115659
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20241211115659
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20241211115659
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20241211115659
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20241211115659
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20241211115659
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20241211115659
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20241211115659
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241211115659
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20241211115659
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20241211115659
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20241211115659
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20241211115659
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241211115659
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241211115659
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20241211115659
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20241211115659
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20241211115659
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241211115659
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241211115659
OBR|8|7341237093^FormNumber||57085-3^Organic acid newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20241211115659
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241211115659
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20241211115659
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20241211115659
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20241211115659
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241211115659
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20241211115659
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20241211115659
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20241211115659
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241211115659
OBR|9|7341237093^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241211115659
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|10|7341237093^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241211115659
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|11|7341237093^FormNumber||54090-6^Thyroid newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241211115659
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|12|7341237093^FormNumber||54079-9^Galactosemia newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|48.00|enzyme units|>50|L|||F|||20241211115659
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241211115659
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241211115659
OBR|13|7341237093^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241211115659
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.�These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241211115659
OBR|14|7341237093^FormNumber||57087-9^Biotinidase newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241211115659
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|15|7341237093^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/�L|>18|N|||F|||20241211115659
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|16|7341237093^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|�mol/L/h|>=18.2|N|||F|||20241211115659
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|17|7341237093^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20241211115659
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|18|7341237093^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241211115659
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241211115659
OBR|19|7341237093^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20241211115659
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|20|7341237093^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|21|7341237093^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|�mol/L|<=3|N|||F|||20241211115659
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|�mol/L||N|||F|||20241211115659
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241211115659
OBR|22|7341237093^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241211115659
OBR|23|7341237093^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20241211115659
diff --git a/examples/Test/Automated/GoldenCopy/Input/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7 b/examples/Test/Automated/GoldenCopy/Input/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7
new file mode 100644
index 000000000..2d0eddb65
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Input/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241211110818||ORU^R01^ORU_R01|010|N|2.5.1
PID|1||80015980^^^&NPI^MR||HIPPO^BOY A ALLIE^^^^^B||202412091336|M||2106-3^White||||||||||||2186-5^Not Hispanic or Latino||Y|1
NK1|1|HIPPO^ALLIE|MTH^Mother|518 BIG BEN WAY^^OCEANSIDE^CA^92058^USA|^^^^^442^2885325|||||||||||19941209
ORC|RE|7302692465^FormNumber||189728187^HospOrdNumber||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI|||||||||UC SAN DIEGO MEDICAL CENTER^^^^^^^^^R508|W 025TS HT71 , C #^^SAN DIEGO^CA^99999-9999
OBR|1|7302692465^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBR|2|7302692465^FormNumber||57128-1^Newborn Screening Report summary panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241211110818
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241211110818
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241211110818
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12533-8^CAH^LN|||N|||F|||20241211110818
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241211110818
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\CAH: An immediate referral to a CCS endocrine center or pediatric endocrinologist, for evaluation and additional testing, is strongly recommended. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Screen for CAH based on 17-OH P level and a steroid ratio level. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241211110818
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241211110818
OBR|3|7302692465^FormNumber||57717-1^Newborn screen card data panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241211110818
OBX|2|NM|8339-4^Birthweight^LN|1|2722|grams||N|||F|||20241211110818
OBX|3|TM|57715-5^Time of birth^LN|1|1336|||N|||F|||20241211110818
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241211110818
OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241211110818
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241211110818
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241211110818
OBX|8|TX|^^^99717-5^Accession Number^L|1|346-10-795/21-2024-21|||N|||F|||20241211110818
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MARVIN ZAGULI|||N|||F|||20241211110818
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|W 025TS HT71 , C # SAN DIEGO CA 99999-9999 USA|||N|||F|||20241211110818
OBR|4|7302692465^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBR|5|7302692465^FormNumber||53261-4^Amino acid newborn screen panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241211110818
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20241211110818
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241211110818
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241211110818
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20241211110818
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241211110818
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20241211110818
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241211110818
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20241211110818
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20241211110818
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20241211110818
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|�mol/L|5-49|N|||F|||20241211110818
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241211110818
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20241211110818
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241211110818
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20241211110818
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241211110818
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20241211110818
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|6|7302692465^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|7|7302692465^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20241211110818
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241211110818
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20241211110818
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241211110818
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20241211110818
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20241211110818
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241211110818
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20241211110818
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20241211110818
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20241211110818
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20241211110818
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20241211110818
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20241211110818
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20241211110818
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241211110818
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20241211110818
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20241211110818
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20241211110818
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20241211110818
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241211110818
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241211110818
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20241211110818
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20241211110818
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20241211110818
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241211110818
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241211110818
OBR|8|7302692465^FormNumber||57085-3^Organic acid newborn screen panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20241211110818
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241211110818
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20241211110818
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20241211110818
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20241211110818
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241211110818
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20241211110818
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20241211110818
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20241211110818
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241211110818
OBR|9|7302692465^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241211110818
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|10|7302692465^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|0065.88|nmol/L|<85|N|||F|||20241211110818
OBX|2|NM|^^^99717-6^17-Hydroxyprogesterone (CAH II)^L|1|39|nmol/L|<38|H|||F|||20241211110818
OBX|3|NM|53343-0^Androstenedione^LN|1|40.15|nmol/L||N|||F|||20241211110818
OBX|4|NM|53345-5^Cortisol^LN|1|85|nmol/L||N|||F|||20241211110818
OBX|5|NM|53336-4^17-Hydroxyprogesterone+Androstenedione/Cortisol^LN|1|0.93|{Ratio}|<1|N|||F|||20241211110818
OBX|6|NM|53341-4^21-Deoxycortisol [Mass/volume] in Dried blood spot^LN|1|90.9|nmol/L|<5|H|||F|||20241211110818
OBX|7|NM|53347-1^11-Deoxycorticosterone [Mass/volume] in Dried blood spot^LN|1|590|nmol/L|<240|H|||F|||20241211110818
OBX|8|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241211110818
OBX|9|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241211110818
OBR|11|7302692465^FormNumber||54090-6^Thyroid newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241211110818
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|12|7302692465^FormNumber||54079-9^Galactosemia newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241211110818
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|13|7302692465^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241211110818
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.�These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241211110818
OBR|14|7302692465^FormNumber||57087-9^Biotinidase newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241211110818
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|15|7302692465^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/�L|>18|N|||F|||20241211110818
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|16|7302692465^FormNumber||63414-7^Pompe Disease newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|�mol/L/h|>=18.2|N|||F|||20241211110818
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|17|7302692465^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20241211110818
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|18|7302692465^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241211110818
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241211110818
OBR|19|7302692465^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20241211110818
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|20|7302692465^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|21|7302692465^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|�mol/L|<=3|N|||F|||20241211110818
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|�mol/L||N|||F|||20241211110818
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241211110818
OBR|22|7302692465^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241211110818
OBR|23|7302692465^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20241211110818
diff --git a/examples/Test/Automated/GoldenCopy/Input/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7 b/examples/Test/Automated/GoldenCopy/Input/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7
new file mode 100644
index 000000000..f1170f0a7
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Input/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241211104422||ORU^R01^ORU_R01|011|N|2.5.1
PID|1||80015981^^^&NPI^MR||HIPPO^BOY B ALLIE^^^^^B||202412091336|M||2106-3^White||||||||||||2186-5^Not Hispanic or Latino||Y|2
NK1|1|HIPPO^ALLIE|MTH^Mother|518 BIG BEN WAY^^OCEANSIDE^CA^92058^USA|^^^^^442^2885325|||||||||||19941209
ORC|RE|7322694174^FormNumber||189728238^HospOrdNumber||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI|||||||||UC SAN DIEGO MEDICAL CENTER^^^^^^^^^R508|W 025TS HT71 , C #^^SAN DIEGO^CA^99999-9999
OBR|1|7322694174^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202412101414|||||||||^JOHNSON^KATHRYN||||||20241211104422|||F
OBR|2|7322694174^FormNumber||57128-1^Newborn Screening Report summary panel|||202412101414|||||||||^JOHNSON^KATHRYN||||||20241211104422|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12427-3^Subsequent screen - for clarification of initial results (not by law or protocol)^LN|||N|||F|||20241211104422
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12443-0^Specimen quantity insufficient for testing^LN|||N|||F|||20241211104422
OBX|3|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241211104422
OBX|4|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241211104422
OBX|5|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\ NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\** This specimen was inadequate for testing for the following reason: ** 13 - Specimen not collected on acceptable filter paper including expired form THE PHYSICIAN LISTED HAS BEEN NOTIFIED \.br\\.br\|||N|||F|||20241211104422
OBX|6|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241211104422
OBR|3|7322694174^FormNumber||57717-1^Newborn screen card data panel|||202412101414|||||||||^JOHNSON^KATHRYN||||||20241211104422|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241211104422
OBX|2|NM|8339-4^Birthweight^LN|1|2812|grams||N|||F|||20241211104422
OBX|3|TM|57715-5^Time of birth^LN|1|1336|||N|||F|||20241211104422
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241211104422
OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241211104422
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241211104422
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241211104422
OBX|8|TX|^^^99717-5^Accession Number^L|1|346-07-783/21-2024-21|||N|||F|||20241211104422
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|EUSTRATIA HUBBARD|||N|||F|||20241211104422
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|W 025TS HT71 , C # SAN DIEGO CA 99999-9999 USA|||N|||F|||20241211104422
OBR|4|7322694174^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202412101414|||||||||^JOHNSON^KATHRYN||||||20241211104422|||F
diff --git a/examples/Test/Automated/GoldenCopy/README.md b/examples/Test/Automated/GoldenCopy/README.md
index 74cee7714..b6ea68a26 100644
--- a/examples/Test/Automated/GoldenCopy/README.md
+++ b/examples/Test/Automated/GoldenCopy/README.md
@@ -17,14 +17,3 @@ The files are required to:
     - We format `MSH-10` based on the file index, like `001` (or `AUTOMATEDTEST-001` for UCSD)
 - `MSH-11` needs to have a value of `N`
 - `MSH-3` needs to be `GOLDEN-COPY`
-
-## Corresponding File Names
-
-The files map to each test scenario with the following naming:
-
-- 001_ORU_R01_golden_copy_input_acylc_1.hl7 -> Acylcarnitine - Indeterminate - SCADD - IBCDD patterns.hl7
-- 002_ORU_R01_golden_copy_input_acylc_2.hl7 -> Acylcarnitine - Indeterminate_2nd_example.hl7
-- 003_ORU_R01_golden_copy_input_aa_unusual.hl7 -> Amino Acid - Unusual Pattern.hl7.hl7
-- 004_ORU_R01_golden_copy_input_in_range.hl7 -> Out of Range - Hemoglobinopathies - Positive Marker.hl7
-- 005_ORU_R01_golden_copy_input_out_of_range.hl7 -> In range example.hl7
-- 006_ORU_R01_golden_copy_input_sma_incomplete.hl7 -> SMA Incomplete - Equivocal - Inadequate Specimen for SMA.hl7

From f5b12202f9b0cb4ae4bfed820b8d903fd63f0b01 Mon Sep 17 00:00:00 2001
From: James Herr <jherr@flexion.us>
Date: Fri, 27 Dec 2024 11:05:49 -0600
Subject: [PATCH 55/61] Fixed bad character

Co-Authored-By: Bella L. Quintero <96704946+pluckyswan@users.noreply.github.com>
Co-Authored-By: Jeremy Rosenfeld <10262289+JeremyIR@users.noreply.github.com>
---
 .../Input/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7  | 2 +-
 .../Input/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7  | 2 +-
 .../Input/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7   | 2 +-
 .../Input/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7   | 2 +-
 .../Input/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7  | 2 +-
 .../Input/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7  | 2 +-
 ...07_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7 | 2 +-
 ...CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7 | 2 +-
 .../010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7      | 2 +-
 9 files changed, 9 insertions(+), 9 deletions(-)

diff --git a/examples/Test/Automated/GoldenCopy/Input/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7 b/examples/Test/Automated/GoldenCopy/Input/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
index b47644b66..74972cc49 100644
--- a/examples/Test/Automated/GoldenCopy/Input/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
+++ b/examples/Test/Automated/GoldenCopy/Input/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
@@ -1 +1 @@
-MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241015054631||ORU^R01^ORU_R01|001|N|2.5.1
PID|1||80015867^^^&NPI^MR||CDPHTWO^GIRL  MOMTWO^^^^^B||202410071025|F||2076-8^Native Hawaiian or Other Pacific Islander||||||||||||2186-5^Not Hispanic or Latino||N|1
NK1|1|CDPHTWO^MOMTWO|MTH^Mother|2 SECOND ST^^SAN DIEGO^CA^92121^USA||||||||||||20000202
ORC|RE|7371237714^FormNumber||189688314^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7371237714^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBR|2|7371237714^FormNumber||57128-1^Newborn Screening Report summary panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12427-3^Subsequent screen - for clarification of initial results (not by law or protocol)^LN|||N|||F|||20241015054631
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241015054631
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241015054631
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12543-7^GALT^LN|||N|||F|||20241015054631
OBX|5|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|2|LA12533-8^CAH^LN|||N|||F|||20241015054631
OBX|6|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA12566-8^SCID^LN|||N|||F|||20241015054631
OBX|7|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|2|LA14037-8^GAA^LN|||N|||F|||20241015054631
OBX|8|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\CAH: An immediate referral to a CCS endocrine center or pediatric endocrinologist, for evaluation and additional testing, is strongly recommended. \.br\\.br\Pompe: Another dried blood specimen MUST be collected for this child. Call your Newborn Screening Coordinator for assistance. \.br\\.br\SCID: Another dried blood specimen MUST be collected for this child. Call your Newborn Screening Coordinator for assistance. \.br\\.br\Galactosemia: Additional testing is required to rule out disorder.�Call your Newborn Screening Coordinator for assistance. \.br\\.br\ATTENTION: THIS CHILD HAS TESTED POSITIVE FOR MORE THAN ONE TEST. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241015054631
OBX|9|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241015054631
OBR|3|7371237714^FormNumber||57717-1^Newborn screen card data panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241015054631
OBX|2|NM|8339-4^Birthweight^LN|1|3175|grams||N|||F|||20241015054631
OBX|3|TM|57715-5^Time of birth^LN|1|1025|||N|||F|||20241015054631
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241015054631
OBX|5|NM|73806-2^Newborn age in hours^LN|1|25|hour(s)||N|||F|||20241015054631
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241015054631
OBX|7|CE|67704-7^Feeding types^LN|1|LA4489-6^Unknown^LN|||N|||F|||20241015054631
OBX|8|TX|^^^99717-5^Accession Number^L|1|282-49-252/21-2024-21|||N|||F|||20241015054631
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DENISE COYLE|||N|||F|||20241015054631
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241015054631
OBR|4|7371237714^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBR|5|7371237714^FormNumber||53261-4^Amino acid newborn screen panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241015054631
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20241015054631
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241015054631
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241015054631
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20241015054631
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241015054631
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20241015054631
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241015054631
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20241015054631
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20241015054631
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20241015054631
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|�mol/L|5-49|N|||F|||20241015054631
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241015054631
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20241015054631
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20241015054631
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241015054631
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20241015054631
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|6|7371237714^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|7|7371237714^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20241015054631
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241015054631
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20241015054631
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241015054631
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20241015054631
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20241015054631
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20241015054631
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20241015054631
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20241015054631
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20241015054631
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20241015054631
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20241015054631
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20241015054631
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20241015054631
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20241015054631
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20241015054631
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20241015054631
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241015054631
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241015054631
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20241015054631
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20241015054631
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20241015054631
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241015054631
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241015054631
OBR|8|7371237714^FormNumber||57085-3^Organic acid newborn screen panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20241015054631
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241015054631
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20241015054631
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20241015054631
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20241015054631
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241015054631
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20241015054631
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20241015054631
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20241015054631
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241015054631
OBR|9|7371237714^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241015054631
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|10|7371237714^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|305|nmol/L|<85|H|||F|||20241015054631
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241015054631
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241015054631
OBR|11|7371237714^FormNumber||54090-6^Thyroid newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241015054631
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|12|7371237714^FormNumber||54079-9^Galactosemia newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|48.00|enzyme units|>50|L|||F|||20241015054631
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241015054631
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241015054631
OBR|13|7371237714^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241015054631
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.�These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241015054631
OBR|14|7371237714^FormNumber||57087-9^Biotinidase newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241015054631
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|15|7371237714^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|2|copies/�L|>18|L|||F|||20241015054631
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241015054631
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Incomplete|||A|||F|||20241015054631
OBR|16|7371237714^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA16205-9^Specimen unsatisfactory for at least one condition^LN|||A|||F|||20241015054631
OBX|2|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Incomplete|||A|||F|||20241015054631
OBR|17|7371237714^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20241015054631
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|18|7371237714^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241015054631
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241015054631
OBR|19|7371237714^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20241015054631
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|20|7371237714^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|21|7371237714^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|�mol/L|<=3|N|||F|||20241015054631
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|�mol/L||N|||F|||20241015054631
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241015054631
OBR|22|7371237714^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241015054631
OBR|23|7371237714^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20241015054631
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241015054631||ORU^R01^ORU_R01|001|N|2.5.1
PID|1||80015867^^^&NPI^MR||CDPHTWO^GIRL  MOMTWO^^^^^B||202410071025|F||2076-8^Native Hawaiian or Other Pacific Islander||||||||||||2186-5^Not Hispanic or Latino||N|1
NK1|1|CDPHTWO^MOMTWO|MTH^Mother|2 SECOND ST^^SAN DIEGO^CA^92121^USA||||||||||||20000202
ORC|RE|7371237714^FormNumber||189688314^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7371237714^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBR|2|7371237714^FormNumber||57128-1^Newborn Screening Report summary panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12427-3^Subsequent screen - for clarification of initial results (not by law or protocol)^LN|||N|||F|||20241015054631
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241015054631
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241015054631
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12543-7^GALT^LN|||N|||F|||20241015054631
OBX|5|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|2|LA12533-8^CAH^LN|||N|||F|||20241015054631
OBX|6|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA12566-8^SCID^LN|||N|||F|||20241015054631
OBX|7|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|2|LA14037-8^GAA^LN|||N|||F|||20241015054631
OBX|8|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\CAH: An immediate referral to a CCS endocrine center or pediatric endocrinologist, for evaluation and additional testing, is strongly recommended. \.br\\.br\Pompe: Another dried blood specimen MUST be collected for this child. Call your Newborn Screening Coordinator for assistance. \.br\\.br\SCID: Another dried blood specimen MUST be collected for this child. Call your Newborn Screening Coordinator for assistance. \.br\\.br\Galactosemia: Additional testing is required to rule out disorder.µCall your Newborn Screening Coordinator for assistance. \.br\\.br\ATTENTION: THIS CHILD HAS TESTED POSITIVE FOR MORE THAN ONE TEST. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241015054631
OBX|9|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241015054631
OBR|3|7371237714^FormNumber||57717-1^Newborn screen card data panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241015054631
OBX|2|NM|8339-4^Birthweight^LN|1|3175|grams||N|||F|||20241015054631
OBX|3|TM|57715-5^Time of birth^LN|1|1025|||N|||F|||20241015054631
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241015054631
OBX|5|NM|73806-2^Newborn age in hours^LN|1|25|hour(s)||N|||F|||20241015054631
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241015054631
OBX|7|CE|67704-7^Feeding types^LN|1|LA4489-6^Unknown^LN|||N|||F|||20241015054631
OBX|8|TX|^^^99717-5^Accession Number^L|1|282-49-252/21-2024-21|||N|||F|||20241015054631
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|DENISE COYLE|||N|||F|||20241015054631
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241015054631
OBR|4|7371237714^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBR|5|7371237714^FormNumber||53261-4^Amino acid newborn screen panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241015054631
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241015054631
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241015054631
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241015054631
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241015054631
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241015054631
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241015054631
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241015054631
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241015054631
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20241015054631
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241015054631
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241015054631
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241015054631
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241015054631
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241015054631
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|6|7371237714^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|7|7371237714^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241015054631
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241015054631
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241015054631
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241015054631
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241015054631
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241015054631
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241015054631
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241015054631
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241015054631
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241015054631
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241015054631
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241015054631
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241015054631
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241015054631
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241015054631
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241015054631
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241015054631
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241015054631
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241015054631
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241015054631
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241015054631
OBR|8|7371237714^FormNumber||57085-3^Organic acid newborn screen panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241015054631
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241015054631
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241015054631
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241015054631
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241015054631
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241015054631
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241015054631
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241015054631
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241015054631
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241015054631
OBR|9|7371237714^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241015054631
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|10|7371237714^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|305|nmol/L|<85|H|||F|||20241015054631
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241015054631
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241015054631
OBR|11|7371237714^FormNumber||54090-6^Thyroid newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241015054631
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|12|7371237714^FormNumber||54079-9^Galactosemia newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|48.00|enzyme units|>50|L|||F|||20241015054631
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241015054631
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241015054631
OBR|13|7371237714^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241015054631
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241015054631
OBR|14|7371237714^FormNumber||57087-9^Biotinidase newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241015054631
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|15|7371237714^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|2|copies/µL|>18|L|||F|||20241015054631
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241015054631
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Incomplete|||A|||F|||20241015054631
OBR|16|7371237714^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA16205-9^Specimen unsatisfactory for at least one condition^LN|||A|||F|||20241015054631
OBX|2|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Incomplete|||A|||F|||20241015054631
OBR|17|7371237714^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241015054631
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|18|7371237714^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241015054631
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241015054631
OBR|19|7371237714^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241015054631
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|20|7371237714^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015054631
OBR|21|7371237714^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20241015054631
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20241015054631
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241015054631
OBR|22|7371237714^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241015054631
OBR|23|7371237714^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410081133|||||||||^HUBBARD^EUSTRATIA||||||20241015054631|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241015054631
diff --git a/examples/Test/Automated/GoldenCopy/Input/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7 b/examples/Test/Automated/GoldenCopy/Input/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7
index 09e8c2ce4..3e4177ee9 100644
--- a/examples/Test/Automated/GoldenCopy/Input/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7
+++ b/examples/Test/Automated/GoldenCopy/Input/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7
@@ -1 +1 @@
-MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241022024155||ORU^R01^ORU_R01|002|N|2.5.1
PID|1||80015887^^^&NPI^MR||CDPHTHREE^BOY B MOMTHREE^^^^^B|||M||2131-1^Other Race||||||||||||UNK^Unknown||Y|2
NK1|1|CDPHTHREE^MOMTHREE|MTH^Mother|3 3RD ST^^SAN DIEGO^CA^92126^USA|^^^^^858^2490007|||||||||||20031007
ORC|RE|7381238055^FormNumber||189693889^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7381238055^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBR|2|7381238055^FormNumber||57128-1^Newborn Screening Report summary panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241022024155
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241022024155
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241022024155
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA16207-5^Hemoglobinopathies^LN|||N|||F|||20241022024155
OBX|5|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|2|LA12537-9^CF^LN|||N|||F|||20241022024155
OBX|6|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241022024155
OBX|7|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Amino Acid Panel: There was insufficient data to determine whether or not this newborn was at least 12 hours old when this specimen was collected. Testing of amino acids at less than 12 hours of age is not reliable for detecting certain metabolic disorder. \.br\\.br\Hb: An immediate referral to a CCS Sickle Cell Disease/Hemoglobinopathies Center is strongly recommended. \.br\\.br\Cystic Fibrosis (CF): An immediate referral to a CCS approved Cystic Fibrosis Center for evaluation and additional testing is strongly recommended. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Screen for CF based on IRT and the California CFTR DNA mutation panel which consists of the following mutations: 1078delT, 1288insTA, 1677delTA, 1717-1G>A, 1812-1G>A, 1898+1G>A, 1898+5G>T, 2055del9>A, 2105-2117del13insAGAAA, 2143delT, 2183AA>G, 2184delA, 2307insA, 2789+5G>A, 2869insG, 3120+1G>A, 3120G>A, 3199del6, 3272-26A>G, 3659delC, 3791delC, 3849+10kbC>T, 3876delA, 3905insT, 394delTT, 405+3A>C, 406-1G>A, 444delA, 621+1G>T, 663delT, 711+1G>T, 935delA, A455E, A559T, CFTRdel2,3(21kb), delF311, delF508, delI507, E60X, G178R, G330X, G542X, G551D, G85E, H199Y, K710X, L206W, M1101K, N1303K, P205S, Q493X, Q890X, Q98R, R1066C, R1158X, R1162X, R117C, R334W, R347H, R347P, R352Q, R553X, R560T, R75X, S1196X, S1255X, S492F, S549N, S549R(T>G), V520F, W1089X, W1204X(3743G>A), W1204X(3744G>A), W1282X, Y1092X(C>A), Y1092X(C>G), Y122X. California CFTR Mutation Panel was run at Stanford Health Care, Molecular Pathology Laboratory, 3375 Hillview Avenue, Palo Alto, CA 94304. Directors: James Zehnder, MD; Christian Kunder, MD, PhD; Carlos J. Suarez, MD; (650) 723-6574. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241022024155
OBX|8|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241022024155
OBR|3|7381238055^FormNumber||57717-1^Newborn screen card data panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241022024155
OBX|2|NM|8339-4^Birthweight^LN|1|2948|grams||N|||F|||20241022024155
OBX|3|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241022024155
OBX|4|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241022024155
OBX|5|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241022024155
OBX|6|TX|^^^99717-5^Accession Number^L|1|282-12-459/21-2024-21|||N|||F|||20241022024155
OBX|7|TX|62324-9^Post-discharge provider name^LN|1|MICHELLE LEFF|||N|||F|||20241022024155
OBX|8|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241022024155
OBR|4|7381238055^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBR|5|7381238055^FormNumber||53261-4^Amino acid newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241022024155
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20241022024155
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241022024155
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241022024155
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20241022024155
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241022024155
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20241022024155
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241022024155
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20241022024155
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20241022024155
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20241022024155
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|�mol/L|5-49|N|||F|||20241022024155
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241022024155
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20241022024155
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241022024155
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20241022024155
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241022024155
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20241022024155
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Collected Early. No Interpretation.|||A|||F|||20241022024155
OBR|6|7381238055^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|7|7381238055^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20241022024155
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241022024155
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20241022024155
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241022024155
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20241022024155
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20241022024155
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241022024155
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20241022024155
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20241022024155
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20241022024155
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20241022024155
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20241022024155
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20241022024155
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20241022024155
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241022024155
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20241022024155
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20241022024155
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20241022024155
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20241022024155
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241022024155
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241022024155
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20241022024155
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20241022024155
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20241022024155
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241022024155
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241022024155
OBR|8|7381238055^FormNumber||57085-3^Organic acid newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20241022024155
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241022024155
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20241022024155
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20241022024155
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20241022024155
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241022024155
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20241022024155
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20241022024155
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20241022024155
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241022024155
OBR|9|7381238055^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|72.00|ng/mL|<69|H|||F|||20241022024155
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241022024155
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Consistent with Cystic Fibrosis (delF508 and delI507 mutations)|||A|||F|||20241022024155
OBR|10|7381238055^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241022024155
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|11|7381238055^FormNumber||54090-6^Thyroid newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241022024155
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|12|7381238055^FormNumber||54079-9^Galactosemia newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241022024155
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|13|7381238055^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|F||||||F|||20241022024155
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Consistent with Beta thalassemia major (Cooley's anemia).||||||F|||20241022024155
OBR|14|7381238055^FormNumber||57087-9^Biotinidase newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241022024155
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|15|7381238055^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/�L|>18|N|||F|||20241022024155
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|16|7381238055^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|�mol/L/h|>=18.2|N|||F|||20241022024155
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|17|7381238055^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20241022024155
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|18|7381238055^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241022024155
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241022024155
OBR|19|7381238055^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20241022024155
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|20|7381238055^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|21|7381238055^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|�mol/L|<=3|N|||F|||20241022024155
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|�mol/L||N|||F|||20241022024155
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241022024155
OBR|22|7381238055^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241022024155
OBR|23|7381238055^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20241022024155
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241022024155||ORU^R01^ORU_R01|002|N|2.5.1
PID|1||80015887^^^&NPI^MR||CDPHTHREE^BOY B MOMTHREE^^^^^B|||M||2131-1^Other Race||||||||||||UNK^Unknown||Y|2
NK1|1|CDPHTHREE^MOMTHREE|MTH^Mother|3 3RD ST^^SAN DIEGO^CA^92126^USA|^^^^^858^2490007|||||||||||20031007
ORC|RE|7381238055^FormNumber||189693889^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7381238055^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBR|2|7381238055^FormNumber||57128-1^Newborn Screening Report summary panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241022024155
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241022024155
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241022024155
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA16207-5^Hemoglobinopathies^LN|||N|||F|||20241022024155
OBX|5|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|2|LA12537-9^CF^LN|||N|||F|||20241022024155
OBX|6|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241022024155
OBX|7|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Amino Acid Panel: There was insufficient data to determine whether or not this newborn was at least 12 hours old when this specimen was collected. Testing of amino acids at less than 12 hours of age is not reliable for detecting certain metabolic disorder. \.br\\.br\Hb: An immediate referral to a CCS Sickle Cell Disease/Hemoglobinopathies Center is strongly recommended. \.br\\.br\Cystic Fibrosis (CF): An immediate referral to a CCS approved Cystic Fibrosis Center for evaluation and additional testing is strongly recommended. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Screen for CF based on IRT and the California CFTR DNA mutation panel which consists of the following mutations: 1078delT, 1288insTA, 1677delTA, 1717-1G>A, 1812-1G>A, 1898+1G>A, 1898+5G>T, 2055del9>A, 2105-2117del13insAGAAA, 2143delT, 2183AA>G, 2184delA, 2307insA, 2789+5G>A, 2869insG, 3120+1G>A, 3120G>A, 3199del6, 3272-26A>G, 3659delC, 3791delC, 3849+10kbC>T, 3876delA, 3905insT, 394delTT, 405+3A>C, 406-1G>A, 444delA, 621+1G>T, 663delT, 711+1G>T, 935delA, A455E, A559T, CFTRdel2,3(21kb), delF311, delF508, delI507, E60X, G178R, G330X, G542X, G551D, G85E, H199Y, K710X, L206W, M1101K, N1303K, P205S, Q493X, Q890X, Q98R, R1066C, R1158X, R1162X, R117C, R334W, R347H, R347P, R352Q, R553X, R560T, R75X, S1196X, S1255X, S492F, S549N, S549R(T>G), V520F, W1089X, W1204X(3743G>A), W1204X(3744G>A), W1282X, Y1092X(C>A), Y1092X(C>G), Y122X. California CFTR Mutation Panel was run at Stanford Health Care, Molecular Pathology Laboratory, 3375 Hillview Avenue, Palo Alto, CA 94304. Directors: James Zehnder, MD; Christian Kunder, MD, PhD; Carlos J. Suarez, MD; (650) 723-6574. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241022024155
OBX|8|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241022024155
OBR|3|7381238055^FormNumber||57717-1^Newborn screen card data panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241022024155
OBX|2|NM|8339-4^Birthweight^LN|1|2948|grams||N|||F|||20241022024155
OBX|3|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241022024155
OBX|4|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241022024155
OBX|5|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241022024155
OBX|6|TX|^^^99717-5^Accession Number^L|1|282-12-459/21-2024-21|||N|||F|||20241022024155
OBX|7|TX|62324-9^Post-discharge provider name^LN|1|MICHELLE LEFF|||N|||F|||20241022024155
OBX|8|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241022024155
OBR|4|7381238055^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBR|5|7381238055^FormNumber||53261-4^Amino acid newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241022024155
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241022024155
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241022024155
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241022024155
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241022024155
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241022024155
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241022024155
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241022024155
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241022024155
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241022024155
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241022024155
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20241022024155
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241022024155
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241022024155
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241022024155
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241022024155
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241022024155
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241022024155
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Collected Early. No Interpretation.|||A|||F|||20241022024155
OBR|6|7381238055^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|7|7381238055^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241022024155
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241022024155
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241022024155
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241022024155
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241022024155
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241022024155
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241022024155
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241022024155
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241022024155
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241022024155
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241022024155
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241022024155
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241022024155
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241022024155
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241022024155
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241022024155
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241022024155
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241022024155
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241022024155
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241022024155
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241022024155
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241022024155
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241022024155
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241022024155
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241022024155
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241022024155
OBR|8|7381238055^FormNumber||57085-3^Organic acid newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241022024155
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241022024155
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241022024155
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241022024155
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241022024155
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241022024155
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241022024155
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241022024155
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241022024155
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241022024155
OBR|9|7381238055^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|72.00|ng/mL|<69|H|||F|||20241022024155
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241022024155
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Consistent with Cystic Fibrosis (delF508 and delI507 mutations)|||A|||F|||20241022024155
OBR|10|7381238055^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241022024155
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|11|7381238055^FormNumber||54090-6^Thyroid newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241022024155
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|12|7381238055^FormNumber||54079-9^Galactosemia newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241022024155
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|13|7381238055^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|F||||||F|||20241022024155
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Consistent with Beta thalassemia major (Cooley's anemia).||||||F|||20241022024155
OBR|14|7381238055^FormNumber||57087-9^Biotinidase newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241022024155
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|15|7381238055^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/µL|>18|N|||F|||20241022024155
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|16|7381238055^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|µmol/L/h|>=18.2|N|||F|||20241022024155
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|17|7381238055^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241022024155
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|18|7381238055^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241022024155
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241022024155
OBR|19|7381238055^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241022024155
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|20|7381238055^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241022024155
OBR|21|7381238055^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20241022024155
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20241022024155
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241022024155
OBR|22|7381238055^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241022024155
OBR|23|7381238055^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241022024155|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241022024155
diff --git a/examples/Test/Automated/GoldenCopy/Input/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7 b/examples/Test/Automated/GoldenCopy/Input/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7
index fcff71fd7..664a3811a 100644
--- a/examples/Test/Automated/GoldenCopy/Input/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7
+++ b/examples/Test/Automated/GoldenCopy/Input/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7
@@ -1 +1 @@
-MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20240930011140||ORU^R01^ORU_R01|003|N|2.5.1
PID|1||80009320^^^&NPI^MR||NEWBORNSCREEN^BOY  RED^^^^^B||202408150826|M||1002-5^American Indian or Alaska Native||||||||||||2186-5^Not Hispanic or Latino||N|1
NK1|1|NEWBORNSCREEN^RED|MTH^Mother|9560 TOWNE CENTRE DR^^SAN DIEGO^CA^92121-1972^USA|^^^^^619^1234567|||||||||||19850426
ORC|RE|7341237093^FormNumber||189671588^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7341237093^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBR|2|7341237093^FormNumber||57128-1^Newborn Screening Report summary panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20240930011140
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20240930011140
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12428-1^All screening is in range for the conditions tested^LN|||N|||F|||20240930011140
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20240930011140
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20240930011140
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Acyl Carnitine Panel: Reference Ranges for acylcarnitines are based on specimens collected on newborns who are less than 10 days old. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20240930011140
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20240930011140
OBR|3|7341237093^FormNumber||57717-1^Newborn screen card data panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20240930011140
OBX|2|NM|8339-4^Birthweight^LN|1|3084|grams||N|||F|||20240930011140
OBX|3|TM|57715-5^Time of birth^LN|1|0826|||N|||F|||20240930011140
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20240930011140
OBX|5|NM|73806-2^Newborn age in hours^LN|1|46|day(s)||N|||F|||20240930011140
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20240930011140
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20240930011140
OBX|8|TX|^^^99717-5^Accession Number^L|1|271-39-356/21-2024-21|||N|||F|||20240930011140
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MARVIN ZAGULI|||N|||F|||20240930011140
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20240930011140
OBR|4|7341237093^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBR|5|7341237093^FormNumber||53261-4^Amino acid newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20240930011140
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20240930011140
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20240930011140
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20240930011140
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20240930011140
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20240930011140
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20240930011140
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20240930011140
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20240930011140
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20240930011140
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20240930011140
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|�mol/L|5-49|N|||F|||20240930011140
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20240930011140
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20240930011140
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20240930011140
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20240930011140
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20240930011140
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20240930011140
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|6|7341237093^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|7|7341237093^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20240930011140
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20240930011140
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20240930011140
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20240930011140
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20240930011140
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20240930011140
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20240930011140
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20240930011140
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20240930011140
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20240930011140
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20240930011140
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20240930011140
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20240930011140
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20240930011140
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20240930011140
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20240930011140
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20240930011140
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20240930011140
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20240930011140
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20240930011140
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20240930011140
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20240930011140
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20240930011140
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20240930011140
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20240930011140
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20240930011140
OBR|8|7341237093^FormNumber||57085-3^Organic acid newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20240930011140
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20240930011140
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20240930011140
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20240930011140
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20240930011140
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20240930011140
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20240930011140
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20240930011140
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20240930011140
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20240930011140
OBR|9|7341237093^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20240930011140
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|10|7341237093^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20240930011140
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|11|7341237093^FormNumber||54090-6^Thyroid newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20240930011140
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|12|7341237093^FormNumber||54079-9^Galactosemia newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20240930011140
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|13|7341237093^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20240930011140
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.�These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20240930011140
OBR|14|7341237093^FormNumber||57087-9^Biotinidase newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20240930011140
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|15|7341237093^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/�L|>18|N|||F|||20240930011140
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|16|7341237093^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|�mol/L/h|>=18.2|N|||F|||20240930011140
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|17|7341237093^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20240930011140
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|18|7341237093^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20240930011140
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20240930011140
OBR|19|7341237093^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20240930011140
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|20|7341237093^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|21|7341237093^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|�mol/L|<=3|N|||F|||20240930011140
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|�mol/L||N|||F|||20240930011140
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20240930011140
OBR|22|7341237093^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20240930011140
OBR|23|7341237093^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20240930011140
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20240930011140||ORU^R01^ORU_R01|003|N|2.5.1
PID|1||80009320^^^&NPI^MR||NEWBORNSCREEN^BOY  RED^^^^^B||202408150826|M||1002-5^American Indian or Alaska Native||||||||||||2186-5^Not Hispanic or Latino||N|1
NK1|1|NEWBORNSCREEN^RED|MTH^Mother|9560 TOWNE CENTRE DR^^SAN DIEGO^CA^92121-1972^USA|^^^^^619^1234567|||||||||||19850426
ORC|RE|7341237093^FormNumber||189671588^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7341237093^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBR|2|7341237093^FormNumber||57128-1^Newborn Screening Report summary panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20240930011140
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20240930011140
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12428-1^All screening is in range for the conditions tested^LN|||N|||F|||20240930011140
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20240930011140
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20240930011140
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Acyl Carnitine Panel: Reference Ranges for acylcarnitines are based on specimens collected on newborns who are less than 10 days old. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20240930011140
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20240930011140
OBR|3|7341237093^FormNumber||57717-1^Newborn screen card data panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20240930011140
OBX|2|NM|8339-4^Birthweight^LN|1|3084|grams||N|||F|||20240930011140
OBX|3|TM|57715-5^Time of birth^LN|1|0826|||N|||F|||20240930011140
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20240930011140
OBX|5|NM|73806-2^Newborn age in hours^LN|1|46|day(s)||N|||F|||20240930011140
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20240930011140
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20240930011140
OBX|8|TX|^^^99717-5^Accession Number^L|1|271-39-356/21-2024-21|||N|||F|||20240930011140
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MARVIN ZAGULI|||N|||F|||20240930011140
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20240930011140
OBR|4|7341237093^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBR|5|7341237093^FormNumber||53261-4^Amino acid newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20240930011140
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20240930011140
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20240930011140
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20240930011140
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20240930011140
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20240930011140
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20240930011140
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20240930011140
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20240930011140
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20240930011140
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20240930011140
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20240930011140
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20240930011140
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20240930011140
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20240930011140
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20240930011140
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20240930011140
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20240930011140
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|6|7341237093^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|7|7341237093^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20240930011140
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20240930011140
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20240930011140
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20240930011140
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20240930011140
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20240930011140
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20240930011140
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20240930011140
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20240930011140
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20240930011140
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20240930011140
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20240930011140
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20240930011140
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20240930011140
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20240930011140
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20240930011140
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20240930011140
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20240930011140
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20240930011140
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20240930011140
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20240930011140
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20240930011140
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20240930011140
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20240930011140
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20240930011140
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20240930011140
OBR|8|7341237093^FormNumber||57085-3^Organic acid newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20240930011140
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20240930011140
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20240930011140
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20240930011140
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20240930011140
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20240930011140
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20240930011140
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20240930011140
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20240930011140
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20240930011140
OBR|9|7341237093^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20240930011140
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|10|7341237093^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20240930011140
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|11|7341237093^FormNumber||54090-6^Thyroid newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20240930011140
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|12|7341237093^FormNumber||54079-9^Galactosemia newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20240930011140
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|13|7341237093^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20240930011140
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20240930011140
OBR|14|7341237093^FormNumber||57087-9^Biotinidase newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20240930011140
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|15|7341237093^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/µL|>18|N|||F|||20240930011140
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|16|7341237093^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|µmol/L/h|>=18.2|N|||F|||20240930011140
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|17|7341237093^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20240930011140
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|18|7341237093^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20240930011140
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20240930011140
OBR|19|7341237093^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20240930011140
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|20|7341237093^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20240930011140
OBR|21|7341237093^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20240930011140
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20240930011140
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20240930011140
OBR|22|7341237093^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20240930011140
OBR|23|7341237093^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20240930011140|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20240930011140
diff --git a/examples/Test/Automated/GoldenCopy/Input/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7 b/examples/Test/Automated/GoldenCopy/Input/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7
index 2826e7995..1ab4d1dd6 100644
--- a/examples/Test/Automated/GoldenCopy/Input/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7
+++ b/examples/Test/Automated/GoldenCopy/Input/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7
@@ -1 +1 @@
-MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241118050532||ORU^R01^ORU_R01|004|N|2.5.1
PID|1||80015913^^^&NPI^MR||CDPHRESULT^GIRL C MARY^^^^^B||202410241550|F||2076-8^Native Hawaiian or Other Pacific Islander||||||||||||2186-5^Not Hispanic or Latino||Y|3
NK1|1|CDPHRESULT^MARY|MTH^Mother|123 ST^^SAN DIEGO^CA^92123^USA|^^^^^858^2490014|||||||||||19981024
ORC|RE|7312693833^FormNumber||189700664^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7312693833^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBR|2|7312693833^FormNumber||57128-1^Newborn Screening Report summary panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241118050532
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241118050532
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12428-1^All screening is in range for the conditions tested^LN|||N|||F|||20241118050532
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241118050532
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241118050532
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241118050532
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241118050532
OBR|3|7312693833^FormNumber||57717-1^Newborn screen card data panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241118050532
OBX|2|NM|8339-4^Birthweight^LN|1|2722|grams||N|||F|||20241118050532
OBX|3|TM|57715-5^Time of birth^LN|1|1550|||N|||F|||20241118050532
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12413-3^Triplets^LN|||N|||F|||20241118050532
OBX|5|NM|73806-2^Newborn age in hours^LN|1|23|hour(s)||N|||F|||20241118050532
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241118050532
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241118050532
OBX|8|TX|^^^99717-5^Accession Number^L|1|306-98-178/21-2024-21|||N|||F|||20241118050532
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MARVIN ZAGULI|||N|||F|||20241118050532
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241118050532
OBR|4|7312693833^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBR|5|7312693833^FormNumber||53261-4^Amino acid newborn screen panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241118050532
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20241118050532
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241118050532
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241118050532
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20241118050532
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241118050532
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20241118050532
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241118050532
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20241118050532
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20241118050532
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20241118050532
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|�mol/L|5-49|N|||F|||20241118050532
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241118050532
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20241118050532
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241118050532
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20241118050532
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241118050532
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20241118050532
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|6|7312693833^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|7|7312693833^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20241118050532
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241118050532
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20241118050532
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241118050532
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20241118050532
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20241118050532
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241118050532
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20241118050532
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20241118050532
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20241118050532
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20241118050532
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20241118050532
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20241118050532
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20241118050532
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241118050532
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20241118050532
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20241118050532
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20241118050532
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20241118050532
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241118050532
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241118050532
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20241118050532
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20241118050532
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20241118050532
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241118050532
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241118050532
OBR|8|7312693833^FormNumber||57085-3^Organic acid newborn screen panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20241118050532
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241118050532
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20241118050532
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20241118050532
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20241118050532
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241118050532
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20241118050532
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20241118050532
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20241118050532
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241118050532
OBR|9|7312693833^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241118050532
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|10|7312693833^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241118050532
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|11|7312693833^FormNumber||54090-6^Thyroid newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241118050532
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|12|7312693833^FormNumber||54079-9^Galactosemia newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241118050532
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|13|7312693833^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241118050532
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.�These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241118050532
OBR|14|7312693833^FormNumber||57087-9^Biotinidase newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241118050532
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|15|7312693833^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/�L|>18|N|||F|||20241118050532
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|16|7312693833^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|�mol/L/h|>=18.2|N|||F|||20241118050532
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|17|7312693833^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20241118050532
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|18|7312693833^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241118050532
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241118050532
OBR|19|7312693833^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20241118050532
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|20|7312693833^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|21|7312693833^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|�mol/L|<=3|N|||F|||20241118050532
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|�mol/L||N|||F|||20241118050532
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.93||<=10|N|||F|||20241118050532
OBR|22|7312693833^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241118050532
OBR|23|7312693833^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20241118050532
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241118050532||ORU^R01^ORU_R01|004|N|2.5.1
PID|1||80015913^^^&NPI^MR||CDPHRESULT^GIRL C MARY^^^^^B||202410241550|F||2076-8^Native Hawaiian or Other Pacific Islander||||||||||||2186-5^Not Hispanic or Latino||Y|3
NK1|1|CDPHRESULT^MARY|MTH^Mother|123 ST^^SAN DIEGO^CA^92123^USA|^^^^^858^2490014|||||||||||19981024
ORC|RE|7312693833^FormNumber||189700664^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7312693833^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBR|2|7312693833^FormNumber||57128-1^Newborn Screening Report summary panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241118050532
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241118050532
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12428-1^All screening is in range for the conditions tested^LN|||N|||F|||20241118050532
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241118050532
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241118050532
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241118050532
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241118050532
OBR|3|7312693833^FormNumber||57717-1^Newborn screen card data panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241118050532
OBX|2|NM|8339-4^Birthweight^LN|1|2722|grams||N|||F|||20241118050532
OBX|3|TM|57715-5^Time of birth^LN|1|1550|||N|||F|||20241118050532
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12413-3^Triplets^LN|||N|||F|||20241118050532
OBX|5|NM|73806-2^Newborn age in hours^LN|1|23|hour(s)||N|||F|||20241118050532
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241118050532
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241118050532
OBX|8|TX|^^^99717-5^Accession Number^L|1|306-98-178/21-2024-21|||N|||F|||20241118050532
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MARVIN ZAGULI|||N|||F|||20241118050532
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241118050532
OBR|4|7312693833^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBR|5|7312693833^FormNumber||53261-4^Amino acid newborn screen panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241118050532
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241118050532
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241118050532
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241118050532
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241118050532
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241118050532
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241118050532
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241118050532
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241118050532
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241118050532
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241118050532
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20241118050532
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241118050532
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241118050532
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241118050532
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241118050532
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241118050532
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241118050532
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|6|7312693833^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|7|7312693833^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241118050532
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241118050532
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241118050532
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241118050532
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241118050532
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241118050532
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241118050532
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241118050532
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241118050532
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241118050532
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241118050532
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241118050532
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241118050532
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241118050532
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241118050532
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241118050532
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241118050532
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241118050532
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241118050532
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241118050532
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241118050532
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241118050532
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241118050532
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241118050532
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241118050532
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241118050532
OBR|8|7312693833^FormNumber||57085-3^Organic acid newborn screen panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241118050532
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241118050532
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241118050532
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241118050532
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241118050532
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241118050532
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241118050532
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241118050532
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241118050532
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241118050532
OBR|9|7312693833^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241118050532
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|10|7312693833^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241118050532
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|11|7312693833^FormNumber||54090-6^Thyroid newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241118050532
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|12|7312693833^FormNumber||54079-9^Galactosemia newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241118050532
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|13|7312693833^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241118050532
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241118050532
OBR|14|7312693833^FormNumber||57087-9^Biotinidase newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241118050532
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|15|7312693833^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/µL|>18|N|||F|||20241118050532
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|16|7312693833^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|µmol/L/h|>=18.2|N|||F|||20241118050532
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|17|7312693833^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241118050532
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|18|7312693833^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241118050532
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241118050532
OBR|19|7312693833^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241118050532
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|20|7312693833^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241118050532
OBR|21|7312693833^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20241118050532
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20241118050532
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.93||<=10|N|||F|||20241118050532
OBR|22|7312693833^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241118050532
OBR|23|7312693833^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410251536|||||||||^HUBBARD^EUSTRATIA||||||20241118050532|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241118050532
diff --git a/examples/Test/Automated/GoldenCopy/Input/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7 b/examples/Test/Automated/GoldenCopy/Input/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7
index e61dbf1a6..a3778b75c 100644
--- a/examples/Test/Automated/GoldenCopy/Input/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7
+++ b/examples/Test/Automated/GoldenCopy/Input/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7
@@ -1 +1 @@
-MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241118030201||ORU^R01^ORU_R01|005|N|2.5.1
PID|1||80015887^^^&NPI^MR||CDPHTHREE^BOY B MOMTHREE^^^^^B||202410161318|M||2131-1^Other Race||||||||||||UNK^Unknown||Y|2
NK1|1|CDPHTHREE^MOMTHREE|MTH^Mother|3 3RD ST^^SAN DIEGO^CA^92126^USA|^^^^^858^2490007|||||||||||20031007
ORC|RE|7381238055^FormNumber||189693889^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7381238055^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBR|2|7381238055^FormNumber||57128-1^Newborn Screening Report summary panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241118030201
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241118030201
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241118030201
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241118030201
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241118030201
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Amino Acid Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241118030201
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241118030201
OBR|3|7381238055^FormNumber||57717-1^Newborn screen card data panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241118030201
OBX|2|NM|8339-4^Birthweight^LN|1|2948|grams||N|||F|||20241118030201
OBX|3|TM|57715-5^Time of birth^LN|1|1318|||N|||F|||20241118030201
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241118030201
OBX|5|NM|73806-2^Newborn age in hours^LN|1|3|hour(s)||N|||F|||20241118030201
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241118030201
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241118030201
OBX|8|TX|^^^99717-5^Accession Number^L|1|290-84-459/21-2024-21|||N|||F|||20241118030201
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MICHELLE LEFF|||N|||F|||20241118030201
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241118030201
OBR|4|7381238055^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBR|5|7381238055^FormNumber||53261-4^Amino acid newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241118030201
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20241118030201
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241118030201
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241118030201
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20241118030201
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241118030201
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20241118030201
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241118030201
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20241118030201
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20241118030201
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20241118030201
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|275|�mol/L|5-49|H|||F|||20241118030201
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|11|{Ratio}|<4.8|H|||F|||20241118030201
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20241118030201
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241118030201
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20241118030201
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241118030201
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20241118030201
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with Citrullinemia (I/II), ASAL Deficiency|||A|||F|||20241118030201
OBR|6|7381238055^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|7|7381238055^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20241118030201
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241118030201
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20241118030201
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241118030201
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20241118030201
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20241118030201
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241118030201
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20241118030201
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20241118030201
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20241118030201
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20241118030201
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20241118030201
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20241118030201
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20241118030201
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241118030201
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20241118030201
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20241118030201
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20241118030201
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20241118030201
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241118030201
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241118030201
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20241118030201
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20241118030201
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20241118030201
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241118030201
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241118030201
OBR|8|7381238055^FormNumber||57085-3^Organic acid newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20241118030201
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241118030201
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20241118030201
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20241118030201
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20241118030201
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241118030201
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20241118030201
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20241118030201
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20241118030201
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241118030201
OBR|9|7381238055^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241118030201
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|10|7381238055^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241118030201
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|11|7381238055^FormNumber||54090-6^Thyroid newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241118030201
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|12|7381238055^FormNumber||54079-9^Galactosemia newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241118030201
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|13|7381238055^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241118030201
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.�These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241118030201
OBR|14|7381238055^FormNumber||57087-9^Biotinidase newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241118030201
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|15|7381238055^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/�L|>18|N|||F|||20241118030201
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|16|7381238055^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|�mol/L/h|>=18.2|N|||F|||20241118030201
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|17|7381238055^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20241118030201
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|18|7381238055^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241118030201
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241118030201
OBR|19|7381238055^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20241118030201
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|20|7381238055^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|21|7381238055^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|�mol/L|<=3|N|||F|||20241118030201
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|�mol/L||N|||F|||20241118030201
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241118030201
OBR|22|7381238055^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241118030201
OBR|23|7381238055^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20241118030201
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241118030201||ORU^R01^ORU_R01|005|N|2.5.1
PID|1||80015887^^^&NPI^MR||CDPHTHREE^BOY B MOMTHREE^^^^^B||202410161318|M||2131-1^Other Race||||||||||||UNK^Unknown||Y|2
NK1|1|CDPHTHREE^MOMTHREE|MTH^Mother|3 3RD ST^^SAN DIEGO^CA^92126^USA|^^^^^858^2490007|||||||||||20031007
ORC|RE|7381238055^FormNumber||189693889^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7381238055^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBR|2|7381238055^FormNumber||57128-1^Newborn Screening Report summary panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241118030201
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241118030201
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241118030201
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241118030201
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241118030201
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Amino Acid Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241118030201
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241118030201
OBR|3|7381238055^FormNumber||57717-1^Newborn screen card data panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241118030201
OBX|2|NM|8339-4^Birthweight^LN|1|2948|grams||N|||F|||20241118030201
OBX|3|TM|57715-5^Time of birth^LN|1|1318|||N|||F|||20241118030201
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241118030201
OBX|5|NM|73806-2^Newborn age in hours^LN|1|3|hour(s)||N|||F|||20241118030201
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241118030201
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241118030201
OBX|8|TX|^^^99717-5^Accession Number^L|1|290-84-459/21-2024-21|||N|||F|||20241118030201
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MICHELLE LEFF|||N|||F|||20241118030201
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241118030201
OBR|4|7381238055^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBR|5|7381238055^FormNumber||53261-4^Amino acid newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241118030201
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241118030201
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241118030201
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241118030201
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241118030201
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241118030201
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241118030201
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241118030201
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241118030201
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241118030201
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241118030201
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|275|µmol/L|5-49|H|||F|||20241118030201
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|11|{Ratio}|<4.8|H|||F|||20241118030201
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241118030201
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241118030201
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241118030201
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241118030201
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241118030201
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with Citrullinemia (I/II), ASAL Deficiency|||A|||F|||20241118030201
OBR|6|7381238055^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|7|7381238055^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241118030201
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241118030201
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241118030201
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241118030201
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241118030201
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241118030201
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241118030201
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241118030201
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241118030201
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241118030201
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241118030201
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241118030201
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241118030201
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241118030201
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241118030201
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241118030201
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241118030201
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241118030201
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241118030201
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241118030201
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241118030201
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241118030201
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241118030201
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241118030201
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241118030201
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241118030201
OBR|8|7381238055^FormNumber||57085-3^Organic acid newborn screen panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241118030201
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241118030201
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241118030201
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241118030201
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241118030201
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241118030201
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241118030201
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241118030201
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241118030201
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241118030201
OBR|9|7381238055^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241118030201
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|10|7381238055^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241118030201
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|11|7381238055^FormNumber||54090-6^Thyroid newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241118030201
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|12|7381238055^FormNumber||54079-9^Galactosemia newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241118030201
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|13|7381238055^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241118030201
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241118030201
OBR|14|7381238055^FormNumber||57087-9^Biotinidase newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241118030201
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|15|7381238055^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/µL|>18|N|||F|||20241118030201
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|16|7381238055^FormNumber||63414-7^Pompe Disease newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|µmol/L/h|>=18.2|N|||F|||20241118030201
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|17|7381238055^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241118030201
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|18|7381238055^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241118030201
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241118030201
OBR|19|7381238055^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241118030201
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|20|7381238055^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241118030201
OBR|21|7381238055^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20241118030201
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20241118030201
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241118030201
OBR|22|7381238055^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241118030201
OBR|23|7381238055^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202410161630|||||||||^HUBBARD^EUSTRATIA||||||20241118030201|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241118030201
diff --git a/examples/Test/Automated/GoldenCopy/Input/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7 b/examples/Test/Automated/GoldenCopy/Input/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7
index 7ba118a0f..0eaaa5f50 100644
--- a/examples/Test/Automated/GoldenCopy/Input/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7
+++ b/examples/Test/Automated/GoldenCopy/Input/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7
@@ -1 +1 @@
-MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241203094445||ORU^R01^ORU_R01|006|N|2.5.1
PID|1||80015959^^^&NPI^MR||INTERFACE^GIRL B CDPHTWO^^^^^B||20241118084900|F||2028-9^Asian||||||||||||2186-5^Not Hispanic or Latino||Y|2
NK1|1|INTERFACE^CDPHTWO|MTH^Mother|9877 7TH ST^^SAN DIEGO^CA^92126^USA|^^^^^619^4704213|||||||||||19961118
ORC|RE|7872697780^FormNumber||189716938^HospOrdNumber||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7872697780^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBR|2|7872697780^FormNumber||57128-1^Newborn Screening Report summary panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241203094445
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241203094445
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241203094445
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|99717-3^Hypothyroidism^L|||N|||F|||20241203094445
OBX|5|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|2|LA12543-7^GALT^LN|||N|||F|||20241203094445
OBX|6|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|3|LA22279-6^SMA^LN|||N|||F|||20241203094445
OBX|7|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|4|LA30113-7^GAMT^LN|||N|||F|||20241203094445
OBX|8|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|5|LA12532-0^BIO^LN|||N|||F|||20241203094445
OBX|9|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241203094445
OBX|10|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Biotinidase Deficiency: This screen for Biotinidase Deficiency was positive. Another specimen MUST be collected on this infant. \.br\\.br\Guanidinoacetate Methyltransferase (GAMT): An immediate referral to a CCS-approved Metabolic Center for evaluation and additional testing is strongly recommended. \.br\\.br\Spinal Muscular Atrophy (SMA): An immediate referral to a CCS-approved Neuromuscular Center for evaluation and additional testing is strongly recommended due an apparent SMN1 exon 7 homozygous deletion. \.br\\.br\Galactosemia: Additional testing is required to rule out disorder.�Call your Newborn Screening Coordinator for assistance. \.br\\.br\Primary Congenital Hypothyroidism: Additional testing in consultation with a CCS-approved Endocrine Center or Pediatric Endocrinologist is strongly recommended.�Call your Newborn Screening Coordinator for assistance. \.br\\.br\ATTENTION: THIS CHILD HAS TESTED POSITIVE FOR MORE THAN ONE TEST. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241203094445
OBX|11|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241203094445
OBR|3|7872697780^FormNumber||57717-1^Newborn screen card data panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241203094445
OBX|2|NM|8339-4^Birthweight^LN|1|2495|grams||N|||F|||20241203094445
OBX|3|TM|57715-5^Time of birth^LN|1|8490|||N|||F|||20241203094445
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241203094445
OBX|5|NM|73806-2^Newborn age in hours^LN|1|82|hour(s)||N|||F|||20241203094445
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241203094445
OBX|7|CE|67704-7^Feeding types^LN|1|LA16915-3^Lactose formula^LN|||N|||F|||20241203094445
OBX|8|TX|^^^99717-5^Accession Number^L|1|326-64-675/21-2024-21|||N|||F|||20241203094445
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MICHELLE LEFF|||N|||F|||20241203094445
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241203094445
OBR|4|7872697780^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBR|5|7872697780^FormNumber||53261-4^Amino acid newborn screen panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241203094445
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20241203094445
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241203094445
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241203094445
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20241203094445
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241203094445
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20241203094445
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241203094445
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20241203094445
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20241203094445
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20241203094445
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|�mol/L|5-49|N|||F|||20241203094445
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241203094445
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20241203094445
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241203094445
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20241203094445
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241203094445
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20241203094445
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|6|7872697780^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|7|7872697780^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20241203094445
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241203094445
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20241203094445
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241203094445
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20241203094445
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20241203094445
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241203094445
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20241203094445
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20241203094445
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20241203094445
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20241203094445
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20241203094445
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20241203094445
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20241203094445
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241203094445
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20241203094445
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20241203094445
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20241203094445
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20241203094445
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241203094445
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241203094445
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20241203094445
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20241203094445
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20241203094445
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241203094445
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241203094445
OBR|8|7872697780^FormNumber||57085-3^Organic acid newborn screen panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20241203094445
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241203094445
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20241203094445
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20241203094445
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20241203094445
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241203094445
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20241203094445
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20241203094445
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20241203094445
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241203094445
OBR|9|7872697780^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241203094445
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|10|7872697780^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<190|N|||F|||20241203094445
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|11|7872697780^FormNumber||54090-6^Thyroid newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|34.00|mIU/L|<29|H|||F|||20241203094445
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241203094445
OBR|12|7872697780^FormNumber||54079-9^Galactosemia newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|48.00|enzyme units|>50|L|||F|||20241203094445
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241203094445
OBR|13|7872697780^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241203094445
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.�These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241203094445
OBR|14|7872697780^FormNumber||57087-9^Biotinidase newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|8.00|ERU|>10|L|||F|||20241203094445
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241203094445
OBR|15|7872697780^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/�L|>18|N|||F|||20241203094445
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|16|7872697780^FormNumber||63414-7^Pompe Disease newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|�mol/L/h|>=18.2|N|||F|||20241203094445
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|17|7872697780^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20241203094445
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|18|7872697780^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Absent||Exon 7 Present|A|||F|||20241203094445
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Positive|||A|||F|||20241203094445
OBR|19|7872697780^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20241203094445
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|20|7872697780^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Positive|||A|||F|||20241203094445
OBR|21|7872697780^FormNumber||^^^99717-57^Guanidinoacetate methyltransferase Tier-2 newborn screening panel^L|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|5.25|�mol/L/h|<=5|H|||F|||20241203094445
OBR|22|7872697780^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241203094445
OBR|23|7872697780^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20241203094445
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241203094445||ORU^R01^ORU_R01|006|N|2.5.1
PID|1||80015959^^^&NPI^MR||INTERFACE^GIRL B CDPHTWO^^^^^B||20241118084900|F||2028-9^Asian||||||||||||2186-5^Not Hispanic or Latino||Y|2
NK1|1|INTERFACE^CDPHTWO|MTH^Mother|9877 7TH ST^^SAN DIEGO^CA^92126^USA|^^^^^619^4704213|||||||||||19961118
ORC|RE|7872697780^FormNumber||189716938^HospOrdNumber||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7872697780^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBR|2|7872697780^FormNumber||57128-1^Newborn Screening Report summary panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241203094445
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241203094445
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241203094445
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|99717-3^Hypothyroidism^L|||N|||F|||20241203094445
OBX|5|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|2|LA12543-7^GALT^LN|||N|||F|||20241203094445
OBX|6|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|3|LA22279-6^SMA^LN|||N|||F|||20241203094445
OBX|7|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|4|LA30113-7^GAMT^LN|||N|||F|||20241203094445
OBX|8|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|5|LA12532-0^BIO^LN|||N|||F|||20241203094445
OBX|9|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241203094445
OBX|10|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Biotinidase Deficiency: This screen for Biotinidase Deficiency was positive. Another specimen MUST be collected on this infant. \.br\\.br\Guanidinoacetate Methyltransferase (GAMT): An immediate referral to a CCS-approved Metabolic Center for evaluation and additional testing is strongly recommended. \.br\\.br\Spinal Muscular Atrophy (SMA): An immediate referral to a CCS-approved Neuromuscular Center for evaluation and additional testing is strongly recommended due an apparent SMN1 exon 7 homozygous deletion. \.br\\.br\Galactosemia: Additional testing is required to rule out disorder.µCall your Newborn Screening Coordinator for assistance. \.br\\.br\Primary Congenital Hypothyroidism: Additional testing in consultation with a CCS-approved Endocrine Center or Pediatric Endocrinologist is strongly recommended.µCall your Newborn Screening Coordinator for assistance. \.br\\.br\ATTENTION: THIS CHILD HAS TESTED POSITIVE FOR MORE THAN ONE TEST. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241203094445
OBX|11|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241203094445
OBR|3|7872697780^FormNumber||57717-1^Newborn screen card data panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241203094445
OBX|2|NM|8339-4^Birthweight^LN|1|2495|grams||N|||F|||20241203094445
OBX|3|TM|57715-5^Time of birth^LN|1|8490|||N|||F|||20241203094445
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241203094445
OBX|5|NM|73806-2^Newborn age in hours^LN|1|82|hour(s)||N|||F|||20241203094445
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241203094445
OBX|7|CE|67704-7^Feeding types^LN|1|LA16915-3^Lactose formula^LN|||N|||F|||20241203094445
OBX|8|TX|^^^99717-5^Accession Number^L|1|326-64-675/21-2024-21|||N|||F|||20241203094445
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MICHELLE LEFF|||N|||F|||20241203094445
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241203094445
OBR|4|7872697780^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBR|5|7872697780^FormNumber||53261-4^Amino acid newborn screen panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241203094445
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241203094445
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241203094445
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241203094445
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241203094445
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241203094445
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241203094445
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241203094445
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241203094445
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241203094445
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241203094445
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20241203094445
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241203094445
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241203094445
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241203094445
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241203094445
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241203094445
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241203094445
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|6|7872697780^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|7|7872697780^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241203094445
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241203094445
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241203094445
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241203094445
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241203094445
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241203094445
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241203094445
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241203094445
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241203094445
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241203094445
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241203094445
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241203094445
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241203094445
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241203094445
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241203094445
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241203094445
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241203094445
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241203094445
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241203094445
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241203094445
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241203094445
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241203094445
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241203094445
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241203094445
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241203094445
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241203094445
OBR|8|7872697780^FormNumber||57085-3^Organic acid newborn screen panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241203094445
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241203094445
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241203094445
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241203094445
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241203094445
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241203094445
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241203094445
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241203094445
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241203094445
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241203094445
OBR|9|7872697780^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241203094445
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|10|7872697780^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<190|N|||F|||20241203094445
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|11|7872697780^FormNumber||54090-6^Thyroid newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|34.00|mIU/L|<29|H|||F|||20241203094445
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241203094445
OBR|12|7872697780^FormNumber||54079-9^Galactosemia newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|48.00|enzyme units|>50|L|||F|||20241203094445
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241203094445
OBR|13|7872697780^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241203094445
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241203094445
OBR|14|7872697780^FormNumber||57087-9^Biotinidase newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|8.00|ERU|>10|L|||F|||20241203094445
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241203094445
OBR|15|7872697780^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/µL|>18|N|||F|||20241203094445
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|16|7872697780^FormNumber||63414-7^Pompe Disease newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|µmol/L/h|>=18.2|N|||F|||20241203094445
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|17|7872697780^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241203094445
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|18|7872697780^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Absent||Exon 7 Present|A|||F|||20241203094445
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Positive|||A|||F|||20241203094445
OBR|19|7872697780^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241203094445
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241203094445
OBR|20|7872697780^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Positive|||A|||F|||20241203094445
OBR|21|7872697780^FormNumber||^^^99717-57^Guanidinoacetate methyltransferase Tier-2 newborn screening panel^L|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|5.25|µmol/L/h|<=5|H|||F|||20241203094445
OBR|22|7872697780^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241203094445
OBR|23|7872697780^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202411211003|||||||||^JOHNSON^KATHRYN||||||20241203094445|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241203094445
diff --git a/examples/Test/Automated/GoldenCopy/Input/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7 b/examples/Test/Automated/GoldenCopy/Input/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7
index 1c6a29d54..32f024724 100644
--- a/examples/Test/Automated/GoldenCopy/Input/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7
+++ b/examples/Test/Automated/GoldenCopy/Input/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7
@@ -1 +1 @@
-MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241206093739||ORU^R01^ORU_R01|007|N|2.5.1
PID|1||80015955^^^&NPI^MR||INTERFACE^BOY A CDPHONE^^^^^B||202411180830|M||2028-9^Asian||||||||||||2186-5^Not Hispanic or Latino||Y|1
NK1|1|INTERFACE^CDPHONE|MTH^Mother|456 ST^^SAN DIEGO^CA^92123^USA|^^^^^858^2490016|||||||||||19921118
ORC|RE|7902698491^FormNumber||189717091^HospOrdNumber||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7902698491^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBR|2|7902698491^FormNumber||57128-1^Newborn Screening Report summary panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241206093739
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241206093739
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241206093739
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12566-8^SCID^LN|||N|||F|||20241206093739
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241206093739
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\SCID: A liquid blood specimen for CBC differential and flow cytometry at Quest Diagnostics is required to rule out or confirm SCID or a related immune disorder. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241206093739
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241206093739
OBR|3|7902698491^FormNumber||57717-1^Newborn screen card data panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241206093739
OBX|2|NM|8339-4^Birthweight^LN|1|2722|grams||N|||F|||20241206093739
OBX|3|TM|57715-5^Time of birth^LN|1|0830|||N|||F|||20241206093739
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241206093739
OBX|5|NM|73806-2^Newborn age in hours^LN|1|73|hour(s)||N|||F|||20241206093739
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241206093739
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241206093739
OBX|8|TX|^^^99717-5^Accession Number^L|1|326-65-211/21-2024-21|||N|||F|||20241206093739
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|KRISHELLE MARC-AURELE|||N|||F|||20241206093739
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241206093739
OBR|4|7902698491^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBR|5|7902698491^FormNumber||53261-4^Amino acid newborn screen panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241206093739
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20241206093739
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241206093739
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241206093739
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20241206093739
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241206093739
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20241206093739
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241206093739
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20241206093739
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20241206093739
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20241206093739
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|�mol/L|5-49|N|||F|||20241206093739
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241206093739
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20241206093739
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241206093739
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20241206093739
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241206093739
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20241206093739
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|6|7902698491^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|7|7902698491^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20241206093739
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241206093739
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20241206093739
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241206093739
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20241206093739
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20241206093739
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241206093739
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20241206093739
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20241206093739
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20241206093739
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20241206093739
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20241206093739
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20241206093739
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20241206093739
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241206093739
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20241206093739
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20241206093739
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20241206093739
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20241206093739
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241206093739
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241206093739
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20241206093739
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20241206093739
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20241206093739
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241206093739
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241206093739
OBR|8|7902698491^FormNumber||57085-3^Organic acid newborn screen panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20241206093739
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241206093739
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20241206093739
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20241206093739
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20241206093739
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241206093739
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20241206093739
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20241206093739
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20241206093739
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241206093739
OBR|9|7902698491^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241206093739
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|10|7902698491^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241206093739
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|11|7902698491^FormNumber||54090-6^Thyroid newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241206093739
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|12|7902698491^FormNumber||54079-9^Galactosemia newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241206093739
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|13|7902698491^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241206093739
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.�These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241206093739
OBR|14|7902698491^FormNumber||57087-9^Biotinidase newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241206093739
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|15|7902698491^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|2|copies/�L|>18|L|||F|||20241206093739
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241206093739
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241206093739
OBR|16|7902698491^FormNumber||63414-7^Pompe Disease newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|�mol/L/h|>=18.2|N|||F|||20241206093739
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|17|7902698491^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20241206093739
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|18|7902698491^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241206093739
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241206093739
OBR|19|7902698491^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20241206093739
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|20|7902698491^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|21|7902698491^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|�mol/L|<=3|N|||F|||20241206093739
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|�mol/L||N|||F|||20241206093739
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241206093739
OBR|22|7902698491^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241206093739
OBR|23|7902698491^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20241206093739
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241206093739||ORU^R01^ORU_R01|007|N|2.5.1
PID|1||80015955^^^&NPI^MR||INTERFACE^BOY A CDPHONE^^^^^B||202411180830|M||2028-9^Asian||||||||||||2186-5^Not Hispanic or Latino||Y|1
NK1|1|INTERFACE^CDPHONE|MTH^Mother|456 ST^^SAN DIEGO^CA^92123^USA|^^^^^858^2490016|||||||||||19921118
ORC|RE|7902698491^FormNumber||189717091^HospOrdNumber||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7902698491^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBR|2|7902698491^FormNumber||57128-1^Newborn Screening Report summary panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241206093739
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241206093739
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241206093739
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12566-8^SCID^LN|||N|||F|||20241206093739
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241206093739
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\SCID: A liquid blood specimen for CBC differential and flow cytometry at Quest Diagnostics is required to rule out or confirm SCID or a related immune disorder. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241206093739
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241206093739
OBR|3|7902698491^FormNumber||57717-1^Newborn screen card data panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241206093739
OBX|2|NM|8339-4^Birthweight^LN|1|2722|grams||N|||F|||20241206093739
OBX|3|TM|57715-5^Time of birth^LN|1|0830|||N|||F|||20241206093739
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241206093739
OBX|5|NM|73806-2^Newborn age in hours^LN|1|73|hour(s)||N|||F|||20241206093739
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241206093739
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241206093739
OBX|8|TX|^^^99717-5^Accession Number^L|1|326-65-211/21-2024-21|||N|||F|||20241206093739
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|KRISHELLE MARC-AURELE|||N|||F|||20241206093739
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241206093739
OBR|4|7902698491^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBR|5|7902698491^FormNumber||53261-4^Amino acid newborn screen panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241206093739
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241206093739
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241206093739
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241206093739
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241206093739
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241206093739
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241206093739
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241206093739
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241206093739
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241206093739
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241206093739
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20241206093739
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241206093739
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241206093739
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241206093739
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241206093739
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241206093739
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241206093739
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|6|7902698491^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|7|7902698491^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241206093739
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241206093739
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241206093739
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241206093739
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241206093739
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241206093739
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241206093739
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241206093739
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241206093739
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241206093739
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241206093739
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241206093739
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241206093739
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241206093739
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241206093739
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241206093739
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241206093739
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241206093739
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241206093739
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241206093739
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241206093739
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241206093739
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241206093739
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241206093739
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241206093739
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241206093739
OBR|8|7902698491^FormNumber||57085-3^Organic acid newborn screen panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241206093739
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241206093739
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241206093739
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241206093739
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241206093739
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241206093739
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241206093739
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241206093739
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241206093739
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241206093739
OBR|9|7902698491^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241206093739
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|10|7902698491^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241206093739
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|11|7902698491^FormNumber||54090-6^Thyroid newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241206093739
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|12|7902698491^FormNumber||54079-9^Galactosemia newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241206093739
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|13|7902698491^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241206093739
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241206093739
OBR|14|7902698491^FormNumber||57087-9^Biotinidase newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241206093739
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|15|7902698491^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|2|copies/µL|>18|L|||F|||20241206093739
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241206093739
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241206093739
OBR|16|7902698491^FormNumber||63414-7^Pompe Disease newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|µmol/L/h|>=18.2|N|||F|||20241206093739
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|17|7902698491^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241206093739
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|18|7902698491^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241206093739
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241206093739
OBR|19|7902698491^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241206093739
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|20|7902698491^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241206093739
OBR|21|7902698491^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20241206093739
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20241206093739
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241206093739
OBR|22|7902698491^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241206093739
OBR|23|7902698491^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202411211015|||||||||^JOHNSON^KATHRYN||||||20241206093739|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241206093739
diff --git a/examples/Test/Automated/GoldenCopy/Input/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7 b/examples/Test/Automated/GoldenCopy/Input/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7
index a16c55aa1..2914afa46 100644
--- a/examples/Test/Automated/GoldenCopy/Input/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7
+++ b/examples/Test/Automated/GoldenCopy/Input/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7
@@ -1 +1 @@
-MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241211115659||ORU^R01^ORU_R01|009|N|2.5.1
PID|1||80009320^^^&NPI^MR||NEWBORNSCREEN^BOY  RED^^^^^B||202408150826|M||1002-5^American Indian or Alaska Native||||||||||||2186-5^Not Hispanic or Latino||N|1
NK1|1|NEWBORNSCREEN^RED|MTH^Mother|9560 TOWNE CENTRE DR^^SAN DIEGO^CA^92121-1972^USA|^^^^^619^1234567|||||||||||19850426
ORC|RE|7341237093^FormNumber||189671588^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7341237093^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBR|2|7341237093^FormNumber||57128-1^Newborn Screening Report summary panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241211115659
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241211115659
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241211115659
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12543-7^GALT^LN|||N|||F|||20241211115659
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241211115659
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Acyl Carnitine Panel: Reference Ranges for acylcarnitines are based on specimens collected on newborns who are less than 10 days old. \.br\\.br\Galactosemia: Additional testing is required to rule out disorder.�Call your Newborn Screening Coordinator for assistance. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241211115659
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241211115659
OBR|3|7341237093^FormNumber||57717-1^Newborn screen card data panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241211115659
OBX|2|NM|8339-4^Birthweight^LN|1|3084|grams||N|||F|||20241211115659
OBX|3|TM|57715-5^Time of birth^LN|1|0826|||N|||F|||20241211115659
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241211115659
OBX|5|NM|73806-2^Newborn age in hours^LN|1|46|day(s)||N|||F|||20241211115659
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241211115659
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241211115659
OBX|8|TX|^^^99717-5^Accession Number^L|1|275-71-453/21-2024-21|||N|||F|||20241211115659
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MARVIN ZAGULI|||N|||F|||20241211115659
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241211115659
OBR|4|7341237093^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBR|5|7341237093^FormNumber||53261-4^Amino acid newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241211115659
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20241211115659
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241211115659
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241211115659
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20241211115659
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241211115659
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20241211115659
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241211115659
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20241211115659
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20241211115659
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20241211115659
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|�mol/L|5-49|N|||F|||20241211115659
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241211115659
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20241211115659
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241211115659
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20241211115659
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241211115659
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20241211115659
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|6|7341237093^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|7|7341237093^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20241211115659
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241211115659
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20241211115659
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241211115659
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20241211115659
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20241211115659
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241211115659
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20241211115659
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20241211115659
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20241211115659
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20241211115659
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20241211115659
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20241211115659
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20241211115659
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241211115659
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20241211115659
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20241211115659
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20241211115659
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20241211115659
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241211115659
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241211115659
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20241211115659
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20241211115659
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20241211115659
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241211115659
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241211115659
OBR|8|7341237093^FormNumber||57085-3^Organic acid newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20241211115659
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241211115659
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20241211115659
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20241211115659
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20241211115659
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241211115659
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20241211115659
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20241211115659
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20241211115659
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241211115659
OBR|9|7341237093^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241211115659
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|10|7341237093^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241211115659
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|11|7341237093^FormNumber||54090-6^Thyroid newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241211115659
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|12|7341237093^FormNumber||54079-9^Galactosemia newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|48.00|enzyme units|>50|L|||F|||20241211115659
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241211115659
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241211115659
OBR|13|7341237093^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241211115659
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.�These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241211115659
OBR|14|7341237093^FormNumber||57087-9^Biotinidase newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241211115659
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|15|7341237093^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/�L|>18|N|||F|||20241211115659
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|16|7341237093^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|�mol/L/h|>=18.2|N|||F|||20241211115659
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|17|7341237093^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20241211115659
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|18|7341237093^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241211115659
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241211115659
OBR|19|7341237093^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20241211115659
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|20|7341237093^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|21|7341237093^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|�mol/L|<=3|N|||F|||20241211115659
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|�mol/L||N|||F|||20241211115659
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241211115659
OBR|22|7341237093^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241211115659
OBR|23|7341237093^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20241211115659
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241211115659||ORU^R01^ORU_R01|009|N|2.5.1
PID|1||80009320^^^&NPI^MR||NEWBORNSCREEN^BOY  RED^^^^^B||202408150826|M||1002-5^American Indian or Alaska Native||||||||||||2186-5^Not Hispanic or Latino||N|1
NK1|1|NEWBORNSCREEN^RED|MTH^Mother|9560 TOWNE CENTRE DR^^SAN DIEGO^CA^92121-1972^USA|^^^^^619^1234567|||||||||||19850426
ORC|RE|7341237093^FormNumber||189671588^HospOrdNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|7341237093^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBR|2|7341237093^FormNumber||57128-1^Newborn Screening Report summary panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241211115659
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241211115659
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241211115659
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12543-7^GALT^LN|||N|||F|||20241211115659
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241211115659
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Acyl Carnitine Panel: Reference Ranges for acylcarnitines are based on specimens collected on newborns who are less than 10 days old. \.br\\.br\Galactosemia: Additional testing is required to rule out disorder.µCall your Newborn Screening Coordinator for assistance. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241211115659
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241211115659
OBR|3|7341237093^FormNumber||57717-1^Newborn screen card data panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241211115659
OBX|2|NM|8339-4^Birthweight^LN|1|3084|grams||N|||F|||20241211115659
OBX|3|TM|57715-5^Time of birth^LN|1|0826|||N|||F|||20241211115659
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241211115659
OBX|5|NM|73806-2^Newborn age in hours^LN|1|46|day(s)||N|||F|||20241211115659
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241211115659
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241211115659
OBX|8|TX|^^^99717-5^Accession Number^L|1|275-71-453/21-2024-21|||N|||F|||20241211115659
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MARVIN ZAGULI|||N|||F|||20241211115659
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241211115659
OBR|4|7341237093^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBR|5|7341237093^FormNumber||53261-4^Amino acid newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241211115659
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241211115659
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241211115659
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241211115659
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241211115659
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241211115659
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241211115659
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241211115659
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241211115659
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241211115659
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241211115659
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20241211115659
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241211115659
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241211115659
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241211115659
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241211115659
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241211115659
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241211115659
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|6|7341237093^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|7|7341237093^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241211115659
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241211115659
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241211115659
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241211115659
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241211115659
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241211115659
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241211115659
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241211115659
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241211115659
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241211115659
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241211115659
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241211115659
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241211115659
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241211115659
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241211115659
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241211115659
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241211115659
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241211115659
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241211115659
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241211115659
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241211115659
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241211115659
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241211115659
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241211115659
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241211115659
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241211115659
OBR|8|7341237093^FormNumber||57085-3^Organic acid newborn screen panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241211115659
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241211115659
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241211115659
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241211115659
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241211115659
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241211115659
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241211115659
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241211115659
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241211115659
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241211115659
OBR|9|7341237093^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241211115659
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|10|7341237093^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241211115659
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|11|7341237093^FormNumber||54090-6^Thyroid newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241211115659
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|12|7341237093^FormNumber||54079-9^Galactosemia newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|48.00|enzyme units|>50|L|||F|||20241211115659
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241211115659
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241211115659
OBR|13|7341237093^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241211115659
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241211115659
OBR|14|7341237093^FormNumber||57087-9^Biotinidase newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241211115659
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|15|7341237093^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/µL|>18|N|||F|||20241211115659
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|16|7341237093^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|µmol/L/h|>=18.2|N|||F|||20241211115659
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|17|7341237093^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241211115659
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|18|7341237093^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241211115659
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241211115659
OBR|19|7341237093^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241211115659
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|20|7341237093^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241211115659
OBR|21|7341237093^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20241211115659
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20241211115659
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241211115659
OBR|22|7341237093^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241211115659
OBR|23|7341237093^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409300941|||||||||^HUBBARD^EUSTRATIA||||||20241211115659|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241211115659
diff --git a/examples/Test/Automated/GoldenCopy/Input/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7 b/examples/Test/Automated/GoldenCopy/Input/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7
index 2d0eddb65..472f9604a 100644
--- a/examples/Test/Automated/GoldenCopy/Input/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7
+++ b/examples/Test/Automated/GoldenCopy/Input/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7
@@ -1 +1 @@
-MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241211110818||ORU^R01^ORU_R01|010|N|2.5.1
PID|1||80015980^^^&NPI^MR||HIPPO^BOY A ALLIE^^^^^B||202412091336|M||2106-3^White||||||||||||2186-5^Not Hispanic or Latino||Y|1
NK1|1|HIPPO^ALLIE|MTH^Mother|518 BIG BEN WAY^^OCEANSIDE^CA^92058^USA|^^^^^442^2885325|||||||||||19941209
ORC|RE|7302692465^FormNumber||189728187^HospOrdNumber||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI|||||||||UC SAN DIEGO MEDICAL CENTER^^^^^^^^^R508|W 025TS HT71 , C #^^SAN DIEGO^CA^99999-9999
OBR|1|7302692465^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBR|2|7302692465^FormNumber||57128-1^Newborn Screening Report summary panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241211110818
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241211110818
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241211110818
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12533-8^CAH^LN|||N|||F|||20241211110818
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241211110818
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\CAH: An immediate referral to a CCS endocrine center or pediatric endocrinologist, for evaluation and additional testing, is strongly recommended. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Screen for CAH based on 17-OH P level and a steroid ratio level. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241211110818
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241211110818
OBR|3|7302692465^FormNumber||57717-1^Newborn screen card data panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241211110818
OBX|2|NM|8339-4^Birthweight^LN|1|2722|grams||N|||F|||20241211110818
OBX|3|TM|57715-5^Time of birth^LN|1|1336|||N|||F|||20241211110818
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241211110818
OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241211110818
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241211110818
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241211110818
OBX|8|TX|^^^99717-5^Accession Number^L|1|346-10-795/21-2024-21|||N|||F|||20241211110818
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MARVIN ZAGULI|||N|||F|||20241211110818
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|W 025TS HT71 , C # SAN DIEGO CA 99999-9999 USA|||N|||F|||20241211110818
OBR|4|7302692465^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBR|5|7302692465^FormNumber||53261-4^Amino acid newborn screen panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241211110818
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|�mol/L|<1000|N|||F|||20241211110818
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|�mol/L||N|||F|||20241211110818
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241211110818
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|�mol/L|<230|N|||F|||20241211110818
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241211110818
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|�mol/L|<175|N|||F|||20241211110818
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241211110818
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|�mol/L|<680|N|||F|||20241211110818
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|�mol/L|<6.1|N|||F|||20241211110818
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|�mol/L|6.3-100|N|||F|||20241211110818
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|�mol/L|5-49|N|||F|||20241211110818
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241211110818
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|�mol/L|<800|N|||F|||20241211110818
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241211110818
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|�mol/L|<63|N|||F|||20241211110818
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241211110818
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|�mol/L|<1500|N|||F|||20241211110818
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|6|7302692465^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|7|7302692465^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|�mol/L|6.4-125|N|||F|||20241211110818
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241211110818
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|�mol/L|10-80|N|||F|||20241211110818
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241211110818
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|�mol/L|<0.95|N|||F|||20241211110818
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|�mol/L|<0.45|N|||F|||20241211110818
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241211110818
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|�mol/L|<0.65|N|||F|||20241211110818
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|�mol/L|<0.65|N|||F|||20241211110818
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|�mol/L|<0.45|N|||F|||20241211110818
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|�mol/L|<2|N|||F|||20241211110818
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|�mol/L||N|||F|||20241211110818
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|�mol/L|<1.2|N|||F|||20241211110818
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|�mol/L|<0.9|N|||F|||20241211110818
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241211110818
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|�mol/L||N|||F|||20241211110818
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|�mol/L|<0.2|N|||F|||20241211110818
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|�mol/L|<12|N|||F|||20241211110818
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|�mol/L|<1.4|N|||F|||20241211110818
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241211110818
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241211110818
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|�mol/L|<3.5|N|||F|||20241211110818
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|�mol/L|<7|N|||F|||20241211110818
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|�mol/L||N|||F|||20241211110818
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241211110818
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|�mol/L|<0.1|N|||F|||20241211110818
OBR|8|7302692465^FormNumber||57085-3^Organic acid newborn screen panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|�mol/L|<7.9|N|||F|||20241211110818
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241211110818
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|�mol/L|<0.48|N|||F|||20241211110818
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|�mol/L|<1.7|N|||F|||20241211110818
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|�mol/L|<0.95|N|||F|||20241211110818
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241211110818
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|�mol/L|<0.5|N|||F|||20241211110818
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|�mol/L|<1.15|N|||F|||20241211110818
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|�mol/L|<0.38|N|||F|||20241211110818
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241211110818
OBR|9|7302692465^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241211110818
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|10|7302692465^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|0065.88|nmol/L|<85|N|||F|||20241211110818
OBX|2|NM|^^^99717-6^17-Hydroxyprogesterone (CAH II)^L|1|39|nmol/L|<38|H|||F|||20241211110818
OBX|3|NM|53343-0^Androstenedione^LN|1|40.15|nmol/L||N|||F|||20241211110818
OBX|4|NM|53345-5^Cortisol^LN|1|85|nmol/L||N|||F|||20241211110818
OBX|5|NM|53336-4^17-Hydroxyprogesterone+Androstenedione/Cortisol^LN|1|0.93|{Ratio}|<1|N|||F|||20241211110818
OBX|6|NM|53341-4^21-Deoxycortisol [Mass/volume] in Dried blood spot^LN|1|90.9|nmol/L|<5|H|||F|||20241211110818
OBX|7|NM|53347-1^11-Deoxycorticosterone [Mass/volume] in Dried blood spot^LN|1|590|nmol/L|<240|H|||F|||20241211110818
OBX|8|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241211110818
OBX|9|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241211110818
OBR|11|7302692465^FormNumber||54090-6^Thyroid newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241211110818
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|12|7302692465^FormNumber||54079-9^Galactosemia newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241211110818
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|13|7302692465^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241211110818
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.�These results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241211110818
OBR|14|7302692465^FormNumber||57087-9^Biotinidase newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241211110818
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|15|7302692465^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/�L|>18|N|||F|||20241211110818
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|16|7302692465^FormNumber||63414-7^Pompe Disease newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|�mol/L/h|>=18.2|N|||F|||20241211110818
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|17|7302692465^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|�mol/L/h|>=18.2|N|||F|||20241211110818
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|18|7302692465^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241211110818
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241211110818
OBR|19|7302692465^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|�mol/L/h|>=2.06|N|||F|||20241211110818
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|20|7302692465^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|21|7302692465^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|�mol/L|<=3|N|||F|||20241211110818
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|�mol/L||N|||F|||20241211110818
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241211110818
OBR|22|7302692465^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241211110818
OBR|23|7302692465^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|�mol/L|<0.47|N|||F|||20241211110818
+MSH|^~\&|GOLDEN-COPY|SISGDSP|SISHIERECEIVER^11903029^L,M,N|^automated-staging-test-receiver-id^L,M,N|20241211110818||ORU^R01^ORU_R01|010|N|2.5.1
PID|1||80015980^^^&NPI^MR||HIPPO^BOY A ALLIE^^^^^B||202412091336|M||2106-3^White||||||||||||2186-5^Not Hispanic or Latino||Y|1
NK1|1|HIPPO^ALLIE|MTH^Mother|518 BIG BEN WAY^^OCEANSIDE^CA^92058^USA|^^^^^442^2885325|||||||||||19941209
ORC|RE|7302692465^FormNumber||189728187^HospOrdNumber||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI|||||||||UC SAN DIEGO MEDICAL CENTER^^^^^^^^^R508|W 025TS HT71 , C #^^SAN DIEGO^CA^99999-9999
OBR|1|7302692465^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBR|2|7302692465^FormNumber||57128-1^Newborn Screening Report summary panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241211110818
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241211110818
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241211110818
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12533-8^CAH^LN|||N|||F|||20241211110818
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241211110818
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\CAH: An immediate referral to a CCS endocrine center or pediatric endocrinologist, for evaluation and additional testing, is strongly recommended. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Screen for CAH based on 17-OH P level and a steroid ratio level. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241211110818
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241211110818
OBR|3|7302692465^FormNumber||57717-1^Newborn screen card data panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241211110818
OBX|2|NM|8339-4^Birthweight^LN|1|2722|grams||N|||F|||20241211110818
OBX|3|TM|57715-5^Time of birth^LN|1|1336|||N|||F|||20241211110818
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241211110818
OBX|5|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241211110818
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241211110818
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241211110818
OBX|8|TX|^^^99717-5^Accession Number^L|1|346-10-795/21-2024-21|||N|||F|||20241211110818
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MARVIN ZAGULI|||N|||F|||20241211110818
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|W 025TS HT71 , C # SAN DIEGO CA 99999-9999 USA|||N|||F|||20241211110818
OBR|4|7302692465^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBR|5|7302692465^FormNumber||53261-4^Amino acid newborn screen panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241211110818
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241211110818
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241211110818
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241211110818
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241211110818
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241211110818
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241211110818
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241211110818
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241211110818
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241211110818
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241211110818
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20241211110818
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241211110818
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241211110818
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241211110818
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241211110818
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241211110818
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241211110818
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|6|7302692465^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|7|7302692465^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241211110818
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241211110818
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241211110818
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241211110818
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241211110818
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241211110818
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241211110818
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241211110818
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241211110818
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241211110818
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241211110818
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241211110818
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241211110818
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241211110818
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241211110818
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241211110818
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241211110818
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241211110818
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241211110818
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241211110818
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241211110818
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241211110818
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241211110818
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241211110818
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241211110818
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241211110818
OBR|8|7302692465^FormNumber||57085-3^Organic acid newborn screen panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241211110818
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241211110818
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241211110818
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241211110818
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241211110818
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241211110818
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241211110818
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241211110818
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241211110818
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241211110818
OBR|9|7302692465^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241211110818
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|10|7302692465^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|0065.88|nmol/L|<85|N|||F|||20241211110818
OBX|2|NM|^^^99717-6^17-Hydroxyprogesterone (CAH II)^L|1|39|nmol/L|<38|H|||F|||20241211110818
OBX|3|NM|53343-0^Androstenedione^LN|1|40.15|nmol/L||N|||F|||20241211110818
OBX|4|NM|53345-5^Cortisol^LN|1|85|nmol/L||N|||F|||20241211110818
OBX|5|NM|53336-4^17-Hydroxyprogesterone+Androstenedione/Cortisol^LN|1|0.93|{Ratio}|<1|N|||F|||20241211110818
OBX|6|NM|53341-4^21-Deoxycortisol [Mass/volume] in Dried blood spot^LN|1|90.9|nmol/L|<5|H|||F|||20241211110818
OBX|7|NM|53347-1^11-Deoxycorticosterone [Mass/volume] in Dried blood spot^LN|1|590|nmol/L|<240|H|||F|||20241211110818
OBX|8|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241211110818
OBX|9|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241211110818
OBR|11|7302692465^FormNumber||54090-6^Thyroid newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241211110818
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|12|7302692465^FormNumber||54079-9^Galactosemia newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241211110818
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|13|7302692465^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241211110818
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241211110818
OBR|14|7302692465^FormNumber||57087-9^Biotinidase newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241211110818
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|15|7302692465^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/µL|>18|N|||F|||20241211110818
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|16|7302692465^FormNumber||63414-7^Pompe Disease newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|µmol/L/h|>=18.2|N|||F|||20241211110818
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|17|7302692465^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241211110818
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|18|7302692465^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241211110818
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241211110818
OBR|19|7302692465^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241211110818
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|20|7302692465^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241211110818
OBR|21|7302692465^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20241211110818
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20241211110818
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241211110818
OBR|22|7302692465^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241211110818
OBR|23|7302692465^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202412101409|||||||||^JOHNSON^KATHRYN||||||20241211110818|||F
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241211110818

From 870cfdb4a75f1203a84c9329e0339c183661aa3a Mon Sep 17 00:00:00 2001
From: James Herr <jherr@flexion.us>
Date: Fri, 27 Dec 2024 11:27:24 -0600
Subject: [PATCH 56/61] Updated readme with env variable steps

Co-Authored-By: Bella L. Quintero <96704946+pluckyswan@users.noreply.github.com>
Co-Authored-By: Jeremy Rosenfeld <10262289+JeremyIR@users.noreply.github.com>
Co-Authored-By: Basilio Bogado <541149+basiliskus@users.noreply.github.com>
---
 .../{ => Assertion}/011_ORM_R01_nte_segment_mapping.hl7      | 0
 examples/Test/Automated/GoldenCopy/README.md                 | 5 +++++
 generate_env.sh                                              | 3 ++-
 3 files changed, 7 insertions(+), 1 deletion(-)
 rename examples/Test/Automated/{ => Assertion}/011_ORM_R01_nte_segment_mapping.hl7 (100%)

diff --git a/examples/Test/Automated/011_ORM_R01_nte_segment_mapping.hl7 b/examples/Test/Automated/Assertion/011_ORM_R01_nte_segment_mapping.hl7
similarity index 100%
rename from examples/Test/Automated/011_ORM_R01_nte_segment_mapping.hl7
rename to examples/Test/Automated/Assertion/011_ORM_R01_nte_segment_mapping.hl7
diff --git a/examples/Test/Automated/GoldenCopy/README.md b/examples/Test/Automated/GoldenCopy/README.md
index b6ea68a26..afbb225af 100644
--- a/examples/Test/Automated/GoldenCopy/README.md
+++ b/examples/Test/Automated/GoldenCopy/README.md
@@ -17,3 +17,8 @@ The files are required to:
     - We format `MSH-10` based on the file index, like `001` (or `AUTOMATEDTEST-001` for UCSD)
 - `MSH-11` needs to have a value of `N`
 - `MSH-3` needs to be `GOLDEN-COPY`
+
+Setup Environment Variable:
+- In generate_env.sh:
+  - Change `LOCAL_FILE_PATH` to actual /Input path
+  - Run generate_env.sh
diff --git a/generate_env.sh b/generate_env.sh
index eb06adac8..648a08a61 100755
--- a/generate_env.sh
+++ b/generate_env.sh
@@ -14,7 +14,8 @@ DB_PORT=5433      # if you run TI via docker: DB_PORT=5432
 DB_NAME=intermediary
 DB_USER=intermediary
 DB_PASS=changeIT!
-DB_SSL=require"
+DB_SSL=require
+LOCAL_FILE_PATH=~/trusted-intermediary/examples/Test/Automated/Assertion"
 
 # Get directory of script file
 script_dir="$(dirname "$0")"

From 4412f6ea2e8211592f0aabea74a2175c4d276317 Mon Sep 17 00:00:00 2001
From: James Herr <jherr@flexion.us>
Date: Fri, 27 Dec 2024 11:27:44 -0600
Subject: [PATCH 57/61] Added pull_request to the workflow

Co-Authored-By: Bella L. Quintero <96704946+pluckyswan@users.noreply.github.com>
Co-Authored-By: Jeremy Rosenfeld <10262289+JeremyIR@users.noreply.github.com>
Co-Authored-By: Basilio Bogado <541149+basiliskus@users.noreply.github.com>
---
 .github/workflows/golden-copy-staging-test-run.yml | 1 +
 1 file changed, 1 insertion(+)

diff --git a/.github/workflows/golden-copy-staging-test-run.yml b/.github/workflows/golden-copy-staging-test-run.yml
index c1f079196..934215027 100644
--- a/.github/workflows/golden-copy-staging-test-run.yml
+++ b/.github/workflows/golden-copy-staging-test-run.yml
@@ -1,6 +1,7 @@
 name: Golden Copy Staging Test - Run integration tests
 
 on:
+  pull_request:
   schedule:
     - cron: "10 7 * * 2-6"  # Tuesday to Saturday at 2am EST (7:10am UTC) - two hours after `automated-staging-test-submit` runs
   workflow_dispatch:

From 59f0c1ad24f78f769c68c7a73dde48f324d9be23 Mon Sep 17 00:00:00 2001
From: James Herr <jherr@flexion.us>
Date: Fri, 27 Dec 2024 11:39:09 -0600
Subject: [PATCH 58/61] Temp testing

Co-Authored-By: Bella L. Quintero <96704946+pluckyswan@users.noreply.github.com>
Co-Authored-By: Jeremy Rosenfeld <10262289+JeremyIR@users.noreply.github.com>
Co-Authored-By: Basilio Bogado <541149+basiliskus@users.noreply.github.com>
---
 .../001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7          | 0
 .../002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7          | 0
 .../003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7           | 0
 .../004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7           | 0
 .../005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7          | 0
 .../006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7          | 0
 .../007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7 | 0
 .../008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7       | 0
 ...9_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7 | 0
 .../010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7        | 0
 .../011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7        | 0
 .../001_Staging_ORM_O01_short_linked_to_002_ORU.hl7               | 0
 .../002_Staging_ORU_O01_short_linked_to_001_ORM.hl7               | 0
 .../Assertion => temp}/003_CA_ORU_R01_CDPH_produced.hl7           | 0
 .../Assertion => temp}/004_CA_ORU_R01_leading_zeroes.hl7          | 0
 .../Assertion => temp}/005_CA_ORU_R01_no_leading_zeroes.hl7       | 0
 .../Test/{Automated/Assertion => temp}/006_CA_ORU_R01_LOINC.hl7   | 0
 .../Test/{Automated/Assertion => temp}/007_CA_ORU_R01_PLT.hl7     | 0
 .../Assertion => temp}/008_ORU_R01_micro_character_encoding.hl7   | 0
 .../Assertion => temp}/009_CA_ORU_R01_remove_99717-5_OBX.hl7      | 0
 .../010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7        | 0
 .../Assertion => temp}/011_ORM_R01_nte_segment_mapping.hl7        | 0
 22 files changed, 0 insertions(+), 0 deletions(-)
 rename examples/Test/Automated/{GoldenCopy/Input => Assertion}/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7 (100%)
 rename examples/Test/Automated/{GoldenCopy/Input => Assertion}/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7 (100%)
 rename examples/Test/Automated/{GoldenCopy/Input => Assertion}/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7 (100%)
 rename examples/Test/Automated/{GoldenCopy/Input => Assertion}/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7 (100%)
 rename examples/Test/Automated/{GoldenCopy/Input => Assertion}/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7 (100%)
 rename examples/Test/Automated/{GoldenCopy/Input => Assertion}/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7 (100%)
 rename examples/Test/Automated/{GoldenCopy/Input => Assertion}/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7 (100%)
 rename examples/Test/Automated/{GoldenCopy/Input => Assertion}/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7 (100%)
 rename examples/Test/Automated/{GoldenCopy/Input => Assertion}/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7 (100%)
 rename examples/Test/Automated/{GoldenCopy/Input => Assertion}/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7 (100%)
 rename examples/Test/Automated/{GoldenCopy/Input => Assertion}/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7 (100%)
 rename examples/Test/{Automated/Assertion => temp}/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7 (100%)
 rename examples/Test/{Automated/Assertion => temp}/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7 (100%)
 rename examples/Test/{Automated/Assertion => temp}/003_CA_ORU_R01_CDPH_produced.hl7 (100%)
 rename examples/Test/{Automated/Assertion => temp}/004_CA_ORU_R01_leading_zeroes.hl7 (100%)
 rename examples/Test/{Automated/Assertion => temp}/005_CA_ORU_R01_no_leading_zeroes.hl7 (100%)
 rename examples/Test/{Automated/Assertion => temp}/006_CA_ORU_R01_LOINC.hl7 (100%)
 rename examples/Test/{Automated/Assertion => temp}/007_CA_ORU_R01_PLT.hl7 (100%)
 rename examples/Test/{Automated/Assertion => temp}/008_ORU_R01_micro_character_encoding.hl7 (100%)
 rename examples/Test/{Automated/Assertion => temp}/009_CA_ORU_R01_remove_99717-5_OBX.hl7 (100%)
 rename examples/Test/{Automated/Assertion => temp}/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7 (100%)
 rename examples/Test/{Automated/Assertion => temp}/011_ORM_R01_nte_segment_mapping.hl7 (100%)

diff --git a/examples/Test/Automated/GoldenCopy/Input/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7 b/examples/Test/Automated/Assertion/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
similarity index 100%
rename from examples/Test/Automated/GoldenCopy/Input/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
rename to examples/Test/Automated/Assertion/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
diff --git a/examples/Test/Automated/GoldenCopy/Input/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7 b/examples/Test/Automated/Assertion/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7
similarity index 100%
rename from examples/Test/Automated/GoldenCopy/Input/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7
rename to examples/Test/Automated/Assertion/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7
diff --git a/examples/Test/Automated/GoldenCopy/Input/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7 b/examples/Test/Automated/Assertion/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7
similarity index 100%
rename from examples/Test/Automated/GoldenCopy/Input/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7
rename to examples/Test/Automated/Assertion/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7
diff --git a/examples/Test/Automated/GoldenCopy/Input/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7 b/examples/Test/Automated/Assertion/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7
similarity index 100%
rename from examples/Test/Automated/GoldenCopy/Input/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7
rename to examples/Test/Automated/Assertion/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7
diff --git a/examples/Test/Automated/GoldenCopy/Input/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7 b/examples/Test/Automated/Assertion/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7
similarity index 100%
rename from examples/Test/Automated/GoldenCopy/Input/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7
rename to examples/Test/Automated/Assertion/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7
diff --git a/examples/Test/Automated/GoldenCopy/Input/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7 b/examples/Test/Automated/Assertion/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7
similarity index 100%
rename from examples/Test/Automated/GoldenCopy/Input/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7
rename to examples/Test/Automated/Assertion/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7
diff --git a/examples/Test/Automated/GoldenCopy/Input/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7 b/examples/Test/Automated/Assertion/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7
similarity index 100%
rename from examples/Test/Automated/GoldenCopy/Input/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7
rename to examples/Test/Automated/Assertion/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7
diff --git a/examples/Test/Automated/GoldenCopy/Input/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7 b/examples/Test/Automated/Assertion/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7
similarity index 100%
rename from examples/Test/Automated/GoldenCopy/Input/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7
rename to examples/Test/Automated/Assertion/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7
diff --git a/examples/Test/Automated/GoldenCopy/Input/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7 b/examples/Test/Automated/Assertion/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7
similarity index 100%
rename from examples/Test/Automated/GoldenCopy/Input/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7
rename to examples/Test/Automated/Assertion/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7
diff --git a/examples/Test/Automated/GoldenCopy/Input/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7 b/examples/Test/Automated/Assertion/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7
similarity index 100%
rename from examples/Test/Automated/GoldenCopy/Input/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7
rename to examples/Test/Automated/Assertion/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7
diff --git a/examples/Test/Automated/GoldenCopy/Input/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7 b/examples/Test/Automated/Assertion/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7
similarity index 100%
rename from examples/Test/Automated/GoldenCopy/Input/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7
rename to examples/Test/Automated/Assertion/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7
diff --git a/examples/Test/Automated/Assertion/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7 b/examples/Test/temp/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7
rename to examples/Test/temp/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7
diff --git a/examples/Test/Automated/Assertion/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7 b/examples/Test/temp/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7
rename to examples/Test/temp/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7
diff --git a/examples/Test/Automated/Assertion/003_CA_ORU_R01_CDPH_produced.hl7 b/examples/Test/temp/003_CA_ORU_R01_CDPH_produced.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/003_CA_ORU_R01_CDPH_produced.hl7
rename to examples/Test/temp/003_CA_ORU_R01_CDPH_produced.hl7
diff --git a/examples/Test/Automated/Assertion/004_CA_ORU_R01_leading_zeroes.hl7 b/examples/Test/temp/004_CA_ORU_R01_leading_zeroes.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/004_CA_ORU_R01_leading_zeroes.hl7
rename to examples/Test/temp/004_CA_ORU_R01_leading_zeroes.hl7
diff --git a/examples/Test/Automated/Assertion/005_CA_ORU_R01_no_leading_zeroes.hl7 b/examples/Test/temp/005_CA_ORU_R01_no_leading_zeroes.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/005_CA_ORU_R01_no_leading_zeroes.hl7
rename to examples/Test/temp/005_CA_ORU_R01_no_leading_zeroes.hl7
diff --git a/examples/Test/Automated/Assertion/006_CA_ORU_R01_LOINC.hl7 b/examples/Test/temp/006_CA_ORU_R01_LOINC.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/006_CA_ORU_R01_LOINC.hl7
rename to examples/Test/temp/006_CA_ORU_R01_LOINC.hl7
diff --git a/examples/Test/Automated/Assertion/007_CA_ORU_R01_PLT.hl7 b/examples/Test/temp/007_CA_ORU_R01_PLT.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/007_CA_ORU_R01_PLT.hl7
rename to examples/Test/temp/007_CA_ORU_R01_PLT.hl7
diff --git a/examples/Test/Automated/Assertion/008_ORU_R01_micro_character_encoding.hl7 b/examples/Test/temp/008_ORU_R01_micro_character_encoding.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/008_ORU_R01_micro_character_encoding.hl7
rename to examples/Test/temp/008_ORU_R01_micro_character_encoding.hl7
diff --git a/examples/Test/Automated/Assertion/009_CA_ORU_R01_remove_99717-5_OBX.hl7 b/examples/Test/temp/009_CA_ORU_R01_remove_99717-5_OBX.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/009_CA_ORU_R01_remove_99717-5_OBX.hl7
rename to examples/Test/temp/009_CA_ORU_R01_remove_99717-5_OBX.hl7
diff --git a/examples/Test/Automated/Assertion/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7 b/examples/Test/temp/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7
rename to examples/Test/temp/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7
diff --git a/examples/Test/Automated/Assertion/011_ORM_R01_nte_segment_mapping.hl7 b/examples/Test/temp/011_ORM_R01_nte_segment_mapping.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/011_ORM_R01_nte_segment_mapping.hl7
rename to examples/Test/temp/011_ORM_R01_nte_segment_mapping.hl7

From 8e9b06905fdf262728a00d1e5878b5ec28203056 Mon Sep 17 00:00:00 2001
From: James Herr <jherr@flexion.us>
Date: Fri, 27 Dec 2024 12:45:44 -0600
Subject: [PATCH 59/61] Added expected files for testing

Co-Authored-By: Bella L. Quintero <96704946+pluckyswan@users.noreply.github.com>
Co-Authored-By: Luis Pabon <2624105+luis-pabon-tf@users.noreply.github.com>
Co-Authored-By: Jeremy Rosenfeld <10262289+JeremyIR@users.noreply.github.com>
Co-Authored-By: Basilio Bogado <541149+basiliskus@users.noreply.github.com>
---
 .../Assertion}/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7   | 0
 .../Assertion}/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7   | 0
 .../Assertion}/003_CA_ORU_R01_CDPH_produced.hl7                  | 0
 .../Assertion}/004_CA_ORU_R01_leading_zeroes.hl7                 | 0
 .../Assertion}/005_CA_ORU_R01_no_leading_zeroes.hl7              | 0
 .../Test/{temp => Automated/Assertion}/006_CA_ORU_R01_LOINC.hl7  | 0
 .../Test/{temp => Automated/Assertion}/007_CA_ORU_R01_PLT.hl7    | 0
 .../Assertion}/008_ORU_R01_micro_character_encoding.hl7          | 0
 .../Assertion}/009_CA_ORU_R01_remove_99717-5_OBX.hl7             | 0
 .../010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7       | 0
 .../Assertion}/011_ORM_R01_nte_segment_mapping.hl7               | 0
 .../001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7         | 1 +
 .../002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7         | 1 +
 .../Expected/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7 | 1 +
 .../Expected/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7 | 1 +
 .../005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7         | 1 +
 .../006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7         | 1 +
 ...007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7 | 1 +
 .../008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7      | 1 +
 ..._CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7 | 1 +
 .../010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7       | 1 +
 .../011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7       | 1 +
 .../Input}/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7  | 0
 .../Input}/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7  | 0
 .../Input}/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7   | 0
 .../Input}/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7   | 0
 .../Input}/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7  | 0
 .../Input}/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7  | 0
 ...007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7 | 0
 .../008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7      | 0
 ..._CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7 | 0
 .../010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7       | 0
 .../011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7       | 0
 33 files changed, 11 insertions(+)
 rename examples/Test/{temp => Automated/Assertion}/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7 (100%)
 rename examples/Test/{temp => Automated/Assertion}/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7 (100%)
 rename examples/Test/{temp => Automated/Assertion}/003_CA_ORU_R01_CDPH_produced.hl7 (100%)
 rename examples/Test/{temp => Automated/Assertion}/004_CA_ORU_R01_leading_zeroes.hl7 (100%)
 rename examples/Test/{temp => Automated/Assertion}/005_CA_ORU_R01_no_leading_zeroes.hl7 (100%)
 rename examples/Test/{temp => Automated/Assertion}/006_CA_ORU_R01_LOINC.hl7 (100%)
 rename examples/Test/{temp => Automated/Assertion}/007_CA_ORU_R01_PLT.hl7 (100%)
 rename examples/Test/{temp => Automated/Assertion}/008_ORU_R01_micro_character_encoding.hl7 (100%)
 rename examples/Test/{temp => Automated/Assertion}/009_CA_ORU_R01_remove_99717-5_OBX.hl7 (100%)
 rename examples/Test/{temp => Automated/Assertion}/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7 (100%)
 rename examples/Test/{temp => Automated/Assertion}/011_ORM_R01_nte_segment_mapping.hl7 (100%)
 create mode 100644 examples/Test/Automated/GoldenCopy/Expected/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Expected/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Expected/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Expected/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Expected/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Expected/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Expected/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Expected/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Expected/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Expected/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7
 create mode 100644 examples/Test/Automated/GoldenCopy/Expected/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7
 rename examples/Test/Automated/{Assertion => GoldenCopy/Input}/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7 (100%)
 rename examples/Test/Automated/{Assertion => GoldenCopy/Input}/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7 (100%)
 rename examples/Test/Automated/{Assertion => GoldenCopy/Input}/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7 (100%)
 rename examples/Test/Automated/{Assertion => GoldenCopy/Input}/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7 (100%)
 rename examples/Test/Automated/{Assertion => GoldenCopy/Input}/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7 (100%)
 rename examples/Test/Automated/{Assertion => GoldenCopy/Input}/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7 (100%)
 rename examples/Test/Automated/{Assertion => GoldenCopy/Input}/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7 (100%)
 rename examples/Test/Automated/{Assertion => GoldenCopy/Input}/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7 (100%)
 rename examples/Test/Automated/{Assertion => GoldenCopy/Input}/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7 (100%)
 rename examples/Test/Automated/{Assertion => GoldenCopy/Input}/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7 (100%)
 rename examples/Test/Automated/{Assertion => GoldenCopy/Input}/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7 (100%)

diff --git a/examples/Test/temp/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7 b/examples/Test/Automated/Assertion/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7
similarity index 100%
rename from examples/Test/temp/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7
rename to examples/Test/Automated/Assertion/001_Staging_ORM_O01_short_linked_to_002_ORU.hl7
diff --git a/examples/Test/temp/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7 b/examples/Test/Automated/Assertion/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7
similarity index 100%
rename from examples/Test/temp/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7
rename to examples/Test/Automated/Assertion/002_Staging_ORU_O01_short_linked_to_001_ORM.hl7
diff --git a/examples/Test/temp/003_CA_ORU_R01_CDPH_produced.hl7 b/examples/Test/Automated/Assertion/003_CA_ORU_R01_CDPH_produced.hl7
similarity index 100%
rename from examples/Test/temp/003_CA_ORU_R01_CDPH_produced.hl7
rename to examples/Test/Automated/Assertion/003_CA_ORU_R01_CDPH_produced.hl7
diff --git a/examples/Test/temp/004_CA_ORU_R01_leading_zeroes.hl7 b/examples/Test/Automated/Assertion/004_CA_ORU_R01_leading_zeroes.hl7
similarity index 100%
rename from examples/Test/temp/004_CA_ORU_R01_leading_zeroes.hl7
rename to examples/Test/Automated/Assertion/004_CA_ORU_R01_leading_zeroes.hl7
diff --git a/examples/Test/temp/005_CA_ORU_R01_no_leading_zeroes.hl7 b/examples/Test/Automated/Assertion/005_CA_ORU_R01_no_leading_zeroes.hl7
similarity index 100%
rename from examples/Test/temp/005_CA_ORU_R01_no_leading_zeroes.hl7
rename to examples/Test/Automated/Assertion/005_CA_ORU_R01_no_leading_zeroes.hl7
diff --git a/examples/Test/temp/006_CA_ORU_R01_LOINC.hl7 b/examples/Test/Automated/Assertion/006_CA_ORU_R01_LOINC.hl7
similarity index 100%
rename from examples/Test/temp/006_CA_ORU_R01_LOINC.hl7
rename to examples/Test/Automated/Assertion/006_CA_ORU_R01_LOINC.hl7
diff --git a/examples/Test/temp/007_CA_ORU_R01_PLT.hl7 b/examples/Test/Automated/Assertion/007_CA_ORU_R01_PLT.hl7
similarity index 100%
rename from examples/Test/temp/007_CA_ORU_R01_PLT.hl7
rename to examples/Test/Automated/Assertion/007_CA_ORU_R01_PLT.hl7
diff --git a/examples/Test/temp/008_ORU_R01_micro_character_encoding.hl7 b/examples/Test/Automated/Assertion/008_ORU_R01_micro_character_encoding.hl7
similarity index 100%
rename from examples/Test/temp/008_ORU_R01_micro_character_encoding.hl7
rename to examples/Test/Automated/Assertion/008_ORU_R01_micro_character_encoding.hl7
diff --git a/examples/Test/temp/009_CA_ORU_R01_remove_99717-5_OBX.hl7 b/examples/Test/Automated/Assertion/009_CA_ORU_R01_remove_99717-5_OBX.hl7
similarity index 100%
rename from examples/Test/temp/009_CA_ORU_R01_remove_99717-5_OBX.hl7
rename to examples/Test/Automated/Assertion/009_CA_ORU_R01_remove_99717-5_OBX.hl7
diff --git a/examples/Test/temp/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7 b/examples/Test/Automated/Assertion/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7
similarity index 100%
rename from examples/Test/temp/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7
rename to examples/Test/Automated/Assertion/010_LA_ORU_R01_NBS_0_initial_obr_flatten_example_1.hl7
diff --git a/examples/Test/temp/011_ORM_R01_nte_segment_mapping.hl7 b/examples/Test/Automated/Assertion/011_ORM_R01_nte_segment_mapping.hl7
similarity index 100%
rename from examples/Test/temp/011_ORM_R01_nte_segment_mapping.hl7
rename to examples/Test/Automated/Assertion/011_ORM_R01_nte_segment_mapping.hl7
diff --git a/examples/Test/Automated/GoldenCopy/Expected/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7 b/examples/Test/Automated/GoldenCopy/Expected/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
new file mode 100644
index 000000000..050386ea7
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Expected/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|CDPH|EPIC|R797|20241015054631||ORU^R01|001|N|2.5.1
PID|1||80015867||CDPHTWO^GIRL  MOMTWO||202410071025|F||2076-8^Native Hawaiian or Other Pacific Islander||||||||||||2186-5^Not Hispanic or Latino||N|1
NK1|1|CDPHTWO^MOMTWO|MTH^Mother|2 SECOND ST^^SAN DIEGO^CA^92121^USA||||||||||||20000202
ORC|RE|189688314^HospOrdNumber||7371237714^FormNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|189688314^HospOrdNumber||54089-8^NB Screen Panel Patient AHIC^CDPHGSPEAP|||202410081133|||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI||||||20241015054631|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12427-3^Subsequent screen - for clarification of initial results (not by law or protocol)^LN|||N|||F|||20241015054631
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241015054631
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241015054631
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12543-7^GALT^LN|||N|||F|||20241015054631
OBX|5|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|2|LA12533-8^CAH^LN|||N|||F|||20241015054631
OBX|6|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA12566-8^SCID^LN|||N|||F|||20241015054631
OBX|7|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|2|LA14037-8^GAA^LN|||N|||F|||20241015054631
OBX|8|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\CAH: An immediate referral to a CCS endocrine center or pediatric endocrinologist, for evaluation and additional testing, is strongly recommended. \.br\\.br\Pompe: Another dried blood specimen MUST be collected for this child. Call your Newborn Screening Coordinator for assistance. \.br\\.br\SCID: Another dried blood specimen MUST be collected for this child. Call your Newborn Screening Coordinator for assistance. \.br\\.br\Galactosemia: Additional testing is required to rule out disorder.µCall your Newborn Screening Coordinator for assistance. \.br\\.br\ATTENTION: THIS CHILD HAS TESTED POSITIVE FOR MORE THAN ONE TEST. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241015054631
OBX|9|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241015054631
OBX|10|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241015054631
OBX|11|NM|8339-4^Birthweight^LN|1|3175|grams||N|||F|||20241015054631
OBX|12|TM|57715-5^Time of birth^LN|1|1025|||N|||F|||20241015054631
OBX|13|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241015054631
OBX|14|NM|73806-2^Newborn age in hours^LN|1|25|hour(s)||N|||F|||20241015054631
OBX|15|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241015054631
OBX|16|CE|67704-7^Feeding types^LN|1|LA4489-6^Unknown^LN|||N|||F|||20241015054631
OBX|17|TX|62324-9^Post-discharge provider name^LN|1|DENISE COYLE|||N|||F|||20241015054631
OBX|18|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241015054631
OBX|19|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|20|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241015054631
OBX|21|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|22|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241015054631
OBX|23|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241015054631
OBX|24|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241015054631
OBX|25|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241015054631
OBX|26|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241015054631
OBX|27|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241015054631
OBX|28|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241015054631
OBX|29|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241015054631
OBX|30|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20241015054631
OBX|31|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241015054631
OBX|32|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241015054631
OBX|33|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|34|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241015054631
OBX|35|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241015054631
OBX|36|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241015054631
OBX|37|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|38|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|39|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|40|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241015054631
OBX|41|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241015054631
OBX|42|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241015054631
OBX|43|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241015054631
OBX|44|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241015054631
OBX|45|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241015054631
OBX|46|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|47|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241015054631
OBX|48|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241015054631
OBX|49|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241015054631
OBX|50|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241015054631
OBX|51|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|52|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241015054631
OBX|53|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241015054631
OBX|54|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|55|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|56|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241015054631
OBX|57|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241015054631
OBX|58|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241015054631
OBX|59|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241015054631
OBX|60|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241015054631
OBX|61|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241015054631
OBX|62|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241015054631
OBX|63|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|64|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241015054631
OBX|65|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241015054631
OBX|66|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241015054631
OBX|67|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241015054631
OBX|68|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241015054631
OBX|69|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241015054631
OBX|70|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241015054631
OBX|71|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241015054631
OBX|72|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241015054631
OBX|73|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241015054631
OBX|74|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241015054631
OBX|75|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241015054631
OBX|76|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241015054631
OBX|77|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|78|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|79|NM|38473-5^17-Hydroxyprogesterone^LN|1|305|nmol/L|<85|H|||F|||20241015054631
OBX|80|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241015054631
OBX|81|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241015054631
OBX|82|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241015054631
OBX|83|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|84|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|85|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|48.00|enzyme units|>50|L|||F|||20241015054631
OBX|86|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241015054631
OBX|87|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241015054631
OBX|88|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241015054631
OBX|89|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241015054631
OBX|90|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241015054631
OBX|91|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|92|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|93|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|2|copies/µL|>18|L|||F|||20241015054631
OBX|94|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241015054631
OBX|95|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Incomplete|||A|||F|||20241015054631
OBX|96|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA16205-9^Specimen unsatisfactory for at least one condition^LN|||A|||F|||20241015054631
OBX|97|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Incomplete|||A|||F|||20241015054631
OBX|98|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241015054631
OBX|99|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|100|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|101|TX|PLT3293^SMN1 exon 7 deletion analysis in DBS by Sequencing^PLT^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241015054631
OBX|102|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|103|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241015054631
OBX|104|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241015054631
OBX|105|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|106|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|107|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|108|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|109|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20241015054631
OBX|110|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20241015054631
OBX|111|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241015054631
OBX|112|CE|85269-9^X-linked Adrenoleukodystrophy (X- ALD) newborn screen interpretation^LN^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|113|TX|85268-1^X-linked Adrenoleukodystrophy (X- ALD) newborn screening comment-discussion^LN^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241015054631
OBX|114|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241015054631
diff --git a/examples/Test/Automated/GoldenCopy/Expected/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7 b/examples/Test/Automated/GoldenCopy/Expected/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7
new file mode 100644
index 000000000..9cde52098
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Expected/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|CDPH|EPIC|R797|20241022024155||ORU^R01|002|N|2.5.1
PID|1||80015887||CDPHTHREE^BOY B MOMTHREE|||M||2131-1^Other Race||||||||||||UNK^Unknown||Y|2
NK1|1|CDPHTHREE^MOMTHREE|MTH^Mother|3 3RD ST^^SAN DIEGO^CA^92126^USA|^^^^^858^2490007|||||||||||20031007
ORC|RE|189693889^HospOrdNumber||7381238055^FormNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|189693889^HospOrdNumber||54089-8^NB Screen Panel Patient AHIC^CDPHGSPEAP|||202410161630|||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI||||||20241022024155|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241022024155
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241022024155
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241022024155
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA16207-5^Hemoglobinopathies^LN|||N|||F|||20241022024155
OBX|5|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|2|LA12537-9^CF^LN|||N|||F|||20241022024155
OBX|6|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241022024155
OBX|7|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Amino Acid Panel: There was insufficient data to determine whether or not this newborn was at least 12 hours old when this specimen was collected. Testing of amino acids at less than 12 hours of age is not reliable for detecting certain metabolic disorder. \.br\\.br\Hb: An immediate referral to a CCS Sickle Cell Disease/Hemoglobinopathies Center is strongly recommended. \.br\\.br\Cystic Fibrosis (CF): An immediate referral to a CCS approved Cystic Fibrosis Center for evaluation and additional testing is strongly recommended. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Screen for CF based on IRT and the California CFTR DNA mutation panel which consists of the following mutations: 1078delT, 1288insTA, 1677delTA, 1717-1G>A, 1812-1G>A, 1898+1G>A, 1898+5G>T, 2055del9>A, 2105-2117del13insAGAAA, 2143delT, 2183AA>G, 2184delA, 2307insA, 2789+5G>A, 2869insG, 3120+1G>A, 3120G>A, 3199del6, 3272-26A>G, 3659delC, 3791delC, 3849+10kbC>T, 3876delA, 3905insT, 394delTT, 405+3A>C, 406-1G>A, 444delA, 621+1G>T, 663delT, 711+1G>T, 935delA, A455E, A559T, CFTRdel2,3(21kb), delF311, delF508, delI507, E60X, G178R, G330X, G542X, G551D, G85E, H199Y, K710X, L206W, M1101K, N1303K, P205S, Q493X, Q890X, Q98R, R1066C, R1158X, R1162X, R117C, R334W, R347H, R347P, R352Q, R553X, R560T, R75X, S1196X, S1255X, S492F, S549N, S549R(T>G), V520F, W1089X, W1204X(3743G>A), W1204X(3744G>A), W1282X, Y1092X(C>A), Y1092X(C>G), Y122X. California CFTR Mutation Panel was run at Stanford Health Care, Molecular Pathology Laboratory, 3375 Hillview Avenue, Palo Alto, CA 94304. Directors: James Zehnder, MD; Christian Kunder, MD, PhD; Carlos J. Suarez, MD; (650) 723-6574. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241022024155
OBX|8|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241022024155
OBX|9|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241022024155
OBX|10|NM|8339-4^Birthweight^LN|1|2948|grams||N|||F|||20241022024155
OBX|11|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241022024155
OBX|12|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241022024155
OBX|13|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241022024155
OBX|14|TX|62324-9^Post-discharge provider name^LN|1|MICHELLE LEFF|||N|||F|||20241022024155
OBX|15|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241022024155
OBX|16|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241022024155
OBX|17|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241022024155
OBX|18|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241022024155
OBX|19|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241022024155
OBX|20|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241022024155
OBX|21|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241022024155
OBX|22|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241022024155
OBX|23|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241022024155
OBX|24|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241022024155
OBX|25|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241022024155
OBX|26|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241022024155
OBX|27|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20241022024155
OBX|28|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241022024155
OBX|29|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241022024155
OBX|30|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241022024155
OBX|31|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241022024155
OBX|32|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241022024155
OBX|33|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241022024155
OBX|34|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Collected Early. No Interpretation.|||A|||F|||20241022024155
OBX|35|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|36|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241022024155
OBX|37|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241022024155
OBX|38|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241022024155
OBX|39|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241022024155
OBX|40|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241022024155
OBX|41|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241022024155
OBX|42|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241022024155
OBX|43|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241022024155
OBX|44|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241022024155
OBX|45|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241022024155
OBX|46|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241022024155
OBX|47|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241022024155
OBX|48|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241022024155
OBX|49|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241022024155
OBX|50|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241022024155
OBX|51|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241022024155
OBX|52|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241022024155
OBX|53|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241022024155
OBX|54|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241022024155
OBX|55|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241022024155
OBX|56|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241022024155
OBX|57|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241022024155
OBX|58|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241022024155
OBX|59|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241022024155
OBX|60|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241022024155
OBX|61|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241022024155
OBX|62|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241022024155
OBX|63|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241022024155
OBX|64|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241022024155
OBX|65|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241022024155
OBX|66|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241022024155
OBX|67|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241022024155
OBX|68|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241022024155
OBX|69|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241022024155
OBX|70|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241022024155
OBX|71|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241022024155
OBX|72|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241022024155
OBX|73|NM|48633-2^Trypsinogen I.free^LN|1|72.00|ng/mL|<69|H|||F|||20241022024155
OBX|74|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241022024155
OBX|75|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Consistent with Cystic Fibrosis (delF508 and delI507 mutations)|||A|||F|||20241022024155
OBX|76|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241022024155
OBX|77|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|78|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBX|79|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241022024155
OBX|80|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|81|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBX|82|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241022024155
OBX|83|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|84|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBX|85|TX|54104-5^Hemoglobin pattern^LN|1|F||||||F|||20241022024155
OBX|86|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Consistent with Beta thalassemia major (Cooley's anemia).||||||F|||20241022024155
OBX|87|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241022024155
OBX|88|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|89|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBX|90|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/µL|>18|N|||F|||20241022024155
OBX|91|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|92|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBX|93|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|µmol/L/h|>=18.2|N|||F|||20241022024155
OBX|94|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|95|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241022024155
OBX|96|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241022024155
OBX|97|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|98|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBX|99|TX|PLT3293^SMN1 exon 7 deletion analysis in DBS by Sequencing^PLT^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241022024155
OBX|100|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|101|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241022024155
OBX|102|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241022024155
OBX|103|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|104|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241022024155
OBX|105|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|106|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241022024155
OBX|107|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20241022024155
OBX|108|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20241022024155
OBX|109|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241022024155
OBX|110|CE|85269-9^X-linked Adrenoleukodystrophy (X- ALD) newborn screen interpretation^LN^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241022024155
OBX|111|TX|85268-1^X-linked Adrenoleukodystrophy (X- ALD) newborn screening comment-discussion^LN^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241022024155
OBX|112|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241022024155
diff --git a/examples/Test/Automated/GoldenCopy/Expected/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7 b/examples/Test/Automated/GoldenCopy/Expected/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7
new file mode 100644
index 000000000..81044ec16
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Expected/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|CDPH|EPIC|R797|20240930011140||ORU^R01|003|N|2.5.1
PID|1||80009320||NEWBORNSCREEN^BOY  RED||202408150826|M||1002-5^American Indian or Alaska Native||||||||||||2186-5^Not Hispanic or Latino||N|1
NK1|1|NEWBORNSCREEN^RED|MTH^Mother|9560 TOWNE CENTRE DR^^SAN DIEGO^CA^92121-1972^USA|^^^^^619^1234567|||||||||||19850426
ORC|RE|189671588^HospOrdNumber||7341237093^FormNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|189671588^HospOrdNumber||54089-8^NB Screen Panel Patient AHIC^CDPHGSPEAP|||202409300941|||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI||||||20240930011140|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20240930011140
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20240930011140
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12428-1^All screening is in range for the conditions tested^LN|||N|||F|||20240930011140
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20240930011140
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20240930011140
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Acyl Carnitine Panel: Reference Ranges for acylcarnitines are based on specimens collected on newborns who are less than 10 days old. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20240930011140
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20240930011140
OBX|8|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20240930011140
OBX|9|NM|8339-4^Birthweight^LN|1|3084|grams||N|||F|||20240930011140
OBX|10|TM|57715-5^Time of birth^LN|1|0826|||N|||F|||20240930011140
OBX|11|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20240930011140
OBX|12|NM|73806-2^Newborn age in hours^LN|1|46|day(s)||N|||F|||20240930011140
OBX|13|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20240930011140
OBX|14|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20240930011140
OBX|15|TX|62324-9^Post-discharge provider name^LN|1|MARVIN ZAGULI|||N|||F|||20240930011140
OBX|16|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20240930011140
OBX|17|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20240930011140
OBX|18|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20240930011140
OBX|19|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20240930011140
OBX|20|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20240930011140
OBX|21|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20240930011140
OBX|22|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20240930011140
OBX|23|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20240930011140
OBX|24|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20240930011140
OBX|25|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20240930011140
OBX|26|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20240930011140
OBX|27|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20240930011140
OBX|28|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20240930011140
OBX|29|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20240930011140
OBX|30|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20240930011140
OBX|31|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20240930011140
OBX|32|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20240930011140
OBX|33|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20240930011140
OBX|34|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20240930011140
OBX|35|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20240930011140
OBX|36|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|37|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20240930011140
OBX|38|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20240930011140
OBX|39|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20240930011140
OBX|40|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20240930011140
OBX|41|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20240930011140
OBX|42|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20240930011140
OBX|43|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20240930011140
OBX|44|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20240930011140
OBX|45|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20240930011140
OBX|46|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20240930011140
OBX|47|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20240930011140
OBX|48|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20240930011140
OBX|49|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20240930011140
OBX|50|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20240930011140
OBX|51|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20240930011140
OBX|52|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20240930011140
OBX|53|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20240930011140
OBX|54|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20240930011140
OBX|55|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20240930011140
OBX|56|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20240930011140
OBX|57|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20240930011140
OBX|58|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20240930011140
OBX|59|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20240930011140
OBX|60|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20240930011140
OBX|61|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20240930011140
OBX|62|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20240930011140
OBX|63|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20240930011140
OBX|64|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20240930011140
OBX|65|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20240930011140
OBX|66|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20240930011140
OBX|67|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20240930011140
OBX|68|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20240930011140
OBX|69|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20240930011140
OBX|70|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20240930011140
OBX|71|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20240930011140
OBX|72|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20240930011140
OBX|73|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20240930011140
OBX|74|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20240930011140
OBX|75|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|76|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20240930011140
OBX|77|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20240930011140
OBX|78|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|79|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBX|80|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20240930011140
OBX|81|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|82|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBX|83|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20240930011140
OBX|84|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|85|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBX|86|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20240930011140
OBX|87|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20240930011140
OBX|88|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20240930011140
OBX|89|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|90|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBX|91|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/µL|>18|N|||F|||20240930011140
OBX|92|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|93|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBX|94|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|µmol/L/h|>=18.2|N|||F|||20240930011140
OBX|95|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|96|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20240930011140
OBX|97|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20240930011140
OBX|98|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|99|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBX|100|TX|PLT3293^SMN1 exon 7 deletion analysis in DBS by Sequencing^PLT^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20240930011140
OBX|101|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|102|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20240930011140
OBX|103|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20240930011140
OBX|104|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|105|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20240930011140
OBX|106|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|107|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20240930011140
OBX|108|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20240930011140
OBX|109|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20240930011140
OBX|110|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20240930011140
OBX|111|CE|85269-9^X-linked Adrenoleukodystrophy (X- ALD) newborn screen interpretation^LN^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20240930011140
OBX|112|TX|85268-1^X-linked Adrenoleukodystrophy (X- ALD) newborn screening comment-discussion^LN^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20240930011140
OBX|113|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20240930011140
diff --git a/examples/Test/Automated/GoldenCopy/Expected/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7 b/examples/Test/Automated/GoldenCopy/Expected/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7
new file mode 100644
index 000000000..979939e86
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Expected/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|CDPH|EPIC|R797|20241118050532||ORU^R01|004|N|2.5.1
PID|1||80015913||CDPHRESULT^GIRL C MARY||202410241550|F||2076-8^Native Hawaiian or Other Pacific Islander||||||||||||2186-5^Not Hispanic or Latino||Y|3
NK1|1|CDPHRESULT^MARY|MTH^Mother|123 ST^^SAN DIEGO^CA^92123^USA|^^^^^858^2490014|||||||||||19981024
ORC|RE|189700664^HospOrdNumber||7312693833^FormNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|189700664^HospOrdNumber||54089-8^NB Screen Panel Patient AHIC^CDPHGSPEAP|||202410251536|||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI||||||20241118050532|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241118050532
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241118050532
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA12428-1^All screening is in range for the conditions tested^LN|||N|||F|||20241118050532
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241118050532
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241118050532
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241118050532
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241118050532
OBX|8|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241118050532
OBX|9|NM|8339-4^Birthweight^LN|1|2722|grams||N|||F|||20241118050532
OBX|10|TM|57715-5^Time of birth^LN|1|1550|||N|||F|||20241118050532
OBX|11|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12413-3^Triplets^LN|||N|||F|||20241118050532
OBX|12|NM|73806-2^Newborn age in hours^LN|1|23|hour(s)||N|||F|||20241118050532
OBX|13|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241118050532
OBX|14|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241118050532
OBX|15|TX|62324-9^Post-discharge provider name^LN|1|MARVIN ZAGULI|||N|||F|||20241118050532
OBX|16|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241118050532
OBX|17|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241118050532
OBX|18|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241118050532
OBX|19|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241118050532
OBX|20|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241118050532
OBX|21|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241118050532
OBX|22|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241118050532
OBX|23|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241118050532
OBX|24|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241118050532
OBX|25|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241118050532
OBX|26|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241118050532
OBX|27|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241118050532
OBX|28|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20241118050532
OBX|29|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241118050532
OBX|30|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241118050532
OBX|31|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241118050532
OBX|32|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241118050532
OBX|33|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241118050532
OBX|34|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241118050532
OBX|35|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118050532
OBX|36|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|37|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118050532
OBX|38|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241118050532
OBX|39|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241118050532
OBX|40|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241118050532
OBX|41|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241118050532
OBX|42|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241118050532
OBX|43|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241118050532
OBX|44|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241118050532
OBX|45|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241118050532
OBX|46|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241118050532
OBX|47|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241118050532
OBX|48|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241118050532
OBX|49|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241118050532
OBX|50|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241118050532
OBX|51|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241118050532
OBX|52|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241118050532
OBX|53|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241118050532
OBX|54|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241118050532
OBX|55|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241118050532
OBX|56|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241118050532
OBX|57|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241118050532
OBX|58|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241118050532
OBX|59|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241118050532
OBX|60|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241118050532
OBX|61|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241118050532
OBX|62|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241118050532
OBX|63|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241118050532
OBX|64|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241118050532
OBX|65|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241118050532
OBX|66|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241118050532
OBX|67|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241118050532
OBX|68|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241118050532
OBX|69|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241118050532
OBX|70|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241118050532
OBX|71|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241118050532
OBX|72|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241118050532
OBX|73|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241118050532
OBX|74|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241118050532
OBX|75|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|76|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118050532
OBX|77|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241118050532
OBX|78|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|79|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBX|80|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241118050532
OBX|81|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|82|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBX|83|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241118050532
OBX|84|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|85|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBX|86|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241118050532
OBX|87|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241118050532
OBX|88|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241118050532
OBX|89|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|90|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBX|91|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/µL|>18|N|||F|||20241118050532
OBX|92|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|93|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBX|94|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|µmol/L/h|>=18.2|N|||F|||20241118050532
OBX|95|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|96|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241118050532
OBX|97|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241118050532
OBX|98|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|99|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBX|100|TX|PLT3293^SMN1 exon 7 deletion analysis in DBS by Sequencing^PLT^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241118050532
OBX|101|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|102|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241118050532
OBX|103|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241118050532
OBX|104|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|105|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118050532
OBX|106|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|107|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241118050532
OBX|108|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20241118050532
OBX|109|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20241118050532
OBX|110|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|2.93||<=10|N|||F|||20241118050532
OBX|111|CE|85269-9^X-linked Adrenoleukodystrophy (X- ALD) newborn screen interpretation^LN^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241118050532
OBX|112|TX|85268-1^X-linked Adrenoleukodystrophy (X- ALD) newborn screening comment-discussion^LN^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241118050532
OBX|113|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241118050532
diff --git a/examples/Test/Automated/GoldenCopy/Expected/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7 b/examples/Test/Automated/GoldenCopy/Expected/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7
new file mode 100644
index 000000000..7ffcdb97c
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Expected/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|CDPH|EPIC|R797|20241118030201||ORU^R01|005|N|2.5.1
PID|1||80015887||CDPHTHREE^BOY B MOMTHREE||202410161318|M||2131-1^Other Race||||||||||||UNK^Unknown||Y|2
NK1|1|CDPHTHREE^MOMTHREE|MTH^Mother|3 3RD ST^^SAN DIEGO^CA^92126^USA|^^^^^858^2490007|||||||||||20031007
ORC|RE|189693889^HospOrdNumber||7381238055^FormNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|189693889^HospOrdNumber||54089-8^NB Screen Panel Patient AHIC^CDPHGSPEAP|||202410161630|||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI||||||20241118030201|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241118030201
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241118030201
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241118030201
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241118030201
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241118030201
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Amino Acid Panel: An immediate referral to a CCS Metabolic Center is strongly recommended. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241118030201
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241118030201
OBX|8|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241118030201
OBX|9|NM|8339-4^Birthweight^LN|1|2948|grams||N|||F|||20241118030201
OBX|10|TM|57715-5^Time of birth^LN|1|1318|||N|||F|||20241118030201
OBX|11|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241118030201
OBX|12|NM|73806-2^Newborn age in hours^LN|1|3|hour(s)||N|||F|||20241118030201
OBX|13|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241118030201
OBX|14|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241118030201
OBX|15|TX|62324-9^Post-discharge provider name^LN|1|MICHELLE LEFF|||N|||F|||20241118030201
OBX|16|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241118030201
OBX|17|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241118030201
OBX|18|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241118030201
OBX|19|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241118030201
OBX|20|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241118030201
OBX|21|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241118030201
OBX|22|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241118030201
OBX|23|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241118030201
OBX|24|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241118030201
OBX|25|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241118030201
OBX|26|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241118030201
OBX|27|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241118030201
OBX|28|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|275|µmol/L|5-49|H|||F|||20241118030201
OBX|29|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|11|{Ratio}|<4.8|H|||F|||20241118030201
OBX|30|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241118030201
OBX|31|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241118030201
OBX|32|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241118030201
OBX|33|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241118030201
OBX|34|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241118030201
OBX|35|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|This pattern of elevations is consistent with Citrullinemia (I/II), ASAL Deficiency|||A|||F|||20241118030201
OBX|36|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|37|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118030201
OBX|38|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241118030201
OBX|39|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241118030201
OBX|40|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241118030201
OBX|41|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241118030201
OBX|42|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241118030201
OBX|43|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241118030201
OBX|44|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241118030201
OBX|45|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241118030201
OBX|46|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241118030201
OBX|47|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241118030201
OBX|48|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241118030201
OBX|49|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241118030201
OBX|50|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241118030201
OBX|51|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241118030201
OBX|52|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241118030201
OBX|53|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241118030201
OBX|54|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241118030201
OBX|55|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241118030201
OBX|56|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241118030201
OBX|57|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241118030201
OBX|58|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241118030201
OBX|59|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241118030201
OBX|60|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241118030201
OBX|61|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241118030201
OBX|62|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241118030201
OBX|63|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241118030201
OBX|64|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241118030201
OBX|65|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241118030201
OBX|66|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241118030201
OBX|67|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241118030201
OBX|68|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241118030201
OBX|69|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241118030201
OBX|70|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241118030201
OBX|71|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241118030201
OBX|72|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241118030201
OBX|73|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241118030201
OBX|74|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241118030201
OBX|75|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|76|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241118030201
OBX|77|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241118030201
OBX|78|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|79|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBX|80|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241118030201
OBX|81|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|82|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBX|83|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241118030201
OBX|84|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|85|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBX|86|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241118030201
OBX|87|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241118030201
OBX|88|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241118030201
OBX|89|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|90|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBX|91|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/µL|>18|N|||F|||20241118030201
OBX|92|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|93|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBX|94|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|µmol/L/h|>=18.2|N|||F|||20241118030201
OBX|95|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|96|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241118030201
OBX|97|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241118030201
OBX|98|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|99|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBX|100|TX|PLT3293^SMN1 exon 7 deletion analysis in DBS by Sequencing^PLT^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241118030201
OBX|101|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|102|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241118030201
OBX|103|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241118030201
OBX|104|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|105|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241118030201
OBX|106|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|107|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241118030201
OBX|108|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20241118030201
OBX|109|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20241118030201
OBX|110|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241118030201
OBX|111|CE|85269-9^X-linked Adrenoleukodystrophy (X- ALD) newborn screen interpretation^LN^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241118030201
OBX|112|TX|85268-1^X-linked Adrenoleukodystrophy (X- ALD) newborn screening comment-discussion^LN^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241118030201
OBX|113|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241118030201
diff --git a/examples/Test/Automated/GoldenCopy/Expected/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7 b/examples/Test/Automated/GoldenCopy/Expected/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7
new file mode 100644
index 000000000..151c91a0d
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Expected/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|CDPH|EPIC|R797|20241203094445||ORU^R01|006|N|2.5.1
PID|1||80015959||INTERFACE^GIRL B CDPHTWO||20241118084900|F||2028-9^Asian||||||||||||2186-5^Not Hispanic or Latino||Y|2
NK1|1|INTERFACE^CDPHTWO|MTH^Mother|9877 7TH ST^^SAN DIEGO^CA^92126^USA|^^^^^619^4704213|||||||||||19961118
ORC|RE|189716938^HospOrdNumber||7872697780^FormNumber||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|189716938^HospOrdNumber||54089-8^NB Screen Panel Patient AHIC^CDPHGSPEAP|||202411211003|||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI||||||20241203094445|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241203094445
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241203094445
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241203094445
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|99717-3^Hypothyroidism^L|||N|||F|||20241203094445
OBX|5|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|2|LA12543-7^GALT^LN|||N|||F|||20241203094445
OBX|6|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|3|LA22279-6^SMA^LN|||N|||F|||20241203094445
OBX|7|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|4|LA30113-7^GAMT^LN|||N|||F|||20241203094445
OBX|8|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|5|LA12532-0^BIO^LN|||N|||F|||20241203094445
OBX|9|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241203094445
OBX|10|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Biotinidase Deficiency: This screen for Biotinidase Deficiency was positive. Another specimen MUST be collected on this infant. \.br\\.br\Guanidinoacetate Methyltransferase (GAMT): An immediate referral to a CCS-approved Metabolic Center for evaluation and additional testing is strongly recommended. \.br\\.br\Spinal Muscular Atrophy (SMA): An immediate referral to a CCS-approved Neuromuscular Center for evaluation and additional testing is strongly recommended due an apparent SMN1 exon 7 homozygous deletion. \.br\\.br\Galactosemia: Additional testing is required to rule out disorder.µCall your Newborn Screening Coordinator for assistance. \.br\\.br\Primary Congenital Hypothyroidism: Additional testing in consultation with a CCS-approved Endocrine Center or Pediatric Endocrinologist is strongly recommended.µCall your Newborn Screening Coordinator for assistance. \.br\\.br\ATTENTION: THIS CHILD HAS TESTED POSITIVE FOR MORE THAN ONE TEST. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241203094445
OBX|11|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241203094445
OBX|12|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241203094445
OBX|13|NM|8339-4^Birthweight^LN|1|2495|grams||N|||F|||20241203094445
OBX|14|TM|57715-5^Time of birth^LN|1|8490|||N|||F|||20241203094445
OBX|15|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241203094445
OBX|16|NM|73806-2^Newborn age in hours^LN|1|82|hour(s)||N|||F|||20241203094445
OBX|17|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241203094445
OBX|18|CE|67704-7^Feeding types^LN|1|LA16915-3^Lactose formula^LN|||N|||F|||20241203094445
OBX|19|TX|62324-9^Post-discharge provider name^LN|1|MICHELLE LEFF|||N|||F|||20241203094445
OBX|20|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241203094445
OBX|21|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241203094445
OBX|22|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241203094445
OBX|23|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241203094445
OBX|24|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241203094445
OBX|25|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241203094445
OBX|26|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241203094445
OBX|27|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241203094445
OBX|28|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241203094445
OBX|29|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241203094445
OBX|30|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241203094445
OBX|31|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241203094445
OBX|32|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20241203094445
OBX|33|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241203094445
OBX|34|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241203094445
OBX|35|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241203094445
OBX|36|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241203094445
OBX|37|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241203094445
OBX|38|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241203094445
OBX|39|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241203094445
OBX|40|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|41|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241203094445
OBX|42|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241203094445
OBX|43|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241203094445
OBX|44|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241203094445
OBX|45|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241203094445
OBX|46|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241203094445
OBX|47|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241203094445
OBX|48|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241203094445
OBX|49|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241203094445
OBX|50|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241203094445
OBX|51|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241203094445
OBX|52|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241203094445
OBX|53|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241203094445
OBX|54|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241203094445
OBX|55|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241203094445
OBX|56|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241203094445
OBX|57|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241203094445
OBX|58|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241203094445
OBX|59|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241203094445
OBX|60|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241203094445
OBX|61|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241203094445
OBX|62|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241203094445
OBX|63|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241203094445
OBX|64|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241203094445
OBX|65|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241203094445
OBX|66|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241203094445
OBX|67|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241203094445
OBX|68|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241203094445
OBX|69|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241203094445
OBX|70|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241203094445
OBX|71|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241203094445
OBX|72|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241203094445
OBX|73|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241203094445
OBX|74|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241203094445
OBX|75|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241203094445
OBX|76|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241203094445
OBX|77|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241203094445
OBX|78|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241203094445
OBX|79|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|80|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241203094445
OBX|81|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<190|N|||F|||20241203094445
OBX|82|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|83|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241203094445
OBX|84|NM|29575-8^Thyrotropin^LN|1|34.00|mIU/L|<29|H|||F|||20241203094445
OBX|85|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|86|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241203094445
OBX|87|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|48.00|enzyme units|>50|L|||F|||20241203094445
OBX|88|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|89|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241203094445
OBX|90|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241203094445
OBX|91|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241203094445
OBX|92|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|8.00|ERU|>10|L|||F|||20241203094445
OBX|93|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|94|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241203094445
OBX|95|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/µL|>18|N|||F|||20241203094445
OBX|96|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|97|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241203094445
OBX|98|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|µmol/L/h|>=18.2|N|||F|||20241203094445
OBX|99|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|100|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241203094445
OBX|101|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241203094445
OBX|102|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|103|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241203094445
OBX|104|TX|PLT3293^SMN1 exon 7 deletion analysis in DBS by Sequencing^PLT^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Absent||Exon 7 Present|A|||F|||20241203094445
OBX|105|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|106|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Positive|||A|||F|||20241203094445
OBX|107|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241203094445
OBX|108|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|109|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241203094445
OBX|110|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241203094445
OBX|111|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Positive|||A|||F|||20241203094445
OBX|112|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|5.25|µmol/L/h|<=5|H|||F|||20241203094445
OBX|113|CE|85269-9^X-linked Adrenoleukodystrophy (X- ALD) newborn screen interpretation^LN^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241203094445
OBX|114|TX|85268-1^X-linked Adrenoleukodystrophy (X- ALD) newborn screening comment-discussion^LN^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241203094445
OBX|115|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241203094445
diff --git a/examples/Test/Automated/GoldenCopy/Expected/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7 b/examples/Test/Automated/GoldenCopy/Expected/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7
new file mode 100644
index 000000000..61a70a2f3
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Expected/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|CDPH|EPIC|R797|20241206093739||ORU^R01|007|N|2.5.1
PID|1||80015955||INTERFACE^BOY A CDPHONE||202411180830|M||2028-9^Asian||||||||||||2186-5^Not Hispanic or Latino||Y|1
NK1|1|INTERFACE^CDPHONE|MTH^Mother|456 ST^^SAN DIEGO^CA^92123^USA|^^^^^858^2490016|||||||||||19921118
ORC|RE|189717091^HospOrdNumber||7902698491^FormNumber||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|189717091^HospOrdNumber||54089-8^NB Screen Panel Patient AHIC^CDPHGSPEAP|||202411211015|||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI||||||20241206093739|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241206093739
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241206093739
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241206093739
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12566-8^SCID^LN|||N|||F|||20241206093739
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241206093739
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\SCID: A liquid blood specimen for CBC differential and flow cytometry at Quest Diagnostics is required to rule out or confirm SCID or a related immune disorder. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241206093739
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241206093739
OBX|8|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241206093739
OBX|9|NM|8339-4^Birthweight^LN|1|2722|grams||N|||F|||20241206093739
OBX|10|TM|57715-5^Time of birth^LN|1|0830|||N|||F|||20241206093739
OBX|11|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241206093739
OBX|12|NM|73806-2^Newborn age in hours^LN|1|73|hour(s)||N|||F|||20241206093739
OBX|13|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241206093739
OBX|14|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241206093739
OBX|15|TX|62324-9^Post-discharge provider name^LN|1|KRISHELLE MARC-AURELE|||N|||F|||20241206093739
OBX|16|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241206093739
OBX|17|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241206093739
OBX|18|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241206093739
OBX|19|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241206093739
OBX|20|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241206093739
OBX|21|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241206093739
OBX|22|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241206093739
OBX|23|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241206093739
OBX|24|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241206093739
OBX|25|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241206093739
OBX|26|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241206093739
OBX|27|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241206093739
OBX|28|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20241206093739
OBX|29|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241206093739
OBX|30|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241206093739
OBX|31|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241206093739
OBX|32|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241206093739
OBX|33|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241206093739
OBX|34|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241206093739
OBX|35|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241206093739
OBX|36|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|37|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241206093739
OBX|38|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241206093739
OBX|39|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241206093739
OBX|40|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241206093739
OBX|41|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241206093739
OBX|42|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241206093739
OBX|43|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241206093739
OBX|44|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241206093739
OBX|45|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241206093739
OBX|46|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241206093739
OBX|47|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241206093739
OBX|48|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241206093739
OBX|49|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241206093739
OBX|50|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241206093739
OBX|51|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241206093739
OBX|52|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241206093739
OBX|53|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241206093739
OBX|54|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241206093739
OBX|55|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241206093739
OBX|56|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241206093739
OBX|57|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241206093739
OBX|58|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241206093739
OBX|59|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241206093739
OBX|60|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241206093739
OBX|61|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241206093739
OBX|62|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241206093739
OBX|63|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241206093739
OBX|64|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241206093739
OBX|65|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241206093739
OBX|66|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241206093739
OBX|67|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241206093739
OBX|68|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241206093739
OBX|69|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241206093739
OBX|70|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241206093739
OBX|71|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241206093739
OBX|72|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241206093739
OBX|73|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241206093739
OBX|74|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241206093739
OBX|75|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|76|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241206093739
OBX|77|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241206093739
OBX|78|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|79|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBX|80|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241206093739
OBX|81|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|82|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBX|83|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241206093739
OBX|84|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|85|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBX|86|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241206093739
OBX|87|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241206093739
OBX|88|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241206093739
OBX|89|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|90|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBX|91|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|2|copies/µL|>18|L|||F|||20241206093739
OBX|92|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241206093739
OBX|93|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241206093739
OBX|94|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|µmol/L/h|>=18.2|N|||F|||20241206093739
OBX|95|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|96|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241206093739
OBX|97|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241206093739
OBX|98|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|99|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBX|100|TX|PLT3293^SMN1 exon 7 deletion analysis in DBS by Sequencing^PLT^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241206093739
OBX|101|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|102|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241206093739
OBX|103|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241206093739
OBX|104|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|105|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241206093739
OBX|106|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|107|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241206093739
OBX|108|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20241206093739
OBX|109|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20241206093739
OBX|110|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241206093739
OBX|111|CE|85269-9^X-linked Adrenoleukodystrophy (X- ALD) newborn screen interpretation^LN^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241206093739
OBX|112|TX|85268-1^X-linked Adrenoleukodystrophy (X- ALD) newborn screening comment-discussion^LN^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241206093739
OBX|113|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241206093739
diff --git a/examples/Test/Automated/GoldenCopy/Expected/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7 b/examples/Test/Automated/GoldenCopy/Expected/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7
new file mode 100644
index 000000000..06cde29c6
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Expected/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|CDPH|EPIC|R797|20241206093739||ORU^R01|008|N|2.5.1
PID|1||80015955||INTERFACE^BOY A CDPHONE||202411180830|M||2131-1^Other Race||||||||||||UNK^Unknown||Y|1
NK1|1|INTERFACE^CDPHONE|MTH^Mother|456 ST^^SAN DIEGO^CA^92123^USA|^^^^^858^2490016|||||||||||19921118
ORC|RE|^HospOrdNumber||7902698491^FormNumber||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI|||||||||^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|^HospOrdNumber||54089-8^NB Screen Panel Patient AHIC^CDPHGSPEAP|||202411021023|||||||202411031023||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI||||||20241206093739|||F
OBX|1|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\Testing Lab - Quest \R\ S W 0094DVLB TESNU, SAN JUAN CAPISTRANO, CA 99999-9999\.br\\.br\Lab Director - Daisydoublek Toulousep, MD,PhD, Quest, (491)154-5445\.br\\.br\SCID Reviewer - Meadowsaffronpa Maxrm\.br\\.br\Lab Remarks: CD3/CD8/CD45RO, Percent:This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. \.br\\.br\Follow-up:\.br\\.br\Clinical Reviewer Comments: Testing\.br\\.br\Follow-up Recommendation: Refer to CCS-approved Immunology Center\.br\\.br\Disclaimer:\.br\\.br\This test was developed and its performance characteristics have been determined by Quest Diagnostics Nichols Institute, San Juan Capistrano. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test. \.br\\.br\|||N|||F|||20241206093739
OBX|2|TM|57715-5^Time of birth^LN|1|0830|||N|||F|||20241206093739
OBX|3|NM|73806-2^Newborn age in hours^LN|1|73|hour(s)||N|||F|||20241206093739
OBX|4|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241206093739
OBX|5|NM|6690-2^Leukocytes [#/volume] in Blood by Automated count^LN|1|45.1|Thousand/uL|9.0-30.0|H|||F|||20241206093739
OBX|6|NM|789-8^Erythrocytes [#/volume] in Blood by Automated count^LN|1|4.25|Million/uL|3.90-5.90||||F|||20241206093739
OBX|7|NM|718-7^Hemoglobin [Mass/volume] in Blood^LN|1|18.1|g/dL|13.4-19.9||||F|||20241206093739
OBX|8|NM|4544-3^Hematocrit [Volume Fraction] of Blood by Automated count^LN|1|50.1|%|42.0-65.0||||F|||20241206093739
OBX|9|NM|787-2^Erythrocyte mean corpuscular volume [Entitic volume] by Automated count^LN|1|100.0|fL|88.0-123.0||||F|||20241206093739
OBX|10|NM|785-6^Erythrocyte mean corpuscular hemoglobin [Entitic mass] by Automated count^LN|1|35.1|pg|31.0-37.0||||F|||20241206093739
OBX|11|NM|786-4^Erythrocyte mean corpuscular hemoglobin concentration [Mass/volume] by Automated count^LN|1|30.2|g/dL|28.0-36.0||||F|||20241206093739
OBX|12|NM|777-3^Platelets [#/volume] in Blood by Automated count^LN|1|200|Thousand/uL|150-450||||F|||20241206093739
OBX|13|NM|776-5^Platelet mean volume [Entitic volume] in Blood by Rees-Ecker^LN|1|11.1|fL|7.5-12.5||||F|||20241206093739
OBX|14|NM|788-0^Erythrocyte distribution width [Ratio] by Automated count^LN|1|14.1|%|13.0-18.0||||F|||20241206093739
OBX|15|NM|751-8^Neutrophils [#/volume] in Blood by Automated count^LN|1|7000|cells/uL|5000-21000||||F|||20241206093739
OBX|16|NM|26507-4^Neutrophils.band form [#/volume] in Blood^LN^29153|1|3000|cells/uL|1500-4200||||F|||20241206093739
OBX|17|NM|30433-7^Metamyelocytes [#/volume] in Blood^LN^29154|1|1|cells/uL|0|H|||F|||20241206093739
OBX|18|NM|30446-9^Myelocytes [#/volume] in Blood^LN^29162|1|0|cells/uL|0||||F|||20241206093739
OBX|19|NM|26523-1^Promyelocytes [#/volume] in Blood^LN^29163|1|0|cells/uL|0||||F|||20241206093739
OBX|20|NM|731-0^Lymphocytes [#/volume] in Blood by Automated count^LN^29164|1|6000|cells/uL|2000-11500||||F|||20241206093739
OBX|21|NM|742-7^Monocytes [#/volume] in Blood by Automated count^LN^29165|1|1200|cells/uL|300-2400||||F|||20241206093739
OBX|22|NM|711-2^Eosinophils [#/volume] in Blood by Automated count^LN^29166|1|600|cells/uL|15-800||||F|||20241206093739
OBX|23|NM|704-7^Basophils [#/volume] in Blood by Automated count^LN^29167|1|200|cells/uL|0-300||||F|||20241206093739
OBX|24|NM|30376-8^Blasts [#/volume] in Blood^LN^29168|1|0|cells/uL|0||||F|||20241206093739
OBX|25|NM|30392-5^Nucleated erythrocytes [#/volume] in Blood^LN^29169|1|300|cells/uL|0-5000||||F|||20241206093739
OBX|26|NM|770-8^Neutrophils/100 leukocytes in Blood by Automated count^LN^29170|1|20|%|||||F|||20241206093739
OBX|27|NM|26508-2^Neutrophils.band form/100 leukocytes in Blood^LN^29171|1|2|%|||||F|||20241206093739
OBX|28|NM|28541-1^Metamyelocytes/100 leukocytes in Blood^LN^29172|1|1|%|||||F|||20241206093739
OBX|29|NM|26498-6^Myelocytes/100 leukocytes in Blood^LN^29173|1|1|%|||||F|||20241206093739
OBX|30|NM|26524-9^Promyelocytes/100 leukocytes in Blood^LN^29174|1|1|%|||||F|||20241206093739
OBX|31|NM|736-9^Lymphocytes/100 leukocytes in Blood by Automated count^LN^29175|1|1|%|||||F|||20241206093739
OBX|32|NM|13046-8^Lymphocytes Variant/100 leukocytes in Blood^LN^29176|1|1|%|0-10||||F|||20241206093739
OBX|33|NM|5905-5^Monocytes/100 leukocytes in Blood by Automated count^LN^29177|1|1|%|||||F|||20241206093739
OBX|34|NM|713-8^Eosinophils/100 leukocytes in Blood by Automated count^LN^29178|1|1|%|||||F|||20241206093739
OBX|35|NM|706-2^Basophils/100 leukocytes in Blood by Automated count^LN^29179|1|1|%|||||F|||20241206093739
OBX|36|NM|26446-5^Blasts/100 leukocytes in Blood^LN^29180|1|1|%|||||F|||20241206093739
OBX|37|NM|19048-8^Nucleated erythrocytes/100 leukocytes [Ratio] in Blood^LN^29181|1|1|/100 WBC|0|H|||F|||20241206093739
OBX|38|NM|8122-4^CD3 cells [#/volume] in Blood^LN^86007711^CD3+ T-Cells, Absolute^L|1|3000|cells/uL|2500-5500||||F|||20241206093739
OBX|39|NM|8124-0^CD3 cells/100 cells in Blood^LN^86007712^CD3+ T-Cells, Percent^L|1|60|% of Lymphs|53-84||||F|||20241206093739
OBX|40|NM|24467-3^CD3+CD4+ (T4 helper) cells [#/volume] in Blood^LN^86007713^CD3+/CD4+ T-Helper, Abs^L|1|2000|cells/uL|1600-4000||||F|||20241206093739
OBX|41|NM|8123-2^CD3+CD4+ (T4 helper) cells/100 cells in Blood^LN^86007714^CD3+/CD4+ T-Helper,Percent^L|1|40|% of Lymphs|35-64||||F|||20241206093739
OBX|42|NM|14135-8^CD3+CD8+ (T8 suppressor cells) cells [#/volume] in Blood^LN^86007715^CD3+/CD8+ T-Cytotoxic, Abs^L|1|1000|cells/uL|560-1700||||F|||20241206093739
OBX|43|NM|8101-8^CD3+CD8+ (T8 suppressor cells) cells/100 cells in Blood^LN^86007716^CD3+/CD8+T-Cytotox,Percent^L|1|15|% of Lymphs|12-28||||F|||20241206093739
OBX|44|NM|8116-6^CD19 cells [#/volume] in Blood^LN^86007717^CD19+ B-cells, Absolute^L|1|500|cells/uL|300-2000||||F|||20241206093739
OBX|45|NM|8117-4^CD19 cells/100 cells in Blood^LN^86007718^CD19+ B-cells, Percent^L|1|10|% of Lymphs|6-32||||F|||20241206093739
OBX|46|NM|9728-7^CD16C+CD56+ cells [#/volume] in Blood^LN^86007719^CD16/CD56 NK-cells, Abs^L|1|200|cells/uL|170-1100||||F|||20241206093739
OBX|47|NM|8112-5^CD16+CD56+ cells/100 cells in Blood^LN^86007720^CD16/CD56 NK-cells,Percent^L|1|9|% of Lymphs|4-18||||F|||20241206093739
OBX|48|NM|26759-1^CD4+CD45RA+cells [#/volume] in Blood^LN^86007721^CD3/CD4/CD45RA, Absolute^L|1|1500|cells/uL|1200-3700||||F|||20241206093739
OBX|49|NM|13336-3^CD4+CD45RA+cells/100 cells in Blood^LN^^CD3/CD4/CD45RA, Percent^L|1|8|% CD4|||||F|||20241206093739
OBX|50|NM|82743-6^CD8+CD45RA+ Cells # Bld^LN^86007723^CD3/CD8/CD45RA, Absolute^L|1|600|cells/uL|450-1500||||F|||20241206093739
OBX|51|NM|82744-4^CD8+CD45RA+ Cells/100 CD8 NFr Bld^LN^86007724^CD3/CD8/CD45RA, Percent^L|1|10|% CD8|||||F|||20241206093739
OBX|52|NM|85792-0^CD3+CD4+CD45RO+ # Bld^LN^86007725^CD3/CD4/CD45RO, Absolute^L|1|500|cells/uL|60-900||||F|||20241206093739
OBX|53|NM|85791-2^CD3+CD4+CD45RO+/100 CD3 NFr Bld^LN^86007726^CD3/CD4/CD45RO, Percent^L|1|5|% CD4|2-22||||F|||20241206093739
OBX|54|NM|85790-4^CD3+CD8+CD45RO+ # Bld^LN^86007727^CD3/CD8/CD45RO, Absolute^L|1|50|cells/uL|30-330||||F|||20241206093739
OBX|55|NM|85789-6^CD3+CD8+CD45RO+/100 CD3 NFr Bld^LN^86007728^CD3/CD8/CD45RO, Percent^L|1|2|% CD8|1-9||||F|||20241206093739
OBX|56|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241206093739
OBX|57|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Refer to CCS-approved Immunology Center|||A|||F|||20241206093739
diff --git a/examples/Test/Automated/GoldenCopy/Expected/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7 b/examples/Test/Automated/GoldenCopy/Expected/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7
new file mode 100644
index 000000000..c39db5416
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Expected/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|CDPH|EPIC|R797|20241211115659||ORU^R01|009|N|2.5.1
PID|1||80009320||NEWBORNSCREEN^BOY  RED||202408150826|M||1002-5^American Indian or Alaska Native||||||||||||2186-5^Not Hispanic or Latino||N|1
NK1|1|NEWBORNSCREEN^RED|MTH^Mother|9560 TOWNE CENTRE DR^^SAN DIEGO^CA^92121-1972^USA|^^^^^619^1234567|||||||||||19850426
ORC|RE|189671588^HospOrdNumber||7341237093^FormNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|189671588^HospOrdNumber||54089-8^NB Screen Panel Patient AHIC^CDPHGSPEAP|||202409300941|||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI||||||20241211115659|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241211115659
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241211115659
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241211115659
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12543-7^GALT^LN|||N|||F|||20241211115659
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241211115659
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\Acyl Carnitine Panel: Reference Ranges for acylcarnitines are based on specimens collected on newborns who are less than 10 days old. \.br\\.br\Galactosemia: Additional testing is required to rule out disorder.µCall your Newborn Screening Coordinator for assistance. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241211115659
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241211115659
OBX|8|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241211115659
OBX|9|NM|8339-4^Birthweight^LN|1|3084|grams||N|||F|||20241211115659
OBX|10|TM|57715-5^Time of birth^LN|1|0826|||N|||F|||20241211115659
OBX|11|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241211115659
OBX|12|NM|73806-2^Newborn age in hours^LN|1|46|day(s)||N|||F|||20241211115659
OBX|13|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241211115659
OBX|14|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241211115659
OBX|15|TX|62324-9^Post-discharge provider name^LN|1|MARVIN ZAGULI|||N|||F|||20241211115659
OBX|16|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241211115659
OBX|17|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241211115659
OBX|18|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241211115659
OBX|19|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241211115659
OBX|20|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241211115659
OBX|21|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241211115659
OBX|22|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241211115659
OBX|23|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241211115659
OBX|24|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241211115659
OBX|25|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241211115659
OBX|26|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241211115659
OBX|27|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241211115659
OBX|28|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20241211115659
OBX|29|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241211115659
OBX|30|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241211115659
OBX|31|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241211115659
OBX|32|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241211115659
OBX|33|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241211115659
OBX|34|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241211115659
OBX|35|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211115659
OBX|36|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|37|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211115659
OBX|38|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241211115659
OBX|39|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241211115659
OBX|40|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241211115659
OBX|41|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241211115659
OBX|42|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241211115659
OBX|43|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241211115659
OBX|44|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241211115659
OBX|45|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241211115659
OBX|46|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241211115659
OBX|47|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241211115659
OBX|48|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241211115659
OBX|49|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241211115659
OBX|50|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241211115659
OBX|51|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241211115659
OBX|52|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241211115659
OBX|53|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241211115659
OBX|54|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241211115659
OBX|55|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241211115659
OBX|56|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241211115659
OBX|57|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241211115659
OBX|58|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241211115659
OBX|59|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241211115659
OBX|60|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241211115659
OBX|61|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241211115659
OBX|62|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241211115659
OBX|63|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241211115659
OBX|64|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241211115659
OBX|65|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241211115659
OBX|66|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241211115659
OBX|67|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241211115659
OBX|68|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241211115659
OBX|69|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241211115659
OBX|70|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241211115659
OBX|71|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241211115659
OBX|72|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241211115659
OBX|73|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241211115659
OBX|74|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241211115659
OBX|75|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|76|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211115659
OBX|77|NM|38473-5^17-Hydroxyprogesterone^LN|1|35|nmol/L|<85|N|||F|||20241211115659
OBX|78|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|79|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBX|80|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241211115659
OBX|81|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|82|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBX|83|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|48.00|enzyme units|>50|L|||F|||20241211115659
OBX|84|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241211115659
OBX|85|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241211115659
OBX|86|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241211115659
OBX|87|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241211115659
OBX|88|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241211115659
OBX|89|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|90|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBX|91|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/µL|>18|N|||F|||20241211115659
OBX|92|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|93|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBX|94|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|µmol/L/h|>=18.2|N|||F|||20241211115659
OBX|95|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|96|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241211115659
OBX|97|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241211115659
OBX|98|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|99|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBX|100|TX|PLT3293^SMN1 exon 7 deletion analysis in DBS by Sequencing^PLT^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241211115659
OBX|101|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|102|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241211115659
OBX|103|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241211115659
OBX|104|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|105|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211115659
OBX|106|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|107|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241211115659
OBX|108|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20241211115659
OBX|109|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20241211115659
OBX|110|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241211115659
OBX|111|CE|85269-9^X-linked Adrenoleukodystrophy (X- ALD) newborn screen interpretation^LN^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241211115659
OBX|112|TX|85268-1^X-linked Adrenoleukodystrophy (X- ALD) newborn screening comment-discussion^LN^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241211115659
OBX|113|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241211115659
diff --git a/examples/Test/Automated/GoldenCopy/Expected/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7 b/examples/Test/Automated/GoldenCopy/Expected/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7
new file mode 100644
index 000000000..253a3373f
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Expected/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|CDPH|EPIC|R508|20241211110818||ORU^R01|010|N|2.5.1
PID|1||80015980||HIPPO^BOY A ALLIE||202412091336|M||2106-3^White||||||||||||2186-5^Not Hispanic or Latino||Y|1
NK1|1|HIPPO^ALLIE|MTH^Mother|518 BIG BEN WAY^^OCEANSIDE^CA^92058^USA|^^^^^442^2885325|||||||||||19941209
ORC|RE|189728187^HospOrdNumber||7302692465^FormNumber||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI|||||||||UC SAN DIEGO MEDICAL CENTER^^^^^^^^^R508|W 025TS HT71 , C #^^SAN DIEGO^CA^99999-9999
OBR|1|189728187^HospOrdNumber||54089-8^NB Screen Panel Patient AHIC^CDPHGSPEAP|||202412101409|||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI||||||20241211110818|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241211110818
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241211110818
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241211110818
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12533-8^CAH^LN|||N|||F|||20241211110818
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241211110818
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\CAH: An immediate referral to a CCS endocrine center or pediatric endocrinologist, for evaluation and additional testing, is strongly recommended. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Screen for CAH based on 17-OH P level and a steroid ratio level. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241211110818
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241211110818
OBX|8|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241211110818
OBX|9|NM|8339-4^Birthweight^LN|1|2722|grams||N|||F|||20241211110818
OBX|10|TM|57715-5^Time of birth^LN|1|1336|||N|||F|||20241211110818
OBX|11|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241211110818
OBX|12|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241211110818
OBX|13|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241211110818
OBX|14|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241211110818
OBX|15|TX|62324-9^Post-discharge provider name^LN|1|MARVIN ZAGULI|||N|||F|||20241211110818
OBX|16|TX|62327-2^Post-discharge provider practice address^LN|1|W 025TS HT71 , C # SAN DIEGO CA 99999-9999 USA|||N|||F|||20241211110818
OBX|17|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241211110818
OBX|18|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241211110818
OBX|19|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241211110818
OBX|20|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241211110818
OBX|21|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241211110818
OBX|22|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241211110818
OBX|23|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241211110818
OBX|24|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241211110818
OBX|25|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241211110818
OBX|26|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241211110818
OBX|27|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241211110818
OBX|28|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20241211110818
OBX|29|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241211110818
OBX|30|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241211110818
OBX|31|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241211110818
OBX|32|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241211110818
OBX|33|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241211110818
OBX|34|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241211110818
OBX|35|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211110818
OBX|36|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|37|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211110818
OBX|38|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241211110818
OBX|39|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241211110818
OBX|40|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241211110818
OBX|41|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241211110818
OBX|42|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241211110818
OBX|43|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241211110818
OBX|44|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241211110818
OBX|45|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241211110818
OBX|46|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241211110818
OBX|47|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241211110818
OBX|48|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241211110818
OBX|49|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241211110818
OBX|50|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241211110818
OBX|51|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241211110818
OBX|52|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241211110818
OBX|53|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241211110818
OBX|54|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241211110818
OBX|55|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241211110818
OBX|56|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241211110818
OBX|57|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241211110818
OBX|58|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241211110818
OBX|59|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241211110818
OBX|60|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241211110818
OBX|61|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241211110818
OBX|62|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241211110818
OBX|63|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241211110818
OBX|64|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241211110818
OBX|65|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241211110818
OBX|66|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241211110818
OBX|67|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241211110818
OBX|68|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241211110818
OBX|69|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241211110818
OBX|70|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241211110818
OBX|71|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241211110818
OBX|72|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241211110818
OBX|73|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241211110818
OBX|74|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241211110818
OBX|75|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|76|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241211110818
OBX|77|NM|38473-5^17-Hydroxyprogesterone^LN|1|65.88|nmol/L|<85|N|||F|||20241211110818
OBX|78|NM|53340-6^17-Hydroxyprogesterone [Moles/volume] in DBS^LN^99717-6^17-Hydroxyprogesterone (CAH II)^L|1|39|nmol/L|<38|H|||F|||20241211110818
OBX|79|NM|53343-0^Androstenedione^LN|1|40.15|nmol/L||N|||F|||20241211110818
OBX|80|NM|53345-5^Cortisol^LN|1|85|nmol/L||N|||F|||20241211110818
OBX|81|NM|53336-4^17-Hydroxyprogesterone+Androstenedione/Cortisol^LN|1|0.93|{Ratio}|<1|N|||F|||20241211110818
OBX|82|NM|53341-4^21-Deoxycortisol [Mass/volume] in Dried blood spot^LN|1|90.9|nmol/L|<5|H|||F|||20241211110818
OBX|83|NM|53347-1^11-Deoxycorticosterone [Mass/volume] in Dried blood spot^LN|1|590|nmol/L|<240|H|||F|||20241211110818
OBX|84|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241211110818
OBX|85|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241211110818
OBX|86|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241211110818
OBX|87|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|88|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBX|89|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|55.00|enzyme units|>50|N|||F|||20241211110818
OBX|90|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|91|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBX|92|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241211110818
OBX|93|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241211110818
OBX|94|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241211110818
OBX|95|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|96|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBX|97|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|33|copies/µL|>18|N|||F|||20241211110818
OBX|98|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|99|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBX|100|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|12.923|µmol/L/h|>=18.2|N|||F|||20241211110818
OBX|101|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|102|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241211110818
OBX|103|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241211110818
OBX|104|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|105|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBX|106|TX|PLT3293^SMN1 exon 7 deletion analysis in DBS by Sequencing^PLT^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241211110818
OBX|107|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|108|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241211110818
OBX|109|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241211110818
OBX|110|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|111|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241211110818
OBX|112|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|113|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241211110818
OBX|114|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20241211110818
OBX|115|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20241211110818
OBX|116|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241211110818
OBX|117|CE|85269-9^X-linked Adrenoleukodystrophy (X- ALD) newborn screen interpretation^LN^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241211110818
OBX|118|TX|85268-1^X-linked Adrenoleukodystrophy (X- ALD) newborn screening comment-discussion^LN^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241211110818
OBX|119|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241211110818
diff --git a/examples/Test/Automated/GoldenCopy/Expected/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7 b/examples/Test/Automated/GoldenCopy/Expected/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7
new file mode 100644
index 000000000..ae2871c8c
--- /dev/null
+++ b/examples/Test/Automated/GoldenCopy/Expected/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7
@@ -0,0 +1 @@
+MSH|^~\&|GOLDEN-COPY|CDPH|EPIC|R508|20241211104422||ORU^R01|011|N|2.5.1
PID|1||80015981||HIPPO^BOY B ALLIE||202412091336|M||2106-3^White||||||||||||2186-5^Not Hispanic or Latino||Y|2
NK1|1|HIPPO^ALLIE|MTH^Mother|518 BIG BEN WAY^^OCEANSIDE^CA^92058^USA|^^^^^442^2885325|||||||||||19941209
ORC|RE|189728238^HospOrdNumber||7322694174^FormNumber||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI|||||||||UC SAN DIEGO MEDICAL CENTER^^^^^^^^^R508|W 025TS HT71 , C #^^SAN DIEGO^CA^99999-9999
OBR|1|189728238^HospOrdNumber||54089-8^NB Screen Panel Patient AHIC^CDPHGSPEAP|||202412101414|||||||||1427255868^JOHNSON^KATHRYN^^^^^^^^^^NPI||||||20241211104422|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12427-3^Subsequent screen - for clarification of initial results (not by law or protocol)^LN|||N|||F|||20241211104422
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12443-0^Specimen quantity insufficient for testing^LN|||N|||F|||20241211104422
OBX|3|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241211104422
OBX|4|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241211104422
OBX|5|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\ NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\** This specimen was inadequate for testing for the following reason: ** 13 - Specimen not collected on acceptable filter paper including expired form THE PHYSICIAN LISTED HAS BEEN NOTIFIED \.br\\.br\|||N|||F|||20241211104422
OBX|6|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241211104422
OBX|7|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241211104422
OBX|8|NM|8339-4^Birthweight^LN|1|2812|grams||N|||F|||20241211104422
OBX|9|TM|57715-5^Time of birth^LN|1|1336|||N|||F|||20241211104422
OBX|10|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12412-5^Twins^LN|||N|||F|||20241211104422
OBX|11|NM|73806-2^Newborn age in hours^LN|1|24|hour(s)||N|||F|||20241211104422
OBX|12|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241211104422
OBX|13|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241211104422
OBX|14|TX|62324-9^Post-discharge provider name^LN|1|EUSTRATIA HUBBARD|||N|||F|||20241211104422
OBX|15|TX|62327-2^Post-discharge provider practice address^LN|1|W 025TS HT71 , C # SAN DIEGO CA 99999-9999 USA|||N|||F|||20241211104422
diff --git a/examples/Test/Automated/Assertion/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7 b/examples/Test/Automated/GoldenCopy/Input/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
rename to examples/Test/Automated/GoldenCopy/Input/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
diff --git a/examples/Test/Automated/Assertion/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7 b/examples/Test/Automated/GoldenCopy/Input/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7
rename to examples/Test/Automated/GoldenCopy/Input/002_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002B.hl7
diff --git a/examples/Test/Automated/Assertion/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7 b/examples/Test/Automated/GoldenCopy/Input/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7
rename to examples/Test/Automated/GoldenCopy/Input/003_CA_ORU_R01_CDPH_UCSD_189671588_pre_TI_TC001.hl7
diff --git a/examples/Test/Automated/Assertion/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7 b/examples/Test/Automated/GoldenCopy/Input/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7
rename to examples/Test/Automated/GoldenCopy/Input/004_CA_ORU_R01_CDPH_UCSD_189700664_pre_TI_TC000.hl7
diff --git a/examples/Test/Automated/Assertion/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7 b/examples/Test/Automated/GoldenCopy/Input/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7
rename to examples/Test/Automated/GoldenCopy/Input/005_CA_ORU_R01_CDPH_UCSD_189693889_pre_TI_TC002C.hl7
diff --git a/examples/Test/Automated/Assertion/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7 b/examples/Test/Automated/GoldenCopy/Input/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7
rename to examples/Test/Automated/GoldenCopy/Input/006_CA_ORU_R01_CDPH_UCSD_189716938_pre_TI_TC002A.hl7
diff --git a/examples/Test/Automated/Assertion/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7 b/examples/Test/Automated/GoldenCopy/Input/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7
rename to examples/Test/Automated/GoldenCopy/Input/007_CA_ORU_R01_CDPH_UCSD_189717091_80015955_pre_TI_TC007A.hl7
diff --git a/examples/Test/Automated/Assertion/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7 b/examples/Test/Automated/GoldenCopy/Input/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7
rename to examples/Test/Automated/GoldenCopy/Input/008_CA_ORU_R01_CDPH_UCSD_MRN_80015955_pre_TI_TC007B.hl7
diff --git a/examples/Test/Automated/Assertion/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7 b/examples/Test/Automated/GoldenCopy/Input/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7
rename to examples/Test/Automated/GoldenCopy/Input/009_CA_ORU_R01_CDPH_UCSD_MRN_80009320_pre_TI_TC001_Corrected.hl7
diff --git a/examples/Test/Automated/Assertion/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7 b/examples/Test/Automated/GoldenCopy/Input/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7
rename to examples/Test/Automated/GoldenCopy/Input/010_CA_ORU_R01_CDPH_UCSD_MRN_80015980_pre_TI_TC006.hl7
diff --git a/examples/Test/Automated/Assertion/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7 b/examples/Test/Automated/GoldenCopy/Input/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7
similarity index 100%
rename from examples/Test/Automated/Assertion/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7
rename to examples/Test/Automated/GoldenCopy/Input/011_CA_ORU_R01_CDPH_UCSD_MRN_80015981_pre_TI_TC008.hl7

From 7ba9b0bae128718c6b0b9ecdba117ba5b1f5de32 Mon Sep 17 00:00:00 2001
From: James Herr <jherr@flexion.us>
Date: Tue, 31 Dec 2024 11:20:20 -0600
Subject: [PATCH 60/61] Pushing to trigger Action

Co-Authored-By: Sylvie <38440028+somesylvie@users.noreply.github.com>
Co-Authored-By: James Gilmore <109554461+GilmoreA6@users.noreply.github.com>
---
 .../rse2e/ruleengine/AssertionRuleEngineTest.groovy             | 2 +-
 1 file changed, 1 insertion(+), 1 deletion(-)

diff --git a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/ruleengine/AssertionRuleEngineTest.groovy b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/ruleengine/AssertionRuleEngineTest.groovy
index 9869d7634..c3bb3ef29 100644
--- a/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/ruleengine/AssertionRuleEngineTest.groovy
+++ b/rs-e2e/src/test/groovy/gov/hhs/cdc/trustedintermediary/rse2e/ruleengine/AssertionRuleEngineTest.groovy
@@ -41,7 +41,7 @@ class AssertionRuleEngineTest extends Specification {
         ruleEngine.getRules().size() == 1
     }
 
-    def "ensureRulesLoaded loads rules only once by default"() {
+    def "ensureRulesLoaded loads rules  only once by default"() {
         given:
         mockRuleLoader.loadRules(_ as InputStream, _ as TypeReference) >> [mockRule]
 

From 1232ae416b3b51aaaf5d98c1e3b1b3b1bab92a30 Mon Sep 17 00:00:00 2001
From: James Herr <jherr@flexion.us>
Date: Tue, 31 Dec 2024 11:28:40 -0600
Subject: [PATCH 61/61] Troubleshooting validation error

Co-Authored-By: Sylvie <38440028+somesylvie@users.noreply.github.com>
Co-Authored-By: James Gilmore <109554461+GilmoreA6@users.noreply.github.com>
---
 .../001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7        | 2 +-
 1 file changed, 1 insertion(+), 1 deletion(-)

diff --git a/examples/Test/Automated/GoldenCopy/Expected/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7 b/examples/Test/Automated/GoldenCopy/Expected/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
index 050386ea7..1103532ad 100644
--- a/examples/Test/Automated/GoldenCopy/Expected/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
+++ b/examples/Test/Automated/GoldenCopy/Expected/001_CA_ORU_R01_CDPH_UCSD_189688314_pre_TI_TC_004.hl7
@@ -1 +1 @@
-MSH|^~\&|GOLDEN-COPY|CDPH|EPIC|R797|20241015054631||ORU^R01|001|N|2.5.1
PID|1||80015867||CDPHTWO^GIRL  MOMTWO||202410071025|F||2076-8^Native Hawaiian or Other Pacific Islander||||||||||||2186-5^Not Hispanic or Latino||N|1
NK1|1|CDPHTWO^MOMTWO|MTH^Mother|2 SECOND ST^^SAN DIEGO^CA^92121^USA||||||||||||20000202
ORC|RE|189688314^HospOrdNumber||7371237714^FormNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|189688314^HospOrdNumber||54089-8^NB Screen Panel Patient AHIC^CDPHGSPEAP|||202410081133|||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI||||||20241015054631|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12427-3^Subsequent screen - for clarification of initial results (not by law or protocol)^LN|||N|||F|||20241015054631
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241015054631
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241015054631
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12543-7^GALT^LN|||N|||F|||20241015054631
OBX|5|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|2|LA12533-8^CAH^LN|||N|||F|||20241015054631
OBX|6|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA12566-8^SCID^LN|||N|||F|||20241015054631
OBX|7|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|2|LA14037-8^GAA^LN|||N|||F|||20241015054631
OBX|8|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\CAH: An immediate referral to a CCS endocrine center or pediatric endocrinologist, for evaluation and additional testing, is strongly recommended. \.br\\.br\Pompe: Another dried blood specimen MUST be collected for this child. Call your Newborn Screening Coordinator for assistance. \.br\\.br\SCID: Another dried blood specimen MUST be collected for this child. Call your Newborn Screening Coordinator for assistance. \.br\\.br\Galactosemia: Additional testing is required to rule out disorder.µCall your Newborn Screening Coordinator for assistance. \.br\\.br\ATTENTION: THIS CHILD HAS TESTED POSITIVE FOR MORE THAN ONE TEST. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241015054631
OBX|9|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241015054631
OBX|10|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241015054631
OBX|11|NM|8339-4^Birthweight^LN|1|3175|grams||N|||F|||20241015054631
OBX|12|TM|57715-5^Time of birth^LN|1|1025|||N|||F|||20241015054631
OBX|13|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241015054631
OBX|14|NM|73806-2^Newborn age in hours^LN|1|25|hour(s)||N|||F|||20241015054631
OBX|15|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241015054631
OBX|16|CE|67704-7^Feeding types^LN|1|LA4489-6^Unknown^LN|||N|||F|||20241015054631
OBX|17|TX|62324-9^Post-discharge provider name^LN|1|DENISE COYLE|||N|||F|||20241015054631
OBX|18|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241015054631
OBX|19|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|20|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241015054631
OBX|21|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|22|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241015054631
OBX|23|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241015054631
OBX|24|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241015054631
OBX|25|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241015054631
OBX|26|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241015054631
OBX|27|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241015054631
OBX|28|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241015054631
OBX|29|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241015054631
OBX|30|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20241015054631
OBX|31|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241015054631
OBX|32|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241015054631
OBX|33|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|34|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241015054631
OBX|35|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241015054631
OBX|36|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241015054631
OBX|37|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|38|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|39|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|40|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241015054631
OBX|41|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241015054631
OBX|42|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241015054631
OBX|43|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241015054631
OBX|44|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241015054631
OBX|45|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241015054631
OBX|46|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|47|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241015054631
OBX|48|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241015054631
OBX|49|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241015054631
OBX|50|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241015054631
OBX|51|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|52|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241015054631
OBX|53|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241015054631
OBX|54|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|55|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|56|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241015054631
OBX|57|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241015054631
OBX|58|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241015054631
OBX|59|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241015054631
OBX|60|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241015054631
OBX|61|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241015054631
OBX|62|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241015054631
OBX|63|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|64|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241015054631
OBX|65|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241015054631
OBX|66|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241015054631
OBX|67|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241015054631
OBX|68|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241015054631
OBX|69|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241015054631
OBX|70|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241015054631
OBX|71|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241015054631
OBX|72|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241015054631
OBX|73|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241015054631
OBX|74|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241015054631
OBX|75|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241015054631
OBX|76|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241015054631
OBX|77|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|78|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|79|NM|38473-5^17-Hydroxyprogesterone^LN|1|305|nmol/L|<85|H|||F|||20241015054631
OBX|80|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241015054631
OBX|81|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241015054631
OBX|82|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241015054631
OBX|83|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|84|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|85|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|48.00|enzyme units|>50|L|||F|||20241015054631
OBX|86|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241015054631
OBX|87|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241015054631
OBX|88|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241015054631
OBX|89|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241015054631
OBX|90|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241015054631
OBX|91|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|92|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|93|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|2|copies/µL|>18|L|||F|||20241015054631
OBX|94|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241015054631
OBX|95|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Incomplete|||A|||F|||20241015054631
OBX|96|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA16205-9^Specimen unsatisfactory for at least one condition^LN|||A|||F|||20241015054631
OBX|97|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Incomplete|||A|||F|||20241015054631
OBX|98|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241015054631
OBX|99|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|100|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|101|TX|PLT3293^SMN1 exon 7 deletion analysis in DBS by Sequencing^PLT^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241015054631
OBX|102|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|103|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241015054631
OBX|104|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241015054631
OBX|105|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|106|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|107|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|108|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|109|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20241015054631
OBX|110|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20241015054631
OBX|111|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241015054631
OBX|112|CE|85269-9^X-linked Adrenoleukodystrophy (X- ALD) newborn screen interpretation^LN^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|113|TX|85268-1^X-linked Adrenoleukodystrophy (X- ALD) newborn screening comment-discussion^LN^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241015054631
OBX|114|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241015054631
+MSH|^~\&|GOLDEN-COPY|CDPH|EPIC|R797|20241015054631||ORU^R01|001|N|2.5.1
PID|1||80015867||CDPHTWO^GIRL  MOMTWO||202410071025|F||2076-8^Native Hawaiian or Other Pacific Islander||||||||||||2186-5^Not Hispanic or Latino||N|1
NK1|1|CDPHTWO^MOMTWO|MTH^Mother|2 SECOND ST^^SAN DIEGO^CA^92121^USA||||||||||||20000202
ORC|RE|189688314^HospOrdNumber||7371237714^FormNumber||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI|||||||||UCSD JACOBS MEDICAL CENTER^^^^^^^^^R797|AG N 005EVA DLEIFR, F N 0037TERTS ONSER^^SAN DIEGO^CA^99999-9999
OBR|1|189688314^HospOrdNumber||54089-8^NB Screen Panel Patient AHIC^CDPHGSPEAP|||202410081133|||||||||1790743185^HUBBARD^EUSTRATIA^^^^^^^^^^NPI||||||20241015054631|||F
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12427-3^Subsequent screen - for clarification of initial results (not by law or protocol)^LN|||N|||F|||20241015054631
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241015054631
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241015054631
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA12543-7^GALT^LN|||N|||F|||20241015054631
OBX|5|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|2|LA12533-8^CAH^LN|||N|||F|||20241015054631
OBX|6|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA12566-8^SCID^LN|||N|||F|||20241015054631
OBX|7|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|2|LA14037-8^GAA^LN|||N|||F|||20241015054631
OBX|8|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\.br\\.br\NBS Testing Lab - COMMUNITY REG MEDICAL CENTER LAB \R\NAR 01303DR OJEIV OHC, TS513 E, FRESNO, CA 99999\.br\\.br\Genetic Disease Laboratory - GDL E 069TS NEERG, RICHMOND, CA 99999-9999\.br\\.br\Lab Director - Genetic Disease Laboratory, (510) 231-1790\.br\\.br\Follow-up:\.br\\.br\CAH: An immediate referral to a CCS endocrine center or pediatric endocrinologist, for evaluation and additional testing, is strongly recommended. \.br\\.br\Pompe: Another dried blood specimen MUST be collected for this child. Call your Newborn Screening Coordinator for assistance. \.br\\.br\SCID: Another dried blood specimen MUST be collected for this child. Call your Newborn Screening Coordinator for assistance. \.br\\.br\Galactosemia: Additional testing is required to rule out disorder.µCall your Newborn Screening Coordinator for assistance. \.br\\.br\ATTENTION: THIS CHILD HAS TESTED POSITIVE FOR MORE THAN ONE TEST. \.br\\.br\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Rady Children's Hospital San Diego at (126) 411-8708. \.br\\.br\Methods and Limitations:\.br\\.br\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \.br\Attention Healthcare Provider:\.br\\.br\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \.br\\.br\|||N|||F|||20241015054631
OBX|9|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241015054631
OBX|10|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241015054631
OBX|11|NM|8339-4^Birthweight^LN|1|3175|grams||N|||F|||20241015054631
OBX|12|TM|57715-5^Time of birth^LN|1|1025|||N|||F|||20241015054631
OBX|13|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241015054631
OBX|14|NM|73806-2^Newborn age in hours^LN|1|25|hour(s)||N|||F|||20241015054631
OBX|15|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241015054631
OBX|16|CE|67704-7^Feeding types^LN|1|LA4489-6^Unknown^LN|||N|||F|||20241015054631
OBX|17|TX|62324-9^Post-discharge provider name^LN|1|DENISE COYLE|||N|||F|||20241015054631
OBX|18|TX|62327-2^Post-discharge provider practice address^LN|1|AG N 005EVA DLEIFR, F N 0037TERTS ONSER SAN DIEGO CA 99999-9999 USA|||N|||F|||20241015054631
OBX|19|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|20|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|500|µmol/L|<1000|N|||F|||20241015054631
OBX|21|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|22|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|0.00645|{Ratio}|<4.3|N|||F|||20241015054631
OBX|23|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|125|µmol/L|<230|N|||F|||20241015054631
OBX|24|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.65|{Ratio}|<1.35|N|||F|||20241015054631
OBX|25|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|77.5|µmol/L|<175|N|||F|||20241015054631
OBX|26|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|0.75|{Ratio}|<2.6|N|||F|||20241015054631
OBX|27|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|425|µmol/L|<680|N|||F|||20241015054631
OBX|28|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|2.25|µmol/L|<6.1|N|||F|||20241015054631
OBX|29|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|27|µmol/L|6.3-100|N|||F|||20241015054631
OBX|30|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|16.25|µmol/L|5-49|N|||F|||20241015054631
OBX|31|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|3|{Ratio}|<4.8|N|||F|||20241015054631
OBX|32|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|400|µmol/L|<800|N|||F|||20241015054631
OBX|33|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|34|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|25|µmol/L|<63|N|||F|||20241015054631
OBX|35|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.7|{Ratio}|<1.9|N|||F|||20241015054631
OBX|36|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|750|µmol/L|<1500|N|||F|||20241015054631
OBX|37|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|38|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|39|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|40|NM|38481-8^Carnitine.free (C0)^LN|1|33|µmol/L|6.4-125|N|||F|||20241015054631
OBX|41|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|37.5|{Ratio}|<70|N|||F|||20241015054631
OBX|42|NM|50157-7^Acetylcarnitine (C2)^LN|1|20.38|µmol/L|10-80|N|||F|||20241015054631
OBX|43|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|0.62500|{Ratio}|<7.6|N|||F|||20241015054631
OBX|44|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.48|µmol/L|<0.95|N|||F|||20241015054631
OBX|45|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.3|µmol/L|<0.45|N|||F|||20241015054631
OBX|46|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|47|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.35|µmol/L|<0.65|N|||F|||20241015054631
OBX|48|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.32|µmol/L|<0.65|N|||F|||20241015054631
OBX|49|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.22|µmol/L|<0.45|N|||F|||20241015054631
OBX|50|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|1|µmol/L|<2|N|||F|||20241015054631
OBX|51|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|52|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.6|µmol/L|<1.2|N|||F|||20241015054631
OBX|53|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.4|µmol/L|<0.9|N|||F|||20241015054631
OBX|54|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|0.5|{Ratio}||N|||F|||20241015054631
OBX|55|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|56|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.1|µmol/L|<0.2|N|||F|||20241015054631
OBX|57|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5|µmol/L|<12|N|||F|||20241015054631
OBX|58|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.7|µmol/L|<1.4|N|||F|||20241015054631
OBX|59|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241015054631
OBX|60|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.01000|{Ratio}|<0.07|N|||F|||20241015054631
OBX|61|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2|µmol/L|<3.5|N|||F|||20241015054631
OBX|62|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|3.5|µmol/L|<7|N|||F|||20241015054631
OBX|63|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.5|µmol/L||N|||F|||20241015054631
OBX|64|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241015054631
OBX|65|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.05|µmol/L|<0.1|N|||F|||20241015054631
OBX|66|NM|53160-8^Propionylcarnitine (C3)^LN|1|3.15|µmol/L|<7.9|N|||F|||20241015054631
OBX|67|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.15|{Ratio}|<0.42|N|||F|||20241015054631
OBX|68|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.2|µmol/L|<0.48|N|||F|||20241015054631
OBX|69|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.85|µmol/L|<1.7|N|||F|||20241015054631
OBX|70|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.5|µmol/L|<0.95|N|||F|||20241015054631
OBX|71|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.15873|{Ratio}|<0.38|N|||F|||20241015054631
OBX|72|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.3|µmol/L|<0.5|N|||F|||20241015054631
OBX|73|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.45|µmol/L|<1.15|N|||F|||20241015054631
OBX|74|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.3|µmol/L|<0.38|N|||F|||20241015054631
OBX|75|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|1.50000|{Ratio}|>0.1|N|||F|||20241015054631
OBX|76|NM|48633-2^Trypsinogen I.free^LN|1|31.00|ng/mL|<69|N|||F|||20241015054631
OBX|77|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|78|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|79|NM|38473-5^17-Hydroxyprogesterone^LN|1|305|nmol/L|<85|H|||F|||20241015054631
OBX|80|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241015054631
OBX|81|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241015054631
OBX|82|NM|29575-8^Thyrotropin^LN|1|14.50|mIU/L|<29|N|||F|||20241015054631
OBX|83|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|84|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|85|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|48.00|enzyme units|>50|L|||F|||20241015054631
OBX|86|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18593-6^Out of range^LN|||A|||F|||20241015054631
OBX|87|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Positive|||A|||F|||20241015054631
OBX|88|TX|54104-5^Hemoglobin pattern^LN|1|FA||||||F|||20241015054631
OBX|89|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|Usual hemoglobin pattern.µThese results assume no transfusion prior to testing and do not rule out the possibility of a thalassemia trait or rare hemoglobin variants.||||||F|||20241015054631
OBX|90|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|15.00|ERU|>10|N|||F|||20241015054631
OBX|91|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|92|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|93|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|2|copies/µL|>18|L|||F|||20241015054631
OBX|94|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA11884-6^Indeterminate^LN|||A|||F|||20241015054631
OBX|95|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Incomplete|||A|||F|||20241015054631
OBX|96|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA16205-9^Specimen unsatisfactory for at least one condition^LN|||A|||F|||20241015054631
OBX|97|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Incomplete|||A|||F|||20241015054631
OBX|98|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|3.117|µmol/L/h|>=18.2|N|||F|||20241015054631
OBX|99|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|100|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|101|TX|PLT3293^SMN1 exon 7 deletion analysis in DBS by Sequencing^PLT^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241015054631
OBX|102|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|103|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241015054631
OBX|104|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|28.1|µmol/L/h|>=2.06|N|||F|||20241015054631
OBX|105|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|106|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|107|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|108|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241015054631
OBX|109|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|2.37|µmol/L|<=3|N|||F|||20241015054631
OBX|110|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|170.08|µmol/L||N|||F|||20241015054631
OBX|111|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|13.93||<=10|H|||F|||20241015054631
OBX|112|CE|85269-9^X-linked Adrenoleukodystrophy (X- ALD) newborn screen interpretation^LN^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241015054631
OBX|113|TX|85268-1^X-linked Adrenoleukodystrophy (X- ALD) newborn screening comment-discussion^LN^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241015054631
OBX|114|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.2|µmol/L|<0.47|N|||F|||20241015054631|